Naloxone	0 8 B-Chemical
reverses	9 8 O
the	18 3 O
antihypertensive	22 16 O
effect	39 6 O
of	46 2 O
clonidine	49 9 B-Chemical
.	58 1 O

In	60 2 O
unanesthetized	63 14 O
,	77 1 O
spontaneously	79 13 O
hypertensive	93 12 B-Disease
rats	106 4 O
the	111 3 O
decrease	115 8 O
in	124 2 O
blood	127 5 O
pressure	133 8 O
and	142 3 O
heart	146 5 O
rate	152 4 O
produced	157 8 O
by	166 2 O
intravenous	169 11 O
clonidine	181 9 B-Chemical
,	190 1 O
5	192 1 O
to	194 2 O
20	197 2 O
micrograms	200 10 O
/	210 1 O
kg	211 2 O
,	213 1 O
was	215 3 O
inhibited	219 9 O
or	229 2 O
reversed	232 8 O
by	241 2 O
nalozone	244 8 B-Chemical
,	252 1 O
0	254 1 O
.	255 1 O
2	256 1 O
to	258 2 O
2	261 1 O
mg	263 2 O
/	265 1 O
kg	266 2 O
.	268 1 O

The	270 3 O
hypotensive	274 11 B-Disease
effect	286 6 O
of	293 2 O
100	296 3 O
mg	300 2 O
/	302 1 O
kg	303 2 O
alpha	306 5 B-Chemical
-	311 1 I-Chemical
methyldopa	312 10 I-Chemical
was	323 3 O
also	327 4 O
partially	332 9 O
reversed	342 8 O
by	351 2 O
naloxone	354 8 B-Chemical
.	362 1 O

Naloxone	364 8 B-Chemical
alone	373 5 O
did	379 3 O
not	383 3 O
affect	387 6 O
either	394 6 O
blood	401 5 O
pressure	407 8 O
or	416 2 O
heart	419 5 O
rate	425 4 O
.	429 1 O

In	431 2 O
brain	434 5 O
membranes	440 9 O
from	450 4 O
spontaneously	455 13 O
hypertensive	469 12 B-Disease
rats	482 4 O
clonidine	487 9 B-Chemical
,	496 1 O
10	498 2 O
(	500 1 O
-	501 1 O
8	502 1 O
)	503 1 O
to	505 2 O
10	508 2 O
(	510 1 O
-	511 1 O
5	512 1 O
)	513 1 O
M	515 1 O
,	516 1 O
did	518 3 O
not	522 3 O
influence	526 9 O
stereoselective	536 15 O
binding	552 7 O
of	560 2 O
[	563 1 B-Chemical
3H	564 2 I-Chemical
]	566 1 I-Chemical
-	567 1 I-Chemical
naloxone	568 8 I-Chemical
(	577 1 O
8	578 1 O
nM	580 2 O
)	582 1 O
,	583 1 O
and	585 3 O
naloxone	589 8 B-Chemical
,	597 1 O
10	599 2 O
(	601 1 O
-	602 1 O
8	603 1 O
)	604 1 O
to	606 2 O
10	609 2 O
(	611 1 O
-	612 1 O
4	613 1 O
)	614 1 O
M	616 1 O
,	617 1 O
did	619 3 O
not	623 3 O
influence	627 9 O
clonidine	637 9 B-Chemical
-	646 1 O
suppressible	647 12 O
binding	660 7 O
of	668 2 O
[	671 1 B-Chemical
3H	672 2 I-Chemical
]	674 1 I-Chemical
-	675 1 I-Chemical
dihydroergocryptine	676 19 I-Chemical
(	696 1 O
1	697 1 O
nM	699 2 O
)	701 1 O
.	702 1 O

These	704 5 O
findings	710 8 O
indicate	719 8 O
that	728 4 O
in	733 2 O
spontaneously	736 13 O
hypertensive	750 12 B-Disease
rats	763 4 O
the	768 3 O
effects	772 7 O
of	780 2 O
central	783 7 O
alpha	791 5 O
-	796 1 O
adrenoceptor	797 12 O
stimulation	810 11 O
involve	822 7 O
activation	830 10 O
of	841 2 O
opiate	844 6 O
receptors	851 9 O
.	860 1 O

As	862 2 O
naloxone	865 8 B-Chemical
and	874 3 O
clonidine	878 9 B-Chemical
do	888 2 O
not	891 3 O
appear	895 6 O
to	902 2 O
interact	905 8 O
with	914 4 O
the	919 3 O
same	923 4 O
receptor	928 8 O
site	937 4 O
,	941 1 O
the	943 3 O
observed	947 8 O
functional	956 10 O
antagonism	967 10 O
suggests	978 8 O
the	987 3 O
release	991 7 O
of	999 2 O
an	1002 2 O
endogenous	1005 10 O
opiate	1016 6 O
by	1023 2 O
clonidine	1026 9 B-Chemical
or	1036 2 O
alpha	1039 5 B-Chemical
-	1044 1 I-Chemical
methyldopa	1045 10 I-Chemical
and	1056 3 O
the	1060 3 O
possible	1064 8 O
role	1073 4 O
of	1078 2 O
the	1081 3 O
opiate	1085 6 O
in	1092 2 O
the	1095 3 O
central	1099 7 O
control	1107 7 O
of	1115 2 O
sympathetic	1118 11 O
tone	1130 4 O
.	1134 1 O

Lidocaine	0 9 B-Chemical
-	9 1 O
induced	10 7 O
cardiac	18 7 B-Disease
asystole	26 8 I-Disease
.	34 1 O

Intravenous	36 11 O
administration	48 14 O
of	63 2 O
a	66 1 O
single	68 6 O
50	75 2 O
-	77 1 O
mg	78 2 O
bolus	81 5 O
of	87 2 O
lidocaine	90 9 B-Chemical
in	100 2 O
a	103 1 O
67	105 2 O
-	107 1 O
year	108 4 O
-	112 1 O
old	113 3 O
man	117 3 O
resulted	121 8 O
in	130 2 O
profound	133 8 O
depression	142 10 B-Disease
of	153 2 O
the	156 3 O
activity	160 8 O
of	169 2 O
the	172 3 O
sinoatrial	176 10 O
and	187 3 O
atrioventricular	191 16 O
nodal	208 5 O
pacemakers	214 10 O
.	224 1 O

The	226 3 O
patient	230 7 O
had	238 3 O
no	242 2 O
apparent	245 8 O
associated	254 10 O
conditions	265 10 O
which	276 5 O
might	282 5 O
have	288 4 O
predisposed	293 11 O
him	305 3 O
to	309 2 O
the	312 3 O
development	316 11 O
of	328 2 O
bradyarrhythmias	331 16 B-Disease
;	347 1 O
and	349 3 O
,	352 1 O
thus	354 4 O
,	358 1 O
this	360 4 O
probably	365 8 O
represented	374 11 O
a	386 1 O
true	388 4 O
idiosyncrasy	393 12 O
to	406 2 O
lidocaine	409 9 B-Chemical
.	418 1 O

Suxamethonium	0 13 B-Chemical
infusion	14 8 O
rate	23 4 O
and	28 3 O
observed	32 8 O
fasciculations	41 14 B-Disease
.	55 1 O

A	57 1 O
dose	59 4 O
-	63 1 O
response	64 8 O
study	73 5 O
.	78 1 O

Suxamethonium	80 13 B-Chemical
chloride	94 8 I-Chemical
(	103 1 O
Sch	104 3 B-Chemical
)	107 1 O
was	109 3 O
administered	113 12 O
i	126 1 O
.	127 1 O
v	128 1 O
.	129 1 O
to	131 2 O
36	134 2 O
adult	137 5 O
males	143 5 O
at	149 2 O
six	152 3 O
rates	156 5 O
:	161 1 O
0	163 1 O
.	164 1 O
25	165 2 O
mg	168 2 O
s	171 1 O
-	172 1 O
1	173 1 O
to	175 2 O
20	178 2 O
mg	181 2 O
s	184 1 O
-	185 1 O
1	186 1 O
.	187 1 O

The	189 3 O
infusion	193 8 O
was	202 3 O
discontinued	206 12 O
either	219 6 O
when	226 4 O
there	231 5 O
was	237 3 O
no	241 2 O
muscular	244 8 O
response	253 8 O
to	262 2 O
tetanic	265 7 B-Disease
stimulation	273 11 O
of	285 2 O
the	288 3 O
ulnar	292 5 O
nerve	298 5 O
or	304 2 O
when	307 4 O
Sch	312 3 B-Chemical
120	316 3 O
mg	320 2 O
was	323 3 O
exceeded	327 8 O
.	335 1 O

Six	337 3 O
additional	341 10 O
patients	352 8 O
received	361 8 O
a	370 1 O
30	372 2 O
-	374 1 O
mg	375 2 O
i	378 1 O
.	379 1 O
v	380 1 O
.	381 1 O
bolus	383 5 O
dose	389 4 O
.	393 1 O

Fasciculations	395 14 B-Disease
in	410 2 O
six	413 3 O
areas	417 5 O
of	423 2 O
the	426 3 O
body	430 4 O
were	435 4 O
scored	440 6 O
from	447 4 O
0	452 1 O
to	454 2 O
3	457 1 O
and	459 3 O
summated	463 8 O
as	472 2 O
a	475 1 O
total	477 5 O
fasciculation	483 13 B-Disease
score	497 5 O
.	502 1 O

The	504 3 O
times	508 5 O
to	514 2 O
first	517 5 O
fasciculation	523 13 B-Disease
,	536 1 O
twitch	538 6 B-Disease
suppression	545 11 O
and	557 3 O
tetanus	561 7 B-Disease
suppression	569 11 O
were	581 4 O
inversely	586 9 O
related	596 7 O
to	604 2 O
the	607 3 O
infusion	611 8 O
rates	620 5 O
.	625 1 O

Fasciculations	627 14 B-Disease
in	642 2 O
the	645 3 O
six	649 3 O
areas	653 5 O
and	659 3 O
the	663 3 O
total	667 5 O
fasciculation	673 13 B-Disease
score	687 5 O
were	693 4 O
related	698 7 O
directly	706 8 O
to	715 2 O
the	718 3 O
rate	722 4 O
of	727 2 O
infusion	730 8 O
.	738 1 O

Total	740 5 O
fasciculation	746 13 B-Disease
scores	760 6 O
in	767 2 O
the	770 3 O
30	774 2 O
-	776 1 O
mg	777 2 O
bolus	780 5 O
group	786 5 O
and	792 3 O
the	796 3 O
5	800 1 O
-	801 1 O
mg	802 2 O
s	805 1 O
-	806 1 O
1	807 1 O
and	809 3 O
20	813 2 O
-	815 1 O
mg	816 2 O
s	819 1 O
-	820 1 O
1	821 1 O
infusion	823 8 O
groups	832 6 O
were	839 4 O
not	844 3 O
significantly	848 13 O
different	862 9 O
.	871 1 O

Galanthamine	0 12 B-Chemical
hydrobromide	13 12 I-Chemical
,	25 1 O
a	27 1 O
longer	29 6 O
acting	36 6 O
anticholinesterase	43 18 O
drug	62 4 O
,	66 1 O
in	68 2 O
the	71 3 O
treatment	75 9 O
of	85 2 O
the	88 3 O
central	92 7 O
effects	100 7 O
of	108 2 O
scopolamine	111 11 B-Chemical
(	123 1 O
Hyoscine	124 8 B-Chemical
)	132 1 O
.	133 1 O

Galanthamine	135 12 B-Chemical
hydrobromide	148 12 I-Chemical
,	160 1 O
an	162 2 O
anticholinesterase	165 18 O
drug	184 4 O
capable	189 7 O
of	197 2 O
penetrating	200 11 O
the	212 3 O
blood	216 5 O
-	221 1 O
brain	222 5 O
barrier	228 7 O
,	235 1 O
was	237 3 O
used	241 4 O
in	246 2 O
a	249 1 O
patient	251 7 O
demonstrating	259 13 O
central	273 7 O
effects	281 7 O
of	289 2 O
scopolamine	292 11 B-Chemical
(	304 1 O
hyoscine	305 8 B-Chemical
)	313 1 O
overdosage	315 10 B-Disease
.	325 1 O

It	327 2 O
is	330 2 O
longer	333 6 O
acting	340 6 O
than	347 4 O
physostigmine	352 13 B-Chemical
and	366 3 O
is	370 2 O
used	373 4 O
in	378 2 O
anaesthesia	381 11 O
to	393 2 O
reverse	396 7 O
the	404 3 O
non	408 3 O
-	411 1 O
depolarizing	412 12 O
neuromuscular	425 13 O
block	439 5 O
.	444 1 O

However	446 7 O
,	453 1 O
studies	455 7 O
into	463 4 O
the	468 3 O
dose	472 4 O
necessary	477 9 O
to	487 2 O
combating	490 9 O
scopolamine	500 11 B-Chemical
intoxication	512 12 O
are	525 3 O
indicated	529 9 O
.	538 1 O

Effects	0 7 O
of	8 2 O
uninephrectomy	11 14 O
and	26 3 O
high	30 4 O
protein	35 7 O
feeding	43 7 O
on	51 2 O
lithium	54 7 B-Chemical
-	61 1 O
induced	62 7 O
chronic	70 7 B-Disease
renal	78 5 I-Disease
failure	84 7 I-Disease
in	92 2 O
rats	95 4 O
.	99 1 O

Rats	101 4 O
with	106 4 O
lithium	111 7 B-Chemical
-	118 1 O
induced	119 7 O
nephropathy	127 11 B-Disease
were	139 4 O
subjected	144 9 O
to	154 2 O
high	157 4 O
protein	162 7 O
(	170 1 O
HP	171 2 O
)	173 1 O
feeding	175 7 O
,	182 1 O
uninephrectomy	184 14 O
(	199 1 O
NX	200 2 O
)	202 1 O
or	204 2 O
a	207 1 O
combination	209 11 O
of	221 2 O
these	224 5 O
,	229 1 O
in	231 2 O
an	234 2 O
attempt	237 7 O
to	245 2 O
induce	248 6 O
glomerular	255 10 O
hyperfiltration	266 15 O
and	282 3 O
further	286 7 O
progression	294 11 O
of	306 2 O
renal	309 5 B-Disease
failure	315 7 I-Disease
.	322 1 O

Newborn	324 7 O
female	332 6 O
Wistar	339 6 O
rats	346 4 O
were	351 4 O
fed	356 3 O
a	360 1 O
lithium	362 7 B-Chemical
-	369 1 O
containing	370 10 O
diet	381 4 O
(	386 1 O
50	387 2 O
mmol	390 4 O
/	394 1 O
kg	395 2 O
)	397 1 O
for	399 3 O
8	403 1 O
weeks	405 5 O
and	411 3 O
then	415 4 O
randomized	420 10 O
to	431 2 O
normal	434 6 O
diet	441 4 O
,	445 1 O
HP	447 2 O
diet	450 4 O
(	455 1 O
40	456 2 O
vs	459 2 O
.	461 1 O
19	463 2 O
%	465 1 O
)	466 1 O
,	467 1 O
NX	469 2 O
or	472 2 O
HP	475 2 O
+	477 1 O
NX	478 2 O
for	481 3 O
another	485 7 O
8	493 1 O
weeks	495 5 O
.	500 1 O

Corresponding	502 13 O
non	516 3 O
-	519 1 O
lithium	520 7 B-Chemical
pretreated	528 10 O
groups	539 6 O
were	546 4 O
generated	551 9 O
.	560 1 O

When	562 4 O
comparing	567 9 O
all	577 3 O
lithium	581 7 B-Chemical
treated	589 7 O
versus	597 6 O
non	604 3 O
-	607 1 O
lithium	608 7 B-Chemical
-	615 1 O
treated	616 7 O
groups	624 6 O
,	630 1 O
lithium	632 7 B-Chemical
caused	640 6 O
a	647 1 O
reduction	649 9 O
in	659 2 O
glomerular	662 10 O
filtration	673 10 O
rate	684 4 O
(	689 1 O
GFR	690 3 O
)	693 1 O
without	695 7 O
significant	703 11 O
changes	715 7 O
in	723 2 O
effective	726 9 O
renal	736 5 O
plasma	742 6 O
flow	749 4 O
(	754 1 O
as	755 2 O
determined	758 10 O
by	769 2 O
a	772 1 O
marker	774 6 O
secreted	781 8 O
into	790 4 O
the	795 3 O
proximal	799 8 O
tubules	808 7 O
)	815 1 O
or	817 2 O
lithium	820 7 B-Chemical
clearance	828 9 O
.	837 1 O

Consequently	839 12 O
,	851 1 O
lithium	853 7 B-Chemical
pretreatment	861 12 O
caused	874 6 O
a	881 1 O
fall	883 4 O
in	888 2 O
filtration	891 10 O
fraction	902 8 O
and	911 3 O
an	915 2 O
increase	918 8 O
in	927 2 O
fractional	930 10 O
Li	941 2 B-Chemical
excretion	944 9 O
.	953 1 O

Lithium	955 7 B-Chemical
also	963 4 O
caused	968 6 O
proteinuria	975 11 B-Disease
and	987 3 O
systolic	991 8 O
hypertension	1000 12 B-Disease
in	1013 2 O
absence	1016 7 O
of	1024 2 O
glomerulosclerosis	1027 18 B-Disease
.	1045 1 O

HP	1047 2 O
failed	1050 6 O
to	1057 2 O
accentuante	1060 11 O
progression	1072 11 O
of	1084 2 O
renal	1087 5 B-Disease
failure	1093 7 I-Disease
and	1101 3 O
in	1105 2 O
fact	1108 4 O
tended	1113 6 O
to	1120 2 O
increase	1123 8 O
GFR	1132 3 O
and	1136 3 O
decrease	1140 8 O
plasma	1149 6 O
creatinine	1156 10 B-Chemical
levels	1167 6 O
in	1174 2 O
lithium	1177 7 B-Chemical
pretreated	1185 10 O
rats	1196 4 O
.	1200 1 O

NX	1202 2 O
caused	1205 6 O
an	1212 2 O
additive	1215 8 O
deterioration	1224 13 O
in	1238 2 O
GFR	1241 3 O
which	1245 5 O
,	1250 1 O
however	1252 7 O
,	1259 1 O
was	1261 3 O
ameliorated	1265 11 O
by	1277 2 O
HP	1280 2 O
.	1282 1 O

NX	1284 2 O
+	1286 1 O
HP	1287 2 O
caused	1290 6 O
a	1297 1 O
further	1299 7 O
rise	1307 4 O
in	1312 2 O
blood	1315 5 O
pressure	1321 8 O
in	1330 2 O
Li	1333 2 B-Chemical
-	1335 1 O
pretreated	1336 10 O
rats	1347 4 O
.	1351 1 O

The	1353 3 O
results	1357 7 O
indicate	1365 8 O
that	1374 4 O
Li	1379 2 B-Chemical
-	1381 1 O
induced	1382 7 O
nephropathy	1390 11 B-Disease
,	1401 1 O
even	1403 4 O
when	1408 4 O
the	1413 3 O
GFR	1417 3 O
is	1421 2 O
only	1424 4 O
modestly	1429 8 O
reduced	1438 7 O
,	1445 1 O
is	1447 2 O
associated	1450 10 O
with	1461 4 O
proteinuria	1466 11 B-Disease
and	1478 3 O
arterial	1482 8 O
systolic	1491 8 O
hypertension	1500 12 B-Disease
.	1512 1 O

In	1514 2 O
this	1517 4 O
model	1522 5 O
of	1528 2 O
chronic	1531 7 B-Disease
renal	1539 5 I-Disease
failure	1545 7 I-Disease
the	1553 3 O
decline	1557 7 O
in	1565 2 O
GFR	1568 3 O
is	1572 2 O
not	1575 3 O
accompanied	1579 11 O
by	1591 2 O
a	1594 1 O
corresponding	1596 13 O
fall	1610 4 O
in	1615 2 O
effective	1618 9 O
renal	1628 5 O
plasma	1634 6 O
flow	1641 4 O
,	1645 1 O
which	1647 5 O
may	1653 3 O
be	1657 2 O
the	1660 3 O
functional	1664 10 O
expression	1675 10 O
of	1686 2 O
the	1689 3 O
formation	1693 9 O
of	1703 2 O
nonfiltrating	1706 13 O
atubular	1720 8 O
glomeruli	1729 9 O
.	1738 1 O

The	1740 3 O
fractional	1744 10 O
reabsorption	1755 12 O
of	1768 2 O
tubular	1771 7 O
fluid	1779 5 O
by	1785 2 O
the	1788 3 O
proximal	1792 8 O
tubules	1801 7 O
is	1809 2 O
reduced	1812 7 O
,	1819 1 O
leaving	1821 7 O
the	1829 3 O
distal	1833 6 O
delivery	1840 8 O
unchanged	1849 9 O
.	1858 1 O
(	1859 1 O
ABSTRACT	1860 8 O
TRUNCATED	1869 9 O
AT	1879 2 O
250	1882 3 O
WORDS	1886 5 O
)	1891 1 O

Treatment	0 9 O
of	10 2 O
Crohn	13 5 B-Disease
'	18 1 I-Disease
s	19 1 I-Disease
disease	21 7 I-Disease
with	29 4 O
fusidic	34 7 B-Chemical
acid	42 4 I-Chemical
:	46 1 O
an	48 2 O
antibiotic	51 10 O
with	62 4 O
immunosuppressive	67 17 O
properties	85 10 O
similar	96 7 O
to	104 2 O
cyclosporin	107 11 B-Chemical
.	118 1 O

Fusidic	120 7 O
acid	128 4 O
is	133 2 O
an	136 2 O
antibiotic	139 10 O
with	150 4 O
T	155 1 O
-	156 1 O
cell	157 4 O
specific	162 8 O
immunosuppressive	171 17 O
effects	189 7 O
similar	197 7 O
to	205 2 O
those	208 5 O
of	214 2 O
cyclosporin	217 11 B-Chemical
.	228 1 O

Because	230 7 O
of	238 2 O
the	241 3 O
need	245 4 O
for	250 3 O
the	254 3 O
development	258 11 O
of	270 2 O
new	273 3 O
treatments	277 10 O
for	288 3 O
Crohn	292 5 B-Disease
'	297 1 I-Disease
s	298 1 I-Disease
disease	300 7 I-Disease
,	307 1 O
a	309 1 O
pilot	311 5 O
study	317 5 O
was	323 3 O
undertaken	327 10 O
to	338 2 O
estimate	341 8 O
the	350 3 O
pharmacodynamics	354 16 O
and	371 3 O
tolerability	375 12 O
of	388 2 O
fusidic	391 7 B-Chemical
acid	399 4 I-Chemical
treatment	404 9 O
in	414 2 O
chronic	417 7 O
active	425 6 O
,	431 1 O
therapy	433 7 O
-	440 1 O
resistant	441 9 O
patients	451 8 O
.	459 1 O

Eight	461 5 O
Crohn	467 5 B-Disease
'	472 1 I-Disease
s	473 1 I-Disease
disease	475 7 I-Disease
patients	483 8 O
were	492 4 O
included	497 8 O
.	505 1 O

Fusidic	507 7 B-Chemical
acid	515 4 I-Chemical
was	520 3 O
administered	524 12 O
orally	537 6 O
in	544 2 O
a	547 1 O
dose	549 4 O
of	554 2 O
500	557 3 O
mg	561 2 O
t	564 1 O
.	565 1 O
d	566 1 O
.	567 1 O
s	568 1 O
.	569 1 O
and	571 3 O
the	575 3 O
treatment	579 9 O
was	589 3 O
planned	593 7 O
to	601 2 O
last	604 4 O
8	609 1 O
weeks	611 5 O
.	616 1 O

The	618 3 O
disease	622 7 O
activity	630 8 O
was	639 3 O
primarily	643 9 O
measured	653 8 O
by	662 2 O
a	665 1 O
modified	667 8 O
individual	676 10 O
grading	687 7 O
score	695 5 O
.	700 1 O

Five	702 4 O
of	707 2 O
8	710 1 O
patients	712 8 O
(	721 1 O
63	722 2 O
%	724 1 O
)	725 1 O
improved	727 8 O
during	736 6 O
fusidic	743 7 B-Chemical
acid	751 4 I-Chemical
treatment	756 9 O
:	765 1 O
3	767 1 O
at	769 2 O
two	772 3 O
weeks	776 5 O
and	782 3 O
2	786 1 O
after	788 5 O
four	794 4 O
weeks	799 5 O
.	804 1 O

There	806 5 O
were	812 4 O
no	817 2 O
serious	820 7 O
clinical	828 8 O
side	837 4 O
effects	842 7 O
,	849 1 O
but	851 3 O
dose	855 4 O
reduction	860 9 O
was	870 3 O
required	874 8 O
in	883 2 O
two	886 3 O
patients	890 8 O
because	899 7 O
of	907 2 O
nausea	910 6 B-Disease
.	916 1 O

Biochemically	918 13 O
,	931 1 O
an	933 2 O
increase	936 8 O
in	945 2 O
alkaline	948 8 O
phosphatases	957 12 O
was	970 3 O
noted	974 5 O
in	980 2 O
5	983 1 O
of	985 2 O
8	988 1 O
cases	990 5 O
(	996 1 O
63	997 2 O
%	999 1 O
)	1000 1 O
,	1001 1 O
and	1003 3 O
the	1007 3 O
greatest	1011 8 O
increases	1020 9 O
were	1030 4 O
seen	1035 4 O
in	1040 2 O
those	1043 5 O
who	1049 3 O
had	1053 3 O
elevated	1057 8 O
levels	1066 6 O
prior	1073 5 O
to	1079 2 O
treatment	1082 9 O
.	1091 1 O

All	1093 3 O
reversed	1097 8 O
to	1106 2 O
pre	1109 3 O
-	1112 1 O
treatment	1113 9 O
levels	1123 6 O
after	1130 5 O
cessation	1136 9 O
of	1146 2 O
treatment	1149 9 O
.	1158 1 O

The	1160 3 O
results	1164 7 O
of	1172 2 O
this	1175 4 O
pilot	1180 5 O
study	1186 5 O
suggest	1192 7 O
that	1200 4 O
fusidic	1205 7 B-Chemical
acid	1213 4 I-Chemical
may	1218 3 O
be	1222 2 O
of	1225 2 O
benefit	1228 7 O
in	1236 2 O
selected	1239 8 O
chronic	1248 7 O
active	1256 6 O
Crohn	1263 5 B-Disease
'	1268 1 I-Disease
s	1269 1 I-Disease
disease	1271 7 I-Disease
patients	1279 8 O
in	1288 2 O
whom	1291 4 O
conventional	1296 12 O
treatment	1309 9 O
is	1319 2 O
ineffective	1322 11 O
.	1333 1 O

Because	1335 7 O
there	1343 5 O
seems	1349 5 O
to	1355 2 O
exist	1358 5 O
a	1364 1 O
scientific	1366 10 O
rationale	1377 9 O
for	1387 3 O
the	1391 3 O
use	1395 3 O
of	1399 2 O
fusidic	1402 7 B-Chemical
acid	1410 4 I-Chemical
at	1415 2 O
the	1418 3 O
cytokine	1422 8 O
level	1431 5 O
in	1437 2 O
inflammatory	1440 12 B-Disease
bowel	1453 5 I-Disease
disease	1459 7 I-Disease
,	1466 1 O
we	1468 2 O
suggest	1471 7 O
that	1479 4 O
the	1484 3 O
role	1488 4 O
of	1493 2 O
this	1496 4 O
treatment	1501 9 O
should	1511 6 O
be	1518 2 O
further	1521 7 O
investigated	1529 12 O
.	1541 1 O

Electrocardiographic	0 20 O
evidence	21 8 O
of	30 2 O
myocardial	33 10 B-Disease
injury	44 6 I-Disease
in	51 2 O
psychiatrically	54 15 O
hospitalized	70 12 O
cocaine	83 7 B-Chemical
abusers	91 7 O
.	98 1 O

The	100 3 O
electrocardiograms	104 18 O
(	123 1 O
ECG	124 3 O
)	127 1 O
of	129 2 O
99	132 2 O
cocaine	135 7 B-Chemical
-	142 1 O
abusing	143 7 O
patients	151 8 O
were	160 4 O
compared	165 8 O
with	174 4 O
the	179 3 O
ECGs	183 4 O
of	188 2 O
50	191 2 O
schizophrenic	194 13 B-Disease
controls	208 8 O
.	216 1 O

Eleven	218 6 O
of	225 2 O
the	228 3 O
cocaine	232 7 B-Chemical
abusers	240 7 O
and	248 3 O
none	252 4 O
of	257 2 O
the	260 3 O
controls	264 8 O
had	273 3 O
ECG	277 3 O
evidence	281 8 O
of	290 2 O
significant	293 11 O
myocardial	305 10 B-Disease
injury	316 6 I-Disease
defined	323 7 O
as	331 2 O
myocardial	334 10 B-Disease
infarction	345 10 I-Disease
,	355 1 O
ischemia	357 8 B-Disease
,	365 1 O
and	367 3 O
bundle	371 6 B-Disease
branch	378 6 I-Disease
block	385 5 I-Disease
.	390 1 O

Sulpiride	0 9 B-Chemical
-	9 1 O
induced	10 7 O
tardive	18 7 B-Disease
dystonia	26 8 I-Disease
.	34 1 O

Sulpiride	36 9 B-Chemical
is	46 2 O
a	49 1 O
selective	51 9 O
D2	61 2 O
-	63 1 O
receptor	64 8 O
antagonist	73 10 O
with	84 4 O
antipsychotic	89 13 O
and	103 3 O
antidepressant	107 14 B-Chemical
properties	122 10 O
.	132 1 O

Although	134 8 O
initially	143 9 O
thought	153 7 O
to	161 2 O
be	164 2 O
free	167 4 O
of	172 2 O
extrapyramidal	175 14 O
side	190 4 O
effects	195 7 O
,	202 1 O
sulpiride	204 9 B-Chemical
-	213 1 O
induced	214 7 O
tardive	222 7 B-Disease
dyskinesia	230 10 I-Disease
and	241 3 O
parkinsonism	245 12 B-Disease
have	258 4 O
been	263 4 O
reported	268 8 O
occasionally	277 12 O
.	289 1 O

We	291 2 O
studied	294 7 O
a	302 1 O
37	304 2 O
-	306 1 O
year	307 4 O
-	311 1 O
old	312 3 O
man	316 3 O
who	320 3 O
developed	324 9 O
persistent	334 10 O
segmental	345 9 O
dystonia	355 8 B-Disease
within	364 6 O
2	371 1 O
months	373 6 O
after	380 5 O
starting	386 8 O
sulpiride	395 9 B-Chemical
therapy	405 7 O
.	412 1 O

We	414 2 O
could	417 5 O
not	423 3 O
find	427 4 O
any	432 3 O
previous	436 8 O
reports	445 7 O
of	453 2 O
sulpiride	456 9 B-Chemical
-	465 1 O
induced	466 7 O
tardive	474 7 B-Disease
dystonia	482 8 I-Disease
.	490 1 O

Ocular	0 6 B-Disease
and	7 3 I-Disease
auditory	11 8 I-Disease
toxicity	20 8 I-Disease
in	29 2 O
hemodialyzed	32 12 O
patients	45 8 O
receiving	54 9 O
desferrioxamine	64 15 B-Chemical
.	79 1 O

During	81 6 O
an	88 2 O
18	91 2 O
-	93 1 O
month	94 5 O
period	100 6 O
of	107 2 O
study	110 5 O
41	116 2 O
hemodialyzed	119 12 O
patients	132 8 O
receiving	141 9 O
desferrioxamine	151 15 B-Chemical
(	167 1 O
10	168 2 O
-	170 1 O
40	171 2 O
mg	174 2 O
/	176 1 O
kg	177 2 O
BW	180 2 O
/	182 1 O
3	183 1 O
times	185 5 O
weekly	191 6 O
)	197 1 O
for	199 3 O
the	203 3 O
first	207 5 O
time	213 4 O
were	218 4 O
monitored	223 9 O
for	233 3 O
detection	237 9 O
of	247 2 O
audiovisual	250 11 B-Disease
toxicity	262 8 I-Disease
.	270 1 O

6	272 1 O
patients	274 8 O
presented	283 9 O
clinical	293 8 O
symptoms	302 8 O
of	311 2 O
visual	314 6 B-Disease
or	321 2 I-Disease
auditory	324 8 I-Disease
toxicity	333 8 I-Disease
.	341 1 O

Moreover	343 8 O
,	351 1 O
detailed	353 8 O
ophthalmologic	362 14 O
and	377 3 O
audiologic	381 10 O
studies	392 7 O
disclosed	400 9 O
abnormalities	410 13 O
in	424 2 O
7	427 1 O
more	429 4 O
asymptomatic	434 12 O
patients	447 8 O
.	455 1 O

Visual	457 6 B-Disease
toxicity	464 8 I-Disease
was	473 3 O
of	477 2 O
retinal	480 7 O
origin	488 6 O
and	495 3 O
was	499 3 O
characterized	503 13 O
by	517 2 O
a	520 1 O
tritan	522 6 O
-	528 1 O
type	529 4 O
dyschromatopsy	534 14 B-Disease
,	548 1 O
sometimes	550 9 O
associated	560 10 O
with	571 4 O
a	576 1 B-Disease
loss	578 4 I-Disease
of	583 2 I-Disease
visual	586 6 I-Disease
acuity	593 6 I-Disease
and	600 3 O
pigmentary	604 10 B-Disease
retinal	615 7 I-Disease
deposits	623 8 I-Disease
.	631 1 O

Auditory	633 8 B-Disease
toxicity	642 8 I-Disease
was	651 3 O
characterized	655 13 O
by	669 2 O
a	672 1 O
mid	674 3 O
-	677 1 O
to	679 2 O
high	682 4 O
-	686 1 O
frequency	687 9 O
neurosensorial	697 14 B-Disease
hearing	712 7 I-Disease
loss	720 4 I-Disease
and	725 3 O
the	729 3 O
lesion	733 6 O
was	740 3 O
of	744 2 O
the	747 3 O
cochlear	751 8 O
type	760 4 O
.	764 1 O

Desferrioxamine	766 15 B-Chemical
withdrawal	782 10 O
resulted	793 8 O
in	802 2 O
a	805 1 O
complete	807 8 O
recovery	816 8 O
of	825 2 O
visual	828 6 O
function	835 8 O
in	844 2 O
1	847 1 O
patient	849 7 O
and	857 3 O
partial	861 7 O
recovery	869 8 O
in	878 2 O
3	881 1 O
,	882 1 O
and	884 3 O
a	888 1 O
complete	890 8 O
reversal	899 8 O
of	908 2 O
hearing	911 7 B-Disease
loss	919 4 I-Disease
in	924 2 O
3	927 1 O
patients	929 8 O
and	938 3 O
partial	942 7 O
recovery	950 8 O
in	959 2 O
3	962 1 O
.	963 1 O

This	965 4 O
toxicity	970 8 B-Disease
appeared	979 8 O
in	988 2 O
patients	991 8 O
receiving	1000 9 O
the	1010 3 O
higher	1014 6 O
doses	1021 5 O
of	1027 2 O
desferrioxamine	1030 15 B-Chemical
or	1046 2 O
coincided	1049 9 O
with	1059 4 O
the	1064 3 O
normalization	1068 13 O
of	1082 2 O
ferritin	1085 8 O
or	1094 2 O
aluminium	1097 9 B-Chemical
serum	1107 5 O
levels	1113 6 O
.	1119 1 O

The	1121 3 O
data	1125 4 O
indicate	1130 8 O
that	1139 4 O
audiovisual	1144 11 B-Disease
toxicity	1156 8 I-Disease
is	1165 2 O
not	1168 3 O
an	1172 2 O
infrequent	1175 10 O
complication	1186 12 O
in	1199 2 O
hemodialyzed	1202 12 O
patients	1215 8 O
receiving	1224 9 O
desferrioxamine	1234 15 B-Chemical
.	1249 1 O

Periodical	1251 10 O
audiovisual	1262 11 O
monitoring	1274 10 O
should	1285 6 O
be	1292 2 O
performed	1295 9 O
on	1305 2 O
hemodialyzed	1308 12 O
patients	1321 8 O
receiving	1330 9 O
the	1340 3 O
drug	1344 4 O
in	1349 2 O
order	1352 5 O
to	1358 2 O
detect	1361 6 O
adverse	1368 7 O
effects	1376 7 O
as	1384 2 O
early	1387 5 O
as	1393 2 O
possible	1396 8 O
.	1404 1 O

Myasthenia	0 10 B-Disease
gravis	11 6 I-Disease
presenting	18 10 O
as	29 2 O
weakness	32 8 O
after	41 5 O
magnesium	47 9 B-Chemical
administration	57 14 O
.	71 1 O

We	73 2 O
studied	76 7 O
a	84 1 O
patient	86 7 O
with	94 4 O
no	99 2 O
prior	102 5 O
history	108 7 O
of	116 2 O
neuromuscular	119 13 B-Disease
disease	133 7 I-Disease
who	141 3 O
became	145 6 O
virtually	152 9 O
quadriplegic	162 12 B-Disease
after	175 5 O
parenteral	181 10 O
magnesium	192 9 B-Chemical
administration	202 14 O
for	217 3 O
preeclampsia	221 12 B-Disease
.	233 1 O

The	235 3 O
serum	239 5 O
magnesium	245 9 B-Chemical
concentration	255 13 O
was	269 3 O
3	273 1 O
.	274 1 O
0	275 1 O
mEq	277 3 O
/	280 1 O
L	281 1 O
,	282 1 O
which	284 5 O
is	290 2 O
usually	293 7 O
well	301 4 O
tolerated	306 9 O
.	315 1 O

The	317 3 O
magnesium	321 9 B-Chemical
was	331 3 O
stopped	335 7 O
and	343 3 O
she	347 3 O
recovered	351 9 O
over	361 4 O
a	366 1 O
few	368 3 O
days	372 4 O
.	376 1 O

While	378 5 O
she	384 3 O
was	388 3 O
weak	392 4 O
,	396 1 O
2	398 1 O
-	399 1 O
Hz	400 2 O
repetitive	403 10 O
stimulation	414 11 O
revealed	426 8 O
a	435 1 O
decrement	437 9 O
without	447 7 O
significant	455 11 O
facilitation	467 12 O
at	480 2 O
rapid	483 5 O
rates	489 5 O
or	495 2 O
after	498 5 O
exercise	504 8 O
,	512 1 O
suggesting	514 10 O
postsynaptic	525 12 B-Disease
neuromuscular	538 13 I-Disease
blockade	552 8 I-Disease
.	560 1 O

After	562 5 O
her	568 3 O
strength	572 8 O
returned	581 8 O
,	589 1 O
repetitive	591 10 O
stimulation	602 11 O
was	614 3 O
normal	618 6 O
,	624 1 O
but	626 3 O
single	630 6 O
fiber	637 5 O
EMG	643 3 O
revealed	647 8 O
increased	656 9 O
jitter	666 6 O
and	673 3 O
blocking	677 8 O
.	685 1 O

Her	687 3 O
acetylcholine	691 13 B-Chemical
receptor	705 8 O
antibody	714 8 O
level	723 5 O
was	729 3 O
markedly	733 8 O
elevated	742 8 O
.	750 1 O

Although	752 8 O
paralysis	761 9 B-Disease
after	771 5 O
magnesium	777 9 B-Chemical
administration	787 14 O
has	802 3 O
been	806 4 O
described	811 9 O
in	821 2 O
patients	824 8 O
with	833 4 O
known	838 5 O
myasthenia	844 10 B-Disease
gravis	855 6 I-Disease
,	861 1 O
it	863 2 O
has	866 3 O
not	870 3 O
previously	874 10 O
been	885 4 O
reported	890 8 O
to	899 2 O
be	902 2 O
the	905 3 O
initial	909 7 O
or	917 2 O
only	920 4 O
manifestation	925 13 O
of	939 2 O
the	942 3 O
disease	946 7 O
.	953 1 O

Patients	955 8 O
who	964 3 O
are	968 3 O
unusually	972 9 O
sensitive	982 9 O
to	992 2 O
the	995 3 O
neuromuscular	999 13 O
effects	1013 7 O
of	1021 2 O
magnesium	1024 9 B-Chemical
should	1034 6 O
be	1041 2 O
suspected	1044 9 O
of	1054 2 O
having	1057 6 O
an	1064 2 O
underlying	1067 10 O
disorder	1078 8 B-Disease
of	1087 2 I-Disease
neuromuscular	1090 13 I-Disease
transmission	1104 12 I-Disease
.	1116 1 O

Chloroacetaldehyde	0 18 B-Chemical
and	19 3 O
its	23 3 O
contribution	27 12 O
to	40 2 O
urotoxicity	43 11 O
during	55 6 O
treatment	62 9 O
with	72 4 O
cyclophosphamide	77 16 B-Chemical
or	94 2 O
ifosfamide	97 10 B-Chemical
.	107 1 O

An	109 2 O
experimental	112 12 O
study	125 5 O
/	130 1 O
short	131 5 O
communication	137 13 O
.	150 1 O

Based	152 5 O
on	158 2 O
clinical	161 8 O
data	170 4 O
,	174 1 O
indicating	176 10 O
that	187 4 O
chloroacetaldehyde	192 18 B-Chemical
(	211 1 O
CAA	212 3 B-Chemical
)	215 1 O
is	217 2 O
an	220 2 O
important	223 9 O
metabolite	233 10 O
of	244 2 O
oxazaphosphorine	247 16 O
cytostatics	264 11 O
,	275 1 O
an	277 2 O
experimental	280 12 O
study	293 5 O
was	299 3 O
carried	303 7 O
out	311 3 O
in	315 2 O
order	318 5 O
to	324 2 O
elucidate	327 9 O
the	337 3 O
role	341 4 O
of	346 2 O
CAA	349 3 B-Chemical
in	353 2 O
the	356 3 O
development	360 11 O
of	372 2 O
hemorrhagic	375 11 B-Disease
cystitis	387 8 I-Disease
.	395 1 O

The	397 3 O
data	401 4 O
demonstrate	406 11 O
that	418 4 O
CAA	423 3 B-Chemical
after	427 5 O
i	433 1 O
.	434 1 O
v	435 1 O
.	436 1 O
administration	438 14 O
does	453 4 O
not	458 3 O
contribute	462 10 O
to	473 2 O
bladder	476 7 B-Disease
damage	484 6 I-Disease
.	490 1 O

When	492 4 O
instilled	497 9 O
directly	507 8 O
into	516 4 O
the	521 3 O
bladder	525 7 O
,	532 1 O
CAA	534 3 B-Chemical
exerts	538 6 O
urotoxic	545 8 O
effects	554 7 O
,	561 1 O
it	563 2 O
is	566 2 O
,	568 1 O
however	570 7 O
,	577 1 O
susceptible	579 11 O
to	591 2 O
detoxification	594 14 O
with	609 4 O
mesna	614 5 B-Chemical
.	619 1 O

Source	0 6 O
of	7 2 O
pain	10 4 B-Disease
and	15 3 O
primitive	19 9 O
dysfunction	29 11 O
in	41 2 O
migraine	44 8 B-Disease
:	52 1 O
an	54 2 O
identical	57 9 O
site	67 4 O
?	71 1 O

Twenty	73 6 O
common	80 6 O
migraine	87 8 B-Disease
patients	96 8 O
received	105 8 O
a	114 1 O
one	116 3 O
sided	120 5 O
frontotemporal	126 14 O
application	141 11 O
of	153 2 O
nitroglycerin	156 13 B-Chemical
(	170 1 O
10	171 2 O
patients	174 8 O
)	182 1 O
or	184 2 O
placebo	187 7 O
ointment	195 8 O
(	204 1 O
10	205 2 O
patients	208 8 O
)	216 1 O
in	218 2 O
a	221 1 O
double	223 6 O
blind	230 5 O
study	236 5 O
.	241 1 O

Early	243 5 O
onset	249 5 O
migraine	255 8 B-Disease
attacks	264 7 O
were	272 4 O
induced	277 7 O
by	285 2 O
nitroglycerin	288 13 B-Chemical
in	302 2 O
seven	305 5 O
out	311 3 O
of	315 2 O
10	318 2 O
patients	321 8 O
versus	330 6 O
no	337 2 O
patient	340 7 O
in	348 2 O
the	351 3 O
placebo	355 7 O
group	363 5 O
.	368 1 O

Subsequently	370 12 O
20	383 2 O
migraine	386 8 B-Disease
patients	395 8 O
,	403 1 O
who	405 3 O
developed	409 9 O
an	419 2 O
early	422 5 O
onset	428 5 O
attack	434 6 O
with	441 4 O
frontotemporal	446 14 O
nitroglycerin	461 13 B-Chemical
,	474 1 O
received	476 8 O
the	485 3 O
drug	489 4 O
in	494 2 O
a	497 1 O
second	499 6 O
induction	506 9 O
test	516 4 O
at	521 2 O
other	524 5 O
body	530 4 O
areas	535 5 O
.	540 1 O

No	542 2 O
early	545 5 O
onset	551 5 O
migraine	557 8 B-Disease
was	566 3 O
observed	570 8 O
.	578 1 O

Thus	580 4 O
the	585 3 O
migraine	589 8 B-Disease
-	597 1 O
inducing	598 8 O
effect	607 6 O
of	614 2 O
nitroglycerin	617 13 B-Chemical
seems	631 5 O
to	637 2 O
depend	640 6 O
on	647 2 O
direct	650 6 O
stimulation	657 11 O
of	669 2 O
the	672 3 O
habitual	676 8 O
site	685 4 O
of	690 2 O
pain	693 4 B-Disease
,	697 1 O
suggesting	699 10 O
that	710 4 O
the	715 3 O
frontotemporal	719 14 O
region	734 6 O
is	741 2 O
of	744 2 O
crucial	747 7 O
importance	755 10 O
in	766 2 O
the	769 3 O
development	773 11 O
of	785 2 O
a	788 1 O
migraine	790 8 B-Disease
crisis	799 6 O
.	805 1 O

This	807 4 O
is	812 2 O
not	815 3 O
consistent	819 10 O
with	830 4 O
a	835 1 O
CNS	837 3 O
origin	841 6 O
of	848 2 O
migraine	851 8 B-Disease
attack	860 6 O
.	866 1 O

Clotiazepam	0 11 B-Chemical
-	11 1 O
induced	12 7 O
acute	20 5 O
hepatitis	26 9 B-Disease
.	35 1 O

We	37 2 O
report	40 6 O
the	47 3 O
case	51 4 O
of	56 2 O
a	59 1 O
patient	61 7 O
who	69 3 O
developed	73 9 O
acute	83 5 O
hepatitis	89 9 B-Disease
with	99 4 O
extensive	104 9 B-Disease
hepatocellular	114 14 I-Disease
necrosis	129 8 I-Disease
,	137 1 O
7	139 1 O
months	141 6 O
after	148 5 O
the	154 3 O
onset	158 5 O
of	164 2 O
administration	167 14 O
of	182 2 O
clotiazepam	185 11 B-Chemical
,	196 1 O
a	198 1 O
thienodiazepine	200 15 B-Chemical
derivative	216 10 O
.	226 1 O

Clotiazepam	228 11 B-Chemical
withdrawal	240 10 O
was	251 3 O
followed	255 8 O
by	264 2 O
prompt	267 6 O
recovery	274 8 O
.	282 1 O

The	284 3 O
administration	288 14 O
of	303 2 O
several	306 7 O
benzodiazepines	314 15 B-Chemical
,	329 1 O
chemically	331 10 O
related	342 7 O
to	350 2 O
clotiazepam	353 11 B-Chemical
,	364 1 O
did	366 3 O
not	370 3 O
interfere	374 9 O
with	384 4 O
recovery	389 8 O
and	398 3 O
did	402 3 O
not	406 3 O
induce	410 6 O
any	417 3 O
relapse	421 7 O
of	429 2 O
hepatitis	432 9 B-Disease
.	441 1 O

This	443 4 O
observation	448 11 O
shows	460 5 O
that	466 4 O
clotiazepam	471 11 B-Chemical
can	483 3 O
induce	487 6 O
acute	494 5 O
hepatitis	500 9 B-Disease
and	510 3 O
suggests	514 8 O
that	523 4 O
there	528 5 O
is	534 2 O
no	537 2 O
cross	540 5 O
hepatotoxicity	546 14 B-Disease
between	561 7 O
clotiazepam	569 11 B-Chemical
and	581 3 O
several	585 7 O
benzodiazepines	593 15 B-Chemical
.	608 1 O

Arterial	0 8 O
hypertension	9 12 B-Disease
as	22 2 O
a	25 1 O
complication	27 12 O
of	40 2 O
prolonged	43 9 O
ketoconazole	53 12 B-Chemical
treatment	66 9 O
.	75 1 O

Two	77 3 O
of	81 2 O
14	84 2 O
patients	87 8 O
with	96 4 O
Cushing	101 7 B-Disease
'	108 1 I-Disease
s	109 1 I-Disease
syndrome	111 8 I-Disease
treated	120 7 O
on	128 2 O
a	131 1 O
long	133 4 O
-	137 1 O
term	138 4 O
basis	143 5 O
with	149 4 O
ketoconazole	154 12 B-Chemical
developed	167 9 O
sustained	177 9 O
hypertension	187 12 B-Disease
.	199 1 O

In	201 2 O
both	204 4 O
cases	209 5 O
normal	215 6 O
plasma	222 6 O
and	229 3 O
urinary	233 7 O
free	241 4 O
cortisol	246 8 B-Chemical
levels	255 6 O
had	262 3 O
been	266 4 O
achieved	271 8 O
following	280 9 O
ketoconazole	290 12 B-Chemical
therapy	303 7 O
,	310 1 O
yet	312 3 O
continuous	316 10 O
blood	327 5 O
pressure	333 8 O
monitoring	342 10 O
demonstrated	353 12 O
hypertension	366 12 B-Disease
31	379 2 O
(	382 1 O
patient	383 7 O
1	391 1 O
)	392 1 O
and	394 3 O
52	398 2 O
weeks	401 5 O
(	407 1 O
patient	408 7 O
2	416 1 O
)	417 1 O
after	419 5 O
treatment	425 9 O
.	434 1 O

In	436 2 O
patient	439 7 O
1	447 1 O
,	448 1 O
plasma	450 6 O
levels	457 6 O
of	464 2 O
deoxycorticosterone	467 19 B-Chemical
and	487 3 O
11	491 2 B-Chemical
-	493 1 I-Chemical
deoxycortisol	494 13 I-Chemical
were	508 4 O
elevated	513 8 O
.	521 1 O

In	523 2 O
patient	526 7 O
2	534 1 O
,	535 1 O
in	537 2 O
addition	540 8 O
to	549 2 O
an	552 2 O
increase	555 8 O
in	564 2 O
both	567 4 O
deoxycorticosterone	572 19 B-Chemical
and	592 3 O
11	596 2 B-Chemical
-	598 1 I-Chemical
deoxycortisol	599 13 I-Chemical
levels	613 6 O
,	619 1 O
plasma	621 6 O
aldosterone	628 11 B-Chemical
values	640 6 O
were	647 4 O
raised	652 6 O
,	658 1 O
with	660 4 O
a	665 1 O
concomitant	667 11 O
suppression	679 11 O
of	691 2 O
renin	694 5 O
levels	700 6 O
.	706 1 O

Our	708 3 O
findings	712 8 O
show	721 4 O
that	726 4 O
long	731 4 O
-	735 1 O
term	736 4 O
treatment	741 9 O
with	751 4 O
high	756 4 O
doses	761 5 O
of	767 2 O
ketoconazole	770 12 B-Chemical
may	783 3 O
induce	787 6 O
enzyme	794 6 O
blockade	801 8 O
leading	810 7 O
to	818 2 O
mineralocorticoid	821 17 O
-	838 1 O
related	839 7 O
hypertension	847 12 B-Disease
.	859 1 O

Effects	0 7 O
of	8 2 O
an	11 2 O
inhibitor	14 9 O
of	24 2 O
angiotensin	27 11 B-Chemical
converting	39 10 O
enzyme	50 6 O
(	57 1 O
Captopril	58 9 B-Chemical
)	67 1 O
on	69 2 O
pulmonary	72 9 B-Disease
and	82 3 I-Disease
renal	86 5 I-Disease
insufficiency	92 13 I-Disease
due	106 3 O
to	110 2 O
intravascular	113 13 B-Disease
coagulation	127 11 I-Disease
in	139 2 O
the	142 3 O
rat	146 3 O
.	149 1 O

Induction	151 9 O
of	161 2 O
intravascular	164 13 B-Disease
coagulation	178 11 I-Disease
and	190 3 O
inhibition	194 10 O
of	205 2 O
fibrinolysis	208 12 O
by	221 2 O
injection	224 9 O
of	234 2 O
thrombin	237 8 O
and	246 3 O
tranexamic	250 10 B-Chemical
acid	261 4 I-Chemical
(	266 1 O
AMCA	267 4 B-Chemical
)	271 1 O
in	273 2 O
the	276 3 O
rat	280 3 O
gives	284 5 O
rise	290 4 O
to	295 2 O
pulmonary	298 9 B-Disease
and	308 3 I-Disease
renal	312 5 I-Disease
insufficiency	318 13 I-Disease
resembling	332 10 O
that	343 4 O
occurring	348 9 O
after	358 5 O
trauma	364 6 B-Disease
or	371 2 O
sepsis	374 6 B-Disease
in	381 2 O
man	384 3 O
.	387 1 O

Injection	389 9 O
of	399 2 O
Captopril	402 9 B-Chemical
(	412 1 O
1	413 1 O
mg	415 2 O
/	417 1 O
kg	418 2 O
)	420 1 O
,	421 1 O
an	423 2 O
inhibitor	426 9 O
of	436 2 O
angiotensin	439 11 B-Chemical
converting	451 10 O
enzyme	462 6 O
(	469 1 O
ACE	470 3 O
)	473 1 O
,	474 1 O
reduced	476 7 O
both	484 4 O
pulmonary	489 9 B-Disease
and	499 3 I-Disease
renal	503 5 I-Disease
insufficiency	509 13 I-Disease
in	523 2 O
this	526 4 O
rat	531 3 O
model	535 5 O
.	540 1 O

The	542 3 O
lung	546 4 O
weights	551 7 O
were	559 4 O
lower	564 5 O
and	570 3 O
PaO2	574 4 O
was	579 3 O
improved	583 8 O
in	592 2 O
rats	595 4 O
given	600 5 O
this	606 4 O
enzyme	611 6 O
-	617 1 O
blocking	618 8 O
agent	627 5 O
.	632 1 O

The	634 3 O
contents	638 8 O
of	647 2 O
albumin	650 7 O
in	658 2 O
the	661 3 O
lungs	665 5 O
were	671 4 O
not	676 3 O
changed	680 7 O
,	687 1 O
indicating	689 10 O
that	700 4 O
Captopril	705 9 B-Chemical
did	715 3 O
not	719 3 O
influence	723 9 O
the	733 3 O
extravasation	737 13 O
of	751 2 O
protein	754 7 O
.	761 1 O

Renal	763 5 B-Disease
damage	769 6 I-Disease
as	776 2 O
reflected	779 9 O
by	789 2 O
an	792 2 O
increase	795 8 O
in	804 2 O
serum	807 5 O
urea	813 4 B-Chemical
and	818 3 O
in	822 2 O
kidney	825 6 O
weight	832 6 O
was	839 3 O
prevented	843 9 O
by	853 2 O
Captopril	856 9 B-Chemical
.	865 1 O

The	867 3 O
amount	871 6 O
of	878 2 O
fibrin	881 6 O
in	888 2 O
the	891 3 O
kidneys	895 7 O
was	903 3 O
also	907 4 O
considerably	912 12 O
lower	925 5 O
than	931 4 O
in	936 2 O
animals	939 7 O
which	947 5 O
received	953 8 O
thrombin	962 8 O
and	971 3 O
AMCA	975 4 B-Chemical
alone	980 5 O
.	985 1 O

It	987 2 O
is	990 2 O
suggested	993 9 O
that	1003 4 O
the	1008 3 O
effects	1012 7 O
of	1020 2 O
Captopril	1023 9 B-Chemical
on	1033 2 O
the	1036 3 O
lungs	1040 5 O
may	1046 3 O
be	1050 2 O
attributable	1053 12 O
to	1066 2 O
a	1069 1 O
vasodilatory	1071 12 O
effect	1084 6 O
due	1091 3 O
to	1095 2 O
a	1098 1 O
reduction	1100 9 O
in	1110 2 O
the	1113 3 O
circulating	1117 11 O
level	1129 5 O
of	1135 2 O
Angiotension	1138 12 B-Chemical
II	1151 2 I-Chemical
and	1154 3 O
an	1158 2 O
increase	1161 8 O
in	1170 2 O
prostacyclin	1173 12 B-Chemical
(	1186 1 O
secondary	1187 9 O
to	1197 2 O
an	1200 2 O
increase	1203 8 O
in	1212 2 O
bradykinin	1215 10 B-Chemical
)	1225 1 O
.	1226 1 O

Captopril	1228 9 B-Chemical
may	1238 3 O
,	1241 1 O
by	1243 2 O
the	1246 3 O
same	1250 4 O
mechanism	1255 9 O
,	1264 1 O
reduce	1266 6 O
the	1273 3 O
increase	1277 8 O
in	1286 2 O
glomerular	1289 10 O
filtration	1300 10 O
that	1311 4 O
is	1316 2 O
known	1319 5 O
to	1325 2 O
occur	1328 5 O
after	1334 5 O
an	1340 2 O
injection	1343 9 O
of	1353 2 O
thrombin	1356 8 O
,	1364 1 O
thereby	1366 7 O
diminishing	1374 11 O
the	1386 3 O
aggregation	1390 11 O
of	1402 2 O
fibrin	1405 6 O
monomers	1412 8 O
in	1421 2 O
the	1424 3 O
glomeruli	1428 9 O
,	1437 1 O
with	1439 4 O
the	1444 3 O
result	1448 6 O
that	1455 4 O
less	1460 4 O
fibrin	1465 6 O
will	1472 4 O
be	1477 2 O
deposited	1480 9 O
and	1490 3 O
thus	1494 4 O
less	1499 4 O
kidney	1504 6 B-Disease
damage	1511 6 I-Disease
will	1518 4 O
be	1523 2 O
produced	1526 8 O
.	1534 1 O

A	0 1 O
randomized	2 10 O
comparison	13 10 O
of	24 2 O
labetalol	27 9 B-Chemical
and	37 3 O
nitroprusside	41 13 B-Chemical
for	55 3 O
induced	59 7 O
hypotension	67 11 B-Disease
.	78 1 O

In	80 2 O
a	83 1 O
randomized	85 10 O
study	96 5 O
,	101 1 O
labetalol	103 9 B-Chemical
-	112 1 O
induced	113 7 O
hypotension	121 11 B-Disease
and	133 3 O
nitroprusside	137 13 B-Chemical
-	150 1 O
induced	151 7 O
hypotension	159 11 B-Disease
were	171 4 O
compared	176 8 O
in	185 2 O
20	188 2 O
patients	191 8 O
(	200 1 O
10	201 2 O
in	204 2 O
each	207 4 O
group	212 5 O
)	217 1 O
scheduled	219 9 O
for	229 3 O
major	233 5 O
orthopedic	239 10 O
procedures	250 10 O
.	260 1 O

Each	262 4 O
patient	267 7 O
was	275 3 O
subjected	279 9 O
to	289 2 O
an	292 2 O
identical	295 9 O
anesthetic	305 10 O
protocol	316 8 O
and	325 3 O
similar	329 7 O
drug	337 4 O
-	341 1 O
induced	342 7 O
reductions	350 10 B-Disease
in	361 2 I-Disease
mean	364 4 I-Disease
arterial	369 8 I-Disease
blood	378 5 I-Disease
pressure	384 8 I-Disease
(	393 1 O
BP	394 2 O
)	396 1 O
(	398 1 O
50	399 2 O
to	402 2 O
55	405 2 O
mmHg	408 4 O
)	412 1 O
.	413 1 O

Nitroprusside	415 13 O
infusion	429 8 O
was	438 3 O
associated	442 10 O
with	453 4 O
a	458 1 O
significant	460 11 O
(	472 1 O
p	473 1 O
less	475 4 O
than	480 4 O
0	485 1 O
.	486 1 O
05	487 2 O
)	489 1 O
increase	491 8 B-Disease
in	500 2 I-Disease
heart	503 5 I-Disease
rate	509 4 I-Disease
and	514 3 I-Disease
cardiac	518 7 I-Disease
output	526 6 I-Disease
;	532 1 O
rebound	534 7 O
hypertension	542 12 B-Disease
was	555 3 O
observed	559 8 O
in	568 2 O
three	571 5 O
patients	577 8 O
after	586 5 O
discontinuation	592 15 O
of	608 2 O
nitroprusside	611 13 B-Chemical
.	624 1 O

Labetalol	626 9 B-Chemical
administration	636 14 O
was	651 3 O
not	655 3 O
associated	659 10 O
with	670 4 O
any	675 3 O
of	679 2 O
these	682 5 O
findings	688 8 O
.	696 1 O

Arterial	698 8 O
PO2	707 3 B-Chemical
decreased	711 9 O
in	721 2 O
both	724 4 O
groups	729 6 O
.	735 1 O

It	737 2 O
was	740 3 O
concluded	744 9 O
that	754 4 O
labetalol	759 9 B-Chemical
offers	769 6 O
advantages	776 10 O
over	787 4 O
nitroprusside	792 13 B-Chemical
.	805 1 O

Chronic	0 7 O
carbamazepine	8 13 B-Chemical
treatment	22 9 O
in	32 2 O
the	35 3 O
rat	39 3 O
:	42 1 O
efficacy	44 8 O
,	52 1 O
toxicity	54 8 B-Disease
,	62 1 O
and	64 3 O
effect	68 6 O
on	75 2 O
plasma	78 6 O
and	85 3 O
tissue	89 6 O
folate	96 6 B-Chemical
concentrations	103 14 O
.	117 1 O

Folate	119 6 B-Chemical
depletion	126 9 O
has	136 3 O
often	140 5 O
been	146 4 O
a	151 1 O
problem	153 7 O
in	161 2 O
chronic	164 7 O
antiepileptic	172 13 O
drug	186 4 O
(	191 1 O
AED	192 3 O
)	195 1 O
therapy	197 7 O
.	204 1 O

Carbamazepine	206 13 B-Chemical
(	220 1 O
CBZ	221 3 B-Chemical
)	224 1 O
,	225 1 O
a	227 1 O
commonly	229 8 O
used	238 4 O
AED	243 3 O
,	246 1 O
has	248 3 O
been	252 4 O
implicated	257 10 O
in	268 2 O
some	271 4 O
clinical	276 8 O
studies	285 7 O
.	292 1 O

A	294 1 O
rat	296 3 O
model	300 5 O
was	306 3 O
developed	310 9 O
to	320 2 O
examine	323 7 O
the	331 3 O
effects	335 7 O
of	343 2 O
chronic	346 7 O
CBZ	354 3 B-Chemical
treatment	358 9 O
on	368 2 O
folate	371 6 B-Chemical
concentrations	378 14 O
in	393 2 O
the	396 3 O
rat	400 3 O
.	403 1 O

In	405 2 O
the	408 3 O
course	412 6 O
of	419 2 O
developing	422 10 O
this	433 4 O
model	438 5 O
,	443 1 O
a	445 1 O
common	447 6 O
vehicle	454 7 O
,	461 1 O
propylene	463 9 B-Chemical
glycol	473 6 I-Chemical
,	479 1 O
by	481 2 O
itself	484 6 O
in	491 2 O
high	494 4 O
doses	499 5 O
,	504 1 O
was	506 3 O
found	510 5 O
to	516 2 O
exhibit	519 7 O
protective	527 10 O
properties	538 10 O
against	549 7 O
induced	557 7 O
seizures	565 8 B-Disease
and	574 3 O
inhibited	578 9 O
weight	588 6 B-Disease
gain	595 4 I-Disease
.	599 1 O

Seizures	601 8 B-Disease
induced	610 7 O
by	618 2 O
hexafluorodiethyl	621 17 B-Chemical
ether	639 5 I-Chemical
(	645 1 O
HFDE	646 4 B-Chemical
)	650 1 O
were	652 4 O
also	657 4 O
found	662 5 O
to	668 2 O
be	671 2 O
a	674 1 O
more	676 4 O
sensitive	681 9 O
measure	691 7 O
of	699 2 O
protection	702 10 O
by	713 2 O
CBZ	716 3 B-Chemical
than	720 4 O
seizures	725 8 B-Disease
induced	734 7 O
by	742 2 O
maximal	745 7 O
electroshock	753 12 O
(	766 1 O
MES	767 3 O
)	770 1 O
.	771 1 O

Oral	773 4 O
administration	778 14 O
of	793 2 O
CBZ	796 3 B-Chemical
as	800 2 O
an	803 2 O
aqueous	806 7 O
suspension	814 10 O
every	825 5 O
8	831 1 O
h	833 1 O
at	835 2 O
a	838 1 O
dose	840 4 O
of	845 2 O
250	848 3 O
mg	852 2 O
/	854 1 O
kg	855 2 O
was	858 3 O
continuously	862 12 O
protective	875 10 O
against	886 7 O
HFDE	894 4 B-Chemical
-	898 1 O
induced	899 7 O
seizures	907 8 B-Disease
and	916 3 O
was	920 3 O
minimally	924 9 O
toxic	934 5 O
as	940 2 O
measured	943 8 O
by	952 2 O
weight	955 6 B-Disease
gain	962 4 I-Disease
over	967 4 O
8	972 1 O
weeks	974 5 O
of	980 2 O
treatment	983 9 O
.	992 1 O

The	994 3 O
CBZ	998 3 B-Chemical
levels	1002 6 O
measured	1009 8 O
in	1018 2 O
plasma	1021 6 O
and	1028 3 O
brain	1032 5 O
of	1038 2 O
these	1041 5 O
animals	1047 7 O
,	1054 1 O
however	1056 7 O
,	1063 1 O
were	1065 4 O
below	1070 5 O
those	1076 5 O
normally	1082 8 O
considered	1091 10 O
protective	1102 10 O
.	1112 1 O

This	1114 4 O
treatment	1119 9 O
with	1129 4 O
CBZ	1134 3 B-Chemical
had	1138 3 O
no	1142 2 O
apparent	1145 8 O
adverse	1154 7 O
effect	1162 6 O
on	1169 2 O
folate	1172 6 B-Chemical
concentrations	1179 14 O
in	1194 2 O
the	1197 3 O
rat	1201 3 O
,	1204 1 O
and	1206 3 O
,	1209 1 O
indeed	1211 6 O
,	1217 1 O
the	1219 3 O
folate	1223 6 B-Chemical
concentration	1230 13 O
increased	1244 9 O
in	1254 2 O
liver	1257 5 O
after	1263 5 O
6	1269 1 O
weeks	1271 5 O
of	1277 2 O
treatment	1280 9 O
and	1290 3 O
in	1294 2 O
plasma	1297 6 O
at	1304 2 O
8	1307 1 O
weeks	1309 5 O
of	1315 2 O
treatment	1318 9 O
.	1327 1 O

Inhibition	0 10 O
of	11 2 O
sympathoadrenal	14 15 O
activity	30 8 O
by	39 2 O
atrial	42 6 O
natriuretic	49 11 O
factor	61 6 O
in	68 2 O
dogs	71 4 O
.	75 1 O

In	77 2 O
six	80 3 O
conscious	84 9 O
,	93 1 O
trained	95 7 O
dogs	103 4 O
,	107 1 O
maintained	109 10 O
on	120 2 O
a	123 1 O
normal	125 6 O
sodium	132 6 B-Chemical
intake	139 6 O
of	146 2 O
2	149 1 O
to	151 2 O
4	154 1 O
mEq	156 3 O
/	159 1 O
kg	160 2 O
/	162 1 O
day	163 3 O
,	166 1 O
sympathetic	168 11 O
activity	180 8 O
was	189 3 O
assessed	193 8 O
as	202 2 O
the	205 3 O
release	209 7 O
rate	217 4 O
of	222 2 O
norepinephrine	225 14 B-Chemical
and	240 3 O
epinephrine	244 11 B-Chemical
during	256 6 O
15	263 2 O
-	265 1 O
minute	266 6 O
i	273 1 O
.	274 1 O
v	275 1 O
.	276 1 O
infusions	278 9 O
of	288 2 O
human	291 5 O
alpha	297 5 O
-	302 1 O
atrial	303 6 O
natriuretic	310 11 O
factor	322 6 O
.	328 1 O

Mean	330 4 O
arterial	335 8 O
pressure	344 8 O
(	353 1 O
as	354 2 O
a	357 1 O
percentage	359 10 O
of	370 2 O
control	373 7 O
+	381 1 O
/	382 1 O
-	383 1 O
SEM	385 3 O
)	388 1 O
during	390 6 O
randomized	397 10 O
infusions	408 9 O
of	418 2 O
0	421 1 O
.	422 1 O
03	423 2 O
,	425 1 O
0	427 1 O
.	428 1 O
1	429 1 O
,	430 1 O
0	432 1 O
.	433 1 O
3	434 1 O
,	435 1 O
or	437 2 O
1	440 1 O
.	441 1 O
0	442 1 O
microgram	444 9 O
/	453 1 O
kg	454 2 O
/	456 1 O
min	457 3 O
was	461 3 O
99	465 2 O
+	468 1 O
/	469 1 O
-	470 1 O
1	472 1 O
,	473 1 O
95	475 2 O
+	478 1 O
/	479 1 O
-	480 1 O
1	482 1 O
(	484 1 O
p	485 1 O
less	487 4 O
than	492 4 O
0	497 1 O
.	498 1 O
05	499 2 O
)	501 1 O
,	502 1 O
93	504 2 O
+	507 1 O
/	508 1 O
-	509 1 O
1	511 1 O
(	513 1 O
p	514 1 O
less	516 4 O
than	521 4 O
0	526 1 O
.	527 1 O
01	528 2 O
)	530 1 O
,	531 1 O
or	533 2 O
79	536 2 O
+	539 1 O
/	540 1 O
-	541 1 O
6	543 1 O
%	544 1 O
(	546 1 O
p	547 1 O
less	549 4 O
than	554 4 O
0	559 1 O
.	560 1 O
001	561 3 O
)	564 1 O
,	565 1 O
respectively	567 12 O
,	579 1 O
but	581 3 O
no	585 2 O
tachycardia	588 11 B-Disease
and	600 3 O
no	604 2 O
augmentation	607 12 O
of	620 2 O
the	623 3 O
norepinephrine	627 14 B-Chemical
release	642 7 O
rate	650 4 O
(	655 1 O
up	656 2 O
to	659 2 O
0	662 1 O
.	663 1 O
3	664 1 O
microgram	666 9 O
/	675 1 O
kg	676 2 O
/	678 1 O
min	679 3 O
)	682 1 O
were	684 4 O
observed	689 8 O
,	697 1 O
which	699 5 O
is	705 2 O
in	708 2 O
contrast	711 8 O
to	720 2 O
comparable	723 10 O
hypotension	734 11 B-Disease
induced	746 7 O
by	754 2 O
hydralazine	757 11 B-Chemical
or	769 2 O
nitroglycerin	772 13 B-Chemical
.	785 1 O

The	787 3 O
release	791 7 O
rate	799 4 O
of	804 2 O
epinephrine	807 11 B-Chemical
(	819 1 O
control	820 7 O
,	827 1 O
6	829 1 O
.	830 1 O
7	831 1 O
+	833 1 O
/	834 1 O
-	835 1 O
0	837 1 O
.	838 1 O
6	839 1 O
ng	841 2 O
/	843 1 O
kg	844 2 O
/	846 1 O
min	847 3 O
)	850 1 O
declined	852 8 O
immediately	861 11 O
during	873 6 O
infusions	880 9 O
of	890 2 O
atrial	893 6 O
natriuretic	900 11 O
factor	912 6 O
to	919 2 O
a	922 1 O
minimum	924 7 O
of	932 2 O
49	935 2 O
+	938 1 O
/	939 1 O
-	940 1 O
5	942 1 O
%	943 1 O
of	945 2 O
control	948 7 O
(	956 1 O
p	957 1 O
less	959 4 O
than	964 4 O
0	969 1 O
.	970 1 O
001	971 3 O
)	974 1 O
during	976 6 O
0	983 1 O
.	984 1 O
1	985 1 O
microgram	987 9 O
/	996 1 O
kg	997 2 O
/	999 1 O
min	1000 3 O
and	1004 3 O
to	1008 2 O
63	1011 2 O
+	1014 1 O
/	1015 1 O
-	1016 1 O
5	1018 1 O
%	1019 1 O
(	1021 1 O
0	1022 1 O
.	1023 1 O
1	1024 1 O
greater	1026 7 O
than	1034 4 O
p	1039 1 O
greater	1041 7 O
than	1049 4 O
0	1054 1 O
.	1055 1 O
05	1056 2 O
)	1058 1 O
or	1060 2 O
95	1063 2 O
+	1066 1 O
/	1067 1 O
-	1068 1 O
13	1070 2 O
%	1072 1 O
(	1074 1 O
not	1075 3 O
significant	1079 11 O
)	1090 1 O
during	1092 6 O
0	1099 1 O
.	1100 1 O
3	1101 1 O
or	1103 2 O
1	1106 1 O
.	1107 1 O
0	1108 1 O
microgram	1110 9 O
/	1119 1 O
kg	1120 2 O
/	1122 1 O
min	1123 3 O
.	1126 1 O

Steady	1128 6 O
state	1135 5 O
arterial	1141 8 O
plasma	1150 6 O
concentrations	1157 14 O
of	1172 2 O
atrial	1175 6 O
natriuretic	1182 11 O
factor	1194 6 O
were	1201 4 O
39	1206 2 O
+	1209 1 O
/	1210 1 O
-	1211 1 O
10	1213 2 O
pg	1216 2 O
/	1218 1 O
ml	1219 2 O
(	1222 1 O
n	1223 1 O
=	1225 1 O
6	1227 1 O
)	1228 1 O
during	1230 6 O
infusions	1237 9 O
of	1247 2 O
saline	1250 6 O
and	1257 3 O
284	1261 3 O
+	1265 1 O
/	1266 1 O
-	1267 1 O
24	1269 2 O
pg	1272 2 O
/	1274 1 O
ml	1275 2 O
(	1278 1 O
n	1279 1 O
=	1281 1 O
6	1283 1 O
)	1284 1 O
and	1286 3 O
1520	1290 4 O
+	1295 1 O
/	1296 1 O
-	1297 1 O
300	1299 3 O
pg	1303 2 O
/	1305 1 O
ml	1306 2 O
(	1309 1 O
n	1310 1 O
=	1312 1 O
9	1314 1 O
)	1315 1 O
during	1317 6 O
0	1324 1 O
.	1325 1 O
03	1326 2 O
and	1329 3 O
0	1333 1 O
.	1334 1 O
1	1335 1 O
microgram	1337 9 O
/	1346 1 O
kg	1347 2 O
/	1349 1 O
min	1350 3 O
infusions	1354 9 O
of	1364 2 O
the	1367 3 O
factor	1371 6 O
.	1377 1 O
(	1378 1 O
ABSTRACT	1379 8 O
TRUNCATED	1388 9 O
AT	1398 2 O
250	1401 3 O
WORDS	1405 5 O
)	1410 1 O

Death	0 5 B-Disease
from	6 4 O
chemotherapy	11 12 O
in	24 2 O
gestational	27 11 B-Disease
trophoblastic	39 13 I-Disease
disease	53 7 I-Disease
.	60 1 O

Multiple	62 8 O
cytotoxic	71 9 O
drug	81 4 O
administration	86 14 O
is	101 2 O
the	104 3 O
generally	108 9 O
accepted	118 8 O
treatment	127 9 O
of	137 2 O
patients	140 8 O
with	149 4 O
a	154 1 O
high	156 4 O
-	160 1 O
risk	161 4 O
stage	166 5 O
of	172 2 O
choriocarcinoma	175 15 B-Disease
.	190 1 O

Based	192 5 O
on	198 2 O
this	201 4 O
principle	206 9 O
a	216 1 O
27	218 2 O
-	220 1 O
year	221 4 O
old	226 3 O
woman	230 5 O
,	235 1 O
classified	237 10 O
as	248 2 O
being	251 5 O
in	257 2 O
the	260 3 O
high	264 4 O
-	268 1 O
risk	269 4 O
group	274 5 O
(	280 1 O
Goldstein	281 9 O
and	291 3 O
Berkowitz	295 9 O
score	305 5 O
:	310 1 O
11	312 2 O
)	314 1 O
,	315 1 O
was	317 3 O
treated	321 7 O
with	329 4 O
multiple	334 8 O
cytotoxic	343 9 O
drugs	353 5 O
.	358 1 O

The	360 3 O
multiple	364 8 O
drug	373 4 O
schema	378 6 O
consisted	385 9 O
of	395 2 O
:	397 1 O
Etoposide	399 9 B-Chemical
16	409 2 O
.	411 1 O
213	412 3 O
,	415 1 O
Methotrexate	417 12 B-Chemical
,	429 1 O
Cyclophosphamide	431 16 B-Chemical
,	447 1 O
Actomycin	449 9 B-Chemical
-	458 1 I-Chemical
D	459 1 I-Chemical
,	460 1 O
and	462 3 O
Cisplatin	466 9 B-Chemical
.	475 1 O

On	477 2 O
the	480 3 O
first	484 5 O
day	490 3 O
of	494 2 O
the	497 3 O
schedule	501 8 O
,	509 1 O
moderate	511 8 O
high	520 4 O
doses	525 5 O
of	531 2 O
Methotrexate	534 12 B-Chemical
,	546 1 O
Etoposide	548 9 B-Chemical
and	558 3 O
Cyclophosphamide	562 16 B-Chemical
were	579 4 O
administered	584 12 O
.	596 1 O

Within	598 6 O
8	605 1 O
hours	607 5 O
after	613 5 O
initiation	619 10 O
of	630 2 O
therapy	633 7 O
the	641 3 O
patient	645 7 O
died	653 4 O
with	658 4 O
a	663 1 O
clinical	665 8 O
picture	674 7 O
resembling	682 10 O
massive	693 7 O
pulmonary	701 9 B-Disease
obstruction	711 11 I-Disease
due	723 3 O
to	727 2 O
choriocarcinomic	730 16 O
tissue	747 6 O
plugs	754 5 O
,	759 1 O
probably	761 8 O
originating	770 11 O
from	782 4 O
the	787 3 O
uterus	791 6 O
.	797 1 O

Formation	799 9 O
of	809 2 O
these	812 5 O
plugs	818 5 O
was	824 3 O
probably	828 8 O
due	837 3 O
to	841 2 O
extensive	844 9 O
tumor	854 5 B-Disease
necrosis	860 8 B-Disease
at	869 2 O
the	872 3 O
level	876 5 O
of	882 2 O
the	885 3 O
walls	889 5 O
of	895 2 O
the	898 3 O
major	902 5 O
uterine	908 7 O
veins	916 5 O
,	921 1 O
which	923 5 O
resulted	929 8 O
in	938 2 O
an	941 2 O
open	944 4 O
exchange	949 8 O
of	958 2 O
tumor	961 5 B-Disease
plugs	967 5 O
to	973 2 O
the	976 3 O
vascular	980 8 O
spaces	989 6 O
;	995 1 O
decrease	997 8 O
in	1006 2 O
tumor	1009 5 B-Disease
tissue	1015 6 O
coherence	1022 9 O
secondary	1032 9 O
to	1042 2 O
chemotherapy	1045 12 O
may	1058 3 O
have	1062 4 O
further	1067 7 O
contributed	1075 11 O
to	1087 2 O
the	1090 3 O
formation	1094 9 O
of	1104 2 O
tumor	1107 5 B-Disease
emboli	1113 6 O
.	1119 1 O

In	1121 2 O
view	1124 4 O
of	1129 2 O
the	1132 3 O
close	1136 5 O
time	1142 4 O
association	1147 11 O
between	1159 7 O
the	1167 3 O
start	1171 5 O
of	1177 2 O
chemotherapy	1180 12 O
and	1193 3 O
the	1197 3 O
acute	1201 5 O
onset	1207 5 O
of	1213 2 O
massive	1216 7 O
embolism	1224 8 B-Disease
other	1233 5 O
explanations	1239 12 O
,	1251 1 O
such	1253 4 O
as	1258 2 O
spontaneous	1261 11 O
necrosis	1273 8 B-Disease
,	1281 1 O
must	1283 4 O
be	1288 2 O
considered	1291 10 O
less	1302 4 O
likely	1307 6 O
.	1313 1 O

Patients	1315 8 O
with	1324 4 O
large	1329 5 O
pelvic	1335 6 B-Disease
tumor	1342 5 I-Disease
loads	1348 5 O
are	1354 3 O
,	1357 1 O
according	1359 9 O
to	1369 2 O
existing	1372 8 O
classifications	1381 15 O
,	1396 1 O
at	1398 2 O
high	1401 4 O
risk	1406 4 O
to	1411 2 O
die	1414 3 O
and	1418 3 O
to	1422 2 O
develop	1425 7 O
drug	1433 4 O
resistance	1438 10 O
.	1448 1 O

Notwithstanding	1450 15 O
these	1466 5 O
facts	1472 5 O
our	1478 3 O
findings	1482 8 O
suggest	1491 7 O
that	1499 4 O
these	1504 5 O
patients	1510 8 O
might	1519 5 O
benefit	1525 7 O
from	1533 4 O
relatively	1538 10 O
mild	1549 4 O
initial	1554 7 O
treatment	1562 9 O
,	1571 1 O
especially	1573 10 O
true	1584 4 O
for	1589 3 O
patients	1593 8 O
not	1602 3 O
previously	1606 10 O
exposed	1617 7 O
to	1625 2 O
this	1628 4 O
drug	1633 4 O
.	1637 1 O

Close	1639 5 O
observation	1645 11 O
of	1657 2 O
the	1660 3 O
response	1664 8 O
status	1673 6 O
both	1680 4 O
clinically	1685 10 O
and	1696 3 O
with	1700 4 O
beta	1705 4 O
-	1709 1 O
hCG	1710 3 O
values	1714 6 O
may	1721 3 O
indicate	1725 8 O
whether	1734 7 O
and	1742 3 O
when	1746 4 O
more	1751 4 O
agressive	1756 9 O
combination	1766 11 O
chemotherapy	1778 12 O
should	1791 6 O
be	1798 2 O
started	1801 7 O
.	1808 1 O
(	1809 1 O
ABSTRACT	1810 8 O
TRUNCATED	1819 9 O
AT	1829 2 O
250	1832 3 O
WORDS	1836 5 O
)	1841 1 O

Sexual	0 6 B-Disease
dysfunction	7 11 I-Disease
among	19 5 O
patients	25 8 O
with	34 4 O
arthritis	39 9 B-Disease
.	48 1 O

The	50 3 O
relationship	54 12 O
of	67 2 O
arthritis	70 9 B-Disease
and	80 3 O
sexual	84 6 B-Disease
dysfunction	91 11 I-Disease
was	103 3 O
investigated	107 12 O
among	120 5 O
169	126 3 O
patients	130 8 O
with	139 4 O
rheumatoid	144 10 B-Disease
arthritis	155 9 I-Disease
,	164 1 O
osteoarthritis	166 14 B-Disease
and	181 3 O
spondyloarthropathy	185 19 B-Disease
,	204 1 O
130	206 3 O
of	210 2 O
whom	213 4 O
were	218 4 O
pair	223 4 O
-	227 1 O
matched	228 7 O
to	236 2 O
controls	239 8 O
.	247 1 O

Assessments	249 11 O
of	261 2 O
marital	264 7 O
happiness	272 9 O
and	282 3 O
depressed	286 9 B-Disease
mood	296 4 I-Disease
were	301 4 O
also	306 4 O
made	311 4 O
using	316 5 O
the	322 3 O
CES	326 3 O
-	329 1 O
D	330 1 O
and	332 3 O
the	336 3 O
Azrin	340 5 O
Marital	346 7 O
Happiness	354 9 O
Scale	364 5 O
(	370 1 O
AMHS	371 4 O
)	375 1 O
.	376 1 O

Sexual	378 6 B-Disease
dysfunctions	385 12 I-Disease
were	398 4 O
found	403 5 O
to	409 2 O
be	412 2 O
common	415 6 O
among	422 5 O
patients	428 8 O
and	437 3 O
controls	441 8 O
,	449 1 O
the	451 3 O
majority	455 8 O
in	464 2 O
both	467 4 O
groups	472 6 O
reporting	479 9 O
one	489 3 O
or	493 2 O
more	496 4 O
dysfunctions	501 12 O
.	513 1 O

Impotence	515 9 B-Disease
was	525 3 O
more	529 4 O
common	534 6 O
among	541 5 O
male	547 4 O
patients	552 8 O
than	561 4 O
controls	566 8 O
and	575 3 O
was	579 3 O
found	583 5 O
to	589 2 O
be	592 2 O
associated	595 10 O
with	606 4 O
co	611 2 O
-	613 1 O
morbidity	614 9 O
and	624 3 O
the	628 3 O
taking	632 6 O
of	639 2 O
methotrexate	642 12 B-Chemical
.	654 1 O

Depressed	656 9 B-Disease
mood	666 4 I-Disease
was	671 3 O
more	675 4 O
common	680 6 O
among	687 5 O
patients	693 8 O
and	702 3 O
was	706 3 O
associated	710 10 O
with	721 4 O
certain	726 7 O
sexual	734 6 O
difficulties	741 12 O
,	753 1 O
but	755 3 O
not	759 3 O
with	763 4 O
impotence	768 9 B-Disease
.	777 1 O

Marital	779 7 O
unhappiness	787 11 O
,	798 1 O
as	800 2 O
indicated	803 9 O
by	813 2 O
AMHS	816 4 O
scores	821 6 O
,	827 1 O
was	829 3 O
not	833 3 O
associated	837 10 O
with	848 4 O
arthritis	853 9 B-Disease
but	863 3 O
was	867 3 O
associated	871 10 O
with	882 4 O
sexual	887 6 B-Disease
dysfunction	894 11 I-Disease
,	905 1 O
sexual	907 6 O
dissatisfaction	914 15 O
and	930 3 O
being	934 5 O
female	940 6 O
.	946 1 O

Does	0 4 O
paracetamol	5 11 B-Chemical
cause	17 5 O
urothelial	23 10 B-Disease
cancer	34 6 I-Disease
or	41 2 O
renal	44 5 B-Disease
papillary	50 9 I-Disease
necrosis	60 8 I-Disease
?	68 1 O

The	70 3 O
risk	74 4 O
of	79 2 O
developing	82 10 O
renal	93 5 B-Disease
papillary	99 9 I-Disease
necrosis	109 8 I-Disease
or	118 2 O
cancer	121 6 B-Disease
of	128 2 I-Disease
the	131 3 I-Disease
renal	135 5 I-Disease
pelvis	141 6 I-Disease
,	147 1 I-Disease
ureter	149 6 I-Disease
or	156 2 I-Disease
bladder	159 7 I-Disease
associated	167 10 O
with	178 4 O
consumption	183 11 O
of	195 2 O
either	198 6 O
phenacetin	205 10 B-Chemical
or	216 2 O
paracetamol	219 11 B-Chemical
was	231 3 O
calculated	235 10 O
from	246 4 O
data	251 4 O
acquired	256 8 O
by	265 2 O
questionnaire	268 13 O
from	282 4 O
381	287 3 O
cases	291 5 O
and	297 3 O
808	301 3 O
controls	305 8 O
.	313 1 O

The	315 3 O
risk	319 4 O
of	324 2 O
renal	327 5 B-Disease
papillary	333 9 I-Disease
necrosis	343 8 I-Disease
was	352 3 O
increased	356 9 O
nearly	366 6 O
20	373 2 O
-	375 1 O
fold	376 4 O
by	381 2 O
consumption	384 11 O
of	396 2 O
phenacetin	399 10 B-Chemical
,	409 1 O
which	411 5 O
also	417 4 O
increased	422 9 O
the	432 3 O
risk	436 4 O
for	441 3 O
cancer	445 6 B-Disease
of	452 2 I-Disease
the	455 3 I-Disease
renal	459 5 I-Disease
pelvis	465 6 I-Disease
and	472 3 I-Disease
bladder	476 7 I-Disease
but	484 3 O
not	488 3 O
for	492 3 O
ureteric	496 8 B-Disease
cancer	505 6 I-Disease
.	511 1 O

By	513 2 O
contrast	516 8 O
,	524 1 O
we	526 2 O
were	529 4 O
unable	534 6 O
to	541 2 O
substantiate	544 12 O
an	557 2 O
increased	560 9 O
risk	570 4 O
from	575 4 O
paracetamol	580 11 B-Chemical
consumption	592 11 O
for	604 3 O
renal	608 5 B-Disease
papillary	614 9 I-Disease
necrosis	624 8 I-Disease
or	633 2 O
any	636 3 O
of	640 2 O
these	643 5 O
cancers	649 7 B-Disease
although	657 8 O
there	666 5 O
was	672 3 O
a	676 1 O
suggestion	678 10 O
of	689 2 O
an	692 2 O
association	695 11 O
with	707 4 O
cancer	712 6 B-Disease
of	719 2 I-Disease
the	722 3 I-Disease
ureter	726 6 I-Disease
.	732 1 O

Dapsone	0 7 B-Chemical
-	7 1 O
associated	8 10 O
Heinz	19 5 O
body	25 4 O
hemolytic	30 9 B-Disease
anemia	40 6 I-Disease
in	47 2 O
a	50 1 O
Cambodian	52 9 O
woman	62 5 O
with	68 4 O
hemoglobin	73 10 O
E	84 1 O
trait	86 5 O
.	91 1 O

A	93 1 O
Cambodian	95 9 O
woman	105 5 O
with	111 4 O
hemoglobin	116 10 O
E	127 1 O
trait	129 5 O
(	135 1 O
AE	136 2 O
)	138 1 O
and	140 3 O
leprosy	144 7 B-Disease
developed	152 9 O
a	162 1 O
Heinz	164 5 O
body	170 4 O
hemolytic	175 9 B-Disease
anemia	185 6 I-Disease
while	192 5 O
taking	198 6 O
a	205 1 O
dose	207 4 O
of	212 2 O
dapsone	215 7 B-Chemical
(	223 1 O
50	224 2 O
mg	227 2 O
/	229 1 O
day	230 3 O
)	233 1 O
not	235 3 O
usually	239 7 O
associated	247 10 O
with	258 4 O
clinical	263 8 O
hemolysis	272 9 B-Disease
.	281 1 O

Her	283 3 O
red	287 3 O
blood	291 5 O
cells	297 5 O
(	303 1 O
RBCs	304 4 O
)	308 1 O
had	310 3 O
increased	314 9 O
incubated	324 9 O
Heinz	334 5 O
body	340 4 O
formation	345 9 O
,	354 1 O
decreased	356 9 O
reduced	366 7 O
glutathione	374 11 B-Chemical
(	386 1 O
GSH	387 3 B-Chemical
)	390 1 O
,	391 1 O
and	393 3 O
decreased	397 9 O
GSH	407 3 B-Chemical
stability	411 9 O
.	420 1 O

The	422 3 O
pentose	426 7 B-Chemical
phosphate	434 9 I-Chemical
shunt	444 5 O
activity	450 8 O
of	459 2 O
the	462 3 O
dapsone	466 7 B-Chemical
-	473 1 O
exposed	474 7 O
AE	482 2 O
RBCs	485 4 O
was	490 3 O
increased	494 9 O
compared	504 8 O
to	513 2 O
normal	516 6 O
RBCs	523 4 O
.	527 1 O

Although	529 8 O
the	538 3 O
AE	542 2 O
RBCs	545 4 O
from	550 4 O
an	555 2 O
individual	558 10 O
not	569 3 O
taking	573 6 O
dapsone	580 7 B-Chemical
had	588 3 O
increased	592 9 O
incubated	602 9 O
Heinz	612 5 O
body	618 4 O
formation	623 9 O
,	632 1 O
the	634 3 O
GSH	638 3 B-Chemical
content	642 7 O
and	650 3 O
GSH	654 3 B-Chemical
stability	658 9 O
were	668 4 O
normal	673 6 O
.	679 1 O

The	681 3 O
pentose	685 7 B-Chemical
phosphate	693 9 I-Chemical
shunt	703 5 O
activity	709 8 O
of	718 2 O
the	721 3 O
non	725 3 O
-	728 1 O
dapsone	729 7 B-Chemical
-	736 1 O
exposed	737 7 O
AE	745 2 O
RBCs	748 4 O
was	753 3 O
decreased	757 9 O
compared	767 8 O
to	776 2 O
normal	779 6 O
RBCs	786 4 O
.	790 1 O

Thus	792 4 O
,	796 1 O
AE	798 2 O
RBCs	801 4 O
appear	806 6 O
to	813 2 O
have	816 4 O
an	821 2 O
increased	824 9 O
sensitivity	834 11 O
to	846 2 O
oxidant	849 7 O
stress	857 6 O
both	864 4 O
in	869 2 O
vitro	872 5 O
and	878 3 O
in	882 2 O
vivo	885 4 O
,	889 1 O
since	891 5 O
dapsone	897 7 B-Chemical
does	905 4 O
not	910 3 O
cause	914 5 O
hemolytic	920 9 B-Disease
anemia	930 6 I-Disease
at	937 2 O
this	940 4 O
dose	945 4 O
in	950 2 O
hematologically	953 15 O
normal	969 6 O
individuals	976 11 O
.	987 1 O

Given	989 5 O
the	995 3 O
influx	999 6 O
of	1006 2 O
Southeast	1009 9 O
Asians	1019 6 O
into	1026 4 O
the	1031 3 O
United	1035 6 O
States	1042 6 O
,	1048 1 O
oxidant	1050 7 O
medications	1058 11 O
should	1070 6 O
be	1077 2 O
used	1080 4 O
with	1085 4 O
caution	1090 7 O
,	1097 1 O
especially	1099 10 O
if	1110 2 O
an	1113 2 O
infection	1116 9 B-Disease
is	1126 2 O
present	1129 7 O
,	1136 1 O
in	1138 2 O
individuals	1141 11 O
of	1153 2 O
ethnic	1156 6 O
backgrounds	1163 11 O
that	1175 4 O
have	1180 4 O
an	1185 2 O
increased	1188 9 O
prevalence	1198 10 O
of	1209 2 O
hemoglobin	1212 10 O
E	1223 1 O
.	1224 1 O

Severe	0 6 O
complications	7 13 O
of	21 2 O
antianginal	24 11 O
drug	36 4 O
therapy	41 7 O
in	49 2 O
a	52 1 O
patient	54 7 O
identified	62 10 O
as	73 2 O
a	76 1 O
poor	78 4 O
metabolizer	83 11 O
of	95 2 O
metoprolol	98 10 B-Chemical
,	108 1 O
propafenone	110 11 B-Chemical
,	121 1 O
diltiazem	123 9 B-Chemical
,	132 1 O
and	134 3 O
sparteine	138 9 B-Chemical
.	147 1 O

A	149 1 O
47	151 2 O
-	153 1 O
year	154 4 O
-	158 1 O
old	159 3 O
patient	163 7 O
suffering	171 9 O
from	181 4 O
coronary	186 8 B-Disease
artery	195 6 I-Disease
disease	202 7 I-Disease
was	210 3 O
admitted	214 8 O
to	223 2 O
the	226 3 O
CCU	230 3 O
in	234 2 O
shock	237 5 B-Disease
with	243 4 O
III	248 3 O
.	251 1 O

AV	253 2 B-Disease
block	256 5 I-Disease
,	261 1 O
severe	263 6 O
hypotension	270 11 B-Disease
,	281 1 O
and	283 3 O
impairment	287 10 B-Disease
of	298 2 I-Disease
ventricular	301 11 I-Disease
function	313 8 I-Disease
.	321 1 O

One	323 3 O
week	327 4 O
prior	332 5 O
to	338 2 O
admission	341 9 O
a	351 1 O
therapy	353 7 O
with	361 4 O
standard	366 8 O
doses	375 5 O
of	381 2 O
metoprolol	384 10 B-Chemical
(	395 1 O
100	396 3 O
mg	400 2 O
t	403 1 O
.	404 1 O
i	405 1 O
.	406 1 O
d	407 1 O
.	408 1 O
and	410 3 O
then	414 4 O
100	419 3 O
mg	423 2 O
b	426 1 O
.	427 1 O
i	428 1 O
.	429 1 O
d	430 1 O
.	431 1 O
)	432 1 O
had	434 3 O
been	438 4 O
initiated	443 9 O
.	452 1 O

Two	454 3 O
days	458 4 O
before	463 6 O
admission	470 9 O
diltiazem	480 9 B-Chemical
(	490 1 O
60	491 2 O
mg	494 2 O
b	497 1 O
.	498 1 O
i	499 1 O
.	500 1 O
d	501 1 O
.	502 1 O
)	503 1 O
was	505 3 O
prescribed	509 10 O
in	520 2 O
addition	523 8 O
.	531 1 O

Analyses	533 8 O
of	542 2 O
a	545 1 O
blood	547 5 O
sample	553 6 O
revealed	560 8 O
unusually	569 9 O
high	579 4 O
plasma	584 6 O
concentrations	591 14 O
of	606 2 O
metoprolol	609 10 B-Chemical
(	620 1 O
greater	621 7 O
than	629 4 O
3000	634 4 O
ng	639 2 O
/	641 1 O
ml	642 2 O
)	644 1 O
and	646 3 O
diltiazem	650 9 B-Chemical
(	660 1 O
526	661 3 O
ng	665 2 O
/	667 1 O
ml	668 2 O
)	670 1 O
.	671 1 O

The	673 3 O
patient	677 7 O
recovered	685 9 O
within	695 6 O
1	702 1 O
week	704 4 O
following	709 9 O
discontinuation	719 15 O
of	735 2 O
antianginal	738 11 O
therapy	750 7 O
.	757 1 O

Three	759 5 O
months	765 6 O
later	772 5 O
the	778 3 O
patient	782 7 O
was	790 3 O
exposed	794 7 O
to	802 2 O
a	805 1 O
single	807 6 O
dose	814 4 O
of	819 2 O
metoprolol	822 10 B-Chemical
,	832 1 O
diltiazem	834 9 B-Chemical
,	843 1 O
propafenone	845 11 B-Chemical
(	857 1 O
since	858 5 O
he	864 2 O
had	867 3 O
received	871 8 O
this	880 4 O
drug	885 4 O
in	890 2 O
the	893 3 O
past	897 4 O
)	901 1 O
,	902 1 O
and	904 3 O
sparteine	908 9 B-Chemical
(	918 1 O
as	919 2 O
a	922 1 O
probe	924 5 O
for	930 3 O
the	934 3 O
debrisoquine	938 12 B-Chemical
/	950 1 O
sparteine	951 9 B-Chemical
type	961 4 O
polymorphism	966 12 O
of	979 2 O
oxidative	982 9 O
drug	992 4 O
metabolism	997 10 O
)	1007 1 O
.	1008 1 O

It	1010 2 O
was	1013 3 O
found	1017 5 O
that	1023 4 O
he	1028 2 O
was	1031 3 O
a	1035 1 O
poor	1037 4 O
metabolizer	1042 11 O
of	1054 2 O
all	1057 3 O
four	1061 4 O
drugs	1066 5 O
,	1071 1 O
indicating	1073 10 O
that	1084 4 O
their	1089 5 O
metabolism	1095 10 O
is	1106 2 O
under	1109 5 O
the	1115 3 O
same	1119 4 O
genetic	1124 7 O
control	1132 7 O
.	1139 1 O

Therefore	1141 9 O
,	1150 1 O
patients	1152 8 O
belonging	1161 9 O
to	1171 2 O
the	1174 3 O
poor	1178 4 O
-	1182 1 O
metabolizer	1183 11 O
phenotype	1195 9 O
of	1205 2 O
sparteine	1208 9 B-Chemical
/	1217 1 O
debrisoquine	1218 12 B-Chemical
polymorphism	1231 12 O
in	1244 2 O
drug	1247 4 O
metabolism	1252 10 O
,	1262 1 O
which	1264 5 O
constitutes	1270 11 O
6	1282 1 O
.	1283 1 O
4	1284 1 O
%	1285 1 O
of	1287 2 O
the	1290 3 O
German	1294 6 O
population	1301 10 O
,	1311 1 O
may	1313 3 O
experience	1317 10 O
adverse	1328 7 B-Disease
drug	1336 4 I-Disease
reactions	1341 9 I-Disease
when	1351 4 O
treated	1356 7 O
with	1364 4 O
standard	1369 8 O
doses	1378 5 O
of	1384 2 O
one	1387 3 O
of	1391 2 O
these	1394 5 O
drugs	1400 5 O
alone	1406 5 O
.	1411 1 O

Moreover	1413 8 O
,	1421 1 O
the	1423 3 O
coadministration	1427 16 O
of	1444 2 O
these	1447 5 O
frequently	1453 10 O
used	1464 4 O
drugs	1469 5 O
is	1475 2 O
expected	1478 8 O
to	1487 2 O
be	1490 2 O
especially	1493 10 O
harmful	1504 7 O
in	1512 2 O
this	1515 4 O
subgroup	1520 8 O
of	1529 2 O
patients	1532 8 O
.	1540 1 O

Triazolam	0 9 B-Chemical
-	9 1 O
induced	10 7 O
brief	18 5 O
episodes	24 8 O
of	33 2 O
secondary	36 9 O
mania	46 5 B-Disease
in	52 2 O
a	55 1 O
depressed	57 9 B-Disease
patient	67 7 O
.	74 1 O

Large	76 5 O
doses	82 5 O
of	88 2 O
triazolam	91 9 B-Chemical
repeatedly	101 10 O
induced	112 7 O
brief	120 5 O
episodes	126 8 O
of	135 2 O
mania	138 5 B-Disease
in	144 2 O
a	147 1 O
depressed	149 9 B-Disease
elderly	159 7 O
woman	167 5 O
.	172 1 O

Features	174 8 O
of	183 2 O
organic	186 7 B-Disease
mental	194 6 I-Disease
disorder	201 8 I-Disease
(	210 1 O
delirium	211 8 B-Disease
)	219 1 O
were	221 4 O
not	226 3 O
present	230 7 O
.	237 1 O

Manic	239 5 B-Disease
excitement	245 10 O
was	256 3 O
coincident	260 10 O
with	271 4 O
the	276 3 O
duration	280 8 O
of	289 2 O
action	292 6 O
of	299 2 O
triazolam	302 9 B-Chemical
.	311 1 O

The	313 3 O
possible	317 8 O
contribution	326 12 O
of	339 2 O
the	342 3 O
triazolo	346 8 B-Chemical
group	355 5 O
to	361 2 O
changes	364 7 O
in	372 2 O
affective	375 9 O
status	385 6 O
is	392 2 O
discussed	395 9 O
.	404 1 O

On	0 2 O
the	3 3 O
mechanisms	7 10 O
of	18 2 O
the	21 3 O
development	25 11 O
of	37 2 O
tolerance	40 9 O
to	50 2 O
the	53 3 O
muscular	57 8 B-Disease
rigidity	66 8 I-Disease
produced	75 8 O
by	84 2 O
morphine	87 8 B-Chemical
in	96 2 O
rats	99 4 O
.	103 1 O

The	105 3 O
development	109 11 O
of	121 2 O
tolerance	124 9 O
to	134 2 O
the	137 3 O
muscular	141 8 B-Disease
rigidity	150 8 I-Disease
produced	159 8 O
by	168 2 O
morphine	171 8 B-Chemical
was	180 3 O
studied	184 7 O
in	192 2 O
rats	195 4 O
.	199 1 O

Saline	201 6 O
-	207 1 O
pretreated	208 10 O
controls	219 8 O
given	228 5 O
a	234 1 O
test	236 4 O
dose	241 4 O
of	246 2 O
morphine	249 8 B-Chemical
(	258 1 O
20	259 2 O
mg	262 2 O
/	264 1 O
kg	265 2 O
i	268 1 O
.	269 1 O
p	270 1 O
.	271 1 O
)	272 1 O
showed	274 6 O
a	281 1 O
pronounced	283 10 O
rigidity	294 8 B-Disease
recorded	303 8 O
as	312 2 O
tonic	315 5 O
activity	321 8 O
in	330 2 O
the	333 3 O
electromyogram	337 14 O
.	351 1 O

Rats	353 4 O
treated	358 7 O
for	366 3 O
11	370 2 O
days	373 4 O
with	378 4 O
morphine	383 8 B-Chemical
and	392 3 O
withdrawn	396 9 O
for	406 3 O
36	410 2 O
-	412 1 O
40	413 2 O
h	416 1 O
showed	418 6 O
differences	425 11 O
in	437 2 O
the	440 3 O
development	444 11 O
of	456 2 O
tolerance	459 9 O
:	468 1 O
about	470 5 O
half	476 4 O
of	481 2 O
the	484 3 O
animals	488 7 O
showed	496 6 O
a	503 1 O
rigidity	505 8 B-Disease
after	514 5 O
the	520 3 O
test	524 4 O
dose	529 4 O
of	534 2 O
morphine	537 8 B-Chemical
that	546 4 O
was	551 3 O
not	555 3 O
significantly	559 13 O
less	573 4 O
than	578 4 O
in	583 2 O
the	586 3 O
controls	590 8 O
and	599 3 O
were	603 4 O
akinetic	608 8 B-Disease
(	617 1 O
A	618 1 O
group	620 5 O
)	625 1 O
.	626 1 O

The	628 3 O
other	632 5 O
rats	638 4 O
showed	643 6 O
a	650 1 O
strong	652 6 O
decrease	659 8 O
in	668 2 O
the	671 3 O
rigidity	675 8 B-Disease
and	684 3 O
the	688 3 O
occurrence	692 10 O
of	703 2 O
stereotyped	706 11 O
(	718 1 O
S	719 1 O
)	720 1 O
licking	722 7 O
and	730 3 O
/	733 1 O
or	734 2 O
gnawing	737 7 O
in	745 2 O
presence	748 8 O
of	757 2 O
akinetic	760 8 B-Disease
or	769 2 O
hyperkinetic	772 12 B-Disease
(	785 1 O
K	786 1 O
)	787 1 O
behaviour	789 9 O
(	799 1 O
AS	800 2 O
/	802 1 O
KS	803 2 O
group	806 5 O
)	811 1 O
,	812 1 O
suggesting	814 10 O
signs	825 5 O
of	831 2 O
dopaminergic	834 12 O
activation	847 10 O
.	857 1 O

The	859 3 O
rigidity	863 8 B-Disease
was	872 3 O
considerably	876 12 O
decreased	889 9 O
in	899 2 O
both	902 4 O
groups	907 6 O
after	914 5 O
20	920 2 O
days	923 4 O
'	927 1 O
treatment	929 9 O
.	938 1 O

In	940 2 O
a	943 1 O
further	945 7 O
series	953 6 O
of	960 2 O
experiments	963 11 O
,	974 1 O
haloperidol	976 11 B-Chemical
(	988 1 O
0	989 1 O
.	990 1 O
2	991 1 O
mg	993 2 O
/	995 1 O
kg	996 2 O
i	999 1 O
.	1000 1 O
p	1001 1 O
.	1002 1 O
)	1003 1 O
was	1005 3 O
used	1009 4 O
in	1014 2 O
order	1017 5 O
to	1023 2 O
block	1026 5 O
the	1032 3 O
dopaminergic	1036 12 O
activation	1049 10 O
and	1060 3 O
to	1064 2 O
estimate	1067 8 O
the	1076 3 O
real	1080 4 O
degree	1085 6 O
of	1092 2 O
the	1095 3 O
tolerance	1099 9 O
to	1109 2 O
the	1112 3 O
rigidity	1116 8 B-Disease
without	1125 7 O
any	1133 3 O
dopaminergic	1137 12 O
interference	1150 12 O
.	1162 1 O

Haloperidol	1164 11 B-Chemical
enhanced	1176 8 O
the	1185 3 O
rigidity	1189 8 B-Disease
in	1198 2 O
the	1201 3 O
A	1205 1 O
group	1207 5 O
.	1212 1 O

However	1214 7 O
,	1221 1 O
the	1223 3 O
level	1227 5 O
in	1233 2 O
the	1236 3 O
AS	1240 2 O
/	1242 1 O
KS	1243 2 O
group	1246 5 O
remained	1252 8 O
considerably	1261 12 O
lower	1274 5 O
than	1280 4 O
in	1285 2 O
the	1288 3 O
A	1292 1 O
group	1294 5 O
.	1299 1 O

The	1301 3 O
results	1305 7 O
suggest	1313 7 O
that	1321 4 O
rigidity	1326 8 B-Disease
,	1334 1 O
which	1336 5 O
is	1342 2 O
assumed	1345 7 O
to	1353 2 O
be	1356 2 O
due	1359 3 O
to	1363 2 O
an	1366 2 O
action	1369 6 O
of	1376 2 O
morphine	1379 8 B-Chemical
in	1388 2 O
the	1391 3 O
striatum	1395 8 O
,	1403 1 O
can	1405 3 O
be	1409 2 O
antagonized	1412 11 O
by	1424 2 O
another	1427 7 O
process	1435 7 O
leading	1443 7 O
to	1451 2 O
dopaminergic	1454 12 O
activation	1467 10 O
in	1478 2 O
the	1481 3 O
striatum	1485 8 O
.	1493 1 O

Nevertheless	1495 12 O
,	1507 1 O
there	1509 5 O
occurs	1515 6 O
some	1522 4 O
real	1527 4 O
tolerance	1532 9 O
to	1542 2 O
this	1545 4 O
effect	1550 6 O
.	1556 1 O

The	1558 3 O
rapid	1562 5 O
alternations	1568 12 O
of	1581 2 O
rigidity	1584 8 B-Disease
and	1593 3 O
the	1597 3 O
signs	1601 5 O
of	1607 2 O
dopaminergic	1610 12 O
activation	1623 10 O
observed	1634 8 O
in	1643 2 O
the	1646 3 O
animals	1650 7 O
of	1658 2 O
the	1661 3 O
AS	1665 2 O
/	1667 1 O
KS	1668 2 O
group	1671 5 O
might	1677 5 O
be	1683 2 O
due	1686 3 O
to	1690 2 O
rapid	1693 5 O
shifts	1699 6 O
in	1706 2 O
the	1709 3 O
predominance	1713 12 O
of	1726 2 O
various	1729 7 O
DA	1737 2 O
-	1739 1 O
innervated	1740 10 O
structures	1751 10 O
.	1761 1 O

Compression	0 11 B-Disease
neuropathy	12 10 I-Disease
of	23 2 I-Disease
the	26 3 I-Disease
radial	30 6 I-Disease
nerve	37 5 I-Disease
due	43 3 O
to	47 2 O
pentazocine	50 11 B-Chemical
-	61 1 O
induced	62 7 O
fibrous	70 7 B-Disease
myopathy	78 8 I-Disease
.	86 1 O

Fibrous	88 7 B-Disease
myopathy	96 8 I-Disease
is	105 2 O
a	108 1 O
common	110 6 O
,	116 1 O
well	118 4 O
-	122 1 O
known	123 5 O
side	129 4 O
effect	134 6 O
of	141 2 O
repeated	144 8 O
pentazocine	153 11 B-Chemical
injection	165 9 O
.	174 1 O

However	176 7 O
,	183 1 O
compression	185 11 B-Disease
neuropathy	197 10 I-Disease
due	208 3 O
to	212 2 O
fibrotic	215 8 O
muscle	224 6 O
affected	231 8 O
by	240 2 O
pentazocine	243 11 B-Chemical
-	254 1 O
induced	255 7 O
myopathy	263 8 B-Disease
has	272 3 O
not	276 3 O
previously	280 10 O
been	291 4 O
reported	296 8 O
.	304 1 O

In	306 2 O
a	309 1 O
37	311 2 O
-	313 1 O
year	314 4 O
-	318 1 O
old	319 3 O
woman	323 5 O
with	329 4 O
documented	334 10 O
pentazocine	345 11 B-Chemical
-	356 1 O
induced	357 7 O
fibrous	365 7 B-Disease
myopathy	373 8 I-Disease
of	382 2 O
triceps	385 7 O
and	393 3 O
deltoid	397 7 O
muscles	405 7 O
bilaterally	413 11 O
and	425 3 O
a	429 1 O
three	431 5 O
-	436 1 O
week	437 4 O
history	442 7 O
of	450 2 O
right	453 5 O
wrist	459 5 O
drop	465 4 O
,	469 1 O
electrodiagnostic	471 17 O
examination	489 11 O
showed	501 6 O
a	508 1 O
severe	510 6 O
but	517 3 O
partial	521 7 O
lesion	529 6 O
of	536 2 O
the	539 3 O
right	543 5 O
radial	549 6 O
nerve	556 5 O
distal	562 6 O
to	569 2 O
the	572 3 O
branches	576 8 O
to	585 2 O
the	588 3 O
triceps	592 7 O
,	599 1 O
in	601 2 O
addition	604 8 O
to	613 2 O
the	616 3 O
fibrous	620 7 B-Disease
myopathy	628 8 I-Disease
.	636 1 O

Surgery	638 7 O
revealed	646 8 O
the	655 3 O
right	659 5 O
radial	665 6 O
nerve	672 5 O
to	678 2 O
be	681 2 O
severely	684 8 O
compressed	693 10 O
by	704 2 O
the	707 3 O
densely	711 7 O
fibrotic	719 8 O
lateral	728 7 O
head	736 4 O
of	741 2 O
the	744 3 O
triceps	748 7 O
.	755 1 O

Decompression	757 13 O
and	771 3 O
neurolysis	775 10 O
were	786 4 O
performed	791 9 O
with	801 4 O
good	806 4 O
subsequent	811 10 O
recovery	822 8 O
of	831 2 O
function	834 8 O
.	842 1 O

Recurrent	0 9 O
reversible	10 10 O
acute	21 5 B-Disease
renal	27 5 I-Disease
failure	33 7 I-Disease
from	41 4 O
amphotericin	46 12 B-Chemical
.	58 1 O

A	60 1 O
patient	62 7 O
with	70 4 O
cryptogenic	75 11 O
cirrhosis	87 9 B-Disease
and	97 3 O
disseminated	101 12 O
sporotrichosis	114 14 B-Disease
developed	129 9 O
acute	139 5 B-Disease
renal	145 5 I-Disease
failure	151 7 I-Disease
immediately	159 11 O
following	171 9 O
the	181 3 O
administration	185 14 O
of	200 2 O
amphotericin	203 12 B-Chemical
B	216 1 I-Chemical
on	218 2 O
four	221 4 O
separate	226 8 O
occasions	235 9 O
.	244 1 O

The	246 3 O
abruptness	250 10 O
of	261 2 O
the	264 3 O
renal	268 5 B-Disease
failure	274 7 I-Disease
and	282 3 O
its	286 3 O
reversibility	290 13 O
within	304 6 O
days	311 4 O
suggests	316 8 O
that	325 4 O
there	330 5 O
was	336 3 O
a	340 1 O
functional	342 10 O
component	353 9 O
to	363 2 O
the	366 3 O
renal	370 5 B-Disease
dysfunction	376 11 I-Disease
.	387 1 O

We	389 2 O
propose	392 7 O
that	400 4 O
amphotericin	405 12 B-Chemical
,	417 1 O
in	419 2 O
the	422 3 O
setting	426 7 O
of	434 2 O
reduced	437 7 O
effective	445 9 O
arterial	455 8 O
volume	464 6 O
,	470 1 O
may	472 3 O
activate	476 8 O
tubuloglomerular	485 16 O
feedback	502 8 O
,	510 1 O
thereby	512 7 O
contributing	520 12 O
to	533 2 O
acute	536 5 B-Disease
renal	542 5 I-Disease
failure	548 7 I-Disease
.	555 1 O

Pneumonitis	0 11 O
with	12 4 O
pleural	17 7 B-Disease
and	25 3 I-Disease
pericardial	29 11 I-Disease
effusion	41 8 I-Disease
and	50 3 O
neuropathy	54 10 B-Disease
during	65 6 O
amiodarone	72 10 B-Chemical
therapy	83 7 O
.	90 1 O

A	92 1 O
patient	94 7 O
with	102 4 O
sinuatrial	107 10 B-Disease
disease	118 7 I-Disease
and	126 3 O
implanted	130 9 O
pacemaker	140 9 O
was	150 3 O
treated	154 7 O
with	162 4 O
amiodarone	167 10 B-Chemical
(	178 1 O
maximum	179 7 O
dose	187 4 O
1000	192 4 O
mg	197 2 O
,	199 1 O
maintenance	201 11 O
dose	213 4 O
800	218 3 O
mg	222 2 O
daily	225 5 O
)	230 1 O
for	232 3 O
10	236 2 O
months	239 6 O
,	245 1 O
for	247 3 O
control	251 7 O
of	259 2 O
supraventricular	262 16 B-Disease
tachyarrhythmias	279 16 I-Disease
.	295 1 O

He	297 2 O
developed	300 9 O
pneumonitis	310 11 B-Disease
,	321 1 O
pleural	323 7 B-Disease
and	331 3 I-Disease
pericardial	335 11 I-Disease
effusions	347 9 I-Disease
,	356 1 O
and	358 3 O
a	362 1 O
predominantly	364 13 O
proximal	378 8 B-Disease
motor	387 5 I-Disease
neuropathy	393 10 I-Disease
.	403 1 O

Immediate	405 9 O
but	415 3 O
gradual	419 7 O
improvement	427 11 O
followed	439 8 O
withdrawal	448 10 O
of	459 2 O
amiodarone	462 10 B-Chemical
and	473 3 O
treatment	477 9 O
with	487 4 O
prednisolone	492 12 B-Chemical
.	504 1 O

Review	506 6 O
of	513 2 O
this	516 4 O
and	521 3 O
previously	525 10 O
reported	536 8 O
cases	545 5 O
indicates	551 9 O
the	561 3 O
need	565 4 O
for	570 3 O
early	574 5 O
diagnosis	580 9 O
of	590 2 O
amiodarone	593 10 B-Chemical
pneumonitis	604 11 B-Disease
,	615 1 O
immediate	617 9 O
withdrawal	627 10 O
of	638 2 O
amiodarone	641 10 B-Chemical
,	651 1 O
and	653 3 O
prompt	657 6 O
but	664 3 O
continued	668 9 O
steroid	678 7 B-Chemical
therapy	686 7 O
to	694 2 O
ensure	697 6 O
full	704 4 O
recovery	709 8 O
.	717 1 O

Indomethacin	0 12 B-Chemical
-	12 1 O
induced	13 7 O
renal	21 5 B-Disease
insufficiency	27 13 I-Disease
:	40 1 O
recurrence	42 10 O
on	53 2 O
rechallenge	56 11 O
.	67 1 O

We	69 2 O
have	72 4 O
reported	77 8 O
a	86 1 O
case	88 4 O
of	93 2 O
acute	96 5 O
oliguric	102 8 O
renal	111 5 B-Disease
failure	117 7 I-Disease
with	125 4 O
hyperkalemia	130 12 B-Disease
in	143 2 O
a	146 1 O
patient	148 7 O
with	156 4 O
cirrhosis	161 9 B-Disease
,	170 1 O
ascites	172 7 B-Disease
,	179 1 O
and	181 3 O
cor	185 3 B-Disease
pulmonale	189 9 I-Disease
after	199 5 O
indomethacin	205 12 B-Chemical
therapy	218 7 O
.	225 1 O

Prompt	227 6 O
restoration	234 11 O
of	246 2 O
renal	249 5 O
function	255 8 O
followed	264 8 O
drug	273 4 O
withdrawal	278 10 O
,	288 1 O
while	290 5 O
re	296 2 O
-	298 1 O
exposure	299 8 O
to	308 2 O
a	311 1 O
single	313 6 O
dose	320 4 O
of	325 2 O
indomethacin	328 12 B-Chemical
caused	341 6 O
recurrence	348 10 O
of	359 2 O
acute	362 5 O
reversible	368 10 O
oliguria	379 8 B-Disease
.	387 1 O

Our	389 3 O
case	393 4 O
supports	398 8 O
the	407 3 O
hypothesis	411 10 O
that	422 4 O
endogenous	427 10 O
renal	438 5 O
prostaglandins	444 14 B-Chemical
play	459 4 O
a	464 1 O
role	466 4 O
in	471 2 O
the	474 3 O
maintenance	478 11 O
of	490 2 O
renal	493 5 O
blood	499 5 O
flow	505 4 O
when	510 4 O
circulating	515 11 O
plasma	527 6 O
volume	534 6 O
is	541 2 O
diminished	544 10 O
.	554 1 O

Since	556 5 O
nonsteroidal	562 12 O
anti	575 4 O
-	579 1 O
inflammatory	580 12 O
agents	593 6 O
interfere	600 9 O
with	610 4 O
this	615 4 O
compensatory	620 12 O
mechanism	633 9 O
and	643 3 O
may	647 3 O
cause	651 5 O
acute	657 5 B-Disease
renal	663 5 I-Disease
failure	669 7 I-Disease
,	676 1 O
they	678 4 O
should	683 6 O
be	690 2 O
used	693 4 O
with	698 4 O
caution	703 7 O
in	711 2 O
such	714 4 O
patients	719 8 O
.	727 1 O

Comparison	0 10 O
of	11 2 O
the	14 3 O
subjective	18 10 O
effects	29 7 O
and	37 3 O
plasma	41 6 O
concentrations	48 14 O
following	63 9 O
oral	73 4 O
and	78 3 O
i	82 1 O
.	83 1 O
m	84 1 O
.	85 1 O
administration	87 14 O
of	102 2 O
flunitrazepam	105 13 B-Chemical
in	119 2 O
volunteers	122 10 O
.	132 1 O

Flunitrazepam	134 13 B-Chemical
0	148 1 O
.	149 1 O
5	150 1 O
,	151 1 O
1	153 1 O
.	154 1 O
0	155 1 O
or	157 2 O
2	160 1 O
.	161 1 O
0	162 1 O
mg	164 2 O
was	167 3 O
given	171 5 O
by	177 2 O
the	180 3 O
oral	184 4 O
or	189 2 O
i	192 1 O
.	193 1 O
m	194 1 O
.	195 1 O
routes	197 6 O
to	204 2 O
groups	207 6 O
of	214 2 O
volunteers	217 10 O
and	228 3 O
its	232 3 O
effects	236 7 O
compared	244 8 O
.	252 1 O

Plasma	254 6 O
concentrations	261 14 O
of	276 2 O
the	279 3 O
drug	283 4 O
were	288 4 O
estimated	293 9 O
by	303 2 O
gas	306 3 O
-	309 1 O
liquid	310 6 O
chromatography	317 14 O
,	331 1 O
in	333 2 O
a	336 1 O
smaller	338 7 O
number	346 6 O
of	353 2 O
the	356 3 O
subjects	360 8 O
.	368 1 O

The	370 3 O
most	374 4 O
striking	379 8 O
effect	388 6 O
was	395 3 O
sedation	399 8 O
which	408 5 O
increased	414 9 O
with	424 4 O
the	429 3 O
dose	433 4 O
,	437 1 O
2	439 1 O
mg	441 2 O
producing	444 9 O
deep	454 4 O
sleep	459 5 O
although	465 8 O
the	474 3 O
subjects	478 8 O
could	487 5 O
still	493 5 O
be	499 2 O
aroused	502 7 O
.	509 1 O

The	511 3 O
effects	515 7 O
of	523 2 O
i	526 1 O
.	527 1 O
m	528 1 O
.	529 1 O
administration	531 14 O
were	546 4 O
apparent	551 8 O
earlier	560 7 O
and	568 3 O
sometimes	572 9 O
lasted	582 6 O
longer	589 6 O
than	596 4 O
those	601 5 O
following	607 9 O
oral	617 4 O
administration	622 14 O
.	636 1 O

Dizziness	638 9 B-Disease
was	648 3 O
less	652 4 O
marked	657 6 O
than	664 4 O
sedation	669 8 O
,	677 1 O
but	679 3 O
increased	683 9 O
with	693 4 O
the	698 3 O
dose	702 4 O
.	706 1 O

There	708 5 O
was	714 3 O
pain	718 4 B-Disease
on	723 2 O
i	726 1 O
.	727 1 O
m	728 1 O
.	729 1 O
injection	731 9 O
of	741 2 O
flunitrazepam	744 13 B-Chemical
significantly	758 13 O
more	772 4 O
often	777 5 O
than	783 4 O
with	788 4 O
isotonic	793 8 O
saline	802 6 O
.	808 1 O

Plasma	810 6 O
concentrations	817 14 O
varied	832 6 O
with	839 4 O
dose	844 4 O
and	849 3 O
route	853 5 O
and	859 3 O
corresponded	863 12 O
qualitatively	876 13 O
with	890 4 O
the	895 3 O
subjective	899 10 O
effects	910 7 O
.	917 1 O

The	919 3 O
drug	923 4 O
was	928 3 O
still	932 5 O
present	938 7 O
in	946 2 O
measurable	949 10 O
quantities	960 10 O
after	971 5 O
24	977 2 O
h	980 1 O
even	982 4 O
with	987 4 O
the	992 3 O
smallest	996 8 O
dose	1005 4 O
.	1009 1 O

Changes	0 7 O
in	8 2 O
heart	11 5 O
size	17 4 O
during	22 6 O
long	29 4 O
-	33 1 O
term	34 4 O
timolol	39 7 B-Chemical
treatment	47 9 O
after	57 5 O
myocardial	63 10 B-Disease
infarction	74 10 I-Disease
.	84 1 O

The	86 3 O
effect	90 6 O
of	97 2 O
long	100 4 O
-	104 1 O
term	105 4 O
timolol	110 7 B-Chemical
treatment	118 9 O
on	128 2 O
heart	131 5 O
size	137 4 O
after	142 5 O
myocardial	148 10 B-Disease
infarction	159 10 I-Disease
was	170 3 O
evaluated	174 9 O
by	184 2 O
X	187 1 O
-	188 1 O
ray	189 3 O
in	193 2 O
a	196 1 O
double	198 6 O
-	204 1 O
blind	205 5 O
study	211 5 O
including	217 9 O
241	227 3 O
patients	231 8 O
(	240 1 O
placebo	241 7 O
126	249 3 O
,	252 1 O
timolol	254 7 B-Chemical
115	262 3 O
)	265 1 O
.	266 1 O

The	268 3 O
follow	272 6 O
-	278 1 O
up	279 2 O
period	282 6 O
was	289 3 O
12	293 2 O
months	296 6 O
.	302 1 O

The	304 3 O
timolol	308 7 B-Chemical
-	315 1 O
treated	316 7 O
patients	324 8 O
showed	333 6 O
a	340 1 O
small	342 5 O
but	348 3 O
significant	352 11 O
increase	364 8 O
in	373 2 O
heart	376 5 O
size	382 4 O
from	387 4 O
baseline	392 8 O
in	401 2 O
contrast	404 8 O
to	413 2 O
a	416 1 O
decrease	418 8 O
in	427 2 O
the	430 3 O
placebo	434 7 O
group	442 5 O
.	447 1 O

These	449 5 O
differences	455 11 O
may	467 3 O
be	471 2 O
caused	474 6 O
by	481 2 O
timolol	484 7 B-Chemical
-	491 1 O
induced	492 7 O
bradycardia	500 11 B-Disease
and	512 3 O
a	516 1 O
compensatory	518 12 O
increase	531 8 O
in	540 2 O
end	543 3 O
-	546 1 O
diastolic	547 9 O
volume	557 6 O
.	563 1 O

The	565 3 O
timolol	569 7 B-Chemical
-	576 1 O
related	577 7 O
increase	585 8 O
in	594 2 O
heart	597 5 O
size	603 4 O
was	608 3 O
observed	612 8 O
only	621 4 O
in	626 2 O
patients	629 8 O
with	638 4 O
normal	643 6 O
and	650 3 O
borderline	654 10 O
heart	665 5 O
size	671 4 O
.	675 1 O

In	677 2 O
patients	680 8 O
with	689 4 O
cardiomegaly	694 12 B-Disease
,	706 1 O
the	708 3 O
increase	712 8 O
in	721 2 O
heart	724 5 O
size	730 4 O
was	735 3 O
similar	739 7 O
in	747 2 O
both	750 4 O
groups	755 6 O
.	761 1 O

After	763 5 O
re	769 2 O
-	771 1 O
infarction	772 10 B-Disease
,	782 1 O
heart	784 5 O
size	790 4 O
increased	795 9 O
in	805 2 O
the	808 3 O
placebo	812 7 O
group	820 5 O
and	826 3 O
remained	830 8 O
unchanged	839 9 O
in	849 2 O
the	852 3 O
timolol	856 7 B-Chemical
group	864 5 O
.	869 1 O

Vitamin	0 7 B-Chemical
D3	8 2 I-Chemical
toxicity	11 8 B-Disease
in	20 2 O
dairy	23 5 O
cows	29 4 O
.	33 1 O

Large	35 5 O
parenteral	41 10 O
doses	52 5 O
of	58 2 O
vitamin	61 7 B-Chemical
D3	69 2 I-Chemical
(	72 1 O
15	73 2 O
to	76 2 O
17	79 2 O
.	81 1 O
5	82 1 O
x	84 1 O
10	86 2 O
(	88 1 O
6	89 1 O
)	90 1 O
IU	92 2 O
vitamin	95 7 B-Chemical
D3	103 2 I-Chemical
)	105 1 O
were	107 4 O
associated	112 10 O
with	123 4 O
prolonged	128 9 O
hypercalcemia	138 13 B-Disease
,	151 1 O
hyperphosphatemia	153 17 B-Disease
,	170 1 O
and	172 3 O
large	176 5 O
increases	182 9 O
of	192 2 O
vitamin	195 7 B-Chemical
D3	203 2 I-Chemical
and	206 3 O
its	210 3 O
metabolites	214 11 O
in	226 2 O
the	229 3 O
blood	233 5 O
plasma	239 6 O
of	246 2 O
nonlactating	249 12 O
nonpregnant	262 11 O
and	274 3 O
pregnant	278 8 O
Jersey	287 6 O
cows	294 4 O
.	298 1 O

Calcium	300 7 B-Chemical
concentrations	308 14 O
1	323 1 O
day	325 3 O
postpartum	329 10 O
were	340 4 O
higher	345 6 O
in	352 2 O
cows	355 4 O
treated	360 7 O
with	368 4 O
vitamin	373 7 B-Chemical
D3	381 2 I-Chemical
about	384 5 O
32	390 2 O
days	393 4 O
prepartum	398 9 O
(	408 1 O
8	409 1 O
.	410 1 O
8	411 1 O
mg	413 2 O
/	415 1 O
100	416 3 O
ml	420 2 O
)	422 1 O
than	424 4 O
in	429 2 O
control	432 7 O
cows	440 4 O
(	445 1 O
5	446 1 O
.	447 1 O
5	448 1 O
mg	450 2 O
/	452 1 O
100	453 3 O
ml	457 2 O
)	459 1 O
.	460 1 O

None	462 4 O
of	467 2 O
the	470 3 O
cows	474 4 O
treated	479 7 O
with	487 4 O
vitamin	492 7 B-Chemical
D3	500 2 I-Chemical
showed	503 6 O
signs	510 5 O
of	516 2 O
milk	519 4 B-Disease
fever	524 5 I-Disease
during	530 6 O
the	537 3 O
peripartal	541 10 O
period	552 6 O
;	558 1 O
however	560 7 O
,	567 1 O
22	569 2 O
%	571 1 O
of	573 2 O
the	576 3 O
control	580 7 O
cows	588 4 O
developed	593 9 O
clinical	603 8 O
signs	612 5 O
of	618 2 O
milk	621 4 B-Disease
fever	626 5 I-Disease
during	632 6 O
this	639 4 O
period	644 6 O
.	650 1 O

Signs	652 5 O
of	658 2 O
vitamin	661 7 B-Chemical
D3	669 2 I-Chemical
toxicity	672 8 B-Disease
were	681 4 O
not	686 3 O
observed	690 8 O
in	699 2 O
nonlactating	702 12 O
nonpregnant	715 11 O
cows	727 4 O
;	731 1 O
however	733 7 O
,	740 1 O
pregnant	742 8 O
cows	751 4 O
commonly	756 8 O
developed	765 9 O
severe	775 6 O
signs	782 5 O
of	788 2 O
vitamin	791 7 B-Chemical
D3	799 2 I-Chemical
toxicity	802 8 B-Disease
and	811 3 O
10	815 2 O
of	818 2 O
17	821 2 O
cows	824 4 O
died	829 4 O
.	833 1 O

There	835 5 O
was	841 3 O
widespread	845 10 O
metastatic	856 10 O
calcification	867 13 O
in	881 2 O
the	884 3 O
cows	888 4 O
that	893 4 O
died	898 4 O
.	902 1 O

Because	904 7 O
of	912 2 O
the	915 3 O
extreme	919 7 O
toxicity	927 8 B-Disease
of	936 2 O
vitamin	939 7 B-Chemical
D3	947 2 I-Chemical
in	950 2 O
pregnant	953 8 O
Jersey	962 6 O
cows	969 4 O
and	974 3 O
the	978 3 O
low	982 3 O
margin	986 6 O
of	993 2 O
safety	996 6 O
between	1003 7 O
doses	1011 5 O
of	1017 2 O
vitamin	1020 7 B-Chemical
D3	1028 2 I-Chemical
that	1031 4 O
prevent	1036 7 O
milk	1044 4 B-Disease
fever	1049 5 I-Disease
and	1055 3 O
doses	1059 5 O
that	1065 4 O
induce	1070 6 O
milk	1077 4 B-Disease
fever	1082 5 I-Disease
,	1087 1 O
we	1089 2 O
concluded	1092 9 O
that	1102 4 O
vitamin	1107 7 B-Chemical
D3	1115 2 I-Chemical
cannot	1118 6 O
be	1125 2 O
used	1128 4 O
practically	1133 11 O
to	1145 2 O
prevent	1148 7 O
milk	1156 4 B-Disease
fever	1161 5 I-Disease
when	1167 4 O
injected	1172 8 O
several	1181 7 O
weeks	1189 5 O
prepartum	1195 9 O
.	1204 1 O

Diseases	0 8 B-Disease
of	9 2 I-Disease
peripheral	12 10 I-Disease
nerves	23 6 I-Disease
as	30 2 O
seen	33 4 O
in	38 2 O
the	41 3 O
Nigerian	45 8 O
African	54 7 O
.	61 1 O

The	63 3 O
anatomical	67 10 O
and	78 3 O
aetiological	82 12 O
diagnoses	95 9 O
of	105 2 O
peripheral	108 10 B-Disease
nerve	119 5 I-Disease
disease	125 7 I-Disease
excluding	133 9 O
its	143 3 O
primary	147 7 O
benign	155 6 O
and	162 3 O
malignant	166 9 O
disorders	176 9 O
,	185 1 O
as	187 2 O
seen	190 4 O
in	195 2 O
358	198 3 O
Nigerians	202 9 O
are	212 3 O
presented	216 9 O
.	225 1 O

There	227 5 O
is	233 2 O
a	236 1 O
male	238 4 O
preponderance	243 13 O
and	257 3 O
the	261 3 O
peak	265 4 O
incidence	270 9 O
is	280 2 O
in	283 2 O
the	286 3 O
fourth	290 6 O
decade	297 6 O
.	303 1 O

Sensori	305 7 B-Disease
-	312 1 I-Disease
motor	313 5 I-Disease
neuropathy	319 10 I-Disease
was	330 3 O
the	334 3 O
commonest	338 9 O
presentation	348 12 O
(	361 1 O
50	362 2 O
%	364 1 O
)	365 1 O
.	366 1 O

Guillain	368 8 B-Disease
-	376 1 I-Disease
Barr	377 4 I-Disease
syndrome	384 8 I-Disease
was	393 3 O
the	397 3 O
commonest	401 9 O
identifiable	411 12 O
cause	424 5 O
(	430 1 O
15	431 2 O
.	433 1 O
6	434 1 O
%	435 1 O
)	436 1 O
,	437 1 O
accounting	439 10 O
for	450 3 O
half	454 4 O
of	459 2 O
the	462 3 O
cases	466 5 O
with	472 4 O
motor	477 5 B-Disease
neuropathy	483 10 I-Disease
.	493 1 O

Peripheral	495 10 B-Disease
neuropathy	506 10 I-Disease
due	517 3 O
to	521 2 O
nutritional	524 11 B-Disease
deficiency	536 10 I-Disease
of	547 2 O
thiamine	550 8 B-Chemical
and	559 3 O
riboflavin	563 10 B-Chemical
was	574 3 O
common	578 6 O
(	585 1 O
10	586 2 O
.	588 1 O
1	589 1 O
%	590 1 O
)	591 1 O
and	593 3 O
presented	597 9 O
mainly	607 6 O
as	614 2 O
sensory	617 7 O
and	625 3 O
sensori	629 7 B-Disease
-	636 1 I-Disease
motor	637 5 I-Disease
neuropathy	643 10 I-Disease
.	653 1 O

Diabetes	655 8 B-Disease
mellitus	664 8 I-Disease
was	673 3 O
the	677 3 O
major	681 5 O
cause	687 5 O
of	693 2 O
autonomic	696 9 B-Disease
neuropathy	706 10 I-Disease
.	716 1 O

Isoniazid	718 9 B-Chemical
was	728 3 O
the	732 3 O
most	736 4 O
frequent	741 8 O
agent	750 5 O
in	756 2 O
drug	759 4 O
-	763 1 O
induced	764 7 O
neuropathy	772 10 B-Disease
.	782 1 O

Migraine	784 8 B-Disease
(	793 1 O
20	794 2 O
%	796 1 O
)	797 1 O
was	799 3 O
not	803 3 O
an	807 2 O
uncommon	810 8 O
cause	819 5 O
of	825 2 O
cranial	828 7 B-Disease
neuropathy	836 10 I-Disease
although	847 8 O
malignancies	856 12 B-Disease
arising	869 7 O
from	877 4 O
the	882 3 O
reticuloendothelial	886 19 O
system	906 6 O
or	913 2 O
related	916 7 O
structures	924 10 O
of	935 2 O
the	938 3 O
head	942 4 O
and	947 3 O
neck	951 4 O
were	956 4 O
more	961 4 O
frequent	966 8 O
(	975 1 O
26	976 2 O
%	978 1 O
)	979 1 O
.	980 1 O

In	982 2 O
26	985 2 O
.	987 1 O
5	988 1 O
%	989 1 O
of	991 2 O
all	994 3 O
the	998 3 O
cases	1002 5 O
,	1007 1 O
the	1009 3 O
aetiology	1013 9 O
of	1023 2 O
the	1026 3 O
neuropathy	1030 10 B-Disease
was	1041 3 O
undetermined	1045 12 O
.	1057 1 O

Heredofamilial	1059 14 O
and	1074 3 O
connective	1078 10 B-Disease
tissue	1089 6 I-Disease
disorders	1096 9 I-Disease
were	1106 4 O
rare	1111 4 O
.	1115 1 O

Some	1117 4 O
of	1122 2 O
the	1125 3 O
factors	1129 7 O
related	1137 7 O
to	1145 2 O
the	1148 3 O
clinical	1152 8 O
presentation	1161 12 O
and	1174 3 O
pathogenesis	1178 12 O
of	1191 2 O
the	1194 3 O
neuropathies	1198 12 B-Disease
are	1211 3 O
briefly	1215 7 O
discussed	1223 9 O
.	1232 1 O

A	0 1 O
double	2 6 O
-	8 1 O
blind	9 5 O
study	15 5 O
of	21 2 O
the	24 3 O
efficacy	28 8 O
and	37 3 O
safety	41 6 O
of	48 2 O
dothiepin	51 9 B-Chemical
hydrochloride	61 13 I-Chemical
in	75 2 O
the	78 3 O
treatment	82 9 O
of	92 2 O
major	95 5 O
depressive	101 10 B-Disease
disorder	112 8 I-Disease
.	120 1 O

In	122 2 O
a	125 1 O
6	127 1 O
-	128 1 O
week	129 4 O
double	134 6 O
-	140 1 O
blind	141 5 O
parallel	147 8 O
treatment	156 9 O
study	166 5 O
,	171 1 O
dothiepin	173 9 B-Chemical
and	183 3 O
amitriptyline	187 13 B-Chemical
were	201 4 O
compared	206 8 O
to	215 2 O
placebo	218 7 O
in	226 2 O
the	229 3 O
treatment	233 9 O
of	243 2 O
33	246 2 O
depressed	249 9 B-Disease
outpatients	259 11 O
.	270 1 O

Dothiepin	272 9 B-Chemical
and	282 3 O
amitriptyline	286 13 B-Chemical
were	300 4 O
equally	305 7 O
effective	313 9 O
in	323 2 O
alleviating	326 11 O
the	338 3 O
symptoms	342 8 O
of	351 2 O
depressive	354 10 B-Disease
illness	365 7 I-Disease
,	372 1 O
and	374 3 O
both	378 4 O
were	383 4 O
significantly	388 13 O
superior	402 8 O
to	411 2 O
placebo	414 7 O
.	421 1 O

The	423 3 O
overall	427 7 O
incidence	435 9 O
of	445 2 O
side	448 4 O
effects	453 7 O
and	461 3 O
the	465 3 O
frequency	469 9 O
and	479 3 O
severity	483 8 O
of	492 2 O
blurred	495 7 B-Disease
vision	503 6 I-Disease
,	509 1 O
dry	511 3 B-Disease
mouth	515 5 I-Disease
,	520 1 O
and	522 3 O
drowsiness	526 10 O
were	537 4 O
significantly	542 13 O
less	556 4 O
with	561 4 O
dothiepin	566 9 B-Chemical
than	576 4 O
with	581 4 O
amitriptyline	586 13 B-Chemical
.	599 1 O

Dothiepin	601 9 B-Chemical
also	611 4 O
produced	616 8 O
fewer	625 5 O
CNS	631 3 O
and	635 3 O
cardiovascular	639 14 O
effects	654 7 O
.	661 1 O

There	663 5 O
were	669 4 O
no	674 2 O
clinically	677 10 O
important	688 9 O
changes	698 7 O
in	706 2 O
laboratory	709 10 O
parameters	720 10 O
.	730 1 O

Dothiepin	732 9 B-Chemical
thus	742 4 O
was	747 3 O
found	751 5 O
to	757 2 O
be	760 2 O
an	763 2 O
effective	766 9 O
antidepressant	776 14 B-Chemical
drug	791 4 O
associated	796 10 O
with	807 4 O
fewer	812 5 O
side	818 4 O
effects	823 7 O
than	831 4 O
amitriptyline	836 13 B-Chemical
in	850 2 O
the	853 3 O
treatment	857 9 O
of	867 2 O
depressed	870 9 B-Disease
outpatients	880 11 O
.	891 1 O

Behavioral	0 10 O
effects	11 7 O
of	19 2 O
diazepam	22 8 B-Chemical
and	31 3 O
propranolol	35 11 B-Chemical
in	47 2 O
patients	50 8 O
with	59 4 O
panic	64 5 B-Disease
disorder	70 8 I-Disease
and	79 3 O
agoraphobia	83 11 B-Disease
.	94 1 O

The	96 3 O
effects	100 7 O
of	108 2 O
oral	111 4 O
doses	116 5 O
of	122 2 O
diazepam	125 8 B-Chemical
(	134 1 O
single	135 6 O
dose	142 4 O
of	147 2 O
10	150 2 O
mg	153 2 O
and	156 3 O
a	160 1 O
median	162 6 O
dose	169 4 O
of	174 2 O
30	177 2 O
mg	180 2 O
/	182 1 O
day	183 3 O
for	187 3 O
2	191 1 O
weeks	193 5 O
)	198 1 O
and	200 3 O
propranolol	204 11 B-Chemical
(	216 1 O
single	217 6 O
dose	224 4 O
of	229 2 O
80	232 2 O
mg	235 2 O
and	238 3 O
a	242 1 O
median	244 6 O
dose	251 4 O
of	256 2 O
240	259 3 O
mg	263 2 O
/	265 1 O
day	266 3 O
for	270 3 O
2	274 1 O
weeks	276 5 O
)	281 1 O
on	283 2 O
psychological	286 13 O
performance	300 11 O
of	312 2 O
patients	315 8 O
with	324 4 O
panic	329 5 B-Disease
disorders	335 9 I-Disease
and	345 3 O
agoraphobia	349 11 B-Disease
were	361 4 O
investigated	366 12 O
in	379 2 O
a	382 1 O
double	384 6 O
-	390 1 O
blind	391 5 O
,	396 1 O
randomized	398 10 O
and	409 3 O
crossover	413 9 O
design	423 6 O
.	429 1 O

Both	431 4 O
drugs	436 5 O
impaired	442 8 B-Disease
immediate	451 9 I-Disease
free	461 4 I-Disease
recall	466 6 I-Disease
but	473 3 O
the	477 3 O
decrease	481 8 O
was	490 3 O
greater	494 7 O
for	502 3 O
diazepam	506 8 B-Chemical
than	515 4 O
propranolol	520 11 B-Chemical
.	531 1 O

Delayed	533 7 B-Disease
free	541 4 I-Disease
recall	546 6 I-Disease
was	553 3 I-Disease
also	557 4 I-Disease
impaired	562 8 I-Disease
but	571 3 O
the	575 3 O
two	579 3 O
drugs	583 5 O
did	589 3 O
not	593 3 O
differ	597 6 O
.	603 1 O

Patients	605 8 O
tapped	614 6 O
faster	621 6 O
after	628 5 O
propranolol	634 11 B-Chemical
than	646 4 O
diazepam	651 8 B-Chemical
and	660 3 O
they	664 4 O
were	669 4 O
more	674 4 O
sedated	679 7 O
after	687 5 O
diazepam	693 8 B-Chemical
than	702 4 O
propranolol	707 11 B-Chemical
.	718 1 O

After	720 5 O
2	726 1 O
weeks	728 5 O
of	734 2 O
treatment	737 9 O
,	746 1 O
patients	748 8 O
tested	757 6 O
5	764 1 O
-	765 1 O
8	766 1 O
h	768 1 O
after	770 5 O
the	776 3 O
last	780 4 O
dose	785 4 O
of	790 2 O
medication	793 10 O
did	804 3 O
not	808 3 O
show	812 4 O
any	817 3 O
decrement	821 9 O
of	831 2 O
performance	834 11 O
.	845 1 O

These	847 5 O
results	853 7 O
are	861 3 O
similar	865 7 O
to	873 2 O
those	876 5 O
previously	882 10 O
found	893 5 O
in	899 2 O
healthy	902 7 O
subjects	910 8 O
.	918 1 O

Accumulation	920 12 O
of	933 2 O
drugs	936 5 O
was	942 3 O
not	946 3 O
reflected	950 9 O
in	960 2 O
prolonged	963 9 O
behavioral	973 10 B-Disease
impairment	984 10 I-Disease
.	994 1 O

Effect	0 6 O
of	7 2 O
aspirin	10 7 B-Chemical
on	18 2 O
N	21 1 B-Chemical
-	22 1 I-Chemical
[	23 1 I-Chemical
4	24 1 I-Chemical
-	25 1 I-Chemical
(	26 1 I-Chemical
5	27 1 I-Chemical
-	28 1 I-Chemical
nitro	29 5 I-Chemical
-	34 1 I-Chemical
2	35 1 I-Chemical
-	36 1 I-Chemical
furyl	37 5 I-Chemical
)	42 1 I-Chemical
-	43 1 I-Chemical
2	44 1 I-Chemical
-	45 1 I-Chemical
thiazolyl	46 9 I-Chemical
]	55 1 I-Chemical
-	56 1 I-Chemical
formamide	57 9 I-Chemical
-	66 1 O
induced	67 7 O
epithelial	75 10 O
proliferation	86 13 O
in	100 2 O
the	103 3 O
urinary	107 7 O
bladder	115 7 O
and	123 3 O
forestomach	127 11 O
of	139 2 O
the	142 3 O
rat	146 3 O
.	149 1 O

The	151 3 O
co	155 2 O
-	157 1 O
administration	158 14 O
of	173 2 O
aspirin	176 7 B-Chemical
with	184 4 O
N	189 1 B-Chemical
-	190 1 I-Chemical
[	191 1 I-Chemical
4	192 1 I-Chemical
-	193 1 I-Chemical
(	194 1 I-Chemical
5	195 1 I-Chemical
-	196 1 I-Chemical
nitro	197 5 I-Chemical
-	202 1 I-Chemical
2	203 1 I-Chemical
-	204 1 I-Chemical
furyl	205 5 I-Chemical
)	210 1 I-Chemical
-	211 1 I-Chemical
2	212 1 I-Chemical
-	213 1 I-Chemical
thiazolyl	214 9 I-Chemical
]	223 1 I-Chemical
-	224 1 I-Chemical
formamide	225 9 I-Chemical
(	235 1 O
FANFT	236 5 B-Chemical
)	241 1 O
to	243 2 O
rats	246 4 O
resulted	251 8 O
in	260 2 O
a	263 1 O
reduced	265 7 O
incidence	273 9 O
of	283 2 O
FANFT	286 5 B-Chemical
-	291 1 O
induced	292 7 O
bladder	300 7 B-Disease
carcinomas	308 10 I-Disease
but	319 3 O
a	323 1 O
concomitant	325 11 O
induction	337 9 O
of	347 2 O
forestomach	350 11 B-Disease
tumors	362 6 I-Disease
.	368 1 O

An	370 2 O
autoradiographic	373 16 O
study	390 5 O
was	396 3 O
performed	400 9 O
on	410 2 O
male	413 4 O
F	418 1 O
-	419 1 O
344	420 3 O
rats	424 4 O
fed	429 3 O
diet	433 4 O
containing	438 10 O
FANFT	449 5 B-Chemical
at	455 2 O
a	458 1 O
level	460 5 O
of	466 2 O
0	469 1 O
.	470 1 O
2	471 1 O
%	472 1 O
and	474 3 O
/	477 1 O
or	478 2 O
aspirin	481 7 B-Chemical
at	489 2 O
a	492 1 O
level	494 5 O
of	500 2 O
0	503 1 O
.	504 1 O
5	505 1 O
%	506 1 O
to	508 2 O
evaluate	511 8 O
the	520 3 O
effect	524 6 O
of	531 2 O
aspirin	534 7 B-Chemical
on	542 2 O
the	545 3 O
increased	549 9 O
cell	559 4 O
proliferation	564 13 O
induced	578 7 O
by	586 2 O
FANFT	589 5 B-Chemical
in	595 2 O
the	598 3 O
forestomach	602 11 O
and	614 3 O
bladder	618 7 O
.	625 1 O

FANFT	627 5 B-Chemical
-	632 1 O
induced	633 7 O
cell	641 4 O
proliferation	646 13 O
in	660 2 O
the	663 3 O
bladder	667 7 O
was	675 3 O
significantly	679 13 O
suppressed	693 10 O
by	704 2 O
aspirin	707 7 B-Chemical
co	715 2 O
-	717 1 O
administration	718 14 O
after	733 5 O
4	739 1 O
weeks	741 5 O
but	747 3 O
not	751 3 O
after	755 5 O
12	761 2 O
weeks	764 5 O
.	769 1 O

In	771 2 O
the	774 3 O
forestomach	778 11 O
,	789 1 O
and	791 3 O
also	795 4 O
in	800 2 O
the	803 3 O
liver	807 5 O
,	812 1 O
aspirin	814 7 B-Chemical
did	822 3 O
not	826 3 O
affect	830 6 O
the	837 3 O
FANFT	841 5 B-Chemical
-	846 1 O
induced	847 7 O
increase	855 8 O
in	864 2 O
labeling	867 8 O
index	876 5 O
.	881 1 O

The	883 3 O
present	887 7 O
results	895 7 O
are	903 3 O
consistent	907 10 O
with	918 4 O
the	923 3 O
carcinogenicity	927 15 O
experiment	943 10 O
suggesting	954 10 O
that	965 4 O
different	970 9 O
mechanisms	980 10 O
are	991 3 O
involved	995 8 O
in	1004 2 O
FANFT	1007 5 B-Chemical
carcinogenesis	1013 14 B-Disease
in	1028 2 O
the	1031 3 O
bladder	1035 7 O
and	1043 3 O
forestomach	1047 11 O
,	1058 1 O
and	1060 3 O
that	1064 4 O
aspirin	1069 7 B-Chemical
'	1076 1 O
s	1077 1 O
effect	1079 6 O
on	1086 2 O
FANFT	1089 5 B-Chemical
in	1095 2 O
the	1098 3 O
forestomach	1102 11 O
is	1114 2 O
not	1117 3 O
due	1121 3 O
to	1125 2 O
an	1128 2 O
irritant	1131 8 O
effect	1140 6 O
associated	1147 10 O
with	1158 4 O
increased	1163 9 O
cell	1173 4 O
proliferation	1178 13 O
.	1191 1 O

Also	1193 4 O
,	1197 1 O
there	1199 5 O
appears	1205 7 O
to	1213 2 O
be	1216 2 O
an	1219 2 O
adaptation	1222 10 O
by	1233 2 O
the	1236 3 O
rats	1240 4 O
to	1245 2 O
the	1248 3 O
chronic	1252 7 O
ingestion	1260 9 O
of	1270 2 O
aspirin	1273 7 B-Chemical
.	1280 1 O

Provocation	0 11 O
of	12 2 O
postural	15 8 O
hypotension	24 11 B-Disease
by	36 2 O
nitroglycerin	39 13 B-Chemical
in	53 2 O
diabetic	56 8 B-Disease
autonomic	65 9 I-Disease
neuropathy	75 10 I-Disease
?	85 1 O

The	87 3 O
effect	91 6 O
of	98 2 O
nitroglycerin	101 13 B-Chemical
on	115 2 O
heart	118 5 O
rate	124 4 O
and	129 3 O
systolic	133 8 O
blood	142 5 O
pressure	148 8 O
was	157 3 O
compared	161 8 O
in	170 2 O
5	173 1 O
normal	175 6 O
subjects	182 8 O
,	190 1 O
12	192 2 O
diabetic	195 8 B-Disease
subjects	204 8 O
without	213 7 O
autonomic	221 9 B-Disease
neuropathy	231 10 I-Disease
,	241 1 O
and	243 3 O
5	247 1 O
diabetic	249 8 B-Disease
subjects	258 8 O
with	267 4 O
autonomic	272 9 B-Disease
neuropathy	282 10 I-Disease
.	292 1 O

The	294 3 O
magnitude	298 9 O
and	308 3 O
time	312 4 O
course	317 6 O
of	324 2 O
the	327 3 O
increase	331 8 O
in	340 2 O
heart	343 5 O
rate	349 4 O
and	354 3 O
the	358 3 O
decrease	362 8 O
in	371 2 O
systolic	374 8 O
blood	383 5 O
pressure	389 8 O
after	398 5 O
nitroglycerin	404 13 B-Chemical
were	418 4 O
similar	423 7 O
in	431 2 O
the	434 3 O
normal	438 6 O
and	445 3 O
diabetic	449 8 B-Disease
subjects	458 8 O
without	467 7 O
autonomic	475 9 B-Disease
neuropathy	485 10 I-Disease
,	495 1 O
whereas	497 7 O
a	505 1 O
lesser	507 6 O
increase	514 8 O
in	523 2 O
heart	526 5 O
rate	532 4 O
and	537 3 O
a	541 1 O
greater	543 7 O
decrease	551 8 O
in	560 2 O
systolic	563 8 O
blood	572 5 O
pressure	578 8 O
occurred	587 8 O
in	596 2 O
the	599 3 O
diabetic	603 8 B-Disease
subjects	612 8 O
with	621 4 O
autonomic	626 9 B-Disease
neuropathy	636 10 I-Disease
.	646 1 O

It	648 2 O
is	651 2 O
therefore	654 9 O
suggested	664 9 O
that	674 4 O
caution	679 7 O
should	687 6 O
be	694 2 O
exercised	697 9 O
when	707 4 O
prescribing	712 11 O
vasodilator	724 11 O
drugs	736 5 O
in	742 2 O
diabetic	745 8 B-Disease
patients	754 8 O
,	762 1 O
particularly	764 12 O
those	777 5 O
with	783 4 O
autonomic	788 9 B-Disease
neuropathy	798 10 I-Disease
.	808 1 O

Characterization	0 16 O
of	17 2 O
estrogen	20 8 B-Chemical
-	28 1 O
induced	29 7 O
adenohypophyseal	37 16 B-Disease
tumors	54 6 I-Disease
in	61 2 O
the	64 3 O
Fischer	68 7 O
344	76 3 O
rat	80 3 O
.	83 1 O

Pituitary	85 9 B-Disease
tumors	95 6 I-Disease
were	102 4 O
induced	107 7 O
in	115 2 O
F344	118 4 O
female	123 6 O
rats	130 4 O
by	135 2 O
chronic	138 7 O
treatment	146 9 O
with	156 4 O
diethylstilbestrol	161 18 B-Chemical
(	180 1 O
DES	181 3 B-Chemical
,	184 1 O
8	186 1 O
-	187 1 O
10	188 2 O
mg	191 2 O
)	193 1 O
implanted	195 9 O
subcutaneously	205 14 O
in	220 2 O
silastic	223 8 O
capsules	232 8 O
.	240 1 O

Over	242 4 O
a	247 1 O
range	249 5 O
of	255 2 O
1	258 1 O
-	259 1 O
150	260 3 O
days	264 4 O
of	269 2 O
DES	272 3 B-Chemical
treatment	276 9 O
,	285 1 O
pairs	287 5 O
of	293 2 O
control	296 7 O
and	304 3 O
DES	308 3 B-Chemical
-	311 1 O
treated	312 7 O
rats	320 4 O
were	325 4 O
sacrificed	330 10 O
,	340 1 O
and	342 3 O
their	346 5 O
pituitaries	352 11 O
dissociated	364 11 O
enzymatically	376 13 O
into	390 4 O
single	395 6 O
-	401 1 O
cell	402 4 O
preparations	407 12 O
.	419 1 O

The	421 3 O
cell	425 4 O
populations	430 11 O
were	442 4 O
examined	447 8 O
regarding	456 9 O
total	466 5 O
cell	472 4 O
recovery	477 8 O
correlated	486 10 O
with	497 4 O
gland	502 5 O
weight	508 6 O
,	514 1 O
intracellular	516 13 O
prolactin	530 9 O
(	540 1 O
PRL	541 3 O
)	544 1 O
content	546 7 O
and	554 3 O
subsequent	558 10 O
release	569 7 O
in	577 2 O
primary	580 7 O
culture	588 7 O
,	595 1 O
immunocytochemical	597 18 O
PRL	616 3 O
staining	620 8 O
,	628 1 O
density	630 7 O
and	638 3 O
/	641 1 O
or	642 2 O
size	645 4 O
alterations	650 11 O
via	662 3 O
separation	666 10 O
on	677 2 O
Ficoll	680 6 O
-	686 1 O
Hypaque	687 7 O
and	695 3 O
by	699 2 O
unit	702 4 O
gravity	707 7 O
sedimentation	715 13 O
,	728 1 O
and	730 3 O
cell	734 4 O
cycle	739 5 O
analysis	745 8 O
,	753 1 O
after	755 5 O
acriflavine	761 11 B-Chemical
DNA	773 3 O
staining	777 8 O
,	785 1 O
by	787 2 O
laser	790 5 O
flow	796 4 O
cytometry	801 9 O
.	810 1 O

Total	812 5 O
cell	818 4 O
yields	823 6 O
from	830 4 O
DES	835 3 B-Chemical
-	838 1 O
treated	839 7 O
pituitaries	847 11 O
increased	859 9 O
from	869 4 O
1	874 1 O
.	875 1 O
3	876 1 O
times	878 5 O
control	884 7 O
yields	892 6 O
at	899 2 O
8	902 1 O
days	904 4 O
of	909 2 O
treatment	912 9 O
to	922 2 O
58	925 2 O
.	927 1 O
9	928 1 O
times	930 5 O
control	936 7 O
values	944 6 O
by	951 2 O
day	954 3 O
150	958 3 O
.	961 1 O

Intracellular	963 13 O
PRL	977 3 O
content	981 7 O
ranged	989 6 O
from	996 4 O
1	1001 1 O
.	1002 1 O
9	1003 1 O
to	1005 2 O
9	1008 1 O
.	1009 1 O
4	1010 1 O
times	1012 5 O
control	1018 7 O
levels	1026 6 O
,	1032 1 O
and	1034 3 O
PRL	1038 3 O
release	1042 7 O
in	1050 2 O
vitro	1053 5 O
was	1059 3 O
significantly	1063 13 O
and	1077 3 O
consistently	1081 12 O
higher	1094 6 O
than	1101 4 O
controls	1106 8 O
,	1114 1 O
after	1116 5 O
at	1122 2 O
least	1125 5 O
8	1131 1 O
days	1133 4 O
of	1138 2 O
DES	1141 3 B-Chemical
exposure	1145 8 O
.	1153 1 O

Beyond	1155 6 O
8	1162 1 O
days	1164 4 O
of	1169 2 O
DES	1172 3 B-Chemical
exposure	1176 8 O
,	1184 1 O
the	1186 3 O
immunochemically	1190 16 O
PRL	1207 3 O
-	1210 1 O
positive	1211 8 O
proportion	1220 10 O
of	1231 2 O
cells	1234 5 O
increased	1240 9 O
to	1250 2 O
over	1253 4 O
50	1258 2 O
%	1260 1 O
of	1262 2 O
the	1265 3 O
total	1269 5 O
population	1275 10 O
.	1285 1 O

Increased	1287 9 O
density	1297 7 O
and	1305 3 O
/	1308 1 O
or	1309 2 O
size	1312 4 O
and	1317 3 O
PRL	1321 3 O
content	1325 7 O
were	1333 4 O
indicated	1338 9 O
for	1348 3 O
the	1352 3 O
majority	1356 8 O
of	1365 2 O
the	1368 3 O
PRL	1372 3 O
cell	1376 4 O
population	1381 10 O
in	1392 2 O
both	1395 4 O
types	1400 5 O
of	1406 2 O
separation	1409 10 O
protocols	1420 9 O
.	1429 1 O

All	1431 3 O
these	1435 5 O
effects	1441 7 O
of	1449 2 O
DES	1452 3 B-Chemical
were	1456 4 O
more	1461 4 O
pronounced	1466 10 O
among	1477 5 O
previously	1483 10 O
ovariectomized	1494 14 O
animals	1509 7 O
.	1516 1 O

The	1518 3 O
data	1522 4 O
extend	1527 6 O
the	1534 3 O
findings	1538 8 O
of	1547 2 O
other	1550 5 O
investigators	1556 13 O
,	1569 1 O
further	1571 7 O
establishing	1579 12 O
the	1592 3 O
DES	1596 3 B-Chemical
-	1599 1 O
induced	1600 7 O
tumor	1608 5 B-Disease
as	1614 2 O
a	1617 1 O
model	1619 5 O
for	1625 3 O
study	1629 5 O
of	1635 2 O
PRL	1638 3 O
cellular	1642 8 O
control	1651 7 O
mechanisms	1659 10 O
.	1669 1 O

Triamterene	0 11 B-Chemical
nephrolithiasis	12 15 B-Disease
complicating	28 12 O
dyazide	41 7 B-Chemical
therapy	49 7 O
.	56 1 O

A	58 1 O
case	60 4 O
of	65 2 O
triamterene	68 11 B-Chemical
nephrolithiasis	80 15 B-Disease
is	96 2 O
reported	99 8 O
in	108 2 O
a	111 1 O
man	113 3 O
after	117 5 O
4	123 1 O
years	125 5 O
of	131 2 O
hydrochlorothiazide	134 19 B-Chemical
-	153 1 I-Chemical
triamterene	154 11 I-Chemical
therapy	166 7 O
for	174 3 O
hypertension	178 12 B-Disease
.	190 1 O

The	192 3 O
stone	196 5 O
passed	202 6 O
spontaneously	209 13 O
and	223 3 O
was	227 3 O
found	231 5 O
to	237 2 O
contain	240 7 O
a	248 1 O
triamterene	250 11 B-Chemical
metabolite	262 10 O
admixed	273 7 O
with	281 4 O
uric	286 4 B-Chemical
acid	291 4 I-Chemical
salts	296 5 I-Chemical
.	301 1 O

Factors	303 7 O
affecting	311 9 O
triamterene	321 11 B-Chemical
nephrolithiasis	333 15 B-Disease
are	349 3 O
discussed	353 9 O
and	363 3 O
2	367 1 O
previously	369 10 O
reported	380 8 O
cases	389 5 O
are	395 3 O
reviewed	399 8 O
.	407 1 O

Metabolic	0 9 O
involvement	10 11 O
in	22 2 O
adriamycin	25 10 B-Chemical
cardiotoxicity	36 14 B-Disease
.	50 1 O

The	52 3 O
cardiotoxic	56 11 B-Disease
effects	68 7 O
of	76 2 O
adriamycin	79 10 B-Chemical
were	90 4 O
studied	95 7 O
in	103 2 O
mammalian	106 9 O
myocardial	116 10 O
cells	127 5 O
in	133 2 O
culture	136 7 O
as	144 2 O
a	147 1 O
model	149 5 O
system	155 6 O
.	161 1 O

Adriamycin	163 10 B-Chemical
inhibited	174 9 O
cell	184 4 O
growth	189 6 O
and	196 3 O
the	200 3 O
rhythmic	204 8 O
contractions	213 12 O
characteristic	226 14 O
of	241 2 O
myocardial	244 10 O
cells	255 5 O
in	261 2 O
culture	264 7 O
.	271 1 O

A	273 1 O
possible	275 8 O
involvement	284 11 O
of	296 2 O
energy	299 6 O
metabolism	306 10 O
was	317 3 O
suggested	321 9 O
previously	331 10 O
,	341 1 O
and	343 3 O
in	347 2 O
this	350 4 O
study	355 5 O
the	361 3 O
adenylate	365 9 O
energy	375 6 O
charge	382 6 O
and	389 3 O
phosphorylcreatine	393 18 B-Chemical
mole	412 4 O
fraction	417 8 O
were	426 4 O
determined	431 10 O
in	442 2 O
the	445 3 O
adriamycin	449 10 B-Chemical
-	459 1 O
treated	460 7 O
cells	468 5 O
.	473 1 O

The	475 3 O
adenylate	479 9 O
energy	489 6 O
charge	496 6 O
was	503 3 O
found	507 5 O
to	513 2 O
be	516 2 O
significantly	519 13 O
decreased	533 9 O
,	542 1 O
while	544 5 O
the	550 3 O
phophorylcreatine	554 17 B-Chemical
mole	572 4 O
fraction	577 8 O
was	586 3 O
unchanged	590 9 O
.	599 1 O

Such	601 4 O
disparity	606 9 O
suggests	616 8 O
an	625 2 O
inhibition	628 10 O
of	639 2 O
creatine	642 8 B-Chemical
phosphokinase	651 13 O
.	664 1 O

The	666 3 O
addition	670 8 O
of	679 2 O
1	682 1 O
mM	684 2 O
adenosine	687 9 B-Chemical
to	697 2 O
the	700 3 O
myocardial	704 10 O
cell	715 4 O
cultures	720 8 O
markedly	729 8 O
increases	738 9 O
the	748 3 O
ATP	752 3 B-Chemical
concentration	756 13 O
through	770 7 O
a	778 1 O
pathway	780 7 O
reportedly	788 10 O
leading	799 7 O
to	807 2 O
a	810 1 O
compartmentalized	812 17 O
ATP	830 3 B-Chemical
pool	834 4 O
.	838 1 O

In	840 2 O
the	843 3 O
adriamycin	847 10 B-Chemical
-	857 1 O
treated	858 7 O
cells	866 5 O
,	871 1 O
the	873 3 O
addition	877 8 O
of	886 2 O
adenosine	889 9 B-Chemical
increased	899 9 O
the	909 3 O
adenylate	913 9 O
charge	923 6 O
and	930 3 O
,	933 1 O
concomitant	935 11 O
with	947 4 O
this	952 4 O
inrcease	957 8 O
,	965 1 O
the	967 3 O
cells	971 5 O
'	976 1 O
functional	978 10 O
integrity	989 9 O
,	998 1 O
in	1000 2 O
terms	1003 5 O
of	1009 2 O
percentage	1012 10 O
of	1023 2 O
beating	1026 7 O
cells	1034 5 O
and	1040 3 O
rate	1044 4 O
of	1049 2 O
contractions	1052 12 O
,	1064 1 O
was	1066 3 O
maintained	1070 10 O
.	1080 1 O

Age	0 3 O
-	3 1 O
dependent	4 9 O
sensitivity	14 11 O
of	26 2 O
the	29 3 O
rat	33 3 O
to	37 2 O
neurotoxic	40 10 B-Disease
effects	51 7 O
of	59 2 O
streptomycin	62 12 B-Chemical
.	74 1 O

Streptomycin	76 12 B-Chemical
sulfate	89 7 O
(	97 1 O
300	98 3 O
mg	102 2 O
/	104 1 O
kg	105 2 O
s	108 1 O
.	109 1 O
c	110 1 O
.	111 1 O
)	112 1 O
was	114 3 O
injected	118 8 O
for	127 3 O
various	131 7 O
periods	139 7 O
into	147 4 O
preweanling	152 11 O
rats	164 4 O
and	169 3 O
for	173 3 O
3	177 1 O
weeks	179 5 O
into	185 4 O
weanling	190 8 O
rats	199 4 O
.	203 1 O

Beginning	205 9 O
at	215 2 O
8	218 1 O
days	220 4 O
of	225 2 O
age	228 3 O
,	231 1 O
body	233 4 O
movement	238 8 O
and	247 3 O
hearing	251 7 O
were	259 4 O
examined	264 8 O
for	273 3 O
6	277 1 O
and	279 3 O
up	283 2 O
to	286 2 O
17	289 2 O
weeks	292 5 O
,	297 1 O
respectively	299 12 O
.	311 1 O

Abnormal	313 8 B-Disease
movements	322 9 I-Disease
and	332 3 O
deafness	336 8 B-Disease
occurred	345 8 O
only	354 4 O
in	359 2 O
rats	362 4 O
treated	367 7 O
during	375 6 O
the	382 3 O
preweaning	386 10 O
period	397 6 O
;	403 1 O
within	405 6 O
this	412 4 O
period	417 6 O
the	424 3 O
greatest	428 8 O
sensitivities	437 13 O
for	451 3 O
these	455 5 O
abnormalities	461 13 O
occurred	475 8 O
from	484 4 O
2	489 1 O
to	491 2 O
11	494 2 O
-	496 1 O
17	497 2 O
and	500 3 O
5	504 1 O
to	506 2 O
11	509 2 O
days	512 4 O
of	517 2 O
age	520 3 O
,	523 1 O
respectively	525 12 O
,	537 1 O
indicating	539 10 O
that	550 4 O
the	555 3 O
cochlea	559 7 O
is	567 2 O
more	570 4 O
sensitive	575 9 O
to	585 2 O
streptomycin	588 12 B-Chemical
than	601 4 O
the	606 3 O
site	610 4 O
(	615 1 O
vestibular	616 10 O
or	627 2 O
central	630 7 O
)	637 1 O
responsible	639 11 O
for	651 3 O
the	655 3 O
dyskinesias	659 11 B-Disease
.	670 1 O

Crescentic	0 10 O
fibrillary	11 10 O
glomerulonephritis	22 18 B-Disease
associated	41 10 O
with	52 4 O
intermittent	57 12 O
rifampin	70 8 B-Chemical
therapy	79 7 O
for	87 3 O
pulmonary	91 9 B-Disease
tuberculosis	101 12 I-Disease
.	113 1 O

This	115 4 O
case	120 4 O
study	125 5 O
reveals	131 7 O
an	139 2 O
unusual	142 7 O
finding	150 7 O
of	158 2 O
rapidly	161 7 O
proliferative	169 13 O
crescentic	183 10 O
glomerulonephritis	194 18 B-Disease
in	213 2 O
a	216 1 O
patient	218 7 O
treated	226 7 O
with	234 4 O
rifampin	239 8 B-Chemical
who	248 3 O
had	252 3 O
no	256 2 O
other	259 5 O
identifiable	265 12 O
causes	278 6 O
for	285 3 O
developing	289 10 O
this	300 4 O
disease	305 7 O
.	312 1 O

This	314 4 O
patient	319 7 O
underwent	327 9 O
a	337 1 O
10	339 2 O
-	341 1 O
month	342 5 O
regimen	348 7 O
of	356 2 O
rifampin	359 8 B-Chemical
and	368 3 O
isoniazid	372 9 B-Chemical
for	382 3 O
pulmonary	386 9 B-Disease
tuberculosis	396 12 I-Disease
and	409 3 O
was	413 3 O
discovered	417 10 O
to	428 2 O
have	431 4 O
developed	436 9 O
signs	446 5 O
of	452 2 O
severe	455 6 O
renal	462 5 B-Disease
failure	468 7 I-Disease
five	476 4 O
weeks	481 5 O
after	487 5 O
completion	493 10 O
of	504 2 O
therapy	507 7 O
.	514 1 O

Renal	516 5 O
biopsy	522 6 O
revealed	529 8 O
severe	538 6 O
glomerulonephritis	545 18 B-Disease
with	564 4 O
crescents	569 9 O
,	578 1 O
electron	580 8 O
dense	589 5 O
fibrillar	595 9 O
deposits	605 8 O
and	614 3 O
moderate	618 8 O
lymphocytic	627 11 O
interstitial	639 12 O
infiltrate	652 10 O
.	662 1 O

Other	664 5 O
possible	670 8 O
causes	679 6 O
of	686 2 O
rapidly	689 7 O
progressive	697 11 O
glomerulonephritis	709 18 B-Disease
were	728 4 O
investigated	733 12 O
and	746 3 O
ruled	750 5 O
out	756 3 O
.	759 1 O

This	761 4 O
report	766 6 O
documents	773 9 O
the	783 3 O
unusual	787 7 O
occurrence	795 10 O
of	806 2 O
rapidly	809 7 O
progressive	817 11 O
glomerulonephritis	829 18 B-Disease
with	848 4 O
crescents	853 9 O
and	863 3 O
fibrillar	867 9 O
glomerulonephritis	877 18 B-Disease
in	896 2 O
a	899 1 O
patient	901 7 O
treated	909 7 O
with	917 4 O
rifampin	922 8 B-Chemical
.	930 1 O

Time	0 4 O
course	5 6 O
of	12 2 O
lipid	15 5 O
peroxidation	21 12 O
in	34 2 O
puromycin	37 9 B-Chemical
aminonucleoside	47 15 I-Chemical
-	62 1 O
induced	63 7 O
nephropathy	71 11 B-Disease
.	82 1 O

Reactive	84 8 O
oxygen	93 6 B-Chemical
species	100 7 O
have	108 4 O
been	113 4 O
implicated	118 10 O
in	129 2 O
the	132 3 O
pathogenesis	136 12 O
of	149 2 O
acute	152 5 O
puromycin	158 9 B-Chemical
aminonucleoside	168 15 I-Chemical
(	184 1 O
PAN	185 3 B-Chemical
)	188 1 O
-	189 1 O
induced	190 7 O
nephropathy	198 11 B-Disease
,	209 1 O
with	211 4 O
antioxidants	216 12 O
significantly	229 13 O
reducing	243 8 O
the	252 3 O
proteinuria	256 11 B-Disease
.	267 1 O

The	269 3 O
temporal	273 8 O
relationship	282 12 O
between	295 7 O
lipid	303 5 O
peroxidation	309 12 O
in	322 2 O
the	325 3 O
kidney	329 6 O
and	336 3 O
proteinuria	340 11 B-Disease
was	352 3 O
examined	356 8 O
in	365 2 O
this	368 4 O
study	373 5 O
.	378 1 O

Rats	380 4 O
were	385 4 O
treated	390 7 O
with	398 4 O
a	403 1 O
single	405 6 O
IV	412 2 O
injection	415 9 O
of	425 2 O
puromycin	428 9 B-Chemical
aminonucleoside	438 15 I-Chemical
,	453 1 O
(	455 1 O
PAN	456 3 B-Chemical
,	459 1 O
7	461 1 O
.	462 1 O
5	463 1 O
mg	465 2 O
/	467 1 O
kg	468 2 O
)	470 1 O
and	472 3 O
24	476 2 O
hour	479 4 O
urine	484 5 O
samples	490 7 O
were	498 4 O
obtained	503 8 O
prior	512 5 O
to	518 2 O
sacrifice	521 9 O
on	531 2 O
days	534 4 O
3	539 1 O
,	540 1 O
5	541 1 O
,	542 1 O
7	543 1 O
,	544 1 O
10	545 2 O
,	547 1 O
17	548 2 O
,	550 1 O
27	551 2 O
,	553 1 O
41	554 2 O
(	557 1 O
N	558 1 O
=	560 1 O
5	562 1 O
-	563 1 O
10	564 2 O
per	567 3 O
group	571 5 O
)	576 1 O
.	577 1 O

The	579 3 O
kidneys	583 7 O
were	591 4 O
removed	596 7 O
,	603 1 O
flushed	605 7 O
with	613 4 O
ice	618 3 O
cold	622 4 O
TRIS	627 4 O
buffer	632 6 O
.	638 1 O

Kidney	640 6 O
cortices	647 8 O
from	656 4 O
each	661 4 O
animal	666 6 O
were	673 4 O
used	678 4 O
to	683 2 O
prepare	686 7 O
homogenates	694 11 O
.	705 1 O

Tissue	707 6 O
lipid	714 5 O
peroxidation	720 12 O
was	733 3 O
measured	737 8 O
in	746 2 O
whole	749 5 O
homogenates	755 11 O
as	767 2 O
well	770 4 O
as	775 2 O
in	778 2 O
lipid	781 5 O
extracts	787 8 O
from	796 4 O
homogenates	801 11 O
as	813 2 O
thiobarbituric	816 14 B-Chemical
acid	831 4 I-Chemical
reactive	836 8 O
substances	845 10 O
.	855 1 O

Proteinuria	857 11 B-Disease
was	869 3 O
evident	873 7 O
at	881 2 O
day	884 3 O
5	888 1 O
,	889 1 O
peaked	891 6 O
at	898 2 O
day	901 3 O
7	905 1 O
and	907 3 O
persisted	911 9 O
to	921 2 O
day	924 3 O
27	928 2 O
.	930 1 O

Lipid	932 5 O
peroxidation	938 12 O
in	951 2 O
homogenates	954 11 O
was	966 3 O
maximal	970 7 O
at	978 2 O
day	981 3 O
3	985 1 O
and	987 3 O
declined	991 8 O
rapidly	1000 7 O
to	1008 2 O
control	1011 7 O
levels	1019 6 O
by	1026 2 O
day	1029 3 O
17	1033 2 O
.	1035 1 O

This	1037 4 O
study	1042 5 O
supports	1048 8 O
the	1057 3 O
role	1061 4 O
of	1066 2 O
lipid	1069 5 O
peroxidation	1075 12 O
in	1088 2 O
mediating	1091 9 O
the	1101 3 O
proteinuric	1105 11 B-Disease
injury	1117 6 I-Disease
in	1124 2 O
PAN	1127 3 B-Chemical
nephropathy	1131 11 B-Disease
.	1142 1 O

Clomipramine	0 12 B-Chemical
-	12 1 O
induced	13 7 O
sleep	21 5 B-Disease
disturbance	27 11 I-Disease
does	39 4 O
not	44 3 O
impair	48 6 O
its	55 3 O
prolactin	59 9 O
-	68 1 O
releasing	69 9 O
action	79 6 O
.	85 1 O

The	87 3 O
present	91 7 O
study	99 5 O
was	105 3 O
undertaken	109 10 O
to	120 2 O
examine	123 7 O
the	131 3 O
role	135 4 O
of	140 2 O
sleep	143 5 B-Disease
disturbance	149 11 I-Disease
,	160 1 O
induced	162 7 O
by	170 2 O
clomipramine	173 12 B-Chemical
administration	186 14 O
,	200 1 O
on	202 2 O
the	205 3 O
secretory	209 9 O
rate	219 4 O
of	224 2 O
prolactin	227 9 O
(	237 1 O
PRL	238 3 O
)	241 1 O
in	243 2 O
addition	246 8 O
to	255 2 O
the	258 3 O
direct	262 6 O
drug	269 4 O
effect	274 6 O
.	280 1 O

Two	282 3 O
groups	286 6 O
of	293 2 O
supine	296 6 O
subjects	303 8 O
were	312 4 O
studied	317 7 O
under	325 5 O
placebo	331 7 O
-	338 1 O
controlled	339 10 O
conditions	350 10 O
,	360 1 O
one	362 3 O
during	366 6 O
the	373 3 O
night	377 5 O
,	382 1 O
when	384 4 O
sleeping	389 8 O
(	398 1 O
n	399 1 O
=	401 1 O
7	403 1 O
)	404 1 O
and	406 3 O
the	410 3 O
other	414 5 O
at	420 2 O
daytime	423 7 O
,	430 1 O
when	432 4 O
awake	437 5 O
(	443 1 O
n	444 1 O
=	446 1 O
6	448 1 O
)	449 1 O
.	450 1 O

Each	452 4 O
subject	457 7 O
received	465 8 O
a	474 1 O
single	476 6 O
50	483 2 O
mg	486 2 O
dose	489 4 O
of	494 2 O
clomipramine	497 12 B-Chemical
given	510 5 O
orally	516 6 O
2	523 1 O
hours	525 5 O
before	531 6 O
blood	538 5 O
collection	544 10 O
.	554 1 O

Plasma	556 6 O
PRL	563 3 O
concentrations	567 14 O
were	582 4 O
analysed	587 8 O
at	596 2 O
10	599 2 O
min	602 3 O
intervals	606 9 O
and	616 3 O
underlying	620 10 O
secretory	631 9 O
rates	641 5 O
calculated	647 10 O
by	658 2 O
a	661 1 O
deconvolution	663 13 O
procedure	677 9 O
.	686 1 O

For	688 3 O
both	692 4 O
experiments	697 11 O
the	709 3 O
drug	713 4 O
intake	718 6 O
led	725 3 O
to	729 2 O
significant	732 11 O
increases	744 9 O
in	754 2 O
PRL	757 3 O
secretion	761 9 O
,	770 1 O
acting	772 6 O
preferentially	779 14 O
on	794 2 O
tonic	797 5 O
secretion	803 9 O
as	813 2 O
pulse	816 5 O
amplitude	822 9 O
and	832 3 O
frequency	836 9 O
did	846 3 O
not	850 3 O
differ	854 6 O
significantly	861 13 O
from	875 4 O
corresponding	880 13 O
control	894 7 O
values	902 6 O
.	908 1 O

During	910 6 O
the	917 3 O
night	921 5 O
clomipramine	927 12 B-Chemical
ingestion	940 9 O
altered	950 7 O
the	958 3 O
complete	962 8 O
sleep	971 5 O
architecture	977 12 O
in	990 2 O
that	993 4 O
it	998 2 O
suppressed	1001 10 O
REM	1012 3 O
sleep	1016 5 O
and	1022 3 O
the	1026 3 O
sleep	1030 5 O
cycles	1036 6 O
and	1043 3 O
induced	1047 7 O
increased	1055 9 O
wakefulness	1065 11 O
.	1076 1 O

As	1078 2 O
the	1081 3 O
relative	1085 8 O
increase	1094 8 O
in	1103 2 O
PRL	1106 3 O
secretion	1110 9 O
expressed	1120 9 O
as	1130 2 O
a	1133 1 O
percentage	1135 10 O
of	1146 2 O
the	1149 3 O
mean	1153 4 O
did	1158 3 O
not	1162 3 O
significantly	1166 13 O
differ	1180 6 O
between	1187 7 O
the	1195 3 O
night	1199 5 O
and	1205 3 O
day	1209 3 O
time	1213 4 O
studies	1218 7 O
(	1226 1 O
46	1227 2 O
+	1230 1 O
/	1231 1 O
-	1232 1 O
19	1234 2 O
%	1236 1 O
vs	1238 2 O
34	1241 2 O
+	1244 1 O
/	1245 1 O
-	1246 1 O
10	1248 2 O
%	1250 1 O
)	1251 1 O
,	1252 1 O
it	1254 2 O
can	1257 3 O
be	1261 2 O
concluded	1264 9 O
that	1274 4 O
the	1279 3 O
observed	1283 8 O
sleep	1292 5 B-Disease
disturbance	1298 11 I-Disease
did	1310 3 O
not	1314 3 O
interfere	1318 9 O
with	1328 4 O
the	1333 3 O
drug	1337 4 O
action	1342 6 O
per	1349 3 O
se	1353 2 O
.	1355 1 O

The	1357 3 O
presence	1361 8 O
of	1370 2 O
REM	1373 3 O
sleep	1377 5 O
was	1383 3 O
shown	1387 5 O
not	1393 3 O
to	1397 2 O
be	1400 2 O
a	1403 1 O
determining	1405 11 O
factor	1417 6 O
either	1424 6 O
for	1431 3 O
secretory	1435 9 O
pulse	1445 5 O
amplitude	1451 9 O
and	1461 3 O
frequency	1465 9 O
,	1474 1 O
as	1476 2 O
,	1478 1 O
for	1480 3 O
both	1484 4 O
,	1488 1 O
mean	1490 4 O
nocturnal	1495 9 O
values	1505 6 O
were	1512 4 O
similar	1517 7 O
with	1525 4 O
and	1530 3 O
without	1534 7 O
prior	1542 5 O
clomipramine	1548 12 B-Chemical
ingestion	1561 9 O
.	1570 1 O

Angioedema	0 10 B-Disease
following	11 9 O
the	21 3 O
intravenous	25 11 O
administration	37 14 O
of	52 2 O
metoprolol	55 10 B-Chemical
.	65 1 O

A	67 1 O
72	69 2 O
-	71 1 O
year	72 4 O
-	76 1 O
old	77 3 O
woman	81 5 O
was	87 3 O
admitted	91 8 O
to	100 2 O
the	103 3 O
hospital	107 8 O
with	116 4 O
"	121 1 O
flash	122 5 O
"	127 1 O
pulmonary	129 9 B-Disease
edema	139 5 I-Disease
,	144 1 O
preceded	146 8 O
by	155 2 O
chest	158 5 B-Disease
pain	164 4 I-Disease
,	168 1 O
requiring	170 9 O
intubation	180 10 O
.	190 1 O

Her	192 3 O
medical	196 7 O
history	204 7 O
included	212 8 O
coronary	221 8 B-Disease
artery	230 6 I-Disease
disease	237 7 I-Disease
with	245 4 O
previous	250 8 O
myocardial	259 10 B-Disease
infarctions	270 11 I-Disease
,	281 1 O
hypertension	283 12 B-Disease
,	295 1 O
and	297 3 O
diabetes	301 8 B-Disease
mellitus	310 8 I-Disease
.	318 1 O

A	320 1 O
history	322 7 O
of	330 2 O
angioedema	333 10 B-Disease
secondary	344 9 O
to	354 2 O
lisinopril	357 10 B-Chemical
therapy	368 7 O
was	376 3 O
elicited	380 8 O
.	388 1 O

Current	390 7 O
medications	398 11 O
did	410 3 O
not	414 3 O
include	418 7 O
angiotensin	426 11 B-Chemical
-	437 1 O
converting	438 10 O
enzyme	449 6 O
inhibitors	456 10 O
or	467 2 O
beta	470 4 O
-	474 1 O
blockers	475 8 O
.	483 1 O

She	485 3 O
had	489 3 O
no	493 2 O
previous	496 8 O
beta	505 4 O
-	509 1 O
blocking	510 8 O
drug	519 4 O
exposure	524 8 O
.	532 1 O

During	534 6 O
the	541 3 O
first	545 5 O
day	551 3 O
of	555 2 O
hospitalization	558 15 O
(	574 1 O
while	575 5 O
intubated	581 9 O
)	590 1 O
,	591 1 O
intravenous	593 11 O
metoprolol	605 10 B-Chemical
was	616 3 O
given	620 5 O
,	625 1 O
resulting	627 9 O
in	637 2 O
severe	640 6 O
angioedema	647 10 B-Disease
.	657 1 O

The	659 3 O
angioedema	663 10 B-Disease
resolved	674 8 O
after	683 5 O
therapy	689 7 O
with	697 4 O
intravenous	702 11 O
steroids	714 8 B-Chemical
and	723 3 O
diphenhydramine	727 15 B-Chemical
hydrochloride	743 13 O
.	756 1 O

Effect	0 6 O
of	7 2 O
coniine	10 7 B-Chemical
on	18 2 O
the	21 3 O
developing	25 10 O
chick	36 5 O
embryo	42 6 O
.	48 1 O

Coniine	50 7 B-Chemical
,	57 1 O
an	59 2 O
alkaloid	62 8 O
from	71 4 O
Conium	76 6 O
maculatum	83 9 O
(	93 1 O
poison	94 6 O
hemlock	101 7 O
)	108 1 O
,	109 1 O
has	111 3 O
been	115 4 O
shown	120 5 O
to	126 2 O
be	129 2 O
teratogenic	132 11 O
in	144 2 O
livestock	147 9 O
.	156 1 O

The	158 3 O
major	162 5 O
teratogenic	168 11 O
outcome	180 7 O
is	188 2 O
arthrogryposis	191 14 B-Disease
,	205 1 O
presumably	207 10 O
due	218 3 O
to	222 2 O
nicotinic	225 9 O
receptor	235 8 O
blockade	244 8 O
.	252 1 O

However	254 7 O
,	261 1 O
coniine	263 7 B-Chemical
has	271 3 O
failed	275 6 O
to	282 2 O
produce	285 7 O
arthrogryposis	293 14 B-Disease
in	308 2 O
rats	311 4 O
or	316 2 O
mice	319 4 O
and	324 3 O
is	328 2 O
only	331 4 O
weakly	336 6 O
teratogenic	343 11 O
in	355 2 O
rabbits	358 7 O
.	365 1 O

The	367 3 O
purpose	371 7 O
of	379 2 O
this	382 4 O
study	387 5 O
was	393 3 O
to	397 2 O
evaluate	400 8 O
and	409 3 O
compare	413 7 O
the	421 3 O
effects	425 7 O
of	433 2 O
coniine	436 7 B-Chemical
and	444 3 O
nicotine	448 8 B-Chemical
in	457 2 O
the	460 3 O
developing	464 10 O
chick	475 5 O
.	480 1 O

Concentrations	482 14 O
of	497 2 O
coniine	500 7 B-Chemical
and	508 3 O
nicotine	512 8 B-Chemical
sulfate	521 7 O
were	529 4 O
0	534 1 O
.	535 1 O
015	536 3 O
%	539 1 O
,	540 1 O
0	542 1 O
.	543 1 O
03	544 2 O
%	546 1 O
,	547 1 O
0	549 1 O
.	550 1 O
075	551 3 O
%	554 1 O
,	555 1 O
0	557 1 O
.	558 1 O
15	559 2 O
%	561 1 O
,	562 1 O
0	564 1 O
.	565 1 O
75	566 2 O
%	568 1 O
,	569 1 O
1	571 1 O
.	572 1 O
5	573 1 O
%	574 1 O
,	575 1 O
3	577 1 O
%	578 1 O
,	579 1 O
and	581 3 O
6	585 1 O
%	586 1 O
and	588 3 O
1	592 1 O
%	593 1 O
,	594 1 O
5	596 1 O
%	597 1 O
,	598 1 O
and	600 3 O
10	604 2 O
%	606 1 O
,	607 1 O
respectively	609 12 O
.	621 1 O

Both	623 4 O
compounds	628 9 O
caused	638 6 O
deformations	645 12 B-Disease
and	658 3 O
lethality	662 9 O
in	672 2 O
a	675 1 O
dose	677 4 O
-	681 1 O
dependent	682 9 O
manner	692 6 O
.	698 1 O

All	700 3 O
concentrations	704 14 O
of	719 2 O
nicotine	722 8 B-Chemical
sulfate	731 7 O
caused	739 6 O
some	746 4 O
lethality	751 9 O
but	761 3 O
a	765 1 O
no	767 2 O
effect	770 6 O
level	777 5 O
for	783 3 O
coniine	787 7 B-Chemical
lethality	795 9 O
was	805 3 O
0	809 1 O
.	810 1 O
75	811 2 O
%	813 1 O
.	814 1 O

The	816 3 O
deformations	820 12 B-Disease
caused	833 6 O
by	840 2 O
both	843 4 O
coniine	848 7 B-Chemical
and	856 3 O
nicotine	860 8 B-Chemical
sulfate	869 7 O
were	877 4 O
excessive	882 9 B-Disease
flexion	892 7 I-Disease
or	900 2 I-Disease
extension	903 9 I-Disease
of	913 2 I-Disease
one	916 3 I-Disease
or	920 2 I-Disease
more	923 4 I-Disease
toes	928 4 I-Disease
.	932 1 O

No	934 2 O
histopathological	937 17 O
alterations	955 11 O
or	967 2 O
differences	970 11 O
in	982 2 O
bone	985 4 O
formation	990 9 O
were	1000 4 O
seen	1005 4 O
in	1010 2 O
the	1013 3 O
limbs	1017 5 O
or	1023 2 O
toes	1026 4 O
of	1031 2 O
any	1034 3 O
chicks	1038 6 O
from	1045 4 O
any	1050 3 O
group	1054 5 O
;	1059 1 O
however	1061 7 O
,	1068 1 O
extensive	1070 9 O
cranial	1080 7 B-Disease
hemorrhage	1088 10 I-Disease
occurred	1099 8 O
in	1108 2 O
all	1111 3 O
nicotine	1115 8 B-Chemical
sulfate	1124 7 O
-	1131 1 O
treated	1132 7 O
chicks	1140 6 O
.	1146 1 O

There	1148 5 O
was	1154 3 O
a	1158 1 O
statistically	1160 13 O
significant	1174 11 O
(	1186 1 O
P	1187 1 O
<	1189 1 O
or	1191 2 O
=	1194 1 O
0	1196 1 O
.	1197 1 O
01	1198 2 O
)	1200 1 O
decrease	1202 8 O
in	1211 2 O
movement	1214 8 O
in	1223 2 O
coniine	1226 7 B-Chemical
and	1234 3 O
nicotine	1238 8 B-Chemical
sulfate	1247 7 O
treated	1255 7 O
chicks	1263 6 O
as	1270 2 O
determined	1273 10 O
by	1284 2 O
ultrasound	1287 10 O
.	1297 1 O

Control	1299 7 O
chicks	1307 6 O
were	1314 4 O
in	1319 2 O
motion	1322 6 O
an	1329 2 O
average	1332 7 O
of	1340 2 O
33	1343 2 O
.	1345 1 O
67	1346 2 O
%	1348 1 O
of	1350 2 O
the	1353 3 O
time	1357 4 O
,	1361 1 O
while	1363 5 O
coniine	1369 7 B-Chemical
-	1376 1 O
treated	1377 7 O
chicks	1385 6 O
were	1392 4 O
only	1397 4 O
moving	1402 6 O
8	1409 1 O
.	1410 1 O
95	1411 2 O
%	1413 1 O
of	1415 2 O
a	1418 1 O
5	1420 1 O
-	1421 1 O
min	1422 3 O
interval	1426 8 O
,	1434 1 O
and	1436 3 O
no	1440 2 O
movement	1443 8 O
was	1452 3 O
observed	1456 8 O
for	1465 3 O
nicotine	1469 8 B-Chemical
sulfate	1478 7 O
treated	1486 7 O
chicks	1494 6 O
.	1500 1 O

In	1502 2 O
summary	1505 7 O
,	1512 1 O
the	1514 3 O
chick	1518 5 O
embryo	1524 6 O
provides	1531 8 O
a	1540 1 O
reliable	1542 8 O
and	1551 3 O
simple	1555 6 O
experimental	1562 12 O
animal	1575 6 O
model	1582 5 O
of	1588 2 O
coniine	1591 7 B-Chemical
-	1598 1 O
induced	1599 7 O
arthrogryposis	1607 14 B-Disease
.	1621 1 O

Data	1623 4 O
from	1628 4 O
this	1633 4 O
model	1638 5 O
support	1644 7 O
a	1652 1 O
mechanism	1654 9 O
involving	1664 9 O
nicotinic	1674 9 O
receptor	1684 8 O
blockade	1693 8 O
with	1702 4 O
subsequent	1707 10 O
decreased	1718 9 O
fetal	1728 5 O
movement	1734 8 O
.	1742 1 O

Epidural	0 8 O
blood	9 5 O
flow	15 4 O
during	20 6 O
prostaglandin	27 13 B-Chemical
E1	41 2 I-Chemical
or	44 2 O
trimethaphan	47 12 B-Chemical
induced	60 7 O
hypotension	68 11 B-Disease
.	79 1 O

To	81 2 O
evaluate	84 8 O
the	93 3 O
effect	97 6 O
of	104 2 O
prostaglandin	107 13 B-Chemical
E1	121 2 I-Chemical
(	124 1 O
PGE1	125 4 B-Chemical
)	129 1 O
or	131 2 O
trimethaphan	134 12 B-Chemical
(	147 1 O
TMP	148 3 B-Chemical
)	151 1 O
induced	153 7 O
hypotension	161 11 B-Disease
on	173 2 O
epidural	176 8 O
blood	185 5 O
flow	191 4 O
(	196 1 O
EBF	197 3 O
)	200 1 O
during	202 6 O
spinal	209 6 O
surgery	216 7 O
,	223 1 O
EBF	225 3 O
was	229 3 O
measured	233 8 O
using	242 5 O
the	248 3 O
heat	252 4 O
clearance	257 9 O
method	267 6 O
in	274 2 O
30	277 2 O
patients	280 8 O
who	289 3 O
underwent	293 9 O
postero	303 7 O
-	310 1 O
lateral	311 7 O
interbody	319 9 O
fusion	329 6 O
under	336 5 O
isoflurane	342 10 B-Chemical
anaesthesia	353 11 O
.	364 1 O

An	366 2 O
initial	369 7 O
dose	377 4 O
of	382 2 O
0	385 1 O
.	386 1 O
1	387 1 O
microgram	389 9 O
.	398 1 O
kg	399 2 O
-	401 1 O
1	402 1 O
.	403 1 O
min	404 3 O
-	407 1 O
1	408 1 O
of	410 2 O
PGE1	413 4 B-Chemical
(	418 1 O
15	419 2 O
patients	422 8 O
)	430 1 O
,	431 1 O
or	433 2 O
10	436 2 O
micrograms	439 10 O
.	449 1 O
kg	450 2 O
-	452 1 O
1	453 1 O
.	454 1 O
min	455 3 O
-	458 1 O
1	459 1 O
of	461 2 O
TMP	464 3 B-Chemical
(	468 1 O
15	469 2 O
patients	472 8 O
)	480 1 O
was	482 3 O
administered	486 12 O
intravenously	499 13 O
after	513 5 O
the	519 3 O
dural	523 5 O
opening	529 7 O
and	537 3 O
the	541 3 O
dose	545 4 O
was	550 3 O
adjusted	554 8 O
to	563 2 O
maintain	566 8 O
the	575 3 O
mean	579 4 O
arterial	584 8 O
blood	593 5 O
pressure	599 8 O
(	608 1 O
MAP	609 3 O
)	612 1 O
at	614 2 O
about	617 5 O
60	623 2 O
mmHg	626 4 O
.	630 1 O

The	632 3 O
hypotensive	636 11 B-Disease
drug	648 4 O
was	653 3 O
discontinued	657 12 O
at	670 2 O
the	673 3 O
completion	677 10 O
of	688 2 O
the	691 3 O
operative	695 9 O
procedure	705 9 O
.	714 1 O

After	716 5 O
starting	722 8 O
PGE1	731 4 B-Chemical
or	736 2 O
TMP	739 3 B-Chemical
,	742 1 O
MAP	744 3 O
and	748 3 O
rate	752 4 O
pressure	757 8 O
product	766 7 O
(	774 1 O
RPP	775 3 O
)	778 1 O
decreased	780 9 O
significantly	790 13 O
compared	804 8 O
with	813 4 O
preinfusion	818 11 O
values	830 6 O
(	837 1 O
P	838 1 O
<	840 1 O
0	842 1 O
.	843 1 O
01	844 2 O
)	846 1 O
,	847 1 O
and	849 3 O
the	853 3 O
degree	857 6 O
of	864 2 O
hypotension	867 11 B-Disease
due	879 3 O
to	883 2 O
PGE1	886 4 B-Chemical
remained	891 8 O
constant	900 8 O
until	909 5 O
60	915 2 O
min	918 3 O
after	922 5 O
its	928 3 O
discontinuation	932 15 O
.	947 1 O

Heart	949 5 O
rate	955 4 O
(	960 1 O
HR	961 2 O
)	963 1 O
did	965 3 O
not	969 3 O
change	973 6 O
in	980 2 O
either	983 6 O
group	990 5 O
.	995 1 O

EBFF	997 4 O
did	1002 3 O
not	1006 3 O
change	1010 6 O
during	1017 6 O
PGE1	1024 4 B-Chemical
infusion	1029 8 O
whereas	1038 7 O
in	1046 2 O
the	1049 3 O
TMP	1053 3 B-Chemical
group	1057 5 O
,	1062 1 O
EBF	1064 3 O
decreased	1068 9 O
significantly	1078 13 O
at	1092 2 O
30	1095 2 O
and	1098 3 O
60	1102 2 O
min	1105 3 O
after	1109 5 O
the	1115 3 O
start	1119 5 O
of	1125 2 O
TMP	1128 3 B-Chemical
(	1132 1 O
preinfusion	1133 11 O
:	1144 1 O
45	1146 2 O
.	1148 1 O
9	1149 1 O
+	1151 1 O
/	1152 1 O
-	1153 1 O
13	1155 2 O
.	1157 1 O
9	1158 1 O
ml	1160 2 O
/	1162 1 O
100g	1163 4 O
/	1167 1 O
min	1168 3 O
.	1171 1 O
30	1173 2 O
min	1176 3 O
:	1179 1 O
32	1181 2 O
.	1183 1 O
3	1184 1 O
+	1186 1 O
/	1187 1 O
-	1188 1 O
9	1190 1 O
.	1191 1 O
9	1192 1 O
ml	1194 2 O
/	1196 1 O
100	1197 3 O
g	1201 1 O
/	1202 1 O
min	1203 3 O
(	1207 1 O
P	1208 1 O
<	1210 1 O
0	1212 1 O
.	1213 1 O
05	1214 2 O
)	1216 1 O
.	1217 1 O
60	1219 2 O
min	1222 3 O
:	1225 1 O
30	1227 2 O
+	1230 1 O
/	1231 1 O
-	1232 1 O
7	1234 1 O
.	1235 1 O
5	1236 1 O
ml	1238 2 O
/	1240 1 O
100	1241 3 O
g	1245 1 O
/	1246 1 O
min	1247 3 O
(	1251 1 O
P	1252 1 O
<	1254 1 O
0	1256 1 O
.	1257 1 O
05	1258 2 O
)	1260 1 O
)	1261 1 O
.	1262 1 O

These	1264 5 O
results	1270 7 O
suggest	1278 7 O
that	1286 4 O
PGE1	1291 4 B-Chemical
may	1296 3 O
be	1300 2 O
preferable	1303 10 O
to	1314 2 O
TMP	1317 3 B-Chemical
for	1321 3 O
hypotensive	1325 11 B-Disease
anaesthesia	1337 11 O
in	1349 2 O
spinal	1352 6 O
surgery	1359 7 O
because	1367 7 O
TMP	1375 3 B-Chemical
decreased	1379 9 O
EBF	1389 3 O
.	1392 1 O

Immunohistochemical	0 19 O
studies	20 7 O
with	28 4 O
antibodies	33 10 O
to	44 2 O
neurofilament	47 13 O
proteins	61 8 O
on	70 2 O
axonal	73 6 B-Disease
damage	80 6 I-Disease
in	87 2 O
experimental	90 12 O
focal	103 5 O
lesions	109 7 O
in	117 2 O
rat	120 3 O
.	123 1 O

Immunohistochemistry	125 20 O
with	146 4 O
monoclonal	151 10 O
antibodies	162 10 O
against	173 7 O
neurofilament	181 13 O
(	195 1 O
NF	196 2 O
)	198 1 O
proteins	200 8 O
of	209 2 O
middle	212 6 O
and	219 3 O
high	223 4 O
molecular	228 9 O
weight	238 6 O
class	245 5 O
,	250 1 O
NF	252 2 O
-	254 1 O
M	255 1 O
and	257 3 O
NF	261 2 O
-	263 1 O
H	264 1 O
,	265 1 O
was	267 3 O
used	271 4 O
to	276 2 O
study	279 5 O
axonal	285 6 B-Disease
injury	292 6 I-Disease
in	299 2 O
the	302 3 O
borderzone	306 10 O
of	317 2 O
focal	320 5 O
lesions	326 7 O
in	334 2 O
rats	337 4 O
.	341 1 O

Focal	343 5 O
injury	349 6 B-Disease
in	356 2 I-Disease
the	359 3 I-Disease
cortex	363 6 I-Disease
was	370 3 O
produced	374 8 O
by	383 2 O
infusion	386 8 O
of	395 2 O
lactate	398 7 B-Chemical
at	406 2 O
acid	409 4 O
pH	414 2 O
or	417 2 O
by	420 2 O
stab	423 4 O
caused	428 6 O
by	435 2 O
needle	438 6 O
insertion	445 9 O
.	454 1 O

Infarcts	456 8 B-Disease
in	465 2 I-Disease
substantia	468 10 I-Disease
nigra	479 5 I-Disease
pars	485 4 I-Disease
reticulata	490 10 I-Disease
were	501 4 O
evoked	506 6 O
by	513 2 O
prolonged	516 9 O
pilocarpine	526 11 B-Chemical
-	537 1 O
induced	538 7 O
status	546 6 B-Disease
epilepticus	553 11 I-Disease
.	564 1 O

Immunohistochemical	566 19 O
staining	586 8 O
for	595 3 O
NFs	599 3 O
showed	603 6 O
characteristic	610 14 O
terminal	625 8 O
clubs	634 5 O
of	640 2 O
axons	643 5 O
in	649 2 O
the	652 3 O
borderzone	656 10 O
of	667 2 O
lesions	670 7 O
.	677 1 O

Differences	679 11 O
in	691 2 O
the	694 3 O
labelling	698 9 O
pattern	708 7 O
occurred	716 8 O
with	725 4 O
different	730 9 O
antibodies	740 10 O
which	751 5 O
apparently	757 10 O
depended	768 8 O
on	777 2 O
molecular	780 9 O
weight	790 6 O
class	797 5 O
of	803 2 O
NFs	806 3 O
and	810 3 O
phosphorylation	814 15 O
state	830 5 O
.	835 1 O

These	837 5 O
immunohistochemical	843 19 O
changes	863 7 O
of	871 2 O
NFs	874 3 O
can	878 3 O
serve	882 5 O
as	888 2 O
a	891 1 O
marker	893 6 O
for	900 3 O
axonal	904 6 B-Disease
damage	911 6 I-Disease
in	918 2 O
various	921 7 O
experimental	929 12 O
traumatic	942 9 B-Disease
or	952 2 O
ischemic	955 8 O
lesions	964 7 O
.	971 1 O

Increase	0 8 O
of	9 2 O
Parkinson	12 9 B-Disease
disability	22 10 I-Disease
after	33 5 O
fluoxetine	39 10 B-Chemical
medication	50 10 O
.	60 1 O

Depression	62 10 B-Disease
is	73 2 O
a	76 1 O
major	78 5 O
clinical	84 8 O
feature	93 7 O
of	101 2 O
Parkinson	104 9 B-Disease
'	113 1 I-Disease
s	114 1 I-Disease
disease	116 7 I-Disease
.	123 1 O

We	125 2 O
report	128 6 O
the	135 3 O
increased	139 9 O
amount	149 6 O
of	156 2 O
motor	159 5 B-Disease
disability	165 10 I-Disease
in	176 2 O
four	179 4 O
patients	184 8 O
with	193 4 O
idiopathic	198 10 B-Disease
Parkinson	209 9 I-Disease
'	218 1 I-Disease
s	219 1 I-Disease
disease	221 7 I-Disease
after	229 5 O
exposure	235 8 O
to	244 2 O
the	247 3 O
antidepressant	251 14 B-Chemical
fluoxetine	266 10 B-Chemical
.	276 1 O

The	278 3 O
possibility	282 11 O
of	294 2 O
a	297 1 O
clinically	299 10 O
relevant	310 8 O
dopamine	319 8 B-Chemical
-	327 1 O
antagonistic	328 12 O
capacity	341 8 O
of	350 2 O
fluoxetine	353 10 B-Chemical
in	364 2 O
Parkinson	367 9 B-Disease
'	376 1 I-Disease
s	377 1 I-Disease
disease	379 7 I-Disease
patients	387 8 O
must	396 4 O
be	401 2 O
considered	404 10 O
.	414 1 O

Acetaminophen	0 13 B-Chemical
-	13 1 O
induced	14 7 O
hypotension	22 11 B-Disease
.	33 1 O

Through	35 7 O
30	43 2 O
years	46 5 O
of	52 2 O
widespread	55 10 O
use	66 3 O
,	69 1 O
acetaminophen	71 13 B-Chemical
has	85 3 O
been	89 4 O
shown	94 5 O
to	100 2 O
be	103 2 O
a	106 1 O
remarkably	108 10 O
safe	119 4 O
medication	124 10 O
in	135 2 O
therapeutic	138 11 O
dosages	150 7 O
.	157 1 O

The	159 3 O
potential	163 9 O
for	173 3 O
acetaminophen	177 13 B-Chemical
to	191 2 O
produce	194 7 O
cardiovascular	202 14 B-Disease
toxicities	217 10 I-Disease
is	228 2 O
very	231 4 O
low	236 3 O
.	239 1 O

However	241 7 O
,	248 1 O
acetaminophen	250 13 B-Chemical
has	264 3 O
been	268 4 O
demonstrated	273 12 O
to	286 2 O
produce	289 7 O
symptoms	297 8 O
of	306 2 O
anaphylaxis	309 11 B-Disease
,	320 1 O
including	322 9 O
hypotension	332 11 B-Disease
,	343 1 O
in	345 2 O
sensitive	348 9 O
individuals	358 11 O
.	369 1 O

This	371 4 O
article	376 7 O
describes	384 9 O
two	394 3 O
critically	398 10 B-Disease
ill	409 3 I-Disease
patients	413 8 O
in	422 2 O
whom	425 4 O
transient	430 9 O
episodes	440 8 O
of	449 2 O
hypotension	452 11 B-Disease
reproducibly	464 12 O
developed	477 9 O
after	487 5 O
administration	493 14 O
of	508 2 O
acetaminophen	511 13 B-Chemical
.	524 1 O

Other	526 5 O
symptoms	532 8 O
of	541 2 O
allergic	544 8 B-Disease
reactions	553 9 I-Disease
were	563 4 O
not	568 3 O
clinically	572 10 O
detectable	583 10 O
.	593 1 O

The	595 3 O
hypotensive	599 11 B-Disease
episodes	611 8 O
were	620 4 O
severe	625 6 O
enough	632 6 O
to	639 2 O
require	642 7 O
vasopressor	650 11 O
administration	662 14 O
.	676 1 O

The	678 3 O
reports	682 7 O
illustrate	690 10 O
the	701 3 O
need	705 4 O
for	710 3 O
clinicians	714 10 O
to	725 2 O
consider	728 8 O
acetaminophen	737 13 B-Chemical
in	751 2 O
patients	754 8 O
with	763 4 O
hypotension	768 11 B-Disease
of	780 2 O
unknown	783 7 O
origin	791 6 O
.	797 1 O

Acute	0 5 O
hepatitis	6 9 B-Disease
,	15 1 O
autoimmune	17 10 B-Disease
hemolytic	28 9 I-Disease
anemia	38 6 I-Disease
,	44 1 O
and	46 3 O
erythroblastocytopenia	50 22 B-Disease
induced	73 7 O
by	81 2 O
ceftriaxone	84 11 B-Chemical
.	95 1 O

An	97 2 O
80	100 2 O
-	102 1 O
yr	103 2 O
-	105 1 O
old	106 3 O
man	110 3 O
developed	114 9 O
acute	124 5 O
hepatitis	130 9 B-Disease
shortly	140 7 O
after	148 5 O
ingesting	154 9 O
oral	164 4 O
ceftriaxone	169 11 B-Chemical
.	180 1 O

Although	182 8 O
the	191 3 O
transaminases	195 13 O
gradually	209 9 O
returned	219 8 O
to	228 2 O
baseline	231 8 O
after	240 5 O
withholding	246 11 O
the	258 3 O
beta	262 4 B-Chemical
lactam	267 6 I-Chemical
antibiotic	274 10 O
,	284 1 O
there	286 5 O
was	292 3 O
a	296 1 O
gradual	298 7 O
increase	306 8 O
in	315 2 O
serum	318 5 O
bilirubin	324 9 B-Chemical
and	334 3 O
a	338 1 O
decrease	340 8 O
in	349 2 O
hemoglobin	352 10 O
concentration	363 13 O
caused	377 6 O
by	384 2 O
an	387 2 O
autoimmune	390 10 B-Disease
hemolytic	401 9 I-Disease
anemia	411 6 I-Disease
and	418 3 O
erythroblastocytopenia	422 22 B-Disease
.	444 1 O

These	446 5 O
responded	452 9 O
to	462 2 O
systemic	465 8 O
steroids	474 8 B-Chemical
and	483 3 O
immunoglobulins	487 15 O
.	502 1 O

Despite	504 7 O
the	512 3 O
widespread	516 10 O
use	527 3 O
of	531 2 O
these	534 5 O
agents	540 6 O
this	547 4 O
triad	552 5 O
of	558 2 O
side	561 4 O
effects	566 7 O
has	574 3 O
not	578 3 O
previously	582 10 O
been	593 4 O
reported	598 8 O
in	607 2 O
connection	610 10 O
with	621 4 O
beta	626 4 B-Chemical
lactam	631 6 I-Chemical
antibiotics	638 11 O
.	649 1 O

Adverse	0 7 O
effects	8 7 O
of	16 2 O
the	19 3 O
atypical	23 8 O
antipsychotics	32 14 O
.	46 1 O

Collaborative	48 13 O
Working	62 7 O
Group	70 5 O
on	76 2 O
Clinical	79 8 O
Trial	88 5 O
Evaluations	94 11 O
.	105 1 O

Adverse	107 7 O
effects	115 7 O
of	123 2 O
antipsychotics	126 14 O
often	141 5 O
lead	147 4 O
to	152 2 O
noncompliance	155 13 O
.	168 1 O

Thus	170 4 O
,	174 1 O
clinicians	176 10 O
should	187 6 O
address	194 7 O
patients	202 8 O
'	210 1 O
concerns	212 8 O
about	221 5 O
adverse	227 7 O
effects	235 7 O
and	243 3 O
attempt	247 7 O
to	255 2 O
choose	258 6 O
medications	265 11 O
that	277 4 O
will	282 4 O
improve	287 7 O
their	295 5 O
patients	301 8 O
'	309 1 O
quality	311 7 O
of	319 2 O
life	322 4 O
as	327 2 O
well	330 4 O
as	335 2 O
overall	338 7 O
health	346 6 O
.	352 1 O

The	354 3 O
side	358 4 O
effect	363 6 O
profiles	370 8 O
of	379 2 O
the	382 3 O
atypical	386 8 O
antipsychotics	395 14 O
are	410 3 O
more	414 4 O
advantageous	419 12 O
than	432 4 O
those	437 5 O
of	443 2 O
the	446 3 O
conventional	450 12 O
neuroleptics	463 12 O
.	475 1 O

Conventional	477 12 O
agents	490 6 O
are	497 3 O
associated	501 10 O
with	512 4 O
unwanted	517 8 O
central	526 7 O
nervous	534 7 O
system	542 6 O
effects	549 7 O
,	556 1 O
including	558 9 O
extrapyramidal	568 14 B-Disease
symptoms	583 8 I-Disease
(	592 1 O
EPS	593 3 B-Disease
)	596 1 O
,	597 1 O
tardive	599 7 B-Disease
dyskinesia	607 10 I-Disease
,	617 1 O
sedation	619 8 O
,	627 1 O
and	629 3 O
possible	633 8 O
impairment	642 10 O
of	653 2 O
some	656 4 O
cognitive	661 9 O
measures	671 8 O
,	679 1 O
as	681 2 O
well	684 4 O
as	689 2 O
cardiac	692 7 O
effects	700 7 O
,	707 1 O
orthostatic	709 11 B-Disease
hypotension	721 11 I-Disease
,	732 1 O
hepatic	734 7 O
changes	742 7 O
,	749 1 O
anticholinergic	751 15 O
side	767 4 O
effects	772 7 O
,	779 1 O
sexual	781 6 B-Disease
dysfunction	788 11 I-Disease
,	799 1 O
and	801 3 O
weight	805 6 B-Disease
gain	812 4 I-Disease
.	816 1 O

The	818 3 O
newer	822 5 O
atypical	828 8 O
agents	837 6 O
have	844 4 O
a	849 1 O
lower	851 5 O
risk	857 4 O
of	862 2 O
EPS	865 3 B-Disease
,	868 1 O
but	870 3 O
are	874 3 O
associated	878 10 O
in	889 2 O
varying	892 7 O
degrees	900 7 O
with	908 4 O
sedation	913 8 O
,	921 1 O
cardiovascular	923 14 O
effects	938 7 O
,	945 1 O
anticholinergic	947 15 O
effects	963 7 O
,	970 1 O
weight	972 6 B-Disease
gain	979 4 I-Disease
,	983 1 O
sexual	985 6 B-Disease
dysfunction	992 11 I-Disease
,	1003 1 O
hepatic	1005 7 O
effects	1013 7 O
,	1020 1 O
lowered	1022 7 O
seizure	1030 7 B-Disease
threshold	1038 9 O
(	1048 1 O
primarily	1049 9 O
clozapine	1059 9 B-Chemical
)	1068 1 O
,	1069 1 O
and	1071 3 O
agranulocytosis	1075 15 B-Disease
(	1091 1 O
clozapine	1092 9 B-Chemical
only	1102 4 O
)	1106 1 O
.	1107 1 O

Since	1109 5 O
the	1115 3 O
incidence	1119 9 O
and	1129 3 O
severity	1133 8 O
of	1142 2 O
specific	1145 8 O
adverse	1154 7 O
effects	1162 7 O
differ	1170 6 O
among	1177 5 O
the	1183 3 O
various	1187 7 O
atypicals	1195 9 O
,	1204 1 O
the	1206 3 O
clinician	1210 9 O
should	1220 6 O
carefully	1227 9 O
consider	1237 8 O
which	1246 5 O
side	1252 4 O
effects	1257 7 O
are	1265 3 O
most	1269 4 O
likely	1274 6 O
to	1281 2 O
lead	1284 4 O
to	1289 2 O
the	1292 3 O
individual	1296 10 O
'	1306 1 O
s	1307 1 O
dissatisfaction	1309 15 O
and	1325 3 O
noncompliance	1329 13 O
before	1343 6 O
choosing	1350 8 O
an	1359 2 O
antipsychotic	1362 13 O
for	1376 3 O
a	1380 1 O
particular	1382 10 O
patient	1393 7 O
.	1400 1 O

Effects	0 7 O
of	8 2 O
tetrandrine	11 11 B-Chemical
and	23 3 O
fangchinoline	27 13 B-Chemical
on	41 2 O
experimental	44 12 O
thrombosis	57 10 B-Disease
in	68 2 O
mice	71 4 O
and	76 3 O
human	80 5 O
platelet	86 8 B-Disease
aggregation	95 11 I-Disease
.	106 1 O

Tetrandrine	108 11 B-Chemical
(	120 1 O
TET	121 3 B-Chemical
)	124 1 O
and	126 3 O
fangchinoline	130 13 B-Chemical
(	144 1 O
FAN	145 3 B-Chemical
)	148 1 O
are	150 3 O
two	154 3 O
naturally	158 9 O
occurring	168 9 O
analogues	178 9 O
with	188 4 O
a	193 1 O
bisbenzylisoquinoline	195 21 B-Chemical
structure	217 9 O
.	226 1 O

The	228 3 O
present	232 7 O
study	240 5 O
was	246 3 O
undertaken	250 10 O
to	261 2 O
investigate	264 11 O
the	276 3 O
effects	280 7 O
of	288 2 O
TET	291 3 B-Chemical
and	295 3 O
FAN	299 3 B-Chemical
on	303 2 O
the	306 3 O
experimental	310 12 O
thrombosis	323 10 B-Disease
induced	334 7 O
by	342 2 O
collagen	345 8 O
plus	354 4 O
epinephrine	359 11 B-Chemical
(	371 1 O
EP	372 2 B-Chemical
)	374 1 O
in	376 2 O
mice	379 4 O
,	383 1 O
and	385 3 O
platelet	389 8 B-Disease
aggregation	398 11 I-Disease
and	410 3 O
blood	414 5 B-Disease
coagulation	420 11 I-Disease
in	432 2 O
vitro	435 5 O
.	440 1 O

In	442 2 O
the	445 3 O
in	449 2 O
vivo	452 4 O
study	457 5 O
,	462 1 O
the	464 3 O
administration	468 14 O
(	483 1 O
50	484 2 O
mg	487 2 O
/	489 1 O
kg	490 2 O
,	492 1 O
i	494 1 O
.	495 1 O
p	496 1 O
.	497 1 O
)	498 1 O
of	500 2 O
TET	503 3 B-Chemical
and	507 3 O
FAN	511 3 B-Chemical
in	515 2 O
mice	518 4 O
showed	523 6 O
the	530 3 O
inhibition	534 10 O
of	545 2 O
thrombosis	548 10 B-Disease
by	559 2 O
55	562 2 O
%	564 1 O
and	566 3 O
35	570 2 O
%	572 1 O
,	573 1 O
respectively	575 12 O
,	587 1 O
while	589 5 O
acetylsalicylic	595 15 B-Chemical
acid	611 4 I-Chemical
(	616 1 O
ASA	617 3 B-Chemical
,	620 1 O
50	622 2 O
mg	625 2 O
/	627 1 O
kg	628 2 O
,	630 1 O
i	632 1 O
.	633 1 O
p	634 1 O
.	635 1 O
)	636 1 O
,	637 1 O
a	639 1 O
positive	641 8 O
control	650 7 O
,	657 1 O
showed	659 6 O
only	666 4 O
30	671 2 O
%	673 1 O
inhibition	675 10 O
.	685 1 O

In	687 2 O
the	690 3 O
vitro	694 5 O
human	700 5 O
platelet	706 8 B-Disease
aggregations	715 12 I-Disease
induced	728 7 O
by	736 2 O
the	739 3 O
agonists	743 8 O
used	752 4 O
in	757 2 O
tests	760 5 O
,	765 1 O
TET	767 3 B-Chemical
and	771 3 O
FAN	775 3 B-Chemical
showed	779 6 O
the	786 3 O
inhibitions	790 11 O
dose	802 4 O
dependently	807 11 O
.	818 1 O

In	820 2 O
addition	823 8 O
,	831 1 O
neither	833 7 O
TET	841 3 B-Chemical
nor	845 3 O
FAN	849 3 B-Chemical
showed	853 6 O
any	860 3 O
anticoagulation	864 15 O
activities	880 10 O
in	891 2 O
the	894 3 O
measurement	898 11 O
of	910 2 O
the	913 3 O
activated	917 9 O
partial	927 7 O
thromboplastin	935 14 O
time	950 4 O
(	955 1 O
APTT	956 4 O
)	960 1 O
,	961 1 O
prothrombin	963 11 O
time	975 4 O
(	980 1 O
PT	981 2 O
)	983 1 O
and	985 3 O
thrombin	989 8 O
time	998 4 O
(	1003 1 O
TT	1004 2 O
)	1006 1 O
using	1008 5 O
human	1014 5 O
-	1019 1 O
citrated	1020 8 O
plasma	1029 6 O
.	1035 1 O

These	1037 5 O
results	1043 7 O
suggest	1051 7 O
that	1059 4 O
antithrombosis	1064 14 O
of	1079 2 O
TET	1082 3 B-Chemical
and	1086 3 O
FAN	1090 3 B-Chemical
in	1094 2 O
mice	1097 4 O
may	1102 3 O
be	1106 2 O
mainly	1109 6 O
related	1116 7 O
to	1124 2 O
the	1127 3 O
antiplatelet	1131 12 O
aggregation	1144 11 O
activities	1156 10 O
.	1166 1 O

Gemcitabine	0 11 B-Chemical
plus	12 4 O
vinorelbine	17 11 B-Chemical
in	29 2 O
nonsmall	32 8 B-Disease
cell	41 4 I-Disease
lung	46 4 I-Disease
carcinoma	51 9 I-Disease
patients	61 8 O
age	70 3 O
70	74 2 O
years	77 5 O
or	83 2 O
older	86 5 O
or	92 2 O
patients	95 8 O
who	104 3 O
cannot	108 6 O
receive	115 7 O
cisplatin	123 9 B-Chemical
.	132 1 O

Oncopaz	134 7 O
Cooperative	142 11 O
Group	154 5 O
.	159 1 O

BACKGROUND	161 10 O
:	171 1 O
Although	173 8 O
the	182 3 O
prevalence	186 10 O
of	197 2 O
nonsmall	200 8 B-Disease
cell	209 4 I-Disease
lung	214 4 I-Disease
carcinoma	219 9 I-Disease
(	229 1 O
NSCLC	230 5 B-Disease
)	235 1 O
is	237 2 O
high	240 4 O
among	245 5 O
elderly	251 7 O
patients	259 8 O
,	267 1 O
few	269 3 O
data	273 4 O
are	278 3 O
available	282 9 O
regarding	292 9 O
the	302 3 O
efficacy	306 8 O
and	315 3 O
toxicity	319 8 B-Disease
of	328 2 O
chemotherapy	331 12 O
in	344 2 O
this	347 4 O
group	352 5 O
of	358 2 O
patients	361 8 O
.	369 1 O

Recent	371 6 O
reports	378 7 O
indicate	386 8 O
that	395 4 O
single	400 6 O
agent	407 5 O
therapy	413 7 O
with	421 4 O
vinorelbine	426 11 B-Chemical
(	438 1 O
VNB	439 3 B-Chemical
)	442 1 O
or	444 2 O
gemcitabine	447 11 B-Chemical
(	459 1 O
GEM	460 3 B-Chemical
)	463 1 O
may	465 3 O
obtain	469 6 O
a	476 1 O
response	478 8 O
rate	487 4 O
of	492 2 O
20	495 2 O
-	497 1 O
30	498 2 O
%	500 1 O
in	502 2 O
elderly	505 7 O
patients	513 8 O
,	521 1 O
with	523 4 O
acceptable	528 10 O
toxicity	539 8 B-Disease
and	548 3 O
improvement	552 11 O
in	564 2 O
symptoms	567 8 O
and	576 3 O
quality	580 7 O
of	588 2 O
life	591 4 O
.	595 1 O

In	597 2 O
the	600 3 O
current	604 7 O
study	612 5 O
the	618 3 O
efficacy	622 8 O
and	631 3 O
toxicity	635 8 B-Disease
of	644 2 O
the	647 3 O
combination	651 11 O
of	663 2 O
GEM	666 3 B-Chemical
and	670 3 O
VNB	674 3 B-Chemical
in	678 2 O
elderly	681 7 O
patients	689 8 O
with	698 4 O
advanced	703 8 O
NSCLC	712 5 B-Disease
or	718 2 O
those	721 5 O
with	727 4 O
some	732 4 O
contraindication	737 16 O
to	754 2 O
receiving	757 9 O
cisplatin	767 9 B-Chemical
were	777 4 O
assessed	782 8 O
.	790 1 O

METHODS	792 7 O
:	799 1 O
Forty	801 5 O
-	806 1 O
nine	807 4 O
patients	812 8 O
with	821 4 O
advanced	826 8 O
NSCLC	835 5 B-Disease
were	841 4 O
included	846 8 O
,	854 1 O
38	856 2 O
of	859 2 O
whom	862 4 O
were	867 4 O
age	872 3 O
>	876 1 O
/	877 1 O
=	878 1 O
70	880 2 O
years	883 5 O
and	889 3 O
11	893 2 O
were	896 4 O
age	901 3 O
<	905 1 O
70	907 2 O
years	910 5 O
but	916 3 O
who	920 3 O
had	924 3 O
some	928 4 O
contraindication	933 16 O
to	950 2 O
receiving	953 9 O
cisplatin	963 9 B-Chemical
.	972 1 O

All	974 3 O
patients	978 8 O
were	987 4 O
evaluable	992 9 O
for	1002 3 O
response	1006 8 O
and	1015 3 O
toxicity	1019 8 B-Disease
.	1027 1 O

Treatment	1029 9 O
was	1039 3 O
comprised	1043 9 O
of	1053 2 O
VNB	1056 3 B-Chemical
,	1059 1 O
25	1061 2 O
mg	1064 2 O
/	1066 1 O
m	1067 1 O
(	1068 1 O
2	1069 1 O
)	1070 1 O
,	1071 1 O
plus	1073 4 O
GEM	1078 3 B-Chemical
,	1081 1 O
1000	1083 4 O
mg	1088 2 O
/	1090 1 O
m	1091 1 O
(	1092 1 O
2	1093 1 O
)	1094 1 O
,	1095 1 O
both	1097 4 O
on	1102 2 O
Days	1105 4 O
1	1110 1 O
,	1111 1 O
8	1113 1 O
,	1114 1 O
and	1116 3 O
15	1120 2 O
every	1123 5 O
28	1129 2 O
days	1132 4 O
.	1136 1 O

Patients	1138 8 O
received	1147 8 O
a	1156 1 O
minimum	1158 7 O
of	1166 2 O
three	1169 5 O
courses	1175 7 O
unless	1183 6 O
progressive	1190 11 O
disease	1202 7 O
was	1210 3 O
detected	1214 8 O
.	1222 1 O

RESULTS	1224 7 O
:	1231 1 O
One	1233 3 O
hundred	1237 7 O
sixty	1245 5 O
-	1250 1 O
five	1251 4 O
courses	1256 7 O
were	1264 4 O
administered	1269 12 O
,	1281 1 O
with	1283 4 O
a	1288 1 O
median	1290 6 O
of	1297 2 O
3	1300 1 O
.	1301 1 O

6	1303 1 O
courses	1305 7 O
per	1313 3 O
patient	1317 7 O
.	1324 1 O

The	1326 3 O
overall	1330 7 O
response	1338 8 O
rate	1347 4 O
was	1352 3 O
26	1356 2 O
%	1358 1 O
(	1360 1 O
95	1361 2 O
%	1363 1 O
confidence	1365 10 O
interval	1376 8 O
,	1384 1 O
15	1386 2 O
-	1388 1 O
41	1389 2 O
%	1391 1 O
)	1392 1 O
.	1393 1 O

Two	1395 3 O
patients	1399 8 O
attained	1408 8 O
a	1417 1 O
complete	1419 8 O
response	1428 8 O
(	1437 1 O
4	1438 1 O
%	1439 1 O
)	1440 1 O
and	1442 3 O
11	1446 2 O
patients	1449 8 O
(	1458 1 O
22	1459 2 O
%	1461 1 O
)	1462 1 O
achieved	1464 8 O
a	1473 1 O
partial	1475 7 O
response	1483 8 O
.	1491 1 O

Eastern	1493 7 O
Cooperative	1501 11 O
Oncology	1513 8 O
Group	1522 5 O
performance	1528 11 O
status	1540 6 O
improved	1547 8 O
in	1556 2 O
35	1559 2 O
%	1561 1 O
of	1563 2 O
those	1566 5 O
patients	1572 8 O
with	1581 4 O
an	1586 2 O
initial	1589 7 O
value	1597 5 O
>	1603 1 O
0	1605 1 O
,	1606 1 O
whereas	1608 7 O
relief	1616 6 O
of	1623 2 O
at	1626 2 O
least	1629 5 O
1	1635 1 O
symptom	1637 7 O
without	1645 7 O
worsening	1653 9 O
of	1663 2 O
other	1666 5 O
symptoms	1672 8 O
was	1681 3 O
noted	1685 5 O
in	1691 2 O
27	1694 2 O
patients	1697 8 O
(	1706 1 O
55	1707 2 O
%	1709 1 O
)	1710 1 O
.	1711 1 O

The	1713 3 O
median	1717 6 O
time	1724 4 O
to	1729 2 O
progression	1732 11 O
was	1744 3 O
16	1748 2 O
weeks	1751 5 O
and	1757 3 O
the	1761 3 O
1	1765 1 O
-	1766 1 O
year	1767 4 O
survival	1772 8 O
rate	1781 4 O
was	1786 3 O
33	1790 2 O
%	1792 1 O
.	1793 1 O

Toxicity	1795 8 B-Disease
was	1804 3 O
mild	1808 4 O
.	1812 1 O

Six	1814 3 O
patients	1818 8 O
(	1827 1 O
12	1828 2 O
%	1830 1 O
)	1831 1 O
had	1833 3 O
World	1837 5 O
Health	1843 6 O
Organization	1850 12 O
Grade	1863 5 O
3	1869 1 O
-	1870 1 O
4	1871 1 O
neutropenia	1873 11 B-Disease
,	1884 1 O
2	1886 1 O
patients	1888 8 O
(	1897 1 O
4	1898 1 O
%	1899 1 O
)	1900 1 O
had	1902 3 O
Grade	1906 5 O
3	1912 1 O
-	1913 1 O
4	1914 1 O
thrombocytopenia	1916 16 B-Disease
,	1932 1 O
and	1934 3 O
2	1938 1 O
patients	1940 8 O
(	1949 1 O
4	1950 1 O
%	1951 1 O
)	1952 1 O
had	1954 3 O
Grade	1958 5 O
3	1964 1 O
neurotoxicity	1966 13 B-Disease
.	1979 1 O

Three	1981 5 O
patients	1987 8 O
with	1996 4 O
severe	2001 6 O
neutropenia	2008 11 B-Disease
(	2020 1 O
6	2021 1 O
%	2022 1 O
)	2023 1 O
died	2025 4 O
of	2030 2 O
sepsis	2033 6 B-Disease
.	2039 1 O

The	2041 3 O
median	2045 6 O
age	2052 3 O
of	2056 2 O
those	2059 5 O
patients	2065 8 O
developing	2074 10 O
Grade	2085 5 O
3	2091 1 O
-	2092 1 O
4	2093 1 O
neutropenia	2095 11 B-Disease
was	2107 3 O
significantly	2111 13 O
higher	2125 6 O
than	2132 4 O
that	2137 4 O
of	2142 2 O
the	2145 3 O
remaining	2149 9 O
patients	2159 8 O
(	2168 1 O
75	2169 2 O
years	2172 5 O
vs	2178 2 O
.	2180 1 O
72	2182 2 O
years	2185 5 O
;	2190 1 O
P	2192 1 O
=	2194 1 O
0	2196 1 O
.	2197 1 O
047	2198 3 O
)	2201 1 O
.	2202 1 O

CONCLUSIONS	2204 11 O
:	2215 1 O
The	2217 3 O
combination	2221 11 O
of	2233 2 O
GEM	2236 3 B-Chemical
and	2240 3 O
VNB	2244 3 B-Chemical
is	2248 2 O
moderately	2251 10 O
active	2262 6 O
and	2269 3 O
well	2273 4 O
tolerated	2278 9 O
except	2288 6 O
in	2295 2 O
patients	2298 8 O
age	2307 3 O
>	2311 1 O
/	2312 1 O
=	2313 1 O
75	2315 2 O
years	2318 5 O
.	2323 1 O

This	2325 4 O
age	2330 3 O
group	2334 5 O
had	2340 3 O
an	2344 2 O
increased	2347 9 O
risk	2357 4 O
of	2362 2 O
myelosuppression	2365 16 B-Disease
.	2381 1 O

Therefore	2383 9 O
the	2393 3 O
prophylactic	2397 12 O
use	2410 3 O
of	2414 2 O
granulocyte	2417 11 O
-	2428 1 O
colony	2429 6 O
stimulating	2436 11 O
factor	2448 6 O
should	2455 6 O
be	2462 2 O
considered	2465 10 O
with	2476 4 O
this	2481 4 O
treatment	2486 9 O
.	2495 1 O

New	2497 3 O
chemotherapy	2501 12 O
combinations	2514 12 O
with	2527 4 O
higher	2532 6 O
activity	2539 8 O
and	2548 3 O
lower	2552 5 O
toxicity	2558 8 B-Disease
are	2567 3 O
needed	2571 6 O
for	2578 3 O
elderly	2582 7 O
patients	2590 8 O
with	2599 4 O
advanced	2604 8 O
NSCLC	2613 5 B-Disease
.	2618 1 O

Warfarin	0 8 B-Chemical
-	8 1 O
induced	9 7 O
artery	17 6 B-Disease
calcification	24 13 I-Disease
is	38 2 O
accelerated	41 11 O
by	53 2 O
growth	56 6 O
and	63 3 O
vitamin	67 7 B-Chemical
D	75 1 I-Chemical
.	76 1 O

The	78 3 O
present	82 7 O
studies	90 7 O
demonstrate	98 11 O
that	110 4 O
growth	115 6 O
and	122 3 O
vitamin	126 7 B-Chemical
D	134 1 I-Chemical
treatment	136 9 O
enhance	146 7 O
the	154 3 O
extent	158 6 O
of	165 2 O
artery	168 6 B-Disease
calcification	175 13 I-Disease
in	189 2 O
rats	192 4 O
given	197 5 O
sufficient	203 10 O
doses	214 5 O
of	220 2 O
Warfarin	223 8 B-Chemical
to	232 2 O
inhibit	235 7 O
gamma	243 5 O
-	248 1 O
carboxylation	249 13 O
of	263 2 O
matrix	266 6 O
Gla	273 3 O
protein	277 7 O
,	284 1 O
a	286 1 O
calcification	288 13 B-Disease
inhibitor	302 9 O
known	312 5 O
to	318 2 O
be	321 2 O
expressed	324 9 O
by	334 2 O
smooth	337 6 O
muscle	344 6 O
cells	351 5 O
and	357 3 O
macrophages	361 11 O
in	373 2 O
the	376 3 O
artery	380 6 O
wall	387 4 O
.	391 1 O

The	393 3 O
first	397 5 O
series	403 6 O
of	410 2 O
experiments	413 11 O
examined	425 8 O
the	434 3 O
influence	438 9 O
of	448 2 O
age	451 3 O
and	455 3 O
growth	459 6 O
status	466 6 O
on	473 2 O
artery	476 6 B-Disease
calcification	483 13 I-Disease
in	497 2 O
Warfarin	500 8 B-Chemical
-	508 1 O
treated	509 7 O
rats	517 4 O
.	521 1 O

Treatment	523 9 O
for	533 3 O
2	537 1 O
weeks	539 5 O
with	545 4 O
Warfarin	550 8 B-Chemical
caused	559 6 O
massive	566 7 O
focal	574 5 O
calcification	580 13 B-Disease
of	594 2 I-Disease
the	597 3 I-Disease
artery	601 6 I-Disease
media	608 5 O
in	614 2 O
20	617 2 O
-	619 1 O
day	620 3 O
-	623 1 O
old	624 3 O
rats	628 4 O
and	633 3 O
less	637 4 O
extensive	642 9 O
focal	652 5 O
calcification	658 13 B-Disease
in	672 2 O
42	675 2 O
-	677 1 O
day	678 3 O
-	681 1 O
old	682 3 O
rats	686 4 O
.	690 1 O

In	692 2 O
contrast	695 8 O
,	703 1 O
no	705 2 O
artery	708 6 B-Disease
calcification	715 13 I-Disease
could	729 5 O
be	735 2 O
detected	738 8 O
in	747 2 O
10	750 2 O
-	752 1 O
month	753 5 O
-	758 1 O
old	759 3 O
adult	763 5 O
rats	769 4 O
even	774 4 O
after	779 5 O
4	785 1 O
weeks	787 5 O
of	793 2 O
Warfarin	796 8 B-Chemical
treatment	805 9 O
.	814 1 O

To	816 2 O
directly	819 8 O
examine	828 7 O
the	836 3 O
importance	840 10 O
of	851 2 O
growth	854 6 O
to	861 2 O
Warfarin	864 8 B-Chemical
-	872 1 O
induced	873 7 O
artery	881 6 B-Disease
calcification	888 13 I-Disease
in	902 2 O
animals	905 7 O
of	913 2 O
the	916 3 O
same	920 4 O
age	925 3 O
,	928 1 O
20	930 2 O
-	932 1 O
day	933 3 O
-	936 1 O
old	937 3 O
rats	941 4 O
were	946 4 O
fed	951 3 O
for	955 3 O
2	959 1 O
weeks	961 5 O
either	967 6 O
an	974 2 O
ad	977 2 O
libitum	980 7 O
diet	988 4 O
or	993 2 O
a	996 1 O
6	998 1 O
-	999 1 O
g	1000 1 O
/	1001 1 O
d	1002 1 O
restricted	1004 10 O
diet	1015 4 O
that	1020 4 O
maintains	1025 9 O
weight	1035 6 O
but	1042 3 O
prevents	1046 8 O
growth	1055 6 O
.	1061 1 O

Concurrent	1063 10 O
treatment	1074 9 O
of	1084 2 O
both	1087 4 O
dietary	1092 7 O
groups	1100 6 O
with	1107 4 O
Warfarin	1112 8 B-Chemical
produced	1121 8 O
massive	1130 7 O
focal	1138 5 O
calcification	1144 13 B-Disease
of	1158 2 I-Disease
the	1161 3 I-Disease
artery	1165 6 I-Disease
media	1172 5 O
in	1178 2 O
the	1181 3 O
ad	1185 2 O
libitum	1188 7 O
-	1195 1 O
fed	1196 3 O
rats	1200 4 O
but	1205 3 O
no	1209 2 O
detectable	1212 10 O
artery	1223 6 B-Disease
calcification	1230 13 I-Disease
in	1244 2 O
the	1247 3 O
restricted	1251 10 O
-	1261 1 O
diet	1262 4 O
,	1266 1 O
growth	1268 6 O
-	1274 1 O
inhibited	1275 9 O
group	1285 5 O
.	1290 1 O

Although	1292 8 O
the	1301 3 O
explanation	1305 11 O
for	1317 3 O
the	1321 3 O
association	1325 11 O
between	1337 7 O
artery	1345 6 B-Disease
calcification	1352 13 I-Disease
and	1366 3 O
growth	1370 6 O
status	1377 6 O
cannot	1384 6 O
be	1391 2 O
determined	1394 10 O
from	1405 4 O
the	1410 3 O
present	1414 7 O
study	1422 5 O
,	1427 1 O
there	1429 5 O
was	1435 3 O
a	1439 1 O
relationship	1441 12 O
between	1454 7 O
higher	1462 6 O
serum	1469 5 O
phosphate	1475 9 B-Chemical
and	1485 3 O
susceptibility	1489 14 O
to	1504 2 O
artery	1507 6 B-Disease
calcification	1514 13 I-Disease
,	1527 1 O
with	1529 4 O
30	1534 2 O
%	1536 1 O
higher	1538 6 O
levels	1545 6 O
of	1552 2 O
serum	1555 5 O
phosphate	1561 9 B-Chemical
in	1571 2 O
young	1574 5 O
,	1579 1 O
ad	1581 2 O
libitum	1584 7 O
-	1591 1 O
fed	1592 3 O
rats	1596 4 O
compared	1601 8 O
with	1610 4 O
either	1615 6 O
of	1622 2 O
the	1625 3 O
groups	1629 6 O
that	1636 4 O
was	1641 3 O
resistant	1645 9 O
to	1655 2 O
Warfarin	1658 8 B-Chemical
-	1666 1 O
induced	1667 7 O
artery	1675 6 B-Disease
calcification	1682 13 I-Disease
,	1695 1 O
ie	1697 2 O
,	1699 1 O
the	1701 3 O
10	1705 2 O
-	1707 1 O
month	1708 5 O
-	1713 1 O
old	1714 3 O
rats	1718 4 O
and	1723 3 O
the	1727 3 O
restricted	1731 10 O
-	1741 1 O
diet	1742 4 O
,	1746 1 O
growth	1748 6 O
-	1754 1 O
inhibited	1755 9 O
young	1765 5 O
rats	1771 4 O
.	1775 1 O

This	1777 4 O
observation	1782 11 O
suggests	1794 8 O
that	1803 4 O
increased	1808 9 O
susceptibility	1818 14 O
to	1833 2 O
Warfarin	1836 8 B-Chemical
-	1844 1 O
induced	1845 7 O
artery	1853 6 B-Disease
calcification	1860 13 I-Disease
could	1874 5 O
be	1880 2 O
related	1883 7 O
to	1891 2 O
higher	1894 6 O
serum	1901 5 O
phosphate	1907 9 B-Chemical
levels	1917 6 O
.	1923 1 O

The	1925 3 O
second	1929 6 O
set	1936 3 O
of	1940 2 O
experiments	1943 11 O
examined	1955 8 O
the	1964 3 O
possible	1968 8 O
synergy	1977 7 O
between	1985 7 O
vitamin	1993 7 B-Chemical
D	2001 1 I-Chemical
and	2003 3 O
Warfarin	2007 8 B-Chemical
in	2016 2 O
artery	2019 6 B-Disease
calcification	2026 13 I-Disease
.	2039 1 O

High	2041 4 O
doses	2046 5 O
of	2052 2 O
vitamin	2055 7 B-Chemical
D	2063 1 I-Chemical
are	2065 3 O
known	2069 5 O
to	2075 2 O
cause	2078 5 O
calcification	2084 13 B-Disease
of	2098 2 I-Disease
the	2101 3 I-Disease
artery	2105 6 I-Disease
media	2112 5 O
in	2118 2 O
as	2121 2 O
little	2124 6 O
as	2131 2 O
3	2134 1 O
to	2136 2 O
4	2139 1 O
days	2141 4 O
.	2145 1 O

High	2147 4 O
doses	2152 5 O
of	2158 2 O
the	2161 3 O
vitamin	2165 7 B-Chemical
K	2173 1 I-Chemical
antagonist	2175 10 O
Warfarin	2186 8 B-Chemical
are	2195 3 O
also	2199 4 O
known	2204 5 O
to	2210 2 O
cause	2213 5 O
calcification	2219 13 B-Disease
of	2233 2 I-Disease
the	2236 3 I-Disease
artery	2240 6 I-Disease
media	2247 5 O
,	2252 1 O
but	2254 3 O
at	2258 2 O
treatment	2261 9 O
times	2271 5 O
of	2277 2 O
2	2280 1 O
weeks	2282 5 O
or	2288 2 O
longer	2291 6 O
yet	2298 3 O
not	2302 3 O
at	2306 2 O
1	2309 1 O
week	2311 4 O
.	2315 1 O

In	2317 2 O
the	2320 3 O
current	2324 7 O
study	2332 5 O
,	2337 1 O
we	2339 2 O
investigated	2342 12 O
the	2355 3 O
synergy	2359 7 O
between	2367 7 O
these	2375 5 O
2	2381 1 O
treatments	2383 10 O
and	2394 3 O
found	2398 5 O
that	2404 4 O
concurrent	2409 10 O
Warfarin	2420 8 B-Chemical
administration	2429 14 O
dramatically	2444 12 O
increased	2457 9 O
the	2467 3 O
extent	2471 6 O
of	2478 2 O
calcification	2481 13 B-Disease
in	2495 2 O
the	2498 3 O
media	2502 5 O
of	2508 2 O
vitamin	2511 7 B-Chemical
D	2519 1 I-Chemical
-	2520 1 O
treated	2521 7 O
rats	2529 4 O
at	2534 2 O
3	2537 1 O
and	2539 3 O
4	2543 1 O
days	2545 4 O
.	2549 1 O

There	2551 5 O
was	2557 3 O
a	2561 1 O
close	2563 5 O
parallel	2569 8 O
between	2578 7 O
the	2586 3 O
effect	2590 6 O
of	2597 2 O
vitamin	2600 7 B-Chemical
D	2608 1 I-Chemical
dose	2610 4 O
on	2615 2 O
artery	2618 6 B-Disease
calcification	2625 13 I-Disease
and	2639 3 O
the	2643 3 O
effect	2647 6 O
of	2654 2 O
vitamin	2657 7 B-Chemical
D	2665 1 I-Chemical
dose	2667 4 O
on	2672 2 O
the	2675 3 O
elevation	2679 9 O
of	2689 2 O
serum	2692 5 O
calcium	2698 7 B-Chemical
,	2705 1 O
which	2707 5 O
suggests	2713 8 O
that	2722 4 O
vitamin	2727 7 B-Chemical
D	2735 1 I-Chemical
may	2737 3 O
induce	2741 6 O
artery	2748 6 B-Disease
calcification	2755 13 I-Disease
through	2769 7 O
its	2777 3 O
effect	2781 6 O
on	2788 2 O
serum	2791 5 O
calcium	2797 7 B-Chemical
.	2804 1 O

Because	2806 7 O
Warfarin	2814 8 B-Chemical
treatment	2823 9 O
had	2833 3 O
no	2837 2 O
effect	2840 6 O
on	2847 2 O
the	2850 3 O
elevation	2854 9 O
in	2864 2 O
serum	2867 5 O
calcium	2873 7 B-Chemical
produced	2881 8 O
by	2890 2 O
vitamin	2893 7 B-Chemical
D	2901 1 I-Chemical
,	2902 1 O
the	2904 3 O
synergy	2908 7 O
between	2916 7 O
Warfarin	2924 8 B-Chemical
and	2933 3 O
vitamin	2937 7 B-Chemical
D	2945 1 I-Chemical
is	2947 2 O
probably	2950 8 O
best	2959 4 O
explained	2964 9 O
by	2974 2 O
the	2977 3 O
hypothesis	2981 10 O
that	2992 4 O
Warfarin	2997 8 B-Chemical
inhibits	3006 8 O
the	3015 3 O
activity	3019 8 O
of	3028 2 O
matrix	3031 6 O
Gla	3038 3 O
protein	3042 7 O
as	3050 2 O
a	3053 1 O
calcification	3055 13 B-Disease
inhibitor	3069 9 O
.	3078 1 O

High	3080 4 O
levels	3085 6 O
of	3092 2 O
matrix	3095 6 O
Gla	3102 3 O
protein	3106 7 O
are	3114 3 O
found	3118 5 O
at	3124 2 O
sites	3127 5 O
of	3133 2 O
artery	3136 6 B-Disease
calcification	3143 13 I-Disease
in	3157 2 O
rats	3160 4 O
treated	3165 7 O
with	3173 4 O
vitamin	3178 7 B-Chemical
D	3186 1 I-Chemical
plus	3188 4 O
Warfarin	3193 8 B-Chemical
,	3201 1 O
and	3203 3 O
chemical	3207 8 O
analysis	3216 8 O
showed	3225 6 O
that	3232 4 O
the	3237 3 O
protein	3241 7 O
that	3249 4 O
accumulated	3254 11 O
was	3266 3 O
indeed	3270 6 O
not	3277 3 O
gamma	3281 5 B-Chemical
-	3286 1 I-Chemical
carboxylated	3287 12 I-Chemical
.	3299 1 O

These	3301 5 O
observations	3307 12 O
indicate	3320 8 O
that	3329 4 O
although	3334 8 O
the	3343 3 O
gamma	3347 5 B-Chemical
-	3352 1 I-Chemical
carboxyglutamate	3353 16 I-Chemical
residues	3370 8 O
of	3379 2 O
matrix	3382 6 O
Gla	3389 3 O
protein	3393 7 O
are	3401 3 O
apparently	3405 10 O
required	3416 8 O
for	3425 3 O
its	3429 3 O
function	3433 8 O
as	3442 2 O
a	3445 1 O
calcification	3447 13 B-Disease
inhibitor	3461 9 O
,	3470 1 O
they	3472 4 O
are	3477 3 O
not	3481 3 O
required	3485 8 O
for	3494 3 O
its	3498 3 O
accumulation	3502 12 O
at	3515 2 O
calcification	3518 13 B-Disease
sites	3532 5 O
.	3537 1 O

Antidepressant	0 14 B-Chemical
-	14 1 O
induced	15 7 O
mania	23 5 B-Disease
in	29 2 O
bipolar	32 7 B-Disease
patients	40 8 O
:	48 1 O
identification	50 14 O
of	65 2 O
risk	68 4 O
factors	73 7 O
.	80 1 O

BACKGROUND	82 10 O
:	92 1 O
Concerns	94 8 O
about	103 5 O
possible	109 8 O
risks	118 5 O
of	124 2 O
switching	127 9 O
to	137 2 O
mania	140 5 B-Disease
associated	146 10 O
with	157 4 O
antidepressants	162 15 B-Chemical
continue	178 8 O
to	187 2 O
interfere	190 9 O
with	200 4 O
the	205 3 O
establishment	209 13 O
of	223 2 O
an	226 2 O
optimal	229 7 O
treatment	237 9 O
paradigm	247 8 O
for	256 3 O
bipolar	260 7 B-Disease
depression	268 10 I-Disease
.	278 1 O

METHOD	280 6 O
:	286 1 O
The	288 3 O
response	292 8 O
of	301 2 O
44	304 2 O
patients	307 8 O
meeting	316 7 O
DSM	324 3 O
-	327 1 O
IV	328 2 O
criteria	331 8 O
for	340 3 O
bipolar	344 7 B-Disease
disorder	352 8 I-Disease
to	361 2 O
naturalistic	364 12 O
treatment	377 9 O
was	387 3 O
assessed	391 8 O
for	400 3 O
at	404 2 O
least	407 5 O
6	413 1 O
weeks	415 5 O
using	421 5 O
the	427 3 O
Montgomery	431 10 O
-	441 1 O
Asberg	442 6 O
Depression	449 10 O
Rating	460 6 O
Scale	467 5 O
and	473 3 O
the	477 3 O
Bech	481 4 O
-	485 1 O
Rafaelson	486 9 O
Mania	496 5 O
Rating	502 6 O
Scale	509 5 O
.	514 1 O

Patients	516 8 O
who	525 3 O
experienced	529 11 O
a	541 1 O
manic	543 5 B-Disease
or	549 2 O
hypomanic	552 9 B-Disease
switch	562 6 O
were	569 4 O
compared	574 8 O
with	583 4 O
those	588 5 O
who	594 3 O
did	598 3 O
not	602 3 O
on	606 2 O
several	609 7 O
variables	617 9 O
including	627 9 O
age	637 3 O
,	640 1 O
sex	642 3 O
,	645 1 O
diagnosis	647 9 O
(	657 1 O
DSM	658 3 B-Disease
-	661 1 I-Disease
IV	662 2 I-Disease
bipolar	665 7 I-Disease
I	673 1 I-Disease
vs	675 2 O
.	677 1 O
bipolar	679 7 B-Disease
II	687 2 I-Disease
)	689 1 O
,	690 1 O
number	692 6 O
of	699 2 O
previous	702 8 O
manic	711 5 B-Disease
episodes	717 8 O
,	725 1 O
type	727 4 O
of	732 2 O
antidepressant	735 14 B-Chemical
therapy	750 7 O
used	758 4 O
(	763 1 O
electroconvulsive	764 17 O
therapy	782 7 O
vs	790 2 O
.	792 1 O
antidepressant	794 14 B-Chemical
drugs	809 5 O
and	815 3 O
,	818 1 O
more	820 4 O
particularly	825 12 O
,	837 1 O
selective	839 9 O
serotonin	849 9 B-Chemical
reuptake	859 8 I-Chemical
inhibitors	868 10 I-Chemical
[	879 1 O
SSRIs	880 5 B-Chemical
]	885 1 O
)	886 1 O
,	887 1 O
use	889 3 O
and	893 3 O
type	897 4 O
of	902 2 O
mood	905 4 O
stabilizers	910 11 O
(	922 1 O
lithium	923 7 B-Chemical
vs	931 2 O
.	933 1 O
anticonvulsants	935 15 O
)	950 1 O
,	951 1 O
and	953 3 O
temperament	957 11 O
of	969 2 O
the	972 3 O
patient	976 7 O
,	983 1 O
assessed	985 8 O
during	994 6 O
a	1001 1 O
normothymic	1003 11 O
period	1015 6 O
using	1022 5 O
the	1028 3 O
hyperthymia	1032 11 O
component	1044 9 O
of	1054 2 O
the	1057 3 O
Semi	1061 4 O
-	1065 1 O
structured	1066 10 O
Affective	1077 9 O
Temperament	1087 11 O
Interview	1099 9 O
.	1108 1 O

RESULTS	1110 7 O
:	1117 1 O
Switches	1119 8 O
to	1128 2 O
hypomania	1131 9 B-Disease
or	1141 2 O
mania	1144 5 B-Disease
occurred	1150 8 O
in	1159 2 O
27	1162 2 O
%	1164 1 O
of	1166 2 O
all	1169 3 O
patients	1173 8 O
(	1182 1 O
N	1183 1 O
=	1185 1 O
12	1187 2 O
)	1189 1 O
(	1191 1 O
and	1192 3 O
in	1196 2 O
24	1199 2 O
%	1201 1 O
of	1203 2 O
the	1206 3 O
subgroup	1210 8 O
of	1219 2 O
patients	1222 8 O
treated	1231 7 O
with	1239 4 O
SSRIs	1244 5 B-Chemical
[	1250 1 O
8	1251 1 O
/	1252 1 O
33	1253 2 O
]	1255 1 O
)	1256 1 O
;	1257 1 O
16	1259 2 O
%	1261 1 O
(	1263 1 O
N	1264 1 O
=	1266 1 O
7	1268 1 O
)	1269 1 O
experienced	1271 11 O
manic	1283 5 B-Disease
episodes	1289 8 O
,	1297 1 O
and	1299 3 O
11	1303 2 O
%	1305 1 O
(	1307 1 O
N	1308 1 O
=	1310 1 O
5	1312 1 O
)	1313 1 O
experienced	1315 11 O
hypomanic	1327 9 B-Disease
episodes	1337 8 O
.	1345 1 O

Sex	1347 3 O
,	1350 1 O
age	1352 3 O
,	1355 1 O
diagnosis	1357 9 O
(	1367 1 O
bipolar	1368 7 B-Disease
I	1376 1 I-Disease
vs	1378 2 O
.	1380 1 O
bipolar	1382 7 B-Disease
II	1390 2 I-Disease
)	1392 1 O
,	1393 1 O
and	1395 3 O
additional	1399 10 O
treatment	1410 9 O
did	1420 3 O
not	1424 3 O
affect	1428 6 O
the	1435 3 O
risk	1439 4 O
of	1444 2 O
switching	1447 9 O
.	1456 1 O

The	1458 3 O
incidence	1462 9 O
of	1472 2 O
mood	1475 4 O
switches	1480 8 O
seemed	1489 6 O
not	1496 3 O
to	1500 2 O
differ	1503 6 O
between	1510 7 O
patients	1518 8 O
receiving	1527 9 O
an	1537 2 O
anticonvulsant	1540 14 O
and	1555 3 O
those	1559 5 O
receiving	1565 9 O
no	1575 2 O
mood	1578 4 O
stabilizer	1583 10 O
.	1593 1 O

In	1595 2 O
contrast	1598 8 O
,	1606 1 O
mood	1608 4 O
switches	1613 8 O
were	1622 4 O
less	1627 4 O
frequent	1632 8 O
in	1641 2 O
patients	1644 8 O
receiving	1653 9 O
lithium	1663 7 B-Chemical
(	1671 1 O
15	1672 2 O
%	1674 1 O
,	1675 1 O
4	1677 1 O
/	1678 1 O
26	1679 2 O
)	1681 1 O
than	1683 4 O
in	1688 2 O
patients	1691 8 O
not	1700 3 O
treated	1704 7 O
with	1712 4 O
lithium	1717 7 B-Chemical
(	1725 1 O
44	1726 2 O
%	1728 1 O
,	1729 1 O
8	1731 1 O
/	1732 1 O
18	1733 2 O
;	1735 1 O
p	1737 1 O
=	1739 1 O
.	1741 1 O
04	1742 2 O
)	1744 1 O
.	1745 1 O

The	1747 3 O
number	1751 6 O
of	1758 2 O
previous	1761 8 O
manic	1770 5 B-Disease
episodes	1776 8 O
did	1785 3 O
not	1789 3 O
affect	1793 6 O
the	1800 3 O
probability	1804 11 O
of	1816 2 O
switching	1819 9 O
,	1828 1 O
whereas	1830 7 O
a	1838 1 O
high	1840 4 O
score	1845 5 O
on	1851 2 O
the	1854 3 O
hyperthymia	1858 11 O
component	1870 9 O
of	1880 2 O
the	1883 3 O
Semistructured	1887 14 O
Affective	1902 9 O
Temperament	1912 11 O
Interview	1924 9 O
was	1934 3 O
associated	1938 10 O
with	1949 4 O
a	1954 1 O
greater	1956 7 O
risk	1964 4 O
of	1969 2 O
switching	1972 9 O
(	1982 1 O
p	1983 1 O
=	1985 1 O
.	1987 1 O
008	1988 3 O
)	1991 1 O
.	1992 1 O

CONCLUSION	1994 10 O
:	2004 1 O
The	2006 3 O
frequency	2010 9 O
of	2020 2 O
mood	2023 4 O
switching	2028 9 O
associated	2038 10 O
with	2049 4 O
acute	2054 5 O
antidepressant	2060 14 B-Chemical
therapy	2075 7 O
may	2083 3 O
be	2087 2 O
reduced	2090 7 O
by	2098 2 O
lithium	2101 7 B-Chemical
treatment	2109 9 O
.	2118 1 O

Particular	2120 10 O
attention	2131 9 O
should	2141 6 O
be	2148 2 O
paid	2151 4 O
to	2156 2 O
patients	2159 8 O
with	2168 4 O
a	2173 1 O
hyperthymic	2175 11 O
temperament	2187 11 O
,	2198 1 O
who	2200 3 O
have	2204 4 O
a	2209 1 O
greater	2211 7 O
risk	2219 4 O
of	2224 2 O
mood	2227 4 O
switches	2232 8 O
.	2240 1 O

Caffeine	0 8 B-Chemical
-	8 1 O
induced	9 7 O
cardiac	17 7 B-Disease
arrhythmia	25 10 I-Disease
:	35 1 O
an	37 2 O
unrecognised	40 12 O
danger	53 6 O
of	60 2 O
healthfood	63 10 O
products	74 8 O
.	82 1 O

We	84 2 O
describe	87 8 O
a	96 1 O
25	98 2 O
-	100 1 O
year	101 4 O
-	105 1 O
old	106 3 O
woman	110 5 O
with	116 4 O
pre	121 3 O
-	124 1 O
existing	125 8 O
mitral	134 6 B-Disease
valve	141 5 I-Disease
prolapse	147 8 I-Disease
who	156 3 O
developed	160 9 O
intractable	170 11 O
ventricular	182 11 B-Disease
fibrillation	194 12 I-Disease
after	207 5 O
consuming	213 9 O
a	223 1 O
"	225 1 O
natural	226 7 O
energy	234 6 O
"	240 1 O
guarana	242 7 O
health	250 6 O
drink	257 5 O
containing	263 10 O
a	274 1 O
high	276 4 O
concentration	281 13 O
of	295 2 O
caffeine	298 8 B-Chemical
.	306 1 O

This	308 4 O
case	313 4 O
highlights	318 10 O
the	329 3 O
need	333 4 O
for	338 3 O
adequate	342 8 O
labelling	351 9 O
and	361 3 O
regulation	365 10 O
of	376 2 O
such	379 4 O
products	384 8 O
.	392 1 O

Bladder	0 7 O
retention	8 9 B-Disease
of	18 2 I-Disease
urine	21 5 I-Disease
as	27 2 O
a	30 1 O
result	32 6 O
of	39 2 O
continuous	42 10 O
intravenous	53 11 O
infusion	65 8 O
of	74 2 O
fentanyl	77 8 B-Chemical
:	85 1 O
2	87 1 O
case	89 4 O
reports	94 7 O
.	101 1 O

Sedation	103 8 O
has	112 3 O
been	116 4 O
commonly	121 8 O
used	130 4 O
in	135 2 O
the	138 3 O
neonate	142 7 O
to	150 2 O
decrease	153 8 O
the	162 3 O
stress	166 6 O
and	173 3 O
pain	177 4 B-Disease
from	182 4 O
the	187 3 O
noxious	191 7 O
stimuli	199 7 O
and	207 3 O
invasive	211 8 O
procedures	220 10 O
in	231 2 O
the	234 3 O
neonatal	238 8 O
intensive	247 9 O
care	257 4 O
unit	262 4 O
,	266 1 O
as	268 2 O
well	271 4 O
as	276 2 O
to	279 2 O
facilitate	282 10 O
synchrony	293 9 O
between	303 7 O
ventilator	311 10 O
and	322 3 O
spontaneous	326 11 O
breaths	338 7 O
.	345 1 O

Fentanyl	347 8 B-Chemical
,	355 1 O
an	357 2 O
opioid	360 6 O
analgesic	367 9 O
,	376 1 O
is	378 2 O
frequently	381 10 O
used	392 4 O
in	397 2 O
the	400 3 O
neonatal	404 8 O
intensive	413 9 O
care	423 4 O
unit	428 4 O
setting	433 7 O
for	441 3 O
these	445 5 O
very	451 4 O
purposes	456 8 O
.	464 1 O

Various	466 7 O
reported	474 8 O
side	483 4 O
effects	488 7 O
of	496 2 O
fentanyl	499 8 B-Chemical
administration	508 14 O
include	523 7 O
chest	531 5 B-Disease
wall	537 4 I-Disease
rigidity	542 8 I-Disease
,	550 1 O
hypotension	552 11 B-Disease
,	563 1 O
respiratory	565 11 B-Disease
depression	577 10 I-Disease
,	587 1 O
and	589 3 O
bradycardia	593 11 B-Disease
.	604 1 O

Here	606 4 O
,	610 1 O
2	612 1 O
cases	614 5 O
of	620 2 O
urinary	623 7 B-Disease
bladder	631 7 I-Disease
retention	639 9 I-Disease
leading	649 7 O
to	657 2 O
renal	660 5 O
pelvocalyceal	666 13 O
dilatation	680 10 O
mimicking	691 9 O
hydronephrosis	701 14 B-Disease
as	716 2 O
a	719 1 O
result	721 6 O
of	728 2 O
continuous	731 10 O
infusion	742 8 O
of	751 2 O
fentanyl	754 8 B-Chemical
are	763 3 O
reported	767 8 O
.	775 1 O

Combined	0 8 O
antiretroviral	9 14 O
therapy	24 7 O
causes	32 6 O
cardiomyopathy	39 14 B-Disease
and	54 3 O
elevates	58 8 O
plasma	67 6 O
lactate	74 7 B-Chemical
in	82 2 O
transgenic	85 10 O
AIDS	96 4 B-Disease
mice	101 4 O
.	105 1 O

Highly	107 6 O
active	114 6 O
antiretroviral	121 14 O
therapy	136 7 O
(	144 1 O
HAART	145 5 O
)	150 1 O
is	152 2 O
implicated	155 10 O
in	166 2 O
cardiomyopathy	169 14 B-Disease
(	184 1 O
CM	185 2 B-Disease
)	187 1 O
and	189 3 O
in	193 2 O
elevated	196 8 O
plasma	205 6 O
lactate	212 7 B-Chemical
(	220 1 O
LA	221 2 B-Chemical
)	223 1 O
in	225 2 O
AIDS	228 4 B-Disease
through	233 7 O
mechanisms	241 10 O
of	252 2 O
mitochondrial	255 13 B-Disease
dysfunction	269 11 I-Disease
.	280 1 O

To	282 2 O
determine	285 9 O
mitochondrial	295 13 O
events	309 6 O
from	316 4 O
HAART	321 5 O
in	327 2 O
vivo	330 4 O
,	334 1 O
8	336 1 O
-	337 1 O
week	338 4 O
-	342 1 O
old	343 3 O
hemizygous	347 10 O
transgenic	358 10 O
AIDS	369 4 B-Disease
mice	374 4 O
(	379 1 O
NL4	380 3 O
-	383 1 O
3Delta	384 6 O
gag	391 3 O
/	394 1 O
pol	395 3 O
;	398 1 O
TG	400 2 O
)	402 1 O
and	404 3 O
wild	408 4 O
-	412 1 O
type	413 4 O
FVB	418 3 O
/	421 1 O
n	422 1 O
littermates	424 11 O
were	436 4 O
treated	441 7 O
with	449 4 O
the	454 3 O
HAART	458 5 O
combination	464 11 O
of	476 2 O
zidovudine	479 10 B-Chemical
,	489 1 O
lamivudine	491 10 B-Chemical
,	501 1 O
and	503 3 O
indinavir	507 9 B-Chemical
or	517 2 O
vehicle	520 7 O
control	528 7 O
for	536 3 O
10	540 2 O
days	543 4 O
or	548 2 O
35	551 2 O
days	554 4 O
.	558 1 O

At	560 2 O
termination	563 11 O
of	575 2 O
the	578 3 O
experiments	582 11 O
,	593 1 O
mice	595 4 O
underwent	600 9 O
echocardiography	610 16 O
,	626 1 O
quantitation	628 12 O
of	641 2 O
abundance	644 9 O
of	654 2 O
molecular	657 9 O
markers	667 7 O
of	675 2 O
CM	678 2 B-Disease
(	681 1 O
ventricular	682 11 O
mRNA	694 4 O
encoding	699 8 O
atrial	708 6 O
natriuretic	715 11 O
factor	727 6 O
[	734 1 O
ANF	735 3 O
]	738 1 O
and	740 3 O
sarcoplasmic	744 12 O
calcium	757 7 B-Chemical
ATPase	765 6 O
[	772 1 O
SERCA2	773 6 O
]	779 1 O
)	780 1 O
,	781 1 O
and	783 3 O
determination	787 13 O
of	801 2 O
plasma	804 6 O
LA	811 2 B-Chemical
.	813 1 O

Myocardial	815 10 O
histologic	826 10 O
features	837 8 O
were	846 4 O
analyzed	851 8 O
semiquantitatively	860 18 O
and	879 3 O
results	883 7 O
were	891 4 O
confirmed	896 9 O
by	906 2 O
transmission	909 12 O
electron	922 8 O
microscopy	931 10 O
.	941 1 O

After	943 5 O
35	949 2 O
days	952 4 O
in	957 2 O
the	960 3 O
TG	964 2 O
+	967 1 O
HAART	969 5 O
cohort	975 6 O
,	981 1 O
left	983 4 O
ventricular	988 11 O
mass	1000 4 O
increased	1005 9 O
160	1015 3 O
%	1018 1 O
by	1020 2 O
echocardiography	1023 16 O
.	1039 1 O

Molecularly	1041 11 O
,	1052 1 O
ANF	1054 3 O
mRNA	1058 4 O
increased	1063 9 O
250	1073 3 O
%	1076 1 O
and	1078 3 O
SERCA2	1082 6 O
mRNA	1089 4 O
decreased	1094 9 O
57	1104 2 O
%	1106 1 O
.	1107 1 O

Biochemically	1109 13 O
,	1122 1 O
LA	1124 2 B-Chemical
was	1127 3 O
elevated	1131 8 O
(	1140 1 O
8	1141 1 O
.	1142 1 O
5	1143 1 O
+	1145 1 O
/	1146 1 O
-	1147 1 O
2	1149 1 O
.	1150 1 O
0	1151 1 O
mM	1153 2 O
)	1155 1 O
.	1156 1 O

Pathologically	1158 14 O
,	1172 1 O
granular	1174 8 O
cytoplasmic	1183 11 O
changes	1195 7 O
were	1203 4 O
found	1208 5 O
in	1214 2 O
cardiac	1217 7 O
myocytes	1225 8 O
,	1233 1 O
indicating	1235 10 O
enlarged	1246 8 O
,	1254 1 O
damaged	1256 7 O
mitochondria	1264 12 O
.	1276 1 O

Findings	1278 8 O
were	1287 4 O
confirmed	1292 9 O
ultrastructurally	1302 17 O
.	1319 1 O

No	1321 2 O
changes	1324 7 O
were	1332 4 O
found	1337 5 O
in	1343 2 O
other	1346 5 O
cohorts	1352 7 O
.	1359 1 O

After	1361 5 O
10	1367 2 O
days	1370 4 O
,	1374 1 O
only	1376 4 O
ANF	1381 3 O
was	1385 3 O
elevated	1389 8 O
,	1397 1 O
and	1399 3 O
only	1403 4 O
in	1408 2 O
the	1411 3 O
TG	1415 2 O
+	1418 1 O
HAART	1420 5 O
cohort	1426 6 O
.	1432 1 O

Results	1434 7 O
show	1442 4 O
that	1447 4 O
cumulative	1452 10 O
HAART	1463 5 O
caused	1469 6 O
mitochondrial	1476 13 O
CM	1490 2 B-Disease
with	1493 4 O
elevated	1498 8 O
LA	1507 2 B-Chemical
in	1510 2 O
AIDS	1513 4 B-Disease
transgenic	1518 10 O
mice	1529 4 O
.	1533 1 O

Oral	0 4 B-Chemical
contraceptives	5 14 I-Chemical
and	20 3 O
the	24 3 O
risk	28 4 O
of	33 2 O
myocardial	36 10 B-Disease
infarction	47 10 I-Disease
.	57 1 O

BACKGROUND	59 10 O
:	69 1 O
An	71 2 O
association	74 11 O
between	86 7 O
the	94 3 O
use	98 3 O
of	102 2 O
oral	105 4 B-Chemical
contraceptives	110 14 I-Chemical
and	125 3 O
the	129 3 O
risk	133 4 O
of	138 2 O
myocardial	141 10 B-Disease
infarction	152 10 I-Disease
has	163 3 O
been	167 4 O
found	172 5 O
in	178 2 O
some	181 4 O
,	185 1 O
but	187 3 O
not	191 3 O
all	195 3 O
,	198 1 O
studies	200 7 O
.	207 1 O

We	209 2 O
investigated	212 12 O
this	225 4 O
association	230 11 O
,	241 1 O
according	243 9 O
to	253 2 O
the	256 3 O
type	260 4 O
of	265 2 O
progestagen	268 11 B-Chemical
included	280 8 O
in	289 2 O
third	292 5 O
-	297 1 O
generation	298 10 O
(	309 1 O
i	310 1 O
.	311 1 O
e	312 1 O
.	313 1 O
,	314 1 O
desogestrel	316 11 B-Chemical
or	328 2 O
gestodene	331 9 B-Chemical
)	340 1 O
and	342 3 O
second	346 6 O
-	352 1 O
generation	353 10 O
(	364 1 O
i	365 1 O
.	366 1 O
e	367 1 O
.	368 1 O
,	369 1 O
levonorgestrel	371 14 B-Chemical
)	385 1 O
oral	387 4 B-Chemical
contraceptives	392 14 I-Chemical
,	406 1 O
the	408 3 O
dose	412 4 O
of	417 2 O
estrogen	420 8 B-Chemical
,	428 1 O
and	430 3 O
the	434 3 O
presence	438 8 O
or	447 2 O
absence	450 7 O
of	458 2 O
prothrombotic	461 13 O
mutations	475 9 O
METHODS	485 7 O
:	492 1 O
In	494 2 O
a	497 1 O
nationwide	499 10 O
,	509 1 O
population	511 10 O
-	521 1 O
based	522 5 O
,	527 1 O
case	529 4 O
-	533 1 O
control	534 7 O
study	542 5 O
,	547 1 O
we	549 2 O
identified	552 10 O
and	563 3 O
enrolled	567 8 O
248	576 3 O
women	580 5 O
18	586 2 O
through	589 7 O
49	597 2 O
years	600 5 O
of	606 2 O
age	609 3 O
who	613 3 O
had	617 3 O
had	621 3 O
a	625 1 O
first	627 5 O
myocardial	633 10 B-Disease
infarction	644 10 I-Disease
between	655 7 O
1990	663 4 O
and	668 3 O
1995	672 4 O
and	677 3 O
925	681 3 O
control	685 7 O
women	693 5 O
who	699 3 O
had	703 3 O
not	707 3 O
had	711 3 O
a	715 1 O
myocardial	717 10 B-Disease
infarction	728 10 I-Disease
and	739 3 O
who	743 3 O
were	747 4 O
matched	752 7 O
for	760 3 O
age	764 3 O
,	767 1 O
calendar	769 8 O
year	778 4 O
of	783 2 O
the	786 3 O
index	790 5 O
event	796 5 O
,	801 1 O
and	803 3 O
area	807 4 O
of	812 2 O
residence	815 9 O
.	824 1 O

Subjects	826 8 O
supplied	835 8 O
information	844 11 O
on	856 2 O
oral	859 4 B-Chemical
-	863 1 I-Chemical
contraceptive	864 13 I-Chemical
use	878 3 O
and	882 3 O
major	886 5 O
cardiovascular	892 14 O
risk	907 4 O
factors	912 7 O
.	919 1 O

An	921 2 O
analysis	924 8 O
for	933 3 O
factor	937 6 O
V	944 1 O
Leiden	946 6 O
and	953 3 O
the	957 3 O
G20210A	961 7 O
mutation	969 8 O
in	978 2 O
the	981 3 O
prothrombin	985 11 O
gene	997 4 O
was	1002 3 O
conducted	1006 9 O
in	1016 2 O
217	1019 3 O
patients	1023 8 O
and	1032 3 O
763	1036 3 O
controls	1040 8 O
RESULTS	1049 7 O
:	1056 1 O
The	1058 3 O
odds	1062 4 O
ratio	1067 5 O
for	1073 3 O
myocardial	1077 10 B-Disease
infarction	1088 10 I-Disease
among	1099 5 O
women	1105 5 O
who	1111 3 O
used	1115 4 O
any	1120 3 O
type	1124 4 O
of	1129 2 O
combined	1132 8 O
oral	1141 4 B-Chemical
contraceptive	1146 13 I-Chemical
,	1159 1 O
as	1161 2 O
compared	1164 8 O
with	1173 4 O
nonusers	1178 8 O
,	1186 1 O
was	1188 3 O
2	1192 1 O
.	1193 1 O
0	1194 1 O
(	1196 1 O
95	1197 2 O
percent	1200 7 O
confidence	1208 10 O
interval	1219 8 O
,	1227 1 O
1	1229 1 O
.	1230 1 O
5	1231 1 O
to	1233 2 O
2	1236 1 O
.	1237 1 O
8	1238 1 O
)	1239 1 O
.	1240 1 O

The	1242 3 O
adjusted	1246 8 O
odds	1255 4 O
ratio	1260 5 O
was	1266 3 O
2	1270 1 O
.	1271 1 O
5	1272 1 O
(	1274 1 O
95	1275 2 O
percent	1278 7 O
confidence	1286 10 O
interval	1297 8 O
,	1305 1 O
1	1307 1 O
.	1308 1 O
5	1309 1 O
to	1311 2 O
4	1314 1 O
.	1315 1 O
1	1316 1 O
)	1317 1 O
among	1319 5 O
women	1325 5 O
who	1331 3 O
used	1335 4 O
second	1340 6 O
-	1346 1 O
generation	1347 10 O
oral	1358 4 B-Chemical
contraceptives	1363 14 I-Chemical
and	1378 3 O
1	1382 1 O
.	1383 1 O
3	1384 1 O
(	1386 1 O
95	1387 2 O
percent	1390 7 O
confidence	1398 10 O
interval	1409 8 O
,	1417 1 O
0	1419 1 O
.	1420 1 O
7	1421 1 O
to	1423 2 O
2	1426 1 O
.	1427 1 O
5	1428 1 O
)	1429 1 O
among	1431 5 O
those	1437 5 O
who	1443 3 O
used	1447 4 O
third	1452 5 O
-	1457 1 O
generation	1458 10 O
oral	1469 4 B-Chemical
contraceptives	1474 14 I-Chemical
.	1488 1 O

Among	1490 5 O
women	1496 5 O
who	1502 3 O
used	1506 4 O
oral	1511 4 B-Chemical
contraceptives	1516 14 I-Chemical
,	1530 1 O
the	1532 3 O
odds	1536 4 O
ratio	1541 5 O
was	1547 3 O
2	1551 1 O
.	1552 1 O
1	1553 1 O
(	1555 1 O
95	1556 2 O
percent	1559 7 O
confidence	1567 10 O
interval	1578 8 O
,	1586 1 O
1	1588 1 O
.	1589 1 O
5	1590 1 O
to	1592 2 O
3	1595 1 O
.	1596 1 O
0	1597 1 O
)	1598 1 O
for	1600 3 O
those	1604 5 O
without	1610 7 O
a	1618 1 O
prothrombotic	1620 13 O
mutation	1634 8 O
and	1643 3 O
1	1647 1 O
.	1648 1 O
9	1649 1 O
(	1651 1 O
95	1652 2 O
percent	1655 7 O
confidence	1663 10 O
interval	1674 8 O
,	1682 1 O
0	1684 1 O
.	1685 1 O
6	1686 1 O
to	1688 2 O
5	1691 1 O
.	1692 1 O
5	1693 1 O
)	1694 1 O
for	1696 3 O
those	1700 5 O
with	1706 4 O
a	1711 1 O
mutation	1713 8 O
CONCLUSIONS	1722 11 O
:	1733 1 O
The	1735 3 O
risk	1739 4 O
of	1744 2 O
myocardial	1747 10 B-Disease
infarction	1758 10 I-Disease
was	1769 3 O
increased	1773 9 O
among	1783 5 O
women	1789 5 O
who	1795 3 O
used	1799 4 O
second	1804 6 O
-	1810 1 O
generation	1811 10 O
oral	1822 4 B-Chemical
contraceptives	1827 14 I-Chemical
.	1841 1 O

The	1843 3 O
results	1847 7 O
with	1855 4 O
respect	1860 7 O
to	1868 2 O
the	1871 3 O
use	1875 3 O
of	1879 2 O
third	1882 5 O
-	1887 1 O
generation	1888 10 O
oral	1899 4 B-Chemical
contraceptives	1904 14 I-Chemical
were	1919 4 O
inconclusive	1924 12 O
but	1937 3 O
suggested	1941 9 O
that	1951 4 O
the	1956 3 O
risk	1960 4 O
was	1965 3 O
lower	1969 5 O
than	1975 4 O
the	1980 3 O
risk	1984 4 O
associated	1989 10 O
with	2000 4 O
second	2005 6 O
-	2011 1 O
generation	2012 10 O
oral	2023 4 B-Chemical
contraceptives	2028 14 I-Chemical
.	2042 1 O

The	2044 3 O
risk	2048 4 O
of	2053 2 O
myocardial	2056 10 B-Disease
infarction	2067 10 I-Disease
was	2078 3 O
similar	2082 7 O
among	2090 5 O
women	2096 5 O
who	2102 3 O
used	2106 4 O
oral	2111 4 B-Chemical
contraceptives	2116 14 I-Chemical
whether	2131 7 O
or	2139 2 O
not	2142 3 O
they	2146 4 O
had	2151 3 O
a	2155 1 O
prothrombotic	2157 13 O
mutation	2171 8 O
.	2179 1 O

Effects	0 7 O
of	8 2 O
5	11 1 O
-	12 1 O
HT1B	13 4 O
receptor	18 8 O
ligands	27 7 O
microinjected	35 13 O
into	49 4 O
the	54 3 O
accumbal	58 8 O
shell	67 5 O
or	73 2 O
core	76 4 O
on	81 2 O
the	84 3 O
cocaine	88 7 B-Chemical
-	95 1 O
induced	96 7 O
locomotor	104 9 B-Disease
hyperactivity	114 13 I-Disease
in	128 2 O
rats	131 4 O
.	135 1 O

The	137 3 O
present	141 7 O
study	149 5 O
was	155 3 O
designed	159 8 O
to	168 2 O
examine	171 7 O
the	179 3 O
effect	183 6 O
of	190 2 O
5	193 1 O
-	194 1 O
HT1B	195 4 O
receptor	200 8 O
ligands	209 7 O
microinjected	217 13 O
into	231 4 O
the	236 3 O
subregions	240 10 O
of	251 2 O
the	254 3 O
nucleus	258 7 O
accumbens	266 9 O
(	276 1 O
the	277 3 O
shell	281 5 O
and	287 3 O
the	291 3 O
core	295 4 O
)	299 1 O
on	301 2 O
the	304 3 O
locomotor	308 9 B-Disease
hyperactivity	318 13 I-Disease
induced	332 7 O
by	340 2 O
cocaine	343 7 B-Chemical
in	351 2 O
rats	354 4 O
.	358 1 O

Male	360 4 O
Wistar	365 6 O
rats	372 4 O
were	377 4 O
implanted	382 9 O
bilaterally	392 11 O
with	404 4 O
cannulae	409 8 O
into	418 4 O
the	423 3 O
accumbens	427 9 O
shell	437 5 O
or	443 2 O
core	446 4 O
,	450 1 O
and	452 3 O
then	456 4 O
were	461 4 O
locally	466 7 O
injected	474 8 O
with	483 4 O
GR	488 2 B-Chemical
55562	491 5 I-Chemical
(	497 1 O
an	498 2 O
antagonist	501 10 O
of	512 2 O
5	515 1 O
-	516 1 O
HT1B	517 4 O
receptors	522 9 O
)	531 1 O
or	533 2 O
CP	536 2 B-Chemical
93129	539 5 I-Chemical
(	545 1 O
an	546 2 O
agonist	549 7 O
of	557 2 O
5	560 1 O
-	561 1 O
HT1B	562 4 O
receptors	567 9 O
)	576 1 O
.	577 1 O

Given	579 5 O
alone	585 5 O
to	591 2 O
any	594 3 O
accumbal	598 8 O
subregion	607 9 O
,	616 1 O
GR	618 2 B-Chemical
55562	621 5 I-Chemical
(	627 1 O
0	628 1 O
.	629 1 O
1	630 1 O
-	631 1 O
10	632 2 O
microg	635 6 O
/	641 1 O
side	642 4 O
)	646 1 O
or	648 2 O
CP	651 2 B-Chemical
93129	654 5 I-Chemical
(	660 1 O
0	661 1 O
.	662 1 O
1	663 1 O
-	664 1 O
10	665 2 O
microg	668 6 O
/	674 1 O
side	675 4 O
)	679 1 O
did	681 3 O
not	685 3 O
change	689 6 O
basal	696 5 O
locomotor	702 9 O
activity	712 8 O
.	720 1 O

Systemic	722 8 O
cocaine	731 7 B-Chemical
(	739 1 O
10	740 2 O
mg	743 2 O
/	745 1 O
kg	746 2 O
)	748 1 O
significantly	750 13 O
increased	764 9 O
the	774 3 O
locomotor	778 9 O
activity	788 8 O
of	797 2 O
rats	800 4 O
.	804 1 O

GR	806 2 B-Chemical
55562	809 5 I-Chemical
(	815 1 O
0	816 1 O
.	817 1 O
1	818 1 O
-	819 1 O
10	820 2 O
microg	823 6 O
/	829 1 O
side	830 4 O
)	834 1 O
,	835 1 O
administered	837 12 O
intra	850 5 O
-	855 1 O
accumbens	856 9 O
shell	866 5 O
prior	872 5 O
to	878 2 O
cocaine	881 7 B-Chemical
,	888 1 O
dose	890 4 O
-	894 1 O
dependently	895 11 O
attenuated	907 10 O
the	918 3 O
psychostimulant	922 15 O
-	937 1 O
induced	938 7 O
locomotor	946 9 B-Disease
hyperactivity	956 13 I-Disease
.	969 1 O

Such	971 4 O
attenuation	976 11 O
was	988 3 O
not	992 3 O
found	996 5 O
in	1002 2 O
animals	1005 7 O
which	1013 5 O
had	1019 3 O
been	1023 4 O
injected	1028 8 O
with	1037 4 O
GR	1042 2 B-Chemical
55562	1045 5 I-Chemical
into	1051 4 O
the	1056 3 O
accumbens	1060 9 O
core	1070 4 O
.	1074 1 O

When	1076 4 O
injected	1081 8 O
into	1090 4 O
the	1095 3 O
accumbens	1099 9 O
shell	1109 5 O
(	1115 1 O
but	1116 3 O
not	1120 3 O
the	1124 3 O
core	1128 4 O
)	1132 1 O
before	1134 6 O
cocaine	1141 7 B-Chemical
,	1148 1 O
CP	1150 2 B-Chemical
93129	1153 5 I-Chemical
(	1159 1 O
0	1160 1 O
.	1161 1 O
1	1162 1 O
-	1163 1 O
10	1164 2 O
microg	1167 6 O
/	1173 1 O
side	1174 4 O
)	1178 1 O
enhanced	1180 8 O
the	1189 3 O
locomotor	1193 9 O
response	1203 8 O
to	1212 2 O
cocaine	1215 7 B-Chemical
;	1222 1 O
the	1224 3 O
maximum	1228 7 O
effect	1236 6 O
being	1243 5 O
observed	1249 8 O
after	1258 5 O
10	1264 2 O
microg	1267 6 O
/	1273 1 O
side	1274 4 O
of	1279 2 O
the	1282 3 O
agonist	1286 7 O
.	1293 1 O

The	1295 3 O
later	1299 5 O
enhancement	1305 11 O
was	1317 3 O
attenuated	1321 10 O
after	1332 5 O
intra	1338 5 O
-	1343 1 O
accumbens	1344 9 O
shell	1354 5 O
treatment	1360 9 O
with	1370 4 O
GR	1375 2 B-Chemical
55562	1378 5 I-Chemical
(	1384 1 O
1	1385 1 O
microg	1387 6 O
/	1393 1 O
side	1394 4 O
)	1398 1 O
.	1399 1 O

Our	1401 3 O
findings	1405 8 O
indicate	1414 8 O
that	1423 4 O
cocaine	1428 7 B-Chemical
induced	1436 7 O
hyperlocomotion	1444 15 B-Disease
is	1460 2 O
modified	1463 8 O
by	1472 2 O
5	1475 1 O
-	1476 1 O
HT1B	1477 4 O
receptor	1482 8 O
ligands	1491 7 O
microinjected	1499 13 O
into	1513 4 O
the	1518 3 O
accumbens	1522 9 O
shell	1532 5 O
,	1537 1 O
but	1539 3 O
not	1543 3 O
core	1547 4 O
,	1551 1 O
this	1553 4 O
modification	1558 12 O
consisting	1571 10 O
in	1582 2 O
inhibitory	1585 10 O
and	1596 3 O
facilitatory	1600 12 O
effects	1613 7 O
of	1621 2 O
the	1624 3 O
5	1628 1 O
-	1629 1 O
HT1B	1630 4 O
receptor	1635 8 O
antagonist	1644 10 O
(	1655 1 O
GR	1656 2 B-Chemical
55562	1659 5 I-Chemical
)	1664 1 O
and	1666 3 O
agonist	1670 7 O
(	1678 1 O
CP	1679 2 B-Chemical
93129	1682 5 I-Chemical
)	1687 1 O
,	1688 1 O
respectively	1690 12 O
.	1702 1 O

In	1704 2 O
other	1707 5 O
words	1713 5 O
,	1718 1 O
the	1720 3 O
present	1724 7 O
results	1732 7 O
suggest	1740 7 O
that	1748 4 O
the	1753 3 O
accumbal	1757 8 O
shell	1766 5 O
5	1772 1 O
-	1773 1 O
HT1B	1774 4 O
receptors	1779 9 O
play	1789 4 O
a	1794 1 O
permissive	1796 10 O
role	1807 4 O
in	1812 2 O
the	1815 3 O
behavioural	1819 11 O
response	1831 8 O
to	1840 2 O
the	1843 3 O
psychostimulant	1847 15 O
.	1862 1 O

Ticlopidine	0 11 B-Chemical
-	11 1 O
induced	12 7 O
cholestatic	20 11 B-Disease
hepatitis	32 9 I-Disease
.	41 1 O

OBJECTIVE	43 9 O
:	52 1 O
To	54 2 O
report	57 6 O
2	64 1 O
cases	66 5 O
of	72 2 O
ticlopidine	75 11 B-Chemical
-	86 1 O
induced	87 7 O
cholestatic	95 11 B-Disease
hepatitis	107 9 I-Disease
,	116 1 O
investigate	118 11 O
its	130 3 O
mechanism	134 9 O
,	143 1 O
and	145 3 O
compare	149 7 O
the	157 3 O
observed	161 8 O
main	170 4 O
characteristics	175 15 O
with	191 4 O
those	196 5 O
of	202 2 O
the	205 3 O
published	209 9 O
cases	219 5 O
.	224 1 O

CASE	226 4 O
SUMMARIES	231 9 O
:	240 1 O
Two	242 3 O
patients	246 8 O
developed	255 9 O
prolonged	265 9 O
cholestatic	275 11 B-Disease
hepatitis	287 9 I-Disease
after	297 5 O
receiving	303 9 O
ticlopidine	313 11 B-Chemical
following	325 9 O
percutaneous	335 12 O
coronary	348 8 O
angioplasty	357 11 O
,	368 1 O
with	370 4 O
complete	375 8 O
remission	384 9 O
during	394 6 O
the	401 3 O
follow	405 6 O
-	411 1 O
up	412 2 O
period	415 6 O
.	421 1 O

T	423 1 O
-	424 1 O
cell	425 4 O
stimulation	430 11 O
by	442 2 O
therapeutic	445 11 O
concentration	457 13 O
of	471 2 O
ticlopidine	474 11 B-Chemical
was	486 3 O
demonstrated	490 12 O
in	503 2 O
vitro	506 5 O
in	512 2 O
the	515 3 O
patients	519 8 O
,	527 1 O
but	529 3 O
not	533 3 O
in	537 2 O
healthy	540 7 O
controls	548 8 O
.	556 1 O

DISCUSSION	558 10 O
:	568 1 O
Cholestatic	570 11 B-Disease
hepatitis	582 9 I-Disease
is	592 2 O
a	595 1 O
rare	597 4 O
complication	602 12 O
of	615 2 O
the	618 3 O
antiplatelet	622 12 O
agent	635 5 O
ticlopidine	641 11 B-Chemical
;	652 1 O
several	654 7 O
cases	662 5 O
have	668 4 O
been	673 4 O
reported	678 8 O
but	687 3 O
few	691 3 O
in	695 2 O
the	698 3 O
English	702 7 O
literature	710 10 O
.	720 1 O

Our	722 3 O
patients	726 8 O
developed	735 9 O
jaundice	745 8 B-Disease
following	754 9 O
treatment	764 9 O
with	774 4 O
ticlopidine	779 11 B-Chemical
and	791 3 O
showed	795 6 O
the	802 3 O
clinical	806 8 O
and	815 3 O
laboratory	819 10 O
characteristics	830 15 O
of	846 2 O
cholestatic	849 11 B-Disease
hepatitis	861 9 I-Disease
,	870 1 O
which	872 5 O
resolved	878 8 O
after	887 5 O
discontinuation	893 15 O
of	909 2 O
the	912 3 O
drug	916 4 O
.	920 1 O

Hepatitis	922 9 B-Disease
may	932 3 O
develop	936 7 O
weeks	944 5 O
after	950 5 O
discontinuation	956 15 O
of	972 2 O
the	975 3 O
drug	979 4 O
and	984 3 O
may	988 3 O
run	992 3 O
a	996 1 O
prolonged	998 9 O
course	1008 6 O
,	1014 1 O
but	1016 3 O
complete	1020 8 O
remission	1029 9 O
was	1039 3 O
observed	1043 8 O
in	1052 2 O
all	1055 3 O
reported	1059 8 O
cases	1068 5 O
.	1073 1 O

An	1075 2 O
objective	1078 9 O
causality	1088 9 O
assessment	1098 10 O
revealed	1109 8 O
that	1118 4 O
the	1123 3 O
adverse	1127 7 O
drug	1135 4 O
event	1140 5 O
was	1146 3 O
probably	1150 8 O
related	1159 7 O
to	1167 2 O
the	1170 3 O
use	1174 3 O
of	1178 2 O
ticlopidine	1181 11 B-Chemical
.	1192 1 O

The	1194 3 O
mechanisms	1198 10 O
of	1209 2 O
this	1212 4 O
ticlopidine	1217 11 B-Chemical
-	1228 1 O
induced	1229 7 O
cholestasis	1237 11 B-Disease
are	1249 3 O
unclear	1253 7 O
.	1260 1 O

Immune	1262 6 O
mechanisms	1269 10 O
may	1280 3 O
be	1284 2 O
involved	1287 8 O
in	1296 2 O
the	1299 3 O
drug	1303 4 O
'	1307 1 O
s	1308 1 O
hepatotoxicity	1310 14 B-Disease
,	1324 1 O
as	1326 2 O
suggested	1329 9 O
by	1339 2 O
the	1342 3 O
T	1346 1 O
-	1347 1 O
cell	1348 4 O
stimulation	1353 11 O
study	1365 5 O
reported	1371 8 O
here	1380 4 O
.	1384 1 O

CONCLUSIONS	1386 11 O
:	1397 1 O
Cholestatic	1399 11 B-Disease
hepatitis	1411 9 I-Disease
is	1421 2 O
a	1424 1 O
rare	1426 4 O
adverse	1431 7 O
effect	1439 6 O
of	1446 2 O
ticlopidine	1449 11 B-Chemical
that	1461 4 O
may	1466 3 O
be	1470 2 O
immune	1473 6 O
mediated	1480 8 O
.	1488 1 O

Patients	1490 8 O
receiving	1499 9 O
the	1509 3 O
drug	1513 4 O
should	1518 6 O
be	1525 2 O
monitored	1528 9 O
with	1538 4 O
liver	1543 5 O
function	1549 8 O
tests	1558 5 O
along	1564 5 O
with	1570 4 O
complete	1575 8 O
blood	1584 5 O
cell	1590 4 O
counts	1595 6 O
.	1601 1 O

This	1603 4 O
complication	1608 12 O
will	1621 4 O
be	1626 2 O
observed	1629 8 O
even	1638 4 O
less	1643 4 O
often	1648 5 O
in	1654 2 O
the	1657 3 O
future	1661 6 O
as	1668 2 O
ticlopidine	1671 11 B-Chemical
is	1683 2 O
being	1686 5 O
replaced	1692 8 O
by	1701 2 O
the	1704 3 O
newer	1708 5 O
antiplatelet	1714 12 O
agent	1727 5 O
clopidogrel	1733 11 B-Chemical
.	1744 1 O

Epithelial	0 10 O
sodium	11 6 B-Chemical
channel	18 7 O
(	26 1 O
ENaC	27 4 O
)	31 1 O
subunit	33 7 O
mRNA	41 4 O
and	46 3 O
protein	50 7 O
expression	58 10 O
in	69 2 O
rats	72 4 O
with	77 4 O
puromycin	82 9 B-Chemical
aminonucleoside	92 15 I-Chemical
-	107 1 O
induced	108 7 O
nephrotic	116 9 B-Disease
syndrome	126 8 I-Disease
.	134 1 O

In	136 2 O
experimental	139 12 O
nephrotic	152 9 B-Disease
syndrome	162 8 I-Disease
,	170 1 O
urinary	172 7 O
sodium	180 6 B-Chemical
excretion	187 9 O
is	197 2 O
decreased	200 9 O
during	210 6 O
the	217 3 O
early	221 5 O
phase	227 5 O
of	233 2 O
the	236 3 O
disease	240 7 O
.	247 1 O

The	249 3 O
molecular	253 9 O
mechanism	263 9 O
(	272 1 O
s	273 1 O
)	274 1 O
leading	276 7 O
to	284 2 O
salt	287 4 O
retention	292 9 O
has	302 3 O
not	306 3 O
been	310 4 O
completely	315 10 O
elucidated	326 10 O
.	336 1 O

The	338 3 O
rate	342 4 O
-	346 1 O
limiting	347 8 O
constituent	356 11 O
of	368 2 O
collecting	371 10 O
duct	382 4 O
sodium	387 6 B-Chemical
transport	394 9 O
is	404 2 O
the	407 3 O
epithelial	411 10 O
sodium	422 6 B-Chemical
channel	429 7 O
(	437 1 O
ENaC	438 4 O
)	442 1 O
.	443 1 O

We	445 2 O
examined	448 8 O
the	457 3 O
abundance	461 9 O
of	471 2 O
ENaC	474 4 O
subunit	479 7 O
mRNAs	487 5 O
and	493 3 O
proteins	497 8 O
in	506 2 O
puromycin	509 9 B-Chemical
aminonucleoside	519 15 I-Chemical
(	535 1 O
PAN	536 3 B-Chemical
)	539 1 O
-	540 1 O
induced	541 7 O
nephrotic	549 9 B-Disease
syndrome	559 8 I-Disease
.	567 1 O

The	569 3 O
time	573 4 O
courses	578 7 O
of	586 2 O
urinary	589 7 O
sodium	597 6 B-Chemical
excretion	604 9 O
,	613 1 O
plasma	615 6 O
aldosterone	622 11 B-Chemical
concentration	634 13 O
and	648 3 O
proteinuria	652 11 B-Disease
were	664 4 O
studied	669 7 O
in	677 2 O
male	680 4 O
Sprague	685 7 O
-	692 1 O
Dawley	693 6 O
rats	700 4 O
treated	705 7 O
with	713 4 O
a	718 1 O
single	720 6 O
dose	727 4 O
of	732 2 O
either	735 6 O
PAN	742 3 B-Chemical
or	746 2 O
vehicle	749 7 O
.	756 1 O

The	758 3 O
relative	762 8 O
amounts	771 7 O
of	779 2 O
alphaENaC	782 9 O
,	791 1 O
betaENaC	793 8 O
and	802 3 O
gammaENaC	806 9 O
mRNAs	816 5 O
were	822 4 O
determined	827 10 O
in	838 2 O
kidneys	841 7 O
from	849 4 O
these	854 5 O
rats	860 4 O
by	865 2 O
real	868 4 O
-	872 1 O
time	873 4 O
quantitative	878 12 O
TaqMan	891 6 O
PCR	898 3 O
,	901 1 O
and	903 3 O
the	907 3 O
amounts	911 7 O
of	919 2 O
proteins	922 8 O
by	931 2 O
Western	934 7 O
blot	942 4 O
.	946 1 O

The	948 3 O
kinetics	952 8 O
of	961 2 O
urinary	964 7 O
sodium	972 6 B-Chemical
excretion	979 9 O
and	989 3 O
the	993 3 O
appearance	997 10 O
of	1008 2 O
proteinuria	1011 11 B-Disease
were	1023 4 O
comparable	1028 10 O
with	1039 4 O
those	1044 5 O
reported	1050 8 O
previously	1059 10 O
.	1069 1 O

Sodium	1071 6 B-Chemical
retention	1078 9 O
occurred	1088 8 O
on	1097 2 O
days	1100 4 O
2	1105 1 O
,	1106 1 O
3	1108 1 O
and	1110 3 O
6	1114 1 O
after	1116 5 O
PAN	1122 3 B-Chemical
injection	1126 9 O
.	1135 1 O

A	1137 1 O
significant	1139 11 O
up	1151 2 O
-	1153 1 O
regulation	1154 10 O
of	1165 2 O
alphaENaC	1168 9 O
and	1178 3 O
betaENaC	1182 8 O
mRNA	1191 4 O
abundance	1196 9 O
on	1206 2 O
days	1209 4 O
1	1214 1 O
and	1216 3 O
2	1220 1 O
preceded	1222 8 O
sodium	1231 6 B-Chemical
retention	1238 9 O
on	1248 2 O
days	1251 4 O
2	1256 1 O
and	1258 3 O
3	1262 1 O
.	1263 1 O

Conversely	1265 10 O
,	1275 1 O
down	1277 4 O
-	1281 1 O
regulation	1282 10 O
of	1293 2 O
alphaENaC	1296 9 O
,	1305 1 O
betaENaC	1307 8 O
and	1316 3 O
gammaENaC	1320 9 O
mRNA	1330 4 O
expression	1335 10 O
on	1346 2 O
day	1349 3 O
3	1353 1 O
occurred	1355 8 O
in	1364 2 O
the	1367 3 O
presence	1371 8 O
of	1380 2 O
high	1383 4 O
aldosterone	1388 11 B-Chemical
concentrations	1400 14 O
,	1414 1 O
and	1416 3 O
was	1420 3 O
followed	1424 8 O
by	1433 2 O
a	1436 1 O
return	1438 6 O
of	1445 2 O
sodium	1448 6 B-Chemical
excretion	1455 9 O
to	1465 2 O
control	1468 7 O
values	1476 6 O
.	1482 1 O

The	1484 3 O
amounts	1488 7 O
of	1496 2 O
alphaENaC	1499 9 O
,	1508 1 O
betaENaC	1510 8 O
and	1519 3 O
gammaENaC	1523 9 O
proteins	1533 8 O
were	1542 4 O
not	1547 3 O
increased	1551 9 O
during	1561 6 O
PAN	1568 3 B-Chemical
-	1571 1 O
induced	1572 7 O
sodium	1580 6 B-Chemical
retention	1587 9 O
.	1596 1 O

In	1598 2 O
conclusion	1601 10 O
,	1611 1 O
ENaC	1613 4 O
mRNA	1618 4 O
expression	1623 10 O
,	1633 1 O
especially	1635 10 O
alphaENaC	1646 9 O
,	1655 1 O
is	1657 2 O
increased	1660 9 O
in	1670 2 O
the	1673 3 O
very	1677 4 O
early	1682 5 O
phase	1688 5 O
of	1694 2 O
the	1697 3 O
experimental	1701 12 O
model	1714 5 O
of	1720 2 O
PAN	1723 3 B-Chemical
-	1726 1 O
induced	1727 7 O
nephrotic	1735 9 B-Disease
syndrome	1745 8 I-Disease
in	1754 2 O
rats	1757 4 O
,	1761 1 O
but	1763 3 O
appears	1767 7 O
to	1775 2 O
escape	1778 6 O
from	1785 4 O
the	1790 3 O
regulation	1794 10 O
by	1805 2 O
aldosterone	1808 11 B-Chemical
after	1820 5 O
day	1826 3 O
3	1830 1 O
.	1831 1 O

NO	0 2 B-Chemical
-	2 1 O
induced	3 7 O
migraine	11 8 B-Disease
attack	20 6 O
:	26 1 O
strong	28 6 O
increase	35 8 O
in	44 2 O
plasma	47 6 O
calcitonin	54 10 B-Chemical
gene	65 4 I-Chemical
-	69 1 I-Chemical
related	70 7 I-Chemical
peptide	78 7 I-Chemical
(	86 1 O
CGRP	87 4 B-Chemical
)	91 1 O
concentration	93 13 O
and	107 3 O
negative	111 8 O
correlation	120 11 O
with	132 4 O
platelet	137 8 O
serotonin	146 9 B-Chemical
release	156 7 O
.	163 1 O

The	165 3 O
aim	169 3 O
of	173 2 O
the	176 3 O
present	180 7 O
study	188 5 O
was	194 3 O
to	198 2 O
investigate	201 11 O
changes	213 7 O
in	221 2 O
the	224 3 O
plasma	228 6 O
calcitonin	235 10 B-Chemical
gene	246 4 I-Chemical
-	250 1 I-Chemical
related	251 7 I-Chemical
peptide	259 7 I-Chemical
(	267 1 O
CGRP	268 4 B-Chemical
)	272 1 O
concentration	274 13 O
and	288 3 O
platelet	292 8 O
serotonin	301 9 B-Chemical
(	311 1 O
5	312 1 B-Chemical
-	313 1 I-Chemical
hydroxytriptamine	314 17 I-Chemical
,	331 1 O
5	333 1 B-Chemical
-	334 1 I-Chemical
HT	335 2 I-Chemical
)	337 1 O
content	339 7 O
during	347 6 O
the	354 3 O
immediate	358 9 O
headache	368 8 B-Disease
and	377 3 O
the	381 3 O
delayed	385 7 O
genuine	393 7 O
migraine	401 8 B-Disease
attack	410 6 O
provoked	417 8 O
by	426 2 O
nitroglycerin	429 13 B-Chemical
.	442 1 O

Fifteen	444 7 O
female	452 6 O
migraineurs	459 11 B-Disease
(	471 1 I-Disease
without	472 7 I-Disease
aura	480 4 I-Disease
)	484 1 I-Disease
and	486 3 O
eight	490 5 O
controls	496 8 O
participated	505 12 O
in	518 2 O
the	521 3 O
study	525 5 O
.	530 1 O

Sublingual	532 10 O
nitroglycerin	543 13 B-Chemical
(	557 1 O
0	558 1 O
.	559 1 O
5	560 1 O
mg	562 2 O
)	564 1 O
was	566 3 O
administered	570 12 O
.	582 1 O

Blood	584 5 O
was	590 3 O
collected	594 9 O
from	604 4 O
the	609 3 O
antecubital	613 11 O
vein	625 4 O
four	630 4 O
times	635 5 O
:	640 1 O
60	642 2 O
min	645 3 O
before	649 6 O
and	656 3 O
after	660 5 O
the	666 3 O
nitroglycerin	670 13 B-Chemical
application	684 11 O
,	695 1 O
and	697 3 O
60	701 2 O
and	704 3 O
120	708 3 O
min	712 3 O
after	716 5 O
the	722 3 O
beginning	726 9 O
of	736 2 O
the	739 3 O
migraine	743 8 B-Disease
attack	752 6 O
(	759 1 O
mean	760 4 O
344	765 3 O
and	769 3 O
404	773 3 O
min	777 3 O
;	780 1 O
12	782 2 O
subjects	785 8 O
)	793 1 O
.	794 1 O

In	796 2 O
those	799 5 O
subjects	805 8 O
who	814 3 O
had	818 3 O
no	822 2 O
migraine	825 8 B-Disease
attack	834 6 O
(	841 1 O
11	842 2 O
subjects	845 8 O
)	853 1 O
a	855 1 O
similar	857 7 O
time	865 4 O
schedule	870 8 O
was	879 3 O
used	883 4 O
.	887 1 O

Plasma	889 6 O
CGRP	896 4 B-Chemical
concentration	901 13 O
increased	915 9 O
significantly	925 13 O
(	939 1 O
P	940 1 O
<	941 1 O
0	942 1 O
.	943 1 O
01	944 2 O
)	946 1 O
during	948 6 O
the	955 3 O
migraine	959 8 B-Disease
attack	968 6 O
and	975 3 O
returned	979 8 O
to	988 2 O
baseline	991 8 O
after	1000 5 O
the	1006 3 O
cessation	1010 9 O
of	1020 2 O
the	1023 3 O
migraine	1027 8 B-Disease
.	1035 1 O

In	1037 2 O
addition	1040 8 O
,	1048 1 O
both	1050 4 O
change	1055 6 O
and	1062 3 O
peak	1066 4 O
,	1070 1 O
showed	1072 6 O
significant	1079 11 O
positive	1091 8 O
correlations	1100 12 O
with	1113 4 O
migraine	1118 8 B-Disease
headache	1127 8 B-Disease
intensity	1136 9 O
(	1146 1 O
P	1147 1 O
<	1148 1 O
0	1149 1 O
.	1150 1 O
001	1151 3 O
)	1154 1 O
.	1155 1 O

However	1157 7 O
,	1164 1 O
plasma	1166 6 O
CGRP	1173 4 B-Chemical
concentrations	1178 14 O
failed	1193 6 O
to	1200 2 O
change	1203 6 O
during	1210 6 O
immediate	1217 9 O
headache	1227 8 B-Disease
and	1236 3 O
in	1240 2 O
the	1243 3 O
subjects	1247 8 O
with	1256 4 O
no	1261 2 O
migraine	1264 8 B-Disease
attack	1273 6 O
.	1279 1 O

Basal	1281 5 O
CGRP	1287 4 B-Chemical
concentration	1292 13 O
was	1306 3 O
significantly	1310 13 O
higher	1324 6 O
and	1331 3 O
platelet	1335 8 O
5	1344 1 B-Chemical
-	1345 1 I-Chemical
HT	1346 2 I-Chemical
content	1349 7 O
tended	1357 6 O
to	1364 2 O
be	1367 2 O
lower	1370 5 O
in	1376 2 O
subjects	1379 8 O
who	1388 3 O
experienced	1392 11 O
a	1404 1 O
migraine	1406 8 B-Disease
attack	1415 6 O
.	1421 1 O

Platelet	1423 8 O
serotonin	1432 9 B-Chemical
content	1442 7 O
decreased	1450 9 O
significantly	1460 13 O
(	1474 1 O
P	1475 1 O
<	1476 1 O
0	1477 1 O
.	1478 1 O
01	1479 2 O
)	1481 1 O
after	1483 5 O
nitroglycerin	1489 13 B-Chemical
in	1503 2 O
subjects	1506 8 O
with	1515 4 O
no	1520 2 O
migraine	1523 8 B-Disease
attack	1532 6 O
but	1539 3 O
no	1543 2 O
consistent	1546 10 O
change	1557 6 O
was	1564 3 O
observed	1568 8 O
in	1577 2 O
patients	1580 8 O
with	1589 4 O
migraine	1594 8 B-Disease
attack	1603 6 O
.	1609 1 O

In	1611 2 O
conclusion	1614 10 O
,	1624 1 O
the	1626 3 O
fact	1630 4 O
that	1635 4 O
plasma	1640 6 O
CGRP	1647 4 B-Chemical
concentration	1652 13 O
correlates	1666 10 O
with	1677 4 O
the	1682 3 O
timing	1686 6 O
and	1693 3 O
severity	1697 8 O
of	1706 2 O
a	1709 1 O
migraine	1711 8 B-Disease
headache	1720 8 B-Disease
suggests	1729 8 O
a	1738 1 O
direct	1740 6 O
relationship	1747 12 O
between	1760 7 O
CGRP	1768 4 B-Chemical
and	1773 3 O
migraine	1777 8 B-Disease
.	1785 1 O

In	1787 2 O
contrast	1790 8 O
,	1798 1 O
serotonin	1800 9 B-Chemical
release	1810 7 O
from	1818 4 O
platelets	1823 9 O
does	1833 4 O
not	1838 3 O
provoke	1842 7 O
migraine	1850 8 B-Disease
,	1858 1 O
it	1860 2 O
may	1863 3 O
even	1867 4 O
counteract	1872 10 O
the	1883 3 O
headache	1887 8 B-Disease
and	1896 3 O
the	1900 3 O
concomitant	1904 11 O
CGRP	1916 4 B-Chemical
release	1921 7 O
in	1929 2 O
this	1932 4 O
model	1937 5 O
.	1942 1 O

Coronary	0 8 B-Disease
aneurysm	9 8 I-Disease
after	18 5 O
implantation	24 12 O
of	37 2 O
a	40 1 O
paclitaxel	42 10 B-Chemical
-	52 1 O
eluting	53 7 O
stent	61 5 O
.	66 1 O

Formation	68 9 O
of	78 2 O
coronary	81 8 B-Disease
aneurysm	90 8 I-Disease
is	99 2 O
a	102 1 O
rare	104 4 O
complication	109 12 O
of	122 2 O
stenting	125 8 O
with	134 4 O
bare	139 4 O
metal	144 5 O
stents	150 6 O
,	156 1 O
but	158 3 O
based	162 5 O
on	168 2 O
experimental	171 12 O
studies	184 7 O
drug	192 4 O
-	196 1 O
eluting	197 7 O
stents	205 6 O
may	212 3 O
induce	216 6 O
toxic	223 5 O
effects	229 7 O
on	237 2 O
the	240 3 O
vessel	244 6 O
wall	251 4 O
with	256 4 O
incomplete	261 10 O
stent	272 5 O
apposition	278 10 O
,	288 1 O
aneurysm	290 8 B-Disease
formation	299 9 O
and	309 3 O
with	313 4 O
the	318 3 O
potential	322 9 O
of	332 2 O
stent	335 5 O
thrombosis	341 10 B-Disease
or	352 2 O
vessel	355 6 B-Disease
rupture	362 7 I-Disease
.	369 1 O

We	371 2 O
present	374 7 O
a	382 1 O
43	384 2 O
-	386 1 O
year	387 4 O
-	391 1 O
old	392 3 O
man	396 3 O
who	400 3 O
developed	404 9 O
a	414 1 O
coronary	416 8 B-Disease
aneurysm	425 8 I-Disease
in	434 2 O
the	437 3 O
right	441 5 O
coronary	447 8 O
artery	456 6 O
6	463 1 O
months	465 6 O
after	472 5 O
receiving	478 9 O
a	488 1 O
paclitaxel	490 10 B-Chemical
-	500 1 O
eluting	501 7 O
stent	509 5 O
.	514 1 O

The	516 3 O
patient	520 7 O
was	528 3 O
asymptomatic	532 12 O
and	545 3 O
the	549 3 O
aneurysm	553 8 B-Disease
was	562 3 O
detected	566 8 O
in	575 2 O
a	578 1 O
routine	580 7 O
control	588 7 O
.	595 1 O

Angiography	597 11 O
and	609 3 O
intracoronary	613 13 O
ultrasound	627 10 O
demonstrated	638 12 O
lack	651 4 O
of	656 2 O
contact	659 7 O
between	667 7 O
stent	675 5 O
and	681 3 O
vessel	685 6 O
wall	692 4 O
in	697 2 O
a	700 1 O
15	702 2 O
-	704 1 O
mm	705 2 O
long	708 4 O
segment	713 7 O
with	721 4 O
maximal	726 7 O
aneurysm	734 8 B-Disease
diameter	743 8 O
of	752 2 O
6	755 1 O
.	756 1 O
0	757 1 O
mm	759 2 O
.	761 1 O

The	763 3 O
patient	767 7 O
was	775 3 O
successfully	779 12 O
treated	792 7 O
with	800 4 O
a	805 1 O
graft	807 5 O
stent	813 5 O
.	818 1 O

Behavioral	0 10 O
effects	11 7 O
of	19 2 O
urotensin	22 9 B-Chemical
-	31 1 I-Chemical
II	32 2 I-Chemical
centrally	35 9 O
administered	45 12 O
in	58 2 O
mice	61 4 O
.	65 1 O

Urotensin	67 9 B-Chemical
-	76 1 I-Chemical
II	77 2 I-Chemical
(	80 1 O
U	81 1 B-Chemical
-	82 1 I-Chemical
II	83 2 I-Chemical
)	85 1 O
receptors	87 9 O
are	97 3 O
widely	101 6 O
distributed	108 11 O
in	120 2 O
the	123 3 O
central	127 7 O
nervous	135 7 O
system	143 6 O
.	149 1 O

Intracerebroventricular	151 23 O
(	175 1 O
i	176 1 O
.	177 1 O
c	178 1 O
.	179 1 O
v	180 1 O
.	181 1 O
)	182 1 O
injection	184 9 O
of	194 2 O
U	197 1 B-Chemical
-	198 1 I-Chemical
II	199 2 I-Chemical
causes	202 6 O
hypertension	209 12 B-Disease
and	222 3 O
bradycardia	226 11 B-Disease
and	238 3 O
stimulates	242 10 O
prolactin	253 9 O
and	263 3 O
thyrotropin	267 11 O
secretion	279 9 O
.	288 1 O

However	290 7 O
,	297 1 O
the	299 3 O
behavioral	303 10 O
effects	314 7 O
of	322 2 O
centrally	325 9 O
administered	335 12 O
U	348 1 B-Chemical
-	349 1 I-Chemical
II	350 2 I-Chemical
have	353 4 O
received	358 8 O
little	367 6 O
attention	374 9 O
.	383 1 O

In	385 2 O
the	388 3 O
present	392 7 O
study	400 5 O
,	405 1 O
we	407 2 O
tested	410 6 O
the	417 3 O
effects	421 7 O
of	429 2 O
i	432 1 O
.	433 1 O
c	434 1 O
.	435 1 O
v	436 1 O
.	437 1 O
injections	439 10 O
of	450 2 O
U	453 1 B-Chemical
-	454 1 I-Chemical
II	455 2 I-Chemical
on	458 2 O
behavioral	461 10 O
,	471 1 O
metabolic	473 9 O
,	482 1 O
and	484 3 O
endocrine	488 9 O
responses	498 9 O
in	508 2 O
mice	511 4 O
.	515 1 O

Administration	517 14 O
of	532 2 O
graded	535 6 O
doses	542 5 O
of	548 2 O
U	551 1 B-Chemical
-	552 1 I-Chemical
II	553 2 I-Chemical
(	556 1 O
1	557 1 O
-	558 1 O
10	559 2 O
,	561 1 O
000	562 3 O
ng	566 2 O
/	568 1 O
mouse	569 5 O
)	574 1 O
provoked	576 8 O
:	584 1 O
(	586 1 O
1	587 1 O
)	588 1 O
a	590 1 O
dose	592 4 O
-	596 1 O
dependent	597 9 O
reduction	607 9 O
in	617 2 O
the	620 3 O
number	624 6 O
of	631 2 O
head	634 4 O
dips	639 4 O
in	644 2 O
the	647 3 O
hole	651 4 O
-	655 1 O
board	656 5 O
test	662 4 O
;	666 1 O
(	668 1 O
2	669 1 O
)	670 1 O
a	672 1 O
dose	674 4 O
-	678 1 O
dependent	679 9 O
reduction	689 9 O
in	699 2 O
the	702 3 O
number	706 6 O
of	713 2 O
entries	716 7 O
in	724 2 O
the	727 3 O
white	731 5 O
chamber	737 7 O
in	745 2 O
the	748 3 O
black	752 5 O
-	757 1 O
and	758 3 O
-	761 1 O
white	762 5 O
compartment	768 11 O
test	780 4 O
,	784 1 O
and	786 3 O
in	790 2 O
the	793 3 O
number	797 6 O
of	804 2 O
entries	807 7 O
in	815 2 O
the	818 3 O
central	822 7 O
platform	830 8 O
and	839 3 O
open	843 4 O
arms	848 4 O
in	853 2 O
the	856 3 O
plus	860 4 O
-	864 1 O
maze	865 4 O
test	870 4 O
;	874 1 O
and	876 3 O
(	880 1 O
3	881 1 O
)	882 1 O
a	884 1 O
dose	886 4 O
-	890 1 O
dependent	891 9 O
increase	901 8 O
in	910 2 O
the	913 3 O
duration	917 8 O
of	926 2 O
immobility	929 10 O
in	940 2 O
the	943 3 O
forced	947 6 O
-	953 1 O
swimming	954 8 O
test	963 4 O
and	968 3 O
tail	972 4 O
suspension	977 10 O
test	988 4 O
.	992 1 O

Intracerebroventricular	994 23 O
injection	1018 9 O
of	1028 2 O
U	1031 1 B-Chemical
-	1032 1 I-Chemical
II	1033 2 I-Chemical
also	1036 4 O
caused	1041 6 O
an	1048 2 O
increase	1051 8 O
in	1060 2 O
:	1062 1 O
food	1064 4 O
intake	1069 6 O
at	1076 2 O
doses	1079 5 O
of	1085 2 O
100	1088 3 O
and	1092 3 O
1	1096 1 O
,	1097 1 O
000	1098 3 O
ng	1102 2 O
/	1104 1 O
mouse	1105 5 O
,	1110 1 O
water	1112 5 O
intake	1118 6 O
at	1125 2 O
doses	1128 5 O
of	1134 2 O
100	1137 3 O
-	1140 1 O
10	1141 2 O
,	1143 1 O
000	1144 3 O
ng	1148 2 O
/	1150 1 O
mouse	1151 5 O
,	1156 1 O
and	1158 3 O
horizontal	1162 10 O
locomotion	1173 10 O
activity	1184 8 O
at	1193 2 O
a	1196 1 O
dose	1198 4 O
of	1203 2 O
10	1206 2 O
,	1208 1 O
000	1209 3 O
ng	1213 2 O
/	1215 1 O
mouse	1216 5 O
.	1221 1 O

Whatever	1223 8 O
was	1232 3 O
the	1236 3 O
dose	1240 4 O
,	1244 1 O
the	1246 3 O
central	1250 7 O
administration	1258 14 O
of	1273 2 O
U	1276 1 B-Chemical
-	1277 1 I-Chemical
II	1278 2 I-Chemical
had	1281 3 O
no	1285 2 O
effect	1288 6 O
on	1295 2 O
body	1298 4 O
temperature	1303 11 O
,	1314 1 O
nociception	1316 11 O
,	1327 1 O
apomorphine	1329 11 B-Chemical
-	1340 1 O
induced	1341 7 O
penile	1349 6 B-Disease
erection	1356 8 I-Disease
and	1365 3 O
climbing	1369 8 O
behavior	1378 8 O
,	1386 1 O
and	1388 3 O
stress	1392 6 O
-	1398 1 O
induced	1399 7 O
plasma	1407 6 O
corticosterone	1414 14 B-Chemical
level	1429 5 O
.	1434 1 O

Taken	1436 5 O
together	1442 8 O
,	1450 1 O
the	1452 3 O
present	1456 7 O
study	1464 5 O
demonstrates	1470 12 O
that	1483 4 O
the	1488 3 O
central	1492 7 O
injection	1500 9 O
of	1510 2 O
U	1513 1 B-Chemical
-	1514 1 I-Chemical
II	1515 2 I-Chemical
at	1518 2 O
doses	1521 5 O
of	1527 2 O
1	1530 1 O
-	1531 1 O
10	1532 2 O
,	1534 1 O
000	1535 3 O
ng	1539 2 O
/	1541 1 O
mouse	1542 5 O
induces	1548 7 O
anxiogenic	1556 10 O
-	1566 1 O
and	1568 3 O
depressant	1572 10 O
-	1582 1 O
like	1583 4 O
effects	1588 7 O
in	1596 2 O
mouse	1599 5 O
.	1604 1 O

These	1606 5 O
data	1612 4 O
suggest	1617 7 O
that	1625 4 O
U	1630 1 B-Chemical
-	1631 1 I-Chemical
II	1632 2 I-Chemical
may	1635 3 O
be	1639 2 O
involved	1642 8 O
in	1651 2 O
some	1654 4 O
aspects	1659 7 O
of	1667 2 O
psychiatric	1670 11 B-Disease
disorders	1682 9 I-Disease
.	1691 1 O

Recurrent	0 9 O
dysphonia	10 9 B-Disease
and	20 3 O
acitretin	24 9 B-Chemical
.	33 1 O

We	35 2 O
report	38 6 O
the	45 3 O
case	49 4 O
of	54 2 O
a	57 1 O
woman	59 5 O
complaining	65 11 O
of	77 2 O
dysphonia	80 9 B-Disease
while	90 5 O
she	96 3 O
was	100 3 O
treated	104 7 O
by	112 2 O
acitretin	115 9 B-Chemical
.	124 1 O

Her	126 3 O
symptoms	130 8 O
totally	139 7 O
regressed	147 9 O
after	157 5 O
drug	163 4 O
withdrawal	168 10 O
and	179 3 O
reappeared	183 10 O
when	194 4 O
acitretin	199 9 B-Chemical
was	209 3 O
reintroduced	213 12 O
.	225 1 O

To	227 2 O
our	230 3 O
knowledge	234 9 O
,	243 1 O
this	245 4 O
is	250 2 O
the	253 3 O
first	257 5 O
case	263 4 O
of	268 2 O
acitretin	271 9 B-Chemical
-	280 1 O
induced	281 7 O
dysphonia	289 9 B-Disease
.	298 1 O

This	300 4 O
effect	305 6 O
may	312 3 O
be	316 2 O
related	319 7 O
to	327 2 O
the	330 3 O
pharmacological	334 15 O
effect	350 6 O
of	357 2 O
this	360 4 O
drug	365 4 O
on	370 2 O
mucous	373 6 O
membranes	380 9 O
.	389 1 O

Pharmacological	0 15 O
modulation	16 10 O
of	27 2 O
pain	30 4 B-Disease
-	34 1 O
related	35 7 O
brain	43 5 O
activity	49 8 O
during	58 6 O
normal	65 6 O
and	72 3 O
central	76 7 O
sensitization	84 13 O
states	98 6 O
in	105 2 O
humans	108 6 O
.	114 1 O

Abnormal	116 8 O
processing	125 10 O
of	136 2 O
somatosensory	139 13 O
inputs	153 6 O
in	160 2 O
the	163 3 O
central	167 7 O
nervous	175 7 O
system	183 6 O
(	190 1 O
central	191 7 O
sensitization	199 13 O
)	212 1 O
is	214 2 O
the	217 3 O
mechanism	221 9 O
accounting	231 10 O
for	242 3 O
the	246 3 O
enhanced	250 8 O
pain	259 4 B-Disease
sensitivity	264 11 O
in	276 2 O
the	279 3 O
skin	283 4 O
surrounding	288 11 O
tissue	300 6 B-Disease
injury	307 6 I-Disease
(	314 1 O
secondary	315 9 B-Disease
hyperalgesia	325 12 I-Disease
)	337 1 O
.	338 1 O

Secondary	340 9 B-Disease
hyperalgesia	350 12 I-Disease
shares	363 6 O
clinical	370 8 O
characteristics	379 15 O
with	395 4 O
neurogenic	400 10 B-Disease
hyperalgesia	411 12 I-Disease
in	424 2 O
patients	427 8 O
with	436 4 O
neuropathic	441 11 B-Disease
pain	453 4 I-Disease
.	457 1 O

Abnormal	459 8 O
brain	468 5 O
responses	474 9 O
to	484 2 O
somatosensory	487 13 O
stimuli	501 7 O
have	509 4 O
been	514 4 O
found	519 5 O
in	525 2 O
patients	528 8 O
with	537 4 O
hyperalgesia	542 12 B-Disease
as	555 2 O
well	558 4 O
as	563 2 O
in	566 2 O
normal	569 6 O
subjects	576 8 O
during	585 6 O
experimental	592 12 O
central	605 7 O
sensitization	613 13 O
.	626 1 O

The	628 3 O
aim	632 3 O
of	636 2 O
this	639 4 O
study	644 5 O
was	650 3 O
to	654 2 O
assess	657 6 O
the	664 3 O
effects	668 7 O
of	676 2 O
gabapentin	679 10 B-Chemical
,	689 1 O
a	691 1 O
drug	693 4 O
effective	698 9 O
in	708 2 O
neuropathic	711 11 B-Disease
pain	723 4 I-Disease
patients	728 8 O
,	736 1 O
on	738 2 O
brain	741 5 O
processing	747 10 O
of	758 2 O
nociceptive	761 11 O
information	773 11 O
in	785 2 O
normal	788 6 O
and	795 3 O
central	799 7 O
sensitization	807 13 O
states	821 6 O
.	827 1 O

Using	829 5 O
functional	835 10 O
magnetic	846 8 O
resonance	855 9 O
imaging	865 7 O
(	873 1 O
fMRI	874 4 O
)	878 1 O
in	880 2 O
normal	883 6 O
volunteers	890 10 O
,	900 1 O
we	902 2 O
studied	905 7 O
the	913 3 O
gabapentin	917 10 B-Chemical
-	927 1 O
induced	928 7 O
modulation	936 10 O
of	947 2 O
brain	950 5 O
activity	956 8 O
in	965 2 O
response	968 8 O
to	977 2 O
nociceptive	980 11 O
mechanical	992 10 O
stimulation	1003 11 O
of	1015 2 O
normal	1018 6 O
skin	1025 4 O
and	1030 3 O
capsaicin	1034 9 B-Chemical
-	1043 1 O
induced	1044 7 O
secondary	1052 9 B-Disease
hyperalgesia	1062 12 I-Disease
.	1074 1 O

The	1076 3 O
dose	1080 4 O
of	1085 2 O
gabapentin	1088 10 B-Chemical
was	1099 3 O
1	1103 1 O
,	1104 1 O
800	1105 3 O
mg	1109 2 O
per	1112 3 O
os	1116 2 O
,	1118 1 O
in	1120 2 O
a	1123 1 O
single	1125 6 O
administration	1132 14 O
.	1146 1 O

We	1148 2 O
found	1151 5 O
that	1157 4 O
(	1162 1 O
i	1163 1 O
)	1164 1 O
gabapentin	1166 10 B-Chemical
reduced	1177 7 O
the	1185 3 O
activations	1189 11 O
in	1201 2 O
the	1204 3 O
bilateral	1208 9 O
operculoinsular	1218 15 O
cortex	1234 6 O
,	1240 1 O
independently	1242 13 O
of	1256 2 O
the	1259 3 O
presence	1263 8 O
of	1272 2 O
central	1275 7 O
sensitization	1283 13 O
;	1296 1 O
(	1298 1 O
ii	1299 2 O
)	1301 1 O
gabapentin	1303 10 B-Chemical
reduced	1314 7 O
the	1322 3 O
activation	1326 10 O
in	1337 2 O
the	1340 3 O
brainstem	1344 9 O
,	1353 1 O
only	1355 4 O
during	1360 6 O
central	1367 7 O
sensitization	1375 13 O
;	1388 1 O
(	1390 1 O
iii	1391 3 O
)	1394 1 O
gabapentin	1396 10 B-Chemical
suppressed	1407 10 O
stimulus	1418 8 O
-	1426 1 O
induced	1427 7 O
deactivations	1435 13 O
,	1448 1 O
only	1450 4 O
during	1455 6 O
central	1462 7 O
sensitization	1470 13 O
;	1483 1 O
this	1485 4 O
effect	1490 6 O
was	1497 3 O
more	1501 4 O
robust	1506 6 O
than	1513 4 O
the	1518 3 O
effect	1522 6 O
on	1529 2 O
brain	1532 5 O
activation	1538 10 O
.	1548 1 O

The	1550 3 O
observed	1554 8 O
drug	1563 4 O
-	1567 1 O
induced	1568 7 O
effects	1576 7 O
were	1584 4 O
not	1589 3 O
due	1593 3 O
to	1597 2 O
changes	1600 7 O
in	1608 2 O
the	1611 3 O
baseline	1615 8 O
fMRI	1624 4 O
signal	1629 6 O
.	1635 1 O

These	1637 5 O
findings	1643 8 O
indicate	1652 8 O
that	1661 4 O
gabapentin	1666 10 B-Chemical
has	1677 3 O
a	1681 1 O
measurable	1683 10 O
antinociceptive	1694 15 O
effect	1710 6 O
and	1717 3 O
a	1721 1 O
stronger	1723 8 O
antihyperalgesic	1732 16 O
effect	1749 6 O
most	1756 4 O
evident	1761 7 O
in	1769 2 O
the	1772 3 O
brain	1776 5 O
areas	1782 5 O
undergoing	1788 10 O
deactivation	1799 12 O
,	1811 1 O
thus	1813 4 O
supporting	1818 10 O
the	1829 3 O
concept	1833 7 O
that	1841 4 O
gabapentin	1846 10 B-Chemical
is	1857 2 O
more	1860 4 O
effective	1865 9 O
in	1875 2 O
modulating	1878 10 O
nociceptive	1889 11 O
transmission	1901 12 O
when	1914 4 O
central	1919 7 O
sensitization	1927 13 O
is	1941 2 O
present	1944 7 O
.	1951 1 O

MDMA	0 4 B-Chemical
polydrug	5 8 O
users	14 5 O
show	20 4 O
process	25 7 O
-	32 1 O
specific	33 8 O
central	42 7 O
executive	50 9 O
impairments	60 11 O
coupled	72 7 O
with	80 4 O
impaired	85 8 B-Disease
social	94 6 I-Disease
and	101 3 I-Disease
emotional	105 9 I-Disease
judgement	115 9 I-Disease
processes	125 9 I-Disease
.	134 1 O

In	136 2 O
recent	139 6 O
years	146 5 O
working	152 7 O
memory	160 6 B-Disease
deficits	167 8 I-Disease
have	176 4 O
been	181 4 O
reported	186 8 O
in	195 2 O
users	198 5 O
of	204 2 O
MDMA	207 4 B-Chemical
(	212 1 O
3	213 1 B-Chemical
,	214 1 I-Chemical
4	215 1 I-Chemical
-	216 1 I-Chemical
methylenedioxymethamphetamine	217 29 I-Chemical
,	246 1 O
ecstasy	248 7 B-Chemical
)	255 1 O
.	256 1 O

The	258 3 O
current	262 7 O
study	270 5 O
aimed	276 5 O
to	282 2 O
assess	285 6 O
the	292 3 O
impact	296 6 O
of	303 2 O
MDMA	306 4 B-Chemical
use	311 3 O
on	315 2 O
three	318 5 O
separate	324 8 O
central	333 7 O
executive	341 9 O
processes	351 9 O
(	361 1 O
set	362 3 O
shifting	366 8 O
,	374 1 O
inhibition	376 10 O
and	387 3 O
memory	391 6 O
updating	398 8 O
)	406 1 O
and	408 3 O
also	412 4 O
on	417 2 O
"	420 1 O
prefrontal	421 10 O
"	431 1 O
mediated	433 8 O
social	442 6 O
and	449 3 O
emotional	453 9 O
judgement	463 9 O
processes	473 9 O
.	482 1 O

Fifteen	484 7 O
polydrug	492 8 O
ecstasy	501 7 B-Chemical
users	509 5 O
and	515 3 O
15	519 2 O
polydrug	522 8 O
non	531 3 O
-	534 1 O
ecstasy	535 7 B-Chemical
user	543 4 O
controls	548 8 O
completed	557 9 O
a	567 1 O
general	569 7 O
drug	577 4 O
use	582 3 O
questionnaire	586 13 O
,	599 1 O
the	601 3 O
Brixton	605 7 O
Spatial	613 7 O
Anticipation	621 12 O
task	634 4 O
(	639 1 O
set	640 3 O
shifting	644 8 O
)	652 1 O
,	653 1 O
Backward	655 8 O
Digit	664 5 O
Span	670 4 O
procedure	675 9 O
(	685 1 O
memory	686 6 O
updating	693 8 O
)	701 1 O
,	702 1 O
Inhibition	704 10 O
of	715 2 O
Return	718 6 O
(	725 1 O
inhibition	726 10 O
)	736 1 O
,	737 1 O
an	739 2 O
emotional	742 9 O
intelligence	752 12 O
scale	765 5 O
,	770 1 O
the	772 3 O
Tromso	776 6 O
Social	783 6 O
Intelligence	790 12 O
Scale	803 5 O
and	809 3 O
the	813 3 O
Dysexecutive	817 12 O
Questionnaire	830 13 O
(	844 1 O
DEX	845 3 O
)	848 1 O
.	849 1 O

Compared	851 8 O
with	860 4 O
MDMA	865 4 B-Chemical
-	869 1 O
free	870 4 O
polydrug	875 8 O
controls	884 8 O
,	892 1 O
MDMA	894 4 B-Chemical
polydrug	899 8 O
users	908 5 O
showed	914 6 O
impairments	921 11 O
in	933 2 O
set	936 3 O
shifting	940 8 O
and	949 3 O
memory	953 6 O
updating	960 8 O
,	968 1 O
and	970 3 O
also	974 4 O
in	979 2 O
social	982 6 O
and	989 3 O
emotional	993 9 O
judgement	1003 9 O
processes	1013 9 O
.	1022 1 O

The	1024 3 O
latter	1028 6 O
two	1035 3 O
deficits	1039 8 O
remained	1048 8 O
significant	1057 11 O
after	1069 5 O
controlling	1075 11 O
for	1087 3 O
other	1091 5 O
drug	1097 4 O
use	1102 3 O
.	1105 1 O

These	1107 5 O
data	1113 4 O
lend	1118 4 O
further	1123 7 O
support	1131 7 O
to	1139 2 O
the	1142 3 O
proposal	1146 8 O
that	1155 4 O
cognitive	1160 9 O
processes	1170 9 O
mediated	1180 8 O
by	1189 2 O
the	1192 3 O
prefrontal	1196 10 O
cortex	1207 6 O
may	1214 3 O
be	1218 2 O
impaired	1221 8 O
by	1230 2 O
recreational	1233 12 O
ecstasy	1246 7 B-Chemical
use	1254 3 O
.	1257 1 O

Severe	0 6 O
citrate	7 7 B-Chemical
toxicity	15 8 B-Disease
complicating	24 12 O
volunteer	37 9 O
apheresis	47 9 O
platelet	57 8 O
donation	66 8 O
.	74 1 O

We	76 2 O
report	79 6 O
a	86 1 O
case	88 4 O
of	93 2 O
severe	96 6 O
citrate	103 7 B-Chemical
toxicity	111 8 B-Disease
during	120 6 O
volunteer	127 9 O
donor	137 5 O
apheresis	143 9 O
platelet	153 8 O
collection	162 10 O
.	172 1 O

The	174 3 O
donor	178 5 O
was	184 3 O
a	188 1 O
40	190 2 O
-	192 1 O
year	193 4 O
-	197 1 O
old	198 3 O
female	202 6 O
,	208 1 O
first	210 5 O
-	215 1 O
time	216 4 O
apheresis	221 9 O
platelet	231 8 O
donor	240 5 O
.	245 1 O

Past	247 4 O
medical	252 7 O
history	260 7 O
was	268 3 O
remarkable	272 10 O
for	283 3 O
hypertension	287 12 B-Disease
,	299 1 O
hyperlipidemia	301 14 B-Disease
,	315 1 O
and	317 3 O
depression	321 10 B-Disease
.	331 1 O

Reported	333 8 O
medications	342 11 O
included	354 8 O
bumetanide	363 10 B-Chemical
,	373 1 O
pravastatin	375 11 B-Chemical
,	386 1 O
and	388 3 O
paroxetine	392 10 B-Chemical
.	402 1 O

Thirty	404 6 O
minutes	411 7 O
from	419 4 O
the	424 3 O
start	428 5 O
of	434 2 O
the	437 3 O
procedure	441 9 O
,	450 1 O
the	452 3 O
donor	456 5 O
noted	462 5 O
tingling	468 8 O
around	477 6 O
the	484 3 O
mouth	488 5 O
,	493 1 O
hands	495 5 O
,	500 1 O
and	502 3 O
feet	506 4 O
.	510 1 O

She	512 3 O
then	516 4 O
very	521 4 O
rapidly	526 7 O
developed	534 9 O
acute	544 5 O
onset	550 5 O
of	556 2 O
severe	559 6 O
facial	566 6 O
and	573 3 O
extremity	577 9 O
tetany	587 6 B-Disease
.	593 1 O

Empirical	595 9 O
treatment	605 9 O
with	615 4 O
intravenous	620 11 O
calcium	632 7 B-Chemical
gluconate	640 9 I-Chemical
was	650 3 O
initiated	654 9 O
,	663 1 O
and	665 3 O
muscle	669 6 B-Disease
contractions	676 12 I-Disease
slowly	689 6 O
subsided	696 8 O
over	705 4 O
approximately	710 13 O
10	724 2 O
to	727 2 O
15	730 2 O
minutes	733 7 O
.	740 1 O

The	742 3 O
events	746 6 O
are	753 3 O
consistent	757 10 O
with	768 4 O
a	773 1 O
severe	775 6 O
reaction	782 8 O
to	791 2 O
calcium	794 7 B-Chemical
chelation	802 9 O
by	812 2 O
sodium	815 6 B-Chemical
citrate	822 7 I-Chemical
anticoagulant	830 13 O
resulting	844 9 O
in	854 2 O
symptomatic	857 11 O
systemic	869 8 O
hypocalcemia	878 12 B-Disease
.	890 1 O

Upon	892 4 O
additional	897 10 O
retrospective	908 13 O
analysis	922 8 O
,	930 1 O
it	932 2 O
was	935 3 O
noted	939 5 O
that	945 4 O
bumetanide	950 10 B-Chemical
is	961 2 O
a	964 1 O
loop	966 4 B-Chemical
diuretic	971 8 I-Chemical
that	980 4 O
may	985 3 O
cause	989 5 O
significant	995 11 O
hypocalcemia	1007 12 B-Disease
.	1019 1 O

We	1021 2 O
conclude	1024 8 O
that	1033 4 O
careful	1038 7 O
screening	1046 9 O
for	1056 3 O
medications	1060 11 O
and	1072 3 O
underlying	1076 10 O
conditions	1087 10 O
predisposing	1098 12 O
to	1111 2 O
hypocalcemia	1114 12 B-Disease
is	1127 2 O
recommended	1130 11 O
to	1142 2 O
help	1145 4 O
prevent	1150 7 O
severe	1158 6 O
reactions	1165 9 O
due	1175 3 O
to	1179 2 O
citrate	1182 7 B-Chemical
toxicity	1190 8 B-Disease
.	1198 1 O

Laboratory	1200 10 O
measurement	1211 11 O
of	1223 2 O
pre	1226 3 O
-	1229 1 O
procedure	1230 9 O
serum	1240 5 O
calcium	1246 7 B-Chemical
levels	1254 6 O
in	1261 2 O
selected	1264 8 O
donors	1273 6 O
may	1280 3 O
identify	1284 8 O
cases	1293 5 O
requiring	1299 9 O
heightened	1309 10 O
vigilance	1320 9 O
.	1329 1 O

The	1331 3 O
case	1335 4 O
also	1340 4 O
illustrates	1345 11 O
the	1357 3 O
importance	1361 10 O
of	1372 2 O
maintaining	1375 11 O
preparedness	1387 12 O
for	1400 3 O
managing	1404 8 O
rare	1413 4 O
but	1418 3 O
serious	1422 7 O
reactions	1430 9 O
in	1440 2 O
volunteer	1443 9 O
apheresis	1453 9 O
blood	1463 5 O
donors	1469 6 O
.	1475 1 O

Proteinuria	0 11 B-Disease
after	12 5 O
conversion	18 10 O
to	29 2 O
sirolimus	32 9 B-Chemical
in	42 2 O
renal	45 5 O
transplant	51 10 O
recipients	62 10 O
.	72 1 O

Sirolimus	74 9 B-Chemical
(	84 1 O
SRL	85 3 B-Chemical
)	88 1 O
is	90 2 O
a	93 1 O
new	95 3 O
,	98 1 O
potent	100 6 O
immunosuppressive	107 17 O
agent	125 5 O
.	130 1 O

More	132 4 O
recently	137 8 O
,	145 1 O
proteinuria	147 11 B-Disease
has	159 3 O
been	163 4 O
reported	168 8 O
as	177 2 O
a	180 1 O
consequence	182 11 O
of	194 2 O
sirolimus	197 9 B-Chemical
therapy	207 7 O
,	214 1 O
although	216 8 O
the	225 3 O
mechanism	229 9 O
has	239 3 O
remained	243 8 O
unclear	252 7 O
.	259 1 O

We	261 2 O
retrospectively	264 15 O
examined	280 8 O
the	289 3 O
records	293 7 O
of	301 2 O
25	304 2 O
renal	307 5 O
transplant	313 10 O
patients	324 8 O
,	332 1 O
who	334 3 O
developed	338 9 O
or	348 2 O
displayed	351 9 O
increased	361 9 O
proteinuria	371 11 B-Disease
after	383 5 O
SRL	389 3 B-Chemical
conversion	393 10 O
.	403 1 O

The	405 3 O
patient	409 7 O
cohort	417 6 O
(	424 1 O
14	425 2 O
men	428 3 O
,	431 1 O
11	433 2 O
women	436 5 O
)	441 1 O
was	443 3 O
treated	447 7 O
with	455 4 O
SRL	460 3 B-Chemical
as	464 2 O
conversion	467 10 O
therapy	478 7 O
,	485 1 O
due	487 3 O
to	491 2 O
chronic	494 7 B-Disease
allograft	502 9 I-Disease
nephropathy	512 11 I-Disease
(	524 1 O
CAN	525 3 B-Disease
)	528 1 O
(	530 1 O
n	531 1 O
=	533 1 O
15	535 2 O
)	537 1 O
neoplasia	539 9 B-Disease
(	549 1 O
n	550 1 O
=	552 1 O
8	554 1 O
)	555 1 O
;	556 1 O
Kaposi	558 6 B-Disease
'	564 1 I-Disease
s	565 1 I-Disease
sarcoma	567 7 I-Disease
,	574 1 O
Four	576 4 O
skin	581 4 B-Disease
cancers	586 7 I-Disease
,	593 1 O
One	595 3 O
intestinal	599 10 B-Disease
tumors	610 6 I-Disease
,	616 1 O
One	618 3 O
renal	622 5 B-Disease
cell	628 4 I-Disease
carsinom	633 8 I-Disease
)	641 1 O
or	643 2 O
BK	646 2 O
virus	649 5 O
nephropathy	655 11 B-Disease
(	667 1 O
n	668 1 O
=	670 1 O
2	672 1 O
)	673 1 O
.	674 1 O

SRL	676 3 B-Chemical
was	680 3 O
started	684 7 O
at	692 2 O
a	695 1 O
mean	697 4 O
of	702 2 O
78	705 2 O
+	708 1 O
/	709 1 O
-	710 1 O
42	712 2 O
(	715 1 O
15	716 2 O
to	719 2 O
163	722 3 O
)	725 1 O
months	727 6 O
after	734 5 O
transplantation	740 15 O
.	755 1 O

Mean	757 4 O
follow	762 6 O
-	768 1 O
up	769 2 O
on	772 2 O
SRL	775 3 B-Chemical
therapy	779 7 O
was	787 3 O
20	791 2 O
+	794 1 O
/	795 1 O
-	796 1 O
12	798 2 O
(	801 1 O
6	802 1 O
to	804 2 O
43	807 2 O
)	809 1 O
months	811 6 O
.	817 1 O

Proteinuria	819 11 B-Disease
increased	831 9 O
from	841 4 O
0	846 1 O
.	847 1 O
445	848 3 O
(	852 1 O
0	853 1 O
to	855 2 O
1	858 1 O
.	859 1 O
5	860 1 O
)	861 1 O
g	863 1 O
/	864 1 O
d	865 1 O
before	867 6 O
conversion	874 10 O
to	885 2 O
3	888 1 O
.	889 1 O
2	890 1 O
g	892 1 O
/	893 1 O
dL	894 2 O
(	897 1 O
0	898 1 O
.	899 1 O
2	900 1 O
to	902 2 O
12	905 2 O
)	907 1 O
after	909 5 O
conversion	915 10 O
(	926 1 O
P	927 1 O
=	929 1 O
0	931 1 O
.	932 1 O
001	933 3 O
)	936 1 O
.	937 1 O

Before	939 6 O
conversion	946 10 O
8	957 1 O
(	959 1 O
32	960 2 O
%	962 1 O
)	963 1 O
patients	965 8 O
had	974 3 O
no	978 2 O
proteinuria	981 11 B-Disease
,	992 1 O
whereas	994 7 O
afterwards	1002 10 O
all	1013 3 O
patients	1017 8 O
had	1026 3 O
proteinuria	1030 11 B-Disease
.	1041 1 O

In	1043 2 O
28	1046 2 O
%	1048 1 O
of	1050 2 O
patients	1053 8 O
proteinuria	1062 11 B-Disease
remained	1074 8 O
unchanged	1083 9 O
,	1092 1 O
whereas	1094 7 O
it	1102 2 O
increased	1105 9 O
in	1115 2 O
68	1118 2 O
%	1120 1 O
of	1122 2 O
patients	1125 8 O
.	1133 1 O

In	1135 2 O
40	1138 2 O
%	1140 1 O
it	1142 2 O
increased	1145 9 O
by	1155 2 O
more	1158 4 O
than	1163 4 O
100	1168 3 O
%	1171 1 O
.	1172 1 O

Twenty	1174 6 O
-	1180 1 O
eight	1181 5 O
percent	1187 7 O
of	1195 2 O
patients	1198 8 O
showed	1207 6 O
increased	1214 9 O
proteinuria	1224 11 B-Disease
to	1236 2 O
the	1239 3 O
nephrotic	1243 9 B-Disease
range	1253 5 O
.	1258 1 O

Biopsies	1260 8 O
performed	1269 9 O
in	1279 2 O
five	1282 4 O
patients	1287 8 O
revealed	1296 8 O
new	1305 3 O
pathological	1309 12 O
changes	1322 7 O
:	1329 1 O
One	1331 3 O
membranoproliferative	1335 21 B-Disease
glomerulopathy	1357 14 I-Disease
and	1372 3 O
interstitial	1376 12 B-Disease
nephritis	1389 9 I-Disease
.	1398 1 O

These	1400 5 O
patients	1406 8 O
showed	1415 6 O
persistently	1422 12 O
good	1435 4 O
graft	1440 5 O
function	1446 8 O
.	1454 1 O

Serum	1456 5 O
creatinine	1462 10 B-Chemical
values	1473 6 O
did	1480 3 O
not	1484 3 O
change	1488 6 O
significantly	1495 13 O
:	1508 1 O
1	1510 1 O
.	1511 1 O
98	1512 2 O
+	1515 1 O
/	1516 1 O
-	1517 1 O
0	1519 1 O
.	1520 1 O
8	1521 1 O
mg	1523 2 O
/	1525 1 O
dL	1526 2 O
before	1529 6 O
SRL	1536 3 B-Chemical
therapy	1540 7 O
and	1548 3 O
2	1552 1 O
.	1553 1 O
53	1554 2 O
+	1557 1 O
/	1558 1 O
-	1559 1 O
1	1561 1 O
.	1562 1 O
9	1563 1 O
mg	1565 2 O
/	1567 1 O
dL	1568 2 O
at	1571 2 O
last	1574 4 O
follow	1579 6 O
-	1585 1 O
up	1586 2 O
(	1589 1 O
P	1590 1 O
=	1592 1 O
.	1594 1 O
14	1595 2 O
)	1597 1 O
.	1598 1 O

Five	1600 4 O
grafts	1605 6 O
were	1612 4 O
lost	1617 4 O
and	1622 3 O
the	1626 3 O
patients	1630 8 O
returned	1639 8 O
to	1648 2 O
dialysis	1651 8 O
.	1659 1 O

Five	1661 4 O
patients	1666 8 O
displayed	1675 9 O
CAN	1685 3 B-Disease
and	1689 3 O
Kaposi	1693 6 B-Disease
'	1699 1 I-Disease
s	1700 1 I-Disease
sarcoma	1702 7 I-Disease
.	1709 1 O

Mean	1711 4 O
urinary	1716 7 O
protein	1724 7 O
of	1732 2 O
patients	1735 8 O
who	1744 3 O
returned	1748 8 O
to	1757 2 O
dialysis	1760 8 O
was	1769 3 O
1	1773 1 O
.	1774 1 O
26	1775 2 O
(	1778 1 O
0	1779 1 O
.	1780 1 O
5	1781 1 O
to	1783 2 O
3	1786 1 O
.	1787 1 O
5	1788 1 O
)	1789 1 O
g	1791 1 O
/	1792 1 O
d	1793 1 O
before	1795 6 O
and	1802 3 O
4	1806 1 O
.	1807 1 O
7	1808 1 O
(	1810 1 O
3	1811 1 O
to	1813 2 O
12	1816 2 O
)	1818 1 O
g	1820 1 O
/	1821 1 O
d	1822 1 O
after	1824 5 O
conversion	1830 10 O
(	1841 1 O
P	1842 1 O
=	1844 1 O
.	1846 1 O
01	1847 2 O
)	1849 1 O
.	1850 1 O

Mean	1852 4 O
serum	1857 5 O
creatinine	1863 10 B-Chemical
level	1874 5 O
before	1880 6 O
conversion	1887 10 O
was	1898 3 O
2	1902 1 O
.	1903 1 O
21	1904 2 O
mg	1907 2 O
/	1909 1 O
dL	1910 2 O
and	1913 3 O
thereafter	1917 10 O
,	1927 1 O
4	1929 1 O
.	1930 1 O
93	1931 2 O
mg	1934 2 O
/	1936 1 O
dL	1937 2 O
(	1940 1 O
P	1941 1 O
=	1943 1 O
.	1945 1 O
02	1946 2 O
)	1948 1 O
.	1949 1 O

Heavy	1951 5 O
proteinuria	1957 11 B-Disease
was	1969 3 O
common	1973 6 O
after	1980 5 O
the	1986 3 O
use	1990 3 O
of	1994 2 O
SRL	1997 3 B-Chemical
as	2001 2 O
rescue	2004 6 O
therapy	2011 7 O
for	2019 3 O
renal	2023 5 O
transplantation	2029 15 O
.	2044 1 O

Therefore	2046 9 O
,	2055 1 O
conversion	2057 10 O
should	2068 6 O
be	2075 2 O
considered	2078 10 O
for	2089 3 O
patients	2093 8 O
who	2102 3 O
have	2106 4 O
not	2111 3 O
developed	2115 9 O
advanced	2125 8 O
CAN	2134 3 B-Disease
and	2138 3 O
proteinuria	2142 11 B-Disease
.	2153 1 O

The	2155 3 O
possibility	2159 11 O
of	2171 2 O
de	2174 2 O
novo	2177 4 O
glomerular	2182 10 O
pathology	2193 9 O
under	2203 5 O
SRL	2209 3 B-Chemical
treatment	2213 9 O
requires	2223 8 O
further	2232 7 O
investigation	2240 13 O
by	2254 2 O
renal	2257 5 O
biopsy	2263 6 O
.	2269 1 O

In	0 2 O
vitro	3 5 O
characterization	9 16 O
of	26 2 O
parasympathetic	29 15 O
and	45 3 O
sympathetic	49 11 O
responses	61 9 O
in	71 2 O
cyclophosphamide	74 16 B-Chemical
-	90 1 O
induced	91 7 O
cystitis	99 8 B-Disease
in	108 2 O
the	111 3 O
rat	115 3 O
.	118 1 O

In	120 2 O
cyclophosphamide	123 16 B-Chemical
-	139 1 O
induced	140 7 O
cystitis	148 8 B-Disease
in	157 2 O
the	160 3 O
rat	164 3 O
,	167 1 O
detrusor	169 8 O
function	178 8 O
is	187 2 O
impaired	190 8 O
and	199 3 O
the	203 3 O
expression	207 10 O
and	218 3 O
effects	222 7 O
of	230 2 O
muscarinic	233 10 O
receptors	244 9 O
altered	254 7 O
.	261 1 O

Whether	263 7 O
or	271 2 O
not	274 3 O
the	278 3 O
neuronal	282 8 O
transmission	291 12 O
may	304 3 O
be	308 2 O
affected	311 8 O
by	320 2 O
cystitis	323 8 B-Disease
was	332 3 O
presently	336 9 O
investigated	346 12 O
.	358 1 O

Responses	360 9 O
of	370 2 O
urinary	373 7 O
strip	381 5 O
preparations	387 12 O
from	400 4 O
control	405 7 O
and	413 3 O
cyclophosphamide	417 16 B-Chemical
-	433 1 O
pretreated	434 10 O
rats	445 4 O
to	450 2 O
electrical	453 10 O
field	464 5 O
stimulation	470 11 O
and	482 3 O
to	486 2 O
agonists	489 8 O
were	498 4 O
assessed	503 8 O
in	512 2 O
the	515 3 O
absence	519 7 O
and	527 3 O
presence	531 8 O
of	540 2 O
muscarinic	543 10 O
,	553 1 O
adrenergic	555 10 O
and	566 3 O
purinergic	570 10 O
receptor	581 8 O
antagonists	590 11 O
.	601 1 O

Generally	603 9 O
,	612 1 O
atropine	614 8 B-Chemical
reduced	623 7 O
contractions	631 12 O
,	643 1 O
but	645 3 O
in	649 2 O
contrast	652 8 O
to	661 2 O
controls	664 8 O
,	672 1 O
it	674 2 O
also	677 4 O
reduced	682 7 O
responses	690 9 O
to	700 2 O
low	703 3 O
electrical	707 10 O
field	718 5 O
stimulation	724 11 O
intensity	736 9 O
(	746 1 O
1	747 1 O
-	748 1 O
5	749 1 O
Hz	751 2 O
)	753 1 O
in	755 2 O
inflamed	758 8 O
preparations	767 12 O
.	779 1 O

In	781 2 O
both	784 4 O
types	789 5 O
,	794 1 O
purinoceptor	796 12 O
desensitization	809 15 O
with	825 4 O
alpha	830 5 B-Chemical
,	835 1 I-Chemical
beta	836 4 I-Chemical
-	840 1 I-Chemical
methylene	841 9 I-Chemical
adenosine	851 9 I-Chemical
-	860 1 I-Chemical
5	861 1 I-Chemical
'	862 1 I-Chemical
-	863 1 I-Chemical
triphosphate	864 12 I-Chemical
(	877 1 O
alpha	878 5 B-Chemical
,	883 1 I-Chemical
beta	884 4 I-Chemical
-	888 1 I-Chemical
meATP	889 5 I-Chemical
)	894 1 O
caused	896 6 O
further	903 7 O
reductions	911 10 O
at	922 2 O
low	925 3 O
frequencies	929 11 O
(	941 1 O
<	942 1 O
10	943 2 O
Hz	946 2 O
)	948 1 O
.	949 1 O

The	951 3 O
muscarinic	955 10 O
receptor	966 8 O
antagonists	975 11 O
atropine	987 8 B-Chemical
,	995 1 O
4	997 1 B-Chemical
-	998 1 I-Chemical
diphenylacetoxy	999 15 I-Chemical
-	1014 1 I-Chemical
N	1015 1 I-Chemical
-	1016 1 I-Chemical
methylpiperidine	1017 16 I-Chemical
(	1034 1 O
4	1035 1 B-Chemical
-	1036 1 I-Chemical
DAMP	1037 4 I-Chemical
)	1041 1 O
(	1043 1 O
'	1044 1 O
M	1045 1 O
(	1046 1 O
1	1047 1 O
)	1048 1 O
/	1049 1 O
M	1050 1 O
(	1051 1 O
3	1052 1 O
)	1053 1 O
/	1054 1 O
M	1055 1 O
(	1056 1 O
5	1057 1 O
)	1058 1 O
-	1059 1 O
selective	1060 9 O
'	1069 1 O
)	1070 1 O
,	1071 1 O
methoctramine	1073 13 B-Chemical
(	1087 1 O
'	1088 1 O
M	1089 1 O
(	1090 1 O
2	1091 1 O
)	1092 1 O
-	1093 1 O
selective	1094 9 O
'	1103 1 O
)	1104 1 O
and	1106 3 O
pirenzepine	1110 11 B-Chemical
(	1122 1 O
'	1123 1 O
M	1124 1 O
(	1125 1 O
1	1126 1 O
)	1127 1 O
-	1128 1 O
selective	1129 9 O
'	1138 1 O
)	1139 1 O
antagonized	1141 11 O
the	1153 3 O
tonic	1157 5 O
component	1163 9 O
of	1173 2 O
the	1176 3 O
electrical	1180 10 O
field	1191 5 O
stimulation	1197 11 O
-	1208 1 O
evoked	1209 6 O
contractile	1216 11 O
response	1228 8 O
more	1237 4 O
potently	1242 8 O
than	1251 4 O
the	1256 3 O
phasic	1260 6 O
component	1267 9 O
.	1276 1 O

4	1278 1 B-Chemical
-	1279 1 I-Chemical
DAMP	1280 4 I-Chemical
inhibited	1285 9 O
the	1295 3 O
tonic	1299 5 O
contractions	1305 12 O
in	1318 2 O
controls	1321 8 O
more	1330 4 O
potently	1335 8 O
than	1344 4 O
methoctramine	1349 13 B-Chemical
and	1363 3 O
pirenzepine	1367 11 B-Chemical
.	1378 1 O

In	1380 2 O
inflamed	1383 8 O
preparations	1392 12 O
,	1404 1 O
the	1406 3 O
muscarinic	1410 10 O
receptor	1421 8 O
antagonism	1430 10 O
on	1441 2 O
the	1444 3 O
phasic	1448 6 O
component	1455 9 O
of	1465 2 O
the	1468 3 O
electrical	1472 10 O
field	1483 5 O
stimulation	1489 11 O
-	1500 1 O
evoked	1501 6 O
contraction	1508 11 O
was	1520 3 O
decreased	1524 9 O
and	1534 3 O
the	1538 3 O
pirenzepine	1542 11 B-Chemical
and	1554 3 O
4	1558 1 B-Chemical
-	1559 1 I-Chemical
DAMP	1560 4 I-Chemical
antagonism	1565 10 O
on	1576 2 O
the	1579 3 O
tonic	1583 5 O
component	1589 9 O
was	1599 3 O
much	1603 4 O
less	1608 4 O
efficient	1613 9 O
than	1623 4 O
in	1628 2 O
controls	1631 8 O
.	1639 1 O

In	1641 2 O
contrast	1644 8 O
to	1653 2 O
controls	1656 8 O
,	1664 1 O
methoctramine	1666 13 B-Chemical
increased	1680 9 O
-	1690 1 O
-	1691 1 O
instead	1693 7 O
of	1701 2 O
decreased	1704 9 O
-	1714 1 O
-	1715 1 O
the	1717 3 O
tonic	1721 5 O
responses	1727 9 O
at	1737 2 O
high	1740 4 O
frequencies	1745 11 O
.	1756 1 O

While	1758 5 O
contractions	1764 12 O
to	1777 2 O
carbachol	1780 9 B-Chemical
and	1790 3 O
ATP	1794 3 B-Chemical
were	1798 4 O
the	1803 3 O
same	1807 4 O
in	1812 2 O
inflamed	1815 8 O
and	1824 3 O
in	1828 2 O
control	1831 7 O
strips	1839 6 O
when	1846 4 O
related	1851 7 O
to	1859 2 O
a	1862 1 O
reference	1864 9 O
potassium	1874 9 B-Chemical
response	1884 8 O
,	1892 1 O
isoprenaline	1894 12 B-Chemical
-	1906 1 O
induced	1907 7 O
relaxations	1915 11 O
were	1927 4 O
smaller	1932 7 O
in	1940 2 O
inflamed	1943 8 O
strips	1952 6 O
.	1958 1 O

Thus	1960 4 O
,	1964 1 O
in	1966 2 O
cystitis	1969 8 B-Disease
substantial	1978 11 O
changes	1990 7 O
of	1998 2 O
the	2001 3 O
efferent	2005 8 O
functional	2014 10 O
responses	2025 9 O
occur	2035 5 O
.	2040 1 O

While	2042 5 O
postjunctional	2048 14 O
beta	2063 4 O
-	2067 1 O
adrenoceptor	2068 12 O
-	2080 1 O
mediated	2081 8 O
relaxations	2090 11 O
are	2102 3 O
reduced	2106 7 O
,	2113 1 O
effects	2115 7 O
by	2123 2 O
prejunctional	2126 13 O
inhibitory	2140 10 O
muscarinic	2151 10 O
receptors	2162 9 O
may	2172 3 O
be	2176 2 O
increased	2179 9 O
.	2188 1 O

Associations	0 12 O
between	13 7 O
use	21 3 O
of	25 2 O
benzodiazepines	28 15 B-Chemical
or	44 2 O
related	47 7 O
drugs	55 5 O
and	61 3 O
health	65 6 O
,	71 1 O
physical	73 8 O
abilities	82 9 O
and	92 3 O
cognitive	96 9 O
function	106 8 O
:	114 1 O
a	116 1 O
non	118 3 O
-	121 1 O
randomised	122 10 O
clinical	133 8 O
study	142 5 O
in	148 2 O
the	151 3 O
elderly	155 7 O
.	162 1 O

OBJECTIVE	164 9 O
:	173 1 O
To	175 2 O
describe	178 8 O
associations	187 12 O
between	200 7 O
the	208 3 O
use	212 3 O
of	216 2 O
benzodiazepines	219 15 B-Chemical
or	235 2 O
related	238 7 O
drugs	246 5 O
(	252 1 O
BZDs	253 4 B-Chemical
/	257 1 O
RDs	258 3 O
)	261 1 O
and	263 3 O
health	267 6 O
,	273 1 O
functional	275 10 O
abilities	286 9 O
and	296 3 O
cognitive	300 9 O
function	310 8 O
in	319 2 O
the	322 3 O
elderly	326 7 O
.	333 1 O

METHODS	335 7 O
:	342 1 O
A	344 1 O
non	346 3 O
-	349 1 O
randomised	350 10 O
clinical	361 8 O
study	370 5 O
of	376 2 O
patients	379 8 O
aged	388 4 O
>	393 1 O
or	395 2 O
=	398 1 O
65	399 2 O
years	402 5 O
admitted	408 8 O
to	417 2 O
acute	420 5 O
hospital	426 8 O
wards	435 5 O
during	441 6 O
1	448 1 O
month	450 5 O
.	455 1 O

164	457 3 O
patients	461 8 O
(	470 1 O
mean	471 4 O
age	476 3 O
+	480 1 O
/	481 1 O
-	482 1 O
standard	484 8 O
deviation	493 9 O
[	503 1 O
SD	504 2 O
]	506 1 O
81	508 2 O
.	510 1 O
6	511 1 O
+	513 1 O
/	514 1 O
-	515 1 O
6	517 1 O
.	518 1 O
8	519 1 O
years	521 5 O
)	526 1 O
were	528 4 O
admitted	533 8 O
.	541 1 O

Of	543 2 O
these	546 5 O
,	551 1 O
nearly	553 6 O
half	560 4 O
(	565 1 O
n	566 1 O
=	568 1 O
78	570 2 O
)	572 1 O
had	574 3 O
used	578 4 O
BZDs	583 4 B-Chemical
/	587 1 O
RDs	588 3 O
before	592 6 O
admission	599 9 O
,	608 1 O
and	610 3 O
the	614 3 O
remainder	618 9 O
(	628 1 O
n	629 1 O
=	631 1 O
86	633 2 O
)	635 1 O
were	637 4 O
non	642 3 O
-	645 1 O
users	646 5 O
.	651 1 O

Cognitive	653 9 O
ability	663 7 O
was	671 3 O
assessed	675 8 O
by	684 2 O
the	687 3 O
Mini	691 4 O
-	695 1 O
Mental	696 6 O
State	703 5 O
Examination	709 11 O
(	721 1 O
MMSE	722 4 O
)	726 1 O
.	727 1 O

Patients	729 8 O
scoring	738 7 O
>	746 1 O
or	748 2 O
=	751 1 O
20	752 2 O
MMSE	755 4 O
sum	760 3 O
points	764 6 O
were	771 4 O
interviewed	776 11 O
(	788 1 O
n	789 1 O
=	791 1 O
79	793 2 O
)	795 1 O
and	797 3 O
questioned	801 10 O
regarding	812 9 O
symptoms	822 8 O
and	831 3 O
functional	835 10 O
abilities	846 9 O
during	856 6 O
the	863 3 O
week	867 4 O
prior	872 5 O
to	878 2 O
admission	881 9 O
.	890 1 O

Data	892 4 O
on	897 2 O
use	900 3 O
of	904 2 O
BZDs	907 4 B-Chemical
/	911 1 O
RDs	912 3 O
before	916 6 O
admission	923 9 O
,	932 1 O
current	934 7 O
medications	942 11 O
and	954 3 O
discharge	958 9 O
diagnoses	968 9 O
were	978 4 O
collected	983 9 O
from	993 4 O
medical	998 7 O
records	1006 7 O
.	1013 1 O

Health	1015 6 O
,	1021 1 O
physical	1023 8 O
abilities	1032 9 O
and	1042 3 O
cognitive	1046 9 O
function	1056 8 O
were	1065 4 O
compared	1070 8 O
between	1079 7 O
BZD	1087 3 O
/	1090 1 O
RD	1091 2 O
users	1094 5 O
and	1100 3 O
non	1104 3 O
-	1107 1 O
users	1108 5 O
,	1113 1 O
and	1115 3 O
adjustments	1119 11 O
were	1131 4 O
made	1136 4 O
for	1141 3 O
confounding	1145 11 O
variables	1157 9 O
.	1166 1 O

The	1168 3 O
residual	1172 8 O
serum	1181 5 O
concentrations	1187 14 O
of	1202 2 O
oxazepam	1205 8 B-Chemical
,	1213 1 O
temazepam	1215 9 B-Chemical
and	1225 3 O
zopiclone	1229 9 B-Chemical
were	1239 4 O
analysed	1244 8 O
.	1252 1 O

RESULTS	1254 7 O
:	1261 1 O
The	1263 3 O
mean	1267 4 O
+	1272 1 O
/	1273 1 O
-	1274 1 O
SD	1276 2 O
duration	1279 8 O
of	1288 2 O
BZD	1291 3 O
/	1294 1 O
RD	1295 2 O
use	1298 3 O
was	1302 3 O
7	1306 1 O
+	1308 1 O
/	1309 1 O
-	1310 1 O
7	1312 1 O
years	1314 5 O
(	1320 1 O
range	1321 5 O
1	1327 1 O
-	1328 1 O
31	1329 2 O
)	1331 1 O
.	1332 1 O

Two	1334 3 O
or	1338 2 O
three	1341 5 O
BZDs	1347 4 B-Chemical
/	1351 1 O
RDs	1352 3 O
were	1356 4 O
concomitantly	1361 13 O
taken	1375 5 O
by	1381 2 O
26	1384 2 O
%	1386 1 O
of	1388 2 O
users	1391 5 O
(	1397 1 O
n	1398 1 O
=	1400 1 O
20	1402 2 O
)	1404 1 O
.	1405 1 O

Long	1407 4 O
-	1411 1 O
term	1412 4 O
use	1417 3 O
of	1421 2 O
these	1424 5 O
drugs	1430 5 O
was	1436 3 O
associated	1440 10 O
with	1451 4 O
female	1456 6 O
sex	1463 3 O
and	1467 3 O
use	1471 3 O
of	1475 2 O
a	1478 1 O
higher	1480 6 O
number	1487 6 O
of	1494 2 O
drugs	1497 5 O
with	1503 4 O
effects	1508 7 O
on	1516 2 O
the	1519 3 O
CNS	1523 3 O
,	1526 1 O
which	1528 5 O
tended	1534 6 O
to	1541 2 O
be	1544 2 O
related	1547 7 O
to	1555 2 O
diagnosed	1558 9 O
dementia	1568 8 B-Disease
.	1576 1 O

After	1578 5 O
adjustment	1584 10 O
for	1595 3 O
these	1599 5 O
variables	1605 9 O
as	1615 2 O
confounders	1618 11 O
,	1629 1 O
use	1631 3 O
of	1635 2 O
BZDs	1638 4 B-Chemical
/	1642 1 O
RDs	1643 3 O
was	1647 3 O
not	1651 3 O
associated	1655 10 O
with	1666 4 O
cognitive	1671 9 O
function	1681 8 O
as	1690 2 O
measured	1693 8 O
by	1702 2 O
the	1705 3 O
MMSE	1709 4 O
.	1713 1 O

However	1715 7 O
,	1722 1 O
use	1724 3 O
of	1728 2 O
BZDs	1731 4 B-Chemical
/	1735 1 O
RDs	1736 3 O
was	1740 3 O
associated	1744 10 O
with	1755 4 O
dizziness	1760 9 B-Disease
,	1769 1 O
inability	1771 9 B-Disease
to	1781 2 I-Disease
sleep	1784 5 I-Disease
after	1790 5 O
awaking	1796 7 O
at	1804 2 O
night	1807 5 O
and	1813 3 O
tiredness	1817 9 B-Disease
in	1827 2 O
the	1830 3 O
mornings	1834 8 O
during	1843 6 O
the	1850 3 O
week	1854 4 O
prior	1859 5 O
to	1865 2 O
admission	1868 9 O
and	1878 3 O
with	1882 4 O
stronger	1887 8 O
depressive	1896 10 B-Disease
symptoms	1907 8 I-Disease
measured	1916 8 O
at	1925 2 O
the	1928 3 O
beginning	1932 9 O
of	1942 2 O
the	1945 3 O
hospital	1949 8 O
stay	1958 4 O
.	1962 1 O

Use	1964 3 O
of	1968 2 O
BZDs	1971 4 B-Chemical
/	1975 1 O
RDs	1976 3 O
tended	1980 6 O
to	1987 2 O
be	1990 2 O
associated	1993 10 O
with	2004 4 O
a	2009 1 O
reduced	2011 7 O
ability	2019 7 O
to	2027 2 O
walk	2030 4 O
and	2035 3 O
shorter	2039 7 O
night	2047 5 O
-	2052 1 O
time	2053 4 O
sleep	2058 5 O
during	2064 6 O
the	2071 3 O
week	2075 4 O
prior	2080 5 O
to	2086 2 O
admission	2089 9 O
.	2098 1 O

A	2100 1 O
higher	2102 6 O
residual	2109 8 O
serum	2118 5 O
concentration	2124 13 O
of	2138 2 O
temazepam	2141 9 B-Chemical
correlated	2151 10 O
with	2162 4 O
a	2167 1 O
lower	2169 5 O
MMSE	2175 4 O
sum	2180 3 O
score	2184 5 O
after	2190 5 O
adjustment	2196 10 O
for	2207 3 O
confounding	2211 11 O
variables	2223 9 O
.	2232 1 O

CONCLUSIONS	2234 11 O
:	2245 1 O
Long	2247 4 O
-	2251 1 O
term	2252 4 O
use	2257 3 O
and	2261 3 O
concomitant	2265 11 O
use	2277 3 O
of	2281 2 O
more	2284 4 O
than	2289 4 O
one	2294 3 O
BZD	2298 3 O
/	2301 1 O
RD	2302 2 O
were	2305 4 O
common	2310 6 O
in	2317 2 O
elderly	2320 7 O
patients	2328 8 O
hospitalised	2337 12 O
because	2350 7 O
of	2358 2 O
acute	2361 5 O
illnesses	2367 9 O
.	2376 1 O

Long	2378 4 O
-	2382 1 O
term	2383 4 O
use	2388 3 O
was	2392 3 O
associated	2396 10 O
with	2407 4 O
daytime	2412 7 O
and	2420 3 O
night	2424 5 O
-	2429 1 O
time	2430 4 O
symptoms	2435 8 O
indicative	2444 10 O
of	2455 2 O
poorer	2458 6 O
health	2465 6 O
and	2472 3 O
potentially	2476 11 O
caused	2488 6 O
by	2495 2 O
the	2498 3 O
adverse	2502 7 O
effects	2510 7 O
of	2518 2 O
these	2521 5 O
drugs	2527 5 O
.	2532 1 O

Acute	0 5 O
vocal	6 5 B-Disease
fold	12 4 I-Disease
palsy	17 5 I-Disease
after	23 5 O
acute	29 5 O
disulfiram	35 10 B-Chemical
intoxication	46 12 O
.	58 1 O

Acute	60 5 O
peripheral	66 10 B-Disease
neuropathy	77 10 I-Disease
caused	88 6 O
by	95 2 O
a	98 1 O
disulfiram	100 10 B-Chemical
overdose	111 8 B-Disease
is	120 2 O
very	123 4 O
rare	128 4 O
and	133 3 O
there	137 5 O
is	143 2 O
no	146 2 O
report	149 6 O
of	156 2 O
it	159 2 O
leading	162 7 O
to	170 2 O
vocal	173 5 B-Disease
fold	179 4 I-Disease
palsy	184 5 I-Disease
.	189 1 O

A	191 1 O
49	193 2 O
-	195 1 O
year	196 4 O
-	200 1 O
old	201 3 O
woman	205 5 O
was	211 3 O
transferred	215 11 O
to	227 2 O
our	230 3 O
department	234 10 O
because	245 7 O
of	253 2 O
quadriparesis	256 13 B-Disease
,	269 1 O
lancinating	271 11 O
pain	283 4 B-Disease
,	287 1 O
sensory	289 7 B-Disease
loss	297 4 I-Disease
,	301 1 O
and	303 3 O
paresthesia	307 11 B-Disease
of	319 2 O
the	322 3 O
distal	326 6 O
limbs	333 5 O
.	338 1 O

One	340 3 O
month	344 5 O
previously	350 10 O
,	360 1 O
she	362 3 O
had	366 3 O
taken	370 5 O
a	376 1 O
single	378 6 O
high	385 4 O
dose	390 4 O
of	395 2 O
disulfiram	398 10 B-Chemical
(	409 1 O
130	410 3 O
tablets	414 7 O
of	422 2 O
ALCOHOL	425 7 B-Chemical
STOP	433 4 O
TAB	438 3 O
,	441 1 O
Shin	443 4 O
-	447 1 O
Poong	448 5 O
Pharm	454 5 O
.	459 1 O
Co	461 2 O
.	463 1 O
,	464 1 O
Ansan	466 5 O
,	471 1 O
Korea	473 5 O
)	478 1 O
in	480 2 O
a	483 1 O
suicide	485 7 O
attempt	493 7 O
.	500 1 O

She	502 3 O
was	506 3 O
not	510 3 O
an	514 2 O
alcoholic	517 9 O
.	526 1 O

For	528 3 O
the	532 3 O
first	536 5 O
few	542 3 O
days	546 4 O
after	551 5 O
ingestion	557 9 O
,	566 1 O
she	568 3 O
was	572 3 O
in	576 2 O
a	579 1 O
confused	581 8 O
state	590 5 O
and	596 3 O
had	600 3 O
mild	604 4 O
to	609 2 O
moderate	612 8 O
ataxia	621 6 B-Disease
and	628 3 O
giddiness	632 9 B-Disease
.	641 1 O

She	643 3 O
noticed	647 7 O
hoarseness	655 10 B-Disease
and	666 3 O
distally	670 8 O
accentuated	679 11 O
motor	691 5 O
and	697 3 O
sensory	701 7 O
dysfunction	709 11 O
after	721 5 O
she	727 3 O
had	731 3 O
recovered	735 9 O
from	745 4 O
this	750 4 O
state	755 5 O
.	760 1 O

A	762 1 O
nerve	764 5 O
conduction	770 10 O
study	781 5 O
was	787 3 O
consistent	791 10 O
with	802 4 O
severe	807 6 O
sensorimotor	814 12 O
axonal	827 6 O
polyneuropathy	834 14 B-Disease
.	848 1 O

Laryngeal	850 9 O
electromyography	860 16 O
(	877 1 O
thyroarytenoid	878 14 O
muscle	893 6 O
)	899 1 O
showed	901 6 O
ample	908 5 O
denervation	914 11 O
potentials	926 10 O
.	936 1 O

Laryngoscopy	938 12 O
revealed	951 8 O
asymmetric	960 10 O
vocal	971 5 O
fold	977 4 O
movements	982 9 O
during	992 6 O
phonation	999 9 O
.	1008 1 O

Her	1010 3 O
vocal	1014 5 O
change	1020 6 O
and	1027 3 O
weakness	1031 8 O
began	1040 5 O
to	1046 2 O
improve	1049 7 O
spontaneously	1057 13 O
about	1071 5 O
3	1077 1 O
weeks	1079 5 O
after	1085 5 O
transfer	1091 8 O
.	1099 1 O

This	1101 4 O
was	1106 3 O
a	1110 1 O
case	1112 4 O
of	1117 2 O
acute	1120 5 O
palsy	1126 5 B-Disease
of	1132 2 O
the	1135 3 O
recurrent	1139 9 O
laryngeal	1149 9 O
nerve	1159 5 O
and	1165 3 O
superimposed	1169 12 O
severe	1182 6 O
acute	1189 5 O
sensorimotor	1195 12 O
axonal	1208 6 O
polyneuropathy	1215 14 B-Disease
caused	1230 6 O
by	1237 2 O
high	1240 4 O
-	1244 1 O
dose	1245 4 O
disulfiram	1250 10 B-Chemical
intoxication	1261 12 O
.	1273 1 O

Higher	0 6 O
optical	7 7 O
density	15 7 O
of	23 2 O
an	26 2 O
antigen	29 7 O
assay	37 5 O
predicts	43 8 O
thrombosis	52 10 B-Disease
in	63 2 O
patients	66 8 O
with	75 4 O
heparin	80 7 B-Chemical
-	87 1 O
induced	88 7 O
thrombocytopenia	96 16 B-Disease
.	112 1 O

OBJECTIVES	114 10 O
:	124 1 O
To	126 2 O
correlate	129 9 O
optical	139 7 O
density	147 7 O
and	155 3 O
percent	159 7 O
inhibition	167 10 O
of	178 2 O
a	181 1 O
two	183 3 O
-	186 1 O
step	187 4 O
heparin	192 7 B-Chemical
-	199 1 O
induced	200 7 O
thrombocytopenia	208 16 B-Disease
(	225 1 O
HIT	226 3 B-Disease
)	229 1 O
antigen	231 7 O
assay	239 5 O
with	245 4 O
thrombosis	250 10 B-Disease
;	260 1 O
the	262 3 O
assay	266 5 O
utilizes	272 8 O
reaction	281 8 O
inhibition	290 10 O
characteristics	301 15 O
of	317 2 O
a	320 1 O
high	322 4 O
heparin	327 7 B-Chemical
concentration	335 13 O
.	348 1 O

PATIENTS	350 8 O
AND	359 3 O
METHODS	363 7 O
:	370 1 O
Patients	372 8 O
with	381 4 O
more	386 4 O
than	391 4 O
50	396 2 O
%	398 1 O
decrease	400 8 O
in	409 2 O
platelet	412 8 O
count	421 5 O
or	427 2 O
thrombocytopenia	430 16 B-Disease
(	447 1 O
<	448 1 O
150	449 3 O
x	453 1 O
10	455 2 O
(	457 1 O
9	458 1 O
)	459 1 O
/	460 1 O
L	461 1 O
)	462 1 O
after	464 5 O
exposure	470 8 O
to	479 2 O
heparin	482 7 B-Chemical
,	489 1 O
who	491 3 O
had	495 3 O
a	499 1 O
positive	501 8 O
two	510 3 O
-	513 1 O
step	514 4 O
antigen	519 7 O
assay	527 5 O
[	533 1 O
optical	534 7 O
density	542 7 O
(	550 1 O
OD	551 2 O
)	553 1 O
>	555 1 O
0	556 1 O
.	557 1 O
4	558 1 O
and	560 3 O
>	564 1 O
50	565 2 O
inhibition	568 10 O
with	579 4 O
high	584 4 O
concentration	589 13 O
of	603 2 O
heparin	606 7 B-Chemical
]	613 1 O
were	615 4 O
included	620 8 O
in	629 2 O
the	632 3 O
study	636 5 O
.	641 1 O

RESULTS	643 7 O
:	650 1 O
Forty	652 5 O
of	658 2 O
94	661 2 O
HIT	664 3 B-Disease
patients	668 8 O
had	677 3 O
thrombosis	681 10 B-Disease
at	692 2 O
diagnosis	695 9 O
;	704 1 O
54	706 2 O
/	708 1 O
94	709 2 O
had	712 3 O
isolated	716 8 O
-	724 1 O
HIT	725 3 B-Disease
without	729 7 O
thrombosis	737 10 B-Disease
.	747 1 O

Eight	749 5 O
of	755 2 O
the	758 3 O
isolated	762 8 O
-	770 1 O
HIT	771 3 B-Disease
patients	775 8 O
developed	784 9 O
thrombosis	794 10 B-Disease
within	805 6 O
the	812 3 O
next	816 4 O
30	821 2 O
d	824 1 O
;	825 1 O
thus	827 4 O
,	831 1 O
a	833 1 O
total	835 5 O
of	841 2 O
48	844 2 O
patients	847 8 O
had	856 3 O
thrombosis	860 10 B-Disease
at	871 2 O
day	874 3 O
30	878 2 O
.	880 1 O

At	882 2 O
diagnosis	885 9 O
there	895 5 O
was	901 3 O
no	905 2 O
significant	908 11 O
difference	920 10 O
in	931 2 O
OD	934 2 O
between	937 7 O
HIT	945 3 B-Disease
patients	949 8 O
with	958 4 O
thrombosis	963 10 B-Disease
and	974 3 O
those	978 5 O
with	984 4 O
isolated	989 8 O
-	997 1 O
HIT	998 3 B-Disease
.	1001 1 O

However	1003 7 O
,	1010 1 O
OD	1012 2 O
was	1015 3 O
significantly	1019 13 O
higher	1033 6 O
in	1040 2 O
all	1043 3 O
patients	1047 8 O
with	1056 4 O
thrombosis	1061 10 B-Disease
(	1072 1 O
n	1073 1 O
=	1075 1 O
48	1077 2 O
,	1079 1 O
1	1081 1 O
.	1082 1 O
34	1083 2 O
+	1086 1 O
/	1087 1 O
-	1088 1 O
0	1090 1 O
.	1091 1 O
89	1092 2 O
)	1094 1 O
,	1095 1 O
including	1097 9 O
isolated	1107 8 O
-	1115 1 O
HIT	1116 3 B-Disease
patients	1120 8 O
who	1129 3 O
later	1133 5 O
developed	1139 9 O
thrombosis	1149 10 B-Disease
within	1160 6 O
30	1167 2 O
d	1170 1 O
(	1172 1 O
n	1173 1 O
=	1175 1 O
8	1177 1 O
,	1178 1 O
1	1180 1 O
.	1181 1 O
84	1182 2 O
+	1185 1 O
/	1186 1 O
-	1187 1 O
0	1189 1 O
.	1190 1 O
64	1191 2 O
)	1193 1 O
as	1195 2 O
compared	1198 8 O
to	1207 2 O
isolated	1210 8 O
-	1218 1 O
HIT	1219 3 B-Disease
patients	1223 8 O
who	1232 3 O
did	1236 3 O
not	1240 3 O
develop	1244 7 O
thrombosis	1252 10 B-Disease
(	1263 1 O
0	1264 1 O
.	1265 1 O
96	1266 2 O
+	1269 1 O
/	1270 1 O
-	1271 1 O
0	1273 1 O
.	1274 1 O
75	1275 2 O
;	1277 1 O
P	1279 1 O
=	1281 1 O
0	1283 1 O
.	1284 1 O
011	1285 3 O
and	1289 3 O
P	1293 1 O
=	1295 1 O
0	1297 1 O
.	1298 1 O
008	1299 3 O
)	1302 1 O
.	1303 1 O

The	1305 3 O
Receiver	1309 8 O
Operative	1318 9 O
Characteristic	1328 14 O
Curve	1343 5 O
showed	1349 6 O
that	1356 4 O
OD	1361 2 O
>	1364 1 O
1	1365 1 O
.	1366 1 O
27	1367 2 O
in	1370 2 O
the	1373 3 O
isolated	1377 8 O
-	1385 1 O
HIT	1386 3 B-Disease
group	1390 5 O
had	1396 3 O
a	1400 1 O
significantly	1402 13 O
higher	1416 6 O
chance	1423 6 O
of	1430 2 O
developing	1433 10 O
thrombosis	1444 10 B-Disease
by	1455 2 O
day	1458 3 O
30	1462 2 O
.	1464 1 O

None	1466 4 O
of	1471 2 O
these	1474 5 O
groups	1480 6 O
showed	1487 6 O
significant	1494 11 O
difference	1506 10 O
in	1517 2 O
percent	1520 7 O
inhibition	1528 10 O
.	1538 1 O

Multivariate	1540 12 O
analysis	1553 8 O
showed	1562 6 O
a	1569 1 O
2	1571 1 O
.	1572 1 O
8	1573 1 O
-	1574 1 O
fold	1575 4 O
increased	1580 9 O
risk	1590 4 O
of	1595 2 O
thrombosis	1598 10 B-Disease
in	1609 2 O
females	1612 7 O
.	1619 1 O

Similarly	1621 9 O
,	1630 1 O
thrombotic	1632 10 B-Disease
risk	1643 4 O
increased	1648 9 O
with	1658 4 O
age	1663 3 O
and	1667 3 O
OD	1671 2 O
values	1674 6 O
.	1680 1 O

CONCLUSION	1682 10 O
:	1692 1 O
Higher	1694 6 O
OD	1701 2 O
is	1704 2 O
associated	1707 10 O
with	1718 4 O
significant	1723 11 O
risk	1735 4 O
of	1740 2 O
subsequent	1743 10 O
thrombosis	1754 10 B-Disease
in	1765 2 O
patients	1768 8 O
with	1777 4 O
isolated	1782 8 O
-	1790 1 O
HIT	1791 3 B-Disease
;	1794 1 O
percent	1796 7 O
inhibition	1804 10 O
,	1814 1 O
however	1816 7 O
,	1823 1 O
was	1825 3 O
not	1829 3 O
predictive	1833 10 O
.	1843 1 O

Central	0 7 O
retinal	8 7 B-Disease
vein	16 4 I-Disease
occlusion	21 9 I-Disease
associated	31 10 O
with	42 4 O
clomiphene	47 10 B-Chemical
-	57 1 O
induced	58 7 O
ovulation	66 9 O
.	75 1 O

OBJECTIVE	77 9 O
:	86 1 O
To	88 2 O
report	91 6 O
a	98 1 O
case	100 4 O
of	105 2 O
central	108 7 O
retinal	116 7 B-Disease
vein	124 4 I-Disease
occlusion	129 9 I-Disease
associated	139 10 O
with	150 4 O
clomiphene	155 10 B-Chemical
citrate	166 7 I-Chemical
(	174 1 O
CC	175 2 B-Chemical
)	177 1 O
.	178 1 O

DESIGN	180 6 O
:	186 1 O
Case	188 4 O
study	193 5 O
.	198 1 O

SETTING	200 7 O
:	207 1 O
Ophthalmology	209 13 O
clinic	223 6 O
of	230 2 O
an	233 2 O
academic	236 8 O
hospital	245 8 O
.	253 1 O

PATIENT	255 7 O
(	262 1 O
S	263 1 O
)	264 1 O
:	265 1 O
A	267 1 O
36	269 2 O
-	271 1 O
year	272 4 O
-	276 1 O
old	277 3 O
woman	281 5 O
referred	287 8 O
from	296 4 O
the	301 3 O
infertility	305 11 B-Disease
clinic	317 6 O
for	324 3 O
blurred	328 7 B-Disease
vision	336 6 I-Disease
.	342 1 O

INTERVENTION	344 12 O
(	356 1 O
S	357 1 O
)	358 1 O
:	359 1 O
Ophthalmic	361 10 O
examination	372 11 O
after	384 5 O
CC	390 2 B-Chemical
therapy	393 7 O
.	400 1 O

MAIN	402 4 O
OUTCOME	407 7 O
MEASURE	415 7 O
(	422 1 O
S	423 1 O
)	424 1 O
:	425 1 O
Central	427 7 O
retinal	435 7 B-Disease
vein	443 4 I-Disease
occlusion	448 9 I-Disease
after	458 5 O
ovulation	464 9 O
induction	474 9 O
with	484 4 O
CC	489 2 B-Chemical
.	491 1 O

RESULT	493 6 O
(	499 1 O
S	500 1 O
)	501 1 O
:	502 1 O
A	504 1 O
36	506 2 O
-	508 1 O
year	509 4 O
-	513 1 O
old	514 3 O
Chinese	518 7 O
woman	526 5 O
developed	532 9 O
central	542 7 O
retinal	550 7 B-Disease
vein	558 4 I-Disease
occlusion	563 9 I-Disease
after	573 5 O
eight	579 5 O
courses	585 7 O
of	593 2 O
CC	596 2 B-Chemical
.	598 1 O

A	600 1 O
search	602 6 O
of	609 2 O
the	612 3 O
literature	616 10 O
on	627 2 O
the	630 3 O
thromboembolic	634 14 B-Disease
complications	649 13 O
of	663 2 O
CC	666 2 B-Chemical
does	669 4 O
not	674 3 O
include	678 7 O
this	686 4 O
severe	691 6 O
ophthalmic	698 10 O
complication	709 12 O
,	721 1 O
although	723 8 O
mild	732 4 O
visual	737 6 B-Disease
disturbance	744 11 I-Disease
after	756 5 O
CC	762 2 B-Chemical
intake	765 6 O
is	772 2 O
not	775 3 O
uncommon	779 8 O
.	787 1 O

CONCLUSION	789 10 O
(	799 1 O
S	800 1 O
)	801 1 O
:	802 1 O
This	804 4 O
is	809 2 O
the	812 3 O
first	816 5 O
reported	822 8 O
case	831 4 O
of	836 2 O
central	839 7 O
retinal	847 7 B-Disease
vein	855 4 I-Disease
occlusion	860 9 I-Disease
after	870 5 O
treatment	876 9 O
with	886 4 O
CC	891 2 B-Chemical
.	893 1 O

Extra	895 5 O
caution	901 7 O
is	909 2 O
warranted	912 9 O
in	922 2 O
treating	925 8 O
infertility	934 11 B-Disease
patients	946 8 O
with	955 4 O
CC	960 2 B-Chemical
,	962 1 O
and	964 3 O
patients	968 8 O
should	977 6 O
be	984 2 O
well	987 4 O
informed	992 8 O
of	1001 2 O
this	1004 4 O
side	1009 4 O
effect	1014 6 O
before	1021 6 O
commencement	1028 12 O
of	1041 2 O
therapy	1044 7 O
.	1051 1 O

Nicotine	0 8 B-Chemical
-	8 1 O
induced	9 7 O
nystagmus	17 9 B-Disease
correlates	27 10 O
with	38 4 O
midpontine	43 10 O
activation	54 10 O
.	64 1 O

The	66 3 O
pathomechanism	70 14 O
of	85 2 O
nicotine	88 8 B-Chemical
-	96 1 O
induced	97 7 O
nystagmus	105 9 B-Disease
(	115 1 O
NIN	116 3 B-Disease
)	119 1 O
is	121 2 O
unknown	124 7 O
.	131 1 O

The	133 3 O
aim	137 3 O
of	141 2 O
this	144 4 O
study	149 5 O
was	155 3 O
to	159 2 O
delineate	162 9 O
brain	172 5 O
structures	178 10 O
that	189 4 O
are	194 3 O
involved	198 8 O
in	207 2 O
NIN	210 3 B-Disease
generation	214 10 O
.	224 1 O

Eight	226 5 O
healthy	232 7 O
volunteers	240 10 O
inhaled	251 7 O
nicotine	259 8 B-Chemical
in	268 2 O
darkness	271 8 O
during	280 6 O
a	287 1 O
functional	289 10 O
magnetic	300 8 O
resonance	309 9 O
imaging	319 7 O
(	327 1 O
fMRI	328 4 O
)	332 1 O
experiment	334 10 O
;	344 1 O
eye	346 3 O
movements	350 9 O
were	360 4 O
registered	365 10 O
using	376 5 O
video	382 5 O
-	387 1 O
oculography	388 11 O
.	399 1 O

NIN	401 3 B-Disease
correlated	405 10 O
with	416 4 O
blood	421 5 O
oxygen	427 6 B-Chemical
level	434 5 O
-	439 1 O
dependent	440 9 O
(	450 1 O
BOLD	451 4 O
)	455 1 O
activity	457 8 O
levels	466 6 O
in	473 2 O
a	476 1 O
midpontine	478 10 O
site	489 4 O
in	494 2 O
the	497 3 O
posterior	501 9 O
basis	511 5 O
pontis	517 6 O
.	523 1 O

NIN	525 3 B-Disease
-	528 1 O
induced	529 7 O
midpontine	537 10 O
activation	548 10 O
may	559 3 O
correspond	563 10 O
to	574 2 O
activation	577 10 O
of	588 2 O
the	591 3 O
dorsomedial	595 11 O
pontine	607 7 O
nuclei	615 6 O
and	622 3 O
the	626 3 O
nucleus	630 7 O
reticularis	638 11 O
tegmenti	650 8 O
pontis	659 6 O
,	665 1 O
structures	667 10 O
known	678 5 O
to	684 2 O
participate	687 11 O
in	699 2 O
the	702 3 O
generation	706 10 O
of	717 2 O
multidirectional	720 16 O
saccades	737 8 O
and	746 3 O
smooth	750 6 O
pursuit	757 7 O
eye	765 3 O
movements	769 9 O
.	778 1 O

Protective	0 10 O
effect	11 6 O
of	18 2 O
verapamil	21 9 B-Chemical
on	31 2 O
gastric	34 7 B-Disease
hemorrhagic	42 11 I-Disease
ulcers	54 6 B-Disease
in	61 2 O
severe	64 6 O
atherosclerotic	71 15 B-Disease
rats	87 4 O
.	91 1 O

Studies	93 7 O
concerning	101 10 O
with	112 4 O
pathogenesis	117 12 O
of	130 2 O
gastric	133 7 B-Disease
hemorrhage	141 10 I-Disease
and	152 3 O
mucosal	156 7 O
ulceration	164 10 O
produced	175 8 O
in	184 2 O
atherosclerotic	187 15 B-Disease
rats	203 4 O
are	208 3 O
lacking	212 7 O
.	219 1 O

The	221 3 O
aim	225 3 O
of	229 2 O
this	232 4 O
study	237 5 O
is	243 2 O
to	246 2 O
examine	249 7 O
the	257 3 O
role	261 4 O
of	266 2 O
gastric	269 7 O
acid	277 4 O
back	282 4 O
-	286 1 O
diffusion	287 9 O
,	296 1 O
mast	298 4 O
cell	303 4 O
histamine	308 9 B-Chemical
release	318 7 O
,	325 1 O
lipid	327 5 O
peroxide	333 8 O
(	342 1 O
LPO	343 3 O
)	346 1 O
generation	348 10 O
and	359 3 O
mucosal	363 7 O
microvascular	371 13 O
permeability	385 12 O
in	398 2 O
modulating	401 10 O
gastric	412 7 B-Disease
hemorrhage	420 10 I-Disease
and	431 3 O
ulcer	435 5 B-Disease
in	441 2 O
rats	444 4 O
with	449 4 O
atherosclerosis	454 15 B-Disease
induced	470 7 O
by	478 2 O
coadministration	481 16 O
of	498 2 O
vitamin	501 7 B-Chemical
D2	509 2 I-Chemical
and	512 3 O
cholesterol	516 11 B-Chemical
.	527 1 O

Additionally	529 12 O
,	541 1 O
the	543 3 O
protective	547 10 O
effect	558 6 O
of	565 2 O
verapamil	568 9 B-Chemical
on	578 2 O
this	581 4 O
ulcer	586 5 B-Disease
model	592 5 O
was	598 3 O
evaluated	602 9 O
.	611 1 O

Male	613 4 O
Wistar	618 6 O
rats	625 4 O
were	630 4 O
challenged	635 10 O
intragastrically	646 16 O
once	663 4 O
daily	668 5 O
for	674 3 O
9	678 1 O
days	680 4 O
with	685 4 O
1	690 1 O
.	691 1 O
0	692 1 O
ml	694 2 O
/	696 1 O
kg	697 2 O
of	700 2 O
corn	703 4 O
oil	708 3 O
containing	712 10 O
vitamin	723 7 B-Chemical
D2	731 2 I-Chemical
and	734 3 O
cholesterol	738 11 B-Chemical
to	750 2 O
induce	753 6 O
atherosclerosis	760 15 B-Disease
.	775 1 O

Control	777 7 O
rats	785 4 O
received	790 8 O
corn	799 4 O
oil	804 3 O
only	808 4 O
.	812 1 O

After	814 5 O
gastric	820 7 O
surgery	828 7 O
,	835 1 O
rat	837 3 O
stomachs	841 8 O
were	850 4 O
irrigated	855 9 O
for	865 3 O
3	869 1 O
h	871 1 O
with	873 4 O
either	878 6 O
simulated	885 9 O
gastric	895 7 O
juice	903 5 O
or	909 2 O
normal	912 6 O
saline	919 6 O
.	925 1 O

Gastric	927 7 O
acid	935 4 O
back	940 4 O
-	944 1 O
diffusion	945 9 O
,	954 1 O
mucosal	956 7 O
LPO	964 3 O
generation	968 10 O
,	978 1 O
histamine	980 9 B-Chemical
concentration	990 13 O
,	1003 1 O
microvascular	1005 13 O
permeability	1019 12 O
,	1031 1 O
luminal	1033 7 B-Chemical
hemoglobin	1041 10 O
content	1052 7 O
and	1060 3 O
ulcer	1064 5 B-Disease
areas	1070 5 O
were	1076 4 O
determined	1081 10 O
.	1091 1 O

Elevated	1093 8 O
atherosclerotic	1102 15 B-Disease
parameters	1118 10 O
,	1128 1 O
such	1130 4 O
as	1135 2 O
serum	1138 5 O
calcium	1144 7 B-Chemical
,	1151 1 O
total	1153 5 O
cholesterol	1159 11 B-Chemical
and	1171 3 O
low	1175 3 O
-	1178 1 O
density	1179 7 O
lipoprotein	1187 11 O
concentration	1199 13 O
were	1213 4 O
obtained	1218 8 O
in	1227 2 O
atherosclerotic	1230 15 B-Disease
rats	1246 4 O
.	1250 1 O

Severe	1252 6 O
gastric	1259 7 O
ulcers	1267 6 B-Disease
accompanied	1274 11 O
with	1286 4 O
increased	1291 9 O
ulcerogenic	1301 11 O
factors	1313 7 O
,	1320 1 O
including	1322 9 O
gastric	1332 7 O
acid	1340 4 O
back	1345 4 O
-	1349 1 O
diffusion	1350 9 O
,	1359 1 O
histamine	1361 9 B-Chemical
release	1371 7 O
,	1378 1 O
LPO	1380 3 O
generation	1384 10 O
and	1395 3 O
luminal	1399 7 B-Chemical
hemoglobin	1407 10 O
content	1418 7 O
were	1426 4 O
also	1431 4 O
observed	1436 8 O
in	1445 2 O
these	1448 5 O
rats	1454 4 O
.	1458 1 O

Moreover	1460 8 O
,	1468 1 O
a	1470 1 O
positive	1472 8 O
correlation	1481 11 O
of	1493 2 O
histamine	1496 9 B-Chemical
to	1506 2 O
gastric	1509 7 B-Disease
hemorrhage	1517 10 I-Disease
and	1528 3 O
to	1532 2 O
ulcer	1535 5 B-Disease
was	1541 3 O
found	1545 5 O
in	1551 2 O
those	1554 5 O
atherosclerotic	1560 15 B-Disease
rats	1576 4 O
.	1580 1 O

This	1582 4 O
hemorrhagic	1587 11 B-Disease
ulcer	1599 5 B-Disease
and	1605 3 O
various	1609 7 O
ulcerogenic	1617 11 O
parameters	1629 10 O
were	1640 4 O
dose	1645 4 O
-	1649 1 O
dependently	1650 11 O
ameliorated	1662 11 O
by	1674 2 O
daily	1677 5 O
intragastric	1683 12 O
verapamil	1696 9 B-Chemical
.	1705 1 O

Atherosclerosis	1707 15 B-Disease
could	1723 5 O
produce	1729 7 O
gastric	1737 7 B-Disease
hemorrhagic	1745 11 I-Disease
ulcer	1757 5 B-Disease
via	1763 3 O
aggravation	1767 11 O
of	1779 2 O
gastric	1782 7 O
acid	1790 4 O
back	1795 4 O
-	1799 1 O
diffusion	1800 9 O
,	1809 1 O
LPO	1811 3 O
generation	1815 10 O
,	1825 1 O
histamine	1827 9 B-Chemical
release	1837 7 O
and	1845 3 O
microvascular	1849 13 O
permeability	1863 12 O
that	1876 4 O
could	1881 5 O
be	1887 2 O
ameliorated	1890 11 O
by	1902 2 O
verapamil	1905 9 B-Chemical
in	1915 2 O
rats	1918 4 O
.	1922 1 O

Adriamycin	0 10 B-Chemical
-	10 1 O
induced	11 7 O
autophagic	19 10 O
cardiomyocyte	30 13 O
death	44 5 B-Disease
plays	50 5 O
a	56 1 O
pathogenic	58 10 O
role	69 4 O
in	74 2 O
a	77 1 O
rat	79 3 O
model	83 5 O
of	89 2 O
heart	92 5 B-Disease
failure	98 7 I-Disease
.	105 1 O

BACKGROUND	107 10 O
:	117 1 O
The	119 3 O
mechanisms	123 10 O
underlying	134 10 O
heart	145 5 B-Disease
failure	151 7 I-Disease
induced	159 7 O
by	167 2 O
adriamycin	170 10 B-Chemical
are	181 3 O
very	185 4 O
complicated	190 11 O
and	202 3 O
still	206 5 O
unclear	212 7 O
.	219 1 O

The	221 3 O
aim	225 3 O
of	229 2 O
this	232 4 O
study	237 5 O
was	243 3 O
to	247 2 O
investigate	250 11 O
whether	262 7 O
autophagy	270 9 O
was	280 3 O
involved	284 8 O
in	293 2 O
the	296 3 O
progression	300 11 O
of	312 2 O
heart	315 5 B-Disease
failure	321 7 I-Disease
induced	329 7 O
by	337 2 O
adriamycin	340 10 B-Chemical
,	350 1 O
so	352 2 O
that	355 4 O
we	360 2 O
can	363 3 O
develop	367 7 O
a	375 1 O
novel	377 5 O
treatment	383 9 O
strategy	393 8 O
for	402 3 O
heart	406 5 B-Disease
failure	412 7 I-Disease
.	419 1 O

METHODS	421 7 O
:	428 1 O
3	430 1 B-Chemical
-	431 1 I-Chemical
methyladenine	432 13 I-Chemical
(	446 1 O
3MA	447 3 B-Chemical
)	450 1 O
,	451 1 O
a	453 1 O
specific	455 8 O
inhibitor	464 9 O
on	474 2 O
autophagy	477 9 O
was	487 3 O
used	491 4 O
in	496 2 O
a	499 1 O
heart	501 5 B-Disease
failure	507 7 I-Disease
model	515 5 O
of	521 2 O
rats	524 4 O
induced	529 7 O
by	537 2 O
adriamycin	540 10 B-Chemical
.	550 1 O

Neonatal	552 8 O
cardiomyocytes	561 14 O
were	576 4 O
isolated	581 8 O
from	590 4 O
Sprague	595 7 O
-	602 1 O
Dawley	603 6 O
rat	610 3 O
hearts	614 6 O
and	621 3 O
randomly	625 8 O
divided	634 7 O
into	642 4 O
controls	647 8 O
,	655 1 O
an	657 2 O
adriamycin	660 10 B-Chemical
-	670 1 O
treated	671 7 O
group	679 5 O
,	684 1 O
and	686 3 O
a	690 1 O
3MA	692 3 B-Chemical
plus	696 4 O
adriamycin	701 10 B-Chemical
-	711 1 O
treated	712 7 O
group	720 5 O
.	725 1 O

We	727 2 O
then	730 4 O
examined	735 8 O
the	744 3 O
morphology	748 10 O
,	758 1 O
expression	760 10 O
of	771 2 O
beclin	774 6 O
1	781 1 O
gene	783 4 O
,	787 1 O
mitochondrial	789 13 O
permeability	803 12 O
transition	816 10 O
(	827 1 O
MPT	828 3 O
)	831 1 O
,	832 1 O
and	834 3 O
Na	838 2 O
+	840 1 O
-	841 1 O
K	842 1 B-Chemical
+	843 1 O
ATPase	845 6 O
activity	852 8 O
in	861 2 O
vivo	864 4 O
.	868 1 O

We	870 2 O
also	873 4 O
assessed	878 8 O
cell	887 4 O
viability	892 9 O
,	901 1 O
mitochondrial	903 13 O
membrane	917 8 O
potential	926 9 O
changes	936 7 O
and	944 3 O
counted	948 7 O
autophagic	956 10 O
vacuoles	967 8 O
in	976 2 O
cultured	979 8 O
cardiomyocytes	988 14 O
.	1002 1 O

In	1004 2 O
addition	1007 8 O
,	1015 1 O
we	1017 2 O
analyzed	1020 8 O
the	1029 3 O
expression	1033 10 O
of	1044 2 O
autophagy	1047 9 O
associated	1057 10 O
gene	1068 4 O
,	1072 1 O
beclin	1074 6 O
1	1081 1 O
using	1083 5 O
RT	1089 2 O
-	1091 1 O
PCR	1092 3 O
and	1096 3 O
Western	1100 7 O
blotting	1108 8 O
in	1117 2 O
an	1120 2 O
animal	1123 6 O
model	1130 5 O
.	1135 1 O

RESULTS	1137 7 O
:	1144 1 O
3MA	1146 3 B-Chemical
significantly	1150 13 O
improved	1164 8 O
cardiac	1173 7 O
function	1181 8 O
and	1190 3 O
reduced	1194 7 O
mitochondrial	1202 13 O
injury	1216 6 O
.	1222 1 O

Furthermore	1224 11 O
,	1235 1 O
adriamycin	1237 10 B-Chemical
induced	1248 7 O
the	1256 3 O
formation	1260 9 O
of	1270 2 O
autophagic	1273 10 O
vacuoles	1284 8 O
,	1292 1 O
and	1294 3 O
3MA	1298 3 B-Chemical
strongly	1302 8 O
downregulated	1311 13 O
the	1325 3 O
expression	1329 10 O
of	1340 2 O
beclin	1343 6 O
1	1350 1 O
in	1352 2 O
adriamycin	1355 10 B-Chemical
-	1365 1 O
induced	1366 7 O
failing	1374 7 O
heart	1382 5 O
and	1388 3 O
inhibited	1392 9 O
the	1402 3 O
formation	1406 9 O
of	1416 2 O
autophagic	1419 10 O
vacuoles	1430 8 O
.	1438 1 O

CONCLUSION	1440 10 O
:	1450 1 O
Autophagic	1452 10 O
cardiomyocyte	1463 13 O
death	1477 5 B-Disease
plays	1483 5 O
an	1489 2 O
important	1492 9 O
role	1502 4 O
in	1507 2 O
the	1510 3 O
pathogenesis	1514 12 O
of	1527 2 O
heart	1530 5 B-Disease
failure	1536 7 I-Disease
in	1544 2 O
rats	1547 4 O
induced	1552 7 O
by	1560 2 O
adriamycin	1563 10 B-Chemical
.	1573 1 O

Mitochondrial	1575 13 O
injury	1589 6 O
may	1596 3 O
be	1600 2 O
involved	1603 8 O
in	1612 2 O
the	1615 3 O
progression	1619 11 O
of	1631 2 O
heart	1634 5 B-Disease
failure	1640 7 I-Disease
caused	1648 6 O
by	1655 2 O
adriamycin	1658 10 B-Chemical
via	1669 3 O
the	1673 3 O
autophagy	1677 9 O
pathway	1687 7 O
.	1694 1 O

Confusion	0 9 B-Disease
,	9 1 O
a	11 1 O
rather	13 6 O
serious	20 7 O
adverse	28 7 O
drug	36 4 O
reaction	41 8 O
with	50 4 O
valproic	55 8 B-Chemical
acid	64 4 I-Chemical
:	68 1 O
a	70 1 O
review	72 6 O
of	79 2 O
the	82 3 O
French	86 6 O
Pharmacovigilance	93 17 O
database	111 8 O
.	119 1 O

INTRODUCTION	121 12 O
:	133 1 O
Confusion	135 9 B-Disease
is	145 2 O
an	148 2 O
adverse	151 7 O
drug	159 4 O
reaction	164 8 O
frequently	173 10 O
observed	184 8 O
with	193 4 O
valproic	198 8 B-Chemical
acid	207 4 I-Chemical
.	211 1 O

Some	213 4 O
case	218 4 O
reports	223 7 O
are	231 3 O
published	235 9 O
in	245 2 O
the	248 3 O
literature	252 10 O
but	263 3 O
no	267 2 O
systematic	270 10 O
study	281 5 O
from	287 4 O
a	292 1 O
sample	294 6 O
of	301 2 O
patients	304 8 O
has	313 3 O
been	317 4 O
published	322 9 O
.	331 1 O

We	333 2 O
performed	336 9 O
this	346 4 O
study	351 5 O
in	357 2 O
order	360 5 O
to	366 2 O
describe	369 8 O
the	378 3 O
main	382 4 O
characteristics	387 15 O
of	403 2 O
this	406 4 O
adverse	411 7 O
drug	419 4 O
reaction	424 8 O
.	432 1 O

METHODS	434 7 O
:	441 1 O
Using	443 5 O
the	449 3 O
French	453 6 O
Pharmacovigilance	460 17 O
database	478 8 O
,	486 1 O
we	488 2 O
selected	491 8 O
the	500 3 O
cases	504 5 O
of	510 2 O
confusion	513 9 B-Disease
reported	523 8 O
since	532 5 O
1985	538 4 O
with	543 4 O
valproic	548 8 B-Chemical
acid	557 4 I-Chemical
.	561 1 O

RESULTS	563 7 O
:	570 1 O
272	572 3 O
cases	576 5 O
of	582 2 O
confusion	585 9 B-Disease
were	595 4 O
reported	600 8 O
with	609 4 O
valproic	614 8 B-Chemical
acid	623 4 I-Chemical
:	627 1 O
153	629 3 O
women	633 5 O
and	639 3 O
119	643 3 O
men	647 3 O
.	650 1 O

Confusion	652 9 B-Disease
mostly	662 6 O
occurred	669 8 O
during	678 6 O
the	685 3 O
two	689 3 O
first	693 5 O
weeks	699 5 O
following	705 9 O
valproic	715 8 B-Chemical
acid	724 4 I-Chemical
exposure	729 8 O
(	738 1 O
39	739 2 O
.	741 1 O
7	742 1 O
%	743 1 O
)	744 1 O
.	745 1 O

It	747 2 O
was	750 3 O
"	754 1 O
serious	755 7 O
"	762 1 O
for	764 3 O
almost	768 6 O
2	775 1 O
/	776 1 O
3	777 1 O
of	779 2 O
the	782 3 O
patients	786 8 O
(	795 1 O
62	796 2 O
.	798 1 O
5	799 1 O
%	800 1 O
)	801 1 O
and	803 3 O
its	807 3 O
outcome	811 7 O
favourable	819 10 O
in	830 2 O
most	833 4 O
of	838 2 O
the	841 3 O
cases	845 5 O
(	851 1 O
82	852 2 O
%	854 1 O
)	855 1 O
.	856 1 O

The	858 3 O
occurrence	862 10 O
of	873 2 O
this	876 4 O
ADR	881 3 O
was	885 3 O
more	889 4 O
frequent	894 8 O
in	903 2 O
patients	906 8 O
aged	915 4 O
between	920 7 O
61	928 2 O
and	931 3 O
80	935 2 O
years	938 5 O
.	943 1 O

CONCLUSION	945 10 O
:	955 1 O
This	957 4 O
work	962 4 O
shows	967 5 O
that	973 4 O
confusion	978 9 B-Disease
with	988 4 O
valproic	993 8 B-Chemical
acid	1002 4 I-Chemical
is	1007 2 O
a	1010 1 O
serious	1012 7 O
,	1019 1 O
rather	1021 6 O
frequent	1028 8 O
but	1037 3 O
reversible	1041 10 O
adverse	1052 7 O
drug	1060 4 O
reaction	1065 8 O
.	1073 1 O

It	1075 2 O
occurs	1078 6 O
especially	1085 10 O
in	1096 2 O
older	1099 5 O
patients	1105 8 O
and	1114 3 O
during	1118 6 O
the	1125 3 O
first	1129 5 O
two	1135 3 O
weeks	1139 5 O
of	1145 2 O
treatment	1148 9 O
.	1157 1 O

Learning	0 8 B-Disease
and	9 3 I-Disease
memory	13 6 I-Disease
deficits	20 8 I-Disease
in	29 2 O
ecstasy	32 7 B-Chemical
users	40 5 O
and	46 3 O
their	50 5 O
neural	56 6 O
correlates	63 10 O
during	74 6 O
a	81 1 O
face	83 4 O
-	87 1 O
learning	88 8 O
task	97 4 O
.	101 1 O

It	103 2 O
has	106 3 O
been	110 4 O
consistently	115 12 O
shown	128 5 O
that	134 4 O
ecstasy	139 7 B-Chemical
users	147 5 O
display	153 7 O
impairments	161 11 B-Disease
in	173 2 I-Disease
learning	176 8 I-Disease
and	185 3 I-Disease
memory	189 6 I-Disease
performance	196 11 O
.	207 1 O

In	209 2 O
addition	212 8 O
,	220 1 O
working	222 7 O
memory	230 6 O
processing	237 10 O
in	248 2 O
ecstasy	251 7 B-Chemical
users	259 5 O
has	265 3 O
been	269 4 O
shown	274 5 O
to	280 2 O
be	283 2 O
associated	286 10 O
with	297 4 O
neural	302 6 O
alterations	309 11 O
in	321 2 O
hippocampal	324 11 O
and	336 3 O
/	339 1 O
or	340 2 O
cortical	343 8 O
regions	352 7 O
as	360 2 O
measured	363 8 O
by	372 2 O
functional	375 10 O
magnetic	386 8 O
resonance	395 9 O
imaging	405 7 O
(	413 1 O
fMRI	414 4 O
)	418 1 O
.	419 1 O

Using	421 5 O
functional	427 10 O
imaging	438 7 O
and	446 3 O
a	450 1 O
face	452 4 O
-	456 1 O
learning	457 8 O
task	466 4 O
,	470 1 O
we	472 2 O
investigated	475 12 O
neural	488 6 O
correlates	495 10 O
of	506 2 O
encoding	509 8 O
and	518 3 O
recalling	522 9 O
face	532 4 O
-	536 1 O
name	537 4 O
associations	542 12 O
in	555 2 O
20	558 2 O
recreational	561 12 O
drug	574 4 O
users	579 5 O
whose	585 5 O
predominant	591 11 O
drug	603 4 O
use	608 3 O
was	612 3 O
ecstasy	616 7 B-Chemical
and	624 3 O
20	628 2 O
controls	631 8 O
.	639 1 O

To	641 2 O
address	644 7 O
the	652 3 O
potential	656 9 O
confounding	666 11 O
effects	678 7 O
of	686 2 O
the	689 3 O
cannabis	693 8 B-Chemical
use	702 3 O
of	706 2 O
the	709 3 O
ecstasy	713 7 B-Chemical
using	721 5 O
group	727 5 O
,	732 1 O
a	734 1 O
second	736 6 O
analysis	743 8 O
included	752 8 O
14	761 2 O
previously	764 10 O
tested	775 6 O
cannabis	782 8 B-Chemical
users	791 5 O
(	797 1 O
Nestor	798 6 O
,	804 1 O
L	806 1 O
.	807 1 O
,	808 1 O
Roberts	810 7 O
,	817 1 O
G	819 1 O
.	820 1 O
,	821 1 O
Garavan	823 7 O
,	830 1 O
H	832 1 O
.	833 1 O
,	834 1 O
Hester	836 6 O
,	842 1 O
R	844 1 O
.	845 1 O
,	846 1 O
2008	848 4 O
.	852 1 O
Deficits	854 8 B-Disease
in	863 2 I-Disease
learning	866 8 I-Disease
and	875 3 I-Disease
memory	879 6 I-Disease
:	885 1 O
parahippocampal	887 15 O
hyperactivity	903 13 B-Disease
and	917 3 O
frontocortical	921 14 O
hypoactivity	936 12 O
in	949 2 O
cannabis	952 8 B-Chemical
users	961 5 O
.	966 1 O
Neuroimage	968 10 O
40	979 2 O
,	981 1 O
1328	983 4 O
-	987 1 O
1339	988 4 O
)	992 1 O
.	993 1 O

Ecstasy	995 7 B-Chemical
users	1003 5 O
performed	1009 9 O
significantly	1019 13 O
worse	1033 5 O
in	1039 2 O
learning	1042 8 O
and	1051 3 O
memory	1055 6 O
compared	1062 8 O
to	1071 2 O
controls	1074 8 O
and	1083 3 O
cannabis	1087 8 B-Chemical
users	1096 5 O
.	1101 1 O

A	1103 1 O
conjunction	1105 11 O
analysis	1117 8 O
of	1126 2 O
the	1129 3 O
encode	1133 6 O
and	1140 3 O
recall	1144 6 O
phases	1151 6 O
of	1158 2 O
the	1161 3 O
task	1165 4 O
revealed	1170 8 O
ecstasy	1179 7 B-Chemical
-	1186 1 O
specific	1187 8 O
hyperactivity	1196 13 B-Disease
in	1210 2 O
bilateral	1213 9 O
frontal	1223 7 O
regions	1231 7 O
,	1238 1 O
left	1240 4 O
temporal	1245 8 O
,	1253 1 O
right	1255 5 O
parietal	1261 8 O
,	1269 1 O
bilateral	1271 9 O
temporal	1281 8 O
,	1289 1 O
and	1291 3 O
bilateral	1295 9 O
occipital	1305 9 O
brain	1315 5 O
regions	1321 7 O
.	1328 1 O

Ecstasy	1330 7 B-Chemical
-	1337 1 O
specific	1338 8 O
hypoactivity	1347 12 O
was	1360 3 O
evident	1364 7 O
in	1372 2 O
the	1375 3 O
right	1379 5 O
dorsal	1385 6 O
anterior	1392 8 O
cingulated	1401 10 O
cortex	1412 6 O
(	1419 1 O
ACC	1420 3 O
)	1423 1 O
and	1425 3 O
left	1429 4 O
posterior	1434 9 O
cingulated	1444 10 O
cortex	1455 6 O
.	1461 1 O

In	1463 2 O
both	1466 4 O
ecstasy	1471 7 B-Chemical
and	1479 3 O
cannabis	1483 8 B-Chemical
groups	1492 6 O
brain	1499 5 O
activation	1505 10 O
was	1516 3 O
decreased	1520 9 O
in	1530 2 O
the	1533 3 O
right	1537 5 O
medial	1543 6 O
frontal	1550 7 O
gyrus	1558 5 O
,	1563 1 O
left	1565 4 O
parahippocampal	1570 15 O
gyrus	1586 5 O
,	1591 1 O
left	1593 4 O
dorsal	1598 6 O
cingulate	1605 9 O
gyrus	1615 5 O
,	1620 1 O
and	1622 3 O
left	1626 4 O
caudate	1631 7 O
.	1638 1 O

These	1640 5 O
results	1646 7 O
elucidated	1654 10 O
ecstasy	1665 7 B-Chemical
-	1672 1 O
related	1673 7 O
deficits	1681 8 O
,	1689 1 O
only	1691 4 O
some	1696 4 O
of	1701 2 O
which	1704 5 O
might	1710 5 O
be	1716 2 O
attributed	1719 10 O
to	1730 2 O
cannabis	1733 8 B-Chemical
use	1742 3 O
.	1745 1 O

These	1747 5 O
ecstasy	1753 7 B-Chemical
-	1760 1 O
specific	1761 8 O
effects	1770 7 O
may	1778 3 O
be	1782 2 O
related	1785 7 O
to	1793 2 O
the	1796 3 O
vulnerability	1800 13 O
of	1814 2 O
isocortical	1817 11 O
and	1829 3 O
allocortical	1833 12 O
regions	1846 7 O
to	1854 2 O
the	1857 3 O
neurotoxic	1861 10 B-Disease
effects	1872 7 O
of	1880 2 O
ecstasy	1883 7 B-Chemical
.	1890 1 O

Prolonged	0 9 O
elevation	10 9 O
of	20 2 O
plasma	23 6 O
argatroban	30 10 B-Chemical
in	41 2 O
a	44 1 O
cardiac	46 7 O
transplant	54 10 O
patient	65 7 O
with	73 4 O
a	78 1 O
suspected	80 9 O
history	90 7 O
of	98 2 O
heparin	101 7 B-Chemical
-	108 1 O
induced	109 7 O
thrombocytopenia	117 16 B-Disease
with	134 4 O
thrombosis	139 10 B-Disease
.	149 1 O

BACKGROUND	151 10 O
:	161 1 O
Direct	163 6 O
thrombin	170 8 O
inhibitors	179 10 O
(	190 1 O
DTIs	191 4 O
)	195 1 O
provide	197 7 O
an	205 2 O
alternative	208 11 O
method	220 6 O
of	227 2 O
anticoagulation	230 15 O
for	246 3 O
patients	250 8 O
with	259 4 O
a	264 1 O
history	266 7 O
of	274 2 O
heparin	277 7 B-Chemical
-	284 1 O
induced	285 7 O
thrombocytopenia	293 16 B-Disease
(	310 1 O
HIT	311 3 B-Disease
)	314 1 O
or	316 2 O
HIT	319 3 B-Disease
with	323 4 O
thrombosis	328 10 B-Disease
(	339 1 O
HITT	340 4 B-Disease
)	344 1 O
undergoing	346 10 O
cardiopulmonary	357 15 O
bypass	373 6 O
(	380 1 O
CPB	381 3 O
)	384 1 O
.	385 1 O

In	387 2 O
the	390 3 O
following	394 9 O
report	404 6 O
,	410 1 O
a	412 1 O
65	414 2 O
-	416 1 O
year	417 4 O
-	421 1 O
old	422 3 O
critically	426 10 B-Disease
ill	437 3 I-Disease
patient	441 7 O
with	449 4 O
a	454 1 O
suspected	456 9 O
history	466 7 O
of	474 2 O
HITT	477 4 B-Disease
was	482 3 O
administered	486 12 O
argatroban	499 10 B-Chemical
for	510 3 O
anticoagulation	514 15 O
on	530 2 O
bypass	533 6 O
during	540 6 O
heart	547 5 O
transplantation	553 15 O
.	568 1 O

The	570 3 O
patient	574 7 O
required	582 8 O
massive	591 7 O
transfusion	599 11 O
support	611 7 O
(	619 1 O
55	620 2 O
units	623 5 O
of	629 2 O
red	632 3 O
blood	636 5 O
cells	642 5 O
,	647 1 O
42	649 2 O
units	652 5 O
of	658 2 O
fresh	661 5 O
-	666 1 O
frozen	667 6 O
plasma	674 6 O
,	680 1 O
40	682 2 O
units	685 5 O
of	691 2 O
cryoprecipitate	694 15 O
,	709 1 O
40	711 2 O
units	714 5 O
of	720 2 O
platelets	723 9 O
,	732 1 O
and	734 3 O
three	738 5 O
doses	744 5 O
of	750 2 O
recombinant	753 11 O
Factor	765 6 O
VIIa	772 4 O
)	776 1 O
for	778 3 O
severe	782 6 O
intraoperative	789 14 B-Disease
and	804 3 I-Disease
postoperative	808 13 I-Disease
bleeding	822 8 I-Disease
.	830 1 O

STUDY	832 5 O
DESIGN	838 6 O
AND	845 3 O
METHODS	849 7 O
:	856 1 O
Plasma	858 6 O
samples	865 7 O
from	873 4 O
before	878 6 O
and	885 3 O
after	889 5 O
CPB	895 3 O
were	899 4 O
analyzed	904 8 O
postoperatively	913 15 O
for	929 3 O
argatroban	933 10 B-Chemical
concentration	944 13 O
using	958 5 O
a	964 1 O
modified	966 8 O
ecarin	975 6 O
clotting	982 8 O
time	991 4 O
(	996 1 O
ECT	997 3 O
)	1000 1 O
assay	1002 5 O
.	1007 1 O

RESULTS	1009 7 O
:	1016 1 O
Unexpectedly	1018 12 O
high	1031 4 O
concentrations	1036 14 O
of	1051 2 O
argatroban	1054 10 B-Chemical
were	1065 4 O
measured	1070 8 O
in	1079 2 O
these	1082 5 O
samples	1088 7 O
(	1096 1 O
range	1097 5 O
,	1102 1 O
0	1104 1 O
-	1105 1 O
32	1106 2 O
microg	1109 6 O
/	1115 1 O
mL	1116 2 O
)	1118 1 O
,	1119 1 O
and	1121 3 O
a	1125 1 O
prolonged	1127 9 O
plasma	1137 6 O
argatroban	1144 10 B-Chemical
half	1155 4 O
life	1160 4 O
(	1165 1 O
t	1166 1 O
(	1167 1 O
1	1168 1 O
/	1169 1 O
2	1170 1 O
)	1171 1 O
)	1172 1 O
of	1174 2 O
514	1177 3 O
minutes	1181 7 O
was	1189 3 O
observed	1193 8 O
(	1202 1 O
published	1203 9 O
elimination	1213 11 O
t	1225 1 O
(	1226 1 O
1	1227 1 O
/	1228 1 O
2	1229 1 O
)	1230 1 O
is	1232 2 O
39	1235 2 O
-	1237 1 O
51	1238 2 O
minutes	1241 7 O
[	1249 1 O
<	1250 1 O
or	1252 2 O
=	1255 1 O
181	1257 3 O
minutes	1261 7 O
with	1269 4 O
hepatic	1274 7 B-Disease
impairment	1282 10 I-Disease
]	1292 1 O
)	1293 1 O
.	1294 1 O

CONCLUSIONS	1296 11 O
:	1307 1 O
Correlation	1309 11 O
of	1321 2 O
plasma	1324 6 O
argatroban	1331 10 B-Chemical
concentration	1342 13 O
versus	1356 6 O
the	1363 3 O
patient	1367 7 O
'	1374 1 O
s	1375 1 O
coagulation	1377 11 O
variables	1389 9 O
and	1399 3 O
clinical	1403 8 O
course	1412 6 O
suggest	1419 7 O
that	1427 4 O
prolonged	1432 9 O
elevated	1442 8 O
levels	1451 6 O
of	1458 2 O
plasma	1461 6 O
argatroban	1468 10 B-Chemical
may	1479 3 O
have	1483 4 O
contributed	1488 11 O
to	1500 2 O
the	1503 3 O
patient	1507 7 O
'	1514 1 O
s	1515 1 O
extended	1517 8 O
coagulopathy	1526 12 B-Disease
.	1538 1 O

Because	1540 7 O
DTIs	1548 4 O
do	1553 2 O
not	1556 3 O
have	1560 4 O
reversal	1565 8 O
agents	1574 6 O
,	1580 1 O
surgical	1582 8 O
teams	1591 5 O
and	1597 3 O
transfusion	1601 11 O
services	1613 8 O
should	1622 6 O
remain	1629 6 O
aware	1636 5 O
of	1642 2 O
the	1645 3 O
possibility	1649 11 O
of	1661 2 O
massive	1664 7 O
transfusion	1672 11 O
events	1684 6 O
during	1691 6 O
anticoagulation	1698 15 O
with	1714 4 O
these	1719 5 O
agents	1725 6 O
.	1731 1 O

This	1733 4 O
is	1738 2 O
the	1741 3 O
first	1745 5 O
report	1751 6 O
to	1758 2 O
measure	1761 7 O
plasma	1769 6 O
argatroban	1776 10 B-Chemical
concentration	1787 13 O
in	1801 2 O
the	1804 3 O
context	1808 7 O
of	1816 2 O
CPB	1819 3 O
and	1823 3 O
extended	1827 8 O
coagulopathy	1836 12 B-Disease
.	1848 1 O

Antituberculosis	0 16 B-Chemical
therapy	17 7 O
-	24 1 O
induced	25 7 O
acute	33 5 B-Disease
liver	39 5 I-Disease
failure	45 7 I-Disease
:	52 1 O
magnitude	54 9 O
,	63 1 O
profile	65 7 O
,	72 1 O
prognosis	74 9 O
,	83 1 O
and	85 3 O
predictors	89 10 O
of	100 2 O
outcome	103 7 O
.	110 1 O

Antituberculosis	112 16 B-Chemical
therapy	129 7 O
(	137 1 O
ATT	138 3 O
)	141 1 O
-	142 1 O
associated	143 10 O
acute	154 5 B-Disease
liver	160 5 I-Disease
failure	166 7 I-Disease
(	174 1 O
ATT	175 3 O
-	178 1 O
ALF	179 3 B-Disease
)	182 1 O
is	184 2 O
the	187 3 O
commonest	191 9 O
drug	201 4 O
-	205 1 O
induced	206 7 O
ALF	214 3 B-Disease
in	218 2 O
South	221 5 O
Asia	227 4 O
.	231 1 O

Prospective	233 11 O
studies	245 7 O
on	253 2 O
ATT	256 3 O
-	259 1 O
ALF	260 3 B-Disease
are	264 3 O
lacking	268 7 O
.	275 1 O

The	277 3 O
current	281 7 O
study	289 5 O
prospectively	295 13 O
evaluated	309 9 O
the	319 3 O
magnitude	323 9 O
,	332 1 O
clinical	334 8 O
course	343 6 O
,	349 1 O
outcome	351 7 O
,	358 1 O
and	360 3 O
prognostic	364 10 O
factors	375 7 O
in	383 2 O
ATT	386 3 O
-	389 1 O
ALF	390 3 B-Disease
.	393 1 O

From	395 4 O
January	400 7 O
1986	408 4 O
to	413 2 O
January	416 7 O
2009	424 4 O
,	428 1 O
1223	430 4 O
consecutive	435 11 O
ALF	447 3 B-Disease
patients	451 8 O
were	460 4 O
evaluated	465 9 O
:	474 1 O
ATT	476 3 O
alone	480 5 O
was	486 3 O
the	490 3 O
cause	494 5 O
in	500 2 O
70	503 2 O
(	506 1 O
5	507 1 O
.	508 1 O
7	509 1 O
%	510 1 O
)	511 1 O
patients	513 8 O
.	521 1 O

Another	523 7 O
15	531 2 O
(	534 1 O
1	535 1 O
.	536 1 O
2	537 1 O
%	538 1 O
)	539 1 O
had	541 3 O
ATT	545 3 O
and	549 3 O
simultaneous	553 12 O
hepatitis	566 9 B-Disease
virus	576 5 I-Disease
infection	582 9 I-Disease
.	591 1 O

In	593 2 O
44	596 2 O
(	599 1 O
62	600 2 O
.	602 1 O
8	603 1 O
%	604 1 O
)	605 1 O
patients	607 8 O
,	615 1 O
ATT	617 3 O
was	621 3 O
prescribed	625 10 O
empirically	636 11 O
without	648 7 O
definitive	656 10 O
evidence	667 8 O
of	676 2 O
tuberculosis	679 12 B-Disease
.	691 1 O

ATT	693 3 O
-	696 1 O
ALF	697 3 B-Disease
patients	701 8 O
were	710 4 O
younger	715 7 O
(	723 1 O
32	724 2 O
.	726 1 O
87	727 2 O
[	730 1 O
+	731 1 O
/	732 1 O
-	733 1 O
15	734 2 O
.	736 1 O
8	737 1 O
]	738 1 O
years	740 5 O
)	745 1 O
,	746 1 O
and	748 3 O
49	752 2 O
(	755 1 O
70	756 2 O
%	758 1 O
)	759 1 O
of	761 2 O
them	764 4 O
were	769 4 O
women	774 5 O
.	779 1 O

Most	781 4 O
had	786 3 O
hyperacute	790 10 O
presentation	801 12 O
;	813 1 O
the	815 3 O
median	819 6 O
icterus	826 7 B-Disease
encephalopathy	834 14 B-Disease
interval	849 8 O
was	858 3 O
4	862 1 O
.	863 1 O
5	864 1 O
(	866 1 O
0	867 1 O
-	868 1 O
30	869 2 O
)	871 1 O
days	873 4 O
.	877 1 O

The	879 3 O
median	883 6 O
duration	890 8 O
of	899 2 O
ATT	902 3 O
before	906 6 O
ALF	913 3 B-Disease
was	917 3 O
30	921 2 O
(	924 1 O
7	925 1 O
-	926 1 O
350	927 3 O
)	930 1 O
days	932 4 O
.	936 1 O

At	938 2 O
presentation	941 12 O
,	953 1 O
advanced	955 8 O
encephalopathy	964 14 B-Disease
and	979 3 O
cerebral	983 8 B-Disease
edema	992 5 I-Disease
were	998 4 O
present	1003 7 O
in	1011 2 O
51	1014 2 O
(	1017 1 O
76	1018 2 O
%	1020 1 O
)	1021 1 O
and	1023 3 O
29	1027 2 O
(	1030 1 O
41	1031 2 O
.	1033 1 O
4	1034 1 O
%	1035 1 O
)	1036 1 O
patients	1038 8 O
,	1046 1 O
respectively	1048 12 O
.	1060 1 O

Gastrointestinal	1062 16 B-Disease
bleed	1079 5 I-Disease
,	1084 1 O
seizures	1086 8 B-Disease
,	1094 1 O
infection	1096 9 B-Disease
,	1105 1 O
and	1107 3 O
acute	1111 5 B-Disease
renal	1117 5 I-Disease
failure	1123 7 I-Disease
were	1131 4 O
documented	1136 10 O
in	1147 2 O
seven	1150 5 O
(	1156 1 O
10	1157 2 O
%	1159 1 O
)	1160 1 O
,	1161 1 O
five	1163 4 O
(	1168 1 O
7	1169 1 O
.	1170 1 O
1	1171 1 O
%	1172 1 O
)	1173 1 O
,	1174 1 O
26	1176 2 O
(	1179 1 O
37	1180 2 O
.	1182 1 O
1	1183 1 O
%	1184 1 O
)	1185 1 O
,	1186 1 O
and	1188 3 O
seven	1192 5 O
(	1198 1 O
10	1199 2 O
%	1201 1 O
)	1202 1 O
patients	1204 8 O
,	1212 1 O
respectively	1214 12 O
.	1226 1 O

Compared	1228 8 O
with	1237 4 O
hepatitis	1242 9 B-Disease
E	1252 1 I-Disease
virus	1254 5 O
(	1260 1 O
HEV	1261 3 O
)	1264 1 O
and	1266 3 O
non	1270 3 O
-	1273 1 O
A	1274 1 O
non	1276 3 O
-	1279 1 O
E	1280 1 O
-	1281 1 O
induced	1282 7 O
ALF	1290 3 B-Disease
,	1293 1 O
ATT	1295 3 O
-	1298 1 O
ALF	1299 3 B-Disease
patients	1303 8 O
had	1312 3 O
nearly	1316 6 O
similar	1323 7 O
presentations	1331 13 O
except	1345 6 O
for	1352 3 O
older	1356 5 O
age	1362 3 O
and	1366 3 O
less	1370 4 O
elevation	1375 9 O
of	1385 2 O
liver	1388 5 O
enzymes	1394 7 O
.	1401 1 O

The	1403 3 O
mortality	1407 9 O
rate	1417 4 O
among	1422 5 O
patients	1428 8 O
with	1437 4 O
ATT	1442 3 O
-	1445 1 O
ALF	1446 3 B-Disease
was	1450 3 O
high	1454 4 O
(	1459 1 O
67	1460 2 O
.	1462 1 O
1	1463 1 O
%	1464 1 O
,	1465 1 O
n	1467 1 O
=	1469 1 O
47	1471 2 O
)	1473 1 O
,	1474 1 O
and	1476 3 O
only	1480 4 O
23	1485 2 O
(	1488 1 O
32	1489 2 O
.	1491 1 O
9	1492 1 O
%	1493 1 O
)	1494 1 O
patients	1496 8 O
recovered	1505 9 O
with	1515 4 O
medical	1520 7 O
treatment	1528 9 O
.	1537 1 O

In	1539 2 O
multivariate	1542 12 O
analysis	1555 8 O
,	1563 1 O
three	1565 5 O
factors	1571 7 O
independently	1579 13 O
predicted	1593 9 O
mortality	1603 9 O
:	1612 1 O
serum	1614 5 O
bilirubin	1620 9 B-Chemical
(	1630 1 O
>	1631 1 O
or	1632 2 O
=	1634 1 O
10	1635 2 O
.	1637 1 O
8	1638 1 O
mg	1640 2 O
/	1642 1 O
dL	1643 2 O
)	1645 1 O
,	1646 1 O
prothrombin	1648 11 O
time	1660 4 O
(	1665 1 O
PT	1666 2 O
)	1668 1 O
prolongation	1670 12 O
(	1683 1 O
>	1684 1 O
or	1685 2 O
=	1687 1 O
26	1688 2 O
seconds	1691 7 O
)	1698 1 O
,	1699 1 O
and	1701 3 O
grade	1705 5 O
III	1711 3 O
/	1714 1 O
IV	1715 2 O
encephalopathy	1718 14 B-Disease
at	1733 2 O
presentation	1736 12 O
.	1748 1 O

CONCLUSION	1750 10 O
:	1760 1 O
ATT	1762 3 O
-	1765 1 O
ALF	1766 3 B-Disease
constituted	1770 11 O
5	1782 1 O
.	1783 1 O
7	1784 1 O
%	1785 1 O
of	1787 2 O
ALF	1790 3 B-Disease
at	1794 2 O
our	1797 3 O
center	1801 6 O
and	1808 3 O
had	1812 3 O
a	1816 1 O
high	1818 4 O
mortality	1823 9 O
rate	1833 4 O
.	1837 1 O

Because	1839 7 O
the	1847 3 O
mortality	1851 9 O
rate	1861 4 O
is	1866 2 O
so	1869 2 O
high	1872 4 O
,	1876 1 O
determining	1878 11 O
which	1890 5 O
factors	1896 7 O
are	1904 3 O
predictors	1908 10 O
is	1919 2 O
less	1922 4 O
important	1927 9 O
.	1936 1 O

A	1938 1 O
high	1940 4 O
proportion	1945 10 O
of	1956 2 O
patients	1959 8 O
had	1968 3 O
consumed	1972 8 O
ATT	1981 3 O
empirically	1985 11 O
,	1996 1 O
which	1998 5 O
could	2004 5 O
have	2010 4 O
been	2015 4 O
prevented	2020 9 O
.	2029 1 O

Central	0 7 B-Disease
nervous	8 7 I-Disease
system	16 6 I-Disease
complications	23 13 I-Disease
during	37 6 O
treatment	44 9 O
of	54 2 O
acute	57 5 B-Disease
lymphoblastic	63 13 I-Disease
leukemia	77 8 I-Disease
in	86 2 O
a	89 1 O
single	91 6 O
pediatric	98 9 O
institution	108 11 O
.	119 1 O

Central	121 7 B-Disease
nervous	129 7 I-Disease
system	137 6 I-Disease
(	144 1 I-Disease
CNS	145 3 I-Disease
)	148 1 I-Disease
complications	150 13 I-Disease
during	164 6 O
treatment	171 9 O
of	181 2 O
childhood	184 9 O
acute	194 5 B-Disease
lymphoblastic	200 13 I-Disease
leukemia	214 8 I-Disease
(	223 1 O
ALL	224 3 B-Disease
)	227 1 O
remain	229 6 O
a	236 1 O
challenging	238 11 O
clinical	250 8 O
problem	259 7 O
.	266 1 O

Outcome	268 7 O
improvement	276 11 O
with	288 4 O
more	293 4 O
intensive	298 9 O
chemotherapy	308 12 O
has	321 3 O
significantly	325 13 O
increased	339 9 O
the	349 3 O
incidence	353 9 O
and	363 3 O
severity	367 8 O
of	376 2 O
adverse	379 7 O
events	387 6 O
.	393 1 O

This	395 4 O
study	400 5 O
analyzed	406 8 O
the	415 3 O
incidence	419 9 O
of	429 2 O
neurological	432 12 B-Disease
complications	445 13 I-Disease
during	459 6 O
ALL	466 3 B-Disease
treatment	470 9 O
in	480 2 O
a	483 1 O
single	485 6 O
pediatric	492 9 O
institution	502 11 O
,	513 1 O
focusing	515 8 O
on	524 2 O
clinical	527 8 O
,	535 1 O
radiological	537 12 O
,	549 1 O
and	551 3 O
electrophysiological	555 20 O
findings	576 8 O
.	584 1 O

Exclusion	586 9 O
criteria	596 8 O
included	605 8 O
CNS	614 3 O
leukemic	618 8 B-Disease
infiltration	627 12 I-Disease
at	640 2 O
diagnosis	643 9 O
,	652 1 O
therapy	654 7 O
-	661 1 O
related	662 7 O
peripheral	670 10 B-Disease
neuropathy	681 10 I-Disease
,	691 1 O
late	693 4 O
-	697 1 O
onset	698 5 O
encephalopathy	704 14 B-Disease
,	718 1 O
or	720 2 O
long	723 4 O
-	727 1 O
term	728 4 O
neurocognitive	733 14 B-Disease
defects	748 7 I-Disease
.	755 1 O

During	757 6 O
a	764 1 O
9	766 1 O
-	767 1 O
year	768 4 O
period	773 6 O
,	779 1 O
we	781 2 O
retrospectively	784 15 O
collected	800 9 O
27	810 2 O
neurological	813 12 O
events	826 6 O
(	833 1 O
11	834 2 O
%	836 1 O
)	837 1 O
in	839 2 O
as	842 2 O
many	845 4 O
patients	850 8 O
,	858 1 O
from	860 4 O
253	865 3 O
children	869 8 O
enrolled	878 8 O
in	887 2 O
the	890 3 O
ALL	894 3 B-Disease
front	898 5 O
-	903 1 O
line	904 4 O
protocol	909 8 O
.	917 1 O

CNS	919 3 O
complications	923 13 O
included	937 8 O
posterior	946 9 O
reversible	956 10 O
leukoencephalopathy	967 19 B-Disease
syndrome	987 8 O
(	996 1 O
n	997 1 O
=	999 1 O
10	1001 2 O
)	1003 1 O
,	1004 1 O
stroke	1006 6 B-Disease
(	1013 1 O
n	1014 1 O
=	1016 1 O
5	1018 1 O
)	1019 1 O
,	1020 1 O
temporal	1022 8 B-Disease
lobe	1031 4 I-Disease
epilepsy	1036 8 I-Disease
(	1045 1 O
n	1046 1 O
=	1048 1 O
2	1050 1 O
)	1051 1 O
,	1052 1 O
high	1054 4 O
-	1058 1 O
dose	1059 4 O
methotrexate	1064 12 B-Chemical
toxicity	1077 8 B-Disease
(	1086 1 O
n	1087 1 O
=	1089 1 O
2	1091 1 O
)	1092 1 O
,	1093 1 O
syndrome	1095 8 O
of	1104 2 O
inappropriate	1107 13 B-Disease
antidiuretic	1121 12 I-Disease
hormone	1134 7 I-Disease
secretion	1142 9 I-Disease
(	1152 1 O
n	1153 1 O
=	1155 1 O
1	1157 1 O
)	1158 1 O
,	1159 1 O
and	1161 3 O
other	1165 5 O
unclassified	1171 12 O
events	1184 6 O
(	1191 1 O
n	1192 1 O
=	1194 1 O
7	1196 1 O
)	1197 1 O
.	1198 1 O

In	1200 2 O
conclusion	1203 10 O
,	1213 1 O
CNS	1215 3 O
complications	1219 13 O
are	1233 3 O
frequent	1237 8 O
events	1246 6 O
during	1253 6 O
ALL	1260 3 B-Disease
therapy	1264 7 O
,	1271 1 O
and	1273 3 O
require	1277 7 O
rapid	1285 5 O
detection	1291 9 O
and	1301 3 O
prompt	1305 6 O
treatment	1312 9 O
to	1322 2 O
limit	1325 5 O
permanent	1331 9 O
damage	1341 6 O
.	1347 1 O

Safety	0 6 O
of	7 2 O
capecitabine	10 12 B-Chemical
:	22 1 O
a	24 1 O
review	26 6 O
.	32 1 O

IMPORTANCE	34 10 O
OF	45 2 O
THE	48 3 O
FIELD	52 5 O
:	57 1 O
Fluoropyrimidines	59 17 B-Chemical
,	76 1 O
in	78 2 O
particular	81 10 O
5	92 1 B-Chemical
-	93 1 I-Chemical
fluorouracil	94 12 I-Chemical
(	107 1 O
5	108 1 B-Chemical
-	109 1 I-Chemical
FU	110 2 I-Chemical
)	112 1 O
,	113 1 O
have	115 4 O
been	120 4 O
the	125 3 O
mainstay	129 8 O
of	138 2 O
treatment	141 9 O
for	151 3 O
several	155 7 O
solid	163 5 O
tumors	169 6 B-Disease
,	175 1 O
including	177 9 O
colorectal	187 10 B-Disease
,	197 1 I-Disease
breast	199 6 I-Disease
and	206 3 I-Disease
head	210 4 I-Disease
and	215 3 I-Disease
neck	219 4 I-Disease
cancers	224 7 I-Disease
,	231 1 O
for	233 3 O
>	237 1 O
40	239 2 O
years	242 5 O
.	247 1 O

AREAS	249 5 O
COVERED	255 7 O
IN	263 2 O
THIS	266 4 O
REVIEW	271 6 O
:	277 1 O
This	279 4 O
article	284 7 O
reviews	292 7 O
the	300 3 O
pharmacology	304 12 O
and	317 3 O
efficacy	321 8 O
of	330 2 O
capecitabine	333 12 B-Chemical
with	346 4 O
a	351 1 O
special	353 7 O
emphasis	361 8 O
on	370 2 O
its	373 3 O
safety	377 6 O
.	383 1 O

WHAT	385 4 O
THE	390 3 O
READER	394 6 O
WILL	401 4 O
GAIN	406 4 O
:	410 1 O
The	412 3 O
reader	416 6 O
will	423 4 O
gain	428 4 O
better	433 6 O
insight	440 7 O
into	448 4 O
the	453 3 O
safety	457 6 O
of	464 2 O
capecitabine	467 12 B-Chemical
in	480 2 O
special	483 7 O
populations	491 11 O
such	503 4 O
as	508 2 O
patients	511 8 O
with	520 4 O
advanced	525 8 O
age	534 3 O
,	537 1 O
renal	539 5 B-Disease
and	545 3 I-Disease
kidney	549 6 I-Disease
disease	556 7 I-Disease
.	563 1 O

We	565 2 O
also	568 4 O
explore	573 7 O
different	581 9 O
dosing	591 6 O
and	598 3 O
schedules	602 9 O
of	612 2 O
capecitabine	615 12 B-Chemical
administration	628 14 O
.	642 1 O

TAKE	644 4 O
HOME	649 4 O
MESSAGE	654 7 O
:	661 1 O
Capecitabine	663 12 B-Chemical
is	676 2 O
an	679 2 O
oral	682 4 O
prodrug	687 7 O
of	695 2 O
5	698 1 B-Chemical
-	699 1 I-Chemical
FU	700 2 I-Chemical
and	703 3 O
was	707 3 O
developed	711 9 O
to	721 2 O
fulfill	724 7 O
the	732 3 O
need	736 4 O
for	741 3 O
a	745 1 O
more	747 4 O
convenient	752 10 O
therapy	763 7 O
and	771 3 O
provide	775 7 O
an	783 2 O
improved	786 8 O
safety	795 6 O
/	801 1 O
efficacy	802 8 O
profile	811 7 O
.	818 1 O

It	820 2 O
has	823 3 O
shown	827 5 O
promising	833 9 O
results	843 7 O
alone	851 5 O
or	857 2 O
in	860 2 O
combination	863 11 O
with	875 4 O
other	880 5 O
chemotherapeutic	886 16 O
agents	903 6 O
in	910 2 O
colorectal	913 10 B-Disease
,	923 1 I-Disease
breast	925 6 I-Disease
,	931 1 I-Disease
pancreaticobiliary	933 18 I-Disease
,	951 1 I-Disease
gastric	953 7 I-Disease
,	960 1 I-Disease
renal	962 5 I-Disease
cell	968 4 I-Disease
and	973 3 I-Disease
head	977 4 I-Disease
and	982 3 I-Disease
neck	986 4 I-Disease
cancers	991 7 I-Disease
.	998 1 O

The	1000 3 O
most	1004 4 O
commonly	1009 8 O
reported	1018 8 O
toxic	1027 5 O
effects	1033 7 O
of	1041 2 O
capecitabine	1044 12 B-Chemical
are	1057 3 O
diarrhea	1061 8 B-Disease
,	1069 1 O
nausea	1071 6 B-Disease
,	1077 1 O
vomiting	1079 8 B-Disease
,	1087 1 O
stomatitis	1089 10 B-Disease
and	1100 3 O
hand	1104 4 B-Disease
-	1108 1 I-Disease
foot	1109 4 I-Disease
syndrome	1114 8 I-Disease
.	1122 1 O

Capecitabine	1124 12 B-Chemical
has	1137 3 O
a	1141 1 O
well	1143 4 O
-	1147 1 O
established	1148 11 O
safety	1160 6 O
profile	1167 7 O
and	1175 3 O
can	1179 3 O
be	1183 2 O
given	1186 5 O
safely	1192 6 O
to	1199 2 O
patients	1202 8 O
with	1211 4 O
advanced	1216 8 O
age	1225 3 O
,	1228 1 O
hepatic	1230 7 B-Disease
and	1238 3 I-Disease
renal	1242 5 I-Disease
dysfunctions	1248 12 I-Disease
.	1260 1 O

Effects	0 7 O
of	8 2 O
pallidal	11 8 O
neurotensin	20 11 B-Chemical
on	32 2 O
haloperidol	35 11 B-Chemical
-	46 1 O
induced	47 7 O
parkinsonian	55 12 B-Disease
catalepsy	68 9 I-Disease
:	77 1 O
behavioral	79 10 O
and	90 3 O
electrophysiological	94 20 O
studies	115 7 O
.	122 1 O

OBJECTIVE	124 9 O
:	133 1 O
The	135 3 O
globus	139 6 O
pallidus	146 8 O
plays	155 5 O
a	161 1 O
critical	163 8 O
role	172 4 O
in	177 2 O
movement	180 8 O
regulation	189 10 O
.	199 1 O

Previous	201 8 O
studies	210 7 O
have	218 4 O
indicated	223 9 O
that	233 4 O
the	238 3 O
globus	242 6 O
pallidus	249 8 O
receives	258 8 O
neurotensinergic	267 16 O
innervation	284 11 O
from	296 4 O
the	301 3 O
striatum	305 8 O
,	313 1 O
and	315 3 O
systemic	319 8 O
administration	328 14 O
of	343 2 O
a	346 1 O
neurotensin	348 11 B-Chemical
analog	360 6 O
could	367 5 O
produce	373 7 O
antiparkinsonian	381 16 O
effects	398 7 O
.	405 1 O

The	407 3 O
present	411 7 O
study	419 5 O
aimed	425 5 O
to	431 2 O
investigate	434 11 O
the	446 3 O
effects	450 7 O
of	458 2 O
pallidal	461 8 O
neurotensin	470 11 B-Chemical
on	482 2 O
haloperidol	485 11 B-Chemical
-	496 1 O
induced	497 7 O
parkinsonian	505 12 B-Disease
symptoms	518 8 I-Disease
.	526 1 O

METHODS	528 7 O
:	535 1 O
Behavioral	537 10 O
experiments	548 11 O
and	560 3 O
electrophysiological	564 20 O
recordings	585 10 O
were	596 4 O
performed	601 9 O
in	611 2 O
the	614 3 O
present	618 7 O
study	626 5 O
.	631 1 O

RESULTS	633 7 O
:	640 1 O
Bilateral	642 9 O
infusions	652 9 O
of	662 2 O
neurotensin	665 11 B-Chemical
into	677 4 O
the	682 3 O
globus	686 6 O
pallidus	693 8 O
reversed	702 8 O
haloperidol	711 11 B-Chemical
-	722 1 O
induced	723 7 O
parkinsonian	731 12 B-Disease
catalepsy	744 9 I-Disease
in	754 2 O
rats	757 4 O
.	761 1 O

Electrophysiological	763 20 O
recordings	784 10 O
showed	795 6 O
that	802 4 O
microinjection	807 14 O
of	822 2 O
neurotensin	825 11 B-Chemical
induced	837 7 O
excitation	845 10 O
of	856 2 O
pallidal	859 8 O
neurons	868 7 O
in	876 2 O
the	879 3 O
presence	883 8 O
of	892 2 O
systemic	895 8 O
haloperidol	904 11 B-Chemical
administration	916 14 O
.	930 1 O

The	932 3 O
neurotensin	936 11 B-Chemical
type	948 4 I-Chemical
-	952 1 I-Chemical
1	953 1 I-Chemical
receptor	955 8 I-Chemical
antagonist	964 10 I-Chemical
SR48692	975 7 B-Chemical
blocked	983 7 O
both	991 4 O
the	996 3 O
behavioral	1000 10 O
and	1011 3 O
the	1015 3 O
electrophysiological	1019 20 O
effects	1040 7 O
induced	1048 7 O
by	1056 2 O
neurotensin	1059 11 B-Chemical
.	1070 1 O

CONCLUSION	1072 10 O
:	1082 1 O
Activation	1084 10 O
of	1095 2 O
pallidal	1098 8 O
neurotensin	1107 11 B-Chemical
receptors	1119 9 O
may	1129 3 O
be	1133 2 O
involved	1136 8 O
in	1145 2 O
neurotensin	1148 11 B-Chemical
-	1159 1 O
induced	1160 7 O
antiparkinsonian	1168 16 O
effects	1185 7 O
.	1192 1 O

Antihypertensive	0 16 O
drugs	17 5 O
and	23 3 O
depression	27 10 B-Disease
:	37 1 O
a	39 1 O
reappraisal	41 11 O
.	52 1 O

Eighty	54 6 O
-	60 1 O
nine	61 4 O
new	66 3 O
referral	70 8 O
hypertensive	79 12 B-Disease
out	92 3 O
-	95 1 O
patients	96 8 O
and	105 3 O
46	109 2 O
new	112 3 O
referral	116 8 O
non	125 3 O
-	128 1 O
hypertensive	129 12 B-Disease
chronically	142 11 O
physically	154 10 O
ill	165 3 O
out	169 3 O
-	172 1 O
patients	173 8 O
completed	182 9 O
a	192 1 O
mood	194 4 O
rating	199 6 O
scale	206 5 O
at	212 2 O
regular	215 7 O
intervals	223 9 O
for	233 3 O
one	237 3 O
year	241 4 O
.	245 1 O

The	247 3 O
results	251 7 O
showed	259 6 O
a	266 1 O
high	268 4 O
prevalence	273 10 O
of	284 2 O
depression	287 10 B-Disease
in	298 2 O
both	301 4 O
groups	306 6 O
of	313 2 O
patients	316 8 O
,	324 1 O
with	326 4 O
no	331 2 O
preponderance	334 13 O
in	348 2 O
the	351 3 O
hypertensive	355 12 B-Disease
group	368 5 O
.	373 1 O

Hypertensive	375 12 B-Disease
patients	388 8 O
with	397 4 O
psychiatric	402 11 B-Disease
histories	414 9 O
had	424 3 O
a	428 1 O
higher	430 6 O
prevalence	437 10 O
of	448 2 O
depression	451 10 B-Disease
than	462 4 O
the	467 3 O
comparison	471 10 O
patients	482 8 O
.	490 1 O

This	492 4 O
was	497 3 O
accounted	501 9 O
for	511 3 O
by	515 2 O
a	518 1 O
significant	520 11 O
number	532 6 O
of	539 2 O
depressions	542 11 B-Disease
occurring	554 9 O
in	564 2 O
methyl	567 6 B-Chemical
dopa	574 4 I-Chemical
treated	579 7 O
patients	587 8 O
with	596 4 O
psychiatric	601 11 B-Disease
histories	613 9 O
.	622 1 O

Pulmonary	0 9 O
shunt	10 5 O
and	16 3 O
cardiovascular	20 14 O
responses	35 9 O
to	45 2 O
CPAP	48 4 O
during	53 6 O
nitroprusside	60 13 B-Chemical
-	73 1 O
induced	74 7 O
hypotension	82 11 B-Disease
.	93 1 O

The	95 3 O
effects	99 7 O
of	107 2 O
continuous	110 10 O
positive	121 8 O
airway	130 6 O
pressure	137 8 O
(	146 1 O
CPAP	147 4 O
)	151 1 O
on	153 2 O
cardiovascular	156 14 O
dynamics	171 8 O
and	180 3 O
pulmonary	184 9 O
shunt	194 5 O
(	200 1 O
QS	201 2 O
/	203 1 O
QT	204 2 O
)	206 1 O
were	208 4 O
investigated	213 12 O
in	226 2 O
12	229 2 O
dogs	232 4 O
before	237 6 O
and	244 3 O
during	248 6 O
sodium	255 6 B-Chemical
nitroprusside	262 13 I-Chemical
infusion	276 8 O
that	285 4 O
decreased	290 9 O
mean	300 4 O
arterial	305 8 O
blood	314 5 O
pressure	320 8 O
40	329 2 O
-	331 1 O
50	332 2 O
per	335 3 O
cent	339 4 O
.	343 1 O

Before	345 6 O
nitroprusside	352 13 B-Chemical
infusion	366 8 O
,	374 1 O
5	376 1 O
cm	378 2 O
H2O	381 3 B-Chemical
CPAP	385 4 O
significantly	390 13 O
,	403 1 O
P	405 1 O
less	407 4 O
than	412 4 O
.	417 1 O
05	418 2 O
,	420 1 O
decreased	422 9 O
arterial	432 8 O
blood	441 5 O
pressure	447 8 O
,	455 1 O
but	457 3 O
did	461 3 O
not	465 3 O
significantly	469 13 O
alter	483 5 O
heart	489 5 O
rate	495 4 O
,	499 1 O
cardiac	501 7 O
output	509 6 O
,	515 1 O
systemic	517 8 O
vascular	526 8 O
resistance	535 10 O
,	545 1 O
or	547 2 O
QS	550 2 O
/	552 1 O
QT	553 2 O
.	555 1 O

Ten	557 3 O
cm	561 2 O
H2O	564 3 B-Chemical
CPAP	568 4 O
before	573 6 O
nitroprusside	580 13 B-Chemical
infusion	594 8 O
produced	603 8 O
a	612 1 O
further	614 7 O
decrease	622 8 B-Disease
in	631 2 I-Disease
arterial	634 8 I-Disease
blood	643 5 I-Disease
pressure	649 8 I-Disease
and	658 3 O
significantly	662 13 O
increased	676 9 O
heart	686 5 O
rate	692 4 O
and	697 3 O
decreased	701 9 B-Disease
cardiac	711 7 I-Disease
output	719 6 I-Disease
and	726 3 O
QS	730 2 O
/	732 1 O
QT	733 2 O
.	735 1 O

Nitroprusside	737 13 B-Chemical
caused	751 6 O
significant	758 11 O
decreases	770 9 B-Disease
in	780 2 I-Disease
arterial	783 8 I-Disease
blood	792 5 I-Disease
pressure	798 8 I-Disease
and	807 3 O
systemic	811 8 O
vascular	820 8 O
resistance	829 10 O
and	840 3 O
increases	844 9 O
in	854 2 O
heart	857 5 O
rate	863 4 O
,	867 1 O
but	869 3 O
did	873 3 O
not	877 3 O
change	881 6 O
cardiac	888 7 O
output	896 6 O
or	903 2 O
QS	906 2 O
/	908 1 O
QT	909 2 O
.	911 1 O

Five	913 4 O
cm	918 2 O
H2O	921 3 B-Chemical
CPAP	925 4 O
during	930 6 O
nitroprusside	937 13 B-Chemical
did	951 3 O
not	955 3 O
further	959 7 O
alter	967 5 O
any	973 3 O
of	977 2 O
the	980 3 O
above	984 5 O
-	989 1 O
mentioned	990 9 O
variables	1000 9 O
.	1009 1 O

However	1011 7 O
,	1018 1 O
10	1020 2 O
cm	1023 2 O
H2O	1026 3 B-Chemical
CPAP	1030 4 O
decreased	1035 9 O
arterial	1045 8 O
blood	1054 5 O
pressure	1060 8 O
,	1068 1 O
cardiac	1070 7 O
output	1078 6 O
,	1084 1 O
and	1086 3 O
QS	1090 2 O
/	1092 1 O
QT	1093 2 O
.	1095 1 O

These	1097 5 O
data	1103 4 O
indicate	1108 8 O
that	1117 4 O
nitroprusside	1122 13 B-Chemical
infusion	1136 8 O
rates	1145 5 O
that	1151 4 O
decrease	1156 8 O
mean	1165 4 O
arterial	1170 8 O
blood	1179 5 O
pressure	1185 8 O
by	1194 2 O
40	1197 2 O
-	1199 1 O
50	1200 2 O
per	1203 3 O
cent	1207 4 O
do	1212 2 O
not	1215 3 O
change	1219 6 O
cardiac	1226 7 O
output	1234 6 O
or	1241 2 O
QS	1244 2 O
/	1246 1 O
QT	1247 2 O
.	1249 1 O

During	1251 6 O
nitroprusside	1258 13 B-Chemical
infusion	1272 8 O
low	1281 3 O
levels	1285 6 O
of	1292 2 O
CPAP	1295 4 O
do	1300 2 O
not	1303 3 O
markedly	1307 8 O
alter	1316 5 O
cardiovascular	1322 14 O
dynamics	1337 8 O
,	1345 1 O
but	1347 3 O
high	1351 4 O
levels	1356 6 O
of	1363 2 O
CPAP	1366 4 O
(	1371 1 O
10	1372 2 O
cm	1375 2 O
H2O	1378 3 B-Chemical
)	1381 1 O
,	1382 1 O
while	1384 5 O
decreasing	1390 10 O
QS	1401 2 O
/	1403 1 O
QT	1404 2 O
,	1406 1 O
produce	1408 7 O
marked	1416 6 O
decreases	1423 9 B-Disease
in	1433 2 I-Disease
arterial	1436 8 I-Disease
blood	1445 5 I-Disease
pressure	1451 8 I-Disease
and	1460 3 I-Disease
cardiac	1464 7 I-Disease
output	1472 6 I-Disease
.	1478 1 O

Mediation	0 9 O
of	10 2 O
enhanced	13 8 O
reflex	22 6 O
vagal	29 5 O
bradycardia	35 11 B-Disease
by	47 2 O
L	50 1 B-Chemical
-	51 1 I-Chemical
dopa	52 4 I-Chemical
via	57 3 O
central	61 7 O
dopamine	69 8 B-Chemical
formation	78 9 O
in	88 2 O
dogs	91 4 O
.	95 1 O

L	97 1 B-Chemical
-	98 1 I-Chemical
Dopa	99 4 I-Chemical
(	104 1 O
5	105 1 O
mg	107 2 O
/	109 1 O
kg	110 2 O
i	113 1 O
.	114 1 O
v	115 1 O
.	116 1 O
)	117 1 O
decreased	119 9 O
blood	129 5 O
pressure	135 8 O
and	144 3 O
heart	148 5 O
rate	154 4 O
after	159 5 O
extracerebral	165 13 O
decarboxylase	179 13 O
inhibition	193 10 O
with	204 4 O
MK	209 2 B-Chemical
-	211 1 I-Chemical
486	212 3 I-Chemical
(	216 1 O
25	217 2 O
mg	220 2 O
/	222 1 O
kg	223 2 O
i	226 1 O
.	227 1 O
v	228 1 O
.	229 1 O
)	230 1 O
in	232 2 O
anesthetize	235 11 O
MAO	247 3 B-Chemical
-	250 1 O
inhibited	251 9 O
dogs	261 4 O
.	265 1 O

In	267 2 O
addition	270 8 O
,	278 1 O
reflex	280 6 O
bradycardia	287 11 B-Disease
caused	299 6 O
by	306 2 O
injected	309 8 O
norepinephrine	318 14 B-Chemical
was	333 3 O
significantly	337 13 O
enhanced	351 8 O
by	360 2 O
L	363 1 B-Chemical
-	364 1 I-Chemical
dopa	365 4 I-Chemical
,	369 1 O
DL	371 2 B-Chemical
-	373 1 I-Chemical
Threo	374 5 I-Chemical
-	379 1 I-Chemical
dihydroxyphenylserine	380 21 I-Chemical
had	402 3 O
no	406 2 O
effect	409 6 O
on	416 2 O
blood	419 5 O
pressure	425 8 O
,	433 1 O
heart	435 5 O
rate	441 4 O
or	446 2 O
reflex	449 6 O
responses	456 9 O
to	466 2 O
norepinephrine	469 14 B-Chemical
.	483 1 O

FLA	485 3 B-Chemical
-	488 1 I-Chemical
63	489 2 I-Chemical
,	491 1 O
a	493 1 O
dopamine	495 8 B-Chemical
-	503 1 O
beta	504 4 O
-	508 1 O
oxidase	509 7 O
inhibitor	517 9 O
,	526 1 O
did	528 3 O
not	532 3 O
have	536 4 O
any	541 3 O
effect	545 6 O
on	552 2 O
the	555 3 O
hypotension	559 11 B-Disease
,	570 1 O
bradycardia	572 11 B-Disease
or	584 2 O
reflex	587 6 O
-	593 1 O
enhancing	594 9 O
effect	604 6 O
of	611 2 O
L	614 1 B-Chemical
-	615 1 I-Chemical
dopa	616 4 I-Chemical
.	620 1 O

Pimozide	622 8 B-Chemical
did	631 3 O
not	635 3 O
affect	639 6 O
the	646 3 O
actions	650 7 O
of	658 2 O
L	661 1 B-Chemical
-	662 1 I-Chemical
dopa	663 4 I-Chemical
on	668 2 O
blood	671 5 O
pressure	677 8 O
and	686 3 O
heart	690 5 O
rate	696 4 O
but	701 3 O
completely	705 10 O
blocked	716 7 O
the	724 3 O
enhancement	728 11 O
of	740 2 O
reflexes	743 8 O
.	751 1 O

Removal	753 7 O
of	761 2 O
the	764 3 O
carotid	768 7 O
sinuses	776 7 O
caused	784 6 O
an	791 2 O
elevation	794 9 O
blood	804 5 O
pressure	810 8 O
and	819 3 O
heart	823 5 O
rate	829 4 O
and	834 3 O
abolished	838 9 O
the	848 3 O
negative	852 8 O
chronotropic	861 12 O
effect	874 6 O
of	881 2 O
norepinephrine	884 14 B-Chemical
.	898 1 O

However	900 7 O
,	907 1 O
L	909 1 B-Chemical
-	910 1 I-Chemical
dopa	911 4 I-Chemical
restored	916 8 O
the	925 3 O
bradycardia	929 11 B-Disease
caused	941 6 O
by	948 2 O
norepinephrine	951 14 B-Chemical
in	966 2 O
addition	969 8 O
to	978 2 O
decreasing	981 10 O
blood	992 5 O
pressure	998 8 O
and	1007 3 O
heart	1011 5 O
rate	1017 4 O
.	1021 1 O

5	1023 1 B-Chemical
-	1024 1 I-Chemical
HTP	1025 3 I-Chemical
(	1029 1 O
5	1030 1 O
mg	1032 2 O
/	1034 1 O
kg	1035 2 O
i	1038 1 O
.	1039 1 O
v	1040 1 O
.	1041 1 O
)	1042 1 O
decreased	1044 9 O
blood	1054 5 O
pressure	1060 8 O
and	1069 3 O
heart	1073 5 O
rate	1079 4 O
and	1084 3 O
decreased	1088 9 O
the	1098 3 O
reflex	1102 6 O
bradycardia	1109 11 B-Disease
to	1121 2 O
norepinephrine	1124 14 B-Chemical
.	1138 1 O

It	1140 2 O
is	1143 2 O
concluded	1146 9 O
that	1156 4 O
L	1161 1 B-Chemical
-	1162 1 I-Chemical
dopa	1163 4 I-Chemical
enhances	1168 8 O
reflex	1177 6 O
bradycardia	1184 11 B-Disease
through	1196 7 O
central	1204 7 O
alpha	1212 5 O
-	1217 1 O
receptor	1218 8 O
stimulation	1227 11 O
.	1238 1 O

Furthermore	1240 11 O
,	1251 1 O
the	1253 3 O
effects	1257 7 O
are	1265 3 O
mediated	1269 8 O
through	1278 7 O
dopamine	1286 8 B-Chemical
rather	1295 6 O
than	1302 4 O
norepinephrine	1307 14 B-Chemical
and	1322 3 O
do	1326 2 O
not	1329 3 O
require	1333 7 O
the	1341 3 O
carotid	1345 7 O
sinus	1353 5 O
baroreceptors	1359 13 O
.	1372 1 O

Cocaine	0 7 B-Chemical
-	7 1 O
induced	8 7 O
myocardial	16 10 B-Disease
infarction	27 10 I-Disease
:	37 1 O
clinical	39 8 O
observations	48 12 O
and	61 3 O
pathogenetic	65 12 O
considerations	78 14 O
.	92 1 O

Clinical	94 8 O
and	103 3 O
experimental	107 12 O
data	120 4 O
published	125 9 O
to	135 2 O
date	138 4 O
suggest	143 7 O
several	151 7 O
possible	159 8 O
mechanisms	168 10 O
by	179 2 O
which	182 5 O
cocaine	188 7 B-Chemical
may	196 3 O
result	200 6 O
in	207 2 O
acute	210 5 B-Disease
myocardial	216 10 I-Disease
infarction	227 10 I-Disease
.	237 1 O

In	239 2 O
individuals	242 11 O
with	254 4 O
preexisting	259 11 O
,	270 1 O
high	272 4 O
-	276 1 O
grade	277 5 O
coronary	283 8 O
arterial	292 8 O
narrowing	301 9 O
,	310 1 O
acute	312 5 B-Disease
myocardial	318 10 I-Disease
infarction	329 10 I-Disease
may	340 3 O
result	344 6 O
from	351 4 O
an	356 2 O
increase	359 8 O
in	368 2 O
myocardial	371 10 O
oxygen	382 6 B-Chemical
demand	389 6 O
associated	396 10 O
with	407 4 O
cocaine	412 7 B-Chemical
-	419 1 O
induced	420 7 O
increase	428 8 O
in	437 2 O
rate	440 4 O
-	444 1 O
pressure	445 8 O
product	454 7 O
.	461 1 O

In	463 2 O
other	466 5 O
individuals	472 11 O
with	484 4 O
no	489 2 O
underlying	492 10 O
atherosclerotic	503 15 B-Disease
obstruction	519 11 I-Disease
,	530 1 O
coronary	532 8 B-Disease
occlusion	541 9 I-Disease
may	551 3 O
be	555 2 O
due	558 3 O
to	562 2 O
spasm	565 5 B-Disease
,	570 1 O
thrombus	572 8 B-Disease
,	580 1 O
or	582 2 O
both	585 4 O
.	589 1 O

With	591 4 O
regard	596 6 O
to	603 2 O
spasm	606 5 B-Disease
,	611 1 O
the	613 3 O
clinical	617 8 O
findings	626 8 O
are	635 3 O
largely	639 7 O
circumstantial	647 14 O
,	661 1 O
and	663 3 O
the	667 3 O
locus	671 5 O
of	677 2 O
cocaine	680 7 B-Chemical
-	687 1 O
induced	688 7 O
vasoconstriction	696 16 O
remains	713 7 O
speculative	721 11 O
.	732 1 O

Although	734 8 O
certain	743 7 O
clinical	751 8 O
and	760 3 O
experimental	764 12 O
findings	777 8 O
support	786 7 O
the	794 3 O
hypothesis	798 10 O
that	809 4 O
spasm	814 5 B-Disease
involves	820 8 O
the	829 3 O
epicardial	833 10 O
,	843 1 O
medium	845 6 O
-	851 1 O
size	852 4 O
vessels	857 7 O
,	864 1 O
other	866 5 O
data	872 4 O
suggest	877 7 O
intramural	885 10 O
vasoconstriction	896 16 O
.	912 1 O

Diffuse	914 7 O
intramural	922 10 O
vasoconstriction	933 16 O
is	950 2 O
not	953 3 O
consistent	957 10 O
with	968 4 O
reports	973 7 O
of	981 2 O
segmental	984 9 O
,	993 1 O
discrete	995 8 O
infarction	1004 10 B-Disease
.	1014 1 O

Whereas	1016 7 O
certain	1024 7 O
in	1032 2 O
vivo	1035 4 O
data	1040 4 O
suggest	1045 7 O
that	1053 4 O
these	1058 5 O
effects	1064 7 O
are	1072 3 O
alpha	1076 5 O
-	1081 1 O
mediated	1082 8 O
,	1090 1 O
other	1092 5 O
in	1098 2 O
vitro	1101 5 O
data	1107 4 O
suggest	1112 7 O
the	1120 3 O
opposite	1124 8 O
.	1132 1 O

The	1134 3 O
finding	1138 7 O
of	1146 2 O
cocaine	1149 7 B-Chemical
-	1156 1 O
induced	1157 7 O
vasoconstriction	1165 16 O
in	1182 2 O
segments	1185 8 O
of	1194 2 O
(	1197 1 O
noninnervated	1198 13 O
)	1211 1 O
human	1213 5 O
umbilical	1219 9 O
artery	1229 6 O
suggests	1236 8 O
that	1245 4 O
the	1250 3 O
presence	1254 8 O
or	1263 2 O
absence	1266 7 O
of	1274 2 O
intact	1277 6 O
innervation	1284 11 O
is	1296 2 O
not	1299 3 O
sufficient	1303 10 O
to	1314 2 O
explain	1317 7 O
the	1325 3 O
discrepant	1329 10 O
data	1340 4 O
involving	1345 9 O
the	1355 3 O
possibility	1359 11 O
of	1371 2 O
alpha	1374 5 O
-	1379 1 O
mediated	1380 8 O
effects	1389 7 O
.	1396 1 O

Finally	1398 7 O
,	1405 1 O
the	1407 3 O
contribution	1411 12 O
of	1424 2 O
a	1427 1 O
primary	1429 7 O
,	1436 1 O
thrombotic	1438 10 B-Disease
effect	1449 6 O
of	1456 2 O
cocaine	1459 7 B-Chemical
has	1467 3 O
not	1471 3 O
been	1475 4 O
excluded	1480 8 O
.	1488 1 O

Rabbit	0 6 B-Disease
syndrome	7 8 I-Disease
,	15 1 O
antidepressant	17 14 B-Chemical
use	32 3 O
,	35 1 O
and	37 3 O
cerebral	41 8 O
perfusion	50 9 O
SPECT	60 5 O
scan	66 4 O
findings	71 8 O
.	79 1 O

The	81 3 O
rabbit	85 6 B-Disease
syndrome	92 8 I-Disease
is	101 2 O
an	104 2 O
extrapyramidal	107 14 O
side	122 4 O
effect	127 6 O
associated	134 10 O
with	145 4 O
chronic	150 7 O
neuroleptic	158 11 O
therapy	170 7 O
.	177 1 O

Its	179 3 O
occurrence	183 10 O
in	194 2 O
a	197 1 O
patient	199 7 O
being	207 5 O
treated	213 7 O
with	221 4 O
imipramine	226 10 B-Chemical
is	237 2 O
described	240 9 O
,	249 1 O
representing	251 12 O
the	264 3 O
first	268 5 O
reported	274 8 O
case	283 4 O
of	288 2 O
this	291 4 O
syndrome	296 8 O
in	305 2 O
conjunction	308 11 O
with	320 4 O
antidepressants	325 15 B-Chemical
.	340 1 O

Repeated	342 8 O
cerebral	351 8 O
perfusion	360 9 O
SPECT	370 5 O
scans	376 5 O
revealed	382 8 O
decreased	391 9 B-Disease
basal	401 5 I-Disease
ganglia	407 7 I-Disease
perfusion	415 9 I-Disease
while	425 5 O
the	431 3 O
movement	435 8 B-Disease
disorder	444 8 I-Disease
was	453 3 O
present	457 7 O
,	464 1 O
and	466 3 O
a	470 1 O
return	472 6 O
to	479 2 O
normal	482 6 O
perfusion	489 9 O
when	499 4 O
the	504 3 O
rabbit	508 6 B-Disease
syndrome	515 8 I-Disease
resolved	524 8 O
.	532 1 O

Acute	0 5 O
bronchodilating	6 15 O
effects	22 7 O
of	30 2 O
ipratropium	33 11 B-Chemical
bromide	45 7 I-Chemical
and	53 3 O
theophylline	57 12 B-Chemical
in	70 2 O
chronic	73 7 B-Disease
obstructive	81 11 I-Disease
pulmonary	93 9 I-Disease
disease	103 7 I-Disease
.	110 1 O

The	112 3 O
bronchodilator	116 14 O
effects	131 7 O
of	139 2 O
a	142 1 O
single	144 6 O
dose	151 4 O
of	156 2 O
ipratropium	159 11 B-Chemical
bromide	171 7 I-Chemical
aerosol	179 7 O
(	187 1 O
36	188 2 O
micrograms	191 10 O
)	201 1 O
and	203 3 O
short	207 5 O
-	212 1 O
acting	213 6 O
theophylline	220 12 B-Chemical
tablets	233 7 O
(	241 1 O
dose	242 4 O
titrated	247 8 O
to	256 2 O
produce	259 7 O
serum	267 5 O
levels	273 6 O
of	280 2 O
10	283 2 O
-	285 1 O
20	286 2 O
micrograms	289 10 O
/	299 1 O
mL	300 2 O
)	302 1 O
were	304 4 O
compared	309 8 O
in	318 2 O
a	321 1 O
double	323 6 O
-	329 1 O
blind	330 5 O
,	335 1 O
placebo	337 7 O
-	344 1 O
controlled	345 10 O
crossover	356 9 O
study	366 5 O
in	372 2 O
21	375 2 O
patients	378 8 O
with	387 4 O
stable	392 6 O
,	398 1 O
chronic	400 7 B-Disease
obstructive	408 11 I-Disease
pulmonary	420 9 I-Disease
disease	430 7 I-Disease
.	437 1 O

Mean	439 4 O
peak	444 4 O
forced	449 6 O
expiratory	456 10 O
volume	467 6 O
in	474 2 O
1	477 1 O
second	479 6 O
(	486 1 O
FEV1	487 4 O
)	491 1 O
increases	493 9 O
over	503 4 O
baseline	508 8 O
and	517 3 O
the	521 3 O
proportion	525 10 O
of	536 2 O
patients	539 8 O
attaining	548 9 O
at	558 2 O
least	561 5 O
a	567 1 O
15	569 2 O
%	571 1 O
increase	573 8 O
in	582 2 O
the	585 3 O
FEV1	589 4 O
(	594 1 O
responders	595 10 O
)	605 1 O
were	607 4 O
31	612 2 O
%	614 1 O
and	616 3 O
90	620 2 O
%	622 1 O
,	623 1 O
respectively	625 12 O
,	637 1 O
for	639 3 O
ipratropium	643 11 B-Chemical
and	655 3 O
17	659 2 O
%	661 1 O
and	663 3 O
50	667 2 O
%	669 1 O
,	670 1 O
respectively	672 12 O
,	684 1 O
for	686 3 O
theophylline	690 12 B-Chemical
.	702 1 O

The	704 3 O
average	708 7 O
FEV1	716 4 O
increases	721 9 O
during	731 6 O
the	738 3 O
6	742 1 O
-	743 1 O
hour	744 4 O
observation	749 11 O
period	761 6 O
were	768 4 O
18	773 2 O
%	775 1 O
for	777 3 O
ipratropium	781 11 B-Chemical
and	793 3 O
8	797 1 O
%	798 1 O
for	800 3 O
theophylline	804 12 B-Chemical
.	816 1 O

The	818 3 O
mean	822 4 O
duration	827 8 O
of	836 2 O
action	839 6 O
was	846 3 O
3	850 1 O
.	851 1 O
8	852 1 O
hours	854 5 O
with	860 4 O
ipratropium	865 11 B-Chemical
and	877 3 O
2	881 1 O
.	882 1 O
4	883 1 O
hours	885 5 O
with	891 4 O
theophylline	896 12 B-Chemical
.	908 1 O

While	910 5 O
side	916 4 O
effects	921 7 O
were	929 4 O
rare	934 4 O
,	938 1 O
those	940 5 O
experienced	946 11 O
after	958 5 O
theophylline	964 12 B-Chemical
use	977 3 O
did	981 3 O
involve	985 7 O
the	993 3 O
cardiovascular	997 14 B-Disease
and	1012 3 I-Disease
gastrointestinal	1016 16 I-Disease
systems	1033 7 I-Disease
.	1040 1 O

These	1042 5 O
results	1048 7 O
show	1056 4 O
that	1061 4 O
ipratropium	1066 11 B-Chemical
is	1078 2 O
a	1081 1 O
more	1083 4 O
potent	1088 6 O
bronchodilator	1095 14 O
than	1110 4 O
oral	1115 4 O
theophylline	1120 12 B-Chemical
in	1133 2 O
patients	1136 8 O
with	1145 4 O
chronic	1150 7 B-Disease
airflow	1158 7 I-Disease
obstruction	1166 11 I-Disease
.	1177 1 O

Irreversible	0 12 O
damage	13 6 O
to	20 2 O
the	23 3 O
medullary	27 9 O
interstitium	37 12 O
in	50 2 O
experimental	53 12 O
analgesic	66 9 O
nephropathy	76 11 B-Disease
in	88 2 O
F344	91 4 O
rats	96 4 O
.	100 1 O

Renal	102 5 B-Disease
papillary	108 9 I-Disease
necrosis	118 8 I-Disease
(	127 1 O
RPN	128 3 B-Disease
)	131 1 O
and	133 3 O
a	137 1 O
decreased	139 9 O
urinary	149 7 O
concentrating	157 13 O
ability	171 7 O
developed	179 9 O
during	189 6 O
continuous	196 10 O
long	207 4 O
-	211 1 O
term	212 4 O
treatment	217 9 O
with	227 4 O
aspirin	232 7 B-Chemical
and	240 3 O
paracetamol	244 11 B-Chemical
in	256 2 O
female	259 6 O
Fischer	266 7 O
344	274 3 O
rats	278 4 O
.	282 1 O

Renal	284 5 O
structure	290 9 O
and	300 3 O
concentrating	304 13 O
ability	318 7 O
were	326 4 O
examined	331 8 O
after	340 5 O
a	346 1 O
recovery	348 8 O
period	357 6 O
of	364 2 O
up	367 2 O
to	370 2 O
18	373 2 O
weeks	376 5 O
,	381 1 O
when	383 4 O
no	388 2 O
analgesics	391 10 O
were	402 4 O
given	407 5 O
,	412 1 O
to	414 2 O
investigate	417 11 O
whether	429 7 O
the	437 3 O
analgesic	441 9 O
-	450 1 O
induced	451 7 O
changes	459 7 O
were	467 4 O
reversible	472 10 O
.	482 1 O

There	484 5 O
was	490 3 O
no	494 2 O
evidence	497 8 O
of	506 2 O
repair	509 6 O
to	516 2 O
the	519 3 O
damaged	523 7 O
medullary	531 9 O
interstitial	541 12 O
matrix	554 6 O
,	560 1 O
or	562 2 O
proliferation	565 13 O
of	579 2 O
remaining	582 9 O
undamaged	592 9 O
type	602 4 O
1	607 1 O
medullary	609 9 O
interstitial	619 12 O
cells	632 5 O
after	638 5 O
the	644 3 O
recovery	648 8 O
period	657 6 O
following	664 9 O
analgesic	674 9 O
treatment	684 9 O
.	693 1 O

The	695 3 O
recovery	699 8 O
of	708 2 O
urinary	711 7 O
concentrating	719 13 O
ability	733 7 O
was	741 3 O
related	745 7 O
to	753 2 O
the	756 3 O
length	760 6 O
of	767 2 O
analgesic	770 9 O
treatment	780 9 O
and	790 3 O
the	794 3 O
extent	798 6 O
of	805 2 O
the	808 3 O
resulting	812 9 O
inner	822 5 O
medullary	828 9 O
structural	838 10 O
damage	849 6 O
.	855 1 O

During	857 6 O
the	864 3 O
early	868 5 O
stages	874 6 O
of	881 2 O
analgesic	884 9 O
treatment	894 9 O
,	903 1 O
the	905 3 O
changes	909 7 O
in	917 2 O
urinary	920 7 O
concentrating	928 13 O
ability	942 7 O
were	950 4 O
reversible	955 10 O
,	965 1 O
but	967 3 O
after	971 5 O
prolonged	977 9 O
analgesic	987 9 O
treatment	997 9 O
,	1006 1 O
maximum	1008 7 O
urinary	1016 7 O
concentrating	1024 13 O
ability	1038 7 O
failed	1046 6 O
to	1053 2 O
recover	1056 7 O
.	1063 1 O

This	1065 4 O
study	1070 5 O
shows	1076 5 O
that	1082 4 O
prolonged	1087 9 O
analgesic	1097 9 O
treatment	1107 9 O
in	1117 2 O
Fischer	1120 7 O
344	1128 3 O
rats	1132 4 O
causes	1137 6 O
progressive	1144 11 O
and	1156 3 O
irreversible	1160 12 O
damage	1173 6 O
to	1180 2 O
the	1183 3 O
interstitial	1187 12 O
matrix	1200 6 O
and	1207 3 O
type	1211 4 O
1	1216 1 O
interstitial	1218 12 O
cells	1231 5 O
leading	1237 7 O
to	1245 2 O
RPN	1248 3 B-Disease
.	1251 1 O

The	1253 3 O
associated	1257 10 O
urinary	1268 7 O
concentrating	1276 13 O
defect	1290 6 O
is	1297 2 O
reversible	1300 10 O
only	1311 4 O
during	1316 6 O
the	1323 3 O
early	1327 5 O
stages	1333 6 O
of	1340 2 O
structural	1343 10 O
damage	1354 6 O
to	1361 2 O
the	1364 3 O
inner	1368 5 O
medulla	1374 7 O
.	1381 1 O

Less	0 4 O
frequent	5 8 O
lithium	14 7 B-Chemical
administration	22 14 O
and	37 3 O
lower	41 5 O
urine	47 5 O
volume	53 6 O
.	59 1 O

OBJECTIVE	61 9 O
:	70 1 O
This	72 4 O
study	77 5 O
was	83 3 O
designed	87 8 O
to	96 2 O
determine	99 9 O
whether	109 7 O
patients	117 8 O
maintained	126 10 O
on	137 2 O
a	140 1 O
regimen	142 7 O
of	150 2 O
lithium	153 7 B-Chemical
on	161 2 O
a	164 1 O
once	166 4 O
-	170 1 O
per	171 3 O
-	174 1 O
day	175 3 O
schedule	179 8 O
have	188 4 O
lower	193 5 O
urine	199 5 O
volumes	205 7 O
than	213 4 O
do	218 2 O
patients	221 8 O
receiving	230 9 O
multiple	240 8 O
doses	249 5 O
per	255 3 O
day	259 3 O
.	262 1 O

METHOD	264 6 O
:	270 1 O
This	272 4 O
was	277 3 O
a	281 1 O
cross	283 5 O
-	288 1 O
sectional	289 9 O
study	299 5 O
of	305 2 O
85	308 2 O
patients	311 8 O
from	320 4 O
a	325 1 O
lithium	327 7 B-Chemical
clinic	335 6 O
who	342 3 O
received	346 8 O
different	355 9 O
dose	365 4 O
schedules	370 9 O
.	379 1 O

Patients	381 8 O
were	390 4 O
admitted	395 8 O
to	404 2 O
the	407 3 O
hospital	411 8 O
for	420 3 O
measurement	424 11 O
of	436 2 O
lithium	439 7 B-Chemical
level	447 5 O
,	452 1 O
creatinine	454 10 B-Chemical
clearance	465 9 O
,	474 1 O
urine	476 5 O
volume	482 6 O
,	488 1 O
and	490 3 O
maximum	494 7 O
osmolality	502 10 O
.	512 1 O

RESULTS	514 7 O
:	521 1 O
Multiple	523 8 O
daily	532 5 O
doses	538 5 O
of	544 2 O
lithium	547 7 B-Chemical
were	555 4 O
associated	560 10 O
with	571 4 O
higher	576 6 O
urine	583 5 O
volumes	589 7 O
.	596 1 O

The	598 3 O
dosing	602 6 O
schedule	609 8 O
,	617 1 O
duration	619 8 O
of	628 2 O
lithium	631 7 B-Chemical
treatment	639 9 O
,	648 1 O
and	650 3 O
daily	654 5 O
dose	660 4 O
of	665 2 O
lithium	668 7 B-Chemical
did	676 3 O
not	680 3 O
affect	684 6 O
maximum	691 7 O
osmolality	699 10 O
or	710 2 O
creatinine	713 10 B-Chemical
clearance	724 9 O
.	733 1 O

CONCLUSIONS	735 11 O
:	746 1 O
Urine	748 5 O
volume	754 6 O
can	761 3 O
be	765 2 O
reduced	768 7 O
by	776 2 O
giving	779 6 O
lithium	786 7 B-Chemical
once	794 4 O
daily	799 5 O
and	805 3 O
/	808 1 O
or	809 2 O
by	812 2 O
lowering	815 8 O
the	824 3 O
total	828 5 O
daily	834 5 O
dose	840 4 O
.	844 1 O

Lithium	846 7 B-Chemical
-	853 1 O
induced	854 7 O
polyuria	862 8 B-Disease
seems	871 5 O
to	877 2 O
be	880 2 O
related	883 7 O
to	891 2 O
extrarenal	894 10 O
as	905 2 O
well	908 4 O
as	913 2 O
to	916 2 O
renal	919 5 O
effects	925 7 O
.	932 1 O

Effect	0 6 O
of	7 2 O
adriamycin	10 10 B-Chemical
combined	21 8 O
with	30 4 O
whole	35 5 O
body	41 4 O
hyperthermia	46 12 B-Disease
on	59 2 O
tumor	62 5 B-Disease
and	68 3 O
normal	72 6 O
tissues	79 7 O
.	86 1 O

Thermal	88 7 O
enhancement	96 11 O
of	108 2 O
Adriamycin	111 10 B-Chemical
-	121 1 O
mediated	122 8 O
antitumor	131 9 O
activity	141 8 O
and	150 3 O
normal	154 6 O
tissue	161 6 O
toxicities	168 10 B-Disease
by	179 2 O
whole	182 5 O
body	188 4 O
hyperthermia	193 12 B-Disease
were	206 4 O
compared	211 8 O
using	220 5 O
a	226 1 O
F344	228 4 O
rat	233 3 O
model	237 5 O
.	242 1 O

Antitumor	244 9 O
activity	254 8 O
was	263 3 O
studied	267 7 O
using	275 5 O
a	281 1 O
tumor	283 5 B-Disease
growth	289 6 O
delay	296 5 O
assay	302 5 O
.	307 1 O

Acute	309 5 O
normal	315 6 O
tissue	322 6 O
toxicities	329 10 B-Disease
(	340 1 O
i	341 1 O
.	342 1 O
e	343 1 O
.	344 1 O
,	345 1 O
leukopenia	347 10 B-Disease
and	358 3 O
thrombocytopenia	362 16 B-Disease
)	378 1 O
and	380 3 O
late	384 4 O
normal	389 6 O
tissue	396 6 O
toxicities	403 10 B-Disease
(	414 1 O
i	415 1 O
.	416 1 O
e	417 1 O
.	418 1 O
,	419 1 O
myocardial	421 10 B-Disease
and	432 3 I-Disease
kidney	436 6 I-Disease
injury	443 6 I-Disease
)	449 1 O
were	451 4 O
evaluated	456 9 O
by	466 2 O
functional	469 10 O
/	479 1 O
physiological	480 13 O
assays	494 6 O
and	501 3 O
by	505 2 O
morphological	508 13 O
techniques	522 10 O
.	532 1 O

Whole	534 5 O
body	540 4 O
hyperthermia	545 12 B-Disease
(	558 1 O
120	559 3 O
min	563 3 O
at	567 2 O
41	570 2 O
.	572 1 O
5	573 1 O
degrees	575 7 O
C	583 1 O
)	584 1 O
enhanced	586 8 O
both	595 4 O
Adriamycin	600 10 B-Chemical
-	610 1 O
mediated	611 8 O
antitumor	620 9 O
activity	630 8 O
and	639 3 O
toxic	643 5 O
side	649 4 O
effects	654 7 O
.	661 1 O

The	663 3 O
thermal	667 7 O
enhancement	675 11 O
ratio	687 5 O
calculated	693 10 O
for	704 3 O
antitumor	708 9 O
activity	718 8 O
was	727 3 O
1	731 1 O
.	732 1 O
6	733 1 O
.	734 1 O

Thermal	736 7 O
enhancement	744 11 O
ratios	756 6 O
estimated	763 9 O
for	773 3 O
"	777 1 O
acute	778 5 O
"	783 1 O
hematological	785 13 O
changes	799 7 O
were	807 4 O
1	812 1 O
.	813 1 O
3	814 1 O
,	815 1 O
whereas	817 7 O
those	825 5 O
estimated	831 9 O
for	841 3 O
"	845 1 O
late	846 4 O
"	850 1 O
damage	852 6 O
(	859 1 O
based	860 5 O
on	866 2 O
morphological	869 13 O
cardiac	883 7 B-Disease
and	891 3 I-Disease
renal	895 5 I-Disease
lesions	901 7 I-Disease
)	908 1 O
varied	910 6 O
between	917 7 O
2	925 1 O
.	926 1 O
4	927 1 O
and	929 3 O
4	933 1 O
.	934 1 O
3	935 1 O
.	936 1 O

Thus	938 4 O
,	942 1 O
while	944 5 O
whole	950 5 O
body	956 4 O
hyperthermia	961 12 B-Disease
enhances	974 8 O
Adriamycin	983 10 B-Chemical
-	993 1 O
mediated	994 8 O
antitumor	1003 9 O
effect	1013 6 O
,	1019 1 O
normal	1021 6 O
tissue	1028 6 O
toxicity	1035 8 B-Disease
is	1044 2 O
also	1047 4 O
increased	1052 9 O
,	1061 1 O
and	1063 3 O
the	1067 3 O
potential	1071 9 O
therapeutic	1081 11 O
gain	1093 4 O
of	1098 2 O
the	1101 3 O
combined	1105 8 O
modality	1114 8 O
treatment	1123 9 O
is	1133 2 O
eroded	1136 6 O
.	1142 1 O

Prazosin	0 8 B-Chemical
-	8 1 O
induced	9 7 O
stress	17 6 B-Disease
incontinence	24 12 I-Disease
.	36 1 O

A	38 1 O
case	40 4 O
of	45 2 O
genuine	48 7 O
stress	56 6 B-Disease
incontinence	63 12 I-Disease
due	76 3 O
to	80 2 O
prazosin	83 8 B-Chemical
,	91 1 O
a	93 1 O
common	95 6 O
antihypertensive	102 16 O
drug	119 4 O
,	123 1 O
is	125 2 O
presented	128 9 O
.	137 1 O

Prazosin	139 8 B-Chemical
exerts	148 6 O
its	155 3 O
antihypertensive	159 16 O
effects	176 7 O
through	184 7 O
vasodilatation	192 14 O
caused	207 6 O
by	214 2 O
selective	217 9 O
blockade	227 8 O
of	236 2 O
postsynaptic	239 12 O
alpha	252 5 O
-	257 1 O
1	258 1 O
adrenergic	260 10 O
receptors	271 9 O
.	280 1 O

As	282 2 O
an	285 2 O
alpha	288 5 O
-	293 1 O
blocker	294 7 O
,	301 1 O
it	303 2 O
also	306 4 O
exerts	311 6 O
a	318 1 O
significant	320 11 O
relaxant	332 8 O
effect	341 6 O
on	348 2 O
the	351 3 O
bladder	355 7 O
neck	363 4 O
and	368 3 O
urethra	372 7 O
.	379 1 O

The	381 3 O
patient	385 7 O
'	392 1 O
s	393 1 O
clinical	395 8 O
course	404 6 O
is	411 2 O
described	414 9 O
and	424 3 O
correlated	428 10 O
with	439 4 O
initial	444 7 O
urodynamic	452 10 O
studies	463 7 O
while	471 5 O
on	477 2 O
prazosin	480 8 B-Chemical
and	489 3 O
subsequent	493 10 O
studies	504 7 O
while	512 5 O
taking	518 6 O
verapamil	525 9 B-Chemical
.	534 1 O

Her	536 3 O
incontinence	540 12 B-Disease
resolved	553 8 O
with	562 4 O
the	567 3 O
change	571 6 O
of	578 2 O
medication	581 10 O
.	591 1 O

The	593 3 O
restoration	597 11 O
of	609 2 O
continence	612 10 O
was	623 3 O
accompanied	627 11 O
by	639 2 O
a	642 1 O
substantial	644 11 O
rise	656 4 O
in	661 2 O
maximum	664 7 O
urethral	672 8 O
pressure	681 8 O
,	689 1 O
maximum	691 7 O
urethral	699 8 O
closure	708 7 O
pressure	716 8 O
,	724 1 O
and	726 3 O
functional	730 10 O
urethral	741 8 O
length	750 6 O
.	756 1 O

Patients	758 8 O
who	767 3 O
present	771 7 O
with	779 4 O
stress	784 6 B-Disease
incontinence	791 12 I-Disease
while	804 5 O
taking	810 6 O
prazosin	817 8 B-Chemical
should	826 6 O
change	833 6 O
their	840 5 O
antihypertensive	846 16 O
medication	863 10 O
before	874 6 O
considering	881 11 O
surgery	893 7 O
,	900 1 O
because	902 7 O
their	910 5 O
incontinence	916 12 B-Disease
may	929 3 O
resolve	933 7 O
spontaneously	941 13 O
with	955 4 O
a	960 1 O
change	962 6 O
in	969 2 O
drug	972 4 O
therapy	977 7 O
.	984 1 O

Myocardial	0 10 B-Disease
infarction	11 10 I-Disease
following	22 9 O
sublingual	32 10 O
administration	43 14 O
of	58 2 O
isosorbide	61 10 B-Chemical
dinitrate	72 9 I-Chemical
.	81 1 O

A	83 1 O
78	85 2 O
-	87 1 O
year	88 4 O
-	92 1 O
old	93 3 O
with	97 4 O
healed	102 6 O
septal	109 6 O
necrosis	116 8 B-Disease
suffered	125 8 O
a	134 1 O
recurrent	136 9 O
myocardial	146 10 B-Disease
infarction	157 10 I-Disease
of	168 2 O
the	171 3 O
anterior	175 8 O
wall	184 4 O
following	189 9 O
the	199 3 O
administration	203 14 O
of	218 2 O
isosorbide	221 10 B-Chemical
dinitrate	232 9 I-Chemical
5	242 1 O
mg	244 2 O
sublingually	247 12 O
.	259 1 O

After	261 5 O
detailing	267 9 O
the	277 3 O
course	281 6 O
of	288 2 O
events	291 6 O
,	297 1 O
we	299 2 O
discuss	302 7 O
the	310 3 O
role	314 4 O
of	319 2 O
paradoxical	322 11 O
coronary	334 8 O
spasm	343 5 B-Disease
and	349 3 O
hypotension	353 11 B-Disease
-	364 1 O
mediated	365 8 O
myocardial	374 10 B-Disease
ischemia	385 8 I-Disease
occurring	394 9 O
downstream	404 10 O
to	415 2 O
significant	418 11 O
coronary	430 8 B-Disease
arterial	439 8 I-Disease
stenosis	448 8 I-Disease
in	457 2 O
the	460 3 O
pathophysiology	464 15 O
of	480 2 O
acute	483 5 B-Disease
coronary	489 8 I-Disease
insufficiency	498 13 I-Disease
.	511 1 O

Fluoxetine	0 10 B-Chemical
-	10 1 O
induced	11 7 O
akathisia	19 9 B-Disease
:	28 1 O
clinical	30 8 O
and	39 3 O
theoretical	43 11 O
implications	55 12 O
.	67 1 O

Five	69 4 O
patients	74 8 O
receiving	83 9 O
fluoxetine	93 10 B-Chemical
for	104 3 O
the	108 3 O
treatment	112 9 O
of	122 2 O
obsessive	125 9 B-Disease
compulsive	135 10 I-Disease
disorder	146 8 I-Disease
or	155 2 O
major	158 5 B-Disease
depression	164 10 I-Disease
developed	175 9 O
akathisia	185 9 B-Disease
.	194 1 O

The	196 3 O
typical	200 7 O
fluoxetine	208 10 B-Chemical
-	218 1 O
induced	219 7 O
symptoms	227 8 O
of	236 2 O
restlessness	239 12 O
,	251 1 O
constant	253 8 O
pacing	262 6 O
,	268 1 O
purposeless	270 11 O
movements	282 9 O
of	292 2 O
the	295 3 O
feet	299 4 O
and	304 3 O
legs	308 4 O
,	312 1 O
and	314 3 O
marked	318 6 O
anxiety	325 7 B-Disease
were	333 4 O
indistinguishable	338 17 O
from	356 4 O
those	361 5 O
of	367 2 O
neuroleptic	370 11 O
-	381 1 O
induced	382 7 O
akathisia	390 9 B-Disease
.	399 1 O

Three	401 5 O
patients	407 8 O
who	416 3 O
had	420 3 O
experienced	424 11 O
neuroleptic	436 11 O
-	447 1 O
induced	448 7 O
akathisia	456 9 B-Disease
in	466 2 O
the	469 3 O
past	473 4 O
reported	478 8 O
that	487 4 O
the	492 3 O
symptoms	496 8 O
of	505 2 O
fluoxetine	508 10 B-Chemical
-	518 1 O
induced	519 7 O
akathisia	527 9 B-Disease
were	537 4 O
identical	542 9 O
,	551 1 O
although	553 8 O
somewhat	562 8 O
milder	571 6 O
.	577 1 O

Akathisia	579 9 B-Disease
appeared	589 8 O
to	598 2 O
be	601 2 O
a	604 1 O
common	606 6 O
side	613 4 O
effect	618 6 O
of	625 2 O
fluoxetine	628 10 B-Chemical
and	639 3 O
generally	643 9 O
responded	653 9 O
well	663 4 O
to	668 2 O
treatment	671 9 O
with	681 4 O
the	686 3 O
beta	690 4 O
-	694 1 O
adrenergic	695 10 O
antagonist	706 10 O
propranolol	717 11 B-Chemical
,	728 1 O
dose	730 4 O
reduction	735 9 O
,	744 1 O
or	746 2 O
both	749 4 O
.	753 1 O

The	755 3 O
authors	759 7 O
suggest	767 7 O
that	775 4 O
fluoxetine	780 10 B-Chemical
-	790 1 O
induced	791 7 O
akathisia	799 9 B-Disease
may	809 3 O
be	813 2 O
caused	816 6 O
by	823 2 O
serotonergically	826 16 O
mediated	843 8 O
inhibition	852 10 O
of	863 2 O
dopaminergic	866 12 O
neurotransmission	879 17 O
and	897 3 O
that	901 4 O
the	906 3 O
pathophysiology	910 15 O
of	926 2 O
fluoxetine	929 10 B-Chemical
-	939 1 O
induced	940 7 O
akathisia	948 9 B-Disease
and	958 3 O
tricyclic	962 9 O
antidepressant	972 14 B-Chemical
-	986 1 O
induced	987 7 O
"	995 1 O
jitteriness	996 11 O
"	1007 1 O
may	1009 3 O
be	1013 2 O
identical	1016 9 O
.	1025 1 O

Chronic	0 7 B-Disease
active	8 6 I-Disease
hepatitis	15 9 I-Disease
associated	25 10 O
with	36 4 O
diclofenac	41 10 B-Chemical
sodium	52 6 I-Chemical
therapy	59 7 O
.	66 1 O

Diclofenac	68 10 B-Chemical
sodium	79 6 I-Chemical
(	86 1 O
Voltarol	87 8 B-Chemical
,	95 1 O
Geigy	97 5 O
Pharmaceuticals	103 15 O
)	118 1 O
is	120 2 O
a	123 1 O
non	125 3 O
-	128 1 O
steroidal	129 9 O
anti	139 4 O
-	143 1 O
inflammatory	144 12 O
derivative	157 10 O
of	168 2 O
phenylacetic	171 12 B-Chemical
acid	184 4 I-Chemical
.	188 1 O

Although	190 8 O
generally	199 9 O
well	209 4 O
-	213 1 O
tolerated	214 9 O
,	223 1 O
asymptomatic	225 12 O
abnormalities	238 13 B-Disease
of	252 2 I-Disease
liver	255 5 I-Disease
function	261 8 I-Disease
have	270 4 O
been	275 4 O
recorded	280 8 O
and	289 3 O
,	292 1 O
less	294 4 O
commonly	299 8 O
,	307 1 O
severe	309 6 O
hepatitis	316 9 B-Disease
induced	326 7 O
by	334 2 O
diclofenac	337 10 B-Chemical
.	347 1 O

The	349 3 O
patient	353 7 O
described	361 9 O
developed	371 9 O
chronic	381 7 B-Disease
active	389 6 I-Disease
hepatitis	396 9 I-Disease
after	406 5 O
six	412 3 O
months	416 6 O
therapy	423 7 O
with	431 4 O
diclofenac	436 10 B-Chemical
sodium	447 6 I-Chemical
which	454 5 O
progressed	460 10 O
despite	471 7 O
the	479 3 O
withdrawal	483 10 O
of	494 2 O
the	497 3 O
drug	501 4 O
,	505 1 O
a	507 1 O
finding	509 7 O
not	517 3 O
previously	521 10 O
reported	532 8 O
.	540 1 O

Stroke	0 6 B-Disease
associated	7 10 O
with	18 4 O
cocaine	23 7 B-Chemical
use	31 3 O
.	34 1 O

We	36 2 O
describe	39 8 O
eight	48 5 O
patients	54 8 O
in	63 2 O
whom	66 4 O
cocaine	71 7 B-Chemical
use	79 3 O
was	83 3 O
related	87 7 O
to	95 2 O
stroke	98 6 B-Disease
and	105 3 O
review	109 6 O
39	116 2 O
cases	119 5 O
from	125 4 O
the	130 3 O
literature	134 10 O
.	144 1 O

Among	146 5 O
these	152 5 O
47	158 2 O
patients	161 8 O
the	170 3 O
mean	174 4 O
(	179 1 O
+	180 1 O
/	181 1 O
-	182 1 O
SD	184 2 O
)	186 1 O
age	188 3 O
was	192 3 O
32	196 2 O
.	198 1 O
5	199 1 O
+	201 1 O
/	202 1 O
-	203 1 O
12	205 2 O
.	207 1 O
1	208 1 O
years	210 5 O
;	215 1 O
76	217 2 O
%	219 1 O
(	221 1 O
34	222 2 O
/	224 1 O
45	225 2 O
)	227 1 O
were	229 4 O
men	234 3 O
.	237 1 O

Stroke	239 6 B-Disease
followed	246 8 O
cocaine	255 7 B-Chemical
use	263 3 O
by	267 2 O
inhalation	270 10 O
,	280 1 O
intranasal	282 10 O
,	292 1 O
intravenous	294 11 O
,	305 1 O
and	307 3 O
intramuscular	311 13 O
routes	325 6 O
.	331 1 O

Intracranial	333 12 B-Disease
aneurysms	346 9 I-Disease
or	356 2 O
arteriovenous	359 13 B-Disease
malformations	373 13 I-Disease
were	387 4 O
present	392 7 O
in	400 2 O
17	403 2 O
of	406 2 O
32	409 2 O
patients	412 8 O
studied	421 7 O
angiographically	429 16 O
or	446 2 O
at	449 2 O
autopsy	452 7 O
;	459 1 O
cerebral	461 8 B-Disease
vasculitis	470 10 I-Disease
was	481 3 O
present	485 7 O
in	493 2 O
two	496 3 O
patients	500 8 O
.	508 1 O

Cerebral	510 8 B-Disease
infarction	519 10 I-Disease
occurred	530 8 O
in	539 2 O
10	542 2 O
patients	545 8 O
(	554 1 O
22	555 2 O
%	557 1 O
)	558 1 O
,	559 1 O
intracerebral	561 13 B-Disease
hemorrhage	575 10 I-Disease
in	586 2 O
22	589 2 O
(	592 1 O
49	593 2 O
%	595 1 O
)	596 1 O
,	597 1 O
and	599 3 O
subarachnoid	603 12 B-Disease
hemorrhage	616 10 I-Disease
in	627 2 O
13	630 2 O
(	633 1 O
29	634 2 O
%	636 1 O
)	637 1 O
.	638 1 O

These	640 5 O
data	646 4 O
indicate	651 8 O
that	660 4 O
(	665 1 O
1	666 1 O
)	667 1 O
the	669 3 O
apparent	673 8 O
incidence	682 9 O
of	692 2 O
stroke	695 6 B-Disease
related	702 7 O
to	710 2 O
cocaine	713 7 B-Chemical
use	721 3 O
is	725 2 O
increasing	728 10 O
;	738 1 O
(	740 1 O
2	741 1 O
)	742 1 O
cocaine	744 7 B-Chemical
-	751 1 O
associated	752 10 O
stroke	763 6 B-Disease
occurs	770 6 O
primarily	777 9 O
in	787 2 O
young	790 5 O
adults	796 6 O
;	802 1 O
(	804 1 O
3	805 1 O
)	806 1 O
stroke	808 6 B-Disease
may	815 3 O
follow	819 6 O
any	826 3 O
route	830 5 O
of	836 2 O
cocaine	839 7 B-Chemical
administration	847 14 O
;	861 1 O
(	863 1 O
4	864 1 O
)	865 1 O
stroke	867 6 B-Disease
after	874 5 O
cocaine	880 7 B-Chemical
use	888 3 O
is	892 2 O
frequently	895 10 O
associated	906 10 O
with	917 4 O
intracranial	922 12 B-Disease
aneurysms	935 9 I-Disease
and	945 3 O
arteriovenous	949 13 B-Disease
malformations	963 13 I-Disease
;	976 1 O
and	978 3 O
(	982 1 O
5	983 1 O
)	984 1 O
in	986 2 O
cocaine	989 7 B-Chemical
-	996 1 O
associated	997 10 O
stroke	1008 6 B-Disease
,	1014 1 O
the	1016 3 O
frequency	1020 9 O
of	1030 2 O
intracranial	1033 12 B-Disease
hemorrhage	1046 10 I-Disease
exceeds	1057 7 O
that	1065 4 O
of	1070 2 O
cerebral	1073 8 B-Disease
infarction	1082 10 I-Disease
.	1092 1 O

Glyburide	0 9 B-Chemical
-	9 1 O
induced	10 7 O
hepatitis	18 9 B-Disease
.	27 1 O

Drug	29 4 O
-	33 1 O
induced	34 7 O
hepatotoxicity	42 14 B-Disease
,	56 1 O
although	58 8 O
common	67 6 O
,	73 1 O
has	75 3 O
been	79 4 O
reported	84 8 O
only	93 4 O
infrequently	98 12 O
with	111 4 O
sulfonylureas	116 13 B-Chemical
.	129 1 O

For	131 3 O
glyburide	135 9 B-Chemical
,	144 1 O
a	146 1 O
second	148 6 O
-	154 1 O
generation	155 10 O
sulfonylurea	166 12 B-Chemical
,	178 1 O
only	180 4 O
two	185 3 O
brief	189 5 O
reports	195 7 O
of	203 2 O
hepatotoxicity	206 14 B-Disease
exist	221 5 O
.	226 1 O

Two	228 3 O
patients	232 8 O
with	241 4 O
type	246 4 B-Disease
II	251 2 I-Disease
diabetes	254 8 I-Disease
mellitus	263 8 I-Disease
developed	272 9 O
an	282 2 O
acute	285 5 B-Disease
hepatitis	291 9 I-Disease
-	300 1 I-Disease
like	301 4 I-Disease
syndrome	306 8 I-Disease
soon	315 4 O
after	320 5 O
initiation	326 10 O
of	337 2 O
glyburide	340 9 B-Chemical
therapy	350 7 O
.	357 1 O

There	359 5 O
was	365 3 O
no	369 2 O
serologic	372 9 O
evidence	382 8 O
of	391 2 O
viral	394 5 B-Disease
infection	400 9 I-Disease
,	409 1 O
and	411 3 O
a	415 1 O
liver	417 5 O
biopsy	423 6 O
sample	430 6 O
showed	437 6 O
a	444 1 O
histologic	446 10 O
pattern	457 7 O
consistent	465 10 O
with	476 4 O
drug	481 4 B-Disease
-	485 1 I-Disease
induced	486 7 I-Disease
hepatitis	494 9 I-Disease
.	503 1 O

Both	505 4 O
patients	510 8 O
recovered	519 9 O
quickly	529 7 O
after	537 5 O
stopping	543 8 O
glyburide	552 9 B-Chemical
therapy	562 7 O
and	570 3 O
have	574 4 O
remained	579 8 O
well	588 4 O
for	593 3 O
a	597 1 O
follow	599 6 O
-	605 1 O
up	606 2 O
period	609 6 O
of	616 2 O
1	619 1 O
year	621 4 O
.	625 1 O

Glyburide	627 9 B-Chemical
can	637 3 O
produce	641 7 O
an	649 2 O
acute	652 5 B-Disease
hepatitis	658 9 I-Disease
-	667 1 I-Disease
like	668 4 I-Disease
illness	673 7 I-Disease
in	681 2 O
some	684 4 O
persons	689 7 O
.	696 1 O

Systolic	0 8 O
pressure	9 8 O
variation	18 9 O
is	28 2 O
greater	31 7 O
during	39 6 O
hemorrhage	46 10 B-Disease
than	57 4 O
during	62 6 O
sodium	69 6 B-Chemical
nitroprusside	76 13 I-Chemical
-	89 1 O
induced	90 7 O
hypotension	98 11 B-Disease
in	110 2 O
ventilated	113 10 O
dogs	124 4 O
.	128 1 O

The	130 3 O
systolic	134 8 O
pressure	143 8 O
variation	152 9 O
(	162 1 O
SPV	163 3 O
)	166 1 O
,	167 1 O
which	169 5 O
is	175 2 O
the	178 3 O
difference	182 10 O
between	193 7 O
the	201 3 O
maximal	205 7 O
and	213 3 O
minimal	217 7 O
values	225 6 O
of	232 2 O
the	235 3 O
systolic	239 8 O
blood	248 5 O
pressure	254 8 O
(	263 1 O
SBP	264 3 O
)	267 1 O
after	269 5 O
one	275 3 O
positive	279 8 O
-	287 1 O
pressure	288 8 O
breath	297 6 O
,	303 1 O
was	305 3 O
studied	309 7 O
in	317 2 O
ventilated	320 10 O
dogs	331 4 O
subjected	336 9 O
to	346 2 O
hypotension	349 11 B-Disease
.	360 1 O

Mean	362 4 O
arterial	367 8 O
pressure	376 8 O
was	385 3 O
decreased	389 9 O
to	399 2 O
50	402 2 O
mm	405 2 O
Hg	408 2 O
for	411 3 O
30	415 2 O
minutes	418 7 O
either	426 6 O
by	433 2 O
hemorrhage	436 10 B-Disease
(	447 1 O
HEM	448 3 B-Disease
,	451 1 O
n	453 1 O
=	455 1 O
7	457 1 O
)	458 1 O
or	460 2 O
by	463 2 O
continuous	466 10 O
infusion	477 8 O
of	486 2 O
sodium	489 6 B-Chemical
nitroprusside	496 13 I-Chemical
(	510 1 O
SNP	511 3 B-Chemical
,	514 1 O
n	516 1 O
=	518 1 O
7	520 1 O
)	521 1 O
.	522 1 O

During	524 6 O
HEM	531 3 B-Disease
-	534 1 O
induced	535 7 O
hypotension	543 11 B-Disease
the	555 3 O
cardiac	559 7 O
output	567 6 O
was	574 3 O
significantly	578 13 O
lower	592 5 O
and	598 3 O
systemic	602 8 O
vascular	611 8 O
resistance	620 10 O
higher	631 6 O
compared	638 8 O
with	647 4 O
that	652 4 O
in	657 2 O
the	660 3 O
SNP	664 3 B-Chemical
group	668 5 O
.	673 1 O

The	675 3 O
systemic	679 8 O
,	687 1 O
central	689 7 O
venous	697 6 O
,	703 1 O
pulmonary	705 9 O
capillary	715 9 O
wedge	725 5 O
pressures	731 9 O
,	740 1 O
and	742 3 O
heart	746 5 O
rates	752 5 O
,	757 1 O
were	759 4 O
similar	764 7 O
in	772 2 O
the	775 3 O
two	779 3 O
groups	783 6 O
.	789 1 O

Analysis	791 8 O
of	800 2 O
the	803 3 O
respiratory	807 11 O
changes	819 7 O
in	827 2 O
the	830 3 O
arterial	834 8 O
pressure	843 8 O
waveform	852 8 O
enabled	861 7 O
differentiation	869 15 O
between	885 7 O
the	893 3 O
two	897 3 O
groups	901 6 O
.	907 1 O

The	909 3 O
SPV	913 3 O
during	917 6 O
hypotension	924 11 B-Disease
was	936 3 O
15	940 2 O
.	942 1 O
7	943 1 O
+	945 1 O
/	946 1 O
-	947 1 O
6	949 1 O
.	950 1 O
7	951 1 O
mm	953 2 O
Hg	956 2 O
in	959 2 O
the	962 3 O
HEM	966 3 B-Disease
group	970 5 O
,	975 1 O
compared	977 8 O
with	986 4 O
9	991 1 O
.	992 1 O
1	993 1 O
+	995 1 O
/	996 1 O
-	997 1 O
2	999 1 O
.	1000 1 O
0	1001 1 O
mm	1003 2 O
Hg	1006 2 O
in	1009 2 O
the	1012 3 O
SNP	1016 3 B-Chemical
group	1020 5 O
(	1026 1 O
P	1027 1 O
less	1029 4 O
than	1034 4 O
0	1039 1 O
.	1040 1 O
02	1041 2 O
)	1043 1 O
.	1044 1 O

The	1046 3 O
delta	1050 5 O
down	1056 4 O
,	1060 1 O
which	1062 5 O
is	1068 2 O
the	1071 3 O
measure	1075 7 O
of	1083 2 O
decrease	1086 8 O
of	1095 2 O
SBP	1098 3 O
after	1102 5 O
a	1108 1 O
mechanical	1110 10 O
breath	1121 6 O
,	1127 1 O
was	1129 3 O
20	1133 2 O
.	1135 1 O
3	1136 1 O
+	1138 1 O
/	1139 1 O
-	1140 1 O
8	1142 1 O
.	1143 1 O
4	1144 1 O
and	1146 3 O
10	1150 2 O
.	1152 1 O
1	1153 1 O
+	1155 1 O
/	1156 1 O
-	1157 1 O
3	1159 1 O
.	1160 1 O
8	1161 1 O
mm	1163 2 O
Hg	1166 2 O
in	1169 2 O
the	1172 3 O
HEM	1176 3 B-Disease
and	1180 3 O
SNP	1184 3 B-Chemical
groups	1188 6 O
,	1194 1 O
respectively	1196 12 O
,	1208 1 O
during	1210 6 O
hypotension	1217 11 B-Disease
(	1229 1 O
P	1230 1 O
less	1232 4 O
than	1237 4 O
0	1242 1 O
.	1243 1 O
02	1244 2 O
)	1246 1 O
.	1247 1 O

It	1249 2 O
is	1252 2 O
concluded	1255 9 O
that	1265 4 O
increases	1270 9 O
in	1280 2 O
the	1283 3 O
SPV	1287 3 O
and	1291 3 O
the	1295 3 O
delta	1299 5 O
down	1305 4 O
are	1310 3 O
characteristic	1314 14 O
of	1329 2 O
a	1332 1 O
hypotensive	1334 11 B-Disease
state	1346 5 O
due	1352 3 O
to	1356 2 O
a	1359 1 O
predominant	1361 11 O
decrease	1373 8 O
in	1382 2 O
preload	1385 7 O
.	1392 1 O

They	1394 4 O
are	1399 3 O
thus	1403 4 O
more	1408 4 O
important	1413 9 O
during	1423 6 O
absolute	1430 8 O
hypovolemia	1439 11 B-Disease
than	1451 4 O
during	1456 6 O
deliberate	1463 10 O
hypotension	1474 11 B-Disease
.	1485 1 O

Drug	0 4 O
-	4 1 O
induced	5 7 O
arterial	13 8 O
spasm	22 5 B-Disease
relieved	28 8 O
by	37 2 O
lidocaine	40 9 B-Chemical
.	49 1 O

Case	51 4 O
report	56 6 O
.	62 1 O

Following	64 9 O
major	74 5 O
intracranial	80 12 O
surgery	93 7 O
in	101 2 O
a	104 1 O
35	106 2 O
-	108 1 O
year	109 4 O
-	113 1 O
old	114 3 O
man	118 3 O
,	121 1 O
sodium	123 6 B-Chemical
pentothal	130 9 I-Chemical
was	140 3 O
intravenously	144 13 O
infused	158 7 O
to	166 2 O
minimize	169 8 O
cerebral	178 8 B-Disease
ischaemia	187 9 I-Disease
.	196 1 O

Intense	198 7 O
vasospasm	206 9 B-Disease
with	216 4 O
threatened	221 10 O
gangrene	232 8 B-Disease
arose	241 5 O
in	247 2 O
the	250 3 O
arm	254 3 O
used	258 4 O
for	263 3 O
the	267 3 O
infusion	271 8 O
.	279 1 O

Since	281 5 O
the	287 3 O
cranial	291 7 O
condition	299 9 O
precluded	309 9 O
use	319 3 O
of	323 2 O
more	326 4 O
usual	331 5 O
methods	337 7 O
,	344 1 O
lidocaine	346 9 B-Chemical
was	356 3 O
given	360 5 O
intra	366 5 O
-	371 1 O
arterially	372 10 O
,	382 1 O
with	384 4 O
careful	389 7 O
cardiovascular	397 14 O
monitoring	412 10 O
,	422 1 O
to	424 2 O
counteract	427 10 O
the	438 3 O
vasospasm	442 9 B-Disease
.	451 1 O

The	453 3 O
treatment	457 9 O
was	467 3 O
rapidly	471 7 O
successful	479 10 O
.	489 1 O

Cerebral	0 8 O
blood	9 5 O
flow	15 4 O
and	20 3 O
metabolism	24 10 O
during	35 6 O
isoflurane	42 10 B-Chemical
-	52 1 O
induced	53 7 O
hypotension	61 11 B-Disease
in	73 2 O
patients	76 8 O
subjected	85 9 O
to	95 2 O
surgery	98 7 O
for	106 3 O
cerebral	110 8 B-Disease
aneurysms	119 9 I-Disease
.	128 1 O

Cerebral	130 8 O
blood	139 5 O
flow	145 4 O
and	150 3 O
cerebral	154 8 O
metabolic	163 9 O
rate	173 4 O
for	178 3 O
oxygen	182 6 B-Chemical
were	189 4 O
measured	194 8 O
during	203 6 O
isoflurane	210 10 B-Chemical
-	220 1 O
induced	221 7 O
hypotension	229 11 B-Disease
in	241 2 O
10	244 2 O
patients	247 8 O
subjected	256 9 O
to	266 2 O
craniotomy	269 10 O
for	280 3 O
clipping	284 8 O
of	293 2 O
a	296 1 O
cerebral	298 8 B-Disease
aneurysm	307 8 I-Disease
.	315 1 O

Flow	317 4 O
and	322 3 O
metabolism	326 10 O
were	337 4 O
measured	342 8 O
5	351 1 O
-	352 1 O
13	353 2 O
days	356 4 O
after	361 5 O
the	367 3 O
subarachnoid	371 12 B-Disease
haemorrhage	384 11 I-Disease
by	396 2 O
a	399 1 O
modification	401 12 O
of	414 2 O
the	417 3 O
classical	421 9 O
Kety	431 4 O
-	435 1 O
Schmidt	436 7 O
technique	444 9 O
using	454 5 O
xenon	460 5 B-Chemical
-	465 1 O
133	466 3 O
i	470 1 O
.	471 1 O
v	472 1 O
.	473 1 O
Anaesthesia	475 11 O
was	487 3 O
maintained	491 10 O
with	502 4 O
an	507 2 O
inspired	510 8 O
isoflurane	519 10 B-Chemical
concentration	530 13 O
of	544 2 O
0	547 1 O
.	548 1 O
75	549 2 O
%	551 1 O
(	553 1 O
plus	554 4 O
67	559 2 O
%	561 1 O
nitrous	563 7 B-Chemical
oxide	571 5 I-Chemical
in	577 2 O
oxygen	580 6 B-Chemical
)	586 1 O
,	587 1 O
during	589 6 O
which	596 5 O
CBF	602 3 O
and	606 3 O
CMRO2	610 5 O
were	616 4 O
34	621 2 O
.	623 1 O
3	624 1 O
+	626 1 O
/	627 1 O
-	628 1 O
2	630 1 O
.	631 1 O
1	632 1 O
ml	634 2 O
/	636 1 O
100	637 3 O
g	641 1 O
min	643 3 O
-	646 1 O
1	647 1 O
and	649 3 O
2	653 1 O
.	654 1 O
32	655 2 O
+	658 1 O
/	659 1 O
-	660 1 O
0	662 1 O
.	663 1 O
16	664 2 O
ml	667 2 O
/	669 1 O
100	670 3 O
g	674 1 O
min	676 3 O
-	679 1 O
1	680 1 O
at	682 2 O
PaCO2	685 5 O
4	691 1 O
.	692 1 O
1	693 1 O
+	695 1 O
/	696 1 O
-	697 1 O
0	699 1 O
.	700 1 O
1	701 1 O
kPa	703 3 O
(	707 1 O
mean	708 4 O
+	713 1 O
/	714 1 O
-	715 1 O
SEM	717 3 O
)	720 1 O
.	721 1 O

Controlled	723 10 O
hypotension	734 11 B-Disease
to	746 2 O
an	749 2 O
average	752 7 O
MAP	760 3 O
of	764 2 O
50	767 2 O
-	769 1 O
55	770 2 O
mm	773 2 O
Hg	776 2 B-Chemical
was	779 3 O
induced	783 7 O
by	791 2 O
increasing	794 10 O
the	805 3 O
dose	809 4 O
of	814 2 O
isoflurane	817 10 B-Chemical
,	827 1 O
and	829 3 O
maintained	833 10 O
at	844 2 O
an	847 2 O
inspired	850 8 O
concentration	859 13 O
of	873 2 O
2	876 1 O
.	877 1 O
2	878 1 O
+	880 1 O
/	881 1 O
-	882 1 O
0	884 1 O
.	885 1 O
2	886 1 O
%	887 1 O
.	888 1 O

This	890 4 O
resulted	895 8 O
in	904 2 O
a	907 1 O
significant	909 11 O
decrease	921 8 O
in	930 2 O
CMRO2	933 5 O
(	939 1 O
to	940 2 O
1	943 1 O
.	944 1 O
73	945 2 O
+	948 1 O
/	949 1 O
-	950 1 O
0	952 1 O
.	953 1 O
16	954 2 O
ml	957 2 O
/	959 1 O
100	960 3 O
g	964 1 O
min	966 3 O
-	969 1 O
1	970 1 O
)	971 1 O
,	972 1 O
while	974 5 O
CBF	980 3 O
was	984 3 O
unchanged	988 9 O
.	997 1 O

After	999 5 O
the	1005 3 O
clipping	1009 8 O
of	1018 2 O
the	1021 3 O
aneurysm	1025 8 B-Disease
the	1034 3 O
isoflurane	1038 10 B-Chemical
concentration	1049 13 O
was	1063 3 O
reduced	1067 7 O
to	1075 2 O
0	1078 1 O
.	1079 1 O
75	1080 2 O
%	1082 1 O
.	1083 1 O

There	1085 5 O
was	1091 3 O
a	1095 1 O
significant	1097 11 O
increase	1109 8 O
in	1118 2 O
CBF	1121 3 O
,	1124 1 O
although	1126 8 O
CMRO2	1135 5 O
was	1141 3 O
unchanged	1145 9 O
,	1154 1 O
compared	1156 8 O
with	1165 4 O
pre	1170 3 O
-	1173 1 O
hypotensive	1174 11 B-Disease
values	1186 6 O
.	1192 1 O

These	1194 5 O
changes	1200 7 O
might	1208 5 O
offer	1214 5 O
protection	1220 10 O
to	1231 2 O
brain	1234 5 O
tissue	1240 6 O
during	1247 6 O
periods	1254 7 O
of	1262 2 O
induced	1265 7 O
hypotension	1273 11 B-Disease
.	1284 1 O

Allergic	0 8 B-Disease
reaction	9 8 I-Disease
to	18 2 O
5	21 1 B-Chemical
-	22 1 I-Chemical
fluorouracil	23 12 I-Chemical
infusion	36 8 O
.	44 1 O

An	46 2 O
allergic	49 8 B-Disease
reaction	58 8 I-Disease
consisting	67 10 O
of	78 2 O
angioneurotic	81 13 B-Disease
edema	95 5 I-Disease
secondary	101 9 O
to	111 2 O
continuous	114 10 O
infusion	125 8 O
5	134 1 B-Chemical
-	135 1 I-Chemical
fluorouracil	136 12 I-Chemical
occurred	149 8 O
in	158 2 O
a	161 1 O
patient	163 7 O
with	171 4 O
recurrent	176 9 O
carcinoma	186 9 B-Disease
of	196 2 I-Disease
the	199 3 I-Disease
oral	203 4 I-Disease
cavity	208 6 I-Disease
,	214 1 O
cirrhosis	216 9 B-Disease
,	225 1 O
and	227 3 O
cisplatin	231 9 B-Chemical
-	240 1 O
induced	241 7 O
impaired	249 8 B-Disease
renal	258 5 I-Disease
function	264 8 I-Disease
.	272 1 O

This	274 4 O
reaction	279 8 O
occurred	288 8 O
during	297 6 O
the	304 3 O
sixth	308 5 O
and	314 3 O
seventh	318 7 O
courses	326 7 O
of	334 2 O
infusional	337 10 O
chemotherapy	348 12 O
.	360 1 O

Oral	362 4 O
diphenhydramine	367 15 B-Chemical
and	383 3 O
prednisone	387 10 B-Chemical
were	398 4 O
ineffective	403 11 O
in	415 2 O
preventing	418 10 O
the	429 3 O
recurrence	433 10 O
of	444 2 O
the	447 3 O
allergic	451 8 B-Disease
reaction	460 8 I-Disease
.	468 1 O

Discontinuance	470 14 O
of	485 2 O
effective	488 9 O
chemotherapy	498 12 O
in	511 2 O
this	514 4 O
patient	519 7 O
during	527 6 O
partial	534 7 O
remission	542 9 O
resulted	552 8 O
in	561 2 O
fatal	564 5 O
disease	570 7 O
progression	578 11 O
.	589 1 O

Amiodarone	0 10 B-Chemical
-	10 1 O
induced	11 7 O
sinoatrial	19 10 B-Disease
block	30 5 I-Disease
.	35 1 O

We	37 2 O
observed	40 8 O
sinoatrial	49 10 B-Disease
block	60 5 I-Disease
due	66 3 O
to	70 2 O
chronic	73 7 O
amiodarone	81 10 B-Chemical
administration	92 14 O
in	107 2 O
a	110 1 O
5	112 1 O
-	113 1 O
year	114 4 O
-	118 1 O
old	119 3 O
boy	123 3 O
with	127 4 O
primary	132 7 B-Disease
cardiomyopathy	140 14 I-Disease
,	154 1 O
Wolff	156 5 B-Disease
-	161 1 I-Disease
Parkinson	162 9 I-Disease
-	171 1 I-Disease
White	172 5 I-Disease
syndrome	178 8 I-Disease
and	187 3 O
supraventricular	191 16 B-Disease
tachycardia	208 11 I-Disease
.	219 1 O

Reduction	221 9 O
in	231 2 O
the	234 3 O
dosage	238 6 O
of	245 2 O
amiodarone	248 10 B-Chemical
resulted	259 8 O
in	268 2 O
the	271 3 O
disappearance	275 13 O
of	289 2 O
the	292 3 O
sinoatrial	296 10 B-Disease
block	307 5 I-Disease
and	313 3 O
the	317 3 O
persistence	321 11 O
of	333 2 O
asymptomatic	336 12 O
sinus	349 5 B-Disease
bradycardia	355 11 I-Disease
.	366 1 O

Possible	0 8 O
teratogenicity	9 14 O
of	24 2 O
sulphasalazine	27 14 B-Chemical
.	41 1 O

Three	43 5 O
infants	49 7 O
,	56 1 O
born	58 4 O
of	63 2 O
two	66 3 O
mothers	70 7 O
with	78 4 O
inflammatory	83 12 B-Disease
bowel	96 5 I-Disease
disease	102 7 I-Disease
who	110 3 O
received	114 8 O
treatment	123 9 O
with	133 4 O
sulphasalazine	138 14 B-Chemical
throughout	153 10 O
pregnancy	164 9 O
,	173 1 O
were	175 4 O
found	180 5 O
to	186 2 O
have	189 4 O
major	194 5 O
congenital	200 10 B-Disease
anomalies	211 9 I-Disease
.	220 1 O

In	222 2 O
the	225 3 O
singleton	229 9 O
pregnancy	239 9 O
,	248 1 O
the	250 3 O
mother	254 6 O
had	261 3 O
ulcerative	265 10 B-Disease
colitis	276 7 I-Disease
,	283 1 O
and	285 3 O
the	289 3 O
infant	293 6 O
,	299 1 O
a	301 1 O
male	303 4 O
,	307 1 O
had	309 3 O
coarctation	313 11 B-Disease
of	325 2 I-Disease
the	328 3 I-Disease
aorta	332 5 I-Disease
and	338 3 O
a	342 1 O
ventricular	344 11 B-Disease
septal	356 6 I-Disease
defect	363 6 I-Disease
.	369 1 O

In	371 2 O
the	374 3 O
twin	378 4 O
pregnancy	383 9 O
,	392 1 O
the	394 3 O
mother	398 6 O
had	405 3 O
Crohn	409 5 B-Disease
'	414 1 I-Disease
s	415 1 I-Disease
disease	417 7 I-Disease
.	424 1 O

The	426 3 O
first	430 5 O
twin	436 4 O
,	440 1 O
a	442 1 O
female	444 6 O
,	450 1 O
had	452 3 O
a	456 1 O
left	458 4 O
Potter	463 6 B-Disease
-	469 1 I-Disease
type	470 4 I-Disease
IIa	475 3 I-Disease
polycystic	479 10 I-Disease
kidney	490 6 I-Disease
and	497 3 O
a	501 1 O
rudimentary	503 11 B-Disease
left	515 4 I-Disease
uterine	520 7 I-Disease
cornu	528 5 I-Disease
.	533 1 O

The	535 3 O
second	539 6 O
twin	546 4 O
,	550 1 O
a	552 1 O
male	554 4 O
,	558 1 O
had	560 3 O
some	564 4 O
features	569 8 O
of	578 2 O
Potter	581 6 B-Disease
'	587 1 I-Disease
s	588 1 I-Disease
facies	590 6 I-Disease
,	596 1 O
hypoplastic	598 11 B-Disease
lungs	610 5 I-Disease
,	615 1 O
absent	617 6 B-Disease
kidneys	624 7 I-Disease
and	632 3 I-Disease
ureters	636 7 I-Disease
,	643 1 O
and	645 3 O
talipes	649 7 B-Disease
equinovarus	657 11 I-Disease
.	668 1 O

Despite	670 7 O
reports	678 7 O
to	686 2 O
the	689 3 O
contrary	693 8 O
,	701 1 O
it	703 2 O
is	706 2 O
suggested	709 9 O
that	719 4 O
sulphasalazine	724 14 B-Chemical
may	739 3 O
be	743 2 O
teratogenic	746 11 O
.	757 1 O

Veno	0 4 B-Disease
-	4 1 I-Disease
occlusive	5 9 I-Disease
liver	15 5 I-Disease
disease	21 7 I-Disease
after	29 5 O
dacarbazine	35 11 B-Chemical
therapy	47 7 O
(	55 1 O
DTIC	56 4 B-Chemical
)	60 1 O
for	62 3 O
melanoma	66 8 B-Disease
.	74 1 O

A	76 1 O
case	78 4 O
of	83 2 O
veno	86 4 B-Disease
-	90 1 I-Disease
occlusive	91 9 I-Disease
disease	101 7 I-Disease
of	109 2 I-Disease
the	112 3 I-Disease
liver	116 5 I-Disease
with	122 4 O
fatal	127 5 O
outcome	133 7 O
after	141 5 O
dacarbazine	147 11 B-Chemical
(	159 1 O
DTIC	160 4 B-Chemical
)	164 1 O
therapy	166 7 O
for	174 3 O
melanoma	178 8 B-Disease
is	187 2 O
reported	190 8 O
.	198 1 O

There	200 5 O
was	206 3 O
a	210 1 O
fulminant	212 9 O
clinical	222 8 O
course	231 6 O
from	238 4 O
start	243 5 O
of	249 2 O
symptoms	252 8 O
until	261 5 O
death	267 5 B-Disease
.	272 1 O

At	274 2 O
autopsy	277 7 O
the	285 3 O
liver	289 5 O
was	295 3 O
enlarged	299 8 O
and	308 3 O
firm	312 4 O
with	317 4 O
signs	322 5 O
of	328 2 O
venous	331 6 B-Disease
congestion	338 10 I-Disease
.	348 1 O

Small	350 5 O
-	355 1 O
and	357 3 O
medium	361 6 O
-	367 1 O
sized	368 5 O
hepatic	374 7 O
veins	382 5 O
were	388 4 O
blocked	393 7 O
by	401 2 O
thrombosis	404 10 B-Disease
.	414 1 O

Eosinophilic	416 12 O
infiltrations	429 13 O
were	443 4 O
found	448 5 O
around	454 6 O
the	461 3 O
vessels	465 7 O
.	472 1 O

Published	474 9 O
cases	484 5 O
from	490 4 O
the	495 3 O
literature	499 10 O
are	510 3 O
reviewed	514 8 O
and	523 3 O
pertinent	527 9 O
features	537 8 O
discussed	546 9 O
.	555 1 O

A	0 1 O
case	2 4 O
of	7 2 O
tardive	10 7 B-Disease
dyskinesia	18 10 I-Disease
caused	29 6 O
by	36 2 O
metoclopramide	39 14 B-Chemical
.	53 1 O

Abnormal	55 8 B-Disease
involuntary	64 11 I-Disease
movements	76 9 I-Disease
appeared	86 8 O
in	95 2 O
the	98 3 O
mouth	102 5 O
,	107 1 O
tongue	109 6 O
,	115 1 O
neck	117 4 O
and	122 3 O
abdomen	126 7 O
of	134 2 O
a	137 1 O
64	139 2 O
-	141 1 O
year	142 4 O
-	146 1 O
old	147 3 O
male	151 4 O
patient	156 7 O
after	164 5 O
he	170 2 O
took	173 4 O
metoclopramide	178 14 B-Chemical
for	193 3 O
gastrointestinal	197 16 B-Disease
disorder	214 8 I-Disease
in	223 2 O
a	226 1 O
regimen	228 7 O
of	236 2 O
30	239 2 O
mg	242 2 O
per	245 3 O
day	249 3 O
for	253 3 O
a	257 1 O
total	259 5 O
of	265 2 O
about	268 5 O
260	274 3 O
days	278 4 O
.	282 1 O

The	284 3 O
symptoms	288 8 O
exacerbated	297 11 O
to	309 2 O
a	312 1 O
maximum	314 7 O
in	322 2 O
a	325 1 O
month	327 5 O
.	332 1 O

When	334 4 O
the	339 3 O
metoclopramide	343 14 B-Chemical
administration	358 14 O
was	373 3 O
discontinued	377 12 O
,	389 1 O
the	391 3 O
abnormal	395 8 B-Disease
movements	404 9 I-Disease
gradually	414 9 O
improved	424 8 O
to	433 2 O
a	436 1 O
considerable	438 12 O
extent	451 6 O
.	457 1 O

Attention	459 9 O
to	469 2 O
the	472 3 O
possible	476 8 O
induction	485 9 O
of	495 2 O
specific	498 8 O
tardive	507 7 B-Disease
dyskinesia	515 10 I-Disease
is	526 2 O
called	529 6 O
for	536 3 O
in	540 2 O
the	543 3 O
use	547 3 O
of	551 2 O
this	554 4 O
drug	559 4 O
.	563 1 O

Further	0 7 O
observations	8 12 O
on	21 2 O
the	24 3 O
electrophysiologic	28 18 O
effects	47 7 O
of	55 2 O
oral	58 4 O
amiodarone	63 10 B-Chemical
therapy	74 7 O
.	81 1 O

A	83 1 O
case	85 4 O
is	90 2 O
presented	93 9 O
of	103 2 O
a	106 1 O
reversible	108 10 O
intra	119 5 B-Disease
-	124 1 I-Disease
Hisian	125 6 I-Disease
block	132 5 I-Disease
occurring	138 9 O
under	148 5 O
amiodarone	154 10 B-Chemical
treatment	165 9 O
for	175 3 O
atrial	179 6 B-Disease
tachycardia	186 11 I-Disease
in	198 2 O
a	201 1 O
patient	203 7 O
without	211 7 O
clear	219 5 O
intraventricular	225 16 B-Disease
conduction	242 10 I-Disease
abnormalities	253 13 I-Disease
.	266 1 O

His	268 3 O
bundle	272 6 O
recordings	279 10 O
showed	290 6 O
an	297 2 O
atrial	300 6 B-Disease
tachycardia	307 11 I-Disease
with	319 4 O
intermittent	324 12 O
exit	337 4 O
block	342 5 O
and	348 3 O
greatly	352 7 O
prolonged	360 9 O
BH	370 2 O
and	373 3 O
HV	377 2 O
intervals	380 9 O
(	390 1 O
40	391 2 O
and	394 3 O
100	398 3 O
msec	402 4 O
,	406 1 O
respectively	408 12 O
)	420 1 O
.	421 1 O

Thirty	423 6 O
days	430 4 O
after	435 5 O
amiodarone	441 10 B-Chemical
discontinuation	452 15 O
,	467 1 O
His	469 3 O
bundle	473 6 O
electrograms	480 12 O
showed	493 6 O
atrial	500 6 B-Disease
flutter	507 7 I-Disease
without	515 7 O
intra	523 5 O
-	528 1 O
Hisian	529 6 O
or	536 2 O
infra	539 5 O
-	544 1 O
Hisian	545 6 O
delay	552 5 O
.	557 1 O

Amiodarone	559 10 B-Chemical
should	570 6 O
be	577 2 O
used	580 4 O
with	585 4 O
caution	590 7 O
during	598 6 O
long	605 4 O
-	609 1 O
term	610 4 O
oral	615 4 O
therapy	620 7 O
in	628 2 O
patients	631 8 O
with	640 4 O
or	645 2 O
without	648 7 O
clear	656 5 O
intraventricular	662 16 O
conduction	679 10 O
defects	690 7 O
.	697 1 O

Busulfan	0 8 B-Chemical
-	8 1 O
induced	9 7 O
hemorrhagic	17 11 B-Disease
cystitis	29 8 I-Disease
.	37 1 O

A	39 1 O
case	41 4 O
of	46 2 O
a	49 1 O
busulfan	51 8 B-Chemical
-	59 1 O
induced	60 7 O
hemorrhage	68 10 B-Disease
cystitis	79 8 I-Disease
is	88 2 O
reported	91 8 O
.	99 1 O

Spontaneous	101 11 O
resolution	113 10 O
occurred	124 8 O
following	133 9 O
cessation	143 9 O
of	153 2 O
the	156 3 O
drug	160 4 O
.	164 1 O

The	166 3 O
similarity	170 10 O
between	181 7 O
the	189 3 O
histologic	193 10 O
appearances	204 11 O
of	216 2 O
busulfan	219 8 B-Chemical
cystitis	228 8 B-Disease
and	237 3 O
both	241 4 O
radiation	246 9 O
and	256 3 O
cyclophosphamide	260 16 B-Chemical
-	276 1 O
induced	277 7 O
cystitis	285 8 B-Disease
is	294 2 O
discussed	297 9 O
and	307 3 O
the	311 3 O
world	315 5 O
literature	321 10 O
reviewed	332 8 O
.	340 1 O

In	342 2 O
view	345 4 O
of	350 2 O
the	353 3 O
known	357 5 O
tendency	363 8 O
of	372 2 O
busulfan	375 8 B-Chemical
to	384 2 O
induce	387 6 O
cellular	394 8 O
atypia	403 6 O
and	410 3 O
carcinoma	414 9 B-Disease
in	424 2 O
other	427 5 O
sites	433 5 O
,	438 1 O
periodic	440 8 O
urinary	449 7 O
cytology	457 8 O
is	466 2 O
suggested	469 9 O
in	479 2 O
patients	482 8 O
on	491 2 O
long	494 4 O
-	498 1 O
term	499 4 O
therapy	504 7 O
.	511 1 O

Rebound	0 7 O
hypertensive	8 12 B-Disease
after	21 5 O
sodium	27 6 B-Chemical
nitroprusside	34 13 I-Chemical
prevented	48 9 O
by	58 2 O
saralasin	61 9 B-Chemical
in	71 2 O
rats	74 4 O
.	78 1 O

The	80 3 O
role	84 4 O
of	89 2 O
the	92 3 O
renin	96 5 O
-	101 1 O
-	102 1 O
angiotensin	103 11 B-Chemical
system	115 6 O
in	122 2 O
the	125 3 O
maintenance	129 11 O
of	141 2 O
blood	144 5 O
pressure	150 8 O
during	159 6 O
halothane	166 9 B-Chemical
anesthesia	176 10 O
and	187 3 O
sodium	191 6 B-Chemical
nitroprusside	198 13 I-Chemical
(	212 1 O
SNP	213 3 B-Chemical
)	216 1 O
-	217 1 O
induced	218 7 O
hypotension	226 11 B-Disease
was	238 3 O
evaluated	242 9 O
.	251 1 O

Control	253 7 O
rats	261 4 O
received	266 8 O
halothane	275 9 B-Chemical
anesthesia	285 10 O
(	296 1 O
1	297 1 O
MAC	299 3 O
)	302 1 O
for	304 3 O
one	308 3 O
hour	312 4 O
,	316 1 O
followed	318 8 O
by	327 2 O
SNP	330 3 B-Chemical
infusion	334 8 O
,	342 1 O
40	344 2 O
microgram	347 9 O
/	356 1 O
kg	357 2 O
/	359 1 O
min	360 3 O
,	363 1 O
for	365 3 O
30	369 2 O
min	372 3 O
,	375 1 O
followed	377 8 O
by	386 2 O
a	389 1 O
30	391 2 O
-	393 1 O
min	394 3 O
recovery	398 8 O
period	407 6 O
.	413 1 O

A	415 1 O
second	417 6 O
group	424 5 O
of	430 2 O
rats	433 4 O
was	438 3 O
treated	442 7 O
identically	450 11 O
and	462 3 O
,	465 1 O
in	467 2 O
addition	470 8 O
,	478 1 O
received	480 8 O
an	489 2 O
infusion	492 8 O
of	501 2 O
saralasin	504 9 B-Chemical
(	514 1 O
a	515 1 O
competitive	517 11 O
inhibitor	529 9 O
of	539 2 O
angiotensin	542 11 B-Chemical
II	554 2 I-Chemical
)	556 1 O
throughout	558 10 O
the	569 3 O
experimental	573 12 O
period	586 6 O
.	592 1 O

In	594 2 O
each	597 4 O
group	602 5 O
,	607 1 O
SNP	609 3 B-Chemical
infusion	613 8 O
resulted	622 8 O
in	631 2 O
an	634 2 O
initial	637 7 O
decrease	645 8 O
in	654 2 O
blood	657 5 O
pressure	663 8 O
from	672 4 O
86	677 2 O
torr	680 4 O
and	685 3 O
83	689 2 O
torr	692 4 O
,	696 1 O
respectively	698 12 O
,	710 1 O
to	712 2 O
48	715 2 O
torr	718 4 O
.	722 1 O

During	724 6 O
the	731 3 O
SNP	735 3 B-Chemical
infusion	739 8 O
the	748 3 O
control	752 7 O
animals	760 7 O
demonstrated	768 12 O
a	781 1 O
progressive	783 11 O
increase	795 8 B-Disease
in	804 2 I-Disease
blood	807 5 I-Disease
pressure	813 8 I-Disease
to	822 2 O
61	825 2 O
torr	828 4 O
,	832 1 O
whereas	834 7 O
the	842 3 O
saralasin	846 9 B-Chemical
-	855 1 O
treated	856 7 O
animals	864 7 O
showed	872 6 O
no	879 2 O
change	882 6 O
.	888 1 O

Following	890 9 O
discontinuation	900 15 O
of	916 2 O
SNP	919 3 B-Chemical
,	922 1 O
blood	924 5 O
pressure	930 8 O
in	939 2 O
the	942 3 O
control	946 7 O
animals	954 7 O
rebounded	962 9 O
to	972 2 O
94	975 2 O
torr	978 4 O
,	982 1 O
as	984 2 O
compared	987 8 O
with	996 4 O
78	1001 2 O
torr	1004 4 O
in	1009 2 O
the	1012 3 O
saralasin	1016 9 B-Chemical
-	1025 1 O
treated	1026 7 O
rats	1034 4 O
.	1038 1 O

This	1040 4 O
study	1045 5 O
indicates	1051 9 O
that	1061 4 O
with	1066 4 O
stable	1071 6 O
halothane	1078 9 B-Chemical
anesthesia	1088 10 O
,	1098 1 O
the	1100 3 O
partial	1104 7 O
recovery	1112 8 O
of	1121 2 O
blood	1124 5 O
pressure	1130 8 O
during	1139 6 O
SNP	1146 3 B-Chemical
infusion	1150 8 O
and	1159 3 O
the	1163 3 O
post	1167 4 O
-	1171 1 O
SNP	1172 3 B-Chemical
rebound	1176 7 O
of	1184 2 O
blood	1187 5 O
pressure	1193 8 O
can	1202 3 O
be	1206 2 O
completely	1209 10 O
blocked	1220 7 O
by	1228 2 O
saralasin	1231 9 B-Chemical
.	1240 1 O

This	1242 4 O
demonstrates	1247 12 O
the	1260 3 O
participation	1264 13 O
of	1278 2 O
the	1281 3 O
renin	1285 5 O
-	1290 1 O
-	1291 1 O
angiotensin	1292 11 B-Chemical
system	1304 6 O
in	1311 2 O
antagonizing	1314 12 O
the	1327 3 O
combined	1331 8 O
hypotensive	1340 11 B-Disease
effects	1352 7 O
of	1360 2 O
halothane	1363 9 B-Chemical
and	1373 3 O
SNP	1377 3 B-Chemical
.	1380 1 O

Toxic	0 5 B-Disease
hepatitis	6 9 I-Disease
induced	16 7 O
by	24 2 O
antithyroid	27 11 O
drugs	39 5 O
:	44 1 O
four	46 4 O
cases	51 5 O
including	57 9 O
one	67 3 O
with	71 4 O
cross	76 5 O
-	81 1 O
reactivity	82 10 O
between	93 7 O
carbimazole	101 11 B-Chemical
and	113 3 O
benzylthiouracil	117 16 B-Chemical
.	133 1 O

OBJECTIVE	135 9 O
:	144 1 O
This	146 4 O
study	151 5 O
was	157 3 O
conducted	161 9 O
to	171 2 O
assess	174 6 O
the	181 3 O
occurrence	185 10 O
of	196 2 O
hepatic	199 7 B-Disease
adverse	207 7 I-Disease
effects	215 7 I-Disease
encountered	223 11 O
with	235 4 O
antithyroid	240 11 O
drugs	252 5 O
.	257 1 O

METHODS	259 7 O
:	266 1 O
Retrospective	268 13 O
review	282 6 O
of	289 2 O
medical	292 7 O
records	300 7 O
of	308 2 O
236	311 3 O
patients	315 8 O
with	324 4 O
hyperthyroidism	329 15 B-Disease
admitted	345 8 O
in	354 2 O
our	357 3 O
department	361 10 O
(	372 1 O
in	373 2 O
-	375 1 O
or	377 2 O
out	380 3 O
-	383 1 O
patients	384 8 O
)	392 1 O
from	394 4 O
1986	399 4 O
to	404 2 O
1992	407 4 O
.	411 1 O

RESULTS	413 7 O
:	420 1 O
Four	422 4 O
patients	427 8 O
(	436 1 O
1	437 1 O
.	438 1 O
7	439 1 O
%	440 1 O
)	441 1 O
were	443 4 O
identified	448 10 O
with	459 4 O
toxic	464 5 B-Disease
hepatitis	470 9 I-Disease
which	480 5 O
could	486 5 O
reasonably	492 10 O
be	503 2 O
attributed	506 10 O
to	517 2 O
the	520 3 O
use	524 3 O
of	528 2 O
antithyroid	531 11 O
agent	543 5 O
.	548 1 O

Two	550 3 O
patients	554 8 O
had	563 3 O
a	567 1 O
cholestatic	569 11 B-Disease
hepatitis	581 9 I-Disease
induced	591 7 O
by	599 2 O
carbimazole	602 11 B-Chemical
(	614 1 O
N	615 1 B-Chemical
omercazole	618 10 I-Chemical
)	628 1 O
.	629 1 O

Two	631 3 O
others	635 6 O
had	642 3 O
a	646 1 O
mixed	648 5 O
(	654 1 O
cholestatic	655 11 B-Disease
and	667 3 O
cytolytic	671 9 O
)	680 1 O
hepatitis	682 9 B-Disease
following	692 9 O
carbimazole	702 11 B-Chemical
.	713 1 O

One	715 3 O
of	719 2 O
the	722 3 O
latter	726 6 O
two	733 3 O
patients	737 8 O
further	746 7 O
experienced	754 11 O
a	766 1 O
cytolytic	768 9 O
hepatitis	778 9 B-Disease
which	788 5 O
appeared	794 8 O
after	803 5 O
Benzylthiouracil	809 16 B-Chemical
(	826 1 O
Basd	827 4 B-Chemical
ne	833 2 I-Chemical
)	835 1 O
had	837 3 O
replaced	841 8 O
carbimazole	850 11 B-Chemical
.	861 1 O

Biological	863 10 O
features	874 8 O
of	883 2 O
hepatitis	886 9 B-Disease
disappeared	896 11 O
in	908 2 O
all	911 3 O
cases	915 5 O
after	921 5 O
cessation	927 9 O
of	937 2 O
the	940 3 O
incriminated	944 12 O
drug	957 4 O
,	961 1 O
while	963 5 O
biliary	969 7 O
,	976 1 O
viral	978 5 O
and	984 3 O
immunological	988 13 O
searches	1002 8 O
were	1011 4 O
negative	1016 8 O
.	1024 1 O

Only	1026 4 O
2	1031 1 O
patients	1033 8 O
of	1042 2 O
our	1045 3 O
retrospective	1049 13 O
study	1063 5 O
experienced	1069 11 O
a	1081 1 O
mild	1083 4 O
or	1088 2 O
severe	1091 6 O
neutropenia	1098 11 B-Disease
.	1109 1 O

CONCLUSION	1111 10 O
:	1121 1 O
Toxic	1123 5 B-Disease
hepatitis	1129 9 I-Disease
is	1139 2 O
a	1142 1 O
potential	1144 9 O
adverse	1154 7 O
effect	1162 6 O
of	1169 2 O
antithyroid	1172 11 O
drugs	1184 5 O
which	1190 5 O
warrants	1196 8 O
,	1204 1 O
as	1206 2 O
for	1209 3 O
haematological	1213 14 O
disturbances	1228 12 O
,	1240 1 O
a	1242 1 O
pre	1244 3 O
-	1247 1 O
therapeutic	1248 11 O
determination	1260 13 O
and	1274 3 O
a	1278 1 O
careful	1280 7 O
follow	1288 6 O
-	1294 1 O
up	1295 2 O
of	1298 2 O
relevant	1301 8 O
biological	1310 10 O
markers	1321 7 O
.	1328 1 O

Moreover	1330 8 O
,	1338 1 O
hepatotoxicity	1340 14 B-Disease
may	1355 3 O
not	1359 3 O
be	1363 2 O
restricted	1366 10 O
to	1377 2 O
one	1380 3 O
class	1384 5 O
of	1390 2 O
antithyroid	1393 11 O
agents	1405 6 O
.	1411 1 O

Study	0 5 O
of	6 2 O
the	9 3 O
role	13 4 O
of	18 2 O
vitamin	21 7 B-Chemical
B12	29 3 I-Chemical
and	33 3 O
folinic	37 7 B-Chemical
acid	45 4 I-Chemical
supplementation	50 15 O
in	66 2 O
preventing	69 10 O
hematologic	80 11 O
toxicity	92 8 B-Disease
of	101 2 O
zidovudine	104 10 B-Chemical
.	114 1 O

A	116 1 O
prospective	118 11 O
,	129 1 O
randomized	131 10 O
study	142 5 O
was	148 3 O
conducted	152 9 O
to	162 2 O
evaluate	165 8 O
the	174 3 O
role	178 4 O
of	183 2 O
vitamin	186 7 B-Chemical
B12	194 3 I-Chemical
and	198 3 O
folinic	202 7 B-Chemical
acid	210 4 I-Chemical
supplementation	215 15 O
in	231 2 O
preventing	234 10 O
zidovudine	245 10 B-Chemical
(	256 1 O
ZDV	257 3 B-Chemical
)	260 1 O
-	261 1 O
induced	262 7 O
bone	270 4 B-Disease
marrow	275 6 I-Disease
suppression	282 11 I-Disease
.	293 1 O

Seventy	295 7 O
-	302 1 O
five	303 4 O
human	308 5 B-Disease
immunodeficiency	314 16 I-Disease
virus	331 5 I-Disease
(	337 1 I-Disease
HIV	338 3 I-Disease
)	341 1 I-Disease
-	342 1 I-Disease
infected	343 8 I-Disease
patients	352 8 O
with	361 4 O
CD4	366 3 O
+	369 1 O
cell	371 4 O
counts	376 6 O
<	383 1 O
500	385 3 O
/	388 1 O
mm3	389 3 O
were	393 4 O
randomized	398 10 O
to	409 2 O
receive	412 7 O
either	420 6 O
ZDV	427 3 B-Chemical
(	431 1 O
500	432 3 O
mg	436 2 O
daily	439 5 O
)	444 1 O
alone	446 5 O
(	452 1 O
group	453 5 O
I	459 1 O
,	460 1 O
n	462 1 O
=	464 1 O
38	466 2 O
)	468 1 O
or	470 2 O
in	473 2 O
combination	476 11 O
with	488 4 O
folinic	493 7 B-Chemical
acid	501 4 I-Chemical
(	506 1 O
15	507 2 O
mg	510 2 O
daily	513 5 O
)	518 1 O
and	520 3 O
intramascular	524 13 O
vitamin	538 7 B-Chemical
B12	546 3 I-Chemical
(	550 1 O
1000	551 4 O
micrograms	556 10 O
monthly	567 7 O
)	574 1 O
(	576 1 O
group	577 5 O
II	583 2 O
,	585 1 O
n	587 1 O
=	589 1 O
37	591 2 O
)	593 1 O
.	594 1 O

Finally	596 7 O
,	603 1 O
15	605 2 O
patients	608 8 O
were	617 4 O
excluded	622 8 O
from	631 4 O
the	636 3 O
study	640 5 O
(	646 1 O
noncompliance	647 13 O
14	661 2 O
,	663 1 O
death	665 5 B-Disease
1	671 1 O
)	672 1 O
;	673 1 O
thus	675 4 O
,	679 1 O
60	681 2 O
patients	684 8 O
(	693 1 O
31	694 2 O
in	697 2 O
group	700 5 O
I	706 1 O
and	708 3 O
29	712 2 O
in	715 2 O
group	718 5 O
II	724 2 O
)	726 1 O
were	728 4 O
eligible	733 8 O
for	742 3 O
analysis	746 8 O
.	754 1 O

No	756 2 O
significant	759 11 O
differences	771 11 O
between	783 7 O
groups	791 6 O
were	798 4 O
found	803 5 O
at	809 2 O
enrollment	812 10 O
.	822 1 O

During	824 6 O
the	831 3 O
study	835 5 O
,	840 1 O
vitamin	842 7 B-Chemical
B12	850 3 I-Chemical
and	854 3 O
folate	858 6 B-Chemical
levels	865 6 O
were	872 4 O
significantly	877 13 O
higher	891 6 O
in	898 2 O
group	901 5 O
II	907 2 O
patients	910 8 O
;	918 1 O
however	920 7 O
,	927 1 O
no	929 2 O
differences	932 11 O
in	944 2 O
hemoglobin	947 10 O
,	957 1 O
hematocrit	959 10 O
,	969 1 O
mean	971 4 O
corpuscular	976 11 O
volume	988 6 O
,	994 1 O
and	996 3 O
white	1000 5 O
-	1005 1 O
cell	1006 4 O
,	1010 1 O
neutrophil	1012 10 O
and	1023 3 O
platelet	1027 8 O
counts	1036 6 O
were	1043 4 O
observed	1048 8 O
between	1057 7 O
groups	1065 6 O
at	1072 2 O
3	1075 1 O
,	1076 1 O
6	1078 1 O
,	1079 1 O
9	1081 1 O
and	1083 3 O
12	1087 2 O
months	1090 6 O
.	1096 1 O

Severe	1098 6 O
hematologic	1105 11 O
toxicity	1117 8 B-Disease
(	1126 1 O
neutrophil	1127 10 O
count	1138 5 O
<	1144 1 O
1000	1146 4 O
/	1150 1 O
mm3	1151 3 O
and	1155 3 O
/	1158 1 O
or	1159 2 O
hemoglobin	1162 10 O
<	1173 1 O
8	1175 1 O
g	1177 1 O
/	1178 1 O
dl	1179 2 O
)	1181 1 O
occurred	1183 8 O
in	1192 2 O
4	1195 1 O
patients	1197 8 O
assigned	1206 8 O
to	1215 2 O
group	1218 5 O
I	1224 1 O
and	1226 3 O
7	1230 1 O
assigned	1232 8 O
to	1241 2 O
group	1244 5 O
II	1250 2 O
.	1252 1 O

There	1254 5 O
was	1260 3 O
no	1264 2 O
correlation	1267 11 O
between	1279 7 O
vitamin	1287 7 B-Chemical
B12	1295 3 I-Chemical
or	1299 2 O
folate	1302 6 B-Chemical
levels	1309 6 O
and	1316 3 O
development	1320 11 O
of	1332 2 O
myelosuppression	1335 16 B-Disease
.	1351 1 O

Vitamin	1353 7 B-Chemical
B12	1361 3 I-Chemical
and	1365 3 O
folinic	1369 7 B-Chemical
acid	1377 4 I-Chemical
supplementation	1382 15 O
of	1398 2 O
ZDV	1401 3 B-Chemical
therapy	1405 7 O
does	1413 4 O
not	1418 3 O
seem	1422 4 O
useful	1427 6 O
in	1434 2 O
preventing	1437 10 O
or	1448 2 O
reducing	1451 8 O
ZDV	1460 3 B-Chemical
-	1463 1 O
induced	1464 7 O
myelotoxicity	1472 13 B-Disease
in	1486 2 O
the	1489 3 O
overall	1493 7 O
treated	1501 7 O
population	1509 10 O
,	1519 1 O
although	1521 8 O
a	1530 1 O
beneficial	1532 10 O
effect	1543 6 O
in	1550 2 O
certain	1553 7 O
subgroups	1561 9 O
of	1571 2 O
patients	1574 8 O
cannot	1583 6 O
be	1590 2 O
excluded	1593 8 O
.	1601 1 O

Acute	0 5 O
confusion	6 9 B-Disease
induced	16 7 O
by	24 2 O
a	27 1 O
high	29 4 O
-	33 1 O
dose	34 4 O
infusion	39 8 O
of	48 2 O
5	51 1 B-Chemical
-	52 1 I-Chemical
fluorouracil	53 12 I-Chemical
and	66 3 O
folinic	70 7 B-Chemical
acid	78 4 I-Chemical
.	82 1 O

A	84 1 O
61	86 2 O
-	88 1 O
year	89 4 O
-	93 1 O
old	94 3 O
man	98 3 O
was	102 3 O
treated	106 7 O
with	114 4 O
combination	119 11 O
chemotherapy	131 12 O
incorporating	144 13 O
cisplatinum	158 11 B-Chemical
,	169 1 O
etoposide	171 9 B-Chemical
,	180 1 O
high	182 4 O
-	186 1 O
dose	187 4 O
5	192 1 B-Chemical
-	193 1 I-Chemical
fluorouracil	194 12 I-Chemical
(	207 1 O
2	208 1 O
,	209 1 O
250	210 3 O
mg	214 2 O
/	216 1 O
m2	217 2 O
/	219 1 O
24	220 2 O
hours	223 5 O
)	228 1 O
and	230 3 O
folinic	234 7 B-Chemical
acid	242 4 I-Chemical
for	247 3 O
an	251 2 O
inoperable	254 10 O
gastric	265 7 B-Disease
adenocarcinoma	273 14 I-Disease
.	287 1 O

He	289 2 O
developed	292 9 O
acute	302 5 O
neurologic	308 10 O
symptoms	319 8 O
of	328 2 O
mental	331 6 O
confusion	338 9 B-Disease
,	347 1 O
disorientation	349 14 B-Disease
and	364 3 O
irritability	368 12 B-Disease
,	380 1 O
and	382 3 O
then	386 4 O
lapsed	391 6 O
into	398 4 O
a	403 1 O
deep	405 4 O
coma	410 4 B-Disease
,	414 1 O
lasting	416 7 O
for	424 3 O
approximately	428 13 O
40	442 2 O
hours	445 5 O
during	451 6 O
the	458 3 O
first	462 5 O
dose	468 4 O
(	473 1 O
day	474 3 O
2	478 1 O
)	479 1 O
of	481 2 O
5	484 1 B-Chemical
-	485 1 I-Chemical
fluorouracil	486 12 I-Chemical
and	499 3 O
folinic	503 7 B-Chemical
acid	511 4 I-Chemical
infusion	516 8 O
.	524 1 O

This	526 4 O
complication	531 12 O
reappeared	544 10 O
on	555 2 O
day	558 3 O
25	562 2 O
during	565 6 O
the	572 3 O
second	576 6 O
dose	583 4 O
of	588 2 O
5	591 1 B-Chemical
-	592 1 I-Chemical
fluorouracil	593 12 I-Chemical
and	606 3 O
folinic	610 7 B-Chemical
acid	618 4 I-Chemical
,	622 1 O
which	624 5 O
were	630 4 O
then	635 4 O
the	640 3 O
only	644 4 O
drugs	649 5 O
given	655 5 O
.	660 1 O

Because	662 7 O
folinic	670 7 B-Chemical
acid	678 4 I-Chemical
was	683 3 O
unlikely	687 8 O
to	696 2 O
be	699 2 O
associated	702 10 O
with	713 4 O
this	718 4 O
condition	723 9 O
,	732 1 O
neurotoxicity	734 13 B-Disease
due	748 3 O
to	752 2 O
high	755 4 O
-	759 1 O
dose	760 4 O
5	765 1 B-Chemical
-	766 1 I-Chemical
fluorouracil	767 12 I-Chemical
was	780 3 O
highly	784 6 O
suspected	791 9 O
.	800 1 O

The	802 3 O
pathogenesis	806 12 O
of	819 2 O
5	822 1 B-Chemical
-	823 1 I-Chemical
fluorouracil	824 12 I-Chemical
neurotoxicity	837 13 B-Disease
may	851 3 O
be	855 2 O
due	858 3 O
to	862 2 O
a	865 1 O
Krebs	867 5 O
cycle	873 5 O
blockade	879 8 O
by	888 2 O
fluoroacetate	891 13 B-Chemical
and	905 3 O
fluorocitrate	909 13 B-Chemical
,	922 1 O
thiamine	924 8 B-Chemical
deficiency	933 10 O
,	943 1 O
or	945 2 O
dihydrouracil	948 13 B-Chemical
dehydrogenase	962 13 O
deficiency	976 10 O
.	986 1 O

High	988 4 O
-	992 1 O
dose	993 4 O
5	998 1 B-Chemical
-	999 1 I-Chemical
fluorouracil	1000 12 I-Chemical
/	1012 1 O
folinic	1013 7 B-Chemical
acid	1021 4 I-Chemical
infusion	1026 8 O
therapy	1035 7 O
has	1043 3 O
recently	1047 8 O
become	1056 6 O
a	1063 1 O
popular	1065 7 O
regimen	1073 7 O
for	1081 3 O
various	1085 7 O
cancers	1093 7 B-Disease
.	1100 1 O

It	1102 2 O
is	1105 2 O
necessary	1108 9 O
that	1118 4 O
both	1123 4 O
oncologists	1128 11 O
and	1140 3 O
neurologists	1144 12 O
be	1157 2 O
fully	1160 5 O
aware	1166 5 O
of	1172 2 O
this	1175 4 O
unusual	1180 7 O
complication	1188 12 O
.	1200 1 O

Effect	0 6 O
of	7 2 O
switching	10 9 O
carbamazepine	20 13 B-Chemical
to	34 2 O
oxcarbazepine	37 13 B-Chemical
on	51 2 O
the	54 3 O
plasma	58 6 O
levels	65 6 O
of	72 2 O
neuroleptics	75 12 O
.	87 1 O

A	89 1 O
case	91 4 O
report	96 6 O
.	102 1 O

Carbamazepine	104 13 B-Chemical
was	118 3 O
switched	122 8 O
to	131 2 O
its	134 3 O
10	138 2 O
-	140 1 O
keto	141 4 O
analogue	146 8 O
oxcarbazepine	155 13 B-Chemical
among	169 5 O
six	175 3 O
difficult	179 9 O
-	188 1 O
to	189 2 O
-	191 1 O
treat	192 5 O
schizophrenic	198 13 B-Disease
or	212 2 O
organic	215 7 B-Disease
psychotic	223 9 I-Disease
patients	233 8 O
using	242 5 O
concomitantly	248 13 O
haloperidol	262 11 B-Chemical
,	273 1 O
chlorpromazine	275 14 B-Chemical
or	290 2 O
clozapine	293 9 B-Chemical
.	302 1 O

This	304 4 O
change	309 6 O
resulted	316 8 O
within	325 6 O
2	332 1 O
-	333 1 O
4	334 1 O
weeks	336 5 O
in	342 2 O
the	345 3 O
50	349 2 O
-	351 1 O
200	352 3 O
%	355 1 O
increase	357 8 O
in	366 2 O
the	369 3 O
plasma	373 6 O
levels	380 6 O
of	387 2 O
these	390 5 O
neuroleptics	396 12 O
and	409 3 O
the	413 3 O
appearance	417 10 O
of	428 2 O
extrapyramidal	431 14 B-Disease
symptoms	446 8 I-Disease
.	454 1 O

None	456 4 O
of	461 2 O
the	464 3 O
patients	468 8 O
showed	477 6 O
any	484 3 O
clinical	488 8 O
deteriotation	497 13 O
during	511 6 O
the	518 3 O
following	522 9 O
3	532 1 O
-	533 1 O
6	534 1 O
months	536 6 O
.	542 1 O

The	544 3 O
results	548 7 O
of	556 2 O
this	559 4 O
case	564 4 O
report	569 6 O
support	576 7 O
the	584 3 O
idea	588 4 O
that	593 4 O
in	598 2 O
contrast	601 8 O
with	610 4 O
carbamazepine	615 13 B-Chemical
oxcarbazepine	629 13 B-Chemical
does	643 4 O
not	648 3 O
induce	652 6 O
the	659 3 O
hepatic	663 7 O
microsomal	671 10 O
enzyme	682 6 O
systems	689 7 O
regulating	697 10 O
the	708 3 O
inactivation	712 12 O
of	725 2 O
antipsychotic	728 13 O
drugs	742 5 O
.	747 1 O

Erythema	0 8 B-Disease
multiforme	9 10 I-Disease
and	20 3 O
hypersensitivity	24 16 B-Disease
myocarditis	41 11 I-Disease
caused	53 6 O
by	60 2 O
ampicillin	63 10 B-Chemical
.	73 1 O

OBJECTIVE	75 9 O
:	84 1 O
To	86 2 O
report	89 6 O
a	96 1 O
case	98 4 O
of	103 2 O
erythema	106 8 B-Disease
multiforme	115 10 I-Disease
and	126 3 O
hypersensitivity	130 16 B-Disease
myocarditis	147 11 I-Disease
caused	159 6 O
by	166 2 O
ampicillin	169 10 B-Chemical
.	179 1 O

CASE	181 4 O
SUMMARY	186 7 O
:	193 1 O
A	195 1 O
13	197 2 O
-	199 1 O
year	200 4 O
-	204 1 O
old	205 3 O
boy	209 3 O
was	213 3 O
treated	217 7 O
with	225 4 O
ampicillin	230 10 B-Chemical
and	241 3 O
gentamicin	245 10 B-Chemical
because	256 7 O
of	264 2 O
suspected	267 9 O
septicemia	277 10 B-Disease
.	287 1 O

Medications	289 11 O
were	301 4 O
discontinued	306 12 O
when	319 4 O
erythema	324 8 B-Disease
multiforme	333 10 I-Disease
and	344 3 O
congestive	348 10 B-Disease
heart	359 5 I-Disease
failure	365 7 I-Disease
caused	373 6 O
by	380 2 O
myocarditis	383 11 B-Disease
occurred	395 8 O
.	403 1 O

The	405 3 O
patient	409 7 O
was	417 3 O
treated	421 7 O
with	429 4 O
methylprednisolone	434 18 B-Chemical
and	453 3 O
gradually	457 9 O
improved	467 8 O
.	475 1 O

Macrophage	477 10 O
-	487 1 O
migration	488 9 O
inhibition	498 10 O
(	509 1 O
MIF	510 3 O
)	513 1 O
test	515 4 O
with	520 4 O
ampicillin	525 10 B-Chemical
was	536 3 O
positive	540 8 O
.	548 1 O

DISCUSSION	550 10 O
:	560 1 O
After	562 5 O
most	568 4 O
infections	573 10 B-Disease
causing	584 7 O
erythema	592 8 B-Disease
multiforme	601 10 I-Disease
and	612 3 O
myocarditis	616 11 B-Disease
were	628 4 O
ruled	633 5 O
out	639 3 O
,	642 1 O
a	644 1 O
drug	646 4 B-Disease
-	650 1 I-Disease
induced	651 7 I-Disease
allergic	659 8 I-Disease
reaction	668 8 I-Disease
was	677 3 O
suspected	681 9 O
.	690 1 O

Positive	692 8 O
MIF	701 3 O
test	705 4 O
for	710 3 O
ampicillin	714 10 B-Chemical
showed	725 6 O
sensitization	732 13 O
of	746 2 O
the	749 3 O
patient	753 7 O
'	760 1 O
s	761 1 O
lymphocytes	763 11 O
to	775 2 O
ampicillin	778 10 B-Chemical
.	788 1 O

CONCLUSIONS	790 11 O
:	801 1 O
Hypersensitivity	803 16 B-Disease
myocarditis	820 11 I-Disease
is	832 2 O
a	835 1 O
rare	837 4 O
and	842 3 O
dangerous	846 9 O
manifestation	856 13 O
of	870 2 O
allergy	873 7 B-Disease
to	881 2 O
penicillins	884 11 B-Chemical
.	895 1 O

Immediate	0 9 O
allergic	10 8 B-Disease
reactions	19 9 I-Disease
to	29 2 O
amoxicillin	32 11 B-Chemical
.	43 1 O

A	45 1 O
large	47 5 O
group	53 5 O
of	59 2 O
patients	62 8 O
with	71 4 O
suspected	76 9 O
allergic	86 8 B-Disease
reactions	95 9 I-Disease
to	105 2 O
beta	108 4 B-Chemical
-	112 1 I-Chemical
lactam	113 6 I-Chemical
antibiotics	120 11 O
was	132 3 O
evaluated	136 9 O
.	145 1 O

A	147 1 O
detailed	149 8 O
clinical	158 8 O
history	167 7 O
,	174 1 O
together	176 8 O
with	185 4 O
skin	190 4 O
tests	195 5 O
,	200 1 O
RAST	202 4 O
(	207 1 O
radioallergosorbent	208 19 O
test	228 4 O
)	232 1 O
,	233 1 O
and	235 3 O
controlled	239 10 O
challenge	250 9 O
tests	260 5 O
,	265 1 O
was	267 3 O
used	271 4 O
to	276 2 O
establish	279 9 O
whether	289 7 O
patients	297 8 O
allergic	306 8 B-Disease
to	315 2 O
beta	318 4 B-Chemical
-	322 1 I-Chemical
lactam	323 6 I-Chemical
antibiotics	330 11 O
had	342 3 O
selective	346 9 O
immediate	356 9 O
allergic	366 8 B-Disease
responses	375 9 O
to	385 2 O
amoxicillin	388 11 B-Chemical
(	400 1 O
AX	401 2 B-Chemical
)	403 1 O
or	405 2 O
were	408 4 O
cross	413 5 O
-	418 1 O
reacting	419 8 O
with	428 4 O
other	433 5 O
penicillin	439 10 B-Chemical
derivatives	450 11 O
.	461 1 O

Skin	463 4 O
tests	468 5 O
were	474 4 O
performed	479 9 O
with	489 4 O
benzylpenicilloyl	494 17 B-Chemical
-	511 1 I-Chemical
poly	512 4 I-Chemical
-	516 1 I-Chemical
L	517 1 I-Chemical
-	518 1 I-Chemical
lysine	519 6 I-Chemical
(	526 1 O
BPO	527 3 B-Chemical
-	530 1 I-Chemical
PLL	531 3 I-Chemical
)	534 1 O
,	535 1 O
benzylpenicilloate	537 18 B-Chemical
,	555 1 O
benzylpenicillin	557 16 B-Chemical
(	574 1 O
PG	575 2 B-Chemical
)	577 1 O
,	578 1 O
ampicillin	580 10 B-Chemical
(	591 1 O
AMP	592 3 B-Chemical
)	595 1 O
,	596 1 O
and	598 3 O
AX	602 2 B-Chemical
.	604 1 O

RAST	606 4 O
for	611 3 O
BPO	615 3 B-Chemical
-	618 1 I-Chemical
PLL	619 3 I-Chemical
and	623 3 O
AX	627 2 B-Chemical
-	629 1 O
PLL	630 3 O
was	634 3 O
done	638 4 O
.	642 1 O

When	644 4 O
both	649 4 O
skin	654 4 O
test	659 4 O
and	664 3 O
RAST	668 4 O
for	673 3 O
BPO	677 3 B-Chemical
were	681 4 O
negative	686 8 O
,	694 1 O
single	696 6 O
-	702 1 O
blind	703 5 O
,	708 1 O
placebo	710 7 O
-	717 1 O
controlled	718 10 O
challenge	729 9 O
tests	739 5 O
were	745 4 O
done	750 4 O
to	755 2 O
ensure	758 6 O
tolerance	765 9 O
of	775 2 O
PG	778 2 B-Chemical
or	781 2 O
sensitivity	784 11 O
to	796 2 O
AX	799 2 B-Chemical
.	801 1 O

A	803 1 O
total	805 5 O
of	811 2 O
177	814 3 O
patients	818 8 O
were	827 4 O
diagnosed	832 9 O
as	842 2 O
allergic	845 8 B-Disease
to	854 2 O
beta	857 4 B-Chemical
-	861 1 I-Chemical
lactam	862 6 I-Chemical
antibiotics	869 11 O
.	880 1 O

We	882 2 O
selected	885 8 O
the	894 3 O
54	898 2 O
(	901 1 O
30	902 2 O
.	904 1 O
5	905 1 O
%	906 1 O
)	907 1 O
cases	909 5 O
of	915 2 O
immediate	918 9 O
AX	928 2 B-Chemical
allergy	931 7 B-Disease
with	939 4 O
good	944 4 O
tolerance	949 9 O
of	959 2 O
PG	962 2 B-Chemical
.	964 1 O

Anaphylaxis	966 11 B-Disease
was	978 3 O
seen	982 4 O
in	987 2 O
37	990 2 O
patients	993 8 O
(	1002 1 O
69	1003 2 O
%	1005 1 O
)	1006 1 O
,	1007 1 O
the	1009 3 O
other	1013 5 O
17	1019 2 O
(	1022 1 O
31	1023 2 O
%	1025 1 O
)	1026 1 O
having	1028 6 O
urticaria	1035 9 B-Disease
and	1045 3 O
/	1048 1 O
or	1049 2 O
angioedema	1052 10 B-Disease
.	1062 1 O

All	1064 3 O
the	1068 3 O
patients	1072 8 O
were	1081 4 O
skin	1086 4 O
test	1091 4 O
negative	1096 8 O
to	1105 2 O
BPO	1108 3 B-Chemical
;	1111 1 O
49	1113 2 O
of	1116 2 O
51	1119 2 O
(	1122 1 O
96	1123 2 O
%	1125 1 O
)	1126 1 O
were	1128 4 O
also	1133 4 O
negative	1138 8 O
to	1147 2 O
MDM	1150 3 B-Disease
,	1153 1 O
and	1155 3 O
44	1159 2 O
of	1162 2 O
46	1165 2 O
(	1168 1 O
96	1169 2 O
%	1171 1 O
)	1172 1 O
to	1174 2 O
PG	1177 2 B-Chemical
.	1179 1 O

Skin	1181 4 O
tests	1186 5 O
with	1192 4 O
AX	1197 2 B-Chemical
were	1200 4 O
positive	1205 8 O
in	1214 2 O
34	1217 2 O
(	1220 1 O
63	1221 2 O
%	1223 1 O
)	1224 1 O
patients	1226 8 O
.	1234 1 O

RAST	1236 4 O
was	1241 3 O
positive	1245 8 O
for	1254 3 O
AX	1258 2 B-Chemical
in	1261 2 O
22	1264 2 O
patients	1267 8 O
(	1276 1 O
41	1277 2 O
%	1279 1 O
)	1280 1 O
and	1282 3 O
to	1286 2 O
BPO	1289 3 B-Chemical
in	1293 2 O
just	1296 4 O
5	1301 1 O
(	1303 1 O
9	1304 1 O
%	1305 1 O
)	1306 1 O
.	1307 1 O

None	1309 4 O
of	1314 2 O
the	1317 3 O
sera	1321 4 O
with	1326 4 O
negative	1331 8 O
RAST	1340 4 O
for	1345 3 O
AX	1349 2 B-Chemical
were	1352 4 O
positive	1357 8 O
to	1366 2 O
BPO	1369 3 B-Chemical
.	1372 1 O

Challenge	1374 9 O
tests	1384 5 O
with	1390 4 O
AX	1395 2 B-Chemical
were	1398 4 O
performed	1403 9 O
in	1413 2 O
23	1416 2 O
subjects	1419 8 O
(	1428 1 O
43	1429 2 O
%	1431 1 O
)	1432 1 O
to	1434 2 O
establish	1437 9 O
the	1447 3 O
diagnosis	1451 9 O
of	1461 2 O
immediate	1464 9 O
allergic	1474 8 B-Disease
reaction	1483 8 I-Disease
to	1492 2 O
AX	1495 2 B-Chemical
,	1497 1 O
and	1499 3 O
in	1503 2 O
15	1506 2 O
cases	1509 5 O
(	1515 1 O
28	1516 2 O
%	1518 1 O
)	1519 1 O
both	1521 4 O
skin	1526 4 O
test	1531 4 O
and	1536 3 O
RAST	1540 4 O
for	1545 3 O
AX	1549 2 B-Chemical
were	1552 4 O
negative	1557 8 O
.	1565 1 O

PG	1567 2 B-Chemical
was	1570 3 O
well	1574 4 O
tolerated	1579 9 O
by	1589 2 O
all	1592 3 O
54	1596 2 O
patients	1599 8 O
.	1607 1 O

We	1609 2 O
describe	1612 8 O
the	1621 3 O
largest	1625 7 O
group	1633 5 O
of	1639 2 O
AX	1642 2 B-Chemical
-	1644 1 O
allergic	1645 8 B-Disease
patients	1654 8 O
who	1663 3 O
have	1667 4 O
tolerated	1672 9 O
PG	1682 2 B-Chemical
reported	1685 8 O
so	1694 2 O
far	1697 3 O
.	1700 1 O

Diagnosis	1702 9 O
of	1712 2 O
these	1715 5 O
patients	1721 8 O
can	1730 3 O
be	1734 2 O
achieved	1737 8 O
only	1746 4 O
if	1751 2 O
specific	1754 8 O
AX	1763 2 B-Chemical
-	1765 1 O
related	1766 7 O
reagents	1774 8 O
are	1783 3 O
employed	1787 8 O
.	1795 1 O

Further	1797 7 O
studies	1805 7 O
are	1813 3 O
necessary	1817 9 O
to	1827 2 O
determine	1830 9 O
the	1840 3 O
exact	1844 5 O
extent	1850 6 O
of	1857 2 O
this	1860 4 O
problem	1865 7 O
and	1873 3 O
to	1877 2 O
improve	1880 7 O
the	1888 3 O
efficacy	1892 8 O
of	1901 2 O
diagnostic	1904 10 O
methods	1915 7 O
.	1922 1 O

Persistent	0 10 O
paralysis	11 9 B-Disease
after	21 5 O
prolonged	27 9 O
use	37 3 O
of	41 2 O
atracurium	44 10 B-Chemical
in	55 2 O
the	58 3 O
absence	62 7 O
of	70 2 O
corticosteroids	73 15 O
.	88 1 O

Neuromuscular	90 13 O
blocking	104 8 O
agents	113 6 O
(	120 1 O
NMBAs	121 5 O
)	126 1 O
are	128 3 O
often	132 5 O
used	138 4 O
for	143 3 O
patients	147 8 O
requiring	156 9 O
prolonged	166 9 O
mechanical	176 10 O
ventilation	187 11 O
.	198 1 O

Reports	200 7 O
of	208 2 O
persistent	211 10 O
paralysis	222 9 B-Disease
after	232 5 O
the	238 3 O
discontinuance	242 14 O
of	257 2 O
these	260 5 O
drugs	266 5 O
have	272 4 O
most	277 4 O
often	282 5 O
involved	288 8 O
aminosteroid	297 12 O
-	309 1 O
based	310 5 O
NMBAs	316 5 O
such	322 4 O
as	327 2 O
vecuronium	330 10 B-Chemical
bromide	341 7 I-Chemical
,	348 1 O
especially	350 10 O
when	361 4 O
used	366 4 O
in	371 2 O
conjunction	374 11 O
with	386 4 O
corticosteroids	391 15 O
.	406 1 O

Atracurium	408 10 B-Chemical
besylate	419 8 I-Chemical
,	427 1 O
a	429 1 O
short	431 5 O
-	436 1 O
acting	437 6 O
benzylisoquinolinium	444 20 B-Chemical
NMBA	465 4 O
that	470 4 O
is	475 2 O
eliminated	478 10 O
independently	489 13 O
of	503 2 O
renal	506 5 O
or	512 2 O
hepatic	515 7 O
function	523 8 O
,	531 1 O
has	533 3 O
also	537 4 O
been	542 4 O
associated	547 10 O
with	558 4 O
persistent	563 10 O
paralysis	574 9 B-Disease
,	583 1 O
but	585 3 O
only	589 4 O
when	594 4 O
used	599 4 O
with	604 4 O
corticosteroids	609 15 O
.	624 1 O

We	626 2 O
report	629 6 O
a	636 1 O
case	638 4 O
of	643 2 O
atracurium	646 10 B-Chemical
-	656 1 O
related	657 7 O
paralysis	665 9 B-Disease
persisting	675 10 O
for	686 3 O
approximately	690 13 O
50	704 2 O
hours	707 5 O
in	713 2 O
a	716 1 O
patient	718 7 O
who	726 3 O
was	730 3 O
not	734 3 O
treated	738 7 O
with	746 4 O
corticosteroids	751 15 O
.	766 1 O

Habitual	0 8 O
use	9 3 O
of	13 2 O
acetaminophen	16 13 B-Chemical
as	30 2 O
a	33 1 O
risk	35 4 O
factor	40 6 O
for	47 3 O
chronic	51 7 B-Disease
renal	59 5 I-Disease
failure	65 7 I-Disease
:	72 1 O
a	74 1 O
comparison	76 10 O
with	87 4 O
phenacetin	92 10 B-Chemical
.	102 1 O

Six	104 3 O
epidemiologic	108 13 O
studies	122 7 O
in	130 2 O
the	133 3 O
United	137 6 O
States	144 6 O
and	151 3 O
Europe	155 6 O
indicate	162 8 O
that	171 4 O
habitual	176 8 O
use	185 3 O
of	189 2 O
phenacetin	192 10 B-Chemical
is	203 2 O
associated	206 10 O
with	217 4 O
the	222 3 O
development	226 11 O
of	238 2 O
chronic	241 7 B-Disease
renal	249 5 I-Disease
failure	255 7 I-Disease
and	263 3 O
end	267 3 B-Disease
-	270 1 I-Disease
stage	271 5 I-Disease
renal	277 5 I-Disease
disease	283 7 I-Disease
(	291 1 O
ESRD	292 4 B-Disease
)	296 1 O
,	297 1 O
with	299 4 O
a	304 1 O
relative	306 8 O
risk	315 4 O
in	320 2 O
the	323 3 O
range	327 5 O
of	333 2 O
4	336 1 O
to	338 2 O
19	341 2 O
.	343 1 O

As	345 2 O
a	348 1 O
result	350 6 O
of	357 2 O
these	360 5 O
and	366 3 O
other	370 5 O
studies	376 7 O
,	383 1 O
phenacetin	385 10 B-Chemical
has	396 3 O
now	400 3 O
been	404 4 O
withdrawn	409 9 O
from	419 4 O
the	424 3 O
market	428 6 O
in	435 2 O
most	438 4 O
countries	443 9 O
.	452 1 O

However	454 7 O
,	461 1 O
three	463 5 O
case	469 4 O
control	474 7 O
studies	482 7 O
,	489 1 O
one	491 3 O
each	495 4 O
in	500 2 O
North	503 5 O
Carolina	509 8 O
,	517 1 O
northern	519 8 O
Maryland	528 8 O
,	536 1 O
and	538 3 O
West	542 4 O
Berlin	547 6 O
,	553 1 O
Germany	555 7 O
,	562 1 O
showed	564 6 O
that	571 4 O
habitual	576 8 O
use	585 3 O
of	589 2 O
acetaminophen	592 13 B-Chemical
is	606 2 O
also	609 4 O
associated	614 10 O
with	625 4 O
chronic	630 7 B-Disease
renal	638 5 I-Disease
failure	644 7 I-Disease
and	652 3 O
ESRD	656 4 B-Disease
,	660 1 O
with	662 4 O
a	667 1 O
relative	669 8 O
risk	678 4 O
in	683 2 O
the	686 3 O
range	690 5 O
of	696 2 O
2	699 1 O
to	701 2 O
4	704 1 O
.	705 1 O

These	707 5 O
studies	713 7 O
suggest	721 7 O
that	729 4 O
both	734 4 O
phenacetin	739 10 B-Chemical
and	750 3 O
acetaminophen	754 13 B-Chemical
may	768 3 O
contribute	772 10 O
to	783 2 O
the	786 3 O
burden	790 6 O
of	797 2 O
ESRD	800 4 B-Disease
,	804 1 O
with	806 4 O
the	811 3 O
risk	815 4 O
of	820 2 O
the	823 3 O
latter	827 6 O
being	834 5 O
somewhat	840 8 O
less	849 4 O
than	854 4 O
that	859 4 O
of	864 2 O
the	867 3 O
former	871 6 O
.	877 1 O

This	879 4 O
apparent	884 8 O
difference	893 10 O
in	904 2 O
risk	907 4 O
may	912 3 O
not	916 3 O
be	920 2 O
due	923 3 O
to	927 2 O
differences	930 11 O
in	942 2 O
nephrotoxic	945 11 B-Disease
potential	957 9 O
of	967 2 O
the	970 3 O
drugs	974 5 O
themselves	980 10 O
.	990 1 O

A	992 1 O
lower	994 5 O
relative	1000 8 O
risk	1009 4 O
would	1014 5 O
be	1020 2 O
expected	1023 8 O
for	1032 3 O
acetaminophen	1036 13 B-Chemical
if	1050 2 O
the	1053 3 O
risk	1057 4 O
of	1062 2 O
both	1065 4 O
drugs	1070 5 O
in	1076 2 O
combination	1079 11 O
with	1091 4 O
other	1096 5 O
analgesics	1102 10 O
was	1113 3 O
higher	1117 6 O
than	1124 4 O
the	1129 3 O
risk	1133 4 O
of	1138 2 O
either	1141 6 O
agent	1148 5 O
alone	1154 5 O
.	1159 1 O

Thus	1161 4 O
,	1165 1 O
acetaminophen	1167 13 B-Chemical
has	1181 3 O
been	1185 4 O
used	1190 4 O
both	1195 4 O
as	1200 2 O
a	1203 1 O
single	1205 6 O
agent	1212 5 O
and	1218 3 O
in	1222 2 O
combination	1225 11 O
with	1237 4 O
other	1242 5 O
analgesics	1248 10 O
,	1258 1 O
whereas	1260 7 O
phenacetin	1268 10 B-Chemical
was	1279 3 O
available	1283 9 O
only	1293 4 O
in	1298 2 O
combinations	1301 12 O
.	1313 1 O

The	1315 3 O
possibility	1319 11 O
that	1331 4 O
habitual	1336 8 O
use	1345 3 O
of	1349 2 O
acetaminophen	1352 13 B-Chemical
alone	1366 5 O
increases	1372 9 O
the	1382 3 O
risk	1386 4 O
of	1391 2 O
ESRD	1394 4 B-Disease
has	1399 3 O
not	1403 3 O
been	1407 4 O
clearly	1412 7 O
demonstrated	1420 12 O
,	1432 1 O
but	1434 3 O
cannot	1438 6 O
be	1445 2 O
dismissed	1448 9 O
.	1457 1 O

Reduction	0 9 O
of	10 2 O
heparan	13 7 B-Chemical
sulphate	21 8 I-Chemical
-	29 1 O
associated	30 10 O
anionic	41 7 O
sites	49 5 O
in	55 2 O
the	58 3 O
glomerular	62 10 O
basement	73 8 O
membrane	82 8 O
of	91 2 O
rats	94 4 O
with	99 4 O
streptozotocin	104 14 B-Chemical
-	118 1 O
induced	119 7 O
diabetic	127 8 B-Disease
nephropathy	136 11 I-Disease
.	147 1 O

Heparan	149 7 B-Chemical
sulphate	157 8 I-Chemical
-	165 1 O
associated	166 10 O
anionic	177 7 O
sites	185 5 O
in	191 2 O
the	194 3 O
glomerular	198 10 O
basement	209 8 O
membrane	218 8 O
were	227 4 O
studied	232 7 O
in	240 2 O
rats	243 4 O
8	248 1 O
months	250 6 O
after	257 5 O
induction	263 9 O
of	273 2 O
diabetes	276 8 B-Disease
by	285 2 O
streptozotocin	288 14 B-Chemical
and	303 3 O
in	307 2 O
age	310 3 O
-	313 1 O
adn	315 3 O
sex	319 3 O
-	322 1 O
matched	323 7 O
control	331 7 O
rats	339 4 O
,	343 1 O
employing	345 9 O
the	355 3 O
cationic	359 8 O
dye	368 3 O
cuprolinic	372 10 B-Chemical
blue	383 4 I-Chemical
.	387 1 O

Morphometric	389 12 O
analysis	402 8 O
at	411 2 O
the	414 3 O
ultrastructural	418 15 O
level	434 5 O
was	440 3 O
performed	444 9 O
using	454 5 O
a	460 1 O
computerized	462 12 O
image	475 5 O
processor	481 9 O
.	490 1 O

The	492 3 O
heparan	496 7 B-Chemical
sulphate	504 8 I-Chemical
specificity	513 11 O
of	525 2 O
the	528 3 O
cuprolinic	532 10 B-Chemical
blue	543 4 I-Chemical
staining	548 8 O
was	557 3 O
demonstrated	561 12 O
by	574 2 O
glycosaminoglycan	577 17 B-Chemical
-	594 1 O
degrading	595 9 O
enzymes	605 7 O
,	612 1 O
showing	614 7 O
that	622 4 O
pretreatment	627 12 O
of	640 2 O
the	643 3 O
sections	647 8 O
with	656 4 O
heparitinase	661 12 O
abolished	674 9 O
all	684 3 O
staining	688 8 O
,	696 1 O
whereas	698 7 O
chondroitinase	706 14 O
ABC	721 3 O
had	725 3 O
no	729 2 O
effect	732 6 O
.	738 1 O

The	740 3 O
majority	744 8 O
of	753 2 O
anionic	756 7 O
sites	764 5 O
(	770 1 O
74	771 2 O
%	773 1 O
in	775 2 O
diabetic	778 8 B-Disease
and	787 3 O
81	791 2 O
%	793 1 O
in	795 2 O
control	798 7 O
rats	806 4 O
)	810 1 O
were	812 4 O
found	817 5 O
within	823 6 O
the	830 3 O
lamina	834 6 O
rara	841 4 O
externa	846 7 O
of	854 2 O
the	857 3 O
glomerular	861 10 O
basement	872 8 O
membrane	881 8 O
.	889 1 O

A	891 1 O
minority	893 8 O
of	902 2 O
anionic	905 7 O
sites	913 5 O
were	919 4 O
scattered	924 9 O
throughout	934 10 O
the	945 3 O
lamina	949 6 O
densa	956 5 O
and	962 3 O
lamina	966 6 O
rara	973 4 O
interna	978 7 O
,	985 1 O
and	987 3 O
were	991 4 O
significantly	996 13 O
smaller	1010 7 O
than	1018 4 O
those	1023 5 O
in	1029 2 O
the	1032 3 O
lamina	1036 6 O
rara	1043 4 O
externa	1048 7 O
of	1056 2 O
the	1059 3 O
glomerular	1063 10 O
basement	1074 8 O
membrane	1083 8 O
(	1092 1 O
p	1093 1 O
<	1094 1 O
0	1095 1 O
.	1096 1 O
001	1097 3 O
and	1101 3 O
p	1105 1 O
<	1106 1 O
0	1107 1 O
.	1108 1 O
01	1109 2 O
for	1112 3 O
diabetic	1116 8 B-Disease
and	1125 3 O
control	1129 7 O
rats	1137 4 O
,	1141 1 O
respectively	1143 12 O
)	1155 1 O
.	1156 1 O

Diabetic	1158 8 B-Disease
rats	1167 4 O
progressively	1172 13 O
developed	1186 9 O
albuminuria	1196 11 B-Disease
reaching	1208 8 O
40	1217 2 O
.	1219 1 O
3	1220 1 O
(	1222 1 O
32	1223 2 O
.	1225 1 O
2	1226 1 O
-	1227 1 O
62	1228 2 O
.	1230 1 O
0	1231 1 O
)	1232 1 O
mg	1234 2 O
/	1236 1 O
24	1237 2 O
h	1240 1 O
after	1242 5 O
8	1248 1 O
months	1250 6 O
in	1257 2 O
contrast	1260 8 O
to	1269 2 O
the	1272 3 O
control	1276 7 O
animals	1284 7 O
(	1292 1 O
0	1293 1 O
.	1294 1 O
8	1295 1 O
(	1297 1 O
0	1298 1 O
.	1299 1 O
2	1300 1 O
-	1301 1 O
0	1302 1 O
.	1303 1 O
9	1304 1 O
)	1305 1 O
mg	1307 2 O
/	1309 1 O
24	1310 2 O
h	1313 1 O
,	1314 1 O
p	1316 1 O
<	1317 1 O
0	1318 1 O
.	1319 1 O
002	1320 3 O
)	1323 1 O
.	1324 1 O

At	1326 2 O
the	1329 3 O
same	1333 4 O
time	1338 4 O
,	1342 1 O
the	1344 3 O
number	1348 6 O
of	1355 2 O
heparan	1358 7 B-Chemical
sulphate	1366 8 I-Chemical
anionic	1375 7 O
sites	1383 5 O
and	1389 3 O
the	1393 3 O
total	1397 5 O
anionic	1403 7 O
site	1411 4 O
surface	1416 7 O
(	1424 1 O
number	1425 6 O
of	1432 2 O
anionic	1435 7 O
sites	1443 5 O
x	1449 1 O
mean	1451 4 O
anionic	1456 7 O
site	1464 4 O
surface	1469 7 O
)	1476 1 O
in	1478 2 O
the	1481 3 O
lamina	1485 6 O
rara	1492 4 O
externa	1497 7 O
of	1505 2 O
the	1508 3 O
glomerular	1512 10 O
basement	1523 8 O
membrane	1532 8 O
was	1541 3 O
reduced	1545 7 O
by	1553 2 O
19	1556 2 O
%	1558 1 O
(	1560 1 O
p	1561 1 O
<	1562 1 O
0	1563 1 O
.	1564 1 O
021	1565 3 O
)	1568 1 O
and	1570 3 O
by	1574 2 O
26	1577 2 O
%	1579 1 O
(	1581 1 O
p	1582 1 O
<	1583 1 O
0	1584 1 O
.	1585 1 O
02	1586 2 O
)	1588 1 O
,	1589 1 O
respectively	1591 12 O
.	1603 1 O

Number	1605 6 O
and	1612 3 O
total	1616 5 O
anionic	1622 7 O
site	1630 4 O
surface	1635 7 O
in	1643 2 O
the	1646 3 O
remaining	1650 9 O
part	1660 4 O
of	1665 2 O
the	1668 3 O
glomerular	1672 10 O
basement	1683 8 O
membrane	1692 8 O
(	1701 1 O
lamina	1702 6 O
densa	1709 5 O
and	1715 3 O
lamina	1719 6 O
rara	1726 4 O
interna	1731 7 O
)	1738 1 O
were	1740 4 O
not	1745 3 O
significantly	1749 13 O
changed	1763 7 O
.	1770 1 O

We	1772 2 O
conclude	1775 8 O
that	1784 4 O
in	1789 2 O
streptozotocin	1792 14 B-Chemical
-	1806 1 O
diabetic	1807 8 B-Disease
rats	1816 4 O
with	1821 4 O
an	1826 2 O
increased	1829 9 O
urinary	1839 7 O
albumin	1847 7 O
excretion	1855 9 O
,	1864 1 O
a	1866 1 O
reduced	1868 7 O
heparan	1876 7 B-Chemical
sulphate	1884 8 I-Chemical
charge	1893 6 O
barrier	1900 7 O
/	1907 1 O
density	1908 7 O
is	1916 2 O
found	1919 5 O
at	1925 2 O
the	1928 3 O
lamina	1932 6 O
rara	1939 4 O
externa	1944 7 O
of	1952 2 O
the	1955 3 O
glomerular	1959 10 O
basement	1970 8 O
membrane	1979 8 O
.	1987 1 O

Effect	0 6 O
of	7 2 O
some	10 4 O
anticancer	15 10 O
drugs	26 5 O
and	32 3 O
combined	36 8 O
chemotherapy	45 12 O
on	58 2 O
renal	61 5 B-Disease
toxicity	67 8 I-Disease
.	75 1 O

The	77 3 O
nephrotoxic	81 11 B-Disease
action	93 6 O
of	100 2 O
anticancer	103 10 O
drugs	114 5 O
such	120 4 O
as	125 2 O
nitrogranulogen	128 15 B-Chemical
(	144 1 O
NG	145 2 B-Chemical
)	147 1 O
,	148 1 O
methotrexate	150 12 B-Chemical
(	163 1 O
MTX	164 3 B-Chemical
)	167 1 O
,	168 1 O
5	170 1 B-Chemical
-	171 1 I-Chemical
fluorouracil	172 12 I-Chemical
(	185 1 O
5	186 1 B-Chemical
-	187 1 I-Chemical
FU	188 2 I-Chemical
)	190 1 O
and	192 3 O
cyclophosphamide	196 16 B-Chemical
(	213 1 O
CY	214 2 B-Chemical
)	216 1 O
administered	218 12 O
alone	231 5 O
or	237 2 O
in	240 2 O
combination	243 11 O
[	255 1 O
MTX	256 3 B-Chemical
+	260 1 O
5	262 1 B-Chemical
-	263 1 I-Chemical
FU	264 2 I-Chemical
+	267 1 O
CY	269 2 B-Chemical
(	272 1 O
CMF	273 3 O
)	276 1 O
]	277 1 O
was	279 3 O
evaluated	283 9 O
in	293 2 O
experiments	296 11 O
on	308 2 O
Wistar	311 6 O
rats	318 4 O
.	322 1 O

After	324 5 O
drug	330 4 O
administration	335 14 O
,	349 1 O
creatinine	351 10 B-Chemical
concentrations	362 14 O
in	377 2 O
the	380 3 O
plasma	384 6 O
and	391 3 O
in	395 2 O
the	398 3 O
urine	402 5 O
of	408 2 O
the	411 3 O
rats	415 4 O
were	420 4 O
determined	425 10 O
,	435 1 O
as	437 2 O
well	440 4 O
as	445 2 O
creatinine	448 10 B-Chemical
clearance	459 9 O
.	468 1 O

Histopathologic	470 15 O
evaluation	486 10 O
of	497 2 O
the	500 3 O
kidneys	504 7 O
was	512 3 O
also	516 4 O
performed	521 9 O
.	530 1 O

After	532 5 O
MTX	538 3 B-Chemical
administration	542 14 O
a	557 1 O
significant	559 11 O
increase	571 8 O
(	580 1 O
p	581 1 O
=	583 1 O
0	585 1 O
.	586 1 O
0228	587 4 O
)	591 1 O
in	593 2 O
the	596 3 O
plasma	600 6 O
creatinine	607 10 B-Chemical
concentration	618 13 O
and	632 3 O
a	636 1 O
significant	638 11 O
(	650 1 O
p	651 1 O
=	653 1 O
0	655 1 O
.	656 1 O
0001	657 4 O
)	661 1 O
decrease	663 8 O
in	672 2 O
creatinine	675 10 B-Chemical
clearance	686 9 O
was	696 3 O
noted	700 5 O
compared	706 8 O
to	715 2 O
controls	718 8 O
.	726 1 O

After	728 5 O
the	734 3 O
administration	738 14 O
of	753 2 O
NG	756 2 B-Chemical
,	758 1 O
5	760 1 B-Chemical
-	761 1 I-Chemical
FU	762 2 I-Chemical
and	765 3 O
CY	769 2 B-Chemical
neither	772 7 O
a	780 1 O
statistically	782 13 O
significant	796 11 O
increase	808 8 O
in	817 2 O
creatinine	820 10 B-Chemical
concentration	831 13 O
nor	845 3 O
an	849 2 O
increase	852 8 O
in	861 2 O
creatinine	864 10 B-Chemical
clearance	875 9 O
was	885 3 O
observed	889 8 O
compared	898 8 O
to	907 2 O
the	910 3 O
group	914 5 O
receiving	920 9 O
no	930 2 O
cytostatics	933 11 O
.	944 1 O

Following	946 9 O
polytherapy	956 11 O
according	968 9 O
to	978 2 O
the	981 3 O
CMF	985 3 O
regimen	989 7 O
,	996 1 O
a	998 1 O
statistically	1000 13 O
significant	1014 11 O
decrease	1026 8 O
(	1035 1 O
p	1036 1 O
=	1038 1 O
0	1040 1 O
.	1041 1 O
0343	1042 4 O
)	1046 1 O
in	1048 2 O
creatinine	1051 10 B-Chemical
clearance	1062 9 O
was	1072 3 O
found	1076 5 O
,	1081 1 O
but	1083 3 O
creatinine	1087 10 B-Chemical
concentration	1098 13 O
did	1112 3 O
not	1116 3 O
increase	1120 8 O
significantly	1129 13 O
compared	1143 8 O
to	1152 2 O
controls	1155 8 O
.	1163 1 O

CY	1165 2 B-Chemical
caused	1168 6 O
hemorrhagic	1175 11 B-Disease
cystitis	1187 8 I-Disease
in	1196 2 O
40	1199 2 O
%	1201 1 O
of	1203 2 O
rats	1206 4 O
,	1210 1 O
but	1212 3 O
it	1216 2 O
did	1219 3 O
not	1223 3 O
cause	1227 5 O
this	1233 4 O
complication	1238 12 O
when	1251 4 O
combined	1256 8 O
with	1265 4 O
5	1270 1 B-Chemical
-	1271 1 I-Chemical
FU	1272 2 I-Chemical
and	1275 3 O
MTX	1279 3 B-Chemical
.	1282 1 O

Histologic	1284 10 O
changes	1295 7 O
were	1303 4 O
found	1308 5 O
in	1314 2 O
rat	1317 3 O
kidneys	1321 7 O
after	1329 5 O
administration	1335 14 O
of	1350 2 O
MTX	1353 3 B-Chemical
,	1356 1 O
CY	1358 2 B-Chemical
and	1361 3 O
NG	1365 2 B-Chemical
,	1367 1 O
while	1369 5 O
no	1375 2 O
such	1378 4 O
change	1383 6 O
was	1390 3 O
observed	1394 8 O
after	1403 5 O
5	1409 1 B-Chemical
-	1410 1 I-Chemical
FU	1411 2 I-Chemical
and	1414 3 O
joint	1418 5 O
administration	1424 14 O
of	1439 2 O
MTX	1442 3 B-Chemical
+	1446 1 O
5	1448 1 B-Chemical
-	1449 1 I-Chemical
FU	1450 2 I-Chemical
+	1453 1 O
CY	1455 2 B-Chemical
compared	1458 8 O
to	1467 2 O
controls	1470 8 O
.	1478 1 O

Our	1480 3 O
studies	1484 7 O
indicate	1492 8 O
that	1501 4 O
nephrotoxicity	1506 14 B-Disease
of	1521 2 O
MTX	1524 3 B-Chemical
+	1528 1 O
5	1530 1 B-Chemical
-	1531 1 I-Chemical
FU	1532 2 I-Chemical
+	1535 1 O
CY	1537 2 B-Chemical
administered	1540 12 O
jointly	1553 7 O
is	1561 2 O
lower	1564 5 O
than	1570 4 O
in	1575 2 O
monotherapy	1578 11 O
.	1589 1 O

Lithium	0 7 B-Chemical
-	7 1 O
associated	8 10 O
cognitive	19 9 B-Disease
and	29 3 I-Disease
functional	33 10 I-Disease
deficits	44 8 I-Disease
reduced	53 7 O
by	61 2 O
a	64 1 O
switch	66 6 O
to	73 2 O
divalproex	76 10 B-Chemical
sodium	87 6 I-Chemical
:	93 1 O
a	95 1 O
case	97 4 O
series	102 6 O
.	108 1 O

BACKGROUND	110 10 O
:	120 1 O
Lithium	122 7 B-Chemical
remains	130 7 O
a	138 1 O
first	140 5 O
-	145 1 O
line	146 4 O
treatment	151 9 O
for	161 3 O
the	165 3 O
acute	169 5 O
and	175 3 O
maintenance	179 11 O
treatment	191 9 O
of	201 2 O
bipolar	204 7 B-Disease
disorder	212 8 I-Disease
.	220 1 O

Although	222 8 O
much	231 4 O
has	236 3 O
been	240 4 O
written	245 7 O
about	253 5 O
the	259 3 O
management	263 10 O
of	274 2 O
the	277 3 O
more	281 4 O
common	286 6 O
adverse	293 7 O
effects	301 7 O
of	309 2 O
lithium	312 7 B-Chemical
,	319 1 O
such	321 4 O
as	326 2 O
polyuria	329 8 B-Disease
and	338 3 O
tremor	342 6 B-Disease
,	348 1 O
more	350 4 O
subtle	355 6 O
lithium	362 7 B-Chemical
side	370 4 O
effects	375 7 O
such	383 4 O
as	388 2 O
cognitive	391 9 B-Disease
deficits	401 8 I-Disease
,	409 1 O
loss	411 4 B-Disease
of	416 2 I-Disease
creativity	419 10 I-Disease
,	429 1 O
and	431 3 O
functional	435 10 B-Disease
impairments	446 11 I-Disease
remain	458 6 O
understudied	465 12 O
.	477 1 O

This	479 4 O
report	484 6 O
summarizes	491 10 O
our	502 3 O
experience	506 10 O
in	517 2 O
switching	520 9 O
bipolar	530 7 B-Disease
patients	538 8 O
from	547 4 O
lithium	552 7 B-Chemical
to	560 2 O
divalproex	563 10 B-Chemical
sodium	574 6 I-Chemical
to	581 2 O
alleviate	584 9 O
such	594 4 O
cognitive	599 9 B-Disease
and	609 3 I-Disease
functional	613 10 I-Disease
impairments	624 11 I-Disease
.	635 1 O

METHOD	637 6 O
:	643 1 O
Open	645 4 O
,	649 1 O
case	651 4 O
series	656 6 O
design	663 6 O
.	669 1 O

RESULTS	671 7 O
:	678 1 O
We	680 2 O
report	683 6 O
seven	690 5 O
cases	696 5 O
where	702 5 O
substitution	708 12 O
of	721 2 O
lithium	724 7 B-Chemical
,	731 1 O
either	733 6 O
fully	740 5 O
or	746 2 O
partially	749 9 O
,	758 1 O
with	760 4 O
divalproex	765 10 B-Chemical
sodium	776 6 I-Chemical
was	783 3 O
extremely	787 9 O
helpful	797 7 O
in	805 2 O
reducing	808 8 O
the	817 3 O
cognitive	821 9 B-Disease
,	830 1 I-Disease
motivational	832 12 I-Disease
,	844 1 I-Disease
or	846 2 I-Disease
creative	849 8 I-Disease
deficits	858 8 I-Disease
attributed	867 10 O
to	878 2 O
lithium	881 7 B-Chemical
in	889 2 O
our	892 3 O
bipolar	896 7 B-Disease
patients	904 8 O
.	912 1 O

CONCLUSION	914 10 O
:	924 1 O
In	926 2 O
this	929 4 O
preliminary	934 11 O
report	946 6 O
,	952 1 O
divalproex	954 10 B-Chemical
sodium	965 6 I-Chemical
was	972 3 O
a	976 1 O
superior	978 8 O
alternative	987 11 O
to	999 2 O
lithium	1002 7 B-Chemical
in	1010 2 O
bipolar	1013 7 B-Disease
patients	1021 8 O
experiencing	1030 12 O
cognitive	1043 9 B-Disease
deficits	1053 8 I-Disease
,	1061 1 O
loss	1063 4 B-Disease
of	1068 2 I-Disease
creativity	1071 10 I-Disease
,	1081 1 O
and	1083 3 O
functional	1087 10 B-Disease
impairments	1098 11 I-Disease
.	1109 1 O

Treatment	0 9 O
of	10 2 O
previously	13 10 O
treated	24 7 O
metastatic	32 10 O
breast	43 6 B-Disease
cancer	50 6 I-Disease
by	57 2 O
mitoxantrone	60 12 B-Chemical
and	73 3 O
48	77 2 O
-	79 1 O
hour	80 4 O
continuous	85 10 O
infusion	96 8 O
of	105 2 O
high	108 4 O
-	112 1 O
dose	113 4 O
5	118 1 B-Chemical
-	119 1 I-Chemical
FU	120 2 I-Chemical
and	123 3 O
leucovorin	127 10 B-Chemical
(	138 1 O
MFL	139 3 B-Chemical
)	142 1 O
:	143 1 O
low	145 3 O
palliative	149 10 O
benefit	160 7 O
and	168 3 O
high	172 4 O
treatment	177 9 O
-	186 1 O
related	187 7 O
toxicity	195 8 B-Disease
.	203 1 O

For	205 3 O
previously	209 10 O
treated	220 7 O
advanced	228 8 O
breast	237 6 B-Disease
cancer	244 6 I-Disease
,	250 1 O
there	252 5 O
is	258 2 O
no	261 2 O
standard	264 8 O
second	273 6 O
-	279 1 O
line	280 4 O
therapy	285 7 O
.	292 1 O

Combination	294 11 O
chemotherapy	306 12 O
with	319 4 O
mitoxantrone	324 12 B-Chemical
,	336 1 O
high	338 4 O
-	342 1 O
dose	343 4 O
5	348 1 B-Chemical
-	349 1 I-Chemical
fluorouracil	350 12 I-Chemical
(	363 1 O
5	364 1 B-Chemical
-	365 1 I-Chemical
FU	366 2 I-Chemical
)	368 1 O
and	370 3 O
leucovorin	374 10 B-Chemical
(	385 1 O
MFL	386 3 B-Chemical
regimen	390 7 I-Chemical
)	397 1 O
had	399 3 O
been	403 4 O
reported	408 8 O
as	417 2 O
an	420 2 O
effective	423 9 O
and	433 3 O
well	437 4 O
tolerated	442 9 O
regimen	452 7 O
.	459 1 O

From	461 4 O
October	466 7 O
1993	474 4 O
to	479 2 O
November	482 8 O
1995	491 4 O
,	495 1 O
we	497 2 O
treated	500 7 O
13	508 2 O
patients	511 8 O
with	520 4 O
previously	525 10 O
chemotherapy	536 12 O
-	548 1 O
treated	549 7 O
metastatic	557 10 O
breast	568 6 B-Disease
cancer	575 6 I-Disease
by	582 2 O
mitoxantrone	585 12 B-Chemical
,	597 1 O
12	599 2 O
mg	602 2 O
/	604 1 O
m2	605 2 O
,	607 1 O
on	609 2 O
day	612 3 O
1	616 1 O
and	618 3 O
continuous	622 10 O
infusion	633 8 O
of	642 2 O
5	645 1 B-Chemical
-	646 1 I-Chemical
FU	647 2 I-Chemical
,	649 1 O
3000	651 4 O
mg	656 2 O
/	658 1 O
m2	659 2 O
,	661 1 O
together	663 8 O
with	672 4 O
leucovorin	677 10 B-Chemical
,	687 1 O
300	689 3 O
mg	693 2 O
/	695 1 O
m2	696 2 O
,	698 1 O
for	700 3 O
48	704 2 O
h	707 1 O
from	709 4 O
day	714 3 O
1	718 1 O
to	720 2 O
2	723 1 O
.	724 1 O

Each	726 4 O
course	731 6 O
of	738 2 O
chemotherapy	741 12 O
was	754 3 O
given	758 5 O
every	764 5 O
4	770 1 O
weeks	772 5 O
.	777 1 O

Most	779 4 O
of	784 2 O
these	787 5 O
patients	793 8 O
had	802 3 O
more	806 4 O
than	811 4 O
two	816 3 O
metastatic	820 10 O
sites	831 5 O
,	836 1 O
with	838 4 O
lung	843 4 O
metastasis	848 10 O
predominant	859 11 O
.	870 1 O

Seven	872 5 O
patients	878 8 O
had	887 3 O
been	891 4 O
treated	896 7 O
with	904 4 O
anthracycline	909 13 B-Chemical
.	922 1 O

Seven	924 5 O
patients	930 8 O
had	939 3 O
previously	943 10 O
received	954 8 O
radiotherapy	963 12 O
and	976 3 O
seven	980 5 O
had	986 3 O
received	990 8 O
hormone	999 7 O
therapy	1007 7 O
.	1014 1 O

Median	1016 6 O
number	1023 6 O
of	1030 2 O
courses	1033 7 O
of	1041 2 O
MFL	1044 3 B-Chemical
regimen	1048 7 I-Chemical
given	1056 5 O
was	1062 3 O
six	1066 3 O
and	1070 3 O
the	1074 3 O
median	1078 6 O
cumulative	1085 10 O
dose	1096 4 O
of	1101 2 O
mitoxantrone	1104 12 B-Chemical
was	1117 3 O
68	1121 2 O
.	1123 1 O
35	1124 2 O
mg	1127 2 O
/	1129 1 O
m2	1130 2 O
.	1132 1 O

One	1134 3 O
patient	1138 7 O
had	1146 3 O
complete	1150 8 O
response	1159 8 O
,	1167 1 O
seven	1169 5 O
had	1175 3 O
stable	1179 6 O
disease	1186 7 O
,	1193 1 O
none	1195 4 O
had	1200 3 O
partial	1204 7 O
response	1212 8 O
and	1221 3 O
five	1225 4 O
had	1230 3 O
progressive	1234 11 O
disease	1246 7 O
.	1253 1 O

The	1255 3 O
overall	1259 7 O
objective	1267 9 O
response	1277 8 O
rate	1286 4 O
was	1291 3 O
7	1295 1 O
.	1296 1 O
6	1297 1 O
%	1298 1 O
.	1299 1 O

The	1301 3 O
median	1305 6 O
follow	1312 6 O
-	1318 1 O
up	1319 2 O
period	1322 6 O
was	1329 3 O
14	1333 2 O
months	1336 6 O
.	1342 1 O

Median	1344 6 O
survival	1351 8 O
was	1360 3 O
16	1364 2 O
months	1367 6 O
.	1373 1 O

Median	1375 6 O
progression	1382 11 O
-	1393 1 O
free	1394 4 O
survival	1399 8 O
was	1408 3 O
5	1412 1 O
months	1414 6 O
.	1420 1 O

A	1422 1 O
complete	1424 8 O
responder	1433 9 O
had	1443 3 O
relapse	1447 7 O
-	1454 1 O
free	1455 4 O
survival	1460 8 O
up	1469 2 O
to	1472 2 O
17	1475 2 O
months	1478 6 O
.	1484 1 O

Major	1486 5 O
toxicities	1492 10 B-Disease
were	1503 4 O
cardiotoxicity	1508 14 B-Disease
and	1523 3 O
leukopenia	1527 10 B-Disease
.	1537 1 O

Eight	1539 5 O
patients	1545 8 O
were	1554 4 O
dead	1559 4 O
in	1564 2 O
the	1567 3 O
last	1571 4 O
follow	1576 6 O
-	1582 1 O
up	1583 2 O
;	1585 1 O
two	1587 3 O
of	1591 2 O
them	1594 4 O
died	1599 4 O
of	1604 2 O
treatment	1607 9 O
-	1616 1 O
related	1617 7 O
toxicity	1625 8 B-Disease
.	1633 1 O

The	1635 3 O
MFL	1639 3 B-Chemical
regimen	1643 7 I-Chemical
achieves	1651 8 O
little	1660 6 O
palliative	1667 10 O
benefit	1678 7 O
and	1686 3 O
induces	1690 7 O
severe	1698 6 O
toxicity	1705 8 B-Disease
at	1714 2 O
a	1717 1 O
fairly	1719 6 O
high	1726 4 O
rate	1731 4 O
.	1735 1 O

Administration	1737 14 O
of	1752 2 O
this	1755 4 O
regimen	1760 7 O
to	1768 2 O
breast	1771 6 B-Disease
cancer	1778 6 I-Disease
patients	1785 8 O
who	1794 3 O
have	1798 4 O
been	1803 4 O
treated	1808 7 O
by	1816 2 O
chemotherapy	1819 12 O
and	1832 3 O
those	1836 5 O
with	1842 4 O
impaired	1847 8 B-Disease
heart	1856 5 I-Disease
function	1862 8 I-Disease
requires	1871 8 O
careful	1880 7 O
attention	1888 9 O
.	1897 1 O

Upregulation	0 12 O
of	13 2 O
the	16 3 O
expression	20 10 O
of	31 2 O
vasopressin	34 11 B-Chemical
gene	46 4 O
in	51 2 O
the	54 3 O
paraventricular	58 15 O
and	74 3 O
supraoptic	78 10 O
nuclei	89 6 O
of	96 2 O
the	99 3 O
lithium	103 7 B-Chemical
-	110 1 O
induced	111 7 O
diabetes	119 8 B-Disease
insipidus	128 9 I-Disease
rat	138 3 O
.	141 1 O

The	143 3 O
expression	147 10 O
of	158 2 O
arginine	161 8 B-Chemical
vasopressin	170 11 I-Chemical
(	182 1 O
AVP	183 3 B-Chemical
)	186 1 O
gene	188 4 O
in	193 2 O
the	196 3 O
paraventricular	200 15 O
(	216 1 O
PVN	217 3 O
)	220 1 O
and	222 3 O
supraoptic	226 10 O
nuclei	237 6 O
(	244 1 O
SON	245 3 O
)	248 1 O
was	250 3 O
investigated	254 12 O
in	267 2 O
rats	270 4 O
with	275 4 O
lithium	280 7 B-Chemical
(	288 1 O
Li	289 2 B-Chemical
)	291 1 O
-	292 1 O
induced	293 7 O
polyuria	301 8 B-Disease
,	309 1 O
using	311 5 O
in	317 2 O
situ	320 4 O
hybridization	325 13 O
histochemistry	339 14 O
and	354 3 O
radioimmunoassay	358 16 O
.	374 1 O

The	376 3 O
male	380 4 O
Wistar	385 6 O
rats	392 4 O
consuming	397 9 O
a	407 1 O
diet	409 4 O
that	414 4 O
contained	419 9 O
LiCl	429 4 B-Chemical
(	434 1 O
60	435 2 O
mmol	438 4 O
/	442 1 O
kg	443 2 O
)	445 1 O
for	447 3 O
4	451 1 O
weeks	453 5 O
developed	459 9 O
marked	469 6 O
polyuria	476 8 B-Disease
.	484 1 O

The	486 3 O
Li	490 2 B-Chemical
-	492 1 O
treated	493 7 O
rats	501 4 O
produced	506 8 O
a	515 1 O
large	517 5 O
volume	523 6 O
of	530 2 O
hypotonic	533 9 O
urine	543 5 O
with	549 4 O
low	554 3 O
ionic	558 5 O
concentrations	564 14 O
.	578 1 O

Plasma	580 6 O
sodium	587 6 B-Chemical
concentrations	594 14 O
were	609 4 O
found	614 5 O
to	620 2 O
be	623 2 O
slightly	626 8 O
increased	635 9 O
in	645 2 O
the	648 3 O
Li	652 2 B-Chemical
-	654 1 O
treated	655 7 O
rats	663 4 O
compared	668 8 O
with	677 4 O
those	682 5 O
in	688 2 O
controls	691 8 O
.	699 1 O

Plasma	701 6 O
concentration	708 13 O
of	722 2 O
AVP	725 3 B-Chemical
and	729 3 O
transcripts	733 11 O
of	745 2 O
AVP	748 3 B-Chemical
gene	752 4 O
in	757 2 O
the	760 3 O
PVN	764 3 O
and	768 3 O
SON	772 3 O
were	776 4 O
significantly	781 13 O
increased	795 9 O
in	805 2 O
the	808 3 O
Li	812 2 B-Chemical
-	814 1 O
treated	815 7 O
rats	823 4 O
compared	828 8 O
with	837 4 O
controls	842 8 O
.	850 1 O

These	852 5 O
results	858 7 O
suggest	866 7 O
that	874 4 O
dehydration	879 11 B-Disease
and	891 3 O
/	894 1 O
or	895 2 O
the	898 3 O
activation	902 10 O
of	913 2 O
visceral	916 8 O
afferent	925 8 O
inputs	934 6 O
may	941 3 O
contribute	945 10 O
to	956 2 O
the	959 3 O
elevation	963 9 O
of	973 2 O
plasma	976 6 O
AVP	983 3 B-Chemical
and	987 3 O
the	991 3 O
upregulation	995 12 O
of	1008 2 O
AVP	1011 3 B-Chemical
gene	1015 4 O
expression	1020 10 O
in	1031 2 O
the	1034 3 O
PVN	1038 3 O
and	1042 3 O
the	1046 3 O
SON	1050 3 O
of	1054 2 O
the	1057 3 O
Li	1061 2 B-Chemical
-	1063 1 O
induced	1064 7 O
diabetes	1072 8 B-Disease
insipidus	1081 9 I-Disease
rat	1091 3 O
.	1094 1 O

Suxamethonium	0 13 B-Chemical
-	13 1 O
induced	14 7 O
cardiac	22 7 B-Disease
arrest	30 6 I-Disease
and	37 3 O
death	41 5 B-Disease
following	47 9 O
5	57 1 O
days	59 4 O
of	64 2 O
immobilization	67 14 O
.	81 1 O

The	83 3 O
present	87 7 O
report	95 6 O
describes	102 9 O
a	112 1 O
case	114 4 O
of	119 2 O
cardiac	122 7 B-Disease
arrest	130 6 I-Disease
and	137 3 O
subsequent	141 10 O
death	152 5 B-Disease
as	158 2 O
a	161 1 O
result	163 6 O
of	170 2 O
hyperkalaemia	173 13 B-Disease
following	187 9 O
the	197 3 O
use	201 3 O
of	205 2 O
suxamethonium	208 13 B-Chemical
in	222 2 O
a	225 1 O
23	227 2 O
-	229 1 O
year	230 4 O
-	234 1 O
old	235 3 O
Malawian	239 8 O
woman	248 5 O
.	253 1 O

Five	255 4 O
days	260 4 O
after	265 5 O
the	271 3 O
onset	275 5 O
of	281 2 O
the	284 3 O
symptoms	288 8 O
of	297 2 O
meningitis	300 10 B-Disease
,	310 1 O
the	312 3 O
patient	316 7 O
aspirated	324 9 O
stomach	334 7 O
contents	342 8 O
and	351 3 O
needed	355 6 O
endotracheal	362 12 O
intubation	375 10 O
.	385 1 O

Forty	387 5 O
seconds	393 7 O
after	401 5 O
injection	407 9 O
of	417 2 O
suxamethonium	420 13 B-Chemical
,	433 1 O
bradycardia	435 11 B-Disease
and	447 3 O
cardiac	451 7 B-Disease
arrest	459 6 I-Disease
occurred	466 8 O
.	474 1 O

Attempts	476 8 O
to	485 2 O
resuscitate	488 11 O
the	500 3 O
patient	504 7 O
were	512 4 O
not	517 3 O
successful	521 10 O
.	531 1 O

The	533 3 O
serum	537 5 O
level	543 5 O
of	549 2 O
potassium	552 9 B-Chemical
was	562 3 O
observed	566 8 O
to	575 2 O
be	578 2 O
8	581 1 O
.	582 1 O
4	583 1 O
mequiv	585 6 O
L	592 1 O
-	593 1 O
1	594 1 O
.	595 1 O

Apart	597 5 O
from	603 4 O
the	608 3 O
reduction	612 9 O
in	622 2 O
the	625 3 O
patient	629 7 O
'	636 1 O
s	637 1 O
level	639 5 O
of	645 2 O
consciousness	648 13 O
,	661 1 O
there	663 5 O
were	669 4 O
no	674 2 O
signs	677 5 O
of	683 2 O
motor	686 5 O
neurone	692 7 O
damage	700 6 O
or	707 2 O
of	710 2 O
any	713 3 O
of	717 2 O
the	720 3 O
other	724 5 O
known	730 5 O
predisposing	736 12 O
conditions	749 10 O
for	760 3 O
hyperkalaemia	764 13 B-Disease
following	778 9 O
the	788 3 O
administration	792 14 O
of	807 2 O
suxamethonium	810 13 B-Chemical
.	823 1 O

It	825 2 O
is	828 2 O
postulated	831 10 O
that	842 4 O
her	847 3 O
death	851 5 B-Disease
was	857 3 O
caused	861 6 O
by	868 2 O
hypersensitivity	871 16 B-Disease
to	888 2 O
suxamethonium	891 13 B-Chemical
,	904 1 O
associated	906 10 O
with	917 4 O
her	922 3 O
5	926 1 O
-	927 1 O
day	928 3 O
immobilization	932 14 O
.	946 1 O

An	0 2 O
unusual	3 7 O
toxic	11 5 O
reaction	17 8 O
to	26 2 O
axillary	29 8 O
block	38 5 O
by	44 2 O
mepivacaine	47 11 B-Chemical
with	59 4 O
adrenaline	64 10 B-Chemical
.	74 1 O

An	76 2 O
increase	79 8 B-Disease
in	88 2 I-Disease
blood	91 5 I-Disease
pressure	97 8 I-Disease
,	105 1 O
accompanied	107 11 O
by	119 2 O
atrial	122 6 B-Disease
fibrillation	129 12 I-Disease
,	141 1 O
agitation	143 9 B-Disease
,	152 1 O
incomprehensible	154 16 B-Disease
shouts	171 6 I-Disease
and	178 3 O
loss	182 4 B-Disease
of	187 2 I-Disease
consciousness	190 13 I-Disease
,	203 1 O
was	205 3 O
observed	209 8 O
in	218 2 O
an	221 2 O
elderly	224 7 O
,	231 1 O
ASA	233 3 O
classification	237 14 O
group	252 5 O
II	258 2 O
,	260 1 O
cardiovascularly	262 16 O
medicated	279 9 O
male	289 4 O
,	293 1 O
12	295 2 O
min	298 3 O
after	302 5 O
performance	308 11 O
of	320 2 O
axillary	323 8 O
block	332 5 O
with	338 4 O
mepivacaine	343 11 B-Chemical
850	355 3 O
mg	359 2 O
containing	362 10 O
adrenaline	373 10 B-Chemical
0	384 1 O
.	385 1 O
225	386 3 O
mg	390 2 O
,	392 1 O
for	394 3 O
correction	398 10 O
of	409 2 O
Dupuytren	412 9 B-Disease
'	421 1 I-Disease
s	422 1 I-Disease
contracture	424 11 I-Disease
.	435 1 O

After	437 5 O
intravenous	443 11 O
administration	455 14 O
of	470 2 O
labetalol	473 9 B-Chemical
,	482 1 O
metoprolol	484 10 B-Chemical
and	495 3 O
midazolam	499 9 B-Chemical
the	509 3 O
patient	513 7 O
'	520 1 O
s	521 1 O
condition	523 9 O
improved	533 8 O
,	541 1 O
and	543 3 O
15	547 2 O
min	550 3 O
later	554 5 O
he	560 2 O
woke	563 4 O
up	568 2 O
.	570 1 O

The	572 3 O
block	576 5 O
was	582 3 O
successful	586 10 O
and	597 3 O
surgery	601 7 O
was	609 3 O
conducted	613 9 O
as	623 2 O
scheduled	626 9 O
despite	636 7 O
persisting	644 10 O
atrial	655 6 B-Disease
fibrillation	662 12 I-Disease
.	674 1 O

Postoperatively	676 15 O
,	691 1 O
the	693 3 O
patient	697 7 O
refused	705 7 O
DC	713 2 O
cardioversion	716 13 O
and	730 3 O
was	734 3 O
treated	738 7 O
medically	746 9 O
.	755 1 O

Both	757 4 O
the	762 3 O
temporal	766 8 O
relationship	775 12 O
of	788 2 O
events	791 6 O
and	798 3 O
the	802 3 O
response	806 8 O
to	815 2 O
treatment	818 9 O
suggest	828 7 O
that	836 4 O
a	841 1 O
rapid	843 5 O
systemic	849 8 O
absorption	858 10 O
of	869 2 O
mepivacaine	872 11 B-Chemical
with	884 4 O
adrenaline	889 10 B-Chemical
and	900 3 O
/	903 1 O
or	904 2 O
interaction	907 11 O
of	919 2 O
these	922 5 O
drugs	928 5 O
with	934 4 O
the	939 3 O
patient	943 7 O
'	950 1 O
s	951 1 O
cardiovascular	953 14 O
medications	968 11 O
were	980 4 O
responsible	985 11 O
for	997 3 O
the	1001 3 O
perioperative	1005 13 O
complications	1019 13 O
.	1032 1 O

Clinical	0 8 O
and	9 3 O
histopathologic	13 15 O
examination	29 11 O
of	41 2 O
renal	44 5 O
allografts	50 10 O
treated	61 7 O
with	69 4 O
tacrolimus	74 10 B-Chemical
(	85 1 O
FK506	86 5 B-Chemical
)	91 1 O
for	93 3 O
at	97 2 O
least	100 5 O
one	106 3 O
year	110 4 O
.	114 1 O

BACKGROUND	116 10 O
:	126 1 O
We	128 2 O
clinically	131 10 O
and	142 3 O
pathologically	146 14 O
analyzed	161 8 O
renal	170 5 O
allografts	176 10 O
from	187 4 O
1	192 1 O
9	194 1 O
renal	196 5 O
transplant	202 10 O
patients	213 8 O
treated	222 7 O
with	230 4 O
tacrolimus	235 10 B-Chemical
(	246 1 O
FK506	247 5 B-Chemical
)	252 1 O
for	254 3 O
more	258 4 O
than	263 4 O
1	268 1 O
year	270 4 O
.	274 1 O

METHODS	276 7 O
:	283 1 O
Twenty	285 6 O
-	291 1 O
six	292 3 O
renal	296 5 O
allograft	302 9 O
biopsy	312 6 O
specimens	319 9 O
from	329 4 O
1	334 1 O
9	336 1 O
renal	338 5 O
transplant	344 10 O
patients	355 8 O
who	364 3 O
underwent	368 9 O
transplantations	378 16 O
between	395 7 O
1991	403 4 O
and	408 3 O
1993	412 4 O
were	417 4 O
evaluated	422 9 O
.	431 1 O

Thirteen	433 8 O
biopsies	442 8 O
were	451 4 O
performed	456 9 O
from	466 4 O
stable	471 6 O
functioning	478 11 O
renal	490 5 O
allografts	496 10 O
with	507 4 O
informed	512 8 O
consent	521 7 O
(	529 1 O
nonepisode	530 10 O
biopsy	541 6 O
)	547 1 O
and	549 3 O
the	553 3 O
other	557 5 O
13	563 2 O
were	566 4 O
from	571 4 O
dysfunctional	576 13 O
renal	590 5 O
allografts	596 10 O
with	607 4 O
a	612 1 O
clinical	614 8 O
indication	623 10 O
for	634 3 O
biopsy	638 6 O
(	645 1 O
episode	646 7 O
biopsy	654 6 O
)	660 1 O
.	661 1 O

RESULTS	663 7 O
:	670 1 O
The	672 3 O
main	676 4 O
pathologic	681 10 O
diagnoses	692 9 O
(	702 1 O
some	703 4 O
overlap	708 7 O
)	715 1 O
were	717 4 O
acute	722 5 O
rejection	728 9 O
(	738 1 O
AR	739 2 O
;	741 1 O
n	743 1 O
=	745 1 O
4	747 1 O
)	748 1 O
,	749 1 O
chronic	751 7 O
rejection	759 9 O
(	769 1 O
CR	770 2 O
;	772 1 O
n	774 1 O
=	775 1 O
5	776 1 O
)	777 1 O
,	778 1 O
AR	780 2 O
+	782 1 O
CR	783 2 O
(	786 1 O
n	787 1 O
=	789 1 O
4	790 1 O
)	791 1 O
,	792 1 O
recurrent	794 9 O
IgA	804 3 B-Disease
nephropathy	808 11 I-Disease
(	820 1 O
n	821 1 O
=	823 1 O
5	824 1 O
)	825 1 O
,	826 1 O
normal	828 6 O
findings	835 8 O
(	844 1 O
n	845 1 O
=	847 1 O
2	848 1 O
)	849 1 O
,	850 1 O
minimal	852 7 O
-	859 1 O
type	860 4 O
chronic	865 7 O
FK506	873 5 B-Chemical
nephropathy	879 11 B-Disease
(	891 1 O
n	892 1 O
=	894 1 O
9	896 1 O
)	897 1 O
,	898 1 O
and	900 3 O
mild	904 4 O
-	908 1 O
type	909 4 O
FK506	914 5 B-Chemical
nephropathy	920 11 B-Disease
(	932 1 O
n	933 1 O
=	935 1 O
11	937 2 O
)	939 1 O
.	940 1 O

Of	942 2 O
the	945 3 O
nonepisode	949 10 O
biopsies	960 8 O
,	968 1 O
7	970 1 O
and	972 3 O
4	976 1 O
biopsies	978 8 O
showed	987 6 O
minimal	994 7 O
-	1001 1 O
type	1002 4 O
and	1007 3 O
mild	1011 4 O
-	1015 1 O
type	1016 4 O
chronic	1021 7 O
FK506	1029 5 B-Chemical
nephropathy	1035 11 B-Disease
,	1046 1 O
respectively	1048 12 O
.	1060 1 O

Chronic	1062 7 O
FK506	1070 5 B-Chemical
nephropathy	1076 11 B-Disease
consisted	1088 9 O
of	1098 2 O
rough	1101 5 O
and	1107 3 O
foamy	1111 5 O
tubular	1117 7 O
vacuolization	1125 13 O
(	1139 1 O
5	1140 1 O
biopsies	1142 8 O
)	1150 1 O
,	1151 1 O
arteriolopathy	1153 14 O
(	1168 1 O
angiodegeneration	1169 17 O
of	1187 2 O
the	1190 3 O
arteriolar	1194 10 O
wall	1205 4 O
;	1209 1 O
20	1211 2 O
biopsies	1214 8 O
)	1222 1 O
,	1223 1 O
focal	1225 5 B-Disease
segmental	1231 9 I-Disease
glomerulosclerosis	1241 18 I-Disease
(	1260 1 O
4	1261 1 O
biopsies	1263 8 O
)	1271 1 O
and	1273 3 O
the	1277 3 O
striped	1281 7 O
form	1289 4 O
of	1294 2 O
interstitial	1297 12 B-Disease
fibrosis	1310 8 I-Disease
(	1319 1 O
11	1320 2 O
biopsies	1323 8 O
)	1331 1 O
.	1332 1 O

The	1334 3 O
serum	1338 5 O
creatinine	1344 10 B-Chemical
levels	1355 6 O
of	1362 2 O
patients	1365 8 O
in	1374 2 O
the	1377 3 O
mild	1381 4 O
-	1385 1 O
type	1386 4 O
chronic	1391 7 O
FK506	1399 5 B-Chemical
nephropathy	1405 11 B-Disease
group	1417 5 O
,	1422 1 O
which	1424 5 O
included	1430 8 O
7	1439 1 O
episode	1441 7 O
biopsies	1449 8 O
,	1457 1 O
were	1459 4 O
statistically	1464 13 O
higher	1478 6 O
than	1485 4 O
those	1490 5 O
in	1496 2 O
the	1499 3 O
minimum	1503 7 O
-	1510 1 O
type	1511 4 O
chronic	1516 7 O
FK506	1524 5 B-Chemical
-	1529 1 O
nephropathy	1530 11 B-Disease
group	1542 5 O
(	1548 1 O
P	1549 1 O
<	1550 1 O
0	1552 1 O
.	1553 1 O
001	1554 3 O
)	1557 1 O
.	1558 1 O

CONCLUSIONS	1560 11 O
:	1571 1 O
This	1573 4 O
study	1578 5 O
demonstrates	1584 12 O
that	1597 4 O
chronic	1602 7 O
FK506	1610 5 B-Chemical
nephropathy	1616 11 B-Disease
consists	1628 8 O
primarily	1637 9 O
of	1647 2 O
arteriolopathy	1650 14 O
manifesting	1665 11 O
as	1677 2 O
insudative	1680 10 O
hyalinosis	1691 10 O
of	1702 2 O
the	1705 3 O
arteriolar	1709 10 O
wall	1720 4 O
,	1724 1 O
and	1726 3 O
suggests	1730 8 O
that	1739 4 O
mild	1744 4 O
-	1748 1 O
type	1749 4 O
chronic	1754 7 O
FK506	1762 5 B-Chemical
nephropathy	1768 11 B-Disease
is	1780 2 O
a	1783 1 O
condition	1785 9 O
which	1795 5 O
may	1801 3 O
lead	1805 4 O
to	1810 2 O
deterioration	1813 13 O
of	1827 2 O
renal	1830 5 O
allograft	1836 9 O
function	1846 8 O
.	1854 1 O

Memory	0 6 O
facilitation	7 12 O
and	20 3 O
stimulation	24 11 O
of	36 2 O
endogenous	39 10 O
nerve	50 5 O
growth	56 6 O
factor	63 6 O
synthesis	70 9 O
by	80 2 O
the	83 3 O
acetylcholine	87 13 B-Chemical
releaser	101 8 O
PG	110 2 B-Chemical
-	112 1 I-Chemical
9	113 1 I-Chemical
.	114 1 O

The	116 3 O
effects	120 7 O
of	128 2 O
PG	131 2 B-Chemical
-	133 1 I-Chemical
9	134 1 I-Chemical
(	136 1 O
3alpha	137 6 B-Chemical
-	143 1 I-Chemical
tropyl	144 6 I-Chemical
2	151 1 I-Chemical
-	152 1 I-Chemical
(	153 1 I-Chemical
p	154 1 I-Chemical
-	155 1 I-Chemical
bromophenyl	156 11 I-Chemical
)	167 1 I-Chemical
propionate	168 10 I-Chemical
)	178 1 O
,	179 1 O
the	181 3 O
acetylcholine	185 13 B-Chemical
releaser	199 8 O
,	207 1 O
on	209 2 O
memory	212 6 O
processes	219 9 O
and	229 3 O
nerve	233 5 O
growth	239 6 O
factor	246 6 O
(	253 1 O
NGF	254 3 O
)	257 1 O
synthesis	259 9 O
were	269 4 O
evaluated	274 9 O
.	283 1 O

In	285 2 O
the	288 3 O
mouse	292 5 O
passive	298 7 O
-	305 1 O
avoidance	306 9 O
test	316 4 O
,	320 1 O
PG	322 2 B-Chemical
-	324 1 I-Chemical
9	325 1 I-Chemical
(	327 1 O
10	328 2 O
-	330 1 O
30	331 2 O
mg	334 2 O
/	336 1 O
kg	337 2 O
,	339 1 O
i	341 1 O
.	342 1 O
p	343 1 O
.	344 1 O
)	345 1 O
,	346 1 O
administered	348 12 O
20	361 2 O
min	364 3 O
before	368 6 O
the	375 3 O
training	379 8 O
session	388 7 O
,	395 1 O
prevented	397 9 O
amnesia	407 7 B-Disease
induced	415 7 O
by	423 2 O
both	426 4 O
the	431 3 O
non	435 3 O
selective	439 9 O
antimuscarinic	449 14 O
drug	464 4 O
scopolamine	469 11 B-Chemical
and	481 3 O
the	485 3 O
M1	489 2 O
-	491 1 O
selective	492 9 O
antagonist	502 10 O
S	513 1 B-Chemical
-	514 1 I-Chemical
(	515 1 I-Chemical
-	516 1 I-Chemical
)	517 1 I-Chemical
-	518 1 I-Chemical
ET	519 2 I-Chemical
-	521 1 I-Chemical
126	522 3 I-Chemical
.	525 1 O

In	527 2 O
the	530 3 O
same	534 4 O
experimental	539 12 O
conditions	552 10 O
,	562 1 O
PG	564 2 B-Chemical
-	566 1 I-Chemical
9	567 1 I-Chemical
(	569 1 O
5	570 1 O
-	571 1 O
20	572 2 O
microg	575 6 O
per	582 3 O
mouse	586 5 O
,	591 1 O
i	593 1 O
.	594 1 O
c	595 1 O
.	596 1 O
v	597 1 O
.	598 1 O
)	599 1 O
was	601 3 O
also	605 4 O
able	610 4 O
to	615 2 O
prevent	618 7 O
antimuscarine	626 13 O
-	639 1 O
induced	640 7 O
amnesia	648 7 B-Disease
,	655 1 O
demonstrating	657 13 O
a	671 1 O
central	673 7 O
localization	681 12 O
of	694 2 O
the	697 3 O
activity	701 8 O
.	709 1 O

At	711 2 O
the	714 3 O
highest	718 7 O
effective	726 9 O
doses	736 5 O
,	741 1 O
PG	743 2 B-Chemical
-	745 1 I-Chemical
9	746 1 I-Chemical
did	748 3 O
not	752 3 O
produce	756 7 O
any	764 3 O
collateral	768 10 O
symptoms	779 8 O
as	788 2 O
revealed	791 8 O
by	800 2 O
the	803 3 O
Irwin	807 5 O
test	813 4 O
,	817 1 O
and	819 3 O
it	823 2 O
did	826 3 O
not	830 3 O
modify	834 6 O
spontaneous	841 11 O
motility	853 8 O
and	862 3 O
inspection	866 10 O
activity	877 8 O
,	885 1 O
as	887 2 O
revealed	890 8 O
by	899 2 O
the	902 3 O
hole	906 4 O
-	910 1 O
board	911 5 O
test	917 4 O
.	921 1 O

PG	923 2 B-Chemical
-	925 1 I-Chemical
9	926 1 I-Chemical
was	928 3 O
also	932 4 O
able	937 4 O
to	942 2 O
increase	945 8 O
the	954 3 O
amount	958 6 O
of	965 2 O
NGF	968 3 O
secreted	972 8 O
in	981 2 O
vitro	984 5 O
by	990 2 O
astrocytes	993 10 O
in	1004 2 O
a	1007 1 O
dose	1009 4 O
-	1013 1 O
dependent	1014 9 O
manner	1024 6 O
.	1030 1 O

The	1032 3 O
maximal	1036 7 O
NGF	1044 3 O
contents	1048 8 O
obtained	1057 8 O
by	1066 2 O
PG	1069 2 B-Chemical
-	1071 1 I-Chemical
9	1072 1 I-Chemical
were	1074 4 O
17	1079 2 O
.	1081 1 O
6	1082 1 O
-	1083 1 O
fold	1084 4 O
of	1089 2 O
the	1092 3 O
control	1096 7 O
value	1104 5 O
.	1109 1 O

During	1111 6 O
culture	1118 7 O
,	1125 1 O
no	1127 2 O
morphological	1130 13 O
changes	1144 7 O
were	1152 4 O
found	1157 5 O
at	1163 2 O
effective	1166 9 O
concentrations	1176 14 O
of	1191 2 O
PG	1194 2 B-Chemical
-	1196 1 I-Chemical
9	1197 1 I-Chemical
.	1198 1 O

The	1200 3 O
current	1204 7 O
work	1212 4 O
indicates	1217 9 O
the	1227 3 O
ability	1231 7 O
of	1239 2 O
PG	1242 2 B-Chemical
-	1244 1 I-Chemical
9	1245 1 I-Chemical
to	1247 2 O
induce	1250 6 O
beneficial	1257 10 O
effects	1268 7 O
on	1276 2 O
cognitive	1279 9 O
processes	1289 9 O
and	1299 3 O
stimulate	1303 9 O
activity	1313 8 O
of	1322 2 O
NGF	1325 3 O
synthesis	1329 9 O
in	1339 2 O
astroglial	1342 10 O
cells	1353 5 O
.	1358 1 O

Therefore	1360 9 O
,	1369 1 O
PG	1371 2 B-Chemical
-	1373 1 I-Chemical
9	1374 1 I-Chemical
could	1376 5 O
represent	1382 9 O
a	1392 1 O
potential	1394 9 O
useful	1404 6 O
drug	1411 4 O
able	1416 4 O
to	1421 2 O
improve	1424 7 O
the	1432 3 O
function	1436 8 O
of	1445 2 O
impaired	1448 8 O
cognitive	1457 9 O
processes	1467 9 O
.	1476 1 O

Angioedema	0 10 B-Disease
due	11 3 O
to	15 2 O
ACE	18 3 B-Chemical
inhibitors	22 10 I-Chemical
:	32 1 O
common	34 6 O
and	41 3 O
inadequately	45 12 O
diagnosed	58 9 O
.	67 1 O

The	69 3 O
estimated	73 9 O
incidence	83 9 O
of	93 2 O
angioedema	96 10 B-Disease
during	107 6 O
angiotensin	114 11 B-Chemical
-	125 1 I-Chemical
converting	126 10 I-Chemical
enzyme	137 6 I-Chemical
(	144 1 I-Chemical
ACE	145 3 I-Chemical
)	148 1 I-Chemical
inhibitor	150 9 I-Chemical
treatment	160 9 O
is	170 2 O
between	173 7 O
1	181 1 O
and	183 3 O
7	187 1 O
per	189 3 O
thousand	193 8 O
patients	202 8 O
.	210 1 O

This	212 4 O
potentially	217 11 O
serious	229 7 O
adverse	237 7 O
effect	245 6 O
is	252 2 O
often	255 5 O
preceded	261 8 O
by	270 2 O
minor	273 5 O
manifestations	279 14 O
that	294 4 O
may	299 3 O
serve	303 5 O
as	309 2 O
a	312 1 O
warning	314 7 O
.	321 1 O

Recurarization	0 14 O
in	15 2 O
the	18 3 O
recovery	22 8 O
room	31 4 O
.	35 1 O

A	37 1 O
case	39 4 O
of	44 2 O
recurarization	47 14 O
in	62 2 O
the	65 3 O
recovery	69 8 O
room	78 4 O
is	83 2 O
reported	86 8 O
.	94 1 O

Accumulation	96 12 O
of	109 2 O
atracurium	112 10 B-Chemical
in	123 2 O
the	126 3 O
intravenous	130 11 O
line	142 4 O
led	147 3 O
to	151 2 O
recurarization	154 14 O
after	169 5 O
flushing	175 8 O
the	184 3 O
line	188 4 O
in	193 2 O
the	196 3 O
recovery	200 8 O
room	209 4 O
.	213 1 O

A	215 1 O
respiratory	217 11 B-Disease
arrest	229 6 I-Disease
with	236 4 O
severe	241 6 O
desaturation	248 12 B-Disease
and	261 3 O
bradycardia	265 11 B-Disease
occurred	277 8 O
.	285 1 O

Circumstances	287 13 O
leading	301 7 O
to	309 2 O
this	312 4 O
event	317 5 O
and	323 3 O
the	327 3 O
mechanisms	331 10 O
enabling	342 8 O
a	351 1 O
neuromuscular	353 13 B-Disease
blockade	367 8 I-Disease
to	376 2 O
occur	379 5 O
,	384 1 O
following	386 9 O
the	396 3 O
administration	400 14 O
of	415 2 O
a	418 1 O
small	420 5 O
dose	426 4 O
of	431 2 O
relaxant	434 8 O
,	442 1 O
are	444 3 O
discussed	448 9 O
.	457 1 O

Recurrent	0 9 O
use	10 3 O
of	14 2 O
newer	17 5 O
oral	23 4 B-Chemical
contraceptives	28 14 I-Chemical
and	43 3 O
the	47 3 O
risk	51 4 O
of	56 2 O
venous	59 6 B-Disease
thromboembolism	66 15 I-Disease
.	81 1 O

The	83 3 O
epidemiological	87 15 O
studies	103 7 O
that	111 4 O
assessed	116 8 O
the	125 3 O
risk	129 4 O
of	134 2 O
venous	137 6 B-Disease
thromboembolism	144 15 I-Disease
(	160 1 O
VTE	161 3 B-Disease
)	164 1 O
associated	166 10 O
with	177 4 O
newer	182 5 O
oral	188 4 B-Chemical
contraceptives	193 14 I-Chemical
(	208 1 O
OC	209 2 B-Chemical
)	211 1 O
did	213 3 O
not	217 3 O
distinguish	221 11 O
between	233 7 O
patterns	241 8 O
of	250 2 O
OC	253 2 B-Chemical
use	256 3 O
,	259 1 O
namely	261 6 O
first	268 5 O
-	273 1 O
time	274 4 O
users	279 5 O
,	284 1 O
repeaters	286 9 O
and	296 3 O
switchers	300 9 O
.	309 1 O

Data	311 4 O
from	316 4 O
a	321 1 O
Transnational	323 13 O
case	337 4 O
-	341 1 O
control	342 7 O
study	350 5 O
were	356 4 O
used	361 4 O
to	366 2 O
assess	369 6 O
the	376 3 O
risk	380 4 O
of	385 2 O
VTE	388 3 B-Disease
for	392 3 O
the	396 3 O
latter	400 6 O
patterns	407 8 O
of	416 2 O
use	419 3 O
,	422 1 O
while	424 5 O
accounting	430 10 O
for	441 3 O
duration	445 8 O
of	454 2 O
use	457 3 O
.	460 1 O

Over	462 4 O
the	467 3 O
period	471 6 O
1993	478 4 O
-	482 1 O
1996	483 4 O
,	487 1 O
551	489 3 O
cases	493 5 O
of	499 2 O
VTE	502 3 B-Disease
were	506 4 O
identified	511 10 O
in	522 2 O
Germany	525 7 O
and	533 3 O
the	537 3 O
UK	541 2 O
along	544 5 O
with	550 4 O
2066	555 4 O
controls	560 8 O
.	568 1 O

Totals	570 6 O
of	577 2 O
128	580 3 O
cases	584 5 O
and	590 3 O
650	594 3 O
controls	598 8 O
were	607 4 O
analysed	612 8 O
for	621 3 O
repeat	625 6 O
use	632 3 O
and	636 3 O
135	640 3 O
cases	644 5 O
and	650 3 O
622	654 3 O
controls	658 8 O
for	667 3 O
switching	671 9 O
patterns	681 8 O
.	689 1 O

The	691 3 O
adjusted	695 8 O
rate	704 4 O
ratio	709 5 O
of	715 2 O
VTE	718 3 B-Disease
for	722 3 O
repeat	726 6 O
users	733 5 O
of	739 2 O
third	742 5 O
generation	748 10 O
OC	759 2 B-Chemical
was	762 3 O
0	766 1 O
.	767 1 O
6	768 1 O
(	770 1 O
95	771 2 O
%	773 1 O
CI	775 2 O
:	777 1 O
0	778 1 O
.	779 1 O
3	780 1 O
-	781 1 O
1	782 1 O
.	783 1 O
2	784 1 O
)	785 1 O
relative	787 8 O
to	796 2 O
repeat	799 6 O
users	806 5 O
of	812 2 O
second	815 6 O
generation	822 10 O
pills	833 5 O
,	838 1 O
whereas	840 7 O
it	848 2 O
was	851 3 O
1	855 1 O
.	856 1 O
3	857 1 O
(	859 1 O
95	860 2 O
%	862 1 O
CI	864 2 O
:	866 1 O
0	867 1 O
.	868 1 O
7	869 1 O
-	870 1 O
2	871 1 O
.	872 1 O
4	873 1 O
)	874 1 O
for	876 3 O
switchers	880 9 O
from	890 4 O
second	895 6 O
to	902 2 O
third	905 5 O
generation	911 10 O
pills	922 5 O
relative	928 8 O
to	937 2 O
switchers	940 9 O
from	950 4 O
third	955 5 O
to	961 2 O
second	964 6 O
generation	971 10 O
pills	982 5 O
.	987 1 O

We	989 2 O
conclude	992 8 O
that	1001 4 O
second	1006 6 O
and	1013 3 O
third	1017 5 O
generation	1023 10 O
agents	1034 6 O
are	1041 3 O
associated	1045 10 O
with	1056 4 O
equivalent	1061 10 O
risks	1072 5 O
of	1078 2 O
VTE	1081 3 B-Disease
when	1085 4 O
the	1090 3 O
same	1094 4 O
agent	1099 5 O
is	1105 2 O
used	1108 4 O
repeatedly	1113 10 O
after	1124 5 O
interruption	1130 12 O
periods	1143 7 O
or	1151 2 O
when	1154 4 O
users	1159 5 O
are	1165 3 O
switched	1169 8 O
between	1178 7 O
the	1186 3 O
two	1190 3 O
generations	1194 11 O
of	1206 2 O
pills	1209 5 O
.	1214 1 O

These	1216 5 O
analyses	1222 8 O
suggest	1231 7 O
that	1239 4 O
the	1244 3 O
higher	1248 6 O
risk	1255 4 O
observed	1260 8 O
for	1269 3 O
the	1273 3 O
newer	1277 5 O
OC	1283 2 B-Chemical
in	1286 2 O
other	1289 5 O
studies	1295 7 O
may	1303 3 O
be	1307 2 O
the	1310 3 O
result	1314 6 O
of	1321 2 O
inadequate	1324 10 O
comparisons	1335 11 O
of	1347 2 O
pill	1350 4 O
users	1355 5 O
with	1361 4 O
different	1366 9 O
patterns	1376 8 O
of	1385 2 O
pill	1388 4 O
use	1393 3 O
.	1396 1 O

Development	0 11 O
of	12 2 O
apomorphine	15 11 B-Chemical
-	26 1 O
induced	27 7 O
aggressive	35 10 B-Disease
behavior	46 8 I-Disease
:	54 1 O
comparison	56 10 O
of	67 2 O
adult	70 5 O
male	76 4 O
and	81 3 O
female	85 6 O
Wistar	92 6 O
rats	99 4 O
.	103 1 O

The	105 3 O
development	109 11 O
of	121 2 O
apomorphine	124 11 B-Chemical
-	135 1 O
induced	136 7 O
(	144 1 O
1	145 1 O
.	146 1 O
0	147 1 O
mg	149 2 O
/	151 1 O
kg	152 2 O
s	155 1 O
.	156 1 O
c	157 1 O
.	158 1 O
once	160 4 O
daily	165 5 O
)	170 1 O
aggressive	172 10 B-Disease
behavior	183 8 I-Disease
of	192 2 O
adult	195 5 O
male	201 4 O
and	206 3 O
female	210 6 O
Wistar	217 6 O
rats	224 4 O
obtained	229 8 O
from	238 4 O
the	243 3 O
same	247 4 O
breeder	252 7 O
was	260 3 O
studied	264 7 O
in	272 2 O
two	275 3 O
consecutive	279 11 O
sets	291 4 O
.	295 1 O

In	297 2 O
male	300 4 O
animals	305 7 O
,	312 1 O
repeated	314 8 O
apomorphine	323 11 B-Chemical
treatment	335 9 O
induced	345 7 O
a	353 1 O
gradual	355 7 O
development	363 11 O
of	375 2 O
aggressive	378 10 B-Disease
behavior	389 8 I-Disease
as	398 2 O
evidenced	401 9 O
by	411 2 O
the	414 3 O
increased	418 9 O
intensity	428 9 O
of	438 2 O
aggressiveness	441 14 B-Disease
and	456 3 O
shortened	460 9 O
latency	470 7 O
before	478 6 O
the	485 3 O
first	489 5 O
attack	495 6 O
toward	502 6 O
the	509 3 O
opponent	513 8 O
.	521 1 O

In	523 2 O
female	526 6 O
rats	533 4 O
,	537 1 O
only	539 4 O
a	544 1 O
weak	546 4 O
tendency	551 8 O
toward	560 6 O
aggressiveness	567 14 B-Disease
was	582 3 O
found	586 5 O
.	591 1 O

In	593 2 O
conclusion	596 10 O
,	606 1 O
the	608 3 O
present	612 7 O
study	620 5 O
demonstrates	626 12 O
gender	639 6 O
differences	646 11 O
in	658 2 O
the	661 3 O
development	665 11 O
of	677 2 O
the	680 3 O
apomorphine	684 11 B-Chemical
-	695 1 O
induced	696 7 O
aggressive	704 10 B-Disease
behavior	715 8 I-Disease
and	724 3 O
indicates	728 9 O
that	738 4 O
the	743 3 O
female	747 6 O
rats	754 4 O
do	759 2 O
not	762 3 O
fill	766 4 O
the	771 3 O
validation	775 10 O
criteria	786 8 O
for	795 3 O
use	799 3 O
in	803 2 O
this	806 4 O
method	811 6 O
.	817 1 O

Serotonergic	0 12 B-Chemical
antidepressants	13 15 I-Chemical
and	29 3 O
urinary	33 7 B-Disease
incontinence	41 12 I-Disease
.	53 1 O

Many	55 4 O
new	60 3 O
serotonergic	64 12 B-Chemical
antidepressants	77 15 I-Chemical
have	93 4 O
been	98 4 O
introduced	103 10 O
over	114 4 O
the	119 3 O
past	123 4 O
decade	128 6 O
.	134 1 O

Although	136 8 O
urinary	145 7 B-Disease
incontinence	153 12 I-Disease
is	166 2 O
listed	169 6 O
as	176 2 O
one	179 3 O
side	183 4 O
effect	188 6 O
of	195 2 O
these	198 5 O
drugs	204 5 O
in	210 2 O
their	213 5 O
package	219 7 O
inserts	227 7 O
there	235 5 O
is	241 2 O
only	244 4 O
one	249 3 O
report	253 6 O
in	260 2 O
the	263 3 O
literature	267 10 O
.	277 1 O

This	279 4 O
concerns	284 8 O
2	293 1 O
male	295 4 O
patients	300 8 O
who	309 3 O
experienced	313 11 O
incontinence	325 12 B-Disease
while	338 5 O
taking	344 6 O
venlafaxine	351 11 B-Chemical
.	362 1 O

In	364 2 O
the	367 3 O
present	371 7 O
paper	379 5 O
the	385 3 O
authors	389 7 O
describe	397 8 O
2	406 1 O
female	408 6 O
patients	415 8 O
who	424 3 O
developed	428 9 O
incontinence	438 12 B-Disease
secondary	451 9 O
to	461 2 O
the	464 3 O
selective	468 9 O
serotonin	478 9 B-Chemical
reuptake	488 8 O
inhibitors	497 10 O
paroxetine	508 10 B-Chemical
and	519 3 O
sertraline	523 10 B-Chemical
,	533 1 O
as	535 2 O
well	538 4 O
as	543 2 O
a	546 1 O
third	548 5 O
who	554 3 O
developed	558 9 O
this	568 4 O
side	573 4 O
effect	578 6 O
on	585 2 O
venlafaxine	588 11 B-Chemical
.	599 1 O

In	601 2 O
2	604 1 O
of	606 2 O
the	609 3 O
3	613 1 O
cases	615 5 O
the	621 3 O
patients	625 8 O
were	634 4 O
also	639 4 O
taking	644 6 O
lithium	651 7 B-Chemical
carbonate	659 9 I-Chemical
and	669 3 O
beta	673 4 O
-	677 1 O
blockers	678 8 O
,	686 1 O
both	688 4 O
of	693 2 O
which	696 5 O
could	702 5 O
have	708 4 O
contributed	713 11 O
to	725 2 O
the	728 3 O
incontinence	732 12 B-Disease
.	744 1 O

Animal	746 6 O
studies	753 7 O
suggest	761 7 O
that	769 4 O
incontinence	774 12 B-Disease
secondary	787 9 O
to	797 2 O
serotonergic	800 12 B-Chemical
antidepressants	813 15 I-Chemical
could	829 5 O
be	835 2 O
mediated	838 8 O
by	847 2 O
the	850 3 O
5HT4	854 4 O
receptors	859 9 O
found	869 5 O
on	875 2 O
the	878 3 O
bladder	882 7 O
.	889 1 O

Further	891 7 O
research	899 8 O
is	908 2 O
needed	911 6 O
to	918 2 O
delineate	921 9 O
the	931 3 O
frequency	935 9 O
of	945 2 O
this	948 4 O
troubling	953 9 O
side	963 4 O
effect	968 6 O
and	975 3 O
how	979 3 O
best	983 4 O
to	988 2 O
treat	991 5 O
it	997 2 O
.	999 1 O

Hypotension	0 11 B-Disease
following	12 9 O
the	22 3 O
initiation	26 10 O
of	37 2 O
tizanidine	40 10 B-Chemical
in	51 2 O
a	54 1 O
patient	56 7 O
treated	64 7 O
with	72 4 O
an	77 2 O
angiotensin	80 11 B-Chemical
converting	92 10 O
enzyme	103 6 O
inhibitor	110 9 O
for	120 3 O
chronic	124 7 O
hypertension	132 12 B-Disease
.	144 1 O

Centrally	146 9 O
acting	156 6 O
alpha	163 5 O
-	168 1 O
2	169 1 O
adrenergic	171 10 O
agonists	182 8 O
are	191 3 O
one	195 3 O
of	199 2 O
several	202 7 O
pharmacologic	210 13 O
agents	224 6 O
used	231 4 O
in	236 2 O
the	239 3 O
treatment	243 9 O
of	253 2 O
spasticity	256 10 B-Disease
related	267 7 O
to	275 2 O
disorders	278 9 B-Disease
of	288 2 I-Disease
the	291 3 I-Disease
central	295 7 I-Disease
nervous	303 7 I-Disease
system	311 6 I-Disease
.	317 1 O

In	319 2 O
addition	322 8 O
to	331 2 O
their	334 5 O
effects	340 7 O
on	348 2 O
spasticity	351 10 B-Disease
,	361 1 O
certain	363 7 O
adverse	371 7 O
cardiorespiratory	379 17 O
effects	397 7 O
have	405 4 O
been	410 4 O
reported	415 8 O
.	423 1 O

Adults	425 6 O
chronically	432 11 O
treated	444 7 O
with	452 4 O
angiotensin	457 11 B-Chemical
converting	469 10 O
enzyme	480 6 O
inhibitors	487 10 O
may	498 3 O
have	502 4 O
a	507 1 O
limited	509 7 O
ability	517 7 O
to	525 2 O
respond	528 7 O
to	536 2 O
hypotension	539 11 B-Disease
when	551 4 O
the	556 3 O
sympathetic	560 11 O
response	572 8 O
is	581 2 O
simultaneously	584 14 O
blocked	599 7 O
.	606 1 O

The	608 3 O
authors	612 7 O
present	620 7 O
a	628 1 O
10	630 2 O
-	632 1 O
year	633 4 O
-	637 1 O
old	638 3 O
boy	642 3 O
chronically	646 11 O
treated	658 7 O
with	666 4 O
lisinopril	671 10 B-Chemical
,	681 1 O
an	683 2 O
angiotensin	686 11 B-Chemical
converting	698 10 O
enzyme	709 6 O
inhibitor	716 9 O
,	725 1 O
to	727 2 O
control	730 7 O
hypertension	738 12 B-Disease
who	751 3 O
developed	755 9 O
hypotension	765 11 B-Disease
following	777 9 O
the	787 3 O
addition	791 8 O
of	800 2 O
tizanidine	803 10 B-Chemical
,	813 1 O
an	815 2 O
alpha	818 5 O
-	823 1 O
2	824 1 O
agonist	826 7 O
,	833 1 O
for	835 3 O
the	839 3 O
treatment	843 9 O
of	853 2 O
spasticity	856 10 B-Disease
.	866 1 O

The	868 3 O
possible	872 8 O
interaction	881 11 O
of	893 2 O
tizanidine	896 10 B-Chemical
and	907 3 O
other	911 5 O
antihypertensive	917 16 O
agents	934 6 O
should	941 6 O
be	948 2 O
kept	951 4 O
in	956 2 O
mind	959 4 O
when	964 4 O
prescribing	969 11 O
therapy	981 7 O
to	989 2 O
treat	992 5 O
either	998 6 O
hypertension	1005 12 B-Disease
or	1018 2 O
spasticity	1021 10 B-Disease
in	1032 2 O
such	1035 4 O
patients	1040 8 O
.	1048 1 O

Peritubular	0 11 O
capillary	12 9 O
basement	22 8 O
membrane	31 8 O
reduplication	40 13 O
in	54 2 O
allografts	57 10 O
and	68 3 O
native	72 6 O
kidney	79 6 B-Disease
disease	86 7 I-Disease
:	93 1 O
a	95 1 O
clinicopathologic	97 17 O
study	115 5 O
of	121 2 O
278	124 3 O
consecutive	128 11 O
renal	140 5 O
specimens	146 9 O
.	155 1 O

BACKGROUND	157 10 O
:	167 1 O
An	169 2 O
association	172 11 O
has	184 3 O
been	188 4 O
found	193 5 O
between	199 7 O
transplant	207 10 B-Disease
glomerulopathy	218 14 I-Disease
(	233 1 O
TG	234 2 B-Disease
)	236 1 O
and	238 3 O
reduplication	242 13 O
of	256 2 O
peritubular	259 11 O
capillary	271 9 O
basement	281 8 O
membranes	290 9 O
(	300 1 O
PTCR	301 4 O
)	305 1 O
.	306 1 O

Although	308 8 O
such	317 4 O
an	322 2 O
association	325 11 O
is	337 2 O
of	340 2 O
practical	343 9 O
and	353 3 O
theoretical	357 11 O
importance	369 10 O
,	379 1 O
only	381 4 O
one	386 3 O
prospective	390 11 O
study	402 5 O
has	408 3 O
tried	412 5 O
to	418 2 O
confirm	421 7 O
it	429 2 O
.	431 1 O

METHODS	433 7 O
:	440 1 O
We	442 2 O
examined	445 8 O
278	454 3 O
consecutive	458 11 O
renal	470 5 O
specimens	476 9 O
(	486 1 O
from	487 4 O
135	492 3 O
transplants	496 11 O
and	508 3 O
143	512 3 O
native	516 6 O
kidneys	523 7 O
)	530 1 O
for	532 3 O
ultrastructural	536 15 O
evidence	552 8 O
of	561 2 O
PTCR	564 4 O
.	568 1 O

In	570 2 O
addition	573 8 O
to	582 2 O
renal	585 5 O
allografts	591 10 O
with	602 4 O
TG	607 2 B-Disease
,	609 1 O
we	611 2 O
also	614 4 O
examined	619 8 O
grafts	628 6 O
with	635 4 O
acute	640 5 O
rejection	646 9 O
,	655 1 O
recurrent	657 9 O
glomerulonephritis	667 18 B-Disease
,	685 1 O
chronic	687 7 B-Disease
allograft	695 9 I-Disease
nephropathy	705 11 I-Disease
and	717 3 O
stable	721 6 O
grafts	728 6 O
(	735 1 O
"	736 1 O
protocol	737 8 O
biopsies	746 8 O
"	754 1 O
)	755 1 O
.	756 1 O

Native	758 6 O
kidney	765 6 O
specimens	772 9 O
included	782 8 O
a	791 1 O
wide	793 4 O
range	798 5 O
of	804 2 O
glomerulopathies	807 16 B-Disease
as	824 2 O
well	827 4 O
as	832 2 O
cases	835 5 O
of	841 2 O
thrombotic	844 10 B-Disease
microangiopathy	855 15 I-Disease
,	870 1 O
malignant	872 9 B-Disease
hypertension	882 12 I-Disease
,	894 1 O
acute	896 5 O
interstitial	902 12 B-Disease
nephritis	915 9 I-Disease
,	924 1 O
and	926 3 O
acute	930 5 B-Disease
tubular	936 7 I-Disease
necrosis	944 8 I-Disease
.	952 1 O

RESULTS	954 7 O
:	961 1 O
We	963 2 O
found	966 5 O
PTCR	972 4 O
in	977 2 O
14	980 2 O
of	983 2 O
15	986 2 O
cases	989 5 O
of	995 2 O
TG	998 2 B-Disease
,	1000 1 O
in	1002 2 O
7	1005 1 O
transplant	1007 10 O
biopsy	1018 6 O
specimens	1025 9 O
without	1035 7 O
TG	1043 2 B-Disease
,	1045 1 O
and	1047 3 O
in	1051 2 O
13	1054 2 O
of	1057 2 O
143	1060 3 O
native	1064 6 O
kidney	1071 6 O
biopsy	1078 6 O
specimens	1085 9 O
.	1094 1 O

These	1096 5 O
13	1102 2 O
included	1105 8 O
cases	1114 5 O
of	1120 2 O
malignant	1123 9 B-Disease
hypertension	1133 12 I-Disease
,	1145 1 O
thrombotic	1147 10 B-Disease
microangiopathy	1158 15 I-Disease
,	1173 1 O
lupus	1175 5 B-Disease
nephritis	1181 9 I-Disease
,	1190 1 O
Henoch	1192 6 B-Disease
-	1198 1 I-Disease
Schonlein	1199 9 I-Disease
nephritis	1209 9 I-Disease
,	1218 1 O
crescentic	1220 10 O
glomerulonephritis	1231 18 B-Disease
,	1249 1 O
and	1251 3 O
cocaine	1255 7 B-Chemical
-	1262 1 O
related	1263 7 O
acute	1271 5 B-Disease
renal	1277 5 I-Disease
failure	1283 7 I-Disease
.	1290 1 O

Mild	1292 4 O
PTCR	1297 4 O
in	1302 2 O
allografts	1305 10 O
without	1316 7 O
TG	1324 2 B-Disease
did	1327 3 O
not	1331 3 O
predict	1335 7 O
renal	1343 5 B-Disease
failure	1349 7 I-Disease
or	1357 2 O
significant	1360 11 O
proteinuria	1372 11 B-Disease
after	1384 5 O
follow	1390 6 O
-	1396 1 O
up	1397 2 O
periods	1400 7 O
of	1408 2 O
between	1411 7 O
3	1419 1 O
months	1421 6 O
and	1428 3 O
1	1432 1 O
year	1434 4 O
.	1438 1 O

CONCLUSIONS	1440 11 O
:	1451 1 O
We	1453 2 O
conclude	1456 8 O
that	1465 4 O
in	1470 2 O
transplants	1473 11 O
,	1484 1 O
there	1486 5 O
is	1492 2 O
a	1495 1 O
strong	1497 6 O
association	1504 11 O
between	1516 7 O
well	1524 4 O
-	1528 1 O
developed	1529 9 O
PTCR	1539 4 O
and	1544 3 O
TG	1548 2 B-Disease
,	1550 1 O
while	1552 5 O
the	1558 3 O
significance	1562 12 O
of	1575 2 O
mild	1578 4 O
PTCR	1583 4 O
and	1588 3 O
its	1592 3 O
predictive	1596 10 O
value	1607 5 O
in	1613 2 O
the	1616 3 O
absence	1620 7 O
of	1628 2 O
TG	1631 2 B-Disease
is	1634 2 O
unclear	1637 7 O
.	1644 1 O

PTCR	1646 4 O
also	1651 4 O
occurs	1656 6 O
in	1663 2 O
certain	1666 7 O
native	1674 6 O
kidney	1681 6 B-Disease
diseases	1688 8 I-Disease
,	1696 1 O
though	1698 6 O
the	1705 3 O
association	1709 11 O
is	1721 2 O
not	1724 3 O
as	1728 2 O
strong	1731 6 O
as	1738 2 O
that	1741 4 O
for	1746 3 O
TG	1750 2 B-Disease
.	1752 1 O

We	1754 2 O
suggest	1757 7 O
that	1765 4 O
repeated	1770 8 O
endothelial	1779 11 B-Disease
injury	1791 6 I-Disease
,	1797 1 O
including	1799 9 O
immunologic	1809 11 B-Disease
injury	1821 6 I-Disease
,	1827 1 O
may	1829 3 O
be	1833 2 O
the	1836 3 O
cause	1840 5 O
of	1846 2 O
this	1849 4 O
lesion	1854 6 O
both	1861 4 O
in	1866 2 O
allografts	1869 10 O
and	1880 3 O
native	1884 6 O
kidneys	1891 7 O
.	1898 1 O

Conformationally	0 16 O
restricted	17 10 O
analogs	28 7 O
of	36 2 O
BD1008	39 6 B-Chemical
and	46 3 O
an	50 2 O
antisense	53 9 O
oligodeoxynucleotide	63 20 B-Chemical
targeting	84 9 O
sigma1	94 6 O
receptors	101 9 O
produce	111 7 O
anti	119 4 O
-	123 1 O
cocaine	124 7 B-Chemical
effects	132 7 O
in	140 2 O
mice	143 4 O
.	147 1 O

Cocaine	149 7 B-Chemical
'	156 1 O
s	157 1 O
ability	159 7 O
to	167 2 O
interact	170 8 O
with	179 4 O
sigma	184 5 O
receptors	190 9 O
suggests	200 8 O
that	209 4 O
these	214 5 O
proteins	220 8 O
mediate	229 7 O
some	237 4 O
of	242 2 O
its	245 3 O
behavioral	249 10 O
effects	260 7 O
.	267 1 O

Therefore	269 9 O
,	278 1 O
three	280 5 O
novel	286 5 O
sigma	292 5 O
receptor	298 8 O
ligands	307 7 O
with	315 4 O
antagonist	320 10 O
activity	331 8 O
were	340 4 O
evaluated	345 9 O
in	355 2 O
Swiss	358 5 O
Webster	364 7 O
mice	372 4 O
:	376 1 O
BD1018	378 6 B-Chemical
(	385 1 O
3S	386 2 B-Chemical
-	388 1 I-Chemical
1	389 1 I-Chemical
-	390 1 I-Chemical
[	391 1 I-Chemical
2	392 1 I-Chemical
-	393 1 I-Chemical
(	394 1 I-Chemical
3	395 1 I-Chemical
,	396 1 I-Chemical
4	397 1 I-Chemical
-	398 1 I-Chemical
dichlorophenyl	399 14 I-Chemical
)	413 1 I-Chemical
ethyl	414 5 I-Chemical
]	419 1 I-Chemical
-	420 1 I-Chemical
1	421 1 I-Chemical
,	422 1 I-Chemical
4	423 1 I-Chemical
-	424 1 I-Chemical
diazabicyclo	425 12 I-Chemical
[	437 1 I-Chemical
4	438 1 I-Chemical
.	439 1 I-Chemical
3	440 1 I-Chemical
.	441 1 I-Chemical
0	442 1 I-Chemical
]	443 1 I-Chemical
nonane	444 6 I-Chemical
)	450 1 O
,	451 1 O
BD1063	453 6 B-Chemical
(	460 1 O
1	461 1 B-Chemical
-	462 1 I-Chemical
[	463 1 I-Chemical
2	464 1 I-Chemical
-	465 1 I-Chemical
(	466 1 I-Chemical
3	467 1 I-Chemical
,	468 1 I-Chemical
4	469 1 I-Chemical
-	470 1 I-Chemical
dichlorophenyl	471 14 I-Chemical
)	485 1 I-Chemical
ethyl	486 5 I-Chemical
]	491 1 I-Chemical
-	492 1 I-Chemical
4	493 1 I-Chemical
-	494 1 I-Chemical
methylpiperazine	495 16 I-Chemical
)	511 1 O
,	512 1 O
and	514 3 O
LR132	518 5 B-Chemical
(	524 1 O
1R	525 2 O
,	527 1 O
2S	528 2 O
-	530 1 O
(	531 1 O
+	532 1 O
)	533 1 O
-	534 1 O
cis	535 3 O
-	538 1 O
N	539 1 O
-	540 1 O
[	541 1 O
2	542 1 O
-	543 1 O
(	544 1 O
3	545 1 O
,	546 1 O
4	547 1 O
-	548 1 O
dichlorophenyl	549 14 O
)	563 1 O
ethyl	564 5 O
]	569 1 O
-	570 1 O
2	571 1 O
-	572 1 O
(	573 1 O
1	574 1 O
-	575 1 O
pyrrolidinyl	576 12 O
)	588 1 O
cyclohexylamine	589 15 O
)	604 1 O
.	605 1 O

Competition	607 11 O
binding	619 7 O
assays	627 6 O
demonstrated	634 12 O
that	647 4 O
all	652 3 O
three	656 5 O
compounds	662 9 O
have	672 4 O
high	677 4 O
affinities	682 10 O
for	693 3 O
sigma1	697 6 O
receptors	704 9 O
.	713 1 O

The	715 3 O
three	719 5 O
compounds	725 9 O
vary	735 4 O
in	740 2 O
their	743 5 O
affinities	749 10 O
for	760 3 O
sigma2	764 6 O
receptors	771 9 O
and	781 3 O
exhibit	785 7 O
negligible	793 10 O
affinities	804 10 O
for	815 3 O
dopamine	819 8 B-Chemical
,	827 1 O
opioid	829 6 O
,	835 1 O
GABA	837 4 B-Chemical
(	841 1 O
A	842 1 O
)	843 1 O
and	845 3 O
NMDA	849 4 B-Chemical
receptors	854 9 O
.	863 1 O

In	865 2 O
behavioral	868 10 O
studies	879 7 O
,	886 1 O
pre	888 3 O
-	891 1 O
treatment	892 9 O
of	902 2 O
mice	905 4 O
with	910 4 O
BD1018	915 6 B-Chemical
,	921 1 O
BD1063	923 6 B-Chemical
,	929 1 O
or	931 2 O
LR132	934 5 B-Chemical
significantly	940 13 O
attenuated	954 10 O
cocaine	965 7 B-Chemical
-	972 1 O
induced	973 7 O
convulsions	981 11 B-Disease
and	993 3 O
lethality	997 9 O
.	1006 1 O

Moreover	1008 8 O
,	1016 1 O
post	1018 4 O
-	1022 1 O
treatment	1023 9 O
with	1033 4 O
LR132	1038 5 B-Chemical
prevented	1044 9 O
cocaine	1054 7 B-Chemical
-	1061 1 O
induced	1062 7 O
lethality	1070 9 O
in	1080 2 O
a	1083 1 O
significant	1085 11 O
proportion	1097 10 O
of	1108 2 O
animals	1111 7 O
.	1118 1 O

In	1120 2 O
contrast	1123 8 O
to	1132 2 O
the	1135 3 O
protection	1139 10 O
provided	1150 8 O
by	1159 2 O
the	1162 3 O
putative	1166 8 O
antagonists	1175 11 O
,	1186 1 O
the	1188 3 O
well	1192 4 O
-	1196 1 O
characterized	1197 13 O
sigma	1211 5 O
receptor	1217 8 O
agonist	1226 7 O
di	1234 2 B-Chemical
-	1236 1 I-Chemical
o	1237 1 I-Chemical
-	1238 1 I-Chemical
tolylguanidine	1239 14 I-Chemical
(	1254 1 O
DTG	1255 3 B-Chemical
)	1258 1 O
and	1260 3 O
the	1264 3 O
novel	1268 5 O
sigma	1274 5 O
receptor	1280 8 O
agonist	1289 7 O
BD1031	1297 6 B-Chemical
(	1304 1 O
3R	1305 2 B-Chemical
-	1307 1 I-Chemical
1	1308 1 I-Chemical
-	1309 1 I-Chemical
[	1310 1 I-Chemical
2	1311 1 I-Chemical
-	1312 1 I-Chemical
(	1313 1 I-Chemical
3	1314 1 I-Chemical
,	1315 1 I-Chemical
4	1316 1 I-Chemical
-	1317 1 I-Chemical
dichlorophenyl	1318 14 I-Chemical
)	1332 1 I-Chemical
ethyl	1333 5 I-Chemical
]	1338 1 I-Chemical
-	1339 1 I-Chemical
1	1340 1 I-Chemical
,	1341 1 I-Chemical
4	1342 1 I-Chemical
-	1343 1 I-Chemical
diazabicyclo	1344 12 I-Chemical
[	1356 1 I-Chemical
4	1357 1 I-Chemical
.	1358 1 I-Chemical
3	1359 1 I-Chemical
.	1360 1 I-Chemical
0	1361 1 I-Chemical
]	1362 1 I-Chemical
nonane	1363 6 I-Chemical
)	1369 1 O
each	1371 4 O
worsened	1376 8 O
the	1385 3 O
behavioral	1389 10 O
toxicity	1400 8 B-Disease
of	1409 2 O
cocaine	1412 7 B-Chemical
.	1419 1 O

At	1421 2 O
doses	1424 5 O
where	1430 5 O
alone	1436 5 O
,	1441 1 O
they	1443 4 O
produced	1448 8 O
no	1457 2 O
significant	1460 11 O
effects	1472 7 O
on	1480 2 O
locomotion	1483 10 O
,	1493 1 O
BD1018	1495 6 B-Chemical
,	1501 1 O
BD1063	1503 6 B-Chemical
and	1510 3 O
LR132	1514 5 B-Chemical
significantly	1520 13 O
attenuated	1534 10 O
the	1545 3 O
locomotor	1549 9 O
stimulatory	1559 11 O
effects	1571 7 O
of	1579 2 O
cocaine	1582 7 B-Chemical
.	1589 1 O

To	1591 2 O
further	1594 7 O
validate	1602 8 O
the	1611 3 O
hypothesis	1615 10 O
that	1626 4 O
the	1631 3 O
anti	1635 4 O
-	1639 1 O
cocaine	1640 7 B-Chemical
effects	1648 7 O
of	1656 2 O
the	1659 3 O
novel	1663 5 O
ligands	1669 7 O
involved	1677 8 O
antagonism	1686 10 O
of	1697 2 O
sigma	1700 5 O
receptors	1706 9 O
,	1715 1 O
an	1717 2 O
antisense	1720 9 O
oligodeoxynucleotide	1730 20 B-Chemical
against	1751 7 O
sigma1	1759 6 O
receptors	1766 9 O
was	1776 3 O
also	1780 4 O
shown	1785 5 O
to	1791 2 O
significantly	1794 13 O
attenuate	1808 9 O
the	1818 3 O
convulsive	1822 10 B-Disease
and	1833 3 O
locomotor	1837 9 O
stimulatory	1847 11 O
effects	1859 7 O
of	1867 2 O
cocaine	1870 7 B-Chemical
.	1877 1 O

Together	1879 8 O
,	1887 1 O
the	1889 3 O
data	1893 4 O
suggests	1898 8 O
that	1907 4 O
functional	1912 10 O
antagonism	1923 10 O
of	1934 2 O
sigma	1937 5 O
receptors	1943 9 O
is	1953 2 O
capable	1956 7 O
of	1964 2 O
attenuating	1967 11 O
a	1979 1 O
number	1981 6 O
of	1988 2 O
cocaine	1991 7 B-Chemical
-	1998 1 O
induced	1999 7 O
behaviors	2007 9 O
.	2016 1 O

Pharmacokinetic	0 15 O
/	15 1 O
pharmacodynamic	16 15 O
assessment	32 10 O
of	43 2 O
the	46 3 O
effects	50 7 O
of	58 2 O
E4031	61 5 B-Chemical
,	66 1 O
cisapride	68 9 B-Chemical
,	77 1 O
terfenadine	79 11 B-Chemical
and	91 3 O
terodiline	95 10 B-Chemical
on	106 2 O
monophasic	109 10 O
action	120 6 O
potential	127 9 O
duration	137 8 O
in	146 2 O
dog	149 3 O
.	152 1 O

1	154 1 O
.	155 1 O

Torsades	157 8 B-Disease
de	166 2 I-Disease
pointes	169 7 I-Disease
(	177 1 O
TDP	178 3 B-Disease
)	181 1 O
is	183 2 O
a	186 1 O
potentially	188 11 O
fatal	200 5 O
ventricular	206 11 B-Disease
tachycardia	218 11 I-Disease
associated	230 10 O
with	241 4 O
increases	246 9 O
in	256 2 O
QT	259 2 O
interval	262 8 O
and	271 3 O
monophasic	275 10 O
action	286 6 O
potential	293 9 O
duration	303 8 O
(	312 1 O
MAPD	313 4 O
)	317 1 O
.	318 1 O

TDP	320 3 B-Disease
is	324 2 O
a	327 1 O
side	329 4 O
-	333 1 O
effect	334 6 O
that	341 4 O
has	346 3 O
led	350 3 O
to	354 2 O
withdrawal	357 10 O
of	368 2 O
several	371 7 O
drugs	379 5 O
from	385 4 O
the	390 3 O
market	394 6 O
(	401 1 O
e	402 1 O
.	403 1 O
g	404 1 O
.	405 1 O
terfenadine	407 11 B-Chemical
and	419 3 O
terodiline	423 10 B-Chemical
)	433 1 O
.	434 1 O

2	436 1 O
.	437 1 O

The	439 3 O
potential	443 9 O
of	453 2 O
compounds	456 9 O
to	466 2 O
cause	469 5 O
TDP	475 3 B-Disease
was	479 3 O
evaluated	483 9 O
by	493 2 O
monitoring	496 10 O
their	507 5 O
effects	513 7 O
on	521 2 O
MAPD	524 4 O
in	529 2 O
dog	532 3 O
.	535 1 O

Four	537 4 O
compounds	542 9 O
known	552 5 O
to	558 2 O
increase	561 8 O
QT	570 2 O
interval	573 8 O
and	582 3 O
cause	586 5 O
TDP	592 3 B-Disease
were	596 4 O
investigated	601 12 O
:	613 1 O
terfenadine	615 11 B-Chemical
,	626 1 O
terodiline	628 10 B-Chemical
,	638 1 O
cisapride	640 9 B-Chemical
and	650 3 O
E4031	654 5 B-Chemical
.	659 1 O

On	661 2 O
the	664 3 O
basis	668 5 O
that	674 4 O
only	679 4 O
free	684 4 O
drug	689 4 O
in	694 2 O
the	697 3 O
systemic	701 8 O
circulation	710 11 O
will	722 4 O
elicit	727 6 O
a	734 1 O
pharmacological	736 15 O
response	752 8 O
target	761 6 O
,	767 1 O
free	769 4 O
concentrations	774 14 O
in	789 2 O
plasma	792 6 O
were	799 4 O
selected	804 8 O
to	813 2 O
mimic	816 5 O
the	822 3 O
free	826 4 O
drug	831 4 O
exposures	836 9 O
in	846 2 O
man	849 3 O
.	852 1 O

Infusion	854 8 O
regimens	863 8 O
were	872 4 O
designed	877 8 O
that	886 4 O
rapidly	891 7 O
achieved	899 8 O
and	908 3 O
maintained	912 10 O
target	923 6 O
-	929 1 O
free	930 4 O
concentrations	935 14 O
of	950 2 O
these	953 5 O
drugs	959 5 O
in	965 2 O
plasma	968 6 O
and	975 3 O
data	979 4 O
on	984 2 O
the	987 3 O
relationship	991 12 O
between	1004 7 O
free	1012 4 O
concentration	1017 13 O
and	1031 3 O
changes	1035 7 O
in	1043 2 O
MAPD	1046 4 O
were	1051 4 O
obtained	1056 8 O
for	1065 3 O
these	1069 5 O
compounds	1075 9 O
.	1084 1 O

3	1086 1 O
.	1087 1 O

These	1089 5 O
data	1095 4 O
indicate	1100 8 O
that	1109 4 O
the	1114 3 O
free	1118 4 O
ED50	1123 4 O
in	1128 2 O
plasma	1131 6 O
for	1138 3 O
terfenadine	1142 11 B-Chemical
(	1154 1 O
1	1155 1 O
.	1156 1 O
9	1157 1 O
nM	1159 2 O
)	1161 1 O
,	1162 1 O
terodiline	1164 10 B-Chemical
(	1175 1 O
76	1176 2 O
nM	1179 2 O
)	1181 1 O
,	1182 1 O
cisapride	1184 9 B-Chemical
(	1194 1 O
11	1195 2 O
nM	1198 2 O
)	1200 1 O
and	1202 3 O
E4031	1206 5 B-Chemical
(	1212 1 O
1	1213 1 O
.	1214 1 O
9	1215 1 O
nM	1217 2 O
)	1219 1 O
closely	1221 7 O
correlate	1229 9 O
with	1239 4 O
the	1244 3 O
free	1248 4 O
concentration	1253 13 O
in	1267 2 O
man	1270 3 O
causing	1274 7 O
QT	1282 2 O
effects	1285 7 O
.	1292 1 O

For	1294 3 O
compounds	1298 9 O
that	1308 4 O
have	1313 4 O
shown	1318 5 O
TDP	1324 3 B-Disease
in	1328 2 O
the	1331 3 O
clinic	1335 6 O
(	1342 1 O
terfenadine	1343 11 B-Chemical
,	1354 1 O
terodiline	1356 10 B-Chemical
,	1366 1 O
cisapride	1368 9 B-Chemical
)	1377 1 O
there	1379 5 O
is	1385 2 O
little	1388 6 O
differentiation	1395 15 O
between	1411 7 O
the	1419 3 O
dog	1423 3 O
ED50	1427 4 O
and	1432 3 O
the	1436 3 O
efficacious	1440 11 O
free	1452 4 O
plasma	1457 6 O
concentrations	1464 14 O
in	1479 2 O
man	1482 3 O
(	1486 1 O
<	1487 1 O
10	1489 2 O
-	1491 1 O
fold	1492 4 O
)	1496 1 O
reflecting	1498 10 O
their	1509 5 O
limited	1515 7 O
safety	1523 6 O
margins	1530 7 O
.	1537 1 O

These	1539 5 O
data	1545 4 O
underline	1550 9 O
the	1560 3 O
need	1564 4 O
to	1569 2 O
maximize	1572 8 O
the	1581 3 O
therapeutic	1585 11 O
ratio	1597 5 O
with	1603 4 O
respect	1608 7 O
to	1616 2 O
TDP	1619 3 B-Disease
in	1623 2 O
potential	1626 9 O
development	1636 11 O
candidates	1648 10 O
and	1659 3 O
the	1663 3 O
importance	1667 10 O
of	1678 2 O
using	1681 5 O
free	1687 4 O
drug	1692 4 O
concentrations	1697 14 O
in	1712 2 O
pharmacokinetic	1715 15 O
/	1730 1 O
pharmacodynamic	1731 15 O
studies	1747 7 O
.	1754 1 O

Fatal	0 5 O
myeloencephalopathy	6 19 B-Disease
due	26 3 O
to	30 2 O
accidental	33 10 O
intrathecal	44 11 O
vincristin	56 10 B-Chemical
administration	67 14 O
:	81 1 O
a	83 1 O
report	85 6 O
of	92 2 O
two	95 3 O
cases	99 5 O
.	104 1 O

We	106 2 O
report	109 6 O
on	116 2 O
two	119 3 O
fatal	123 5 O
cases	129 5 O
of	135 2 O
accidental	138 10 O
intrathecal	149 11 O
vincristine	161 11 B-Chemical
instillation	173 12 O
in	186 2 O
a	189 1 O
5	191 1 O
-	192 1 O
year	193 4 O
old	198 3 O
girl	202 4 O
with	207 4 O
recurrent	212 9 O
acute	222 5 B-Disease
lymphoblastic	228 13 I-Disease
leucemia	242 8 I-Disease
and	251 3 O
a	255 1 O
57	257 2 O
-	259 1 O
year	260 4 O
old	265 3 O
man	269 3 O
with	273 4 O
lymphoblastic	278 13 B-Disease
lymphoma	292 8 I-Disease
.	300 1 O

The	302 3 O
girl	306 4 O
died	311 4 O
seven	316 5 O
days	322 4 O
,	326 1 O
the	328 3 O
man	332 3 O
four	336 4 O
weeks	341 5 O
after	347 5 O
intrathecal	353 11 O
injection	365 9 O
of	375 2 O
vincristine	378 11 B-Chemical
.	389 1 O

Clinically	391 10 O
,	401 1 O
the	403 3 O
onset	407 5 O
was	413 3 O
characterized	417 13 O
by	431 2 O
the	434 3 O
signs	438 5 O
of	444 2 O
opistothonus	447 12 B-Disease
,	459 1 I-Disease
sensory	461 7 I-Disease
and	469 3 I-Disease
motor	473 5 I-Disease
dysfunction	479 11 I-Disease
and	491 3 O
ascending	495 9 O
paralysis	505 9 B-Disease
.	514 1 O

Histological	516 12 O
and	529 3 O
immunohistochemical	533 19 O
investigations	553 14 O
(	568 1 O
HE	569 2 O
-	571 1 O
LFB	572 3 O
,	575 1 O
CD	577 2 O
-	579 1 O
68	580 2 O
,	582 1 O
Neurofilament	584 13 O
)	597 1 O
revealed	599 8 O
degeneration	608 12 B-Disease
of	621 2 I-Disease
myelin	624 6 I-Disease
and	631 3 I-Disease
axons	635 5 I-Disease
as	641 2 O
well	644 4 O
as	649 2 O
pseudocystic	652 12 B-Disease
transformation	665 14 I-Disease
in	680 2 O
areas	683 5 O
exposed	689 7 O
to	697 2 O
vincristine	700 11 B-Chemical
,	711 1 O
accompanied	713 11 O
by	725 2 O
secondary	728 9 O
changes	738 7 O
with	746 4 O
numerous	751 8 O
prominent	760 9 O
macrophages	770 11 O
.	781 1 O

The	783 3 O
clinical	787 8 O
course	796 6 O
and	803 3 O
histopathological	807 17 O
results	825 7 O
of	833 2 O
the	836 3 O
two	840 3 O
cases	844 5 O
are	850 3 O
presented	854 9 O
.	863 1 O

A	865 1 O
review	867 6 O
of	874 2 O
all	877 3 O
reported	881 8 O
cases	890 5 O
in	896 2 O
the	899 3 O
literature	903 10 O
is	914 2 O
given	917 5 O
.	922 1 O

A	924 1 O
better	926 6 O
controlled	933 10 O
regimen	944 7 O
for	952 3 O
administering	956 13 O
vincristine	970 11 B-Chemical
and	982 3 O
intrathecal	986 11 O
chemotherapy	998 12 O
is	1011 2 O
recommended	1014 11 O
.	1025 1 O

Intravenous	0 11 O
administration	12 14 O
of	27 2 O
prochlorperazine	30 16 B-Chemical
by	47 2 O
15	50 2 O
-	52 1 O
minute	53 6 O
infusion	60 8 O
versus	69 6 O
2	76 1 O
-	77 1 O
minute	78 6 O
bolus	85 5 O
does	91 4 O
not	96 3 O
affect	100 6 O
the	107 3 O
incidence	111 9 O
of	121 2 O
akathisia	124 9 B-Disease
:	133 1 O
a	135 1 O
prospective	137 11 O
,	148 1 O
randomized	150 10 O
,	160 1 O
controlled	162 10 O
trial	173 5 O
.	178 1 O

STUDY	180 5 O
OBJECTIVE	186 9 O
:	195 1 O
We	197 2 O
sought	200 6 O
to	207 2 O
compare	210 7 O
the	218 3 O
rate	222 4 O
of	227 2 O
akathisia	230 9 B-Disease
after	240 5 O
administration	246 14 O
of	261 2 O
intravenous	264 11 O
prochlorperazine	276 16 B-Chemical
as	293 2 O
a	296 1 O
2	298 1 O
-	299 1 O
minute	300 6 O
bolus	307 5 O
or	313 2 O
15	316 2 O
-	318 1 O
minute	319 6 O
infusion	326 8 O
.	334 1 O

METHODS	336 7 O
:	343 1 O
We	345 2 O
conducted	348 9 O
a	358 1 O
prospective	360 11 O
,	371 1 O
randomized	373 10 O
,	383 1 O
double	385 6 O
-	391 1 O
blind	392 5 O
study	398 5 O
in	404 2 O
the	407 3 O
emergency	411 9 O
department	421 10 O
of	432 2 O
a	435 1 O
central	437 7 O
-	444 1 O
city	445 4 O
teaching	450 8 O
hospital	459 8 O
.	467 1 O

Patients	469 8 O
aged	478 4 O
18	483 2 O
years	486 5 O
or	492 2 O
older	495 5 O
treated	501 7 O
with	509 4 O
prochlorperazine	514 16 B-Chemical
for	531 3 O
headache	535 8 B-Disease
,	543 1 O
nausea	545 6 B-Disease
,	551 1 O
or	553 2 O
vomiting	556 8 B-Disease
were	565 4 O
eligible	570 8 O
for	579 3 O
inclusion	583 9 O
.	592 1 O

Study	594 5 O
participants	600 12 O
were	613 4 O
randomized	618 10 O
to	629 2 O
receive	632 7 O
10	640 2 O
mg	643 2 O
of	646 2 O
prochlorperazine	649 16 B-Chemical
administered	666 12 O
intravenously	679 13 O
by	693 2 O
means	696 5 O
of	702 2 O
2	705 1 O
-	706 1 O
minute	707 6 O
push	714 4 O
(	719 1 O
bolus	720 5 O
group	726 5 O
)	731 1 O
or	733 2 O
10	736 2 O
mg	739 2 O
diluted	742 7 O
in	750 2 O
50	753 2 O
mL	756 2 O
of	759 2 O
normal	762 6 O
saline	769 6 O
solution	776 8 O
administered	785 12 O
by	798 2 O
means	801 5 O
of	807 2 O
intravenous	810 11 O
infusion	822 8 O
during	831 6 O
a	838 1 O
15	840 2 O
-	842 1 O
minute	843 6 O
period	850 6 O
(	857 1 O
infusion	858 8 O
group	867 5 O
)	872 1 O
.	873 1 O

The	875 3 O
main	879 4 O
outcome	884 7 O
was	892 3 O
the	896 3 O
number	900 6 O
of	907 2 O
study	910 5 O
participants	916 12 O
experiencing	929 12 O
akathisia	942 9 B-Disease
within	952 6 O
60	959 2 O
minutes	962 7 O
of	970 2 O
administration	973 14 O
.	987 1 O

Akathisia	989 9 O
was	999 3 O
defined	1003 7 O
as	1011 2 O
either	1014 6 O
a	1021 1 O
spontaneous	1023 11 O
report	1035 6 O
of	1042 2 O
restlessness	1045 12 O
or	1058 2 O
agitation	1061 9 B-Disease
or	1071 2 O
a	1074 1 O
change	1076 6 O
of	1083 2 O
2	1086 1 O
or	1088 2 O
more	1091 4 O
in	1096 2 O
the	1099 3 O
patient	1103 7 O
-	1110 1 O
reported	1111 8 O
akathisia	1120 9 B-Disease
rating	1130 6 O
scale	1137 5 O
and	1143 3 O
a	1147 1 O
change	1149 6 O
of	1156 2 O
at	1159 2 O
least	1162 5 O
1	1168 1 O
in	1170 2 O
the	1173 3 O
investigator	1177 12 O
-	1189 1 O
observed	1190 8 O
akathisia	1199 9 B-Disease
rating	1209 6 O
scale	1216 5 O
.	1221 1 O

The	1223 3 O
intensity	1227 9 O
of	1237 2 O
headache	1240 8 B-Disease
and	1249 3 O
nausea	1253 6 B-Disease
was	1260 3 O
measured	1264 8 O
with	1273 4 O
a	1278 1 O
100	1280 3 O
-	1283 1 O
mm	1284 2 O
visual	1287 6 O
analog	1294 6 O
scale	1301 5 O
.	1306 1 O

RESULTS	1308 7 O
:	1315 1 O
One	1317 3 O
hundred	1321 7 O
patients	1329 8 O
were	1338 4 O
enrolled	1343 8 O
.	1351 1 O

One	1353 3 O
study	1357 5 O
participant	1363 11 O
was	1375 3 O
excluded	1379 8 O
after	1388 5 O
protocol	1394 8 O
violation	1403 9 O
.	1412 1 O

Seventy	1414 7 O
-	1421 1 O
three	1422 5 O
percent	1428 7 O
(	1436 1 O
73	1437 2 O
/	1439 1 O
99	1440 2 O
)	1442 1 O
of	1444 2 O
the	1447 3 O
study	1451 5 O
participants	1457 12 O
were	1470 4 O
treated	1475 7 O
for	1483 3 O
headache	1487 8 B-Disease
and	1496 3 O
70	1500 2 O
%	1502 1 O
(	1504 1 O
70	1505 2 O
/	1507 1 O
99	1508 2 O
)	1510 1 O
for	1512 3 O
nausea	1516 6 B-Disease
.	1522 1 O

In	1524 2 O
the	1527 3 O
bolus	1531 5 O
group	1537 5 O
,	1542 1 O
26	1544 2 O
.	1546 1 O
0	1547 1 O
%	1548 1 O
(	1550 1 O
13	1551 2 O
/	1553 1 O
50	1554 2 O
)	1556 1 O
had	1558 3 O
akathisia	1562 9 B-Disease
compared	1572 8 O
with	1581 4 O
32	1586 2 O
.	1588 1 O
7	1589 1 O
%	1590 1 O
(	1592 1 O
16	1593 2 O
/	1595 1 O
49	1596 2 O
)	1598 1 O
in	1600 2 O
the	1603 3 O
infusion	1607 8 O
group	1616 5 O
(	1622 1 O
Delta	1623 5 O
=	1628 1 O
-	1629 1 O
6	1630 1 O
.	1631 1 O
7	1632 1 O
%	1633 1 O
;	1634 1 O
95	1636 2 O
%	1638 1 O
confidence	1640 10 O
interval	1651 8 O
[	1660 1 O
CI	1661 2 O
]	1663 1 O
-	1665 1 O
24	1666 2 O
.	1668 1 O
6	1669 1 O
%	1670 1 O
to	1672 2 O
11	1675 2 O
.	1677 1 O
2	1678 1 O
%	1679 1 O
)	1680 1 O
.	1681 1 O

The	1683 3 O
difference	1687 10 O
between	1698 7 O
the	1706 3 O
bolus	1710 5 O
and	1716 3 O
infusion	1720 8 O
groups	1729 6 O
in	1736 2 O
the	1739 3 O
percentage	1743 10 O
of	1754 2 O
participants	1757 12 O
who	1770 3 O
saw	1774 3 O
a	1778 1 O
50	1780 2 O
%	1782 1 O
reduction	1784 9 O
in	1794 2 O
their	1797 5 O
headache	1803 8 B-Disease
intensity	1812 9 O
within	1822 6 O
30	1829 2 O
minutes	1832 7 O
was	1840 3 O
11	1844 2 O
.	1846 1 O
8	1847 1 O
%	1848 1 O
(	1850 1 O
95	1851 2 O
%	1853 1 O
CI	1855 2 O
-	1858 1 O
9	1859 1 O
.	1860 1 O
6	1861 1 O
%	1862 1 O
to	1864 2 O
33	1867 2 O
.	1869 1 O
3	1870 1 O
%	1871 1 O
)	1872 1 O
.	1873 1 O

The	1875 3 O
difference	1879 10 O
in	1890 2 O
the	1893 3 O
percentage	1897 10 O
of	1908 2 O
patients	1911 8 O
with	1920 4 O
a	1925 1 O
50	1927 2 O
%	1929 1 O
reduction	1931 9 O
in	1941 2 O
their	1944 5 O
nausea	1950 6 B-Disease
was	1957 3 O
12	1961 2 O
.	1963 1 O
6	1964 1 O
%	1965 1 O
(	1967 1 O
95	1968 2 O
%	1970 1 O
CI	1972 2 O
-	1975 1 O
4	1976 1 O
.	1977 1 O
6	1978 1 O
%	1979 1 O
to	1981 2 O
29	1984 2 O
.	1986 1 O
8	1987 1 O
%	1988 1 O
)	1989 1 O
.	1990 1 O

CONCLUSION	1992 10 O
:	2002 1 O
A	2004 1 O
50	2006 2 O
%	2008 1 O
reduction	2010 9 O
in	2020 2 O
the	2023 3 O
incidence	2027 9 O
of	2037 2 O
akathisia	2040 9 B-Disease
when	2050 4 O
prochlorperazine	2055 16 B-Chemical
was	2072 3 O
administered	2076 12 O
by	2089 2 O
means	2092 5 O
of	2098 2 O
15	2101 2 O
-	2103 1 O
minute	2104 6 O
intravenous	2111 11 O
infusion	2123 8 O
versus	2132 6 O
a	2139 1 O
2	2141 1 O
-	2142 1 O
minute	2143 6 O
intravenous	2150 11 O
push	2162 4 O
was	2167 3 O
not	2171 3 O
detected	2175 8 O
.	2183 1 O

The	2185 3 O
efficacy	2189 8 O
of	2198 2 O
prochlorperazine	2201 16 B-Chemical
in	2218 2 O
the	2221 3 O
treatment	2225 9 O
of	2235 2 O
headache	2238 8 B-Disease
and	2247 3 O
nausea	2251 6 B-Disease
likewise	2258 8 O
did	2267 3 O
not	2271 3 O
appear	2275 6 O
to	2282 2 O
be	2285 2 O
affected	2288 8 O
by	2297 2 O
the	2300 3 O
rate	2304 4 O
of	2309 2 O
administration	2312 14 O
,	2326 1 O
although	2328 8 O
no	2337 2 O
formal	2340 6 O
statistical	2347 11 O
comparisons	2359 11 O
were	2371 4 O
made	2376 4 O
.	2380 1 O

Antithymocyte	0 13 B-Chemical
globulin	14 8 I-Chemical
in	23 2 O
the	26 3 O
treatment	30 9 O
of	40 2 O
D	43 1 B-Chemical
-	44 1 I-Chemical
penicillamine	45 13 I-Chemical
-	58 1 O
induced	59 7 O
aplastic	67 8 B-Disease
anemia	76 6 I-Disease
.	82 1 O

A	84 1 O
patient	86 7 O
who	94 3 O
received	98 8 O
antithymocyte	107 13 B-Chemical
globulin	121 8 I-Chemical
therapy	130 7 O
for	138 3 O
aplastic	142 8 B-Disease
anemia	151 6 I-Disease
due	158 3 O
to	162 2 O
D	165 1 B-Chemical
-	166 1 I-Chemical
penicillamine	167 13 I-Chemical
therapy	181 7 O
is	189 2 O
described	192 9 O
.	201 1 O

Bone	203 4 O
marrow	208 6 O
recovery	215 8 O
and	224 3 O
peripheral	228 10 O
blood	239 5 O
recovery	245 8 O
were	254 4 O
complete	259 8 O
1	268 1 O
month	270 5 O
and	276 3 O
3	280 1 O
months	282 6 O
,	288 1 O
respectively	290 12 O
,	302 1 O
after	304 5 O
treatment	310 9 O
,	319 1 O
and	321 3 O
blood	325 5 O
transfusion	331 11 O
or	343 2 O
other	346 5 O
therapies	352 9 O
were	362 4 O
not	367 3 O
necessary	371 9 O
in	381 2 O
a	384 1 O
follow	386 6 O
-	392 1 O
up	393 2 O
period	396 6 O
of	403 2 O
more	406 4 O
than	411 4 O
2	416 1 O
years	418 5 O
.	423 1 O

Use	425 3 O
of	429 2 O
antithymocyte	432 13 B-Chemical
globulin	446 8 I-Chemical
may	455 3 O
be	459 2 O
the	462 3 O
optimal	466 7 O
treatment	474 9 O
of	484 2 O
D	487 1 B-Chemical
-	488 1 I-Chemical
penicillamine	489 13 I-Chemical
-	502 1 O
induced	503 7 O
aplastic	511 8 B-Disease
anemia	520 6 I-Disease
.	526 1 O

The	0 3 O
relationship	4 12 O
between	17 7 O
hippocampal	25 11 O
acetylcholine	37 13 B-Chemical
release	51 7 O
and	59 3 O
cholinergic	63 11 O
convulsant	75 10 O
sensitivity	86 11 O
in	98 2 O
withdrawal	101 10 O
seizure	112 7 B-Disease
-	119 1 O
prone	120 5 O
and	126 3 O
withdrawal	130 10 O
seizure	141 7 B-Disease
-	148 1 O
resistant	149 9 O
selected	159 8 O
mouse	168 5 O
lines	174 5 O
.	179 1 O

BACKGROUND	181 10 O
:	191 1 O
The	193 3 O
septo	197 5 O
-	202 1 O
hippocampal	203 11 O
cholinergic	215 11 O
pathway	227 7 O
has	235 3 O
been	239 4 O
implicated	244 10 O
in	255 2 O
epileptogenesis	258 15 O
,	273 1 O
and	275 3 O
genetic	279 7 O
factors	287 7 O
influence	295 9 O
the	305 3 O
response	309 8 O
to	318 2 O
cholinergic	321 11 O
agents	333 6 O
,	339 1 O
but	341 3 O
limited	345 7 O
data	353 4 O
are	358 3 O
available	362 9 O
on	372 2 O
cholinergic	375 11 O
involvement	387 11 O
in	399 2 O
alcohol	402 7 B-Chemical
withdrawal	410 10 O
severity	421 8 O
.	429 1 O

Thus	431 4 O
,	435 1 O
the	437 3 O
relationship	441 12 O
between	454 7 O
cholinergic	462 11 O
activity	474 8 O
and	483 3 O
responsiveness	487 14 O
and	502 3 O
alcohol	506 7 B-Chemical
withdrawal	514 10 O
was	525 3 O
investigated	529 12 O
in	542 2 O
a	545 1 O
genetic	547 7 O
animal	555 6 O
model	562 5 O
of	568 2 O
ethanol	571 7 B-Chemical
withdrawal	579 10 O
severity	590 8 O
.	598 1 O

METHODS	600 7 O
:	607 1 O
Cholinergic	609 11 O
convulsant	621 10 O
sensitivity	632 11 O
was	644 3 O
examined	648 8 O
in	657 2 O
alcohol	660 7 B-Chemical
-	667 1 O
na	668 2 O
ve	672 2 O
Withdrawal	675 10 O
Seizure	686 7 B-Disease
-	693 1 O
Prone	694 5 O
(	700 1 O
WSP	701 3 O
)	704 1 O
and	706 3 O
-	709 1 O
Resistant	710 9 O
(	720 1 O
WSR	721 3 O
)	724 1 O
mice	726 4 O
.	730 1 O

Animals	732 7 O
were	740 4 O
administered	745 12 O
nicotine	758 8 B-Chemical
,	766 1 O
carbachol	768 9 B-Chemical
,	777 1 O
or	779 2 O
neostigmine	782 11 B-Chemical
via	794 3 O
timed	798 5 O
tail	804 4 O
vein	809 4 O
infusion	814 8 O
,	822 1 O
and	824 3 O
the	828 3 O
latencies	832 9 O
to	842 2 O
onset	845 5 O
of	851 2 O
tremor	854 6 B-Disease
and	861 3 O
clonus	865 6 O
were	872 4 O
recorded	877 8 O
and	886 3 O
converted	890 9 O
to	900 2 O
threshold	903 9 O
dose	913 4 O
.	917 1 O

We	919 2 O
also	922 4 O
used	927 4 O
microdialysis	932 13 O
to	946 2 O
measure	949 7 O
basal	957 5 O
and	963 3 O
potassium	967 9 B-Chemical
-	976 1 O
stimulated	977 10 O
acetylcholine	988 13 B-Chemical
(	1002 1 O
ACh	1003 3 B-Chemical
)	1006 1 O
release	1008 7 O
in	1016 2 O
the	1019 3 O
CA1	1023 3 O
region	1027 6 O
of	1034 2 O
the	1037 3 O
hippocampus	1041 11 O
.	1052 1 O

Potassium	1054 9 B-Chemical
was	1064 3 O
applied	1068 7 O
by	1076 2 O
reverse	1079 7 O
dialysis	1087 8 O
twice	1096 5 O
,	1101 1 O
separated	1103 9 O
by	1113 2 O
75	1116 2 O
min	1119 3 O
.	1122 1 O

Hippocampal	1124 11 O
ACh	1136 3 B-Chemical
also	1140 4 O
was	1145 3 O
measured	1149 8 O
during	1158 6 O
testing	1165 7 O
for	1173 3 O
handling	1177 8 O
-	1185 1 O
induced	1186 7 O
convulsions	1194 11 B-Disease
.	1205 1 O

RESULTS	1207 7 O
:	1214 1 O
Sensitivity	1216 11 O
to	1228 2 O
several	1231 7 O
convulsion	1239 10 B-Disease
endpoints	1250 9 O
induced	1260 7 O
by	1268 2 O
nicotine	1271 8 B-Chemical
,	1279 1 O
carbachol	1281 9 B-Chemical
,	1290 1 O
and	1292 3 O
neostigmine	1296 11 B-Chemical
were	1308 4 O
significantly	1313 13 O
greater	1327 7 O
in	1335 2 O
WSR	1338 3 O
versus	1342 6 O
WSP	1349 3 O
mice	1353 4 O
.	1357 1 O

In	1359 2 O
microdialysis	1362 13 O
experiments	1376 11 O
,	1387 1 O
the	1389 3 O
lines	1393 5 O
did	1399 3 O
not	1403 3 O
differ	1407 6 O
in	1414 2 O
basal	1417 5 O
release	1423 7 O
of	1431 2 O
ACh	1434 3 B-Chemical
,	1437 1 O
and	1439 3 O
50	1443 2 O
mM	1446 2 O
KCl	1449 3 B-Chemical
increased	1453 9 O
ACh	1463 3 B-Chemical
output	1467 6 O
in	1474 2 O
both	1477 4 O
lines	1482 5 O
of	1488 2 O
mice	1491 4 O
.	1495 1 O

However	1497 7 O
,	1504 1 O
the	1506 3 O
increase	1510 8 O
in	1519 2 O
release	1522 7 O
of	1530 2 O
ACh	1533 3 B-Chemical
produced	1537 8 O
by	1546 2 O
the	1549 3 O
first	1553 5 O
application	1559 11 O
of	1571 2 O
KCl	1574 3 B-Chemical
was	1578 3 O
2	1582 1 O
-	1583 1 O
fold	1584 4 O
higher	1589 6 O
in	1596 2 O
WSP	1599 3 O
versus	1603 6 O
WSR	1610 3 O
mice	1614 4 O
.	1618 1 O

When	1620 4 O
hippocampal	1625 11 O
ACh	1637 3 B-Chemical
was	1641 3 O
measured	1645 8 O
during	1654 6 O
testing	1661 7 O
for	1669 3 O
handling	1673 8 O
-	1681 1 O
induced	1682 7 O
convulsions	1690 11 B-Disease
,	1701 1 O
extracellular	1703 13 O
ACh	1717 3 B-Chemical
was	1721 3 O
significantly	1725 13 O
elevated	1739 8 O
(	1748 1 O
192	1749 3 O
%	1752 1 O
)	1753 1 O
in	1755 2 O
WSP	1758 3 O
mice	1762 4 O
,	1766 1 O
but	1768 3 O
was	1772 3 O
nonsignificantly	1776 16 O
elevated	1793 8 O
(	1802 1 O
59	1803 2 O
%	1805 1 O
)	1806 1 O
in	1808 2 O
WSR	1811 3 O
mice	1815 4 O
.	1819 1 O

CONCLUSIONS	1821 11 O
:	1832 1 O
These	1834 5 O
results	1840 7 O
suggest	1848 7 O
that	1856 4 O
differences	1861 11 O
in	1873 2 O
cholinergic	1876 11 O
activity	1888 8 O
and	1897 3 O
postsynaptic	1901 12 O
sensitivity	1914 11 O
to	1926 2 O
cholinergic	1929 11 O
convulsants	1941 11 B-Disease
may	1953 3 O
be	1957 2 O
associated	1960 10 O
with	1971 4 O
ethanol	1976 7 B-Chemical
withdrawal	1984 10 O
severity	1995 8 O
and	2004 3 O
implicate	2008 9 O
cholinergic	2018 11 O
mechanisms	2030 10 O
in	2041 2 O
alcohol	2044 7 B-Chemical
withdrawal	2052 10 O
.	2062 1 O

Specifically	2064 12 O
,	2076 1 O
WSP	2078 3 O
mice	2082 4 O
may	2087 3 O
have	2091 4 O
lower	2096 5 O
sensitivity	2102 11 O
to	2114 2 O
cholinergic	2117 11 O
convulsants	2129 11 B-Disease
compared	2141 8 O
with	2150 4 O
WSR	2155 3 O
because	2159 7 O
of	2167 2 O
postsynaptic	2170 12 O
receptor	2183 8 O
desensitization	2192 15 O
brought	2208 7 O
on	2216 2 O
by	2219 2 O
higher	2222 6 O
activity	2229 8 O
of	2238 2 O
cholinergic	2241 11 O
neurons	2253 7 O
.	2260 1 O

Prenatal	0 8 O
dexamethasone	9 13 B-Chemical
programs	23 8 O
hypertension	32 12 B-Disease
and	45 3 O
renal	49 5 B-Disease
injury	55 6 I-Disease
in	62 2 O
the	65 3 O
rat	69 3 O
.	72 1 O

Dexamethasone	74 13 O
is	88 2 O
frequently	91 10 O
administered	102 12 O
to	115 2 O
the	118 3 O
developing	122 10 O
fetus	133 5 O
to	139 2 O
accelerate	142 10 O
pulmonary	153 9 O
development	163 11 O
.	174 1 O

The	176 3 O
purpose	180 7 O
of	188 2 O
the	191 3 O
present	195 7 O
study	203 5 O
was	209 3 O
to	213 2 O
determine	216 9 O
if	226 2 O
prenatal	229 8 O
dexamethasone	238 13 B-Chemical
programmed	252 10 O
a	263 1 O
progressive	265 11 O
increase	277 8 B-Disease
in	286 2 I-Disease
blood	289 5 I-Disease
pressure	295 8 I-Disease
and	304 3 O
renal	308 5 B-Disease
injury	314 6 I-Disease
in	321 2 O
rats	324 4 O
.	328 1 O

Pregnant	330 8 O
rats	339 4 O
were	344 4 O
given	349 5 O
either	355 6 O
vehicle	362 7 O
or	370 2 O
2	373 1 O
daily	375 5 O
intraperitoneal	381 15 O
injections	397 10 O
of	408 2 O
dexamethasone	411 13 B-Chemical
(	425 1 O
0	426 1 O
.	427 1 O
2	428 1 O
mg	430 2 O
/	432 1 O
kg	433 2 O
body	436 4 O
weight	441 6 O
)	447 1 O
on	449 2 O
gestational	452 11 O
days	464 4 O
11	469 2 O
and	472 3 O
12	476 2 O
,	478 1 O
13	480 2 O
and	483 3 O
14	487 2 O
,	489 1 O
15	491 2 O
and	494 3 O
16	498 2 O
,	500 1 O
17	502 2 O
and	505 3 O
18	509 2 O
,	511 1 O
or	513 2 O
19	516 2 O
and	519 3 O
20	523 2 O
.	525 1 O

Offspring	527 9 O
of	537 2 O
rats	540 4 O
administered	545 12 O
dexamethasone	558 13 B-Chemical
on	572 2 O
days	575 4 O
15	580 2 O
and	583 3 O
16	587 2 O
gestation	590 9 O
had	600 3 O
a	604 1 O
20	606 2 O
%	608 1 O
reduction	610 9 B-Disease
in	620 2 I-Disease
glomerular	623 10 I-Disease
number	634 6 I-Disease
compared	641 8 O
with	650 4 O
control	655 7 O
at	663 2 O
6	666 1 O
to	668 2 O
9	671 1 O
months	673 6 O
of	680 2 O
age	683 3 O
(	687 1 O
22	688 2 O
527	691 3 O
+	694 1 O
/	695 1 O
-	696 1 O
509	697 3 O
versus	701 6 O
28	708 2 O
050	711 3 O
+	714 1 O
/	715 1 O
-	716 1 O
561	717 3 O
,	720 1 O
P	722 1 O
<	723 1 O
0	724 1 O
.	725 1 O
05	726 2 O
)	728 1 O
,	729 1 O
which	731 5 O
was	737 3 O
comparable	741 10 O
to	752 2 O
the	755 3 O
percent	759 7 O
reduction	767 9 O
in	777 2 O
glomeruli	780 9 O
measured	790 8 O
at	799 2 O
3	802 1 O
weeks	804 5 O
of	810 2 O
age	813 3 O
.	816 1 O

Six	818 3 O
-	821 1 O
to	823 2 O
9	826 1 O
-	827 1 O
month	828 5 O
old	834 3 O
rats	838 4 O
receiving	843 9 O
prenatal	853 8 O
dexamethasone	862 13 B-Chemical
on	876 2 O
days	879 4 O
17	884 2 O
and	887 3 O
18	891 2 O
of	894 2 O
gestation	897 9 O
had	907 3 O
a	911 1 O
17	913 2 O
%	915 1 O
reduction	917 9 O
in	927 2 O
glomeruli	930 9 O
(	940 1 O
23	941 2 O
380	944 3 O
+	947 1 O
/	948 1 O
-	949 1 O
587	950 3 O
)	953 1 O
compared	955 8 O
with	964 4 O
control	969 7 O
rats	977 4 O
(	982 1 O
P	983 1 O
<	984 1 O
0	985 1 O
.	986 1 O
05	987 2 O
)	989 1 O
.	990 1 O

Male	992 4 O
rats	997 4 O
that	1002 4 O
received	1007 8 O
prenatal	1016 8 O
dexamethasone	1025 13 B-Chemical
on	1039 2 O
days	1042 4 O
15	1047 2 O
and	1050 3 O
16	1054 2 O
,	1056 1 O
17	1058 2 O
and	1061 3 O
18	1065 2 O
,	1067 1 O
and	1069 3 O
13	1073 2 O
and	1076 3 O
14	1080 2 O
of	1083 2 O
gestation	1086 9 O
had	1096 3 O
elevated	1100 8 B-Disease
blood	1109 5 I-Disease
pressures	1115 9 I-Disease
at	1125 2 O
6	1128 1 O
months	1130 6 O
of	1137 2 O
age	1140 3 O
;	1143 1 O
the	1145 3 O
latter	1149 6 O
group	1156 5 O
did	1162 3 O
not	1166 3 O
have	1170 4 O
a	1175 1 O
reduction	1177 9 B-Disease
in	1187 2 I-Disease
glomerular	1190 10 I-Disease
number	1201 6 I-Disease
.	1207 1 O

Adult	1209 5 O
rats	1215 4 O
given	1220 5 O
dexamethasone	1226 13 B-Chemical
on	1240 2 O
days	1243 4 O
15	1248 2 O
and	1251 3 O
16	1255 2 O
of	1258 2 O
gestation	1261 9 O
had	1271 3 O
more	1275 4 O
glomeruli	1280 9 O
with	1290 4 O
glomerulosclerosis	1295 18 B-Disease
than	1314 4 O
control	1319 7 O
rats	1327 4 O
.	1331 1 O

This	1333 4 O
study	1338 5 O
shows	1344 5 O
that	1350 4 O
prenatal	1355 8 O
dexamethasone	1364 13 B-Chemical
in	1378 2 O
rats	1381 4 O
results	1386 7 O
in	1394 2 O
a	1397 1 O
reduction	1399 9 B-Disease
in	1409 2 I-Disease
glomerular	1412 10 I-Disease
number	1423 6 I-Disease
,	1429 1 O
glomerulosclerosis	1431 18 B-Disease
,	1449 1 O
and	1451 3 O
hypertension	1455 12 B-Disease
when	1468 4 O
administered	1473 12 O
at	1486 2 O
specific	1489 8 O
points	1498 6 O
during	1505 6 O
gestation	1512 9 O
.	1521 1 O

Hypertension	1523 12 B-Disease
was	1536 3 O
observed	1540 8 O
in	1549 2 O
animals	1552 7 O
that	1560 4 O
had	1565 3 O
a	1569 1 O
reduction	1571 9 O
in	1581 2 O
glomeruli	1584 9 O
as	1594 2 O
well	1597 4 O
as	1602 2 O
in	1605 2 O
a	1608 1 O
group	1610 5 O
that	1616 4 O
did	1621 3 O
not	1625 3 O
have	1629 4 O
a	1634 1 O
reduction	1636 9 B-Disease
in	1646 2 I-Disease
glomerular	1649 10 I-Disease
number	1660 6 I-Disease
,	1666 1 O
suggesting	1668 10 O
that	1679 4 O
a	1684 1 O
reduction	1686 9 B-Disease
in	1696 2 I-Disease
glomerular	1699 10 I-Disease
number	1710 6 I-Disease
is	1717 2 O
not	1720 3 O
the	1724 3 O
sole	1728 4 O
cause	1733 5 O
for	1739 3 O
the	1743 3 O
development	1747 11 O
of	1759 2 O
hypertension	1762 12 B-Disease
.	1774 1 O

The	0 3 O
risk	4 4 O
of	9 2 O
venous	12 6 B-Disease
thromboembolism	19 15 I-Disease
in	35 2 O
women	38 5 O
prescribed	44 10 O
cyproterone	55 11 B-Chemical
acetate	67 7 I-Chemical
in	75 2 O
combination	78 11 O
with	90 4 O
ethinyl	95 7 B-Chemical
estradiol	103 9 I-Chemical
:	112 1 O
a	114 1 O
nested	116 6 O
cohort	123 6 O
analysis	130 8 O
and	139 3 O
case	143 4 O
-	147 1 O
control	148 7 O
study	156 5 O
.	161 1 O

BACKGROUND	163 10 O
:	173 1 O
Cyproterone	175 11 B-Chemical
acetate	187 7 I-Chemical
combined	195 8 O
with	204 4 O
ethinyl	209 7 B-Chemical
estradiol	217 9 I-Chemical
(	227 1 O
CPA	228 3 B-Chemical
/	231 1 O
EE	232 2 B-Chemical
)	234 1 O
is	236 2 O
licensed	239 8 O
in	248 2 O
the	251 3 O
UK	255 2 O
for	258 3 O
the	262 3 O
treatment	266 9 O
of	276 2 O
women	279 5 O
with	285 4 O
acne	290 4 B-Disease
and	295 3 O
hirsutism	299 9 B-Disease
and	309 3 O
is	313 2 O
also	316 4 O
a	321 1 O
treatment	323 9 O
option	333 6 O
for	340 3 O
polycystic	344 10 B-Disease
ovary	355 5 I-Disease
syndrome	361 8 I-Disease
(	370 1 O
PCOS	371 4 B-Disease
)	375 1 O
.	376 1 O

Previous	378 8 O
studies	387 7 O
have	395 4 O
demonstrated	400 12 O
an	413 2 O
increased	416 9 O
risk	426 4 O
of	431 2 O
venous	434 6 B-Disease
thromboembolism	441 15 I-Disease
(	457 1 O
VTE	458 3 B-Disease
)	461 1 O
associated	463 10 O
with	474 4 O
CPA	479 3 B-Chemical
/	482 1 O
EE	483 2 B-Chemical
compared	486 8 O
with	495 4 O
conventional	500 12 O
combined	513 8 O
oral	522 4 B-Chemical
contraceptives	527 14 I-Chemical
(	542 1 O
COCs	543 4 O
)	547 1 O
.	548 1 O

We	550 2 O
believe	553 7 O
the	561 3 O
results	565 7 O
of	573 2 O
those	576 5 O
studies	582 7 O
may	590 3 O
have	594 4 O
been	599 4 O
affected	604 8 O
by	613 2 O
residual	616 8 O
confounding	625 11 O
.	636 1 O

METHODS	638 7 O
:	645 1 O
Using	647 5 O
the	653 3 O
General	657 7 O
Practice	665 8 O
Research	674 8 O
Database	683 8 O
we	692 2 O
conducted	695 9 O
a	705 1 O
cohort	707 6 O
analysis	714 8 O
and	723 3 O
case	727 4 O
-	731 1 O
control	732 7 O
study	740 5 O
nested	746 6 O
within	753 6 O
a	760 1 O
population	762 10 O
of	773 2 O
women	776 5 O
aged	782 4 O
between	787 7 O
15	795 2 O
and	798 3 O
39	802 2 O
years	805 5 O
with	811 4 O
acne	816 4 B-Disease
,	820 1 O
hirsutism	822 9 B-Disease
or	832 2 O
PCOS	835 4 B-Disease
to	840 2 O
estimate	843 8 O
the	852 3 O
risk	856 4 O
of	861 2 O
VTE	864 3 B-Disease
associated	868 10 O
with	879 4 O
CPA	884 3 B-Chemical
/	887 1 O
EE	888 2 B-Chemical
.	890 1 O

RESULTS	892 7 O
:	899 1 O
The	901 3 O
age	905 3 O
-	908 1 O
adjusted	909 8 O
incidence	918 9 O
rate	928 4 O
ratio	933 5 O
for	939 3 O
CPA	943 3 B-Chemical
/	946 1 O
EE	947 2 B-Chemical
versus	950 6 O
conventional	957 12 O
COCs	970 4 O
was	975 3 O
2	979 1 O
.	980 1 O
20	981 2 O
[	984 1 O
95	985 2 O
%	987 1 O
confidence	989 10 O
interval	1000 8 O
(	1009 1 O
CI	1010 2 O
)	1012 1 O
1	1014 1 O
.	1015 1 O
35	1016 2 O
-	1018 1 O
3	1019 1 O
.	1020 1 O
58	1021 2 O
]	1023 1 O
.	1024 1 O

Using	1026 5 O
as	1032 2 O
the	1035 3 O
reference	1039 9 O
group	1049 5 O
women	1055 5 O
who	1061 3 O
were	1065 4 O
not	1070 3 O
using	1074 5 O
oral	1080 4 O
contraception	1085 13 O
,	1098 1 O
had	1100 3 O
no	1104 2 O
recent	1107 6 O
pregnancy	1114 9 O
or	1124 2 O
menopausal	1127 10 O
symptoms	1138 8 O
,	1146 1 O
the	1148 3 O
case	1152 4 O
-	1156 1 O
control	1157 7 O
analysis	1165 8 O
gave	1174 4 O
an	1179 2 O
adjusted	1182 8 O
odds	1191 4 O
ratio	1196 5 O
(	1202 1 O
OR	1203 2 O
(	1205 1 O
adj	1206 3 O
)	1209 1 O
)	1210 1 O
of	1212 2 O
7	1215 1 O
.	1216 1 O
44	1217 2 O
(	1220 1 O
95	1221 2 O
%	1223 1 O
CI	1225 2 O
3	1228 1 O
.	1229 1 O
67	1230 2 O
-	1232 1 O
15	1233 2 O
.	1235 1 O
08	1236 2 O
)	1238 1 O
for	1240 3 O
CPA	1244 3 B-Chemical
/	1247 1 O
EE	1248 2 B-Chemical
use	1251 3 O
compared	1255 8 O
with	1264 4 O
an	1269 2 O
OR	1272 2 O
(	1274 1 O
adj	1275 3 O
)	1278 1 O
of	1280 2 O
2	1283 1 O
.	1284 1 O
58	1285 2 O
(	1288 1 O
95	1289 2 O
%	1291 1 O
CI	1293 2 O
1	1296 1 O
.	1297 1 O
60	1298 2 O
-	1300 1 O
4	1301 1 O
.	1302 1 O
18	1303 2 O
)	1305 1 O
for	1307 3 O
use	1311 3 O
of	1315 2 O
conventional	1318 12 O
COCs	1331 4 O
.	1335 1 O

CONCLUSIONS	1337 11 O
:	1348 1 O
We	1350 2 O
have	1353 4 O
demonstrated	1358 12 O
an	1371 2 O
increased	1374 9 O
risk	1384 4 O
of	1389 2 O
VTE	1392 3 B-Disease
associated	1396 10 O
with	1407 4 O
the	1412 3 O
use	1416 3 O
of	1420 2 O
CPA	1423 3 B-Chemical
/	1426 1 O
EE	1427 2 B-Chemical
in	1430 2 O
women	1433 5 O
with	1439 4 O
acne	1444 4 B-Disease
,	1448 1 O
hirsutism	1450 9 B-Disease
or	1460 2 O
PCOS	1463 4 B-Disease
although	1468 8 O
residual	1477 8 O
confounding	1486 11 O
by	1498 2 O
indication	1501 10 O
cannot	1512 6 O
be	1519 2 O
excluded	1522 8 O
.	1530 1 O

Pseudoacromegaly	0 16 B-Disease
induced	17 7 O
by	25 2 O
the	28 3 O
long	32 4 O
-	36 1 O
term	37 4 O
use	42 3 O
of	46 2 O
minoxidil	49 9 B-Chemical
.	58 1 O

Acromegaly	60 10 B-Disease
is	71 2 O
an	74 2 O
endocrine	77 9 B-Disease
disorder	87 8 I-Disease
caused	96 6 O
by	103 2 O
chronic	106 7 O
excessive	114 9 O
growth	124 6 O
hormone	131 7 O
secretion	139 9 O
from	149 4 O
the	154 3 O
anterior	158 8 O
pituitary	167 9 O
gland	177 5 O
.	182 1 O

Significant	184 11 O
disfiguring	196 11 O
changes	208 7 O
occur	216 5 O
as	222 2 O
a	225 1 O
result	227 6 O
of	234 2 O
bone	237 4 O
,	241 1 O
cartilage	243 9 O
,	252 1 O
and	254 3 O
soft	258 4 O
tissue	263 6 O
hypertrophy	270 11 B-Disease
,	281 1 O
including	283 9 O
the	293 3 O
thickening	297 10 O
of	308 2 O
the	311 3 O
skin	315 4 O
,	319 1 O
coarsening	321 10 O
of	332 2 O
facial	335 6 O
features	342 8 O
,	350 1 O
and	352 3 O
cutis	356 5 B-Disease
verticis	362 8 I-Disease
gyrata	371 6 I-Disease
.	377 1 O

Pseudoacromegaly	379 16 B-Disease
,	395 1 O
on	397 2 O
the	400 3 O
other	404 5 O
hand	410 4 O
,	414 1 O
is	416 2 O
the	419 3 O
presence	423 8 O
of	432 2 O
similar	435 7 O
acromegaloid	443 12 O
features	456 8 O
in	465 2 O
the	468 3 O
absence	472 7 O
of	480 2 O
elevated	483 8 O
growth	492 6 O
hormone	499 7 O
or	507 2 O
insulin	510 7 O
-	517 1 O
like	518 4 O
growth	523 6 O
factor	530 6 O
levels	537 6 O
.	543 1 O

We	545 2 O
present	548 7 O
a	556 1 O
patient	558 7 O
with	566 4 O
pseudoacromegaly	571 16 B-Disease
that	588 4 O
resulted	593 8 O
from	602 4 O
the	607 3 O
long	611 4 O
-	615 1 O
term	616 4 O
use	621 3 O
of	625 2 O
minoxidil	628 9 B-Chemical
at	638 2 O
an	641 2 O
unusually	644 9 O
high	654 4 O
dose	659 4 O
.	663 1 O

This	665 4 O
is	670 2 O
the	673 3 O
first	677 5 O
case	683 4 O
report	688 6 O
of	695 2 O
pseudoacromegaly	698 16 B-Disease
as	715 2 O
a	718 1 O
side	720 4 O
effect	725 6 O
of	732 2 O
minoxidil	735 9 B-Chemical
use	745 3 O
.	748 1 O

Combined	0 8 O
androgen	9 8 O
blockade	18 8 O
-	26 1 O
induced	27 7 O
anemia	35 6 B-Disease
in	42 2 O
prostate	45 8 B-Disease
cancer	54 6 I-Disease
patients	61 8 O
without	70 7 O
bone	78 4 O
involvement	83 11 O
.	94 1 O

BACKGROUND	96 10 O
:	106 1 O
To	108 2 O
determine	111 9 O
the	121 3 O
onset	125 5 O
and	131 3 O
extent	135 6 O
of	142 2 O
combined	145 8 O
androgen	154 8 O
blockade	163 8 O
(	172 1 O
CAB	173 3 O
)	176 1 O
-	177 1 O
induced	178 7 O
anemia	186 6 B-Disease
in	193 2 O
prostate	196 8 B-Disease
cancer	205 6 I-Disease
patients	212 8 O
without	221 7 O
bone	229 4 O
involvement	234 11 O
.	245 1 O

PATIENTS	247 8 O
AND	256 3 O
METHODS	260 7 O
:	267 1 O
Forty	269 5 O
-	274 1 O
two	275 3 O
patients	279 8 O
with	288 4 O
biopsy	293 6 O
-	299 1 O
proven	300 6 O
prostatic	307 9 B-Disease
adenocarcinoma	317 14 I-Disease
[	332 1 O
26	333 2 O
with	336 4 O
stage	341 5 O
C	347 1 O
(	349 1 O
T3N0M0	350 6 O
)	356 1 O
and	358 3 O
16	362 2 O
with	365 4 O
stage	370 5 O
D1	376 2 O
(	379 1 O
T3N1M0	380 6 O
)	386 1 O
]	387 1 O
were	389 4 O
included	394 8 O
in	403 2 O
this	406 4 O
study	411 5 O
.	416 1 O

All	418 3 O
patients	422 8 O
received	431 8 O
CAB	440 3 O
[	444 1 O
leuprolide	445 10 B-Chemical
acetate	456 7 I-Chemical
(	464 1 O
LHRH	465 4 B-Chemical
-	469 1 I-Chemical
A	470 1 I-Chemical
)	471 1 O
3	473 1 O
.	474 1 O
75	475 2 O
mg	478 2 O
,	480 1 O
intramuscularly	482 15 O
,	497 1 O
every	499 5 O
28	505 2 O
days	508 4 O
plus	513 4 O
250	518 3 O
mg	522 2 O
flutamide	525 9 B-Chemical
,	534 1 O
tid	536 3 O
,	539 1 O
per	541 3 O
Os	545 2 O
]	547 1 O
and	549 3 O
were	553 4 O
evaluated	558 9 O
for	568 3 O
anemia	572 6 B-Disease
by	579 2 O
physical	582 8 O
examination	591 11 O
and	603 3 O
laboratory	607 10 O
tests	618 5 O
at	624 2 O
baseline	627 8 O
and	636 3 O
4	640 1 O
subsequent	642 10 O
intervals	653 9 O
(	663 1 O
1	664 1 O
,	665 1 O
2	667 1 O
,	668 1 O
3	670 1 O
and	672 3 O
6	676 1 O
months	678 6 O
post	685 4 O
-	689 1 O
CAB	690 3 O
)	693 1 O
.	694 1 O

Hb	696 2 O
,	698 1 O
PSA	700 3 O
and	704 3 O
Testosterone	708 12 B-Chemical
measurements	721 12 O
were	734 4 O
recorded	739 8 O
.	747 1 O

Patients	749 8 O
with	758 4 O
stage	763 5 O
D2	769 2 O
-	771 1 O
3	772 1 O
disease	774 7 O
,	781 1 O
abnormal	783 8 O
hemoglobin	792 10 O
level	803 5 O
or	809 2 O
renal	812 5 O
and	818 3 O
liver	822 5 O
function	828 8 O
tests	837 5 O
that	843 4 O
were	848 4 O
higher	853 6 O
than	860 4 O
the	865 3 O
upper	869 5 O
limits	875 6 O
were	882 4 O
excluded	887 8 O
from	896 4 O
the	901 3 O
study	905 5 O
.	910 1 O

The	912 3 O
duration	916 8 O
of	925 2 O
the	928 3 O
study	932 5 O
was	938 3 O
six	942 3 O
months	946 6 O
.	952 1 O

RESULTS	954 7 O
:	961 1 O
The	963 3 O
mean	967 4 O
hemoglobin	972 10 O
(	983 1 O
Hb	984 2 O
)	986 1 O
levels	988 6 O
were	995 4 O
significantly	1000 13 O
declined	1014 8 O
in	1023 2 O
all	1026 3 O
patients	1030 8 O
from	1039 4 O
baseline	1044 8 O
of	1053 2 O
14	1056 2 O
.	1058 1 O
2	1059 1 O
g	1061 1 O
/	1062 1 O
dl	1063 2 O
to	1066 2 O
14	1069 2 O
.	1071 1 O
0	1072 1 O
g	1074 1 O
/	1075 1 O
dl	1076 2 O
,	1078 1 O
13	1080 2 O
.	1082 1 O
5	1083 1 O
g	1085 1 O
/	1086 1 O
dl	1087 2 O
,	1089 1 O
13	1091 2 O
.	1093 1 O
2	1094 1 O
g	1096 1 O
/	1097 1 O
dl	1098 2 O
and	1101 3 O
12	1105 2 O
.	1107 1 O
7	1108 1 O
g	1110 1 O
/	1111 1 O
dl	1112 2 O
at	1115 2 O
1	1118 1 O
,	1119 1 O
2	1121 1 O
,	1122 1 O
3	1124 1 O
and	1126 3 O
6	1130 1 O
months	1132 6 O
post	1139 4 O
-	1143 1 O
CAB	1144 3 O
,	1147 1 O
respectively	1149 12 O
.	1161 1 O

Severe	1163 6 O
and	1170 3 O
clinically	1174 10 O
evident	1185 7 O
anemia	1193 6 B-Disease
of	1200 2 O
Hb	1203 2 O
<	1206 1 O
11	1208 2 O
g	1211 1 O
/	1212 1 O
dl	1213 2 O
with	1216 4 O
clinical	1221 8 O
symptoms	1230 8 O
was	1239 3 O
detected	1243 8 O
in	1252 2 O
6	1255 1 O
patients	1257 8 O
(	1266 1 O
14	1267 2 O
.	1269 1 O
3	1270 1 O
%	1271 1 O
)	1272 1 O
.	1273 1 O

This	1275 4 O
CAB	1280 3 O
-	1283 1 O
induced	1284 7 O
anemia	1292 6 B-Disease
was	1299 3 O
normochromic	1303 12 O
and	1316 3 O
normocytic	1320 10 O
.	1330 1 O

At	1332 2 O
six	1335 3 O
months	1339 6 O
post	1346 4 O
-	1350 1 O
CAB	1351 3 O
,	1354 1 O
patients	1356 8 O
with	1365 4 O
severe	1370 6 O
anemia	1377 6 B-Disease
had	1384 3 O
a	1388 1 O
Hb	1390 2 O
mean	1393 4 O
value	1398 5 O
of	1404 2 O
10	1407 2 O
.	1409 1 O
2	1410 1 O
+	1412 1 O
/	1413 1 O
-	1414 1 O
0	1416 1 O
.	1417 1 O
1	1418 1 O
g	1420 1 O
/	1421 1 O
dl	1422 2 O
(	1425 1 O
X	1426 1 O
+	1428 1 O
/	1429 1 O
-	1430 1 O
SE	1432 2 O
)	1434 1 O
,	1435 1 O
whereas	1437 7 O
the	1445 3 O
other	1449 5 O
patients	1455 8 O
had	1464 3 O
mild	1468 4 O
anemia	1473 6 B-Disease
with	1480 4 O
Hb	1485 2 O
mean	1488 4 O
value	1493 5 O
of	1499 2 O
13	1502 2 O
.	1504 1 O
2	1505 1 O
+	1507 1 O
/	1508 1 O
-	1509 1 O
0	1511 1 O
.	1512 1 O
17	1513 2 O
(	1516 1 O
X	1517 1 O
+	1519 1 O
/	1520 1 O
-	1521 1 O
SE	1523 2 O
)	1525 1 O
.	1526 1 O

The	1528 3 O
development	1532 11 O
of	1544 2 O
severe	1547 6 O
anemia	1554 6 B-Disease
at	1561 2 O
6	1564 1 O
months	1566 6 O
post	1573 4 O
-	1577 1 O
CAB	1578 3 O
was	1582 3 O
predictable	1586 11 O
by	1598 2 O
the	1601 3 O
reduction	1605 9 O
of	1615 2 O
Hb	1618 2 O
baseline	1621 8 O
value	1630 5 O
of	1636 2 O
more	1639 4 O
than	1644 4 O
2	1649 1 O
.	1650 1 O
5	1651 1 O
g	1653 1 O
/	1654 1 O
dl	1655 2 O
after	1658 5 O
3	1664 1 O
months	1666 6 O
of	1673 2 O
CAB	1676 3 O
(	1680 1 O
p	1681 1 O
=	1683 1 O
0	1685 1 O
.	1686 1 O
01	1687 2 O
)	1689 1 O
.	1690 1 O

The	1692 3 O
development	1696 11 O
of	1708 2 O
severe	1711 6 O
CAB	1718 3 O
-	1721 1 O
induced	1722 7 O
anemia	1730 6 B-Disease
in	1737 2 O
prostate	1740 8 B-Disease
cancer	1749 6 I-Disease
patients	1756 8 O
did	1765 3 O
not	1769 3 O
correlate	1773 9 O
with	1783 4 O
T	1788 1 O
baseline	1790 8 O
values	1799 6 O
(	1806 1 O
T	1807 1 O
<	1809 1 O
3	1811 1 O
ng	1813 2 O
/	1815 1 O
ml	1816 2 O
versus	1819 6 O
T	1826 1 O
>	1828 1 O
or	1830 2 O
=	1833 1 O
3	1835 1 O
ng	1837 2 O
/	1839 1 O
ml	1840 2 O
)	1842 1 O
,	1843 1 O
with	1845 4 O
age	1850 3 O
(	1854 1 O
<	1855 1 O
76	1857 2 O
yrs	1860 3 O
versus	1864 6 O
>	1871 1 O
or	1873 2 O
=	1876 1 O
76	1878 2 O
yrs	1881 3 O
)	1884 1 O
,	1885 1 O
and	1887 3 O
clinical	1891 8 O
stage	1900 5 O
(	1906 1 O
stage	1907 5 O
C	1913 1 O
versus	1915 6 O
stage	1922 5 O
D1	1928 2 O
)	1930 1 O
.	1931 1 O

Severe	1933 6 O
and	1940 3 O
clinically	1944 10 O
evident	1955 7 O
anemia	1963 6 B-Disease
was	1970 3 O
easily	1974 6 O
corrected	1981 9 O
by	1991 2 O
subcutaneous	1994 12 O
injections	2007 10 O
(	2018 1 O
3	2019 1 O
times	2021 5 O
/	2026 1 O
week	2027 4 O
for	2032 3 O
1	2036 1 O
month	2038 5 O
)	2043 1 O
of	2045 2 O
recombinant	2048 11 O
erythropoietin	2060 14 O
(	2075 1 O
rHuEPO	2076 6 O
-	2082 1 O
beta	2083 4 O
)	2087 1 O
.	2088 1 O

CONCLUSION	2090 10 O
:	2100 1 O
Our	2102 3 O
data	2106 4 O
suggest	2111 7 O
that	2119 4 O
rHuEPO	2124 6 O
-	2130 1 O
beta	2131 4 O
correctable	2136 11 O
CAB	2148 3 O
-	2151 1 O
induced	2152 7 O
anemia	2160 6 B-Disease
occurs	2167 6 O
in	2174 2 O
14	2177 2 O
.	2179 1 O
3	2180 1 O
%	2181 1 O
of	2183 2 O
prostate	2186 8 B-Disease
cancer	2195 6 I-Disease
patients	2202 8 O
after	2211 5 O
6	2217 1 O
months	2219 6 O
of	2226 2 O
therapy	2229 7 O
.	2236 1 O

Reversible	0 10 O
dilated	11 7 B-Disease
cardiomyopathy	19 14 I-Disease
related	34 7 O
to	42 2 O
amphotericin	45 12 B-Chemical
B	58 1 I-Chemical
therapy	60 7 O
.	67 1 O

We	69 2 O
describe	72 8 O
a	81 1 O
patient	83 7 O
who	91 3 O
developed	95 9 O
dilated	105 7 B-Disease
cardiomyopathy	113 14 I-Disease
and	128 3 O
clinical	132 8 O
congestive	141 10 O
heart	152 5 B-Disease
failure	158 7 I-Disease
after	166 5 O
2	172 1 O
months	174 6 O
of	181 2 O
therapy	184 7 O
with	192 4 O
amphotericin	197 12 B-Chemical
B	210 1 I-Chemical
(	212 1 O
AmB	213 3 B-Chemical
)	216 1 O
for	218 3 O
disseminated	222 12 O
coccidioidomycosis	235 18 B-Disease
.	253 1 O

His	255 3 O
echocardiographic	259 17 O
abnormalities	277 13 O
and	291 3 O
heart	295 5 B-Disease
failure	301 7 I-Disease
resolved	309 8 O
after	318 5 O
posaconazole	324 12 B-Chemical
was	337 3 O
substituted	341 11 O
for	353 3 O
AmB	357 3 B-Chemical
.	360 1 O

It	362 2 O
is	365 2 O
important	368 9 O
to	378 2 O
recognize	381 9 O
the	391 3 O
rare	395 4 O
and	400 3 O
potentially	404 11 O
reversible	416 10 O
toxicity	427 8 B-Disease
of	436 2 O
AmB	439 3 B-Chemical
.	442 1 O

Risks	0 5 O
of	6 2 O
the	9 3 O
consumption	13 11 O
of	25 2 O
beverages	28 9 O
containing	38 10 O
quinine	49 7 B-Chemical
.	56 1 O

Although	58 8 O
the	67 3 O
United	71 6 O
States	78 6 O
Food	85 4 O
and	90 3 O
Drug	94 4 O
Administration	99 14 O
banned	114 6 O
its	121 3 O
use	125 3 O
for	129 3 O
nocturnal	133 9 B-Disease
leg	143 3 I-Disease
cramps	147 6 I-Disease
due	154 3 O
to	158 2 O
lack	161 4 O
of	166 2 O
safety	169 6 O
and	176 3 O
efficacy	180 8 O
,	188 1 O
quinine	190 7 B-Chemical
is	198 2 O
widely	201 6 O
available	208 9 O
in	218 2 O
beverages	221 9 O
including	231 9 O
tonic	241 5 O
water	247 5 O
and	253 3 O
bitter	257 6 O
lemon	264 5 O
.	269 1 O

Numerous	271 8 O
anecdotal	280 9 O
reports	290 7 O
suggest	298 7 O
that	306 4 O
products	311 8 O
containing	320 10 O
quinine	331 7 B-Chemical
may	339 3 O
produce	343 7 O
neurological	351 12 B-Disease
complications	364 13 I-Disease
,	377 1 O
including	379 9 O
confusion	389 9 B-Disease
,	398 1 O
altered	400 7 O
mental	408 6 O
status	415 6 O
,	421 1 O
seizures	423 8 B-Disease
,	431 1 O
and	433 3 O
coma	437 4 B-Disease
,	441 1 O
particularly	443 12 O
in	456 2 O
older	459 5 O
women	465 5 O
.	470 1 O

Psychologists	472 13 O
need	486 4 O
to	491 2 O
inquire	494 7 O
about	502 5 O
consumption	508 11 O
of	520 2 O
quinine	523 7 B-Chemical
-	530 1 O
containing	531 10 O
beverages	542 9 O
as	552 2 O
part	555 4 O
of	560 2 O
an	563 2 O
evaluation	566 10 O
process	577 7 O
.	584 1 O

Organophosphate	0 15 B-Chemical
-	15 1 O
induced	16 7 O
convulsions	24 11 B-Disease
and	36 3 O
prevention	40 10 O
of	51 2 O
neuropathological	54 17 B-Disease
damages	72 7 I-Disease
.	79 1 O

Such	81 4 O
organophosphorus	86 16 B-Chemical
(	103 1 O
OP	104 2 B-Chemical
)	106 1 O
compounds	108 9 O
as	118 2 O
diisopropylfluorophosphate	121 26 B-Chemical
(	148 1 O
DFP	149 3 B-Chemical
)	152 1 O
,	153 1 O
sarin	155 5 B-Chemical
and	161 3 O
soman	165 5 B-Chemical
are	171 3 O
potent	175 6 O
inhibitors	182 10 O
of	193 2 O
acetylcholinesterases	196 21 O
(	218 1 O
AChEs	219 5 O
)	224 1 O
and	226 3 O
butyrylcholinesterases	230 22 O
(	253 1 O
BChEs	254 5 O
)	259 1 O
.	260 1 O

The	262 3 O
acute	266 5 O
toxicity	272 8 B-Disease
of	281 2 O
OPs	284 3 B-Chemical
is	288 2 O
the	291 3 O
result	295 6 O
of	302 2 O
their	305 5 O
irreversible	311 12 O
binding	324 7 O
with	332 4 O
AChEs	337 5 O
in	343 2 O
the	346 3 O
central	350 7 O
nervous	358 7 O
system	366 6 O
(	373 1 O
CNS	374 3 O
)	377 1 O
,	378 1 O
which	380 5 O
elevates	386 8 O
acetylcholine	395 13 B-Chemical
(	409 1 O
ACh	410 3 B-Chemical
)	413 1 O
levels	415 6 O
.	421 1 O

The	423 3 O
protective	427 10 O
action	438 6 O
of	445 2 O
subcutaneously	448 14 O
(	463 1 O
SC	464 2 O
)	466 1 O
administered	468 12 O
antidotes	481 9 O
or	491 2 O
their	494 5 O
combinations	500 12 O
in	513 2 O
DFP	516 3 B-Chemical
(	520 1 O
2	521 1 O
.	522 1 O
0	523 1 O
mg	525 2 O
/	527 1 O
kg	528 2 O
BW	531 2 O
)	533 1 O
intoxication	535 12 O
was	548 3 O
studied	552 7 O
in	560 2 O
9	563 1 O
-	564 1 O
10	565 2 O
-	567 1 O
weeks	568 5 O
-	573 1 O
old	574 3 O
Han	578 3 O
-	581 1 O
Wistar	582 6 O
male	589 4 O
rats	594 4 O
.	598 1 O

The	600 3 O
rats	604 4 O
received	609 8 O
AChE	618 4 O
reactivator	623 11 O
pralidoxime	635 11 B-Chemical
-	646 1 I-Chemical
2	647 1 I-Chemical
-	648 1 I-Chemical
chloride	649 8 I-Chemical
(	658 1 O
2PAM	659 4 B-Chemical
)	663 1 O
(	665 1 O
30	666 2 O
.	668 1 O
0	669 1 O
mg	671 2 O
/	673 1 O
kg	674 2 O
BW	677 2 O
)	679 1 O
,	680 1 O
anticonvulsant	682 14 O
diazepam	697 8 B-Chemical
(	706 1 O
2	707 1 O
.	708 1 O
0	709 1 O
mg	711 2 O
/	713 1 O
kg	714 2 O
BW	717 2 O
)	719 1 O
,	720 1 O
A	722 1 O
(	723 1 O
1	724 1 O
)	725 1 O
-	726 1 O
adenosine	727 9 B-Chemical
receptor	737 8 O
agonist	746 7 O
N	754 1 B-Chemical
(	755 1 I-Chemical
6	756 1 I-Chemical
)	757 1 I-Chemical
-	758 1 I-Chemical
cyclopentyl	759 11 I-Chemical
adenosine	771 9 I-Chemical
(	781 1 O
CPA	782 3 B-Chemical
)	785 1 O
(	787 1 O
2	788 1 O
.	789 1 O
0	790 1 O
mg	792 2 O
/	794 1 O
kg	795 2 O
BW	798 2 O
)	800 1 O
,	801 1 O
NMDA	803 4 B-Chemical
-	807 1 O
receptor	808 8 O
antagonist	817 10 O
dizocilpine	828 11 B-Chemical
maleate	840 7 I-Chemical
(	848 1 O
+	849 1 O
-	850 1 O
MK801	851 5 O
hydrogen	857 8 O
maleate	866 7 O
)	873 1 O
(	875 1 O
2	876 1 O
.	877 1 O
0	878 1 O
mg	880 2 O
/	882 1 O
kg	883 2 O
BW	886 2 O
)	888 1 O
or	890 2 O
their	893 5 O
combinations	899 12 O
with	912 4 O
cholinolytic	917 12 O
drug	930 4 O
atropine	935 8 B-Chemical
sulfate	944 7 I-Chemical
(	952 1 O
50	953 2 O
.	955 1 O
0	956 1 O
mg	958 2 O
/	960 1 O
kg	961 2 O
BW	964 2 O
)	966 1 O
immediately	968 11 O
or	980 2 O
30	983 2 O
min	986 3 O
after	990 5 O
the	996 3 O
single	1000 6 O
SC	1007 2 O
injection	1010 9 O
of	1020 2 O
DFP	1023 3 B-Chemical
.	1026 1 O

The	1028 3 O
control	1032 7 O
rats	1040 4 O
received	1045 8 O
atropine	1054 8 B-Chemical
sulfate	1063 7 I-Chemical
,	1070 1 O
but	1072 3 O
also	1076 4 O
saline	1081 6 O
and	1088 3 O
olive	1092 5 O
oil	1098 3 O
instead	1102 7 O
of	1110 2 O
other	1113 5 O
antidotes	1119 9 O
and	1129 3 O
DFP	1133 3 B-Chemical
,	1136 1 O
respectively	1138 12 O
.	1150 1 O

All	1152 3 O
rats	1156 4 O
were	1161 4 O
terminated	1166 10 O
either	1177 6 O
24	1184 2 O
h	1187 1 O
or	1189 2 O
3	1192 1 O
weeks	1194 5 O
after	1200 5 O
the	1206 3 O
DFP	1210 3 B-Chemical
injection	1214 9 O
.	1223 1 O

The	1225 3 O
rats	1229 4 O
treated	1234 7 O
with	1242 4 O
DFP	1247 3 B-Chemical
-	1250 1 O
atropine	1251 8 B-Chemical
showed	1260 6 O
severe	1267 6 O
typical	1274 7 O
OP	1282 2 B-Chemical
-	1284 1 O
induced	1285 7 O
toxicity	1293 8 B-Disease
signs	1302 5 O
.	1307 1 O

When	1309 4 O
CPA	1314 3 B-Chemical
,	1317 1 O
diazepam	1319 8 B-Chemical
or	1328 2 O
2PAM	1331 4 B-Chemical
was	1336 3 O
given	1340 5 O
immediately	1346 11 O
after	1358 5 O
DFP	1364 3 B-Chemical
-	1367 1 O
atropine	1368 8 B-Chemical
,	1376 1 O
these	1378 5 O
treatments	1384 10 O
prevented	1395 9 O
,	1404 1 O
delayed	1406 7 O
or	1414 2 O
shortened	1417 9 O
the	1427 3 O
occurrence	1431 10 O
of	1442 2 O
serious	1445 7 O
signs	1453 5 O
of	1459 2 O
poisoning	1462 9 B-Disease
.	1471 1 O

Atropine	1473 8 B-Chemical
-	1481 1 O
MK801	1482 5 B-Chemical
did	1488 3 O
not	1492 3 O
offer	1496 5 O
any	1502 3 O
additional	1506 10 O
protection	1517 10 O
against	1528 7 O
DFP	1536 3 B-Chemical
toxicity	1540 8 B-Disease
.	1548 1 O

In	1550 2 O
conclusion	1553 10 O
,	1563 1 O
CPA	1565 3 B-Chemical
,	1568 1 O
diazepam	1570 8 B-Chemical
and	1579 3 O
2PAM	1583 4 B-Chemical
in	1588 2 O
combination	1591 11 O
with	1603 4 O
atropine	1608 8 B-Chemical
prevented	1617 9 O
the	1627 3 O
occurrence	1631 10 O
of	1642 2 O
serious	1645 7 O
signs	1653 5 O
of	1659 2 O
poisoning	1662 9 B-Disease
and	1672 3 O
thus	1676 4 O
reduced	1681 7 O
the	1689 3 O
toxicity	1693 8 B-Disease
of	1702 2 O
DFP	1705 3 B-Chemical
in	1709 2 O
rat	1712 3 O
.	1715 1 O

Differential	0 12 O
modulation	13 10 O
by	24 2 O
estrogen	27 8 B-Chemical
of	36 2 O
alpha2	39 6 O
-	45 1 O
adrenergic	46 10 O
and	57 3 O
I1	61 2 O
-	63 1 O
imidazoline	64 11 B-Chemical
receptor	76 8 O
-	84 1 O
mediated	85 8 O
hypotension	94 11 B-Disease
in	106 2 O
female	109 6 O
rats	116 4 O
.	120 1 O

We	122 2 O
have	125 4 O
recently	130 8 O
shown	139 5 O
that	145 4 O
estrogen	150 8 B-Chemical
negatively	159 10 O
modulates	170 9 O
the	180 3 O
hypotensive	184 11 B-Disease
effect	196 6 O
of	203 2 O
clonidine	206 9 B-Chemical
(	216 1 O
mixed	217 5 O
alpha2	223 6 O
-	229 1 O
/	230 1 O
I1	231 2 O
-	233 1 O
receptor	234 8 O
agonist	243 7 O
)	250 1 O
in	252 2 O
female	255 6 O
rats	262 4 O
and	267 3 O
implicates	271 10 O
the	282 3 O
cardiovascular	286 14 O
autonomic	301 9 O
control	311 7 O
in	319 2 O
this	322 4 O
interaction	327 11 O
.	338 1 O

The	340 3 O
present	344 7 O
study	352 5 O
investigated	358 12 O
whether	371 7 O
this	379 4 O
effect	384 6 O
of	391 2 O
estrogen	394 8 B-Chemical
involves	403 8 O
interaction	412 11 O
with	424 4 O
alpha2	429 6 O
-	435 1 O
and	437 3 O
/	440 1 O
or	441 2 O
I1	444 2 O
-	446 1 O
receptors	447 9 O
.	456 1 O

Changes	458 7 O
evoked	466 6 O
by	473 2 O
a	476 1 O
single	478 6 O
intraperitoneal	485 15 O
injection	501 9 O
of	511 2 O
rilmenidine	514 11 B-Chemical
(	526 1 O
600	527 3 O
microg	531 6 O
/	537 1 O
kg	538 2 O
)	540 1 O
or	542 2 O
alpha	545 5 B-Chemical
-	550 1 I-Chemical
methyldopa	551 10 I-Chemical
(	562 1 O
100	563 3 O
mg	567 2 O
/	569 1 O
kg	570 2 O
)	572 1 O
,	573 1 O
selective	575 9 O
I1	585 2 O
-	587 1 O
and	589 3 O
alpha2	593 6 O
-	599 1 O
receptor	600 8 O
agonists	609 8 O
,	617 1 O
respectively	619 12 O
,	631 1 O
in	633 2 O
blood	636 5 O
pressure	642 8 O
,	650 1 O
hemodynamic	652 11 O
variability	664 11 O
,	675 1 O
and	677 3 O
locomotor	681 9 O
activity	691 8 O
were	700 4 O
assessed	705 8 O
in	714 2 O
radiotelemetered	717 16 O
sham	734 4 O
-	738 1 O
operated	739 8 O
and	748 3 O
ovariectomized	752 14 O
(	767 1 O
Ovx	768 3 O
)	771 1 O
Sprague	773 7 O
-	780 1 O
Dawley	781 6 O
female	788 6 O
rats	795 4 O
with	800 4 O
or	805 2 O
without	808 7 O
12	816 2 O
-	818 1 O
wk	819 2 O
estrogen	822 8 B-Chemical
replacement	831 11 O
.	842 1 O

Three	844 5 O
time	850 4 O
domain	855 6 O
indexes	862 7 O
of	870 2 O
hemodynamic	873 11 O
variability	885 11 O
were	897 4 O
employed	902 8 O
:	910 1 O
the	912 3 O
standard	916 8 O
deviation	925 9 O
of	935 2 O
mean	938 4 O
arterial	943 8 O
pressure	952 8 O
as	961 2 O
a	964 1 O
measure	966 7 O
of	974 2 O
blood	977 5 O
pressure	983 8 O
variability	992 11 O
and	1004 3 O
the	1008 3 O
standard	1012 8 O
deviation	1021 9 O
of	1031 2 O
beat	1034 4 O
-	1038 1 O
to	1039 2 O
-	1041 1 O
beat	1042 4 O
intervals	1047 9 O
(	1057 1 O
SDRR	1058 4 O
)	1062 1 O
and	1064 3 O
the	1068 3 O
root	1072 4 O
mean	1077 4 O
square	1082 6 O
of	1089 2 O
successive	1092 10 O
differences	1103 11 O
in	1115 2 O
R	1118 1 O
-	1119 1 O
wave	1120 4 O
-	1124 1 O
to	1125 2 O
-	1127 1 O
R	1128 1 O
-	1129 1 O
wave	1130 4 O
intervals	1135 9 O
as	1145 2 O
measures	1148 8 O
of	1157 2 O
heart	1160 5 O
rate	1166 4 O
variability	1171 11 O
.	1182 1 O

In	1184 2 O
sham	1187 4 O
-	1191 1 O
operated	1192 8 O
rats	1201 4 O
,	1205 1 O
rilmenidine	1207 11 B-Chemical
or	1219 2 O
alpha	1222 5 B-Chemical
-	1227 1 I-Chemical
methyldopa	1228 10 I-Chemical
elicited	1239 8 O
similar	1248 7 O
hypotension	1256 11 B-Disease
that	1268 4 O
lasted	1273 6 O
at	1280 2 O
least	1283 5 O
5	1289 1 O
h	1291 1 O
and	1293 3 O
was	1297 3 O
associated	1301 10 O
with	1312 4 O
reductions	1317 10 O
in	1328 2 O
standard	1331 8 O
deviation	1340 9 O
of	1350 2 O
mean	1353 4 O
arterial	1358 8 O
pressure	1367 8 O
.	1375 1 O

SDRR	1377 4 O
was	1382 3 O
reduced	1386 7 O
only	1394 4 O
by	1399 2 O
alpha	1402 5 B-Chemical
-	1407 1 I-Chemical
methyldopa	1408 10 I-Chemical
.	1418 1 O

Ovx	1420 3 O
significantly	1424 13 O
enhanced	1438 8 O
the	1447 3 O
hypotensive	1451 11 B-Disease
response	1463 8 O
to	1472 2 O
alpha	1475 5 B-Chemical
-	1480 1 I-Chemical
methyldopa	1481 10 I-Chemical
,	1491 1 O
in	1493 2 O
contrast	1496 8 O
to	1505 2 O
no	1508 2 O
effect	1511 6 O
on	1518 2 O
rilmenidine	1521 11 B-Chemical
hypotension	1533 11 B-Disease
.	1544 1 O

The	1546 3 O
enhanced	1550 8 O
alpha	1559 5 B-Chemical
-	1564 1 I-Chemical
methyldopa	1565 10 I-Chemical
hypotension	1576 11 B-Disease
in	1588 2 O
Ovx	1591 3 O
rats	1595 4 O
was	1600 3 O
paralleled	1604 10 O
with	1615 4 O
further	1620 7 O
reduction	1628 9 O
in	1638 2 O
SDRR	1641 4 O
and	1646 3 O
a	1650 1 B-Disease
reduced	1652 7 I-Disease
locomotor	1660 9 I-Disease
activity	1670 8 I-Disease
.	1678 1 O

Estrogen	1680 8 O
replacement	1689 11 O
(	1701 1 O
17beta	1702 6 B-Chemical
-	1708 1 I-Chemical
estradiol	1709 9 I-Chemical
subcutaneous	1719 12 O
pellet	1732 6 O
,	1738 1 O
14	1740 2 O
.	1742 1 O
2	1743 1 O
microg	1745 6 O
/	1751 1 O
day	1752 3 O
,	1755 1 O
12	1757 2 O
wk	1760 2 O
)	1762 1 O
of	1764 2 O
Ovx	1767 3 O
rats	1771 4 O
restored	1776 8 O
the	1785 3 O
hemodynamic	1789 11 O
and	1801 3 O
locomotor	1805 9 O
effects	1815 7 O
of	1823 2 O
alpha	1826 5 B-Chemical
-	1831 1 I-Chemical
methyldopa	1832 10 I-Chemical
to	1843 2 O
sham	1846 4 O
-	1850 1 O
operated	1851 8 O
levels	1860 6 O
.	1866 1 O

These	1868 5 O
findings	1874 8 O
suggest	1883 7 O
that	1891 4 O
estrogen	1896 8 B-Chemical
downregulates	1905 13 O
alpha2	1919 6 O
-	1925 1 O
but	1927 3 O
not	1931 3 O
I1	1935 2 O
-	1937 1 O
receptor	1938 8 O
-	1946 1 O
mediated	1947 8 O
hypotension	1956 11 B-Disease
and	1968 3 O
highlight	1972 9 O
a	1982 1 O
role	1984 4 O
for	1989 3 O
the	1993 3 O
cardiac	1997 7 O
autonomic	2005 9 O
control	2015 7 O
in	2023 2 O
alpha	2026 5 B-Chemical
-	2031 1 I-Chemical
methyldopa	2032 10 I-Chemical
-	2042 1 O
estrogen	2043 8 B-Chemical
interaction	2052 11 O
.	2063 1 O

Cardioprotective	0 16 O
effect	17 6 O
of	24 2 O
tincture	27 8 B-Chemical
of	36 2 I-Chemical
Crataegus	39 9 I-Chemical
on	49 2 O
isoproterenol	52 13 B-Chemical
-	65 1 O
induced	66 7 O
myocardial	74 10 B-Disease
infarction	85 10 I-Disease
in	96 2 O
rats	99 4 O
.	103 1 O

Tincture	105 8 B-Chemical
of	114 2 I-Chemical
Crataegus	117 9 I-Chemical
(	127 1 O
TCR	128 3 B-Chemical
)	131 1 O
,	132 1 O
an	134 2 O
alcoholic	137 9 B-Chemical
extract	147 7 I-Chemical
of	155 2 I-Chemical
the	158 3 I-Chemical
berries	162 7 I-Chemical
of	170 2 I-Chemical
hawthorn	173 8 I-Chemical
(	182 1 O
Crataegus	183 9 B-Chemical
oxycantha	193 9 I-Chemical
)	202 1 O
,	203 1 O
is	205 2 O
used	208 4 O
in	213 2 O
herbal	216 6 O
and	223 3 O
homeopathic	227 11 O
medicine	239 8 O
.	247 1 O

The	249 3 O
present	253 7 O
study	261 5 O
was	267 3 O
done	271 4 O
to	276 2 O
investigate	279 11 O
the	291 3 O
protective	295 10 O
effect	306 6 O
of	313 2 O
TCR	316 3 B-Chemical
on	320 2 O
experimentally	323 14 O
induced	338 7 O
myocardial	346 10 B-Disease
infarction	357 10 I-Disease
in	368 2 O
rats	371 4 O
.	375 1 O

Pretreatment	377 12 O
of	390 2 O
TCR	393 3 B-Chemical
,	396 1 O
at	398 2 O
a	401 1 O
dose	403 4 O
of	408 2 O
0	411 1 O
.	412 1 O
5	413 1 O
mL	415 2 O
/	417 1 O
100	418 3 O
g	422 1 O
bodyweight	424 10 O
per	435 3 O
day	439 3 O
,	442 1 O
orally	444 6 O
for	451 3 O
30	455 2 O
days	458 4 O
,	462 1 O
prevented	464 9 O
the	474 3 O
increase	478 8 O
in	487 2 O
lipid	490 5 O
peroxidation	496 12 O
and	509 3 O
activity	513 8 O
of	522 2 O
marker	525 6 O
enzymes	532 7 O
observed	540 8 O
in	549 2 O
isoproterenol	552 13 B-Chemical
-	565 1 O
induced	566 7 O
rats	574 4 O
(	579 1 O
85	580 2 O
mg	583 2 O
kg	586 2 O
(	588 1 O
-	589 1 O
1	590 1 O
)	591 1 O
s	593 1 O
.	594 1 O
c	596 1 O
.	597 1 O
for	599 3 O
2	603 1 O
days	605 4 O
at	610 2 O
an	613 2 O
interval	616 8 O
of	625 2 O
24	628 2 O
h	631 1 O
)	632 1 O
.	633 1 O

TCR	635 3 B-Chemical
prevented	639 9 O
the	649 3 O
isoproterenol	653 13 B-Chemical
-	666 1 O
induced	667 7 O
decrease	675 8 O
in	684 2 O
antioxidant	687 11 O
enzymes	699 7 O
in	707 2 O
the	710 3 O
heart	714 5 O
and	720 3 O
increased	724 9 O
the	734 3 O
rate	738 4 O
of	743 2 O
ADP	746 3 B-Chemical
-	749 1 O
stimulated	750 10 O
oxygen	761 6 B-Chemical
uptake	768 6 O
and	775 3 O
respiratory	779 11 O
coupling	791 8 O
ratio	800 5 O
.	805 1 O

TCR	807 3 B-Chemical
protected	811 9 O
against	821 7 O
pathological	829 12 O
changes	842 7 O
induced	850 7 O
by	858 2 O
isoproterenol	861 13 B-Chemical
in	875 2 O
rat	878 3 O
heart	882 5 O
.	887 1 O

The	889 3 O
results	893 7 O
show	901 4 O
that	906 4 O
pretreatment	911 12 O
with	924 4 O
TCR	929 3 B-Chemical
may	933 3 O
be	937 2 O
useful	940 6 O
in	947 2 O
preventing	950 10 O
the	961 3 O
damage	965 6 O
induced	972 7 O
by	980 2 O
isoproterenol	983 13 B-Chemical
in	997 2 O
rat	1000 3 O
heart	1004 5 O
.	1009 1 O

Safety	0 6 O
and	7 3 O
adverse	11 7 O
effects	19 7 O
associated	27 10 O
with	38 4 O
raloxifene	43 10 B-Chemical
:	53 1 O
multiple	55 8 O
outcomes	64 8 O
of	73 2 O
raloxifene	76 10 B-Chemical
evaluation	87 10 O
.	97 1 O

OBJECTIVE	99 9 O
:	108 1 O
To	110 2 O
examine	113 7 O
the	121 3 O
effect	125 6 O
of	132 2 O
raloxifene	135 10 B-Chemical
on	146 2 O
major	149 5 O
adverse	155 7 O
events	163 6 O
that	170 4 O
occur	175 5 O
with	181 4 O
postmenopausal	186 14 O
estrogen	201 8 B-Chemical
therapy	210 7 O
or	218 2 O
tamoxifen	221 9 B-Chemical
.	230 1 O

METHODS	232 7 O
:	239 1 O
The	241 3 O
Multiple	245 8 O
Outcomes	254 8 O
of	263 2 O
Raloxifene	266 10 B-Chemical
Evaluation	277 10 O
,	287 1 O
a	289 1 O
multicenter	291 11 O
,	302 1 O
randomized	304 10 O
,	314 1 O
double	316 6 O
-	322 1 O
blind	323 5 O
trial	329 5 O
,	334 1 O
enrolled	336 8 O
7	345 1 O
,	346 1 O
705	347 3 O
postmenopausal	351 14 O
women	366 5 O
with	372 4 O
osteoporosis	377 12 B-Disease
.	389 1 O

Women	391 5 O
were	397 4 O
randomly	402 8 O
assigned	411 8 O
to	420 2 O
raloxifene	423 10 B-Chemical
60	434 2 O
mg	437 2 O
/	439 1 O
d	440 1 O
or	442 2 O
120	445 3 O
mg	449 2 O
/	451 1 O
d	452 1 O
or	454 2 O
placebo	457 7 O
.	464 1 O

Outcomes	466 8 O
included	475 8 O
venous	484 6 B-Disease
thromboembolism	491 15 I-Disease
,	506 1 O
cataracts	508 9 B-Disease
,	517 1 O
gallbladder	519 11 B-Disease
disease	531 7 I-Disease
,	538 1 O
and	540 3 O
endometrial	544 11 B-Disease
hyperplasia	556 11 I-Disease
or	568 2 I-Disease
cancer	571 6 I-Disease
.	577 1 O

RESULTS	579 7 O
:	586 1 O
During	588 6 O
a	595 1 O
mean	597 4 O
follow	602 6 O
-	608 1 O
up	609 2 O
of	612 2 O
3	615 1 O
.	616 1 O
3	617 1 O
years	619 5 O
,	624 1 O
raloxifene	626 10 B-Chemical
was	637 3 O
associated	641 10 O
with	652 4 O
an	657 2 O
increased	660 9 O
risk	670 4 O
for	675 3 O
venous	679 6 B-Disease
thromboembolism	686 15 I-Disease
(	702 1 O
relative	703 8 O
risk	712 4 O
[	717 1 O
RR	718 2 O
]	720 1 O
2	722 1 O
.	723 1 O
1	724 1 O
;	725 1 O
95	727 2 O
%	729 1 O
confidence	731 10 O
interval	742 8 O
[	751 1 O
CI	752 2 O
]	754 1 O
1	756 1 O
.	757 1 O
2	758 1 O
-	759 1 O
3	760 1 O
.	761 1 O
8	762 1 O
)	763 1 O
.	764 1 O

The	766 3 O
excess	770 6 O
event	777 5 O
rate	783 4 O
was	788 3 O
1	792 1 O
.	793 1 O
8	794 1 O
per	796 3 O
1	800 1 O
,	801 1 O
000	802 3 O
woman	806 5 O
-	811 1 O
years	812 5 O
(	818 1 O
95	819 2 O
%	821 1 O
CI	823 2 O
-	826 1 O
0	827 1 O
.	828 1 O
5	829 1 O
-	830 1 O
4	831 1 O
.	832 1 O
1	833 1 O
)	834 1 O
,	835 1 O
and	837 3 O
the	841 3 O
number	845 6 O
needed	852 6 O
to	859 2 O
treat	862 5 O
to	868 2 O
cause	871 5 O
1	877 1 O
event	879 5 O
was	885 3 O
170	889 3 O
(	893 1 O
95	894 2 O
%	896 1 O
CI	898 2 O
100	901 3 O
-	904 1 O
582	905 3 O
)	908 1 O
over	910 4 O
3	915 1 O
.	916 1 O
3	917 1 O
years	919 5 O
.	924 1 O

Risk	926 4 O
in	931 2 O
the	934 3 O
raloxifene	938 10 B-Chemical
group	949 5 O
was	955 3 O
higher	959 6 O
than	966 4 O
in	971 2 O
the	974 3 O
placebo	978 7 O
group	986 5 O
for	992 3 O
the	996 3 O
first	1000 5 O
2	1006 1 O
years	1008 5 O
,	1013 1 O
but	1015 3 O
decreased	1019 9 O
to	1029 2 O
about	1032 5 O
the	1038 3 O
same	1042 4 O
rate	1047 4 O
as	1052 2 O
in	1055 2 O
the	1058 3 O
placebo	1062 7 O
group	1070 5 O
thereafter	1076 10 O
.	1086 1 O

Raloxifene	1088 10 B-Chemical
did	1099 3 O
not	1103 3 O
increase	1107 8 O
risk	1116 4 O
for	1121 3 O
cataracts	1125 9 B-Disease
(	1135 1 O
RR	1136 2 O
0	1139 1 O
.	1140 1 O
9	1141 1 O
;	1142 1 O
95	1144 2 O
%	1146 1 O
CI	1148 2 O
0	1151 1 O
.	1152 1 O
8	1153 1 O
-	1154 1 O
1	1155 1 O
.	1156 1 O
1	1157 1 O
)	1158 1 O
,	1159 1 O
gallbladder	1161 11 B-Disease
disease	1173 7 I-Disease
(	1181 1 O
RR	1182 2 O
1	1185 1 O
.	1186 1 O
0	1187 1 O
;	1188 1 O
95	1190 2 O
%	1192 1 O
CI	1194 2 O
0	1197 1 O
.	1198 1 O
7	1199 1 O
-	1200 1 O
1	1201 1 O
.	1202 1 O
3	1203 1 O
)	1204 1 O
,	1205 1 O
endometrial	1207 11 B-Disease
hyperplasia	1219 11 I-Disease
(	1231 1 O
RR	1232 2 O
1	1235 1 O
.	1236 1 O
3	1237 1 O
;	1238 1 O
95	1240 2 O
%	1242 1 O
CI	1244 2 O
0	1247 1 O
.	1248 1 O
4	1249 1 O
-	1250 1 O
5	1251 1 O
.	1252 1 O
1	1253 1 O
)	1254 1 O
,	1255 1 O
or	1257 2 O
endometrial	1260 11 B-Disease
cancer	1272 6 I-Disease
(	1279 1 O
RR	1280 2 O
0	1283 1 O
.	1284 1 O
9	1285 1 O
;	1286 1 O
95	1288 2 O
%	1290 1 O
CI	1292 2 O
0	1295 1 O
.	1296 1 O
3	1297 1 O
-	1298 1 O
2	1299 1 O
.	1300 1 O
7	1301 1 O
)	1302 1 O
.	1303 1 O

CONCLUSION	1305 10 O
:	1315 1 O
Raloxifene	1317 10 B-Chemical
was	1328 3 O
associated	1332 10 O
with	1343 4 O
an	1348 2 O
increased	1351 9 O
risk	1361 4 O
for	1366 3 O
venous	1370 6 B-Disease
thromboembolism	1377 15 I-Disease
,	1392 1 O
but	1394 3 O
there	1398 5 O
was	1404 3 O
no	1408 2 O
increased	1411 9 O
risk	1421 4 O
for	1426 3 O
cataracts	1430 9 B-Disease
,	1439 1 O
gallbladder	1441 11 B-Disease
disease	1453 7 I-Disease
,	1460 1 O
endometrial	1462 11 B-Disease
hyperplasia	1474 11 I-Disease
,	1485 1 O
or	1487 2 O
endometrial	1490 11 B-Disease
cancer	1502 6 I-Disease
.	1508 1 O

LEVEL	1510 5 O
OF	1516 2 O
EVIDENCE	1519 8 O
:	1527 1 O
I	1529 1 O

Ceftriaxone	0 11 B-Chemical
-	11 1 O
associated	12 10 O
biliary	23 7 B-Disease
pseudolithiasis	31 15 I-Disease
in	47 2 O
paediatric	50 10 O
surgical	61 8 O
patients	70 8 O
.	78 1 O

It	80 2 O
is	83 2 O
well	86 4 O
known	91 5 O
that	97 4 O
ceftriaxone	102 11 B-Chemical
leads	114 5 O
to	120 2 O
pseudolithiasis	123 15 B-Disease
in	139 2 O
some	142 4 O
patients	147 8 O
.	155 1 O

Clinical	157 8 O
and	166 3 O
experimental	170 12 O
studies	183 7 O
also	191 4 O
suggest	196 7 O
that	204 4 O
situations	209 10 O
causing	220 7 O
gallbladder	228 11 B-Disease
dysfunction	240 11 I-Disease
,	251 1 O
such	253 4 O
as	258 2 O
fasting	261 7 O
,	268 1 O
may	270 3 O
have	274 4 O
a	279 1 O
role	281 4 O
for	286 3 O
the	290 3 O
development	294 11 O
of	306 2 O
pseudolithiasis	309 15 B-Disease
.	324 1 O

In	326 2 O
this	329 4 O
study	334 5 O
,	339 1 O
we	341 2 O
prospectively	344 13 O
evaluated	358 9 O
the	368 3 O
incidence	372 9 O
and	382 3 O
clinical	386 8 O
importance	395 10 O
of	406 2 O
pseudolithiasis	409 15 B-Disease
in	425 2 O
paediatric	428 10 O
surgical	439 8 O
patients	448 8 O
receiving	457 9 O
ceftriaxone	467 11 B-Chemical
treatment	479 9 O
,	488 1 O
who	490 3 O
often	494 5 O
had	500 3 O
to	504 2 O
fast	507 4 O
in	512 2 O
the	515 3 O
post	519 4 O
-	523 1 O
operative	524 9 O
period	534 6 O
.	540 1 O

Fifty	542 5 O
children	548 8 O
who	557 3 O
were	561 4 O
given	566 5 O
ceftriaxone	572 11 B-Chemical
were	584 4 O
evaluated	589 9 O
by	599 2 O
serial	602 6 O
abdominal	609 9 O
sonograms	619 9 O
.	628 1 O

Of	630 2 O
those	633 5 O
,	638 1 O
13	640 2 O
(	643 1 O
26	644 2 O
%	646 1 O
)	647 1 O
developed	649 9 O
biliary	659 7 O
pathology	667 9 O
.	676 1 O

Comparison	678 10 O
of	689 2 O
the	692 3 O
patients	696 8 O
with	705 4 O
or	710 2 O
without	713 7 O
pseudolithiasis	721 15 B-Disease
revealed	737 8 O
no	746 2 O
significant	749 11 O
difference	761 10 O
with	772 4 O
respect	777 7 O
to	785 2 O
age	788 3 O
,	791 1 O
sex	793 3 O
,	796 1 O
duration	798 8 O
of	807 2 O
the	810 3 O
treatment	814 9 O
and	824 3 O
starvation	828 10 O
variables	839 9 O
.	848 1 O

After	850 5 O
cessation	856 9 O
of	866 2 O
the	869 3 O
treatment	873 9 O
,	882 1 O
pseudolithiasis	884 15 B-Disease
resolved	900 8 O
spontaneously	909 13 O
within	923 6 O
a	930 1 O
short	932 5 O
period	938 6 O
.	944 1 O

The	946 3 O
incidence	950 9 O
of	960 2 O
pseudolithiasis	963 15 B-Disease
is	979 2 O
not	982 3 O
affected	986 8 O
by	995 2 O
fasting	998 7 O
.	1005 1 O

Evaluation	0 10 O
of	11 2 O
the	14 3 O
anticocaine	18 11 O
monoclonal	30 10 O
antibody	41 8 O
GNC92H2	50 7 B-Chemical
as	58 2 O
an	61 2 O
immunotherapy	64 13 O
for	78 3 O
cocaine	82 7 B-Disease
overdose	90 8 I-Disease
.	98 1 O

The	100 3 O
illicit	104 7 O
use	112 3 O
of	116 2 O
cocaine	119 7 B-Chemical
continues	127 9 O
in	137 2 O
epidemic	140 8 O
proportions	149 11 O
and	161 3 O
treatment	165 9 O
for	175 3 O
cocaine	179 7 B-Disease
overdose	187 8 I-Disease
remains	196 7 O
elusive	204 7 O
.	211 1 O

Current	213 7 O
protein	221 7 O
-	228 1 O
based	229 5 O
technology	235 10 O
offers	246 6 O
a	253 1 O
new	255 3 O
therapeutic	259 11 O
venue	271 5 O
by	277 2 O
which	280 5 O
antibodies	286 10 O
bind	297 4 O
the	302 3 O
drug	306 4 O
in	311 2 O
the	314 3 O
blood	318 5 O
stream	324 6 O
,	330 1 O
inactivating	332 12 O
its	345 3 O
toxic	349 5 O
effects	355 7 O
.	362 1 O

The	364 3 O
therapeutic	368 11 O
potential	380 9 O
of	390 2 O
the	393 3 O
anticocaine	397 11 O
antibody	409 8 O
GNC92H2	418 7 B-Chemical
was	426 3 O
examined	430 8 O
using	439 5 O
a	445 1 O
model	447 5 O
of	453 2 O
cocaine	456 7 B-Disease
overdose	464 8 I-Disease
.	472 1 O

Swiss	474 5 O
albino	480 6 O
mice	487 4 O
prepared	492 8 O
with	501 4 O
intrajugular	506 12 O
catheters	519 9 O
were	529 4 O
tested	534 6 O
in	541 2 O
photocell	544 9 O
cages	554 5 O
after	560 5 O
administration	566 14 O
of	581 2 O
93	584 2 O
mg	587 2 O
/	589 1 O
kg	590 2 O
(	593 1 O
LD50	594 4 O
)	598 1 O
of	600 2 O
cocaine	603 7 B-Chemical
and	611 3 O
GNC92H2	615 7 B-Chemical
infusions	623 9 O
ranging	633 7 O
from	641 4 O
30	646 2 O
to	649 2 O
190	652 3 O
mg	656 2 O
/	658 1 O
kg	659 2 O
.	661 1 O

GNC92H2	663 7 B-Chemical
was	671 3 O
delivered	675 9 O
30	685 2 O
min	688 3 O
before	692 6 O
,	698 1 O
concomitantly	700 13 O
or	714 2 O
3	717 1 O
min	719 3 O
after	723 5 O
cocaine	729 7 B-Chemical
treatment	737 9 O
.	746 1 O

Significant	748 11 O
blockade	760 8 O
of	769 2 O
cocaine	772 7 B-Chemical
toxicity	780 8 B-Disease
was	789 3 O
observed	793 8 O
with	802 4 O
the	807 3 O
higher	811 6 O
dose	818 4 O
of	823 2 O
GNC92H2	826 7 B-Chemical
(	834 1 O
190	835 3 O
mg	839 2 O
/	841 1 O
kg	842 2 O
)	844 1 O
,	845 1 O
where	847 5 O
premorbid	853 9 O
behaviors	863 9 O
were	873 4 O
reduced	878 7 O
up	886 2 O
to	889 2 O
40	892 2 O
%	894 1 O
,	895 1 O
seizures	897 8 B-Disease
up	906 2 O
to	909 2 O
77	912 2 O
%	914 1 O
and	916 3 O
death	920 5 B-Disease
by	926 2 O
72	929 2 O
%	931 1 O
.	932 1 O

Importantly	934 11 O
,	945 1 O
GNC92H2	947 7 B-Chemical
prevented	955 9 O
death	965 5 B-Disease
even	971 4 O
post	976 4 O
-	980 1 O
cocaine	981 7 B-Chemical
injection	989 9 O
.	998 1 O

The	1000 3 O
results	1004 7 O
support	1012 7 O
the	1020 3 O
important	1024 9 O
potential	1034 9 O
of	1044 2 O
GNC92H2	1047 7 B-Chemical
as	1055 2 O
a	1058 1 O
therapeutic	1060 11 O
tool	1072 4 O
against	1077 7 O
cocaine	1085 7 B-Disease
overdose	1093 8 I-Disease
.	1101 1 O

The	0 3 O
effects	4 7 O
of	12 2 O
short	15 5 O
-	20 1 O
term	21 4 O
raloxifene	26 10 B-Chemical
therapy	37 7 O
on	45 2 O
fibrinolysis	48 12 O
markers	61 7 O
:	68 1 O
TAFI	70 4 O
,	74 1 O
tPA	76 3 O
,	79 1 O
and	81 3 O
PAI	85 3 O
-	88 1 O
1	89 1 O
.	90 1 O

BACKGROUND	92 10 O
:	102 1 O
Markers	104 7 O
of	112 2 O
fibrinolysis	115 12 O
,	127 1 O
thrombin	129 8 O
-	137 1 O
activatable	138 11 O
fibrinolysis	150 12 O
inhibitor	163 9 O
(	173 1 O
TAFI	174 4 O
)	178 1 O
,	179 1 O
tissue	181 6 O
-	187 1 O
type	188 4 O
plasminogen	193 11 O
activator	205 9 O
(	215 1 O
tPA	216 3 O
)	219 1 O
,	220 1 O
and	222 3 O
plasminogen	226 11 O
activator	238 9 O
inhibitor	248 9 O
-	257 1 O
1	258 1 O
(	260 1 O
PAI	261 3 O
-	264 1 O
1	265 1 O
)	266 1 O
levels	268 6 O
were	275 4 O
studied	280 7 O
for	288 3 O
the	292 3 O
evaluation	296 10 O
of	307 2 O
short	310 5 O
-	315 1 O
term	316 4 O
effects	321 7 O
of	329 2 O
raloxifene	332 10 B-Chemical
administration	343 14 O
in	358 2 O
postmenopausal	361 14 O
women	376 5 O
.	381 1 O

METHODS	383 7 O
:	390 1 O
Thirty	392 6 O
-	398 1 O
nine	399 4 O
postmenopausal	404 14 O
women	419 5 O
with	425 4 O
osteopenia	430 10 B-Disease
or	441 2 O
osteoporosis	444 12 B-Disease
were	457 4 O
included	462 8 O
in	471 2 O
this	474 4 O
prospective	479 11 O
,	490 1 O
controlled	492 10 O
clinical	503 8 O
study	512 5 O
.	517 1 O

Twenty	519 6 O
-	525 1 O
five	526 4 O
women	531 5 O
were	537 4 O
given	542 5 O
raloxifene	548 10 B-Chemical
hydrochloride	559 13 I-Chemical
(	573 1 O
60	574 2 O
mg	577 2 O
/	579 1 O
day	580 3 O
)	583 1 O
plus	585 4 O
calcium	590 7 B-Chemical
(	598 1 O
500	599 3 O
mg	603 2 O
/	605 1 O
day	606 3 O
)	609 1 O
.	610 1 O

Age	612 3 O
-	615 1 O
matched	616 7 O
controls	624 8 O
(	633 1 O
n	634 1 O
=	636 1 O
14	638 2 O
)	640 1 O
were	642 4 O
given	647 5 O
only	653 4 O
calcium	658 7 B-Chemical
.	665 1 O

Plasma	667 6 O
TAFI	674 4 O
,	678 1 O
tPA	680 3 O
,	683 1 O
and	685 3 O
PAI	689 3 O
-	692 1 O
1	693 1 O
antigen	695 7 O
levels	703 6 O
were	710 4 O
measured	715 8 O
at	724 2 O
baseline	727 8 O
and	736 3 O
after	740 5 O
3	746 1 O
months	748 6 O
of	755 2 O
treatment	758 9 O
by	768 2 O
commercially	771 12 O
available	784 9 O
ELISA	794 5 O
kits	800 4 O
.	804 1 O

Variations	806 10 O
of	817 2 O
individuals	820 11 O
were	832 4 O
assessed	837 8 O
by	846 2 O
Wilcoxon	849 8 O
'	857 1 O
s	858 1 O
test	860 4 O
.	864 1 O

Relationship	866 12 O
between	879 7 O
those	887 5 O
markers	893 7 O
and	901 3 O
demographic	905 11 O
characteristics	917 15 O
were	933 4 O
investigated	938 12 O
.	950 1 O

RESULTS	952 7 O
:	959 1 O
Three	961 5 O
months	967 6 O
of	974 2 O
raloxifene	977 10 B-Chemical
treatment	988 9 O
was	998 3 O
associated	1002 10 O
with	1013 4 O
a	1018 1 O
significant	1020 11 O
decrease	1032 8 O
in	1041 2 O
the	1044 3 O
plasma	1048 6 O
TAFI	1055 4 O
antigen	1060 7 O
concentrations	1068 14 O
(	1083 1 O
16	1084 2 O
%	1086 1 O
change	1088 6 O
,	1094 1 O
P	1096 1 O
<	1098 1 O
0	1100 1 O
.	1101 1 O
01	1102 2 O
)	1104 1 O
,	1105 1 O
and	1107 3 O
a	1111 1 O
significant	1113 11 O
increase	1125 8 O
in	1134 2 O
tPA	1137 3 O
antigen	1141 7 O
concentrations	1149 14 O
(	1164 1 O
25	1165 2 O
%	1167 1 O
change	1169 6 O
,	1175 1 O
P	1177 1 O
<	1179 1 O
0	1181 1 O
.	1182 1 O
05	1183 2 O
)	1185 1 O
.	1186 1 O

A	1188 1 O
significant	1190 11 O
correlation	1202 11 O
was	1214 3 O
found	1218 5 O
between	1224 7 O
baseline	1232 8 O
TAFI	1241 4 O
antigen	1246 7 O
concentrations	1254 14 O
and	1269 3 O
the	1273 3 O
duration	1277 8 O
of	1286 2 O
amenorrhea	1289 10 B-Disease
(	1300 1 O
P	1301 1 O
<	1303 1 O
0	1305 1 O
.	1306 1 O
05	1307 2 O
;	1309 1 O
r	1311 1 O
=	1313 1 O
0	1315 1 O
.	1316 1 O
33	1317 2 O
)	1319 1 O
.	1320 1 O

CONCLUSION	1322 10 O
:	1332 1 O
We	1334 2 O
suggest	1337 7 O
that	1345 4 O
the	1350 3 O
increased	1354 9 O
risk	1364 4 O
of	1369 2 O
venous	1372 6 B-Disease
thromboembolism	1379 15 I-Disease
due	1395 3 O
to	1399 2 O
raloxifene	1402 10 B-Chemical
treatment	1413 9 O
may	1423 3 O
be	1427 2 O
related	1430 7 O
to	1438 2 O
increased	1441 9 O
tPA	1451 3 O
levels	1455 6 O
,	1461 1 O
but	1463 3 O
not	1467 3 O
TAFI	1471 4 O
levels	1476 6 O
.	1482 1 O

Ketoconazole	0 12 B-Chemical
induced	13 7 O
torsades	21 8 B-Disease
de	30 2 I-Disease
pointes	33 7 I-Disease
without	41 7 O
concomitant	49 11 O
use	61 3 O
of	65 2 O
QT	68 2 O
interval	71 8 O
-	79 1 O
prolonging	80 10 O
drug	91 4 O
.	95 1 O

Ketoconazole	97 12 B-Chemical
is	110 2 O
not	113 3 O
known	117 5 O
to	123 2 O
be	126 2 O
proarrhythmic	129 13 O
without	143 7 O
concomitant	151 11 O
use	163 3 O
of	167 2 O
QT	170 2 O
interval	173 8 O
-	181 1 O
prolonging	182 10 O
drugs	193 5 O
.	198 1 O

We	200 2 O
report	203 6 O
a	210 1 O
woman	212 5 O
with	218 4 O
coronary	223 8 B-Disease
artery	232 6 I-Disease
disease	239 7 I-Disease
who	247 3 O
developed	251 9 O
a	261 1 O
markedly	263 8 O
prolonged	272 9 B-Disease
QT	282 2 I-Disease
interval	285 8 I-Disease
and	294 3 O
torsades	298 8 B-Disease
de	307 2 I-Disease
pointes	310 7 I-Disease
(	318 1 O
TdP	319 3 B-Disease
)	322 1 O
after	324 5 O
taking	330 6 O
ketoconazole	337 12 B-Chemical
for	350 3 O
treatment	354 9 O
of	364 2 O
fungal	367 6 B-Disease
infection	374 9 I-Disease
.	383 1 O

Her	385 3 O
QT	389 2 O
interval	392 8 O
returned	401 8 O
to	410 2 O
normal	413 6 O
upon	420 4 O
withdrawal	425 10 O
of	436 2 O
ketoconazole	439 12 B-Chemical
.	451 1 O

Genetic	453 7 O
study	461 5 O
did	467 3 O
not	471 3 O
find	475 4 O
any	480 3 O
mutation	484 8 O
in	493 2 O
her	496 3 O
genes	500 5 O
that	506 4 O
encode	511 6 O
cardiac	518 7 O
IKr	526 3 O
channel	530 7 O
proteins	538 8 O
.	546 1 O

We	548 2 O
postulate	551 9 O
that	561 4 O
by	566 2 O
virtue	569 6 O
of	576 2 O
its	579 3 O
direct	583 6 O
blocking	590 8 O
action	599 6 O
on	606 2 O
IKr	609 3 O
,	612 1 O
ketoconazole	614 12 B-Chemical
alone	627 5 O
may	633 3 O
prolong	637 7 O
QT	645 2 O
interval	648 8 O
and	657 3 O
induce	661 6 O
TdP	668 3 B-Disease
.	671 1 O

This	673 4 O
calls	678 5 O
for	684 3 O
attention	688 9 O
when	698 4 O
ketoconazole	703 12 B-Chemical
is	716 2 O
administered	719 12 O
to	732 2 O
patients	735 8 O
with	744 4 O
risk	749 4 O
factors	754 7 O
for	762 3 O
acquired	766 8 O
long	775 4 B-Disease
QT	780 2 I-Disease
syndrome	783 8 I-Disease
.	791 1 O

Pharmacological	0 15 O
evidence	16 8 O
for	25 3 O
the	29 3 O
potential	33 9 O
of	43 2 O
Daucus	46 6 O
carota	53 6 O
in	60 2 O
the	63 3 O
management	67 10 O
of	78 2 O
cognitive	81 9 B-Disease
dysfunctions	91 12 I-Disease
.	103 1 O

The	105 3 O
present	109 7 O
study	117 5 O
was	123 3 O
aimed	127 5 O
at	133 2 O
investigating	136 13 O
the	150 3 O
effects	154 7 O
of	162 2 O
Daucus	165 6 O
carota	172 6 O
seeds	179 5 O
on	185 2 O
cognitive	188 9 O
functions	198 9 O
,	207 1 O
total	209 5 O
serum	215 5 O
cholesterol	221 11 B-Chemical
levels	233 6 O
and	240 3 O
brain	244 5 O
cholinesterase	250 14 O
activity	265 8 O
in	274 2 O
mice	277 4 O
.	281 1 O

The	283 3 O
ethanolic	287 9 O
extract	297 7 B-Chemical
of	305 2 I-Chemical
Daucus	308 6 I-Chemical
carota	315 6 I-Chemical
seeds	322 5 I-Chemical
(	328 1 O
DCE	329 3 B-Chemical
)	332 1 O
was	334 3 O
administered	338 12 O
orally	351 6 O
in	358 2 O
three	361 5 O
doses	367 5 O
(	373 1 O
100	374 3 O
,	377 1 O
200	379 3 O
,	382 1 O
400	384 3 O
mg	388 2 O
/	390 1 O
kg	391 2 O
)	393 1 O
for	395 3 O
seven	399 5 O
successive	405 10 O
days	416 4 O
to	421 2 O
different	424 9 O
groups	434 6 O
of	441 2 O
young	444 5 O
and	450 3 O
aged	454 4 O
mice	459 4 O
.	463 1 O

Elevated	465 8 O
plus	474 4 O
maze	479 4 O
and	484 3 O
passive	488 7 O
avoidance	496 9 O
apparatus	506 9 O
served	516 6 O
as	523 2 O
the	526 3 O
exteroceptive	530 13 O
behavioral	544 10 O
models	555 6 O
for	562 3 O
testing	566 7 O
memory	574 6 O
.	580 1 O

Diazepam	582 8 B-Chemical
-	590 1 O
,	591 1 O
scopolamine	593 11 B-Chemical
-	604 1 O
and	606 3 O
ageing	610 6 O
-	616 1 O
induced	617 7 O
amnesia	625 7 B-Disease
served	633 6 O
as	640 2 O
the	643 3 O
interoceptive	647 13 O
behavioral	661 10 O
models	672 6 O
.	678 1 O

DCE	680 3 B-Chemical
(	684 1 O
200	685 3 O
,	688 1 O
400	690 3 O
mg	694 2 O
/	696 1 O
kg	697 2 O
,	699 1 O
p	701 1 O
.	702 1 O
o	703 1 O
.	704 1 O
)	705 1 O
showed	707 6 O
significant	714 11 O
improvement	726 11 O
in	738 2 O
memory	741 6 O
scores	748 6 O
of	755 2 O
young	758 5 O
and	764 3 O
aged	768 4 O
mice	773 4 O
.	777 1 O

The	779 3 O
extent	783 6 O
of	790 2 O
memory	793 6 O
improvement	800 11 O
evoked	812 6 O
by	819 2 O
DCE	822 3 B-Chemical
was	826 3 O
23	830 2 O
%	832 1 O
at	834 2 O
the	837 3 O
dose	841 4 O
of	846 2 O
200	849 3 O
mg	853 2 O
/	855 1 O
kg	856 2 O
and	859 3 O
35	863 2 O
%	865 1 O
at	867 2 O
the	870 3 O
dose	874 4 O
of	879 2 O
400	882 3 O
mg	886 2 O
/	888 1 O
kg	889 2 O
in	892 2 O
young	895 5 O
mice	901 4 O
using	906 5 O
elevated	912 8 O
plus	921 4 O
maze	926 4 O
.	930 1 O

Similarly	932 9 O
,	941 1 O
significant	943 11 O
improvements	955 12 O
in	968 2 O
memory	971 6 O
scores	978 6 O
were	985 4 O
observed	990 8 O
using	999 5 O
passive	1005 7 O
avoidance	1013 9 O
apparatus	1023 9 O
and	1033 3 O
aged	1037 4 O
mice	1042 4 O
.	1046 1 O

Furthermore	1048 11 O
,	1059 1 O
DCE	1061 3 B-Chemical
reversed	1065 8 O
the	1074 3 O
amnesia	1078 7 B-Disease
induced	1086 7 O
by	1094 2 O
scopolamine	1097 11 B-Chemical
(	1109 1 O
0	1110 1 O
.	1111 1 O
4	1112 1 O
mg	1114 2 O
/	1116 1 O
kg	1117 2 O
,	1119 1 O
i	1121 1 O
.	1122 1 O
p	1123 1 O
.	1124 1 O
)	1125 1 O
and	1127 3 O
diazepam	1131 8 B-Chemical
(	1140 1 O
1	1141 1 O
mg	1143 2 O
/	1145 1 O
kg	1146 2 O
,	1148 1 O
i	1150 1 O
.	1151 1 O
p	1152 1 O
.	1153 1 O
)	1154 1 O
.	1155 1 O

Daucus	1157 6 B-Chemical
carota	1164 6 I-Chemical
extract	1171 7 I-Chemical
(	1179 1 O
200	1180 3 O
,	1183 1 O
400	1185 3 O
mg	1189 2 O
/	1191 1 O
kg	1192 2 O
,	1194 1 O
p	1196 1 O
.	1197 1 O
o	1198 1 O
.	1199 1 O
)	1200 1 O
reduced	1202 7 O
significantly	1210 13 O
the	1224 3 O
brain	1228 5 O
acetylcholinesterase	1234 20 O
activity	1255 8 O
and	1264 3 O
cholesterol	1268 11 B-Chemical
levels	1280 6 O
in	1287 2 O
young	1290 5 O
and	1296 3 O
aged	1300 4 O
mice	1305 4 O
.	1309 1 O

The	1311 3 O
extent	1315 6 O
of	1322 2 O
inhibition	1325 10 O
of	1336 2 O
brain	1339 5 O
cholinesterase	1345 14 O
activity	1360 8 O
evoked	1369 6 O
by	1376 2 O
DCE	1379 3 B-Chemical
at	1383 2 O
the	1386 3 O
dose	1390 4 O
of	1395 2 O
400	1398 3 O
mg	1402 2 O
/	1404 1 O
kg	1405 2 O
was	1408 3 O
22	1412 2 O
%	1414 1 O
in	1416 2 O
young	1419 5 O
and	1425 3 O
19	1429 2 O
%	1431 1 O
in	1433 2 O
aged	1436 4 O
mice	1441 4 O
.	1445 1 O

There	1447 5 O
was	1453 3 O
a	1457 1 O
remarkable	1459 10 O
reduction	1470 9 O
in	1480 2 O
total	1483 5 O
cholesterol	1489 11 B-Chemical
level	1501 5 O
as	1507 2 O
well	1510 4 O
,	1514 1 O
to	1516 2 O
the	1519 3 O
extent	1523 6 O
of	1530 2 O
23	1533 2 O
%	1535 1 O
in	1537 2 O
young	1540 5 O
and	1546 3 O
21	1550 2 O
%	1552 1 O
in	1554 2 O
aged	1557 4 O
animals	1562 7 O
with	1570 4 O
this	1575 4 O
dose	1580 4 O
of	1585 2 O
DCE	1588 3 B-Chemical
.	1591 1 O

Therefore	1593 9 O
,	1602 1 O
DCE	1604 3 B-Chemical
may	1608 3 O
prove	1612 5 O
to	1618 2 O
be	1621 2 O
a	1624 1 O
useful	1626 6 O
remedy	1633 6 O
for	1640 3 O
the	1644 3 O
management	1648 10 O
of	1659 2 O
cognitive	1662 9 B-Disease
dysfunctions	1672 12 I-Disease
on	1685 2 O
account	1688 7 O
of	1696 2 O
its	1699 3 O
multifarious	1703 12 O
beneficial	1716 10 O
effects	1727 7 O
such	1735 4 O
as	1740 2 O
,	1742 1 O
memory	1744 6 O
improving	1751 9 O
property	1761 8 O
,	1769 1 O
cholesterol	1771 11 B-Chemical
lowering	1783 8 O
property	1792 8 O
and	1801 3 O
anticholinesterase	1805 18 O
activity	1824 8 O
.	1832 1 O

Cauda	0 5 B-Disease
equina	6 6 I-Disease
syndrome	13 8 I-Disease
after	22 5 O
epidural	28 8 O
steroid	37 7 B-Chemical
injection	45 9 O
:	54 1 O
a	56 1 O
case	58 4 O
report	63 6 O
.	69 1 O

OBJECTIVE	71 9 O
:	80 1 O
Conventional	82 12 O
treatment	95 9 O
methods	105 7 O
of	113 2 O
lumbusacral	116 11 O
radiculopathy	128 13 B-Disease
are	142 3 O
physical	146 8 O
therapy	155 7 O
,	162 1 O
epidural	164 8 O
steroid	173 7 B-Chemical
injections	181 10 O
,	191 1 O
oral	193 4 O
medications	198 11 O
,	209 1 O
and	211 3 O
spinal	215 6 O
manipulative	222 12 O
therapy	235 7 O
.	242 1 O

Cauda	244 5 B-Disease
equina	250 6 I-Disease
syndrome	257 8 I-Disease
is	266 2 O
a	269 1 O
rare	271 4 O
complication	276 12 O
of	289 2 O
epidural	292 8 O
anesthesia	301 10 O
.	311 1 O

The	313 3 O
following	317 9 O
case	327 4 O
is	332 2 O
a	335 1 O
report	337 6 O
of	344 2 O
cauda	347 5 B-Disease
equina	353 6 I-Disease
syndrome	360 8 I-Disease
possibly	369 8 O
caused	378 6 O
by	385 2 O
epidural	388 8 O
injection	397 9 O
of	407 2 O
triamcinolone	410 13 B-Chemical
and	424 3 O
bupivacaine	428 11 B-Chemical
.	439 1 O

CLINICAL	441 8 O
FEATURES	450 8 O
:	458 1 O
A	460 1 O
50	462 2 O
-	464 1 O
year	465 4 O
-	469 1 O
old	470 3 O
woman	474 5 O
with	480 4 O
low	485 3 B-Disease
back	489 4 I-Disease
and	494 3 I-Disease
right	498 5 I-Disease
leg	504 3 I-Disease
pain	508 4 I-Disease
was	513 3 O
scheduled	517 9 O
for	527 3 O
epidural	531 8 O
steroid	540 7 B-Chemical
injection	548 9 O
.	557 1 O

INTERVENTION	559 12 O
AND	572 3 O
OUTCOME	576 7 O
:	583 1 O
An	585 2 O
18	588 2 O
-	590 1 O
gauge	591 5 O
Touhy	597 5 O
needle	603 6 O
was	610 3 O
inserted	614 8 O
until	623 5 O
loss	629 4 O
of	634 2 O
resistance	637 10 O
occurred	648 8 O
at	657 2 O
the	660 3 O
L4	664 2 O
-	666 1 O
5	667 1 O
level	669 5 O
.	674 1 O

Spread	676 6 O
of	683 2 O
the	686 3 O
contrast	690 8 O
medium	699 6 O
within	706 6 O
the	713 3 O
epidural	717 8 O
space	726 5 O
was	732 3 O
determined	736 10 O
by	747 2 O
radiographic	750 12 O
imaging	763 7 O
.	770 1 O

After	772 5 O
verifying	778 9 O
the	788 3 O
epidural	792 8 O
space	801 5 O
,	806 1 O
bupivacaine	808 11 B-Chemical
and	820 3 O
triamcinolone	824 13 B-Chemical
diacetate	838 9 I-Chemical
were	848 4 O
injected	853 8 O
.	861 1 O

After	863 5 O
the	869 3 O
injection	873 9 O
,	882 1 O
there	884 5 O
was	890 3 O
a	894 1 O
reduction	896 9 O
in	906 2 O
radicular	909 9 O
symptoms	919 8 O
.	927 1 O

Three	929 5 O
hours	935 5 O
later	941 5 O
,	946 1 O
she	948 3 O
complained	952 10 O
of	963 2 O
perineal	966 8 O
numbness	975 8 B-Disease
and	984 3 O
lower	988 5 B-Disease
extremity	994 9 I-Disease
weakness	1004 8 I-Disease
.	1012 1 O

The	1014 3 O
neurologic	1018 10 O
evaluation	1029 10 O
revealed	1040 8 O
loss	1049 4 B-Disease
of	1054 2 I-Disease
sensation	1057 9 I-Disease
in	1067 2 O
the	1070 3 O
saddle	1074 6 O
area	1081 4 O
and	1086 3 O
medial	1090 6 O
aspect	1097 6 O
of	1104 2 O
her	1107 3 O
right	1111 5 O
leg	1117 3 O
.	1120 1 O

There	1122 5 O
was	1128 3 O
a	1132 1 O
decrease	1134 8 O
in	1143 2 O
the	1146 3 O
perception	1150 10 O
of	1161 2 O
pinprick	1164 8 O
test	1173 4 O
.	1177 1 O

Deep	1179 4 O
-	1183 1 O
tendon	1184 6 O
reflexes	1191 8 O
were	1200 4 O
decreased	1205 9 O
especially	1215 10 O
in	1226 2 O
the	1229 3 O
right	1233 5 O
leg	1239 3 O
.	1242 1 O

She	1244 3 O
was	1248 3 O
unable	1252 6 O
to	1259 2 O
urinate	1262 7 O
.	1269 1 O

The	1271 3 O
patient	1275 7 O
'	1282 1 O
s	1283 1 O
symptoms	1285 8 O
improved	1294 8 O
slightly	1303 8 O
over	1312 4 O
the	1317 3 O
next	1321 4 O
few	1326 3 O
hours	1330 5 O
.	1335 1 O

She	1337 3 O
had	1341 3 O
a	1345 1 O
gradual	1347 7 O
return	1355 6 O
of	1362 2 O
motor	1365 5 O
function	1371 8 O
and	1380 3 O
ability	1384 7 O
of	1392 2 O
feeling	1395 7 O
Foley	1403 5 O
catheter	1409 8 O
.	1417 1 O

All	1419 3 O
of	1423 2 O
the	1426 3 O
symptoms	1430 8 O
were	1439 4 O
completely	1444 10 O
resolved	1455 8 O
over	1464 4 O
the	1469 3 O
next	1473 4 O
8	1478 1 O
hours	1480 5 O
.	1485 1 O

CONCLUSION	1487 10 O
:	1497 1 O
Complications	1499 13 O
associated	1513 10 O
with	1524 4 O
epidural	1529 8 O
steroid	1538 7 B-Chemical
injections	1546 10 O
are	1557 3 O
rare	1561 4 O
.	1565 1 O

Clinical	1567 8 O
examination	1576 11 O
and	1588 3 O
continued	1592 9 O
vigilance	1602 9 O
for	1612 3 O
neurologic	1616 10 B-Disease
deterioration	1627 13 I-Disease
after	1641 5 O
epidural	1647 8 O
steroid	1656 7 B-Chemical
injections	1664 10 O
is	1675 2 O
important	1678 9 O
.	1687 1 O

High	0 4 O
-	4 1 O
dose	5 4 O
testosterone	10 12 B-Chemical
is	23 2 O
associated	26 10 O
with	37 4 O
atherosclerosis	42 15 B-Disease
in	58 2 O
postmenopausal	61 14 O
women	76 5 O
.	81 1 O

OBJECTIVES	83 10 O
:	93 1 O
To	95 2 O
study	98 5 O
the	104 3 O
long	108 4 O
-	112 1 O
term	113 4 O
effects	118 7 O
of	126 2 O
androgen	129 8 O
treatment	138 9 O
on	148 2 O
atherosclerosis	151 15 B-Disease
in	167 2 O
postmenopausal	170 14 O
women	185 5 O
.	190 1 O

METHODS	192 7 O
:	199 1 O
In	201 2 O
a	204 1 O
population	206 10 O
-	216 1 O
based	217 5 O
study	223 5 O
in	229 2 O
513	232 3 O
naturally	236 9 O
postmenopausal	246 14 O
women	261 5 O
aged	267 4 O
54	272 2 O
-	274 1 O
67	275 2 O
years	278 5 O
,	283 1 O
we	285 2 O
studied	288 7 O
the	296 3 O
association	300 11 O
between	312 7 O
self	320 4 O
-	324 1 O
reported	325 8 O
intramuscularly	334 15 O
administered	350 12 O
high	363 4 O
-	367 1 O
dose	368 4 O
estrogen	373 8 B-Chemical
-	381 1 O
testosterone	382 12 B-Chemical
therapy	395 7 O
(	403 1 O
estradiol	404 9 B-Chemical
-	413 1 I-Chemical
and	415 3 I-Chemical
testosterone	419 12 I-Chemical
esters	432 6 I-Chemical
)	438 1 O
and	440 3 O
aortic	444 6 O
atherosclerosis	451 15 B-Disease
.	466 1 O

Aortic	468 6 O
atherosclerosis	475 15 B-Disease
was	491 3 O
diagnosed	495 9 O
by	505 2 O
radiographic	508 12 O
detection	521 9 O
of	531 2 O
calcified	534 9 O
deposits	544 8 O
in	553 2 O
the	556 3 O
abdominal	560 9 O
aorta	570 5 O
,	575 1 O
which	577 5 O
have	583 4 O
been	588 4 O
shown	593 5 O
to	599 2 O
reflect	602 7 O
intima	610 6 O
atherosclerosis	617 15 B-Disease
.	632 1 O

Hormone	634 7 O
therapy	642 7 O
users	650 5 O
were	656 4 O
compared	661 8 O
with	670 4 O
never	675 5 O
users	681 5 O
.	686 1 O

RESULTS	688 7 O
:	695 1 O
Intramuscular	697 13 O
hormone	711 7 O
therapy	719 7 O
use	727 3 O
for	731 3 O
1	735 1 O
year	737 4 O
or	742 2 O
longer	745 6 O
was	752 3 O
reported	756 8 O
by	765 2 O
25	768 2 O
women	771 5 O
.	776 1 O

In	778 2 O
almost	781 6 O
half	788 4 O
of	793 2 O
these	796 5 O
women	802 5 O
severe	808 6 O
atherosclerosis	815 15 B-Disease
of	831 2 O
the	834 3 O
aorta	838 5 O
was	844 3 O
present	848 7 O
(	856 1 O
n	857 1 O
=	858 1 O
11	859 2 O
)	861 1 O
,	862 1 O
while	864 5 O
in	870 2 O
women	873 5 O
without	879 7 O
hormone	887 7 O
use	895 3 O
severe	899 6 O
atherosclerosis	906 15 B-Disease
of	922 2 O
the	925 3 O
aorta	929 5 O
was	935 3 O
present	939 7 O
in	947 2 O
less	950 4 O
than	955 4 O
20	960 2 O
%	962 1 O
(	964 1 O
OR	965 2 O
3	968 1 O
.	969 1 O
1	970 1 O
;	971 1 O
95	973 2 O
%	975 1 O
CI	977 2 O
,	979 1 O
1	981 1 O
.	982 1 O
1	983 1 O
-	984 1 O
8	985 1 O
.	986 1 O
5	987 1 O
,	988 1 O
adjusted	990 8 O
for	999 3 O
age	1003 3 O
,	1006 1 O
years	1008 5 O
since	1014 5 O
menopause	1020 9 O
,	1029 1 O
smoking	1031 7 O
,	1038 1 O
and	1040 3 O
body	1044 4 O
mass	1049 4 O
index	1054 5 O
)	1059 1 O
.	1060 1 O

The	1062 3 O
association	1066 11 O
remained	1078 8 O
after	1087 5 O
additional	1093 10 O
adjustment	1104 10 O
for	1115 3 O
diabetes	1119 8 B-Disease
,	1127 1 O
cholesterol	1129 11 B-Chemical
level	1141 5 O
,	1146 1 O
systolic	1148 8 O
blood	1157 5 O
pressure	1163 8 O
,	1171 1 O
or	1173 2 O
alcohol	1176 7 B-Chemical
use	1184 3 O
.	1187 1 O

No	1189 2 O
association	1192 11 O
was	1204 3 O
found	1208 5 O
for	1214 3 O
hormone	1218 7 O
use	1226 3 O
less	1230 4 O
than	1235 4 O
1	1240 1 O
year	1242 4 O
.	1246 1 O

CONCLUSION	1248 10 O
:	1258 1 O
Our	1260 3 O
results	1264 7 O
suggest	1272 7 O
that	1280 4 O
high	1285 4 O
-	1289 1 O
dose	1290 4 O
testosterone	1295 12 B-Chemical
therapy	1308 7 O
may	1316 3 O
adversely	1320 9 O
affect	1330 6 O
atherosclerosis	1337 15 B-Disease
in	1353 2 O
postmenopausal	1356 14 O
women	1371 5 O
and	1377 3 O
indicate	1381 8 O
that	1390 4 O
androgen	1395 8 O
replacement	1404 11 O
in	1416 2 O
these	1419 5 O
women	1425 5 O
may	1431 3 O
not	1435 3 O
be	1439 2 O
harmless	1442 8 O
.	1450 1 O

Sirolimus	0 9 B-Chemical
-	9 1 O
associated	10 10 O
proteinuria	21 11 B-Disease
and	33 3 O
renal	37 5 B-Disease
dysfunction	43 11 I-Disease
.	54 1 O

Sirolimus	56 9 B-Chemical
is	66 2 O
a	69 1 O
novel	71 5 O
immunosuppressant	77 17 O
with	95 4 O
potent	100 6 O
antiproliferative	107 17 O
actions	125 7 O
through	133 7 O
its	141 3 O
ability	145 7 O
to	153 2 O
inhibit	156 7 O
the	164 3 O
raptor	168 6 O
-	174 1 O
containing	175 10 O
mammalian	186 9 O
target	196 6 O
of	203 2 O
rapamycin	206 9 B-Chemical
protein	216 7 O
kinase	224 6 O
.	230 1 O

Sirolimus	232 9 B-Chemical
represents	242 10 O
a	253 1 O
major	255 5 O
therapeutic	261 11 O
advance	273 7 O
in	281 2 O
the	284 3 O
prevention	288 10 O
of	299 2 O
acute	302 5 O
renal	308 5 O
allograft	314 9 O
rejection	324 9 O
and	334 3 O
chronic	338 7 O
allograft	346 9 O
nephropathy	356 11 B-Disease
.	367 1 O

Its	369 3 O
role	373 4 O
in	378 2 O
the	381 3 O
therapy	385 7 O
of	393 2 O
glomerulonephritis	396 18 B-Disease
,	414 1 O
autoimmunity	416 12 B-Disease
,	428 1 O
cystic	430 6 B-Disease
renal	437 5 I-Disease
diseases	443 8 I-Disease
and	452 3 O
renal	456 5 B-Disease
cancer	462 6 I-Disease
is	469 2 O
under	472 5 O
investigation	478 13 O
.	491 1 O

Because	493 7 O
sirolimus	501 9 B-Chemical
does	511 4 O
not	516 3 O
share	520 5 O
the	526 3 O
vasomotor	530 9 O
renal	540 5 O
adverse	546 7 O
effects	554 7 O
exhibited	562 9 O
by	572 2 O
calcineurin	575 11 O
inhibitors	587 10 O
,	597 1 O
it	599 2 O
has	602 3 O
been	606 4 O
designated	611 10 O
a	622 1 O
'	624 1 O
non	625 3 O
-	628 1 O
nephrotoxic	629 11 B-Disease
drug	641 4 O
'	645 1 O
.	646 1 O

However	648 7 O
,	655 1 O
clinical	657 8 O
reports	666 7 O
suggest	674 7 O
that	682 4 O
,	686 1 O
under	688 5 O
some	694 4 O
circumstances	699 13 O
,	712 1 O
sirolimus	714 9 B-Chemical
is	724 2 O
associated	727 10 O
with	738 4 O
proteinuria	743 11 B-Disease
and	755 3 O
acute	759 5 B-Disease
renal	765 5 I-Disease
dysfunction	771 11 I-Disease
.	782 1 O

A	784 1 O
common	786 6 O
risk	793 4 O
factor	798 6 O
appears	805 7 O
to	813 2 O
be	816 2 O
presence	819 8 O
of	828 2 O
pre	831 3 O
-	834 1 O
existing	835 8 O
chronic	844 7 B-Disease
renal	852 5 I-Disease
damage	858 6 I-Disease
.	864 1 O

The	866 3 O
mechanisms	870 10 O
of	881 2 O
sirolimus	884 9 B-Chemical
-	893 1 O
associated	894 10 O
proteinuria	905 11 B-Disease
are	917 3 O
multifactorial	921 14 O
and	936 3 O
may	940 3 O
be	944 2 O
due	947 3 O
to	951 2 O
an	954 2 O
increase	957 8 O
in	966 2 O
glomerular	969 10 O
capillary	980 9 O
pressure	990 8 O
following	999 9 O
calcineurin	1009 11 O
inhibitor	1021 9 O
withdrawal	1031 10 O
.	1041 1 O

It	1043 2 O
has	1046 3 O
also	1050 4 O
been	1055 4 O
suggested	1060 9 O
that	1070 4 O
sirolimus	1075 9 B-Chemical
directly	1085 8 O
causes	1094 6 O
increased	1101 9 O
glomerular	1111 10 O
permeability	1122 12 O
/	1134 1 O
injury	1135 6 O
,	1141 1 O
but	1143 3 O
evidence	1147 8 O
for	1156 3 O
this	1160 4 O
mechanism	1165 9 O
is	1175 2 O
currently	1178 9 O
inconclusive	1188 12 O
.	1200 1 O

The	1202 3 O
acute	1206 5 B-Disease
renal	1212 5 I-Disease
dysfunction	1218 11 I-Disease
associated	1230 10 O
with	1241 4 O
sirolimus	1246 9 B-Chemical
(	1256 1 O
such	1257 4 O
as	1262 2 O
in	1265 2 O
delayed	1268 7 O
graft	1276 5 O
function	1282 8 O
)	1290 1 O
may	1292 3 O
be	1296 2 O
due	1299 3 O
to	1303 2 O
suppression	1306 11 O
of	1318 2 O
compensatory	1321 12 O
renal	1334 5 O
cell	1340 4 O
proliferation	1345 13 O
and	1359 3 O
survival	1363 8 O
/	1371 1 O
repair	1372 6 O
processes	1379 9 O
.	1388 1 O

Although	1390 8 O
these	1399 5 O
adverse	1405 7 O
effects	1413 7 O
occur	1421 5 O
in	1427 2 O
some	1430 4 O
patients	1435 8 O
,	1443 1 O
their	1445 5 O
occurrence	1451 10 O
could	1462 5 O
be	1468 2 O
minimised	1471 9 O
by	1481 2 O
knowledge	1484 9 O
of	1494 2 O
the	1497 3 O
molecular	1501 9 O
effects	1511 7 O
of	1519 2 O
sirolimus	1522 9 B-Chemical
on	1532 2 O
the	1535 3 O
kidney	1539 6 O
,	1545 1 O
the	1547 3 O
use	1551 3 O
of	1555 2 O
sirolimus	1558 9 B-Chemical
in	1568 2 O
appropriate	1571 11 O
patient	1583 7 O
populations	1591 11 O
,	1602 1 O
close	1604 5 O
monitoring	1610 10 O
of	1621 2 O
proteinuria	1624 11 B-Disease
and	1636 3 O
renal	1640 5 O
function	1646 8 O
,	1654 1 O
use	1656 3 O
of	1660 2 O
angiotensin	1663 11 B-Chemical
-	1674 1 O
converting	1675 10 O
enzyme	1686 6 O
inhibitors	1693 10 O
or	1704 2 O
angiotensin	1707 11 B-Chemical
II	1719 2 I-Chemical
receptor	1722 8 O
blockers	1731 8 O
if	1740 2 O
proteinuria	1743 11 B-Disease
occurs	1755 6 O
and	1762 3 O
withdrawal	1766 10 O
if	1777 2 O
needed	1780 6 O
.	1786 1 O

Further	1788 7 O
long	1796 4 O
-	1800 1 O
term	1801 4 O
analysis	1806 8 O
of	1815 2 O
renal	1818 5 O
allograft	1824 9 O
studies	1834 7 O
using	1842 5 O
sirolimus	1848 9 B-Chemical
as	1858 2 O
de	1861 2 O
novo	1864 4 O
immunosuppression	1869 17 O
along	1887 5 O
with	1893 4 O
clinical	1898 8 O
and	1907 3 O
laboratory	1911 10 O
studies	1922 7 O
will	1930 4 O
refine	1935 6 O
these	1942 5 O
issues	1948 6 O
in	1955 2 O
the	1958 3 O
future	1962 6 O
.	1968 1 O

Progressive	0 11 O
myopathy	12 8 B-Disease
with	21 4 O
up	26 2 O
-	28 1 O
regulation	29 10 O
of	40 2 O
MHC	43 3 O
-	46 1 O
I	47 1 O
associated	49 10 O
with	60 4 O
statin	65 6 B-Chemical
therapy	72 7 O
.	79 1 O

Statins	81 7 B-Chemical
can	89 3 O
cause	93 5 O
a	99 1 O
necrotizing	101 11 O
myopathy	113 8 B-Disease
and	122 3 O
hyperCKaemia	126 12 B-Disease
which	139 5 O
is	145 2 O
reversible	148 10 O
on	159 2 O
cessation	162 9 O
of	172 2 O
the	175 3 O
drug	179 4 O
.	183 1 O

What	185 4 O
is	190 2 O
less	193 4 O
well	198 4 O
known	203 5 O
is	209 2 O
a	212 1 O
phenomenon	214 10 O
whereby	225 7 O
statins	233 7 B-Chemical
may	241 3 O
induce	245 6 O
a	252 1 O
myopathy	254 8 B-Disease
,	262 1 O
which	264 5 O
persists	270 8 O
or	279 2 O
may	282 3 O
progress	286 8 O
after	295 5 O
stopping	301 8 O
the	310 3 O
drug	314 4 O
.	318 1 O

We	320 2 O
investigated	323 12 O
the	336 3 O
muscle	340 6 O
pathology	347 9 O
in	357 2 O
8	360 1 O
such	362 4 O
cases	367 5 O
.	372 1 O

All	374 3 O
had	378 3 O
myofibre	382 8 O
necrosis	391 8 B-Disease
but	400 3 O
only	404 4 O
3	409 1 O
had	411 3 O
an	415 2 O
inflammatory	418 12 O
infiltrate	431 10 O
.	441 1 O

In	443 2 O
all	446 3 O
cases	450 5 O
there	456 5 O
was	462 3 O
diffuse	466 7 O
or	474 2 O
multifocal	477 10 O
up	488 2 O
-	490 1 O
regulation	491 10 O
of	502 2 O
MHC	505 3 O
-	508 1 O
I	509 1 O
expression	511 10 O
even	522 4 O
in	527 2 O
non	530 3 O
-	533 1 O
necrotic	534 8 B-Disease
fibres	543 6 O
.	549 1 O

Progressive	551 11 O
improvement	563 11 O
occurred	575 8 O
in	584 2 O
7	587 1 O
cases	589 5 O
after	595 5 O
commencement	601 12 O
of	614 2 O
prednisolone	617 12 B-Chemical
and	630 3 O
methotrexate	634 12 B-Chemical
,	646 1 O
and	648 3 O
in	652 2 O
one	655 3 O
case	659 4 O
spontaneously	664 13 O
.	677 1 O

These	679 5 O
observations	685 12 O
suggest	698 7 O
that	706 4 O
statins	711 7 B-Chemical
may	719 3 O
initiate	723 8 O
an	732 2 O
immune	735 6 O
-	741 1 O
mediated	742 8 O
myopathy	751 8 B-Disease
that	760 4 O
persists	765 8 O
after	774 5 O
withdrawal	780 10 O
of	791 2 O
the	794 3 O
drug	798 4 O
and	803 3 O
responds	807 8 O
to	816 2 O
immunosuppressive	819 17 O
therapy	837 7 O
.	844 1 O

The	846 3 O
mechanism	850 9 O
of	860 2 O
this	863 4 O
myopathy	868 8 B-Disease
is	877 2 O
uncertain	880 9 O
but	890 3 O
may	894 3 O
involve	898 7 O
the	906 3 O
induction	910 9 O
by	920 2 O
statins	923 7 B-Chemical
of	931 2 O
an	934 2 O
endoplasmic	937 11 O
reticulum	949 9 O
stress	959 6 O
response	966 8 O
with	975 4 O
associated	980 10 O
up	991 2 O
-	993 1 O
regulation	994 10 O
of	1005 2 O
MHC	1008 3 O
-	1011 1 O
I	1012 1 O
expression	1014 10 O
and	1025 3 O
antigen	1029 7 O
presentation	1037 12 O
by	1050 2 O
muscle	1053 6 O
fibres	1060 6 O
.	1066 1 O

Direct	0 6 O
inhibition	7 10 O
of	18 2 O
cardiac	21 7 O
hyperpolarization	29 17 O
-	46 1 O
activated	47 9 O
cyclic	57 6 B-Chemical
nucleotide	64 10 I-Chemical
-	74 1 O
gated	75 5 O
pacemaker	81 9 O
channels	91 8 O
by	100 2 O
clonidine	103 9 B-Chemical
.	112 1 O

BACKGROUND	114 10 O
:	124 1 O
Inhibition	126 10 O
of	137 2 O
cardiac	140 7 O
sympathetic	148 11 O
tone	160 4 O
represents	165 10 O
an	176 2 O
important	179 9 O
strategy	189 8 O
for	198 3 O
treatment	202 9 O
of	212 2 O
cardiovascular	215 14 B-Disease
disease	230 7 I-Disease
,	237 1 O
including	239 9 O
arrhythmia	249 10 B-Disease
,	259 1 O
coronary	261 8 B-Disease
heart	270 5 I-Disease
disease	276 7 I-Disease
,	283 1 O
and	285 3 O
chronic	289 7 O
heart	297 5 B-Disease
failure	303 7 I-Disease
.	310 1 O

Activation	312 10 O
of	323 2 O
presynaptic	326 11 O
alpha2	338 6 O
-	344 1 O
adrenoceptors	345 13 O
is	359 2 O
the	362 3 O
most	366 4 O
widely	371 6 O
accepted	378 8 O
mechanism	387 9 O
of	397 2 O
action	400 6 O
of	407 2 O
the	410 3 O
antisympathetic	414 15 O
drug	430 4 O
clonidine	435 9 B-Chemical
;	444 1 O
however	446 7 O
,	453 1 O
other	455 5 O
target	461 6 O
proteins	468 8 O
have	477 4 O
been	482 4 O
postulated	487 10 O
to	498 2 O
contribute	501 10 O
to	512 2 O
the	515 3 O
in	519 2 O
vivo	522 4 O
actions	527 7 O
of	535 2 O
clonidine	538 9 B-Chemical
.	547 1 O

METHODS	549 7 O
AND	557 3 O
RESULTS	561 7 O
:	568 1 O
To	570 2 O
test	573 4 O
whether	578 7 O
clonidine	586 9 B-Chemical
elicits	596 7 O
pharmacological	604 15 O
effects	620 7 O
independent	628 11 O
of	640 2 O
alpha2	643 6 O
-	649 1 O
adrenoceptors	650 13 O
,	663 1 O
we	665 2 O
have	668 4 O
generated	673 9 O
mice	683 4 O
with	688 4 O
a	693 1 O
targeted	695 8 O
deletion	704 8 O
of	713 2 O
all	716 3 O
3	720 1 O
alpha2	722 6 O
-	728 1 O
adrenoceptor	729 12 O
subtypes	742 8 O
(	751 1 O
alpha2ABC	752 9 O
-	761 1 O
/	762 1 O
-	763 1 O
)	764 1 O
.	765 1 O

Alpha2ABC	767 9 O
-	776 1 O
/	777 1 O
-	778 1 O
mice	780 4 O
were	785 4 O
completely	790 10 O
unresponsive	801 12 O
to	814 2 O
the	817 3 O
analgesic	821 9 O
and	831 3 O
hypnotic	835 8 O
effects	844 7 O
of	852 2 O
clonidine	855 9 B-Chemical
;	864 1 O
however	866 7 O
,	873 1 O
clonidine	875 9 B-Chemical
significantly	885 13 O
lowered	899 7 O
heart	907 5 O
rate	913 4 O
in	918 2 O
alpha2ABC	921 9 O
-	930 1 O
/	931 1 O
-	932 1 O
mice	934 4 O
by	939 2 O
up	942 2 O
to	945 2 O
150	948 3 O
bpm	952 3 O
.	955 1 O

Clonidine	957 9 B-Chemical
-	966 1 O
induced	967 7 O
bradycardia	975 11 B-Disease
in	987 2 O
conscious	990 9 O
alpha2ABC	1000 9 O
-	1009 1 O
/	1010 1 O
-	1011 1 O
mice	1013 4 O
was	1018 3 O
32	1022 2 O
.	1024 1 O
3	1025 1 O
%	1026 1 O
(	1028 1 O
10	1029 2 O
microg	1032 6 O
/	1038 1 O
kg	1039 2 O
)	1041 1 O
and	1043 3 O
26	1047 2 O
.	1049 1 O
6	1050 1 O
%	1051 1 O
(	1053 1 O
100	1054 3 O
microg	1058 6 O
/	1064 1 O
kg	1065 2 O
)	1067 1 O
of	1069 2 O
the	1072 3 O
effect	1076 6 O
in	1083 2 O
wild	1086 4 O
-	1090 1 O
type	1091 4 O
mice	1096 4 O
.	1100 1 O

A	1102 1 O
similar	1104 7 O
bradycardic	1112 11 O
effect	1124 6 O
of	1131 2 O
clonidine	1134 9 B-Chemical
was	1144 3 O
observed	1148 8 O
in	1157 2 O
isolated	1160 8 O
spontaneously	1169 13 O
beating	1183 7 O
right	1191 5 O
atria	1197 5 O
from	1203 4 O
alpha2ABC	1208 9 O
-	1217 1 O
knockout	1218 8 O
and	1227 3 O
wild	1231 4 O
-	1235 1 O
type	1236 4 O
mice	1241 4 O
.	1245 1 O

Clonidine	1247 9 B-Chemical
inhibited	1257 9 O
the	1267 3 O
native	1271 6 O
pacemaker	1278 9 O
current	1288 7 O
(	1296 1 O
I	1297 1 O
(	1298 1 O
f	1299 1 O
)	1300 1 O
)	1301 1 O
in	1303 2 O
isolated	1306 8 O
sinoatrial	1315 10 O
node	1326 4 O
pacemaker	1331 9 O
cells	1341 5 O
and	1347 3 O
the	1351 3 O
I	1355 1 O
(	1356 1 O
f	1357 1 O
)	1358 1 O
-	1359 1 O
generating	1360 10 O
hyperpolarization	1371 17 O
-	1388 1 O
activated	1389 9 O
cyclic	1399 6 B-Chemical
nucleotide	1406 10 I-Chemical
-	1416 1 O
gated	1417 5 O
(	1423 1 O
HCN	1424 3 O
)	1427 1 O
2	1429 1 O
and	1431 3 O
HCN4	1435 4 O
channels	1440 8 O
in	1449 2 O
transfected	1452 11 O
HEK293	1464 6 O
cells	1471 5 O
.	1476 1 O

As	1478 2 O
a	1481 1 O
consequence	1483 11 O
of	1495 2 O
blocking	1498 8 O
I	1507 1 O
(	1508 1 O
f	1509 1 O
)	1510 1 O
,	1511 1 O
clonidine	1513 9 B-Chemical
reduced	1523 7 O
the	1531 3 O
slope	1535 5 O
of	1541 2 O
the	1544 3 O
diastolic	1548 9 O
depolarization	1558 14 O
and	1573 3 O
the	1577 3 O
frequency	1581 9 O
of	1591 2 O
pacemaker	1594 9 O
potentials	1604 10 O
in	1615 2 O
sinoatrial	1618 10 O
node	1629 4 O
cells	1634 5 O
from	1640 4 O
wild	1645 4 O
-	1649 1 O
type	1650 4 O
and	1655 3 O
alpha2ABC	1659 9 O
-	1668 1 O
knockout	1669 8 O
mice	1678 4 O
.	1682 1 O

CONCLUSIONS	1684 11 O
:	1695 1 O
Direct	1697 6 O
inhibition	1704 10 O
of	1715 2 O
cardiac	1718 7 O
HCN	1726 3 O
pacemaker	1730 9 O
channels	1740 8 O
contributes	1749 11 O
to	1761 2 O
the	1764 3 O
bradycardic	1768 11 O
effects	1780 7 O
of	1788 2 O
clonidine	1791 9 B-Chemical
gene	1801 4 O
-	1805 1 O
targeted	1806 8 O
mice	1815 4 O
in	1820 2 O
vivo	1823 4 O
,	1827 1 O
and	1829 3 O
thus	1833 4 O
,	1837 1 O
clonidine	1839 9 B-Chemical
-	1848 1 O
like	1849 4 O
drugs	1854 5 O
represent	1860 9 O
novel	1870 5 O
structures	1876 10 O
for	1887 3 O
future	1891 6 O
HCN	1898 3 O
channel	1902 7 O
inhibitors	1910 10 O
.	1920 1 O

Influence	0 9 O
of	10 2 O
smoking	13 7 B-Chemical
on	21 2 O
developing	24 10 O
cochlea	35 7 O
.	42 1 O

Does	44 4 O
smoking	49 7 B-Chemical
during	57 6 O
pregnancy	64 9 O
affect	74 6 O
the	81 3 O
amplitudes	85 10 O
of	96 2 O
transient	99 9 O
evoked	109 6 O
otoacoustic	116 11 O
emissions	128 9 O
in	138 2 O
newborns	141 8 O
?	149 1 O

OBJECTIVE	151 9 O
:	160 1 O
Maternal	162 8 O
tobacco	171 7 O
smoking	179 7 B-Chemical
has	187 3 O
negative	191 8 O
effects	200 7 O
on	208 2 O
fetal	211 5 O
growth	217 6 O
.	223 1 O

The	225 3 O
influence	229 9 O
of	239 2 O
smoking	242 7 B-Chemical
during	250 6 O
pregnancy	257 9 O
on	267 2 O
the	270 3 O
developing	274 10 O
cochlea	285 7 O
has	293 3 O
not	297 3 O
been	301 4 O
estimated	306 9 O
,	315 1 O
although	317 8 O
smoking	326 7 B-Chemical
has	334 3 O
been	338 4 O
positively	343 10 O
associated	354 10 O
with	365 4 O
hearing	370 7 B-Disease
loss	378 4 I-Disease
in	383 2 O
adults	386 6 O
.	392 1 O

The	394 3 O
objective	398 9 O
of	408 2 O
this	411 4 O
study	416 5 O
was	422 3 O
to	426 2 O
determine	429 9 O
the	439 3 O
effects	443 7 O
of	451 2 O
maternal	454 8 O
smoking	463 7 B-Chemical
on	471 2 O
transient	474 9 O
evoked	484 6 O
otoacoustic	491 11 O
emissions	503 9 O
(	513 1 O
TEOAEs	514 6 O
)	520 1 O
of	522 2 O
healthy	525 7 O
neonates	533 8 O
.	541 1 O

METHODS	543 7 O
:	550 1 O
This	552 4 O
study	557 5 O
was	563 3 O
undertaken	567 10 O
as	578 2 O
part	581 4 O
of	586 2 O
neonatal	589 8 O
screening	598 9 O
for	608 3 O
hearing	612 7 B-Disease
impairment	620 10 I-Disease
and	631 3 O
involved	635 8 O
both	644 4 O
ears	649 4 O
of	654 2 O
200	657 3 O
newborns	661 8 O
.	669 1 O

Newborns	671 8 O
whose	680 5 O
mothers	686 7 O
reported	694 8 O
smoking	703 7 B-Chemical
during	711 6 O
pregnancy	718 9 O
(	728 1 O
n	729 1 O
=	730 1 O
200	731 3 O
ears	735 4 O
)	739 1 O
were	741 4 O
compared	746 8 O
to	755 2 O
a	758 1 O
control	760 7 O
group	768 5 O
of	774 2 O
newborns	777 8 O
(	786 1 O
n	787 1 O
=	788 1 O
200	789 3 O
ears	793 4 O
)	797 1 O
,	798 1 O
whose	800 5 O
mothers	806 7 O
were	814 4 O
non	819 3 O
-	822 1 O
smokers	823 7 O
.	830 1 O

Exposure	832 8 O
to	841 2 O
tobacco	844 7 O
was	852 3 O
characterized	856 13 O
as	870 2 O
low	873 3 O
(	877 1 O
<	878 1 O
5	879 1 O
cigarettes	881 10 O
per	892 3 O
day	896 3 O
,	899 1 O
n	901 1 O
=	902 1 O
88	903 2 O
ears	906 4 O
)	910 1 O
,	911 1 O
moderate	913 8 O
(	922 1 O
5	923 1 O
<	924 1 O
or	926 2 O
=	929 1 O
cigarettes	930 10 O
per	941 3 O
day	945 3 O
<	948 1 O
10	949 2 O
,	951 1 O
n	953 1 O
=	954 1 O
76	955 2 O
)	957 1 O
or	959 2 O
high	962 4 O
(	967 1 O
>	968 1 O
or	970 2 O
=	973 1 O
10	974 2 O
cigarettes	977 10 O
per	988 3 O
day	992 3 O
,	995 1 O
n	997 1 O
=	998 1 O
36	999 2 O
)	1001 1 O
.	1002 1 O

RESULTS	1004 7 O
:	1011 1 O
In	1013 2 O
exposed	1016 7 O
neonates	1024 8 O
,	1032 1 O
TEOAEs	1034 6 O
mean	1041 4 O
response	1046 8 O
(	1055 1 O
across	1056 6 O
frequency	1063 9 O
)	1072 1 O
and	1074 3 O
mean	1078 4 O
amplitude	1083 9 O
at	1093 2 O
4000Hz	1096 6 O
was	1103 3 O
significantly	1107 13 O
lower	1121 5 O
than	1127 4 O
in	1132 2 O
non	1135 3 O
-	1138 1 O
exposed	1139 7 O
neonates	1147 8 O
.	1155 1 O

Comparisons	1157 11 O
between	1169 7 O
exposed	1177 7 O
newborns	1185 8 O
'	1193 1 O
subgroups	1195 9 O
revealed	1205 8 O
no	1214 2 O
significant	1217 11 O
differences	1229 11 O
.	1240 1 O

However	1242 7 O
,	1249 1 O
by	1251 2 O
comparing	1254 9 O
each	1264 4 O
subgroup	1269 8 O
to	1278 2 O
control	1281 7 O
group	1289 5 O
,	1294 1 O
we	1296 2 O
found	1299 5 O
statistically	1305 13 O
significant	1319 11 O
decreases	1331 9 B-Disease
of	1341 2 I-Disease
TEOAEs	1344 6 I-Disease
amplitudes	1351 10 I-Disease
at	1362 2 O
4000Hz	1365 6 O
for	1372 3 O
all	1376 3 O
three	1380 5 O
groups	1386 6 O
.	1392 1 O

Mean	1394 4 O
TEOAEs	1399 6 O
responses	1406 9 O
of	1416 2 O
highly	1419 6 O
exposed	1426 7 O
newborns	1434 8 O
were	1443 4 O
also	1448 4 O
significantly	1453 13 O
lower	1467 5 O
in	1473 2 O
comparison	1476 10 O
to	1487 2 O
our	1490 3 O
control	1494 7 O
group	1502 5 O
.	1507 1 O

CONCLUSION	1509 10 O
:	1519 1 O
In	1521 2 O
utero	1524 5 O
,	1529 1 O
exposure	1531 8 O
to	1540 2 O
tobacco	1543 7 O
smoking	1551 7 B-Chemical
seems	1559 5 O
to	1565 2 O
have	1568 4 O
a	1573 1 O
small	1575 5 O
impact	1581 6 O
on	1588 2 O
outer	1591 5 O
hair	1597 4 O
cells	1602 5 O
.	1607 1 O

These	1609 5 O
effects	1615 7 O
seem	1623 4 O
to	1628 2 O
be	1631 2 O
equally	1634 7 O
true	1642 4 O
for	1647 3 O
all	1651 3 O
exposed	1655 7 O
newborns	1663 8 O
,	1671 1 O
regardless	1673 10 O
of	1684 2 O
the	1687 3 O
degree	1691 6 O
of	1698 2 O
exposure	1701 8 O
.	1709 1 O

Further	1711 7 O
studies	1719 7 O
are	1727 3 O
needed	1731 6 O
in	1738 2 O
order	1741 5 O
to	1747 2 O
establish	1750 9 O
a	1760 1 O
potential	1762 9 O
negative	1772 8 O
effect	1781 6 O
of	1788 2 O
maternal	1791 8 O
smoking	1800 7 B-Chemical
on	1808 2 O
the	1811 3 O
neonate	1815 7 O
'	1822 1 O
s	1823 1 O
hearing	1825 7 O
acuity	1833 6 O
.	1839 1 O

Neuroinflammation	0 17 B-Disease
and	18 3 O
behavioral	22 10 B-Disease
abnormalities	33 13 I-Disease
after	47 5 O
neonatal	53 8 O
terbutaline	62 11 B-Chemical
treatment	74 9 O
in	84 2 O
rats	87 4 O
:	91 1 O
implications	93 12 O
for	106 3 O
autism	110 6 B-Disease
.	116 1 O

Autism	118 6 B-Disease
is	125 2 O
a	128 1 O
neurodevelopmental	130 18 B-Disease
disorder	149 8 I-Disease
presenting	158 10 O
before	169 6 O
3	176 1 O
years	178 5 O
of	184 2 O
age	187 3 O
with	191 4 O
deficits	196 8 B-Disease
in	205 2 I-Disease
communication	208 13 I-Disease
and	222 3 I-Disease
social	226 6 I-Disease
skills	233 6 I-Disease
and	240 3 O
repetitive	244 10 B-Disease
behaviors	255 9 I-Disease
.	264 1 O

In	266 2 O
addition	269 8 O
to	278 2 O
genetic	281 7 O
influences	289 10 O
,	299 1 O
recent	301 6 O
studies	308 7 O
suggest	316 7 O
that	324 4 O
prenatal	329 8 O
drug	338 4 O
or	343 2 O
chemical	346 8 O
exposures	355 9 O
are	365 3 O
risk	369 4 O
factors	374 7 O
for	382 3 O
autism	386 6 B-Disease
.	392 1 O

Terbutaline	394 11 B-Chemical
,	405 1 O
a	407 1 O
beta2	409 5 O
-	414 1 O
adrenoceptor	415 12 O
agonist	428 7 O
used	436 4 O
to	441 2 O
arrest	444 6 O
preterm	451 7 B-Disease
labor	459 5 I-Disease
,	464 1 O
has	466 3 O
been	470 4 O
associated	475 10 O
with	486 4 O
increased	491 9 O
concordance	501 11 O
for	513 3 O
autism	517 6 B-Disease
in	524 2 O
dizygotic	527 9 O
twins	537 5 O
.	542 1 O

We	544 2 O
studied	547 7 O
the	555 3 O
effects	559 7 O
of	567 2 O
terbutaline	570 11 B-Chemical
on	582 2 O
microglial	585 10 O
activation	596 10 O
in	607 2 O
different	610 9 O
brain	620 5 O
regions	626 7 O
and	634 3 O
behavioral	638 10 O
outcomes	649 8 O
in	658 2 O
developing	661 10 O
rats	672 4 O
.	676 1 O

Newborn	678 7 O
rats	686 4 O
were	691 4 O
given	696 5 O
terbutaline	702 11 B-Chemical
(	714 1 O
10	715 2 O
mg	718 2 O
/	720 1 O
kg	721 2 O
)	723 1 O
daily	725 5 O
on	731 2 O
postnatal	734 9 O
days	744 4 O
(	749 1 O
PN	750 2 O
)	752 1 O
2	754 1 O
to	756 2 O
5	759 1 O
or	761 2 O
PN	764 2 O
11	767 2 O
to	770 2 O
14	773 2 O
and	776 3 O
examined	780 8 O
24	789 2 O
h	792 1 O
after	794 5 O
the	800 3 O
last	804 4 O
dose	809 4 O
and	814 3 O
at	818 2 O
PN	821 2 O
30	824 2 O
.	826 1 O

Immunohistochemical	828 19 O
studies	848 7 O
showed	856 6 O
that	863 4 O
administration	868 14 O
of	883 2 O
terbutaline	886 11 B-Chemical
on	898 2 O
PN	901 2 O
2	904 1 O
to	906 2 O
5	909 1 O
produced	911 8 O
a	920 1 O
robust	922 6 O
increase	929 8 O
in	938 2 O
microglial	941 10 O
activation	952 10 O
on	963 2 O
PN	966 2 O
30	969 2 O
in	972 2 O
the	975 3 O
cerebral	979 8 O
cortex	988 6 O
,	994 1 O
as	996 2 O
well	999 4 O
as	1004 2 O
in	1007 2 O
cerebellar	1010 10 O
and	1021 3 O
cerebrocortical	1025 15 O
white	1041 5 O
matter	1047 6 O
.	1053 1 O

None	1055 4 O
of	1060 2 O
these	1063 5 O
effects	1069 7 O
occurred	1077 8 O
in	1086 2 O
animals	1089 7 O
given	1097 5 O
terbutaline	1103 11 B-Chemical
on	1115 2 O
PN	1118 2 O
11	1121 2 O
to	1124 2 O
14	1127 2 O
.	1129 1 O

In	1131 2 O
behavioral	1134 10 O
tests	1145 5 O
,	1150 1 O
animals	1152 7 O
treated	1160 7 O
with	1168 4 O
terbutaline	1173 11 B-Chemical
on	1185 2 O
PN	1188 2 O
2	1191 1 O
to	1193 2 O
5	1196 1 O
showed	1198 6 O
consistent	1205 10 O
patterns	1216 8 O
of	1225 2 O
hyper	1228 5 O
-	1233 1 O
reactivity	1234 10 O
to	1245 2 O
novelty	1248 7 O
and	1256 3 O
aversive	1260 8 O
stimuli	1269 7 O
when	1277 4 O
assessed	1282 8 O
in	1291 2 O
a	1294 1 O
novel	1296 5 O
open	1302 4 O
field	1307 5 O
,	1312 1 O
as	1314 2 O
well	1317 4 O
as	1322 2 O
in	1325 2 O
the	1328 3 O
acoustic	1332 8 O
startle	1341 7 O
response	1349 8 O
test	1358 4 O
.	1362 1 O

Our	1364 3 O
findings	1368 8 O
indicate	1377 8 O
that	1386 4 O
beta2	1391 5 O
-	1396 1 O
adrenoceptor	1397 12 O
overstimulation	1410 15 O
during	1426 6 O
an	1433 2 O
early	1436 5 O
critical	1442 8 O
period	1451 6 O
results	1458 7 O
in	1466 2 O
microglial	1469 10 O
activation	1480 10 O
associated	1491 10 O
with	1502 4 O
innate	1507 6 O
neuroinflammatory	1514 17 O
pathways	1532 8 O
and	1541 3 O
behavioral	1545 10 B-Disease
abnormalities	1556 13 I-Disease
,	1569 1 O
similar	1571 7 O
to	1579 2 O
those	1582 5 O
described	1588 9 O
in	1598 2 O
autism	1601 6 B-Disease
.	1607 1 O

This	1609 4 O
study	1614 5 O
provides	1620 8 O
a	1629 1 O
useful	1631 6 O
animal	1638 6 O
model	1645 5 O
for	1651 3 O
understanding	1655 13 O
the	1669 3 O
neuropathological	1673 17 O
processes	1691 9 O
underlying	1701 10 O
autism	1712 6 B-Disease
spectrum	1719 8 I-Disease
disorders	1728 9 I-Disease
.	1737 1 O

Acute	0 5 O
myocarditis	6 11 B-Disease
associated	18 10 O
with	29 4 O
clozapine	34 9 B-Chemical
.	43 1 O

OBJECTIVE	45 9 O
:	54 1 O
A	56 1 O
case	58 4 O
of	63 2 O
acute	66 5 O
myocarditis	72 11 B-Disease
associated	84 10 O
with	95 4 O
the	100 3 O
commencement	104 12 O
of	117 2 O
clozapine	120 9 B-Chemical
is	130 2 O
described	133 9 O
,	142 1 O
highlighting	144 12 O
the	157 3 O
onset	161 5 O
,	166 1 O
course	168 6 O
and	175 3 O
possible	179 8 O
contributing	188 12 O
factors	201 7 O
.	208 1 O

There	210 5 O
is	216 2 O
an	219 2 O
urgent	222 6 O
need	229 4 O
to	234 2 O
raise	237 5 O
awareness	243 9 O
about	253 5 O
this	259 4 O
potentially	264 11 O
fatal	276 5 O
complication	282 12 O
of	295 2 O
clozapine	298 9 B-Chemical
use	308 3 O
.	311 1 O

RESULTS	313 7 O
:	320 1 O
A	322 1 O
20	324 2 O
-	326 1 O
year	327 4 O
-	331 1 O
old	332 3 O
male	336 4 O
with	341 4 O
schizophrenia	346 13 B-Disease
developed	360 9 O
a	370 1 O
sudden	372 6 O
onset	379 5 O
of	385 2 O
myocarditis	388 11 B-Disease
after	400 5 O
commencement	406 12 O
of	419 2 O
clozapine	422 9 B-Chemical
.	431 1 O

The	433 3 O
patient	437 7 O
recovered	445 9 O
with	455 4 O
intensive	460 9 O
medical	470 7 O
support	478 7 O
.	485 1 O

The	487 3 O
symptoms	491 8 O
occurred	500 8 O
around	509 6 O
2	516 1 O
weeks	518 5 O
after	524 5 O
starting	530 8 O
clozapine	539 9 B-Chemical
in	549 2 O
an	552 2 O
inpatient	555 9 O
setting	565 7 O
.	572 1 O

Possible	574 8 O
contributing	583 12 O
factors	596 7 O
may	604 3 O
have	608 4 O
been	613 4 O
concomitant	618 11 O
antidepressant	630 14 B-Chemical
use	645 3 O
and	649 3 O
unaccustomed	653 12 O
physical	666 8 O
activity	675 8 O
.	683 1 O

CONCLUSIONS	685 11 O
:	696 1 O
Myocarditis	698 11 B-Disease
is	710 2 O
an	713 2 O
increasingly	716 12 O
recognized	729 10 O
complication	740 12 O
associated	753 10 O
with	764 4 O
the	769 3 O
use	773 3 O
of	777 2 O
clozapine	780 9 B-Chemical
.	789 1 O

It	791 2 O
can	794 3 O
be	798 2 O
fatal	801 5 O
if	807 2 O
not	810 3 O
recognized	814 10 O
and	825 3 O
treated	829 7 O
early	837 5 O
.	842 1 O

Considering	844 11 O
that	856 4 O
clozapine	861 9 B-Chemical
remains	871 7 O
the	879 3 O
gold	883 4 O
standard	888 8 O
in	897 2 O
treatment	900 9 O
of	910 2 O
resistant	913 9 O
psychosis	923 9 B-Disease
,	932 1 O
there	934 5 O
is	940 2 O
an	943 2 O
urgent	946 6 O
need	953 4 O
to	958 2 O
raise	961 5 O
awareness	967 9 O
among	977 5 O
medical	983 7 O
and	991 3 O
paramedical	995 11 O
staff	1007 5 O
involved	1013 8 O
in	1022 2 O
the	1025 3 O
care	1029 4 O
of	1034 2 O
these	1037 5 O
patients	1043 8 O
.	1051 1 O

There	1053 5 O
are	1059 3 O
also	1063 4 O
implications	1068 12 O
for	1081 3 O
recommendations	1085 15 O
and	1101 3 O
regulations	1105 11 O
regarding	1117 9 O
the	1127 3 O
use	1131 3 O
of	1135 2 O
clozapine	1138 9 B-Chemical
.	1147 1 O

Encephalopathy	0 14 B-Disease
induced	15 7 O
by	23 2 O
levetiracetam	26 13 B-Chemical
added	40 5 O
to	46 2 O
valproate	49 9 B-Chemical
.	58 1 O

BACKGROUND	60 10 O
:	70 1 O
We	72 2 O
report	75 6 O
on	82 2 O
the	85 3 O
manifestation	89 13 O
of	103 2 O
a	106 1 O
levetiracetam	108 13 B-Chemical
(	122 1 O
LEV	123 3 B-Chemical
)	126 1 O
-	127 1 O
induced	128 7 O
encephalopathy	136 14 B-Disease
.	150 1 O

FINDINGS	152 8 O
:	160 1 O
A	162 1 O
28	164 2 O
-	166 1 O
year	167 4 O
-	171 1 O
old	172 3 O
man	176 3 O
suffering	180 9 O
from	190 4 O
idiopathic	195 10 B-Disease
epilepsy	206 8 I-Disease
with	215 4 O
generalized	220 11 O
seizures	232 8 B-Disease
was	241 3 O
treated	245 7 O
with	253 4 O
LEV	258 3 B-Chemical
(	262 1 O
3000	263 4 O
mg	268 2 O
)	270 1 O
added	272 5 O
to	278 2 O
valproate	281 9 B-Chemical
(	291 1 O
VPA	292 3 B-Chemical
)	295 1 O
(	297 1 O
2000	298 4 O
mg	303 2 O
)	305 1 O
.	306 1 O

Frequency	308 9 O
of	318 2 O
generalized	321 11 O
tonic	333 5 B-Disease
-	338 1 I-Disease
clonic	339 6 I-Disease
seizures	346 8 I-Disease
increased	355 9 O
from	365 4 O
one	370 3 O
per	374 3 O
6	378 1 O
months	380 6 O
to	387 2 O
two	390 3 O
per	394 3 O
month	398 5 O
.	403 1 O

Neuropsychological	405 18 O
testing	424 7 O
showed	432 6 O
impaired	439 8 B-Disease
word	448 4 I-Disease
fluency	453 7 I-Disease
,	460 1 I-Disease
psychomotor	462 11 I-Disease
speed	474 5 I-Disease
and	480 3 I-Disease
working	484 7 I-Disease
memory	492 6 I-Disease
.	498 1 O

The	500 3 O
interictal	504 10 O
electroencephalogram	515 20 O
(	536 1 O
EEG	537 3 O
)	540 1 O
showed	542 6 O
a	549 1 O
generalized	551 11 O
slowing	563 7 O
to	571 2 O
5	574 1 O
per	576 3 O
second	580 6 O
theta	587 5 O
rhythms	593 7 O
with	601 4 O
bilateral	606 9 O
generalized	616 11 O
high	628 4 O
-	632 1 O
amplitude	633 9 O
discharges	643 10 O
.	653 1 O

OUTCOME	655 7 O
:	662 1 O
Following	664 9 O
discontinuation	674 15 O
of	690 2 O
LEV	693 3 B-Chemical
,	696 1 O
EEG	698 3 O
and	702 3 O
neuropsychological	706 18 O
findings	725 8 O
improved	734 8 O
and	743 3 O
seizure	747 7 B-Disease
frequency	755 9 O
decreased	765 9 O
.	774 1 O

Norepinephrine	0 14 B-Chemical
signaling	15 9 O
through	25 7 O
beta	33 4 O
-	37 1 O
adrenergic	38 10 O
receptors	49 9 O
is	59 2 O
critical	62 8 O
for	71 3 O
expression	75 10 O
of	86 2 O
cocaine	89 7 B-Chemical
-	96 1 O
induced	97 7 O
anxiety	105 7 B-Disease
.	112 1 O

BACKGROUND	114 10 O
:	124 1 O
Cocaine	126 7 B-Chemical
is	134 2 O
a	137 1 O
widely	139 6 O
abused	146 6 O
psychostimulant	153 15 O
that	169 4 O
has	174 3 O
both	178 4 O
rewarding	183 9 O
and	193 3 O
aversive	197 8 O
properties	206 10 O
.	216 1 O

While	218 5 O
the	224 3 O
mechanisms	228 10 O
underlying	239 10 O
cocaine	250 7 B-Chemical
'	257 1 O
s	258 1 O
rewarding	260 9 O
effects	270 7 O
have	278 4 O
been	283 4 O
studied	288 7 O
extensively	296 11 O
,	307 1 O
less	309 4 O
attention	314 9 O
has	324 3 O
been	328 4 O
paid	333 4 O
to	338 2 O
the	341 3 O
unpleasant	345 10 O
behavioral	356 10 O
states	367 6 O
induced	374 7 O
by	382 2 O
cocaine	385 7 B-Chemical
,	392 1 O
such	394 4 O
as	399 2 O
anxiety	402 7 B-Disease
.	409 1 O

METHODS	411 7 O
:	418 1 O
In	420 2 O
this	423 4 O
study	428 5 O
,	433 1 O
we	435 2 O
evaluated	438 9 O
the	448 3 O
performance	452 11 O
of	464 2 O
dopamine	467 8 B-Chemical
beta	476 4 O
-	480 1 O
hydroxylase	481 11 O
knockout	493 8 O
(	502 1 O
Dbh	503 3 O
-	507 1 O
/	508 1 O
-	509 1 O
)	510 1 O
mice	512 4 O
,	516 1 O
which	518 5 O
lack	524 4 O
norepinephrine	529 14 B-Chemical
(	544 1 O
NE	545 2 B-Chemical
)	547 1 O
,	548 1 O
in	550 2 O
the	553 3 O
elevated	557 8 O
plus	566 4 O
maze	571 4 O
(	576 1 O
EPM	577 3 O
)	580 1 O
to	582 2 O
examine	585 7 O
the	593 3 O
contribution	597 12 O
of	610 2 O
noradrenergic	613 13 O
signaling	627 9 O
to	637 2 O
cocaine	640 7 B-Chemical
-	647 1 O
induced	648 7 O
anxiety	656 7 B-Disease
.	663 1 O

RESULTS	665 7 O
:	672 1 O
We	674 2 O
found	677 5 O
that	683 4 O
cocaine	688 7 B-Chemical
dose	696 4 O
-	700 1 O
dependently	701 11 O
increased	713 9 O
anxiety	723 7 B-Disease
-	730 1 O
like	731 4 O
behavior	736 8 O
in	745 2 O
control	748 7 O
(	756 1 O
Dbh	757 3 O
+	761 1 O
/	762 1 O
-	763 1 O
)	764 1 O
mice	766 4 O
,	770 1 O
as	772 2 O
measured	775 8 O
by	784 2 O
a	787 1 O
decrease	789 8 O
in	798 2 O
open	801 4 O
arm	806 3 O
exploration	810 11 O
.	821 1 O

The	823 3 O
Dbh	827 3 O
-	831 1 O
/	832 1 O
-	833 1 O
mice	835 4 O
had	840 3 O
normal	844 6 O
baseline	851 8 O
performance	860 11 O
in	872 2 O
the	875 3 O
EPM	879 3 O
but	883 3 O
were	887 4 O
completely	892 10 O
resistant	903 9 O
to	913 2 O
the	916 3 O
anxiogenic	920 10 O
effects	931 7 O
of	939 2 O
cocaine	942 7 B-Chemical
.	949 1 O

Cocaine	951 7 B-Chemical
-	958 1 O
induced	959 7 O
anxiety	967 7 B-Disease
was	975 3 O
also	979 4 O
attenuated	984 10 O
in	995 2 O
Dbh	998 3 O
+	1002 1 O
/	1003 1 O
-	1004 1 O
mice	1006 4 O
following	1011 9 O
administration	1021 14 O
of	1036 2 O
disulfiram	1039 10 B-Chemical
,	1049 1 O
a	1051 1 O
dopamine	1053 8 B-Chemical
beta	1062 4 O
-	1066 1 O
hydroxylase	1067 11 O
(	1079 1 O
DBH	1080 3 O
)	1083 1 O
inhibitor	1085 9 O
.	1094 1 O

In	1096 2 O
experiments	1099 11 O
using	1111 5 O
specific	1117 8 O
adrenergic	1126 10 O
antagonists	1137 11 O
,	1148 1 O
we	1150 2 O
found	1153 5 O
that	1159 4 O
pretreatment	1164 12 O
with	1177 4 O
the	1182 3 O
beta	1186 4 O
-	1190 1 O
adrenergic	1191 10 O
receptor	1202 8 O
antagonist	1211 10 O
propranolol	1222 11 B-Chemical
blocked	1234 7 O
cocaine	1242 7 B-Chemical
-	1249 1 O
induced	1250 7 O
anxiety	1258 7 B-Disease
-	1265 1 O
like	1266 4 O
behavior	1271 8 O
in	1280 2 O
Dbh	1283 3 O
+	1287 1 O
/	1288 1 O
-	1289 1 O
and	1291 3 O
wild	1295 4 O
-	1299 1 O
type	1300 4 O
C57BL6	1305 6 O
/	1311 1 O
J	1312 1 O
mice	1314 4 O
,	1318 1 O
while	1320 5 O
the	1326 3 O
alpha	1330 5 O
(	1335 1 O
1	1336 1 O
)	1337 1 O
antagonist	1339 10 O
prazosin	1350 8 B-Chemical
and	1359 3 O
the	1363 3 O
alpha	1367 5 O
(	1372 1 O
2	1373 1 O
)	1374 1 O
antagonist	1376 10 O
yohimbine	1387 9 B-Chemical
had	1397 3 O
no	1401 2 O
effect	1404 6 O
.	1410 1 O

CONCLUSIONS	1412 11 O
:	1423 1 O
These	1425 5 O
results	1431 7 O
indicate	1439 8 O
that	1448 4 O
noradrenergic	1453 13 O
signaling	1467 9 O
via	1477 3 O
beta	1481 4 O
-	1485 1 O
adrenergic	1486 10 O
receptors	1497 9 O
is	1507 2 O
required	1510 8 O
for	1519 3 O
cocaine	1523 7 B-Chemical
-	1530 1 O
induced	1531 7 O
anxiety	1539 7 B-Disease
in	1547 2 O
mice	1550 4 O
.	1554 1 O

Clonidine	0 9 B-Chemical
for	10 3 O
attention	14 9 B-Disease
-	23 1 I-Disease
deficit	24 7 I-Disease
/	31 1 I-Disease
hyperactivity	32 13 I-Disease
disorder	46 8 I-Disease
:	54 1 O
II	56 2 O
.	58 1 O

ECG	60 3 O
changes	64 7 O
and	72 3 O
adverse	76 7 O
events	84 6 O
analysis	91 8 O
.	99 1 O

OBJECTIVE	101 9 O
:	110 1 O
To	112 2 O
examine	115 7 O
the	123 3 O
safety	127 6 O
and	134 3 O
tolerability	138 12 O
of	151 2 O
clonidine	154 9 B-Chemical
used	164 4 O
alone	169 5 O
or	175 2 O
with	178 4 O
methylphenidate	183 15 B-Chemical
in	199 2 O
children	202 8 O
with	211 4 O
attention	216 9 B-Disease
-	225 1 I-Disease
deficit	226 7 I-Disease
/	233 1 I-Disease
hyperactivity	234 13 I-Disease
disorder	248 8 I-Disease
(	257 1 O
ADHD	258 4 B-Disease
)	262 1 O
.	263 1 O

METHOD	265 6 O
:	271 1 O
In	273 2 O
a	276 1 O
16	278 2 O
-	280 1 O
week	281 4 O
multicenter	286 11 O
,	297 1 O
double	299 6 O
-	305 1 O
blind	306 5 O
trial	312 5 O
,	317 1 O
122	319 3 O
children	323 8 O
with	332 4 O
ADHD	337 4 B-Disease
were	342 4 O
randomly	347 8 O
assigned	356 8 O
to	365 2 O
clonidine	368 9 B-Chemical
(	378 1 O
n	379 1 O
=	381 1 O
31	383 2 O
)	385 1 O
,	386 1 O
methylphenidate	388 15 B-Chemical
(	404 1 O
n	405 1 O
=	407 1 O
29	409 2 O
)	411 1 O
,	412 1 O
clonidine	414 9 B-Chemical
and	424 3 O
methylphenidate	428 15 B-Chemical
(	444 1 O
n	445 1 O
=	447 1 O
32	449 2 O
)	451 1 O
,	452 1 O
or	454 2 O
placebo	457 7 O
(	465 1 O
n	466 1 O
=	468 1 O
30	470 2 O
)	472 1 O
.	473 1 O

Doses	475 5 O
were	481 4 O
flexibly	486 8 O
titrated	495 8 O
up	504 2 O
to	507 2 O
0	510 1 O
.	511 1 O
6	512 1 O
mg	514 2 O
/	516 1 O
day	517 3 O
for	521 3 O
clonidine	525 9 B-Chemical
and	535 3 O
60	539 2 O
mg	542 2 O
/	544 1 O
day	545 3 O
for	549 3 O
methylphenidate	553 15 B-Chemical
(	569 1 O
both	570 4 O
with	575 4 O
divided	580 7 O
dosing	588 6 O
)	594 1 O
.	595 1 O

Groups	597 6 O
were	604 4 O
compared	609 8 O
regarding	618 9 O
adverse	628 7 O
events	636 6 O
and	643 3 O
changes	647 7 O
from	655 4 O
baseline	660 8 O
to	669 2 O
week	672 4 O
16	677 2 O
in	680 2 O
electrocardiograms	683 18 O
and	702 3 O
vital	706 5 O
signs	712 5 O
.	717 1 O

RESULTS	719 7 O
:	726 1 O
There	728 5 O
were	734 4 O
more	739 4 O
incidents	744 9 O
of	754 2 O
bradycardia	757 11 B-Disease
in	769 2 O
subjects	772 8 O
treated	781 7 O
with	789 4 O
clonidine	794 9 B-Chemical
compared	804 8 O
with	813 4 O
those	818 5 O
not	824 3 O
treated	828 7 O
with	836 4 O
clonidine	841 9 B-Chemical
(	851 1 O
17	852 2 O
.	854 1 O
5	855 1 O
%	856 1 O
versus	858 6 O
3	865 1 O
.	866 1 O
4	867 1 O
%	868 1 O
;	869 1 O
p	871 1 O
=	873 1 O
.	874 1 O
02	875 2 O
)	877 1 O
,	878 1 O
but	880 3 O
no	884 2 O
other	887 5 O
significant	893 11 O
group	905 5 O
differences	911 11 O
regarding	923 9 O
electrocardiogram	933 17 O
and	951 3 O
other	955 5 O
cardiovascular	961 14 O
outcomes	976 8 O
.	984 1 O

There	986 5 O
were	992 4 O
no	997 2 O
suggestions	1000 11 O
of	1012 2 O
interactions	1015 12 O
between	1028 7 O
clonidine	1036 9 B-Chemical
and	1046 3 O
methylphenidate	1050 15 B-Chemical
regarding	1066 9 O
cardiovascular	1076 14 O
outcomes	1091 8 O
.	1099 1 O

Moderate	1101 8 O
or	1110 2 O
severe	1113 6 O
adverse	1120 7 O
events	1128 6 O
were	1135 4 O
more	1140 4 O
common	1145 6 O
in	1152 2 O
subjects	1155 8 O
on	1164 2 O
clonidine	1167 9 B-Chemical
(	1177 1 O
79	1178 2 O
.	1180 1 O
4	1181 1 O
%	1182 1 O
versus	1184 6 O
49	1191 2 O
.	1193 1 O
2	1194 1 O
%	1195 1 O
;	1196 1 O
p	1198 1 O
=	1200 1 O
.	1201 1 O
0006	1202 4 O
)	1206 1 O
but	1208 3 O
not	1212 3 O
associated	1216 10 O
with	1227 4 O
higher	1232 6 O
rates	1239 5 O
of	1245 2 O
early	1248 5 O
study	1254 5 O
withdrawal	1260 10 O
.	1270 1 O

Drowsiness	1272 10 B-Disease
was	1283 3 O
common	1287 6 O
on	1294 2 O
clonidine	1297 9 B-Chemical
,	1306 1 O
but	1308 3 O
generally	1312 9 O
resolved	1322 8 O
by	1331 2 O
6	1334 1 O
to	1336 2 O
8	1339 1 O
weeks	1341 5 O
.	1346 1 O

CONCLUSIONS	1348 11 O
:	1359 1 O
Clonidine	1361 9 B-Chemical
,	1370 1 O
used	1372 4 O
alone	1377 5 O
or	1383 2 O
with	1386 4 O
methylphenidate	1391 15 B-Chemical
,	1406 1 O
appears	1408 7 O
safe	1416 4 O
and	1421 3 O
well	1425 4 O
tolerated	1430 9 O
in	1440 2 O
childhood	1443 9 O
ADHD	1453 4 B-Disease
.	1457 1 O

Physicians	1459 10 O
prescribing	1470 11 O
clonidine	1482 9 B-Chemical
should	1492 6 O
monitor	1499 7 O
for	1507 3 O
bradycardia	1511 11 B-Disease
and	1523 3 O
advise	1527 6 O
patients	1534 8 O
about	1543 5 O
the	1549 3 O
high	1553 4 O
likelihood	1558 10 O
of	1569 2 O
initial	1572 7 O
drowsiness	1580 10 B-Disease
.	1590 1 O

Thalidomide	0 11 B-Chemical
has	12 3 O
limited	16 7 O
single	24 6 O
-	30 1 O
agent	31 5 O
activity	37 8 O
in	46 2 O
relapsed	49 8 O
or	58 2 O
refractory	61 10 O
indolent	72 8 O
non	81 3 B-Disease
-	84 1 I-Disease
Hodgkin	85 7 I-Disease
lymphomas	93 9 I-Disease
:	102 1 O
a	104 1 O
phase	106 5 O
II	112 2 O
trial	115 5 O
of	121 2 O
the	124 3 O
Cancer	128 6 B-Disease
and	135 3 O
Leukemia	139 8 B-Disease
Group	148 5 O
B	154 1 O
.	155 1 O

Thalidomide	157 11 B-Chemical
is	169 2 O
an	172 2 O
immunomodulatory	175 16 O
agent	192 5 O
with	198 4 O
demonstrated	203 12 O
activity	216 8 O
in	225 2 O
multiple	228 8 B-Disease
myeloma	237 7 I-Disease
,	244 1 O
mantle	246 6 B-Disease
cell	253 4 I-Disease
lymphoma	258 8 I-Disease
and	267 3 O
lymphoplasmacytic	271 17 B-Disease
lymphoma	289 8 I-Disease
.	297 1 O

Its	299 3 O
activity	303 8 O
is	312 2 O
believed	315 8 O
to	324 2 O
be	327 2 O
due	330 3 O
modulation	334 10 O
of	345 2 O
the	348 3 O
tumour	352 6 B-Disease
milieu	359 6 O
,	365 1 O
including	367 9 O
downregulation	377 14 O
of	392 2 O
angiogenesis	395 12 O
and	408 3 O
inflammatory	412 12 O
cytokines	425 9 O
.	434 1 O

Between	436 7 O
July	444 4 O
2001	449 4 O
and	454 3 O
April	458 5 O
2004	464 4 O
,	468 1 O
24	470 2 O
patients	473 8 O
with	482 4 O
relapsed	487 8 O
/	495 1 O
refractory	496 10 O
indolent	507 8 O
lymphomas	516 9 B-Disease
received	526 8 O
thalidomide	535 11 B-Chemical
200	547 3 O
mg	551 2 O
daily	554 5 O
with	560 4 O
escalation	565 10 O
by	576 2 O
100	579 3 O
mg	583 2 O
daily	586 5 O
every	592 5 O
1	598 1 O
-	599 1 O
2	600 1 O
weeks	602 5 O
as	608 2 O
tolerated	611 9 O
,	620 1 O
up	622 2 O
to	625 2 O
a	628 1 O
maximum	630 7 O
of	638 2 O
800	641 3 O
mg	645 2 O
daily	648 5 O
.	653 1 O

Patients	655 8 O
had	664 3 O
received	668 8 O
a	677 1 O
median	679 6 O
of	686 2 O
2	689 1 O
(	691 1 O
range	692 5 O
,	697 1 O
1	699 1 O
-	700 1 O
4	701 1 O
)	702 1 O
prior	704 5 O
regimens	710 8 O
.	718 1 O

Of	720 2 O
24	723 2 O
evaluable	726 9 O
patients	736 8 O
,	744 1 O
two	746 3 O
achieved	750 8 O
a	759 1 O
complete	761 8 O
remission	770 9 O
and	780 3 O
one	784 3 O
achieved	788 8 O
a	797 1 O
partial	799 7 O
remission	807 9 O
for	817 3 O
an	821 2 O
overall	824 7 O
response	832 8 O
rate	841 4 O
of	846 2 O
12	849 2 O
.	851 1 O
5	852 1 O
%	853 1 O
(	855 1 O
95	856 2 O
%	858 1 O
confidence	860 10 O
interval	871 8 O
:	879 1 O
2	881 1 O
.	882 1 O
6	883 1 O
-	884 1 O
32	885 2 O
.	887 1 O
4	888 1 O
%	889 1 O
)	890 1 O
.	891 1 O

Eleven	893 6 O
patients	900 8 O
progressed	909 10 O
during	920 6 O
therapy	927 7 O
.	934 1 O

Grade	936 5 O
3	942 1 O
-	943 1 O
4	944 1 O
adverse	946 7 O
effects	954 7 O
included	962 8 O
myelosuppression	971 16 B-Disease
,	987 1 O
fatigue	989 7 B-Disease
,	996 1 O
somnolence	998 10 B-Disease
/	1008 1 O
depressed	1009 9 B-Disease
mood	1019 4 I-Disease
,	1023 1 O
neuropathy	1025 10 B-Disease
and	1036 3 O
dyspnea	1040 7 B-Disease
.	1047 1 O

Of	1049 2 O
concern	1052 7 O
was	1060 3 O
the	1064 3 O
occurrence	1068 10 O
of	1079 2 O
four	1082 4 O
thromboembolic	1087 14 B-Disease
events	1102 6 O
.	1108 1 O

Our	1110 3 O
results	1114 7 O
failed	1122 6 O
to	1129 2 O
demonstrate	1132 11 O
an	1144 2 O
important	1147 9 O
response	1157 8 O
rate	1166 4 O
to	1171 2 O
single	1174 6 O
agent	1181 5 O
thalidomide	1187 11 B-Chemical
in	1199 2 O
indolent	1202 8 O
lymphomas	1211 9 B-Disease
and	1221 3 O
contrast	1225 8 O
with	1234 4 O
the	1239 3 O
higher	1243 6 O
activity	1250 8 O
level	1259 5 O
reported	1265 8 O
with	1274 4 O
the	1279 3 O
second	1283 6 O
generation	1290 10 O
immunomodulatory	1301 16 O
agent	1318 5 O
,	1323 1 O
lenalidomide	1325 12 B-Chemical
.	1337 1 O

Intracavernous	0 14 O
epinephrine	15 11 B-Chemical
:	26 1 O
a	28 1 O
minimally	30 9 O
invasive	40 8 O
treatment	49 9 O
for	59 3 O
priapism	63 8 B-Disease
in	72 2 O
the	75 3 O
emergency	79 9 O
department	89 10 O
.	99 1 O

Priapism	101 8 B-Disease
is	110 2 O
the	113 3 O
prolonged	117 9 O
erection	127 8 O
of	136 2 O
the	139 3 O
penis	143 5 O
in	149 2 O
the	152 3 O
absence	156 7 O
of	164 2 O
sexual	167 6 O
arousal	174 7 O
.	181 1 O

A	183 1 O
45	185 2 O
-	187 1 O
year	188 4 O
-	192 1 O
old	193 3 O
man	197 3 O
,	200 1 O
an	202 2 O
admitted	205 8 O
frequent	214 8 O
cocaine	223 7 B-Chemical
user	231 4 O
,	235 1 O
presented	237 9 O
to	247 2 O
the	250 3 O
Emergency	254 9 O
Department	264 10 O
(	275 1 O
ED	276 2 O
)	278 1 O
on	280 2 O
two	283 3 O
separate	287 8 O
occasions	296 9 O
with	306 4 O
a	311 1 O
history	313 7 O
of	321 2 O
priapism	324 8 B-Disease
after	333 5 O
cocaine	339 7 B-Chemical
use	347 3 O
.	350 1 O

The	352 3 O
management	356 10 O
options	367 7 O
in	375 2 O
the	378 3 O
ED	382 2 O
,	384 1 O
as	386 2 O
exemplified	389 11 O
by	401 2 O
four	404 4 O
individual	409 10 O
case	420 4 O
reports	425 7 O
,	432 1 O
in	434 2 O
particular	437 10 O
the	448 3 O
use	452 3 O
of	456 2 O
a	459 1 O
minimally	461 9 O
invasive	471 8 O
method	480 6 O
of	487 2 O
intracorporal	490 13 O
epinephrine	504 11 B-Chemical
instillation	516 12 O
,	528 1 O
are	530 3 O
discussed	534 9 O
.	543 1 O

Effect	0 6 O
of	7 2 O
green	10 5 B-Chemical
tea	16 3 I-Chemical
and	20 3 O
vitamin	24 7 B-Chemical
E	32 1 I-Chemical
combination	34 11 O
in	46 2 O
isoproterenol	49 13 B-Chemical
induced	63 7 O
myocardial	71 10 B-Disease
infarction	82 10 I-Disease
in	93 2 O
rats	96 4 O
.	100 1 O

The	102 3 O
present	106 7 O
study	114 5 O
was	120 3 O
aimed	124 5 O
to	130 2 O
investigate	133 11 O
the	145 3 O
combined	149 8 O
effects	158 7 O
of	166 2 O
green	169 5 B-Chemical
tea	175 3 I-Chemical
and	179 3 O
vitamin	183 7 B-Chemical
E	191 1 I-Chemical
on	193 2 O
heart	196 5 O
weight	202 6 O
,	208 1 O
body	210 4 O
weight	215 6 O
,	221 1 O
serum	223 5 O
marker	229 6 O
enzymes	236 7 O
,	243 1 O
lipid	245 5 O
peroxidation	251 12 O
,	263 1 O
endogenous	265 10 O
antioxidants	276 12 O
and	289 3 O
membrane	293 8 O
bound	302 5 O
ATPases	308 7 O
in	316 2 O
isoproterenol	319 13 B-Chemical
(	333 1 O
ISO	334 3 B-Chemical
)	337 1 O
-	338 1 O
induced	339 7 O
myocardial	347 10 B-Disease
infarction	358 10 I-Disease
in	369 2 O
rats	372 4 O
.	376 1 O

Adult	378 5 O
male	384 4 O
albino	389 6 O
rats	396 4 O
,	400 1 O
treated	402 7 O
with	410 4 O
ISO	415 3 B-Chemical
(	419 1 O
200	420 3 O
mg	424 2 O
/	426 1 O
kg	427 2 O
,	429 1 O
s	431 1 O
.	432 1 O
c	433 1 O
.	434 1 O
)	435 1 O
for	437 3 O
2	441 1 O
days	443 4 O
at	448 2 O
an	451 2 O
interval	454 8 O
of	463 2 O
24	466 2 O
h	469 1 O
caused	471 6 O
a	478 1 O
significant	480 11 O
(	492 1 O
P	493 1 O
<	494 1 O
0	495 1 O
.	496 1 O
05	497 2 O
)	499 1 O
elevation	501 9 O
of	511 2 O
heart	514 5 O
weight	520 6 O
,	526 1 O
serum	528 5 O
marker	534 6 O
enzymes	541 7 O
,	548 1 O
lipid	550 5 O
peroxidation	556 12 O
and	569 3 O
Ca	573 2 B-Chemical
+	575 1 O
2	576 1 O
ATPase	578 6 O
level	585 5 O
whereas	591 7 O
there	599 5 O
was	605 3 O
a	609 1 O
significant	611 11 O
(	623 1 O
P	624 1 O
<	625 1 O
0	626 1 O
.	627 1 O
05	628 2 O
)	630 1 O
decrease	632 8 O
in	641 2 O
body	644 4 O
weight	649 6 O
,	655 1 O
endogenous	657 10 O
antioxidants	668 12 O
,	680 1 O
Na	682 2 B-Chemical
+	684 1 O
/	685 1 O
K	687 1 B-Chemical
+	688 1 O
ATPase	690 6 O
and	697 3 O
Mg	701 2 B-Chemical
+	703 1 O
2	704 1 O
ATPase	706 6 O
levels	713 6 O
.	719 1 O

Administration	721 14 O
of	736 2 O
green	739 5 B-Chemical
tea	745 3 I-Chemical
(	749 1 O
100	750 3 O
mg	754 2 O
/	756 1 O
kg	757 2 O
/	759 1 O
day	760 3 O
,	763 1 O
p	765 1 O
.	766 1 O
o	767 1 O
.	768 1 O
)	769 1 O
and	771 3 O
vitamin	775 7 B-Chemical
E	783 1 I-Chemical
(	785 1 O
100	786 3 O
mg	790 2 O
/	792 1 O
kg	793 2 O
/	795 1 O
day	796 3 O
,	799 1 O
p	801 1 O
.	802 1 O
o	803 1 O
.	804 1 O
)	805 1 O
together	807 8 O
for	816 3 O
30	820 2 O
consecutive	823 11 O
days	835 4 O
and	840 3 O
challenged	844 10 O
with	855 4 O
ISO	860 3 B-Chemical
on	864 2 O
the	867 3 O
day	871 3 O
29th	875 4 O
and	880 3 O
30th	884 4 O
,	888 1 O
showed	890 6 O
a	897 1 O
significant	899 11 O
(	911 1 O
P	912 1 O
<	913 1 O
0	914 1 O
.	915 1 O
05	916 2 O
)	918 1 O
decrease	920 8 O
in	929 2 O
heart	932 5 O
weight	938 6 O
,	944 1 O
serum	946 5 O
marker	952 6 O
enzymes	959 7 O
,	966 1 O
lipid	968 5 O
peroxidation	974 12 O
,	986 1 O
Ca	988 2 B-Chemical
+	990 1 O
2	991 1 O
ATPase	993 6 O
and	1000 3 O
a	1004 1 O
significant	1006 11 O
increase	1018 8 O
in	1027 2 O
the	1030 3 O
body	1034 4 O
weight	1039 6 O
,	1045 1 O
endogenous	1047 10 O
antioxidants	1058 12 O
,	1070 1 O
Na	1072 2 B-Chemical
+	1074 1 O
/	1075 1 O
K	1076 1 B-Chemical
+	1077 1 O
ATPase	1079 6 O
and	1086 3 O
Mg	1090 2 B-Chemical
+	1092 1 O
2	1093 1 O
ATPase	1095 6 O
when	1102 4 O
compared	1107 8 O
with	1116 4 O
ISO	1121 3 B-Chemical
treated	1125 7 O
group	1133 5 O
and	1139 3 O
green	1143 5 B-Chemical
tea	1149 3 I-Chemical
or	1153 2 O
vitamin	1156 7 B-Chemical
E	1164 1 I-Chemical
alone	1166 5 O
treated	1172 7 O
groups	1180 6 O
.	1186 1 O

These	1188 5 O
findings	1194 8 O
indicate	1203 8 O
the	1212 3 O
synergistic	1216 11 O
protective	1228 10 O
effect	1239 6 O
of	1246 2 O
green	1249 5 B-Chemical
tea	1255 3 I-Chemical
and	1259 3 O
vitamin	1263 7 B-Chemical
E	1271 1 I-Chemical
during	1273 6 O
ISO	1280 3 B-Chemical
induced	1284 7 O
myocardial	1292 10 B-Disease
infarction	1303 10 I-Disease
in	1314 2 O
rats	1317 4 O
.	1321 1 O

Development	0 11 O
of	12 2 O
ocular	15 6 B-Disease
myasthenia	22 10 I-Disease
during	33 6 O
pegylated	40 9 B-Chemical
interferon	50 10 I-Chemical
and	61 3 O
ribavirin	65 9 B-Chemical
treatment	75 9 O
for	85 3 O
chronic	89 7 B-Disease
hepatitis	97 9 I-Disease
C	107 1 I-Disease
.	108 1 O

A	110 1 O
63	112 2 O
-	114 1 O
year	115 4 O
-	119 1 O
old	120 3 O
male	124 4 O
experienced	129 11 O
sudden	141 6 O
diplopia	148 8 B-Disease
after	157 5 O
9	163 1 O
weeks	165 5 O
of	171 2 O
administration	174 14 O
of	189 2 O
pegylated	192 9 B-Chemical
interferon	202 10 I-Chemical
(	213 1 I-Chemical
IFN	214 3 I-Chemical
)	217 1 I-Chemical
alpha	219 5 I-Chemical
-	224 1 I-Chemical
2b	225 2 I-Chemical
and	228 3 O
ribavirin	232 9 B-Chemical
for	242 3 O
chronic	246 7 B-Disease
hepatitis	254 9 I-Disease
C	264 1 I-Disease
(	266 1 O
CHC	267 3 B-Disease
)	270 1 O
.	271 1 O

Ophthalmologic	273 14 O
examinations	288 12 O
showed	301 6 O
ptosis	308 6 B-Disease
on	315 2 I-Disease
the	318 3 I-Disease
right	322 5 I-Disease
upper	328 5 I-Disease
lid	334 3 I-Disease
and	338 3 O
restricted	342 10 B-Disease
right	353 5 I-Disease
eye	359 3 I-Disease
movement	363 8 I-Disease
without	372 7 O
any	380 3 O
other	384 5 O
neurological	390 12 O
signs	403 5 O
.	408 1 O

A	410 1 O
brain	412 5 O
imaging	418 7 O
study	426 5 O
and	432 3 O
repetitive	436 10 O
nerve	447 5 O
stimulation	453 11 O
test	465 4 O
indicated	470 9 O
no	480 2 O
abnormality	483 11 O
.	494 1 O

The	496 3 O
acetylcholine	500 13 B-Chemical
receptor	514 8 O
antibody	523 8 O
titer	532 5 O
and	538 3 O
response	542 8 O
to	551 2 O
acetylcholinesterase	554 20 O
inhibitors	575 10 O
were	586 4 O
negative	591 8 O
,	599 1 O
and	601 3 O
the	605 3 O
results	609 7 O
of	617 2 O
thyroid	620 7 O
function	628 8 O
tests	637 5 O
were	643 4 O
normal	648 6 O
.	654 1 O

The	656 3 O
patient	660 7 O
'	667 1 O
s	668 1 O
ophthalmological	670 16 O
symptoms	687 8 O
improved	696 8 O
rapidly	705 7 O
3	713 1 O
weeks	715 5 O
after	721 5 O
discontinuation	727 15 O
of	743 2 O
pegylated	746 9 B-Chemical
IFN	756 3 I-Chemical
alpha	760 5 I-Chemical
-	765 1 I-Chemical
2b	766 2 I-Chemical
and	769 3 O
ribavirin	773 9 B-Chemical
.	782 1 O

The	784 3 O
ocular	788 6 B-Disease
myasthenia	795 10 I-Disease
associated	806 10 O
with	817 4 O
combination	822 11 O
therapy	834 7 O
of	842 2 O
pegylated	845 9 B-Chemical
IFN	855 3 I-Chemical
alpha	859 5 I-Chemical
-	864 1 I-Chemical
2b	865 2 I-Chemical
and	868 3 O
ribavirin	872 9 B-Chemical
for	882 3 O
CHC	886 3 B-Disease
is	890 2 O
very	893 4 O
rarely	898 6 O
reported	905 8 O
;	913 1 O
therefore	915 9 O
,	924 1 O
we	926 2 O
present	929 7 O
this	937 4 O
case	942 4 O
with	947 4 O
a	952 1 O
review	954 6 O
of	961 2 O
the	964 3 O
various	968 7 O
eye	976 3 O
complications	980 13 O
of	994 2 O
IFN	997 3 B-Chemical
therapy	1001 7 O
.	1008 1 O

The	0 3 O
glycine	4 7 B-Chemical
transporter	12 11 O
-	23 1 O
1	24 1 O
inhibitor	26 9 O
SSR103800	36 9 B-Chemical
displays	46 8 O
a	55 1 O
selective	57 9 O
and	67 3 O
specific	71 8 O
antipsychotic	80 13 O
-	93 1 O
like	94 4 O
profile	99 7 O
in	107 2 O
normal	110 6 O
and	117 3 O
transgenic	121 10 O
mice	132 4 O
.	136 1 O

Schizophrenia	138 13 B-Disease
has	152 3 O
been	156 4 O
initially	161 9 O
associated	171 10 O
with	182 4 O
dysfunction	187 11 O
in	199 2 O
dopamine	202 8 B-Chemical
neurotransmission	211 17 O
.	228 1 O

However	230 7 O
,	237 1 O
the	239 3 O
observation	243 11 O
that	255 4 O
antagonists	260 11 O
of	272 2 O
the	275 3 O
glutamate	279 9 B-Chemical
N	289 1 B-Chemical
-	290 1 I-Chemical
methyl	291 6 I-Chemical
-	297 1 I-Chemical
D	298 1 I-Chemical
-	299 1 I-Chemical
aspartate	300 9 I-Chemical
(	310 1 O
NMDA	311 4 B-Chemical
)	315 1 O
receptor	317 8 O
produce	326 7 O
schizophrenic	334 13 B-Disease
-	347 1 O
like	348 4 O
symptoms	353 8 O
in	362 2 O
humans	365 6 O
has	372 3 O
led	376 3 O
to	380 2 O
the	383 3 O
idea	387 4 O
of	392 2 O
a	395 1 O
dysfunctioning	397 14 O
of	412 2 O
the	415 3 O
glutamatergic	419 13 O
system	433 6 O
via	440 3 O
its	444 3 O
NMDA	448 4 B-Chemical
receptor	453 8 O
.	461 1 O

As	463 2 O
a	466 1 O
result	468 6 O
,	474 1 O
there	476 5 O
is	482 2 O
a	485 1 O
growing	487 7 O
interest	495 8 O
in	504 2 O
the	507 3 O
development	511 11 O
of	523 2 O
pharmacological	526 15 O
agents	542 6 O
with	549 4 O
potential	554 9 O
antipsychotic	564 13 O
properties	578 10 O
that	589 4 O
enhance	594 7 O
the	602 3 O
activity	606 8 O
of	615 2 O
the	618 3 O
glutamatergic	622 13 O
system	636 6 O
via	643 3 O
a	647 1 O
modulation	649 10 O
of	660 2 O
the	663 3 O
NMDA	667 4 B-Chemical
receptor	672 8 O
.	680 1 O

Among	682 5 O
them	688 4 O
are	693 3 O
glycine	697 7 B-Chemical
transporter	705 11 O
-	716 1 O
1	717 1 O
(	719 1 O
GlyT1	720 5 O
)	725 1 O
inhibitors	727 10 O
such	738 4 O
as	743 2 O
SSR103800	746 9 B-Chemical
,	755 1 O
which	757 5 O
indirectly	763 10 O
enhance	774 7 O
NMDA	782 4 B-Chemical
receptor	787 8 O
function	796 8 O
by	805 2 O
increasing	808 10 O
the	819 3 O
glycine	823 7 B-Chemical
(	831 1 O
a	832 1 O
co	834 2 O
-	836 1 O
agonist	837 7 O
for	845 3 O
the	849 3 O
NMDA	853 4 B-Chemical
receptor	858 8 O
)	866 1 O
levels	868 6 O
in	875 2 O
the	878 3 O
synapse	882 7 O
.	889 1 O

This	891 4 O
study	896 5 O
aimed	902 5 O
at	908 2 O
investigating	911 13 O
the	925 3 O
potential	929 9 O
antipsychotic	939 13 O
-	952 1 O
like	953 4 O
properties	958 10 O
of	969 2 O
SSR103800	972 9 B-Chemical
,	981 1 O
with	983 4 O
a	988 1 O
particular	990 10 O
focus	1001 5 O
on	1007 2 O
models	1010 6 O
of	1017 2 O
hyperactivity	1020 13 B-Disease
,	1033 1 O
involving	1035 9 O
either	1045 6 O
drug	1052 4 O
challenge	1057 9 O
(	1067 1 O
ie	1068 2 O
,	1070 1 O
amphetamine	1072 11 B-Chemical
and	1084 3 O
MK	1088 2 B-Chemical
-	1090 1 I-Chemical
801	1091 3 I-Chemical
)	1094 1 O
or	1096 2 O
transgenic	1099 10 O
mice	1110 4 O
(	1115 1 O
ie	1116 2 O
,	1118 1 O
NMDA	1120 4 B-Chemical
Nr1	1125 3 O
(	1128 1 O
neo	1129 3 O
-	1132 1 O
/	1133 1 O
-	1134 1 O
)	1135 1 O
and	1137 3 O
DAT	1141 3 O
(	1144 1 O
-	1145 1 O
/	1146 1 O
-	1147 1 O
)	1148 1 O
)	1149 1 O
.	1150 1 O

Results	1152 7 O
showed	1160 6 O
that	1167 4 O
SSR103800	1172 9 B-Chemical
(	1182 1 O
10	1183 2 O
-	1185 1 O
30	1186 2 O
mg	1189 2 O
/	1191 1 O
kg	1192 2 O
p	1195 1 O
.	1196 1 O
o	1197 1 O
.	1198 1 O
)	1199 1 O
blocked	1201 7 O
hyperactivity	1209 13 B-Disease
induced	1223 7 O
by	1231 2 O
the	1234 3 O
non	1238 3 O
-	1241 1 O
competitive	1242 11 O
NMDA	1254 4 B-Chemical
receptor	1259 8 O
antagonist	1268 10 O
,	1278 1 O
MK	1280 2 B-Chemical
-	1282 1 I-Chemical
801	1283 3 I-Chemical
and	1287 3 O
partially	1291 9 O
reversed	1301 8 O
spontaneous	1310 11 O
hyperactivity	1322 13 B-Disease
of	1336 2 O
NMDA	1339 4 B-Chemical
Nr1	1344 3 O
(	1347 1 O
neo	1348 3 O
-	1351 1 O
/	1352 1 O
-	1353 1 O
)	1354 1 O
mice	1356 4 O
.	1360 1 O

In	1362 2 O
contrast	1365 8 O
,	1373 1 O
SSR103800	1375 9 B-Chemical
failed	1385 6 O
to	1392 2 O
affect	1395 6 O
hyperactivity	1402 13 B-Disease
induced	1416 7 O
by	1424 2 O
amphetamine	1427 11 B-Chemical
or	1439 2 O
naturally	1442 9 O
observed	1452 8 O
in	1461 2 O
dopamine	1464 8 B-Chemical
transporter	1473 11 O
(	1485 1 O
DAT	1486 3 O
(	1489 1 O
-	1490 1 O
/	1491 1 O
-	1492 1 O
)	1493 1 O
)	1494 1 O
knockout	1496 8 O
mice	1505 4 O
(	1510 1 O
10	1511 2 O
-	1513 1 O
30	1514 2 O
mg	1517 2 O
/	1519 1 O
kg	1520 2 O
p	1523 1 O
.	1524 1 O
o	1525 1 O
.	1526 1 O
)	1527 1 O
.	1528 1 O

Importantly	1530 11 O
,	1541 1 O
both	1543 4 O
classical	1548 9 O
(	1558 1 O
haloperidol	1559 11 B-Chemical
)	1570 1 O
and	1572 3 O
atypical	1576 8 O
(	1585 1 O
olanzapine	1586 10 B-Chemical
,	1596 1 O
clozapine	1598 9 B-Chemical
and	1608 3 O
aripiprazole	1612 12 B-Chemical
)	1624 1 O
antipsychotics	1626 14 O
were	1641 4 O
effective	1646 9 O
in	1656 2 O
all	1659 3 O
these	1663 5 O
models	1669 6 O
of	1676 2 O
hyperactivity	1679 13 B-Disease
.	1692 1 O

However	1694 7 O
,	1701 1 O
unlike	1703 6 O
these	1710 5 O
latter	1716 6 O
,	1722 1 O
SSR103800	1724 9 B-Chemical
did	1734 3 O
not	1738 3 O
produce	1742 7 O
catalepsy	1750 9 B-Disease
(	1760 1 O
retention	1761 9 O
on	1771 2 O
the	1774 3 O
bar	1778 3 O
test	1782 4 O
)	1786 1 O
up	1788 2 O
to	1791 2 O
30	1794 2 O
mg	1797 2 O
/	1799 1 O
kg	1800 2 O
p	1803 1 O
.	1804 1 O
o	1805 1 O
.	1806 1 O

Together	1808 8 O
these	1817 5 O
findings	1823 8 O
show	1832 4 O
that	1837 4 O
the	1842 3 O
GlyT1	1846 5 O
inhibitor	1852 9 O
,	1861 1 O
SSR103800	1863 9 B-Chemical
,	1872 1 O
produces	1874 8 O
antipsychotic	1883 13 O
-	1896 1 O
like	1897 4 O
effects	1902 7 O
,	1909 1 O
which	1911 5 O
differ	1917 6 O
from	1924 4 O
those	1929 5 O
observed	1935 8 O
with	1944 4 O
compounds	1949 9 O
primarily	1959 9 O
targeting	1969 9 O
the	1979 3 O
dopaminergic	1983 12 O
system	1996 6 O
,	2002 1 O
and	2004 3 O
has	2008 3 O
a	2012 1 O
reduced	2014 7 O
side	2022 4 O
-	2026 1 O
effect	2027 6 O
potential	2034 9 O
as	2044 2 O
compared	2047 8 O
with	2056 4 O
these	2061 5 O
latter	2067 6 O
drugs	2074 5 O
.	2079 1 O

Phenylephrine	0 13 B-Chemical
but	14 3 O
not	18 3 O
ephedrine	22 9 B-Chemical
reduces	32 7 B-Disease
frontal	40 7 I-Disease
lobe	48 4 I-Disease
oxygenation	53 11 I-Disease
following	65 9 O
anesthesia	75 10 O
-	85 1 O
induced	86 7 O
hypotension	94 11 B-Disease
.	105 1 O

BACKGROUND	107 10 O
:	117 1 O
Vasopressor	119 11 O
agents	131 6 O
are	138 3 O
used	142 4 O
to	147 2 O
correct	150 7 O
anesthesia	158 10 O
-	168 1 O
induced	169 7 O
hypotension	177 11 B-Disease
.	188 1 O

We	190 2 O
describe	193 8 O
the	202 3 O
effect	206 6 O
of	213 2 O
phenylephrine	216 13 B-Chemical
and	230 3 O
ephedrine	234 9 B-Chemical
on	244 2 O
frontal	247 7 O
lobe	255 4 O
oxygenation	260 11 O
(	272 1 O
S	273 1 O
(	274 1 O
c	275 1 O
)	276 1 O
O	277 1 O
(	278 1 O
2	279 1 O
)	280 1 O
)	281 1 O
following	283 9 O
anesthesia	293 10 O
-	303 1 O
induced	304 7 O
hypotension	312 11 B-Disease
.	323 1 O

METHODS	325 7 O
:	332 1 O
Following	334 9 O
induction	344 9 O
of	354 2 O
anesthesia	357 10 O
by	368 2 O
fentanyl	371 8 B-Chemical
(	380 1 O
0	381 1 O
.	382 1 O
15	383 2 O
mg	386 2 O
kg	389 2 O
(	391 1 O
-	392 1 O
1	393 1 O
)	394 1 O
)	395 1 O
and	397 3 O
propofol	401 8 B-Chemical
(	410 1 O
2	411 1 O
.	412 1 O
0	413 1 O
mg	415 2 O
kg	418 2 O
(	420 1 O
-	421 1 O
1	422 1 O
)	423 1 O
)	424 1 O
,	425 1 O
13	427 2 O
patients	430 8 O
received	439 8 O
phenylephrine	448 13 B-Chemical
(	462 1 O
0	463 1 O
.	464 1 O
1	465 1 O
mg	467 2 O
iv	470 2 O
)	472 1 O
and	474 3 O
12	478 2 O
patients	481 8 O
received	490 8 O
ephedrine	499 9 B-Chemical
(	509 1 O
10	510 2 O
mg	513 2 O
iv	516 2 O
)	518 1 O
to	520 2 O
restore	523 7 O
mean	531 4 O
arterial	536 8 O
pressure	545 8 O
(	554 1 O
MAP	555 3 O
)	558 1 O
.	559 1 O

Heart	561 5 O
rate	567 4 O
(	572 1 O
HR	573 2 O
)	575 1 O
,	576 1 O
MAP	578 3 O
,	581 1 O
stroke	583 6 B-Disease
volume	590 6 O
(	597 1 O
SV	598 2 O
)	600 1 O
,	601 1 O
cardiac	603 7 O
output	611 6 O
(	618 1 O
CO	619 2 O
)	621 1 O
,	622 1 O
and	624 3 O
frontal	628 7 O
lobe	636 4 O
oxygenation	641 11 O
(	653 1 O
S	654 1 O
(	655 1 O
c	656 1 O
)	657 1 O
O	658 1 O
(	659 1 O
2	660 1 O
)	661 1 O
)	662 1 O
were	664 4 O
registered	669 10 O
.	679 1 O

RESULTS	681 7 O
:	688 1 O
Induction	690 9 O
of	700 2 O
anesthesia	703 10 O
was	714 3 O
followed	718 8 O
by	727 2 O
a	730 1 B-Disease
decrease	732 8 I-Disease
in	741 2 I-Disease
MAP	744 3 I-Disease
,	747 1 I-Disease
HR	749 2 I-Disease
,	751 1 I-Disease
SV	753 2 I-Disease
,	755 1 I-Disease
and	757 3 I-Disease
CO	761 2 I-Disease
concomitant	764 11 O
with	776 4 O
an	781 2 O
elevation	784 9 O
in	794 2 O
S	797 1 O
(	798 1 O
c	799 1 O
)	800 1 O
O	801 1 O
(	802 1 O
2	803 1 O
)	804 1 O
.	805 1 O

After	807 5 O
administration	813 14 O
of	828 2 O
phenylephrine	831 13 B-Chemical
,	844 1 O
MAP	846 3 O
increased	850 9 O
(	860 1 O
51	861 2 O
+	864 1 O
/	865 1 O
-	866 1 O
12	868 2 O
to	871 2 O
81	874 2 O
+	877 1 O
/	878 1 O
-	879 1 O
13	881 2 O
mmHg	884 4 O
;	888 1 O
P	890 1 O
<	892 1 O
0	894 1 O
.	895 1 O
001	896 3 O
;	899 1 O
mean	901 4 O
+	906 1 O
/	907 1 O
-	908 1 O
SD	910 2 O
)	912 1 O
.	913 1 O

However	915 7 O
,	922 1 O
a	924 1 O
14	926 2 O
%	928 1 O
(	930 1 O
from	931 4 O
70	936 2 O
+	939 1 O
/	940 1 O
-	941 1 O
8	943 1 O
%	944 1 O
to	946 2 O
60	949 2 O
+	952 1 O
/	953 1 O
-	954 1 O
7	956 1 O
%	957 1 O
)	958 1 O
reduction	960 9 O
in	970 2 O
S	973 1 O
(	974 1 O
c	975 1 O
)	976 1 O
O	977 1 O
(	978 1 O
2	979 1 O
)	980 1 O
(	982 1 O
P	983 1 O
<	985 1 O
0	987 1 O
.	988 1 O
05	989 2 O
)	991 1 O
followed	993 8 O
with	1002 4 O
no	1007 2 O
change	1010 6 O
in	1017 2 O
CO	1020 2 O
(	1023 1 O
3	1024 1 O
.	1025 1 O
7	1026 1 O
+	1028 1 O
/	1029 1 O
-	1030 1 O
1	1032 1 O
.	1033 1 O
1	1034 1 O
to	1036 2 O
3	1039 1 O
.	1040 1 O
4	1041 1 O
+	1043 1 O
/	1044 1 O
-	1045 1 O
0	1047 1 O
.	1048 1 O
9	1049 1 O
l	1051 1 O
min	1053 3 O
(	1056 1 O
-	1057 1 O
1	1058 1 O
)	1059 1 O
)	1060 1 O
.	1061 1 O

The	1063 3 O
administration	1067 14 O
of	1082 2 O
ephedrine	1085 9 B-Chemical
led	1095 3 O
to	1099 2 O
a	1102 1 O
similar	1104 7 O
increase	1112 8 O
in	1121 2 O
MAP	1124 3 O
(	1128 1 O
53	1129 2 O
+	1132 1 O
/	1133 1 O
-	1134 1 O
9	1136 1 O
to	1138 2 O
79	1141 2 O
+	1144 1 O
/	1145 1 O
-	1146 1 O
8	1148 1 O
mmHg	1150 4 O
;	1154 1 O
P	1156 1 O
<	1158 1 O
0	1160 1 O
.	1161 1 O
001	1162 3 O
)	1165 1 O
,	1166 1 O
restored	1168 8 O
CO	1177 2 O
(	1180 1 O
3	1181 1 O
.	1182 1 O
2	1183 1 O
+	1185 1 O
/	1186 1 O
-	1187 1 O
1	1189 1 O
.	1190 1 O
2	1191 1 O
to	1193 2 O
5	1196 1 O
.	1197 1 O
0	1198 1 O
+	1200 1 O
/	1201 1 O
-	1202 1 O
1	1204 1 O
.	1205 1 O
3	1206 1 O
l	1208 1 O
min	1210 3 O
(	1213 1 O
-	1214 1 O
1	1215 1 O
)	1216 1 O
)	1217 1 O
,	1218 1 O
and	1220 3 O
preserved	1224 9 O
S	1234 1 O
(	1235 1 O
c	1236 1 O
)	1237 1 O
O	1238 1 O
(	1239 1 O
2	1240 1 O
)	1241 1 O
.	1242 1 O

CONCLUSIONS	1244 11 O
:	1255 1 O
The	1257 3 O
utilization	1261 11 O
of	1273 2 O
phenylephrine	1276 13 B-Chemical
to	1290 2 O
correct	1293 7 O
hypotension	1301 11 B-Disease
induced	1313 7 O
by	1321 2 O
anesthesia	1324 10 O
has	1335 3 O
a	1339 1 O
negative	1341 8 O
impact	1350 6 O
on	1357 2 O
S	1360 1 O
(	1361 1 O
c	1362 1 O
)	1363 1 O
O	1364 1 O
(	1365 1 O
2	1366 1 O
)	1367 1 O
while	1369 5 O
ephedrine	1375 9 B-Chemical
maintains	1385 9 O
frontal	1395 7 O
lobe	1403 4 O
oxygenation	1408 11 O
potentially	1420 11 O
related	1432 7 O
to	1440 2 O
an	1443 2 O
increase	1446 8 O
in	1455 2 O
CO	1458 2 O
.	1460 1 O

A	0 1 O
novel	2 5 O
,	7 1 O
multiple	9 8 O
symptom	18 7 O
model	26 5 O
of	32 2 O
obsessive	35 9 B-Disease
-	44 1 I-Disease
compulsive	45 10 I-Disease
-	55 1 I-Disease
like	56 4 I-Disease
behaviors	61 9 I-Disease
in	71 2 O
animals	74 7 O
.	81 1 O

BACKGROUND	83 10 O
:	93 1 O
Current	95 7 O
animal	103 6 O
models	110 6 O
of	117 2 O
obsessive	120 9 B-Disease
-	129 1 I-Disease
compulsive	130 10 I-Disease
disorder	141 8 I-Disease
(	150 1 O
OCD	151 3 B-Disease
)	154 1 O
typically	156 9 O
involve	166 7 O
acute	174 5 O
,	179 1 O
drug	181 4 O
-	185 1 O
induced	186 7 O
symptom	194 7 O
provocation	202 11 O
or	214 2 O
a	217 1 O
genetic	219 7 O
association	227 11 O
with	239 4 O
stereotypies	244 12 O
or	257 2 O
anxiety	260 7 B-Disease
.	267 1 O

None	269 4 O
of	274 2 O
these	277 5 O
current	283 7 O
models	291 6 O
demonstrate	298 11 O
multiple	310 8 O
OCD	319 3 B-Disease
-	322 1 O
like	323 4 O
behaviors	328 9 O
.	337 1 O

METHODS	339 7 O
:	346 1 O
Neonatal	348 8 O
rats	357 4 O
were	362 4 O
treated	367 7 O
with	375 4 O
the	380 3 O
tricyclic	384 9 O
antidepressant	394 14 B-Chemical
clomipramine	409 12 B-Chemical
or	422 2 O
vehicle	425 7 O
between	433 7 O
days	441 4 O
9	446 1 O
and	448 3 O
16	452 2 O
twice	455 5 O
daily	461 5 O
and	467 3 O
behaviorally	471 12 O
tested	484 6 O
in	491 2 O
adulthood	494 9 O
.	503 1 O

RESULTS	505 7 O
:	512 1 O
Clomipramine	514 12 B-Chemical
exposure	527 8 O
in	536 2 O
immature	539 8 O
rats	548 4 O
produced	553 8 O
significant	562 11 O
behavioral	574 10 O
and	585 3 O
biochemical	589 11 O
changes	601 7 O
that	609 4 O
include	614 7 O
enhanced	622 8 O
anxiety	631 7 B-Disease
(	639 1 O
elevated	640 8 O
plus	649 4 O
maze	654 4 O
and	659 3 O
marble	663 6 O
burying	670 7 O
)	677 1 O
,	678 1 O
behavioral	680 10 B-Disease
inflexibility	691 13 I-Disease
(	705 1 O
perseveration	706 13 O
in	720 2 O
the	723 3 O
spontaneous	727 11 O
alternation	739 11 O
task	751 4 O
and	756 3 O
impaired	760 8 O
reversal	769 8 O
learning	778 8 O
)	786 1 O
,	787 1 O
working	789 7 O
memory	797 6 B-Disease
impairment	804 10 I-Disease
(	815 1 O
e	816 1 O
.	817 1 O
g	818 1 O
.	819 1 O
,	820 1 O
win	822 3 O
-	825 1 O
shift	826 5 O
paradigm	832 8 O
)	840 1 O
,	841 1 O
hoarding	843 8 B-Disease
,	851 1 O
and	853 3 O
corticostriatal	857 15 B-Disease
dysfunction	873 11 I-Disease
.	884 1 O

Dopamine	886 8 B-Chemical
D2	895 2 O
receptors	898 9 O
were	908 4 O
elevated	913 8 O
in	922 2 O
the	925 3 O
striatum	929 8 O
,	937 1 O
whereas	939 7 O
serotonin	947 9 B-Chemical
2C	957 2 O
,	959 1 O
but	961 3 O
not	965 3 O
serotonin	969 9 B-Chemical
1A	979 2 O
,	981 1 O
receptors	983 9 O
were	993 4 O
elevated	998 8 O
in	1007 2 O
the	1010 3 O
orbital	1014 7 O
frontal	1022 7 O
cortex	1030 6 O
.	1036 1 O

CONCLUSIONS	1038 11 O
:	1049 1 O
This	1051 4 O
is	1056 2 O
the	1059 3 O
first	1063 5 O
demonstration	1069 13 O
of	1083 2 O
multiple	1086 8 O
symptoms	1095 8 O
consistent	1104 10 O
with	1115 4 O
an	1120 2 O
OCD	1123 3 B-Disease
-	1126 1 O
like	1127 4 O
profile	1132 7 O
in	1140 2 O
animals	1143 7 O
.	1150 1 O

Moreover	1152 8 O
,	1160 1 O
these	1162 5 O
behaviors	1168 9 O
are	1178 3 O
accompanied	1182 11 O
by	1194 2 O
biochemical	1197 11 O
changes	1209 7 O
in	1217 2 O
brain	1220 5 O
regions	1226 7 O
previously	1234 10 O
identified	1245 10 O
as	1256 2 O
relevant	1259 8 O
to	1268 2 O
OCD	1271 3 B-Disease
.	1274 1 O

This	1276 4 O
novel	1281 5 O
model	1287 5 O
of	1293 2 O
OCD	1296 3 B-Disease
demonstrates	1300 12 O
that	1313 4 O
drug	1318 4 O
exposure	1323 8 O
during	1332 6 O
a	1339 1 O
sensitive	1341 9 O
period	1351 6 O
can	1358 3 O
program	1362 7 O
disease	1370 7 O
-	1377 1 O
like	1378 4 O
systems	1383 7 O
permanently	1391 11 O
,	1402 1 O
which	1404 5 O
could	1410 5 O
have	1416 4 O
implications	1421 12 O
for	1434 3 O
current	1438 7 O
and	1446 3 O
future	1450 6 O
therapeutic	1457 11 O
strategies	1469 10 O
for	1480 3 O
this	1484 4 O
and	1489 3 O
other	1493 5 O
psychiatric	1499 11 B-Disease
disorders	1511 9 I-Disease
.	1520 1 O

Late	0 4 O
recovery	5 8 O
of	14 2 O
renal	17 5 O
function	23 8 O
in	32 2 O
a	35 1 O
woman	37 5 O
with	43 4 O
the	48 3 O
hemolytic	52 9 B-Disease
uremic	62 6 I-Disease
syndrome	69 8 I-Disease
.	77 1 O

A	79 1 O
case	81 4 O
is	86 2 O
reported	89 8 O
of	98 2 O
the	101 3 O
hemolytic	105 9 B-Disease
uremic	115 6 I-Disease
syndrome	122 8 I-Disease
(	131 1 O
HUS	132 3 B-Disease
)	135 1 O
in	137 2 O
a	140 1 O
woman	142 5 O
taking	148 6 O
oral	155 4 B-Chemical
contraceptives	160 14 I-Chemical
.	174 1 O

She	176 3 O
was	180 3 O
treated	184 7 O
with	192 4 O
heparin	197 7 B-Chemical
,	204 1 O
dipyridamole	206 12 B-Chemical
and	219 3 O
hemodialysis	223 12 O
;	235 1 O
and	237 3 O
after	241 5 O
more	247 4 O
than	252 4 O
three	257 5 O
months	263 6 O
,	269 1 O
her	271 3 O
urinary	275 7 O
output	283 6 O
rose	290 4 O
above	295 5 O
500	301 3 O
ml	305 2 O
;	307 1 O
and	309 3 O
six	313 3 O
months	317 6 O
after	324 5 O
the	330 3 O
onset	334 5 O
of	340 2 O
anuria	343 6 B-Disease
,	349 1 O
dialysis	351 8 O
treatment	360 9 O
was	370 3 O
stopped	374 7 O
.	381 1 O

This	383 4 O
case	388 4 O
emphasizes	393 10 O
the	404 3 O
possibility	408 11 O
that	420 4 O
HUS	425 3 B-Disease
in	429 2 O
adults	432 6 O
is	439 2 O
not	442 3 O
invariably	446 10 O
irreversible	457 12 O
and	470 3 O
that	474 4 O
,	478 1 O
despite	480 7 O
prolonged	488 9 O
oliguria	498 8 B-Disease
,	506 1 O
recovery	508 8 O
of	517 2 O
renal	520 5 O
function	526 8 O
can	535 3 O
be	539 2 O
obtained	542 8 O
.	550 1 O

Therefore	552 9 O
,	561 1 O
in	563 2 O
adult	566 5 O
patients	572 8 O
affected	581 8 O
by	590 2 O
HUS	593 3 B-Disease
,	596 1 O
dialysis	598 8 O
should	607 6 O
not	614 3 O
be	618 2 O
discontinued	621 12 O
prematurely	634 11 O
;	645 1 O
moreover	647 8 O
,	655 1 O
bilateral	657 9 O
nephrectomy	667 11 O
,	678 1 O
for	680 3 O
treatment	684 9 O
of	694 2 O
severe	697 6 O
hypertension	704 12 B-Disease
and	717 3 O
microangiopathic	721 16 B-Disease
hemolytic	738 9 I-Disease
anemia	748 6 I-Disease
,	754 1 O
should	756 6 O
be	763 2 O
performed	766 9 O
with	776 4 O
caution	781 7 O
.	788 1 O

Effects	0 7 O
of	8 2 O
acetylsalicylic	11 15 B-Chemical
acid	27 4 I-Chemical
,	31 1 O
dipyridamole	33 12 B-Chemical
,	45 1 O
and	47 3 O
hydrocortisone	51 14 B-Chemical
on	66 2 O
epinephrine	69 11 B-Chemical
-	80 1 O
induced	81 7 O
myocardial	89 10 B-Disease
injury	100 6 I-Disease
in	107 2 O
dogs	110 4 O
.	114 1 O

A	116 1 O
reproducible	118 12 O
model	131 5 O
for	137 3 O
producing	141 9 O
diffuse	151 7 O
myocardial	159 10 B-Disease
injury	170 6 I-Disease
(	177 1 O
epinephrine	178 11 B-Chemical
infusion	190 8 O
)	198 1 O
has	200 3 O
been	204 4 O
developed	209 9 O
to	219 2 O
study	222 5 O
the	228 3 O
cardioprotective	232 16 O
effects	249 7 O
of	257 2 O
agents	260 6 O
or	267 2 O
maneuvers	270 9 O
which	280 5 O
might	286 5 O
alter	292 5 O
the	298 3 O
evolution	302 9 O
of	312 2 O
acute	315 5 O
myocardial	321 10 B-Disease
infarction	332 10 I-Disease
.	342 1 O

Infusions	344 9 O
of	354 2 O
epinephrine	357 11 B-Chemical
(	369 1 O
4	370 1 O
mug	372 3 O
per	376 3 O
kilogram	380 8 O
per	389 3 O
minute	393 6 O
for	400 3 O
6	404 1 O
hours	406 5 O
)	411 1 O
increased	413 9 O
radiocalcium	423 12 B-Chemical
uptakes	436 7 O
into	444 4 O
intact	449 6 O
myocardium	456 10 O
and	467 3 O
each	471 4 O
of	476 2 O
its	479 3 O
subcellular	483 11 O
components	495 10 O
with	506 4 O
the	511 3 O
mitochondrial	515 13 O
fraction	529 8 O
showing	538 7 O
the	546 3 O
most	550 4 O
consistent	555 10 O
changes	566 7 O
when	574 4 O
compared	579 8 O
to	588 2 O
saline	591 6 O
-	597 1 O
infused	598 7 O
control	606 7 O
animals	614 7 O
(	622 1 O
4	623 1 O
,	624 1 O
957	625 3 O
vs	629 2 O
.	631 1 O
827	633 3 O
counts	637 6 O
per	644 3 O
minute	648 6 O
per	655 3 O
gram	659 4 O
of	664 2 O
dried	667 5 O
tissue	673 6 O
or	680 2 O
fraction	683 8 O
)	691 1 O
.	692 1 O

Myocardial	694 10 O
concentrations	705 14 O
of	720 2 O
calcium	723 7 B-Chemical
also	731 4 O
increased	736 9 O
significantly	746 13 O
(	760 1 O
12	761 2 O
.	763 1 O
0	764 1 O
vs	766 2 O
.	768 1 O
5	770 1 O
.	771 1 O
0	772 1 O
mg	774 2 O
.	776 1 O
per	777 3 O
100	781 3 O
Gm	785 2 O
.	787 1 O
of	789 2 O
fat	792 3 O
-	795 1 O
free	796 4 O
dry	801 3 O
weight	805 6 O
)	811 1 O
.	812 1 O

Infusions	814 9 O
of	824 2 O
calcium	827 7 B-Chemical
chloride	835 8 I-Chemical
sufficient	844 10 O
to	855 2 O
raise	858 5 O
serum	864 5 O
calcium	870 7 B-Chemical
concentrations	878 14 O
2	893 1 O
mEq	895 3 O
.	898 1 O
per	900 3 O
liter	904 5 O
failed	910 6 O
to	917 2 O
increase	920 8 O
calcium	929 7 B-Chemical
influx	937 6 O
into	944 4 O
the	949 3 O
myocardial	953 10 O
cell	964 4 O
.	968 1 O

Mitochondrial	970 13 O
radiocalcium	984 12 B-Chemical
uptakes	997 7 O
were	1005 4 O
significantly	1010 13 O
decreased	1024 9 O
in	1034 2 O
animals	1037 7 O
pretreated	1045 10 O
with	1056 4 O
acetylsalicylic	1061 15 B-Chemical
acid	1077 4 I-Chemical
or	1082 2 O
dipyridamole	1085 12 B-Chemical
or	1098 2 O
when	1101 4 O
hydrocortisone	1106 14 B-Chemical
was	1121 3 O
added	1125 5 O
to	1131 2 O
the	1134 3 O
epinephrine	1138 11 B-Chemical
infusion	1150 8 O
(	1159 1 O
2	1160 1 O
,	1161 1 O
682	1162 3 O
,	1165 1 O
2	1166 1 O
,	1167 1 O
803	1168 3 O
,	1171 1 O
and	1173 3 O
3	1177 1 O
,	1178 1 O
424	1179 3 O
counts	1183 6 O
per	1190 3 O
minute	1194 6 O
per	1201 3 O
gram	1205 4 O
of	1210 2 O
dried	1213 5 O
fraction	1219 8 O
,	1227 1 O
respectively	1229 12 O
)	1241 1 O
.	1242 1 O

Myocardial	1244 10 O
calcium	1255 7 B-Chemical
concentrations	1263 14 O
also	1278 4 O
were	1283 4 O
decreased	1288 9 O
(	1298 1 O
11	1299 2 O
.	1301 1 O
2	1302 1 O
,	1303 1 O
8	1305 1 O
.	1306 1 O
3	1307 1 O
,	1308 1 O
and	1310 3 O
8	1314 1 O
.	1315 1 O
9	1316 1 O
mg	1318 2 O
.	1320 1 O
per	1322 3 O
100	1326 3 O
Gm	1330 2 O
.	1332 1 O
of	1334 2 O
fat	1337 3 O
-	1340 1 O
free	1341 4 O
dry	1346 3 O
weight	1350 6 O
,	1356 1 O
respectively	1358 12 O
)	1370 1 O
in	1372 2 O
the	1375 3 O
three	1379 5 O
treatment	1385 9 O
groups	1395 6 O
,	1401 1 O
being	1403 5 O
significantly	1409 13 O
decreased	1423 9 O
only	1433 4 O
in	1438 2 O
the	1441 3 O
last	1445 4 O
two	1450 3 O
.	1453 1 O

Evidence	1455 8 O
of	1464 2 O
microscopic	1467 11 O
damage	1479 6 O
was	1486 3 O
graded	1490 6 O
as	1497 2 O
less	1500 4 O
severe	1505 6 O
in	1512 2 O
the	1515 3 O
three	1519 5 O
treatment	1525 9 O
groups	1535 6 O
.	1541 1 O

Acetylsalicylic	1543 15 B-Chemical
acid	1559 4 I-Chemical
,	1563 1 O
dipyridamole	1565 12 B-Chemical
,	1577 1 O
and	1579 3 O
hydrocortisone	1583 14 B-Chemical
all	1598 3 O
appear	1602 6 O
to	1609 2 O
have	1612 4 O
cardioprotective	1617 16 O
effects	1634 7 O
when	1642 4 O
tested	1647 6 O
in	1654 2 O
this	1657 4 O
model	1662 5 O
.	1667 1 O

Changes	0 7 O
in	8 2 O
depressive	11 10 B-Disease
status	22 6 O
associated	29 10 O
with	40 4 O
topical	45 7 O
beta	53 4 O
-	57 1 O
blockers	58 8 O
.	66 1 O

Depression	68 10 B-Disease
and	79 3 O
sexual	83 6 B-Disease
dysfunction	90 11 I-Disease
have	102 4 O
been	107 4 O
related	112 7 O
to	120 2 O
side	123 4 O
effects	128 7 O
of	136 2 O
topical	139 7 O
beta	147 4 O
-	151 1 O
blockers	152 8 O
.	160 1 O

We	162 2 O
performed	165 9 O
a	175 1 O
preliminary	177 11 O
study	189 5 O
in	195 2 O
order	198 5 O
to	204 2 O
determine	207 9 O
any	217 3 O
difference	221 10 O
between	232 7 O
a	240 1 O
non	242 3 O
selective	246 9 O
beta	256 4 O
-	260 1 O
blocker	261 7 O
(	269 1 O
timolol	270 7 B-Chemical
)	277 1 O
and	279 3 O
a	283 1 O
selective	285 9 O
beta	295 4 O
-	299 1 O
blocker	300 7 O
(	308 1 O
betaxolol	309 9 B-Chemical
)	318 1 O
regarding	320 9 O
CNS	330 3 O
side	334 4 O
effects	339 7 O
.	346 1 O

Eight	348 5 O
glaucomatous	354 12 B-Disease
patients	367 8 O
chronically	376 11 O
treated	388 7 O
with	396 4 O
timolol	401 7 B-Chemical
0	409 1 O
.	410 1 O
5	411 1 O
%	412 1 O
/	413 1 O
12h	414 3 O
,	417 1 O
suffering	419 9 O
from	429 4 O
depression	434 10 B-Disease
diagnosed	445 9 O
through	455 7 O
DMS	463 3 O
-	466 1 O
III	467 3 O
-	470 1 O
R	471 1 O
criteria	473 8 O
,	481 1 O
were	483 4 O
included	488 8 O
in	497 2 O
the	500 3 O
study	504 5 O
.	509 1 O

During	511 6 O
the	518 3 O
six	522 3 O
-	525 1 O
month	526 5 O
follow	532 6 O
up	539 2 O
,	541 1 O
depression	543 10 B-Disease
was	554 3 O
quantified	558 10 O
through	569 7 O
the	577 3 O
Beck	581 4 O
and	586 3 O
Zung	590 4 O
-	594 1 O
Conde	595 5 O
scales	601 6 O
every	608 5 O
two	614 3 O
months	618 6 O
.	624 1 O

In	626 2 O
a	629 1 O
double	631 6 O
blind	638 5 O
cross	644 5 O
-	649 1 O
over	650 4 O
study	655 5 O
with	661 4 O
control	666 7 O
group	674 5 O
,	679 1 O
the	681 3 O
patients	685 8 O
under	694 5 O
timolol	700 7 B-Chemical
treatment	708 9 O
presented	718 9 O
higher	728 6 O
depression	735 10 B-Disease
values	746 6 O
measured	753 8 O
through	762 7 O
the	770 3 O
Beck	774 4 O
and	779 3 O
the	783 3 O
Zung	787 4 O
-	791 1 O
Conde	792 5 O
scales	798 6 O
(	805 1 O
p	806 1 O
<	808 1 O
0	810 1 O
.	811 1 O
001	812 3 O
vs	816 2 O
control	819 7 O
)	826 1 O
.	827 1 O

These	829 5 O
results	835 7 O
suggest	843 7 O
that	851 4 O
betaxolol	856 9 B-Chemical
could	866 5 O
be	872 2 O
less	875 4 O
of	880 2 O
a	883 1 O
depression	885 10 B-Disease
-	895 1 O
inducer	896 7 O
than	904 4 O
timolol	909 7 B-Chemical
in	917 2 O
predisposed	920 11 O
patients	932 8 O
.	940 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
follow	10 6 O
-	16 1 O
up	17 2 O
of	20 2 O
ifosfamide	23 10 B-Chemical
renal	34 5 B-Disease
toxicity	40 8 I-Disease
in	49 2 O
children	52 8 O
treated	61 7 O
for	69 3 O
malignant	73 9 B-Disease
mesenchymal	83 11 I-Disease
tumors	95 6 I-Disease
:	101 1 O
an	103 2 O
International	106 13 O
Society	120 7 O
of	128 2 O
Pediatric	131 9 O
Oncology	141 8 O
report	150 6 O
.	156 1 O

The	158 3 O
renal	162 5 O
function	168 8 O
of	177 2 O
74	180 2 O
children	183 8 O
with	192 4 O
malignant	197 9 B-Disease
mesenchymal	207 11 I-Disease
tumors	219 6 I-Disease
in	226 2 O
complete	229 8 O
remission	238 9 O
and	248 3 O
who	252 3 O
have	256 4 O
received	261 8 O
the	270 3 O
same	274 4 O
ifosfamide	279 10 B-Chemical
chemotherapy	290 12 O
protocol	303 8 O
(	312 1 O
International	313 13 O
Society	327 7 O
of	335 2 O
Pediatric	338 9 O
Oncology	348 8 O
Malignant	357 9 B-Disease
Mesenchymal	367 11 I-Disease
Tumor	379 5 I-Disease
Study	385 5 O
84	391 2 O
[	394 1 O
SIOP	395 4 O
MMT	400 3 O
84	404 2 O
]	406 1 O
)	407 1 O
were	409 4 O
studied	414 7 O
1	422 1 O
year	424 4 O
after	429 5 O
the	435 3 O
completion	439 10 O
of	450 2 O
treatment	453 9 O
.	462 1 O

Total	464 5 O
cumulative	470 10 O
doses	481 5 O
were	487 4 O
36	492 2 O
or	495 2 O
60	498 2 O
g	501 1 O
/	502 1 O
m2	503 2 O
of	506 2 O
ifosfamide	509 10 B-Chemical
(	520 1 O
six	521 3 O
or	525 2 O
10	528 2 O
cycles	531 6 O
of	538 2 O
ifosfamide	541 10 B-Chemical
,	551 1 I-Chemical
vincristine	553 11 I-Chemical
,	564 1 I-Chemical
and	566 3 I-Chemical
dactinomycin	570 12 I-Chemical
[	583 1 O
IVA	584 3 B-Chemical
]	587 1 O
)	588 1 O
.	589 1 O

None	591 4 O
of	596 2 O
them	599 4 O
had	604 3 O
received	608 8 O
cisplatin	617 9 B-Chemical
chemotherapy	627 12 O
.	639 1 O

Ages	641 4 O
ranged	646 6 O
from	653 4 O
4	658 1 O
months	660 6 O
to	667 2 O
17	670 2 O
years	673 5 O
;	678 1 O
58	680 2 O
patients	683 8 O
were	692 4 O
males	697 5 O
and	703 3 O
42	707 2 O
females	710 7 O
.	717 1 O

The	719 3 O
most	723 4 O
common	728 6 O
primary	735 7 O
tumor	743 5 B-Disease
site	749 4 O
was	754 3 O
the	758 3 O
head	762 4 O
and	767 3 O
neck	771 4 O
.	775 1 O

Renal	777 5 O
function	783 8 O
was	792 3 O
investigated	796 12 O
by	809 2 O
measuring	812 9 O
plasma	822 6 O
and	829 3 O
urinary	833 7 O
electrolytes	841 12 O
,	853 1 O
glucosuria	855 10 B-Disease
,	865 1 O
proteinuria	867 11 B-Disease
,	878 1 O
aminoaciduria	880 13 B-Disease
,	893 1 O
urinary	895 7 O
pH	903 2 O
,	905 1 O
osmolarity	907 10 O
,	917 1 O
creatinine	919 10 B-Chemical
clearance	930 9 O
,	939 1 O
phosphate	941 9 B-Chemical
tubular	951 7 O
reabsorption	959 12 O
,	971 1 O
beta	973 4 O
2	978 1 O
microglobulinuria	980 17 O
,	997 1 O
and	999 3 O
lysozymuria	1003 11 O
.	1014 1 O

Fifty	1016 5 O
-	1021 1 O
eight	1022 5 O
patients	1028 8 O
(	1037 1 O
78	1038 2 O
%	1040 1 O
)	1041 1 O
had	1043 3 O
normal	1047 6 O
renal	1054 5 O
tests	1060 5 O
,	1065 1 O
whereas	1067 7 O
16	1075 2 O
patients	1078 8 O
(	1087 1 O
22	1088 2 O
%	1090 1 O
)	1091 1 O
had	1093 3 O
renal	1097 5 B-Disease
abnormalities	1103 13 I-Disease
.	1116 1 O

Two	1118 3 O
subsets	1122 7 O
of	1130 2 O
patients	1133 8 O
were	1142 4 O
identified	1147 10 O
from	1158 4 O
this	1163 4 O
latter	1168 6 O
group	1175 5 O
:	1180 1 O
the	1182 3 O
first	1186 5 O
included	1192 8 O
four	1201 4 O
patients	1206 8 O
(	1215 1 O
5	1216 1 O
%	1217 1 O
of	1219 2 O
the	1222 3 O
total	1226 5 O
population	1232 10 O
)	1242 1 O
who	1244 3 O
developed	1248 9 O
major	1258 5 O
toxicity	1264 8 B-Disease
resulting	1273 9 O
in	1283 2 O
Fanconi	1286 7 B-Disease
'	1293 1 I-Disease
s	1294 1 I-Disease
syndrome	1296 8 I-Disease
(	1305 1 O
TDFS	1306 4 B-Disease
)	1310 1 O
;	1311 1 O
and	1313 3 O
the	1317 3 O
second	1321 6 O
group	1328 5 O
included	1334 8 O
five	1343 4 O
patients	1348 8 O
with	1357 4 O
elevated	1362 8 O
beta	1371 4 O
2	1376 1 O
microglobulinuria	1378 17 O
and	1396 3 O
low	1400 3 O
phosphate	1404 9 B-Chemical
reabsorption	1414 12 O
.	1426 1 O

The	1428 3 O
remaining	1432 9 O
seven	1442 5 O
patients	1448 8 O
had	1457 3 O
isolated	1461 8 O
beta	1470 4 O
2	1475 1 O
microglobulinuria	1477 17 O
.	1494 1 O

Severe	1496 6 O
toxicity	1503 8 B-Disease
was	1512 3 O
correlated	1516 10 O
with	1527 4 O
the	1532 3 O
higher	1536 6 O
cumulative	1543 10 O
dose	1554 4 O
of	1559 2 O
60	1562 2 O
g	1565 1 O
/	1566 1 O
m2	1567 2 O
of	1570 2 O
ifosfamide	1573 10 B-Chemical
,	1583 1 O
a	1585 1 O
younger	1587 7 O
age	1595 3 O
(	1599 1 O
less	1600 4 O
than	1605 4 O
2	1610 1 O
1	1612 1 O
/	1613 1 O
2	1614 1 O
years	1616 5 O
old	1622 3 O
)	1625 1 O
,	1626 1 O
and	1628 3 O
a	1632 1 O
predominance	1634 12 O
of	1647 2 O
vesicoprostatic	1650 15 O
tumor	1666 5 B-Disease
involvement	1672 11 O
.	1683 1 O

This	1685 4 O
low	1690 3 O
percentage	1694 10 O
(	1705 1 O
5	1706 1 O
%	1707 1 O
)	1708 1 O
of	1710 2 O
TDFS	1713 4 O
must	1718 4 O
be	1723 2 O
evaluated	1726 9 O
with	1736 4 O
respect	1741 7 O
to	1749 2 O
the	1752 3 O
efficacy	1756 8 O
of	1765 2 O
ifosfamide	1768 10 B-Chemical
in	1779 2 O
the	1782 3 O
treatment	1786 9 O
of	1796 2 O
mesenchymal	1799 11 B-Disease
tumors	1811 6 I-Disease
in	1818 2 O
children	1821 8 O
.	1829 1 O

Evidence	0 8 O
for	9 3 O
an	13 2 O
involvement	16 11 O
of	28 2 O
D1	31 2 O
and	34 3 O
D2	38 2 O
dopamine	41 8 B-Chemical
receptors	50 9 O
in	60 2 O
mediating	63 9 O
nicotine	73 8 B-Chemical
-	81 1 O
induced	82 7 O
hyperactivity	90 13 B-Disease
in	104 2 O
rats	107 4 O
.	111 1 O

Previous	113 8 O
studies	122 7 O
have	130 4 O
suggested	135 9 O
that	145 4 O
repeated	150 8 O
exposure	159 8 O
of	168 2 O
rats	171 4 O
to	176 2 O
the	179 3 O
drug	183 4 O
or	188 2 O
to	191 2 O
the	194 3 O
experimental	198 12 O
environment	211 11 O
is	223 2 O
necessary	226 9 O
to	236 2 O
observe	239 7 O
nicotine	247 8 B-Chemical
-	255 1 O
induced	256 7 O
locomotor	264 9 O
stimulation	274 11 O
.	285 1 O

In	287 2 O
the	290 3 O
present	294 7 O
study	302 5 O
the	308 3 O
role	312 4 O
of	317 2 O
habituation	320 11 O
to	332 2 O
the	335 3 O
experimental	339 12 O
environment	352 11 O
on	364 2 O
the	367 3 O
stimulant	371 9 O
effect	381 6 O
of	388 2 O
nicotine	391 8 B-Chemical
in	400 2 O
rats	403 4 O
was	408 3 O
examined	412 8 O
.	420 1 O

In	422 2 O
addition	425 8 O
,	433 1 O
the	435 3 O
role	439 4 O
of	444 2 O
dopamine	447 8 B-Chemical
receptors	456 9 O
in	466 2 O
mediating	469 9 O
nicotine	479 8 B-Chemical
-	487 1 O
induced	488 7 O
locomotor	496 9 O
stimulation	506 11 O
was	518 3 O
investigated	522 12 O
by	535 2 O
examining	538 9 O
the	548 3 O
effects	552 7 O
of	560 2 O
selective	563 9 O
D1	573 2 O
and	576 3 O
D2	580 2 O
dopamine	583 8 B-Chemical
receptor	592 8 O
antagonists	601 11 O
on	613 2 O
activity	616 8 O
induced	625 7 O
by	633 2 O
nicotine	636 8 B-Chemical
.	644 1 O

Locomotor	646 9 O
activity	656 8 O
was	665 3 O
assessed	669 8 O
in	678 2 O
male	681 4 O
Sprague	686 7 O
-	693 1 O
Dawley	694 6 O
rats	701 4 O
tested	706 6 O
in	713 2 O
photocell	716 9 O
cages	726 5 O
.	731 1 O

Nicotine	733 8 B-Chemical
(	742 1 O
1	743 1 O
.	744 1 O
0	745 1 O
mg	747 2 O
/	749 1 O
kg	750 2 O
)	752 1 O
caused	754 6 O
a	761 1 O
significant	763 11 O
increase	775 8 B-Disease
in	784 2 I-Disease
locomotor	787 9 I-Disease
activity	797 8 I-Disease
in	806 2 O
rats	809 4 O
that	814 4 O
were	819 4 O
habituated	824 10 O
to	835 2 O
the	838 3 O
test	842 4 O
environment	847 11 O
,	858 1 O
but	860 3 O
had	864 3 O
only	868 4 O
a	873 1 O
weak	875 4 O
and	880 3 O
delayed	884 7 O
stimulant	892 9 O
action	902 6 O
in	909 2 O
rats	912 4 O
that	917 4 O
were	922 4 O
unfamiliar	927 10 O
with	938 4 O
the	943 3 O
test	947 4 O
environment	952 11 O
.	963 1 O

The	965 3 O
stimulant	969 9 O
action	979 6 O
of	986 2 O
nicotine	989 8 B-Chemical
was	998 3 O
blocked	1002 7 O
by	1010 2 O
the	1013 3 O
central	1017 7 O
nicotinic	1025 9 O
antagonist	1035 10 O
mecamylamine	1046 12 B-Chemical
but	1059 3 O
not	1063 3 O
by	1067 2 O
the	1070 3 O
peripheral	1074 10 O
nicotinic	1085 9 O
blocker	1095 7 O
hexamethonium	1103 13 B-Chemical
,	1116 1 O
indicating	1118 10 O
that	1129 4 O
the	1134 3 O
response	1138 8 O
is	1147 2 O
probably	1150 8 O
mediated	1159 8 O
by	1168 2 O
central	1171 7 O
nicotinic	1179 9 O
receptors	1189 9 O
.	1198 1 O

Nicotine	1200 8 B-Chemical
-	1208 1 O
induced	1209 7 O
hyperactivity	1217 13 B-Disease
was	1231 3 O
blocked	1235 7 O
by	1243 2 O
the	1246 3 O
selective	1250 9 O
D1	1260 2 O
antagonist	1263 10 O
SCH	1274 3 B-Chemical
23390	1278 5 I-Chemical
,	1283 1 O
the	1285 3 O
selective	1289 9 O
D2	1299 2 O
antagonist	1302 10 O
raclopride	1313 10 B-Chemical
and	1324 3 O
the	1328 3 O
D1	1332 2 O
/	1334 1 O
D2	1335 2 O
antagonist	1338 10 O
fluphenazine	1349 12 B-Chemical
.	1361 1 O

Pretreatment	1363 12 O
with	1376 4 O
the	1381 3 O
D2	1385 2 O
agonist	1388 7 O
PHNO	1396 4 B-Chemical
enhanced	1401 8 O
nicotine	1410 8 B-Chemical
-	1418 1 O
induced	1419 7 O
hyperactivity	1427 13 B-Disease
,	1440 1 O
whereas	1442 7 O
the	1450 3 O
D1	1454 2 O
agonist	1457 7 O
SKF	1465 3 B-Chemical
38393	1469 5 I-Chemical
had	1475 3 O
no	1479 2 O
effect	1482 6 O
.	1488 1 O

The	1490 3 O
results	1494 7 O
indicate	1502 8 O
that	1511 4 O
acute	1516 5 O
nicotine	1522 8 B-Chemical
injection	1531 9 O
induces	1541 7 O
a	1549 1 O
pronounced	1551 10 O
hyperactivity	1562 13 B-Disease
in	1576 2 O
rats	1579 4 O
habituated	1584 10 O
to	1595 2 O
the	1598 3 O
test	1602 4 O
environment	1607 11 O
.	1618 1 O

The	1620 3 O
effect	1624 6 O
appears	1631 7 O
to	1639 2 O
be	1642 2 O
mediated	1645 8 O
by	1654 2 O
central	1657 7 O
nicotine	1665 8 B-Chemical
receptors	1674 9 O
,	1683 1 O
possibly	1685 8 O
located	1694 7 O
on	1702 2 O
dopaminergic	1705 12 O
neurons	1718 7 O
,	1725 1 O
and	1727 3 O
also	1731 4 O
requires	1736 8 O
the	1745 3 O
activation	1749 10 O
of	1760 2 O
both	1763 4 O
D1	1768 2 O
and	1771 3 O
D2	1775 2 O
dopamine	1778 8 B-Chemical
receptors	1787 9 O
.	1796 1 O

Neuropsychiatric	0 16 O
side	17 4 O
effects	22 7 O
after	30 5 O
the	36 3 O
use	40 3 O
of	44 2 O
mefloquine	47 10 B-Chemical
.	57 1 O

This	59 4 O
study	64 5 O
describes	70 9 O
neuropsychiatric	80 16 O
side	97 4 O
effects	102 7 O
in	110 2 O
patients	113 8 O
after	122 5 O
treatment	128 9 O
with	138 4 O
mefloquine	143 10 B-Chemical
.	153 1 O

Reactions	155 9 O
consisted	165 9 O
mainly	175 6 O
of	182 2 O
seizures	185 8 B-Disease
,	193 1 O
acute	195 5 O
psychoses	201 9 B-Disease
,	210 1 O
anxiety	212 7 B-Disease
neurosis	220 8 I-Disease
,	228 1 O
and	230 3 O
major	234 5 O
disturbances	240 12 B-Disease
of	253 2 I-Disease
sleep	256 5 I-Disease
-	261 1 I-Disease
wake	262 4 I-Disease
rhythm	267 6 I-Disease
.	273 1 O

Side	275 4 O
effects	280 7 O
occurred	288 8 O
after	297 5 O
both	303 4 O
therapeutic	308 11 O
and	320 3 O
prophylactic	324 12 O
intake	337 6 O
and	344 3 O
were	348 4 O
graded	353 6 O
from	360 4 O
moderate	365 8 O
to	374 2 O
severe	377 6 O
.	383 1 O

In	385 2 O
a	388 1 O
risk	390 4 O
analysis	395 8 O
of	404 2 O
neuropsychiatric	407 16 O
side	424 4 O
effects	429 7 O
in	437 2 O
Germany	440 7 O
,	447 1 O
it	449 2 O
is	452 2 O
estimated	455 9 O
that	465 4 O
one	470 3 O
of	474 2 O
8	477 1 O
,	478 1 O
000	479 3 O
mefloquine	483 10 B-Chemical
users	494 5 O
suffers	500 7 O
from	508 4 O
such	513 4 O
reactions	518 9 O
.	527 1 O

The	529 3 O
incidence	533 9 O
calculation	543 11 O
revealed	555 8 O
that	564 4 O
one	569 3 O
of	573 2 O
215	576 3 O
therapeutic	580 11 O
users	592 5 O
had	598 3 O
reactions	602 9 O
,	611 1 O
compared	613 8 O
with	622 4 O
one	627 3 O
of	631 2 O
13	634 2 O
,	636 1 O
000	637 3 O
in	641 2 O
the	644 3 O
prophylaxis	648 11 O
group	660 5 O
,	665 1 O
making	667 6 O
the	674 3 O
risk	678 4 O
of	683 2 O
neuropsychiatric	686 16 O
reactions	703 9 O
after	713 5 O
mefloquine	719 10 B-Chemical
treatment	730 9 O
60	740 2 O
times	743 5 O
higher	749 6 O
than	756 4 O
after	761 5 O
prophylaxis	767 11 O
.	778 1 O

Therefore	780 9 O
,	789 1 O
certain	791 7 O
limitations	799 11 O
for	811 3 O
malaria	815 7 B-Disease
prophylaxis	823 11 O
and	835 3 O
treatment	839 9 O
with	849 4 O
mefloquine	854 10 B-Chemical
are	865 3 O
recommended	869 11 O
.	880 1 O

Reduction	0 9 O
in	10 2 O
injection	13 9 O
pain	23 4 B-Disease
using	28 5 O
buffered	34 8 O
lidocaine	43 9 B-Chemical
as	53 2 O
a	56 1 O
local	58 5 O
anesthetic	64 10 O
before	75 6 O
cardiac	82 7 O
catheterization	90 15 O
.	105 1 O

Previous	107 8 O
reports	116 7 O
have	124 4 O
suggested	129 9 O
that	139 4 O
pain	144 4 B-Disease
associated	149 10 O
with	160 4 O
the	165 3 O
injection	169 9 O
of	179 2 O
lidocaine	182 9 B-Chemical
is	192 2 O
related	195 7 O
to	203 2 O
the	206 3 O
acidic	210 6 O
pH	217 2 O
of	220 2 O
the	223 3 O
solution	227 8 O
.	235 1 O

To	237 2 O
determine	240 9 O
if	250 2 O
the	253 3 O
addition	257 8 O
of	266 2 O
a	269 1 O
buffering	271 9 O
solution	281 8 O
to	290 2 O
adjust	293 6 O
the	300 3 O
pH	304 2 O
of	307 2 O
lidocaine	310 9 B-Chemical
into	320 4 O
the	325 3 O
physiologic	329 11 O
range	341 5 O
would	347 5 O
reduce	353 6 O
pain	360 4 B-Disease
during	365 6 O
injection	372 9 O
,	381 1 O
we	383 2 O
performed	386 9 O
a	396 1 O
blinded	398 7 O
randomized	406 10 O
study	417 5 O
in	423 2 O
patients	426 8 O
undergoing	435 10 O
cardiac	446 7 O
catheterization	454 15 O
.	469 1 O

Twenty	471 6 O
patients	478 8 O
were	487 4 O
asked	492 5 O
to	498 2 O
quantify	501 8 O
the	510 3 O
severity	514 8 O
of	523 2 O
pain	526 4 B-Disease
after	531 5 O
receiving	537 9 O
standard	547 8 O
lidocaine	556 9 B-Chemical
in	566 2 O
one	569 3 O
femoral	573 7 O
area	581 4 O
and	586 3 O
buffered	590 8 O
lidocaine	599 9 B-Chemical
in	609 2 O
the	612 3 O
opposite	616 8 O
femoral	625 7 O
area	633 4 O
.	637 1 O

The	639 3 O
mean	643 4 O
pain	648 4 B-Disease
score	653 5 O
for	659 3 O
buffered	663 8 O
lidocaine	672 9 B-Chemical
was	682 3 O
significantly	686 13 O
lower	700 5 O
than	706 4 O
the	711 3 O
mean	715 4 O
score	720 5 O
for	726 3 O
standard	730 8 O
lidocaine	739 9 B-Chemical
(	749 1 O
2	750 1 O
.	751 1 O
7	752 1 O
+	754 1 O
/	755 1 O
-	756 1 O
1	758 1 O
.	759 1 O
9	760 1 O
vs	762 2 O
.	764 1 O
3	766 1 O
.	767 1 O
8	768 1 O
+	770 1 O
/	771 1 O
-	772 1 O
2	774 1 O
.	775 1 O
2	776 1 O
,	777 1 O
P	779 1 O
=	781 1 O
0	783 1 O
.	784 1 O
03	785 2 O
)	787 1 O
.	788 1 O

The	790 3 O
pH	794 2 O
adjustment	797 10 O
of	808 2 O
standard	811 8 O
lidocaine	820 9 B-Chemical
can	830 3 O
be	834 2 O
accomplished	837 12 O
easily	850 6 O
in	857 2 O
the	860 3 O
catheterization	864 15 O
laboratory	880 10 O
before	891 6 O
injection	898 9 O
and	908 3 O
results	912 7 O
in	920 2 O
a	923 1 O
reduction	925 9 O
of	935 2 O
the	938 3 O
pain	942 4 B-Disease
occurring	947 9 O
during	957 6 O
the	964 3 O
infiltration	968 12 O
of	981 2 O
tissues	984 7 O
.	991 1 O

Randomized	0 10 O
,	10 1 O
double	12 6 O
-	18 1 O
blind	19 5 O
trial	25 5 O
of	31 2 O
mazindol	34 8 B-Chemical
in	43 2 O
Duchenne	46 8 B-Disease
dystrophy	55 9 I-Disease
.	64 1 O

There	66 5 O
is	72 2 O
evidence	75 8 O
that	84 4 O
growth	89 6 O
hormone	96 7 O
may	104 3 O
be	108 2 O
related	111 7 O
to	119 2 O
the	122 3 O
progression	126 11 O
of	138 2 O
weakness	141 8 B-Disease
in	150 2 O
Duchenne	153 8 B-Disease
dystrophy	162 9 I-Disease
.	171 1 O

We	173 2 O
conducted	176 9 O
a	186 1 O
12	188 2 O
-	190 1 O
month	191 5 O
controlled	197 10 O
trial	208 5 O
of	214 2 O
mazindol	217 8 B-Chemical
,	225 1 O
a	227 1 O
putative	229 8 O
growth	238 6 O
hormone	245 7 O
secretion	253 9 O
inhibitor	263 9 O
,	272 1 O
in	274 2 O
83	277 2 O
boys	280 4 O
with	285 4 O
Duchenne	290 8 B-Disease
dystrophy	299 9 I-Disease
.	308 1 O

Muscle	310 6 O
strength	317 8 O
,	325 1 O
contractures	327 12 O
,	339 1 O
functional	341 10 O
ability	352 7 O
and	360 3 O
pulmonary	364 9 O
function	374 8 O
were	383 4 O
tested	388 6 O
at	395 2 O
baseline	398 8 O
,	406 1 O
and	408 3 O
6	412 1 O
and	414 3 O
12	418 2 O
months	421 6 O
after	428 5 O
treatment	434 9 O
with	444 4 O
mazindol	449 8 B-Chemical
(	458 1 O
3	459 1 O
mg	461 2 O
/	463 1 O
d	464 1 O
)	465 1 O
or	467 2 O
placebo	470 7 O
.	477 1 O

The	479 3 O
study	483 5 O
was	489 3 O
designed	493 8 O
to	502 2 O
have	505 4 O
a	510 1 O
power	512 5 O
of	518 2 O
greater	521 7 O
than	529 4 O
0	534 1 O
.	535 1 O
90	536 2 O
to	539 2 O
detect	542 6 O
a	549 1 O
slowing	551 7 O
to	559 2 O
25	562 2 O
%	564 1 O
of	566 2 O
the	569 3 O
expected	573 8 O
rate	582 4 O
of	587 2 O
progression	590 11 O
of	602 2 O
weakness	605 8 B-Disease
at	614 2 O
P	617 1 O
less	619 4 O
than	624 4 O
0	629 1 O
.	630 1 O
05	631 2 O
.	633 1 O

Mazindol	635 8 B-Chemical
did	644 3 O
not	648 3 O
benefit	652 7 O
strength	660 8 O
at	669 2 O
any	672 3 O
point	676 5 O
in	682 2 O
the	685 3 O
study	689 5 O
.	694 1 O

Side	696 4 O
effects	701 7 O
attributable	709 12 O
to	722 2 O
mazindol	725 8 B-Chemical
included	734 8 O
decreased	743 9 B-Disease
appetite	753 8 I-Disease
(	762 1 O
36	763 2 O
%	765 1 O
)	766 1 O
,	767 1 O
dry	769 3 B-Disease
mouth	773 5 I-Disease
(	779 1 O
10	780 2 O
%	782 1 O
)	783 1 O
,	784 1 O
behavioral	786 10 O
change	797 6 O
(	804 1 O
22	805 2 O
%	807 1 O
)	808 1 O
,	809 1 O
and	811 3 O
gastrointestinal	815 16 B-Disease
symptoms	832 8 I-Disease
(	841 1 O
18	842 2 O
%	844 1 O
)	845 1 O
;	846 1 O
mazindol	848 8 B-Chemical
dosage	857 6 O
was	864 3 O
reduced	868 7 O
in	876 2 O
43	879 2 O
%	881 1 O
of	883 2 O
patients	886 8 O
.	894 1 O

The	896 3 O
effect	900 6 O
of	907 2 O
mazindol	910 8 B-Chemical
on	919 2 O
GH	922 2 O
secretion	925 9 O
was	935 3 O
estimated	939 9 O
indirectly	949 10 O
by	960 2 O
comparing	963 9 O
the	973 3 O
postabsorptive	977 14 O
IGF	992 3 O
-	995 1 O
I	996 1 O
levels	998 6 O
obtained	1005 8 O
following	1014 9 O
3	1024 1 O
,	1025 1 O
6	1027 1 O
,	1028 1 O
9	1030 1 O
,	1031 1 O
and	1033 3 O
12	1037 2 O
months	1040 6 O
in	1047 2 O
the	1050 3 O
mazindol	1054 8 B-Chemical
treated	1063 7 O
to	1071 2 O
those	1074 5 O
in	1080 2 O
the	1083 3 O
placebo	1087 7 O
groups	1095 6 O
.	1101 1 O

Although	1103 8 O
mazindol	1112 8 B-Chemical
-	1120 1 O
treated	1121 7 O
patients	1129 8 O
gained	1138 6 O
less	1145 4 O
weight	1150 6 O
and	1157 3 O
height	1161 6 O
than	1168 4 O
placebo	1173 7 O
-	1180 1 O
treated	1181 7 O
patients	1189 8 O
,	1197 1 O
no	1199 2 O
significant	1202 11 O
effect	1214 6 O
on	1221 2 O
IGF	1224 3 O
-	1227 1 O
I	1228 1 O
levels	1230 6 O
was	1237 3 O
observed	1241 8 O
.	1249 1 O

Mazindol	1251 8 B-Chemical
doses	1260 5 O
not	1266 3 O
slow	1270 4 O
the	1275 3 O
progression	1279 11 O
of	1291 2 O
weakness	1294 8 B-Disease
in	1303 2 O
Duchenne	1306 8 B-Disease
dystrophy	1315 9 I-Disease
.	1324 1 O

Pentoxifylline	0 14 B-Chemical
(	15 1 O
Trental	16 7 B-Chemical
)	23 1 O
does	25 4 O
not	30 3 O
inhibit	34 7 O
dipyridamole	42 12 B-Chemical
-	54 1 O
induced	55 7 O
coronary	63 8 O
hyperemia	72 9 B-Disease
:	81 1 O
implications	83 12 O
for	96 3 O
dipyridamole	100 12 B-Chemical
-	112 1 O
thallium	113 8 B-Chemical
-	121 1 O
201	122 3 O
myocardial	126 10 O
imaging	137 7 O
.	144 1 O

Dipyridamole	146 12 B-Chemical
-	158 1 O
thallium	159 8 B-Chemical
-	167 1 O
201	168 3 O
imaging	172 7 O
is	180 2 O
often	183 5 O
performed	189 9 O
in	199 2 O
patients	202 8 O
unable	211 6 O
to	218 2 O
exercise	221 8 O
because	230 7 O
of	238 2 O
peripheral	241 10 B-Disease
vascular	252 8 I-Disease
disease	261 7 I-Disease
.	268 1 O

Many	270 4 O
of	275 2 O
these	278 5 O
patients	284 8 O
are	293 3 O
taking	297 6 O
pentoxifylline	304 14 B-Chemical
(	319 1 O
Trental	320 7 B-Chemical
)	327 1 O
,	328 1 O
a	330 1 O
methylxanthine	332 14 B-Chemical
derivative	347 10 O
which	358 5 O
may	364 3 O
improve	368 7 O
intermittent	376 12 B-Disease
claudication	389 12 I-Disease
.	401 1 O

Whether	403 7 O
pentoxifylline	411 14 B-Chemical
inhibits	426 8 O
dipyridamole	435 12 B-Chemical
-	447 1 O
induced	448 7 O
coronary	456 8 O
hyperemia	465 9 B-Disease
like	475 4 O
other	480 5 O
methylxanthines	486 15 B-Chemical
such	502 4 O
as	507 2 O
theophylline	510 12 B-Chemical
and	523 3 O
should	527 6 O
be	534 2 O
stopped	537 7 O
prior	545 5 O
to	551 2 O
dipyridamole	554 12 B-Chemical
-	566 1 O
thallium	567 8 B-Chemical
-	575 1 O
201	576 3 O
imaging	580 7 O
is	588 2 O
unknown	591 7 O
.	598 1 O

Therefore	600 9 O
,	609 1 O
we	611 2 O
studied	614 7 O
the	622 3 O
hyperemic	626 9 O
response	636 8 O
to	645 2 O
dipyridamole	648 12 B-Chemical
in	661 2 O
seven	664 5 O
open	670 4 O
-	674 1 O
chest	675 5 O
anesthetized	681 12 O
dogs	694 4 O
after	699 5 O
pretreatment	705 12 O
with	718 4 O
either	723 6 O
pentoxifylline	730 14 B-Chemical
(	745 1 O
0	746 1 O
,	747 1 O
7	749 1 O
.	750 1 O
5	751 1 O
,	752 1 O
or	754 2 O
15	757 2 O
mg	760 2 O
/	762 1 O
kg	763 2 O
i	766 1 O
.	767 1 O
v	768 1 O
.	769 1 O
)	770 1 O
or	772 2 O
theophylline	775 12 B-Chemical
(	788 1 O
3	789 1 O
mg	791 2 O
/	793 1 O
kg	794 2 O
i	797 1 O
.	798 1 O
v	799 1 O
.	800 1 O
)	801 1 O
.	802 1 O

Baseline	804 8 O
circumflex	813 10 O
coronary	824 8 O
blood	833 5 O
flows	839 5 O
did	845 3 O
not	849 3 O
differ	853 6 O
significantly	860 13 O
among	874 5 O
treatment	880 9 O
groups	890 6 O
.	896 1 O

Dipyridamole	898 12 B-Chemical
significantly	911 13 O
increased	925 9 O
coronary	935 8 O
blood	944 5 O
flow	950 4 O
before	955 6 O
and	962 3 O
after	966 5 O
7	972 1 O
.	973 1 O
5	974 1 O
or	976 2 O
15	979 2 O
mm	982 2 O
/	984 1 O
kg	985 2 O
i	988 1 O
.	989 1 O
v	990 1 O
.	991 1 O
pentoxifylline	993 14 B-Chemical
(	1008 1 O
p	1009 1 O
less	1011 4 O
than	1016 4 O
0	1021 1 O
.	1022 1 O
002	1023 3 O
)	1026 1 O
.	1027 1 O

Neither	1029 7 O
dose	1037 4 O
of	1042 2 O
pentoxifylline	1045 14 B-Chemical
significantly	1060 13 O
decreased	1074 9 O
the	1084 3 O
dipyridamole	1088 12 B-Chemical
-	1100 1 O
induced	1101 7 O
hyperemia	1109 9 B-Disease
,	1118 1 O
while	1120 5 O
peak	1126 4 O
coronary	1131 8 O
blood	1140 5 O
flow	1146 4 O
was	1151 3 O
significantly	1155 13 O
lower	1169 5 O
after	1175 5 O
theophylline	1181 12 B-Chemical
(	1194 1 O
p	1195 1 O
less	1197 4 O
than	1202 4 O
0	1207 1 O
.	1208 1 O
01	1209 2 O
)	1211 1 O
.	1212 1 O

We	1214 2 O
conclude	1217 8 O
that	1226 4 O
pentoxyifylline	1231 15 B-Chemical
does	1247 4 O
not	1252 3 O
inhibit	1256 7 O
dipyridamole	1264 12 B-Chemical
-	1276 1 O
induced	1277 7 O
coronary	1285 8 O
hyperemia	1294 9 B-Disease
even	1304 4 O
at	1309 2 O
high	1312 4 O
doses	1317 5 O
.	1322 1 O

Cause	0 5 O
of	6 2 O
death	9 5 B-Disease
among	15 5 O
patients	21 8 O
with	30 4 O
Parkinson	35 9 B-Disease
'	44 1 I-Disease
s	45 1 I-Disease
disease	47 7 I-Disease
:	54 1 O
a	56 1 O
rare	58 4 O
mortality	63 9 O
due	73 3 O
to	77 2 O
cerebral	80 8 B-Disease
haemorrhage	89 11 I-Disease
.	100 1 O

Causes	102 6 O
of	109 2 O
death	112 5 B-Disease
,	117 1 O
with	119 4 O
special	124 7 O
reference	132 9 O
to	142 2 O
cerebral	145 8 B-Disease
haemorrhage	154 11 I-Disease
,	165 1 O
among	167 5 O
240	173 3 O
patients	177 8 O
with	186 4 O
pathologically	191 14 O
verified	206 8 O
Parkinson	215 9 B-Disease
'	224 1 I-Disease
s	225 1 I-Disease
disease	227 7 I-Disease
were	235 4 O
investigated	240 12 O
using	253 5 O
the	259 3 O
Annuals	263 7 O
of	271 2 O
the	274 3 O
Pathological	278 12 O
Autopsy	291 7 O
Cases	299 5 O
in	305 2 O
Japan	308 5 O
from	314 4 O
1981	319 4 O
to	324 2 O
1985	327 4 O
.	331 1 O

The	333 3 O
leading	337 7 O
causes	345 6 O
of	352 2 O
death	355 5 B-Disease
were	361 4 O
pneumonia	366 9 B-Disease
and	376 3 O
bronchitis	380 10 B-Disease
(	391 1 O
44	392 2 O
.	394 1 O
1	395 1 O
%	396 1 O
)	397 1 O
,	398 1 O
malignant	400 9 O
neoplasms	410 9 B-Disease
(	420 1 O
11	421 2 O
.	423 1 O
6	424 1 O
%	425 1 O
)	426 1 O
,	427 1 O
heart	429 5 B-Disease
diseases	435 8 I-Disease
(	444 1 O
4	445 1 O
.	446 1 O
1	447 1 O
%	448 1 O
)	449 1 O
,	450 1 O
cerebral	452 8 B-Disease
infarction	461 10 I-Disease
(	472 1 O
3	473 1 O
.	474 1 O
7	475 1 O
%	476 1 O
)	477 1 O
and	479 3 O
septicaemia	483 11 B-Disease
(	495 1 O
3	496 1 O
.	497 1 O
3	498 1 O
%	499 1 O
)	500 1 O
.	501 1 O

Cerebral	503 8 B-Disease
haemorrhage	512 11 I-Disease
was	524 3 O
the	528 3 O
11th	532 4 O
most	537 4 O
frequent	542 8 O
cause	551 5 O
of	557 2 O
death	560 5 B-Disease
,	565 1 O
accounting	567 10 O
for	578 3 O
only	582 4 O
0	587 1 O
.	588 1 O
8	589 1 O
%	590 1 O
of	592 2 O
deaths	595 6 B-Disease
among	602 5 O
the	608 3 O
patients	612 8 O
,	620 1 O
whereas	622 7 O
it	630 2 O
was	633 3 O
the	637 3 O
5th	641 3 O
most	645 4 O
common	650 6 O
cause	657 5 O
of	663 2 O
death	666 5 B-Disease
among	672 5 O
the	678 3 O
Japanese	682 8 O
general	691 7 O
population	699 10 O
in	710 2 O
1985	713 4 O
.	717 1 O

The	719 3 O
low	723 3 O
incidence	727 9 O
of	737 2 O
cerebral	740 8 B-Disease
haemorrhage	749 11 I-Disease
as	761 2 O
a	764 1 O
cause	766 5 O
of	772 2 O
death	775 5 B-Disease
in	781 2 O
patients	784 8 O
with	793 4 O
Parkinson	798 9 B-Disease
'	807 1 I-Disease
s	808 1 I-Disease
disease	810 7 I-Disease
may	818 3 O
reflect	822 7 O
the	830 3 O
hypotensive	834 11 B-Disease
effect	846 6 O
of	853 2 O
levodopa	856 8 B-Chemical
and	865 3 O
a	869 1 O
hypotensive	871 11 B-Disease
mechanism	883 9 O
due	893 3 O
to	897 2 O
reduced	900 7 O
noradrenaline	908 13 B-Chemical
levels	922 6 O
in	929 2 O
the	932 3 O
parkinsonian	936 12 B-Disease
brain	949 5 O
.	954 1 O

Tolerance	0 9 O
and	10 3 O
antiviral	14 9 O
effect	24 6 O
of	31 2 O
ribavirin	34 9 B-Chemical
in	44 2 O
patients	47 8 O
with	56 4 O
Argentine	61 9 B-Disease
hemorrhagic	71 11 I-Disease
fever	83 5 I-Disease
.	88 1 O

Tolerance	90 9 O
and	100 3 O
antiviral	104 9 O
effect	114 6 O
of	121 2 O
ribavirin	124 9 B-Chemical
was	134 3 O
studied	138 7 O
in	146 2 O
6	149 1 O
patients	151 8 O
with	160 4 O
Argentine	165 9 B-Disease
hemorrhagic	175 11 I-Disease
fever	187 5 I-Disease
(	193 1 O
AHF	194 3 B-Disease
)	197 1 O
of	199 2 O
more	202 4 O
than	207 4 O
8	212 1 O
days	214 4 O
of	219 2 O
evolution	222 9 O
.	231 1 O

Administration	233 14 O
of	248 2 O
ribavirin	251 9 B-Chemical
resulted	261 8 O
in	270 2 O
a	273 1 O
neutralization	275 14 O
of	290 2 O
viremia	293 7 B-Disease
and	301 3 O
a	305 1 O
drop	307 4 O
of	312 2 O
endogenous	315 10 O
interferon	326 10 O
titers	337 6 O
.	343 1 O

The	345 3 O
average	349 7 O
time	357 4 O
of	362 2 O
death	365 5 B-Disease
was	371 3 O
delayed	375 7 O
.	382 1 O

A	384 1 O
reversible	386 10 O
anemia	397 6 B-Disease
was	404 3 O
the	408 3 O
only	412 4 O
adverse	417 7 O
effect	425 6 O
observed	432 8 O
.	440 1 O

From	442 4 O
these	447 5 O
results	453 7 O
,	460 1 O
we	462 2 O
conclude	465 8 O
that	474 4 O
ribavirin	479 9 B-Chemical
has	489 3 O
an	493 2 O
antiviral	496 9 O
effect	506 6 O
in	513 2 O
advanced	516 8 O
cases	525 5 O
of	531 2 O
AHF	534 3 B-Disease
,	537 1 O
and	539 3 O
that	543 4 O
anemia	548 6 B-Disease
,	554 1 O
the	556 3 O
only	560 4 O
secondary	565 9 O
reaction	575 8 O
observed	584 8 O
,	592 1 O
can	594 3 O
be	598 2 O
easily	601 6 O
managed	608 7 O
.	615 1 O

The	617 3 O
possible	621 8 O
beneficial	630 10 O
effect	641 6 O
of	648 2 O
ribavirin	651 9 B-Chemical
during	661 6 O
the	668 3 O
initial	672 7 O
days	680 4 O
of	685 2 O
AHF	688 3 B-Disease
is	692 2 O
discussed	695 9 O
.	704 1 O

Dipyridamole	0 12 B-Chemical
-	12 1 O
induced	13 7 O
myocardial	21 10 B-Disease
ischemia	32 8 I-Disease
.	40 1 O

Angina	42 6 B-Disease
and	49 3 O
ischemic	53 8 O
electrocardiographic	62 20 O
changes	83 7 O
occurred	91 8 O
after	100 5 O
administration	106 14 O
of	121 2 O
oral	124 4 O
dipyridamole	129 12 B-Chemical
in	142 2 O
four	145 4 O
patients	150 8 O
awaiting	159 8 O
urgent	168 6 O
myocardial	175 10 O
revascularization	186 17 O
procedures	204 10 O
.	214 1 O

To	216 2 O
our	219 3 O
knowledge	223 9 O
,	232 1 O
this	234 4 O
has	239 3 O
not	243 3 O
previously	247 10 O
been	258 4 O
reported	263 8 O
as	272 2 O
a	275 1 O
side	277 4 O
effect	282 6 O
of	289 2 O
preoperative	292 12 O
dipyridamole	305 12 B-Chemical
therapy	318 7 O
,	325 1 O
although	327 8 O
dipyridamole	336 12 B-Chemical
-	348 1 O
induced	349 7 O
myocardial	357 10 B-Disease
ischemia	368 8 I-Disease
has	377 3 O
been	381 4 O
demonstrated	386 12 O
to	399 2 O
occur	402 5 O
in	408 2 O
animals	411 7 O
and	419 3 O
humans	423 6 O
with	430 4 O
coronary	435 8 B-Disease
artery	444 6 I-Disease
disease	451 7 I-Disease
.	458 1 O

Epicardial	460 10 O
coronary	471 8 O
collateral	480 10 O
vessels	491 7 O
were	499 4 O
demonstrated	504 12 O
in	517 2 O
all	520 3 O
four	524 4 O
patients	529 8 O
;	537 1 O
a	539 1 O
coronary	541 8 O
"	550 1 O
steal	551 5 O
"	556 1 O
phenomenon	558 10 O
may	569 3 O
be	573 2 O
the	576 3 O
mechanism	580 9 O
of	590 2 O
the	593 3 O
dipyridamole	597 12 B-Chemical
-	609 1 O
induced	610 7 O
ischemia	618 8 B-Disease
observed	627 8 O
.	635 1 O

Inhibition	0 10 O
of	11 2 O
immunoreactive	14 14 O
corticotropin	29 13 O
-	42 1 O
releasing	43 9 O
factor	53 6 O
secretion	60 9 O
into	70 4 O
the	75 3 O
hypophysial	79 11 O
-	90 1 O
portal	91 6 O
circulation	98 11 O
by	110 2 O
delayed	113 7 O
glucocorticoid	121 14 O
feedback	136 8 O
.	144 1 O

Nitroprusside	146 13 B-Chemical
-	159 1 O
induced	160 7 O
hypotension	168 11 B-Disease
evokes	180 6 O
ACTH	187 4 O
secretion	192 9 O
which	202 5 O
is	208 2 O
primarily	211 9 O
mediated	221 8 O
by	230 2 O
enhanced	233 8 O
secretion	242 9 O
of	252 2 O
immunoreactive	255 14 O
corticotropin	270 13 O
-	283 1 O
releasing	284 9 O
factor	294 6 O
(	301 1 O
irCRF	302 5 O
)	307 1 O
into	309 4 O
the	314 3 O
hypophysial	318 11 O
-	329 1 O
portal	330 6 O
circulation	337 11 O
.	348 1 O

Portal	350 6 O
plasma	357 6 O
concentrations	364 14 O
of	379 2 O
neither	382 7 O
arginine	390 8 B-Chemical
vasopressin	399 11 I-Chemical
nor	411 3 O
oxytocin	415 8 B-Chemical
are	424 3 O
significantly	428 13 O
altered	442 7 O
in	450 2 O
this	453 4 O
paradigm	458 8 O
.	466 1 O

Application	468 11 O
of	480 2 O
a	483 1 O
delayed	485 7 O
feedback	493 8 O
signal	502 6 O
,	508 1 O
in	510 2 O
the	513 3 O
form	517 4 O
of	522 2 O
a	525 1 O
2	527 1 O
-	528 1 O
h	529 1 O
systemic	531 8 O
corticosterone	540 14 B-Chemical
infusion	555 8 O
in	564 2 O
urethane	567 8 B-Chemical
-	575 1 O
anesthetized	576 12 O
rats	589 4 O
with	594 4 O
pharmacological	599 15 O
blockade	615 8 O
of	624 2 O
glucocorticoid	627 14 O
synthesis	642 9 O
,	651 1 O
is	653 2 O
without	656 7 O
effect	664 6 O
on	671 2 O
the	674 3 O
resting	678 7 O
secretion	686 9 O
of	696 2 O
arginine	699 8 B-Chemical
vasopressin	708 11 I-Chemical
and	720 3 O
oxytocin	724 8 B-Chemical
at	733 2 O
any	736 3 O
corticosterone	740 14 B-Chemical
feedback	755 8 O
dose	764 4 O
tested	769 6 O
.	775 1 O

Resting	777 7 O
irCRF	785 5 O
levels	791 6 O
are	798 3 O
suppressed	802 10 O
only	813 4 O
at	818 2 O
the	821 3 O
highest	825 7 O
corticosterone	833 14 B-Chemical
infusion	848 8 O
rate	857 4 O
,	861 1 O
which	863 5 O
resulted	869 8 O
in	878 2 O
systemic	881 8 O
corticosterone	890 14 B-Chemical
levels	905 6 O
of	912 2 O
40	915 2 O
micrograms	918 10 O
/	928 1 O
dl	929 2 O
.	931 1 O

Suppression	933 11 O
of	945 2 O
irCRF	948 5 O
secretion	954 9 O
in	964 2 O
response	967 8 O
to	976 2 O
nitroprusside	979 13 B-Chemical
-	992 1 O
induced	993 7 O
hypotension	1001 11 B-Disease
is	1013 2 O
observed	1016 8 O
and	1025 3 O
occurs	1029 6 O
at	1036 2 O
a	1039 1 O
plasma	1041 6 O
corticosterone	1048 14 B-Chemical
level	1063 5 O
between	1069 7 O
8	1077 1 O
-	1078 1 O
12	1079 2 O
micrograms	1082 10 O
/	1092 1 O
dl	1093 2 O
.	1095 1 O

These	1097 5 O
studies	1103 7 O
provide	1111 7 O
further	1119 7 O
evidence	1127 8 O
for	1136 3 O
a	1140 1 O
strong	1142 6 O
central	1149 7 O
component	1157 9 O
of	1167 2 O
the	1170 3 O
delayed	1174 7 O
feedback	1182 8 O
process	1191 7 O
which	1199 5 O
is	1205 2 O
mediated	1208 8 O
by	1217 2 O
modulation	1220 10 O
of	1231 2 O
irCRF	1234 5 O
release	1240 7 O
.	1247 1 O

Noradrenergic	0 13 O
involvement	14 11 O
in	26 2 O
catalepsy	29 9 B-Disease
induced	39 7 O
by	47 2 O
delta	50 5 B-Chemical
9	56 1 I-Chemical
-	57 1 I-Chemical
tetrahydrocannabinol	58 20 I-Chemical
.	78 1 O

In	80 2 O
order	83 5 O
to	89 2 O
elucidate	92 9 O
the	102 3 O
role	106 4 O
of	111 2 O
the	114 3 O
catecholaminergic	118 17 O
system	136 6 O
in	143 2 O
the	146 3 O
cataleptogenic	150 14 O
effect	165 6 O
of	172 2 O
delta	175 5 B-Chemical
9	181 1 I-Chemical
-	182 1 I-Chemical
tetrahydrocannabinol	183 20 I-Chemical
(	204 1 O
THC	205 3 B-Chemical
)	208 1 O
,	209 1 O
the	211 3 O
effect	215 6 O
of	222 2 O
pretreatment	225 12 O
with	238 4 O
6	243 1 B-Chemical
-	244 1 I-Chemical
hydroxydopamine	245 15 I-Chemical
(	261 1 O
6	262 1 B-Chemical
-	263 1 I-Chemical
OHDA	264 4 I-Chemical
)	268 1 O
or	270 2 O
with	273 4 O
desipramine	278 11 B-Chemical
and	290 3 O
6	294 1 B-Chemical
-	295 1 I-Chemical
OHDA	296 4 I-Chemical
and	301 3 O
lesions	305 7 O
of	313 2 O
the	316 3 O
locus	320 5 O
coeruleus	326 9 O
were	336 4 O
investigated	341 12 O
in	354 2 O
rats	357 4 O
.	361 1 O

The	363 3 O
cataleptogenic	367 14 O
effect	382 6 O
of	389 2 O
THC	392 3 B-Chemical
was	396 3 O
significantly	400 13 O
reduced	414 7 O
in	422 2 O
rats	425 4 O
treated	430 7 O
with	438 4 O
6	443 1 B-Chemical
-	444 1 I-Chemical
OHDA	445 4 I-Chemical
and	450 3 O
in	454 2 O
rats	457 4 O
with	462 4 O
lesions	467 7 O
of	475 2 O
the	478 3 O
locus	482 5 O
coeruleus	488 9 O
but	498 3 O
not	502 3 O
in	506 2 O
rats	509 4 O
treated	514 7 O
with	522 4 O
desipramine	527 11 B-Chemical
and	539 3 O
6	543 1 B-Chemical
-	544 1 I-Chemical
OHDA	545 4 I-Chemical
,	549 1 O
as	551 2 O
compared	554 8 O
with	563 4 O
control	568 7 O
rats	576 4 O
.	580 1 O

On	582 2 O
the	585 3 O
contrary	589 8 O
,	597 1 O
the	599 3 O
cataleptogenic	603 14 O
effect	618 6 O
of	625 2 O
haloperidol	628 11 B-Chemical
was	640 3 O
significantly	644 13 O
reduced	658 7 O
in	666 2 O
rats	669 4 O
treated	674 7 O
with	682 4 O
desipramine	687 11 B-Chemical
and	699 3 O
6	703 1 B-Chemical
-	704 1 I-Chemical
OHDA	705 4 I-Chemical
but	710 3 O
not	714 3 O
in	718 2 O
rats	721 4 O
treated	726 7 O
with	734 4 O
6	739 1 B-Chemical
-	740 1 I-Chemical
OHDA	741 4 I-Chemical
or	746 2 O
in	749 2 O
rats	752 4 O
with	757 4 O
lesions	762 7 O
of	770 2 O
the	773 3 O
locus	777 5 O
coeruleus	783 9 O
.	792 1 O

These	794 5 O
results	800 7 O
indicate	808 8 O
that	817 4 O
noradrenergic	822 13 O
neurons	836 7 O
have	844 4 O
an	849 2 O
important	852 9 O
role	862 4 O
in	867 2 O
the	870 3 O
manifestation	874 13 O
of	888 2 O
catalepsy	891 9 B-Disease
induced	901 7 O
by	909 2 O
THC	912 3 B-Chemical
,	915 1 O
whereas	917 7 O
dopaminergic	925 12 O
neurons	938 7 O
are	946 3 O
important	950 9 O
in	960 2 O
catalepsy	963 9 B-Disease
induced	973 7 O
by	981 2 O
haloperidol	984 11 B-Chemical
.	995 1 O

Intracranial	0 12 O
pressure	13 8 O
increases	22 9 O
during	32 6 O
alfentanil	39 10 B-Chemical
-	49 1 O
induced	50 7 O
rigidity	58 8 B-Disease
.	66 1 O

Intracranial	68 12 O
pressure	81 8 O
(	90 1 O
ICP	91 3 O
)	94 1 O
was	96 3 O
measured	100 8 O
during	109 6 O
alfentanil	116 10 B-Chemical
-	126 1 O
induced	127 7 O
rigidity	135 8 B-Disease
in	144 2 O
rats	147 4 O
.	151 1 O

Ten	153 3 O
rats	157 4 O
had	162 3 O
arterial	166 8 O
,	174 1 O
central	176 7 O
venous	184 6 O
(	191 1 O
CVP	192 3 O
)	195 1 O
,	196 1 O
and	198 3 O
subdural	202 8 O
cannulae	211 8 O
inserted	220 8 O
under	229 5 O
halothane	235 9 B-Chemical
anesthesia	245 10 O
.	255 1 O

The	257 3 O
animals	261 7 O
were	269 4 O
mechanically	274 12 O
ventilated	287 10 O
to	298 2 O
achieve	301 7 O
normocarbia	309 11 O
(	321 1 O
PCO2	322 4 O
=	327 1 O
42	329 2 O
+	332 1 O
/	333 1 O
-	334 1 O
1	336 1 O
mmHg	338 4 O
,	342 1 O
mean	344 4 O
+	349 1 O
/	350 1 O
-	351 1 O
SE	353 2 O
)	355 1 O
.	356 1 O

Following	358 9 O
instrumentation	368 15 O
,	383 1 O
halothane	385 9 B-Chemical
was	395 3 O
discontinued	399 12 O
and	412 3 O
alfentanil	416 10 B-Chemical
(	427 1 O
125	428 3 O
mu	432 2 O
/	434 1 O
kg	435 2 O
)	437 1 O
administered	439 12 O
iv	452 2 O
during	455 6 O
emergence	462 9 O
from	472 4 O
halothane	477 9 B-Chemical
anesthesia	487 10 O
.	497 1 O

In	499 2 O
the	502 3 O
five	506 4 O
rats	511 4 O
that	516 4 O
developed	521 9 O
somatic	531 7 B-Disease
rigidity	539 8 I-Disease
,	547 1 O
ICP	549 3 O
and	553 3 O
CVP	557 3 O
increased	561 9 O
significantly	571 13 O
above	585 5 O
baseline	591 8 O
(	600 1 O
delta	601 5 O
ICP	607 3 O
7	611 1 O
.	612 1 O
5	613 1 O
+	615 1 O
/	616 1 O
-	617 1 O
1	619 1 O
.	620 1 O
0	621 1 O
mmHg	623 4 O
,	627 1 O
delta	629 5 O
CVP	635 3 O
5	639 1 O
.	640 1 O
9	641 1 O
+	643 1 O
/	644 1 O
-	645 1 O
1	647 1 O
.	648 1 O
3	649 1 O
mmHg	651 4 O
)	655 1 O
.	656 1 O

These	658 5 O
variables	664 9 O
returned	674 8 O
to	683 2 O
baseline	686 8 O
when	695 4 O
rigidity	700 8 B-Disease
was	709 3 O
abolished	713 9 O
with	723 4 O
metocurine	728 10 B-Chemical
.	738 1 O

In	740 2 O
five	743 4 O
rats	748 4 O
that	753 4 O
did	758 3 O
not	762 3 O
become	766 6 O
rigid	773 5 O
,	778 1 O
ICP	780 3 O
and	784 3 O
CVP	788 3 O
did	792 3 O
not	796 3 O
change	800 6 O
following	807 9 O
alfentanil	817 10 B-Chemical
.	827 1 O

These	829 5 O
observations	835 12 O
suggest	848 7 O
that	856 4 O
rigidity	861 8 B-Disease
should	870 6 O
be	877 2 O
prevented	880 9 O
when	890 4 O
alfentanil	895 10 B-Chemical
,	905 1 O
and	907 3 O
,	910 1 O
presumably	912 10 O
,	922 1 O
other	924 5 O
opiates	930 7 O
,	937 1 O
are	939 3 O
used	943 4 O
in	948 2 O
the	951 3 O
anesthetic	955 10 O
management	966 10 O
of	977 2 O
patients	980 8 O
with	989 4 O
ICP	994 3 O
problems	998 8 O
.	1006 1 O

Adverse	0 7 O
cardiac	8 7 O
effects	16 7 O
during	24 6 O
induction	31 9 O
chemotherapy	41 12 O
treatment	54 9 O
with	64 4 O
cis	69 3 B-Chemical
-	72 1 I-Chemical
platin	73 6 I-Chemical
and	80 3 O
5	84 1 B-Chemical
-	85 1 I-Chemical
fluorouracil	86 12 I-Chemical
.	98 1 O

Survival	100 8 O
for	109 3 O
patients	113 8 O
with	122 4 O
advanced	127 8 O
head	136 4 B-Disease
and	141 3 I-Disease
neck	145 4 I-Disease
carcinoma	150 9 I-Disease
and	160 3 O
esophageal	164 10 B-Disease
carcinoma	175 9 I-Disease
is	185 2 O
poor	188 4 O
with	193 4 O
radiotherapy	198 12 O
and	211 3 O
/	214 1 O
or	215 2 O
surgery	218 7 O
.	225 1 O

Obviously	227 9 O
,	236 1 O
there	238 5 O
is	244 2 O
a	247 1 O
need	249 4 O
for	254 3 O
effective	258 9 O
chemotherapy	268 12 O
.	280 1 O

In	282 2 O
the	285 3 O
present	289 7 O
study	297 5 O
,	302 1 O
cis	304 3 B-Chemical
-	307 1 I-Chemical
platin	308 6 I-Chemical
(	315 1 O
80	316 2 O
-	318 1 O
120	319 3 O
mg	323 2 O
/	325 1 O
m2BSA	326 5 O
)	331 1 O
and	333 3 O
5	337 1 B-Chemical
-	338 1 I-Chemical
FU	339 2 I-Chemical
(	342 1 O
1000	343 4 O
mg	348 2 O
/	350 1 O
m2BSA	351 5 O
daily	357 5 O
as	363 2 O
a	366 1 O
continuous	368 10 O
infusion	379 8 O
during	388 6 O
5	395 1 O
days	397 4 O
)	401 1 O
were	403 4 O
given	408 5 O
to	414 2 O
76	417 2 O
patients	420 8 O
before	429 6 O
radiotherapy	436 12 O
and	449 3 O
surgery	453 7 O
.	460 1 O

The	462 3 O
aim	466 3 O
of	470 2 O
the	473 3 O
study	477 5 O
was	483 3 O
to	487 2 O
clarify	490 7 O
the	498 3 O
incidence	502 9 O
and	512 3 O
severity	516 8 O
of	525 2 O
adverse	528 7 O
cardiac	536 7 O
effects	544 7 O
to	552 2 O
this	555 4 O
treatment	560 9 O
.	569 1 O

Before	571 6 O
treatment	578 9 O
all	588 3 O
patients	592 8 O
had	601 3 O
a	605 1 O
cardiac	607 7 O
evaluation	615 10 O
and	626 3 O
during	630 6 O
treatment	637 9 O
serial	647 6 O
ECG	654 3 O
recordings	658 10 O
were	669 4 O
performed	674 9 O
.	683 1 O

In	685 2 O
the	688 3 O
pre	692 3 O
-	695 1 O
treatment	696 9 O
evaluation	706 10 O
,	716 1 O
signs	718 5 O
of	724 2 O
cardiovascular	727 14 B-Disease
disease	742 7 I-Disease
were	750 4 O
found	755 5 O
in	761 2 O
33	764 2 O
patients	767 8 O
(	776 1 O
43	777 2 O
%	779 1 O
)	780 1 O
.	781 1 O

During	783 6 O
treatment	790 9 O
,	799 1 O
adverse	801 7 O
cardiac	809 7 O
effects	817 7 O
were	825 4 O
observed	830 8 O
in	839 2 O
14	842 2 O
patients	845 8 O
(	854 1 O
18	855 2 O
%	857 1 O
)	858 1 O
.	859 1 O

The	861 3 O
mean	865 4 O
age	870 3 O
of	874 2 O
these	877 5 O
patients	883 8 O
was	892 3 O
the	896 3 O
same	900 4 O
as	905 2 O
for	908 3 O
the	912 3 O
entire	916 6 O
group	923 5 O
,	928 1 O
64	930 2 O
years	933 5 O
.	938 1 O

The	940 3 O
incidence	944 9 O
of	954 2 O
cardiotoxicity	957 14 B-Disease
was	972 3 O
not	976 3 O
higher	980 6 O
in	987 2 O
patients	990 8 O
with	999 4 O
signs	1004 5 O
of	1010 2 O
cardiovascular	1013 14 B-Disease
disease	1028 7 I-Disease
than	1036 4 O
in	1041 2 O
those	1044 5 O
without	1050 7 O
in	1058 2 O
the	1061 3 O
pre	1065 3 O
-	1068 1 O
treatment	1069 9 O
evaluation	1079 10 O
.	1089 1 O

The	1091 3 O
most	1095 4 O
common	1100 6 O
signs	1107 5 O
of	1113 2 O
cardiotoxicity	1116 14 B-Disease
were	1131 4 O
chest	1136 5 B-Disease
pain	1142 4 I-Disease
,	1146 1 O
ST	1148 2 O
-	1150 1 O
T	1151 1 O
wave	1153 4 O
changes	1158 7 O
and	1166 3 O
atrial	1170 6 B-Disease
fibrillation	1177 12 I-Disease
.	1189 1 O

This	1191 4 O
was	1196 3 O
followed	1200 8 O
by	1209 2 O
ventricular	1212 11 B-Disease
fibrillation	1224 12 I-Disease
in	1237 2 O
one	1240 3 O
patient	1244 7 O
and	1252 3 O
sudden	1256 6 B-Disease
death	1263 5 I-Disease
in	1269 2 O
another	1272 7 O
.	1279 1 O

It	1281 2 O
is	1284 2 O
concluded	1287 9 O
that	1297 4 O
patients	1302 8 O
on	1311 2 O
5	1314 1 B-Chemical
-	1315 1 I-Chemical
FU	1316 2 I-Chemical
treatment	1319 9 O
should	1329 6 O
be	1336 2 O
under	1339 5 O
close	1345 5 O
supervision	1351 11 O
and	1363 3 O
that	1367 4 O
the	1372 3 O
treatment	1376 9 O
should	1386 6 O
be	1393 2 O
discontinued	1396 12 O
if	1409 2 O
chest	1412 5 B-Disease
pain	1418 4 I-Disease
or	1423 2 O
tachyarrhythmia	1426 15 B-Disease
is	1442 2 O
observed	1445 8 O
.	1453 1 O

Verapamil	0 9 B-Chemical
-	9 1 O
induced	10 7 O
carbamazepine	18 13 B-Chemical
neurotoxicity	32 13 B-Disease
.	45 1 O

A	47 1 O
report	49 6 O
of	56 2 O
two	59 3 O
cases	63 5 O
.	68 1 O

Two	70 3 O
patients	74 8 O
with	83 4 O
signs	88 5 O
of	94 2 O
carbamazepine	97 13 B-Chemical
neurotoxicity	111 13 B-Disease
after	125 5 O
combined	131 8 O
treatment	140 9 O
with	150 4 O
verapamil	155 9 B-Chemical
showed	165 6 O
complete	172 8 O
recovery	181 8 O
after	190 5 O
discontinuation	196 15 O
of	212 2 O
the	215 3 O
calcium	219 7 B-Chemical
entry	227 5 O
blocker	233 7 O
.	240 1 O

Use	242 3 O
of	246 2 O
verapamil	249 9 B-Chemical
in	259 2 O
combination	262 11 O
with	274 4 O
carbamazepine	279 13 B-Chemical
should	293 6 O
either	300 6 O
be	307 2 O
avoided	310 7 O
or	318 2 O
prescribed	321 10 O
only	332 4 O
with	337 4 O
appropriate	342 11 O
adjustment	354 10 O
of	365 2 O
the	368 3 O
carbamazepine	372 13 B-Chemical
dose	386 4 O
(	391 1 O
usually	392 7 O
reduction	400 9 O
of	410 2 O
the	413 3 O
carbamazepine	417 13 B-Chemical
dose	431 4 O
by	436 2 O
one	439 3 O
half	443 4 O
)	447 1 O
.	448 1 O

Serial	0 6 O
studies	7 7 O
of	15 2 O
auditory	18 8 B-Disease
neurotoxicity	27 13 I-Disease
in	41 2 O
patients	44 8 O
receiving	53 9 O
deferoxamine	63 12 B-Chemical
therapy	76 7 O
.	83 1 O

Visual	85 6 B-Disease
and	92 3 I-Disease
auditory	96 8 I-Disease
neurotoxicity	105 13 I-Disease
was	119 3 O
previously	123 10 O
documented	134 10 O
in	145 2 O
42	148 2 O
of	151 2 O
89	154 2 O
patients	157 8 O
with	166 4 O
transfusion	171 11 O
-	182 1 O
dependent	183 9 O
anemia	193 6 B-Disease
who	200 3 O
were	204 4 O
receiving	209 9 O
iron	219 4 B-Chemical
chelation	224 9 O
therapy	234 7 O
with	242 4 O
daily	247 5 O
subcutaneous	253 12 O
deferoxamine	266 12 B-Chemical
.	278 1 O

Twenty	280 6 O
-	286 1 O
two	287 3 O
patients	291 8 O
in	300 2 O
the	303 3 O
affected	307 8 O
group	316 5 O
had	322 3 O
abnormal	326 8 B-Disease
audiograms	335 10 I-Disease
with	346 4 I-Disease
deficits	351 8 I-Disease
mostly	360 6 I-Disease
in	367 2 I-Disease
the	370 3 I-Disease
high	374 4 I-Disease
frequency	379 9 I-Disease
range	389 5 I-Disease
of	395 2 I-Disease
4	398 1 I-Disease
,	399 1 I-Disease
000	400 3 I-Disease
to	404 2 I-Disease
8	407 1 I-Disease
,	408 1 I-Disease
000	409 3 I-Disease
Hz	413 2 I-Disease
and	416 3 O
in	420 2 O
the	423 3 O
hearing	427 7 O
threshold	435 9 O
levels	445 6 O
of	452 2 O
30	455 2 O
to	458 2 O
100	461 3 O
decibels	465 8 O
.	473 1 O

When	475 4 O
deferoxamine	480 12 B-Chemical
therapy	493 7 O
was	501 3 O
discontinued	505 12 O
and	518 3 O
serial	522 6 O
studies	529 7 O
were	537 4 O
performed	542 9 O
,	551 1 O
audiograms	553 10 O
in	564 2 O
seven	567 5 O
cases	573 5 O
reverted	579 8 O
to	588 2 O
normal	591 6 O
or	598 2 O
near	601 4 O
normal	606 6 O
within	613 6 O
two	620 3 O
to	624 2 O
three	627 5 O
weeks	633 5 O
,	638 1 O
and	640 3 O
nine	644 4 O
of	649 2 O
13	652 2 O
patients	655 8 O
with	664 4 O
symptoms	669 8 O
became	678 6 O
asymptomatic	685 12 O
.	697 1 O

Audiograms	699 10 O
from	710 4 O
15	715 2 O
patients	718 8 O
remained	727 8 O
abnormal	736 8 O
and	745 3 O
four	749 4 O
patients	754 8 O
required	763 8 O
hearing	772 7 O
aids	780 4 O
because	785 7 O
of	793 2 O
permanent	796 9 B-Disease
disability	806 10 I-Disease
.	816 1 O

Since	818 5 O
18	824 2 O
of	827 2 O
the	830 3 O
22	834 2 O
patients	837 8 O
were	846 4 O
initially	851 9 O
receiving	861 9 O
deferoxamine	871 12 B-Chemical
doses	884 5 O
in	890 2 O
excess	893 6 O
of	900 2 O
the	903 3 O
commonly	907 8 O
recommended	916 11 O
50	928 2 O
mg	931 2 O
/	933 1 O
kg	934 2 O
per	937 3 O
dose	941 4 O
,	945 1 O
therapy	947 7 O
was	955 3 O
restarted	959 9 O
with	969 4 O
lower	974 5 O
doses	980 5 O
,	985 1 O
usually	987 7 O
50	995 2 O
mg	998 2 O
/	1000 1 O
kg	1001 2 O
per	1004 3 O
dose	1008 4 O
or	1013 2 O
less	1016 4 O
depending	1021 9 O
on	1031 2 O
the	1034 3 O
degree	1038 6 O
of	1045 2 O
auditory	1048 8 B-Disease
abnormality	1057 11 I-Disease
,	1068 1 O
and	1070 3 O
with	1074 4 O
the	1079 3 O
exception	1083 9 O
of	1093 2 O
two	1096 3 O
cases	1100 5 O
no	1106 2 O
further	1109 7 O
toxicity	1117 8 B-Disease
was	1126 3 O
demonstrated	1130 12 O
.	1142 1 O

Auditory	1144 8 O
deterioration	1153 13 O
and	1167 3 O
improvement	1171 11 O
,	1182 1 O
demonstrated	1184 12 O
serially	1197 8 O
in	1206 2 O
individual	1209 10 O
patients	1220 8 O
receiving	1229 9 O
and	1239 3 O
not	1243 3 O
receiving	1247 9 O
deferoxamine	1257 12 B-Chemical
,	1269 1 O
respectively	1271 12 O
,	1283 1 O
provided	1285 8 O
convincing	1294 10 O
evidence	1305 8 O
for	1314 3 O
a	1318 1 O
cause	1320 5 O
-	1325 1 O
and	1326 3 O
-	1329 1 O
effect	1330 6 O
relation	1337 8 O
between	1346 7 O
deferoxamine	1354 12 B-Chemical
administration	1367 14 O
and	1382 3 O
ototoxicity	1386 11 B-Disease
.	1397 1 O

Based	1399 5 O
on	1405 2 O
these	1408 5 O
data	1414 4 O
,	1418 1 O
a	1420 1 O
plan	1422 4 O
of	1427 2 O
management	1430 10 O
was	1441 3 O
developed	1445 9 O
that	1455 4 O
allows	1460 6 O
effective	1467 9 O
yet	1477 3 O
safe	1481 4 O
administration	1486 14 O
of	1501 2 O
deferoxamine	1504 12 B-Chemical
.	1516 1 O

A	1518 1 O
dose	1520 4 O
of	1525 2 O
50	1528 2 O
mg	1531 2 O
/	1533 1 O
kg	1534 2 O
is	1537 2 O
recommended	1540 11 O
in	1552 2 O
those	1555 5 O
without	1561 7 O
audiogram	1569 9 O
abnormalities	1579 13 O
.	1592 1 O

With	1594 4 O
mild	1599 4 O
toxicity	1604 8 B-Disease
,	1612 1 O
a	1614 1 O
reduction	1616 9 O
to	1626 2 O
30	1629 2 O
or	1632 2 O
40	1635 2 O
mg	1638 2 O
/	1640 1 O
kg	1641 2 O
per	1644 3 O
dose	1648 4 O
should	1653 6 O
result	1660 6 O
in	1667 2 O
a	1670 1 O
reversal	1672 8 O
of	1681 2 O
the	1684 3 O
abnormal	1688 8 O
results	1697 7 O
to	1705 2 O
normal	1708 6 O
within	1715 6 O
four	1722 4 O
weeks	1727 5 O
.	1732 1 O

Moderate	1734 8 O
abnormalities	1743 13 O
require	1757 7 O
a	1765 1 O
reduction	1767 9 O
of	1777 2 O
deferoxamine	1780 12 B-Chemical
to	1793 2 O
25	1796 2 O
mg	1799 2 O
/	1801 1 O
kg	1802 2 O
per	1805 3 O
dose	1809 4 O
with	1814 4 O
careful	1819 7 O
monitoring	1827 10 O
.	1837 1 O

In	1839 2 O
those	1842 5 O
with	1848 4 O
symptoms	1853 8 O
of	1862 2 O
hearing	1865 7 B-Disease
loss	1873 4 I-Disease
,	1877 1 O
the	1879 3 O
drug	1883 4 O
should	1888 6 O
be	1895 2 O
stopped	1898 7 O
for	1906 3 O
four	1910 4 O
weeks	1915 5 O
,	1920 1 O
and	1922 3 O
when	1926 4 O
the	1931 3 O
audiogram	1935 9 O
is	1945 2 O
stable	1948 6 O
or	1955 2 O
improved	1958 8 O
,	1966 1 O
therapy	1968 7 O
should	1976 6 O
be	1983 2 O
restarted	1986 9 O
at	1996 2 O
10	1999 2 O
to	2002 2 O
25	2005 2 O
mg	2008 2 O
/	2010 1 O
kg	2011 2 O
per	2014 3 O
dose	2018 4 O
.	2022 1 O

Serial	2024 6 O
audiograms	2031 10 O
should	2042 6 O
be	2049 2 O
performed	2052 9 O
every	2062 5 O
six	2068 3 O
months	2072 6 O
in	2079 2 O
those	2082 5 O
without	2088 7 O
problems	2096 8 O
and	2105 3 O
more	2109 4 O
frequently	2114 10 O
in	2125 2 O
young	2128 5 O
patients	2134 8 O
with	2143 4 O
normal	2148 6 O
serum	2155 5 O
ferritin	2161 8 O
values	2170 6 O
and	2177 3 O
in	2181 2 O
those	2184 5 O
with	2190 4 O
auditory	2195 8 B-Disease
dysfunction	2204 11 I-Disease
.	2215 1 O

Flurbiprofen	0 12 B-Chemical
in	13 2 O
the	16 3 O
treatment	20 9 O
of	30 2 O
juvenile	33 8 B-Disease
rheumatoid	42 10 I-Disease
arthritis	53 9 I-Disease
.	62 1 O

Thirty	64 6 O
-	70 1 O
four	71 4 O
patients	76 8 O
with	85 4 O
juvenile	90 8 B-Disease
rheumatoid	99 10 I-Disease
arthritis	110 9 I-Disease
,	119 1 O
who	121 3 O
were	125 4 O
treated	130 7 O
with	138 4 O
flurbiprofen	143 12 B-Chemical
at	156 2 O
a	159 1 O
maximum	161 7 O
dose	169 4 O
of	174 2 O
4	177 1 O
mg	179 2 O
/	181 1 O
kg	182 2 O
/	184 1 O
day	185 3 O
,	188 1 O
had	190 3 O
statistically	194 13 O
significant	208 11 O
decreases	220 9 O
from	230 4 O
baseline	235 8 O
in	244 2 O
6	247 1 O
arthritis	249 9 B-Disease
indices	259 7 O
after	267 5 O
12	273 2 O
weeks	276 5 O
of	282 2 O
treatment	285 9 O
.	294 1 O

Improvements	296 12 O
were	309 4 O
seen	314 4 O
in	319 2 O
the	322 3 O
number	326 6 O
of	333 2 O
tender	336 6 B-Disease
joints	343 6 I-Disease
,	349 1 O
the	351 3 O
severity	355 8 O
of	364 2 O
swelling	367 8 B-Disease
and	376 3 O
tenderness	380 10 B-Disease
,	390 1 O
the	392 3 O
time	396 4 O
of	401 2 O
walk	404 4 O
50	409 2 O
feet	412 4 O
,	416 1 O
the	418 3 O
duration	422 8 O
of	431 2 O
morning	434 7 B-Disease
stiffness	442 9 I-Disease
and	452 3 O
the	456 3 O
circumference	460 13 O
of	474 2 O
the	477 3 O
left	481 4 O
knee	486 4 O
.	490 1 O

The	492 3 O
most	496 4 O
frequently	501 10 O
observed	512 8 O
side	521 4 O
effect	526 6 O
was	533 3 O
fecal	537 5 B-Disease
occult	543 6 I-Disease
blood	550 5 I-Disease
(	556 1 O
25	557 2 O
%	559 1 O
of	561 2 O
patients	564 8 O
)	572 1 O
;	573 1 O
however	575 7 O
,	582 1 O
there	584 5 O
was	590 3 O
no	594 2 O
other	597 5 O
evidence	603 8 O
of	612 2 O
gastrointestinal	615 16 B-Disease
(	632 1 I-Disease
GI	633 2 I-Disease
)	635 1 I-Disease
bleeding	637 8 I-Disease
in	646 2 O
these	649 5 O
patients	655 8 O
.	663 1 O

One	665 3 O
patient	669 7 O
was	677 3 O
prematurely	681 11 O
discontinued	693 12 O
from	706 4 O
the	711 3 O
study	715 5 O
for	721 3 O
severe	725 6 O
headache	732 8 B-Disease
and	741 3 O
abdominal	745 9 B-Disease
pain	755 4 I-Disease
.	759 1 O

Most	761 4 O
side	766 4 O
effects	771 7 O
were	779 4 O
mild	784 4 O
and	789 3 O
related	793 7 O
to	801 2 O
the	804 3 O
GI	808 2 O
tract	811 5 O
.	816 1 O

The	0 3 O
correlation	4 11 O
between	16 7 O
neurotoxic	24 10 B-Disease
esterase	35 8 O
inhibition	44 10 O
and	55 3 O
mipafox	59 7 B-Chemical
-	66 1 O
induced	67 7 O
neuropathic	75 11 B-Disease
damage	87 6 I-Disease
in	94 2 O
rats	97 4 O
.	101 1 O

The	103 3 O
correlation	107 11 O
between	119 7 O
neuropathic	127 11 B-Disease
damage	139 6 I-Disease
and	146 3 O
inhibition	150 10 O
of	161 2 O
neurotoxic	164 10 B-Disease
esterase	175 8 O
or	184 2 O
neuropathy	187 10 B-Disease
target	198 6 O
enzyme	205 6 O
(	212 1 O
NTE	213 3 O
)	216 1 O
was	218 3 O
examined	222 8 O
in	231 2 O
rats	234 4 O
acutely	239 7 O
exposed	247 7 O
to	255 2 O
Mipafox	258 7 B-Chemical
(	266 1 O
N	267 1 B-Chemical
,	268 1 I-Chemical
N	270 1 I-Chemical
'	271 1 I-Chemical
-	272 1 I-Chemical
diisopropylphosphorodiamidofluoridate	273 37 I-Chemical
)	310 1 O
,	311 1 O
a	313 1 O
neurotoxic	315 10 B-Disease
organophosphate	326 15 B-Chemical
.	341 1 O

Brain	343 5 O
and	349 3 O
spinal	353 6 O
cord	360 4 O
NTE	365 3 O
activities	369 10 O
were	380 4 O
measured	385 8 O
in	394 2 O
Long	397 4 O
-	401 1 O
Evans	402 5 O
male	408 4 O
rats	413 4 O
1	418 1 O
hr	420 2 O
post	423 4 O
-	427 1 O
exposure	428 8 O
to	437 2 O
various	440 7 O
dosages	448 7 O
of	456 2 O
Mipafox	459 7 B-Chemical
(	467 1 O
ip	468 2 O
,	470 1 O
1	472 1 O
-	473 1 O
15	474 2 O
mg	477 2 O
/	479 1 O
kg	480 2 O
)	482 1 O
.	483 1 O

These	485 5 O
data	491 4 O
were	496 4 O
correlated	501 10 O
with	512 4 O
histologically	517 14 O
scored	532 6 O
cervical	539 8 O
cord	548 4 B-Disease
damage	553 6 I-Disease
in	560 2 O
a	563 1 O
separate	565 8 O
group	574 5 O
of	580 2 O
similarly	583 9 O
dosed	593 5 O
rats	599 4 O
sampled	604 7 O
14	612 2 O
-	614 1 O
21	615 2 O
days	618 4 O
post	623 4 O
-	627 1 O
exposure	628 8 O
.	636 1 O

Those	638 5 O
dosages	644 7 O
(	652 1 O
greater	653 7 O
than	661 4 O
or	666 2 O
equal	669 5 O
to	675 2 O
10	678 2 O
mg	681 2 O
/	683 1 O
kg	684 2 O
)	686 1 O
that	688 4 O
inhibited	693 9 O
mean	703 4 O
NTE	708 3 O
activity	712 8 O
in	721 2 O
the	724 3 O
spinal	728 6 O
cord	735 4 O
greater	740 7 O
than	748 4 O
or	753 2 O
equal	756 5 O
to	762 2 O
73	765 2 O
%	767 1 O
and	769 3 O
brain	773 5 O
greater	779 7 O
than	787 4 O
or	792 2 O
equal	795 5 O
to	801 2 O
67	804 2 O
%	806 1 O
of	808 2 O
control	811 7 O
values	819 6 O
produced	826 8 O
severe	835 6 O
(	842 1 O
greater	843 7 O
than	851 4 O
or	856 2 O
equal	859 5 O
to	865 2 O
3	868 1 O
)	869 1 O
cervical	871 8 O
cord	880 4 O
pathology	885 9 O
in	895 2 O
85	898 2 O
%	900 1 O
of	902 2 O
the	905 3 O
rats	909 4 O
.	913 1 O

In	915 2 O
contrast	918 8 O
,	926 1 O
dosages	928 7 O
of	936 2 O
Mipafox	939 7 B-Chemical
(	947 1 O
less	948 4 O
than	953 4 O
or	958 2 O
equal	961 5 O
to	967 2 O
5	970 1 O
mg	972 2 O
/	974 1 O
kg	975 2 O
)	977 1 O
which	979 5 O
inhibited	985 9 O
mean	995 4 O
NTE	1000 3 O
activity	1004 8 O
in	1013 2 O
spinal	1016 6 O
cord	1023 4 O
less	1028 4 O
than	1033 4 O
or	1038 2 O
equal	1041 5 O
to	1047 2 O
61	1050 2 O
%	1052 1 O
and	1054 3 O
brain	1058 5 O
less	1064 4 O
than	1069 4 O
or	1074 2 O
equal	1077 5 O
to	1083 2 O
60	1086 2 O
%	1088 1 O
produced	1090 8 O
this	1099 4 O
degree	1104 6 O
of	1111 2 O
cord	1114 4 B-Disease
damage	1119 6 I-Disease
in	1126 2 O
only	1129 4 O
9	1134 1 O
%	1135 1 O
of	1137 2 O
the	1140 3 O
animals	1144 7 O
.	1151 1 O

These	1153 5 O
data	1159 4 O
indicate	1164 8 O
that	1173 4 O
a	1178 1 O
critical	1180 8 O
percentage	1189 10 O
of	1200 2 O
NTE	1203 3 O
inhibition	1207 10 O
in	1218 2 O
brain	1221 5 O
and	1227 3 O
spinal	1231 6 O
cord	1238 4 O
sampled	1243 7 O
shortly	1251 7 O
after	1259 5 O
Mipafox	1265 7 B-Chemical
exposure	1273 8 O
can	1282 3 O
predict	1286 7 O
neuropathic	1294 11 B-Disease
damage	1306 6 I-Disease
in	1313 2 O
rats	1316 4 O
several	1321 7 O
weeks	1329 5 O
later	1335 5 O
.	1340 1 O

Cerebral	0 8 B-Disease
infarction	9 10 I-Disease
with	20 4 O
a	25 1 O
single	27 6 O
oral	34 4 O
dose	39 4 O
of	44 2 O
phenylpropanolamine	47 19 B-Chemical
.	66 1 O

Phenylpropanolamine	68 19 B-Chemical
(	88 1 O
PPA	89 3 B-Chemical
)	92 1 O
,	93 1 O
a	95 1 O
synthetic	97 9 O
sympathomimetic	107 15 O
that	123 4 O
is	128 2 O
structurally	131 12 O
similar	144 7 O
to	152 2 O
amphetamine	155 11 B-Chemical
,	166 1 O
is	168 2 O
available	171 9 O
over	181 4 O
the	186 3 O
counter	190 7 O
in	198 2 O
anorectics	201 10 O
,	211 1 O
nasal	213 5 O
congestants	219 11 O
,	230 1 O
and	232 3 O
cold	236 4 O
preparations	241 12 O
.	253 1 O

Its	255 3 O
prolonged	259 9 O
use	269 3 O
or	273 2 O
overuse	276 7 O
has	284 3 O
been	288 4 O
associated	293 10 O
with	304 4 O
seizures	309 8 B-Disease
,	317 1 O
intracerebral	319 13 B-Disease
hemorrhage	333 10 I-Disease
,	343 1 O
neuropsychiatric	345 16 B-Disease
symptoms	362 8 I-Disease
,	370 1 O
and	372 3 O
nonhemorrhagic	376 14 O
cerebral	391 8 B-Disease
infarction	400 10 I-Disease
.	410 1 O

We	412 2 O
report	415 6 O
the	422 3 O
case	426 4 O
of	431 2 O
a	434 1 O
young	436 5 O
woman	442 5 O
who	448 3 O
suffered	452 8 O
a	461 1 O
cerebral	463 8 B-Disease
infarction	472 10 I-Disease
after	483 5 O
taking	489 6 O
a	496 1 O
single	498 6 O
oral	505 4 O
dose	510 4 O
of	515 2 O
PPA	518 3 B-Chemical
.	521 1 O

Treatment	0 9 O
of	10 2 O
psoriasis	13 9 B-Disease
with	23 4 O
azathioprine	28 12 B-Chemical
.	40 1 O

Azathioprine	42 12 B-Chemical
treatment	55 9 O
benefited	65 9 O
19	75 2 O
(	78 1 O
66	79 2 O
%	81 1 O
)	82 1 O
out	84 3 O
of	88 2 O
29	91 2 O
patients	94 8 O
suffering	103 9 O
from	113 4 O
severe	118 6 O
psoriasis	125 9 B-Disease
.	134 1 O

Haematological	136 14 O
complications	151 13 O
were	165 4 O
not	170 3 O
troublesome	174 11 O
and	186 3 O
results	190 7 O
of	198 2 O
biochemical	201 11 O
liver	213 5 O
function	219 8 O
tests	228 5 O
remained	234 8 O
normal	243 6 O
.	249 1 O

Minimal	251 7 O
cholestasis	259 11 B-Disease
was	271 3 O
seen	275 4 O
in	280 2 O
two	283 3 O
cases	287 5 O
and	293 3 O
portal	297 6 O
fibrosis	304 8 B-Disease
of	313 2 O
a	316 1 O
reversible	318 10 O
degree	329 6 O
in	336 2 O
eight	339 5 O
.	344 1 O

Liver	346 5 O
biopsies	352 8 O
should	361 6 O
be	368 2 O
undertaken	371 10 O
at	382 2 O
regular	385 7 O
intervals	393 9 O
if	403 2 O
azathioprine	406 12 B-Chemical
therapy	419 7 O
is	427 2 O
continued	430 9 O
so	440 2 O
that	443 4 O
structural	448 10 O
liver	459 5 B-Disease
damage	465 6 I-Disease
may	472 3 O
be	476 2 O
detected	479 8 O
at	488 2 O
an	491 2 O
early	494 5 O
and	500 3 O
reversible	504 10 O
stage	515 5 O
.	520 1 O

Maternal	0 8 O
lithium	9 7 B-Chemical
and	17 3 O
neonatal	21 8 O
Ebstein	30 7 B-Disease
'	37 1 I-Disease
s	38 1 I-Disease
anomaly	40 7 I-Disease
:	47 1 O
evaluation	49 10 O
with	60 4 O
cross	65 5 O
-	70 1 O
sectional	71 9 O
echocardiography	81 16 O
.	97 1 O

Cross	99 5 O
-	104 1 O
sectional	105 9 O
echocardiography	115 16 O
was	132 3 O
used	136 4 O
to	141 2 O
evaluate	144 8 O
two	153 3 O
neonates	157 8 O
whose	166 5 O
mothers	172 7 O
ingested	180 8 O
lithium	189 7 B-Chemical
during	197 6 O
pregnancy	204 9 O
.	213 1 O

In	215 2 O
one	218 3 O
infant	222 6 O
,	228 1 O
Ebstein	230 7 B-Disease
'	237 1 I-Disease
s	238 1 I-Disease
anomaly	240 7 I-Disease
of	248 2 O
the	251 3 O
tricuspid	255 9 O
valve	265 5 O
was	271 3 O
identified	275 10 O
.	285 1 O

In	287 2 O
the	290 3 O
other	294 5 O
infant	300 6 O
cross	307 5 O
-	312 1 O
sectional	313 9 O
echocardiography	323 16 O
provided	340 8 O
reassurance	349 11 O
that	361 4 O
the	366 3 O
infant	370 6 O
did	377 3 O
not	381 3 O
have	385 4 O
Ebstein	390 7 B-Disease
'	397 1 I-Disease
s	398 1 I-Disease
anomaly	400 7 I-Disease
.	407 1 O

Cross	409 5 O
-	414 1 O
sectional	415 9 O
echocardiographic	425 17 O
screening	443 9 O
of	453 2 O
newborns	456 8 O
exposed	465 7 O
to	473 2 O
lithium	476 7 B-Chemical
during	484 6 O
gestation	491 9 O
can	501 3 O
provide	505 7 O
highly	513 6 O
accurate	520 8 O
,	528 1 O
noninvasive	530 11 O
assessment	542 10 O
of	553 2 O
the	556 3 O
presence	560 8 O
or	569 2 O
absence	572 7 O
of	580 2 O
lithium	583 7 B-Chemical
-	590 1 O
induced	591 7 O
cardiac	599 7 B-Disease
malformations	607 13 I-Disease
.	620 1 O

Effects	0 7 O
of	8 2 O
training	11 8 O
on	20 2 O
the	23 3 O
extent	27 6 O
of	34 2 O
experimental	37 12 O
myocardial	50 10 B-Disease
infarction	61 10 I-Disease
in	72 2 O
aging	75 5 O
rats	81 4 O
.	85 1 O

The	87 3 O
effects	91 7 O
of	99 2 O
exercise	102 8 O
on	111 2 O
the	114 3 O
severity	118 8 O
of	127 2 O
isoproterenol	130 13 B-Chemical
-	143 1 O
induced	144 7 O
myocardial	152 10 B-Disease
infarction	163 10 I-Disease
were	174 4 O
studied	179 7 O
in	187 2 O
female	190 6 O
albino	197 6 O
rats	204 4 O
of	209 2 O
20	212 2 O
,	214 1 O
40	215 2 O
,	217 1 O
60	218 2 O
and	221 3 O
80	225 2 O
weeks	228 5 O
of	234 2 O
age	237 3 O
.	240 1 O

The	242 3 O
rats	246 4 O
were	251 4 O
trained	256 7 O
to	264 2 O
swim	267 4 O
for	272 3 O
a	276 1 O
specific	278 8 O
duration	287 8 O
and	296 3 O
for	300 3 O
a	304 1 O
particular	306 10 O
period	317 6 O
.	323 1 O

The	325 3 O
occurrence	329 10 O
of	340 2 O
infarcts	343 8 B-Disease
were	352 4 O
confirmed	357 9 O
by	367 2 O
histological	370 12 O
methods	383 7 O
.	390 1 O

Elevations	392 10 O
in	403 2 O
the	406 3 O
serum	410 5 O
GOT	416 3 O
and	420 3 O
GPT	424 3 O
were	428 4 O
maximum	433 7 O
in	441 2 O
the	444 3 O
sedentary	448 9 O
-	457 1 O
isoproterenols	458 14 B-Chemical
and	473 3 O
minimum	477 7 O
in	485 2 O
the	488 3 O
exercise	492 8 O
-	500 1 O
controls	501 8 O
.	509 1 O

These	511 5 O
changes	517 7 O
in	525 2 O
the	528 3 O
serum	532 5 O
transaminases	538 13 O
were	552 4 O
associated	557 10 O
with	568 4 O
corresponding	573 13 O
depletions	587 10 O
in	598 2 O
the	601 3 O
cardiac	605 7 O
GOT	613 3 O
and	617 3 O
GPT	621 3 O
.	624 1 O

However	626 7 O
,	633 1 O
age	635 3 O
was	639 3 O
seen	643 4 O
to	648 2 O
interfere	651 9 O
with	661 4 O
the	666 3 O
responses	670 9 O
exhibited	680 9 O
by	690 2 O
the	693 3 O
young	697 5 O
and	703 3 O
old	707 3 O
rats	711 4 O
.	715 1 O

Studies	717 7 O
dealing	725 7 O
with	733 4 O
myocardial	738 10 B-Disease
infarction	749 10 I-Disease
are	760 3 O
more	764 4 O
informative	769 11 O
when	781 4 O
dealt	786 5 O
with	792 4 O
age	797 3 O
.	800 1 O

Effect	0 6 O
of	7 2 O
polyethylene	10 12 B-Chemical
glycol	23 6 I-Chemical
400	30 3 I-Chemical
on	34 2 O
adriamycin	37 10 B-Chemical
toxicity	48 8 B-Disease
in	57 2 O
mice	60 4 O
.	64 1 O

The	66 3 O
effect	70 6 O
of	77 2 O
a	80 1 O
widely	82 6 O
used	89 4 O
organic	94 7 O
solvent	102 7 O
,	109 1 O
polyethylene	111 12 B-Chemical
glycol	124 6 I-Chemical
400	131 3 I-Chemical
(	135 1 O
PEG	136 3 B-Chemical
400	140 3 I-Chemical
)	143 1 O
,	144 1 O
on	146 2 O
the	149 3 O
toxic	153 5 O
action	159 6 O
of	166 2 O
an	169 2 O
acute	172 5 O
or	178 2 O
chronic	181 7 O
treatment	189 9 O
with	199 4 O
adriamycin	204 10 B-Chemical
(	215 1 O
ADR	216 3 B-Chemical
)	219 1 O
was	221 3 O
evaluated	225 9 O
in	235 2 O
mice	238 4 O
.	242 1 O

PEG	244 3 B-Chemical
400	248 3 I-Chemical
impressively	252 12 O
decreased	265 9 O
both	275 4 O
acute	280 5 O
high	286 4 O
-	290 1 O
dose	291 4 O
and	296 3 O
chronic	300 7 O
low	308 3 O
-	311 1 O
dose	312 4 O
-	316 1 O
ADR	317 3 B-Chemical
-	320 1 O
associated	321 10 O
lethality	332 9 O
.	341 1 O

Light	343 5 O
microscopic	349 11 O
analysis	361 8 O
showed	370 6 O
a	377 1 O
significant	379 11 O
protection	391 10 O
against	402 7 O
ADR	410 3 B-Chemical
-	413 1 O
induced	414 7 O
cardiac	422 7 B-Disease
morphological	430 13 I-Disease
alterations	444 11 I-Disease
.	455 1 O

Such	457 4 O
treatment	462 9 O
did	472 3 O
not	476 3 O
diminish	480 8 O
the	489 3 O
ADR	493 3 B-Chemical
antitumor	497 9 O
activity	507 8 O
in	516 2 O
L1210	519 5 B-Disease
leukemia	525 8 I-Disease
and	534 3 O
in	538 2 O
Ehrlich	541 7 B-Disease
ascites	549 7 I-Disease
tumor	557 5 I-Disease
.	562 1 O

Intra	0 5 O
-	5 1 O
arterial	6 8 O
BCNU	15 4 B-Chemical
chemotherapy	20 12 O
for	33 3 O
treatment	37 9 O
of	47 2 O
malignant	50 9 B-Disease
gliomas	60 7 I-Disease
of	68 2 O
the	71 3 O
central	75 7 O
nervous	83 7 O
system	91 6 O
.	97 1 O

Because	99 7 O
of	107 2 O
the	110 3 O
rapid	114 5 O
systemic	120 8 O
clearance	129 9 O
of	139 2 O
BCNU	142 4 B-Chemical
(	147 1 O
1	148 1 B-Chemical
,	149 1 I-Chemical
3	150 1 I-Chemical
-	151 1 I-Chemical
bis	152 3 I-Chemical
-	155 1 I-Chemical
(	156 1 I-Chemical
2	157 1 I-Chemical
-	158 1 I-Chemical
chloroethyl	159 11 I-Chemical
)	170 1 I-Chemical
-	171 1 I-Chemical
1	172 1 I-Chemical
-	173 1 I-Chemical
nitrosourea	174 11 I-Chemical
)	185 1 O
,	186 1 O
intra	188 5 O
-	193 1 O
arterial	194 8 O
administration	203 14 O
should	218 6 O
provide	225 7 O
a	233 1 O
substantial	235 11 O
advantage	247 9 O
over	257 4 O
intravenous	262 11 O
administration	274 14 O
for	289 3 O
the	293 3 O
treatment	297 9 O
of	307 2 O
malignant	310 9 B-Disease
gliomas	320 7 I-Disease
.	327 1 O

Thirty	329 6 O
-	335 1 O
six	336 3 O
patients	340 8 O
were	349 4 O
treated	354 7 O
with	362 4 O
BCNU	367 4 B-Chemical
every	372 5 O
6	378 1 O
to	380 2 O
8	383 1 O
weeks	385 5 O
,	390 1 O
either	392 6 O
by	399 2 O
transfemoral	402 12 O
catheterization	415 15 O
of	431 2 O
the	434 3 O
internal	438 8 O
carotid	447 7 O
or	455 2 O
vertebral	458 9 O
artery	468 6 O
or	475 2 O
through	478 7 O
a	486 1 O
fully	488 5 O
implantable	494 11 O
intracarotid	506 12 O
drug	519 4 O
delivery	524 8 O
system	533 6 O
,	539 1 O
beginning	541 9 O
with	551 4 O
a	556 1 O
dose	558 4 O
of	563 2 O
200	566 3 O
mg	570 2 O
/	572 1 O
sq	573 2 O
m	576 1 O
body	578 4 O
surface	583 7 O
area	591 4 O
.	595 1 O

Twelve	597 6 O
patients	604 8 O
with	613 4 O
Grade	618 5 O
III	624 3 O
or	628 2 O
IV	631 2 O
astrocytomas	634 12 B-Disease
were	647 4 O
treated	652 7 O
after	660 5 O
partial	666 7 O
resection	674 9 O
of	684 2 O
the	687 3 O
tumor	691 5 B-Disease
without	697 7 O
prior	705 5 O
radiation	711 9 O
therapy	721 7 O
.	728 1 O

After	730 5 O
two	736 3 O
to	740 2 O
seven	743 5 O
cycles	749 6 O
of	756 2 O
chemotherapy	759 12 O
,	771 1 O
nine	773 4 O
patients	778 8 O
showed	787 6 O
a	794 1 O
decrease	796 8 O
in	805 2 O
tumor	808 5 B-Disease
size	814 4 O
and	819 3 O
surrounding	823 11 O
edema	835 5 B-Disease
on	841 2 O
contrast	844 8 O
-	852 1 O
enhanced	853 8 O
computerized	862 12 O
tomography	875 10 O
scans	886 5 O
.	891 1 O

In	893 2 O
the	896 3 O
nine	900 4 O
responders	905 10 O
,	915 1 O
median	917 6 O
duration	924 8 O
of	933 2 O
chemotherapy	936 12 O
response	949 8 O
from	958 4 O
the	963 3 O
time	967 4 O
of	972 2 O
operation	975 9 O
was	985 3 O
25	989 2 O
weeks	992 5 O
(	998 1 O
range	999 5 O
12	1005 2 O
to	1008 2 O
more	1011 4 O
than	1016 4 O
91	1021 2 O
weeks	1024 5 O
)	1029 1 O
.	1030 1 O

The	1032 3 O
median	1036 6 O
duration	1043 8 O
of	1052 2 O
survival	1055 8 O
in	1064 2 O
the	1067 3 O
12	1071 2 O
patients	1074 8 O
was	1083 3 O
54	1087 2 O
weeks	1090 5 O
(	1096 1 O
range	1097 5 O
21	1103 2 O
to	1106 2 O
more	1109 4 O
than	1114 4 O
156	1119 3 O
weeks	1123 5 O
)	1128 1 O
,	1129 1 O
with	1131 4 O
an	1136 2 O
18	1139 2 O
-	1141 1 O
month	1142 5 O
survival	1148 8 O
rate	1157 4 O
of	1162 2 O
42	1165 2 O
%	1167 1 O
.	1168 1 O

Twenty	1170 6 O
-	1176 1 O
four	1177 4 O
patients	1182 8 O
with	1191 4 O
recurrent	1196 9 O
Grade	1206 5 O
I	1212 1 O
to	1214 2 O
IV	1217 2 O
astrocytomas	1220 12 B-Disease
,	1232 1 O
whose	1234 5 O
resection	1240 9 O
and	1250 3 O
irradiation	1254 11 O
therapy	1266 7 O
had	1274 3 O
failed	1278 6 O
,	1284 1 O
received	1286 8 O
two	1295 3 O
to	1299 2 O
eight	1302 5 O
courses	1308 7 O
of	1316 2 O
intra	1319 5 O
-	1324 1 O
arterial	1325 8 O
BCNU	1334 4 B-Chemical
therapy	1339 7 O
.	1346 1 O

Seventeen	1348 9 O
of	1358 2 O
these	1361 5 O
had	1367 3 O
a	1371 1 O
response	1373 8 O
or	1382 2 O
were	1385 4 O
stable	1390 6 O
for	1397 3 O
a	1401 1 O
median	1403 6 O
of	1410 2 O
20	1413 2 O
weeks	1416 5 O
(	1422 1 O
range	1423 5 O
6	1429 1 O
to	1431 2 O
more	1434 4 O
than	1439 4 O
66	1444 2 O
weeks	1447 5 O
)	1452 1 O
.	1453 1 O

The	1455 3 O
catheterization	1459 15 O
procedure	1475 9 O
is	1485 2 O
safe	1488 4 O
,	1492 1 O
with	1494 4 O
no	1499 2 O
immediate	1502 9 O
complication	1512 12 O
in	1525 2 O
111	1528 3 O
infusions	1532 9 O
of	1542 2 O
BCNU	1545 4 B-Chemical
.	1549 1 O

A	1551 1 O
delayed	1553 7 O
complication	1561 12 O
in	1574 2 O
nine	1577 4 O
patients	1582 8 O
has	1591 3 O
been	1595 4 O
unilateral	1600 10 O
loss	1611 4 B-Disease
of	1616 2 I-Disease
vision	1619 6 I-Disease
secondary	1626 9 O
to	1636 2 O
a	1639 1 O
retinal	1641 7 B-Disease
vasculitis	1649 10 I-Disease
.	1659 1 O

The	1661 3 O
frequency	1665 9 O
of	1675 2 O
visual	1678 6 B-Disease
loss	1685 4 I-Disease
decreased	1690 9 O
after	1700 5 O
the	1706 3 O
concentration	1710 13 O
of	1724 2 O
the	1727 3 O
ethanol	1731 7 B-Chemical
diluent	1739 7 O
was	1747 3 O
lowered	1751 7 O
.	1758 1 O

Blood	0 5 O
pressure	6 8 O
response	15 8 O
to	24 2 O
chronic	27 7 O
low	35 3 O
-	38 1 O
dose	39 4 O
intrarenal	44 10 O
noradrenaline	55 13 B-Chemical
infusion	69 8 O
in	78 2 O
conscious	81 9 O
rats	91 4 O
.	95 1 O

Sodium	97 6 B-Chemical
chloride	104 8 I-Chemical
solution	113 8 O
(	122 1 O
0	123 1 O
.	124 1 O
9	125 1 O
%	126 1 O
)	127 1 O
or	129 2 O
noradrenaline	132 13 B-Chemical
in	146 2 O
doses	149 5 O
of	155 2 O
4	158 1 O
,	159 1 O
12	161 2 O
and	164 3 O
36	168 2 O
micrograms	171 10 O
h	182 1 O
-	183 1 O
1	184 1 O
kg	186 2 O
-	188 1 O
1	189 1 O
was	191 3 O
infused	195 7 O
for	203 3 O
five	207 4 O
consecutive	212 11 O
days	224 4 O
,	228 1 O
either	230 6 O
intrarenally	237 12 O
(	250 1 O
by	251 2 O
a	254 1 O
new	256 3 O
technique	260 9 O
)	269 1 O
or	271 2 O
intravenously	274 13 O
into	288 4 O
rats	293 4 O
with	298 4 O
one	303 3 O
kidney	307 6 O
removed	314 7 O
.	321 1 O

Intrarenal	323 10 O
infusion	334 8 O
of	343 2 O
noradrenaline	346 13 B-Chemical
caused	360 6 O
hypertension	367 12 B-Disease
at	380 2 O
doses	383 5 O
which	389 5 O
did	395 3 O
not	399 3 O
do	403 2 O
so	406 2 O
when	409 4 O
infused	414 7 O
intravenously	422 13 O
.	435 1 O

Intrarenal	437 10 O
compared	448 8 O
with	457 4 O
intravenous	462 11 O
infusion	474 8 O
of	483 2 O
noradrenaline	486 13 B-Chemical
caused	500 6 O
higher	507 6 O
plasma	514 6 O
noradrenaline	521 13 B-Chemical
concentrations	535 14 O
and	550 3 O
a	554 1 O
shift	556 5 O
of	562 2 O
the	565 3 O
plasma	569 6 O
noradrenaline	576 13 B-Chemical
concentration	590 13 O
-	603 1 O
blood	604 5 O
pressure	610 8 O
effect	619 6 O
curve	626 5 O
towards	632 7 O
lower	640 5 O
plasma	646 6 O
noradrenaline	653 13 B-Chemical
levels	667 6 O
.	673 1 O

These	675 5 O
results	681 7 O
suggest	689 7 O
that	697 4 O
hypertension	702 12 B-Disease
after	715 5 O
chronic	721 7 O
intrarenal	729 10 O
noradrenaline	740 13 B-Chemical
infusion	754 8 O
is	763 2 O
produced	766 8 O
by	775 2 O
relatively	778 10 O
higher	789 6 O
levels	796 6 O
of	803 2 O
circulating	806 11 O
noradrenaline	818 13 B-Chemical
and	832 3 O
by	836 2 O
triggering	839 10 O
of	850 2 O
an	853 2 O
additional	856 10 O
intrarenal	867 10 O
pressor	878 7 O
mechanism	886 9 O
.	895 1 O

Age	0 3 O
and	4 3 O
renal	8 5 O
clearance	14 9 O
of	24 2 O
cimetidine	27 10 B-Chemical
.	37 1 O

In	39 2 O
35	42 2 O
patients	45 8 O
(	54 1 O
ages	55 4 O
20	60 2 O
to	63 2 O
86	66 2 O
yr	69 2 O
)	71 1 O
receiving	73 9 O
cimetidine	83 10 B-Chemical
therapeutically	94 15 O
two	110 3 O
serum	114 5 O
samples	120 7 O
and	128 3 O
all	132 3 O
urine	136 5 O
formed	142 6 O
in	149 2 O
the	152 3 O
interim	156 7 O
were	164 4 O
collected	169 9 O
for	179 3 O
analysis	183 8 O
of	192 2 O
cimetidine	195 10 B-Chemical
by	206 2 O
high	209 4 O
-	213 1 O
pressure	214 8 O
liquid	223 6 O
chromatography	230 14 O
and	245 3 O
for	249 3 O
creatinine	253 10 B-Chemical
.	263 1 O

Cimetidine	265 10 B-Chemical
clearance	276 9 O
decreased	286 9 O
with	296 4 O
age	301 3 O
.	304 1 O

The	306 3 O
extrapolated	310 12 O
6	323 1 O
-	324 1 O
hr	325 2 O
serum	328 5 O
concentration	334 13 O
of	348 2 O
cimetidine	351 10 B-Chemical
per	362 3 O
unit	366 4 O
dose	371 4 O
,	375 1 O
after	377 5 O
intravenous	383 11 O
cimetidine	395 10 B-Chemical
,	405 1 O
increased	407 9 O
with	417 4 O
age	422 3 O
of	426 2 O
the	429 3 O
patients	433 8 O
.	441 1 O

The	443 3 O
ratio	447 5 O
of	453 2 O
cimetidine	456 10 B-Chemical
clearance	467 9 O
to	477 2 O
creatinine	480 10 B-Chemical
clearance	491 9 O
(	501 1 O
Rc	502 2 O
)	504 1 O
averaged	506 8 O
4	515 1 O
.	516 1 O
8	517 1 O
+	519 1 O
/	520 1 O
-	521 1 O
2	523 1 O
.	524 1 O
0	525 1 O
,	526 1 O
indicating	528 10 O
net	539 3 O
tubular	543 7 O
secretion	551 9 O
for	561 3 O
cimetidine	565 10 B-Chemical
.	575 1 O

Rc	577 2 O
seemed	580 6 O
to	587 2 O
be	590 2 O
independent	593 11 O
of	605 2 O
age	608 3 O
and	612 3 O
decreased	616 9 O
with	626 4 O
increasing	631 10 O
serum	642 5 O
concentration	648 13 O
of	662 2 O
cimetidine	665 10 B-Chemical
,	675 1 O
suggesting	677 10 O
that	688 4 O
secretion	693 9 O
of	703 2 O
cimetidine	706 10 B-Chemical
is	717 2 O
a	720 1 O
saturable	722 9 O
process	732 7 O
.	739 1 O

There	741 5 O
was	747 3 O
only	751 4 O
one	756 3 O
case	760 4 O
of	765 2 O
dementia	768 8 B-Disease
possibly	777 8 O
due	786 3 O
to	790 2 O
cimetidine	793 10 B-Chemical
(	804 1 O
with	805 4 O
a	810 1 O
drug	812 4 O
level	817 5 O
of	823 2 O
1	826 1 O
.	827 1 O
9	828 1 O
microgram	830 9 O
/	839 1 O
ml	840 2 O
6	843 1 O
hr	845 2 O
after	848 5 O
a	854 1 O
dose	856 4 O
)	860 1 O
in	862 2 O
a	865 1 O
group	867 5 O
of	873 2 O
13	876 2 O
patients	879 8 O
without	888 7 O
liver	896 5 B-Disease
or	902 2 I-Disease
kidney	905 6 I-Disease
disease	912 7 I-Disease
who	920 3 O
had	924 3 O
cimetidine	928 10 B-Chemical
levels	939 6 O
above	946 5 O
1	952 1 O
.	953 1 O
25	954 2 O
microgram	957 9 O
/	966 1 O
ml	967 2 O
.	969 1 O

Thus	971 4 O
,	975 1 O
high	977 4 O
cimetidine	982 10 B-Chemical
levels	993 6 O
alone	1000 5 O
do	1006 2 O
not	1009 3 O
always	1013 6 O
induce	1020 6 O
dementia	1027 8 B-Disease
.	1035 1 O

Development	0 11 O
of	12 2 O
clear	15 5 B-Disease
cell	21 4 I-Disease
adenocarcinoma	26 14 I-Disease
in	41 2 O
DES	44 3 B-Chemical
-	47 1 O
exposed	48 7 O
offspring	56 9 O
under	66 5 O
observation	72 11 O
.	83 1 O

Two	85 3 O
cases	89 5 O
of	95 2 O
clear	98 5 B-Disease
cell	104 4 I-Disease
adenocarcinoma	109 14 I-Disease
of	124 2 I-Disease
the	127 3 I-Disease
vagina	131 6 I-Disease
detected	138 8 O
at	147 2 O
follow	150 6 O
-	156 1 O
up	157 2 O
in	160 2 O
young	163 5 O
women	169 5 O
exposed	175 7 O
in	183 2 O
utero	186 5 O
to	192 2 O
diethylstilbestrol	195 18 B-Chemical
are	214 3 O
reported	218 8 O
.	226 1 O

One	228 3 O
patient	232 7 O
,	239 1 O
aged	241 4 O
23	246 2 O
,	248 1 O
had	250 3 O
been	254 4 O
followed	259 8 O
for	268 3 O
2	272 1 O
years	274 5 O
before	280 6 O
carcinoma	287 9 B-Disease
was	297 3 O
diagnosed	301 9 O
;	310 1 O
the	312 3 O
second	316 6 O
patient	323 7 O
,	330 1 O
aged	332 4 O
22	337 2 O
,	339 1 O
had	341 3 O
been	345 4 O
seen	350 4 O
on	355 2 O
a	358 1 O
regular	360 7 O
basis	368 5 O
for	374 3 O
5	378 1 O
years	380 5 O
,	385 1 O
8	387 1 O
months	389 6 O
.	395 1 O

In	397 2 O
both	400 4 O
instances	405 9 O
,	414 1 O
suspicion	416 9 O
of	426 2 O
the	429 3 O
presence	433 8 O
of	442 2 O
carcinoma	445 9 B-Disease
was	455 3 O
aroused	459 7 O
by	467 2 O
the	470 3 O
palpation	474 9 O
of	484 2 O
a	487 1 O
small	489 5 O
nodule	495 6 O
in	502 2 O
the	505 3 O
vaginal	509 7 O
fornix	517 6 O
.	523 1 O

Hysterosalpingography	525 21 O
was	547 3 O
performed	551 9 O
on	561 2 O
both	564 4 O
patients	569 8 O
and	578 3 O
,	581 1 O
in	583 2 O
1	586 1 O
instance	588 8 O
,	596 1 O
an	598 2 O
abnormal	601 8 O
x	610 1 O
-	611 1 O
ray	612 3 O
film	616 4 O
was	621 3 O
reflected	625 9 O
by	635 2 O
the	638 3 O
gross	642 5 O
appearance	648 10 O
of	659 2 O
the	662 3 O
uterine	666 7 O
cavity	674 6 O
found	681 5 O
in	687 2 O
the	690 3 O
surgical	694 8 O
specimen	703 8 O
.	711 1 O

Phenobarbitone	0 14 B-Chemical
-	14 1 O
induced	15 7 O
enlargement	23 11 B-Disease
of	35 2 I-Disease
the	38 3 I-Disease
liver	42 5 I-Disease
in	48 2 O
the	51 3 O
rat	55 3 O
:	58 1 O
its	60 3 O
relationship	64 12 O
to	77 2 O
carbon	80 6 B-Chemical
tetrachloride	87 13 I-Chemical
-	100 1 O
induced	101 7 O
cirrhosis	109 9 B-Disease
.	118 1 O

The	120 3 O
yield	124 5 O
of	130 2 O
severe	133 6 O
cirrhosis	140 9 B-Disease
of	150 2 I-Disease
the	153 3 I-Disease
liver	157 5 I-Disease
(	163 1 O
defined	164 7 O
as	172 2 O
a	175 1 O
shrunken	177 8 O
finely	186 6 O
nodular	193 7 O
liver	201 5 O
with	207 4 O
micronodular	212 12 O
histology	225 9 O
,	234 1 O
ascites	236 7 B-Disease
greater	244 7 O
than	252 4 O
30	257 2 O
ml	260 2 O
,	262 1 O
plasma	264 6 O
albumin	271 7 O
less	279 4 O
than	284 4 O
2	289 1 O
.	290 1 O
2	291 1 O
g	293 1 O
/	294 1 O
dl	295 2 O
,	297 1 O
splenomegaly	299 12 B-Disease
2	312 1 O
-	313 1 O
3	314 1 O
times	316 5 O
normal	322 6 O
,	328 1 O
and	330 3 O
testicular	334 10 O
atrophy	345 7 B-Disease
approximately	353 13 O
half	367 4 O
normal	372 6 O
weight	379 6 O
)	385 1 O
after	387 5 O
12	393 2 O
doses	396 5 O
of	402 2 O
carbon	405 6 B-Chemical
tetrachloride	412 13 I-Chemical
given	426 5 O
intragastrically	432 16 O
in	449 2 O
the	452 3 O
phenobarbitone	456 14 B-Chemical
-	470 1 O
primed	471 6 O
rat	478 3 O
was	482 3 O
increased	486 9 O
from	496 4 O
25	501 2 O
%	503 1 O
to	505 2 O
56	508 2 O
%	510 1 O
by	512 2 O
giving	515 6 O
the	522 3 O
initial	526 7 O
"	534 1 O
calibrating	535 11 O
"	546 1 O
dose	548 4 O
of	553 2 O
carbon	556 6 B-Chemical
tetrachloride	563 13 I-Chemical
at	577 2 O
the	580 3 O
peak	584 4 O
of	589 2 O
the	592 3 O
phenobarbitone	596 14 B-Chemical
-	610 1 O
induced	611 7 O
enlargement	619 11 B-Disease
of	631 2 I-Disease
the	634 3 I-Disease
liver	638 5 I-Disease
.	643 1 O

At	645 2 O
this	648 4 O
point	653 5 O
it	659 2 O
was	662 3 O
assumed	666 7 O
that	674 4 O
the	679 3 O
cytochrome	683 10 O
P450	694 4 O
/	698 1 O
CCl4	699 4 B-Chemical
toxic	704 5 O
state	710 5 O
was	716 3 O
both	720 4 O
maximal	725 7 O
and	733 3 O
stable	737 6 O
.	743 1 O

The	745 3 O
optimal	749 7 O
rat	757 3 O
size	761 4 O
to	766 2 O
begin	769 5 O
phenobarbitone	775 14 B-Chemical
was	790 3 O
determined	794 10 O
as	805 2 O
100	808 3 O
g	812 1 O
,	813 1 O
and	815 3 O
this	819 4 O
size	824 4 O
as	829 2 O
a	832 1 O
group	834 5 O
had	840 3 O
a	844 1 O
mean	846 4 O
maximum	851 7 O
relative	859 8 O
liver	868 5 O
weight	874 6 O
increase	881 8 O
47	890 2 O
%	892 1 O
greater	894 7 O
than	902 4 O
normal	907 6 O
rats	914 4 O
of	919 2 O
the	922 3 O
same	926 4 O
body	931 4 O
weight	936 6 O
.	942 1 O

The	944 3 O
optimal	948 7 O
time	956 4 O
for	961 3 O
the	965 3 O
initial	969 7 O
dose	977 4 O
of	982 2 O
carbon	985 6 B-Chemical
tetrachloride	992 13 I-Chemical
was	1006 3 O
after	1010 5 O
14	1016 2 O
days	1019 4 O
on	1024 2 O
phenobarbitone	1027 14 B-Chemical
.	1041 1 O

Attenuation	0 11 O
of	12 2 O
the	15 3 O
lithium	19 7 B-Chemical
-	26 1 O
induced	27 7 O
diabetes	35 8 B-Disease
-	43 1 I-Disease
insipidus	44 9 I-Disease
-	53 1 I-Disease
like	54 4 I-Disease
syndrome	59 8 I-Disease
by	68 2 O
amiloride	71 9 B-Chemical
in	81 2 O
rats	84 4 O
.	88 1 O

The	90 3 O
effect	94 6 O
of	101 2 O
amiloride	104 9 B-Chemical
on	114 2 O
lithium	117 7 B-Chemical
-	124 1 O
induced	125 7 O
polydipsia	133 10 B-Disease
and	144 3 O
polyuria	148 8 B-Disease
and	157 3 O
on	161 2 O
the	164 3 O
lithium	168 7 B-Chemical
concentration	176 13 O
in	190 2 O
the	193 3 O
plasma	197 6 O
,	203 1 O
brain	205 5 O
,	210 1 O
kidney	212 6 O
,	218 1 O
thyroid	220 7 O
and	228 3 O
red	232 3 O
blood	236 5 O
cells	242 5 O
was	248 3 O
investigated	252 12 O
in	265 2 O
rats	268 4 O
,	272 1 O
chronically	274 11 O
treated	286 7 O
with	294 4 O
LiCl	299 4 B-Chemical
.	303 1 O

Amiloride	305 9 B-Chemical
reduced	315 7 O
the	323 3 O
drinking	327 8 O
and	336 3 O
urine	340 5 O
volume	346 6 O
of	353 2 O
rats	356 4 O
in	361 2 O
an	364 2 O
acute	367 5 O
(	373 1 O
6	374 1 O
or	376 2 O
12	379 2 O
h	382 1 O
)	383 1 O
and	385 3 O
a	389 1 O
subacute	391 8 O
(	400 1 O
3	401 1 O
days	403 4 O
)	407 1 O
experiment	409 10 O
.	419 1 O

6	421 1 O
h	423 1 O
after	425 5 O
the	431 3 O
administration	435 14 O
of	450 2 O
amiloride	453 9 B-Chemical
,	462 1 O
a	464 1 O
reduction	466 9 O
was	476 3 O
observed	480 8 O
in	489 2 O
the	492 3 O
lithium	496 7 B-Chemical
content	504 7 O
of	512 2 O
the	515 3 O
renal	519 5 O
medulla	525 7 O
but	533 3 O
not	537 3 O
in	541 2 O
the	544 3 O
other	548 5 O
organs	554 6 O
studied	561 7 O
.	568 1 O

At	570 2 O
12	573 2 O
h	576 1 O
,	577 1 O
all	579 3 O
the	583 3 O
tissues	587 7 O
showed	595 6 O
a	602 1 O
slight	604 6 O
increase	611 8 O
in	620 2 O
lithium	623 7 B-Chemical
levels	631 6 O
.	637 1 O

After	639 5 O
3	645 1 O
days	647 4 O
of	652 2 O
combined	655 8 O
treatment	664 9 O
,	673 1 O
a	675 1 O
marked	677 6 O
elevation	684 9 O
in	694 2 O
plasma	697 6 O
and	704 3 O
tissue	708 6 O
lithium	715 7 B-Chemical
levels	723 6 O
accompanied	730 11 O
a	742 1 O
reduction	744 9 O
in	754 2 O
water	757 5 O
intake	763 6 O
.	769 1 O

In	771 2 O
all	774 3 O
the	778 3 O
experiments	782 11 O
,	793 1 O
the	795 3 O
attenuation	799 11 O
of	811 2 O
the	814 3 O
lithium	818 7 B-Chemical
-	825 1 O
induced	826 7 O
diabetes	834 8 B-Disease
-	842 1 I-Disease
insipidus	843 9 I-Disease
-	852 1 I-Disease
like	853 4 I-Disease
syndrome	858 8 I-Disease
by	867 2 O
amiloride	870 9 B-Chemical
was	880 3 O
accompanied	884 11 O
by	896 2 O
a	899 1 O
reduction	901 9 O
of	911 2 O
the	914 3 O
ratio	918 5 O
between	924 7 O
the	932 3 O
lithium	936 7 B-Chemical
concentration	944 13 O
in	958 2 O
the	961 3 O
renal	965 5 O
medulla	971 7 O
and	979 3 O
its	983 3 O
levels	987 6 O
in	994 2 O
the	997 3 O
blood	1001 5 O
and	1007 3 O
an	1011 2 O
elevation	1014 9 O
in	1024 2 O
the	1027 3 O
plasma	1031 6 O
potassium	1038 9 B-Chemical
level	1048 5 O
.	1053 1 O

It	1055 2 O
is	1058 2 O
concluded	1061 9 O
that	1071 4 O
acute	1076 5 O
amiloride	1082 9 B-Chemical
administration	1092 14 O
to	1107 2 O
lithium	1110 7 B-Chemical
-	1117 1 O
treated	1118 7 O
patients	1126 8 O
suffering	1135 9 O
from	1145 4 O
polydipsia	1150 10 B-Disease
and	1161 3 O
polyuria	1165 8 B-Disease
might	1174 5 O
relieve	1180 7 O
these	1188 5 O
patients	1194 8 O
but	1203 3 O
prolonged	1207 9 O
amiloride	1217 9 B-Chemical
supplementation	1227 15 O
would	1243 5 O
result	1249 6 O
in	1256 2 O
elevated	1259 8 O
lithium	1268 7 B-Chemical
levels	1276 6 O
and	1283 3 O
might	1287 5 O
be	1293 2 O
hazardous	1296 9 O
.	1305 1 O

Safety	0 6 O
and	7 3 O
side	11 4 O
-	15 1 O
effects	16 7 O
of	24 2 O
alprazolam	27 10 B-Chemical
.	37 1 O

Controlled	39 10 O
study	50 5 O
in	56 2 O
agoraphobia	59 11 B-Disease
with	71 4 O
panic	76 5 B-Disease
disorder	82 8 I-Disease
.	90 1 O

BACKGROUND	92 10 O
:	102 1 O
The	104 3 O
widespread	108 10 O
use	119 3 O
of	123 2 O
benzodiazepines	126 15 B-Chemical
has	142 3 O
led	146 3 O
to	150 2 O
increasing	153 10 O
recognition	164 11 O
of	176 2 O
their	179 5 O
unwanted	185 8 O
effects	194 7 O
.	201 1 O

The	203 3 O
efficacy	207 8 O
of	216 2 O
alprazolam	219 10 B-Chemical
and	230 3 O
placebo	234 7 O
in	242 2 O
panic	245 5 B-Disease
disorder	251 8 I-Disease
with	260 4 O
agoraphobia	265 11 B-Disease
,	276 1 O
and	278 3 O
the	282 3 O
side	286 4 O
-	290 1 O
effect	291 6 O
and	298 3 O
adverse	302 7 O
effect	310 6 O
profiles	317 8 O
of	326 2 O
both	329 4 O
drug	334 4 O
groups	339 6 O
were	346 4 O
measured	351 8 O
.	359 1 O

METHOD	361 6 O
:	367 1 O
In	369 2 O
London	372 6 O
and	379 3 O
Toronto	383 7 O
154	391 3 O
patients	395 8 O
who	404 3 O
met	408 3 O
DSM	412 3 O
-	415 1 O
III	416 3 O
criteria	420 8 O
for	429 3 O
panic	433 5 B-Disease
disorder	439 8 I-Disease
with	448 4 O
agoraphobia	453 11 B-Disease
were	465 4 O
randomised	470 10 O
to	481 2 O
alprazolam	484 10 B-Chemical
or	495 2 O
placebo	498 7 O
.	505 1 O

Subjects	507 8 O
in	516 2 O
each	519 4 O
drug	524 4 O
group	529 5 O
also	535 4 O
received	540 8 O
either	549 6 O
exposure	556 8 O
or	565 2 O
relaxation	568 10 O
.	578 1 O

Treatment	580 9 O
was	590 3 O
from	594 4 O
weeks	599 5 O
0	605 1 O
to	607 2 O
8	610 1 O
and	612 3 O
was	616 3 O
then	620 4 O
tapered	625 7 O
from	633 4 O
weeks	638 5 O
8	644 1 O
to	646 2 O
16	649 2 O
.	651 1 O

RESULTS	653 7 O
:	660 1 O
Mean	662 4 O
alprazolam	667 10 B-Chemical
dose	678 4 O
was	683 3 O
5	687 1 O
mg	689 2 O
daily	692 5 O
.	697 1 O

Compared	699 8 O
with	708 4 O
placebo	713 7 O
subjects	721 8 O
,	729 1 O
alprazolam	731 10 B-Chemical
patients	742 8 O
developed	751 9 O
more	761 4 O
adverse	766 7 O
reactions	774 9 O
(	784 1 O
21	785 2 O
%	787 1 O
v	789 1 O
.	790 1 O
0	792 1 O
%	793 1 O
)	794 1 O
of	796 2 O
depression	799 10 B-Disease
,	809 1 O
enuresis	811 8 B-Disease
,	819 1 O
disinhibition	821 13 O
and	835 3 O
aggression	839 10 B-Disease
;	849 1 O
and	851 3 O
more	855 4 O
side	860 4 O
-	864 1 O
effects	865 7 O
,	872 1 O
particularly	874 12 O
sedation	887 8 O
,	895 1 O
irritability	897 12 B-Disease
,	909 1 O
impaired	911 8 B-Disease
memory	920 6 I-Disease
,	926 1 O
weight	928 6 B-Disease
loss	935 4 I-Disease
and	940 3 O
ataxia	944 6 B-Disease
.	950 1 O

Side	952 4 O
-	956 1 O
effects	957 7 O
tended	965 6 O
to	972 2 O
diminish	975 8 O
during	984 6 O
treatment	991 9 O
but	1001 3 O
remained	1005 8 O
significant	1014 11 O
at	1026 2 O
week	1029 4 O
8	1034 1 O
.	1035 1 O

Despite	1037 7 O
this	1045 4 O
,	1049 1 O
the	1051 3 O
drop	1055 4 O
-	1059 1 O
out	1060 3 O
rate	1064 4 O
was	1069 3 O
low	1073 3 O
.	1076 1 O

CONCLUSIONS	1078 11 O
:	1089 1 O
Alprazolam	1091 10 B-Chemical
caused	1102 6 O
side	1109 4 O
-	1113 1 O
effects	1114 7 O
and	1122 3 O
adverse	1126 7 O
effects	1134 7 O
during	1142 6 O
treatment	1149 9 O
but	1159 3 O
many	1163 4 O
patients	1168 8 O
were	1177 4 O
willing	1182 7 O
to	1190 2 O
accept	1193 6 O
these	1200 5 O
.	1205 1 O

Dup	0 3 B-Chemical
753	4 3 I-Chemical
prevents	8 8 O
the	17 3 O
development	21 11 O
of	33 2 O
puromycin	36 9 B-Chemical
aminonucleoside	46 15 I-Chemical
-	61 1 O
induced	62 7 O
nephrosis	70 9 B-Disease
.	79 1 O

The	81 3 O
appearance	85 10 O
of	96 2 O
nephrotic	99 9 B-Disease
syndromes	109 9 I-Disease
such	119 4 O
as	124 2 O
proteinuria	127 11 B-Disease
,	138 1 O
hypoalbuminemia	140 15 B-Disease
,	155 1 O
hypercholesterolemia	157 20 B-Disease
and	178 3 O
increase	182 8 O
in	191 2 O
blood	194 5 B-Chemical
nitrogen	200 8 I-Chemical
urea	209 4 I-Chemical
,	213 1 O
induced	215 7 O
in	223 2 O
rats	226 4 O
by	231 2 O
injection	234 9 O
of	244 2 O
puromycin	247 9 B-Chemical
aminonucleoside	257 15 I-Chemical
was	273 3 O
markedly	277 8 O
inhibited	286 9 O
by	296 2 O
oral	299 4 O
administration	304 14 O
of	319 2 O
Dup	322 3 B-Chemical
753	326 3 I-Chemical
(	330 1 O
losartan	331 8 B-Chemical
)	339 1 O
,	340 1 O
a	342 1 O
novel	344 5 O
angiotensin	350 11 B-Chemical
II	362 2 I-Chemical
receptor	365 8 O
antagonist	374 10 O
,	384 1 O
at	386 2 O
a	389 1 O
dose	391 4 O
of	396 2 O
1	399 1 O
or	401 2 O
2	404 1 O
mg	406 2 O
/	408 1 O
kg	409 2 O
per	412 3 O
day	416 3 O
.	419 1 O

The	421 3 O
results	425 7 O
suggest	433 7 O
a	441 1 O
possible	443 8 O
involvement	452 11 O
of	464 2 O
the	467 3 O
renin	471 5 O
-	476 1 O
angiotensin	477 11 B-Chemical
system	489 6 O
in	496 2 O
the	499 3 O
development	503 11 O
of	515 2 O
puromycin	518 9 B-Chemical
aminonucleoside	528 15 I-Chemical
-	543 1 O
induced	544 7 O
nephrosis	552 9 B-Disease
.	561 1 O

Sodium	0 6 B-Chemical
bicarbonate	7 11 I-Chemical
alleviates	19 10 O
penile	30 6 B-Disease
pain	37 4 I-Disease
induced	42 7 O
by	50 2 O
intracavernous	53 14 O
injections	68 10 O
for	79 3 O
erectile	83 8 B-Disease
dysfunction	92 11 I-Disease
.	103 1 O

In	105 2 O
an	108 2 O
attempt	111 7 O
to	119 2 O
determine	122 9 O
whether	132 7 O
penile	140 6 B-Disease
pain	147 4 I-Disease
associated	152 10 O
with	163 4 O
intracorporeal	168 14 O
injections	183 10 O
could	194 5 O
be	200 2 O
due	203 3 O
to	207 2 O
the	210 3 O
acidity	214 7 O
of	222 2 O
the	225 3 O
medication	229 10 O
,	239 1 O
we	241 2 O
performed	244 9 O
a	254 1 O
randomized	256 10 O
study	267 5 O
comparing	273 9 O
the	283 3 O
incidence	287 9 O
of	297 2 O
penile	300 6 B-Disease
pain	307 4 I-Disease
following	312 9 O
intracorporeal	322 14 O
injections	337 10 O
with	348 4 O
or	353 2 O
without	356 7 O
the	364 3 O
addition	368 8 O
of	377 2 O
sodium	380 6 B-Chemical
bicarbonate	387 11 I-Chemical
to	399 2 O
the	402 3 O
intracorporeal	406 14 O
medications	421 11 O
.	432 1 O

A	434 1 O
total	436 5 O
of	442 2 O
38	445 2 O
consecutive	448 11 O
patients	460 8 O
who	469 3 O
presented	473 9 O
to	483 2 O
our	486 3 O
clinic	490 6 O
with	497 4 O
impotence	502 9 B-Disease
received	512 8 O
0	521 1 O
.	522 1 O
2	523 1 O
ml	525 2 O
.	527 1 O
of	529 2 O
a	532 1 O
combination	534 11 O
of	546 2 O
3	549 1 O
drugs	551 5 O
:	556 1 O
6	558 1 O
mg	560 2 O
.	562 1 O
papaverine	564 10 B-Chemical
,	574 1 O
100	576 3 O
micrograms	580 10 O
.	590 1 O
phentolamine	592 12 B-Chemical
and	605 3 O
10	609 2 O
micrograms	612 10 O
.	622 1 O
prostaglandin	624 13 B-Chemical
E1	638 2 I-Chemical
with	641 4 O
(	646 1 O
pH	647 2 O
7	650 1 O
.	651 1 O
05	652 2 O
)	654 1 O
or	656 2 O
without	659 7 O
(	667 1 O
pH	668 2 O
4	671 1 O
.	672 1 O
17	673 2 O
)	675 1 O
the	677 3 O
addition	681 8 O
of	690 2 O
sodium	693 6 B-Chemical
bicarbonate	700 11 I-Chemical
(	712 1 O
0	713 1 O
.	714 1 O
03	715 2 O
mEq	718 3 O
.	721 1 O
)	722 1 O
.	723 1 O

Of	725 2 O
the	728 3 O
19	732 2 O
patients	735 8 O
without	744 7 O
sodium	752 6 B-Chemical
bicarbonate	759 11 I-Chemical
added	771 5 O
to	777 2 O
the	780 3 O
medication	784 10 O
11	795 2 O
(	798 1 O
58	799 2 O
%	801 1 O
)	802 1 O
complained	804 10 O
of	815 2 O
penile	818 6 B-Disease
pain	825 4 I-Disease
due	830 3 O
to	834 2 O
the	837 3 O
medication	841 10 O
,	851 1 O
while	853 5 O
only	859 4 O
1	864 1 O
of	866 2 O
the	869 3 O
19	873 2 O
men	876 3 O
(	880 1 O
5	881 1 O
%	882 1 O
)	883 1 O
who	885 3 O
received	889 8 O
sodium	898 6 B-Chemical
bicarbonate	905 11 I-Chemical
complained	917 10 O
of	928 2 O
penile	931 6 B-Disease
pain	938 4 I-Disease
.	942 1 O

From	944 4 O
these	949 5 O
data	955 4 O
we	960 2 O
conclude	963 8 O
that	972 4 O
the	977 3 O
penile	981 6 B-Disease
pain	988 4 I-Disease
following	993 9 O
intracorporeal	1003 14 O
injections	1018 10 O
is	1029 2 O
most	1032 4 O
likely	1037 6 O
due	1044 3 O
to	1048 2 O
the	1051 3 O
acidity	1055 7 O
of	1063 2 O
the	1066 3 O
medication	1070 10 O
,	1080 1 O
which	1082 5 O
can	1088 3 O
be	1092 2 O
overcome	1095 8 O
by	1104 2 O
elevating	1107 9 O
the	1117 3 O
pH	1121 2 O
to	1124 2 O
a	1127 1 O
neutral	1129 7 O
level	1137 5 O
.	1142 1 O

Prospective	0 11 O
study	12 5 O
of	18 2 O
the	21 3 O
long	25 4 O
-	29 1 O
term	30 4 O
effects	35 7 O
of	43 2 O
somatostatin	46 12 O
analog	59 6 O
(	66 1 O
octreotide	67 10 B-Chemical
)	77 1 O
on	79 2 O
gallbladder	82 11 O
function	94 8 O
and	103 3 O
gallstone	107 9 B-Disease
formation	117 9 O
in	127 2 O
Chinese	130 7 O
acromegalic	138 11 B-Disease
patients	150 8 O
.	158 1 O

This	160 4 O
article	165 7 O
reports	173 7 O
the	181 3 O
changes	185 7 O
in	193 2 O
gallbladder	196 11 O
function	208 8 O
examined	217 8 O
by	226 2 O
ultrasonography	229 15 O
in	245 2 O
20	248 2 O
Chinese	251 7 O
patients	259 8 O
with	268 4 O
active	273 6 O
acromegaly	280 10 B-Disease
treated	291 7 O
with	299 4 O
sc	304 2 O
injection	307 9 O
of	317 2 O
the	320 3 O
somatostatin	324 12 O
analog	337 6 O
octreotide	344 10 B-Chemical
in	355 2 O
dosages	358 7 O
of	366 2 O
300	369 3 O
-	372 1 O
1500	373 4 O
micrograms	378 10 O
/	388 1 O
day	389 3 O
for	393 3 O
a	397 1 O
mean	399 4 O
of	404 2 O
24	407 2 O
.	409 1 O
2	410 1 O
+	412 1 O
/	413 1 O
-	414 1 O
13	416 2 O
.	418 1 O
9	419 1 O
months	421 6 O
.	427 1 O

During	429 6 O
treatment	436 9 O
with	446 4 O
octreotide	451 10 B-Chemical
,	461 1 O
17	463 2 O
patients	466 8 O
developed	475 9 O
sludge	485 6 O
,	491 1 O
10	493 2 O
had	496 3 O
gallstones	500 10 B-Disease
,	510 1 O
and	512 3 O
1	516 1 O
developed	518 9 O
acute	528 5 B-Disease
cholecystitis	534 13 I-Disease
requiring	548 9 O
surgery	558 7 O
.	565 1 O

In	567 2 O
all	570 3 O
of	574 2 O
7	577 1 O
patients	579 8 O
examined	588 8 O
acutely	597 7 O
,	604 1 O
gallbladder	606 11 O
contractility	618 13 O
was	632 3 O
inhibited	636 9 O
after	646 5 O
a	652 1 O
single	654 6 O
100	661 3 O
-	664 1 O
micrograms	665 10 O
injection	676 9 O
.	685 1 O

In	687 2 O
8	690 1 O
patients	692 8 O
followed	701 8 O
for	710 3 O
24	714 2 O
weeks	717 5 O
,	722 1 O
gallbladder	724 11 O
contractility	736 13 O
remained	750 8 O
depressed	759 9 B-Disease
throughout	769 10 O
therapy	780 7 O
.	787 1 O

After	789 5 O
withdrawal	795 10 O
of	806 2 O
octreotide	809 10 B-Chemical
in	820 2 O
10	823 2 O
patients	826 8 O
without	835 7 O
gallstones	843 10 B-Disease
,	853 1 O
8	855 1 O
patients	857 8 O
assessed	866 8 O
had	875 3 O
return	879 6 O
of	886 2 O
normal	889 6 O
gallbladder	896 11 O
contractility	908 13 O
within	922 6 O
1	929 1 O
month	931 5 O
.	936 1 O

In	938 2 O
8	941 1 O
of	943 2 O
the	946 3 O
remaining	950 9 O
10	960 2 O
patients	963 8 O
who	972 3 O
developed	976 9 O
gallstones	986 10 B-Disease
during	997 6 O
treatment	1004 9 O
,	1013 1 O
gallbladder	1015 11 O
contractility	1027 13 O
normalized	1041 10 O
in	1052 2 O
5	1055 1 O
patients	1057 8 O
(	1066 1 O
3	1067 1 O
of	1069 2 O
whom	1072 4 O
has	1077 3 O
disappearance	1081 13 O
of	1095 2 O
their	1098 5 O
stones	1104 6 O
within	1111 6 O
3	1118 1 O
weeks	1120 5 O
)	1125 1 O
,	1126 1 O
and	1128 3 O
remained	1132 8 O
depressed	1141 9 B-Disease
in	1151 2 O
3	1154 1 O
(	1156 1 O
2	1157 1 O
of	1159 2 O
whom	1162 4 O
had	1167 3 O
stones	1171 6 O
present	1178 7 O
at	1186 2 O
6	1189 1 O
months	1191 6 O
)	1197 1 O
.	1198 1 O

Our	1200 3 O
results	1204 7 O
suggest	1212 7 O
that	1220 4 O
the	1225 3 O
suppression	1229 11 O
of	1241 2 O
gallbladder	1244 11 O
contractility	1256 13 O
is	1270 2 O
the	1273 3 O
cause	1277 5 O
of	1283 2 O
the	1286 3 O
successive	1290 10 O
formation	1301 9 O
of	1311 2 O
bile	1314 4 O
sludge	1319 6 O
,	1325 1 O
gallstones	1327 10 B-Disease
,	1337 1 O
and	1339 3 O
cholecystitis	1343 13 B-Disease
during	1357 6 O
octreotide	1364 10 B-Chemical
therapy	1375 7 O
in	1383 2 O
Chinese	1386 7 O
acromegalic	1394 11 B-Disease
patients	1406 8 O
.	1414 1 O

It	1416 2 O
is	1419 2 O
therefore	1422 9 O
very	1432 4 O
important	1437 9 O
to	1447 2 O
follow	1450 6 O
the	1457 3 O
changes	1461 7 O
of	1469 2 O
gallbladder	1472 11 O
function	1484 8 O
during	1493 6 O
long	1500 4 O
-	1504 1 O
term	1505 4 O
octreotide	1510 10 B-Chemical
therapy	1521 7 O
of	1529 2 O
acromegalic	1532 11 B-Disease
patients	1544 8 O
.	1552 1 O

Improvement	0 11 O
of	12 2 O
levodopa	15 8 B-Chemical
-	23 1 O
induced	24 7 O
dyskinesia	32 10 B-Disease
by	43 2 O
propranolol	46 11 B-Chemical
in	58 2 O
Parkinson	61 9 B-Disease
'	70 1 I-Disease
s	71 1 I-Disease
disease	73 7 I-Disease
.	80 1 O

Seven	82 5 O
patients	88 8 O
suffering	97 9 O
from	107 4 O
Parkinson	112 9 B-Disease
'	121 1 I-Disease
s	122 1 I-Disease
disease	124 7 I-Disease
(	132 1 O
PD	133 2 B-Disease
)	135 1 O
with	137 4 O
severely	142 8 O
disabling	151 9 O
dyskinesia	161 10 B-Disease
received	172 8 O
low	181 3 O
-	184 1 O
dose	185 4 O
propranolol	190 11 B-Chemical
as	202 2 O
an	205 2 O
adjunct	208 7 O
to	216 2 O
the	219 3 O
currently	223 9 O
used	233 4 O
medical	238 7 O
treatment	246 9 O
.	255 1 O

There	257 5 O
was	263 3 O
a	267 1 O
significant	269 11 O
40	281 2 O
%	283 1 O
improvement	285 11 O
in	297 2 O
the	300 3 O
dyskinesia	304 10 B-Disease
score	315 5 O
without	321 7 O
increase	329 8 O
of	338 2 O
parkinsonian	341 12 B-Disease
motor	354 5 B-Disease
disability	360 10 I-Disease
.	370 1 O

Ballistic	372 9 O
and	382 3 O
choreic	386 7 O
dyskinesia	394 10 B-Disease
were	405 4 O
markedly	410 8 O
ameliorated	419 11 O
,	430 1 O
whereas	432 7 O
dystonia	440 8 B-Disease
was	449 3 O
not	453 3 O
.	456 1 O

This	458 4 O
study	463 5 O
suggests	469 8 O
that	478 4 O
administration	483 14 O
of	498 2 O
low	501 3 O
doses	505 5 O
of	511 2 O
beta	514 4 O
-	518 1 O
blockers	519 8 O
may	528 3 O
improve	532 7 O
levodopa	540 8 B-Chemical
-	548 1 O
induced	549 7 O
ballistic	557 9 O
and	567 3 O
choreic	571 7 O
dyskinesia	579 10 B-Disease
in	590 2 O
PD	593 2 B-Disease
.	595 1 O

Morphological	0 13 O
features	14 8 O
of	23 2 O
encephalopathy	26 14 B-Disease
after	41 5 O
chronic	47 7 O
administration	55 14 O
of	70 2 O
the	73 3 O
antiepileptic	77 13 O
drug	91 4 O
valproate	96 9 B-Chemical
to	106 2 O
rats	109 4 O
.	113 1 O

A	115 1 O
transmission	117 12 O
electron	130 8 O
microscopic	139 11 O
study	151 5 O
of	157 2 O
capillaries	160 11 O
in	172 2 O
the	175 3 O
cerebellar	179 10 O
cortex	190 6 O
.	196 1 O

Long	198 4 O
-	202 1 O
term	203 4 O
intragastric	208 12 O
application	221 11 O
of	233 2 O
the	236 3 O
antiepileptic	240 13 O
drug	254 4 O
sodium	259 6 B-Chemical
valproate	266 9 I-Chemical
(	276 1 O
Vupral	277 6 O
"	284 1 O
Polfa	285 5 O
"	290 1 O
)	291 1 O
at	293 2 O
the	296 3 O
effective	300 9 O
dose	310 4 O
of	315 2 O
200	318 3 O
mg	322 2 O
/	324 1 O
kg	325 2 O
b	328 1 O
.	329 1 O

w	331 1 O
.	332 1 O
once	334 4 O
daily	339 5 O
to	345 2 O
rats	348 4 O
for	353 3 O
1	357 1 O
,	358 1 O
3	360 1 O
,	361 1 O
6	363 1 O
,	364 1 O
9	366 1 O
and	368 3 O
12	372 2 O
months	375 6 O
revealed	382 8 O
neurological	391 12 B-Disease
disorders	404 9 I-Disease
indicating	414 10 O
cerebellum	425 10 B-Disease
damage	436 6 I-Disease
(	443 1 O
"	444 1 O
valproate	445 9 B-Chemical
encephalopathy	455 14 B-Disease
"	469 1 O
)	470 1 O
.	471 1 O

The	473 3 O
first	477 5 O
ultrastructural	483 15 O
changes	499 7 O
in	507 2 O
structural	510 10 O
elements	521 8 O
of	530 2 O
the	533 3 O
blood	537 5 O
-	542 1 O
brain	543 5 O
-	548 1 O
barrier	549 7 O
(	557 1 O
BBB	558 3 O
)	561 1 O
in	563 2 O
the	566 3 O
cerebellar	570 10 O
cortex	581 6 O
were	588 4 O
detectable	593 10 O
after	604 5 O
3	610 1 O
months	612 6 O
of	619 2 O
the	622 3 O
experiment	626 10 O
.	636 1 O

They	638 4 O
became	643 6 O
more	650 4 O
severe	655 6 O
in	662 2 O
the	665 3 O
later	669 5 O
months	675 6 O
of	682 2 O
the	685 3 O
experiment	689 10 O
,	699 1 O
and	701 3 O
were	705 4 O
most	710 4 O
severe	715 6 O
after	722 5 O
12	728 2 O
months	731 6 O
,	737 1 O
located	739 7 O
mainly	747 6 O
in	754 2 O
the	757 3 O
molecular	761 9 O
layer	771 5 O
of	777 2 O
the	780 3 O
cerebellar	784 10 O
cortex	795 6 O
.	801 1 O

Lesions	803 7 O
of	811 2 O
the	814 3 O
capillary	818 9 O
included	828 8 O
necrosis	837 8 B-Disease
of	846 2 O
endothelial	849 11 O
cells	861 5 O
.	866 1 O

Organelles	868 10 O
of	879 2 O
these	882 5 O
cells	888 5 O
,	893 1 O
in	895 2 O
particular	898 10 O
the	909 3 O
mitochondria	913 12 O
(	926 1 O
increased	927 9 O
number	937 6 O
and	944 3 O
size	948 4 O
,	952 1 O
distinct	954 8 O
degeneration	963 12 O
of	976 2 O
their	979 5 O
matrix	985 6 O
and	992 3 O
cristae	996 7 O
)	1003 1 O
and	1005 3 O
Golgi	1009 5 O
apparatus	1015 9 O
were	1025 4 O
altered	1030 7 O
.	1037 1 O

Reduced	1039 7 O
size	1047 4 O
of	1052 2 O
capillary	1055 9 O
lumen	1065 5 O
and	1071 3 O
occlusion	1075 9 O
were	1085 4 O
caused	1090 6 O
by	1097 2 O
swollen	1100 7 O
endothelial	1108 11 O
cells	1120 5 O
which	1126 5 O
had	1132 3 O
luminal	1136 7 B-Chemical
protrusions	1144 11 O
and	1156 3 O
swollen	1160 7 O
microvilli	1168 10 O
.	1178 1 O

Pressure	1180 8 O
on	1189 2 O
the	1192 3 O
vessel	1196 6 O
wall	1203 4 O
was	1208 3 O
produced	1212 8 O
by	1221 2 O
enlarged	1224 8 O
perivascular	1233 12 O
astrocytic	1246 10 O
processes	1257 9 O
.	1266 1 O

Fragments	1268 9 O
of	1278 2 O
necrotic	1281 8 B-Disease
endothelial	1290 11 O
cells	1302 5 O
were	1308 4 O
in	1313 2 O
the	1316 3 O
vascular	1320 8 O
lumens	1329 6 O
and	1336 3 O
in	1340 2 O
these	1343 5 O
there	1349 5 O
was	1355 3 O
loosening	1359 9 O
and	1369 3 O
breaking	1373 8 O
of	1382 2 O
tight	1385 5 O
cellular	1391 8 O
junctions	1400 9 O
.	1409 1 O

Damage	1411 6 O
to	1418 2 O
the	1421 3 O
vascular	1425 8 O
basement	1434 8 O
lamina	1443 6 O
was	1450 3 O
also	1454 4 O
observed	1459 8 O
.	1467 1 O

Damage	1469 6 O
to	1476 2 O
the	1479 3 O
capillary	1483 9 O
was	1493 3 O
accompanied	1497 11 O
by	1509 2 O
marked	1512 6 O
damage	1519 6 O
to	1526 2 O
neuroglial	1529 10 O
cells	1540 5 O
,	1545 1 O
mainly	1547 6 O
to	1554 2 O
perivascular	1557 12 O
processes	1570 9 O
of	1580 2 O
astrocytes	1583 10 O
.	1593 1 O

The	1595 3 O
proliferation	1599 13 O
of	1613 2 O
astrocytes	1616 10 O
(	1627 1 O
Bergmann	1628 8 O
'	1636 1 O
s	1637 1 O
in	1639 2 O
particular	1642 10 O
)	1652 1 O
and	1654 3 O
occasionally	1658 12 O
of	1671 2 O
oligodendrocytes	1674 16 O
was	1691 3 O
found	1695 5 O
.	1700 1 O

Alterations	1702 11 O
in	1714 2 O
the	1717 3 O
structural	1721 10 O
elements	1732 8 O
of	1741 2 O
the	1744 3 O
BBB	1748 3 O
coexisted	1752 9 O
with	1762 4 O
marked	1767 6 O
lesions	1774 7 O
of	1782 2 O
neurons	1785 7 O
of	1793 2 O
the	1796 3 O
cerebellum	1800 10 O
(	1811 1 O
Purkinje	1812 8 O
cells	1821 5 O
are	1827 3 O
earliest	1831 8 O
)	1839 1 O
.	1840 1 O

In	1842 2 O
electron	1845 8 O
micrographs	1854 11 O
both	1866 4 O
luminal	1871 7 B-Chemical
and	1879 3 O
antiluminal	1883 11 O
sides	1895 5 O
of	1901 2 O
the	1904 3 O
BBB	1908 3 O
of	1912 2 O
the	1915 3 O
cerebellar	1919 10 O
cortex	1930 6 O
had	1937 3 O
similar	1941 7 O
lesions	1949 7 O
.	1956 1 O

The	1958 3 O
possible	1962 8 O
influence	1971 9 O
of	1981 2 O
the	1984 3 O
hepatic	1988 7 B-Disease
damage	1996 6 I-Disease
,	2002 1 O
mainly	2004 6 O
hyperammonemia	2011 14 B-Disease
,	2025 1 O
upon	2027 4 O
the	2032 3 O
development	2036 11 O
of	2048 2 O
valproate	2051 9 B-Chemical
encephalopathy	2061 14 B-Disease
is	2076 2 O
discussed	2079 9 O
.	2088 1 O

Macula	0 6 O
toxicity	7 8 B-Disease
after	16 5 O
intravitreal	22 12 O
amikacin	35 8 B-Chemical
.	43 1 O

BACKGROUND	45 10 O
:	55 1 O
Although	57 8 O
intravitreal	66 12 O
aminoglycosides	79 15 B-Chemical
have	95 4 O
substantially	100 13 O
improved	114 8 O
visual	123 6 O
prognosis	130 9 O
in	140 2 O
endophthalmitis	143 15 B-Disease
,	158 1 O
macular	160 7 O
infarction	168 10 B-Disease
may	179 3 O
impair	183 6 O
full	190 4 O
visual	195 6 O
recovery	202 8 O
.	210 1 O

METHODS	212 7 O
:	219 1 O
We	221 2 O
present	224 7 O
a	232 1 O
case	234 4 O
of	239 2 O
presumed	242 8 O
amikacin	251 8 B-Chemical
retinal	260 7 B-Disease
toxicity	268 8 I-Disease
following	277 9 O
treatment	287 9 O
with	297 4 O
amikacin	302 8 B-Chemical
and	311 3 O
vancomycin	315 10 B-Chemical
for	326 3 O
alpha	330 5 O
-	335 1 O
haemolytic	336 10 O
streptococcal	347 13 B-Disease
endophthalmitis	361 15 I-Disease
.	376 1 O

RESULTS	378 7 O
:	385 1 O
Endophthalmitis	387 15 B-Disease
resolved	403 8 O
with	412 4 O
improvement	417 11 O
in	429 2 O
visual	432 6 O
acuity	439 6 O
to	446 2 O
6	449 1 O
/	450 1 O
24	451 2 O
at	454 2 O
three	457 5 O
months	463 6 O
.	469 1 O

Fundus	471 6 O
fluorescein	478 11 B-Chemical
angiography	490 11 O
confirmed	502 9 O
macular	512 7 O
capillary	520 9 O
closure	530 7 O
and	538 3 O
telangiectasis	542 14 B-Disease
.	556 1 O

CONCLUSIONS	558 11 O
:	569 1 O
Currently	571 9 O
accepted	581 8 O
intravitreal	590 12 O
antibiotic	603 10 O
regimens	614 8 O
may	623 3 O
cause	627 5 O
retinal	633 7 B-Disease
toxicity	641 8 I-Disease
and	650 3 O
macular	654 7 O
ischaemia	662 9 B-Disease
.	671 1 O

Treatment	673 9 O
strategies	683 10 O
aimed	694 5 O
at	700 2 O
avoiding	703 8 O
retinal	712 7 B-Disease
toxicity	720 8 I-Disease
are	729 3 O
discussed	733 9 O
.	742 1 O

Iatrogenically	0 14 O
induced	15 7 O
intractable	23 11 O
atrioventricular	35 16 B-Disease
reentrant	52 9 I-Disease
tachycardia	62 11 I-Disease
after	74 5 O
verapamil	80 9 B-Chemical
and	90 3 O
catheter	94 8 O
ablation	103 8 O
in	112 2 O
a	115 1 O
patient	117 7 O
with	125 4 O
Wolff	130 5 B-Disease
-	135 1 I-Disease
Parkinson	136 9 I-Disease
-	145 1 I-Disease
White	146 5 I-Disease
syndrome	152 8 I-Disease
and	161 3 O
idiopathic	165 10 B-Disease
dilated	176 7 I-Disease
cardiomyopathy	184 14 I-Disease
.	198 1 O

In	200 2 O
a	203 1 O
patient	205 7 O
with	213 4 O
WPW	218 3 B-Disease
syndrome	222 8 I-Disease
and	231 3 O
idiopathic	235 10 B-Disease
dilated	246 7 I-Disease
cardiomyopathy	254 14 I-Disease
,	268 1 O
intractable	270 11 O
atrioventricular	282 16 B-Disease
reentrant	299 9 I-Disease
tachycardia	309 11 I-Disease
(	321 1 O
AVRT	322 4 B-Disease
)	326 1 O
was	328 3 O
iatrogenically	332 14 O
induced	347 7 O
.	354 1 O

QRS	356 3 O
without	360 7 O
preexcitation	368 13 O
,	381 1 O
caused	383 6 O
by	390 2 O
junctional	393 10 O
escape	404 6 O
beats	411 5 O
after	417 5 O
verapamil	423 9 B-Chemical
or	433 2 O
unidirectional	436 14 O
antegrade	451 9 O
block	461 5 O
of	467 2 O
accessory	470 9 O
pathway	480 7 O
after	488 5 O
catheter	494 8 O
ablation	503 8 O
,	511 1 O
established	513 11 O
frequent	525 8 O
AVRT	534 4 B-Disease
attack	539 6 O
.	545 1 O

Epidemic	0 8 O
of	9 2 O
liver	12 5 B-Disease
disease	18 7 I-Disease
caused	26 6 O
by	33 2 O
hydrochlorofluorocarbons	36 24 B-Chemical
used	61 4 O
as	66 2 O
ozone	69 5 B-Chemical
-	74 1 O
sparing	75 7 O
substitutes	83 11 O
of	95 2 O
chlorofluorocarbons	98 19 B-Chemical
.	117 1 O

BACKGROUND	119 10 O
:	129 1 O
Hydrochlorofluorocarbons	131 24 B-Chemical
(	156 1 O
HCFCs	157 5 B-Chemical
)	162 1 O
are	164 3 O
used	168 4 O
increasingly	173 12 O
in	186 2 O
industry	189 8 O
as	198 2 O
substitutes	201 11 O
for	213 3 O
ozone	217 5 B-Chemical
-	222 1 O
depleting	223 9 O
chlorofluorocarbons	233 19 B-Chemical
(	253 1 O
CFCs	254 4 B-Chemical
)	258 1 O
.	259 1 O

Limited	261 7 O
studies	269 7 O
in	277 2 O
animals	280 7 O
indicate	288 8 O
potential	297 9 O
hepatotoxicity	307 14 B-Disease
of	322 2 O
some	325 4 O
of	330 2 O
these	333 5 O
compounds	339 9 O
.	348 1 O

We	350 2 O
investigated	353 12 O
an	366 2 O
epidemic	369 8 O
of	378 2 O
liver	381 5 B-Disease
disease	387 7 I-Disease
in	395 2 O
nine	398 4 O
industrial	403 10 O
workers	414 7 O
who	422 3 O
had	426 3 O
had	430 3 O
repeated	434 8 O
accidental	443 10 O
exposure	454 8 O
to	463 2 O
a	466 1 O
mixture	468 7 O
of	476 2 O
1	479 1 B-Chemical
,	480 1 I-Chemical
1	481 1 I-Chemical
-	482 1 I-Chemical
dichloro	483 8 I-Chemical
-	491 1 I-Chemical
2	492 1 I-Chemical
,	493 1 I-Chemical
2	494 1 I-Chemical
,	495 1 I-Chemical
2	496 1 I-Chemical
-	497 1 I-Chemical
trifluoroethane	498 15 I-Chemical
(	514 1 O
HCFC	515 4 B-Chemical
123	520 3 I-Chemical
)	523 1 O
and	525 3 O
1	529 1 B-Chemical
-	530 1 I-Chemical
chloro	531 6 I-Chemical
-	537 1 I-Chemical
1	538 1 I-Chemical
,	539 1 I-Chemical
2	540 1 I-Chemical
,	541 1 I-Chemical
2	542 1 I-Chemical
,	543 1 I-Chemical
2	544 1 I-Chemical
-	545 1 I-Chemical
tetrafluoroethane	546 17 I-Chemical
(	564 1 O
HCFC	565 4 B-Chemical
124	570 3 I-Chemical
)	573 1 O
.	574 1 O

All	576 3 O
nine	580 4 O
exposed	585 7 O
workers	593 7 O
were	601 4 O
affected	606 8 O
to	615 2 O
various	618 7 O
degrees	626 7 O
.	633 1 O

Both	635 4 O
compounds	640 9 O
are	650 3 O
metabolised	654 11 O
in	666 2 O
the	669 3 O
same	673 4 O
way	678 3 O
as	682 2 O
1	685 1 B-Chemical
-	686 1 I-Chemical
bromo	687 5 I-Chemical
-	692 1 I-Chemical
1	693 1 I-Chemical
-	694 1 I-Chemical
chloro	695 6 I-Chemical
-	701 1 I-Chemical
2	702 1 I-Chemical
,	703 1 I-Chemical
2	704 1 I-Chemical
,	705 1 I-Chemical
2	706 1 I-Chemical
-	707 1 I-Chemical
trifluoroethane	708 15 I-Chemical
(	724 1 O
halothane	725 9 B-Chemical
)	734 1 O
to	736 2 O
form	739 4 O
reactive	744 8 O
trifluoroacetyl	753 15 B-Chemical
halide	769 6 O
intermediates	776 13 O
,	789 1 O
which	791 5 O
have	797 4 O
been	802 4 O
implicated	807 10 O
in	818 2 O
the	821 3 O
hepatotoxicity	825 14 B-Disease
of	840 2 O
halothane	843 9 B-Chemical
.	852 1 O

We	854 2 O
aimed	857 5 O
to	863 2 O
test	866 4 O
whether	871 7 O
HCFCs	879 5 B-Chemical
123	885 3 I-Chemical
and	889 3 I-Chemical
124	893 3 I-Chemical
can	897 3 O
result	901 6 O
in	908 2 O
serious	911 7 O
liver	919 5 B-Disease
disease	925 7 I-Disease
.	932 1 O

METHODS	934 7 O
:	941 1 O
For	943 3 O
one	947 3 O
severely	951 8 O
affected	960 8 O
worker	969 6 O
liver	976 5 O
biopsy	982 6 O
and	989 3 O
immunohistochemical	993 19 O
stainings	1013 9 O
for	1023 3 O
the	1027 3 O
presence	1031 8 O
of	1040 2 O
trifluoroacetyl	1043 15 B-Chemical
protein	1059 7 O
adducts	1067 7 O
were	1075 4 O
done	1080 4 O
.	1084 1 O

The	1086 3 O
serum	1090 5 O
of	1096 2 O
six	1099 3 O
affected	1103 8 O
workers	1112 7 O
and	1120 3 O
five	1124 4 O
controls	1129 8 O
was	1138 3 O
tested	1142 6 O
for	1149 3 O
autoantibodies	1153 14 O
that	1168 4 O
react	1173 5 O
with	1179 4 O
human	1184 5 O
liver	1190 5 O
cytochrome	1196 10 O
-	1206 1 O
P450	1207 4 O
2E1	1212 3 O
(	1216 1 O
P450	1217 4 O
2E1	1222 3 O
)	1225 1 O
and	1227 3 O
P58	1231 3 O
protein	1235 7 O
disulphide	1243 10 O
isomerase	1254 9 O
isoform	1264 7 O
(	1272 1 O
P58	1273 3 O
)	1276 1 O
.	1277 1 O

FINDINGS	1279 8 O
:	1287 1 O
The	1289 3 O
liver	1293 5 O
biopsy	1299 6 O
sample	1306 6 O
showed	1313 6 O
hepatocellular	1320 14 O
necrosis	1335 8 B-Disease
which	1344 5 O
was	1350 3 O
prominent	1354 9 O
in	1364 2 O
perivenular	1367 11 O
zone	1379 4 O
three	1384 5 O
and	1390 3 O
extended	1394 8 O
focally	1403 7 O
from	1411 4 O
portal	1416 6 O
tracts	1423 6 O
to	1430 2 O
portal	1433 6 O
tracts	1440 6 O
and	1447 3 O
centrilobular	1451 13 O
areas	1465 5 O
(	1471 1 O
bridging	1472 8 O
necrosis	1481 8 B-Disease
)	1489 1 O
.	1490 1 O

Trifluoroacetyl	1492 15 B-Chemical
-	1507 1 O
adducted	1508 8 O
proteins	1517 8 O
were	1526 4 O
detected	1531 8 O
in	1540 2 O
surviving	1543 9 O
hepatocytes	1553 11 O
.	1564 1 O

Autoantibodies	1566 14 O
against	1581 7 O
P450	1589 4 O
2E1	1594 3 O
or	1598 2 O
P58	1601 3 O
,	1604 1 O
previously	1606 10 O
associated	1617 10 O
with	1628 4 O
halothane	1633 9 B-Disease
hepatitis	1643 9 I-Disease
,	1652 1 O
were	1654 4 O
detected	1659 8 O
in	1668 2 O
the	1671 3 O
serum	1675 5 O
of	1681 2 O
five	1684 4 O
affected	1689 8 O
workers	1698 7 O
.	1705 1 O

INTERPRETATION	1707 14 O
:	1721 1 O
Repeated	1723 8 O
exposure	1732 8 O
of	1741 2 O
human	1744 5 O
beings	1750 6 O
to	1757 2 O
HCFCs	1760 5 B-Chemical
123	1766 3 I-Chemical
and	1770 3 I-Chemical
124	1774 3 I-Chemical
can	1778 3 O
result	1782 6 O
in	1789 2 O
serious	1792 7 O
liver	1800 5 B-Disease
injury	1806 6 I-Disease
in	1813 2 O
a	1816 1 O
large	1818 5 O
proportion	1824 10 O
of	1835 2 O
the	1838 3 O
exposed	1842 7 O
population	1850 10 O
.	1860 1 O

Although	1862 8 O
the	1871 3 O
exact	1875 5 O
mechanism	1881 9 O
of	1891 2 O
hepatotoxicity	1894 14 B-Disease
of	1909 2 O
these	1912 5 O
agents	1918 6 O
is	1925 2 O
not	1928 3 O
known	1932 5 O
,	1937 1 O
the	1939 3 O
results	1943 7 O
suggest	1951 7 O
that	1959 4 O
trifluoroacetyl	1964 15 B-Chemical
-	1979 1 O
altered	1980 7 O
liver	1988 5 O
proteins	1994 8 O
are	2003 3 O
involved	2007 8 O
.	2015 1 O

In	2017 2 O
view	2020 4 O
of	2025 2 O
the	2028 3 O
potentially	2032 11 O
widespread	2044 10 O
use	2055 3 O
of	2059 2 O
these	2062 5 O
compounds	2068 9 O
,	2077 1 O
there	2079 5 O
is	2085 2 O
an	2088 2 O
urgent	2091 6 O
need	2098 4 O
to	2103 2 O
develop	2106 7 O
safer	2114 5 O
alternatives	2120 12 O
.	2132 1 O

The	0 3 O
effect	4 6 O
of	11 2 O
different	14 9 O
anaesthetic	24 11 O
agents	36 6 O
in	43 2 O
hearing	46 7 B-Disease
loss	54 4 I-Disease
following	59 9 O
spinal	69 6 O
anaesthesia	76 11 O
.	87 1 O

The	89 3 O
cause	93 5 O
of	99 2 O
hearing	102 7 B-Disease
loss	110 4 I-Disease
after	115 5 O
spinal	121 6 O
anaesthesia	128 11 O
is	140 2 O
unknown	143 7 O
.	150 1 O

Up	152 2 O
until	155 5 O
now	161 3 O
,	164 1 O
the	166 3 O
only	170 4 O
factor	175 6 O
studied	182 7 O
has	190 3 O
been	194 4 O
the	199 3 O
effect	203 6 O
of	210 2 O
the	213 3 O
diameter	217 8 O
of	226 2 O
the	229 3 O
spinal	233 6 O
needle	240 6 O
on	247 2 O
post	250 4 O
-	254 1 O
operative	255 9 O
sensorineural	265 13 B-Disease
hearing	279 7 I-Disease
loss	287 4 I-Disease
.	291 1 O

The	293 3 O
aim	297 3 O
of	301 2 O
this	304 4 O
study	309 5 O
was	315 3 O
to	319 2 O
describe	322 8 O
this	331 4 O
hearing	336 7 B-Disease
loss	344 4 I-Disease
and	349 3 O
to	353 2 O
investigate	356 11 O
other	368 5 O
factors	374 7 O
influencing	382 11 O
the	394 3 O
degree	398 6 O
of	405 2 O
hearing	408 7 B-Disease
loss	416 4 I-Disease
.	420 1 O

Two	422 3 O
groups	426 6 O
of	433 2 O
22	436 2 O
similar	439 7 O
patients	447 8 O
were	456 4 O
studied	461 7 O
:	468 1 O
one	470 3 O
group	474 5 O
received	480 8 O
6	489 1 O
mL	491 2 O
prilocaine	494 10 B-Chemical
2	505 1 O
%	506 1 O
;	507 1 O
and	509 3 O
the	513 3 O
other	517 5 O
received	523 8 O
3	532 1 O
mL	534 2 O
bupivacaine	537 11 B-Chemical
0	549 1 O
.	550 1 O
5	551 1 O
%	552 1 O
.	553 1 O

Patients	555 8 O
given	564 5 O
prilocaine	570 10 B-Chemical
were	581 4 O
more	586 4 O
likely	591 6 O
to	598 2 O
develop	601 7 O
hearing	609 7 B-Disease
loss	617 4 I-Disease
(	622 1 O
10	623 2 O
out	626 3 O
of	630 2 O
22	633 2 O
)	635 1 O
than	637 4 O
those	642 5 O
given	648 5 O
bupivacaine	654 11 B-Chemical
(	666 1 O
4	667 1 O
out	669 3 O
of	673 2 O
22	676 2 O
)	678 1 O
(	680 1 O
P	681 1 O
<	683 1 O
0	685 1 O
.	686 1 O
05	687 2 O
)	689 1 O
.	690 1 O

The	692 3 O
average	696 7 O
hearing	704 7 B-Disease
loss	712 4 I-Disease
for	717 3 O
speech	721 6 O
frequencies	728 11 O
was	740 3 O
about	744 5 O
10	750 2 O
dB	753 2 O
after	756 5 O
prilocaine	762 10 B-Chemical
and	773 3 O
15	777 2 O
dB	780 2 O
after	783 5 O
bupivacaine	789 11 B-Chemical
.	800 1 O

None	802 4 O
of	807 2 O
the	810 3 O
patients	814 8 O
complained	823 10 O
of	834 2 O
subjective	837 10 O
hearing	848 7 B-Disease
loss	856 4 I-Disease
.	860 1 O

Long	862 4 O
-	866 1 O
term	867 4 O
follow	872 6 O
-	878 1 O
up	879 2 O
of	882 2 O
the	885 3 O
patients	889 8 O
was	898 3 O
not	902 3 O
possible	906 8 O
.	914 1 O

A	0 1 O
transient	2 9 O
neurological	12 12 B-Disease
deficit	25 7 I-Disease
following	33 9 O
intrathecal	43 11 O
injection	55 9 O
of	65 2 O
1	68 1 O
%	69 1 O
hyperbaric	71 10 O
bupivacaine	82 11 B-Chemical
for	94 3 O
unilateral	98 10 O
spinal	109 6 O
anaesthesia	116 11 O
.	127 1 O

We	129 2 O
describe	132 8 O
a	141 1 O
case	143 4 O
of	148 2 O
transient	151 9 O
neurological	161 12 B-Disease
deficit	174 7 I-Disease
that	182 4 O
occurred	187 8 O
after	196 5 O
unilateral	202 10 O
spinal	213 6 O
anaesthesia	220 11 O
with	232 4 O
8	237 1 O
mg	239 2 O
of	242 2 O
1	245 1 O
%	246 1 O
hyperbaric	248 10 O
bupivacaine	259 11 B-Chemical
slowly	271 6 O
injected	278 8 O
through	287 7 O
a	295 1 O
25	297 2 O
-	299 1 O
gauge	300 5 O
pencil	306 6 O
-	312 1 O
point	313 5 O
spinal	319 6 O
needle	326 6 O
.	332 1 O

The	334 3 O
surgery	338 7 O
and	346 3 O
anaesthesia	350 11 O
were	362 4 O
uneventful	367 10 O
,	377 1 O
but	379 3 O
3	383 1 O
days	385 4 O
after	390 5 O
surgery	396 7 O
,	403 1 O
the	405 3 O
patient	409 7 O
reported	417 8 O
an	426 2 O
area	429 4 O
of	434 2 O
hypoaesthesia	437 13 O
over	451 4 O
L3	456 2 O
-	458 1 O
L4	459 2 O
dermatomes	462 10 O
of	473 2 O
the	476 3 O
leg	480 3 O
which	484 5 O
had	490 3 O
been	494 4 O
operated	499 8 O
on	508 2 O
(	511 1 O
loss	512 4 B-Disease
of	517 2 I-Disease
pinprick	520 8 I-Disease
sensation	529 9 I-Disease
)	538 1 O
without	540 7 O
reduction	548 9 O
in	558 2 O
muscular	561 8 O
strength	570 8 O
.	578 1 O

Sensation	580 9 O
in	590 2 O
this	593 4 O
area	598 4 O
returned	603 8 O
to	612 2 O
normal	615 6 O
over	622 4 O
the	627 3 O
following	631 9 O
2	641 1 O
weeks	643 5 O
.	648 1 O

Prospective	650 11 O
multicentre	662 11 O
studies	674 7 O
with	682 4 O
a	687 1 O
large	689 5 O
population	695 10 O
and	706 3 O
a	710 1 O
long	712 4 O
follow	717 6 O
-	723 1 O
up	724 2 O
should	727 6 O
be	734 2 O
performed	737 9 O
in	747 2 O
order	750 5 O
to	756 2 O
evaluate	759 8 O
the	768 3 O
incidence	772 9 O
of	782 2 O
this	785 4 O
unusual	790 7 O
side	798 4 O
effect	803 6 O
.	809 1 O

However	811 7 O
,	818 1 O
we	820 2 O
suggest	823 7 O
that	831 4 O
a	836 1 O
low	838 3 O
solution	842 8 O
concentration	851 13 O
should	865 6 O
be	872 2 O
preferred	875 9 O
for	885 3 O
unilateral	889 10 O
spinal	900 6 O
anaesthesia	907 11 O
with	919 4 O
a	924 1 O
hyperbaric	926 10 O
anaesthetic	937 11 O
solution	949 8 O
(	958 1 O
if	959 2 O
pencil	962 6 O
-	968 1 O
point	969 5 O
needle	975 6 O
and	982 3 O
slow	986 4 O
injection	991 9 O
rate	1001 4 O
are	1006 3 O
employed	1010 8 O
)	1018 1 O
,	1019 1 O
in	1021 2 O
order	1024 5 O
to	1030 2 O
minimize	1033 8 O
the	1042 3 O
risk	1046 4 O
of	1051 2 O
a	1054 1 O
localized	1056 9 O
high	1066 4 O
peak	1071 4 O
anaesthetic	1076 11 O
concentration	1088 13 O
,	1101 1 O
which	1103 5 O
might	1109 5 O
lead	1115 4 O
to	1120 2 O
a	1123 1 O
transient	1125 9 O
neurological	1135 12 B-Disease
deficit	1148 7 I-Disease
.	1155 1 O

Pethidine	0 9 B-Chemical
-	9 1 O
associated	10 10 O
seizure	21 7 B-Disease
in	29 2 O
a	32 1 O
healthy	34 7 O
adolescent	42 10 O
receiving	53 9 O
pethidine	63 9 B-Chemical
for	73 3 O
postoperative	77 13 B-Disease
pain	91 4 I-Disease
control	96 7 O
.	103 1 O

A	105 1 O
healthy	107 7 O
17	115 2 O
-	117 1 O
year	118 4 O
-	122 1 O
old	123 3 O
male	127 4 O
received	132 8 O
standard	141 8 O
intermittent	150 12 O
doses	163 5 O
of	169 2 O
pethidine	172 9 B-Chemical
via	182 3 O
a	186 1 O
patient	188 7 O
-	195 1 O
controlled	196 10 O
analgesia	207 9 O
(	217 1 O
PCA	218 3 O
)	221 1 O
pump	223 4 O
for	228 3 O
management	232 10 O
of	243 2 O
postoperative	246 13 B-Disease
pain	260 4 I-Disease
control	265 7 O
.	272 1 O

Twenty	274 6 O
-	280 1 O
three	281 5 O
h	287 1 O
postoperatively	289 15 O
he	305 2 O
developed	308 9 O
a	318 1 O
brief	320 5 O
self	326 4 O
-	330 1 O
limited	331 7 O
seizure	339 7 B-Disease
.	346 1 O

Both	348 4 O
plasma	353 6 O
pethidine	360 9 B-Chemical
and	370 3 O
norpethidine	374 12 B-Chemical
were	387 4 O
elevated	392 8 O
in	401 2 O
the	404 3 O
range	408 5 O
associated	414 10 O
with	425 4 O
clinical	430 8 O
manifestations	439 14 O
of	454 2 O
central	457 7 O
nervous	465 7 O
system	473 6 O
excitation	480 10 O
.	490 1 O

No	492 2 O
other	495 5 O
risk	501 4 O
factors	506 7 O
for	514 3 O
CNS	518 3 O
toxicity	522 8 B-Disease
were	531 4 O
identified	536 10 O
.	546 1 O

This	548 4 O
method	553 6 O
allowed	560 7 O
frequent	568 8 O
self	577 4 O
-	581 1 O
dosing	582 6 O
of	589 2 O
pethidine	592 9 B-Chemical
at	602 2 O
short	605 5 O
time	611 4 O
intervals	616 9 O
and	626 3 O
rapid	630 5 O
accumulation	636 12 O
of	649 2 O
pethidine	652 9 B-Chemical
and	662 3 O
norpethidine	666 12 B-Chemical
.	678 1 O

The	680 3 O
routine	684 7 O
use	692 3 O
of	696 2 O
pethidine	699 9 B-Chemical
via	709 3 O
PCA	713 3 O
even	717 4 O
for	722 3 O
a	726 1 O
brief	728 5 O
postoperative	734 13 O
analgesia	748 9 O
should	758 6 O
be	765 2 O
reconsidered	768 12 O
.	780 1 O

Drug	0 4 O
-	4 1 O
associated	5 10 O
acute	16 5 O
-	21 1 O
onset	22 5 O
vanishing	28 9 B-Disease
bile	38 4 I-Disease
duct	43 4 I-Disease
and	48 3 O
Stevens	52 7 B-Disease
-	59 1 I-Disease
Johnson	60 7 I-Disease
syndromes	68 9 I-Disease
in	78 2 O
a	81 1 O
child	83 5 O
.	88 1 O

Acute	90 5 O
vanishing	96 9 B-Disease
bile	106 4 I-Disease
duct	111 4 I-Disease
syndrome	116 8 O
is	125 2 O
a	128 1 O
rare	130 4 O
but	135 3 O
established	139 11 O
cause	151 5 O
of	157 2 O
progressive	160 11 O
cholestasis	172 11 B-Disease
in	184 2 O
adults	187 6 O
,	193 1 O
is	195 2 O
most	198 4 O
often	203 5 O
drug	209 4 O
or	214 2 O
toxin	217 5 O
related	223 7 O
,	230 1 O
and	232 3 O
is	236 2 O
of	239 2 O
unknown	242 7 O
pathogenesis	250 12 O
.	262 1 O

It	264 2 O
has	267 3 O
not	271 3 O
been	275 4 O
reported	280 8 O
previously	289 10 O
in	300 2 O
children	303 8 O
.	311 1 O

Stevens	313 7 B-Disease
-	320 1 I-Disease
Johnson	321 7 I-Disease
syndrome	329 8 I-Disease
is	338 2 O
a	341 1 O
well	343 4 O
-	347 1 O
recognized	348 10 O
immune	359 6 O
complex	366 7 O
-	373 1 O
mediated	374 8 O
hypersensitivity	383 16 B-Disease
reaction	400 8 O
that	409 4 O
affects	414 7 O
all	422 3 O
age	426 3 O
groups	430 6 O
,	436 1 O
is	438 2 O
drug	441 4 O
or	446 2 O
infection	449 9 B-Disease
induced	459 7 O
,	466 1 O
and	468 3 O
has	472 3 O
classic	476 7 O
systemic	484 8 O
,	492 1 O
mucosal	494 7 O
,	501 1 O
and	503 3 O
dermatologic	507 12 O
manifestations	520 14 O
.	534 1 O

A	536 1 O
previously	538 10 O
healthy	549 7 O
child	557 5 O
who	563 3 O
developed	567 9 O
acute	577 5 O
,	582 1 O
severe	584 6 O
,	590 1 O
rapidly	592 7 O
progressive	600 11 O
vanishing	612 9 B-Disease
bile	622 4 I-Disease
duct	627 4 I-Disease
syndrome	632 8 I-Disease
shortly	641 7 O
after	649 5 O
Stevens	655 7 B-Disease
-	662 1 I-Disease
Johnson	663 7 I-Disease
syndrome	671 8 I-Disease
is	680 2 O
described	683 9 O
;	692 1 O
this	694 4 O
was	699 3 O
temporally	703 10 O
associated	714 10 O
with	725 4 O
ibuprofen	730 9 B-Chemical
use	740 3 O
.	743 1 O

Despite	745 7 O
therapy	753 7 O
with	761 4 O
ursodeoxycholic	766 15 B-Chemical
acid	782 4 I-Chemical
,	786 1 O
prednisone	788 10 B-Chemical
,	798 1 O
and	800 3 O
then	804 4 O
tacrolimus	809 10 B-Chemical
,	819 1 O
her	821 3 O
cholestatic	825 11 B-Disease
disease	837 7 I-Disease
was	845 3 O
unrelenting	849 11 O
,	860 1 O
with	862 4 O
cirrhosis	867 9 B-Disease
shown	877 5 O
by	883 2 O
biopsy	886 6 O
6	893 1 O
months	895 6 O
after	902 5 O
presentation	908 12 O
.	920 1 O

This	922 4 O
case	927 4 O
documents	932 9 O
acute	942 5 O
drug	948 4 O
-	952 1 O
related	953 7 O
vanishing	961 9 B-Disease
bile	971 4 I-Disease
duct	976 4 I-Disease
syndrome	981 8 I-Disease
in	990 2 O
the	993 3 O
pediatric	997 9 O
age	1007 3 O
group	1011 5 O
and	1017 3 O
suggests	1021 8 O
shared	1030 6 O
immune	1037 6 O
mechanisms	1044 10 O
in	1055 2 O
the	1058 3 O
pathogenesis	1062 12 O
of	1075 2 O
both	1078 4 O
Stevens	1083 7 B-Disease
-	1090 1 I-Disease
Johnson	1091 7 I-Disease
syndrome	1099 8 I-Disease
and	1108 3 O
vanishing	1112 9 B-Disease
bile	1122 4 I-Disease
duct	1127 4 I-Disease
syndrome	1132 8 I-Disease
.	1140 1 O

High	0 4 O
incidence	5 9 O
of	15 2 O
primary	18 7 B-Disease
pulmonary	26 9 I-Disease
hypertension	36 12 I-Disease
associated	49 10 O
with	60 4 O
appetite	65 8 B-Chemical
suppressants	74 12 I-Chemical
in	87 2 O
Belgium	90 7 O
.	97 1 O

Primary	99 7 B-Disease
pulmonary	107 9 I-Disease
hypertension	117 12 I-Disease
is	130 2 O
a	133 1 O
rare	135 4 O
,	139 1 O
progressive	141 11 O
and	153 3 O
incurable	157 9 O
disease	167 7 O
,	174 1 O
which	176 5 O
has	182 3 O
been	186 4 O
associated	191 10 O
with	202 4 O
the	207 3 O
intake	211 6 O
of	218 2 O
appetite	221 8 B-Chemical
suppressant	230 11 I-Chemical
drugs	242 5 O
.	247 1 O

The	249 3 O
importance	253 10 O
of	264 2 O
this	267 4 O
association	272 11 O
was	284 3 O
evaluated	288 9 O
in	298 2 O
Belgium	301 7 O
while	309 5 O
this	315 4 O
country	320 7 O
still	328 5 O
had	334 3 O
no	338 2 O
restriction	341 11 O
on	353 2 O
the	356 3 O
prescription	360 12 O
of	373 2 O
appetite	376 8 B-Chemical
suppressants	385 12 I-Chemical
.	397 1 O

Thirty	399 6 O
-	405 1 O
five	406 4 O
patients	411 8 O
with	420 4 O
primary	425 7 B-Disease
pulmonary	433 9 I-Disease
hypertension	443 12 I-Disease
and	456 3 O
85	460 2 O
matched	463 7 O
controls	471 8 O
were	480 4 O
recruited	485 9 O
over	495 4 O
32	500 2 O
months	503 6 O
(	510 1 O
1992	511 4 O
-	515 1 O
1994	516 4 O
)	520 1 O
in	522 2 O
Belgium	525 7 O
.	532 1 O

Exposure	534 8 O
to	543 2 O
appetite	546 8 B-Chemical
-	554 1 I-Chemical
suppressants	555 12 I-Chemical
was	568 3 O
assessed	572 8 O
on	581 2 O
the	584 3 O
basis	588 5 O
of	594 2 O
hospital	597 8 O
records	606 7 O
and	614 3 O
standardized	618 12 O
interview	631 9 O
.	640 1 O

Twenty	642 6 O
-	648 1 O
three	649 5 O
of	655 2 O
the	658 3 O
patients	662 8 O
had	671 3 O
previously	675 10 O
taken	686 5 O
appetite	692 8 B-Chemical
suppressants	701 12 I-Chemical
,	713 1 O
mainly	715 6 O
fenfluramines	722 13 B-Chemical
,	735 1 O
as	737 2 O
compared	740 8 O
with	749 4 O
only	754 4 O
5	759 1 O
of	761 2 O
the	764 3 O
controls	768 8 O
(	777 1 O
66	778 2 O
versus	781 6 O
6	788 1 O
%	789 1 O
,	790 1 O
p	792 1 O
<	793 1 O
0	794 1 O
.	795 1 O
0001	796 4 O
)	800 1 O
.	801 1 O

Five	803 4 O
patients	808 8 O
died	817 4 O
before	822 6 O
the	829 3 O
interview	833 9 O
,	842 1 O
all	844 3 O
of	848 2 O
them	851 4 O
had	856 3 O
taken	860 5 O
appetite	866 8 B-Chemical
suppressants	875 12 I-Chemical
.	887 1 O

In	889 2 O
8	892 1 O
patients	894 8 O
the	903 3 O
diagnosis	907 9 O
of	917 2 O
primary	920 7 B-Disease
pulmonary	928 9 I-Disease
hypertension	938 12 I-Disease
was	951 3 O
uncertain	955 9 O
,	964 1 O
5	966 1 O
of	968 2 O
them	971 4 O
had	976 3 O
taken	980 5 O
appetite	986 8 B-Chemical
suppressants	995 12 I-Chemical
.	1007 1 O

The	1009 3 O
patients	1013 8 O
who	1022 3 O
had	1026 3 O
been	1030 4 O
exposed	1035 7 O
to	1043 2 O
appetite	1046 8 B-Chemical
suppressants	1055 12 I-Chemical
tended	1068 6 O
to	1075 2 O
be	1078 2 O
on	1081 2 O
average	1084 7 O
more	1092 4 O
severely	1097 8 O
ill	1106 3 O
,	1109 1 O
and	1111 3 O
to	1115 2 O
have	1118 4 O
a	1123 1 O
shorter	1125 7 O
median	1133 6 O
delay	1140 5 O
between	1146 7 O
onset	1154 5 O
of	1160 2 O
symptoms	1163 8 O
and	1172 3 O
diagnosis	1176 9 O
.	1185 1 O

A	1187 1 O
policy	1189 6 O
of	1196 2 O
unrestricted	1199 12 O
prescription	1212 12 O
of	1225 2 O
appetite	1228 8 B-Chemical
suppressants	1237 12 I-Chemical
may	1250 3 O
lead	1254 4 O
to	1259 2 O
a	1262 1 O
high	1264 4 O
incidence	1269 9 O
of	1279 2 O
associated	1282 10 O
primary	1293 7 B-Disease
pulmonary	1301 9 I-Disease
hypertension	1311 12 I-Disease
.	1323 1 O

Intake	1325 6 O
of	1332 2 O
appetite	1335 8 B-Chemical
suppressants	1344 12 I-Chemical
may	1357 3 O
accelerate	1361 10 O
the	1372 3 O
progression	1376 11 O
of	1388 2 O
the	1391 3 O
disease	1395 7 O
.	1402 1 O

Choreoathetoid	0 14 B-Disease
movements	15 9 I-Disease
associated	25 10 O
with	36 4 O
rapid	41 5 O
adjustment	47 10 O
to	58 2 O
methadone	61 9 B-Chemical
.	70 1 O

Choreatiform	72 12 B-Disease
hyperkinesias	85 13 I-Disease
are	99 3 O
known	103 5 O
to	109 2 O
be	112 2 O
occasional	115 10 O
movement	126 8 B-Disease
abnormalities	135 13 I-Disease
during	149 6 O
intoxications	156 13 O
with	170 4 O
cocaine	175 7 B-Chemical
but	183 3 O
not	187 3 O
opiates	191 7 O
.	198 1 O

This	200 4 O
is	205 2 O
a	208 1 O
case	210 4 O
report	215 6 O
of	222 2 O
euphoria	225 8 O
and	234 3 O
choreoathetoid	238 14 B-Disease
movements	253 9 I-Disease
both	263 4 O
transiently	268 11 O
induced	280 7 O
by	288 2 O
rapid	291 5 O
adjustment	297 10 O
to	308 2 O
the	311 3 O
selective	315 9 O
mu	325 2 O
-	327 1 O
opioid	328 6 O
receptor	335 8 O
agonist	344 7 O
methadone	352 9 B-Chemical
in	362 2 O
an	365 2 O
inpatient	368 9 O
previously	378 10 O
abusing	389 7 O
heroine	397 7 B-Chemical
and	405 3 O
cocaine	409 7 B-Chemical
.	416 1 O

In	418 2 O
addition	421 8 O
,	429 1 O
minor	431 5 O
EEG	437 3 O
abnormalities	441 13 O
occurred	455 8 O
.	463 1 O

Possible	465 8 O
underlying	474 10 O
neurobiological	485 15 O
phenomena	501 9 O
are	511 3 O
discussed	515 9 O
.	524 1 O

Cocaine	0 7 B-Chemical
-	7 1 O
induced	8 7 O
mood	16 4 B-Disease
disorder	21 8 I-Disease
:	29 1 O
prevalence	31 10 O
rates	42 5 O
and	48 3 O
psychiatric	52 11 B-Disease
symptoms	64 8 O
in	73 2 O
an	76 2 O
outpatient	79 10 O
cocaine	90 7 B-Chemical
-	97 1 O
dependent	98 9 O
sample	108 6 O
.	114 1 O

This	116 4 O
paper	121 5 O
attempts	127 8 O
to	136 2 O
examine	139 7 O
and	147 3 O
compare	151 7 O
prevalence	159 10 O
rates	170 5 O
and	176 3 O
symptom	180 7 O
patterns	188 8 O
of	197 2 O
DSM	200 3 O
substance	204 9 O
-	213 1 O
induced	214 7 O
and	222 3 O
other	226 5 O
mood	232 4 B-Disease
disorders	237 9 I-Disease
.	246 1 O

243	248 3 O
cocaine	252 7 B-Chemical
-	259 1 O
dependent	260 9 O
outpatients	270 11 O
with	282 4 O
cocaine	287 7 B-Chemical
-	294 1 O
induced	295 7 O
mood	303 4 B-Disease
disorder	308 8 I-Disease
(	317 1 O
CIMD	318 4 B-Disease
)	322 1 O
,	323 1 O
other	325 5 O
mood	331 4 B-Disease
disorders	336 9 I-Disease
,	345 1 O
or	347 2 O
no	350 2 O
mood	353 4 B-Disease
disorder	358 8 I-Disease
were	367 4 O
compared	372 8 O
on	381 2 O
measures	384 8 O
of	393 2 O
psychiatric	396 11 B-Disease
symptoms	408 8 O
.	416 1 O

The	418 3 O
prevalence	422 10 O
rate	433 4 O
for	438 3 O
CIMD	442 4 B-Disease
was	447 3 O
12	451 2 O
%	453 1 O
at	455 2 O
baseline	458 8 O
.	466 1 O

Introduction	468 12 O
of	481 2 O
the	484 3 O
DSM	488 3 O
-	491 1 O
IV	492 2 O
diagnosis	495 9 O
of	505 2 O
CIMD	508 4 B-Disease
did	513 3 O
not	517 3 O
substantially	521 13 O
affect	535 6 O
rates	542 5 O
of	548 2 O
the	551 3 O
other	555 5 O
depressive	561 10 B-Disease
disorders	572 9 I-Disease
.	581 1 O

Patients	583 8 O
with	592 4 O
CIMD	597 4 B-Disease
had	602 3 O
symptom	606 7 O
severity	614 8 O
levels	623 6 O
between	630 7 O
those	638 5 O
of	644 2 O
patients	647 8 O
with	656 4 O
and	661 3 O
without	665 7 O
a	673 1 O
mood	675 4 B-Disease
disorder	680 8 I-Disease
.	688 1 O

These	690 5 O
findings	696 8 O
suggest	705 7 O
some	713 4 O
validity	718 8 O
for	727 3 O
the	731 3 O
new	735 3 O
DSM	739 3 O
-	742 1 O
IV	743 2 O
diagnosis	746 9 O
of	756 2 O
CIMD	759 4 B-Disease
,	763 1 O
but	765 3 O
also	769 4 O
suggest	774 7 O
that	782 4 O
it	787 2 O
requires	790 8 O
further	799 7 O
specification	807 13 O
and	821 3 O
replication	825 11 O
.	836 1 O

Hemolysis	0 9 B-Disease
of	10 2 O
human	13 5 O
erythrocytes	19 12 O
induced	32 7 O
by	40 2 O
tamoxifen	43 9 B-Chemical
is	53 2 O
related	56 7 O
to	64 2 O
disruption	67 10 O
of	78 2 O
membrane	81 8 O
structure	90 9 O
.	99 1 O

Tamoxifen	101 9 B-Chemical
(	111 1 O
TAM	112 3 B-Chemical
)	115 1 O
,	116 1 O
the	118 3 O
antiestrogenic	122 14 O
drug	137 4 O
most	142 4 O
widely	147 6 O
prescribed	154 10 O
in	165 2 O
the	168 3 O
chemotherapy	172 12 O
of	185 2 O
breast	188 6 B-Disease
cancer	195 6 I-Disease
,	201 1 O
induces	203 7 O
changes	211 7 O
in	219 2 O
normal	222 6 O
discoid	229 7 O
shape	237 5 O
of	243 2 O
erythrocytes	246 12 O
and	259 3 O
hemolytic	263 9 B-Disease
anemia	273 6 I-Disease
.	279 1 O

This	281 4 O
work	286 4 O
evaluates	291 9 O
the	301 3 O
effects	305 7 O
of	313 2 O
TAM	316 3 B-Chemical
on	320 2 O
isolated	323 8 O
human	332 5 O
erythrocytes	338 12 O
,	350 1 O
attempting	352 10 O
to	363 2 O
identify	366 8 O
the	375 3 O
underlying	379 10 O
mechanisms	390 10 O
on	401 2 O
TAM	404 3 B-Chemical
-	407 1 O
induced	408 7 O
hemolytic	416 9 B-Disease
anemia	426 6 I-Disease
and	433 3 O
the	437 3 O
involvement	441 11 O
of	453 2 O
biomembranes	456 12 O
in	469 2 O
its	472 3 O
cytostatic	476 10 O
action	487 6 O
mechanisms	494 10 O
.	504 1 O

TAM	506 3 B-Chemical
induces	510 7 O
hemolysis	518 9 B-Disease
of	528 2 O
erythrocytes	531 12 O
as	544 2 O
a	547 1 O
function	549 8 O
of	558 2 O
concentration	561 13 O
.	574 1 O

The	576 3 O
extension	580 9 O
of	590 2 O
hemolysis	593 9 B-Disease
is	603 2 O
variable	606 8 O
with	615 4 O
erythrocyte	620 11 O
samples	632 7 O
,	639 1 O
but	641 3 O
12	645 2 O
.	647 1 O
5	648 1 O
microM	650 6 O
TAM	657 3 B-Chemical
induces	661 7 O
total	669 5 O
hemolysis	675 9 B-Disease
of	685 2 O
all	688 3 O
tested	692 6 O
suspensions	699 11 O
.	710 1 O

Despite	712 7 O
inducing	720 8 O
extensive	729 9 O
erythrocyte	739 11 O
lysis	751 5 O
,	756 1 O
TAM	758 3 B-Chemical
does	762 4 O
not	767 3 O
shift	771 5 O
the	777 3 O
osmotic	781 7 O
fragility	789 9 O
curves	799 6 O
of	806 2 O
erythrocytes	809 12 O
.	821 1 O

The	823 3 O
hemolytic	827 9 B-Disease
effect	837 6 O
of	844 2 O
TAM	847 3 B-Chemical
is	851 2 O
prevented	854 9 O
by	864 2 O
low	867 3 O
concentrations	871 14 O
of	886 2 O
alpha	889 5 B-Chemical
-	894 1 I-Chemical
tocopherol	895 10 I-Chemical
(	906 1 O
alpha	907 5 B-Chemical
-	912 1 I-Chemical
T	913 1 I-Chemical
)	914 1 O
and	916 3 O
alpha	920 5 B-Chemical
-	925 1 I-Chemical
tocopherol	926 10 I-Chemical
acetate	937 7 I-Chemical
(	945 1 O
alpha	946 5 B-Chemical
-	951 1 I-Chemical
TAc	952 3 I-Chemical
)	955 1 O
(	957 1 O
inactivated	958 11 O
functional	970 10 O
hydroxyl	981 8 B-Chemical
)	989 1 O
indicating	991 10 O
that	1002 4 O
TAM	1007 3 B-Chemical
-	1010 1 O
induced	1011 7 O
hemolysis	1019 9 B-Disease
is	1029 2 O
not	1032 3 O
related	1036 7 O
to	1044 2 O
oxidative	1047 9 O
membrane	1057 8 O
damage	1066 6 O
.	1072 1 O

This	1074 4 O
was	1079 3 O
further	1083 7 O
evidenced	1091 9 O
by	1101 2 O
absence	1104 7 O
of	1112 2 O
oxygen	1115 6 B-Chemical
consumption	1122 11 O
and	1134 3 O
hemoglobin	1138 10 O
oxidation	1149 9 O
both	1159 4 O
determined	1164 10 O
in	1175 2 O
parallel	1178 8 O
with	1187 4 O
TAM	1192 3 B-Chemical
-	1195 1 O
induced	1196 7 O
hemolysis	1204 9 B-Disease
.	1213 1 O

Furthermore	1215 11 O
,	1226 1 O
it	1228 2 O
was	1231 3 O
observed	1235 8 O
that	1244 4 O
TAM	1249 3 B-Chemical
inhibits	1253 8 O
the	1262 3 O
peroxidation	1266 12 O
of	1279 2 O
human	1282 5 O
erythrocytes	1288 12 O
induced	1301 7 O
by	1309 2 O
AAPH	1312 4 B-Chemical
,	1316 1 O
thus	1318 4 O
ruling	1323 6 O
out	1330 3 O
TAM	1334 3 B-Chemical
-	1337 1 O
induced	1338 7 O
cell	1346 4 O
oxidative	1351 9 O
stress	1361 6 O
.	1367 1 O

Hemolysis	1369 9 B-Disease
caused	1379 6 O
by	1386 2 O
TAM	1389 3 B-Chemical
was	1393 3 O
not	1397 3 O
preceded	1401 8 O
by	1410 2 O
the	1413 3 O
leakage	1417 7 O
of	1425 2 O
K	1428 1 B-Chemical
(	1429 1 O
+	1430 1 O
)	1431 1 O
from	1433 4 O
the	1438 3 O
cells	1442 5 O
,	1447 1 O
also	1449 4 O
excluding	1454 9 O
a	1464 1 O
colloid	1466 7 O
-	1473 1 O
osmotic	1474 7 O
type	1482 4 O
mechanism	1487 9 O
of	1497 2 O
hemolysis	1500 9 B-Disease
,	1509 1 O
according	1511 9 O
to	1521 2 O
the	1524 3 O
effects	1528 7 O
on	1536 2 O
osmotic	1539 7 O
fragility	1547 9 O
curves	1557 6 O
.	1563 1 O

However	1565 7 O
,	1572 1 O
TAM	1574 3 B-Chemical
induces	1578 7 O
release	1586 7 O
of	1594 2 O
peripheral	1597 10 O
proteins	1608 8 O
of	1617 2 O
membrane	1620 8 O
-	1628 1 O
cytoskeleton	1629 12 O
and	1642 3 O
cytosol	1646 7 O
proteins	1654 8 O
essentially	1663 11 O
bound	1675 5 O
to	1681 2 O
band	1684 4 O
3	1689 1 O
.	1690 1 O

Either	1692 6 O
alpha	1699 5 B-Chemical
-	1704 1 I-Chemical
T	1705 1 I-Chemical
or	1707 2 O
alpha	1710 5 B-Chemical
-	1715 1 I-Chemical
TAc	1716 3 I-Chemical
increases	1720 9 O
membrane	1730 8 O
packing	1739 7 O
and	1747 3 O
prevents	1751 8 O
TAM	1760 3 B-Chemical
partition	1764 9 O
into	1774 4 O
model	1779 5 O
membranes	1785 9 O
.	1794 1 O

These	1796 5 O
effects	1802 7 O
suggest	1810 7 O
that	1818 4 O
the	1823 3 O
protection	1827 10 O
from	1838 4 O
hemolysis	1843 9 B-Disease
by	1853 2 O
tocopherols	1856 11 B-Chemical
is	1868 2 O
related	1871 7 O
to	1879 2 O
a	1882 1 O
decreased	1884 9 O
TAM	1894 3 B-Chemical
incorporation	1898 13 O
in	1912 2 O
condensed	1915 9 O
membranes	1925 9 O
and	1935 3 O
the	1939 3 O
structural	1943 10 O
damage	1954 6 O
of	1961 2 O
the	1964 3 O
erythrocyte	1968 11 O
membrane	1980 8 O
is	1989 2 O
consequently	1992 12 O
avoided	2005 7 O
.	2012 1 O

Therefore	2014 9 O
,	2023 1 O
TAM	2025 3 B-Chemical
-	2028 1 O
induced	2029 7 O
hemolysis	2037 9 B-Disease
results	2047 7 O
from	2055 4 O
a	2060 1 O
structural	2062 10 O
perturbation	2073 12 O
of	2086 2 O
red	2089 3 O
cell	2093 4 O
membrane	2098 8 O
,	2106 1 O
leading	2108 7 O
to	2116 2 O
changes	2119 7 O
in	2127 2 O
the	2130 3 O
framework	2134 9 O
of	2144 2 O
the	2147 3 O
erythrocyte	2151 11 O
membrane	2163 8 O
and	2172 3 O
its	2176 3 O
cytoskeleton	2180 12 O
caused	2193 6 O
by	2200 2 O
its	2203 3 O
high	2207 4 O
partition	2212 9 O
in	2222 2 O
the	2225 3 O
membrane	2229 8 O
.	2237 1 O

These	2239 5 O
defects	2245 7 O
explain	2253 7 O
the	2261 3 O
abnormal	2265 8 O
erythrocyte	2274 11 O
shape	2286 5 O
and	2292 3 O
decreased	2296 9 O
mechanical	2306 10 O
stability	2317 9 O
promoted	2327 8 O
by	2336 2 O
TAM	2339 3 B-Chemical
,	2342 1 O
resulting	2344 9 O
in	2354 2 O
hemolytic	2357 9 B-Disease
anemia	2367 6 I-Disease
.	2373 1 O

Additionally	2375 12 O
,	2387 1 O
since	2389 5 O
membrane	2395 8 O
leakage	2404 7 O
is	2412 2 O
a	2415 1 O
final	2417 5 O
stage	2423 5 O
of	2429 2 O
cytotoxicity	2432 12 O
,	2444 1 O
the	2446 3 O
disruption	2450 10 O
of	2461 2 O
the	2464 3 O
structural	2468 10 O
characteristics	2479 15 O
of	2495 2 O
biomembranes	2498 12 O
by	2511 2 O
TAM	2514 3 B-Chemical
may	2518 3 O
contribute	2522 10 O
to	2533 2 O
the	2536 3 O
multiple	2540 8 O
mechanisms	2549 10 O
of	2560 2 O
its	2563 3 O
anticancer	2567 10 O
action	2578 6 O
.	2584 1 O

Changes	0 7 O
of	8 2 O
sodium	11 6 B-Chemical
and	18 3 O
ATP	22 3 B-Chemical
affinities	26 10 O
of	37 2 O
the	40 3 O
cardiac	44 7 O
(	52 1 O
Na	53 2 B-Chemical
,	55 1 O
K	56 1 B-Chemical
)	57 1 O
-	58 1 O
ATPase	59 6 O
during	66 6 O
and	73 3 O
after	77 5 O
nitric	83 6 B-Chemical
oxide	90 5 I-Chemical
deficient	96 9 O
hypertension	106 12 B-Disease
.	118 1 O

In	120 2 O
the	123 3 O
cardiovascular	127 14 O
system	142 6 O
,	148 1 O
NO	150 2 B-Chemical
is	153 2 O
involved	156 8 O
in	165 2 O
the	168 3 O
regulation	172 10 O
of	183 2 O
a	186 1 O
variety	188 7 O
of	196 2 O
functions	199 9 O
.	208 1 O

Inhibition	210 10 O
of	221 2 O
NO	224 2 B-Chemical
synthesis	227 9 O
induces	237 7 O
sustained	245 9 O
hypertension	255 12 B-Disease
.	267 1 O

In	269 2 O
several	272 7 O
models	280 6 O
of	287 2 O
hypertension	290 12 B-Disease
,	302 1 O
elevation	304 9 O
of	314 2 O
intracellular	317 13 O
sodium	331 6 B-Chemical
level	338 5 O
was	344 3 O
documented	348 10 O
in	359 2 O
cardiac	362 7 O
tissue	370 6 O
.	376 1 O

To	378 2 O
assess	381 6 O
the	388 3 O
molecular	392 9 O
basis	402 5 O
of	408 2 O
disturbances	411 12 O
in	424 2 O
transmembraneous	427 16 O
transport	444 9 O
of	454 2 O
Na	457 2 B-Chemical
+	459 1 O
,	460 1 O
we	462 2 O
studied	465 7 O
the	473 3 O
response	477 8 O
of	486 2 O
cardiac	489 7 O
(	497 1 O
Na	498 2 B-Chemical
,	500 1 O
K	501 1 B-Chemical
)	502 1 O
-	503 1 O
ATPase	504 6 O
to	511 2 O
NO	514 2 B-Chemical
-	516 1 O
deficient	517 9 O
hypertension	527 12 B-Disease
induced	540 7 O
in	548 2 O
rats	551 4 O
by	556 2 O
NO	559 2 B-Chemical
-	561 1 O
synthase	562 8 O
inhibition	571 10 O
with	582 4 O
40	587 2 O
mg	590 2 O
/	592 1 O
kg	593 2 O
/	595 1 O
day	596 3 O
N	600 1 B-Chemical
(	601 1 I-Chemical
G	602 1 I-Chemical
)	603 1 I-Chemical
-	604 1 I-Chemical
nitro	605 5 I-Chemical
-	610 1 I-Chemical
L	611 1 I-Chemical
-	612 1 I-Chemical
arginine	613 8 I-Chemical
methyl	622 6 I-Chemical
ester	629 5 I-Chemical
(	635 1 O
L	636 1 B-Chemical
-	637 1 I-Chemical
NAME	638 4 I-Chemical
)	642 1 O
for	644 3 O
4	648 1 O
four	650 4 O
weeks	655 5 O
.	660 1 O

After	662 5 O
4	668 1 O
-	669 1 O
week	670 4 O
administration	675 14 O
of	690 2 O
L	693 1 B-Chemical
-	694 1 I-Chemical
NAME	695 4 I-Chemical
,	699 1 O
the	701 3 O
systolic	705 8 O
blood	714 5 O
pressure	720 8 O
(	729 1 O
SBP	730 3 O
)	733 1 O
increased	735 9 O
by	745 2 O
36	748 2 O
%	750 1 O
.	751 1 O

Two	753 3 O
weeks	757 5 O
after	763 5 O
terminating	769 11 O
the	781 3 O
treatment	785 9 O
,	794 1 O
the	796 3 O
SBP	800 3 O
recovered	804 9 O
to	814 2 O
control	817 7 O
value	825 5 O
.	830 1 O

When	832 4 O
activating	837 10 O
the	848 3 O
(	852 1 O
Na	853 2 B-Chemical
,	855 1 O
K	856 1 B-Chemical
)	857 1 O
-	858 1 O
ATPase	859 6 O
with	866 4 O
its	871 3 O
substrate	875 9 O
ATP	885 3 B-Chemical
,	888 1 O
no	890 2 O
changes	893 7 O
in	901 2 O
Km	904 2 O
and	907 3 O
Vmax	911 4 O
values	916 6 O
were	923 4 O
observed	928 8 O
in	937 2 O
NO	940 2 B-Chemical
-	942 1 O
deficient	943 9 O
rats	953 4 O
.	957 1 O

During	959 6 O
activation	966 10 O
with	977 4 O
Na	982 2 B-Chemical
+	984 1 O
,	985 1 O
the	987 3 O
Vmax	991 4 O
remained	996 8 O
unchanged	1005 9 O
,	1014 1 O
however	1016 7 O
the	1024 3 O
K	1028 1 B-Chemical
(	1029 1 O
Na	1030 2 B-Chemical
)	1032 1 O
increased	1034 9 O
by	1044 2 O
50	1047 2 O
%	1049 1 O
,	1050 1 O
indicating	1052 10 O
a	1063 1 O
profound	1065 8 O
decrease	1074 8 O
in	1083 2 O
the	1086 3 O
affinity	1090 8 O
of	1099 2 O
the	1102 3 O
Na	1106 2 B-Chemical
+	1108 1 O
-	1109 1 O
binding	1110 7 O
site	1118 4 O
in	1123 2 O
NO	1126 2 B-Chemical
-	1128 1 O
deficient	1129 9 O
rats	1139 4 O
.	1143 1 O

After	1145 5 O
recovery	1151 8 O
from	1160 4 O
hypertension	1165 12 B-Disease
,	1177 1 O
the	1179 3 O
activity	1183 8 O
of	1192 2 O
(	1195 1 O
Na	1196 2 B-Chemical
,	1198 1 O
K	1199 1 B-Chemical
)	1200 1 O
-	1201 1 O
ATPase	1202 6 O
increased	1209 9 O
,	1218 1 O
due	1220 3 O
to	1224 2 O
higher	1227 6 O
affinity	1234 8 O
of	1243 2 O
the	1246 3 O
ATP	1250 3 B-Chemical
-	1253 1 O
binding	1254 7 O
site	1262 4 O
,	1266 1 O
as	1268 2 O
revealed	1271 8 O
from	1280 4 O
the	1285 3 O
lowered	1289 7 O
Km	1297 2 O
value	1300 5 O
for	1306 3 O
ATP	1310 3 B-Chemical
.	1313 1 O

The	1315 3 O
K	1319 1 B-Chemical
(	1320 1 O
Na	1321 2 B-Chemical
)	1323 1 O
value	1325 5 O
for	1331 3 O
Na	1335 2 B-Chemical
+	1337 1 O
returned	1339 8 O
to	1348 2 O
control	1351 7 O
value	1359 5 O
.	1364 1 O

Inhibition	1366 10 O
of	1377 2 O
NO	1380 2 B-Chemical
-	1382 1 O
synthase	1383 8 O
induced	1392 7 O
a	1400 1 O
reversible	1402 10 O
hypertension	1413 12 B-Disease
accompanied	1426 11 O
by	1438 2 O
depressed	1441 9 B-Disease
Na	1451 2 B-Chemical
+	1453 1 O
-	1454 1 O
extrusion	1455 9 O
from	1465 4 O
cardiac	1470 7 O
cells	1478 5 O
as	1484 2 O
a	1487 1 O
consequence	1489 11 O
of	1501 2 O
deteriorated	1504 12 O
Na	1517 2 B-Chemical
+	1519 1 O
-	1520 1 O
binding	1521 7 O
properties	1529 10 O
of	1540 2 O
the	1543 3 O
(	1547 1 O
Na	1548 2 B-Chemical
,	1550 1 O
K	1551 1 B-Chemical
)	1552 1 O
-	1553 1 O
ATPase	1554 6 O
.	1560 1 O

After	1562 5 O
recovery	1568 8 O
of	1577 2 O
blood	1580 5 O
pressure	1586 8 O
to	1595 2 O
control	1598 7 O
values	1606 6 O
,	1612 1 O
the	1614 3 O
extrusion	1618 9 O
of	1628 2 O
Na	1631 2 B-Chemical
+	1633 1 O
from	1635 4 O
cardiac	1640 7 O
cells	1648 5 O
was	1654 3 O
normalized	1658 10 O
,	1668 1 O
as	1670 2 O
revealed	1673 8 O
by	1682 2 O
restoration	1685 11 O
of	1697 2 O
the	1700 3 O
(	1704 1 O
Na	1705 2 B-Chemical
,	1707 1 O
K	1708 1 B-Chemical
)	1709 1 O
-	1710 1 O
ATPase	1711 6 O
activity	1718 8 O
.	1726 1 O

Effects	0 7 O
of	8 2 O
long	11 4 O
-	15 1 O
term	16 4 O
pretreatment	21 12 O
with	34 4 O
isoproterenol	39 13 B-Chemical
on	53 2 O
bromocriptine	56 13 B-Chemical
-	69 1 O
induced	70 7 O
tachycardia	78 11 B-Disease
in	90 2 O
conscious	93 9 O
rats	103 4 O
.	107 1 O

It	109 2 O
has	112 3 O
been	116 4 O
shown	121 5 O
that	127 4 O
bromocriptine	132 13 B-Chemical
-	145 1 O
induced	146 7 O
tachycardia	154 11 B-Disease
,	165 1 O
which	167 5 O
persisted	173 9 O
after	183 5 O
adrenalectomy	189 13 O
,	202 1 O
is	204 2 O
(	207 1 O
i	208 1 O
)	209 1 O
mediated	211 8 O
by	220 2 O
central	223 7 O
dopamine	231 8 B-Chemical
D2	240 2 O
receptor	243 8 O
activation	252 10 O
and	263 3 O
(	267 1 O
ii	268 2 O
)	270 1 O
reduced	272 7 O
by	280 2 O
5	283 1 O
-	284 1 O
day	285 3 O
isoproterenol	289 13 B-Chemical
pretreatment	303 12 O
,	315 1 O
supporting	317 10 O
therefore	328 9 O
the	338 3 O
hypothesis	342 10 O
that	353 4 O
this	358 4 O
effect	363 6 O
is	370 2 O
dependent	373 9 O
on	383 2 O
sympathetic	386 11 O
outflow	398 7 O
to	406 2 O
the	409 3 O
heart	413 5 O
.	418 1 O

This	420 4 O
study	425 5 O
was	431 3 O
conducted	435 9 O
to	445 2 O
examine	448 7 O
whether	456 7 O
prolonged	464 9 O
pretreatment	474 12 O
with	487 4 O
isoproterenol	492 13 B-Chemical
could	506 5 O
abolish	512 7 O
bromocriptine	520 13 B-Chemical
-	533 1 O
induced	534 7 O
tachycardia	542 11 B-Disease
in	554 2 O
conscious	557 9 O
rats	567 4 O
.	571 1 O

Isoproterenol	573 13 B-Chemical
pretreatment	587 12 O
for	600 3 O
15	604 2 O
days	607 4 O
caused	612 6 O
cardiac	619 7 B-Disease
hypertrophy	627 11 I-Disease
without	639 7 O
affecting	647 9 O
baseline	657 8 O
blood	666 5 O
pressure	672 8 O
and	681 3 O
heart	685 5 O
rate	691 4 O
.	695 1 O

In	697 2 O
control	700 7 O
rats	708 4 O
,	712 1 O
intravenous	714 11 O
bromocriptine	726 13 B-Chemical
(	740 1 O
150	741 3 O
microg	745 6 O
/	751 1 O
kg	752 2 O
)	754 1 O
induced	756 7 O
significant	764 11 O
hypotension	776 11 B-Disease
and	788 3 O
tachycardia	792 11 B-Disease
.	803 1 O

Bromocriptine	805 13 B-Chemical
-	818 1 O
induced	819 7 O
hypotension	827 11 B-Disease
was	839 3 O
unaffected	843 10 O
by	854 2 O
isoproterenol	857 13 B-Chemical
pretreatment	871 12 O
,	883 1 O
while	885 5 O
tachycardia	891 11 B-Disease
was	903 3 O
reversed	907 8 O
to	916 2 O
significant	919 11 O
bradycardia	931 11 B-Disease
,	942 1 O
an	944 2 O
effect	947 6 O
that	954 4 O
was	959 3 O
partly	963 6 O
reduced	970 7 O
by	978 2 O
i	981 1 O
.	982 1 O
v	983 1 O
.	984 1 O
domperidone	986 11 B-Chemical
(	998 1 O
0	999 1 O
.	1000 1 O
5	1001 1 O
mg	1003 2 O
/	1005 1 O
kg	1006 2 O
)	1008 1 O
.	1009 1 O

Neither	1011 7 O
cardiac	1019 7 O
vagal	1027 5 O
nor	1033 3 O
sympathetic	1037 11 O
tone	1049 4 O
was	1054 3 O
altered	1058 7 O
by	1066 2 O
isoproterenol	1069 13 B-Chemical
pretreatment	1083 12 O
.	1095 1 O

In	1097 2 O
isolated	1100 8 O
perfused	1109 8 O
heart	1118 5 O
preparations	1124 12 O
from	1137 4 O
isoproterenol	1142 13 B-Chemical
-	1155 1 O
pretreated	1156 10 O
rats	1167 4 O
,	1171 1 O
the	1173 3 O
isoproterenol	1177 13 B-Chemical
-	1190 1 O
induced	1191 7 O
maximal	1199 7 O
increase	1207 8 O
in	1216 2 O
left	1219 4 O
ventricular	1224 11 O
systolic	1236 8 O
pressure	1245 8 O
was	1254 3 O
significantly	1258 13 O
reduced	1272 7 O
,	1279 1 O
compared	1281 8 O
with	1290 4 O
saline	1295 6 O
-	1301 1 O
pretreated	1302 10 O
rats	1313 4 O
(	1318 1 O
the	1319 3 O
EC50	1323 4 O
of	1328 2 O
the	1331 3 O
isoproterenol	1335 13 B-Chemical
-	1348 1 O
induced	1349 7 O
increase	1357 8 O
in	1366 2 O
left	1369 4 O
ventricular	1374 11 O
systolic	1386 8 O
pressure	1395 8 O
was	1404 3 O
enhanced	1408 8 O
approximately	1417 13 O
22	1431 2 O
-	1433 1 O
fold	1434 4 O
)	1438 1 O
.	1439 1 O

These	1441 5 O
results	1447 7 O
show	1455 4 O
that	1460 4 O
15	1465 2 O
-	1467 1 O
day	1468 3 O
isoproterenol	1472 13 B-Chemical
pretreatment	1486 12 O
not	1499 3 O
only	1503 4 O
abolished	1508 9 O
but	1518 3 O
reversed	1522 8 O
bromocriptine	1531 13 B-Chemical
-	1544 1 O
induced	1545 7 O
tachycardia	1553 11 B-Disease
to	1565 2 O
bradycardia	1568 11 B-Disease
,	1579 1 O
an	1581 2 O
effect	1584 6 O
that	1591 4 O
is	1596 2 O
mainly	1599 6 O
related	1606 7 O
to	1614 2 O
further	1617 7 O
cardiac	1625 7 O
beta	1633 4 O
-	1637 1 O
adrenoceptor	1638 12 O
desensitization	1651 15 O
rather	1667 6 O
than	1674 4 O
to	1679 2 O
impairment	1682 10 O
of	1693 2 O
autonomic	1696 9 O
regulation	1706 10 O
of	1717 2 O
the	1720 3 O
heart	1724 5 O
.	1729 1 O

They	1731 4 O
suggest	1736 7 O
that	1744 4 O
,	1748 1 O
in	1750 2 O
normal	1753 6 O
conscious	1760 9 O
rats	1770 4 O
,	1774 1 O
the	1776 3 O
central	1780 7 O
tachycardia	1788 11 B-Disease
of	1800 2 O
bromocriptine	1803 13 B-Chemical
appears	1817 7 O
to	1825 2 O
predominate	1828 11 O
and	1840 3 O
to	1844 2 O
mask	1847 4 O
the	1852 3 O
bradycardia	1856 11 B-Disease
of	1868 2 O
this	1871 4 O
agonist	1876 7 O
at	1884 2 O
peripheral	1887 10 O
dopamine	1898 8 B-Chemical
D2	1907 2 O
receptors	1910 9 O
.	1919 1 O

A	0 1 O
developmental	2 13 O
analysis	16 8 O
of	25 2 O
clonidine	28 9 B-Chemical
'	37 1 O
s	38 1 O
effects	40 7 O
on	48 2 O
cardiac	51 7 O
rate	59 4 O
and	64 3 O
ultrasound	68 10 O
production	79 10 O
in	90 2 O
infant	93 6 O
rats	100 4 O
.	104 1 O

Under	106 5 O
controlled	112 10 O
conditions	123 10 O
,	133 1 O
infant	135 6 O
rats	142 4 O
emit	147 4 O
ultrasonic	152 10 O
vocalizations	163 13 O
during	177 6 O
extreme	184 7 O
cold	192 4 O
exposure	197 8 O
and	206 3 O
after	210 5 O
administration	216 14 O
of	231 2 O
the	234 3 O
alpha	238 5 O
(	243 1 O
2	244 1 O
)	245 1 O
adrenoceptor	247 12 O
agonist	260 7 O
,	267 1 O
clonidine	269 9 B-Chemical
.	278 1 O

Previous	280 8 O
investigations	289 14 O
have	304 4 O
determined	309 10 O
that	320 4 O
,	324 1 O
in	326 2 O
response	329 8 O
to	338 2 O
clonidine	341 9 B-Chemical
,	350 1 O
ultrasound	352 10 O
production	363 10 O
increases	374 9 O
through	384 7 O
the	392 3 O
2nd	396 3 O
-	399 1 O
week	400 4 O
postpartum	405 10 O
and	416 3 O
decreases	420 9 O
thereafter	430 10 O
.	440 1 O

Given	442 5 O
that	448 4 O
sympathetic	453 11 O
neural	465 6 O
dominance	472 9 O
exhibits	482 8 O
a	491 1 O
similar	493 7 O
developmental	501 13 O
pattern	515 7 O
,	522 1 O
and	524 3 O
given	528 5 O
that	534 4 O
clonidine	539 9 B-Chemical
induces	549 7 O
sympathetic	557 11 O
withdrawal	569 10 O
and	580 3 O
bradycardia	584 11 B-Disease
,	595 1 O
we	597 2 O
hypothesized	600 12 O
that	613 4 O
clonidine	618 9 B-Chemical
'	627 1 O
s	628 1 O
developmental	630 13 O
effects	644 7 O
on	652 2 O
cardiac	655 7 O
rate	663 4 O
and	668 3 O
ultrasound	672 10 O
production	683 10 O
would	694 5 O
mirror	700 6 O
each	707 4 O
other	712 5 O
.	717 1 O

Therefore	719 9 O
,	728 1 O
in	730 2 O
the	733 3 O
present	737 7 O
experiment	745 10 O
,	755 1 O
the	757 3 O
effects	761 7 O
of	769 2 O
clonidine	772 9 B-Chemical
administration	782 14 O
(	797 1 O
0	798 1 O
.	799 1 O
5	800 1 O
mg	802 2 O
/	804 1 O
kg	805 2 O
)	807 1 O
on	809 2 O
cardiac	812 7 O
rate	820 4 O
and	825 3 O
ultrasound	829 10 O
production	840 10 O
were	851 4 O
examined	856 8 O
in	865 2 O
2	868 1 O
-	869 1 O
,	870 1 O
8	872 1 O
-	873 1 O
,	874 1 O
15	876 2 O
-	878 1 O
,	879 1 O
and	881 3 O
20	885 2 O
-	887 1 O
day	888 3 O
-	891 1 O
old	892 3 O
rats	896 4 O
.	900 1 O

Age	902 3 O
-	905 1 O
related	906 7 O
changes	914 7 O
in	922 2 O
ultrasound	925 10 O
production	936 10 O
corresponded	947 12 O
with	960 4 O
changes	965 7 O
in	973 2 O
cardiovascular	976 14 O
variables	991 9 O
,	1000 1 O
including	1002 9 O
baseline	1012 8 O
cardiac	1021 7 O
rate	1029 4 O
and	1034 3 O
clonidine	1038 9 B-Chemical
-	1047 1 O
induced	1048 7 O
bradycardia	1056 11 B-Disease
.	1067 1 O

This	1069 4 O
experiment	1074 10 O
is	1085 2 O
discussed	1088 9 O
with	1098 4 O
regard	1103 6 O
to	1110 2 O
the	1113 3 O
hypothesis	1117 10 O
that	1128 4 O
ultrasound	1133 10 O
production	1144 10 O
is	1155 2 O
the	1158 3 O
acoustic	1162 8 O
by	1171 2 O
-	1173 1 O
product	1174 7 O
of	1182 2 O
a	1185 1 O
physiological	1187 13 O
maneuver	1201 8 O
that	1210 4 O
compensates	1215 11 O
for	1227 3 O
clonidine	1231 9 B-Chemical
'	1240 1 O
s	1241 1 O
detrimental	1243 11 O
effects	1255 7 O
on	1263 2 O
cardiovascular	1266 14 O
function	1281 8 O
.	1289 1 O

Differential	0 12 O
effects	13 7 O
of	21 2 O
systemically	24 12 O
administered	37 12 O
ketamine	50 8 B-Chemical
and	59 3 O
lidocaine	63 9 B-Chemical
on	73 2 O
dynamic	76 7 O
and	84 3 O
static	88 6 O
hyperalgesia	95 12 B-Disease
induced	108 7 O
by	116 2 O
intradermal	119 11 O
capsaicin	131 9 B-Chemical
in	141 2 O
humans	144 6 O
.	150 1 O

We	152 2 O
have	155 4 O
examined	160 8 O
the	169 3 O
effect	173 6 O
of	180 2 O
systemic	183 8 O
administration	192 14 O
of	207 2 O
ketamine	210 8 B-Chemical
and	219 3 O
lidocaine	223 9 B-Chemical
on	233 2 O
brush	236 5 O
-	241 1 O
evoked	242 6 O
(	249 1 O
dynamic	250 7 O
)	257 1 O
pain	259 4 B-Disease
and	264 3 O
punctate	268 8 O
-	276 1 O
evoked	277 6 O
(	284 1 O
static	285 6 O
)	291 1 O
hyperalgesia	293 12 B-Disease
induced	306 7 O
by	314 2 O
capsaicin	317 9 B-Chemical
.	326 1 O

In	328 2 O
a	331 1 O
randomized	333 10 O
,	343 1 O
double	345 6 O
-	351 1 O
blind	352 5 O
,	357 1 O
placebo	359 7 O
-	366 1 O
controlled	367 10 O
,	377 1 O
crossover	379 9 O
study	389 5 O
,	394 1 O
we	396 2 O
studied	399 7 O
12	407 2 O
volunteers	410 10 O
in	421 2 O
three	424 5 O
experiments	430 11 O
.	441 1 O

Capsaicin	443 9 B-Chemical
100	453 3 O
micrograms	457 10 O
was	468 3 O
injected	472 8 O
intradermally	481 13 O
on	495 2 O
the	498 3 O
volar	502 5 O
forearm	508 7 O
followed	516 8 O
by	525 2 O
an	528 2 O
i	531 1 O
.	532 1 O
v	533 1 O
.	534 1 O
infusion	536 8 O
of	545 2 O
ketamine	548 8 B-Chemical
(	557 1 O
bolus	558 5 O
0	564 1 O
.	565 1 O
1	566 1 O
mg	568 2 O
kg	571 2 O
-	573 1 O
1	574 1 O
over	576 4 O
10	581 2 O
min	584 3 O
followed	588 8 O
by	597 2 O
infusion	600 8 O
of	609 2 O
7	612 1 O
micrograms	614 10 O
kg	625 2 O
-	627 1 O
1	628 1 O
min	630 3 O
-	633 1 O
1	634 1 O
)	635 1 O
,	636 1 O
lidocaine	638 9 B-Chemical
5	648 1 O
mg	650 2 O
kg	653 2 O
-	655 1 O
1	656 1 O
or	658 2 O
saline	661 6 O
for	668 3 O
50	672 2 O
min	675 3 O
.	678 1 O

Infusion	680 8 O
started	689 7 O
15	697 2 O
min	700 3 O
after	704 5 O
injection	710 9 O
of	720 2 O
capsaicin	723 9 B-Chemical
.	732 1 O

The	734 3 O
following	738 9 O
were	748 4 O
measured	753 8 O
:	761 1 O
spontaneous	763 11 O
pain	775 4 B-Disease
,	779 1 O
pain	781 4 B-Disease
evoked	786 6 O
by	793 2 O
punctate	796 8 O
and	805 3 O
brush	809 5 O
stimuli	815 7 O
(	823 1 O
VAS	824 3 O
)	827 1 O
,	828 1 O
and	830 3 O
areas	834 5 O
of	840 2 O
brush	843 5 O
-	848 1 O
evoked	849 6 O
and	856 3 O
punctate	860 8 O
-	868 1 O
evoked	869 6 O
hyperalgesia	876 12 B-Disease
.	888 1 O

Ketamine	890 8 B-Chemical
reduced	899 7 O
both	907 4 O
the	912 3 O
area	916 4 O
of	921 2 O
brush	924 5 O
-	929 1 O
evoked	930 6 O
and	937 3 O
punctate	941 8 O
-	949 1 O
evoked	950 6 O
hyperalgesia	957 12 B-Disease
significantly	970 13 O
and	984 3 O
it	988 2 O
tended	991 6 O
to	998 2 O
reduce	1001 6 O
brush	1008 5 O
-	1013 1 O
evoked	1014 6 O
pain	1021 4 B-Disease
.	1025 1 O

Lidocaine	1027 9 B-Chemical
reduced	1037 7 O
the	1045 3 O
area	1049 4 O
of	1054 2 O
punctate	1057 8 O
-	1065 1 O
evoked	1066 6 O
hyperalgesia	1073 12 B-Disease
significantly	1086 13 O
.	1099 1 O

It	1101 2 O
tended	1104 6 O
to	1111 2 O
reduce	1114 6 O
VAS	1121 3 O
scores	1125 6 O
of	1132 2 O
spontaneous	1135 11 O
pain	1147 4 B-Disease
but	1152 3 O
had	1156 3 O
no	1160 2 O
effect	1163 6 O
on	1170 2 O
evoked	1173 6 O
pain	1180 4 B-Disease
.	1184 1 O

The	1186 3 O
differential	1190 12 O
effects	1203 7 O
of	1211 2 O
ketamine	1214 8 B-Chemical
and	1223 3 O
lidocaine	1227 9 B-Chemical
on	1237 2 O
static	1240 6 O
and	1247 3 O
dynamic	1251 7 O
hyperalgesia	1259 12 B-Disease
suggest	1272 7 O
that	1280 4 O
the	1285 3 O
two	1289 3 O
types	1293 5 O
of	1299 2 O
hyperalgesia	1302 12 B-Disease
are	1315 3 O
mediated	1319 8 O
by	1328 2 O
separate	1331 8 O
mechanisms	1340 10 O
and	1351 3 O
have	1355 4 O
a	1360 1 O
distinct	1362 8 O
pharmacology	1371 12 O
.	1383 1 O

Cyclosporine	0 12 B-Chemical
and	13 3 O
tacrolimus	17 10 B-Chemical
-	27 1 O
associated	28 10 O
thrombotic	39 10 B-Disease
microangiopathy	50 15 I-Disease
.	65 1 O

The	67 3 O
development	71 11 O
of	83 2 O
thrombotic	86 10 B-Disease
microangiopathy	97 15 I-Disease
(	113 1 O
TMA	114 3 B-Disease
)	117 1 O
associated	119 10 O
with	130 4 O
the	135 3 O
use	139 3 O
of	143 2 O
cyclosporine	146 12 B-Chemical
has	159 3 O
been	163 4 O
well	168 4 O
documented	173 10 O
.	183 1 O

Treatments	185 10 O
have	196 4 O
included	201 8 O
discontinuation	210 15 O
or	226 2 O
reduction	229 9 O
of	239 2 O
cyclosporine	242 12 B-Chemical
dose	255 4 O
with	260 4 O
or	265 2 O
without	268 7 O
concurrent	276 10 O
plasma	287 6 O
exchange	294 8 O
,	302 1 O
plasma	304 6 O
infusion	311 8 O
,	319 1 O
anticoagulation	321 15 O
,	336 1 O
and	338 3 O
intravenous	342 11 O
immunoglobulin	354 14 O
G	369 1 O
infusion	371 8 O
.	379 1 O

However	381 7 O
,	388 1 O
for	390 3 O
recipients	394 10 O
of	405 2 O
organ	408 5 O
transplantation	414 15 O
,	429 1 O
removing	431 8 O
the	440 3 O
inciting	444 8 O
agent	453 5 O
is	459 2 O
not	462 3 O
without	466 7 O
the	474 3 O
attendant	478 9 O
risk	488 4 O
of	493 2 O
precipitating	496 13 O
acute	510 5 O
rejection	516 9 O
and	526 3 O
graft	530 5 O
loss	536 4 O
.	540 1 O

The	542 3 O
last	546 4 O
decade	551 6 O
has	558 3 O
seen	562 4 O
the	567 3 O
emergence	571 9 O
of	581 2 O
tacrolimus	584 10 B-Chemical
as	595 2 O
a	598 1 O
potent	600 6 O
immunosuppressive	607 17 O
agent	625 5 O
with	631 4 O
mechanisms	636 10 O
of	647 2 O
action	650 6 O
virtually	657 9 O
identical	667 9 O
to	677 2 O
those	680 5 O
of	686 2 O
cyclosporine	689 12 B-Chemical
.	701 1 O

As	703 2 O
a	706 1 O
result	708 6 O
,	714 1 O
switching	716 9 O
to	726 2 O
tacrolimus	729 10 B-Chemical
has	740 3 O
been	744 4 O
reported	749 8 O
to	758 2 O
be	761 2 O
a	764 1 O
viable	766 6 O
therapeutic	773 11 O
option	785 6 O
in	792 2 O
the	795 3 O
setting	799 7 O
of	807 2 O
cyclosporine	810 12 B-Chemical
-	822 1 O
induced	823 7 O
TMA	831 3 B-Disease
.	834 1 O

With	836 4 O
the	841 3 O
more	845 4 O
widespread	850 10 O
application	861 11 O
of	873 2 O
tacrolimus	876 10 B-Chemical
in	887 2 O
organ	890 5 O
transplantation	896 15 O
,	911 1 O
tacrolimus	913 10 B-Chemical
-	923 1 O
associated	924 10 O
TMA	935 3 B-Disease
has	939 3 O
also	943 4 O
been	948 4 O
recognized	953 10 O
.	963 1 O

However	965 7 O
,	972 1 O
literature	974 10 O
regarding	985 9 O
the	995 3 O
incidence	999 9 O
of	1009 2 O
the	1012 3 O
recurrence	1016 10 O
of	1027 2 O
TMA	1030 3 B-Disease
in	1034 2 O
patients	1037 8 O
exposed	1046 7 O
sequentially	1054 12 O
to	1067 2 O
cyclosporine	1070 12 B-Chemical
and	1083 3 O
tacrolimus	1087 10 B-Chemical
is	1098 2 O
limited	1101 7 O
.	1108 1 O

We	1110 2 O
report	1113 6 O
a	1120 1 O
case	1122 4 O
of	1127 2 O
a	1130 1 O
living	1132 6 O
donor	1139 5 O
renal	1145 5 O
transplant	1151 10 O
recipient	1162 9 O
who	1172 3 O
developed	1176 9 O
cyclosporine	1186 12 B-Chemical
-	1198 1 O
induced	1199 7 O
TMA	1207 3 B-Disease
that	1211 4 O
responded	1216 9 O
to	1226 2 O
the	1229 3 O
withdrawal	1233 10 O
of	1244 2 O
cyclosporine	1247 12 B-Chemical
in	1260 2 O
conjunction	1263 11 O
with	1275 4 O
plasmapheresis	1280 14 O
and	1295 3 O
fresh	1299 5 O
frozen	1305 6 O
plasma	1312 6 O
replacement	1319 11 O
therapy	1331 7 O
.	1338 1 O

Introduction	1340 12 O
of	1353 2 O
tacrolimus	1356 10 B-Chemical
as	1367 2 O
an	1370 2 O
alternative	1373 11 O
immunosuppressive	1385 17 O
agent	1403 5 O
resulted	1409 8 O
in	1418 2 O
the	1421 3 O
recurrence	1425 10 O
of	1436 2 O
TMA	1439 3 B-Disease
and	1443 3 O
the	1447 3 O
subsequent	1451 10 O
loss	1462 4 O
of	1467 2 O
the	1470 3 O
renal	1474 5 O
allograft	1480 9 O
.	1489 1 O

Patients	1491 8 O
who	1500 3 O
are	1504 3 O
switched	1508 8 O
from	1517 4 O
cyclosporine	1522 12 B-Chemical
to	1535 2 O
tacrolimus	1538 10 B-Chemical
or	1549 2 O
vice	1552 4 O
versa	1557 5 O
should	1563 6 O
be	1570 2 O
closely	1573 7 O
monitored	1581 9 O
for	1591 3 O
the	1595 3 O
signs	1599 5 O
and	1605 3 O
symptoms	1609 8 O
of	1618 2 O
recurrent	1621 9 O
TMA	1631 3 B-Disease
.	1634 1 O

Repeated	0 8 O
transient	9 9 O
anuria	19 6 B-Disease
following	26 9 O
losartan	36 8 B-Chemical
administration	45 14 O
in	60 2 O
a	63 1 O
patient	65 7 O
with	73 4 O
a	78 1 O
solitary	80 8 O
kidney	89 6 O
.	95 1 O

We	97 2 O
report	100 6 O
the	107 3 O
case	111 4 O
of	116 2 O
a	119 1 O
70	121 2 O
-	123 1 O
year	124 4 O
-	128 1 O
old	129 3 O
hypertensive	133 12 B-Disease
man	146 3 O
with	150 4 O
a	155 1 O
solitary	157 8 O
kidney	166 6 O
and	173 3 O
chronic	177 7 B-Disease
renal	185 5 I-Disease
insufficiency	191 13 I-Disease
who	205 3 O
developed	209 9 O
two	219 3 O
episodes	223 8 O
of	232 2 O
transient	235 9 O
anuria	245 6 B-Disease
after	252 5 O
losartan	258 8 B-Chemical
administration	267 14 O
.	281 1 O

He	283 2 O
was	286 3 O
hospitalized	290 12 O
for	303 3 O
a	307 1 O
myocardial	309 10 B-Disease
infarction	320 10 I-Disease
with	331 4 O
pulmonary	336 9 B-Disease
edema	346 5 I-Disease
,	351 1 O
treated	353 7 O
with	361 4 O
high	366 4 O
-	370 1 O
dose	371 4 O
diuretics	376 9 O
.	385 1 O

Due	387 3 O
to	391 2 O
severe	394 6 O
systolic	401 8 B-Disease
dysfunction	410 11 I-Disease
losartan	422 8 B-Chemical
was	431 3 O
prescribed	435 10 O
.	445 1 O

Surprisingly	447 12 O
,	459 1 O
the	461 3 O
first	465 5 O
dose	471 4 O
of	476 2 O
50	479 2 O
mg	482 2 O
of	485 2 O
losartan	488 8 B-Chemical
resulted	497 8 O
in	506 2 O
a	509 1 O
sudden	511 6 O
anuria	518 6 B-Disease
,	524 1 O
which	526 5 O
lasted	532 6 O
eight	539 5 O
hours	545 5 O
despite	551 7 O
high	559 4 O
-	563 1 O
dose	564 4 O
furosemide	569 10 B-Chemical
and	580 3 O
amine	584 5 B-Chemical
infusion	590 8 O
.	598 1 O

One	600 3 O
week	604 4 O
later	609 5 O
,	614 1 O
by	616 2 O
mistake	619 7 O
,	626 1 O
losartan	628 8 B-Chemical
was	637 3 O
prescribed	641 10 O
again	652 5 O
and	658 3 O
after	662 5 O
the	668 3 O
second	672 6 O
dose	679 4 O
of	684 2 O
50	687 2 O
mg	690 2 O
,	692 1 O
the	694 3 O
patient	698 7 O
developed	706 9 O
a	716 1 O
second	718 6 O
episode	725 7 O
of	733 2 O
transient	736 9 O
anuria	746 6 B-Disease
lasting	753 7 O
10	761 2 O
hours	764 5 O
.	769 1 O

During	771 6 O
these	778 5 O
two	784 3 O
episodes	788 8 O
,	796 1 O
his	798 3 O
blood	802 5 O
pressure	808 8 O
diminished	817 10 O
but	828 3 O
no	832 2 O
severe	835 6 O
hypotension	842 11 B-Disease
was	854 3 O
noted	858 5 O
.	863 1 O

Ultimately	865 10 O
,	875 1 O
an	877 2 O
arteriography	880 13 O
showed	894 6 O
a	901 1 O
70	903 2 O
-	905 1 O
80	906 2 O
%	908 1 O
renal	910 5 B-Disease
artery	916 6 I-Disease
stenosis	923 8 I-Disease
.	931 1 O

In	933 2 O
this	936 4 O
patient	941 7 O
,	948 1 O
renal	950 5 B-Disease
artery	956 6 I-Disease
stenosis	963 8 I-Disease
combined	972 8 O
with	981 4 O
heart	986 5 B-Disease
failure	992 7 I-Disease
and	1000 3 O
diuretic	1004 8 O
therapy	1013 7 O
certainly	1021 9 O
resulted	1031 8 O
in	1040 2 O
a	1043 1 O
strong	1045 6 O
activation	1052 10 O
of	1063 2 O
the	1066 3 O
renin	1070 5 O
-	1075 1 O
angiotensin	1076 11 B-Chemical
system	1088 6 O
(	1095 1 O
RAS	1096 3 O
)	1099 1 O
.	1100 1 O

Under	1102 5 O
such	1108 4 O
conditions	1113 10 O
,	1123 1 O
angiotensin	1125 11 B-Chemical
II	1137 2 I-Chemical
receptor	1140 8 O
blockade	1149 8 O
by	1158 2 O
losartan	1161 8 B-Chemical
probably	1170 8 O
induced	1179 7 O
a	1187 1 O
critical	1189 8 O
fall	1198 4 O
in	1203 2 O
glomerular	1206 10 O
filtration	1217 10 O
pressure	1228 8 O
.	1236 1 O

This	1238 4 O
case	1243 4 O
report	1248 6 O
highlights	1255 10 O
the	1266 3 O
fact	1270 4 O
that	1275 4 O
the	1280 3 O
angiotensin	1284 11 B-Chemical
II	1296 2 I-Chemical
receptor	1299 8 O
antagonist	1308 10 O
losartan	1319 8 B-Chemical
can	1328 3 O
cause	1332 5 O
serious	1338 7 O
unexpected	1346 10 O
complications	1357 13 O
in	1371 2 O
patients	1374 8 O
with	1383 4 O
renovascular	1388 12 B-Disease
disease	1401 7 I-Disease
and	1409 3 O
should	1413 6 O
be	1420 2 O
used	1423 4 O
with	1428 4 O
extreme	1433 7 O
caution	1441 7 O
in	1449 2 O
this	1452 4 O
setting	1457 7 O
.	1464 1 O

In	0 2 O
vivo	3 4 O
protection	8 10 O
of	19 2 O
dna	22 3 O
damage	26 6 O
associated	33 10 O
apoptotic	44 9 O
and	54 3 O
necrotic	58 8 B-Disease
cell	67 4 O
deaths	72 6 O
during	79 6 O
acetaminophen	86 13 B-Chemical
-	99 1 O
induced	100 7 O
nephrotoxicity	108 14 B-Disease
,	122 1 O
amiodarone	124 10 B-Chemical
-	134 1 O
induced	135 7 O
lung	143 4 B-Disease
toxicity	148 8 I-Disease
and	157 3 O
doxorubicin	161 11 B-Chemical
-	172 1 O
induced	173 7 O
cardiotoxicity	181 14 B-Disease
by	196 2 O
a	199 1 O
novel	201 5 O
IH636	207 5 B-Chemical
grape	213 5 I-Chemical
seed	219 4 I-Chemical
proanthocyanidin	224 16 I-Chemical
extract	241 7 I-Chemical
.	248 1 O

Grape	250 5 B-Chemical
seed	256 4 I-Chemical
extract	261 7 I-Chemical
,	268 1 O
primarily	270 9 O
a	280 1 O
mixture	282 7 O
of	290 2 O
proanthocyanidins	293 17 B-Chemical
,	310 1 O
has	312 3 O
been	316 4 O
shown	321 5 O
to	327 2 O
modulate	330 8 O
a	339 1 O
wide	341 4 O
-	345 1 O
range	346 5 O
of	352 2 O
biological	355 10 O
,	365 1 O
pharmacological	367 15 O
and	383 3 O
toxicological	387 13 O
effects	401 7 O
which	409 5 O
are	415 3 O
mainly	419 6 O
cytoprotective	426 14 O
.	440 1 O

This	442 4 O
study	447 5 O
assessed	453 8 O
the	462 3 O
ability	466 7 O
of	474 2 O
IH636	477 5 B-Chemical
grape	483 5 I-Chemical
seed	489 4 I-Chemical
proanthocyanidin	494 16 I-Chemical
extract	511 7 I-Chemical
(	519 1 O
GSPE	520 4 B-Chemical
)	524 1 O
to	526 2 O
prevent	529 7 O
acetaminophen	537 13 B-Chemical
(	551 1 O
AAP	552 3 B-Chemical
)	555 1 O
-	556 1 O
induced	557 7 O
nephrotoxicity	565 14 B-Disease
,	579 1 O
amiodarone	581 10 B-Chemical
(	592 1 O
AMI	593 3 B-Chemical
)	596 1 O
-	597 1 O
induced	598 7 O
lung	606 4 B-Disease
toxicity	611 8 I-Disease
,	619 1 O
and	621 3 O
doxorubicin	625 11 B-Chemical
(	637 1 O
DOX	638 3 B-Chemical
)	641 1 O
-	642 1 O
induced	643 7 O
cardiotoxicity	651 14 B-Disease
in	666 2 O
mice	669 4 O
.	673 1 O

Experimental	675 12 O
design	688 6 O
consisted	695 9 O
of	705 2 O
four	708 4 O
groups	713 6 O
:	719 1 O
control	721 7 O
(	729 1 O
vehicle	730 7 O
alone	738 5 O
)	743 1 O
,	744 1 O
GSPE	746 4 B-Chemical
alone	751 5 O
,	756 1 O
drug	758 4 O
alone	763 5 O
and	769 3 O
GSPE	773 4 B-Chemical
+	777 1 O
drug	778 4 O
.	782 1 O

For	784 3 O
the	788 3 O
cytoprotection	792 14 O
study	807 5 O
,	812 1 O
animals	814 7 O
were	822 4 O
orally	827 6 O
gavaged	834 7 O
100	842 3 O
mg	846 2 O
/	848 1 O
Kg	849 2 O
GSPE	852 4 B-Chemical
for	857 3 O
7	861 1 O
-	862 1 O
10	863 2 O
days	866 4 O
followed	871 8 O
by	880 2 O
i	883 1 O
.	884 1 O
p	885 1 O
.	886 1 O
injections	888 10 O
of	899 2 O
organ	902 5 O
specific	908 8 O
three	917 5 O
drugs	923 5 O
(	929 1 O
AAP	930 3 B-Chemical
:	933 1 O
500	935 3 O
mg	939 2 O
/	941 1 O
Kg	942 2 O
for	945 3 O
24	949 2 O
h	952 1 O
;	953 1 O
AMI	955 3 B-Chemical
:	958 1 O
50	960 2 O
mg	963 2 O
/	965 1 O
Kg	966 2 O
/	968 1 O
day	969 3 O
for	973 3 O
four	977 4 O
days	982 4 O
;	986 1 O
DOX	988 3 B-Chemical
:	991 1 O
20	993 2 O
mg	996 2 O
/	998 1 O
Kg	999 2 O
for	1002 3 O
48	1006 2 O
h	1009 1 O
)	1010 1 O
.	1011 1 O

Parameters	1013 10 O
of	1024 2 O
study	1027 5 O
included	1033 8 O
analysis	1042 8 O
of	1051 2 O
serum	1054 5 O
chemistry	1060 9 O
(	1070 1 O
ALT	1071 3 O
,	1074 1 O
BUN	1076 3 O
and	1080 3 O
CPK	1084 3 O
)	1087 1 O
,	1088 1 O
and	1090 3 O
orderly	1094 7 O
fragmentation	1102 13 O
of	1116 2 O
genomic	1119 7 O
DNA	1127 3 O
(	1131 1 O
both	1132 4 O
endonuclease	1137 12 O
-	1149 1 O
dependent	1150 9 O
and	1160 3 O
independent	1164 11 O
)	1175 1 O
in	1177 2 O
addition	1180 8 O
to	1189 2 O
microscopic	1192 11 O
evaluation	1204 10 O
of	1215 2 O
damage	1218 6 O
and	1225 3 O
/	1228 1 O
or	1229 2 O
protection	1232 10 O
in	1243 2 O
corresponding	1246 13 O
PAS	1260 3 O
stained	1264 7 O
tissues	1272 7 O
.	1279 1 O

Results	1281 7 O
indicate	1289 8 O
that	1298 4 O
GSPE	1303 4 B-Chemical
preexposure	1308 11 O
prior	1320 5 O
to	1326 2 O
AAP	1329 3 B-Chemical
,	1332 1 O
AMI	1334 3 B-Chemical
and	1338 3 O
DOX	1342 3 B-Chemical
,	1345 1 O
provided	1347 8 O
near	1356 4 O
complete	1361 8 O
protection	1370 10 O
in	1381 2 O
terms	1384 5 O
of	1390 2 O
serum	1393 5 O
chemistry	1399 9 O
changes	1409 7 O
(	1417 1 O
ALT	1418 3 O
,	1421 1 O
BUN	1423 3 O
and	1427 3 O
CPK	1431 3 O
)	1434 1 O
,	1435 1 O
and	1437 3 O
significantly	1441 13 O
reduced	1455 7 O
DNA	1463 3 O
fragmentation	1467 13 O
.	1480 1 O

Histopathological	1482 17 O
examination	1500 11 O
of	1512 2 O
kidney	1515 6 O
,	1521 1 O
heart	1523 5 O
and	1529 3 O
lung	1533 4 O
sections	1538 8 O
revealed	1547 8 O
moderate	1556 8 O
to	1565 2 O
massive	1568 7 O
tissue	1576 6 B-Disease
damage	1583 6 I-Disease
with	1590 4 O
a	1595 1 O
variety	1597 7 O
of	1605 2 O
morphological	1608 13 O
aberrations	1622 11 O
by	1634 2 O
all	1637 3 O
the	1641 3 O
three	1645 5 O
drugs	1651 5 O
in	1657 2 O
the	1660 3 O
absence	1664 7 O
of	1672 2 O
GSPE	1675 4 B-Chemical
preexposure	1680 11 O
than	1692 4 O
in	1697 2 O
its	1700 3 O
presence	1704 8 O
.	1712 1 O

GSPE	1714 4 B-Chemical
+	1718 1 O
drug	1719 4 O
exposed	1724 7 O
tissues	1732 7 O
exhibited	1740 9 O
minor	1750 5 O
residual	1756 8 O
damage	1765 6 O
or	1772 2 O
near	1775 4 O
total	1780 5 O
recovery	1786 8 O
.	1794 1 O

Additionally	1796 12 O
,	1808 1 O
histopathological	1810 17 O
alterations	1828 11 O
mirrored	1840 8 O
both	1849 4 O
serum	1854 5 O
chemistry	1860 9 O
changes	1870 7 O
and	1878 3 O
the	1882 3 O
pattern	1886 7 O
of	1894 2 O
DNA	1897 3 O
fragmentation	1901 13 O
.	1914 1 O

Interestingly	1916 13 O
,	1929 1 O
all	1931 3 O
the	1935 3 O
drugs	1939 5 O
,	1944 1 O
such	1946 4 O
as	1951 2 O
,	1953 1 O
AAP	1955 3 B-Chemical
,	1958 1 O
AMI	1960 3 B-Chemical
and	1964 3 O
DOX	1968 3 B-Chemical
induced	1972 7 O
apoptotic	1980 9 O
death	1990 5 O
in	1996 2 O
addition	1999 8 O
to	2008 2 O
necrosis	2011 8 B-Disease
in	2020 2 O
the	2023 3 O
respective	2027 10 O
organs	2038 6 O
which	2045 5 O
was	2051 3 O
very	2055 4 O
effectively	2060 11 O
blocked	2072 7 O
by	2080 2 O
GSPE	2083 4 B-Chemical
.	2087 1 O

Since	2089 5 O
AAP	2095 3 B-Chemical
,	2098 1 O
AMI	2100 3 B-Chemical
and	2104 3 O
DOX	2108 3 B-Chemical
undergo	2112 7 O
biotransformation	2120 17 O
and	2138 3 O
are	2142 3 O
known	2146 5 O
to	2152 2 O
produce	2155 7 O
damaging	2163 8 O
radicals	2172 8 O
in	2181 2 O
vivo	2184 4 O
,	2188 1 O
the	2190 3 O
protection	2194 10 O
by	2205 2 O
GSPE	2208 4 B-Chemical
may	2213 3 O
be	2217 2 O
linked	2220 6 O
to	2227 2 O
both	2230 4 O
inhibition	2235 10 O
of	2246 2 O
metabolism	2249 10 O
and	2260 3 O
/	2263 1 O
or	2264 2 O
detoxification	2267 14 O
of	2282 2 O
cytotoxic	2285 9 O
radicals	2295 8 O
.	2303 1 O

In	2305 2 O
addition	2308 8 O
,	2316 1 O
its	2318 3 O
'	2321 1 O
presumed	2323 8 O
contribution	2332 12 O
to	2345 2 O
DNA	2348 3 O
repair	2352 6 O
may	2359 3 O
be	2363 2 O
another	2366 7 O
important	2374 9 O
attribute	2384 9 O
,	2393 1 O
which	2395 5 O
played	2401 6 O
a	2408 1 O
role	2410 4 O
in	2415 2 O
the	2418 3 O
chemoprevention	2422 15 O
process	2438 7 O
.	2445 1 O

Additionally	2447 12 O
,	2459 1 O
this	2461 4 O
may	2466 3 O
have	2470 4 O
been	2475 4 O
the	2480 3 O
first	2484 5 O
report	2490 6 O
on	2497 2 O
AMI	2500 3 B-Chemical
-	2503 1 O
induced	2504 7 O
apoptotic	2512 9 O
death	2522 5 O
in	2528 2 O
the	2531 3 O
lung	2535 4 O
tissue	2540 6 O
.	2546 1 O

Taken	2548 5 O
together	2554 8 O
,	2562 1 O
these	2564 5 O
events	2570 6 O
undoubtedly	2577 11 O
establish	2589 9 O
GSPE	2599 4 B-Chemical
'	2603 1 O
s	2604 1 O
abundant	2606 8 O
bioavailability	2615 15 O
,	2630 1 O
and	2632 3 O
the	2636 3 O
power	2640 5 O
to	2646 2 O
defend	2649 6 O
multiple	2656 8 O
target	2665 6 O
organs	2672 6 O
from	2679 4 O
toxic	2684 5 O
assaults	2690 8 O
induced	2699 7 O
by	2707 2 O
structurally	2710 12 O
diverse	2723 7 O
and	2731 3 O
functionally	2735 12 O
different	2748 9 O
entities	2758 8 O
in	2767 2 O
vivo	2770 4 O
.	2774 1 O

Palpebral	0 9 B-Disease
twitching	10 9 I-Disease
in	20 2 O
a	23 1 O
depressed	25 9 B-Disease
adolescent	35 10 O
on	46 2 O
citalopram	49 10 B-Chemical
.	59 1 O

Current	61 7 O
estimates	69 9 O
suggest	79 7 O
that	87 4 O
between	92 7 O
0	100 1 O
.	101 1 O
4	102 1 O
%	103 1 O
and	105 3 O
8	109 1 O
.	110 1 O
3	111 1 O
%	112 1 O
of	114 2 O
children	117 8 O
and	126 3 O
adolescents	130 11 O
are	142 3 O
affected	146 8 O
by	155 2 O
major	158 5 B-Disease
depression	164 10 I-Disease
.	174 1 O

We	176 2 O
report	179 6 O
a	186 1 O
favorable	188 9 O
response	198 8 O
to	207 2 O
treatment	210 9 O
with	220 4 O
citalopram	225 10 B-Chemical
by	236 2 O
a	239 1 O
15	241 2 O
-	243 1 O
year	244 4 O
-	248 1 O
old	249 3 O
boy	253 3 O
with	257 4 O
major	262 5 B-Disease
depression	268 10 I-Disease
who	279 3 O
exhibited	283 9 O
palpebral	293 9 B-Disease
twitching	303 9 I-Disease
during	313 6 O
his	320 3 O
first	324 5 O
2	330 1 O
weeks	332 5 O
of	338 2 O
treatment	341 9 O
.	350 1 O

This	352 4 O
may	357 3 O
have	361 4 O
been	366 4 O
a	371 1 O
side	373 4 O
effect	378 6 O
of	385 2 O
citalopram	388 10 B-Chemical
as	399 2 O
it	402 2 O
remitted	405 8 O
with	414 4 O
redistribution	419 14 O
of	434 2 O
doses	437 5 O
.	442 1 O

Metamizol	0 9 B-Chemical
potentiates	10 11 O
morphine	22 8 B-Chemical
antinociception	31 15 O
but	47 3 O
not	51 3 O
constipation	55 12 B-Disease
after	68 5 O
chronic	74 7 O
treatment	82 9 O
.	91 1 O

This	93 4 O
work	98 4 O
evaluates	103 9 O
the	113 3 O
antinociceptive	117 15 O
and	133 3 O
constipating	137 12 B-Disease
effects	150 7 O
of	158 2 O
the	161 3 O
combination	165 11 O
of	177 2 O
3	180 1 O
.	181 1 O
2	182 1 O
mg	184 2 O
/	186 1 O
kg	187 2 O
s	190 1 O
.	191 1 O
c	192 1 O
.	193 1 O
morphine	195 8 B-Chemical
with	204 4 O
177	209 3 O
.	212 1 O
8	213 1 O
mg	215 2 O
/	217 1 O
kg	218 2 O
s	221 1 O
.	222 1 O
c	223 1 O
.	224 1 O
metamizol	226 9 B-Chemical
in	236 2 O
acutely	239 7 O
and	247 3 O
chronically	251 11 O
treated	263 7 O
(	271 1 O
once	272 4 O
a	277 1 O
day	279 3 O
for	283 3 O
12	287 2 O
days	290 4 O
)	294 1 O
rats	296 4 O
.	300 1 O

On	302 2 O
the	305 3 O
13th	309 4 O
day	314 3 O
,	317 1 O
antinociceptive	319 15 O
effects	335 7 O
were	343 4 O
assessed	348 8 O
using	357 5 O
a	363 1 O
model	365 5 O
of	371 2 O
inflammatory	374 12 O
nociception	387 11 O
,	398 1 O
pain	400 4 B-Disease
-	404 1 O
induced	405 7 O
functional	413 10 O
impairment	424 10 O
model	435 5 O
,	440 1 O
and	442 3 O
the	446 3 O
charcoal	450 8 B-Chemical
meal	459 4 O
test	464 4 O
was	469 3 O
used	473 4 O
to	478 2 O
evaluate	481 8 O
the	490 3 O
intestinal	494 10 O
transit	505 7 O
.	512 1 O

Simultaneous	514 12 O
administration	527 14 O
of	542 2 O
morphine	545 8 B-Chemical
with	554 4 O
metamizol	559 9 B-Chemical
resulted	569 8 O
in	578 2 O
a	581 1 O
markedly	583 8 O
antinociceptive	592 15 O
potentiation	608 12 O
and	621 3 O
an	625 2 O
increasing	628 10 O
of	639 2 O
the	642 3 O
duration	646 8 O
of	655 2 O
action	658 6 O
after	665 5 O
a	671 1 O
single	673 6 O
(	680 1 O
298	681 3 O
+	684 1 O
/	685 1 O
-	686 1 O
7	687 1 O
vs	689 2 O
.	691 1 O
139	693 3 O
+	696 1 O
/	697 1 O
-	698 1 O
36	699 2 O
units	702 5 O
area	708 4 O
(	713 1 O
ua	714 2 O
)	716 1 O
;	717 1 O
P	719 1 O
<	720 1 O
0	721 1 O
.	722 1 O
001	723 3 O
)	726 1 O
and	728 3 O
repeated	732 8 O
administration	741 14 O
(	756 1 O
280	757 3 O
+	760 1 O
/	761 1 O
-	762 1 O
17	763 2 O
vs	766 2 O
.	768 1 O
131	770 3 O
+	773 1 O
/	774 1 O
-	775 1 O
22	776 2 O
ua	779 2 O
;	781 1 O
P	783 1 O
<	784 1 O
0	785 1 O
.	786 1 O
001	787 3 O
)	790 1 O
.	791 1 O

Antinociceptive	793 15 O
effect	809 6 O
of	816 2 O
morphine	819 8 B-Chemical
was	828 3 O
reduced	832 7 O
in	840 2 O
chronically	843 11 O
treated	855 7 O
rats	863 4 O
(	868 1 O
39	869 2 O
+	871 1 O
/	872 1 O
-	873 1 O
10	874 2 O
vs	877 2 O
.	879 1 O
18	881 2 O
+	883 1 O
/	884 1 O
-	885 1 O
5	886 1 O
au	888 2 O
)	890 1 O
while	892 5 O
the	898 3 O
combination	902 11 O
-	913 1 O
induced	914 7 O
antinociception	922 15 O
was	938 3 O
remained	942 8 O
similar	951 7 O
as	959 2 O
an	962 2 O
acute	965 5 O
treatment	971 9 O
(	981 1 O
298	982 3 O
+	985 1 O
/	986 1 O
-	987 1 O
7	988 1 O
vs	990 2 O
.	992 1 O
280	994 3 O
+	997 1 O
/	998 1 O
-	999 1 O
17	1000 2 O
au	1003 2 O
)	1005 1 O
.	1006 1 O

Acute	1008 5 O
antinociceptive	1014 15 O
effects	1030 7 O
of	1038 2 O
the	1041 3 O
combination	1045 11 O
were	1057 4 O
partially	1062 9 O
prevented	1072 9 O
by	1082 2 O
3	1085 1 O
.	1086 1 O
2	1087 1 O
mg	1089 2 O
/	1091 1 O
kg	1092 2 O
naloxone	1095 8 B-Chemical
s	1104 1 O
.	1105 1 O
c	1106 1 O
.	1107 1 O

(	1109 1 O
P	1110 1 O
<	1111 1 O
0	1112 1 O
.	1113 1 O
05	1114 2 O
)	1116 1 O
,	1117 1 O
suggesting	1119 10 O
the	1130 3 O
partial	1134 7 O
involvement	1142 11 O
of	1154 2 O
the	1157 3 O
opioidergic	1161 11 O
system	1173 6 O
in	1180 2 O
the	1183 3 O
synergism	1187 9 O
observed	1197 8 O
.	1205 1 O

In	1207 2 O
independent	1210 11 O
groups	1222 6 O
,	1228 1 O
morphine	1230 8 B-Chemical
inhibited	1239 9 O
the	1249 3 O
intestinal	1253 10 O
transit	1264 7 O
in	1272 2 O
48	1275 2 O
+	1277 1 O
/	1278 1 O
-	1279 1 O
4	1280 1 O
%	1281 1 O
and	1283 3 O
38	1287 2 O
+	1289 1 O
/	1290 1 O
-	1291 1 O
4	1292 1 O
%	1293 1 O
after	1295 5 O
acute	1301 5 O
and	1307 3 O
chronic	1311 7 O
treatment	1319 9 O
,	1328 1 O
respectively	1330 12 O
,	1342 1 O
suggesting	1344 10 O
that	1355 4 O
tolerance	1360 9 O
did	1370 3 O
not	1374 3 O
develop	1378 7 O
to	1386 2 O
the	1389 3 O
constipating	1393 12 B-Disease
effects	1406 7 O
.	1413 1 O

The	1415 3 O
combination	1419 11 O
inhibited	1431 9 O
intestinal	1441 10 O
transit	1452 7 O
similar	1460 7 O
to	1468 2 O
that	1471 4 O
produced	1476 8 O
by	1485 2 O
morphine	1488 8 B-Chemical
regardless	1497 10 O
of	1508 2 O
the	1511 3 O
time	1515 4 O
of	1520 2 O
treatment	1523 9 O
,	1532 1 O
suggesting	1534 10 O
that	1545 4 O
metamizol	1550 9 B-Chemical
did	1560 3 O
not	1564 3 O
potentiate	1568 10 O
morphine	1579 8 B-Chemical
-	1587 1 O
induced	1588 7 O
constipation	1596 12 B-Disease
.	1608 1 O

These	1610 5 O
findings	1616 8 O
show	1625 4 O
a	1630 1 O
significant	1632 11 O
interaction	1644 11 O
between	1656 7 O
morphine	1664 8 B-Chemical
and	1673 3 O
metamizol	1677 9 B-Chemical
in	1687 2 O
chronically	1690 11 O
treated	1702 7 O
rats	1710 4 O
,	1714 1 O
suggesting	1716 10 O
that	1727 4 O
this	1732 4 O
combination	1737 11 O
could	1749 5 O
be	1755 2 O
useful	1758 6 O
for	1765 3 O
the	1769 3 O
treatment	1773 9 O
of	1783 2 O
chronic	1786 7 B-Disease
pain	1794 4 I-Disease
.	1798 1 O

Ifosfamide	0 10 B-Chemical
encephalopathy	11 14 B-Disease
presenting	26 10 O
with	37 4 O
asterixis	42 9 B-Disease
.	51 1 O

CNS	53 3 O
toxic	57 5 O
effects	63 7 O
of	71 2 O
the	74 3 O
antineoplastic	78 14 O
agent	93 5 O
ifosfamide	99 10 B-Chemical
(	110 1 O
IFX	111 3 B-Chemical
)	114 1 O
are	116 3 O
frequent	120 8 O
and	129 3 O
include	133 7 O
a	141 1 O
variety	143 7 O
of	151 2 O
neurological	154 12 O
symptoms	167 8 O
that	176 4 O
can	181 3 O
limit	185 5 O
drug	191 4 O
use	196 3 O
.	199 1 O

We	201 2 O
report	204 6 O
a	211 1 O
case	213 4 O
of	218 2 O
a	221 1 O
51	223 2 O
-	225 1 O
year	226 4 O
-	230 1 O
old	231 3 O
man	235 3 O
who	239 3 O
developed	243 9 O
severe	253 6 O
,	259 1 O
disabling	261 9 O
negative	271 8 O
myoclonus	280 9 B-Disease
of	290 2 O
the	293 3 O
upper	297 5 O
and	303 3 O
lower	307 5 O
extremities	313 11 O
after	325 5 O
the	331 3 O
infusion	335 8 O
of	344 2 O
ifosfamide	347 10 B-Chemical
for	358 3 O
plasmacytoma	362 12 B-Disease
.	374 1 O

He	376 2 O
was	379 3 O
awake	383 5 O
,	388 1 O
revealed	390 8 O
no	399 2 O
changes	402 7 O
of	410 2 O
mental	413 6 O
status	420 6 O
and	427 3 O
at	431 2 O
rest	434 4 O
there	439 5 O
were	445 4 O
no	450 2 O
further	453 7 O
motor	461 5 O
symptoms	467 8 O
.	475 1 O

Cranial	477 7 O
magnetic	485 8 O
resonance	494 9 O
imaging	504 7 O
and	512 3 O
extensive	516 9 O
laboratory	526 10 O
studies	537 7 O
failed	545 6 O
to	552 2 O
reveal	555 6 O
structural	562 10 B-Disease
lesions	573 7 I-Disease
of	581 2 I-Disease
the	584 3 I-Disease
brain	588 5 I-Disease
and	594 3 O
metabolic	598 9 B-Disease
abnormalities	608 13 I-Disease
.	621 1 O

An	623 2 O
electroencephalogram	626 20 O
showed	647 6 O
continuous	654 10 O
,	664 1 O
generalized	666 11 O
irregular	678 9 O
slowing	688 7 O
with	696 4 O
admixed	701 7 O
periodic	709 8 O
triphasic	718 9 O
waves	728 5 O
indicating	734 10 O
symptomatic	745 11 O
encephalopathy	757 14 B-Disease
.	771 1 O

The	773 3 O
administration	777 14 O
of	792 2 O
ifosfamide	795 10 B-Chemical
was	806 3 O
discontinued	810 12 O
and	823 3 O
within	827 6 O
12	834 2 O
h	837 1 O
the	839 3 O
asterixis	843 9 B-Disease
resolved	853 8 O
completely	862 10 O
.	872 1 O

In	874 2 O
the	877 3 O
patient	881 7 O
described	889 9 O
,	898 1 O
the	900 3 O
presence	904 8 O
of	913 2 O
asterixis	916 9 B-Disease
during	926 6 O
infusion	933 8 O
of	942 2 O
ifosfamide	945 10 B-Chemical
,	955 1 O
normal	957 6 O
laboratory	964 10 O
findings	975 8 O
and	984 3 O
imaging	988 7 O
studies	996 7 O
and	1004 3 O
the	1008 3 O
resolution	1012 10 O
of	1023 2 O
symptoms	1026 8 O
following	1035 9 O
the	1045 3 O
discontinuation	1049 15 O
of	1065 2 O
the	1068 3 O
drug	1072 4 O
suggest	1077 7 O
that	1085 4 O
negative	1090 8 O
myoclonus	1099 9 B-Disease
is	1109 2 O
associated	1112 10 O
with	1123 4 O
the	1128 3 O
use	1132 3 O
of	1136 2 O
IFX	1139 3 B-Chemical
.	1142 1 O

Sub	0 3 O
-	3 1 O
chronic	4 7 O
low	12 3 O
dose	16 4 O
gamma	21 5 B-Chemical
-	26 1 I-Chemical
vinyl	27 5 I-Chemical
GABA	33 4 I-Chemical
(	38 1 O
vigabatrin	39 10 B-Chemical
)	49 1 O
inhibits	51 8 O
cocaine	60 7 B-Chemical
-	67 1 O
induced	68 7 O
increases	76 9 O
in	86 2 O
nucleus	89 7 O
accumbens	97 9 O
dopamine	107 8 B-Chemical
.	115 1 O

RATIONALE	117 9 O
:	126 1 O
gamma	128 5 B-Chemical
-	133 1 I-Chemical
Vinyl	134 5 I-Chemical
GABA	140 4 I-Chemical
(	145 1 O
GVG	146 3 B-Chemical
)	149 1 O
irreversibly	151 12 O
inhibits	164 8 O
GABA	173 4 B-Chemical
-	177 1 O
transaminase	178 12 O
.	190 1 O

This	192 4 O
non	197 3 O
-	200 1 O
receptor	201 8 O
mediated	210 8 O
inhibition	219 10 O
requires	230 8 O
de	239 2 O
novo	242 4 O
synthesis	247 9 O
for	257 3 O
restoration	261 11 O
of	273 2 O
functional	276 10 O
GABA	287 4 B-Chemical
catabolism	292 10 O
.	302 1 O

OBJECTIVES	304 10 O
:	314 1 O
Given	316 5 O
its	322 3 O
preclinical	326 11 O
success	338 7 O
for	346 3 O
treating	350 8 O
substance	359 9 B-Disease
abuse	369 5 I-Disease
and	375 3 O
the	379 3 O
increased	383 9 O
risk	393 4 O
of	398 2 O
visual	401 6 B-Disease
field	408 5 I-Disease
defects	414 7 I-Disease
(	422 1 O
VFD	423 3 B-Disease
)	426 1 O
associated	428 10 O
with	439 4 O
cumulative	444 10 O
lifetime	455 8 O
exposure	464 8 O
,	472 1 O
we	474 2 O
explored	477 8 O
the	486 3 O
effects	490 7 O
of	498 2 O
sub	501 3 O
-	504 1 O
chronic	505 7 O
low	513 3 O
dose	517 4 O
GVG	522 3 B-Chemical
on	526 2 O
cocaine	529 7 B-Chemical
-	536 1 O
induced	537 7 O
increases	545 9 O
in	555 2 O
nucleus	558 7 O
accumbens	566 9 O
(	576 1 O
NAcc	577 4 O
)	581 1 O
dopamine	583 8 B-Chemical
(	592 1 O
DA	593 2 B-Chemical
)	595 1 O
.	596 1 O

METHODS	598 7 O
:	605 1 O
Using	607 5 O
in	613 2 O
vivo	616 4 O
microdialysis	621 13 O
,	634 1 O
we	636 2 O
compared	639 8 O
acute	648 5 O
exposure	654 8 O
(	663 1 O
450	664 3 O
mg	668 2 O
/	670 1 O
kg	671 2 O
)	673 1 O
to	675 2 O
an	678 2 O
identical	681 9 O
sub	691 3 O
-	694 1 O
chronic	695 7 O
exposure	703 8 O
(	712 1 O
150	713 3 O
mg	717 2 O
/	719 1 O
kg	720 2 O
per	723 3 O
day	727 3 O
for	731 3 O
3	735 1 O
days	737 4 O
)	741 1 O
,	742 1 O
followed	744 8 O
by	753 2 O
1	756 1 O
-	757 1 O
or	759 2 O
3	762 1 O
-	763 1 O
day	764 3 O
washout	768 7 O
.	775 1 O

Finally	777 7 O
,	784 1 O
we	786 2 O
examined	789 8 O
the	798 3 O
low	802 3 O
dose	806 4 O
of	811 2 O
150	814 3 O
mg	818 2 O
/	820 1 O
kg	821 2 O
(	824 1 O
50	825 2 O
mg	828 2 O
/	830 1 O
kg	831 2 O
per	834 3 O
day	838 3 O
)	841 1 O
using	843 5 O
a	849 1 O
similar	851 7 O
washout	859 7 O
period	867 6 O
.	873 1 O

RESULTS	875 7 O
:	882 1 O
Sub	884 3 O
-	887 1 O
chronic	888 7 O
GVG	896 3 B-Chemical
exposure	900 8 O
inhibited	909 9 O
the	919 3 O
effect	923 6 O
of	930 2 O
cocaine	933 7 B-Chemical
for	941 3 O
3	945 1 O
days	947 4 O
,	951 1 O
which	953 5 O
exceeded	959 8 O
in	968 2 O
magnitude	971 9 O
and	981 3 O
duration	985 8 O
the	994 3 O
identical	998 9 O
acute	1008 5 O
dose	1014 4 O
.	1018 1 O

CONCLUSIONS	1020 11 O
:	1031 1 O
Sub	1033 3 O
-	1036 1 O
chronic	1037 7 O
low	1045 3 O
dose	1049 4 O
GVG	1054 3 B-Chemical
potentiates	1058 11 O
and	1070 3 O
extends	1074 7 O
the	1082 3 O
inhibition	1086 10 O
of	1097 2 O
cocaine	1100 7 B-Chemical
-	1107 1 O
induced	1108 7 O
increases	1116 9 O
in	1126 2 O
dopamine	1129 8 B-Chemical
,	1137 1 O
effectively	1139 11 O
reducing	1151 8 O
cumulative	1160 10 O
exposures	1171 9 O
and	1181 3 O
the	1185 3 O
risk	1189 4 O
for	1194 3 O
VFDS	1198 4 O
.	1202 1 O

Amount	0 6 O
of	7 2 O
bleeding	10 8 B-Disease
and	19 3 O
hematoma	23 8 B-Disease
size	32 4 O
in	37 2 O
the	40 3 O
collagenase	44 11 O
-	55 1 O
induced	56 7 O
intracerebral	64 13 B-Disease
hemorrhage	78 10 I-Disease
rat	89 3 O
model	93 5 O
.	98 1 O

The	100 3 O
aggravated	104 10 O
risk	115 4 O
on	120 2 O
intracerebral	123 13 B-Disease
hemorrhage	137 10 I-Disease
(	148 1 O
ICH	149 3 B-Disease
)	152 1 O
with	154 4 O
drugs	159 5 O
used	165 4 O
for	170 3 O
stroke	174 6 B-Disease
patients	181 8 O
should	190 6 O
be	197 2 O
estimated	200 9 O
carefully	210 9 O
.	219 1 O

We	221 2 O
therefore	224 9 O
established	234 11 O
sensitive	246 9 O
quantification	256 14 O
methods	271 7 O
and	279 3 O
provided	283 8 O
a	292 1 O
rat	294 3 O
ICH	298 3 B-Disease
model	302 5 O
for	308 3 O
detection	312 9 O
of	322 2 O
ICH	325 3 B-Disease
deterioration	329 13 O
.	342 1 O

In	344 2 O
ICH	347 3 B-Disease
intrastriatally	351 15 O
induced	367 7 O
by	375 2 O
0	378 1 O
.	379 1 O
014	380 3 O
-	383 1 O
unit	384 4 O
,	388 1 O
0	390 1 O
.	391 1 O
070	392 3 O
-	395 1 O
unit	396 4 O
,	400 1 O
and	402 3 O
0	406 1 O
.	407 1 O
350	408 3 O
-	411 1 O
unit	412 4 O
collagenase	417 11 O
,	428 1 O
the	430 3 O
amount	434 6 O
of	441 2 O
bleeding	444 8 B-Disease
was	453 3 O
measured	457 8 O
using	466 5 O
a	472 1 O
hemoglobin	474 10 O
assay	485 5 O
developed	491 9 O
in	501 2 O
the	504 3 O
present	508 7 O
study	516 5 O
and	522 3 O
was	526 3 O
compared	530 8 O
with	539 4 O
the	544 3 O
morphologically	548 15 O
determined	564 10 O
hematoma	575 8 B-Disease
volume	584 6 O
.	590 1 O

The	592 3 O
blood	596 5 O
amounts	602 7 O
and	610 3 O
hematoma	614 8 B-Disease
volumes	623 7 O
were	631 4 O
significantly	636 13 O
correlated	650 10 O
,	660 1 O
and	662 3 O
the	666 3 O
hematoma	670 8 B-Disease
induced	679 7 O
by	687 2 O
0	690 1 O
.	691 1 O
014	692 3 O
-	695 1 O
unit	696 4 O
collagenase	701 11 O
was	713 3 O
adequate	717 8 O
to	726 2 O
detect	729 6 O
ICH	736 3 B-Disease
deterioration	740 13 O
.	753 1 O

In	755 2 O
ICH	758 3 B-Disease
induction	762 9 O
using	772 5 O
0	778 1 O
.	779 1 O
014	780 3 O
-	783 1 O
unit	784 4 O
collagenase	789 11 O
,	800 1 O
heparin	802 7 B-Chemical
enhanced	810 8 O
the	819 3 O
hematoma	823 8 B-Disease
volume	832 6 O
3	839 1 O
.	840 1 O
4	841 1 O
-	842 1 O
fold	843 4 O
over	848 4 O
that	853 4 O
seen	858 4 O
in	863 2 O
control	866 7 O
ICH	874 3 B-Disease
animals	878 7 O
and	886 3 O
the	890 3 O
bleeding	894 8 B-Disease
7	903 1 O
.	904 1 O
6	905 1 O
-	906 1 O
fold	907 4 O
.	911 1 O

Data	913 4 O
suggest	918 7 O
that	926 4 O
this	931 4 O
sensitive	936 9 O
hemoglobin	946 10 O
assay	957 5 O
is	963 2 O
useful	966 6 O
for	973 3 O
ICH	977 3 B-Disease
detection	981 9 O
,	990 1 O
and	992 3 O
that	996 4 O
a	1001 1 O
model	1003 5 O
with	1009 4 O
a	1014 1 O
small	1016 5 O
ICH	1022 3 B-Disease
induced	1026 7 O
with	1034 4 O
a	1039 1 O
low	1041 3 O
-	1044 1 O
dose	1045 4 O
collagenase	1050 11 O
should	1062 6 O
be	1069 2 O
used	1072 4 O
for	1077 3 O
evaluation	1081 10 O
of	1092 2 O
drugs	1095 5 O
that	1101 4 O
may	1106 3 O
affect	1110 6 O
ICH	1117 3 B-Disease
.	1120 1 O

Estradiol	0 9 B-Chemical
reduces	10 7 O
seizure	18 7 B-Disease
-	25 1 O
induced	26 7 O
hippocampal	34 11 B-Disease
injury	46 6 I-Disease
in	53 2 O
ovariectomized	56 14 O
female	71 6 O
but	78 3 O
not	82 3 O
in	86 2 O
male	89 4 O
rats	94 4 O
.	98 1 O

Estrogens	100 9 O
protect	110 7 O
ovariectomized	118 14 O
rats	133 4 O
from	138 4 O
hippocampal	143 11 B-Disease
injury	155 6 I-Disease
induced	162 7 O
by	170 2 O
kainic	173 6 B-Chemical
acid	180 4 I-Chemical
-	184 1 O
induced	185 7 O
status	193 6 B-Disease
epilepticus	200 11 I-Disease
(	212 1 O
SE	213 2 B-Disease
)	215 1 O
.	216 1 O

We	218 2 O
compared	221 8 O
the	230 3 O
effects	234 7 O
of	242 2 O
17beta	245 6 B-Chemical
-	251 1 I-Chemical
estradiol	252 9 I-Chemical
in	262 2 O
adult	265 5 O
male	271 4 O
and	276 3 O
ovariectomized	280 14 O
female	295 6 O
rats	302 4 O
subjected	307 9 O
to	317 2 O
lithium	320 7 B-Chemical
-	327 1 O
pilocarpine	328 11 B-Chemical
-	339 1 O
induced	340 7 O
SE	348 2 B-Disease
.	350 1 O

Rats	352 4 O
received	357 8 O
subcutaneous	366 12 O
injections	379 10 O
of	390 2 O
17beta	393 6 B-Chemical
-	399 1 I-Chemical
estradiol	400 9 I-Chemical
(	410 1 O
2	411 1 O
microg	413 6 O
/	419 1 O
rat	420 3 O
)	423 1 O
or	425 2 O
oil	428 3 O
once	432 4 O
daily	437 5 O
for	443 3 O
four	447 4 O
consecutive	452 11 O
days	464 4 O
.	468 1 O

SE	470 2 B-Disease
was	473 3 O
induced	477 7 O
20	485 2 O
h	488 1 O
following	490 9 O
the	500 3 O
second	504 6 O
injection	511 9 O
and	521 3 O
terminated	525 10 O
3	536 1 O
h	538 1 O
later	540 5 O
.	545 1 O

The	547 3 O
extent	551 6 O
of	558 2 O
silver	561 6 B-Chemical
-	567 1 O
stained	568 7 O
CA3	576 3 O
and	580 3 O
CA1	584 3 O
hippocampal	588 11 O
neurons	600 7 O
was	608 3 O
evaluated	612 9 O
2	622 1 O
days	624 4 O
after	629 5 O
SE	635 2 B-Disease
.	637 1 O

17beta	639 6 B-Chemical
-	645 1 I-Chemical
Estradiol	646 9 I-Chemical
did	656 3 O
not	660 3 O
alter	664 5 O
the	670 3 O
onset	674 5 O
of	680 2 O
first	683 5 O
clonus	689 6 O
in	696 2 O
ovariectomized	699 14 O
rats	714 4 O
but	719 3 O
accelerated	723 11 O
it	735 2 O
in	738 2 O
males	741 5 O
.	746 1 O

17beta	748 6 B-Chemical
-	754 1 I-Chemical
Estradiol	755 9 I-Chemical
reduced	765 7 O
the	773 3 O
argyrophilic	777 12 O
neurons	790 7 O
in	798 2 O
the	801 3 O
CA1	805 3 O
and	809 3 O
CA3	813 3 O
-	816 1 O
C	817 1 O
sectors	819 7 O
of	827 2 O
ovariectomized	830 14 O
rats	845 4 O
.	849 1 O

In	851 2 O
males	854 5 O
,	859 1 O
estradiol	861 9 B-Chemical
increased	871 9 O
the	881 3 O
total	885 5 O
damage	891 6 O
score	898 5 O
.	903 1 O

These	905 5 O
findings	911 8 O
suggest	920 7 O
that	928 4 O
the	933 3 O
effects	937 7 O
of	945 2 O
estradiol	948 9 B-Chemical
on	958 2 O
seizure	961 7 B-Disease
threshold	969 9 O
and	979 3 O
damage	983 6 O
may	990 3 O
be	994 2 O
altered	997 7 O
by	1005 2 O
sex	1008 3 O
-	1011 1 O
related	1012 7 O
differences	1020 11 O
in	1032 2 O
the	1035 3 O
hormonal	1039 8 O
environment	1048 11 O
.	1059 1 O

Delirium	0 8 B-Disease
during	9 6 O
clozapine	16 9 B-Chemical
treatment	26 9 O
:	35 1 O
incidence	37 9 O
and	47 3 O
associated	51 10 O
risk	62 4 O
factors	67 7 O
.	74 1 O

BACKGROUND	76 10 O
:	86 1 O
Incidence	88 9 O
and	98 3 O
risk	102 4 O
factors	107 7 O
for	115 3 O
delirium	119 8 B-Disease
during	128 6 O
clozapine	135 9 B-Chemical
treatment	145 9 O
require	155 7 O
further	163 7 O
clarification	171 13 O
.	184 1 O

METHODS	186 7 O
:	193 1 O
We	195 2 O
used	198 4 O
computerized	203 12 O
pharmacy	216 8 O
records	225 7 O
to	233 2 O
identify	236 8 O
all	245 3 O
adult	249 5 O
psychiatric	255 11 B-Disease
inpatients	267 10 O
treated	278 7 O
with	286 4 O
clozapine	291 9 B-Chemical
(	301 1 O
1995	302 4 O
-	306 1 O
96	307 2 O
)	309 1 O
,	310 1 O
reviewed	312 8 O
their	321 5 O
medical	327 7 O
records	335 7 O
to	343 2 O
score	346 5 O
incidence	352 9 O
and	362 3 O
severity	366 8 O
of	375 2 O
delirium	378 8 B-Disease
,	386 1 O
and	388 3 O
tested	392 6 O
associations	399 12 O
with	412 4 O
potential	417 9 O
risk	427 4 O
factors	432 7 O
.	439 1 O

RESULTS	441 7 O
:	448 1 O
Subjects	450 8 O
(	459 1 O
n	460 1 O
=	462 1 O
139	464 3 O
)	467 1 O
were	469 4 O
72	474 2 O
women	477 5 O
and	483 3 O
67	487 2 O
men	490 3 O
,	493 1 O
aged	495 4 O
40	500 2 O
.	502 1 O
8	503 1 O
+	505 1 O
/	506 1 O
-	507 1 O
12	509 2 O
.	511 1 O
1	512 1 O
years	514 5 O
,	519 1 O
hospitalized	521 12 O
for	534 3 O
24	538 2 O
.	540 1 O
9	541 1 O
+	543 1 O
/	544 1 O
-	545 1 O
23	547 2 O
.	549 1 O
3	550 1 O
days	552 4 O
,	556 1 O
and	558 3 O
given	562 5 O
clozapine	568 9 B-Chemical
,	577 1 O
gradually	579 9 O
increased	589 9 O
to	599 2 O
an	602 2 O
average	605 7 O
daily	613 5 O
dose	619 4 O
of	624 2 O
282	627 3 O
+	631 1 O
/	632 1 O
-	633 1 O
203	635 3 O
mg	639 2 O
(	642 1 O
3	643 1 O
.	644 1 O
45	645 2 O
+	648 1 O
/	649 1 O
-	650 1 O
2	652 1 O
.	653 1 O
45	654 2 O
mg	657 2 O
/	659 1 O
kg	660 2 O
)	662 1 O
for	664 3 O
18	668 2 O
.	670 1 O
9	671 1 O
+	673 1 O
/	674 1 O
-	675 1 O
16	677 2 O
.	679 1 O
4	680 1 O
days	682 4 O
.	686 1 O

Delirium	688 8 B-Disease
was	697 3 O
diagnosed	701 9 O
in	711 2 O
14	714 2 O
(	717 1 O
10	718 2 O
.	720 1 O
1	721 1 O
%	723 1 O
incidence	725 9 O
,	734 1 O
or	736 2 O
1	739 1 O
.	740 1 O
48	741 2 O
cases	744 5 O
/	749 1 O
person	750 6 O
-	756 1 O
years	757 5 O
of	763 2 O
exposure	766 8 O
)	774 1 O
;	775 1 O
71	777 2 O
.	779 1 O
4	780 1 O
%	782 1 O
of	784 2 O
cases	787 5 O
were	793 4 O
moderate	798 8 O
or	807 2 O
severe	810 6 O
.	816 1 O

Associated	818 10 O
factors	829 7 O
were	837 4 O
co	842 2 O
-	844 1 O
treatment	845 9 O
with	855 4 O
other	860 5 O
centrally	866 9 O
antimuscarinic	876 14 O
agents	891 6 O
,	897 1 O
poor	899 4 O
clinical	904 8 O
outcome	913 7 O
,	920 1 O
older	922 5 O
age	928 3 O
,	931 1 O
and	933 3 O
longer	937 6 O
hospitalization	944 15 O
(	960 1 O
by	961 2 O
17	964 2 O
.	966 1 O
5	967 1 O
days	969 4 O
,	973 1 O
increasing	975 10 O
cost	986 4 O
)	990 1 O
;	991 1 O
sex	993 3 O
,	996 1 O
diagnosis	998 9 O
or	1008 2 O
medical	1011 7 O
co	1019 2 O
-	1021 1 O
morbidity	1022 9 O
,	1031 1 O
and	1033 3 O
daily	1037 5 O
clozapine	1043 9 B-Chemical
dose	1053 4 O
,	1057 1 O
which	1059 5 O
fell	1065 4 O
with	1070 4 O
age	1075 3 O
,	1078 1 O
were	1080 4 O
unrelated	1085 9 O
.	1094 1 O

CONCLUSIONS	1096 11 O
:	1107 1 O
Delirium	1109 8 B-Disease
was	1118 3 O
found	1122 5 O
in	1128 2 O
10	1131 2 O
%	1134 1 O
of	1136 2 O
clozapine	1139 9 B-Chemical
-	1148 1 O
treated	1149 7 O
inpatients	1157 10 O
,	1167 1 O
particularly	1169 12 O
in	1182 2 O
older	1185 5 O
patients	1191 8 O
exposed	1200 7 O
to	1208 2 O
other	1211 5 O
central	1217 7 O
anticholinergics	1225 16 O
.	1241 1 O

Delirium	1243 8 B-Disease
was	1252 3 O
inconsistently	1256 14 O
recognized	1271 10 O
clinically	1282 10 O
in	1293 2 O
milder	1296 6 O
cases	1303 5 O
and	1309 3 O
was	1313 3 O
associated	1317 10 O
with	1328 4 O
increased	1333 9 O
length	1343 6 O
-	1349 1 O
of	1350 2 O
-	1352 1 O
stay	1353 4 O
and	1358 3 O
higher	1362 6 O
costs	1369 5 O
,	1374 1 O
and	1376 3 O
inferior	1380 8 O
clinical	1389 8 O
outcome	1398 7 O
.	1405 1 O

Ketoconazole	0 12 B-Chemical
-	12 1 O
induced	13 7 O
neurologic	21 10 B-Disease
sequelae	32 8 I-Disease
.	40 1 O

A	42 1 O
77	44 2 O
-	46 1 O
y	47 1 O
-	48 1 O
old	49 3 O
patient	53 7 O
developed	61 9 O
weakness	71 8 B-Disease
of	80 2 I-Disease
extremities	83 11 I-Disease
,	94 1 O
legs	96 4 B-Disease
paralysis	101 9 I-Disease
,	110 1 O
dysarthria	112 10 B-Disease
and	123 3 O
tremor	127 6 B-Disease
1	134 1 O
h	136 1 O
after	138 5 O
ingestion	144 9 O
of	154 2 O
200	157 3 O
mg	161 2 O
ketoconazole	164 12 B-Chemical
for	177 3 O
the	181 3 O
first	185 5 O
time	191 4 O
in	196 2 O
his	199 3 O
life	203 4 O
.	207 1 O

All	209 3 O
complaints	213 10 O
faded	224 5 O
away	230 4 O
within	235 6 O
24	242 2 O
h	245 1 O
.	246 1 O

Few	248 3 O
days	252 4 O
later	257 5 O
,	262 1 O
the	264 3 O
patient	268 7 O
used	276 4 O
another	281 7 O
200	289 3 O
mg	293 2 O
ketoconazole	296 12 B-Chemical
tablet	309 6 O
,	315 1 O
and	317 3 O
within	321 6 O
an	328 2 O
hour	331 4 O
experienced	336 11 O
a	348 1 O
similar	350 7 O
clinical	358 8 O
picture	367 7 O
,	374 1 O
which	376 5 O
resolved	382 8 O
again	391 5 O
spontaneously	397 13 O
within	411 6 O
hours	418 5 O
.	423 1 O

Laboratory	425 10 O
evaluations	436 11 O
,	447 1 O
including	449 9 O
head	459 4 O
CT	464 2 O
scan	467 4 O
,	471 1 O
were	473 4 O
normal	478 6 O
.	484 1 O

This	486 4 O
case	491 4 O
illustrates	496 11 O
the	508 3 O
need	512 4 O
for	517 3 O
close	521 5 O
vigilance	527 9 O
in	537 2 O
adverse	540 7 B-Disease
drug	548 4 I-Disease
reactions	553 9 I-Disease
,	562 1 O
particularly	564 12 O
in	577 2 O
the	580 3 O
elderly	584 7 O
.	591 1 O

Noxious	0 7 O
chemical	8 8 O
stimulation	17 11 O
of	29 2 O
rat	32 3 O
facial	36 6 O
mucosa	43 6 O
increases	50 9 O
intracranial	60 12 O
blood	73 5 O
flow	79 4 O
through	84 7 O
a	92 1 O
trigemino	94 9 O
-	103 1 O
parasympathetic	104 15 O
reflex	120 6 O
-	126 1 O
-	127 1 O
an	128 2 O
experimental	131 12 O
model	144 5 O
for	150 3 O
vascular	154 8 B-Disease
dysfunctions	163 12 I-Disease
in	176 2 O
cluster	179 7 B-Disease
headache	187 8 I-Disease
.	195 1 O

Cluster	197 7 B-Disease
headache	205 8 I-Disease
is	214 2 O
characterized	217 13 O
by	231 2 O
typical	234 7 O
autonomic	242 9 O
dysfunctions	252 12 O
including	265 9 O
facial	275 6 O
and	282 3 O
intracranial	286 12 B-Disease
vascular	299 8 I-Disease
disturbances	308 12 I-Disease
.	320 1 O

Both	322 4 O
the	327 3 O
trigeminal	331 10 O
and	342 3 O
the	346 3 O
cranial	350 7 O
parasympathetic	358 15 O
systems	374 7 O
may	382 3 O
be	386 2 O
involved	389 8 O
in	398 2 O
mediating	401 9 O
these	411 5 O
dysfunctions	417 12 O
.	429 1 O

An	431 2 O
experimental	434 12 O
model	447 5 O
was	453 3 O
developed	457 9 O
in	467 2 O
the	470 3 O
rat	474 3 O
to	478 2 O
measure	481 7 O
changes	489 7 O
in	497 2 O
lacrimation	500 11 O
and	512 3 O
intracranial	516 12 O
blood	529 5 O
flow	535 4 O
following	540 9 O
noxious	550 7 O
chemical	558 8 O
stimulation	567 11 O
of	579 2 O
facial	582 6 O
mucosa	589 6 O
.	595 1 O

Blood	597 5 O
flow	603 4 O
was	608 3 O
monitored	612 9 O
in	622 2 O
arteries	625 8 O
of	634 2 O
the	637 3 O
exposed	641 7 O
cranial	649 7 O
dura	657 4 O
mater	662 5 O
and	668 3 O
the	672 3 O
parietal	676 8 O
cortex	685 6 O
using	692 5 O
laser	698 5 O
Doppler	704 7 O
flowmetry	712 9 O
.	721 1 O

Capsaicin	723 9 B-Chemical
(	733 1 O
0	734 1 O
.	735 1 O
01	736 2 O
-	738 1 O
1	739 1 O
mm	741 2 O
)	743 1 O
applied	745 7 O
to	753 2 O
oral	756 4 O
or	761 2 O
nasal	764 5 O
mucosa	770 6 O
induced	777 7 O
increases	785 9 B-Disease
in	795 2 I-Disease
dural	798 5 I-Disease
and	804 3 I-Disease
cortical	808 8 I-Disease
blood	817 5 I-Disease
flow	823 4 I-Disease
and	828 3 O
provoked	832 8 O
lacrimation	841 11 O
.	852 1 O

These	854 5 O
responses	860 9 O
were	870 4 O
blocked	875 7 O
by	883 2 O
systemic	886 8 O
pre	895 3 O
-	898 1 O
administration	899 14 O
of	914 2 O
hexamethonium	917 13 B-Chemical
chloride	931 8 I-Chemical
(	940 1 O
20	941 2 O
mg	944 2 O
/	946 1 O
kg	947 2 O
)	949 1 O
.	950 1 O

The	952 3 O
evoked	956 6 O
increases	963 9 B-Disease
in	973 2 I-Disease
dural	976 5 I-Disease
blood	982 5 I-Disease
flow	988 4 I-Disease
were	993 4 O
also	998 4 O
abolished	1003 9 O
by	1013 2 O
topical	1016 7 O
pre	1024 3 O
-	1027 1 O
administration	1028 14 O
of	1043 2 O
atropine	1046 8 B-Chemical
(	1055 1 O
1	1056 1 O
mm	1058 2 O
)	1060 1 O
and	1062 3 O
[	1066 1 O
Lys1	1067 4 O
,	1071 1 O
Pro2	1073 4 O
,	1077 1 O
5	1078 1 O
,	1079 1 O
Arg3	1081 4 O
,	1085 1 O
4	1086 1 O
,	1087 1 O
Tyr6	1089 4 O
]	1093 1 O
-	1094 1 O
VIP	1095 3 O
(	1099 1 O
0	1100 1 O
.	1101 1 O
1	1102 1 O
mm	1104 2 O
)	1106 1 O
,	1107 1 O
a	1109 1 O
vasoactive	1111 10 O
intestinal	1122 10 O
polypeptide	1133 11 O
(	1145 1 O
VIP	1146 3 O
)	1149 1 O
antagonist	1151 10 O
,	1161 1 O
onto	1163 4 O
the	1168 3 O
exposed	1172 7 O
dura	1180 4 O
mater	1185 5 O
.	1190 1 O

We	1192 2 O
conclude	1195 8 O
that	1204 4 O
noxious	1209 7 O
stimulation	1217 11 O
of	1229 2 O
facial	1232 6 O
mucosa	1239 6 O
increases	1246 9 O
intracranial	1256 12 O
blood	1269 5 O
flow	1275 4 O
and	1280 3 O
lacrimation	1284 11 O
via	1296 3 O
a	1300 1 O
trigemino	1302 9 O
-	1311 1 O
parasympathetic	1312 15 O
reflex	1328 6 O
.	1334 1 O

The	1336 3 O
blood	1340 5 O
flow	1346 4 O
responses	1351 9 O
seem	1361 4 O
to	1366 2 O
be	1369 2 O
mediated	1372 8 O
by	1381 2 O
the	1384 3 O
release	1388 7 O
of	1396 2 O
acetylcholine	1399 13 B-Chemical
and	1413 3 O
VIP	1417 3 O
within	1421 6 O
the	1428 3 O
meninges	1432 8 O
.	1440 1 O

Similar	1442 7 O
mechanisms	1450 10 O
may	1461 3 O
be	1465 2 O
involved	1468 8 O
in	1477 2 O
the	1480 3 O
pathogenesis	1484 12 O
of	1497 2 O
cluster	1500 7 B-Disease
headache	1508 8 I-Disease
.	1516 1 O

Recurrent	0 9 O
excitation	10 10 O
in	21 2 O
the	24 3 O
dentate	28 7 O
gyrus	36 5 O
of	42 2 O
a	45 1 O
murine	47 6 O
model	54 5 O
of	60 2 O
temporal	63 8 B-Disease
lobe	72 4 I-Disease
epilepsy	77 8 I-Disease
.	85 1 O

Similar	87 7 O
to	95 2 O
rats	98 4 O
,	102 1 O
systemic	104 8 O
pilocarpine	113 11 B-Chemical
injection	125 9 O
causes	135 6 O
status	142 6 B-Disease
epilepticus	149 11 I-Disease
(	161 1 O
SE	162 2 B-Disease
)	164 1 O
and	166 3 O
the	170 3 O
eventual	174 8 O
development	183 11 O
of	195 2 O
spontaneous	198 11 O
seizures	210 8 B-Disease
and	219 3 O
mossy	223 5 O
fiber	229 5 O
sprouting	235 9 O
in	245 2 O
C57BL	248 5 O
/	253 1 O
6	254 1 O
and	256 3 O
CD1	260 3 O
mice	264 4 O
,	268 1 O
but	270 3 O
the	274 3 O
physiological	278 13 O
correlates	292 10 O
of	303 2 O
these	306 5 O
events	312 6 O
have	319 4 O
not	324 3 O
been	328 4 O
identified	333 10 O
in	344 2 O
mice	347 4 O
.	351 1 O

Population	353 10 O
responses	364 9 O
in	374 2 O
granule	377 7 O
cells	385 5 O
of	391 2 O
the	394 3 O
dentate	398 7 O
gyrus	406 5 O
were	412 4 O
examined	417 8 O
in	426 2 O
transverse	429 10 O
slices	440 6 O
of	447 2 O
the	450 3 O
ventral	454 7 O
hippocampus	462 11 O
from	474 4 O
pilocarpine	479 11 B-Chemical
-	490 1 O
treated	491 7 O
and	499 3 O
untreated	503 9 O
mice	513 4 O
.	517 1 O

In	519 2 O
Mg	522 2 B-Chemical
(	524 1 O
2	525 1 O
+	526 1 O
)	527 1 O
-	528 1 O
free	529 4 O
bathing	534 7 O
medium	542 6 O
containing	549 10 O
bicuculline	560 11 B-Chemical
,	571 1 O
conditions	573 10 O
designed	584 8 O
to	593 2 O
increase	596 8 O
excitability	605 12 O
in	618 2 O
the	621 3 O
slices	625 6 O
,	631 1 O
electrical	633 10 O
stimulation	644 11 O
of	656 2 O
the	659 3 O
hilus	663 5 O
resulted	669 8 O
in	678 2 O
a	681 1 O
single	683 6 O
population	690 10 O
spike	701 5 O
in	707 2 O
granule	710 7 O
cells	718 5 O
from	724 4 O
control	729 7 O
mice	737 4 O
and	742 3 O
pilocarpine	746 11 B-Chemical
-	757 1 O
treated	758 7 O
mice	766 4 O
that	771 4 O
did	776 3 O
not	780 3 O
experience	784 10 O
SE	795 2 B-Disease
.	797 1 O

In	799 2 O
SE	802 2 B-Disease
survivors	805 9 O
,	814 1 O
similar	816 7 O
stimulation	824 11 O
resulted	836 8 O
in	845 2 O
a	848 1 O
population	850 10 O
spike	861 5 O
followed	867 8 O
,	875 1 O
at	877 2 O
a	880 1 O
variable	882 8 O
latency	891 7 O
,	898 1 O
by	900 2 O
negative	903 8 O
DC	912 2 O
shifts	915 6 O
and	922 3 O
repetitive	926 10 O
afterdischarges	937 15 O
of	953 2 O
3	956 1 O
-	957 1 O
60	958 2 O
s	961 1 O
duration	963 8 O
,	971 1 O
which	973 5 O
were	979 4 O
blocked	984 7 O
by	992 2 O
ionotropic	995 10 O
glutamate	1006 9 B-Chemical
receptor	1016 8 O
antagonists	1025 11 O
.	1036 1 O

Focal	1038 5 O
glutamate	1044 9 B-Chemical
photostimulation	1054 16 O
of	1071 2 O
the	1074 3 O
granule	1078 7 O
cell	1086 4 O
layer	1091 5 O
at	1097 2 O
sites	1100 5 O
distant	1106 7 O
from	1114 4 O
the	1119 3 O
recording	1123 9 O
pipette	1133 7 O
resulted	1141 8 O
in	1150 2 O
population	1153 10 O
responses	1164 9 O
of	1174 2 O
1	1177 1 O
-	1178 1 O
30	1179 2 O
s	1182 1 O
duration	1184 8 O
in	1193 2 O
slices	1196 6 O
from	1203 4 O
SE	1208 2 B-Disease
survivors	1211 9 O
but	1221 3 O
not	1225 3 O
other	1229 5 O
groups	1235 6 O
.	1241 1 O

These	1243 5 O
data	1249 4 O
support	1254 7 O
the	1262 3 O
hypothesis	1266 10 O
that	1277 4 O
SE	1282 2 B-Disease
-	1284 1 O
induced	1285 7 O
mossy	1293 5 O
fiber	1299 5 O
sprouting	1305 9 O
and	1315 3 O
synaptic	1319 8 O
reorganization	1328 14 O
are	1343 3 O
relevant	1347 8 O
characteristics	1356 15 O
of	1372 2 O
seizure	1375 7 B-Disease
development	1383 11 O
in	1395 2 O
these	1398 5 O
murine	1404 6 O
strains	1411 7 O
,	1418 1 O
resembling	1420 10 O
rat	1431 3 O
models	1435 6 O
of	1442 2 O
human	1445 5 O
temporal	1451 8 B-Disease
lobe	1460 4 I-Disease
epilepsy	1465 8 I-Disease
.	1473 1 O

The	0 3 O
alpha3	4 6 O
and	11 3 O
beta4	15 5 O
nicotinic	21 9 O
acetylcholine	31 13 B-Chemical
receptor	45 8 O
subunits	54 8 O
are	63 3 O
necessary	67 9 O
for	77 3 O
nicotine	81 8 B-Chemical
-	89 1 O
induced	90 7 O
seizures	98 8 B-Disease
and	107 3 O
hypolocomotion	111 14 B-Disease
in	126 2 O
mice	129 4 O
.	133 1 O

Binding	135 7 O
of	143 2 O
nicotine	146 8 B-Chemical
to	155 2 O
nicotinic	158 9 O
acetylcholine	168 13 B-Chemical
receptors	182 9 O
(	192 1 O
nAChRs	193 6 O
)	199 1 O
elicits	201 7 O
a	209 1 O
series	211 6 O
of	218 2 O
dose	221 4 O
-	225 1 O
dependent	226 9 O
behaviors	236 9 O
that	246 4 O
go	251 2 O
from	254 4 O
altered	259 7 O
exploration	267 11 O
,	278 1 O
sedation	280 8 O
,	288 1 O
and	290 3 O
tremors	294 7 B-Disease
,	301 1 O
to	303 2 O
seizures	306 8 B-Disease
and	315 3 O
death	319 5 B-Disease
.	324 1 O

nAChRs	326 6 O
are	333 3 O
pentameric	337 10 O
ion	348 3 O
channels	352 8 O
usually	361 7 O
composed	369 8 O
of	378 2 O
alpha	381 5 O
and	387 3 O
beta	391 4 O
subunits	396 8 O
.	404 1 O

A	406 1 O
gene	408 4 O
cluster	413 7 O
comprises	421 9 O
the	431 3 O
alpha3	435 6 O
,	441 1 O
alpha5	443 6 O
and	450 3 O
beta4	454 5 O
subunits	460 8 O
,	468 1 O
which	470 5 O
coassemble	476 10 O
to	487 2 O
form	490 4 O
functional	495 10 O
receptors	506 9 O
.	515 1 O

We	517 2 O
examined	520 8 O
the	529 3 O
role	533 4 O
of	538 2 O
the	541 3 O
beta4	545 5 O
subunits	551 8 O
in	560 2 O
nicotine	563 8 B-Chemical
-	571 1 O
induced	572 7 O
seizures	580 8 B-Disease
and	589 3 O
hypolocomotion	593 14 B-Disease
in	608 2 O
beta4	611 5 O
homozygous	617 10 O
null	628 4 O
(	633 1 O
beta4	634 5 O
-	640 1 O
/	641 1 O
-	642 1 O
)	643 1 O
and	645 3 O
alpha3	649 6 O
heterozygous	656 12 O
(	669 1 O
+	670 1 O
/	671 1 O
-	672 1 O
)	673 1 O
mice	675 4 O
.	679 1 O

beta4	681 5 O
-	687 1 O
/	688 1 O
-	689 1 O
mice	691 4 O
were	696 4 O
less	701 4 O
sensitive	706 9 O
to	716 2 O
the	719 3 O
effects	723 7 O
of	731 2 O
nicotine	734 8 B-Chemical
both	743 4 O
at	748 2 O
low	751 3 O
doses	755 5 O
,	760 1 O
measured	762 8 O
as	771 2 O
decreased	774 9 O
exploration	784 11 O
in	796 2 O
an	799 2 O
open	802 4 O
field	807 5 O
,	812 1 O
and	814 3 O
at	818 2 O
high	821 4 O
doses	826 5 O
,	831 1 O
measured	833 8 O
as	842 2 O
sensitivity	845 11 O
to	857 2 O
nicotine	860 8 B-Chemical
-	868 1 O
induced	869 7 O
seizures	877 8 B-Disease
.	885 1 O

Using	887 5 O
in	893 2 O
situ	896 4 O
hybridization	901 13 O
probes	915 6 O
for	922 3 O
the	926 3 O
alpha3	930 6 O
and	937 3 O
alpha5	941 6 O
subunits	948 8 O
,	956 1 O
we	958 2 O
showed	961 6 O
that	968 4 O
alpha5	973 6 O
mRNA	980 4 O
levels	985 6 O
are	992 3 O
unchanged	996 9 O
,	1005 1 O
whereas	1007 7 O
alpha3	1015 6 O
mRNA	1022 4 O
levels	1027 6 O
are	1034 3 O
selectively	1038 11 O
decreased	1050 9 O
in	1060 2 O
the	1063 3 O
mitral	1067 6 O
cell	1074 4 O
layer	1079 5 O
of	1085 2 O
the	1088 3 O
olfactory	1092 9 O
bulb	1102 4 O
,	1106 1 O
and	1108 3 O
the	1112 3 O
inferior	1116 8 O
and	1125 3 O
the	1129 3 O
superior	1133 8 O
colliculus	1142 10 O
of	1153 2 O
beta4	1156 5 O
-	1162 1 O
/	1163 1 O
-	1164 1 O
brains	1166 6 O
.	1172 1 O

alpha3	1174 6 O
+	1181 1 O
/	1182 1 O
-	1183 1 O
mice	1185 4 O
were	1190 4 O
partially	1195 9 O
resistant	1205 9 O
to	1215 2 O
nicotine	1218 8 B-Chemical
-	1226 1 O
induced	1227 7 O
seizures	1235 8 B-Disease
when	1244 4 O
compared	1249 8 O
to	1258 2 O
wild	1261 4 O
-	1265 1 O
type	1266 4 O
littermates	1271 11 O
.	1282 1 O

mRNA	1284 4 O
levels	1289 6 O
for	1296 3 O
the	1300 3 O
alpha5	1304 6 O
and	1311 3 O
the	1315 3 O
beta4	1319 5 O
subunits	1325 8 O
were	1334 4 O
unchanged	1339 9 O
in	1349 2 O
alpha3	1352 6 O
+	1359 1 O
/	1360 1 O
-	1361 1 O
brains	1363 6 O
.	1369 1 O

Together	1371 8 O
,	1379 1 O
these	1381 5 O
results	1387 7 O
suggest	1395 7 O
that	1403 4 O
the	1408 3 O
beta4	1412 5 O
and	1418 3 O
the	1422 3 O
alpha3	1426 6 O
subunits	1433 8 O
are	1442 3 O
mediators	1446 9 O
of	1456 2 O
nicotine	1459 8 B-Chemical
-	1467 1 O
induced	1468 7 O
seizures	1476 8 B-Disease
and	1485 3 O
hypolocomotion	1489 14 B-Disease
.	1503 1 O

Recurrent	0 9 O
acute	10 5 O
interstitial	16 12 B-Disease
nephritis	29 9 I-Disease
induced	39 7 O
by	47 2 O
azithromycin	50 12 B-Chemical
.	62 1 O

A	64 1 O
14	66 2 O
-	68 1 O
year	69 4 O
-	73 1 O
old	74 3 O
girl	78 4 O
is	83 2 O
reported	86 8 O
with	95 4 O
recurrent	100 9 O
,	109 1 O
azithromycin	111 12 B-Chemical
-	123 1 O
induced	124 7 O
,	131 1 O
acute	133 5 O
interstitial	139 12 B-Disease
nephritis	152 9 I-Disease
.	161 1 O

The	163 3 O
second	167 6 O
episode	174 7 O
was	182 3 O
more	186 4 O
severe	191 6 O
than	198 4 O
the	203 3 O
first	207 5 O
;	212 1 O
and	214 3 O
although	218 8 O
both	227 4 O
were	232 4 O
treated	237 7 O
with	245 4 O
intensive	250 9 O
corticosteroid	260 14 O
therapy	275 7 O
,	282 1 O
renal	284 5 O
function	290 8 O
remained	299 8 O
impaired	308 8 O
.	316 1 O

Although	318 8 O
most	327 4 O
cases	332 5 O
of	338 2 O
antibiotic	341 10 O
induced	352 7 O
acute	360 5 O
interstitial	366 12 B-Disease
nephritis	379 9 I-Disease
are	389 3 O
benign	393 6 O
and	400 3 O
self	404 4 O
-	408 1 O
limited	409 7 O
,	416 1 O
some	418 4 O
patients	423 8 O
are	432 3 O
at	436 2 O
risk	439 4 O
for	444 3 O
permanent	448 9 O
renal	458 5 B-Disease
injury	464 6 I-Disease
.	470 1 O

Valproate	0 9 B-Chemical
-	9 1 O
induced	10 7 O
encephalopathy	18 14 B-Disease
.	32 1 O

Valproate	34 9 B-Chemical
-	43 1 O
induced	44 7 O
encephalopathy	52 14 B-Disease
is	67 2 O
a	70 1 O
rare	72 4 O
syndrome	77 8 O
that	86 4 O
may	91 3 O
manifest	95 8 O
in	104 2 O
otherwise	107 9 O
normal	117 6 O
epileptic	124 9 B-Disease
individuals	134 11 O
.	145 1 O

It	147 2 O
may	150 3 O
even	154 4 O
present	159 7 O
in	167 2 O
patients	170 8 O
who	179 3 O
have	183 4 O
tolerated	188 9 O
this	198 4 O
medicine	203 8 O
well	212 4 O
in	217 2 O
the	220 3 O
past	224 4 O
.	228 1 O

It	230 2 O
is	233 2 O
usually	236 7 O
but	244 3 O
not	248 3 O
necessarily	252 11 O
associated	264 10 O
with	275 4 O
hyperammonemia	280 14 B-Disease
.	294 1 O

The	296 3 O
EEG	300 3 O
shows	304 5 O
characteristic	310 14 O
triphasic	325 9 O
waves	335 5 O
in	341 2 O
most	344 4 O
patients	349 8 O
with	358 4 O
this	363 4 O
complication	368 12 O
.	380 1 O

A	382 1 O
case	384 4 O
of	389 2 O
valproate	392 9 B-Chemical
-	401 1 O
induced	402 7 O
encephalopathy	410 14 B-Disease
is	425 2 O
presented	428 9 O
.	437 1 O

The	439 3 O
problems	443 8 O
in	452 2 O
diagnosing	455 10 O
this	466 4 O
condition	471 9 O
are	481 3 O
subsequently	485 12 O
discussed	498 9 O
.	507 1 O

Nitro	0 5 B-Chemical
-	5 1 I-Chemical
L	6 1 I-Chemical
-	7 1 I-Chemical
arginine	8 8 I-Chemical
methyl	17 6 I-Chemical
ester	24 5 I-Chemical
:	29 1 O
a	31 1 O
potential	33 9 O
protector	43 9 O
against	53 7 O
gentamicin	61 10 B-Chemical
ototoxicity	72 11 B-Disease
.	83 1 O

The	85 3 O
nitric	89 6 B-Chemical
oxide	96 5 I-Chemical
(	102 1 O
NO	103 2 B-Chemical
)	105 1 O
inhibitor	107 9 O
nitro	117 5 B-Chemical
-	122 1 I-Chemical
L	123 1 I-Chemical
-	124 1 I-Chemical
arginine	125 8 I-Chemical
methyl	134 6 I-Chemical
ester	141 5 I-Chemical
(	147 1 O
L	148 1 B-Chemical
-	149 1 I-Chemical
NAME	150 4 I-Chemical
)	154 1 O
may	156 3 O
act	160 3 O
as	164 2 O
an	167 2 O
otoprotectant	170 13 O
against	184 7 O
high	192 4 B-Disease
-	196 1 I-Disease
frequency	197 9 I-Disease
hearing	207 7 I-Disease
loss	215 4 I-Disease
caused	220 6 O
by	227 2 O
gentamicin	230 10 B-Chemical
,	240 1 O
but	242 3 O
further	246 7 O
studies	254 7 O
are	262 3 O
needed	266 6 O
to	273 2 O
confirm	276 7 O
this	284 4 O
.	288 1 O
Aminoglycoside	289 14 B-Chemical
antibiotics	304 11 O
are	316 3 O
still	320 5 O
widely	326 6 O
used	333 4 O
by	338 2 O
virtue	341 6 O
of	348 2 O
their	351 5 O
efficacy	357 8 O
and	366 3 O
low	370 3 O
cost	374 4 O
.	378 1 O

Their	380 5 O
ototoxicity	386 11 B-Disease
is	398 2 O
a	401 1 O
serious	403 7 O
health	411 6 O
problem	418 7 O
and	426 3 O
,	429 1 O
as	431 2 O
their	434 5 O
ototoxic	440 8 B-Disease
mechanism	449 9 O
involves	459 8 O
the	468 3 O
production	472 10 O
of	483 2 O
NO	486 2 B-Chemical
,	488 1 O
we	490 2 O
need	493 4 O
to	498 2 O
assess	501 6 O
the	508 3 O
use	512 3 O
of	516 2 O
NO	519 2 B-Chemical
inhibitors	522 10 O
for	533 3 O
the	537 3 O
prevention	541 10 O
of	552 2 O
aminoglycoside	555 14 B-Chemical
-	569 1 O
induced	570 7 O
sensorineural	578 13 B-Disease
hearing	592 7 I-Disease
loss	600 4 I-Disease
.	604 1 O

In	606 2 O
this	609 4 O
experimental	614 12 O
study	627 5 O
we	633 2 O
used	636 4 O
30	641 2 O
Sprague	644 7 O
-	651 1 O
Dawley	652 6 O
rats	659 4 O
,	663 1 O
27	665 2 O
of	668 2 O
which	671 5 O
had	677 3 O
gentamicin	681 10 B-Chemical
instilled	692 9 O
into	702 4 O
the	707 3 O
middle	711 6 O
ear	718 3 O
.	721 1 O

The	723 3 O
otoprotectant	727 13 O
L	741 1 B-Chemical
-	742 1 I-Chemical
NAME	743 4 I-Chemical
was	748 3 O
administered	752 12 O
topically	765 9 O
to	775 2 O
12	778 2 O
/	780 1 O
27	781 2 O
animals	784 7 O
.	791 1 O

Its	793 3 O
effect	797 6 O
was	804 3 O
determined	808 10 O
in	819 2 O
terms	822 5 O
of	828 2 O
attenuation	831 11 O
of	843 2 O
hearing	846 7 B-Disease
loss	854 4 I-Disease
,	858 1 O
measured	860 8 O
by	869 2 O
shifts	872 6 O
in	879 2 O
the	882 3 O
auditory	886 8 O
brainstem	895 9 O
response	905 8 O
threshold	914 9 O
.	923 1 O

L	925 1 B-Chemical
-	926 1 I-Chemical
NAME	927 4 I-Chemical
reduced	932 7 O
gentamicin	940 10 B-Chemical
-	950 1 O
induced	951 7 O
hearing	959 7 B-Disease
loss	967 4 I-Disease
in	972 2 O
the	975 3 O
high	979 4 O
-	983 1 O
frequency	984 9 O
range	994 5 O
,	999 1 O
but	1001 3 O
gave	1005 4 O
no	1010 2 O
protection	1013 10 O
in	1024 2 O
the	1027 3 O
middle	1031 6 O
or	1038 2 O
low	1041 3 O
frequencies	1045 11 O
.	1056 1 O

Cerebral	0 8 B-Disease
vasculitis	9 10 I-Disease
following	20 9 O
oral	30 4 O
methylphenidate	35 15 B-Chemical
intake	51 6 O
in	58 2 O
an	61 2 O
adult	64 5 O
:	69 1 O
a	71 1 O
case	73 4 O
report	78 6 O
.	84 1 O

Methylphenidate	86 15 B-Chemical
is	102 2 O
structurally	105 12 O
and	118 3 O
functionally	122 12 O
similar	135 7 O
to	143 2 O
amphetamine	146 11 B-Chemical
.	157 1 O

Cerebral	159 8 B-Disease
vasculitis	168 10 I-Disease
associated	179 10 O
with	190 4 O
amphetamine	195 11 B-Disease
abuse	207 5 I-Disease
is	213 2 O
well	216 4 O
documented	221 10 O
,	231 1 O
and	233 3 O
in	237 2 O
rare	240 4 O
cases	245 5 O
ischaemic	251 9 B-Disease
stroke	261 6 I-Disease
has	268 3 O
been	272 4 O
reported	277 8 O
after	286 5 O
methylphenidate	292 15 B-Chemical
intake	308 6 O
in	315 2 O
children	318 8 O
.	326 1 O

We	328 2 O
report	331 6 O
the	338 3 O
case	342 4 O
of	347 2 O
a	350 1 O
63	352 2 O
-	354 1 O
year	355 4 O
-	359 1 O
old	360 3 O
female	364 6 O
who	371 3 O
was	375 3 O
treated	379 7 O
with	387 4 O
methylphenidate	392 15 B-Chemical
due	408 3 O
to	412 2 O
hyperactivity	415 13 B-Disease
and	429 3 O
suffered	433 8 O
from	442 4 O
multiple	447 8 O
ischaemic	456 9 B-Disease
strokes	466 7 I-Disease
.	473 1 O

We	475 2 O
consider	478 8 O
drug	487 4 O
-	491 1 O
induced	492 7 O
cerebral	500 8 B-Disease
vasculitis	509 10 I-Disease
as	520 2 O
the	523 3 O
most	527 4 O
likely	532 6 O
cause	539 5 O
of	545 2 O
recurrent	548 9 O
ischaemic	558 9 B-Disease
strokes	568 7 I-Disease
in	576 2 O
the	579 3 O
absence	583 7 O
of	591 2 O
any	594 3 O
pathological	598 12 O
findings	611 8 O
during	620 6 O
the	627 3 O
diagnostic	631 10 O
work	642 4 O
-	646 1 O
up	647 2 O
.	649 1 O

We	651 2 O
conclude	654 8 O
that	663 4 O
methylphenidate	668 15 B-Chemical
mediated	684 8 O
vasculitis	693 10 B-Disease
should	704 6 O
be	711 2 O
considered	714 10 O
in	725 2 O
patients	728 8 O
with	737 4 O
neurological	742 12 O
symptoms	755 8 O
and	764 3 O
a	768 1 O
history	770 7 O
of	778 2 O
methylphenidate	781 15 B-Chemical
therapy	797 7 O
.	804 1 O

This	806 4 O
potential	811 9 O
side	821 4 O
-	825 1 O
effect	826 6 O
,	832 1 O
though	834 6 O
very	841 4 O
rare	846 4 O
,	850 1 O
represents	852 10 O
one	863 3 O
more	867 4 O
reason	872 6 O
to	879 2 O
be	882 2 O
very	885 4 O
restrictive	890 11 O
in	902 2 O
the	905 3 O
use	909 3 O
of	913 2 O
methylphenidate	916 15 B-Chemical
.	931 1 O

Cerebral	0 8 B-Disease
haemorrhage	9 11 I-Disease
induced	21 7 O
by	29 2 O
warfarin	32 8 B-Chemical
-	41 1 O
the	43 3 O
influence	47 9 O
of	57 2 O
drug	60 4 O
-	64 1 O
drug	65 4 O
interactions	70 12 O
.	82 1 O

PURPOSE	84 7 O
:	91 1 O
To	93 2 O
evaluate	96 8 O
the	105 3 O
frequency	109 9 O
,	118 1 O
severity	120 8 O
and	129 3 O
preventability	133 14 O
of	148 2 O
warfarin	151 8 B-Chemical
-	159 1 O
induced	160 7 O
cerebral	168 8 B-Disease
haemorrhages	177 12 I-Disease
due	190 3 O
to	194 2 O
warfarin	197 8 B-Chemical
and	206 3 O
warfarin	210 8 B-Chemical
-	218 1 O
drug	219 4 O
interactions	224 12 O
in	237 2 O
patients	240 8 O
living	249 6 O
in	256 2 O
the	259 3 O
county	263 6 O
of	270 2 O
Osterg	273 6 O
tland	281 5 O
,	286 1 O
Sweden	288 6 O
.	294 1 O

METHODS	296 7 O
:	303 1 O
All	305 3 O
patients	309 8 O
with	318 4 O
a	323 1 O
diagnosed	325 9 O
cerebral	335 8 B-Disease
haemorrhage	344 11 I-Disease
at	356 2 O
three	359 5 O
hospitals	365 9 O
during	375 6 O
the	382 3 O
period	386 6 O
2000	393 4 O
-	397 1 O
2002	398 4 O
were	403 4 O
identified	408 10 O
.	418 1 O

Medical	420 7 O
records	428 7 O
were	436 4 O
studied	441 7 O
retrospectively	449 15 O
to	465 2 O
evaluate	468 8 O
whether	477 7 O
warfarin	485 8 B-Chemical
and	494 3 O
warfarin	498 8 B-Chemical
-	506 1 O
drug	507 4 O
interactions	512 12 O
could	525 5 O
have	531 4 O
caused	536 6 O
the	543 3 O
cerebral	547 8 B-Disease
haemorrhage	556 11 I-Disease
.	567 1 O

The	569 3 O
proportion	573 10 O
of	584 2 O
possibly	587 8 O
avoidable	596 9 O
cases	606 5 O
due	612 3 O
to	616 2 O
drug	619 4 O
interactions	624 12 O
was	637 3 O
estimated	641 9 O
.	650 1 O

RESULTS	652 7 O
:	659 1 O
Among	661 5 O
593	667 3 O
patients	671 8 O
with	680 4 O
cerebral	685 8 B-Disease
haemorrhage	694 11 I-Disease
,	705 1 O
59	707 2 O
(	710 1 O
10	711 2 O
%	713 1 O
)	714 1 O
were	716 4 O
assessed	721 8 O
as	730 2 O
related	733 7 O
to	741 2 O
warfarin	744 8 B-Chemical
treatment	753 9 O
.	762 1 O

This	764 4 O
imply	769 5 O
an	775 2 O
incidence	778 9 O
of	788 2 O
1	791 1 O
.	792 1 O
7	793 1 O
/	794 1 O
100	795 3 O
,	798 1 O
000	799 3 O
treatment	803 9 O
years	813 5 O
.	818 1 O

Of	820 2 O
the	823 3 O
59	827 2 O
cases	830 5 O
,	835 1 O
26	837 2 O
(	840 1 O
44	841 2 O
%	843 1 O
)	844 1 O
had	846 3 O
a	850 1 O
fatal	852 5 O
outcome	858 7 O
,	865 1 O
compared	867 8 O
to	876 2 O
136	879 3 O
(	883 1 O
25	884 2 O
%	886 1 O
)	887 1 O
among	889 5 O
the	895 3 O
non	899 3 O
-	902 1 O
warfarin	903 8 B-Chemical
patients	912 8 O
(	921 1 O
p	922 1 O
<	924 1 O
0	926 1 O
.	927 1 O
01	928 2 O
)	930 1 O
.	931 1 O

A	933 1 O
warfarin	935 8 B-Chemical
-	943 1 O
drug	944 4 O
interaction	949 11 O
could	961 5 O
have	967 4 O
contributed	972 11 O
to	984 2 O
the	987 3 O
haemorrhage	991 11 B-Disease
in	1003 2 O
24	1006 2 O
(	1009 1 O
41	1010 2 O
%	1012 1 O
)	1013 1 O
of	1015 2 O
the	1018 3 O
warfarin	1022 8 B-Chemical
patients	1031 8 O
and	1040 3 O
in	1044 2 O
7	1047 1 O
of	1049 2 O
these	1052 5 O
(	1058 1 O
12	1059 2 O
%	1061 1 O
)	1062 1 O
the	1064 3 O
bleeding	1068 8 B-Disease
complication	1077 12 O
was	1090 3 O
considered	1094 10 O
being	1105 5 O
possible	1111 8 O
to	1120 2 O
avoid	1123 5 O
.	1128 1 O

CONCLUSIONS	1130 11 O
:	1141 1 O
Warfarin	1143 8 B-Chemical
-	1151 1 O
induced	1152 7 O
cerebral	1160 8 B-Disease
haemorrhages	1169 12 I-Disease
are	1182 3 O
a	1186 1 O
major	1188 5 O
clinical	1194 8 O
problem	1203 7 O
with	1211 4 O
a	1216 1 O
high	1218 4 O
fatality	1223 8 O
rate	1232 4 O
.	1236 1 O

Almost	1238 6 O
half	1245 4 O
of	1250 2 O
the	1253 3 O
cases	1257 5 O
was	1263 3 O
related	1267 7 O
to	1275 2 O
a	1278 1 O
warfarin	1280 8 B-Chemical
-	1288 1 O
drug	1289 4 O
interaction	1294 11 O
.	1305 1 O

A	1307 1 O
significant	1309 11 O
proportion	1321 10 O
of	1332 2 O
warfarin	1335 8 B-Chemical
-	1343 1 O
related	1344 7 O
cerebral	1352 8 B-Disease
haemorrhages	1361 12 I-Disease
might	1374 5 O
have	1380 4 O
been	1385 4 O
prevented	1390 9 O
if	1400 2 O
greater	1403 7 O
caution	1411 7 O
had	1419 3 O
been	1423 4 O
taken	1428 5 O
when	1434 4 O
prescribing	1439 11 O
drugs	1451 5 O
known	1457 5 O
to	1463 2 O
interact	1466 8 O
with	1475 4 O
warfarin	1480 8 B-Chemical
.	1488 1 O

Side	0 4 O
effects	5 7 O
of	13 2 O
postoperative	16 13 O
administration	30 14 O
of	45 2 O
methylprednisolone	48 18 B-Chemical
and	67 3 O
gentamicin	71 10 B-Chemical
into	82 4 O
the	87 3 O
posterior	91 9 O
sub	101 3 O
-	104 1 O
Tenon	105 5 O
'	110 1 O
s	111 1 O
space	113 5 O
.	118 1 O

PURPOSE	120 7 O
:	127 1 O
To	129 2 O
assess	132 6 O
the	139 3 O
incidence	143 9 O
of	153 2 O
postoperative	156 13 O
emetic	170 6 O
side	177 4 O
effects	182 7 O
after	190 5 O
the	196 3 O
administration	200 14 O
of	215 2 O
methylprednisolone	218 18 B-Chemical
and	237 3 O
gentamicin	241 10 B-Chemical
into	252 4 O
the	257 3 O
posterior	261 9 O
sub	271 3 O
-	274 1 O
Tenon	275 5 O
'	280 1 O
s	281 1 O
space	283 5 O
at	289 2 O
the	292 3 O
end	296 3 O
of	300 2 O
routine	303 7 O
cataract	311 8 B-Disease
surgery	320 7 O
.	327 1 O

SETTING	329 7 O
:	336 1 O
St	338 2 O
.	340 1 O

Luke	342 4 O
'	346 1 O
s	347 1 O
Hospital	349 8 O
,	357 1 O
Gwardamangia	359 12 O
,	371 1 O
Malta	373 5 O
.	378 1 O

METHODS	380 7 O
:	387 1 O
A	389 1 O
double	391 6 O
-	397 1 O
blind	398 5 O
double	404 6 O
-	410 1 O
armed	411 5 O
prospective	417 11 O
study	429 5 O
comprised	435 9 O
40	445 2 O
patients	448 8 O
who	457 3 O
had	461 3 O
uneventful	465 10 O
sutureless	476 10 O
phacoemulsification	487 19 O
under	507 5 O
sub	513 3 O
-	516 1 O
Tenon	517 5 O
'	522 1 O
s	523 1 O
local	525 5 O
infiltration	531 12 O
of	544 2 O
3	547 1 O
mL	549 2 O
of	552 2 O
plain	555 5 O
lignocaine	561 10 B-Chemical
.	571 1 O

At	573 2 O
the	576 3 O
end	580 3 O
of	584 2 O
the	587 3 O
procedure	591 9 O
,	600 1 O
Group	602 5 O
A	608 1 O
(	610 1 O
n	611 1 O
=	613 1 O
20	615 2 O
)	617 1 O
had	619 3 O
20	623 2 O
mg	626 2 O
/	628 1 O
0	629 1 O
.	630 1 O
5	631 1 O
mL	633 2 O
of	636 2 O
methylprednisolone	639 18 B-Chemical
and	658 3 O
10	662 2 O
mg	665 2 O
/	667 1 O
0	668 1 O
.	669 1 O
5	670 1 O
mL	672 2 O
of	675 2 O
gentamicin	678 10 B-Chemical
injected	689 8 O
into	698 4 O
the	703 3 O
posterior	707 9 O
sub	717 3 O
-	720 1 O
Tenon	721 5 O
'	726 1 O
s	727 1 O
space	729 5 O
and	735 3 O
Group	739 5 O
B	745 1 O
(	747 1 O
n	748 1 O
=	750 1 O
20	752 2 O
)	754 1 O
had	756 3 O
the	760 3 O
same	764 4 O
combination	769 11 O
injected	781 8 O
into	790 4 O
the	795 3 O
anterior	799 8 O
sub	808 3 O
-	811 1 O
Tenon	812 5 O
'	817 1 O
s	818 1 O
space	820 5 O
.	825 1 O

Postoperatively	827 15 O
,	842 1 O
all	844 3 O
patients	848 8 O
were	857 4 O
assessed	862 8 O
for	871 3 O
symptoms	875 8 O
of	884 2 O
nausea	887 6 B-Disease
,	893 1 I-Disease
vomiting	895 8 I-Disease
,	903 1 O
and	905 3 O
headache	909 8 B-Disease
.	917 1 O

A	919 1 O
chi	921 3 O
-	924 1 O
square	925 6 O
test	932 4 O
was	937 3 O
used	941 4 O
to	946 2 O
assess	949 6 O
the	956 3 O
statistical	960 11 O
significance	972 12 O
of	985 2 O
results	988 7 O
.	995 1 O

RESULTS	997 7 O
:	1004 1 O
Sixty	1006 5 O
percent	1012 7 O
in	1020 2 O
Group	1023 5 O
A	1029 1 O
developed	1031 9 O
postoperative	1041 13 B-Disease
emetic	1055 6 I-Disease
symptoms	1062 8 I-Disease
,	1070 1 O
headache	1072 8 B-Disease
,	1080 1 O
or	1082 2 O
both	1085 4 O
;	1089 1 O
1	1091 1 O
patient	1093 7 O
in	1101 2 O
Group	1104 5 O
B	1110 1 O
developed	1112 9 O
symptoms	1122 8 O
.	1130 1 O

CONCLUSIONS	1132 11 O
:	1143 1 O
The	1145 3 O
administration	1149 14 O
of	1164 2 O
methylprednisolone	1167 18 B-Chemical
and	1186 3 O
gentamicin	1190 10 B-Chemical
in	1201 2 O
the	1204 3 O
posterior	1208 9 O
sub	1218 3 O
-	1221 1 O
Tenon	1222 5 O
'	1227 1 O
s	1228 1 O
space	1230 5 O
was	1236 3 O
related	1240 7 O
to	1248 2 O
a	1251 1 O
high	1253 4 O
incidence	1258 9 O
of	1268 2 O
side	1271 4 O
effects	1276 7 O
including	1284 9 O
nausea	1294 6 B-Disease
,	1300 1 I-Disease
vomiting	1302 8 I-Disease
,	1310 1 O
and	1312 3 O
headache	1316 8 B-Disease
.	1324 1 O

All	1326 3 O
adverse	1330 7 O
effects	1338 7 O
were	1346 4 O
self	1351 4 O
-	1355 1 O
limiting	1356 8 O
.	1364 1 O

Cardiac	0 7 O
Angiography	8 11 O
in	20 2 O
Renally	23 7 O
Impaired	31 8 O
Patients	40 8 O
(	49 1 O
CARE	50 4 O
)	54 1 O
study	56 5 O
:	61 1 O
a	63 1 O
randomized	65 10 O
double	76 6 O
-	82 1 O
blind	83 5 O
trial	89 5 O
of	95 2 O
contrast	98 8 O
-	106 1 O
induced	107 7 O
nephropathy	115 11 B-Disease
in	127 2 O
patients	130 8 O
with	139 4 O
chronic	144 7 B-Disease
kidney	152 6 I-Disease
disease	159 7 I-Disease
.	166 1 O

BACKGROUND	168 10 O
:	178 1 O
No	180 2 O
direct	183 6 O
comparisons	190 11 O
exist	202 5 O
of	208 2 O
the	211 3 O
renal	215 5 O
tolerability	221 12 O
of	234 2 O
the	237 3 O
low	241 3 O
-	244 1 O
osmolality	245 10 O
contrast	256 8 B-Chemical
medium	265 6 I-Chemical
iopamidol	272 9 B-Chemical
with	282 4 O
that	287 4 O
of	292 2 O
the	295 3 O
iso	299 3 O
-	302 1 O
osmolality	303 10 O
contrast	314 8 B-Chemical
medium	323 6 I-Chemical
iodixanol	330 9 B-Chemical
in	340 2 O
high	343 4 O
-	347 1 O
risk	348 4 O
patients	353 8 O
.	361 1 O

METHODS	363 7 O
AND	371 3 O
RESULTS	375 7 O
:	382 1 O
The	384 3 O
present	388 7 O
study	396 5 O
is	402 2 O
a	405 1 O
multicenter	407 11 O
,	418 1 O
randomized	420 10 O
,	430 1 O
double	432 6 O
-	438 1 O
blind	439 5 O
comparison	445 10 O
of	456 2 O
iopamidol	459 9 B-Chemical
and	469 3 O
iodixanol	473 9 B-Chemical
in	483 2 O
patients	486 8 O
with	495 4 O
chronic	500 7 B-Disease
kidney	508 6 I-Disease
disease	515 7 I-Disease
(	523 1 O
estimated	524 9 O
glomerular	534 10 O
filtration	545 10 O
rate	556 4 O
,	560 1 O
20	562 2 O
to	565 2 O
59	568 2 O
mL	571 2 O
/	573 1 O
min	574 3 O
)	577 1 O
who	579 3 O
underwent	583 9 O
cardiac	593 7 O
angiography	601 11 O
or	613 2 O
percutaneous	616 12 O
coronary	629 8 O
interventions	638 13 O
.	651 1 O

Serum	653 5 O
creatinine	659 10 B-Chemical
(	670 1 O
SCr	671 3 O
)	674 1 O
levels	676 6 O
and	683 3 O
estimated	687 9 O
glomerular	697 10 O
filtration	708 10 O
rate	719 4 O
were	724 4 O
assessed	729 8 O
at	738 2 O
baseline	741 8 O
and	750 3 O
2	754 1 O
to	756 2 O
5	759 1 O
days	761 4 O
after	766 5 O
receiving	772 9 O
medications	782 11 O
.	793 1 O

The	795 3 O
primary	799 7 O
outcome	807 7 O
was	815 3 O
a	819 1 O
postdose	821 8 O
SCr	830 3 O
increase	834 8 O
>	843 1 O
or	845 2 O
=	848 1 O
0	850 1 O
.	851 1 O
5	852 1 O
mg	854 2 O
/	856 1 O
dL	857 2 O
(	860 1 O
44	861 2 O
.	863 1 O
2	864 1 O
micromol	866 8 O
/	874 1 O
L	875 1 O
)	876 1 O
over	878 4 O
baseline	883 8 O
.	891 1 O

Secondary	893 9 O
outcomes	903 8 O
were	912 4 O
a	917 1 O
postdose	919 8 O
SCr	928 3 O
increase	932 8 O
>	941 1 O
or	943 2 O
=	946 1 O
25	948 2 O
%	950 1 O
,	951 1 O
a	953 1 O
postdose	955 8 O
estimated	964 9 O
glomerular	974 10 O
filtration	985 10 O
rate	996 4 O
decrease	1001 8 O
of	1010 2 O
>	1013 1 O
or	1015 2 O
=	1018 1 O
25	1020 2 O
%	1022 1 O
,	1023 1 O
and	1025 3 O
the	1029 3 O
mean	1033 4 O
peak	1038 4 O
change	1043 6 O
in	1050 2 O
SCr	1053 3 O
.	1056 1 O

In	1058 2 O
414	1061 3 O
patients	1065 8 O
,	1073 1 O
contrast	1075 8 O
volume	1084 6 O
,	1090 1 O
presence	1092 8 O
of	1101 2 O
diabetes	1104 8 B-Disease
mellitus	1113 8 I-Disease
,	1121 1 O
use	1123 3 O
of	1127 2 O
N	1130 1 B-Chemical
-	1131 1 I-Chemical
acetylcysteine	1132 14 I-Chemical
,	1146 1 O
mean	1148 4 O
baseline	1153 8 O
SCr	1162 3 O
,	1165 1 O
and	1167 3 O
estimated	1171 9 O
glomerular	1181 10 O
filtration	1192 10 O
rate	1203 4 O
were	1208 4 O
comparable	1213 10 O
in	1224 2 O
the	1227 3 O
2	1231 1 O
groups	1233 6 O
.	1239 1 O

SCr	1241 3 O
increases	1245 9 O
>	1255 1 O
or	1257 2 O
=	1260 1 O
0	1262 1 O
.	1263 1 O
5	1264 1 O
mg	1266 2 O
/	1268 1 O
dL	1269 2 O
occurred	1272 8 O
in	1281 2 O
4	1284 1 O
.	1285 1 O
4	1286 1 O
%	1287 1 O
(	1289 1 O
9	1290 1 O
of	1292 2 O
204	1295 3 O
patients	1299 8 O
)	1307 1 O
after	1309 5 O
iopamidol	1315 9 B-Chemical
and	1325 3 O
6	1329 1 O
.	1330 1 O
7	1331 1 O
%	1332 1 O
(	1334 1 O
14	1335 2 O
of	1338 2 O
210	1341 3 O
patients	1345 8 O
)	1353 1 O
after	1355 5 O
iodixanol	1361 9 B-Chemical
(	1371 1 O
P	1372 1 O
=	1373 1 O
0	1374 1 O
.	1375 1 O
39	1376 2 O
)	1378 1 O
,	1379 1 O
whereas	1381 7 O
rates	1389 5 O
of	1395 2 O
SCr	1398 3 O
increases	1402 9 O
>	1412 1 O
or	1414 2 O
=	1417 1 O
25	1419 2 O
%	1421 1 O
were	1423 4 O
9	1428 1 O
.	1429 1 O
8	1430 1 O
%	1431 1 O
and	1433 3 O
12	1437 2 O
.	1439 1 O
4	1440 1 O
%	1441 1 O
,	1442 1 O
respectively	1444 12 O
(	1457 1 O
P	1458 1 O
=	1459 1 O
0	1460 1 O
.	1461 1 O
44	1462 2 O
)	1464 1 O
.	1465 1 O

In	1467 2 O
patients	1470 8 O
with	1479 4 O
diabetes	1484 8 B-Disease
,	1492 1 O
SCr	1494 3 O
increases	1498 9 O
>	1508 1 O
or	1510 2 O
=	1513 1 O
0	1515 1 O
.	1516 1 O
5	1517 1 O
mg	1519 2 O
/	1521 1 O
dL	1522 2 O
were	1525 4 O
5	1530 1 O
.	1531 1 O
1	1532 1 O
%	1533 1 O
(	1535 1 O
4	1536 1 O
of	1538 2 O
78	1541 2 O
patients	1544 8 O
)	1552 1 O
with	1554 4 O
iopamidol	1559 9 B-Chemical
and	1569 3 O
13	1573 2 O
.	1575 1 O
0	1576 1 O
%	1577 1 O
(	1579 1 O
12	1580 2 O
of	1583 2 O
92	1586 2 O
patients	1589 8 O
)	1597 1 O
with	1599 4 O
iodixanol	1604 9 B-Chemical
(	1614 1 O
P	1615 1 O
=	1616 1 O
0	1617 1 O
.	1618 1 O
11	1619 2 O
)	1621 1 O
,	1622 1 O
whereas	1624 7 O
SCr	1632 3 O
increases	1636 9 O
>	1646 1 O
or	1648 2 O
=	1651 1 O
25	1653 2 O
%	1655 1 O
were	1657 4 O
10	1662 2 O
.	1664 1 O
3	1665 1 O
%	1666 1 O
and	1668 3 O
15	1672 2 O
.	1674 1 O
2	1675 1 O
%	1676 1 O
,	1677 1 O
respectively	1679 12 O
(	1692 1 O
P	1693 1 O
=	1694 1 O
0	1695 1 O
.	1696 1 O
37	1697 2 O
)	1699 1 O
.	1700 1 O

Mean	1702 4 O
post	1707 4 O
-	1711 1 O
SCr	1712 3 O
increases	1716 9 O
were	1726 4 O
significantly	1731 13 O
less	1745 4 O
with	1750 4 O
iopamidol	1755 9 B-Chemical
(	1765 1 O
all	1766 3 O
patients	1770 8 O
:	1778 1 O
0	1780 1 O
.	1781 1 O
07	1782 2 O
versus	1785 6 O
0	1792 1 O
.	1793 1 O
12	1794 2 O
mg	1797 2 O
/	1799 1 O
dL	1800 2 O
,	1802 1 O
6	1804 1 O
.	1805 1 O
2	1806 1 O
versus	1808 6 O
10	1815 2 O
.	1817 1 O
6	1818 1 O
micromol	1820 8 O
/	1828 1 O
L	1829 1 O
,	1830 1 O
P	1832 1 O
=	1833 1 O
0	1834 1 O
.	1835 1 O
03	1836 2 O
;	1838 1 O
patients	1840 8 O
with	1849 4 O
diabetes	1854 8 B-Disease
:	1862 1 O
0	1864 1 O
.	1865 1 O
07	1866 2 O
versus	1869 6 O
0	1876 1 O
.	1877 1 O
16	1878 2 O
mg	1881 2 O
/	1883 1 O
dL	1884 2 O
,	1886 1 O
6	1888 1 O
.	1889 1 O
2	1890 1 O
versus	1892 6 O
14	1899 2 O
.	1901 1 O
1	1902 1 O
micromol	1904 8 O
/	1912 1 O
L	1913 1 O
,	1914 1 O
P	1916 1 O
=	1917 1 O
0	1918 1 O
.	1919 1 O
01	1920 2 O
)	1922 1 O
.	1923 1 O

CONCLUSIONS	1925 11 O
:	1936 1 O
The	1938 3 O
rate	1942 4 O
of	1947 2 O
contrast	1950 8 O
-	1958 1 O
induced	1959 7 O
nephropathy	1967 11 B-Disease
,	1978 1 O
defined	1980 7 O
by	1988 2 O
multiple	1991 8 O
end	2000 3 O
points	2004 6 O
,	2010 1 O
is	2012 2 O
not	2015 3 O
statistically	2019 13 O
different	2033 9 O
after	2043 5 O
the	2049 3 O
intraarterial	2053 13 O
administration	2067 14 O
of	2082 2 O
iopamidol	2085 9 B-Chemical
or	2095 2 O
iodixanol	2098 9 B-Chemical
to	2108 2 O
high	2111 4 O
-	2115 1 O
risk	2116 4 O
patients	2121 8 O
,	2129 1 O
with	2131 4 O
or	2136 2 O
without	2139 7 O
diabetes	2147 8 B-Disease
mellitus	2156 8 I-Disease
.	2164 1 O

Any	2166 3 O
true	2170 4 O
difference	2175 10 O
between	2186 7 O
the	2194 3 O
agents	2198 6 O
is	2205 2 O
small	2208 5 O
and	2214 3 O
not	2218 3 O
likely	2222 6 O
to	2229 2 O
be	2232 2 O
clinically	2235 10 O
significant	2246 11 O
.	2257 1 O

A	0 1 O
novel	2 5 O
compound	8 8 O
,	16 1 O
maltolyl	18 8 B-Chemical
p	27 1 I-Chemical
-	28 1 I-Chemical
coumarate	29 9 I-Chemical
,	38 1 O
attenuates	40 10 O
cognitive	51 9 B-Disease
deficits	61 8 I-Disease
and	70 3 O
shows	74 5 O
neuroprotective	80 15 O
effects	96 7 O
in	104 2 O
vitro	107 5 O
and	113 3 O
in	117 2 O
vivo	120 4 O
dementia	125 8 B-Disease
models	134 6 O
.	140 1 O

To	142 2 O
develop	145 7 O
a	153 1 O
novel	155 5 O
and	161 3 O
effective	165 9 O
drug	175 4 O
that	180 4 O
could	185 5 O
enhance	191 7 O
cognitive	199 9 O
function	209 8 O
and	218 3 O
neuroprotection	222 15 O
,	237 1 O
we	239 2 O
newly	242 5 O
synthesized	248 11 O
maltolyl	260 8 B-Chemical
p	269 1 I-Chemical
-	270 1 I-Chemical
coumarate	271 9 I-Chemical
by	281 2 O
the	284 3 O
esterification	288 14 O
of	303 2 O
maltol	306 6 B-Chemical
and	313 3 O
p	317 1 B-Chemical
-	318 1 I-Chemical
coumaric	319 8 I-Chemical
acid	328 4 I-Chemical
.	332 1 O

In	334 2 O
the	337 3 O
present	341 7 O
study	349 5 O
,	354 1 O
we	356 2 O
investigated	359 12 O
whether	372 7 O
maltolyl	380 8 B-Chemical
p	389 1 I-Chemical
-	390 1 I-Chemical
coumarate	391 9 I-Chemical
could	401 5 O
improve	407 7 O
cognitive	415 9 B-Disease
decline	425 7 I-Disease
in	433 2 O
scopolamine	436 11 B-Chemical
-	447 1 O
injected	448 8 O
rats	457 4 O
and	462 3 O
in	466 2 O
amyloid	469 7 B-Chemical
beta	477 4 I-Chemical
peptide	482 7 I-Chemical
(	489 1 I-Chemical
1	490 1 I-Chemical
-	491 1 I-Chemical
42	492 2 I-Chemical
)	494 1 I-Chemical
-	495 1 O
infused	496 7 O
rats	504 4 O
.	508 1 O

Maltolyl	510 8 B-Chemical
p	519 1 I-Chemical
-	520 1 I-Chemical
coumarate	521 9 I-Chemical
was	531 3 O
found	535 5 O
to	541 2 O
attenuate	544 9 O
cognitive	554 9 B-Disease
deficits	564 8 I-Disease
in	573 2 O
both	576 4 O
rat	581 3 O
models	585 6 O
using	592 5 O
passive	598 7 O
avoidance	606 9 O
test	616 4 O
and	621 3 O
to	625 2 O
reduce	628 6 O
apoptotic	635 9 O
cell	645 4 O
death	650 5 O
observed	656 8 O
in	665 2 O
the	668 3 O
hippocampus	672 11 O
of	684 2 O
the	687 3 O
amyloid	691 7 B-Chemical
beta	699 4 I-Chemical
peptide	704 7 I-Chemical
(	711 1 I-Chemical
1	712 1 I-Chemical
-	713 1 I-Chemical
42	714 2 I-Chemical
)	716 1 I-Chemical
-	717 1 O
infused	718 7 O
rats	726 4 O
.	730 1 O

We	732 2 O
also	735 4 O
examined	740 8 O
the	749 3 O
neuroprotective	753 15 O
effects	769 7 O
of	777 2 O
maltolyl	780 8 B-Chemical
p	789 1 I-Chemical
-	790 1 I-Chemical
coumarate	791 9 I-Chemical
in	801 2 O
vitro	804 5 O
using	810 5 O
SH	816 2 O
-	818 1 O
SY5Y	819 4 O
cells	824 5 O
.	829 1 O

Cells	831 5 O
were	837 4 O
pretreated	842 10 O
with	853 4 O
maltolyl	858 8 B-Chemical
p	867 1 I-Chemical
-	868 1 I-Chemical
coumarate	869 9 I-Chemical
,	878 1 O
before	880 6 O
exposed	887 7 O
to	895 2 O
amyloid	898 7 B-Chemical
beta	906 4 I-Chemical
peptide	911 7 I-Chemical
(	918 1 I-Chemical
1	919 1 I-Chemical
-	920 1 I-Chemical
42	921 2 I-Chemical
)	923 1 I-Chemical
,	924 1 O
glutamate	926 9 B-Chemical
or	936 2 O
H2O2	939 4 B-Chemical
.	943 1 O

We	945 2 O
found	948 5 O
that	954 4 O
maltolyl	959 8 B-Chemical
p	968 1 I-Chemical
-	969 1 I-Chemical
coumarate	970 9 I-Chemical
significantly	980 13 O
decreased	994 9 O
apoptotic	1004 9 O
cell	1014 4 O
death	1019 5 O
and	1025 3 O
reduced	1029 7 O
reactive	1037 8 O
oxygen	1046 6 O
species	1053 7 O
,	1060 1 O
cytochrome	1062 10 O
c	1073 1 O
release	1075 7 O
,	1082 1 O
and	1084 3 O
caspase	1088 7 O
3	1096 1 O
activation	1098 10 O
.	1108 1 O

Taking	1110 6 O
these	1117 5 O
in	1123 2 O
vitro	1126 5 O
and	1132 3 O
in	1136 2 O
vivo	1139 4 O
results	1144 7 O
together	1152 8 O
,	1160 1 O
our	1162 3 O
study	1166 5 O
suggests	1172 8 O
that	1181 4 O
maltolyl	1186 8 B-Chemical
p	1195 1 I-Chemical
-	1196 1 I-Chemical
coumarate	1197 9 I-Chemical
is	1207 2 O
a	1210 1 O
potentially	1212 11 O
effective	1224 9 O
candidate	1234 9 O
against	1244 7 O
Alzheimer	1252 9 B-Disease
'	1261 1 I-Disease
s	1262 1 I-Disease
disease	1264 7 I-Disease
that	1272 4 O
is	1277 2 O
characterized	1280 13 O
by	1294 2 O
wide	1297 4 O
spread	1302 6 O
neuronal	1309 8 B-Disease
death	1318 5 I-Disease
and	1324 3 O
progressive	1328 11 O
decline	1340 7 B-Disease
of	1348 2 I-Disease
cognitive	1351 9 I-Disease
function	1361 8 I-Disease
.	1369 1 O

Interaction	0 11 O
between	12 7 O
warfarin	20 8 B-Chemical
and	29 3 O
levofloxacin	33 12 B-Chemical
:	45 1 O
case	47 4 O
series	52 6 O
.	58 1 O

Warfarin	60 8 B-Chemical
is	69 2 O
the	72 3 O
most	76 4 O
widely	81 6 O
used	88 4 O
oral	93 4 O
anticoagulant	98 13 O
and	112 3 O
is	116 2 O
indicated	119 9 O
for	129 3 O
many	133 4 O
clinical	138 8 O
conditions	147 10 O
.	157 1 O

Levofloxacin	159 12 B-Chemical
,	171 1 O
a	173 1 O
fluoroquinolone	175 15 B-Chemical
,	190 1 O
is	192 2 O
one	195 3 O
of	199 2 O
the	202 3 O
most	206 4 O
commonly	211 8 O
prescribed	220 10 O
antibiotics	231 11 O
in	243 2 O
clinical	246 8 O
practice	255 8 O
and	264 3 O
is	268 2 O
effective	271 9 O
against	281 7 O
Gram	289 4 O
-	293 1 O
positive	294 8 O
,	302 1 O
Gram	304 4 O
-	308 1 O
negative	309 8 O
,	317 1 O
and	319 3 O
atypical	323 8 O
bacteria	332 8 O
.	340 1 O

While	342 5 O
small	348 5 O
prospective	354 11 O
studies	366 7 O
have	374 4 O
not	379 3 O
revealed	383 8 O
any	392 3 O
significant	396 11 O
drug	408 4 O
-	412 1 O
drug	413 4 O
interaction	418 11 O
between	430 7 O
warfarin	438 8 B-Chemical
and	447 3 O
levofloxacin	451 12 B-Chemical
,	463 1 O
several	465 7 O
case	473 4 O
reports	478 7 O
have	486 4 O
indicated	491 9 O
that	501 4 O
levofloxacin	506 12 B-Chemical
may	519 3 O
significantly	523 13 O
potentiate	537 10 O
the	548 3 O
anticoagulation	552 15 O
effect	568 6 O
of	575 2 O
warfarin	578 8 B-Chemical
.	586 1 O

We	588 2 O
report	591 6 O
3	598 1 O
cases	600 5 O
of	606 2 O
serious	609 7 O
bleeding	617 8 B-Disease
complications	626 13 O
that	640 4 O
appear	645 6 O
to	652 2 O
be	655 2 O
the	658 3 O
result	662 6 O
of	669 2 O
the	672 3 O
interaction	676 11 O
between	688 7 O
warfarin	696 8 B-Chemical
and	705 3 O
levofloxacin	709 12 B-Chemical
.	721 1 O

Physicians	723 10 O
should	734 6 O
be	741 2 O
aware	744 5 O
of	750 2 O
this	753 4 O
potential	758 9 O
interaction	768 11 O
and	780 3 O
use	784 3 O
caution	788 7 O
when	796 4 O
prescribing	801 11 O
levofloxacin	813 12 B-Chemical
to	826 2 O
patients	829 8 O
taking	838 6 O
warfarin	845 8 B-Chemical
.	853 1 O

Mutations	0 9 O
associated	10 10 O
with	21 4 O
lamivudine	26 10 B-Chemical
-	36 1 O
resistance	37 10 O
in	48 2 O
therapy	51 7 O
-	58 1 O
na	59 2 B-Chemical
ve	63 2 O
hepatitis	66 9 B-Disease
B	76 1 I-Disease
virus	78 5 I-Disease
(	84 1 I-Disease
HBV	85 3 I-Disease
)	88 1 I-Disease
infected	90 8 I-Disease
patients	99 8 O
with	108 4 O
and	113 3 O
without	117 7 O
HIV	125 3 B-Disease
co	129 2 I-Disease
-	131 1 I-Disease
infection	132 9 I-Disease
:	141 1 O
implications	143 12 O
for	156 3 O
antiretroviral	160 14 O
therapy	175 7 O
in	183 2 O
HBV	186 3 B-Disease
and	190 3 I-Disease
HIV	194 3 I-Disease
co	198 2 I-Disease
-	200 1 I-Disease
infected	201 8 I-Disease
South	210 5 O
African	216 7 O
patients	224 8 O
.	232 1 O

This	234 4 O
was	239 3 O
an	243 2 O
exploratory	246 11 O
study	258 5 O
to	264 2 O
investigate	267 11 O
lamivudine	279 10 B-Chemical
-	289 1 O
resistant	290 9 O
hepatitis	300 9 B-Disease
B	310 1 I-Disease
virus	312 5 O
(	318 1 O
HBV	319 3 O
)	322 1 O
strains	324 7 O
in	332 2 O
selected	335 8 O
lamivudine	344 10 B-Chemical
-	354 1 O
na	355 2 B-Chemical
ve	359 2 O
HBV	362 3 O
carriers	366 8 O
with	375 4 O
and	380 3 O
without	384 7 O
human	392 5 B-Disease
immunodeficiency	398 16 I-Disease
virus	415 5 I-Disease
(	421 1 I-Disease
HIV	422 3 I-Disease
)	425 1 I-Disease
co	427 2 I-Disease
-	429 1 I-Disease
infection	430 9 I-Disease
in	440 2 O
South	443 5 O
African	449 7 O
patients	457 8 O
.	465 1 O

Thirty	467 6 O
-	473 1 O
five	474 4 O
lamivudine	479 10 B-Chemical
-	489 1 O
na	490 2 B-Chemical
ve	494 2 O
HBV	497 3 B-Disease
infected	501 8 I-Disease
patients	510 8 O
with	519 4 O
or	524 2 O
without	527 7 O
HIV	535 3 B-Disease
co	539 2 I-Disease
-	541 1 I-Disease
infection	542 9 I-Disease
were	552 4 O
studied	557 7 O
:	564 1 O
15	566 2 O
chronic	569 7 O
HBV	577 3 B-Disease
mono	581 4 I-Disease
-	585 1 I-Disease
infected	586 8 I-Disease
patients	595 8 O
and	604 3 O
20	608 2 O
HBV	611 3 B-Disease
-	614 1 I-Disease
HIV	615 3 I-Disease
co	619 2 I-Disease
-	621 1 I-Disease
infected	622 8 I-Disease
patients	631 8 O
.	639 1 O

The	641 3 O
latter	645 6 O
group	652 5 O
was	658 3 O
further	662 7 O
sub	670 3 O
-	673 1 O
divided	674 7 O
into	682 4 O
13	687 2 O
occult	690 6 O
HBV	697 3 O
(	701 1 O
HBsAg	702 5 B-Chemical
-	707 1 O
negative	708 8 O
)	716 1 O
and	718 3 O
7	722 1 O
overt	724 5 O
HBV	730 3 O
(	734 1 O
HBsAg	735 5 B-Chemical
-	740 1 O
positive	742 8 O
)	750 1 O
patients	752 8 O
.	760 1 O

HBsAg	762 5 B-Chemical
,	767 1 O
anti	769 4 O
-	773 1 O
HBs	774 3 O
,	777 1 O
anti	779 4 O
-	783 1 O
HBc	784 3 O
,	787 1 O
and	789 3 O
anti	793 4 O
-	797 1 O
HIV	798 3 O
1	802 1 O
/	803 1 O
2	804 1 O
were	806 4 O
determined	811 10 O
as	822 2 O
part	825 4 O
of	830 2 O
routine	833 7 O
diagnosis	841 9 O
using	851 5 O
Axsym	857 5 O
assays	863 6 O
(	870 1 O
Abbott	871 6 O
Laboratories	878 12 O
,	890 1 O
North	892 5 O
Chicago	898 7 O
,	905 1 O
IL	907 2 O
)	909 1 O
.	910 1 O

Serum	912 5 O
samples	918 7 O
were	926 4 O
PCR	931 3 O
amplified	935 9 O
with	945 4 O
HBV	950 3 O
reverse	954 7 O
transcriptase	962 13 O
(	976 1 O
RT	977 2 O
)	979 1 O
primers	981 7 O
,	988 1 O
followed	990 8 O
by	999 2 O
direct	1002 6 O
sequencing	1009 10 O
across	1020 6 O
the	1027 3 O
tyrosine	1031 8 B-Chemical
-	1039 1 O
methionine	1040 10 B-Chemical
-	1050 1 O
aspartate	1051 9 B-Chemical
-	1060 1 O
aspartate	1061 9 B-Chemical
(	1071 1 O
YMDD	1072 4 O
)	1076 1 O
motif	1078 5 O
of	1084 2 O
the	1087 3 O
major	1091 5 O
catalytic	1097 9 O
region	1107 6 O
in	1114 2 O
the	1117 3 O
C	1121 1 O
domain	1123 6 O
of	1130 2 O
the	1133 3 O
HBV	1137 3 O
RT	1141 2 O
enzyme	1144 6 O
.	1150 1 O

HBV	1152 3 O
viral	1156 5 O
load	1162 4 O
was	1167 3 O
performed	1171 9 O
with	1181 4 O
Amplicor	1186 8 O
HBV	1195 3 O
Monitor	1199 7 O
test	1207 4 O
v2	1212 2 O
.	1214 1 O
0	1215 1 O
(	1217 1 O
Roche	1218 5 O
Diagnostics	1224 11 O
,	1235 1 O
Penzberg	1237 8 O
,	1245 1 O
Germany	1247 7 O
)	1254 1 O
.	1255 1 O

HBV	1257 3 O
lamivudine	1261 10 B-Chemical
-	1271 1 O
resistant	1272 9 O
strains	1282 7 O
were	1290 4 O
detected	1295 8 O
in	1304 2 O
3	1307 1 O
of	1309 2 O
15	1312 2 O
mono	1315 4 O
-	1319 1 O
infected	1320 8 O
chronic	1329 7 O
hepatitis	1337 9 B-Disease
B	1347 1 I-Disease
patients	1349 8 O
and	1358 3 O
10	1362 2 O
of	1365 2 O
20	1368 2 O
HBV	1371 3 B-Disease
-	1374 1 I-Disease
HIV	1375 3 I-Disease
co	1379 2 I-Disease
-	1381 1 I-Disease
infected	1382 8 I-Disease
patients	1391 8 O
.	1399 1 O

To	1401 2 O
the	1404 3 O
best	1408 4 O
of	1413 2 O
our	1416 3 O
knowledge	1420 9 O
,	1429 1 O
this	1431 4 O
constitutes	1436 11 O
the	1448 3 O
first	1452 5 O
report	1458 6 O
of	1465 2 O
HBV	1468 3 O
lamivudine	1472 10 B-Chemical
-	1482 1 O
resistant	1483 9 O
strains	1493 7 O
in	1501 2 O
therapy	1504 7 O
-	1511 1 O
na	1512 2 B-Chemical
ve	1516 2 O
HBV	1519 3 B-Disease
-	1522 1 I-Disease
HIV	1523 3 I-Disease
co	1527 2 I-Disease
-	1529 1 I-Disease
infected	1530 8 I-Disease
patients	1539 8 O
.	1547 1 O

The	1549 3 O
HBV	1553 3 O
viral	1557 5 O
loads	1563 5 O
for	1569 3 O
mono	1573 4 O
-	1577 1 O
infected	1578 8 O
and	1587 3 O
co	1591 2 O
-	1593 1 O
infected	1594 8 O
patients	1603 8 O
ranged	1612 6 O
from	1619 4 O
3	1624 1 O
.	1625 1 O
32	1626 2 O
x	1629 1 O
10	1631 2 O
(	1633 1 O
2	1634 1 O
)	1635 1 O
to	1637 2 O
3	1640 1 O
.	1641 1 O
82	1642 2 O
x	1645 1 O
10	1647 2 O
(	1649 1 O
7	1650 1 O
)	1651 1 O
and	1653 3 O
<	1657 1 O
200	1658 3 O
to	1662 2 O
4	1665 1 O
.	1666 1 O
40	1667 2 O
x	1670 1 O
10	1672 2 O
(	1674 1 O
3	1675 1 O
)	1676 1 O
copies	1678 6 O
/	1684 1 O
ml	1685 2 O
,	1687 1 O
respectively	1689 12 O
.	1701 1 O

It	1703 2 O
remains	1706 7 O
to	1714 2 O
be	1717 2 O
seen	1720 4 O
whether	1725 7 O
such	1733 4 O
pre	1738 3 O
-	1741 1 O
existing	1742 8 O
antiviral	1751 9 O
mutations	1761 9 O
could	1771 5 O
result	1777 6 O
in	1784 2 O
widespread	1787 10 O
emergence	1798 9 O
of	1808 2 O
HBV	1811 3 O
resistant	1815 9 O
strains	1825 7 O
when	1833 4 O
lamivudine	1838 10 B-Chemical
-	1848 1 O
containing	1849 10 O
highly	1860 6 O
active	1867 6 O
antiretroviral	1874 14 O
(	1889 1 O
ARV	1890 3 O
)	1893 1 O
treatment	1895 9 O
(	1905 1 O
HAART	1906 5 O
)	1911 1 O
regimens	1913 8 O
become	1922 6 O
widely	1929 6 O
applied	1936 7 O
in	1944 2 O
South	1947 5 O
Africa	1953 6 O
,	1959 1 O
as	1961 2 O
this	1964 4 O
is	1969 2 O
likely	1972 6 O
to	1979 2 O
have	1982 4 O
potential	1987 9 O
implications	1997 12 O
in	2010 2 O
the	2013 3 O
management	2017 10 O
of	2028 2 O
HBV	2031 3 B-Disease
-	2034 1 I-Disease
HIV	2035 3 I-Disease
co	2039 2 I-Disease
-	2041 1 I-Disease
infected	2042 8 I-Disease
patients	2051 8 O
.	2059 1 O

Sex	0 3 O
differences	4 11 O
in	16 2 O
NMDA	19 4 B-Chemical
antagonist	24 10 O
enhancement	35 11 O
of	47 2 O
morphine	50 8 B-Chemical
antihyperalgesia	59 16 O
in	76 2 O
a	79 1 O
capsaicin	81 9 B-Chemical
model	91 5 O
of	97 2 O
persistent	100 10 O
pain	111 4 B-Disease
:	115 1 O
comparisons	117 11 O
to	129 2 O
two	132 3 O
models	136 6 O
of	143 2 O
acute	146 5 B-Disease
pain	152 4 I-Disease
.	156 1 O

In	158 2 O
acute	161 5 B-Disease
pain	167 4 I-Disease
models	172 6 O
,	178 1 O
N	180 1 B-Chemical
-	181 1 I-Chemical
methyl	182 6 I-Chemical
-	188 1 I-Chemical
D	189 1 I-Chemical
-	190 1 I-Chemical
aspartate	191 9 I-Chemical
(	201 1 O
NMDA	202 4 B-Chemical
)	206 1 O
antagonists	208 11 O
enhance	220 7 O
the	228 3 O
antinociceptive	232 15 O
effects	248 7 O
of	256 2 O
morphine	259 8 B-Chemical
to	268 2 O
a	271 1 O
greater	273 7 O
extent	281 6 O
in	288 2 O
males	291 5 O
than	297 4 O
females	302 7 O
.	309 1 O

The	311 3 O
purpose	315 7 O
of	323 2 O
this	326 4 O
investigation	331 13 O
was	345 3 O
to	349 2 O
extend	352 6 O
these	359 5 O
findings	365 8 O
to	374 2 O
a	377 1 O
persistent	379 10 O
pain	390 4 B-Disease
model	395 5 O
which	401 5 O
could	407 5 O
be	413 2 O
distinguished	416 13 O
from	430 4 O
acute	435 5 B-Disease
pain	441 4 I-Disease
models	446 6 O
on	453 2 O
the	456 3 O
basis	460 5 O
of	466 2 O
the	469 3 O
nociceptive	473 11 O
fibers	485 6 O
activated	492 9 O
,	501 1 O
neurochemical	503 13 O
substrates	517 10 O
,	527 1 O
and	529 3 O
duration	533 8 O
of	542 2 O
the	545 3 O
nociceptive	549 11 O
stimulus	561 8 O
.	569 1 O

To	571 2 O
this	574 4 O
end	579 3 O
,	582 1 O
persistent	584 10 O
hyperalgesia	595 12 B-Disease
was	608 3 O
induced	612 7 O
by	620 2 O
administration	623 14 O
of	638 2 O
capsaicin	641 9 B-Chemical
in	651 2 O
the	654 3 O
tail	658 4 O
of	663 2 O
gonadally	666 9 O
intact	676 6 O
F344	683 4 O
rats	688 4 O
,	692 1 O
following	694 9 O
which	704 5 O
the	710 3 O
tail	714 4 O
was	719 3 O
immersed	723 8 O
in	732 2 O
a	735 1 O
mildly	737 6 O
noxious	744 7 O
thermal	752 7 O
stimulus	760 8 O
,	768 1 O
and	770 3 O
tail	774 4 O
-	778 1 O
withdrawal	779 10 O
latencies	790 9 O
measured	800 8 O
.	808 1 O

For	810 3 O
comparison	814 10 O
,	824 1 O
tests	826 5 O
were	832 4 O
conducted	837 9 O
in	847 2 O
two	850 3 O
acute	854 5 B-Disease
pain	860 4 I-Disease
models	865 6 O
,	871 1 O
the	873 3 O
hotplate	877 8 O
and	886 3 O
warm	890 4 O
water	895 5 O
tail	901 4 O
-	905 1 O
withdrawal	906 10 O
procedures	917 10 O
.	927 1 O

In	929 2 O
males	932 5 O
,	937 1 O
the	939 3 O
non	943 3 O
-	946 1 O
competitive	947 11 O
NMDA	959 4 B-Chemical
antagonist	964 10 O
dextromethorphan	975 16 B-Chemical
enhanced	992 8 O
the	1001 3 O
antihyperalgesic	1005 16 O
effect	1022 6 O
of	1029 2 O
low	1032 3 O
to	1036 2 O
moderate	1039 8 O
doses	1048 5 O
of	1054 2 O
morphine	1057 8 B-Chemical
in	1066 2 O
a	1069 1 O
dose	1071 4 O
-	1075 1 O
and	1076 3 O
time	1080 4 O
-	1084 1 O
dependent	1085 9 O
manner	1095 6 O
.	1101 1 O

Across	1103 6 O
the	1110 3 O
doses	1114 5 O
and	1120 3 O
pretreatment	1124 12 O
times	1137 5 O
examined	1143 8 O
,	1151 1 O
enhancement	1153 11 O
was	1165 3 O
not	1169 3 O
observed	1173 8 O
in	1182 2 O
females	1185 7 O
.	1192 1 O

Enhancement	1194 11 O
of	1206 2 O
morphine	1209 8 B-Chemical
antinociception	1218 15 O
by	1234 2 O
dextromethorphan	1237 16 B-Chemical
was	1254 3 O
seen	1258 4 O
in	1263 2 O
both	1266 4 O
males	1271 5 O
and	1277 3 O
females	1281 7 O
in	1289 2 O
the	1292 3 O
acute	1296 5 B-Disease
pain	1302 4 I-Disease
models	1307 6 O
,	1313 1 O
with	1315 4 O
the	1320 3 O
magnitude	1324 9 O
of	1334 2 O
this	1337 4 O
effect	1342 6 O
being	1349 5 O
greater	1355 7 O
in	1363 2 O
males	1366 5 O
.	1371 1 O

These	1373 5 O
findings	1379 8 O
demonstrate	1388 11 O
a	1400 1 O
sexually	1402 8 O
-	1410 1 O
dimorphic	1411 9 O
interaction	1421 11 O
between	1433 7 O
NMDA	1441 4 B-Chemical
antagonists	1446 11 O
and	1458 3 O
morphine	1462 8 B-Chemical
in	1471 2 O
a	1474 1 O
persistent	1476 10 O
pain	1487 4 B-Disease
model	1492 5 O
that	1498 4 O
can	1503 3 O
be	1507 2 O
distinguished	1510 13 O
from	1524 4 O
those	1529 5 O
observed	1535 8 O
in	1544 2 O
acute	1547 5 B-Disease
pain	1553 4 I-Disease
models	1558 6 O
.	1564 1 O

Development	0 11 O
of	12 2 O
proteinuria	15 11 B-Disease
after	27 5 O
switch	33 6 O
to	40 2 O
sirolimus	43 9 B-Chemical
-	52 1 O
based	53 5 O
immunosuppression	59 17 O
in	77 2 O
long	80 4 O
-	84 1 O
term	85 4 O
cardiac	90 7 O
transplant	98 10 O
patients	109 8 O
.	117 1 O

Calcineurin	119 11 O
-	130 1 O
inhibitor	131 9 O
therapy	141 7 O
can	149 3 O
lead	153 4 O
to	158 2 O
renal	161 5 B-Disease
dysfunction	167 11 I-Disease
in	179 2 O
heart	182 5 O
transplantation	188 15 O
patients	204 8 O
.	212 1 O

The	214 3 O
novel	218 5 O
immunosuppressive	224 17 O
(	242 1 O
IS	243 2 O
)	245 1 O
drug	247 4 O
sirolmus	252 8 B-Chemical
(	261 1 O
Srl	262 3 B-Chemical
)	265 1 O
lacks	267 5 O
nephrotoxic	273 11 B-Disease
effects	285 7 O
;	292 1 O
however	294 7 O
,	301 1 O
proteinuria	303 11 B-Disease
associated	315 10 O
with	326 4 O
Srl	331 3 B-Chemical
has	335 3 O
been	339 4 O
reported	344 8 O
following	353 9 O
renal	363 5 O
transplantation	369 15 O
.	384 1 O

In	386 2 O
cardiac	389 7 O
transplantation	397 15 O
,	412 1 O
the	414 3 O
incidence	418 9 O
of	428 2 O
proteinuria	431 11 B-Disease
associated	443 10 O
with	454 4 O
Srl	459 3 B-Chemical
is	463 2 O
unknown	466 7 O
.	473 1 O

In	475 2 O
this	478 4 O
study	483 5 O
,	488 1 O
long	490 4 O
-	494 1 O
term	495 4 O
cardiac	500 7 O
transplant	508 10 O
patients	519 8 O
were	528 4 O
switched	533 8 O
from	542 4 O
cyclosporine	547 12 B-Chemical
to	560 2 O
Srl	563 3 B-Chemical
-	566 1 O
based	567 5 O
IS	573 2 O
.	575 1 O

Concomitant	577 11 O
IS	589 2 O
consisted	592 9 O
of	602 2 O
mycophenolate	605 13 B-Chemical
mofetil	619 7 I-Chemical
+	627 1 O
/	628 1 O
-	629 1 O
steroids	631 8 B-Chemical
.	639 1 O

Proteinuria	641 11 O
increased	653 9 O
significantly	663 13 O
from	677 4 O
a	682 1 O
median	684 6 O
of	691 2 O
0	694 1 O
.	695 1 O
13	696 2 O
g	699 1 O
/	700 1 O
day	701 3 O
(	705 1 O
range	706 5 O
0	712 1 O
-	713 1 O
5	714 1 O
.	715 1 O
7	716 1 O
)	717 1 O
preswitch	719 9 O
to	729 2 O
0	732 1 O
.	733 1 O
23	734 2 O
g	737 1 O
/	738 1 O
day	739 3 O
(	743 1 O
0	744 1 O
-	745 1 O
9	746 1 O
.	747 1 O
88	748 2 O
)	750 1 O
at	752 2 O
24	755 2 O
months	758 6 O
postswitch	765 10 O
(	776 1 O
p	777 1 O
=	779 1 O
0	781 1 O
.	782 1 O
0024	783 4 O
)	787 1 O
.	788 1 O

Before	790 6 O
the	797 3 O
switch	801 6 O
,	807 1 O
11	809 2 O
.	811 1 O
5	812 1 O
%	813 1 O
of	815 2 O
patients	818 8 O
had	827 3 O
high	831 4 O
-	835 1 O
grade	836 5 O
proteinuria	842 11 B-Disease
(	854 1 O
>	855 1 O
1	856 1 O
.	857 1 O
0	858 1 O
g	860 1 O
/	861 1 O
day	862 3 O
)	865 1 O
;	866 1 O
this	868 4 O
increased	873 9 O
to	883 2 O
22	886 2 O
.	888 1 O
9	889 1 O
%	890 1 O
postswitch	892 10 O
(	903 1 O
p	904 1 O
=	906 1 O
0	908 1 O
.	909 1 O
006	910 3 O
)	913 1 O
.	914 1 O

ACE	916 3 B-Chemical
inhibitor	920 9 I-Chemical
and	930 3 O
angiotensin	934 11 B-Chemical
-	945 1 I-Chemical
releasing	946 9 I-Chemical
blocker	956 7 I-Chemical
(	964 1 O
ARB	965 3 B-Chemical
)	968 1 O
therapy	970 7 O
reduced	978 7 O
proteinuria	986 11 B-Disease
development	998 11 O
.	1009 1 O

Patients	1011 8 O
without	1020 7 O
proteinuria	1028 11 B-Disease
had	1040 3 O
increased	1044 9 O
renal	1054 5 O
function	1060 8 O
(	1069 1 O
median	1070 6 O
42	1077 2 O
.	1079 1 O
5	1080 1 O
vs	1082 2 O
.	1084 1 O
64	1086 2 O
.	1088 1 O
1	1089 1 O
,	1090 1 O
p	1092 1 O
=	1094 1 O
0	1096 1 O
.	1097 1 O
25	1098 2 O
)	1100 1 O
,	1101 1 O
whereas	1103 7 O
patients	1111 8 O
who	1120 3 O
developed	1124 9 O
high	1134 4 O
-	1138 1 O
grade	1139 5 O
proteinuria	1145 11 B-Disease
showed	1157 6 O
decreased	1164 9 O
renal	1174 5 O
function	1180 8 O
at	1189 2 O
the	1192 3 O
end	1196 3 O
of	1200 2 O
follow	1203 6 O
-	1209 1 O
up	1210 2 O
(	1213 1 O
median	1214 6 O
39	1221 2 O
.	1223 1 O
6	1224 1 O
vs	1226 2 O
.	1228 1 O
29	1230 2 O
.	1232 1 O
2	1233 1 O
,	1234 1 O
p	1236 1 O
=	1238 1 O
0	1240 1 O
.	1241 1 O
125	1242 3 O
)	1245 1 O
.	1246 1 O

Thus	1248 4 O
,	1252 1 O
proteinuria	1254 11 B-Disease
may	1266 3 O
develop	1270 7 O
in	1278 2 O
cardiac	1281 7 O
transplant	1289 10 O
patients	1300 8 O
after	1309 5 O
switch	1315 6 O
to	1322 2 O
Srl	1325 3 B-Chemical
,	1328 1 O
which	1330 5 O
may	1336 3 O
have	1340 4 O
an	1345 2 O
adverse	1348 7 O
effect	1356 6 O
on	1363 2 O
renal	1366 5 O
function	1372 8 O
in	1381 2 O
these	1384 5 O
patients	1390 8 O
.	1398 1 O

Srl	1400 3 B-Chemical
should	1404 6 O
be	1411 2 O
used	1414 4 O
with	1419 4 O
ACEi	1424 4 B-Chemical
/	1428 1 O
ARB	1429 3 B-Chemical
therapy	1433 7 O
and	1441 3 O
patients	1445 8 O
monitored	1454 9 O
for	1464 3 O
proteinuria	1468 11 B-Disease
and	1480 3 O
increased	1484 9 O
renal	1494 5 B-Disease
dysfunction	1500 11 I-Disease
.	1511 1 O

Synthesis	0 9 O
of	10 2 O
N	13 1 B-Chemical
-	14 1 I-Chemical
pyrimidinyl	15 11 I-Chemical
-	26 1 I-Chemical
2	27 1 I-Chemical
-	28 1 I-Chemical
phenoxyacetamides	29 17 I-Chemical
as	47 2 O
adenosine	50 9 B-Chemical
A2A	60 3 O
receptor	64 8 O
antagonists	73 11 O
.	84 1 O

A	86 1 O
series	88 6 O
of	95 2 O
N	98 1 B-Chemical
-	99 1 I-Chemical
pyrimidinyl	100 11 I-Chemical
-	111 1 I-Chemical
2	112 1 I-Chemical
-	113 1 I-Chemical
phenoxyacetamide	114 16 I-Chemical
adenosine	131 9 B-Chemical
A	141 1 O
(	142 1 O
2A	143 2 O
)	145 1 O
antagonists	147 11 O
is	159 2 O
described	162 9 O
.	171 1 O

SAR	173 3 O
studies	177 7 O
led	185 3 O
to	189 2 O
compound	192 8 O
14	201 2 O
with	204 4 O
excellent	209 9 O
potency	219 7 O
(	227 1 O
K	228 1 O
(	229 1 O
i	230 1 O
)	231 1 O
=	233 1 O
0	235 1 O
.	236 1 O
4	237 1 O
nM	239 2 O
)	241 1 O
,	242 1 O
selectivity	244 11 O
(	256 1 O
A	257 1 O
(	258 1 O
1	259 1 O
)	260 1 O
/	261 1 O
A	262 1 O
(	263 1 O
2A	264 2 O
)	266 1 O
>	268 1 O
100	270 3 O
)	273 1 O
,	274 1 O
and	276 3 O
efficacy	280 8 O
(	289 1 O
MED	290 3 O
10	294 2 O
mg	297 2 O
/	299 1 O
kg	300 2 O
p	303 1 O
.	304 1 O
o	305 1 O
.	306 1 O
)	307 1 O
in	309 2 O
the	312 3 O
rat	316 3 O
haloperidol	320 11 B-Chemical
-	331 1 O
induced	332 7 O
catalepsy	340 9 B-Disease
model	350 5 O
for	356 3 O
Parkinson	360 9 B-Disease
'	369 1 I-Disease
s	370 1 I-Disease
disease	372 7 I-Disease
.	379 1 O

Methamphetamine	0 15 B-Chemical
-	15 1 O
induced	16 7 O
neurotoxicity	24 13 B-Disease
and	38 3 O
microglial	42 10 O
activation	53 10 O
are	64 3 O
not	68 3 O
mediated	72 8 O
by	81 2 O
fractalkine	84 11 O
receptor	96 8 O
signaling	105 9 O
.	114 1 O

Methamphetamine	116 15 B-Chemical
(	132 1 O
METH	133 4 B-Chemical
)	137 1 O
damages	139 7 O
dopamine	147 8 B-Chemical
(	156 1 O
DA	157 2 B-Chemical
)	159 1 O
nerve	161 5 O
endings	167 7 O
by	175 2 O
a	178 1 O
process	180 7 O
that	188 4 O
has	193 3 O
been	197 4 O
linked	202 6 O
to	209 2 O
microglial	212 10 O
activation	223 10 O
but	234 3 O
the	238 3 O
signaling	242 9 O
pathways	252 8 O
that	261 4 O
mediate	266 7 O
this	274 4 O
response	279 8 O
have	288 4 O
not	293 3 O
yet	297 3 O
been	301 4 O
delineated	306 10 O
.	316 1 O

Cardona	318 7 O
et	326 2 O
al	329 2 O
.	331 1 O

[	333 1 O
Nat	334 3 O
.	337 1 O
Neurosci	339 8 O
.	347 1 O
9	349 1 O
(	351 1 O
2006	352 4 O
)	356 1 O
,	357 1 O
917	359 3 O
]	362 1 O
recently	364 8 O
identified	373 10 O
the	384 3 O
microglial	388 10 O
-	398 1 O
specific	399 8 O
fractalkine	408 11 O
receptor	420 8 O
(	429 1 O
CX3CR1	430 6 O
)	436 1 O
as	438 2 O
an	441 2 O
important	444 9 O
mediator	454 8 O
of	463 2 O
MPTP	466 4 B-Chemical
-	470 1 O
induced	471 7 O
neurodegeneration	479 17 B-Disease
of	497 2 O
DA	500 2 B-Chemical
neurons	503 7 O
.	510 1 O

Because	512 7 O
the	520 3 O
CNS	524 3 B-Disease
damage	528 6 I-Disease
caused	535 6 O
by	542 2 O
METH	545 4 B-Chemical
and	550 3 O
MPTP	554 4 B-Chemical
is	559 2 O
highly	562 6 O
selective	569 9 O
for	579 3 O
the	583 3 O
DA	587 2 B-Chemical
neuronal	590 8 O
system	599 6 O
in	606 2 O
mouse	609 5 O
models	615 6 O
of	622 2 O
neurotoxicity	625 13 B-Disease
,	638 1 O
we	640 2 O
hypothesized	643 12 O
that	656 4 O
the	661 3 O
CX3CR1	665 6 O
plays	672 5 O
a	678 1 O
role	680 4 O
in	685 2 O
METH	688 4 B-Chemical
-	692 1 O
induced	693 7 O
neurotoxicity	701 13 B-Disease
and	715 3 O
microglial	719 10 O
activation	730 10 O
.	740 1 O

Mice	742 4 O
in	747 2 O
which	750 5 O
the	756 3 O
CX3CR1	760 6 O
gene	767 4 O
has	772 3 O
been	776 4 O
deleted	781 7 O
and	789 3 O
replaced	793 8 O
with	802 4 O
a	807 1 O
cDNA	809 4 O
encoding	814 8 O
enhanced	823 8 O
green	832 5 O
fluorescent	838 11 O
protein	850 7 O
(	858 1 O
eGFP	859 4 O
)	863 1 O
were	865 4 O
treated	870 7 O
with	878 4 O
METH	883 4 B-Chemical
and	888 3 O
examined	892 8 O
for	901 3 O
striatal	905 8 O
neurotoxicity	914 13 B-Disease
.	927 1 O

METH	929 4 B-Chemical
depleted	934 8 O
DA	943 2 B-Chemical
,	945 1 O
caused	947 6 O
microglial	954 10 O
activation	965 10 O
,	975 1 O
and	977 3 O
increased	981 9 O
body	991 4 O
temperature	996 11 O
in	1008 2 O
CX3CR1	1011 6 O
knockout	1018 8 O
mice	1027 4 O
to	1032 2 O
the	1035 3 O
same	1039 4 O
extent	1044 6 O
and	1051 3 O
over	1055 4 O
the	1060 3 O
same	1064 4 O
time	1069 4 O
course	1074 6 O
seen	1081 4 O
in	1086 2 O
wild	1089 4 O
-	1093 1 O
type	1094 4 O
controls	1099 8 O
.	1107 1 O

The	1109 3 O
effects	1113 7 O
of	1121 2 O
METH	1124 4 B-Chemical
in	1129 2 O
CX3CR1	1132 6 O
knockout	1139 8 O
mice	1148 4 O
were	1153 4 O
not	1158 3 O
gender	1162 6 O
-	1168 1 O
dependent	1169 9 O
and	1179 3 O
did	1183 3 O
not	1187 3 O
extend	1191 6 O
beyond	1198 6 O
the	1205 3 O
striatum	1209 8 O
.	1217 1 O

Striatal	1219 8 O
microglia	1228 9 O
expressing	1238 10 O
eGFP	1249 4 O
constitutively	1254 14 O
show	1269 4 O
morphological	1274 13 O
changes	1288 7 O
after	1296 5 O
METH	1302 4 B-Chemical
that	1307 4 O
are	1312 3 O
characteristic	1316 14 O
of	1331 2 O
activation	1334 10 O
.	1344 1 O

This	1346 4 O
response	1351 8 O
was	1360 3 O
restricted	1364 10 O
to	1375 2 O
the	1378 3 O
striatum	1382 8 O
and	1391 3 O
contrasted	1395 10 O
sharply	1406 7 O
with	1414 4 O
unresponsive	1419 12 O
eGFP	1432 4 O
-	1436 1 O
microglia	1437 9 O
in	1447 2 O
surrounding	1450 11 O
brain	1462 5 O
areas	1468 5 O
that	1474 4 O
are	1479 3 O
not	1483 3 O
damaged	1487 7 O
by	1495 2 O
METH	1498 4 B-Chemical
.	1502 1 O

We	1504 2 O
conclude	1507 8 O
from	1516 4 O
these	1521 5 O
studies	1527 7 O
that	1535 4 O
CX3CR1	1540 6 O
signaling	1547 9 O
does	1557 4 O
not	1562 3 O
modulate	1566 8 O
METH	1575 4 B-Chemical
neurotoxicity	1580 13 B-Disease
or	1594 2 O
microglial	1597 10 O
activation	1608 10 O
.	1618 1 O

Furthermore	1620 11 O
,	1631 1 O
it	1633 2 O
appears	1636 7 O
that	1644 4 O
striatal	1649 8 O
-	1657 1 O
resident	1658 8 O
microglia	1667 9 O
respond	1677 7 O
to	1685 2 O
METH	1688 4 B-Chemical
with	1693 4 O
an	1698 2 O
activation	1701 10 O
cascade	1712 7 O
and	1720 3 O
then	1724 4 O
return	1729 6 O
to	1736 2 O
a	1739 1 O
surveying	1741 9 O
state	1751 5 O
without	1757 7 O
undergoing	1765 10 O
apoptosis	1776 9 O
or	1786 2 O
migration	1789 9 O
.	1798 1 O

Recovery	0 8 O
of	9 2 O
tacrolimus	12 10 B-Chemical
-	22 1 O
associated	23 10 O
brachial	34 8 B-Disease
neuritis	43 8 I-Disease
after	52 5 O
conversion	58 10 O
to	69 2 O
everolimus	72 10 B-Chemical
in	83 2 O
a	86 1 O
pediatric	88 9 O
renal	98 5 O
transplant	104 10 O
recipient	115 9 O
-	124 1 O
-	125 1 O
case	126 4 O
report	131 6 O
and	138 3 O
review	142 6 O
of	149 2 O
the	152 3 O
literature	156 10 O
.	166 1 O

TAC	168 3 B-Chemical
has	172 3 O
been	176 4 O
shown	181 5 O
to	187 2 O
be	190 2 O
a	193 1 O
potent	195 6 O
immunosuppressive	202 17 O
agent	220 5 O
for	226 3 O
solid	230 5 O
organ	236 5 O
transplantation	242 15 O
in	258 2 O
pediatrics	261 10 O
.	271 1 O

Neurotoxicity	273 13 B-Disease
is	287 2 O
a	290 1 O
potentially	292 11 O
serious	304 7 O
toxic	312 5 O
effect	318 6 O
.	324 1 O

It	326 2 O
is	329 2 O
characterized	332 13 O
by	346 2 O
encephalopathy	349 14 B-Disease
,	363 1 O
headaches	365 9 B-Disease
,	374 1 O
seizures	376 8 B-Disease
,	384 1 O
or	386 2 O
neurological	389 12 B-Disease
deficits	402 8 I-Disease
.	410 1 O

Here	412 4 O
,	416 1 O
we	418 2 O
describe	421 8 O
an	430 2 O
eight	433 5 O
-	438 1 O
and	439 3 O
-	442 1 O
a	443 1 O
-	444 1 O
half	445 4 O
-	449 1 O
yr	450 2 O
-	452 1 O
old	453 3 O
male	457 4 O
renal	462 5 O
transplant	468 10 O
recipient	479 9 O
with	489 4 O
right	494 5 O
BN	500 2 O
.	502 1 O

MRI	504 3 O
demonstrated	508 12 O
hyperintense	521 12 O
T2	534 2 O
signals	537 7 O
in	545 2 O
the	548 3 O
cervical	552 8 O
cord	561 4 O
and	566 3 O
right	570 5 O
brachial	576 8 O
plexus	585 6 O
roots	592 5 O
indicative	598 10 O
of	609 2 O
both	612 4 O
myelitis	617 8 B-Disease
and	626 3 O
right	630 5 O
brachial	636 8 B-Disease
plexitis	645 8 I-Disease
.	653 1 O

Symptoms	655 8 O
persisted	664 9 O
for	674 3 O
three	678 5 O
months	684 6 O
despite	691 7 O
TAC	699 3 B-Chemical
dose	703 4 O
reduction	708 9 O
,	717 1 O
administration	719 14 O
of	734 2 O
IVIG	737 4 O
and	742 3 O
four	746 4 O
doses	751 5 O
of	757 2 O
methylprednisolone	760 18 B-Chemical
pulse	779 5 O
therapy	785 7 O
.	792 1 O

Improvement	794 11 O
and	806 3 O
eventually	810 10 O
full	821 4 O
recovery	826 8 O
only	835 4 O
occurred	840 8 O
after	849 5 O
TAC	855 3 B-Chemical
was	859 3 O
completely	863 10 O
discontinued	874 12 O
and	887 3 O
successfully	891 12 O
replaced	904 8 O
by	913 2 O
everolimus	916 10 B-Chemical
.	926 1 O

Valvular	0 8 B-Disease
heart	9 5 I-Disease
disease	15 7 I-Disease
in	23 2 O
patients	26 8 O
with	35 4 O
Parkinson	40 9 B-Disease
'	49 1 I-Disease
s	50 1 I-Disease
disease	52 7 I-Disease
treated	60 7 O
with	68 4 O
pergolide	73 9 B-Chemical
.	82 1 O

Course	84 6 O
following	91 9 O
treatment	101 9 O
modifications	111 13 O
.	124 1 O

Valvular	126 8 B-Disease
heart	135 5 I-Disease
abnormalities	141 13 I-Disease
have	155 4 O
been	160 4 O
reported	165 8 O
in	174 2 O
patients	177 8 O
with	186 4 O
Parkinson	191 9 B-Disease
'	200 1 I-Disease
s	201 1 I-Disease
disease	203 7 I-Disease
(	211 1 O
PD	212 2 B-Disease
)	214 1 O
treated	216 7 O
with	224 4 O
pergolide	229 9 B-Chemical
.	238 1 O

However	240 7 O
,	247 1 O
the	249 3 O
incidence	253 9 O
and	263 3 O
severity	267 8 O
of	276 2 O
these	279 5 O
abnormalities	285 13 O
vary	299 4 O
from	304 4 O
study	309 5 O
to	315 2 O
study	318 5 O
and	324 3 O
their	328 5 O
course	334 6 O
after	341 5 O
drug	347 4 O
withdrawal	352 10 O
has	363 3 O
not	367 3 O
been	371 4 O
systematically	376 14 O
assessed	391 8 O
.	399 1 O

OBJECTIVES	401 10 O
:	411 1 O
To	413 2 O
estimate	416 8 O
the	425 3 O
frequency	429 9 O
and	439 3 O
severity	443 8 O
of	452 2 O
valvular	455 8 B-Disease
heart	464 5 I-Disease
abnormality	470 11 I-Disease
and	482 3 O
its	486 3 O
possible	490 8 O
reversibility	499 13 O
after	513 5 O
drug	519 4 O
withdrawal	524 10 O
in	535 2 O
a	538 1 O
case	540 4 O
-	544 1 O
control	545 7 O
study	553 5 O
.	558 1 O

METHODS	560 7 O
:	567 1 O
All	569 3 O
PD	573 2 B-Disease
patients	576 8 O
in	585 2 O
the	588 3 O
Amiens	592 6 O
area	599 4 O
treated	604 7 O
with	612 4 O
pergolide	617 9 B-Chemical
were	627 4 O
invited	632 7 O
to	640 2 O
attend	643 6 O
a	650 1 O
cardiologic	652 11 O
assessment	664 10 O
including	675 9 O
transthoracic	685 13 O
echocardiography	699 16 O
.	715 1 O

Thirty	717 6 O
PD	724 2 B-Disease
patients	727 8 O
participated	736 12 O
in	749 2 O
the	752 3 O
study	756 5 O
.	761 1 O

A	763 1 O
second	765 6 O
echocardiography	772 16 O
was	789 3 O
performed	793 9 O
(	803 1 O
median	804 6 O
interval	811 8 O
:	819 1 O
13	821 2 O
months	824 6 O
)	830 1 O
after	832 5 O
pergolide	838 9 B-Chemical
withdrawal	848 10 O
(	859 1 O
n	860 1 O
=	861 1 O
10	862 2 O
patients	865 8 O
)	873 1 O
.	874 1 O

Controls	876 8 O
were	885 4 O
age	890 3 O
-	893 1 O
and	895 3 O
sex	899 3 O
-	902 1 O
matched	903 7 O
non	911 3 O
-	914 1 O
PD	915 2 B-Disease
patients	918 8 O
referred	927 8 O
to	936 2 O
the	939 3 O
cardiology	943 10 O
department	954 10 O
.	964 1 O

RESULTS	966 7 O
:	973 1 O
Compared	975 8 O
to	984 2 O
controls	987 8 O
,	995 1 O
aortic	997 6 B-Disease
regurgitation	1004 13 I-Disease
(	1018 1 O
OR	1019 2 O
:	1021 1 O
3	1023 1 O
.	1024 1 O
1	1025 1 O
;	1026 1 O
95	1028 2 O
%	1030 1 O
IC	1032 2 O
:	1034 1 O
1	1036 1 O
.	1037 1 O
1	1038 1 O
-	1039 1 O
8	1040 1 O
.	1041 1 O
8	1042 1 O
)	1043 1 O
and	1045 3 O
mitral	1049 6 B-Disease
regurgitation	1056 13 I-Disease
(	1070 1 O
OR	1071 2 O
:	1073 1 O
10	1075 2 O
.	1077 1 O
7	1078 1 O
;	1079 1 O
95	1081 2 O
%	1083 1 O
IC	1085 2 O
:	1087 1 O
2	1089 1 O
.	1090 1 O
1	1091 1 O
-	1092 1 O
53	1093 2 O
)	1095 1 O
were	1097 4 O
more	1102 4 O
frequent	1107 8 O
in	1116 2 O
PD	1119 2 B-Disease
patients	1122 8 O
(	1131 1 O
tricuspid	1132 9 O
:	1141 1 O
NS	1143 2 O
)	1145 1 O
.	1146 1 O

The	1148 3 O
number	1152 6 O
of	1159 2 O
affected	1162 8 O
valves	1171 6 O
(	1178 1 O
n	1179 1 O
=	1180 1 O
2	1181 1 O
.	1182 1 O
4	1183 1 O
+	1184 1 O
/	1185 1 O
-	1186 1 O
0	1187 1 O
.	1188 1 O
7	1189 1 O
)	1190 1 O
and	1192 3 O
the	1196 3 O
sum	1200 3 O
of	1204 2 O
regurgitation	1207 13 O
grades	1221 6 O
(	1228 1 O
n	1229 1 O
=	1230 1 O
2	1231 1 O
.	1232 1 O
8	1233 1 O
+	1234 1 O
/	1235 1 O
-	1236 1 O
1	1237 1 O
.	1238 1 O
09	1239 2 O
)	1241 1 O
were	1243 4 O
higher	1248 6 O
(	1255 1 O
p	1256 1 O
=	1257 1 O
0	1258 1 O
.	1259 1 O
008	1260 3 O
and	1264 3 O
p	1268 1 O
=	1269 1 O
0	1270 1 O
.	1271 1 O
006	1272 3 O
,	1275 1 O
respectively	1277 12 O
)	1289 1 O
in	1291 2 O
the	1294 3 O
pergolide	1298 9 B-Chemical
group	1308 5 O
.	1313 1 O

Severity	1315 8 O
of	1324 2 O
regurgitation	1327 13 O
was	1341 3 O
not	1345 3 O
correlated	1349 10 O
with	1360 4 O
pergolide	1365 9 B-Chemical
cumulative	1375 10 O
dose	1386 4 O
.	1390 1 O

A	1392 1 O
restrictive	1394 11 O
pattern	1406 7 O
of	1414 2 O
valvular	1417 8 B-Disease
regurgitation	1426 13 I-Disease
,	1439 1 O
suggestive	1441 10 O
of	1452 2 O
the	1455 3 O
role	1459 4 O
of	1464 2 O
pergolide	1467 9 B-Chemical
,	1476 1 O
was	1478 3 O
observed	1482 8 O
in	1491 2 O
12	1494 2 O
/	1496 1 O
30	1497 2 O
(	1500 1 O
40	1501 2 O
%	1503 1 O
)	1504 1 O
patients	1506 8 O
including	1515 9 O
two	1525 3 O
with	1529 4 O
heart	1534 5 B-Disease
failure	1540 7 I-Disease
.	1547 1 O

Pergolide	1549 9 B-Chemical
was	1559 3 O
discontinued	1563 12 O
in	1576 2 O
10	1579 2 O
patients	1582 8 O
with	1591 4 O
valvular	1596 8 B-Disease
heart	1605 5 I-Disease
disease	1611 7 I-Disease
,	1618 1 O
resulting	1620 9 O
in	1630 2 O
a	1633 1 O
lower	1635 5 O
regurgitation	1641 13 O
grade	1655 5 O
(	1661 1 O
p	1662 1 O
=	1663 1 O
0	1664 1 O
.	1665 1 O
01	1666 2 O
)	1668 1 O
at	1670 2 O
the	1673 3 O
second	1677 6 O
transthoracic	1684 13 O
echocardiography	1698 16 O
and	1715 3 O
the	1719 3 O
two	1723 3 O
patients	1727 8 O
with	1736 4 O
heart	1741 5 B-Disease
failure	1747 7 I-Disease
returned	1755 8 O
to	1764 2 O
nearly	1767 6 O
normal	1774 6 O
clinical	1781 8 O
examination	1790 11 O
.	1801 1 O

This	1803 4 O
study	1808 5 O
supports	1814 8 O
the	1823 3 O
high	1827 4 O
frequency	1832 9 O
of	1842 2 O
restrictive	1845 11 O
valve	1857 5 B-Disease
regurgitation	1863 13 I-Disease
in	1877 2 O
PD	1880 2 B-Disease
patients	1883 8 O
treated	1892 7 O
with	1900 4 O
pergolide	1905 9 B-Chemical
and	1915 3 O
reveals	1919 7 O
that	1927 4 O
a	1932 1 O
significant	1934 11 O
improvement	1946 11 O
is	1958 2 O
usual	1961 5 O
when	1967 4 O
the	1972 3 O
treatment	1976 9 O
is	1986 2 O
converted	1989 9 O
to	1999 2 O
non	2002 3 O
-	2005 1 O
ergot	2006 5 O
dopamine	2012 8 B-Chemical
agonists	2021 8 O
.	2029 1 O

Adverse	0 7 O
effects	8 7 O
of	16 2 O
topical	19 7 O
papaverine	27 10 B-Chemical
on	38 2 O
auditory	41 8 O
nerve	50 5 O
function	56 8 O
.	64 1 O

BACKGROUND	66 10 O
:	76 1 O
Papaverine	78 10 B-Chemical
hydrochloride	89 13 I-Chemical
is	103 2 O
a	106 1 O
direct	108 6 O
-	114 1 O
acting	115 6 O
vasodilator	122 11 O
used	134 4 O
to	139 2 O
manage	142 6 O
vasospasm	149 9 B-Disease
during	159 6 O
various	166 7 O
neurosurgical	174 13 O
operations	188 10 O
.	198 1 O

Transient	200 9 O
cranial	210 7 B-Disease
nerve	218 5 I-Disease
dysfunction	224 11 I-Disease
has	236 3 O
been	240 4 O
described	245 9 O
in	255 2 O
a	258 1 O
few	260 3 O
cases	264 5 O
with	270 4 O
topical	275 7 O
papaverine	283 10 B-Chemical
.	293 1 O

This	295 4 O
study	300 5 O
supports	306 8 O
previous	315 8 O
reports	324 7 O
and	332 3 O
provides	336 8 O
neurophysiological	345 18 O
evidence	364 8 O
of	373 2 O
an	376 2 O
adverse	379 7 O
effect	387 6 O
on	394 2 O
the	397 3 O
auditory	401 8 O
nerve	410 5 O
.	415 1 O

METHODS	417 7 O
:	424 1 O
We	426 2 O
conducted	429 9 O
a	439 1 O
retrospective	441 13 O
review	455 6 O
of	462 2 O
70	465 2 O
consecutive	468 11 O
microvascular	480 13 O
decompression	494 13 O
operations	508 10 O
and	519 3 O
studied	523 7 O
those	531 5 O
patients	537 8 O
who	546 3 O
received	550 8 O
topical	559 7 O
papaverine	567 10 B-Chemical
for	578 3 O
vasospasm	582 9 B-Disease
.	591 1 O

Topical	593 7 O
papaverine	601 10 B-Chemical
was	612 3 O
used	616 4 O
as	621 2 O
a	624 1 O
direct	626 6 O
therapeutic	633 11 O
action	645 6 O
to	652 2 O
manage	655 6 O
vasospasm	662 9 B-Disease
in	672 2 O
a	675 1 O
total	677 5 O
of	683 2 O
11	686 2 O
patients	689 8 O
.	697 1 O

The	699 3 O
timing	703 6 O
of	710 2 O
papaverine	713 10 B-Chemical
application	724 11 O
and	736 3 O
ongoing	740 7 O
operative	748 9 O
events	758 6 O
was	765 3 O
reviewed	769 8 O
relative	778 8 O
to	787 2 O
changes	790 7 O
in	798 2 O
neurophysiological	801 18 O
recordings	820 10 O
.	830 1 O

Brainstem	832 9 O
auditory	842 8 O
evoked	851 6 O
potentials	858 10 O
(	869 1 O
BAEPs	870 5 O
)	875 1 O
were	877 4 O
routinely	882 9 O
used	892 4 O
to	897 2 O
monitor	900 7 O
cochlear	908 8 O
nerve	917 5 O
function	923 8 O
during	932 6 O
these	939 5 O
operations	945 10 O
.	955 1 O

FINDINGS	957 8 O
:	965 1 O
A	967 1 O
temporal	969 8 O
relationship	978 12 O
was	991 3 O
found	995 5 O
between	1001 7 O
topical	1009 7 O
papaverine	1017 10 B-Chemical
and	1028 3 O
BAEP	1032 4 O
changes	1037 7 O
leading	1045 7 O
to	1053 2 O
complete	1056 8 O
waveform	1065 8 O
loss	1074 4 O
.	1078 1 O

The	1080 3 O
average	1084 7 O
temporal	1092 8 O
delay	1101 5 O
between	1107 7 O
papaverine	1115 10 B-Chemical
and	1126 3 O
the	1130 3 O
onset	1134 5 O
of	1140 2 O
an	1143 2 O
adverse	1146 7 O
BAEP	1154 4 O
change	1159 6 O
was	1166 3 O
5	1170 1 O
min	1172 3 O
.	1175 1 O

In	1177 2 O
10	1180 2 O
of	1183 2 O
11	1186 2 O
patients	1189 8 O
,	1197 1 O
BAEP	1199 4 O
waves	1204 5 O
II	1210 2 O
/	1212 1 O
III	1213 3 O
-	1216 1 O
V	1217 1 O
completely	1219 10 O
disappeared	1230 11 O
within	1242 6 O
2	1249 1 O
to	1251 2 O
25	1254 2 O
min	1257 3 O
after	1261 5 O
papaverine	1267 10 B-Chemical
.	1277 1 O

Eight	1279 5 O
of	1285 2 O
these	1288 5 O
10	1294 2 O
patients	1297 8 O
had	1306 3 O
complete	1310 8 O
loss	1319 4 O
of	1324 2 O
BAEP	1327 4 O
waveforms	1332 9 O
within	1342 6 O
10	1349 2 O
min	1352 3 O
.	1355 1 O

One	1357 3 O
patient	1361 7 O
showed	1369 6 O
no	1376 2 O
recovery	1379 8 O
of	1388 2 O
later	1391 5 O
waves	1397 5 O
and	1403 3 O
a	1407 1 O
delayed	1409 7 O
profound	1417 8 O
sensorineural	1426 13 B-Disease
hearing	1440 7 I-Disease
loss	1448 4 I-Disease
.	1452 1 O

The	1454 3 O
average	1458 7 O
recovery	1466 8 O
time	1475 4 O
of	1480 2 O
BAEP	1483 4 O
waveforms	1488 9 O
to	1498 2 O
pre	1501 3 O
-	1504 1 O
papaverine	1505 10 B-Chemical
baseline	1516 8 O
values	1525 6 O
was	1532 3 O
39	1536 2 O
min	1539 3 O
.	1542 1 O

CONCLUSIONS	1544 11 O
:	1555 1 O
Topical	1557 7 O
papaverine	1565 10 B-Chemical
for	1576 3 O
the	1580 3 O
treatment	1584 9 O
of	1594 2 O
vasospasm	1597 9 B-Disease
was	1607 3 O
associated	1611 10 O
with	1622 4 O
the	1627 3 O
onset	1631 5 O
of	1637 2 O
a	1640 1 O
transient	1642 9 O
disturbance	1652 11 O
in	1664 2 O
neurophysiological	1667 18 O
function	1686 8 O
of	1695 2 O
the	1698 3 O
ascending	1702 9 O
auditory	1712 8 O
brainstem	1721 9 O
pathway	1731 7 O
.	1738 1 O

The	1740 3 O
complete	1744 8 O
disappearance	1753 13 O
of	1767 2 O
BAEP	1770 4 O
waveforms	1775 9 O
with	1785 4 O
a	1790 1 O
consistent	1792 10 O
temporal	1803 8 O
delay	1812 5 O
suggests	1818 8 O
a	1827 1 O
possible	1829 8 O
adverse	1838 7 B-Disease
effect	1846 6 I-Disease
on	1853 2 I-Disease
the	1856 3 I-Disease
proximal	1860 8 I-Disease
eighth	1869 6 I-Disease
nerve	1876 5 I-Disease
.	1881 1 O

Recommendations	1883 15 O
to	1899 2 O
avoid	1902 5 O
potential	1908 9 O
cranial	1918 7 B-Disease
nerve	1926 5 I-Disease
deficits	1932 8 I-Disease
from	1941 4 O
papaverine	1946 10 B-Chemical
are	1957 3 O
provided	1961 8 O
.	1969 1 O

Massive	0 7 O
proteinuria	8 11 B-Disease
and	20 3 O
acute	24 5 B-Disease
renal	30 5 I-Disease
failure	36 7 I-Disease
after	44 5 O
oral	50 4 O
bisphosphonate	55 14 B-Chemical
(	70 1 O
alendronate	71 11 B-Chemical
)	82 1 O
administration	84 14 O
in	99 2 O
a	102 1 O
patient	104 7 O
with	112 4 O
focal	117 5 B-Disease
segmental	123 9 I-Disease
glomerulosclerosis	133 18 I-Disease
.	151 1 O

A	153 1 O
61	155 2 O
-	157 1 O
year	158 4 O
-	162 1 O
old	163 3 O
Japanese	167 8 O
man	176 3 O
with	180 4 O
nephrotic	185 9 B-Disease
syndrome	195 8 I-Disease
due	204 3 O
to	208 2 O
focal	211 5 B-Disease
segmental	217 9 I-Disease
glomerulosclerosis	227 18 I-Disease
was	246 3 O
initially	250 9 O
responding	260 10 O
well	271 4 O
to	276 2 O
steroid	279 7 B-Chemical
therapy	287 7 O
.	294 1 O

The	296 3 O
amount	300 6 O
of	307 2 O
daily	310 5 O
urinary	316 7 O
protein	324 7 O
decreased	332 9 O
from	342 4 O
15	347 2 O
.	349 1 O
6	350 1 O
to	352 2 O
2	355 1 O
.	356 1 O
8	357 1 O
g	359 1 O
.	360 1 O

Within	362 6 O
14	369 2 O
days	372 4 O
of	377 2 O
the	380 3 O
oral	384 4 O
bisphosphonate	389 14 B-Chemical
(	404 1 O
alendronate	405 11 B-Chemical
sodium	417 6 I-Chemical
)	423 1 O
administration	425 14 O
,	439 1 O
the	441 3 O
amount	445 6 O
of	452 2 O
daily	455 5 O
urinary	461 7 O
protein	469 7 O
increased	477 9 O
rapidly	487 7 O
up	495 2 O
to	498 2 O
12	501 2 O
.	503 1 O
8	504 1 O
g	506 1 O
with	508 4 O
acute	513 5 B-Disease
renal	519 5 I-Disease
failure	525 7 I-Disease
.	532 1 O

After	534 5 O
discontinuing	540 13 O
the	554 3 O
oral	558 4 O
alendronate	563 11 B-Chemical
,	574 1 O
the	576 3 O
patient	580 7 O
underwent	588 9 O
six	598 3 O
cycles	602 6 O
of	609 2 O
hemodialysis	612 12 O
and	625 3 O
four	629 4 O
cycles	634 6 O
of	641 2 O
LDL	644 3 O
apheresis	648 9 O
.	657 1 O

Urinary	659 7 O
volume	667 6 O
and	674 3 O
serum	678 5 O
creatinine	684 10 B-Chemical
levels	695 6 O
recovered	702 9 O
to	712 2 O
the	715 3 O
normal	719 6 O
range	726 5 O
,	731 1 O
with	733 4 O
urinary	738 7 O
protein	746 7 O
disappearing	754 12 O
completely	767 10 O
within	778 6 O
40	785 2 O
days	788 4 O
.	792 1 O

This	794 4 O
report	799 6 O
demonstrates	806 12 O
that	819 4 O
not	824 3 O
only	828 4 O
intravenous	833 11 O
,	844 1 O
but	846 3 O
also	850 4 O
oral	855 4 O
bisphosphonates	860 15 B-Chemical
can	876 3 O
aggravate	880 9 O
proteinuria	890 11 B-Disease
and	902 3 O
acute	906 5 B-Disease
renal	912 5 I-Disease
failure	918 7 I-Disease
.	925 1 O

Serum	0 5 O
-	5 1 O
and	7 3 O
glucocorticoid	11 14 O
-	25 1 O
inducible	26 9 O
kinase	36 6 O
1	43 1 O
in	45 2 O
doxorubicin	48 11 B-Chemical
-	59 1 O
induced	60 7 O
nephrotic	68 9 B-Disease
syndrome	78 8 I-Disease
.	86 1 O

Doxorubicin	88 11 B-Chemical
-	99 1 O
induced	100 7 O
nephropathy	108 11 B-Disease
leads	120 5 O
to	126 2 O
epithelial	129 10 O
sodium	140 6 B-Chemical
channel	147 7 O
(	155 1 O
ENaC	156 4 O
)	160 1 O
-	161 1 O
dependent	162 9 O
volume	172 6 B-Disease
retention	179 9 I-Disease
and	189 3 O
renal	193 5 O
fibrosis	199 8 B-Disease
.	207 1 O

The	209 3 O
aldosterone	213 11 B-Chemical
-	224 1 O
sensitive	225 9 O
serum	235 5 O
-	240 1 O
and	242 3 O
glucocorticoid	246 14 O
-	260 1 O
inducible	261 9 O
kinase	271 6 O
SGK1	278 4 O
has	283 3 O
been	287 4 O
shown	292 5 O
to	298 2 O
participate	301 11 O
in	313 2 O
the	316 3 O
stimulation	320 11 O
of	332 2 O
ENaC	335 4 O
and	340 3 O
to	344 2 O
mediate	347 7 O
renal	355 5 O
fibrosis	361 8 B-Disease
following	370 9 O
mineralocorticoid	380 17 O
and	398 3 O
salt	402 4 O
excess	407 6 O
.	413 1 O

The	415 3 O
present	419 7 O
study	427 5 O
was	433 3 O
performed	437 9 O
to	447 2 O
elucidate	450 9 O
the	460 3 O
role	464 4 O
of	469 2 O
SGK1	472 4 O
in	477 2 O
the	480 3 O
volume	484 6 B-Disease
retention	491 9 I-Disease
and	501 3 O
fibrosis	505 8 B-Disease
during	514 6 O
nephrotic	521 9 B-Disease
syndrome	531 8 I-Disease
.	539 1 O

To	541 2 O
this	544 4 O
end	549 3 O
,	552 1 O
doxorubicin	554 11 B-Chemical
(	566 1 O
15	567 2 O
mug	570 3 O
/	573 1 O
g	574 1 O
body	576 4 O
wt	581 2 O
)	583 1 O
was	585 3 O
injected	589 8 O
intravenously	598 13 O
into	612 4 O
gene	617 4 O
-	621 1 O
targeted	622 8 O
mice	631 4 O
lacking	636 7 O
SGK1	644 4 O
(	649 1 O
sgk1	650 4 O
(	654 1 O
-	655 1 O
/	656 1 O
-	657 1 O
)	658 1 O
)	659 1 O
and	661 3 O
their	665 5 O
wild	671 4 O
-	675 1 O
type	676 4 O
littermates	681 11 O
(	693 1 O
sgk1	694 4 O
(	698 1 O
+	699 1 O
/	700 1 O
+	701 1 O
)	702 1 O
)	703 1 O
.	704 1 O

Doxorubicin	706 11 B-Chemical
treatment	718 9 O
resulted	728 8 O
in	737 2 O
heavy	740 5 O
proteinuria	746 11 B-Disease
(	758 1 O
>	759 1 O
100	760 3 O
mg	764 2 O
protein	767 7 O
/	774 1 O
mg	775 2 O
crea	778 4 O
)	782 1 O
in	784 2 O
15	787 2 O
/	789 1 O
44	790 2 O
of	793 2 O
sgk1	796 4 O
(	800 1 O
+	801 1 O
/	802 1 O
+	803 1 O
)	804 1 O
and	806 3 O
15	810 2 O
/	812 1 O
44	813 2 O
of	816 2 O
sgk1	819 4 O
(	823 1 O
-	824 1 O
/	825 1 O
-	826 1 O
)	827 1 O
mice	829 4 O
leading	834 7 O
to	842 2 O
severe	845 6 O
nephrotic	852 9 B-Disease
syndrome	862 8 I-Disease
with	871 4 O
ascites	876 7 B-Disease
,	883 1 O
lipidemia	885 9 B-Disease
,	894 1 O
and	896 3 O
hypoalbuminemia	900 15 B-Disease
in	916 2 O
both	919 4 O
genotypes	924 9 O
.	933 1 O

Plasma	935 6 O
aldosterone	942 11 B-Chemical
levels	954 6 O
increased	961 9 O
in	971 2 O
nephrotic	974 9 B-Disease
mice	984 4 O
of	989 2 O
both	992 4 O
genotypes	997 9 O
and	1007 3 O
was	1011 3 O
followed	1015 8 O
by	1024 2 O
increased	1027 9 O
SGK1	1037 4 O
protein	1042 7 O
expression	1050 10 O
in	1061 2 O
sgk1	1064 4 O
(	1068 1 O
+	1069 1 O
/	1070 1 O
+	1071 1 O
)	1072 1 O
mice	1074 4 O
.	1078 1 O

Urinary	1080 7 O
sodium	1088 6 B-Chemical
excretion	1095 9 O
reached	1105 7 O
signficantly	1113 12 O
lower	1126 5 O
values	1132 6 O
in	1139 2 O
sgk1	1142 4 O
(	1146 1 O
+	1147 1 O
/	1148 1 O
+	1149 1 O
)	1150 1 O
mice	1152 4 O
(	1157 1 O
15	1158 2 O
+	1161 1 O
/	1162 1 O
-	1163 1 O
5	1165 1 O
mumol	1167 5 O
/	1172 1 O
mg	1173 2 O
crea	1176 4 O
)	1180 1 O
than	1182 4 O
in	1187 2 O
sgk1	1190 4 O
(	1194 1 O
-	1195 1 O
/	1196 1 O
-	1197 1 O
)	1198 1 O
mice	1200 4 O
(	1205 1 O
35	1206 2 O
+	1209 1 O
/	1210 1 O
-	1211 1 O
5	1213 1 O
mumol	1215 5 O
/	1220 1 O
mg	1221 2 O
crea	1224 4 O
)	1228 1 O
and	1230 3 O
was	1234 3 O
associated	1238 10 O
with	1249 4 O
a	1254 1 O
significantly	1256 13 O
higher	1270 6 O
body	1277 4 O
weight	1282 6 B-Disease
gain	1289 4 I-Disease
in	1294 2 O
sgk1	1297 4 O
(	1301 1 O
+	1302 1 O
/	1303 1 O
+	1304 1 O
)	1305 1 O
compared	1307 8 O
with	1316 4 O
sgk1	1321 4 O
(	1325 1 O
-	1326 1 O
/	1327 1 O
-	1328 1 O
)	1329 1 O
mice	1331 4 O
(	1336 1 O
+	1337 1 O
6	1338 1 O
.	1339 1 O
6	1340 1 O
+	1342 1 O
/	1343 1 O
-	1344 1 O
0	1346 1 O
.	1347 1 O
7	1348 1 O
vs	1350 2 O
.	1352 1 O
+	1354 1 O
4	1355 1 O
.	1356 1 O
1	1357 1 O
+	1359 1 O
/	1360 1 O
-	1361 1 O
0	1363 1 O
.	1364 1 O
8	1365 1 O
g	1367 1 O
)	1368 1 O
.	1369 1 O

During	1371 6 O
the	1378 3 O
course	1382 6 O
of	1389 2 O
nephrotic	1392 9 B-Disease
syndrome	1402 8 I-Disease
,	1410 1 O
serum	1412 5 O
urea	1418 4 B-Chemical
concentrations	1423 14 O
increased	1438 9 O
significantly	1448 13 O
faster	1462 6 O
in	1469 2 O
sgk1	1472 4 O
(	1476 1 O
-	1477 1 O
/	1478 1 O
-	1479 1 O
)	1480 1 O
mice	1482 4 O
than	1487 4 O
in	1492 2 O
sgk1	1495 4 O
(	1499 1 O
+	1500 1 O
/	1501 1 O
+	1502 1 O
)	1503 1 O
mice	1505 4 O
leading	1510 7 O
to	1518 2 O
uremia	1521 6 B-Disease
and	1528 3 O
a	1532 1 O
reduced	1534 7 O
median	1542 6 O
survival	1549 8 O
in	1558 2 O
sgk1	1561 4 O
(	1565 1 O
-	1566 1 O
/	1567 1 O
-	1568 1 O
)	1569 1 O
mice	1571 4 O
(	1576 1 O
29	1577 2 O
vs	1580 2 O
.	1582 1 O
40	1584 2 O
days	1587 4 O
in	1592 2 O
sgk1	1595 4 O
(	1599 1 O
+	1600 1 O
/	1601 1 O
+	1602 1 O
)	1603 1 O
mice	1605 4 O
)	1609 1 O
.	1610 1 O

In	1612 2 O
conclusion	1615 10 O
,	1625 1 O
gene	1627 4 O
-	1631 1 O
targeted	1632 8 O
mice	1641 4 O
lacking	1646 7 O
SGK1	1654 4 O
showed	1659 6 O
blunted	1666 7 O
volume	1674 6 B-Disease
retention	1681 9 I-Disease
,	1690 1 O
yet	1692 3 O
were	1696 4 O
not	1701 3 O
protected	1705 9 O
against	1715 7 O
renal	1723 5 O
fibrosis	1729 8 B-Disease
during	1738 6 O
experimental	1745 12 O
nephrotic	1758 9 B-Disease
syndrome	1768 8 I-Disease
.	1776 1 O

Severe	0 6 O
and	7 3 O
long	11 4 O
lasting	16 7 O
cholestasis	24 11 B-Disease
after	36 5 O
high	42 4 O
-	46 1 O
dose	47 4 O
co	52 2 B-Chemical
-	54 1 I-Chemical
trimoxazole	55 11 I-Chemical
treatment	67 9 O
for	77 3 O
Pneumocystis	81 12 B-Disease
pneumonia	94 9 I-Disease
in	104 2 O
HIV	107 3 B-Disease
-	110 1 I-Disease
infected	111 8 I-Disease
patients	120 8 O
-	128 1 O
-	129 1 O
a	130 1 O
report	132 6 O
of	139 2 O
two	142 3 O
cases	146 5 O
.	151 1 O

Pneumocystis	153 12 B-Disease
pneumonia	166 9 I-Disease
(	176 1 O
PCP	177 3 B-Disease
)	180 1 O
,	181 1 O
a	183 1 O
common	185 6 O
opportunistic	192 13 B-Disease
infection	206 9 I-Disease
in	216 2 O
HIV	219 3 B-Disease
-	222 1 I-Disease
infected	223 8 I-Disease
individuals	232 11 O
,	243 1 O
is	245 2 O
generally	248 9 O
treated	258 7 O
with	266 4 O
high	271 4 O
doses	276 5 O
of	282 2 O
co	285 2 B-Chemical
-	287 1 I-Chemical
trimoxazole	288 11 I-Chemical
.	299 1 O

However	301 7 O
,	308 1 O
treatment	310 9 O
is	320 2 O
often	323 5 O
limited	329 7 O
by	337 2 O
adverse	340 7 O
effects	348 7 O
.	355 1 O

Here	357 4 O
,	361 1 O
we	363 2 O
report	366 6 O
two	373 3 O
cases	377 5 O
of	383 2 O
severely	386 8 O
immunocompromised	395 17 O
HIV	413 3 B-Disease
-	416 1 I-Disease
infected	417 8 I-Disease
patients	426 8 O
who	435 3 O
developed	439 9 O
severe	449 6 O
intrahepatic	456 12 B-Disease
cholestasis	469 11 I-Disease
,	480 1 O
and	482 3 O
in	486 2 O
one	489 3 O
patient	493 7 O
lesions	501 7 O
mimicking	509 9 O
liver	519 5 B-Disease
abscess	525 7 I-Disease
formation	533 9 O
on	543 2 O
radiologic	546 10 O
exams	557 5 O
,	562 1 O
during	564 6 O
co	571 2 B-Chemical
-	573 1 I-Chemical
trimoxazole	574 11 I-Chemical
treatment	586 9 O
for	596 3 O
PCP	600 3 B-Disease
.	603 1 O

Whereas	605 7 O
patient	613 7 O
1	621 1 O
showed	623 6 O
lesions	630 7 O
of	638 2 O
up	641 2 O
to	644 2 O
1	647 1 O
cm	649 2 O
readily	652 7 O
detectable	660 10 O
on	671 2 O
magnetic	674 8 O
resonance	683 9 O
imaging	693 7 O
under	701 5 O
prolonged	707 9 O
co	717 2 B-Chemical
-	719 1 I-Chemical
trimoxazole	720 11 I-Chemical
treatment	732 9 O
,	741 1 O
therapy	743 7 O
of	751 2 O
patient	754 7 O
2	762 1 O
was	764 3 O
switched	768 8 O
early	777 5 O
.	782 1 O

Clinically	0 10 O
significant	11 11 O
proteinuria	23 11 B-Disease
following	35 9 O
the	45 3 O
administration	49 14 O
of	64 2 O
sirolimus	67 9 B-Chemical
to	77 2 O
renal	80 5 O
transplant	86 10 O
recipients	97 10 O
.	107 1 O

BACKGROUND	109 10 O
:	119 1 O
Sirolimus	121 9 B-Chemical
is	131 2 O
the	134 3 O
latest	138 6 O
immunosuppressive	145 17 O
agent	163 5 O
used	169 4 O
to	174 2 O
prevent	177 7 O
rejection	185 9 O
,	194 1 O
and	196 3 O
may	200 3 O
have	204 4 O
less	209 4 O
nephrotoxicity	214 14 B-Disease
than	229 4 O
calcineurin	234 11 O
inhibitor	246 9 O
(	256 1 O
CNI	257 3 O
)	260 1 O
-	261 1 O
based	262 5 O
regimens	268 8 O
.	276 1 O

To	278 2 O
date	281 4 O
there	286 5 O
has	292 3 O
been	296 4 O
little	301 6 O
documentation	308 13 O
of	322 2 O
clinically	325 10 O
significant	336 11 O
proteinuria	348 11 B-Disease
linked	360 6 O
with	367 4 O
the	372 3 O
use	376 3 O
of	380 2 O
sirolimus	383 9 B-Chemical
.	392 1 O

We	394 2 O
have	397 4 O
encountered	402 11 O
several	414 7 O
patients	422 8 O
who	431 3 O
developed	435 9 O
substantial	445 11 O
proteinuria	457 11 B-Disease
associated	469 10 O
with	480 4 O
sirolimus	485 9 B-Chemical
use	495 3 O
.	498 1 O

In	500 2 O
each	503 4 O
patient	508 7 O
,	515 1 O
the	517 3 O
close	521 5 O
temporal	527 8 O
association	536 11 O
between	548 7 O
the	556 3 O
commencement	560 12 O
of	573 2 O
sirolimus	576 9 B-Chemical
therapy	586 7 O
and	594 3 O
proteinuria	598 11 B-Disease
implicated	610 10 O
sirolimus	621 9 B-Chemical
as	631 2 O
the	634 3 O
most	638 4 O
likely	643 6 O
etiology	650 8 O
of	659 2 O
the	662 3 O
proteinuria	666 11 B-Disease
.	677 1 O

METHODS	679 7 O
:	686 1 O
We	688 2 O
analyzed	691 8 O
the	700 3 O
clinical	704 8 O
and	713 3 O
laboratory	717 10 O
information	728 11 O
available	740 9 O
for	750 3 O
all	754 3 O
119	758 3 O
patients	762 8 O
transplanted	771 12 O
at	784 2 O
the	787 3 O
Washington	791 10 O
Hospital	802 8 O
Center	811 6 O
between	818 7 O
1999	826 4 O
-	830 1 O
2003	831 4 O
for	836 3 O
whom	840 4 O
sirolimus	845 9 B-Chemical
was	855 3 O
a	859 1 O
component	861 9 O
of	871 2 O
their	874 5 O
immunosuppressant	880 17 O
regimen	898 7 O
.	905 1 O

In	907 2 O
these	910 5 O
patients	916 8 O
,	924 1 O
the	926 3 O
magnitude	930 9 O
of	940 2 O
proteinuria	943 11 B-Disease
was	955 3 O
assessed	959 8 O
on	968 2 O
morning	971 7 O
urine	979 5 O
samples	985 7 O
by	993 2 O
turbidometric	996 13 O
measurement	1010 11 O
or	1022 2 O
random	1025 6 O
urine	1032 5 O
protein	1038 7 O
:	1045 1 O
creatinine	1046 10 B-Chemical
ratios	1057 6 O
,	1063 1 O
an	1065 2 O
estimate	1068 8 O
of	1077 2 O
grams	1080 5 O
of	1086 2 O
proteinuria	1089 11 B-Disease
/	1100 1 O
day	1101 3 O
.	1104 1 O

Laboratory	1106 10 O
results	1117 7 O
were	1125 4 O
compared	1130 8 O
between	1139 7 O
prior	1147 5 O
,	1152 1 O
during	1154 6 O
and	1161 3 O
following	1165 9 O
sirolimus	1175 9 B-Chemical
use	1185 3 O
.	1188 1 O

RESULTS	1190 7 O
:	1197 1 O
Twenty	1199 6 O
-	1205 1 O
eight	1206 5 O
patients	1212 8 O
(	1221 1 O
24	1222 2 O
%	1224 1 O
)	1225 1 O
developed	1227 9 O
increased	1237 9 O
proteinuria	1247 11 B-Disease
from	1259 4 O
baseline	1264 8 O
during	1273 6 O
their	1280 5 O
post	1286 4 O
-	1290 1 O
transplantation	1291 15 O
course	1307 6 O
.	1313 1 O

In	1315 2 O
21	1318 2 O
patients	1321 8 O
an	1330 2 O
alternative	1333 11 O
cause	1345 5 O
of	1351 2 O
proteinuria	1354 11 B-Disease
was	1366 3 O
either	1370 6 O
obvious	1377 7 O
or	1385 2 O
insufficient	1388 12 O
data	1401 4 O
was	1406 3 O
available	1410 9 O
to	1420 2 O
be	1423 2 O
conclusive	1426 10 O
.	1436 1 O

In	1438 2 O
7	1441 1 O
of	1443 2 O
the	1446 3 O
28	1450 2 O
patients	1453 8 O
there	1462 5 O
was	1468 3 O
a	1472 1 O
striking	1474 8 O
temporal	1483 8 O
association	1492 11 O
between	1504 7 O
the	1512 3 O
initiation	1516 10 O
of	1527 2 O
sirolimus	1530 9 B-Chemical
and	1540 3 O
the	1544 3 O
development	1548 11 O
of	1560 2 O
nephrotic	1563 9 B-Disease
-	1572 1 O
range	1573 5 O
proteinuria	1579 11 B-Disease
.	1590 1 O

Proteinuria	1592 11 B-Disease
correlated	1604 10 O
most	1615 4 O
strongly	1620 8 O
with	1629 4 O
sirolimus	1634 9 B-Chemical
therapy	1644 7 O
when	1652 4 O
compared	1657 8 O
to	1666 2 O
other	1669 5 O
demographic	1675 11 O
and	1687 3 O
clinical	1691 8 O
variables	1700 9 O
.	1709 1 O

In	1711 2 O
most	1714 4 O
patients	1719 8 O
,	1727 1 O
discontinuation	1729 15 O
of	1745 2 O
sirolimus	1748 9 B-Chemical
resulted	1758 8 O
in	1767 2 O
a	1770 1 O
decrease	1772 8 O
,	1780 1 O
but	1782 3 O
not	1786 3 O
resolution	1790 10 O
,	1800 1 O
of	1802 2 O
proteinuria	1805 11 B-Disease
.	1816 1 O

CONCLUSIONS	1818 11 O
:	1829 1 O
Sirolimus	1831 9 B-Chemical
induces	1841 7 O
or	1849 2 O
aggravates	1852 10 O
pre	1863 3 O
-	1866 1 O
existing	1867 8 O
proteinuria	1876 11 B-Disease
in	1888 2 O
an	1891 2 O
unpredictable	1894 13 O
subset	1908 6 O
of	1915 2 O
renal	1918 5 O
allograft	1924 9 O
recipients	1934 10 O
.	1944 1 O

Proteinuria	1946 11 B-Disease
may	1958 3 O
improve	1962 7 O
,	1969 1 O
but	1971 3 O
does	1975 4 O
not	1980 3 O
resolve	1984 7 O
,	1991 1 O
when	1993 4 O
sirolimus	1998 9 B-Chemical
is	2008 2 O
withdrawn	2011 9 O
.	2020 1 O

Comparative	0 11 O
cognitive	12 9 O
and	22 3 O
subjective	26 10 O
side	37 4 O
effects	42 7 O
of	50 2 O
immediate	53 9 O
-	62 1 O
release	63 7 O
oxycodone	71 9 B-Chemical
in	81 2 O
healthy	84 7 O
middle	92 6 O
-	98 1 O
aged	99 4 O
and	104 3 O
older	108 5 O
adults	114 6 O
.	120 1 O

This	122 4 O
study	127 5 O
measured	133 8 O
the	142 3 O
objective	146 9 O
and	156 3 O
subjective	160 10 O
neurocognitive	171 14 O
effects	186 7 O
of	194 2 O
a	197 1 O
single	199 6 O
10	206 2 O
-	208 1 O
mg	209 2 O
dose	212 4 O
of	217 2 O
immediate	220 9 O
-	229 1 O
release	230 7 O
oxycodone	238 9 B-Chemical
in	248 2 O
healthy	251 7 O
,	258 1 O
older	260 5 O
(	266 1 O
>	267 1 O
65	269 2 O
years	272 5 O
)	277 1 O
,	278 1 O
and	280 3 O
middle	284 6 O
-	290 1 O
aged	291 4 O
(	296 1 O
35	297 2 O
to	300 2 O
55	303 2 O
years	306 5 O
)	311 1 O
adults	313 6 O
who	320 3 O
were	324 4 O
not	329 3 O
suffering	333 9 O
from	343 4 O
chronic	348 7 O
or	356 2 O
significant	359 11 O
daily	371 5 O
pain	377 4 B-Disease
.	381 1 O

Seventy	383 7 O
-	390 1 O
one	391 3 O
participants	395 12 O
completed	408 9 O
2	418 1 O
separate	420 8 O
study	429 5 O
days	435 4 O
and	440 3 O
were	444 4 O
blind	449 5 O
to	455 2 O
medication	458 10 O
condition	469 9 O
(	479 1 O
placebo	480 7 O
,	487 1 O
10	489 2 O
-	491 1 O
mg	492 2 O
oxycodone	495 9 B-Chemical
)	504 1 O
.	505 1 O

Plasma	507 6 O
oxycodone	514 9 B-Chemical
concentration	524 13 O
peaked	538 6 O
between	545 7 O
60	553 2 O
and	556 3 O
90	560 2 O
minutes	563 7 O
postdose	571 8 O
(	580 1 O
P	581 1 O
<	583 1 O
.	585 1 O
01	586 2 O
)	588 1 O
and	590 3 O
pupil	594 5 O
size	600 4 O
,	604 1 O
an	606 2 O
indication	609 10 O
of	620 2 O
physiological	623 13 O
effects	637 7 O
of	645 2 O
the	648 3 O
medication	652 10 O
,	662 1 O
peaked	664 6 O
at	671 2 O
approximately	674 13 O
90	688 2 O
to	691 2 O
120	694 3 O
minutes	698 7 O
postdose	706 8 O
(	715 1 O
P	716 1 O
<	718 1 O
.	720 1 O
01	721 2 O
)	723 1 O
.	724 1 O

Significant	726 11 O
declines	738 8 B-Disease
in	747 2 I-Disease
simple	750 6 I-Disease
and	757 3 I-Disease
sustained	761 9 I-Disease
attention	771 9 I-Disease
,	780 1 I-Disease
working	782 7 I-Disease
memory	790 6 I-Disease
,	796 1 I-Disease
and	798 3 I-Disease
verbal	802 6 I-Disease
memory	809 6 I-Disease
were	816 4 O
observed	821 8 O
at	830 2 O
1	833 1 O
hour	835 4 O
postdose	840 8 O
compared	849 8 O
to	858 2 O
baseline	861 8 O
for	870 3 O
both	874 4 O
age	879 3 O
groups	883 6 O
with	890 4 O
a	895 1 O
trend	897 5 O
toward	903 6 O
return	910 6 O
to	917 2 O
baseline	920 8 O
by	929 2 O
5	932 1 O
hours	934 5 O
postdose	940 8 O
.	948 1 O

For	950 3 O
almost	954 6 O
all	961 3 O
cognitive	965 9 O
measures	975 8 O
,	983 1 O
there	985 5 O
were	991 4 O
no	996 2 O
medication	999 10 O
by	1010 2 O
age	1013 3 O
-	1016 1 O
interaction	1017 11 O
effects	1029 7 O
,	1036 1 O
which	1038 5 O
indicates	1044 9 O
that	1054 4 O
the	1059 3 O
2	1063 1 O
age	1065 3 O
groups	1069 6 O
exhibited	1076 9 O
similar	1086 7 O
responses	1094 9 O
to	1104 2 O
the	1107 3 O
medication	1111 10 O
challenge	1122 9 O
.	1131 1 O

This	1133 4 O
study	1138 5 O
suggests	1144 8 O
that	1153 4 O
for	1158 3 O
healthy	1162 7 O
older	1170 5 O
adults	1176 6 O
who	1183 3 O
are	1187 3 O
not	1191 3 O
suffering	1195 9 O
from	1205 4 O
chronic	1210 7 B-Disease
pain	1218 4 I-Disease
,	1222 1 O
neurocognitive	1224 14 O
and	1239 3 O
pharmacodynamic	1243 15 O
changes	1259 7 O
in	1267 2 O
response	1270 8 O
to	1279 2 O
a	1282 1 O
10	1284 2 O
-	1286 1 O
mg	1287 2 O
dose	1290 4 O
of	1295 2 O
immediate	1298 9 O
-	1307 1 O
release	1308 7 O
oxycodone	1316 9 B-Chemical
are	1326 3 O
similar	1330 7 O
to	1338 2 O
those	1341 5 O
observed	1347 8 O
for	1356 3 O
middle	1360 6 O
-	1366 1 O
aged	1367 4 O
adults	1372 6 O
.	1378 1 O

PERSPECTIVE	1380 11 O
:	1391 1 O
Study	1393 5 O
findings	1399 8 O
indicate	1408 8 O
that	1417 4 O
the	1422 3 O
metabolism	1426 10 O
,	1436 1 O
neurocognitive	1438 14 O
effects	1453 7 O
,	1460 1 O
and	1462 3 O
physical	1466 8 O
side	1475 4 O
effects	1480 7 O
of	1488 2 O
oral	1491 4 O
oxycodone	1496 9 B-Chemical
are	1506 3 O
similar	1510 7 O
for	1518 3 O
healthy	1522 7 O
middle	1530 6 O
-	1536 1 O
aged	1537 4 O
and	1542 3 O
older	1546 5 O
adults	1552 6 O
.	1558 1 O

Therefore	1560 9 O
,	1569 1 O
clinicians	1571 10 O
should	1582 6 O
not	1589 3 O
avoid	1593 5 O
prescribing	1599 11 O
oral	1611 4 O
opioids	1616 7 O
to	1624 2 O
older	1627 5 O
adults	1633 6 O
based	1640 5 O
on	1646 2 O
the	1649 3 O
belief	1653 6 O
that	1660 4 O
older	1665 5 O
adults	1671 6 O
are	1678 3 O
at	1682 2 O
higher	1685 6 O
risk	1692 4 O
for	1697 3 O
side	1701 4 O
effects	1706 7 O
than	1714 4 O
younger	1719 7 O
adults	1727 6 O
.	1733 1 O

Normalizing	0 11 O
effects	12 7 O
of	20 2 O
modafinil	23 9 B-Chemical
on	33 2 O
sleep	36 5 O
in	42 2 O
chronic	45 7 O
cocaine	53 7 B-Chemical
users	61 5 O
.	66 1 O

OBJECTIVE	68 9 O
:	77 1 O
The	79 3 O
purpose	83 7 O
of	91 2 O
the	94 3 O
present	98 7 O
study	106 5 O
was	112 3 O
to	116 2 O
determine	119 9 O
the	129 3 O
effect	133 6 O
of	140 2 O
morning	143 7 O
-	150 1 O
dosed	151 5 O
modafinil	157 9 B-Chemical
on	167 2 O
sleep	170 5 O
and	176 3 O
daytime	180 7 B-Disease
sleepiness	188 10 I-Disease
in	199 2 O
chronic	202 7 O
cocaine	210 7 B-Chemical
users	218 5 O
.	223 1 O

METHOD	225 6 O
:	231 1 O
Twenty	233 6 O
cocaine	240 7 B-Chemical
-	247 1 O
dependent	248 9 O
participants	258 12 O
were	271 4 O
randomly	276 8 O
assigned	285 8 O
to	294 2 O
receive	297 7 O
modafinil	305 9 B-Chemical
,	314 1 O
400	316 3 O
mg	320 2 O
(	323 1 O
N	324 1 O
=	325 1 O
10	326 2 O
)	328 1 O
,	329 1 O
or	331 2 O
placebo	334 7 O
(	342 1 O
N	343 1 O
=	344 1 O
10	345 2 O
)	347 1 O
every	349 5 O
morning	355 7 O
at	363 2 O
7	366 1 O
:	367 1 O
30	368 2 O
a	371 1 O
.	372 1 O
m	373 1 O
.	374 1 O
for	376 3 O
16	380 2 O
days	383 4 O
in	388 2 O
an	391 2 O
inpatient	394 9 O
,	403 1 O
double	405 6 O
-	411 1 O
blind	412 5 O
randomized	418 10 O
trial	429 5 O
.	434 1 O

Participants	436 12 O
underwent	449 9 O
polysomnographic	459 16 O
sleep	476 5 O
recordings	482 10 O
on	493 2 O
days	496 4 O
1	501 1 O
to	503 2 O
3	506 1 O
,	507 1 O
7	509 1 O
to	511 2 O
9	514 1 O
,	515 1 O
and	517 3 O
14	521 2 O
to	524 2 O
16	527 2 O
(	530 1 O
first	531 5 O
,	536 1 O
second	538 6 O
,	544 1 O
and	546 3 O
third	550 5 O
weeks	556 5 O
of	562 2 O
abstinence	565 10 O
)	575 1 O
.	576 1 O

The	578 3 O
Multiple	582 8 O
Sleep	591 5 O
Latency	597 7 O
Test	605 4 O
was	610 3 O
performed	614 9 O
at	624 2 O
11	627 2 O
:	629 1 O
30	630 2 O
a	633 1 O
.	634 1 O
m	635 1 O
.	636 1 O
,	637 1 O
2	639 1 O
:	640 1 O
00	641 2 O
p	644 1 O
.	645 1 O
m	646 1 O
.	647 1 O
,	648 1 O
and	650 3 O
4	654 1 O
:	655 1 O
30	656 2 O
p	659 1 O
.	660 1 O
m	661 1 O
.	662 1 O
on	664 2 O
days	667 4 O
2	672 1 O
,	673 1 O
8	675 1 O
,	676 1 O
and	678 3 O
15	682 2 O
.	684 1 O

For	686 3 O
comparison	690 10 O
of	701 2 O
sleep	704 5 O
architecture	710 12 O
variables	723 9 O
,	732 1 O
12	734 2 O
healthy	737 7 O
comparison	745 10 O
participants	756 12 O
underwent	769 9 O
a	779 1 O
single	781 6 O
night	788 5 O
of	794 2 O
experimental	797 12 O
polysomnography	810 15 O
that	826 4 O
followed	831 8 O
1	840 1 O
night	842 5 O
of	848 2 O
accommodation	851 13 O
polysomnography	865 15 O
.	880 1 O

RESULTS	882 7 O
:	889 1 O
Progressive	891 11 O
abstinence	903 10 O
from	914 4 O
cocaine	919 7 B-Chemical
was	927 3 O
associated	931 10 O
with	942 4 O
worsening	947 9 O
of	957 2 O
all	960 3 O
measured	964 8 O
polysomnographic	973 16 O
sleep	990 5 O
outcomes	996 8 O
.	1004 1 O

Compared	1006 8 O
with	1015 4 O
placebo	1020 7 O
,	1027 1 O
modafinil	1029 9 B-Chemical
decreased	1039 9 O
nighttime	1049 9 O
sleep	1059 5 O
latency	1065 7 O
and	1073 3 O
increased	1077 9 O
slow	1087 4 O
-	1091 1 O
wave	1092 4 O
sleep	1097 5 O
time	1103 4 O
in	1108 2 O
cocaine	1111 7 B-Chemical
-	1118 1 O
dependent	1119 9 O
participants	1129 12 O
.	1141 1 O

The	1143 3 O
effect	1147 6 O
of	1154 2 O
modafinil	1157 9 B-Chemical
interacted	1167 10 O
with	1178 4 O
the	1183 3 O
abstinence	1187 10 O
week	1198 4 O
and	1203 3 O
was	1207 3 O
associated	1211 10 O
with	1222 4 O
longer	1227 6 O
total	1234 5 O
sleep	1240 5 O
time	1246 4 O
and	1251 3 O
shorter	1255 7 O
REM	1263 3 O
sleep	1267 5 O
latency	1273 7 O
in	1281 2 O
the	1284 3 O
third	1288 5 O
week	1294 4 O
of	1299 2 O
abstinence	1302 10 O
.	1312 1 O

Comparison	1314 10 O
of	1325 2 O
slow	1328 4 O
-	1332 1 O
wave	1333 4 O
sleep	1338 5 O
time	1344 4 O
,	1348 1 O
total	1350 5 O
sleep	1356 5 O
time	1362 4 O
,	1366 1 O
and	1368 3 O
sleep	1372 5 O
latency	1378 7 O
in	1386 2 O
cocaine	1389 7 B-Chemical
-	1396 1 O
dependent	1397 9 O
and	1407 3 O
healthy	1411 7 O
participants	1419 12 O
revealed	1432 8 O
a	1441 1 O
normalizing	1443 11 O
effect	1455 6 O
of	1462 2 O
modafinil	1465 9 B-Chemical
in	1475 2 O
cocaine	1478 7 B-Chemical
-	1485 1 O
dependent	1486 9 O
participants	1496 12 O
.	1508 1 O

Modafinil	1510 9 B-Chemical
was	1520 3 O
associated	1524 10 O
with	1535 4 O
increased	1540 9 O
daytime	1550 7 O
sleep	1558 5 O
latency	1564 7 O
,	1571 1 O
as	1573 2 O
measured	1576 8 O
by	1585 2 O
the	1588 3 O
Multiple	1592 8 O
Sleep	1601 5 O
Latency	1607 7 O
Test	1615 4 O
,	1619 1 O
and	1621 3 O
a	1625 1 O
nearly	1627 6 O
significant	1634 11 O
decrease	1646 8 O
in	1655 2 O
subjective	1658 10 O
daytime	1669 7 B-Disease
sleepiness	1677 10 I-Disease
.	1687 1 O

CONCLUSIONS	1689 11 O
:	1700 1 O
Morning	1702 7 O
-	1709 1 O
dosed	1710 5 O
modafinil	1716 9 B-Chemical
promotes	1726 8 O
nocturnal	1735 9 O
sleep	1745 5 O
,	1750 1 O
normalizes	1752 10 O
sleep	1763 5 O
architecture	1769 12 O
,	1781 1 O
and	1783 3 O
decreases	1787 9 O
daytime	1797 7 B-Disease
sleepiness	1805 10 I-Disease
in	1816 2 O
abstinent	1819 9 O
cocaine	1829 7 B-Chemical
users	1837 5 O
.	1842 1 O

These	1844 5 O
effects	1850 7 O
may	1858 3 O
be	1862 2 O
relevant	1865 8 O
in	1874 2 O
the	1877 3 O
treatment	1881 9 O
of	1891 2 O
cocaine	1894 7 B-Chemical
dependence	1902 10 O
.	1912 1 O

Efficacy	0 8 O
and	9 3 O
safety	13 6 O
of	20 2 O
asenapine	23 9 B-Chemical
in	33 2 O
a	36 1 O
placebo	38 7 O
-	45 1 O
and	47 3 O
haloperidol	51 11 B-Chemical
-	62 1 O
controlled	63 10 O
trial	74 5 O
in	80 2 O
patients	83 8 O
with	92 4 O
acute	97 5 O
exacerbation	103 12 O
of	116 2 O
schizophrenia	119 13 B-Disease
.	132 1 O

Asenapine	134 9 B-Chemical
is	144 2 O
approved	147 8 O
by	156 2 O
the	159 3 O
Food	163 4 O
and	168 3 O
Drugs	172 5 O
Administration	178 14 O
in	193 2 O
adults	196 6 O
for	203 3 O
acute	207 5 O
treatment	213 9 O
of	223 2 O
schizophrenia	226 13 B-Disease
or	240 2 O
of	243 2 O
manic	246 5 B-Disease
or	252 2 O
mixed	255 5 O
episodes	261 8 O
associated	270 10 O
with	281 4 O
bipolar	286 7 B-Disease
I	294 1 I-Disease
disorder	296 8 I-Disease
with	305 4 O
or	310 2 O
without	313 7 O
psychotic	321 9 B-Disease
features	331 8 O
.	339 1 O

In	341 2 O
a	344 1 O
double	346 6 O
-	352 1 O
blind	353 5 O
6	359 1 O
-	360 1 O
week	361 4 O
trial	366 5 O
,	371 1 O
458	373 3 O
patients	377 8 O
with	386 4 O
acute	391 5 O
schizophrenia	397 13 B-Disease
were	411 4 O
randomly	416 8 O
assigned	425 8 O
to	434 2 O
fixed	437 5 O
-	442 1 O
dose	443 4 O
treatment	448 9 O
with	458 4 O
asenapine	463 9 B-Chemical
at	473 2 O
5	476 1 O
mg	478 2 O
twice	481 5 O
daily	487 5 O
(	493 1 O
BID	494 3 O
)	497 1 O
,	498 1 O
asenapine	500 9 B-Chemical
at	510 2 O
10	513 2 O
mg	516 2 O
BID	519 3 O
,	522 1 O
placebo	524 7 O
,	531 1 O
or	533 2 O
haloperidol	536 11 B-Chemical
at	548 2 O
4	551 1 O
mg	553 2 O
BID	556 3 O
(	560 1 O
to	561 2 O
verify	564 6 O
assay	571 5 O
sensitivity	577 11 O
)	588 1 O
.	589 1 O

With	591 4 O
last	596 4 O
observations	601 12 O
carried	614 7 O
forward	622 7 O
(	630 1 O
LOCF	631 4 O
)	635 1 O
,	636 1 O
mean	638 4 O
Positive	643 8 O
and	652 3 O
Negative	656 8 O
Syndrome	665 8 O
Scale	674 5 O
total	680 5 O
score	686 5 O
reductions	692 10 O
from	703 4 O
baseline	708 8 O
to	717 2 O
endpoint	720 8 O
were	729 4 O
significantly	734 13 O
greater	748 7 O
with	756 4 O
asenapine	761 9 B-Chemical
at	771 2 O
5	774 1 O
mg	776 2 O
BID	779 3 O
(	783 1 O
-	784 1 O
16	785 2 O
.	787 1 O
2	788 1 O
)	789 1 O
and	791 3 O
haloperidol	795 11 B-Chemical
(	807 1 O
-	808 1 O
15	809 2 O
.	811 1 O
4	812 1 O
)	813 1 O
than	815 4 O
placebo	820 7 O
(	828 1 O
-	829 1 O
10	830 2 O
.	832 1 O
7	833 1 O
;	834 1 O
both	836 4 O
P	841 1 O
<	843 1 O
0	845 1 O
.	846 1 O
05	847 2 O
)	849 1 O
;	850 1 O
using	852 5 O
mixed	858 5 O
model	864 5 O
for	870 3 O
repeated	874 8 O
measures	883 8 O
(	892 1 O
MMRM	893 4 O
)	897 1 O
,	898 1 O
changes	900 7 O
at	908 2 O
day	911 3 O
42	915 2 O
were	918 4 O
significantly	923 13 O
greater	937 7 O
with	945 4 O
asenapine	950 9 B-Chemical
at	960 2 O
5	963 1 O
and	965 3 O
10	969 2 O
mg	972 2 O
BID	975 3 O
(	979 1 O
-	980 1 O
21	981 2 O
.	983 1 O
3	984 1 O
and	986 3 O
-	990 1 O
19	991 2 O
.	993 1 O
4	994 1 O
,	995 1 O
respectively	997 12 O
)	1009 1 O
and	1011 3 O
haloperidol	1015 11 B-Chemical
(	1027 1 O
-	1028 1 O
20	1029 2 O
.	1031 1 O
0	1032 1 O
)	1033 1 O
than	1035 4 O
placebo	1040 7 O
(	1048 1 O
-	1049 1 O
14	1050 2 O
.	1052 1 O
6	1053 1 O
;	1054 1 O
all	1056 3 O
P	1060 1 O
<	1062 1 O
0	1064 1 O
.	1065 1 O
05	1066 2 O
)	1068 1 O
.	1069 1 O

On	1071 2 O
the	1074 3 O
Positive	1078 8 O
and	1087 3 O
Negative	1091 8 O
Syndrome	1100 8 O
Scale	1109 5 O
positive	1115 8 O
subscale	1124 8 O
,	1132 1 O
all	1134 3 O
treatments	1138 10 O
were	1149 4 O
superior	1154 8 O
to	1163 2 O
placebo	1166 7 O
with	1174 4 O
LOCF	1179 4 O
and	1184 3 O
MMRM	1188 4 O
;	1192 1 O
asenapine	1194 9 B-Chemical
at	1204 2 O
5	1207 1 O
mg	1209 2 O
BID	1212 3 O
was	1216 3 O
superior	1220 8 O
to	1229 2 O
placebo	1232 7 O
on	1240 2 O
the	1243 3 O
negative	1247 8 O
subscale	1256 8 O
with	1265 4 O
MMRM	1270 4 O
and	1275 3 O
on	1279 2 O
the	1282 3 O
general	1286 7 O
psychopathology	1294 15 O
subscale	1310 8 O
with	1319 4 O
LOCF	1324 4 O
and	1329 3 O
MMRM	1333 4 O
.	1337 1 O

Treatment	1339 9 O
-	1348 1 O
related	1349 7 O
adverse	1357 7 O
events	1365 6 O
(	1372 1 O
AEs	1373 3 O
)	1376 1 O
occurred	1378 8 O
in	1387 2 O
44	1390 2 O
%	1392 1 O
and	1394 3 O
52	1398 2 O
%	1400 1 O
,	1401 1 O
57	1403 2 O
%	1405 1 O
,	1406 1 O
and	1408 3 O
41	1412 2 O
%	1414 1 O
of	1416 2 O
the	1419 3 O
asenapine	1423 9 B-Chemical
at	1433 2 O
5	1436 1 O
and	1438 3 O
10	1442 2 O
mg	1445 2 O
BID	1448 3 O
,	1451 1 O
haloperidol	1453 11 B-Chemical
,	1464 1 O
and	1466 3 O
placebo	1470 7 O
groups	1478 6 O
,	1484 1 O
respectively	1486 12 O
.	1498 1 O

Extrapyramidal	1500 14 B-Disease
symptoms	1515 8 I-Disease
reported	1524 8 O
as	1533 2 O
AEs	1536 3 O
occurred	1540 8 O
in	1549 2 O
15	1552 2 O
%	1554 1 O
and	1556 3 O
18	1560 2 O
%	1562 1 O
,	1563 1 O
34	1565 2 O
%	1567 1 O
,	1568 1 O
and	1570 3 O
10	1574 2 O
%	1576 1 O
of	1578 2 O
the	1581 3 O
asenapine	1585 9 B-Chemical
at	1595 2 O
5	1598 1 O
and	1600 3 O
10	1604 2 O
mg	1607 2 O
BID	1610 3 O
,	1613 1 O
haloperidol	1615 11 B-Chemical
,	1626 1 O
and	1628 3 O
placebo	1632 7 O
groups	1640 6 O
,	1646 1 O
respectively	1648 12 O
.	1660 1 O

Across	1662 6 O
all	1669 3 O
groups	1673 6 O
,	1679 1 O
no	1681 2 O
more	1684 4 O
than	1689 4 O
5	1694 1 O
%	1695 1 O
of	1697 2 O
patients	1700 8 O
had	1709 3 O
clinically	1713 10 O
significant	1724 11 O
weight	1736 6 O
change	1743 6 O
.	1749 1 O

Post	1751 4 O
hoc	1756 3 O
analyses	1760 8 O
indicated	1769 9 O
that	1779 4 O
efficacy	1784 8 O
was	1793 3 O
similar	1797 7 O
with	1805 4 O
asenapine	1810 9 B-Chemical
and	1820 3 O
haloperidol	1824 11 B-Chemical
;	1835 1 O
greater	1837 7 O
contrasts	1845 9 O
were	1855 4 O
seen	1860 4 O
in	1865 2 O
AEs	1868 3 O
,	1871 1 O
especially	1873 10 O
extrapyramidal	1884 14 B-Disease
symptoms	1899 8 I-Disease
.	1907 1 O

Permeability	0 12 O
,	12 1 O
ultrastructural	14 15 O
changes	30 7 O
,	37 1 O
and	39 3 O
distribution	43 12 O
of	56 2 O
novel	59 5 O
proteins	65 8 O
in	74 2 O
the	77 3 O
glomerular	81 10 O
barrier	92 7 O
in	100 2 O
early	103 5 O
puromycin	109 9 B-Chemical
aminonucleoside	119 15 I-Chemical
nephrosis	135 9 B-Disease
.	144 1 O

BACKGROUND	146 10 O
/	156 1 O
AIMS	157 4 O
:	161 1 O
It	163 2 O
is	166 2 O
still	169 5 O
unclear	175 7 O
what	183 4 O
happens	188 7 O
in	196 2 O
the	199 3 O
glomerulus	203 10 O
when	214 4 O
proteinuria	219 11 B-Disease
starts	231 6 O
.	237 1 O

Using	239 5 O
puromycin	245 9 B-Chemical
aminonucleoside	255 15 I-Chemical
nephrosis	271 9 B-Disease
(	281 1 O
PAN	282 3 O
)	285 1 O
rats	287 4 O
,	291 1 O
we	293 2 O
studied	296 7 O
early	304 5 O
ultrastructural	310 15 O
and	326 3 O
permeability	330 12 O
changes	343 7 O
in	351 2 O
relation	354 8 O
to	363 2 O
the	366 3 O
expression	370 10 O
of	381 2 O
the	384 3 O
podocyte	388 8 O
-	396 1 O
associated	397 10 O
molecules	408 9 O
nephrin	418 7 O
,	425 1 O
a	427 1 O
-	428 1 O
actinin	429 7 O
,	436 1 O
dendrin	438 7 O
,	445 1 O
and	447 3 O
plekhh2	451 7 O
,	458 1 O
the	460 3 O
last	464 4 O
two	469 3 O
of	473 2 O
which	476 5 O
were	482 4 O
only	487 4 O
recently	492 8 O
discovered	501 10 O
in	512 2 O
podocytes	515 9 O
.	524 1 O

METHODS	526 7 O
:	533 1 O
Using	535 5 O
immune	541 6 O
stainings	548 9 O
,	557 1 O
semiquantitative	559 16 O
measurement	576 11 O
was	588 3 O
performed	592 9 O
under	602 5 O
the	608 3 O
electron	612 8 O
microscope	621 10 O
.	631 1 O

Permeability	633 12 O
was	646 3 O
assessed	650 8 O
using	659 5 O
isolated	665 8 O
kidney	674 6 O
perfusion	681 9 O
with	691 4 O
tracers	696 7 O
.	703 1 O

Possible	705 8 O
effects	714 7 O
of	722 2 O
ACE	725 3 O
inhibition	729 10 O
were	740 4 O
tested	745 6 O
.	751 1 O

RESULTS	753 7 O
:	760 1 O
By	762 2 O
day	765 3 O
2	769 1 O
,	770 1 O
some	772 4 O
patchy	777 6 O
foot	784 4 O
process	789 7 O
effacement	797 10 O
,	807 1 O
but	809 3 O
no	813 2 O
proteinuria	816 11 B-Disease
,	827 1 O
appeared	829 8 O
.	837 1 O

The	839 3 O
amount	843 6 O
of	850 2 O
nephrin	853 7 O
was	861 3 O
reduced	865 7 O
in	873 2 O
both	876 4 O
diseased	881 8 O
and	890 3 O
normal	894 6 O
areas	901 5 O
.	906 1 O

The	908 3 O
other	912 5 O
proteins	918 8 O
showed	927 6 O
few	934 3 O
changes	938 7 O
,	945 1 O
which	947 5 O
were	953 4 O
limited	958 7 O
to	966 2 O
diseased	969 8 O
areas	978 5 O
.	983 1 O

By	985 2 O
day	988 3 O
4	992 1 O
,	993 1 O
foot	995 4 O
process	1000 7 O
effacement	1008 10 O
was	1019 3 O
complete	1023 8 O
and	1032 3 O
proteinuria	1036 11 B-Disease
appeared	1048 8 O
in	1057 2 O
parallel	1060 8 O
with	1069 4 O
signs	1074 5 O
of	1080 2 O
size	1083 4 O
barrier	1088 7 O
damage	1096 6 O
.	1102 1 O

Nephrin	1104 7 O
decreased	1112 9 O
further	1122 7 O
,	1129 1 O
while	1131 5 O
dendrin	1137 7 O
and	1145 3 O
plekhh2	1149 7 O
also	1157 4 O
decreased	1162 9 O
but	1172 3 O
a	1176 1 O
-	1177 1 O
actinin	1178 7 O
remained	1186 8 O
unchanged	1195 9 O
.	1204 1 O

ACE	1206 3 O
inhibition	1210 10 O
had	1221 3 O
no	1225 2 O
significant	1228 11 O
protective	1240 10 O
effect	1251 6 O
.	1257 1 O

CONCLUSIONS	1259 11 O
:	1270 1 O
PAN	1272 3 O
glomeruli	1276 9 O
already	1286 7 O
showed	1294 6 O
significant	1301 11 O
pathology	1313 9 O
by	1323 2 O
day	1326 3 O
4	1330 1 O
,	1331 1 O
despite	1333 7 O
relatively	1341 10 O
mild	1352 4 O
proteinuria	1357 11 B-Disease
.	1368 1 O

This	1370 4 O
was	1375 3 O
preceded	1379 8 O
by	1388 2 O
altered	1391 7 O
nephrin	1399 7 O
expression	1407 10 O
,	1417 1 O
supporting	1419 10 O
its	1430 3 O
pivotal	1434 7 O
role	1442 4 O
in	1447 2 O
podocyte	1450 8 O
morphology	1459 10 O
.	1469 1 O

The	1471 3 O
novel	1475 5 O
proteins	1481 8 O
dendrin	1490 7 O
and	1498 3 O
plekhh2	1502 7 O
were	1510 4 O
both	1515 4 O
reduced	1520 7 O
,	1527 1 O
suggesting	1529 10 O
roles	1540 5 O
in	1546 2 O
PAN	1549 3 O
,	1552 1 O
whereas	1554 7 O
a	1562 1 O
-	1563 1 O
actinin	1564 7 O
was	1572 3 O
unchanged	1576 9 O
.	1585 1 O

Twin	0 4 O
preterm	5 7 O
neonates	13 8 O
with	22 4 O
cardiac	27 7 B-Disease
toxicity	35 8 I-Disease
related	44 7 O
to	52 2 O
lopinavir	55 9 B-Chemical
/	64 1 I-Chemical
ritonavir	65 9 I-Chemical
therapy	75 7 O
.	82 1 O

We	84 2 O
report	87 6 O
twin	94 4 O
neonates	99 8 O
who	108 3 O
were	112 4 O
born	117 4 O
prematurely	122 11 O
at	134 2 O
32	137 2 O
weeks	140 5 O
of	146 2 O
gestation	149 9 O
to	159 2 O
a	162 1 O
mother	164 6 O
with	171 4 O
human	176 5 B-Disease
immunodeficiency	182 16 I-Disease
virus	199 5 I-Disease
infection	205 9 I-Disease
.	214 1 O

One	216 3 O
of	220 2 O
the	223 3 O
twins	227 5 O
developed	233 9 O
complete	243 8 O
heart	252 5 B-Disease
block	258 5 I-Disease
and	264 3 O
dilated	268 7 B-Disease
cardiomyopathy	276 14 I-Disease
related	291 7 O
to	299 2 O
lopinavir	302 9 B-Chemical
/	311 1 I-Chemical
ritonavir	312 9 I-Chemical
therapy	322 7 O
,	329 1 O
a	331 1 O
boosted	333 7 O
protease	341 8 O
-	349 1 O
inhibitor	350 9 O
agent	360 5 O
,	365 1 O
while	367 5 O
the	373 3 O
other	377 5 O
twin	383 4 O
developed	388 9 O
mild	398 4 O
bradycardia	403 11 B-Disease
.	414 1 O

We	416 2 O
recommend	419 9 O
caution	429 7 O
in	437 2 O
the	440 3 O
use	444 3 O
of	448 2 O
lopinavir	451 9 B-Chemical
/	460 1 I-Chemical
ritonavir	461 9 I-Chemical
in	471 2 O
the	474 3 O
immediate	478 9 O
neonatal	488 8 O
period	497 6 O
.	503 1 O

Learning	0 8 O
of	9 2 O
rats	12 4 O
under	17 5 O
amnesia	23 7 B-Disease
caused	31 6 O
by	38 2 O
pentobarbital	41 13 B-Chemical
.	54 1 O

Dissociated	56 11 O
learning	68 8 O
of	77 2 O
rats	80 4 O
in	85 2 O
the	88 3 O
normal	92 6 O
state	99 5 O
and	105 3 O
the	109 3 O
state	113 5 O
of	119 2 O
amnesia	122 7 B-Disease
produced	130 8 O
by	139 2 O
pentobarbital	142 13 B-Chemical
(	156 1 O
15	157 2 O
mg	160 2 O
/	162 1 O
kg	163 2 O
,	165 1 O
ip	167 2 O
)	169 1 O
was	171 3 O
carried	175 7 O
out	183 3 O
.	186 1 O

Rats	188 4 O
were	193 4 O
trained	198 7 O
to	206 2 O
approach	209 8 O
a	218 1 O
shelf	220 5 O
where	226 5 O
they	232 4 O
received	237 8 O
food	246 4 O
reinforcement	251 13 O
.	264 1 O

In	266 2 O
Group	269 5 O
1	275 1 O
the	277 3 O
rats	281 4 O
were	286 4 O
trained	291 7 O
under	299 5 O
the	305 3 O
influence	309 9 O
of	319 2 O
pentobarbital	322 13 B-Chemical
to	336 2 O
run	339 3 O
to	343 2 O
the	346 3 O
same	350 4 O
shelf	355 5 O
as	361 2 O
in	364 2 O
the	367 3 O
normal	371 6 O
state	378 5 O
.	383 1 O

In	385 2 O
Group	388 5 O
2	394 1 O
the	396 3 O
rats	400 4 O
were	405 4 O
trained	410 7 O
to	418 2 O
approach	421 8 O
different	430 9 O
shelves	440 7 O
in	448 2 O
different	451 9 O
drug	461 4 O
states	466 6 O
.	472 1 O

It	474 2 O
was	477 3 O
shown	481 5 O
that	487 4 O
memory	492 6 B-Disease
dissociation	499 12 I-Disease
occurred	512 8 O
in	521 2 O
both	524 4 O
groups	529 6 O
.	535 1 O

Differences	537 11 O
in	549 2 O
the	552 3 O
parameters	556 10 O
of	567 2 O
training	570 8 O
under	579 5 O
the	585 3 O
influence	589 9 O
of	599 2 O
pentobarbital	602 13 B-Chemical
between	616 7 O
Groups	624 6 O
1	631 1 O
and	633 3 O
2	637 1 O
were	639 4 O
revealed	644 8 O
.	652 1 O

These	654 5 O
findings	660 8 O
show	669 4 O
that	674 4 O
the	679 3 O
brain	683 5 O
-	688 1 O
dissociated	689 11 O
state	701 5 O
induced	707 7 O
by	715 2 O
pentobarbital	718 13 B-Chemical
is	732 2 O
formed	735 6 O
with	742 4 O
the	747 3 O
participation	751 13 O
of	765 2 O
the	768 3 O
mechanisms	772 10 O
of	783 2 O
information	786 11 O
perception	798 10 O
.	808 1 O

Angiosarcoma	0 12 B-Disease
of	13 2 I-Disease
the	16 3 I-Disease
liver	20 5 I-Disease
associated	26 10 O
with	37 4 O
diethylstilbestrol	42 18 B-Chemical
.	60 1 O

Angiosarcoma	62 12 B-Disease
of	75 2 I-Disease
the	78 3 I-Disease
liver	82 5 I-Disease
occurred	88 8 O
in	97 2 O
a	100 1 O
76	102 2 O
-	104 1 O
year	105 4 O
-	109 1 O
old	110 3 O
man	114 3 O
who	118 3 O
had	122 3 O
been	126 4 O
treated	131 7 O
for	139 3 O
a	143 1 O
well	145 4 O
-	149 1 O
differentiated	150 14 O
adenocarcinoma	165 14 B-Disease
of	180 2 I-Disease
the	183 3 I-Disease
liver	187 5 I-Disease
with	193 4 O
diethylstilbestrol	198 18 B-Chemical
for	217 3 O
13	221 2 O
years	224 5 O
.	229 1 O

Angiosarcoma	231 12 B-Disease
was	244 3 O
also	248 4 O
present	253 7 O
within	261 6 O
pulmonary	268 9 O
and	278 3 O
renal	282 5 O
arteries	288 8 O
.	296 1 O

The	298 3 O
possibility	302 11 O
that	314 4 O
the	319 3 O
intraarterial	323 13 B-Disease
lesions	337 7 I-Disease
might	345 5 O
represent	351 9 O
independent	361 11 O
primary	373 7 O
tumors	381 6 B-Disease
is	388 2 O
considered	391 10 O
.	401 1 O

Role	0 4 O
of	5 2 O
xanthine	8 8 B-Chemical
oxidase	17 7 O
in	25 2 O
dexamethasone	28 13 B-Chemical
-	41 1 O
induced	42 7 O
hypertension	50 12 B-Disease
in	63 2 O
rats	66 4 O
.	70 1 O

1	72 1 O
.	73 1 O

Glucocorticoid	75 14 O
-	89 1 O
induced	90 7 O
hypertension	98 12 B-Disease
(	111 1 O
GC	112 2 O
-	114 1 O
HT	115 2 B-Disease
)	117 1 O
in	119 2 O
the	122 3 O
rat	126 3 O
is	130 2 O
associated	133 10 O
with	144 4 O
nitric	149 6 B-Chemical
oxide	156 5 I-Chemical
-	161 1 O
redox	162 5 O
imbalance	168 9 O
.	177 1 O

2	179 1 O
.	180 1 O

We	182 2 O
studied	185 7 O
the	193 3 O
role	197 4 O
of	202 2 O
xanthine	205 8 B-Chemical
oxidase	214 7 O
(	222 1 O
XO	223 2 O
)	225 1 O
,	226 1 O
which	228 5 O
is	234 2 O
implicated	237 10 O
in	248 2 O
the	251 3 O
production	255 10 O
of	266 2 O
reactive	269 8 O
oxygen	278 6 O
species	285 7 O
,	292 1 O
in	294 2 O
dexamethasone	297 13 B-Chemical
-	310 1 O
induced	311 7 O
hypertension	319 12 B-Disease
(	332 1 O
dex	333 3 B-Chemical
-	336 1 O
HT	337 2 B-Disease
)	339 1 O
.	340 1 O

3	342 1 O
.	343 1 O

Thirty	345 6 O
male	352 4 O
Sprague	357 7 O
-	364 1 O
Dawley	365 6 O
rats	372 4 O
were	377 4 O
divided	382 7 O
randomly	390 8 O
into	399 4 O
four	404 4 O
treatment	409 9 O
groups	419 6 O
:	425 1 O
saline	427 6 O
,	433 1 O
dexamethasone	435 13 B-Chemical
(	449 1 O
dex	450 3 B-Chemical
)	453 1 O
,	454 1 O
allopurinol	456 11 B-Chemical
plus	468 4 O
saline	473 6 O
,	479 1 O
and	481 3 O
allopurinol	485 11 B-Chemical
plus	497 4 O
dex	502 3 B-Chemical
.	505 1 O

4	507 1 O
.	508 1 O

Systolic	510 8 O
blood	519 5 O
pressures	525 9 O
(	535 1 O
SBP	536 3 O
)	539 1 O
and	541 3 O
bodyweights	545 11 O
were	557 4 O
recorded	562 8 O
each	571 4 O
alternate	576 9 O
day	586 3 O
.	589 1 O

Thymus	591 6 O
weight	598 6 O
was	605 3 O
used	609 4 O
as	614 2 O
a	617 1 O
marker	619 6 O
of	626 2 O
glucocorticoid	629 14 O
activity	644 8 O
,	652 1 O
and	654 3 O
serum	658 5 O
urate	664 5 B-Chemical
to	670 2 O
assess	673 6 O
XO	680 2 O
inhibition	683 10 O
.	693 1 O

5	695 1 O
.	696 1 O

Dex	698 3 B-Chemical
increased	702 9 B-Disease
SBP	712 3 I-Disease
(	716 1 O
110	717 3 O
+	721 1 O
/	722 1 O
-	723 1 O
2	725 1 O
-	726 1 O
126	727 3 O
+	731 1 O
/	732 1 O
-	733 1 O
3	735 1 O
mmHg	737 4 O
;	741 1 O
P	743 1 O
<	745 1 O
0	747 1 O
.	748 1 O
001	749 3 O
)	752 1 O
and	754 3 O
decreased	758 9 B-Disease
thymus	768 6 I-Disease
(	775 1 I-Disease
P	776 1 I-Disease
<	778 1 I-Disease
0	780 1 I-Disease
.	781 1 I-Disease
001	782 3 I-Disease
)	785 1 I-Disease
and	787 3 I-Disease
bodyweights	791 11 I-Disease
(	803 1 O
P	804 1 O
"	805 1 O
<	807 1 O
0	809 1 O
.	810 1 O
01	811 2 O
)	813 1 O
.	814 1 O

Allopurinol	816 11 B-Chemical
decreased	828 9 O
serum	838 5 O
urate	844 5 B-Chemical
from	850 4 O
76	855 2 O
+	858 1 O
/	859 1 O
-	860 1 O
5	862 1 O
to	864 2 O
30	867 2 O
+	870 1 O
/	871 1 O
-	872 1 O
3	874 1 O
micromol	876 8 O
/	884 1 O
L	885 1 O
(	887 1 O
P	888 1 O
<	890 1 O
0	892 1 O
.	893 1 O
001	894 3 O
)	897 1 O
in	899 2 O
saline	902 6 O
and	909 3 O
from	913 4 O
84	918 2 O
+	921 1 O
/	922 1 O
-	923 1 O
13	925 2 O
to	928 2 O
28	931 2 O
+	934 1 O
/	935 1 O
-	936 1 O
2	938 1 O
micromol	940 8 O
/	948 1 O
L	949 1 O
in	951 2 O
dex	954 3 B-Chemical
-	957 1 O
treated	958 7 O
(	966 1 O
P	967 1 O
<	969 1 O
0	971 1 O
.	972 1 O
01	973 2 O
)	975 1 O
groups	977 6 O
.	983 1 O

6	985 1 O
.	986 1 O

Allopurinol	988 11 B-Chemical
did	1000 3 O
not	1004 3 O
prevent	1008 7 O
dex	1016 3 B-Chemical
-	1019 1 O
HT	1020 2 B-Disease
.	1022 1 O

This	1024 4 O
,	1028 1 O
together	1030 8 O
with	1039 4 O
our	1044 3 O
previous	1048 8 O
findings	1057 8 O
that	1066 4 O
allopurinol	1071 11 B-Chemical
failed	1083 6 O
to	1090 2 O
prevent	1093 7 O
adrenocorticotrophic	1101 20 O
hormone	1122 7 O
induced	1130 7 O
hypertension	1138 12 B-Disease
,	1150 1 O
suggests	1152 8 O
that	1161 4 O
XO	1166 2 O
activity	1169 8 O
is	1178 2 O
not	1181 3 O
a	1185 1 O
major	1187 5 O
determinant	1193 11 O
of	1205 2 O
GC	1208 2 O
-	1210 1 O
HT	1211 2 B-Disease
in	1214 2 O
the	1217 3 O
rat	1221 3 O
.	1224 1 O

Extrapyramidal	0 14 O
side	15 4 O
effects	20 7 O
with	28 4 O
risperidone	33 11 B-Chemical
and	45 3 O
haloperidol	49 11 B-Chemical
at	61 2 O
comparable	64 10 O
D2	75 2 O
receptor	78 8 O
occupancy	87 9 O
levels	97 6 O
.	103 1 O

Risperidone	105 11 B-Chemical
is	117 2 O
an	120 2 O
antipsychotic	123 13 O
drug	137 4 O
with	142 4 O
high	147 4 O
affinity	152 8 O
at	161 2 O
dopamine	164 8 B-Chemical
D2	173 2 O
and	176 3 O
serotonin	180 9 B-Chemical
5	190 1 I-Chemical
-	191 1 I-Chemical
HT2	192 3 I-Chemical
receptors	196 9 O
.	205 1 O

Previous	207 8 O
clinical	216 8 O
studies	225 7 O
have	233 4 O
proposed	238 8 O
that	247 4 O
risperidone	252 11 B-Chemical
'	263 1 O
s	264 1 O
pharmacologic	266 13 O
profile	280 7 O
may	288 3 O
produce	292 7 O
improved	300 8 O
efficacy	309 8 O
for	318 3 O
negative	322 8 O
psychotic	331 9 B-Disease
symptoms	341 8 I-Disease
and	350 3 O
decreased	354 9 O
propensity	364 10 O
for	375 3 O
extrapyramidal	379 14 O
side	394 4 O
effects	399 7 O
;	406 1 O
features	408 8 O
shared	417 6 O
by	424 2 O
so	427 2 O
-	429 1 O
called	430 6 O
'	437 1 O
atypical	438 8 O
'	446 1 O
neuroleptics	448 12 O
.	460 1 O

To	462 2 O
determine	465 9 O
if	475 2 O
routine	478 7 O
risperidone	486 11 B-Chemical
treatment	498 9 O
is	508 2 O
associated	511 10 O
with	522 4 O
a	527 1 O
unique	529 6 O
degree	536 6 O
of	543 2 O
D2	546 2 O
receptor	549 8 O
occupancy	558 9 O
and	568 3 O
pattern	572 7 O
of	580 2 O
clinical	583 8 O
effects	592 7 O
,	599 1 O
we	601 2 O
used	604 4 O
[	609 1 O
123I	610 4 O
]	614 1 O
IBZM	615 4 O
SPECT	620 5 O
to	626 2 O
determine	629 9 O
D2	639 2 O
occupancy	642 9 O
in	652 2 O
subjects	655 8 O
treated	664 7 O
with	672 4 O
routine	677 7 O
clinical	685 8 O
doses	694 5 O
of	700 2 O
risperidone	703 11 B-Chemical
(	715 1 O
n	716 1 O
=	718 1 O
12	720 2 O
)	722 1 O
or	724 2 O
haloperidol	727 11 B-Chemical
(	739 1 O
n	740 1 O
=	742 1 O
7	744 1 O
)	745 1 O
.	746 1 O

Both	748 4 O
risperidone	753 11 B-Chemical
and	765 3 O
haloperidol	769 11 B-Chemical
produced	781 8 O
D2	790 2 O
occupancy	793 9 O
levels	803 6 O
between	810 7 O
approximately	818 13 O
60	832 2 O
and	835 3 O
90	839 2 O
%	841 1 O
at	843 2 O
standard	846 8 O
clinical	855 8 O
doses	864 5 O
.	869 1 O

There	871 5 O
was	877 3 O
no	881 2 O
significant	884 11 O
difference	896 10 O
between	907 7 O
occupancy	915 9 O
levels	925 6 O
obtained	932 8 O
with	941 4 O
haloperidol	946 11 B-Chemical
or	958 2 O
risperidone	961 11 B-Chemical
.	972 1 O

Drug	974 4 B-Disease
-	978 1 I-Disease
induced	979 7 I-Disease
parkinsonism	987 12 I-Disease
was	1000 3 O
observed	1004 8 O
in	1013 2 O
subjects	1016 8 O
treated	1025 7 O
with	1033 4 O
risperidone	1038 11 B-Chemical
(	1050 1 O
42	1051 2 O
%	1053 1 O
)	1054 1 O
and	1056 3 O
haloperidol	1060 11 B-Chemical
(	1072 1 O
29	1073 2 O
%	1075 1 O
)	1076 1 O
and	1078 3 O
was	1082 3 O
observed	1086 8 O
at	1095 2 O
occupancy	1098 9 O
levels	1108 6 O
above	1115 5 O
60	1121 2 O
%	1123 1 O
.	1124 1 O

Based	1126 5 O
on	1132 2 O
these	1135 5 O
observations	1141 12 O
,	1153 1 O
it	1155 2 O
is	1158 2 O
concluded	1161 9 O
that	1171 4 O
5	1176 1 O
-	1177 1 O
HT2	1178 3 O
blockade	1182 8 O
obtained	1191 8 O
with	1200 4 O
risperidone	1205 11 B-Chemical
at	1217 2 O
D2	1220 2 O
occupancy	1223 9 O
rates	1233 5 O
of	1239 2 O
60	1242 2 O
%	1244 1 O
and	1246 3 O
above	1250 5 O
does	1256 4 O
not	1261 3 O
appear	1265 6 O
to	1272 2 O
protect	1275 7 O
against	1283 7 O
the	1291 3 O
risk	1295 4 O
for	1300 3 O
extrapyramidal	1304 14 O
side	1319 4 O
effects	1324 7 O
.	1331 1 O

Simvastatin	0 11 B-Chemical
-	11 1 I-Chemical
ezetimibe	12 9 I-Chemical
-	21 1 O
induced	22 7 O
hepatic	30 7 B-Disease
failure	38 7 I-Disease
necessitating	46 13 O
liver	60 5 O
transplantation	66 15 O
.	81 1 O

Abstract	83 8 O
Serum	92 5 O
aminotransferase	98 16 O
elevations	115 10 O
are	126 3 O
a	130 1 O
commonly	132 8 O
known	141 5 O
adverse	147 7 O
effect	155 6 O
of	162 2 O
3	165 1 O
-	166 1 O
hydroxy	167 7 O
-	174 1 O
3	175 1 O
-	176 1 O
methylglutaryl	177 14 O
coenzyme	192 8 O
A	201 1 O
reductase	203 9 O
inhibitor	213 9 O
(	223 1 O
statin	224 6 B-Chemical
)	230 1 O
therapy	232 7 O
.	239 1 O

However	241 7 O
,	248 1 O
hepatotoxic	250 11 B-Disease
events	262 6 O
have	269 4 O
not	274 3 O
been	278 4 O
widely	283 6 O
published	290 9 O
with	300 4 O
ezetimibe	305 9 B-Chemical
or	315 2 O
the	318 3 O
combination	322 11 O
agent	334 5 O
simvastatin	340 11 B-Chemical
-	351 1 I-Chemical
ezetimibe	352 9 I-Chemical
.	361 1 O

We	363 2 O
describe	366 8 O
a	375 1 O
70	377 2 O
-	379 1 O
year	380 4 O
-	384 1 O
old	385 3 O
Hispanic	389 8 O
woman	398 5 O
who	404 3 O
developed	408 9 O
fulminant	418 9 B-Disease
hepatic	428 7 I-Disease
failure	436 7 I-Disease
necessitating	444 13 O
liver	458 5 O
transplantation	464 15 O
10	480 2 O
weeks	483 5 O
after	489 5 O
conversion	495 10 O
from	506 4 O
simvastatin	511 11 B-Chemical
40	523 2 O
mg	526 2 O
/	528 1 O
day	529 3 O
to	533 2 O
simvastatin	536 11 B-Chemical
10	548 2 I-Chemical
mg	551 2 I-Chemical
-	553 1 I-Chemical
ezetimibe	554 9 I-Chemical
40	564 2 I-Chemical
mg	567 2 I-Chemical
/	569 1 O
day	570 3 O
.	573 1 O

The	575 3 O
patient	579 7 O
'	586 1 O
s	587 1 O
lipid	589 5 O
panel	595 5 O
had	601 3 O
been	605 4 O
maintained	610 10 O
with	621 4 O
simvastatin	626 11 B-Chemical
for	638 3 O
18	642 2 O
months	645 6 O
before	652 6 O
the	659 3 O
conversion	663 10 O
without	674 7 O
evidence	682 8 O
of	691 2 O
hepatotoxicity	694 14 B-Disease
.	708 1 O

A	710 1 O
routine	712 7 O
laboratory	720 10 O
work	731 4 O
-	735 1 O
up	736 2 O
10	739 2 O
weeks	742 5 O
after	748 5 O
conversion	754 10 O
revealed	765 8 O
elevated	774 8 O
serum	783 5 O
aminotransferase	789 16 O
levels	806 6 O
.	812 1 O

Simvastatinezetimibe	814 20 B-Chemical
and	835 3 O
escitalopram	839 12 B-Chemical
(	852 1 O
which	853 5 O
she	859 3 O
was	863 3 O
taking	867 6 O
for	874 3 O
depression	878 10 B-Disease
)	888 1 O
were	890 4 O
discontinued	895 12 O
,	907 1 O
and	909 3 O
other	913 5 O
potential	919 9 O
causes	929 6 O
of	936 2 O
hepatotoxicity	939 14 B-Disease
were	954 4 O
excluded	959 8 O
.	967 1 O

A	969 1 O
repeat	971 6 O
work	978 4 O
-	982 1 O
up	983 2 O
revealed	986 8 O
further	995 7 O
elevations	1003 10 O
in	1014 2 O
aminotransferase	1017 16 O
levels	1034 6 O
,	1040 1 O
and	1042 3 O
liver	1046 5 O
biopsy	1052 6 O
revealed	1059 8 O
evidence	1068 8 O
of	1077 2 O
moderate	1080 8 O
-	1088 1 O
to	1089 2 O
-	1091 1 O
severe	1092 6 O
drug	1099 4 B-Disease
toxicity	1104 8 I-Disease
.	1112 1 O

She	1114 3 O
underwent	1118 9 O
liver	1128 5 O
transplantation	1134 15 O
with	1150 4 O
an	1155 2 O
uneventful	1158 10 O
postoperative	1169 13 O
course	1183 6 O
.	1189 1 O

Her	1191 3 O
aminotransferase	1195 16 O
levels	1212 6 O
returned	1219 8 O
to	1228 2 O
normal	1231 6 O
by	1238 2 O
postoperative	1241 13 O
day	1255 3 O
23	1259 2 O
,	1261 1 O
and	1263 3 O
her	1267 3 O
2	1271 1 O
-	1272 1 O
year	1273 4 O
follow	1278 6 O
-	1284 1 O
up	1285 2 O
showed	1288 6 O
no	1295 2 O
adverse	1298 7 O
events	1306 6 O
.	1312 1 O

Ezetimibe	1314 9 B-Chemical
undergoes	1324 9 O
extensive	1334 9 O
glucuronidation	1344 15 O
by	1360 2 O
uridine	1363 7 B-Chemical
diphosphate	1371 11 I-Chemical
glucoronosyltransferases	1383 24 O
(	1408 1 O
UGT	1409 3 O
)	1412 1 O
in	1414 2 O
the	1417 3 O
intestine	1421 9 O
and	1431 3 O
liver	1435 5 O
and	1441 3 O
may	1445 3 O
have	1449 4 O
inhibited	1454 9 O
the	1464 3 O
glucuronidation	1468 15 O
of	1484 2 O
simvastatin	1487 11 B-Chemical
hydroxy	1499 7 I-Chemical
acid	1507 4 I-Chemical
,	1511 1 O
resulting	1513 9 O
in	1523 2 O
increased	1526 9 O
simvastatin	1536 11 B-Chemical
exposure	1548 8 O
and	1557 3 O
subsequent	1561 10 O
hepatotoxicity	1572 14 B-Disease
.	1586 1 O

To	1588 2 O
our	1591 3 O
knowledge	1595 9 O
,	1604 1 O
this	1606 4 O
is	1611 2 O
the	1614 3 O
first	1618 5 O
case	1624 4 O
report	1629 6 O
of	1636 2 O
simvastatin	1639 11 B-Chemical
-	1650 1 I-Chemical
ezetimibe	1651 9 I-Chemical
-	1660 1 O
induced	1661 7 O
liver	1669 5 B-Disease
failure	1675 7 I-Disease
that	1683 4 O
resulted	1688 8 O
in	1697 2 O
liver	1700 5 O
transplantation	1706 15 O
.	1721 1 O

We	1723 2 O
postulate	1726 9 O
that	1736 4 O
the	1741 3 O
mechanism	1745 9 O
of	1755 2 O
the	1758 3 O
simvastatinezetimibe	1762 20 B-Chemical
-	1782 1 O
induced	1783 7 O
hepatotoxicity	1791 14 B-Disease
is	1806 2 O
the	1809 3 O
increased	1813 9 O
simvastatin	1823 11 B-Chemical
exposure	1835 8 O
by	1844 2 O
ezetimibe	1847 9 B-Chemical
inhibition	1857 10 O
of	1868 2 O
UGT	1871 3 O
enzymes	1875 7 O
.	1882 1 O

Clinicians	1884 10 O
should	1895 6 O
be	1902 2 O
aware	1905 5 O
of	1911 2 O
potential	1914 9 O
hepatotoxicity	1924 14 B-Disease
with	1939 4 O
simvastatin	1944 11 B-Chemical
-	1955 1 I-Chemical
ezetimibe	1956 9 I-Chemical
especially	1966 10 O
in	1977 2 O
elderly	1980 7 O
patients	1988 8 O
and	1997 3 O
should	2001 6 O
carefully	2008 9 O
monitor	2018 7 O
serum	2026 5 O
aminotransferase	2032 16 O
levels	2049 6 O
when	2056 4 O
starting	2061 8 O
therapy	2070 7 O
and	2078 3 O
titrating	2082 9 O
the	2092 3 O
dosage	2096 6 O
.	2102 1 O

Oral	0 4 O
manifestations	5 14 O
of	20 2 O
"	23 1 O
meth	24 4 B-Disease
mouth	29 5 I-Disease
"	34 1 O
:	35 1 O
a	37 1 O
case	39 4 O
report	44 6 O
.	50 1 O

AIM	52 3 O
:	55 1 O
The	57 3 O
aim	61 3 O
of	65 2 O
the	68 3 O
documentation	72 13 O
of	86 2 O
this	89 4 O
clinical	94 8 O
case	103 4 O
is	108 2 O
to	111 2 O
make	114 4 O
clinicians	119 10 O
aware	130 5 O
of	136 2 O
"	139 1 O
meth	140 4 B-Disease
mouth	145 5 I-Disease
"	150 1 O
and	152 3 O
the	156 3 O
medical	160 7 O
risks	168 5 O
associated	174 10 O
with	185 4 O
this	190 4 O
serious	195 7 O
condition	203 9 O
.	212 1 O

BACKGROUND	214 10 O
:	224 1 O
Methamphetamine	226 15 B-Chemical
is	242 2 O
a	245 1 O
very	247 4 O
addictive	252 9 O
,	261 1 O
powerful	263 8 O
stimulant	272 9 O
that	282 4 O
increases	287 9 O
wakefulness	297 11 O
and	309 3 O
physical	313 8 O
activity	322 8 O
and	331 3 O
can	335 3 O
produce	339 7 O
other	347 5 O
effects	353 7 O
such	361 4 O
as	366 2 O
cardiac	369 7 B-Disease
dysrhythmias	377 12 I-Disease
,	389 1 O
hypertension	391 12 B-Disease
,	403 1 O
hallucinations	405 14 B-Disease
,	419 1 O
and	421 3 O
violent	425 7 B-Disease
behavior	433 8 I-Disease
.	441 1 O

Dental	443 6 O
patients	450 8 O
abusing	459 7 O
methamphetamine	467 15 B-Chemical
can	483 3 O
present	487 7 O
with	495 4 O
poor	500 4 O
oral	505 4 O
hygiene	510 7 O
,	517 1 O
xerostomia	519 10 B-Disease
,	529 1 O
rampant	531 7 O
caries	539 6 B-Disease
(	546 1 O
"	547 1 O
meth	548 4 B-Disease
mouth	553 5 I-Disease
"	558 1 O
)	559 1 O
,	560 1 O
and	562 3 O
excessive	566 9 O
tooth	576 5 B-Disease
wear	582 4 I-Disease
.	586 1 O

Oral	588 4 O
rehabilitation	593 14 O
of	608 2 O
patients	611 8 O
using	620 5 O
methamphetamine	626 15 B-Chemical
can	642 3 O
be	646 2 O
challenging	649 11 O
.	660 1 O

CASE	662 4 O
DESCRIPTION	667 11 O
:	678 1 O
A	680 1 O
30	682 2 O
-	684 1 O
year	685 4 O
-	689 1 O
old	690 3 O
Caucasian	694 9 O
woman	704 5 O
presented	710 9 O
with	720 4 O
dental	725 6 O
pain	732 4 B-Disease
,	736 1 O
bad	738 3 B-Disease
breath	742 6 I-Disease
,	748 1 O
and	750 3 O
self	754 4 O
-	758 1 O
reported	759 8 O
poor	768 4 O
esthetics	773 9 O
.	782 1 O

A	784 1 O
comprehensive	786 13 O
examination	800 11 O
including	812 9 O
her	822 3 O
medical	826 7 O
history	834 7 O
,	841 1 O
panoramic	843 9 O
radiograph	853 10 O
,	863 1 O
and	865 3 O
intraoral	869 9 O
examination	879 11 O
revealed	891 8 O
19	900 2 O
carious	903 7 B-Disease
lesions	911 7 I-Disease
,	918 1 O
which	920 5 O
is	926 2 O
not	929 3 O
very	933 4 O
common	938 6 O
for	945 3 O
a	949 1 O
healthy	951 7 O
adult	959 5 O
.	964 1 O

She	966 3 O
reported	970 8 O
her	979 3 O
use	983 3 O
of	987 2 O
methamphetamine	990 15 B-Chemical
for	1006 3 O
five	1010 4 O
years	1015 5 O
and	1021 3 O
had	1025 3 O
not	1029 3 O
experienced	1033 11 O
any	1045 3 O
major	1049 5 O
carious	1055 7 B-Disease
episodes	1063 8 I-Disease
before	1072 6 O
she	1079 3 O
started	1083 7 O
using	1091 5 O
the	1097 3 O
drug	1101 4 O
.	1105 1 O

SUMMARY	1107 7 O
:	1114 1 O
The	1116 3 O
patient	1120 7 O
'	1127 1 O
s	1128 1 O
medical	1130 7 O
and	1138 3 O
dental	1142 6 O
histories	1149 9 O
along	1159 5 O
with	1165 4 O
radiographic	1170 12 O
and	1183 3 O
clinical	1187 8 O
findings	1196 8 O
lead	1205 4 O
to	1210 2 O
a	1213 1 O
diagnosis	1215 9 O
of	1225 2 O
"	1228 1 O
meth	1229 4 B-Disease
mouth	1234 5 I-Disease
.	1239 1 O
"	1240 1 O
Although	1242 8 O
three	1251 5 O
different	1257 9 O
dental	1267 6 O
treatment	1274 9 O
modalities	1284 10 O
(	1295 1 O
either	1296 6 O
conventional	1303 12 O
or	1316 2 O
implant	1319 7 O
-	1326 1 O
supported	1327 9 O
)	1336 1 O
have	1338 4 O
been	1343 4 O
offered	1348 7 O
to	1356 2 O
the	1359 3 O
patient	1363 7 O
since	1371 5 O
August	1377 6 O
2007	1384 4 O
,	1388 1 O
the	1390 3 O
patient	1394 7 O
has	1402 3 O
yet	1406 3 O
to	1410 2 O
initiate	1413 8 O
any	1422 3 O
treatment	1426 9 O
.	1435 1 O

CLINICAL	1437 8 O
SIGNIFICANCE	1446 12 O
:	1458 1 O
This	1460 4 O
clinical	1465 8 O
case	1474 4 O
showing	1479 7 O
oral	1487 4 O
manifestations	1492 14 O
of	1507 2 O
meth	1510 4 B-Disease
mouth	1515 5 I-Disease
was	1521 3 O
presented	1525 9 O
to	1535 2 O
help	1538 4 O
dental	1543 6 O
practitioners	1550 13 O
recognize	1564 9 O
and	1574 3 O
manage	1578 6 O
patients	1585 8 O
who	1594 3 O
may	1598 3 O
be	1602 2 O
abusing	1605 7 O
methamphetamines	1613 16 B-Chemical
.	1629 1 O

Dental	1631 6 O
practitioners	1638 13 O
also	1652 4 O
may	1657 3 O
be	1661 2 O
skeptical	1664 9 O
about	1674 5 O
the	1680 3 O
reliability	1684 11 O
of	1696 2 O
appointment	1699 11 O
keeping	1711 7 O
by	1719 2 O
these	1722 5 O
patients	1728 8 O
,	1736 1 O
as	1738 2 O
they	1741 4 O
frequently	1746 10 O
miss	1757 4 O
their	1762 5 O
appointments	1768 12 O
without	1781 7 O
reasonable	1789 10 O
justification	1800 13 O
.	1813 1 O

Thyroxine	0 9 B-Chemical
abuse	10 5 O
:	15 1 O
an	17 2 O
unusual	20 7 O
case	28 4 O
of	33 2 O
thyrotoxicosis	36 14 B-Disease
in	51 2 O
pregnancy	54 9 O
.	63 1 O

Eating	65 6 B-Disease
disorders	72 9 I-Disease
and	82 3 O
the	86 3 O
associated	90 10 O
behavioural	101 11 O
problems	113 8 O
and	122 3 O
drug	126 4 B-Disease
abuse	131 5 I-Disease
are	137 3 O
uncommon	141 8 O
in	150 2 O
pregnancy	153 9 O
.	162 1 O

When	164 4 O
they	169 4 O
do	174 2 O
occur	177 5 O
they	183 4 O
are	188 3 O
often	192 5 O
unrecognized	198 12 O
because	211 7 O
of	219 2 O
denial	222 6 O
but	229 3 O
when	233 4 O
significant	238 11 O
may	250 3 O
pose	254 4 O
a	259 1 O
risk	261 4 O
to	266 2 O
both	269 4 O
the	274 3 O
mother	278 6 O
and	285 3 O
her	289 3 O
fetus	293 5 O
.	298 1 O

This	300 4 O
case	305 4 O
illustrates	310 11 O
a	322 1 O
number	324 6 O
of	331 2 O
problems	334 8 O
that	343 4 O
may	348 3 O
be	352 2 O
encountered	355 11 O
in	367 2 O
women	370 5 O
with	376 4 O
eating	381 6 B-Disease
disorders	388 9 I-Disease
in	398 2 O
pregnancy	401 9 O
,	410 1 O
including	412 9 O
prolonged	422 9 O
and	432 3 O
recurrent	436 9 O
metabolic	446 9 O
disturbances	456 12 O
and	469 3 O
diuretic	473 8 O
abuse	482 5 O
.	487 1 O

In	489 2 O
particular	492 10 O
it	503 2 O
illustrates	506 11 O
the	518 3 O
derangements	522 12 O
of	535 2 O
thyroid	538 7 O
function	546 8 O
seen	555 4 O
in	560 2 O
pregnant	563 8 O
women	572 5 O
with	578 4 O
eating	583 6 B-Disease
disorders	590 9 I-Disease
and	600 3 O
reminds	604 7 O
us	612 2 O
that	615 4 O
when	620 4 O
a	625 1 O
cause	627 5 O
for	633 3 O
thyrotoxicosis	637 14 B-Disease
remains	652 7 O
obscure	660 7 O
,	667 1 O
thyroxine	669 9 B-Chemical
abuse	679 5 O
should	685 6 O
be	692 2 O
considered	695 10 O
and	706 3 O
explored	710 8 O
.	718 1 O

Attenuation	0 11 O
of	12 2 O
methamphetamine	15 15 B-Chemical
-	30 1 O
induced	31 7 O
nigrostriatal	39 13 O
dopaminergic	53 12 O
neurotoxicity	66 13 B-Disease
in	80 2 O
mice	83 4 O
by	88 2 O
lipopolysaccharide	91 18 B-Chemical
pretreatment	110 12 O
.	122 1 O

Immunological	124 13 O
activation	138 10 O
has	149 3 O
been	153 4 O
proposed	158 8 O
to	167 2 O
play	170 4 O
a	175 1 O
role	177 4 O
in	182 2 O
methamphetamine	185 15 B-Chemical
-	200 1 O
induced	201 7 O
dopaminergic	209 12 B-Disease
terminal	222 8 I-Disease
damage	231 6 I-Disease
.	237 1 O

In	239 2 O
this	242 4 O
study	247 5 O
,	252 1 O
we	254 2 O
examined	257 8 O
the	266 3 O
roles	270 5 O
of	276 2 O
lipopolysaccharide	279 18 B-Chemical
,	297 1 O
a	299 1 O
pro	301 3 O
-	304 1 O
inflammatory	305 12 O
and	318 3 O
inflammatory	322 12 O
factor	335 6 O
,	341 1 O
treatment	343 9 O
in	353 2 O
modulating	356 10 O
the	367 3 O
methamphetamine	371 15 B-Chemical
-	386 1 O
induced	387 7 O
nigrostriatal	395 13 O
dopamine	409 8 B-Chemical
neurotoxicity	418 13 B-Disease
.	431 1 O

Lipopolysaccharide	433 18 B-Chemical
pretreatment	452 12 O
did	465 3 O
not	469 3 O
affect	473 6 O
the	480 3 O
basal	484 5 O
body	490 4 O
temperature	495 11 O
or	507 2 O
methamphetamine	510 15 B-Chemical
-	525 1 O
elicited	526 8 O
hyperthermia	535 12 B-Disease
three	548 5 O
days	554 4 O
later	559 5 O
.	564 1 O

Such	566 4 O
systemic	571 8 O
lipopolysaccharide	580 18 B-Chemical
treatment	599 9 O
mitigated	609 9 O
methamphetamine	619 15 B-Chemical
-	634 1 O
induced	635 7 O
striatal	643 8 O
dopamine	652 8 B-Chemical
and	661 3 O
3	665 1 B-Chemical
,	666 1 I-Chemical
4	667 1 I-Chemical
-	668 1 I-Chemical
dihydroxyphenylacetic	669 21 I-Chemical
acid	691 4 I-Chemical
depletions	696 10 O
in	707 2 O
a	710 1 O
dose	712 4 O
-	716 1 O
dependent	717 9 O
manner	727 6 O
.	733 1 O

As	735 2 O
the	738 3 O
most	742 4 O
potent	747 6 O
dose	754 4 O
(	759 1 O
1	760 1 O
mg	762 2 O
/	764 1 O
kg	765 2 O
)	767 1 O
of	769 2 O
lipopolysaccharide	772 18 B-Chemical
was	791 3 O
administered	795 12 O
two	808 3 O
weeks	812 5 O
,	817 1 O
one	819 3 O
day	823 3 O
before	827 6 O
or	834 2 O
after	837 5 O
the	843 3 O
methamphetamine	847 15 B-Chemical
dosing	863 6 O
regimen	870 7 O
,	877 1 O
methamphetamine	879 15 B-Chemical
-	894 1 O
induced	895 7 O
striatal	903 8 O
dopamine	912 8 B-Chemical
and	921 3 O
3	925 1 B-Chemical
,	926 1 I-Chemical
4	927 1 I-Chemical
-	928 1 I-Chemical
dihydroxyphenylacetic	929 21 I-Chemical
acid	951 4 I-Chemical
depletions	956 10 O
remained	967 8 O
unaltered	976 9 O
.	985 1 O

Moreover	987 8 O
,	995 1 O
systemic	997 8 O
lipopolysaccharide	1006 18 B-Chemical
pretreatment	1025 12 O
(	1038 1 O
1	1039 1 O
mg	1041 2 O
/	1043 1 O
kg	1044 2 O
)	1046 1 O
attenuated	1048 10 O
local	1059 5 O
methamphetamine	1065 15 B-Chemical
infusion	1081 8 O
-	1089 1 O
produced	1090 8 O
dopamine	1099 8 B-Chemical
and	1108 3 O
3	1112 1 B-Chemical
,	1113 1 I-Chemical
4	1114 1 I-Chemical
-	1115 1 I-Chemical
dihydroxyphenylacetic	1116 21 I-Chemical
acid	1138 4 I-Chemical
depletions	1143 10 O
in	1154 2 O
the	1157 3 O
striatum	1161 8 O
,	1169 1 O
indicating	1171 10 O
that	1182 4 O
the	1187 3 O
protective	1191 10 O
effect	1202 6 O
of	1209 2 O
lipopolysaccharide	1212 18 B-Chemical
is	1231 2 O
less	1234 4 O
likely	1239 6 O
due	1246 3 O
to	1250 2 O
interrupted	1253 11 O
peripheral	1265 10 O
distribution	1276 12 O
or	1289 2 O
metabolism	1292 10 O
of	1303 2 O
methamphetamine	1306 15 B-Chemical
.	1321 1 O

We	1323 2 O
concluded	1326 9 O
a	1336 1 O
critical	1338 8 O
time	1347 4 O
window	1352 6 O
for	1359 3 O
systemic	1363 8 O
lipopolysaccharide	1372 18 B-Chemical
pretreatment	1391 12 O
in	1404 2 O
exerting	1407 8 O
effective	1416 9 O
protection	1426 10 O
against	1437 7 O
methamphetamine	1445 15 B-Chemical
-	1460 1 O
induced	1461 7 O
nigrostriatal	1469 13 O
dopamine	1483 8 B-Chemical
neurotoxicity	1492 13 B-Disease
.	1505 1 O

Effect	0 6 O
of	7 2 O
converting	10 10 O
enzyme	21 6 O
inhibition	28 10 O
on	39 2 O
the	42 3 O
course	46 6 O
of	53 2 O
adriamycin	56 10 B-Chemical
-	66 1 O
induced	67 7 O
nephropathy	75 11 B-Disease
.	86 1 O

The	88 3 O
effect	92 6 O
of	99 2 O
the	102 3 O
converting	106 10 O
enzyme	117 6 O
inhibitor	124 9 O
(	134 1 O
CEI	135 3 O
)	138 1 O
enalapril	140 9 B-Chemical
was	150 3 O
assessed	154 8 O
in	163 2 O
Munich	166 6 O
-	172 1 O
Wistar	173 6 O
rats	180 4 O
with	185 4 O
established	190 11 O
adriamycin	202 10 B-Chemical
nephrosis	213 9 B-Disease
.	222 1 O

Rats	224 4 O
were	229 4 O
given	234 5 O
a	240 1 O
single	242 6 O
dose	249 4 O
of	254 2 O
adriamycin	257 10 B-Chemical
and	268 3 O
one	272 3 O
month	276 5 O
later	282 5 O
divided	288 7 O
into	296 4 O
four	301 4 O
groups	306 6 O
matched	313 7 O
for	321 3 O
albuminuria	325 11 B-Disease
,	336 1 O
blood	338 5 O
pressure	344 8 O
,	352 1 O
and	354 3 O
plasma	358 6 O
albumin	365 7 O
concentration	373 13 O
.	386 1 O

Groups	388 6 O
1	395 1 O
and	397 3 O
3	401 1 O
remained	403 8 O
untreated	412 9 O
while	422 5 O
groups	428 6 O
2	435 1 O
and	437 3 O
4	441 1 O
received	443 8 O
enalapril	452 9 B-Chemical
.	461 1 O

Groups	463 6 O
1	470 1 O
and	472 3 O
2	476 1 O
underwent	478 9 O
micropuncture	488 13 O
studies	502 7 O
after	510 5 O
10	516 2 O
days	519 4 O
.	523 1 O

These	525 5 O
short	531 5 O
-	536 1 O
term	537 4 O
studies	542 7 O
showed	550 6 O
that	557 4 O
enalapril	562 9 B-Chemical
reduced	572 7 O
arterial	580 8 O
blood	589 5 O
pressure	595 8 O
(	604 1 O
101	605 3 O
+	609 1 O
/	610 1 O
-	611 1 O
2	613 1 O
vs	615 2 O
.	617 1 O
124	619 3 O
+	623 1 O
/	624 1 O
-	625 1 O
3	627 1 O
mm	629 2 O
Hg	632 2 O
,	634 1 O
group	636 5 O
2	642 1 O
vs	644 2 O
.	646 1 O
1	648 1 O
,	649 1 O
P	651 1 O
less	653 4 O
than	658 4 O
0	663 1 O
.	664 1 O
05	665 2 O
)	667 1 O
and	669 3 O
glomerular	673 10 O
capillary	684 9 O
pressure	694 8 O
(	703 1 O
54	704 2 O
+	707 1 O
/	708 1 O
-	709 1 O
1	711 1 O
vs	713 2 O
.	715 1 O
61	717 2 O
+	720 1 O
/	721 1 O
-	722 1 O
2	724 1 O
mm	726 2 O
Hg	729 2 O
,	731 1 O
P	733 1 O
less	735 4 O
than	740 4 O
0	745 1 O
.	746 1 O
05	747 2 O
)	749 1 O
without	751 7 O
reducing	759 8 O
albuminuria	768 11 B-Disease
(	780 1 O
617	781 3 O
+	785 1 O
/	786 1 O
-	787 1 O
50	789 2 O
vs	792 2 O
.	794 1 O
570	796 3 O
+	800 1 O
/	801 1 O
-	802 1 O
47	804 2 O
mg	807 2 O
/	809 1 O
day	810 3 O
)	813 1 O
or	815 2 O
GFR	818 3 O
(	822 1 O
1	823 1 O
.	824 1 O
03	825 2 O
+	828 1 O
/	829 1 O
-	830 1 O
0	832 1 O
.	833 1 O
04	834 2 O
vs	837 2 O
.	839 1 O
1	841 1 O
.	842 1 O
04	843 2 O
+	846 1 O
/	847 1 O
-	848 1 O
0	850 1 O
.	851 1 O
11	852 2 O
ml	855 2 O
/	857 1 O
min	858 3 O
)	861 1 O
.	862 1 O

Groups	864 6 O
3	871 1 O
and	873 3 O
4	877 1 O
were	879 4 O
studied	884 7 O
at	892 2 O
four	895 4 O
and	900 3 O
at	904 2 O
six	907 3 O
months	911 6 O
to	918 2 O
assess	921 6 O
the	928 3 O
effect	932 6 O
of	939 2 O
enalapril	942 9 B-Chemical
on	952 2 O
progression	955 11 O
of	967 2 O
renal	970 5 B-Disease
injury	976 6 I-Disease
in	983 2 O
adriamycin	986 10 B-Chemical
nephrosis	997 9 B-Disease
.	1006 1 O

Chronic	1008 7 O
enalapril	1016 9 B-Chemical
treatment	1026 9 O
reduced	1036 7 O
blood	1044 5 O
pressure	1050 8 O
without	1059 7 O
reducing	1067 8 O
albuminuria	1076 11 B-Disease
in	1088 2 O
group	1091 5 O
4	1097 1 O
.	1098 1 O

Untreated	1100 9 O
group	1110 5 O
3	1116 1 O
rats	1118 4 O
exhibited	1123 9 O
a	1133 1 O
progressive	1135 11 O
reduction	1147 9 O
in	1157 2 O
GFR	1160 3 O
(	1164 1 O
0	1165 1 O
.	1166 1 O
35	1167 2 O
+	1170 1 O
/	1171 1 O
-	1172 1 O
0	1174 1 O
.	1175 1 O
08	1176 2 O
ml	1179 2 O
/	1181 1 O
min	1182 3 O
at	1186 2 O
4	1189 1 O
months	1191 6 O
,	1197 1 O
0	1199 1 O
.	1200 1 O
27	1201 2 O
+	1204 1 O
/	1205 1 O
-	1206 1 O
0	1208 1 O
.	1209 1 O
07	1210 2 O
ml	1213 2 O
/	1215 1 O
min	1216 3 O
at	1220 2 O
6	1223 1 O
months	1225 6 O
)	1231 1 O
.	1232 1 O

Enalapril	1234 9 B-Chemical
treatment	1244 9 O
blunted	1254 7 O
but	1262 3 O
did	1266 3 O
not	1270 3 O
prevent	1274 7 O
reduction	1282 9 O
in	1292 2 O
GFR	1295 3 O
in	1299 2 O
group	1302 5 O
4	1308 1 O
(	1310 1 O
0	1311 1 O
.	1312 1 O
86	1313 2 O
+	1316 1 O
/	1317 1 O
-	1318 1 O
0	1320 1 O
.	1321 1 O
15	1322 2 O
ml	1325 2 O
/	1327 1 O
min	1328 3 O
at	1332 2 O
4	1335 1 O
months	1337 6 O
,	1343 1 O
0	1345 1 O
.	1346 1 O
69	1347 2 O
+	1350 1 O
/	1351 1 O
-	1352 1 O
0	1354 1 O
.	1355 1 O
13	1356 2 O
ml	1359 2 O
/	1361 1 O
min	1362 3 O
at	1366 2 O
6	1369 1 O
months	1371 6 O
,	1377 1 O
both	1379 4 O
P	1384 1 O
less	1386 4 O
than	1391 4 O
0	1396 1 O
.	1397 1 O
05	1398 2 O
vs	1401 2 O
.	1403 1 O
group	1405 5 O
3	1411 1 O
)	1412 1 O
.	1413 1 O

Reduction	1415 9 O
in	1425 2 O
GFR	1428 3 O
was	1432 3 O
associated	1436 10 O
with	1447 4 O
the	1452 3 O
development	1456 11 O
of	1468 2 O
glomerular	1471 10 B-Disease
sclerosis	1482 9 I-Disease
in	1492 2 O
both	1495 4 O
treated	1500 7 O
and	1508 3 O
untreated	1512 9 O
rats	1522 4 O
.	1526 1 O
(	1527 1 O
ABSTRACT	1528 8 O
TRUNCATED	1537 9 O
AT	1547 2 O
250	1550 3 O
WORDS	1554 5 O
)	1559 1 O

Butyrylcholinesterase	0 21 O
gene	22 4 O
mutations	27 9 O
in	37 2 O
patients	40 8 O
with	49 4 O
prolonged	54 9 O
apnea	64 5 B-Disease
after	70 5 O
succinylcholine	76 15 B-Chemical
for	92 3 O
electroconvulsive	96 17 O
therapy	114 7 O
.	121 1 O

BACKGROUND	123 10 O
:	133 1 O
patients	135 8 O
undergoing	144 10 O
electroconvulsive	155 17 O
therapy	173 7 O
(	181 1 O
ECT	182 3 O
)	185 1 O
often	187 5 O
receive	193 7 O
succinylcholine	201 15 B-Chemical
as	217 2 O
part	220 4 O
of	225 2 O
the	228 3 O
anesthetic	232 10 O
procedure	243 9 O
.	252 1 O

The	254 3 O
duration	258 8 O
of	267 2 O
action	270 6 O
may	277 3 O
be	281 2 O
prolonged	284 9 O
in	294 2 O
patients	297 8 O
with	306 4 O
genetic	311 7 O
variants	319 8 O
of	328 2 O
the	331 3 O
butyrylcholinesterase	335 21 O
enzyme	357 6 O
(	364 1 O
BChE	365 4 O
)	369 1 O
,	370 1 O
the	372 3 O
most	376 4 O
common	381 6 O
being	388 5 O
the	394 3 O
K	398 1 O
-	399 1 O
and	401 3 O
the	405 3 O
A	409 1 O
-	410 1 O
variants	411 8 O
.	419 1 O

The	421 3 O
aim	425 3 O
of	429 2 O
the	432 3 O
study	436 5 O
was	442 3 O
to	446 2 O
assess	449 6 O
the	456 3 O
clinical	460 8 O
significance	469 12 O
of	482 2 O
genetic	485 7 O
variants	493 8 O
in	502 2 O
butyrylcholinesterase	505 21 O
gene	527 4 O
(	532 1 O
BCHE	533 4 O
)	537 1 O
in	539 2 O
patients	542 8 O
with	551 4 O
a	556 1 O
suspected	558 9 O
prolonged	568 9 O
duration	578 8 O
of	587 2 O
action	590 6 O
of	597 2 O
succinylcholine	600 15 B-Chemical
after	616 5 O
ECT	622 3 O
.	625 1 O

METHODS	627 7 O
:	634 1 O
a	636 1 O
total	638 5 O
of	644 2 O
13	647 2 O
patients	650 8 O
were	659 4 O
referred	664 8 O
to	673 2 O
the	676 3 O
Danish	680 6 O
Cholinesterase	687 14 O
Research	702 8 O
Unit	711 4 O
after	716 5 O
ECT	722 3 O
during	726 6 O
38	733 2 O
months	736 6 O
.	742 1 O

We	744 2 O
determined	747 10 O
the	758 3 O
BChE	762 4 O
activity	767 8 O
and	776 3 O
the	780 3 O
BCHE	784 4 O
genotype	789 8 O
using	798 5 O
molecular	804 9 O
genetic	814 7 O
methods	822 7 O
,	829 1 O
the	831 3 O
duration	835 8 O
of	844 2 O
apnea	847 5 B-Disease
,	852 1 O
time	854 4 O
to	859 2 O
sufficient	862 10 O
spontaneous	873 11 O
ventilation	885 11 O
and	897 3 O
whether	901 7 O
neuromuscular	909 13 O
monitoring	923 10 O
was	934 3 O
used	938 4 O
.	942 1 O

The	944 3 O
duration	948 8 O
of	957 2 O
apnea	960 5 B-Disease
was	966 3 O
compared	970 8 O
with	979 4 O
published	984 9 O
data	994 4 O
on	999 2 O
normal	1002 6 O
subjects	1009 8 O
.	1017 1 O

RESULTS	1019 7 O
:	1026 1 O
in	1028 2 O
11	1031 2 O
patients	1034 8 O
,	1042 1 O
mutations	1044 9 O
were	1054 4 O
found	1059 5 O
in	1065 2 O
the	1068 3 O
BCHE	1072 4 O
gene	1077 4 O
,	1081 1 O
the	1083 3 O
K	1087 1 O
-	1088 1 O
variant	1089 7 O
being	1097 5 O
the	1103 3 O
most	1107 4 O
frequent	1112 8 O
.	1120 1 O

The	1122 3 O
duration	1126 8 O
of	1135 2 O
apnea	1138 5 B-Disease
was	1144 3 O
5	1148 1 O
-	1149 1 O
15	1150 2 O
min	1153 3 O
compared	1157 8 O
with	1166 4 O
3	1171 1 O
-	1172 1 O
5	1173 1 O
.	1174 1 O
3	1175 1 O
min	1177 3 O
from	1181 4 O
the	1186 3 O
literature	1190 10 O
.	1200 1 O

Severe	1202 6 O
distress	1209 8 O
was	1218 3 O
noted	1222 5 O
in	1228 2 O
the	1231 3 O
recovery	1235 8 O
phase	1244 5 O
in	1250 2 O
two	1253 3 O
patients	1257 8 O
.	1265 1 O

Neuromuscular	1267 13 O
monitoring	1281 10 O
was	1292 3 O
used	1296 4 O
in	1301 2 O
two	1304 3 O
patients	1308 8 O
.	1316 1 O

CONCLUSION	1318 10 O
:	1328 1 O
eleven	1330 6 O
of	1337 2 O
13	1340 2 O
patients	1343 8 O
with	1352 4 O
a	1357 1 O
prolonged	1359 9 O
duration	1369 8 O
of	1378 2 O
action	1381 6 O
of	1388 2 O
succinylcholine	1391 15 B-Chemical
had	1407 3 O
mutations	1411 9 O
in	1421 2 O
BCHE	1424 4 O
,	1428 1 O
indicating	1430 10 O
that	1441 4 O
this	1446 4 O
is	1451 2 O
the	1454 3 O
possible	1458 8 O
reason	1467 6 O
for	1474 3 O
a	1478 1 O
prolonged	1480 9 O
period	1490 6 O
of	1497 2 O
apnea	1500 5 B-Disease
.	1505 1 O

We	1507 2 O
recommend	1510 9 O
objective	1520 9 O
neuromuscular	1530 13 O
monitoring	1544 10 O
during	1555 6 O
the	1562 3 O
first	1566 5 O
ECT	1572 3 O
.	1575 1 O

Ketamine	0 8 B-Chemical
sedation	9 8 O
for	18 3 O
the	22 3 O
reduction	26 9 O
of	36 2 O
children	39 8 O
'	47 1 O
s	48 1 O
fractures	50 9 B-Disease
in	60 2 O
the	63 3 O
emergency	67 9 O
department	77 10 O
.	87 1 O

BACKGROUND	89 10 O
:	99 1 O
There	101 5 O
recently	107 8 O
has	116 3 O
been	120 4 O
a	125 1 O
resurgence	127 10 O
in	138 2 O
the	141 3 O
utilization	145 11 O
of	157 2 O
ketamine	160 8 B-Chemical
,	168 1 O
a	170 1 O
unique	172 6 O
anesthetic	179 10 O
,	189 1 O
for	191 3 O
emergency	195 9 O
-	204 1 O
department	205 10 O
procedures	216 10 O
requiring	227 9 O
sedation	237 8 O
.	245 1 O

The	247 3 O
purpose	251 7 O
of	259 2 O
the	262 3 O
present	266 7 O
study	274 5 O
was	280 3 O
to	284 2 O
examine	287 7 O
the	295 3 O
safety	299 6 O
and	306 3 O
efficacy	310 8 O
of	319 2 O
ketamine	322 8 B-Chemical
for	331 3 O
sedation	335 8 O
in	344 2 O
the	347 3 O
treatment	351 9 O
of	361 2 O
children	364 8 O
'	372 1 O
s	373 1 O
fractures	375 9 B-Disease
in	385 2 O
the	388 3 O
emergency	392 9 O
department	402 10 O
.	412 1 O

METHODS	414 7 O
:	421 1 O
One	423 3 O
hundred	427 7 O
and	435 3 O
fourteen	439 8 O
children	448 8 O
(	457 1 O
average	458 7 O
age	466 3 O
,	469 1 O
5	471 1 O
.	472 1 O
3	473 1 O
years	475 5 O
;	480 1 O
range	482 5 O
,	487 1 O
twelve	489 6 O
months	496 6 O
to	503 2 O
ten	506 3 O
years	510 5 O
and	516 3 O
ten	520 3 O
months	524 6 O
)	530 1 O
who	532 3 O
underwent	536 9 O
closed	546 6 O
reduction	553 9 O
of	563 2 O
an	566 2 O
isolated	569 8 O
fracture	578 8 B-Disease
or	587 2 O
dislocation	590 11 B-Disease
in	602 2 O
the	605 3 O
emergency	609 9 O
department	619 10 O
at	630 2 O
a	633 1 O
level	635 5 O
-	640 1 O
I	641 1 O
trauma	643 6 B-Disease
center	650 6 O
were	657 4 O
prospectively	662 13 O
evaluated	676 9 O
.	685 1 O

Ketamine	687 8 B-Chemical
hydrochloride	696 13 I-Chemical
was	710 3 O
administered	714 12 O
intravenously	727 13 O
(	741 1 O
at	742 2 O
a	745 1 O
dose	747 4 O
of	752 2 O
two	755 3 O
milligrams	759 10 O
per	770 3 O
kilogram	774 8 O
of	783 2 O
body	786 4 O
weight	791 6 O
)	797 1 O
in	799 2 O
ninety	802 6 O
-	808 1 O
nine	809 4 O
of	814 2 O
the	817 3 O
patients	821 8 O
and	830 3 O
intramuscularly	834 15 O
(	850 1 O
at	851 2 O
a	854 1 O
dose	856 4 O
of	861 2 O
four	864 4 O
milligrams	869 10 O
per	880 3 O
kilogram	884 8 O
of	893 2 O
body	896 4 O
weight	901 6 O
)	907 1 O
in	909 2 O
the	912 3 O
other	916 5 O
fifteen	922 7 O
.	929 1 O

A	931 1 O
board	933 5 O
-	938 1 O
certified	939 9 O
emergency	949 9 O
physician	959 9 O
skilled	969 7 O
in	977 2 O
airway	980 6 O
management	987 10 O
supervised	998 10 O
administration	1009 14 O
of	1024 2 O
the	1027 3 O
anesthetic	1031 10 O
,	1041 1 O
and	1043 3 O
the	1047 3 O
patients	1051 8 O
were	1060 4 O
monitored	1065 9 O
by	1075 2 O
a	1078 1 O
registered	1080 10 O
nurse	1091 5 O
.	1096 1 O

Any	1098 3 O
pain	1102 4 B-Disease
during	1107 6 O
the	1114 3 O
reduction	1118 9 O
was	1128 3 O
rated	1132 5 O
by	1138 2 O
the	1141 3 O
orthopaedic	1145 11 O
surgeon	1157 7 O
treating	1165 8 O
the	1174 3 O
patient	1178 7 O
according	1186 9 O
to	1196 2 O
the	1199 3 O
Children	1203 8 O
'	1211 1 O
s	1212 1 O
Hospital	1214 8 O
of	1223 2 O
Eastern	1226 7 O
Ontario	1234 7 O
Pain	1242 4 B-Disease
Scale	1247 5 O
(	1253 1 O
CHEOPS	1254 6 O
)	1260 1 O
.	1261 1 O

RESULTS	1263 7 O
:	1270 1 O
The	1272 3 O
average	1276 7 O
time	1284 4 O
from	1289 4 O
intravenous	1294 11 O
administration	1306 14 O
of	1321 2 O
ketamine	1324 8 B-Chemical
to	1333 2 O
manipulation	1336 12 O
of	1349 2 O
the	1352 3 O
fracture	1356 8 B-Disease
or	1365 2 O
dislocation	1368 11 B-Disease
was	1380 3 O
one	1384 3 O
minute	1388 6 O
and	1395 3 O
thirty	1399 6 O
-	1405 1 O
six	1406 3 O
seconds	1410 7 O
(	1418 1 O
range	1419 5 O
,	1424 1 O
twenty	1426 6 O
seconds	1433 7 O
to	1441 2 O
five	1444 4 O
minutes	1449 7 O
)	1456 1 O
,	1457 1 O
and	1459 3 O
the	1463 3 O
average	1467 7 O
time	1475 4 O
from	1480 4 O
intramuscular	1485 13 O
administration	1499 14 O
to	1514 2 O
manipulation	1517 12 O
was	1530 3 O
four	1534 4 O
minutes	1539 7 O
and	1547 3 O
forty	1551 5 O
-	1556 1 O
two	1557 3 O
seconds	1561 7 O
(	1569 1 O
range	1570 5 O
,	1575 1 O
sixty	1577 5 O
seconds	1583 7 O
to	1591 2 O
fifteen	1594 7 O
minutes	1602 7 O
)	1609 1 O
.	1610 1 O

The	1612 3 O
average	1616 7 O
score	1624 5 O
according	1630 9 O
to	1640 2 O
the	1643 3 O
Children	1647 8 O
'	1655 1 O
s	1656 1 O
Hospital	1658 8 O
of	1667 2 O
Eastern	1670 7 O
Ontario	1678 7 O
Pain	1686 4 B-Disease
Scale	1691 5 O
was	1697 3 O
6	1701 1 O
.	1702 1 O
4	1703 1 O
points	1705 6 O
(	1712 1 O
range	1713 5 O
,	1718 1 O
5	1720 1 O
to	1722 2 O
10	1725 2 O
points	1728 6 O
)	1734 1 O
,	1735 1 O
reflecting	1737 10 O
minimal	1748 7 O
or	1756 2 O
no	1759 2 O
pain	1762 4 B-Disease
during	1767 6 O
fracture	1774 8 B-Disease
reduction	1783 9 O
.	1792 1 O

Adequate	1794 8 O
fracture	1803 8 B-Disease
reduction	1812 9 O
was	1822 3 O
obtained	1826 8 O
in	1835 2 O
111	1838 3 O
of	1842 2 O
the	1845 3 O
children	1849 8 O
.	1857 1 O

Ninety	1859 6 O
-	1865 1 O
nine	1866 4 O
percent	1871 7 O
(	1879 1 O
sixty	1880 5 O
-	1885 1 O
eight	1886 5 O
)	1891 1 O
of	1893 2 O
the	1896 3 O
sixty	1900 5 O
-	1905 1 O
nine	1906 4 O
parents	1911 7 O
present	1919 7 O
during	1927 6 O
the	1934 3 O
reduction	1938 9 O
were	1948 4 O
pleased	1953 7 O
with	1961 4 O
the	1966 3 O
sedation	1970 8 O
and	1979 3 O
would	1983 5 O
allow	1989 5 O
it	1995 2 O
to	1998 2 O
be	2001 2 O
used	2004 4 O
again	2009 5 O
in	2015 2 O
a	2018 1 O
similar	2020 7 O
situation	2028 9 O
.	2037 1 O

Patency	2039 7 O
of	2047 2 O
the	2050 3 O
airway	2054 6 O
and	2061 3 O
independent	2065 11 O
respiration	2077 11 O
were	2089 4 O
maintained	2094 10 O
in	2105 2 O
all	2108 3 O
of	2112 2 O
the	2115 3 O
patients	2119 8 O
.	2127 1 O

Blood	2129 5 O
pressure	2135 8 O
and	2144 3 O
heart	2148 5 O
rate	2154 4 O
remained	2159 8 O
stable	2168 6 O
.	2174 1 O

Minor	2176 5 O
side	2182 4 O
effects	2187 7 O
included	2195 8 O
nausea	2204 6 B-Disease
(	2211 1 O
thirteen	2212 8 O
patients	2221 8 O
)	2229 1 O
,	2230 1 O
emesis	2232 6 B-Disease
(	2239 1 O
eight	2240 5 O
of	2246 2 O
the	2249 3 O
thirteen	2253 8 O
patients	2262 8 O
with	2271 4 O
nausea	2276 6 B-Disease
)	2282 1 O
,	2283 1 O
clumsiness	2285 10 B-Disease
(	2296 1 O
evident	2297 7 O
as	2305 2 O
ataxic	2308 6 B-Disease
movements	2315 9 I-Disease
in	2325 2 O
ten	2328 3 O
patients	2332 8 O
)	2340 1 O
,	2341 1 O
and	2343 3 O
dysphoric	2347 9 B-Disease
reaction	2357 8 I-Disease
(	2366 1 O
one	2367 3 O
patient	2371 7 O
)	2378 1 O
.	2379 1 O

No	2381 2 O
long	2384 4 O
-	2388 1 O
term	2389 4 O
sequelae	2394 8 O
were	2403 4 O
noted	2408 5 O
,	2413 1 O
and	2415 3 O
no	2419 2 O
patients	2422 8 O
had	2431 3 O
hallucinations	2435 14 B-Disease
or	2450 2 O
nightmares	2453 10 O
.	2463 1 O

CONCLUSIONS	2465 11 O
:	2476 1 O
Ketamine	2478 8 B-Chemical
reliably	2487 8 O
,	2495 1 O
safely	2497 6 O
,	2503 1 O
and	2505 3 O
quickly	2509 7 O
provided	2517 8 O
adequate	2526 8 O
sedation	2535 8 O
to	2544 2 O
effectively	2547 11 O
facilitate	2559 10 O
the	2570 3 O
reduction	2574 9 O
of	2584 2 O
children	2587 8 O
'	2595 1 O
s	2596 1 O
fractures	2598 9 B-Disease
in	2608 2 O
the	2611 3 O
emergency	2615 9 O
department	2625 10 O
at	2636 2 O
our	2639 3 O
institution	2643 11 O
.	2654 1 O

Ketamine	2656 8 B-Chemical
should	2665 6 O
only	2672 4 O
be	2677 2 O
used	2680 4 O
in	2685 2 O
an	2688 2 O
environment	2691 11 O
such	2703 4 O
as	2708 2 O
the	2711 3 O
emergency	2715 9 O
department	2725 10 O
,	2735 1 O
where	2737 5 O
proper	2743 6 O
one	2750 3 O
-	2753 1 O
on	2754 2 O
-	2756 1 O
one	2757 3 O
monitoring	2761 10 O
is	2772 2 O
used	2775 4 O
and	2780 3 O
board	2784 5 O
-	2789 1 O
certified	2790 9 O
physicians	2800 10 O
skilled	2811 7 O
in	2819 2 O
airway	2822 6 O
management	2829 10 O
are	2840 3 O
directly	2844 8 O
involved	2853 8 O
in	2862 2 O
the	2865 3 O
care	2869 4 O
of	2874 2 O
the	2877 3 O
patient	2881 7 O
.	2888 1 O

Prophylactic	0 12 O
use	13 3 O
of	17 2 O
lamivudine	20 10 B-Chemical
with	31 4 O
chronic	36 7 O
immunosuppressive	44 17 O
therapy	62 7 O
for	70 3 O
rheumatologic	74 13 B-Disease
disorders	88 9 I-Disease
.	97 1 O

The	99 3 O
objective	103 9 O
of	113 2 O
this	116 4 O
study	121 5 O
was	127 3 O
to	131 2 O
report	134 6 O
our	141 3 O
experience	145 10 O
concerning	156 10 O
the	167 3 O
effectiveness	171 13 O
of	185 2 O
the	188 3 O
prophylactic	192 12 O
administration	205 14 O
of	220 2 O
lamivudine	223 10 B-Chemical
in	234 2 O
hepatitis	237 9 B-Chemical
B	247 1 I-Chemical
virus	249 5 I-Chemical
surface	255 7 I-Chemical
antigen	263 7 I-Chemical
(	271 1 O
HBs	272 3 B-Chemical
Ag	276 2 I-Chemical
)	278 1 O
positive	280 8 O
patients	289 8 O
with	298 4 O
rheumatologic	303 13 B-Disease
disease	317 7 I-Disease
.	324 1 O

From	326 4 O
June	331 4 O
2004	336 4 O
to	341 2 O
October	344 7 O
2006	352 4 O
,	356 1 O
11	358 2 O
HBs	361 3 B-Chemical
Ag	365 2 I-Chemical
positive	368 8 O
patients	377 8 O
with	386 4 O
rheumatologic	391 13 B-Disease
diseases	405 8 I-Disease
,	413 1 O
who	415 3 O
were	419 4 O
on	424 2 O
both	427 4 O
immunosuppressive	432 17 O
and	450 3 O
prophylactic	454 12 O
lamivudine	467 10 B-Chemical
therapies	478 9 O
,	487 1 O
were	489 4 O
retrospectively	494 15 O
assessed	510 8 O
.	518 1 O

Liver	520 5 O
function	526 8 O
tests	535 5 O
,	540 1 O
hepatitis	542 9 B-Disease
B	552 1 I-Disease
virus	554 5 O
(	560 1 O
HBV	561 3 O
)	564 1 O
serologic	566 9 O
markers	576 7 O
,	583 1 O
and	585 3 O
HBV	589 3 O
DNA	593 3 O
levels	597 6 O
of	604 2 O
the	607 3 O
patients	611 8 O
during	620 6 O
follow	627 6 O
-	633 1 O
up	634 2 O
were	637 4 O
obtained	642 8 O
from	651 4 O
hospital	656 8 O
file	665 4 O
records	670 7 O
.	677 1 O

Eleven	679 6 O
patients	686 8 O
(	695 1 O
six	696 3 O
male	700 4 O
)	704 1 O
with	706 4 O
median	711 6 O
age	718 3 O
47	722 2 O
years	725 5 O
(	731 1 O
range	732 5 O
27	738 2 O
-	740 1 O
73	741 2 O
)	743 1 O
,	744 1 O
median	746 6 O
disease	753 7 O
duration	761 8 O
50	770 2 O
months	773 6 O
(	780 1 O
range	781 5 O
9	787 1 O
-	788 1 O
178	789 3 O
)	792 1 O
and	794 3 O
median	798 6 O
follow	805 6 O
-	811 1 O
up	812 2 O
period	815 6 O
of	822 2 O
patients	825 8 O
13	834 2 O
.	836 1 O
8	837 1 O
months	839 6 O
(	846 1 O
range	847 5 O
5	853 1 O
-	854 1 O
27	855 2 O
)	857 1 O
were	859 4 O
enrolled	864 8 O
in	873 2 O
this	876 4 O
study	881 5 O
.	886 1 O

Lamivudine	888 10 B-Chemical
therapy	899 7 O
was	907 3 O
started	911 7 O
3	919 1 O
-	920 1 O
7	921 1 O
days	923 4 O
prior	928 5 O
to	934 2 O
immunosuppressive	937 17 O
therapy	955 7 O
in	963 2 O
all	966 3 O
patients	970 8 O
.	978 1 O

Baseline	980 8 O
,	988 1 O
liver	990 5 O
function	996 8 O
tests	1005 5 O
were	1011 4 O
elevated	1016 8 O
in	1025 2 O
two	1028 3 O
patients	1032 8 O
(	1041 1 O
fourth	1042 6 O
patient	1049 7 O
:	1056 1 O
ALT	1058 3 O
:	1061 1 O
122	1062 3 O
IU	1066 2 O
/	1068 1 O
l	1069 1 O
,	1070 1 O
AST	1072 3 O
:	1075 1 O
111	1076 3 O
IU	1080 2 O
/	1082 1 O
l	1083 1 O
,	1084 1 O
tenth	1086 5 O
patient	1092 7 O
:	1099 1 O
ALT	1100 3 O
:	1103 1 O
294	1104 3 O
IU	1108 2 O
/	1110 1 O
l	1111 1 O
,	1112 1 O
AST	1114 3 O
:	1117 1 O
274	1118 3 O
IU	1122 2 O
/	1124 1 O
l	1125 1 O
,	1126 1 O
with	1128 4 O
minimal	1133 7 O
changes	1141 7 O
in	1149 2 O
the	1152 3 O
liver	1156 5 O
biopsy	1162 6 O
in	1169 2 O
both	1172 4 O
)	1176 1 O
.	1177 1 O

Shortly	1179 7 O
after	1187 5 O
treatment	1193 9 O
their	1203 5 O
tests	1209 5 O
normalized	1215 10 O
and	1226 3 O
during	1230 6 O
follow	1237 6 O
-	1243 1 O
up	1244 2 O
period	1247 6 O
none	1254 4 O
of	1259 2 O
the	1262 3 O
patients	1266 8 O
had	1275 3 O
abnormal	1279 8 B-Disease
liver	1288 5 I-Disease
function	1294 8 I-Disease
tests	1303 5 O
.	1308 1 O

In	1310 2 O
four	1313 4 O
patients	1318 8 O
HBV	1327 3 O
DNA	1331 3 O
levels	1335 6 O
were	1342 4 O
higher	1347 6 O
than	1354 4 O
normal	1359 6 O
at	1366 2 O
baseline	1369 8 O
.	1377 1 O

Two	1379 3 O
of	1383 2 O
these	1386 5 O
normalized	1392 10 O
and	1403 3 O
the	1407 3 O
others	1411 6 O
increased	1418 9 O
later	1428 5 O
.	1433 1 O

In	1435 2 O
three	1438 5 O
additional	1444 10 O
patients	1455 8 O
,	1463 1 O
HBV	1465 3 O
DNA	1469 3 O
levels	1473 6 O
were	1480 4 O
increased	1485 9 O
during	1495 6 O
follow	1502 6 O
-	1508 1 O
up	1509 2 O
.	1511 1 O

None	1513 4 O
of	1518 2 O
the	1521 3 O
patients	1525 8 O
had	1534 3 O
significant	1538 11 O
clinical	1550 8 O
sings	1559 5 O
of	1565 2 O
HBV	1568 3 O
activation	1572 10 O
.	1582 1 O

Lamivudine	1584 10 B-Chemical
was	1595 3 O
well	1599 4 O
tolerated	1604 9 O
and	1614 3 O
was	1618 3 O
continued	1622 9 O
in	1632 2 O
all	1635 3 O
patients	1639 8 O
.	1647 1 O

Prophylactic	1649 12 O
administration	1662 14 O
of	1677 2 O
lamivudine	1680 10 B-Chemical
in	1691 2 O
patients	1694 8 O
who	1703 3 O
required	1707 8 O
immunosuppressive	1716 17 O
therapy	1734 7 O
seems	1742 5 O
to	1748 2 O
be	1751 2 O
safe	1754 4 O
,	1758 1 O
well	1760 4 O
tolerated	1765 9 O
and	1775 3 O
effective	1779 9 O
in	1789 2 O
preventing	1792 10 O
HBV	1803 3 O
reactivation	1807 12 O
.	1819 1 O

Safety	0 6 O
of	7 2 O
transesophageal	10 15 O
echocardiography	26 16 O
in	43 2 O
adults	46 6 O
:	52 1 O
study	54 5 O
in	60 2 O
a	63 1 O
multidisciplinary	65 17 O
hospital	83 8 O
.	91 1 O

BACKGROUND	93 10 O
:	103 1 O
TEE	105 3 O
is	109 2 O
a	112 1 O
semi	114 4 O
-	118 1 O
invasive	119 8 O
tool	128 4 O
broadly	133 7 O
used	141 4 O
and	146 3 O
its	150 3 O
utilization	154 11 O
associated	166 10 O
to	177 2 O
sedatives	180 9 O
drugs	190 5 O
might	196 5 O
to	202 2 O
affect	205 6 O
the	212 3 O
procedure	216 9 O
safety	226 6 O
.	232 1 O

OBJECTIVE	234 9 O
:	243 1 O
to	245 2 O
analyze	248 7 O
aspects	256 7 O
of	264 2 O
TEE	267 3 O
safety	271 6 O
associated	278 10 O
to	289 2 O
the	292 3 O
use	296 3 O
of	300 2 O
Midazolan	303 9 B-Chemical
(	313 1 O
MZ	314 2 B-Chemical
)	316 1 O
and	318 3 O
Flumazenil	322 10 B-Chemical
(	333 1 O
FL	334 2 B-Chemical
)	336 1 O
and	338 3 O
the	342 3 O
influence	346 9 O
of	356 2 O
the	359 3 O
clinical	363 8 O
variables	372 9 O
on	382 2 O
the	385 3 O
event	389 5 O
rate	395 4 O
.	399 1 O

METHOD	401 6 O
:	407 1 O
prospective	409 11 O
study	421 5 O
with	427 4 O
137	432 3 O
patients	436 8 O
that	445 4 O
underwent	450 9 O
TEE	460 3 O
with	464 4 O
MZ	469 2 B-Chemical
associated	472 10 O
to	483 2 O
moderate	486 8 O
sedation	495 8 O
.	503 1 O

We	505 2 O
analyzed	508 8 O
the	517 3 O
following	521 9 O
events	531 6 O
:	537 1 O
complications	539 13 O
related	553 7 O
with	561 4 O
the	566 3 O
topical	570 7 O
anesthesia	578 10 O
,	588 1 O
with	590 4 O
MZ	595 2 B-Chemical
use	598 3 O
and	602 3 O
with	606 4 O
the	611 3 O
procedure	615 9 O
.	624 1 O

Uni	626 3 O
-	629 1 O
and	631 3 O
multivariate	635 12 O
analyses	648 8 O
were	657 4 O
used	662 4 O
to	667 2 O
test	670 4 O
the	675 3 O
influence	679 9 O
of	689 2 O
the	692 3 O
clinical	696 8 O
variables	705 9 O
:	714 1 O
age	716 3 O
,	719 1 O
sex	721 3 O
,	724 1 O
stroke	726 6 B-Disease
,	732 1 O
myocardiopathy	734 14 B-Disease
(	749 1 O
MP	750 2 B-Disease
)	752 1 O
,	753 1 O
duration	755 8 O
of	764 2 O
the	767 3 O
test	771 4 O
,	775 1 O
mitral	777 6 B-Disease
regurgitation	784 13 I-Disease
(	798 1 O
MR	799 2 B-Disease
)	801 1 O
and	803 3 O
the	807 3 O
MZ	811 2 B-Chemical
dose	814 4 O
.	818 1 O

RESULTS	820 7 O
:	827 1 O
All	829 3 O
patients	833 8 O
(	842 1 O
65	843 2 O
+	845 1 O
/	846 1 O
-	847 1 O
16	848 2 O
yrs	851 3 O
;	854 1 O
58	856 2 O
%	858 1 O
males	860 5 O
)	865 1 O
finished	867 8 O
the	876 3 O
examination	880 11 O
.	891 1 O

The	893 3 O
mean	897 4 O
doses	902 5 O
of	908 2 O
MZ	911 2 B-Chemical
and	914 3 O
FL	918 2 B-Chemical
were	921 4 O
4	926 1 O
.	927 1 O
3	928 1 O
+	929 1 O
/	930 1 O
-	931 1 O
1	932 1 O
.	933 1 O
9	934 1 O
mg	936 2 O
and	939 3 O
0	943 1 O
.	944 1 O
28	945 2 O
+	947 1 O
/	948 1 O
-	949 1 O
0	950 1 O
.	951 1 O
2	952 1 O
mg	954 2 O
,	956 1 O
respectively	958 12 O
.	970 1 O

The	972 3 O
duration	976 8 O
of	985 2 O
the	988 3 O
examination	992 11 O
and	1004 3 O
the	1008 3 O
mean	1012 4 O
ejection	1017 8 O
fraction	1026 8 O
(	1035 1 O
EF	1036 2 O
)	1038 1 O
were	1040 4 O
16	1045 2 O
.	1047 1 O
4	1048 1 O
+	1049 1 O
/	1050 1 O
-	1051 1 O
6	1052 1 O
.	1053 1 O
1	1054 1 O
minutes	1056 7 O
and	1064 3 O
60	1068 2 O
+	1070 1 O
/	1071 1 O
-	1072 1 O
9	1073 1 O
%	1074 1 O
,	1075 1 O
respectively	1077 12 O
.	1089 1 O

Mild	1091 4 O
hypoxia	1096 7 B-Disease
(	1104 1 O
SO2	1105 3 O
<	1108 1 O
90	1109 2 O
%	1111 1 O
)	1112 1 O
was	1114 3 O
the	1118 3 O
most	1122 4 O
common	1127 6 O
event	1134 5 O
(	1140 1 O
11	1141 2 O
patients	1144 8 O
)	1152 1 O
;	1153 1 O
3	1155 1 O
patients	1157 8 O
(	1166 1 O
2	1167 1 O
%	1168 1 O
)	1169 1 O
presented	1171 9 O
transient	1181 9 O
hypoxia	1191 7 B-Disease
due	1199 3 O
to	1203 2 O
upper	1206 5 O
airway	1212 6 B-Disease
obstruction	1219 11 I-Disease
by	1231 2 O
probe	1234 5 O
introduction	1240 12 O
and	1253 3 O
8	1257 1 O
(	1259 1 O
5	1260 1 O
.	1261 1 O
8	1262 1 O
%	1263 1 O
)	1264 1 O
due	1266 3 O
to	1270 2 O
hypoxia	1273 7 B-Disease
caused	1281 6 O
by	1288 2 O
MZ	1291 2 B-Chemical
use	1294 3 O
.	1297 1 O

Transient	1299 9 O
hypotension	1309 11 B-Disease
(	1321 1 O
SAP	1322 3 O
<	1325 1 O
90mmHg	1326 6 O
)	1332 1 O
occurred	1334 8 O
in	1343 2 O
1	1346 1 O
patient	1348 7 O
(	1356 1 O
0	1357 1 O
.	1358 1 O
7	1359 1 O
%	1360 1 O
)	1361 1 O
.	1362 1 O

The	1364 3 O
multivariate	1368 12 O
analysis	1381 8 O
showed	1390 6 O
that	1397 4 O
severe	1402 6 O
MR	1409 2 B-Disease
,	1411 1 O
MP	1413 2 B-Disease
(	1416 1 O
EF	1417 2 O
<	1419 1 O
45	1420 2 O
%	1422 1 O
)	1423 1 O
and	1425 3 O
high	1429 4 O
doses	1434 5 O
of	1440 2 O
MZ	1443 2 B-Chemical
(	1446 1 O
>	1447 1 O
5mg	1448 3 O
)	1451 1 O
were	1453 4 O
associated	1458 10 O
with	1469 4 O
events	1474 6 O
(	1481 1 O
p	1482 1 O
<	1483 1 O
0	1484 1 O
.	1485 1 O
001	1486 3 O
)	1489 1 O
.	1490 1 O

The	1492 3 O
EF	1496 2 O
was	1499 3 O
40	1503 2 O
%	1505 1 O
,	1506 1 O
in	1508 2 O
the	1511 3 O
group	1515 5 O
with	1521 4 O
MP	1526 2 B-Disease
and	1529 3 O
44	1533 2 O
%	1535 1 O
in	1537 2 O
the	1540 3 O
group	1544 5 O
with	1550 4 O
severe	1555 6 O
MR	1562 2 B-Disease
and	1565 3 O
it	1569 2 O
can	1572 3 O
be	1576 2 O
a	1579 1 O
factor	1581 6 O
associated	1588 10 O
with	1599 4 O
clinical	1604 8 O
events	1613 6 O
in	1620 2 O
the	1623 3 O
last	1627 4 O
group	1632 5 O
.	1637 1 O

CONCLUSION	1639 10 O
:	1649 1 O
TEE	1651 3 O
with	1655 4 O
sedation	1660 8 O
presents	1669 8 O
a	1678 1 O
low	1680 3 O
rate	1684 4 O
of	1689 2 O
events	1692 6 O
.	1698 1 O

There	1700 5 O
were	1706 4 O
no	1711 2 O
severe	1714 6 O
events	1721 6 O
and	1728 3 O
there	1732 5 O
was	1738 3 O
no	1742 2 O
need	1745 4 O
to	1750 2 O
interrupt	1753 9 O
the	1763 3 O
examinations	1767 12 O
.	1779 1 O

Effects	0 7 O
of	8 2 O
calcium	11 7 B-Chemical
channel	19 7 O
blockers	27 8 O
on	36 2 O
bupivacaine	39 11 B-Chemical
-	50 1 O
induced	51 7 O
toxicity	59 8 B-Disease
.	67 1 O

The	69 3 O
purpose	73 7 O
of	81 2 O
this	84 4 O
study	89 5 O
was	95 3 O
to	99 2 O
investigate	102 11 O
the	114 3 O
influence	118 9 O
of	128 2 O
calcium	131 7 B-Chemical
channel	139 7 O
blockers	147 8 O
on	156 2 O
bupivacaine	159 11 B-Chemical
-	170 1 O
induced	171 7 O
acute	179 5 O
toxicity	185 8 B-Disease
.	193 1 O

For	195 3 O
each	199 4 O
of	204 2 O
the	207 3 O
three	211 5 O
tested	217 6 O
calcium	224 7 B-Chemical
channel	232 7 O
blockers	240 8 O
(	249 1 O
diltiazem	250 9 B-Chemical
,	259 1 O
verapamil	261 9 B-Chemical
and	271 3 O
bepridil	275 8 B-Chemical
)	283 1 O
6	285 1 O
groups	287 6 O
of	294 2 O
mice	297 4 O
were	302 4 O
treated	307 7 O
by	315 2 O
two	318 3 O
different	322 9 O
doses	332 5 O
,	337 1 O
i	339 1 O
.	340 1 O
e	341 1 O
.	342 1 O
2	344 1 O
and	346 3 O
10	350 2 O
mg	353 2 O
/	355 1 O
kg	356 2 O
/	358 1 O
i	359 1 O
.	360 1 O
p	361 1 O
.	362 1 O
,	363 1 O
or	365 2 O
an	368 2 O
equal	371 5 O
volume	377 6 O
of	384 2 O
saline	387 6 O
for	394 3 O
the	398 3 O
control	402 7 O
group	410 5 O
(	416 1 O
n	417 1 O
=	419 1 O
20	421 2 O
)	423 1 O
;	424 1 O
15	426 2 O
minutes	429 7 O
later	437 5 O
,	442 1 O
all	444 3 O
the	448 3 O
animals	452 7 O
were	460 4 O
injected	465 8 O
with	474 4 O
a	479 1 O
single	481 6 O
50	488 2 O
mg	491 2 O
/	493 1 O
kg	494 2 O
/	496 1 O
i	497 1 O
.	498 1 O
p	499 1 O
.	500 1 O
dose	502 4 O
of	507 2 O
bupivacaine	510 11 B-Chemical
.	521 1 O

The	523 3 O
convulsant	527 10 O
activity	538 8 O
,	546 1 O
the	548 3 O
time	552 4 O
of	557 2 O
latency	560 7 O
to	568 2 O
convulse	571 8 O
and	580 3 O
the	584 3 O
mortality	588 9 O
rate	598 4 O
were	603 4 O
assessed	608 8 O
in	617 2 O
each	620 4 O
group	625 5 O
.	630 1 O

The	632 3 O
local	636 5 O
anesthetic	642 10 O
-	652 1 O
induced	653 7 O
mortality	661 9 O
was	671 3 O
significantly	675 13 O
increased	689 9 O
by	699 2 O
the	702 3 O
three	706 5 O
different	712 9 O
calcium	722 7 B-Chemical
channel	730 7 O
blockers	738 8 O
.	746 1 O

The	748 3 O
convulsant	752 10 O
activity	763 8 O
of	772 2 O
bupivacaine	775 11 B-Chemical
was	787 3 O
not	791 3 O
significantly	795 13 O
modified	809 8 O
but	818 3 O
calcium	822 7 B-Chemical
channel	830 7 O
blockers	838 8 O
decreased	847 9 O
the	857 3 O
time	861 4 O
of	866 2 O
latency	869 7 O
to	877 2 O
obtain	880 6 O
bupivacaine	887 11 B-Chemical
-	898 1 O
induced	899 7 O
convulsions	907 11 B-Disease
;	918 1 O
this	920 4 O
effect	925 6 O
was	932 3 O
less	936 4 O
pronounced	941 10 O
with	952 4 O
bepridil	957 8 B-Chemical
.	965 1 O

Selegiline	0 10 B-Chemical
-	10 1 O
induced	11 7 O
postural	19 8 B-Disease
hypotension	28 11 I-Disease
in	40 2 O
Parkinson	43 9 B-Disease
'	52 1 I-Disease
s	53 1 I-Disease
disease	55 7 I-Disease
:	62 1 O
a	64 1 O
longitudinal	66 12 O
study	79 5 O
on	85 2 O
the	88 3 O
effects	92 7 O
of	100 2 O
drug	103 4 O
withdrawal	108 10 O
.	118 1 O

OBJECTIVES	120 10 O
:	130 1 O
The	132 3 O
United	136 6 O
Kingdom	143 7 O
Parkinson	151 9 B-Disease
'	160 1 I-Disease
s	161 1 I-Disease
Disease	163 7 I-Disease
Research	171 8 O
Group	180 5 O
(	186 1 O
UKPDRG	187 6 O
)	193 1 O
trial	195 5 O
found	201 5 O
an	207 2 O
increased	210 9 O
mortality	220 9 O
in	230 2 O
patients	233 8 O
with	242 4 O
Parkinson	247 9 B-Disease
'	256 1 I-Disease
s	257 1 I-Disease
disease	259 7 I-Disease
(	267 1 O
PD	268 2 B-Disease
)	270 1 O
randomized	272 10 O
to	283 2 O
receive	286 7 O
10	294 2 O
mg	297 2 O
selegiline	300 10 B-Chemical
per	311 3 O
day	315 3 O
and	319 3 O
L	323 1 B-Chemical
-	324 1 I-Chemical
dopa	325 4 I-Chemical
compared	330 8 O
with	339 4 O
those	344 5 O
taking	350 6 O
L	357 1 B-Chemical
-	358 1 I-Chemical
dopa	359 4 I-Chemical
alone	364 5 O
.	369 1 O

Recently	371 8 O
,	379 1 O
we	381 2 O
found	384 5 O
that	390 4 O
therapy	395 7 O
with	403 4 O
selegiline	408 10 B-Chemical
and	419 3 O
L	423 1 B-Chemical
-	424 1 I-Chemical
dopa	425 4 I-Chemical
was	430 3 O
associated	434 10 O
with	445 4 O
selective	450 9 O
systolic	460 8 B-Disease
orthostatic	469 11 I-Disease
hypotension	481 11 I-Disease
which	493 5 O
was	499 3 O
abolished	503 9 O
by	513 2 O
withdrawal	516 10 O
of	527 2 O
selegiline	530 10 B-Chemical
.	540 1 O

This	542 4 O
unwanted	547 8 O
effect	556 6 O
on	563 2 O
postural	566 8 O
blood	575 5 O
pressure	581 8 O
was	590 3 O
not	594 3 O
the	598 3 O
result	602 6 O
of	609 2 O
underlying	612 10 O
autonomic	623 9 O
failure	633 7 O
.	640 1 O

The	642 3 O
aims	646 4 O
of	651 2 O
this	654 4 O
study	659 5 O
were	665 4 O
to	670 2 O
confirm	673 7 O
our	681 3 O
previous	685 8 O
findings	694 8 O
in	703 2 O
a	706 1 O
separate	708 8 O
cohort	717 6 O
of	724 2 O
patients	727 8 O
and	736 3 O
to	740 2 O
determine	743 9 O
the	753 3 O
time	757 4 O
course	762 6 O
of	769 2 O
the	772 3 O
cardiovascular	776 14 O
consequences	791 12 O
of	804 2 O
stopping	807 8 O
selegiline	816 10 B-Chemical
in	827 2 O
the	830 3 O
expectation	834 11 O
that	846 4 O
this	851 4 O
might	856 5 O
shed	862 4 O
light	867 5 O
on	873 2 O
the	876 3 O
mechanisms	880 10 O
by	891 2 O
which	894 5 O
the	900 3 O
drug	904 4 O
causes	909 6 O
orthostatic	916 11 B-Disease
hypotension	928 11 I-Disease
.	939 1 O

METHODS	941 7 O
:	948 1 O
The	950 3 O
cardiovascular	954 14 O
responses	969 9 O
to	979 2 O
standing	982 8 O
and	991 3 O
head	995 4 O
-	999 1 O
up	1000 2 O
tilt	1003 4 O
were	1008 4 O
studied	1013 7 O
repeatedly	1021 10 O
in	1032 2 O
PD	1035 2 B-Disease
patients	1038 8 O
receiving	1047 9 O
selegiline	1057 10 B-Chemical
and	1068 3 O
as	1072 2 O
the	1075 3 O
drug	1079 4 O
was	1084 3 O
withdrawn	1088 9 O
.	1097 1 O

RESULTS	1099 7 O
:	1106 1 O
Head	1108 4 O
-	1112 1 O
up	1113 2 O
tilt	1116 4 O
caused	1121 6 O
systolic	1128 8 B-Disease
orthostatic	1137 11 I-Disease
hypotension	1149 11 I-Disease
which	1161 5 O
was	1167 3 O
marked	1171 6 O
in	1178 2 O
six	1181 3 O
of	1185 2 O
20	1188 2 O
PD	1191 2 B-Disease
patients	1194 8 O
on	1203 2 O
selegiline	1206 10 B-Chemical
,	1216 1 O
one	1218 3 O
of	1222 2 O
whom	1225 4 O
lost	1230 4 O
consciousness	1235 13 O
with	1249 4 O
unrecordable	1254 12 O
blood	1267 5 O
pressures	1273 9 O
.	1282 1 O

A	1284 1 O
lesser	1286 6 O
degree	1293 6 O
of	1300 2 O
orthostatic	1303 11 B-Disease
hypotension	1315 11 I-Disease
occurred	1327 8 O
with	1336 4 O
standing	1341 8 O
.	1349 1 O

Orthostatic	1351 11 B-Disease
hypotension	1363 11 I-Disease
was	1375 3 O
ameliorated	1379 11 O
4	1391 1 O
days	1393 4 O
after	1398 5 O
withdrawal	1404 10 O
of	1415 2 O
selegiline	1418 10 B-Chemical
and	1429 3 O
totally	1433 7 O
abolished	1441 9 O
7	1451 1 O
days	1453 4 O
after	1458 5 O
discontinuation	1464 15 O
of	1480 2 O
the	1483 3 O
drug	1487 4 O
.	1491 1 O

Stopping	1493 8 O
selegiline	1502 10 B-Chemical
also	1513 4 O
significantly	1518 13 O
reduced	1532 7 B-Disease
the	1540 3 I-Disease
supine	1544 6 I-Disease
systolic	1551 8 I-Disease
and	1560 3 I-Disease
diastolic	1564 9 I-Disease
blood	1574 5 I-Disease
pressures	1580 9 I-Disease
consistent	1590 10 O
with	1601 4 O
a	1606 1 O
previously	1608 10 O
undescribed	1619 11 O
supine	1631 6 O
pressor	1638 7 O
action	1646 6 O
.	1652 1 O

CONCLUSION	1654 10 O
:	1664 1 O
This	1666 4 O
study	1671 5 O
confirms	1677 8 O
our	1686 3 O
previous	1690 8 O
finding	1699 7 O
that	1707 4 O
selegiline	1712 10 B-Chemical
in	1723 2 O
combination	1726 11 O
with	1738 4 O
L	1743 1 B-Chemical
-	1744 1 I-Chemical
dopa	1745 4 I-Chemical
is	1750 2 O
associated	1753 10 O
with	1764 4 O
selective	1769 9 O
orthostatic	1779 11 B-Disease
hypotension	1791 11 I-Disease
.	1802 1 O

The	1804 3 O
possibilities	1808 13 O
that	1822 4 O
these	1827 5 O
cardiovascular	1833 14 O
findings	1848 8 O
might	1857 5 O
be	1863 2 O
the	1866 3 O
result	1870 6 O
of	1877 2 O
non	1880 3 O
-	1883 1 O
selective	1884 9 O
inhibition	1894 10 O
of	1905 2 O
monoamine	1908 9 O
oxidase	1918 7 O
or	1926 2 O
of	1929 2 O
amphetamine	1932 11 B-Chemical
and	1944 3 O
metamphetamine	1948 14 B-Chemical
are	1963 3 O
discussed	1967 9 O
.	1976 1 O

Explicit	0 8 O
episodic	9 8 O
memory	18 6 O
for	25 3 O
sensory	29 7 O
-	36 1 O
discriminative	37 14 O
components	52 10 O
of	63 2 O
capsaicin	66 9 B-Chemical
-	75 1 O
induced	76 7 O
pain	84 4 B-Disease
:	88 1 O
immediate	90 9 O
and	100 3 O
delayed	104 7 O
ratings	112 7 O
.	119 1 O

Pain	121 4 B-Disease
memory	126 6 O
is	133 2 O
thought	136 7 O
to	144 2 O
affect	147 6 O
future	154 6 O
pain	161 4 B-Disease
sensitivity	166 11 O
and	178 3 O
thus	182 4 O
contribute	187 10 O
to	198 2 O
clinical	201 8 O
pain	210 4 B-Disease
conditions	215 10 O
.	225 1 O

Systematic	227 10 O
investigations	238 14 O
of	253 2 O
the	256 3 O
human	260 5 O
capacity	266 8 O
to	275 2 O
remember	278 8 O
sensory	287 7 O
features	295 8 O
of	304 2 O
experimental	307 12 O
pain	320 4 B-Disease
are	325 3 O
sparse	329 6 O
.	335 1 O

In	337 2 O
order	340 5 O
to	346 2 O
address	349 7 O
long	357 4 O
-	361 1 O
term	362 4 O
pain	367 4 B-Disease
memory	372 6 O
,	378 1 O
nine	380 4 O
healthy	385 7 O
male	393 4 O
volunteers	398 10 O
received	409 8 O
intradermal	418 11 O
injections	430 10 O
of	441 2 O
three	444 5 O
doses	450 5 O
of	456 2 O
capsaicin	459 9 B-Chemical
(	469 1 O
0	470 1 O
.	471 1 O
05	472 2 O
,	474 1 O
1	476 1 O
and	478 3 O
20	482 2 O
microg	485 6 O
,	491 1 O
separated	493 9 O
by	503 2 O
15	506 2 O
min	509 3 O
breaks	513 6 O
)	519 1 O
,	520 1 O
each	522 4 O
given	527 5 O
three	533 5 O
times	539 5 O
in	545 2 O
a	548 1 O
balanced	550 8 O
design	559 6 O
across	566 6 O
three	573 5 O
sessions	579 8 O
at	588 2 O
one	591 3 O
week	595 4 O
intervals	600 9 O
.	609 1 O

Pain	611 4 B-Disease
rating	616 6 O
was	623 3 O
performed	627 9 O
using	637 5 O
a	643 1 O
computerized	645 12 O
visual	658 6 O
analogue	665 8 O
scale	674 5 O
(	680 1 O
0	681 1 O
-	682 1 O
100	683 3 O
)	686 1 O
digitized	688 9 O
at	698 2 O
1	701 1 O
/	702 1 O
s	703 1 O
,	704 1 O
either	706 6 O
immediately	713 11 O
online	725 6 O
or	732 2 O
one	735 3 O
hour	739 4 O
or	744 2 O
one	747 3 O
day	751 3 O
after	755 5 O
injection	761 9 O
.	770 1 O

Subjects	772 8 O
also	781 4 O
recalled	786 8 O
their	795 5 O
pains	801 5 B-Disease
one	807 3 O
week	811 4 O
later	816 5 O
.	821 1 O

Capsaicin	823 9 B-Chemical
injection	833 9 O
reliably	843 8 O
induced	852 7 O
a	860 1 O
dose	862 4 O
-	866 1 O
dependent	867 9 O
flare	877 5 O
(	883 1 O
p	884 1 O
<	885 1 O
0	886 1 O
.	887 1 O
001	888 3 O
)	891 1 O
without	893 7 O
any	901 3 O
difference	905 10 O
within	916 6 O
or	923 2 O
across	926 6 O
sessions	933 8 O
.	941 1 O

The	943 3 O
strong	947 6 O
burning	954 7 O
pain	962 4 B-Disease
decayed	967 7 O
exponentially	975 13 O
within	989 6 O
a	996 1 O
few	998 3 O
minutes	1002 7 O
.	1009 1 O

Subjects	1011 8 O
were	1020 4 O
able	1025 4 O
to	1030 2 O
reliably	1033 8 O
discriminate	1042 12 O
pain	1055 4 B-Disease
magnitude	1060 9 O
and	1070 3 O
duration	1074 8 O
across	1083 6 O
capsaicin	1090 9 B-Chemical
doses	1100 5 O
(	1106 1 O
both	1107 4 O
p	1112 1 O
<	1113 1 O
0	1114 1 O
.	1115 1 O
001	1116 3 O
)	1119 1 O
,	1120 1 O
regardless	1122 10 O
of	1133 2 O
whether	1136 7 O
first	1144 5 O
-	1149 1 O
time	1150 4 O
ratings	1155 7 O
were	1163 4 O
requested	1168 9 O
immediately	1178 11 O
,	1189 1 O
after	1191 5 O
one	1197 3 O
hour	1201 4 O
or	1206 2 O
after	1209 5 O
one	1215 3 O
day	1219 3 O
.	1222 1 O

Pain	1224 4 B-Disease
recall	1229 6 O
after	1236 5 O
one	1242 3 O
week	1246 4 O
was	1251 3 O
similarly	1255 9 O
precise	1265 7 O
(	1273 1 O
magnitude	1274 9 O
:	1283 1 O
p	1285 1 O
<	1286 1 O
0	1287 1 O
.	1288 1 O
01	1289 2 O
,	1291 1 O
duration	1293 8 O
:	1301 1 O
p	1303 1 O
<	1304 1 O
0	1305 1 O
.	1306 1 O
05	1307 2 O
)	1309 1 O
.	1310 1 O

Correlation	1312 11 O
with	1324 4 O
rating	1329 6 O
recall	1336 6 O
after	1343 5 O
one	1349 3 O
week	1353 4 O
was	1358 3 O
best	1362 4 O
when	1367 4 O
first	1372 5 O
-	1377 1 O
time	1378 4 O
ratings	1383 7 O
were	1391 4 O
requested	1396 9 O
as	1406 2 O
late	1409 4 O
as	1414 2 O
one	1417 3 O
day	1421 3 O
after	1425 5 O
injection	1431 9 O
(	1441 1 O
R	1442 1 O
(	1443 1 O
2	1444 1 O
)	1445 1 O
=	1446 1 O
0	1447 1 O
.	1448 1 O
79	1449 2 O
)	1451 1 O
indicating	1453 10 O
that	1464 4 O
both	1469 4 O
rating	1474 6 O
retrievals	1481 10 O
utilized	1492 8 O
similar	1501 7 O
memory	1509 6 O
traces	1516 6 O
.	1522 1 O

These	1524 5 O
results	1530 7 O
indicate	1538 8 O
a	1547 1 O
reliable	1549 8 O
memory	1558 6 O
for	1565 3 O
magnitude	1569 9 O
and	1579 3 O
duration	1583 8 O
of	1592 2 O
experimentally	1595 14 O
induced	1610 7 O
pain	1618 4 B-Disease
.	1622 1 O

The	1624 3 O
data	1628 4 O
further	1633 7 O
suggest	1641 7 O
that	1649 4 O
the	1654 3 O
consolidation	1658 13 O
of	1672 2 O
this	1675 4 O
memory	1680 6 O
is	1687 2 O
an	1690 2 O
important	1693 9 O
interim	1703 7 O
stage	1711 5 O
,	1716 1 O
and	1718 3 O
may	1722 3 O
take	1726 4 O
up	1731 2 O
to	1734 2 O
one	1737 3 O
day	1741 3 O
.	1744 1 O

Reversibility	0 13 O
of	14 2 O
captopril	17 9 B-Chemical
-	26 1 O
induced	27 7 O
renal	35 5 B-Disease
insufficiency	41 13 I-Disease
after	55 5 O
prolonged	61 9 O
use	71 3 O
in	75 2 O
an	78 2 O
unusual	81 7 O
case	89 4 O
of	94 2 O
renovascular	97 12 B-Disease
hypertension	110 12 I-Disease
.	122 1 O

We	124 2 O
report	127 6 O
a	134 1 O
case	136 4 O
of	141 2 O
severe	144 6 O
hypertension	151 12 B-Disease
with	164 4 O
an	169 2 O
occluded	172 8 O
renal	181 5 O
artery	187 6 O
to	194 2 O
a	197 1 O
solitary	199 8 O
kidney	208 6 O
,	214 1 O
who	216 3 O
developed	220 9 O
sudden	230 6 B-Disease
deterioration	237 13 I-Disease
of	251 2 I-Disease
renal	254 5 I-Disease
function	260 8 I-Disease
following	269 9 O
treatment	279 9 O
with	289 4 O
captopril	294 9 B-Chemical
.	303 1 O

His	305 3 O
renal	309 5 O
function	315 8 O
remained	324 8 O
impaired	333 8 O
but	342 3 O
stable	346 6 O
during	353 6 O
2	360 1 O
years	362 5 O
'	367 1 O
treatment	369 9 O
with	379 4 O
captopril	384 9 B-Chemical
but	394 3 O
returned	398 8 O
to	407 2 O
pre	410 3 O
-	413 1 O
treatment	414 9 O
levels	424 6 O
soon	431 4 O
after	436 5 O
cessation	442 9 O
of	452 2 O
the	455 3 O
drug	459 4 O
.	463 1 O

This	465 4 O
indicates	470 9 O
reversibility	480 13 O
in	494 2 O
captopril	497 9 B-Chemical
-	506 1 O
induced	507 7 O
renal	515 5 B-Disease
failure	521 7 I-Disease
even	529 4 O
after	534 5 O
its	540 3 O
prolonged	544 9 O
use	554 3 O
and	558 3 O
suggests	562 8 O
that	571 4 O
no	576 2 O
organic	579 7 O
damage	587 6 O
occurs	594 6 O
to	601 2 O
glomerular	604 10 O
arterioles	615 10 O
following	626 9 O
chronic	636 7 O
ACE	644 3 O
inhibition	648 10 O
.	658 1 O

Liver	0 5 B-Disease
disease	6 7 I-Disease
caused	14 6 O
by	21 2 O
propylthiouracil	24 16 B-Chemical
.	40 1 O

This	42 4 O
report	47 6 O
presents	54 8 O
the	63 3 O
clinical	67 8 O
,	75 1 O
laboratory	77 10 O
,	87 1 O
and	89 3 O
light	93 5 O
and	99 3 O
electron	103 8 O
microscopic	112 11 O
observations	124 12 O
on	137 2 O
a	140 1 O
patient	142 7 O
with	150 4 O
chronic	155 7 B-Disease
active	163 6 I-Disease
(	170 1 I-Disease
aggressive	171 10 I-Disease
)	181 1 I-Disease
hepatitis	183 9 I-Disease
caused	193 6 O
by	200 2 O
the	203 3 O
administration	207 14 O
of	222 2 O
propylthiouracil	225 16 B-Chemical
.	241 1 O

This	243 4 O
is	248 2 O
an	251 2 O
addition	254 8 O
to	263 2 O
the	266 3 O
list	270 4 O
of	275 2 O
drugs	278 5 O
that	284 4 O
must	289 4 O
be	294 2 O
considered	297 10 O
in	308 2 O
the	311 3 O
evaluation	315 10 O
of	326 2 O
chronic	329 7 O
liver	337 5 B-Disease
disease	343 7 I-Disease
.	350 1 O

Capsaicin	0 9 B-Chemical
-	9 1 O
induced	10 7 O
muscle	18 6 B-Disease
pain	25 4 I-Disease
alters	30 6 O
the	37 3 O
excitability	41 12 O
of	54 2 O
the	57 3 O
human	61 5 O
jaw	67 3 O
-	70 1 O
stretch	71 7 O
reflex	79 6 O
.	85 1 O

The	87 3 O
pathophysiology	91 15 O
of	107 2 O
painful	110 7 O
temporomandibular	118 17 B-Disease
disorders	136 9 I-Disease
is	146 2 O
not	149 3 O
fully	153 5 O
understood	159 10 O
,	169 1 O
but	171 3 O
evidence	175 8 O
suggests	184 8 O
that	193 4 O
muscle	198 6 B-Disease
pain	205 4 I-Disease
modulates	210 9 O
motor	220 5 O
function	226 8 O
in	235 2 O
characteristic	238 14 O
ways	253 4 O
.	257 1 O

This	259 4 O
study	264 5 O
tested	270 6 O
the	277 3 O
hypothesis	281 10 O
that	292 4 O
activation	297 10 O
of	308 2 O
nociceptive	311 11 B-Disease
muscle	323 6 I-Disease
afferent	330 8 O
fibers	339 6 O
would	346 5 O
be	352 2 O
linked	355 6 O
to	362 2 O
an	365 2 O
increased	368 9 O
excitability	378 12 O
of	391 2 O
the	394 3 O
human	398 5 O
jaw	404 3 O
-	407 1 O
stretch	408 7 O
reflex	416 6 O
and	423 3 O
whether	427 7 O
this	435 4 O
process	440 7 O
would	448 5 O
be	454 2 O
sensitive	457 9 O
to	467 2 O
length	470 6 O
and	477 3 O
velocity	481 8 O
of	490 2 O
the	493 3 O
stretch	497 7 O
.	504 1 O

Capsaicin	506 9 B-Chemical
(	516 1 O
10	517 2 O
micro	520 5 O
g	526 1 O
)	527 1 O
was	529 3 O
injected	533 8 O
into	542 4 O
the	547 3 O
masseter	551 8 O
muscle	560 6 O
to	567 2 O
induce	570 6 O
pain	577 4 B-Disease
in	582 2 O
11	585 2 O
healthy	588 7 O
volunteers	596 10 O
.	606 1 O

Short	608 5 O
-	613 1 O
latency	614 7 O
reflex	622 6 O
responses	629 9 O
were	639 4 O
evoked	644 6 O
in	651 2 O
the	654 3 O
masseter	658 8 O
and	667 3 O
temporalis	671 10 O
muscles	682 7 O
by	690 2 O
a	693 1 O
stretch	695 7 O
device	703 6 O
with	710 4 O
different	715 9 O
velocities	725 10 O
and	736 3 O
displacements	740 13 O
before	754 6 O
,	760 1 O
during	762 6 O
,	768 1 O
and	770 3 O
after	774 5 O
the	780 3 O
pain	784 4 B-Disease
.	788 1 O

The	790 3 O
normalized	794 10 O
reflex	805 6 O
amplitude	812 9 O
increased	822 9 O
with	832 4 O
an	837 2 O
increase	840 8 O
in	849 2 O
velocity	852 8 O
at	861 2 O
a	864 1 O
given	866 5 O
displacement	872 12 O
,	884 1 O
but	886 3 O
remained	890 8 O
constant	899 8 O
with	908 4 O
different	913 9 O
displacements	923 13 O
at	937 2 O
a	940 1 O
given	942 5 O
velocity	948 8 O
.	956 1 O

The	958 3 O
normalized	962 10 O
reflex	973 6 O
amplitude	980 9 O
was	990 3 O
significantly	994 13 O
higher	1008 6 O
during	1015 6 O
pain	1022 4 B-Disease
,	1026 1 O
but	1028 3 O
only	1032 4 O
at	1037 2 O
faster	1040 6 O
stretches	1047 9 O
in	1057 2 O
the	1060 3 O
painful	1064 7 B-Disease
muscle	1072 6 I-Disease
.	1078 1 O

Increased	1080 9 O
sensitivity	1090 11 O
of	1102 2 O
the	1105 3 O
fusimotor	1109 9 O
system	1119 6 O
during	1126 6 O
acute	1133 5 O
muscle	1139 6 B-Disease
pain	1146 4 I-Disease
could	1151 5 O
be	1157 2 O
one	1160 3 O
likely	1164 6 O
mechanism	1171 9 O
to	1181 2 O
explain	1184 7 O
the	1192 3 O
findings	1196 8 O
.	1204 1 O

Repetitive	0 10 O
transcranial	11 12 O
magnetic	24 8 O
stimulation	33 11 O
for	45 3 O
levodopa	49 8 B-Chemical
-	57 1 O
induced	58 7 O
dyskinesias	66 11 B-Disease
in	78 2 O
Parkinson	81 9 B-Disease
'	90 1 I-Disease
s	91 1 I-Disease
disease	93 7 I-Disease
.	100 1 O

In	102 2 O
a	105 1 O
placebo	107 7 O
-	114 1 O
controlled	115 10 O
,	125 1 O
single	127 6 O
-	133 1 O
blinded	134 7 O
,	141 1 O
crossover	143 9 O
study	153 5 O
,	158 1 O
we	160 2 O
assessed	163 8 O
the	172 3 O
effect	176 6 O
of	183 2 O
"	186 1 O
real	187 4 O
"	191 1 O
repetitive	193 10 O
transcranial	204 12 O
magnetic	217 8 O
stimulation	226 11 O
(	238 1 O
rTMS	239 4 O
)	243 1 O
versus	245 6 O
"	252 1 O
sham	253 4 O
"	257 1 O
rTMS	259 4 O
(	264 1 O
placebo	265 7 O
)	272 1 O
on	274 2 O
peak	277 4 O
dose	282 4 O
dyskinesias	287 11 B-Disease
in	299 2 O
patients	302 8 O
with	311 4 O
Parkinson	316 9 B-Disease
'	325 1 I-Disease
s	326 1 I-Disease
disease	328 7 I-Disease
(	336 1 O
PD	337 2 B-Disease
)	339 1 O
.	340 1 O

Ten	342 3 O
patients	346 8 O
with	355 4 O
PD	360 2 B-Disease
and	363 3 O
prominent	367 9 O
dyskinesias	377 11 B-Disease
had	389 3 O
rTMS	393 4 O
(	398 1 O
1	399 1 O
,	400 1 O
800	401 3 O
pulses	405 6 O
;	411 1 O
1	413 1 O
Hz	415 2 O
rate	418 4 O
)	422 1 O
delivered	424 9 O
over	434 4 O
the	439 3 O
motor	443 5 O
cortex	449 6 O
for	456 3 O
4	460 1 O
consecutive	462 11 O
days	474 4 O
twice	479 5 O
,	484 1 O
once	486 4 O
real	491 4 O
stimuli	496 7 O
and	504 3 O
once	508 4 O
sham	513 4 O
stimulation	518 11 O
were	530 4 O
used	535 4 O
;	539 1 O
evaluations	541 11 O
were	553 4 O
done	558 4 O
at	563 2 O
the	566 3 O
baseline	570 8 O
and	579 3 O
1	583 1 O
day	585 3 O
after	589 5 O
the	595 3 O
end	599 3 O
of	603 2 O
each	606 4 O
of	611 2 O
the	614 3 O
treatment	618 9 O
series	628 6 O
.	634 1 O

Direct	636 6 O
comparison	643 10 O
between	654 7 O
sham	662 4 O
and	667 3 O
real	671 4 O
rTMS	676 4 O
effects	681 7 O
showed	689 6 O
no	696 2 O
significant	699 11 O
difference	711 10 O
in	722 2 O
clinician	725 9 O
-	734 1 O
assessed	735 8 O
dyskinesia	744 10 B-Disease
severity	755 8 O
.	763 1 O

However	765 7 O
,	772 1 O
comparison	774 10 O
with	785 4 O
the	790 3 O
baseline	794 8 O
showed	803 6 O
small	810 5 O
but	816 3 O
significant	820 11 O
reduction	832 9 O
in	842 2 O
dyskinesia	845 10 B-Disease
severity	856 8 O
following	865 9 O
real	875 4 O
rTMS	880 4 O
but	885 3 O
not	889 3 O
placebo	893 7 O
.	900 1 O

The	902 3 O
major	906 5 O
effect	912 6 O
was	919 3 O
on	923 2 O
dystonia	926 8 B-Disease
subscore	935 8 O
.	943 1 O

Similarly	945 9 O
,	954 1 O
in	956 2 O
patient	959 7 O
diaries	967 7 O
,	974 1 O
although	976 8 O
both	985 4 O
treatments	990 10 O
caused	1001 6 O
reduction	1008 9 O
in	1018 2 O
subjective	1021 10 O
dyskinesia	1032 10 B-Disease
scores	1043 6 O
during	1050 6 O
the	1057 3 O
days	1061 4 O
of	1066 2 O
intervention	1069 12 O
,	1081 1 O
the	1083 3 O
effect	1087 6 O
was	1094 3 O
sustained	1098 9 O
for	1108 3 O
3	1112 1 O
days	1114 4 O
after	1119 5 O
the	1125 3 O
intervention	1129 12 O
for	1142 3 O
the	1146 3 O
real	1150 4 O
rTMS	1155 4 O
only	1160 4 O
.	1164 1 O

Following	1166 9 O
rTMS	1176 4 O
,	1180 1 O
no	1182 2 O
side	1185 4 O
effects	1190 7 O
and	1198 3 O
no	1202 2 O
adverse	1205 7 O
effects	1213 7 O
on	1221 2 O
motor	1224 5 O
function	1230 8 O
and	1239 3 O
PD	1243 2 B-Disease
symptoms	1246 8 O
were	1255 4 O
noted	1260 5 O
.	1265 1 O

The	1267 3 O
results	1271 7 O
suggest	1279 7 O
the	1287 3 O
existence	1291 9 O
of	1301 2 O
residual	1304 8 O
beneficial	1313 10 O
clinical	1324 8 O
aftereffects	1333 12 O
of	1346 2 O
consecutive	1349 11 O
daily	1361 5 O
applications	1367 12 O
of	1380 2 O
low	1383 3 O
-	1386 1 O
frequency	1387 9 O
rTMS	1397 4 O
on	1402 2 O
dyskinesias	1405 11 B-Disease
in	1417 2 O
PD	1420 2 B-Disease
.	1422 1 O

The	1424 3 O
effects	1428 7 O
may	1436 3 O
be	1440 2 O
further	1443 7 O
exploited	1451 9 O
for	1461 3 O
potential	1465 9 O
therapeutic	1475 11 O
uses	1487 4 O
.	1491 1 O

Disulfiram	0 10 B-Chemical
-	10 1 O
like	11 4 O
syndrome	16 8 O
after	25 5 O
hydrogen	31 8 B-Chemical
cyanamide	40 9 I-Chemical
professional	50 12 O
skin	63 4 O
exposure	68 8 O
:	76 1 O
two	78 3 O
case	82 4 O
reports	87 7 O
in	95 2 O
France	98 6 O
.	104 1 O

Hydrogen	106 8 B-Chemical
cyanamide	115 9 I-Chemical
is	125 2 O
a	128 1 O
plant	130 5 O
growth	136 6 O
regulator	143 9 O
used	153 4 O
in	158 2 O
agriculture	161 11 O
to	173 2 O
induce	176 6 O
bud	183 3 O
break	187 5 O
in	193 2 O
fruit	196 5 O
trees	202 5 O
.	207 1 O

Contact	209 7 O
with	217 4 O
the	222 3 O
skin	226 4 O
can	231 3 O
result	235 6 O
in	242 2 O
percutaneous	245 12 O
absorption	258 10 O
of	269 2 O
the	272 3 O
substance	276 9 O
that	286 4 O
inhibits	291 8 O
aldehyde	300 8 B-Chemical
dehydrogenase	309 13 O
and	323 3 O
can	327 3 O
induce	331 6 O
acetaldehyde	338 12 B-Chemical
syndrome	351 8 O
in	360 2 O
case	363 4 O
of	368 2 O
alcohol	371 7 B-Chemical
use	379 3 O
.	382 1 O

The	384 3 O
purpose	388 7 O
of	396 2 O
this	399 4 O
report	404 6 O
is	411 2 O
to	414 2 O
describe	417 8 O
two	426 3 O
cases	430 5 O
of	436 2 O
a	439 1 O
disulfiram	441 10 B-Chemical
-	451 1 O
like	452 4 O
syndrome	457 8 O
following	466 9 O
occupational	476 12 O
exposure	489 8 O
to	498 2 O
hydrogen	501 8 B-Chemical
cyanamide	510 9 I-Chemical
.	519 1 O

The	521 3 O
first	525 5 O
case	531 4 O
involved	536 8 O
a	545 1 O
59	547 2 O
-	549 1 O
year	550 4 O
-	554 1 O
old	555 3 O
man	559 3 O
who	563 3 O
used	567 4 O
Dormex	572 6 B-Chemical
,	578 1 O
which	580 5 O
contains	586 8 O
hydrogen	595 8 B-Chemical
cyanamide	604 9 I-Chemical
,	613 1 O
without	615 7 O
protection	623 10 O
after	634 5 O
consuming	640 9 O
a	650 1 O
large	652 5 O
amount	658 6 O
of	665 2 O
alcohol	668 7 B-Chemical
during	676 6 O
a	683 1 O
meal	685 4 O
.	689 1 O

In	691 2 O
less	694 4 O
than	699 4 O
1	704 1 O
hour	706 4 O
after	711 5 O
the	717 3 O
ingestion	721 9 O
of	731 2 O
alcohol	734 7 B-Chemical
,	741 1 O
he	743 2 O
developed	746 9 O
malaise	756 7 O
with	764 4 O
flushing	769 8 B-Disease
of	778 2 I-Disease
the	781 3 I-Disease
face	785 4 I-Disease
,	789 1 O
tachycardia	791 11 B-Disease
,	802 1 O
and	804 3 O
dyspnea	808 7 B-Disease
.	815 1 O

Manifestations	817 14 O
regressed	832 9 O
spontaneously	842 13 O
under	856 5 O
surveillance	862 12 O
in	875 2 O
the	878 3 O
hospital	882 8 O
.	890 1 O

The	892 3 O
second	896 6 O
case	903 4 O
occurred	908 8 O
in	917 2 O
a	920 1 O
55	922 2 O
-	924 1 O
year	925 4 O
-	929 1 O
old	930 3 O
farmer	934 6 O
following	941 9 O
cutaneous	951 9 O
contact	961 7 O
with	969 4 O
Dormex	974 6 B-Chemical
.	980 1 O

Five	982 4 O
hours	987 5 O
after	993 5 O
exposure	999 8 O
,	1007 1 O
he	1009 2 O
developed	1012 9 O
disulfiram	1022 10 B-Chemical
-	1032 1 O
like	1033 4 O
syndrome	1038 8 O
with	1047 4 O
flushing	1052 8 B-Disease
,	1060 1 O
tachycardia	1062 11 B-Disease
,	1073 1 O
and	1075 3 O
arterial	1079 8 B-Disease
hypotension	1088 11 I-Disease
after	1100 5 O
consuming	1106 9 O
three	1116 5 O
glasses	1122 7 O
of	1130 2 O
wine	1133 4 O
.	1137 1 O

The	1139 3 O
patient	1143 7 O
recovered	1151 9 O
spontaneously	1161 13 O
in	1175 2 O
3	1178 1 O
hours	1180 5 O
under	1186 5 O
surveillance	1192 12 O
in	1205 2 O
the	1208 3 O
hospital	1212 8 O
.	1220 1 O

These	1222 5 O
cases	1228 5 O
confirm	1234 7 O
the	1242 3 O
necessity	1246 9 O
of	1256 2 O
avoiding	1259 8 O
alcohol	1268 7 B-Chemical
consumption	1276 11 O
as	1288 2 O
recommended	1291 11 O
in	1303 2 O
the	1306 3 O
instructions	1310 12 O
for	1323 3 O
use	1327 3 O
of	1331 2 O
Dormex	1334 6 B-Chemical
and	1341 3 O
of	1345 2 O
preventing	1348 10 O
cutaneous	1359 9 O
contact	1369 7 O
during	1377 6 O
use	1384 3 O
.	1387 1 O

Repeated	0 8 O
trimipramine	9 12 B-Chemical
induces	22 7 O
dopamine	30 8 B-Chemical
D2	39 2 O
/	41 1 O
D3	42 2 O
and	45 3 O
alpha1	49 6 O
-	55 1 O
adrenergic	56 10 O
up	67 2 O
-	69 1 O
regulation	70 10 O
.	80 1 O

Trimipramine	82 12 B-Chemical
(	95 1 O
TRI	96 3 B-Chemical
)	99 1 O
,	100 1 O
which	102 5 O
shows	108 5 O
a	114 1 O
clinical	116 8 O
antidepressant	125 14 B-Chemical
activity	140 8 O
,	148 1 O
is	150 2 O
chemically	153 10 O
related	164 7 O
to	172 2 O
imipramine	175 10 B-Chemical
but	186 3 O
does	190 4 O
not	195 3 O
inhibit	199 7 O
the	207 3 O
reuptake	211 8 O
of	220 2 O
noradrenaline	223 13 B-Chemical
and	237 3 O
5	241 1 B-Chemical
-	242 1 I-Chemical
hydroxytryptamine	243 17 I-Chemical
,	260 1 O
nor	262 3 O
does	266 4 O
it	271 2 O
induce	274 6 O
beta	281 4 O
-	285 1 O
adrenergic	286 10 O
down	297 4 O
-	301 1 O
regulation	302 10 O
.	312 1 O

The	314 3 O
mechanism	318 9 O
of	328 2 O
its	331 3 O
antidepressant	335 14 B-Chemical
activity	350 8 O
is	359 2 O
still	362 5 O
unknown	368 7 O
.	375 1 O

The	377 3 O
aim	381 3 O
of	385 2 O
the	388 3 O
present	392 7 O
study	400 5 O
was	406 3 O
to	410 2 O
find	413 4 O
out	418 3 O
whether	422 7 O
TRI	430 3 B-Chemical
given	434 5 O
repeatedly	440 10 O
was	451 3 O
able	455 4 O
to	460 2 O
induce	463 6 O
adaptive	470 8 O
changes	479 7 O
in	487 2 O
the	490 3 O
dopaminergic	494 12 O
and	507 3 O
alpha1	511 6 O
-	517 1 O
adrenergic	518 10 O
systems	529 7 O
,	536 1 O
demonstrated	538 12 O
by	551 2 O
us	554 2 O
previously	557 10 O
for	568 3 O
various	572 7 O
antidepressants	580 15 B-Chemical
.	595 1 O

TRI	597 3 B-Chemical
was	601 3 O
given	605 5 O
to	611 2 O
male	614 4 O
Wistar	619 6 O
rats	626 4 O
and	631 3 O
male	635 4 O
Albino	640 6 O
Swiss	647 5 O
mice	653 4 O
perorally	658 9 O
twice	668 5 O
daily	674 5 O
for	680 3 O
14	684 2 O
days	687 4 O
.	691 1 O

In	693 2 O
the	696 3 O
acute	700 5 O
experiment	706 10 O
TRI	717 3 B-Chemical
(	721 1 O
given	722 5 O
i	728 1 O
.	729 1 O
p	730 1 O
.	731 1 O
)	732 1 O
does	734 4 O
not	739 3 O
antagonize	743 10 O
the	754 3 O
reserpine	758 9 B-Chemical
hypothermia	768 11 B-Disease
in	780 2 O
mice	783 4 O
and	788 3 O
does	792 4 O
not	797 3 O
potentiate	801 10 O
the	812 3 O
5	816 1 B-Chemical
-	817 1 I-Chemical
hydroxytryptophan	818 17 I-Chemical
head	836 4 O
twitches	841 8 O
in	850 2 O
rats	853 4 O
.	857 1 O

TRI	859 3 B-Chemical
given	863 5 O
repeatedly	869 10 O
to	880 2 O
rats	883 4 O
increases	888 9 O
the	898 3 O
locomotor	902 9 O
hyperactivity	912 13 B-Disease
induced	926 7 O
by	934 2 O
d	937 1 B-Chemical
-	938 1 I-Chemical
amphetamine	939 11 I-Chemical
,	950 1 O
quinpirole	952 10 B-Chemical
and	963 3 O
(	967 1 O
+	968 1 O
)	969 1 O
-	970 1 O
7	971 1 O
-	972 1 O
hydroxy	973 7 O
-	980 1 O
dipropyloaminotetralin	981 22 O
(	1004 1 O
dopamine	1005 8 B-Chemical
D2	1014 2 O
and	1017 3 O
D3	1021 2 O
effects	1024 7 O
)	1031 1 O
.	1032 1 O

The	1034 3 O
stereotypies	1038 12 O
induced	1051 7 O
by	1059 2 O
d	1062 1 B-Chemical
-	1063 1 I-Chemical
amphetamine	1064 11 I-Chemical
or	1076 2 O
apomorphine	1079 11 B-Chemical
are	1091 3 O
not	1095 3 O
potentiated	1099 11 O
by	1111 2 O
TRI	1114 3 B-Chemical
.	1117 1 O

It	1119 2 O
increases	1122 9 O
the	1132 3 O
behaviour	1136 9 O
stimulation	1146 11 O
evoked	1158 6 O
by	1165 2 O
phenylephrine	1168 13 B-Chemical
(	1182 1 O
given	1183 5 O
intraventricularly	1189 18 O
)	1207 1 O
in	1209 2 O
rats	1212 4 O
,	1216 1 O
evaluated	1218 9 O
in	1228 2 O
the	1231 3 O
open	1235 4 O
field	1240 5 O
test	1246 4 O
as	1251 2 O
well	1254 4 O
as	1259 2 O
the	1262 3 O
aggressiveness	1266 14 B-Disease
evoked	1281 6 O
by	1288 2 O
clonidine	1291 9 B-Chemical
in	1301 2 O
mice	1304 4 O
,	1308 1 O
both	1310 4 O
these	1315 5 O
effects	1321 7 O
being	1329 5 O
mediated	1335 8 O
by	1344 2 O
an	1347 2 O
alpha1	1350 6 O
-	1356 1 O
adrenergic	1357 10 O
receptor	1368 8 O
.	1376 1 O

It	1378 2 O
may	1381 3 O
be	1385 2 O
concluded	1388 9 O
that	1398 4 O
,	1402 1 O
like	1404 4 O
other	1409 5 O
tricyclic	1415 9 O
antidepressants	1425 15 B-Chemical
studied	1441 7 O
previously	1449 10 O
,	1459 1 O
TRI	1461 3 B-Chemical
given	1465 5 O
repeatedly	1471 10 O
increases	1482 9 O
the	1492 3 O
responsiveness	1496 14 O
of	1511 2 O
brain	1514 5 O
dopamine	1520 8 B-Chemical
D2	1529 2 O
and	1532 3 O
D3	1536 2 O
(	1539 1 O
locomotor	1540 9 O
activity	1550 8 O
but	1559 3 O
not	1563 3 O
stereotypy	1567 10 O
)	1577 1 O
as	1579 2 O
well	1582 4 O
as	1587 2 O
alpha1	1590 6 O
-	1596 1 O
adrenergic	1597 10 O
receptors	1608 9 O
to	1618 2 O
their	1621 5 O
agonists	1627 8 O
.	1635 1 O

A	1637 1 O
question	1639 8 O
arises	1648 6 O
whether	1655 7 O
the	1663 3 O
reuptake	1667 8 O
inhibition	1676 10 O
is	1687 2 O
of	1690 2 O
any	1693 3 O
importance	1697 10 O
to	1708 2 O
the	1711 3 O
adaptive	1715 8 O
changes	1724 7 O
induced	1732 7 O
by	1740 2 O
repeated	1743 8 O
antidepressants	1752 15 B-Chemical
,	1767 1 O
suggested	1769 9 O
to	1779 2 O
be	1782 2 O
responsible	1785 11 O
for	1797 3 O
the	1801 3 O
antidepressant	1805 14 B-Chemical
activity	1820 8 O
.	1828 1 O

Ranitidine	0 10 B-Chemical
-	10 1 O
induced	11 7 O
acute	19 5 O
interstitial	25 12 B-Disease
nephritis	38 9 I-Disease
in	48 2 O
a	51 1 O
cadaveric	53 9 O
renal	63 5 O
allograft	69 9 O
.	78 1 O

Ranitidine	80 10 B-Chemical
frequently	91 10 O
is	102 2 O
used	105 4 O
for	110 3 O
preventing	114 10 O
peptic	125 6 O
ulceration	132 10 O
after	143 5 O
renal	149 5 O
transplantation	155 15 O
.	170 1 O

This	172 4 O
drug	177 4 O
occasionally	182 12 O
has	195 3 O
been	199 4 O
associated	204 10 O
with	215 4 O
acute	220 5 O
interstitial	226 12 B-Disease
nephritis	239 9 I-Disease
in	249 2 O
native	252 6 O
kidneys	259 7 O
.	266 1 O

There	268 5 O
are	274 3 O
no	278 2 O
similar	281 7 O
reports	289 7 O
with	297 4 O
renal	302 5 O
transplantation	308 15 O
.	323 1 O

We	325 2 O
report	328 6 O
a	335 1 O
case	337 4 O
of	342 2 O
ranitidine	345 10 B-Chemical
-	355 1 O
induced	356 7 O
acute	364 5 O
interstitial	370 12 B-Disease
nephritis	383 9 I-Disease
in	393 2 O
a	396 1 O
recipient	398 9 O
of	408 2 O
a	411 1 O
cadaveric	413 9 O
renal	423 5 O
allograft	429 9 O
presenting	439 10 O
with	450 4 O
acute	455 5 O
allograft	461 9 O
dysfunction	471 11 O
within	483 6 O
48	490 2 O
hours	493 5 O
of	499 2 O
exposure	502 8 O
to	511 2 O
the	514 3 O
drug	518 4 O
.	522 1 O

The	524 3 O
biopsy	528 6 O
specimen	535 8 O
showed	544 6 O
pathognomonic	551 13 O
features	565 8 O
,	573 1 O
including	575 9 O
eosinophilic	585 12 O
infiltration	598 12 O
of	611 2 O
the	614 3 O
interstitial	618 12 O
compartment	631 11 O
.	642 1 O

Allograft	644 9 O
function	654 8 O
improved	663 8 O
rapidly	672 7 O
and	680 3 O
returned	684 8 O
to	693 2 O
baseline	696 8 O
after	705 5 O
stopping	711 8 O
the	720 3 O
drug	724 4 O
.	728 1 O

Late	0 4 O
,	4 1 O
late	6 4 O
doxorubicin	11 11 B-Chemical
cardiotoxicity	23 14 B-Disease
.	37 1 O

Cardiac	39 7 B-Disease
toxicity	47 8 I-Disease
is	56 2 O
a	59 1 O
major	61 5 O
complication	67 12 O
which	80 5 O
limits	86 6 O
the	93 3 O
use	97 3 O
of	101 2 O
adriamycin	104 10 B-Chemical
as	115 2 O
a	118 1 O
chemotherapeutic	120 16 O
agent	137 5 O
.	142 1 O

Cardiomyopathy	144 14 B-Disease
is	159 2 O
frequent	162 8 O
when	171 4 O
the	176 3 O
total	180 5 O
dose	186 4 O
exceeds	191 7 O
600	199 3 O
mg	203 2 O
/	205 1 O
m2	206 2 O
and	209 3 O
occurs	213 6 O
within	220 6 O
one	227 3 O
to	231 2 O
six	234 3 O
months	238 6 O
after	245 5 O
cessation	251 9 O
of	261 2 O
therapy	264 7 O
.	271 1 O

A	273 1 O
patient	275 7 O
is	283 2 O
reported	286 8 O
who	295 3 O
developed	299 9 O
progressive	309 11 O
cardiomyopathy	321 14 B-Disease
two	336 3 O
and	340 3 O
one	344 3 O
-	347 1 O
half	348 4 O
years	353 5 O
after	359 5 O
receiving	365 9 O
580	375 3 O
mg	379 2 O
/	381 1 O
m2	382 2 O
which	385 5 O
apparently	391 10 O
represents	402 10 O
late	413 4 O
,	417 1 O
late	419 4 O
cardiotoxicity	424 14 B-Disease
.	438 1 O

Acetazolamide	0 13 B-Chemical
-	13 1 O
induced	14 7 O
nephrolithiasis	22 15 B-Disease
:	37 1 O
implications	39 12 O
for	52 3 O
treatment	56 9 O
of	66 2 O
neuromuscular	69 13 B-Disease
disorders	83 9 I-Disease
.	92 1 O

Carbonic	94 8 O
anhydrase	103 9 O
inhibitors	113 10 O
can	124 3 O
cause	128 5 O
nephrolithiasis	134 15 B-Disease
.	149 1 O

We	151 2 O
studied	154 7 O
20	162 2 O
patients	165 8 O
receiving	174 9 O
long	184 4 O
-	188 1 O
term	189 4 O
carbonic	194 8 O
anhydrase	203 9 O
inhibitor	213 9 O
treatment	223 9 O
for	233 3 O
periodic	237 8 O
paralysis	246 9 B-Disease
and	256 3 O
myotonia	260 8 B-Disease
.	268 1 O

Three	270 5 O
patients	276 8 O
on	285 2 O
acetazolamide	288 13 B-Chemical
(	302 1 O
15	303 2 O
%	305 1 O
)	306 1 O
developed	308 9 O
renal	318 5 B-Disease
calculi	324 7 I-Disease
.	331 1 O

Extracorporeal	333 14 O
lithotripsy	348 11 O
successfully	360 12 O
removed	373 7 O
a	381 1 O
renal	383 5 B-Disease
calculus	389 8 I-Disease
in	398 2 O
one	401 3 O
patient	405 7 O
and	413 3 O
surgery	417 7 O
removed	425 7 O
a	433 1 O
staghorn	435 8 O
calculus	444 8 B-Disease
in	453 2 O
another	456 7 O
,	463 1 O
permitting	465 10 O
continued	476 9 O
treatment	486 9 O
.	495 1 O

Renal	497 5 O
function	503 8 O
remained	512 8 O
normal	521 6 O
in	528 2 O
all	531 3 O
patients	535 8 O
.	543 1 O

Nephrolithiasis	545 15 B-Disease
is	561 2 O
a	564 1 O
complication	566 12 O
of	579 2 O
acetazolamide	582 13 B-Chemical
but	596 3 O
does	600 4 O
not	605 3 O
preclude	609 8 O
its	618 3 O
use	622 3 O
.	625 1 O

Is	0 2 O
the	3 3 O
treatment	7 9 O
of	17 2 O
scabies	20 7 B-Disease
hazardous	28 9 O
?	37 1 O

Treatment	39 9 O
for	49 3 O
scabies	53 7 B-Disease
is	61 2 O
usually	64 7 O
initiated	72 9 O
by	82 2 O
general	85 7 O
practitioners	93 13 O
;	106 1 O
most	108 4 O
consider	113 8 O
lindane	122 7 B-Chemical
(	130 1 O
gamma	131 5 B-Chemical
benzene	137 7 I-Chemical
hexachloride	145 12 I-Chemical
)	157 1 O
the	159 3 O
treatment	163 9 O
of	173 2 O
choice	176 6 O
.	182 1 O

Lindane	184 7 B-Chemical
is	192 2 O
also	195 4 O
widely	200 6 O
used	207 4 O
as	212 2 O
an	215 2 O
agricultural	218 12 O
and	231 3 O
industrial	235 10 O
pesticide	246 9 O
,	255 1 O
and	257 3 O
as	261 2 O
a	264 1 O
result	266 6 O
the	273 3 O
toxic	277 5 O
profile	283 7 O
of	291 2 O
this	294 4 O
insecticide	299 11 O
is	311 2 O
well	314 4 O
understood	319 10 O
.	329 1 O

Evidence	331 8 O
is	340 2 O
accumulating	343 12 O
that	356 4 O
lindane	361 7 B-Chemical
can	369 3 O
be	373 2 O
toxic	376 5 B-Disease
to	382 2 I-Disease
the	385 3 I-Disease
central	389 7 I-Disease
nervous	397 7 I-Disease
system	405 6 I-Disease
and	412 3 O
may	416 3 O
be	420 2 O
associated	423 10 O
with	434 4 O
aplastic	439 8 B-Disease
anaemia	448 7 I-Disease
.	455 1 O

Preparations	457 12 O
containing	470 10 O
lindane	481 7 B-Chemical
continue	489 8 O
to	498 2 O
be	501 2 O
sold	504 4 O
over	509 4 O
the	514 3 O
counter	518 7 O
and	526 3 O
may	530 3 O
represent	534 9 O
a	544 1 O
hazard	546 6 O
to	553 2 O
poorly	556 6 O
informed	563 8 O
patients	572 8 O
.	580 1 O

This	582 4 O
literature	587 10 O
review	598 6 O
suggests	605 8 O
that	614 4 O
general	619 7 O
practitioners	627 13 O
should	641 6 O
prescribe	648 9 O
scabicides	658 10 O
with	669 4 O
increased	674 9 O
caution	684 7 O
for	692 3 O
certain	696 7 O
at	704 2 O
-	706 1 O
risk	707 4 O
groups	712 6 O
,	718 1 O
and	720 3 O
give	724 4 O
adequate	729 8 O
warnings	738 8 O
regarding	747 9 O
potential	757 9 O
toxicity	767 8 B-Disease
.	775 1 O

Anaesthetists	0 13 O
'	13 1 O
nightmare	15 9 O
:	24 1 O
masseter	26 8 B-Disease
spasm	35 5 I-Disease
after	41 5 O
induction	47 9 O
in	57 2 O
an	60 2 O
undiagnosed	63 11 O
case	75 4 O
of	80 2 O
myotonia	83 8 B-Disease
congenita	92 9 I-Disease
.	101 1 O

We	103 2 O
report	106 6 O
an	113 2 O
undiagnosed	116 11 O
case	128 4 O
of	133 2 O
myotonia	136 8 B-Disease
congenita	145 9 I-Disease
in	155 2 O
a	158 1 O
24	160 2 O
-	162 1 O
year	163 4 O
-	167 1 O
old	168 3 O
previously	172 10 O
healthy	183 7 O
primigravida	191 12 O
,	203 1 O
who	205 3 O
developed	209 9 O
life	219 4 O
threatening	224 11 O
masseter	236 8 B-Disease
spasm	245 5 I-Disease
following	251 9 O
a	261 1 O
standard	263 8 O
dose	272 4 O
of	277 2 O
intravenous	280 11 O
suxamethonium	292 13 B-Chemical
for	306 3 O
induction	310 9 O
of	320 2 O
anaesthesia	323 11 O
.	334 1 O

Neither	336 7 O
the	344 3 O
patient	348 7 O
nor	356 3 O
the	360 3 O
anaesthetist	364 12 O
was	377 3 O
aware	381 5 O
of	387 2 O
the	390 3 O
diagnosis	394 9 O
before	404 6 O
this	411 4 O
potentially	416 11 O
lethal	428 6 O
complication	435 12 O
occurred	448 8 O
.	456 1 O

Toxicity	0 8 B-Disease
in	9 2 O
rhesus	12 6 O
monkeys	19 7 O
following	27 9 O
administration	37 14 O
of	52 2 O
the	55 3 O
8	59 1 B-Chemical
-	60 1 I-Chemical
aminoquinoline	61 14 I-Chemical
8	76 1 B-Chemical
-	77 1 I-Chemical
[	78 1 I-Chemical
(	79 1 I-Chemical
4	80 1 I-Chemical
-	81 1 I-Chemical
amino	82 5 I-Chemical
-	87 1 I-Chemical
l	88 1 I-Chemical
-	89 1 I-Chemical
methylbutyl	90 11 I-Chemical
)	101 1 I-Chemical
amino	102 5 I-Chemical
]	107 1 I-Chemical
-	108 1 I-Chemical
5	110 1 I-Chemical
-	111 1 I-Chemical
(	112 1 I-Chemical
l	113 1 I-Chemical
-	114 1 I-Chemical
hexyloxy	115 8 I-Chemical
)	123 1 I-Chemical
-	124 1 I-Chemical
6	125 1 I-Chemical
-	126 1 I-Chemical
methoxy	127 7 I-Chemical
-	134 1 I-Chemical
4	135 1 I-Chemical
-	136 1 I-Chemical
methylquinoline	137 15 I-Chemical
(	153 1 O
WR242511	154 8 B-Chemical
)	162 1 O
.	163 1 O

INTRODUCTION	165 12 O
:	177 1 O
Many	179 4 O
substances	184 10 O
that	195 4 O
form	200 4 O
methemoglobin	205 13 O
(	219 1 O
MHb	220 3 O
)	223 1 O
effectively	225 11 O
counter	237 7 O
cyanide	245 7 O
(	253 1 O
CN	254 2 O
)	256 1 O
toxicity	258 8 B-Disease
.	266 1 O

Although	268 8 O
MHb	277 3 O
formers	281 7 O
are	289 3 O
generally	293 9 O
applied	303 7 O
as	311 2 O
treatments	314 10 O
for	325 3 O
CN	329 2 O
poisoning	332 9 B-Disease
,	341 1 O
it	343 2 O
has	346 3 O
been	350 4 O
proposed	355 8 O
that	364 4 O
a	369 1 O
stable	371 6 O
,	377 1 O
long	379 4 O
-	383 1 O
acting	384 6 O
MHb	391 3 O
former	395 6 O
could	402 5 O
serve	408 5 O
as	414 2 O
a	417 1 O
CN	419 2 O
pretreatment	422 12 O
.	434 1 O

Using	436 5 O
this	442 4 O
rationale	447 9 O
,	456 1 O
the	458 3 O
8	462 1 B-Chemical
-	463 1 I-Chemical
aminoquinoline	464 14 I-Chemical
WR242511	479 8 B-Chemical
,	487 1 O
a	489 1 O
potent	491 6 O
long	498 4 O
-	502 1 O
lasting	503 7 O
MHb	511 3 O
former	515 6 O
in	522 2 O
rodents	525 7 O
and	533 3 O
beagle	537 6 O
dogs	544 4 O
,	548 1 O
was	550 3 O
studied	554 7 O
in	562 2 O
the	565 3 O
rhesus	569 6 O
monkey	576 6 O
for	583 3 O
advanced	587 8 O
development	596 11 O
as	608 2 O
a	611 1 O
potential	613 9 O
CN	623 2 O
pretreatment	626 12 O
.	638 1 O

METHODS	640 7 O
:	647 1 O
In	649 2 O
this	652 4 O
study	657 5 O
,	662 1 O
WR242511	664 8 B-Chemical
was	673 3 O
administered	677 12 O
intravenously	690 13 O
(	704 1 O
IV	705 2 O
)	707 1 O
in	709 2 O
2	712 1 O
female	714 6 O
and	721 3 O
4	725 1 O
male	727 4 O
rhesus	732 6 O
monkeys	739 7 O
in	747 2 O
doses	750 5 O
of	756 2 O
3	759 1 O
.	760 1 O
5	761 1 O
and	763 3 O
/	766 1 O
or	767 2 O
7	770 1 O
.	771 1 O
0	772 1 O
mg	774 2 O
/	776 1 O
kg	777 2 O
;	779 1 O
a	781 1 O
single	783 6 O
male	790 4 O
also	795 4 O
received	800 8 O
WR242511	809 8 B-Chemical
orally	818 6 O
(	825 1 O
PO	826 2 O
)	828 1 O
at	830 2 O
7	833 1 O
.	834 1 O
0	835 1 O
mg	837 2 O
/	839 1 O
kg	840 2 O
.	842 1 O

Health	844 6 O
status	851 6 O
and	858 3 O
MHb	862 3 O
levels	866 6 O
were	873 4 O
monitored	878 9 O
following	888 9 O
exposure	898 8 O
.	906 1 O

RESULTS	908 7 O
:	915 1 O
The	917 3 O
selected	921 8 O
doses	930 5 O
of	936 2 O
WR242511	939 8 B-Chemical
,	947 1 O
which	949 5 O
produced	955 8 O
significant	964 11 O
methemoglobinemia	976 17 B-Disease
in	994 2 O
beagle	997 6 O
dogs	1004 4 O
in	1009 2 O
earlier	1012 7 O
studies	1020 7 O
conducted	1028 9 O
elsewhere	1038 9 O
,	1047 1 O
produced	1049 8 O
very	1058 4 O
little	1063 6 O
MHb	1070 3 O
(	1074 1 O
mean	1075 4 O
<	1080 1 O
2	1082 1 O
.	1083 1 O
0	1084 1 O
%	1085 1 O
)	1086 1 O
in	1088 2 O
the	1091 3 O
rhesus	1095 6 O
monkey	1102 6 O
.	1108 1 O

Furthermore	1110 11 O
,	1121 1 O
transient	1123 9 O
hemoglobinuria	1133 14 B-Disease
was	1148 3 O
noted	1152 5 O
approximately	1158 13 O
60	1172 2 O
minutes	1175 7 O
postinjection	1183 13 O
of	1197 2 O
WR242511	1200 8 B-Chemical
(	1209 1 O
3	1210 1 O
.	1211 1 O
5	1212 1 O
or	1214 2 O
7	1217 1 O
.	1218 1 O
0	1219 1 O
mg	1221 2 O
/	1223 1 O
kg	1224 2 O
)	1226 1 O
,	1227 1 O
and	1229 3 O
2	1233 1 O
lethalities	1235 11 O
occurred	1247 8 O
(	1256 1 O
one	1257 3 O
IV	1261 2 O
and	1264 3 O
one	1268 3 O
PO	1272 2 O
)	1274 1 O
following	1276 9 O
the	1286 3 O
7	1290 1 O
.	1291 1 O
0	1292 1 O
mg	1294 2 O
/	1296 1 O
kg	1297 2 O
dose	1300 4 O
.	1304 1 O

Myoglobinuria	1306 13 B-Disease
was	1320 3 O
also	1324 4 O
observed	1329 8 O
following	1338 9 O
the	1348 3 O
7	1352 1 O
.	1353 1 O
0	1354 1 O
mg	1356 2 O
/	1358 1 O
kg	1359 2 O
dose	1362 4 O
.	1366 1 O

Histopathology	1368 14 O
analyses	1383 8 O
in	1392 2 O
the	1395 3 O
2	1399 1 O
animals	1401 7 O
that	1409 4 O
died	1414 4 O
revealed	1419 8 O
liver	1428 5 B-Disease
and	1434 3 I-Disease
kidney	1438 6 I-Disease
toxicity	1445 8 I-Disease
,	1453 1 O
with	1455 4 O
greater	1460 7 O
severity	1468 8 O
in	1477 2 O
the	1480 3 O
orally	1484 6 O
-	1490 1 O
treated	1491 7 O
animal	1499 6 O
.	1505 1 O

CONCLUSIONS	1507 11 O
:	1518 1 O
These	1520 5 O
data	1526 4 O
demonstrate	1531 11 O
direct	1543 6 O
and	1550 3 O
/	1553 1 O
or	1554 2 O
indirect	1557 8 O
drug	1566 4 O
-	1570 1 O
induced	1571 7 O
toxicity	1579 8 B-Disease
.	1587 1 O

It	1589 2 O
is	1592 2 O
concluded	1595 9 O
that	1605 4 O
WR242511	1610 8 B-Chemical
should	1619 6 O
not	1626 3 O
be	1630 2 O
pursued	1633 7 O
as	1641 2 O
a	1644 1 O
pretreatment	1646 12 O
for	1659 3 O
CN	1663 2 O
poisoning	1666 9 B-Disease
unless	1676 6 O
the	1683 3 O
anti	1687 4 O
-	1691 1 O
CN	1692 2 O
characteristics	1695 15 O
of	1711 2 O
this	1714 4 O
compound	1719 8 O
can	1728 3 O
be	1732 2 O
successfully	1735 12 O
dissociated	1748 11 O
from	1760 4 O
those	1765 5 O
producing	1771 9 O
undesirable	1781 11 O
toxicity	1793 8 B-Disease
.	1801 1 O

Neuroplasticity	0 15 O
of	16 2 O
the	19 3 O
adult	23 5 O
primate	29 7 O
auditory	37 8 O
cortex	46 6 O
following	53 9 O
cochlear	63 8 O
hearing	72 7 B-Disease
loss	80 4 I-Disease
.	84 1 O

Tonotopic	86 9 O
organization	96 12 O
is	109 2 O
an	112 2 O
essential	115 9 O
feature	125 7 O
of	133 2 O
the	136 3 O
primary	140 7 O
auditory	148 8 O
area	157 4 O
(	162 1 O
A1	163 2 O
)	165 1 O
of	167 2 O
primate	170 7 O
cortex	178 6 O
.	184 1 O

In	186 2 O
A1	189 2 O
of	192 2 O
macaque	195 7 O
monkeys	203 7 O
,	210 1 O
low	212 3 O
frequencies	216 11 O
are	228 3 O
represented	232 11 O
rostrolaterally	244 15 O
and	260 3 O
high	264 4 O
frequencies	269 11 O
are	281 3 O
represented	285 11 O
caudomedially	297 13 O
.	310 1 O

The	312 3 O
purpose	316 7 O
of	324 2 O
this	327 4 O
study	332 5 O
was	338 3 O
to	342 2 O
determine	345 9 O
if	355 2 O
changes	358 7 O
occur	366 5 O
in	372 2 O
this	375 4 O
tonotopic	380 9 O
organization	390 12 O
following	403 9 O
cochlear	413 8 O
hearing	422 7 B-Disease
loss	430 4 I-Disease
.	434 1 O

Under	436 5 O
anesthesia	442 10 O
,	452 1 O
the	454 3 O
superior	458 8 O
temporal	467 8 O
gyrus	476 5 O
of	482 2 O
adult	485 5 O
macaque	491 7 O
monkeys	499 7 O
was	507 3 O
exposed	511 7 O
,	518 1 O
and	520 3 O
the	524 3 O
tonotopic	528 9 O
organization	538 12 O
of	551 2 O
A1	554 2 O
was	557 3 O
mapped	561 6 O
using	568 5 O
conventional	574 12 O
microelectrode	587 14 O
recording	602 9 O
techniques	612 10 O
.	622 1 O

Following	624 9 O
recovery	634 8 O
,	642 1 O
the	644 3 O
monkeys	648 7 O
were	656 4 O
selectively	661 11 O
deafened	673 8 O
for	682 3 O
high	686 4 O
frequencies	691 11 O
using	703 5 O
kanamycin	709 9 B-Chemical
and	719 3 O
furosemide	723 10 B-Chemical
.	733 1 O

The	735 3 O
actual	739 6 O
frequencies	746 11 O
deafened	758 8 O
were	767 4 O
determined	772 10 O
by	783 2 O
the	786 3 O
loss	790 4 O
of	795 2 O
tone	798 4 O
-	802 1 O
burst	803 5 O
elicited	809 8 O
auditory	818 8 O
brainstem	827 9 O
responses	837 9 O
.	846 1 O

Three	848 5 O
months	854 6 O
after	861 5 O
deafening	867 9 O
,	876 1 O
A1	878 2 O
was	881 3 O
remapped	885 8 O
.	893 1 O

Postmortem	895 10 O
cytoarchitectural	906 17 O
features	924 8 O
identifying	933 11 O
A1	945 2 O
were	948 4 O
correlated	953 10 O
with	964 4 O
the	969 3 O
electrophysiologic	973 18 O
data	992 4 O
.	996 1 O

The	998 3 O
results	1002 7 O
indicate	1010 8 O
that	1019 4 O
the	1024 3 O
deprived	1028 8 O
area	1037 4 O
of	1042 2 O
A1	1045 2 O
undergoes	1048 9 O
extensive	1058 9 O
reorganization	1068 14 O
and	1083 3 O
becomes	1087 7 O
responsive	1095 10 O
to	1106 2 O
intact	1109 6 O
cochlear	1116 8 O
frequencies	1125 11 O
.	1136 1 O

The	1138 3 O
region	1142 6 O
of	1149 2 O
cortex	1152 6 O
that	1159 4 O
represents	1164 10 O
the	1175 3 O
low	1179 3 O
frequencies	1183 11 O
was	1195 3 O
not	1199 3 O
obviously	1203 9 O
affected	1213 8 O
by	1222 2 O
the	1225 3 O
cochlear	1229 8 O
hearing	1238 7 B-Disease
loss	1246 4 I-Disease
.	1250 1 O

The	0 3 O
site	4 4 O
of	9 2 O
common	12 6 O
side	19 4 O
effects	24 7 O
of	32 2 O
sumatriptan	35 11 B-Chemical
.	46 1 O

Atypical	48 8 B-Disease
sensations	57 10 I-Disease
following	68 9 O
the	78 3 O
use	82 3 O
of	86 2 O
subcutaneous	89 12 O
sumatriptan	102 11 B-Chemical
are	114 3 O
common	118 6 O
,	124 1 O
but	126 3 O
of	130 2 O
uncertain	133 9 O
origin	143 6 O
.	149 1 O

They	151 4 O
are	156 3 O
almost	160 6 O
always	167 6 O
benign	174 6 O
,	180 1 O
but	182 3 O
can	186 3 O
be	190 2 O
mistaken	193 8 O
for	202 3 O
a	206 1 O
serious	208 7 O
adverse	216 7 O
event	224 5 O
by	230 2 O
the	233 3 O
patient	237 7 O
.	244 1 O

Two	246 3 O
patients	250 8 O
are	259 3 O
presented	263 9 O
with	273 4 O
tingling	278 8 B-Disease
or	287 2 I-Disease
burning	290 7 I-Disease
sensations	298 10 I-Disease
limited	309 7 O
to	317 2 O
areas	320 5 O
of	326 2 O
heat	329 4 O
exposure	334 8 O
or	343 2 O
sunburn	346 7 B-Disease
.	353 1 O

In	355 2 O
these	358 5 O
individuals	364 11 O
,	375 1 O
side	377 4 O
effects	382 7 O
are	390 3 O
most	394 4 O
likely	399 6 O
generated	406 9 O
superficially	416 13 O
in	430 2 O
the	433 3 O
skin	437 4 O
.	441 1 O

Tremor	0 6 B-Disease
side	7 4 O
effects	12 7 O
of	20 2 O
salbutamol	23 10 B-Chemical
,	33 1 O
quantified	35 10 O
by	46 2 O
a	49 1 O
laser	51 5 O
pointer	57 7 O
technique	65 9 O
.	74 1 O

OBJECTIVE	76 9 O
:	85 1 O
To	87 2 O
study	90 5 O
tremor	96 6 B-Disease
side	103 4 O
effects	108 7 O
of	116 2 O
salbutamol	119 10 B-Chemical
an	130 2 O
easily	133 6 O
applicable	140 10 O
,	150 1 O
quick	152 5 O
and	158 3 O
low	162 3 O
-	165 1 O
priced	166 6 O
method	173 6 O
is	180 2 O
needed	183 6 O
.	189 1 O

A	191 1 O
new	193 3 O
method	197 6 O
using	204 5 O
a	210 1 O
commercially	212 12 O
available	225 9 O
,	234 1 O
pen	236 3 O
-	239 1 O
shaped	240 6 O
laser	247 5 O
pointer	253 7 O
was	261 3 O
developed	265 9 O
.	274 1 O

Aim	276 3 O
of	280 2 O
the	283 3 O
study	287 5 O
was	293 3 O
to	297 2 O
determine	300 9 O
sensitivity	310 11 O
,	321 1 O
reproducibility	323 15 O
,	338 1 O
reference	340 9 O
values	350 6 O
and	357 3 O
the	361 3 O
agreement	365 9 O
with	375 4 O
a	380 1 O
questionnaire	382 13 O
.	395 1 O

METHODS	397 7 O
:	404 1 O
Tremor	406 6 B-Disease
was	413 3 O
measured	417 8 O
using	426 5 O
a	432 1 O
laser	434 5 O
pointer	440 7 O
technique	448 9 O
.	457 1 O

To	459 2 O
determine	462 9 O
sensitivity	472 11 O
we	484 2 O
assessed	487 8 O
tremor	496 6 B-Disease
in	503 2 O
44	506 2 O
patients	509 8 O
with	518 4 O
obstructive	523 11 B-Disease
lung	535 4 I-Disease
disease	540 7 I-Disease
after	548 5 O
administration	554 14 O
of	569 2 O
cumulative	572 10 O
doses	583 5 O
of	589 2 O
salbutamol	592 10 B-Chemical
.	602 1 O

Subjects	604 8 O
were	613 4 O
asked	618 5 O
to	624 2 O
aim	627 3 O
at	631 2 O
the	634 3 O
centre	638 6 O
of	645 2 O
a	648 1 O
target	650 6 O
,	656 1 O
subdivided	658 10 O
in	669 2 O
concentric	672 10 O
circles	683 7 O
,	690 1 O
from	692 4 O
5	697 1 O
m	699 1 O
distance	701 8 O
.	709 1 O

The	711 3 O
circle	715 6 O
in	722 2 O
which	725 5 O
the	731 3 O
participant	735 11 O
succeeded	747 9 O
to	757 2 O
aim	760 3 O
was	764 3 O
recorded	768 8 O
in	777 2 O
millimetres	780 11 O
radius	792 6 O
.	798 1 O

In	800 2 O
another	803 7 O
series	811 6 O
of	818 2 O
measurements	821 12 O
,	833 1 O
reproducibility	835 15 O
and	851 3 O
reference	855 9 O
values	865 6 O
of	872 2 O
the	875 3 O
tremor	879 6 B-Disease
was	886 3 O
assessed	890 8 O
in	899 2 O
65	902 2 O
healthy	905 7 O
subjects	913 8 O
in	922 2 O
three	925 5 O
sessions	931 8 O
,	939 1 O
at	941 2 O
9	944 1 O
a	946 1 O
.	947 1 O
m	948 1 O
.	949 1 O
,	950 1 O
4	952 1 O
p	954 1 O
.	955 1 O
m	956 1 O
.	957 1 O
and	959 3 O
9	963 1 O
a	965 1 O
.	966 1 O
m	967 1 O
.	968 1 O
,	969 1 O
respectively	971 12 O
,	983 1 O
1	985 1 O
week	987 4 O
later	992 5 O
.	997 1 O

Postural	999 8 O
tremor	1008 6 B-Disease
was	1015 3 O
measured	1019 8 O
with	1028 4 O
the	1033 3 O
arm	1037 3 O
horizontally	1041 12 O
outstretched	1054 12 O
rest	1067 4 O
tremor	1072 6 B-Disease
with	1079 4 O
the	1084 3 O
arm	1088 3 O
supported	1092 9 O
by	1102 2 O
an	1105 2 O
armrest	1108 7 O
and	1116 3 O
finally	1120 7 O
tremor	1128 6 B-Disease
was	1135 3 O
measured	1139 8 O
after	1148 5 O
holding	1154 7 O
a	1162 1 O
2	1164 1 O
-	1165 1 O
kg	1166 2 O
weight	1169 6 O
until	1176 5 O
exhaustion	1182 10 O
.	1192 1 O

Inter	1194 5 O
-	1199 1 O
observer	1200 8 O
variability	1209 11 O
was	1221 3 O
measured	1225 8 O
in	1234 2 O
a	1237 1 O
series	1239 6 O
of	1246 2 O
10	1249 2 O
healthy	1252 7 O
subjects	1260 8 O
.	1268 1 O

Tremor	1270 6 B-Disease
was	1277 3 O
measured	1281 8 O
simultaneously	1290 14 O
by	1305 2 O
two	1308 3 O
independent	1312 11 O
observers	1324 9 O
.	1333 1 O

RESULTS	1335 7 O
:	1342 1 O
Salbutamol	1344 10 B-Chemical
significantly	1355 13 O
increased	1369 9 O
tremor	1379 6 B-Disease
severity	1386 8 O
in	1395 2 O
patients	1398 8 O
in	1407 2 O
a	1410 1 O
dose	1412 4 O
-	1416 1 O
dependent	1417 9 O
way	1427 3 O
.	1430 1 O

Within	1432 6 O
healthy	1439 7 O
adults	1447 6 O
no	1454 2 O
age	1457 3 O
-	1460 1 O
dependency	1461 10 O
could	1472 5 O
be	1478 2 O
found	1481 5 O
(	1487 1 O
b	1488 1 O
=	1490 1 O
0	1492 1 O
.	1493 1 O
262	1494 3 O
mm	1498 2 O
/	1500 1 O
year	1501 4 O
;	1505 1 O
P	1507 1 O
=	1509 1 O
0	1511 1 O
.	1512 1 O
72	1513 2 O
)	1515 1 O
.	1516 1 O

There	1518 5 O
was	1524 3 O
no	1528 2 O
agreement	1531 9 O
between	1541 7 O
the	1549 3 O
questionnaire	1553 13 O
and	1567 3 O
tremor	1571 6 B-Disease
severity	1578 8 O
(	1587 1 O
r	1588 1 O
=	1590 1 O
0	1592 1 O
.	1593 1 O
093	1594 3 O
;	1597 1 O
P	1599 1 O
=	1601 1 O
0	1603 1 O
.	1604 1 O
53	1605 2 O
)	1607 1 O
.	1608 1 O

Postural	1610 8 O
tremor	1619 6 B-Disease
showed	1626 6 O
no	1633 2 O
significant	1636 11 O
difference	1648 10 O
between	1659 7 O
the	1667 3 O
first	1671 5 O
and	1677 3 O
third	1681 5 O
session	1687 7 O
(	1695 1 O
P	1696 1 O
=	1698 1 O
0	1700 1 O
.	1701 1 O
07	1702 2 O
)	1704 1 O
.	1705 1 O

Support	1707 7 O
of	1715 2 O
the	1718 3 O
arm	1722 3 O
decreased	1726 9 O
tremor	1736 6 B-Disease
severity	1743 8 O
,	1751 1 O
exhaustion	1753 10 O
increased	1764 9 O
tremor	1774 6 B-Disease
severity	1781 8 O
significantly	1790 13 O
.	1803 1 O

A	1805 1 O
good	1807 4 O
agreement	1812 9 O
was	1822 3 O
found	1826 5 O
between	1832 7 O
two	1840 3 O
independent	1844 11 O
observers	1856 9 O
(	1866 1 O
interclass	1867 10 O
correlation	1878 11 O
coefficient	1890 11 O
0	1902 1 O
.	1903 1 O
72	1904 2 O
)	1906 1 O
.	1907 1 O

DISCUSSION	1909 10 O
:	1919 1 O
Quantifying	1921 11 O
tremor	1933 6 B-Disease
by	1940 2 O
using	1943 5 O
an	1949 2 O
inexpensive	1952 11 O
laser	1964 5 O
pointer	1970 7 O
is	1978 2 O
,	1980 1 O
with	1982 4 O
the	1987 3 O
exception	1991 9 O
of	2001 2 O
children	2004 8 O
(	2013 1 O
<	2014 1 O
12	2015 2 O
years	2018 5 O
)	2023 1 O
a	2025 1 O
sensitive	2027 9 O
and	2037 3 O
reproducible	2041 12 O
method	2054 6 O
.	2060 1 O

Increased	0 9 O
frequency	10 9 O
of	20 2 O
venous	23 6 B-Disease
thromboembolism	30 15 I-Disease
with	46 4 O
the	51 3 O
combination	55 11 O
of	67 2 O
docetaxel	70 9 B-Chemical
and	80 3 O
thalidomide	84 11 B-Chemical
in	96 2 O
patients	99 8 O
with	108 4 O
metastatic	113 10 O
androgen	124 8 O
-	132 1 O
independent	133 11 O
prostate	145 8 B-Disease
cancer	154 6 I-Disease
.	160 1 O

STUDY	162 5 O
OBJECTIVE	168 9 O
:	177 1 O
To	179 2 O
evaluate	182 8 O
the	191 3 O
frequency	195 9 O
of	205 2 O
venous	208 6 B-Disease
thromboembolism	215 15 I-Disease
(	231 1 O
VTE	232 3 B-Disease
)	235 1 O
in	237 2 O
patients	240 8 O
with	249 4 O
advanced	254 8 O
androgen	263 8 O
-	271 1 O
independent	272 11 O
prostate	284 8 B-Disease
cancer	293 6 I-Disease
who	300 3 O
were	304 4 O
treated	309 7 O
with	317 4 O
docetaxel	322 9 B-Chemical
alone	332 5 O
or	338 2 O
in	341 2 O
combination	344 11 O
with	356 4 O
thalidomide	361 11 B-Chemical
.	372 1 O

DESIGN	374 6 O
:	380 1 O
Retrospective	382 13 O
analysis	396 8 O
of	405 2 O
a	408 1 O
randomized	410 10 O
phase	421 5 O
II	427 2 O
trial	430 5 O
.	435 1 O

SETTING	437 7 O
:	444 1 O
National	446 8 O
Institutes	455 10 O
of	466 2 O
Health	469 6 O
clinical	476 8 O
research	485 8 O
center	494 6 O
.	500 1 O

PATIENTS	502 8 O
:	510 1 O
Seventy	512 7 O
men	520 3 O
,	523 1 O
aged	525 4 O
50	530 2 O
-	532 1 O
80	533 2 O
years	536 5 O
,	541 1 O
with	543 4 O
advanced	548 8 O
androgen	557 8 O
-	565 1 O
independent	566 11 O
prostate	578 8 B-Disease
cancer	587 6 I-Disease
.	593 1 O

INTERVENTION	595 12 O
:	607 1 O
Each	609 4 O
patient	614 7 O
received	622 8 O
either	631 6 O
intravenous	638 11 O
docetaxel	650 9 B-Chemical
30	660 2 O
mg	663 2 O
/	665 1 O
m2	666 2 O
/	668 1 O
week	669 4 O
for	674 3 O
3	678 1 O
consecutive	680 11 O
weeks	692 5 O
,	697 1 O
followed	699 8 O
by	708 2 O
1	711 1 O
week	713 4 O
off	718 3 O
,	721 1 O
or	723 2 O
the	726 3 O
combination	730 11 O
of	742 2 O
continuous	745 10 O
oral	756 4 O
thalidomide	761 11 B-Chemical
200	773 3 O
mg	777 2 O
every	780 5 O
evening	786 7 O
plus	794 4 O
the	799 3 O
same	803 4 O
docetaxel	808 9 B-Chemical
regimen	818 7 O
.	825 1 O

This	827 4 O
4	832 1 O
-	833 1 O
week	834 4 O
cycle	839 5 O
was	845 3 O
repeated	849 8 O
until	858 5 O
there	864 5 O
was	870 3 O
evidence	874 8 O
of	883 2 O
excessive	886 9 O
toxicity	896 8 B-Disease
or	905 2 O
disease	908 7 O
progression	916 11 O
.	927 1 O

MEASUREMENTS	929 12 O
AND	942 3 O
MAIN	946 4 O
RESULTS	951 7 O
:	958 1 O
None	960 4 O
of	965 2 O
23	968 2 O
patients	971 8 O
who	980 3 O
received	984 8 O
docetaxel	993 9 B-Chemical
alone	1003 5 O
developed	1009 9 O
VTE	1019 3 B-Disease
,	1022 1 O
whereas	1024 7 O
9	1032 1 O
of	1034 2 O
47	1037 2 O
patients	1040 8 O
(	1049 1 O
19	1050 2 O
%	1052 1 O
)	1053 1 O
who	1055 3 O
received	1059 8 O
docetaxel	1068 9 B-Chemical
plus	1078 4 O
thalidomide	1083 11 B-Chemical
developed	1095 9 O
VTE	1105 3 B-Disease
(	1109 1 O
p	1110 1 O
=	1111 1 O
0	1112 1 O
.	1113 1 O
025	1114 3 O
)	1117 1 O
.	1118 1 O

CONCLUSION	1120 10 O
:	1130 1 O
The	1132 3 O
addition	1136 8 O
of	1145 2 O
thalidomide	1148 11 B-Chemical
to	1160 2 O
docetaxel	1163 9 B-Chemical
in	1173 2 O
the	1176 3 O
treatment	1180 9 O
of	1190 2 O
prostate	1193 8 B-Disease
cancer	1202 6 I-Disease
significantly	1209 13 O
increases	1223 9 O
the	1233 3 O
frequency	1237 9 O
of	1247 2 O
VTE	1250 3 B-Disease
.	1253 1 O

Clinicians	1255 10 O
should	1266 6 O
be	1273 2 O
aware	1276 5 O
of	1282 2 O
this	1285 4 O
potential	1290 9 O
complication	1300 12 O
when	1313 4 O
adding	1318 6 O
thalidomide	1325 11 B-Chemical
to	1337 2 O
chemotherapeutic	1340 16 O
regimens	1357 8 O
.	1365 1 O

Sublingual	0 10 O
absorption	11 10 O
of	22 2 O
the	25 3 O
quaternary	29 10 B-Chemical
ammonium	40 8 I-Chemical
antiarrhythmic	49 14 O
agent	64 5 O
,	69 1 O
UM	71 2 B-Chemical
-	73 1 I-Chemical
272	74 3 I-Chemical
.	77 1 O

UM	79 2 B-Chemical
-	81 1 I-Chemical
272	82 3 I-Chemical
(	86 1 O
N	87 1 B-Chemical
,	88 1 I-Chemical
N	89 1 I-Chemical
-	90 1 I-Chemical
dimethylpropranolol	91 19 I-Chemical
)	110 1 O
,	111 1 O
a	113 1 O
quaternary	115 10 O
antiarrhythmic	126 14 O
agent	141 5 O
,	146 1 O
was	148 3 O
administered	152 12 O
sublingually	165 12 O
to	178 2 O
dogs	181 4 O
with	186 4 O
ouabain	191 7 B-Chemical
-	198 1 O
induced	199 7 O
ventricular	207 11 B-Disease
tachycardias	219 12 I-Disease
.	231 1 O

Both	233 4 O
anti	238 4 O
-	242 1 O
arrhythmic	243 10 O
efficacy	254 8 O
and	263 3 O
bioavailability	267 15 O
were	283 4 O
compared	288 8 O
to	297 2 O
oral	300 4 O
drug	305 4 O
.	309 1 O

Sublingual	311 10 O
UM	322 2 B-Chemical
-	324 1 I-Chemical
272	325 3 I-Chemical
converted	329 9 O
ventricular	339 11 B-Disease
tachycardia	351 11 I-Disease
to	363 2 O
sinus	366 5 O
rhythm	372 6 O
in	379 2 O
all	382 3 O
5	386 1 O
dogs	388 4 O
.	392 1 O

The	394 3 O
area	398 4 O
under	403 5 O
the	409 3 O
plasma	413 6 O
concentration	420 13 O
time	434 4 O
curve	439 5 O
at	445 2 O
90	448 2 O
min	451 3 O
was	455 3 O
4	459 1 O
-	460 1 O
12	461 2 O
times	464 5 O
greater	470 7 O
than	478 4 O
for	483 3 O
oral	487 4 O
drug	492 4 O
,	496 1 O
suggesting	498 10 O
the	509 3 O
existence	513 9 O
of	523 2 O
an	526 2 O
absorption	529 10 O
-	539 1 O
limiting	540 8 O
process	549 7 O
in	557 2 O
the	560 3 O
intestine	564 9 O
,	573 1 O
and	575 3 O
providing	579 9 O
an	589 2 O
alternate	592 9 O
form	602 4 O
of	607 2 O
administration	610 14 O
for	625 3 O
quaternary	629 10 O
drugs	640 5 O
.	645 1 O

Severe	0 6 O
thrombocytopenia	7 16 B-Disease
and	24 3 O
haemolytic	28 10 B-Disease
anaemia	39 7 I-Disease
associated	47 10 O
with	58 4 O
ciprofloxacin	63 13 B-Chemical
:	76 1 O
a	78 1 O
case	80 4 O
report	85 6 O
with	92 4 O
fatal	97 5 O
outcome	103 7 O
.	110 1 O

Haematological	112 14 O
adverse	127 7 O
reactions	135 9 O
associated	145 10 O
with	156 4 O
fatal	161 5 O
outcome	167 7 O
are	175 3 O
rare	179 4 O
during	184 6 O
treatment	191 9 O
with	201 4 O
ciprofloxacin	206 13 B-Chemical
.	219 1 O

A	221 1 O
30	223 2 O
-	225 1 O
year	226 4 O
old	231 3 O
Caucasian	235 9 O
man	245 3 O
reported	249 8 O
with	258 4 O
abdominal	263 9 B-Disease
pain	273 4 I-Disease
and	278 3 O
jaundice	282 8 B-Disease
after	291 5 O
3	297 1 O
-	298 1 O
day	299 3 O
administration	303 14 O
of	318 2 O
oral	321 4 O
ciprofloxacin	326 13 B-Chemical
for	340 3 O
a	344 1 O
suspect	346 7 O
of	354 2 O
urinary	357 7 B-Disease
tract	365 5 I-Disease
infection	371 9 I-Disease
.	380 1 O

Clinical	382 8 O
evaluations	391 11 O
suggested	403 9 O
an	413 2 O
initial	416 7 O
diagnosis	424 9 O
of	434 2 O
severe	437 6 O
thrombocytopenia	444 16 B-Disease
and	461 3 O
haemolysis	465 10 B-Disease
.	475 1 O

The	477 3 O
patient	481 7 O
progressively	489 13 O
developed	503 9 O
petechiae	513 9 B-Disease
and	523 3 O
purpura	527 7 B-Disease
on	535 2 O
thorax	538 6 O
and	545 3 O
lower	549 5 O
limbs	555 5 O
.	560 1 O

Despite	562 7 O
pharmacological	570 15 O
and	586 3 O
supportive	590 10 O
interventions	601 13 O
,	614 1 O
laboratory	616 10 O
parameters	627 10 O
worsened	638 8 O
and	647 3 O
the	651 3 O
patient	655 7 O
died	663 4 O
17	668 2 O
hours	671 5 O
after	677 5 O
admission	683 9 O
.	692 1 O

An	694 2 O
accurate	697 8 O
autopsy	706 7 O
revealed	714 8 O
most	723 4 O
organs	728 6 O
with	735 4 O
diffuse	740 7 O
petechial	748 9 O
haemorrhages	758 12 B-Disease
.	770 1 O

No	772 2 O
signs	775 5 O
of	781 2 O
bone	784 4 B-Disease
marrow	789 6 I-Disease
depression	796 10 I-Disease
were	807 4 O
found	812 5 O
.	817 1 O

No	819 2 O
thrombi	822 7 B-Disease
or	830 2 O
signs	833 5 O
of	839 2 O
microangiopathies	842 17 B-Disease
were	860 4 O
observed	865 8 O
in	874 2 O
arterial	877 8 O
vessels	886 7 O
.	893 1 O

Blood	895 5 O
and	901 3 O
urine	905 5 O
cultures	911 8 O
did	920 3 O
not	924 3 O
show	928 4 O
any	933 3 O
bacterial	937 9 O
growth	947 6 O
.	953 1 O

This	955 4 O
case	960 4 O
report	965 6 O
shows	972 5 O
that	978 4 O
ciprofloxacin	983 13 B-Chemical
may	997 3 O
precipitate	1001 11 O
life	1013 4 O
-	1017 1 O
threatening	1018 11 O
thrombocytopenia	1030 16 B-Disease
and	1047 3 O
haemolytic	1051 10 B-Disease
anaemia	1062 7 I-Disease
,	1069 1 O
even	1071 4 O
in	1076 2 O
the	1079 3 O
early	1083 5 O
phases	1089 6 O
of	1096 2 O
treatment	1099 9 O
and	1109 3 O
without	1113 7 O
apparent	1121 8 O
previous	1130 8 O
exposures	1139 9 O
.	1148 1 O

Simvastatin	0 11 B-Chemical
-	11 1 O
induced	12 7 O
bilateral	20 9 O
leg	30 3 O
compartment	34 11 B-Disease
syndrome	46 8 I-Disease
and	55 3 O
myonecrosis	59 11 B-Disease
associated	71 10 O
with	82 4 O
hypothyroidism	87 14 B-Disease
.	101 1 O

A	103 1 O
54	105 2 O
-	107 1 O
year	108 4 O
-	112 1 O
old	113 3 O
hypothyroid	117 11 B-Disease
male	129 4 O
taking	134 6 O
thyroxine	141 9 B-Chemical
and	151 3 O
simvastatin	155 11 B-Chemical
presented	167 9 O
with	177 4 O
bilateral	182 9 O
leg	192 3 O
compartment	196 11 B-Disease
syndrome	208 8 I-Disease
and	217 3 O
myonecrosis	221 11 B-Disease
.	232 1 O

Urgent	234 6 O
fasciotomies	241 12 O
were	254 4 O
performed	259 9 O
and	269 3 O
the	273 3 O
patient	277 7 O
made	285 4 O
an	290 2 O
uneventful	293 10 O
recovery	304 8 O
with	313 4 O
the	318 3 O
withdrawal	322 10 O
of	333 2 O
simvastatin	336 11 B-Chemical
.	347 1 O

It	349 2 O
is	352 2 O
likely	355 6 O
that	362 4 O
this	367 4 O
complication	372 12 O
will	385 4 O
be	390 2 O
seen	393 4 O
more	398 4 O
often	403 5 O
with	409 4 O
the	414 3 O
increased	418 9 O
worldwide	428 9 O
use	438 3 O
of	442 2 O
this	445 4 O
drug	450 4 O
and	455 3 O
its	459 3 O
approval	463 8 O
for	472 3 O
all	476 3 O
arteriopathic	480 13 B-Disease
patients	494 8 O
.	502 1 O

Bile	0 4 B-Disease
duct	5 4 I-Disease
hamartoma	10 9 I-Disease
occurring	20 9 O
in	30 2 O
association	33 11 O
with	45 4 O
long	50 4 O
-	54 1 O
term	55 4 O
treatment	60 9 O
with	70 4 O
danazol	75 7 B-Chemical
.	82 1 O

We	84 2 O
report	87 6 O
a	94 1 O
case	96 4 O
of	101 2 O
bile	104 4 B-Disease
duct	109 4 I-Disease
hamartoma	114 9 I-Disease
which	124 5 O
developed	130 9 O
in	140 2 O
a	143 1 O
patient	145 7 O
who	153 3 O
had	157 3 O
been	161 4 O
on	166 2 O
long	169 4 O
-	173 1 O
term	174 4 O
danazol	179 7 B-Chemical
treatment	187 9 O
.	196 1 O

Such	198 4 O
patients	203 8 O
should	212 6 O
be	219 2 O
under	222 5 O
close	228 5 O
follow	234 6 O
-	240 1 O
up	241 2 O
,	243 1 O
preferably	245 10 O
with	256 4 O
periodic	261 8 O
ultrasound	270 10 O
examination	281 11 O
of	293 2 O
the	296 3 O
liver	300 5 O
.	305 1 O

If	307 2 O
the	310 3 O
patient	314 7 O
develops	322 8 O
a	331 1 O
liver	333 5 B-Disease
mass	339 4 I-Disease
,	343 1 O
because	345 7 O
of	353 2 O
non	356 3 O
-	359 1 O
specific	360 8 O
clinical	369 8 O
features	378 8 O
and	387 3 O
imaging	391 7 O
appearances	399 11 O
,	410 1 O
biopsy	412 6 O
may	419 3 O
be	423 2 O
the	426 3 O
only	430 4 O
way	435 3 O
to	439 2 O
achieve	442 7 O
a	450 1 O
definitive	452 10 O
diagnosis	463 9 O
.	472 1 O

Granulomatous	0 13 B-Disease
hepatitis	14 9 I-Disease
due	24 3 O
to	28 2 O
combination	31 11 B-Chemical
of	43 2 I-Chemical
amoxicillin	46 11 I-Chemical
and	58 3 I-Chemical
clavulanic	62 10 I-Chemical
acid	73 4 I-Chemical
.	77 1 O

We	79 2 O
report	82 6 O
the	89 3 O
case	93 4 O
of	98 2 O
a	101 1 O
patient	103 7 O
with	111 4 O
amoxicillin	116 11 B-Chemical
-	127 1 I-Chemical
clavulanic	128 10 I-Chemical
acid	139 4 I-Chemical
-	143 1 O
induced	144 7 O
hepatitis	152 9 B-Disease
with	162 4 O
histologic	167 10 O
multiple	178 8 O
granulomas	187 10 B-Disease
.	197 1 O

This	199 4 O
type	204 4 O
of	209 2 O
lesion	212 6 O
broadens	219 8 O
the	228 3 O
spectrum	232 8 O
of	241 2 O
liver	244 5 B-Disease
injury	250 6 I-Disease
due	257 3 O
to	261 2 O
this	264 4 O
drug	269 4 O
combination	274 11 O
,	285 1 O
mainly	287 6 O
represented	294 11 O
by	306 2 O
a	309 1 O
benign	311 6 O
cholestatic	318 11 B-Disease
syndrome	330 8 I-Disease
.	338 1 O

The	340 3 O
association	344 11 O
of	356 2 O
granulomas	359 10 B-Disease
and	370 3 O
eosinophilia	374 12 B-Disease
favor	387 5 O
an	393 2 O
immunoallergic	396 14 O
mechanism	411 9 O
.	420 1 O

As	422 2 O
penicillin	425 10 B-Chemical
derivatives	436 11 O
and	448 3 O
amoxicillin	452 11 B-Chemical
alone	464 5 O
are	470 3 O
known	474 5 O
to	480 2 O
induce	483 6 O
such	490 4 O
types	495 5 O
of	501 2 O
lesions	504 7 O
,	511 1 O
the	513 3 O
amoxicillin	517 11 B-Chemical
component	529 9 O
,	538 1 O
with	540 4 O
or	545 2 O
without	548 7 O
a	556 1 O
potentiating	558 12 O
effect	571 6 O
of	578 2 O
clavulanic	581 10 B-Chemical
acid	592 4 I-Chemical
,	596 1 O
might	598 5 O
have	604 4 O
a	609 1 O
major	611 5 O
role	617 4 O
.	621 1 O

Intracranial	0 12 B-Disease
aneurysms	13 9 I-Disease
and	23 3 O
cocaine	27 7 B-Disease
abuse	35 5 I-Disease
:	40 1 O
analysis	42 8 O
of	51 2 O
prognostic	54 10 O
indicators	65 10 O
.	75 1 O

OBJECTIVE	77 9 O
:	86 1 O
The	88 3 O
outcome	92 7 O
of	100 2 O
subarachnoid	103 12 B-Disease
hemorrhage	116 10 I-Disease
associated	127 10 O
with	138 4 O
cocaine	143 7 B-Disease
abuse	151 5 I-Disease
is	157 2 O
reportedly	160 10 O
poor	171 4 O
.	175 1 O

However	177 7 O
,	184 1 O
no	186 2 O
study	189 5 O
in	195 2 O
the	198 3 O
literature	202 10 O
has	213 3 O
reported	217 8 O
the	226 3 O
use	230 3 O
of	234 2 O
a	237 1 O
statistical	239 11 O
model	251 5 O
to	257 2 O
analyze	260 7 O
the	268 3 O
variables	272 9 O
that	282 4 O
influence	287 9 O
outcome	297 7 O
.	304 1 O

METHODS	306 7 O
:	313 1 O
A	315 1 O
review	317 6 O
of	324 2 O
admissions	327 10 O
during	338 6 O
a	345 1 O
6	347 1 O
-	348 1 O
year	349 4 O
period	354 6 O
revealed	361 8 O
14	370 2 O
patients	373 8 O
with	382 4 O
cocaine	387 7 B-Chemical
-	394 1 O
related	395 7 O
aneurysms	403 9 B-Disease
.	412 1 O

This	414 4 O
group	419 5 O
was	425 3 O
compared	429 8 O
with	438 4 O
a	443 1 O
control	445 7 O
group	453 5 O
of	459 2 O
135	462 3 O
patients	466 8 O
with	475 4 O
ruptured	480 8 B-Disease
aneurysms	489 9 I-Disease
and	499 3 O
no	503 2 O
history	506 7 O
of	514 2 O
cocaine	517 7 B-Disease
abuse	525 5 I-Disease
.	530 1 O

Age	532 3 O
at	536 2 O
presentation	539 12 O
,	551 1 O
time	553 4 O
of	558 2 O
ictus	561 5 O
after	567 5 O
intoxication	573 12 O
,	585 1 O
Hunt	587 4 O
and	592 3 O
Hess	596 4 O
grade	601 5 O
of	607 2 O
subarachnoid	610 12 B-Disease
hemorrhage	623 10 I-Disease
,	633 1 O
size	635 4 O
of	640 2 O
the	643 3 O
aneurysm	647 8 B-Disease
,	655 1 O
location	657 8 O
of	666 2 O
the	669 3 O
aneurysm	673 8 B-Disease
,	681 1 O
and	683 3 O
the	687 3 O
Glasgow	691 7 O
Outcome	699 7 O
Scale	707 5 O
score	713 5 O
were	719 4 O
assessed	724 8 O
and	733 3 O
compared	737 8 O
.	745 1 O

RESULTS	747 7 O
:	754 1 O
The	756 3 O
patients	760 8 O
in	769 2 O
the	772 3 O
study	776 5 O
group	782 5 O
were	788 4 O
significantly	793 13 O
younger	807 7 O
than	815 4 O
the	820 3 O
patients	824 8 O
in	833 2 O
the	836 3 O
control	840 7 O
group	848 5 O
(	854 1 O
P	855 1 O
<	857 1 O
0	859 1 O
.	860 1 O
002	861 3 O
)	864 1 O
.	865 1 O

In	867 2 O
patients	870 8 O
in	879 2 O
the	882 3 O
study	886 5 O
group	892 5 O
,	897 1 O
all	899 3 O
aneurysms	903 9 B-Disease
were	913 4 O
located	918 7 O
in	926 2 O
the	929 3 O
anterior	933 8 O
circulation	942 11 O
.	953 1 O

The	955 3 O
majority	959 8 O
of	968 2 O
these	971 5 O
aneurysms	977 9 B-Disease
were	987 4 O
smaller	992 7 O
than	1000 4 O
those	1005 5 O
of	1011 2 O
the	1014 3 O
control	1018 7 O
group	1026 5 O
(	1032 1 O
8	1033 1 O
+	1035 1 O
/	1036 1 O
-	1037 1 O
6	1039 1 O
.	1040 1 O
08	1041 2 O
mm	1044 2 O
versus	1047 6 O
11	1054 2 O
+	1057 1 O
/	1058 1 O
-	1059 1 O
5	1061 1 O
.	1062 1 O
4	1063 1 O
mm	1065 2 O
;	1067 1 O
P	1069 1 O
=	1071 1 O
0	1073 1 O
.	1074 1 O
05	1075 2 O
)	1077 1 O
.	1078 1 O

The	1080 3 O
differences	1084 11 O
in	1096 2 O
mortality	1099 9 O
and	1109 3 O
morbidity	1113 9 O
between	1123 7 O
the	1131 3 O
two	1135 3 O
groups	1139 6 O
were	1146 4 O
not	1151 3 O
significant	1155 11 O
.	1166 1 O

Hunt	1168 4 O
and	1173 3 O
Hess	1177 4 O
grade	1182 5 O
(	1188 1 O
P	1189 1 O
<	1191 1 O
0	1193 1 O
.	1194 1 O
005	1195 3 O
)	1198 1 O
and	1200 3 O
age	1204 3 O
(	1208 1 O
P	1209 1 O
<	1211 1 O
0	1213 1 O
.	1214 1 O
007	1215 3 O
)	1218 1 O
were	1220 4 O
significant	1225 11 O
predictors	1237 10 O
of	1248 2 O
outcome	1251 7 O
for	1259 3 O
the	1263 3 O
patients	1267 8 O
with	1276 4 O
cocaine	1281 7 B-Chemical
-	1288 1 O
related	1289 7 O
aneurysms	1297 9 B-Disease
.	1306 1 O

CONCLUSION	1308 10 O
:	1318 1 O
Cocaine	1320 7 B-Chemical
use	1328 3 O
predisposed	1332 11 O
aneurysmal	1344 10 B-Disease
rupture	1355 7 I-Disease
at	1363 2 O
a	1366 1 O
significantly	1368 13 O
earlier	1382 7 O
age	1390 3 O
and	1394 3 O
in	1398 2 O
much	1401 4 O
smaller	1406 7 O
aneurysms	1414 9 B-Disease
.	1423 1 O

Contrary	1425 8 O
to	1434 2 O
the	1437 3 O
published	1441 9 O
literature	1451 10 O
,	1461 1 O
this	1463 4 O
group	1468 5 O
did	1474 3 O
reasonably	1478 10 O
well	1489 4 O
with	1494 4 O
aggressive	1499 10 O
management	1510 10 O
.	1520 1 O

Anti	0 4 O
-	4 1 O
epileptic	5 9 B-Disease
drugs	15 5 O
-	20 1 O
induced	21 7 O
de	29 2 O
novo	32 4 O
absence	37 7 B-Disease
seizures	45 8 I-Disease
.	53 1 O

The	55 3 O
authors	59 7 O
present	67 7 O
three	75 5 O
patients	81 8 O
with	90 4 O
de	95 2 O
novo	98 4 O
absence	103 7 B-Disease
epilepsy	111 8 I-Disease
after	120 5 O
administration	126 14 O
of	141 2 O
carbamazepine	144 13 B-Chemical
and	158 3 O
vigabatrin	162 10 B-Chemical
.	172 1 O

Despite	174 7 O
the	182 3 O
underlying	186 10 O
diseases	197 8 O
,	205 1 O
the	207 3 O
prognosis	211 9 O
for	221 3 O
drug	225 4 O
-	229 1 O
induced	230 7 O
de	238 2 O
novo	241 4 O
absence	246 7 B-Disease
seizure	254 7 I-Disease
is	262 2 O
good	265 4 O
because	270 7 O
it	278 2 O
subsides	281 8 O
rapidly	290 7 O
after	298 5 O
discontinuing	304 13 O
the	318 3 O
use	322 3 O
of	326 2 O
the	329 3 O
offending	333 9 O
drugs	343 5 O
.	348 1 O

The	350 3 O
gamma	354 5 B-Chemical
-	359 1 I-Chemical
aminobutyric	360 12 I-Chemical
acid	373 4 I-Chemical
-	377 1 O
transmitted	378 11 O
thalamocortical	390 15 O
circuitry	406 9 O
accounts	416 8 O
for	425 3 O
a	429 1 O
major	431 5 O
part	437 4 O
of	442 2 O
the	445 3 O
underlying	449 10 O
neurophysiology	460 15 O
of	476 2 O
the	479 3 O
absence	483 7 B-Disease
epilepsy	491 8 I-Disease
.	499 1 O

Because	501 7 O
drug	509 4 O
-	513 1 O
induced	514 7 O
de	522 2 O
novo	525 4 O
absence	530 7 B-Disease
seizure	538 7 I-Disease
is	546 2 O
rare	549 4 O
,	553 1 O
pro	555 3 O
-	558 1 O
absence	559 7 O
drugs	567 5 O
can	573 3 O
only	577 4 O
be	582 2 O
considered	585 10 O
a	596 1 O
promoting	598 9 O
factor	608 6 O
.	614 1 O

The	616 3 O
underlying	620 10 O
epileptogenecity	631 16 O
of	648 2 O
the	651 3 O
patients	655 8 O
or	664 2 O
the	667 3 O
synergistic	671 11 O
effects	683 7 O
of	691 2 O
the	694 3 O
accompanying	698 12 O
drugs	711 5 O
is	717 2 O
required	720 8 O
to	729 2 O
trigger	732 7 O
the	740 3 O
de	744 2 O
novo	747 4 O
absence	752 7 B-Disease
seizure	760 7 I-Disease
.	767 1 O

The	769 3 O
possibility	773 11 O
of	785 2 O
drug	788 4 O
-	792 1 O
induced	793 7 O
aggravation	801 11 O
should	813 6 O
be	820 2 O
considered	823 10 O
whenever	834 8 O
an	843 2 O
unexpected	846 10 O
increase	857 8 O
in	866 2 O
seizure	869 7 B-Disease
frequency	877 9 O
and	887 3 O
/	890 1 O
or	891 2 O
new	894 3 O
seizure	898 7 B-Disease
types	906 5 O
appear	912 6 O
following	919 9 O
a	929 1 O
change	931 6 O
in	938 2 O
drug	941 4 O
treatment	946 9 O
.	955 1 O

By	957 2 O
understanding	960 13 O
the	974 3 O
underlying	978 10 O
mechanism	989 9 O
of	999 2 O
absence	1002 7 B-Disease
epilepsy	1010 8 I-Disease
,	1018 1 O
we	1020 2 O
can	1023 3 O
avoid	1027 5 O
the	1033 3 O
inappropriate	1037 13 O
use	1051 3 O
of	1055 2 O
anticonvulsants	1058 15 O
in	1074 2 O
children	1077 8 O
with	1086 4 O
epilepsy	1091 8 B-Disease
and	1100 3 O
prevent	1104 7 O
drug	1112 4 O
-	1116 1 O
induced	1117 7 O
absence	1125 7 B-Disease
seizures	1133 8 I-Disease
.	1141 1 O

Procainamide	0 12 B-Chemical
-	12 1 O
induced	13 7 O
polymorphous	21 12 O
ventricular	34 11 B-Disease
tachycardia	46 11 I-Disease
.	57 1 O

Seven	59 5 O
cases	65 5 O
of	71 2 O
procainamide	74 12 B-Chemical
-	86 1 O
induced	87 7 O
polymorphous	95 12 O
ventricular	108 11 B-Disease
tachycardia	120 11 I-Disease
are	132 3 O
presented	136 9 O
.	145 1 O

In	147 2 O
four	150 4 O
patients	155 8 O
,	163 1 O
polymorphous	165 12 O
ventricular	178 11 B-Disease
tachycardia	190 11 I-Disease
appeared	202 8 O
after	211 5 O
intravenous	217 11 O
administration	229 14 O
of	244 2 O
200	247 3 O
to	251 2 O
400	254 3 O
mg	258 2 O
of	261 2 O
procainamide	264 12 B-Chemical
for	277 3 O
the	281 3 O
treatment	285 9 O
of	295 2 O
sustained	298 9 O
ventricular	308 11 B-Disease
tachycardia	320 11 I-Disease
.	331 1 O

In	333 2 O
the	336 3 O
remaining	340 9 O
three	350 5 O
patients	356 8 O
,	364 1 O
procainamide	366 12 B-Chemical
was	379 3 O
administered	383 12 O
orally	396 6 O
for	403 3 O
treatment	407 9 O
of	417 2 O
chronic	420 7 O
premature	428 9 B-Disease
ventricular	438 11 I-Disease
contractions	450 12 I-Disease
or	463 2 O
atrial	466 6 B-Disease
flutter	473 7 I-Disease
.	480 1 O

These	482 5 O
patients	488 8 O
had	497 3 O
Q	501 1 B-Disease
-	502 1 I-Disease
T	503 1 I-Disease
prolongation	505 12 I-Disease
and	518 3 O
recurrent	522 9 O
syncope	532 7 B-Disease
due	540 3 O
to	544 2 O
polymorphous	547 12 O
ventricular	560 11 B-Disease
tachycardia	572 11 I-Disease
.	583 1 O

In	585 2 O
four	588 4 O
patients	593 8 O
,	601 1 O
the	603 3 O
arrhythmia	607 10 B-Disease
was	618 3 O
rapidly	622 7 O
diagnosed	630 9 O
and	640 3 O
treated	644 7 O
with	652 4 O
disappearance	657 13 O
of	671 2 O
further	674 7 O
episodes	682 8 O
of	691 2 O
the	694 3 O
arrhythmia	698 10 B-Disease
.	708 1 O

In	710 2 O
two	713 3 O
patients	717 8 O
,	725 1 O
the	727 3 O
arrhythmia	731 10 B-Disease
degenerated	742 11 O
into	754 4 O
irreversible	759 12 O
ventricular	772 11 B-Disease
fibrillation	784 12 I-Disease
and	797 3 O
both	801 4 O
patients	806 8 O
died	815 4 O
.	819 1 O

In	821 2 O
the	824 3 O
seventh	828 7 O
patient	836 7 O
,	843 1 O
a	845 1 O
permanent	847 9 O
ventricular	857 11 O
pacemaker	869 9 O
was	879 3 O
inserted	883 8 O
and	892 3 O
,	895 1 O
despite	897 7 O
continuation	905 12 O
of	918 2 O
procainamide	921 12 B-Chemical
therapy	934 7 O
,	941 1 O
polymorphous	943 12 O
ventricular	956 11 B-Disease
tachycardia	968 11 I-Disease
did	980 3 O
not	984 3 O
reoccur	988 7 O
.	995 1 O

These	997 5 O
seven	1003 5 O
cases	1009 5 O
demonstrate	1015 11 O
that	1027 4 O
procainamide	1032 12 B-Chemical
can	1045 3 O
produce	1049 7 O
an	1057 2 O
acquired	1060 8 O
prolonged	1069 9 B-Disease
Q	1079 1 I-Disease
-	1080 1 I-Disease
T	1081 1 I-Disease
syndrome	1083 8 I-Disease
with	1092 4 O
polymorphous	1097 12 O
ventricular	1110 11 B-Disease
tachycardia	1122 11 I-Disease
.	1133 1 O

Role	0 4 O
of	5 2 O
activation	8 10 O
of	19 2 O
bradykinin	22 10 B-Chemical
B2	33 2 O
receptors	36 9 O
in	46 2 O
disruption	49 10 O
of	60 2 O
the	63 3 O
blood	67 5 O
-	72 1 O
brain	73 5 O
barrier	79 7 O
during	87 6 O
acute	94 5 O
hypertension	100 12 B-Disease
.	112 1 O

Cellular	114 8 O
mechanisms	123 10 O
which	134 5 O
account	140 7 O
for	148 3 O
disruption	152 10 O
the	163 3 O
blood	167 5 O
-	172 1 O
brain	173 5 O
barrier	179 7 O
during	187 6 O
acute	194 5 O
hypertension	200 12 B-Disease
are	213 3 O
not	217 3 O
clear	221 5 O
.	226 1 O

The	228 3 O
goal	232 4 O
of	237 2 O
this	240 4 O
study	245 5 O
was	251 3 O
to	255 2 O
determine	258 9 O
the	268 3 O
role	272 4 O
of	277 2 O
synthesis	280 9 O
/	289 1 O
release	290 7 O
of	298 2 O
bradykinin	301 10 B-Chemical
to	312 2 O
activate	315 8 O
B2	324 2 O
receptors	327 9 O
in	337 2 O
disruption	340 10 O
of	351 2 O
the	354 3 O
blood	358 5 O
-	363 1 O
brain	364 5 O
barrier	370 7 O
during	378 6 O
acute	385 5 O
hypertension	391 12 B-Disease
.	403 1 O

Permeability	405 12 O
of	418 2 O
the	421 3 O
blood	425 5 O
-	430 1 O
brain	431 5 O
barrier	437 7 O
was	445 3 O
quantitated	449 11 O
by	461 2 O
clearance	464 9 O
of	474 2 O
fluorescent	477 11 O
-	488 1 O
labeled	489 7 O
dextran	497 7 B-Chemical
before	505 6 O
and	512 3 O
during	516 6 O
phenylephrine	523 13 B-Chemical
-	536 1 O
induced	537 7 O
acute	545 5 O
hypertension	551 12 B-Disease
in	564 2 O
rats	567 4 O
treated	572 7 O
with	580 4 O
vehicle	585 7 O
and	593 3 O
Hoe	597 3 B-Chemical
-	600 1 I-Chemical
140	601 3 I-Chemical
(	605 1 O
0	606 1 O
.	607 1 O
1	608 1 O
microM	610 6 O
)	616 1 O
.	617 1 O

Phenylephrine	619 13 B-Chemical
infusion	633 8 O
increased	642 9 O
arterial	652 8 O
pressure	661 8 O
,	669 1 O
arteriolar	671 10 O
diameter	682 8 O
and	691 3 O
clearance	695 9 O
of	705 2 O
fluorescent	708 11 O
dextran	720 7 B-Chemical
by	728 2 O
a	731 1 O
similar	733 7 O
magnitude	741 9 O
in	751 2 O
both	754 4 O
groups	759 6 O
.	765 1 O

These	767 5 O
findings	773 8 O
suggest	782 7 O
that	790 4 O
disruption	795 10 O
of	806 2 O
the	809 3 O
blood	813 5 O
-	818 1 O
brain	819 5 O
barrier	825 7 O
during	833 6 O
acute	840 5 O
hypertension	846 12 B-Disease
is	859 2 O
not	862 3 O
related	866 7 O
to	874 2 O
the	877 3 O
synthesis	881 9 O
/	890 1 O
release	891 7 O
of	899 2 O
bradykinin	902 10 B-Chemical
to	913 2 O
activate	916 8 O
B2	925 2 O
receptors	928 9 O
.	937 1 O

5	0 1 B-Chemical
-	1 1 I-Chemical
azacytidine	2 11 I-Chemical
potentiates	14 11 O
initiation	26 10 B-Disease
induced	37 7 I-Disease
by	45 2 I-Disease
carcinogens	48 11 I-Disease
in	60 2 O
rat	63 3 O
liver	67 5 O
.	72 1 O

To	74 2 O
test	77 4 O
the	82 3 O
validity	86 8 O
of	95 2 O
the	98 3 O
hypothesis	102 10 O
that	113 4 O
hypomethylation	118 15 O
of	134 2 O
DNA	137 3 O
plays	141 5 O
an	147 2 O
important	150 9 O
role	160 4 O
in	165 2 O
the	168 3 O
initiation	172 10 B-Disease
of	183 2 I-Disease
carcinogenic	186 12 I-Disease
process	199 7 I-Disease
,	206 1 O
5	208 1 B-Chemical
-	209 1 I-Chemical
azacytidine	210 11 I-Chemical
(	222 1 O
5	223 1 B-Chemical
-	224 1 I-Chemical
AzC	225 3 I-Chemical
)	228 1 O
(	230 1 O
10	231 2 O
mg	234 2 O
/	236 1 O
kg	237 2 O
)	239 1 O
,	240 1 O
an	242 2 O
inhibitor	245 9 O
of	255 2 O
DNA	258 3 O
methylation	262 11 O
,	273 1 O
was	275 3 O
given	279 5 O
to	285 2 O
rats	288 4 O
during	293 6 O
the	300 3 O
phase	304 5 O
of	310 2 O
repair	313 6 O
synthesis	320 9 O
induced	330 7 O
by	338 2 O
the	341 3 O
three	345 5 O
carcinogens	351 11 O
,	362 1 O
benzo	364 5 B-Chemical
[	369 1 I-Chemical
a	370 1 I-Chemical
]	371 1 I-Chemical
-	372 1 I-Chemical
pyrene	373 6 I-Chemical
(	380 1 O
200	381 3 O
mg	385 2 O
/	387 1 O
kg	388 2 O
)	390 1 O
,	391 1 O
N	393 1 B-Chemical
-	394 1 I-Chemical
methyl	395 6 I-Chemical
-	401 1 I-Chemical
N	402 1 I-Chemical
-	403 1 I-Chemical
nitrosourea	404 11 I-Chemical
(	416 1 O
60	417 2 O
mg	420 2 O
/	422 1 O
kg	423 2 O
)	425 1 O
and	427 3 O
1	431 1 B-Chemical
,	432 1 I-Chemical
2	433 1 I-Chemical
-	434 1 I-Chemical
dimethylhydrazine	435 17 I-Chemical
(	453 1 O
1	454 1 B-Chemical
,	455 1 I-Chemical
2	456 1 I-Chemical
-	457 1 I-Chemical
DMH	458 3 I-Chemical
)	461 1 O
(	463 1 O
100	464 3 O
mg	468 2 O
/	470 1 O
kg	471 2 O
)	473 1 O
.	474 1 O

The	476 3 O
initiated	480 9 O
hepatocytes	490 11 O
in	502 2 O
the	505 3 O
liver	509 5 O
were	515 4 O
assayed	520 7 O
as	528 2 O
the	531 3 O
gamma	535 5 O
-	540 1 O
glutamyltransferase	541 19 O
(	561 1 O
gamma	562 5 O
-	567 1 O
GT	568 2 O
)	570 1 O
positive	572 8 O
foci	581 4 O
formed	586 6 O
following	593 9 O
a	603 1 O
2	605 1 O
-	606 1 O
week	607 4 O
selection	612 9 O
regimen	622 7 O
consisting	630 10 O
of	641 2 O
dietary	644 7 O
0	652 1 O
.	653 1 O
02	654 2 O
%	656 1 O
2	658 1 B-Chemical
-	659 1 I-Chemical
acetylaminofluorene	660 19 I-Chemical
coupled	680 7 O
with	688 4 O
a	693 1 O
necrogenic	695 10 O
dose	706 4 O
of	711 2 O
CCl4	714 4 B-Chemical
.	718 1 O

The	720 3 O
results	724 7 O
obtained	732 8 O
indicate	741 8 O
that	750 4 O
with	755 4 O
all	760 3 O
three	764 5 O
carcinogens	770 11 O
,	781 1 O
administration	783 14 O
of	798 2 O
5	801 1 B-Chemical
-	802 1 I-Chemical
AzC	803 3 I-Chemical
during	807 6 O
repair	814 6 O
synthesis	821 9 O
increased	831 9 O
the	841 3 O
incidence	845 9 O
of	855 2 O
initiated	858 9 O
hepatocytes	868 11 O
,	879 1 O
for	881 3 O
example	885 7 O
10	893 2 O
-	895 1 O
20	896 2 O
foci	899 4 O
/	903 1 O
cm2	904 3 O
in	908 2 O
5	911 1 B-Chemical
-	912 1 I-Chemical
AzC	913 3 I-Chemical
and	917 3 O
carcinogen	921 10 O
-	931 1 O
treated	932 7 O
rats	940 4 O
compared	945 8 O
with	954 4 O
3	959 1 O
-	960 1 O
5	961 1 O
foci	963 4 O
/	967 1 O
cm2	968 3 O
in	972 2 O
rats	975 4 O
treated	980 7 O
with	988 4 O
carcinogen	993 10 O
only	1004 4 O
.	1008 1 O

Administration	1010 14 O
of	1025 2 O
[	1028 1 B-Chemical
3H	1029 2 I-Chemical
]	1031 1 I-Chemical
-	1032 1 I-Chemical
5	1033 1 I-Chemical
-	1034 1 I-Chemical
azadeoxycytidine	1035 16 I-Chemical
during	1052 6 O
the	1059 3 O
repair	1063 6 O
synthesis	1070 9 O
induced	1080 7 O
by	1088 2 O
1	1091 1 B-Chemical
,	1092 1 I-Chemical
2	1093 1 I-Chemical
-	1094 1 I-Chemical
DMH	1095 3 I-Chemical
further	1099 7 O
showed	1107 6 O
that	1114 4 O
0	1119 1 O
.	1120 1 O
019	1121 3 O
mol	1125 3 O
%	1129 1 O
of	1131 2 O
cytosine	1134 8 B-Chemical
residues	1143 8 O
in	1152 2 O
DNA	1155 3 O
were	1159 4 O
substituted	1164 11 O
by	1176 2 O
the	1179 3 O
analogue	1183 8 O
,	1191 1 O
indicating	1193 10 O
that	1204 4 O
incorporation	1209 13 O
of	1223 2 O
5	1226 1 B-Chemical
-	1227 1 I-Chemical
AzC	1228 3 I-Chemical
occurs	1232 6 O
during	1239 6 O
repair	1246 6 O
synthesis	1253 9 O
.	1262 1 O

In	1264 2 O
the	1267 3 O
absence	1271 7 O
of	1279 2 O
the	1282 3 O
carcinogen	1286 10 O
,	1296 1 O
5	1298 1 B-Chemical
-	1299 1 I-Chemical
AzC	1300 3 I-Chemical
given	1304 5 O
after	1310 5 O
a	1316 1 O
two	1318 3 O
thirds	1322 6 O
partial	1329 7 O
hepatectomy	1337 11 O
,	1348 1 O
when	1350 4 O
its	1355 3 O
incorporation	1359 13 O
should	1373 6 O
be	1380 2 O
maximum	1383 7 O
,	1390 1 O
failed	1392 6 O
to	1399 2 O
induce	1402 6 O
any	1409 3 O
gamma	1413 5 O
-	1418 1 O
GT	1419 2 O
positive	1422 8 O
foci	1431 4 O
.	1435 1 O

The	1437 3 O
results	1441 7 O
suggest	1449 7 O
that	1457 4 O
hypomethylation	1462 15 O
of	1478 2 O
DNA	1481 3 O
per	1485 3 O
se	1489 2 O
may	1492 3 O
not	1496 3 O
be	1500 2 O
sufficient	1503 10 O
for	1514 3 O
initiation	1518 10 O
.	1528 1 O

Perhaps	1530 7 O
two	1538 3 O
events	1542 6 O
might	1549 5 O
be	1555 2 O
necessary	1558 9 O
for	1568 3 O
initiation	1572 10 O
,	1582 1 O
the	1584 3 O
first	1588 5 O
caused	1594 6 O
by	1601 2 O
the	1604 3 O
carcinogen	1608 10 O
and	1619 3 O
a	1623 1 O
second	1625 6 O
involving	1632 9 O
hypomethylation	1642 15 O
of	1658 2 O
DNA	1661 3 O
.	1664 1 O

Withdrawal	0 10 B-Disease
-	10 1 I-Disease
emergent	11 8 I-Disease
rabbit	20 6 I-Disease
syndrome	27 8 I-Disease
during	36 6 O
dose	43 4 O
reduction	48 9 O
of	58 2 O
risperidone	61 11 B-Chemical
.	72 1 O

Rabbit	74 6 B-Disease
syndrome	81 8 I-Disease
(	90 1 O
RS	91 2 B-Disease
)	93 1 O
is	95 2 O
a	98 1 O
rare	100 4 O
extrapyramidal	105 14 O
side	120 4 O
effect	125 6 O
caused	132 6 O
by	139 2 O
prolonged	142 9 O
neuroleptic	152 11 O
medication	164 10 O
.	174 1 O

Here	176 4 O
we	181 2 O
present	184 7 O
a	192 1 O
case	194 4 O
of	199 2 O
withdrawal	202 10 B-Disease
-	212 1 I-Disease
emergent	213 8 I-Disease
RS	222 2 I-Disease
,	224 1 O
which	226 5 O
is	232 2 O
the	235 3 O
first	239 5 O
of	245 2 O
its	248 3 O
kind	252 4 O
to	257 2 O
be	260 2 O
reported	263 8 O
.	271 1 O

The	273 3 O
patient	277 7 O
developed	285 9 O
RS	295 2 B-Disease
during	298 6 O
dose	305 4 O
reduction	310 9 O
of	320 2 O
risperidone	323 11 B-Chemical
.	334 1 O

The	336 3 O
symptom	340 7 O
was	348 3 O
treated	352 7 O
successfully	360 12 O
with	373 4 O
trihexyphenidyl	378 15 B-Chemical
anticholinergic	394 15 O
therapy	410 7 O
.	417 1 O

The	419 3 O
underlying	423 10 O
mechanism	434 9 O
of	444 2 O
withdrawal	447 10 B-Disease
-	457 1 I-Disease
emergent	458 8 I-Disease
RS	467 2 I-Disease
in	470 2 O
the	473 3 O
present	477 7 O
case	485 4 O
may	490 3 O
have	494 4 O
been	499 4 O
related	504 7 O
to	512 2 O
the	515 3 O
pharmacological	519 15 O
profile	535 7 O
of	543 2 O
risperidone	546 11 B-Chemical
,	557 1 O
a	559 1 O
serotonin	561 9 B-Chemical
-	570 1 O
dopamine	571 8 B-Chemical
antagonist	580 10 O
,	590 1 O
suggesting	592 10 O
the	603 3 O
pathophysiologic	607 16 O
influence	624 9 O
of	634 2 O
the	637 3 O
serotonin	641 9 B-Chemical
system	651 6 O
in	658 2 O
the	661 3 O
development	665 11 O
of	677 2 O
RS	680 2 B-Disease
.	682 1 O

Verapamil	0 9 B-Chemical
withdrawal	10 10 O
as	21 2 O
a	24 1 O
possible	26 8 O
cause	35 5 O
of	41 2 O
myocardial	44 10 B-Disease
infarction	55 10 I-Disease
in	66 2 O
a	69 1 O
hypertensive	71 12 B-Disease
woman	84 5 O
with	90 4 O
a	95 1 O
normal	97 6 O
coronary	104 8 O
angiogram	113 9 O
.	122 1 O

Verapamil	124 9 B-Chemical
is	134 2 O
an	137 2 O
effective	140 9 O
and	150 3 O
relatively	154 10 O
-	164 1 O
safe	165 4 O
antihypertensive	170 16 O
drug	187 4 O
.	191 1 O

Serious	193 7 O
adverse	201 7 O
effects	209 7 O
are	217 3 O
uncommon	221 8 O
and	230 3 O
mainly	234 6 O
have	241 4 O
been	246 4 O
related	251 7 O
to	259 2 O
the	262 3 O
depression	266 10 B-Disease
of	277 2 O
cardiac	280 7 O
contractility	288 13 O
and	302 3 O
conduction	306 10 O
,	316 1 O
especially	318 10 O
when	329 4 O
the	334 3 O
drug	338 4 O
is	343 2 O
combined	346 8 O
with	355 4 O
beta	360 4 O
-	364 1 O
blocking	365 8 O
agents	374 6 O
.	380 1 O

We	382 2 O
report	385 6 O
a	392 1 O
case	394 4 O
in	399 2 O
which	402 5 O
myocardial	408 10 B-Disease
infarction	419 10 I-Disease
coincided	430 9 O
with	440 4 O
the	445 3 O
introduction	449 12 O
of	462 2 O
captopril	465 9 B-Chemical
and	475 3 O
the	479 3 O
withdrawal	483 10 O
of	494 2 O
verapamil	497 9 B-Chemical
in	507 2 O
a	510 1 O
previously	512 10 O
asymptomatic	523 12 O
woman	536 5 O
with	542 4 O
severe	547 6 O
hypertension	554 12 B-Disease
.	566 1 O

Possible	568 8 O
mechanisms	577 10 O
that	588 4 O
involve	593 7 O
a	601 1 O
verapamil	603 9 B-Chemical
-	612 1 O
related	613 7 O
increase	621 8 O
in	630 2 O
platelet	633 8 O
and	642 3 O
/	645 1 O
or	646 2 O
vascular	649 8 O
alpha	658 5 O
2	664 1 O
-	665 1 O
adrenoreceptor	666 14 O
affinity	681 8 O
for	690 3 O
catecholamines	694 14 B-Chemical
are	709 3 O
discussed	713 9 O
.	722 1 O

Remission	0 9 O
induction	10 9 O
of	20 2 O
meningeal	23 9 B-Disease
leukemia	33 8 I-Disease
with	42 4 O
high	47 4 O
-	51 1 O
dose	52 4 O
intravenous	57 11 O
methotrexate	69 12 B-Chemical
.	81 1 O

Twenty	83 6 O
children	90 8 O
with	99 4 O
acute	104 5 B-Disease
lymphoblastic	110 13 I-Disease
leukemia	124 8 I-Disease
who	133 3 O
developed	137 9 O
meningeal	147 9 B-Disease
disease	157 7 I-Disease
were	165 4 O
treated	170 7 O
with	178 4 O
a	183 1 O
high	185 4 O
-	189 1 O
dose	190 4 O
intravenous	195 11 O
methotrexate	207 12 B-Chemical
regimen	220 7 O
that	228 4 O
was	233 3 O
designed	237 8 O
to	246 2 O
achieve	249 7 O
and	257 3 O
maintain	261 8 O
CSF	270 3 O
methotrexate	274 12 B-Chemical
concentrations	287 14 O
of	302 2 O
10	305 2 O
(	307 1 O
-	308 1 O
5	309 1 O
)	310 1 O
mol	312 3 O
/	315 1 O
L	316 1 O
without	318 7 O
the	326 3 O
need	330 4 O
for	335 3 O
concomitant	339 11 O
intrathecal	351 11 O
dosing	363 6 O
.	369 1 O

The	371 3 O
methotrexate	375 12 B-Chemical
was	388 3 O
administered	392 12 O
as	405 2 O
a	408 1 O
loading	410 7 O
dose	418 4 O
of	423 2 O
6	426 1 O
,	427 1 O
000	428 3 O
mg	432 2 O
/	434 1 O
m2	435 2 O
for	438 3 O
a	442 1 O
period	444 6 O
of	451 2 O
one	454 3 O
hour	458 4 O
followed	463 8 O
by	472 2 O
an	475 2 O
infusion	478 8 O
of	487 2 O
1	490 1 O
,	491 1 O
200	492 3 O
mg	496 2 O
/	498 1 O
m2	499 2 O
/	501 1 O
h	502 1 O
for	504 3 O
23	508 2 O
hours	511 5 O
.	516 1 O

Leucovorin	518 10 B-Chemical
rescue	529 6 O
was	536 3 O
initiated	540 9 O
12	550 2 O
hours	553 5 O
after	559 5 O
the	565 3 O
end	569 3 O
of	573 2 O
the	576 3 O
infusion	580 8 O
with	589 4 O
a	594 1 O
loading	596 7 O
dose	604 4 O
of	609 2 O
200	612 3 O
mg	616 2 O
/	618 1 O
m2	619 2 O
followed	622 8 O
by	631 2 O
12	634 2 O
mg	637 2 O
/	639 1 O
m2	640 2 O
every	643 5 O
three	649 5 O
hours	655 5 O
for	661 3 O
six	665 3 O
doses	669 5 O
and	675 3 O
then	679 4 O
every	684 5 O
six	690 3 O
hours	694 5 O
until	700 5 O
the	706 3 O
plasma	710 6 O
methotrexate	717 12 B-Chemical
level	730 5 O
decreased	736 9 O
to	746 2 O
less	749 4 O
than	754 4 O
1	759 1 O
X	761 1 O
10	763 2 O
(	765 1 O
-	766 1 O
7	767 1 O
)	768 1 O
mol	770 3 O
/	773 1 O
L	774 1 O
.	775 1 O

The	777 3 O
mean	781 4 O
steady	786 6 O
-	792 1 O
state	793 5 O
plasma	799 6 O
and	806 3 O
CSF	810 3 O
methotrexate	814 12 B-Chemical
concentrations	827 14 O
achieved	842 8 O
were	851 4 O
1	856 1 O
.	857 1 O
1	858 1 O
X	860 1 O
10	862 2 O
(	864 1 O
-	865 1 O
3	866 1 O
)	867 1 O
mol	869 3 O
/	872 1 O
L	873 1 O
and	875 3 O
3	879 1 O
.	880 1 O
6	881 1 O
X	883 1 O
10	885 2 O
(	887 1 O
-	888 1 O
5	889 1 O
)	890 1 O
mol	892 3 O
/	895 1 O
L	896 1 O
,	897 1 O
respectively	899 12 O
.	911 1 O

All	913 3 O
20	917 2 O
patients	920 8 O
responded	929 9 O
to	939 2 O
this	942 4 O
regimen	947 7 O
,	954 1 O
16	956 2 O
/	958 1 O
20	959 2 O
(	962 1 O
80	963 2 O
%	965 1 O
)	966 1 O
achieved	968 8 O
a	977 1 O
complete	979 8 O
remission	988 9 O
,	997 1 O
and	999 3 O
20	1003 2 O
%	1005 1 O
obtained	1007 8 O
a	1016 1 O
partial	1018 7 O
remission	1026 9 O
.	1035 1 O

The	1037 3 O
most	1041 4 O
common	1046 6 O
toxicities	1053 10 B-Disease
encountered	1064 11 O
were	1076 4 O
transient	1081 9 O
serum	1091 5 O
transaminase	1097 12 O
and	1110 3 O
bilirubin	1114 9 B-Chemical
elevations	1124 10 O
,	1134 1 O
neutropenia	1136 11 B-Disease
,	1147 1 O
and	1149 3 O
mucositis	1153 9 B-Disease
.	1162 1 O

One	1164 3 O
patient	1168 7 O
had	1176 3 O
focal	1180 5 O
seizures	1186 8 B-Disease
and	1195 3 O
transient	1199 9 B-Disease
hemiparesis	1209 11 I-Disease
but	1221 3 O
recovered	1225 9 O
completely	1235 10 O
.	1245 1 O

High	1247 4 O
-	1251 1 O
dose	1252 4 O
intravenous	1257 11 O
methotrexate	1269 12 B-Chemical
is	1282 2 O
an	1285 2 O
effective	1288 9 O
treatment	1298 9 O
for	1308 3 O
the	1312 3 O
induction	1316 9 O
of	1326 2 O
remission	1329 9 O
after	1339 5 O
meningeal	1345 9 O
relapse	1355 7 O
in	1363 2 O
acute	1366 5 B-Disease
lymphoblastic	1372 13 I-Disease
leukemia	1386 8 I-Disease
.	1394 1 O

Hypersensitivity	0 16 B-Disease
to	17 2 O
carbamazepine	20 13 B-Chemical
presenting	34 10 O
with	45 4 O
a	50 1 O
leukemoid	52 9 B-Disease
reaction	62 8 I-Disease
,	70 1 O
eosinophilia	72 12 B-Disease
,	84 1 O
erythroderma	86 12 B-Disease
,	98 1 O
and	100 3 O
renal	104 5 B-Disease
failure	110 7 I-Disease
.	117 1 O

We	119 2 O
report	122 6 O
a	129 1 O
patient	131 7 O
in	139 2 O
whom	142 4 O
hypersensitivity	147 16 B-Disease
to	164 2 O
carbamazepine	167 13 B-Chemical
presented	181 9 O
with	191 4 O
generalized	196 11 O
erythroderma	208 12 B-Disease
,	220 1 O
a	222 1 O
severe	224 6 O
leukemoid	231 9 B-Disease
reaction	241 8 I-Disease
,	249 1 O
eosinophilia	251 12 B-Disease
,	263 1 O
hyponatremia	265 12 B-Disease
,	277 1 O
and	279 3 O
renal	283 5 B-Disease
failure	289 7 I-Disease
.	296 1 O

This	298 4 O
is	303 2 O
the	306 3 O
first	310 5 O
report	316 6 O
of	323 2 O
such	326 4 O
an	331 2 O
unusual	334 7 O
reaction	342 8 O
to	351 2 O
carbamazepine	354 13 B-Chemical
.	367 1 O

The	0 3 O
interpeduncular	4 15 O
nucleus	20 7 O
regulates	28 9 O
nicotine	38 8 B-Chemical
'	46 1 O
s	47 1 O
effects	49 7 O
on	57 2 O
free	60 4 O
-	64 1 O
field	65 5 O
activity	71 8 O
.	79 1 O

Partial	81 7 O
lesions	89 7 O
were	97 4 O
made	102 4 O
with	107 4 O
kainic	112 6 B-Chemical
acid	119 4 I-Chemical
in	124 2 O
the	127 3 O
interpeduncular	131 15 O
nucleus	147 7 O
of	155 2 O
the	158 3 O
ventral	162 7 O
midbrain	170 8 O
of	179 2 O
the	182 3 O
rat	186 3 O
.	189 1 O

Compared	191 8 O
with	200 4 O
sham	205 4 O
-	209 1 O
operated	210 8 O
controls	219 8 O
,	227 1 O
lesions	229 7 O
significantly	237 13 O
(	251 1 O
p	252 1 O
<	254 1 O
0	256 1 O
.	257 1 O
25	258 2 O
)	260 1 O
blunted	262 7 O
the	270 3 O
early	274 5 O
(	280 1 O
<	281 1 O
60	282 2 O
min	285 3 O
)	288 1 O
free	290 4 O
-	294 1 O
field	295 5 O
locomotor	301 9 B-Disease
hypoactivity	311 12 I-Disease
caused	324 6 O
by	331 2 O
nicotine	334 8 B-Chemical
(	343 1 O
0	344 1 O
.	345 1 O
5	346 1 O
mg	348 2 O
kg	351 2 O
(	353 1 O
-	354 1 O
1	355 1 O
)	356 1 O
,	357 1 O
i	359 1 O
.	360 1 O
m	361 1 O
.	362 1 O
)	363 1 O
,	364 1 O
enhanced	366 8 O
the	375 3 O
later	379 5 O
(	385 1 O
60	386 2 O
-	388 1 O
120	389 3 O
min	393 3 O
)	396 1 O
nicotine	398 8 B-Chemical
-	406 1 O
induced	407 7 O
hyperactivity	415 13 B-Disease
,	428 1 O
and	430 3 O
raised	434 6 O
spontaneous	441 11 O
nocturnal	453 9 O
activity	463 8 O
.	471 1 O

Lesions	473 7 O
reduced	481 7 O
the	489 3 O
extent	493 6 O
of	500 2 O
immunohistological	503 18 O
staining	522 8 O
for	531 3 O
choline	535 7 B-Chemical
acetyltransferase	543 17 O
in	561 2 O
the	564 3 O
interpeduncular	568 15 O
nucleus	584 7 O
(	592 1 O
p	593 1 O
<	595 1 O
0	596 1 O
.	597 1 O
025	598 3 O
)	601 1 O
,	602 1 O
but	604 3 O
not	608 3 O
for	612 3 O
tyrosine	616 8 B-Chemical
hydroxylase	625 11 O
in	637 2 O
the	640 3 O
surrounding	644 11 O
catecholaminergic	656 17 O
A10	674 3 O
region	678 6 O
.	684 1 O

We	686 2 O
conclude	689 8 O
that	698 4 O
the	703 3 O
interpeduncular	707 15 O
nucleus	723 7 O
mediates	731 8 O
nicotinic	740 9 O
depression	750 10 B-Disease
of	761 2 O
locomotor	764 9 O
activity	774 8 O
and	783 3 O
dampens	787 7 O
nicotinic	795 9 O
arousal	805 7 O
mechanisms	813 10 O
located	824 7 O
elsewhere	832 9 O
in	842 2 O
the	845 3 O
brain	849 5 O
.	854 1 O

Assessment	0 10 O
of	11 2 O
a	14 1 O
new	16 3 O
non	20 3 O
-	23 1 O
invasive	24 8 O
index	33 5 O
of	39 2 O
cardiac	42 7 O
performance	50 11 O
for	62 3 O
detection	66 9 O
of	76 2 O
dobutamine	79 10 B-Chemical
-	89 1 O
induced	90 7 O
myocardial	98 10 B-Disease
ischemia	109 8 I-Disease
.	117 1 O

BACKGROUND	119 10 O
:	129 1 O
Electrocardiography	131 19 O
has	151 3 O
a	155 1 O
very	157 4 O
low	162 3 O
sensitivity	166 11 O
in	178 2 O
detecting	181 9 O
dobutamine	191 10 B-Chemical
-	201 1 O
induced	202 7 O
myocardial	210 10 B-Disease
ischemia	221 8 I-Disease
.	229 1 O

OBJECTIVES	231 10 O
:	241 1 O
To	243 2 O
assess	246 6 O
the	253 3 O
added	257 5 O
diagnostic	263 10 O
value	274 5 O
of	280 2 O
a	283 1 O
new	285 3 O
cardiac	289 7 O
performance	297 11 O
index	309 5 O
(	315 1 O
dP	316 2 O
/	318 1 O
dtejc	319 5 O
)	324 1 O
measurement	326 11 O
,	337 1 O
based	339 5 O
on	345 2 O
brachial	348 8 O
artery	357 6 O
flow	364 4 O
changes	369 7 O
,	376 1 O
as	378 2 O
compared	381 8 O
to	390 2 O
standard	393 8 O
12	402 2 O
-	404 1 O
lead	405 4 O
ECG	410 3 O
,	413 1 O
for	415 3 O
detecting	419 9 O
dobutamine	429 10 B-Chemical
-	439 1 O
induced	440 7 O
myocardial	448 10 B-Disease
ischemia	459 8 I-Disease
,	467 1 O
using	469 5 O
Tc99m	475 5 B-Chemical
-	480 1 I-Chemical
Sestamibi	481 9 I-Chemical
single	491 6 O
-	497 1 O
photon	498 6 O
emission	505 8 O
computed	514 8 O
tomography	523 10 O
as	534 2 O
the	537 3 O
gold	541 4 O
standard	546 8 O
of	555 2 O
comparison	558 10 O
to	569 2 O
assess	572 6 O
the	579 3 O
presence	583 8 O
or	592 2 O
absence	595 7 O
of	603 2 O
ischemia	606 8 B-Disease
.	614 1 O

METHODS	616 7 O
:	623 1 O
The	625 3 O
study	629 5 O
group	635 5 O
comprised	641 9 O
40	651 2 O
patients	654 8 O
undergoing	663 10 O
Sestamibi	674 9 B-Chemical
-	683 1 O
SPECT	684 5 O
/	689 1 O
dobutamine	690 10 B-Chemical
stress	701 6 O
test	708 4 O
.	712 1 O

Simultaneous	714 12 O
measurements	727 12 O
of	740 2 O
ECG	743 3 O
and	747 3 O
brachial	751 8 O
artery	760 6 O
dP	767 2 O
/	769 1 O
dtejc	770 5 O
were	776 4 O
performed	781 9 O
at	791 2 O
each	794 4 O
dobutamine	799 10 B-Chemical
level	810 5 O
.	815 1 O

In	817 2 O
19	820 2 O
of	823 2 O
the	826 3 O
40	830 2 O
patients	833 8 O
perfusion	842 9 O
defects	852 7 O
compatible	860 10 O
with	871 4 O
ischemia	876 8 B-Disease
were	885 4 O
detected	890 8 O
on	899 2 O
SPECT	902 5 O
.	907 1 O

The	909 3 O
increase	913 8 O
in	922 2 O
dP	925 2 O
/	927 1 O
dtejc	928 5 O
during	934 6 O
infusion	941 8 O
of	950 2 O
dobutamine	953 10 B-Chemical
in	964 2 O
this	967 4 O
group	972 5 O
was	978 3 O
severely	982 8 O
impaired	991 8 O
as	1000 2 O
compared	1003 8 O
to	1012 2 O
the	1015 3 O
non	1019 3 O
-	1022 1 O
ischemic	1023 8 O
group	1032 5 O
.	1037 1 O

dP	1039 2 O
/	1041 1 O
dtejc	1042 5 O
outcome	1048 7 O
was	1056 3 O
combined	1060 8 O
with	1069 4 O
the	1074 3 O
ECG	1078 3 O
results	1082 7 O
,	1089 1 O
giving	1091 6 O
an	1098 2 O
ECG	1101 3 O
-	1104 1 O
enhanced	1105 8 O
value	1114 5 O
,	1119 1 O
and	1121 3 O
compared	1125 8 O
to	1134 2 O
ECG	1137 3 O
alone	1141 5 O
.	1146 1 O

RESULTS	1148 7 O
:	1155 1 O
The	1157 3 O
sensitivity	1161 11 O
improved	1173 8 O
dramatically	1182 12 O
from	1195 4 O
16	1200 2 O
%	1202 1 O
to	1204 2 O
79	1207 2 O
%	1209 1 O
,	1210 1 O
positive	1212 8 O
predictive	1221 10 O
value	1232 5 O
increased	1238 9 O
from	1248 4 O
60	1253 2 O
%	1255 1 O
to	1257 2 O
68	1260 2 O
%	1262 1 O
and	1264 3 O
negative	1268 8 O
predictive	1277 10 O
value	1288 5 O
from	1294 4 O
54	1299 2 O
%	1301 1 O
to	1303 2 O
78	1306 2 O
%	1308 1 O
,	1309 1 O
and	1311 3 O
specificity	1315 11 O
decreased	1327 9 O
from	1337 4 O
90	1342 2 O
%	1344 1 O
to	1346 2 O
67	1349 2 O
%	1351 1 O
.	1352 1 O

CONCLUSIONS	1354 11 O
:	1365 1 O
If	1367 2 O
ECG	1370 3 O
alone	1374 5 O
is	1380 2 O
used	1383 4 O
for	1388 3 O
specificity	1392 11 O
,	1403 1 O
the	1405 3 O
combination	1409 11 O
with	1421 4 O
dP	1426 2 O
/	1428 1 O
dtejc	1429 5 O
improved	1435 8 O
the	1444 3 O
sensitivity	1448 11 O
of	1460 2 O
the	1463 3 O
test	1467 4 O
and	1472 3 O
could	1476 5 O
be	1482 2 O
a	1485 1 O
cost	1487 4 O
-	1491 1 O
savings	1492 7 O
alternative	1500 11 O
to	1512 2 O
cardiac	1515 7 O
imaging	1523 7 O
or	1531 2 O
perfusion	1534 9 O
studies	1544 7 O
to	1552 2 O
detect	1555 6 O
myocardial	1562 10 B-Disease
ischemia	1573 8 I-Disease
,	1581 1 O
especially	1583 10 O
in	1594 2 O
patients	1597 8 O
unable	1606 6 O
to	1613 2 O
exercise	1616 8 O
.	1624 1 O

Acute	0 5 B-Disease
liver	6 5 I-Disease
failure	12 7 I-Disease
in	20 2 O
two	23 3 O
patients	27 8 O
with	36 4 O
regular	41 7 O
alcohol	49 7 B-Chemical
consumption	57 11 O
ingesting	69 9 O
paracetamol	79 11 B-Chemical
at	91 2 O
therapeutic	94 11 O
dosage	106 6 O
.	112 1 O

BACKGROUND	114 10 O
:	124 1 O
The	126 3 O
possible	130 8 O
role	139 4 O
of	144 2 O
alcohol	147 7 B-Chemical
in	155 2 O
the	158 3 O
development	162 11 O
of	174 2 O
hepatotoxicity	177 14 B-Disease
associated	192 10 O
with	203 4 O
therapeutic	208 11 O
doses	220 5 O
of	226 2 O
paracetamol	229 11 B-Chemical
(	241 1 O
acetaminophen	242 13 B-Chemical
)	255 1 O
is	257 2 O
currently	260 9 O
debated	270 7 O
.	277 1 O

CASE	279 4 O
REPORT	284 6 O
:	290 1 O
We	292 2 O
describe	295 8 O
2	304 1 O
patients	306 8 O
who	315 3 O
were	319 4 O
regular	324 7 O
consumers	332 9 O
of	342 2 O
alcohol	345 7 B-Chemical
and	353 3 O
who	357 3 O
developed	361 9 O
liver	371 5 B-Disease
failure	377 7 I-Disease
within	385 6 O
3	392 1 O
-	393 1 O
5	394 1 O
days	396 4 O
after	401 5 O
hospitalization	407 15 O
and	423 3 O
stopping	427 8 O
alcohol	436 7 B-Chemical
consumption	444 11 O
while	456 5 O
being	462 5 O
treated	468 7 O
with	476 4 O
4	481 1 O
g	483 1 O
paracetamol	485 11 B-Chemical
/	496 1 O
day	497 3 O
.	500 1 O

A	502 1 O
paracetamol	504 11 B-Chemical
serum	516 5 O
level	522 5 O
obtained	528 8 O
in	537 2 O
one	540 3 O
of	544 2 O
these	547 5 O
patients	553 8 O
was	562 3 O
not	566 3 O
in	570 2 O
the	573 3 O
toxic	577 5 O
range	583 5 O
.	588 1 O

Possible	590 8 O
risk	599 4 O
factors	604 7 O
for	612 3 O
the	616 3 O
development	620 11 O
of	632 2 O
hepatotoxicity	635 14 B-Disease
in	650 2 O
patients	653 8 O
treated	662 7 O
with	670 4 O
therapeutic	675 11 O
doses	687 5 O
of	693 2 O
paracetamol	696 11 B-Chemical
are	708 3 O
discussed	712 9 O
.	721 1 O

CONCLUSION	723 10 O
:	733 1 O
In	735 2 O
patients	738 8 O
with	747 4 O
risk	752 4 O
factors	757 7 O
,	764 1 O
e	766 1 O
.	767 1 O
g	768 1 O
.	769 1 O
regular	771 7 O
consumption	779 11 O
of	791 2 O
alcohol	794 7 B-Chemical
,	801 1 O
liver	803 5 B-Disease
failure	809 7 I-Disease
is	817 2 O
possible	820 8 O
when	829 4 O
therapeutic	834 11 O
doses	846 5 O
are	852 3 O
ingested	856 8 O
.	864 1 O

We	866 2 O
propose	869 7 O
that	877 4 O
the	882 3 O
paracetamol	886 11 B-Chemical
dose	898 4 O
should	903 6 O
not	910 3 O
exceed	914 6 O
2	921 1 O
g	923 1 O
/	924 1 O
day	925 3 O
in	929 2 O
such	932 4 O
patients	937 8 O
and	946 3 O
that	950 4 O
their	955 5 O
liver	961 5 O
function	967 8 O
should	976 6 O
be	983 2 O
monitored	986 9 O
closely	996 7 O
while	1004 5 O
being	1010 5 O
treated	1016 7 O
with	1024 4 O
paracetamol	1029 11 B-Chemical
.	1040 1 O

Cocaine	0 7 B-Chemical
related	8 7 O
chest	16 5 B-Disease
pain	22 4 I-Disease
:	26 1 O
are	28 3 O
we	32 2 O
seeing	35 6 O
the	42 3 O
tip	46 3 O
of	50 2 O
an	53 2 O
iceberg	56 7 O
?	63 1 O

The	65 3 O
recreational	69 12 O
use	82 3 O
of	86 2 O
cocaine	89 7 B-Chemical
is	97 2 O
on	100 2 O
the	103 3 O
increase	107 8 O
.	115 1 O

The	117 3 O
emergency	121 9 O
nurse	131 5 O
ought	137 5 O
to	143 2 O
be	146 2 O
familiar	149 8 O
with	158 4 O
some	163 4 O
of	168 2 O
the	171 3 O
cardiovascular	175 14 O
consequences	190 12 O
of	203 2 O
cocaine	206 7 B-Chemical
use	214 3 O
.	217 1 O

In	219 2 O
particular	222 10 O
,	232 1 O
the	234 3 O
tendency	238 8 O
of	247 2 O
cocaine	250 7 B-Chemical
to	258 2 O
produce	261 7 O
chest	269 5 B-Disease
pain	275 4 I-Disease
ought	280 5 O
to	286 2 O
be	289 2 O
in	292 2 O
the	295 3 O
mind	299 4 O
of	304 2 O
the	307 3 O
emergency	311 9 O
nurse	321 5 O
when	327 4 O
faced	332 5 O
with	338 4 O
a	343 1 O
young	345 5 O
victim	351 6 O
of	358 2 O
chest	361 5 B-Disease
pain	367 4 I-Disease
who	372 3 O
is	376 2 O
otherwise	379 9 O
at	389 2 O
low	392 3 O
risk	396 4 O
.	400 1 O

The	402 3 O
mechanism	406 9 O
of	416 2 O
chest	419 5 B-Disease
pain	425 4 I-Disease
related	430 7 O
to	438 2 O
cocaine	441 7 B-Chemical
use	449 3 O
is	453 2 O
discussed	456 9 O
and	466 3 O
treatment	470 9 O
dilemmas	480 8 O
are	489 3 O
discussed	493 9 O
.	502 1 O

Finally	504 7 O
,	511 1 O
moral	513 5 O
issues	519 6 O
relating	526 8 O
to	535 2 O
the	538 3 O
testing	542 7 O
of	550 2 O
potential	553 9 O
cocaine	563 7 B-Chemical
users	571 5 O
will	577 4 O
be	582 2 O
addressed	585 9 O
.	594 1 O

Severe	0 6 O
rhabdomyolysis	7 14 B-Disease
and	22 3 O
acute	26 5 B-Disease
renal	32 5 I-Disease
failure	38 7 I-Disease
secondary	46 9 O
to	56 2 O
concomitant	59 11 O
use	71 3 O
of	75 2 O
simvastatin	78 11 B-Chemical
,	89 1 O
amiodarone	91 10 B-Chemical
,	101 1 O
and	103 3 O
atazanavir	107 10 B-Chemical
.	117 1 O

OBJECTIVE	119 9 O
:	128 1 O
To	130 2 O
report	133 6 O
a	140 1 O
case	142 4 O
of	147 2 O
a	150 1 O
severe	152 6 O
interaction	159 11 O
between	171 7 O
simvastatin	179 11 B-Chemical
,	190 1 O
amiodarone	192 10 B-Chemical
,	202 1 O
and	204 3 O
atazanavir	208 10 B-Chemical
resulting	219 9 O
in	229 2 O
rhabdomyolysis	232 14 B-Disease
and	247 3 O
acute	251 5 B-Disease
renal	257 5 I-Disease
failure	263 7 I-Disease
.	270 1 O

BACKGROUND	272 10 O
:	282 1 O
A	284 1 O
72	286 2 O
-	288 1 O
year	289 4 O
-	293 1 O
old	294 3 O
white	298 5 O
man	304 3 O
with	308 4 O
underlying	313 10 O
human	324 5 B-Disease
immunodeficiency	330 16 I-Disease
virus	347 5 I-Disease
,	352 1 O
atrial	354 6 B-Disease
fibrillation	361 12 I-Disease
,	373 1 O
coronary	375 8 B-Disease
artery	384 6 I-Disease
disease	391 7 I-Disease
,	398 1 O
and	400 3 O
hyperlipidemia	404 14 B-Disease
presented	419 9 O
with	429 4 O
generalized	434 11 O
pain	446 4 B-Disease
,	450 1 O
fatigue	452 7 B-Disease
,	459 1 O
and	461 3 O
dark	465 4 O
orange	470 6 O
urine	477 5 O
for	483 3 O
3	487 1 O
days	489 4 O
.	493 1 O

The	495 3 O
patient	499 7 O
was	507 3 O
taking	511 6 O
80	518 2 O
mg	521 2 O
simvastatin	524 11 B-Chemical
at	536 2 O
bedtime	539 7 O
(	547 1 O
initiated	548 9 O
27	558 2 O
days	561 4 O
earlier	566 7 O
)	573 1 O
;	574 1 O
amiodarone	576 10 B-Chemical
at	587 2 O
a	590 1 O
dose	592 4 O
of	597 2 O
400	600 3 O
mg	604 2 O
daily	607 5 O
for	613 3 O
7	617 1 O
days	619 4 O
,	623 1 O
then	625 4 O
200	630 3 O
mg	634 2 O
daily	637 5 O
(	643 1 O
initiated	644 9 O
19	654 2 O
days	657 4 O
earlier	662 7 O
)	669 1 O
;	670 1 O
and	672 3 O
400	676 3 O
mg	680 2 O
atazanavir	683 10 B-Chemical
daily	694 5 O
(	700 1 O
initiated	701 9 O
at	711 2 O
least	714 5 O
2	720 1 O
years	722 5 O
previously	728 10 O
)	738 1 O
.	739 1 O

Laboratory	741 10 O
evaluation	752 10 O
revealed	763 8 O
66	772 2 O
,	774 1 O
680	775 3 O
U	779 1 O
/	780 1 O
L	781 1 O
creatine	783 8 B-Chemical
kinase	792 6 O
,	798 1 O
93	800 2 O
mg	803 2 O
/	805 1 O
dL	806 2 O
blood	809 5 B-Chemical
urea	815 4 I-Chemical
nitrogen	820 8 I-Chemical
,	828 1 O
4	830 1 O
.	831 1 O
6	832 1 O
mg	834 2 O
/	836 1 O
dL	837 2 O
creatinine	840 10 B-Chemical
,	850 1 O
1579	852 4 O
U	857 1 O
/	858 1 O
L	859 1 O
aspartate	861 9 B-Chemical
aminotransferase	871 16 O
,	887 1 O
and	889 3 O
738	893 3 O
U	897 1 O
/	898 1 O
L	899 1 O
alanine	901 7 B-Chemical
aminotransferase	909 16 O
.	925 1 O

Simvastatin	927 11 B-Chemical
,	938 1 O
amiodarone	940 10 B-Chemical
,	950 1 O
and	952 3 O
the	956 3 O
patient	960 7 O
'	967 1 O
s	968 1 O
human	970 5 B-Disease
immunodeficiency	976 16 I-Disease
virus	993 5 I-Disease
medications	999 11 O
were	1011 4 O
all	1016 3 O
temporarily	1020 11 O
discontinued	1032 12 O
and	1045 3 O
the	1049 3 O
patient	1053 7 O
was	1061 3 O
given	1065 5 O
forced	1071 6 O
alkaline	1078 8 O
diuresis	1087 8 O
and	1096 3 O
started	1100 7 O
on	1108 2 O
dialysis	1111 8 O
.	1119 1 O

Nine	1121 4 O
days	1126 4 O
later	1131 5 O
the	1137 3 O
patient	1141 7 O
'	1148 1 O
s	1149 1 O
creatine	1151 8 B-Chemical
kinase	1160 6 O
had	1167 3 O
dropped	1171 7 O
to	1179 2 O
1695	1182 4 O
U	1187 1 O
/	1188 1 O
L	1189 1 O
and	1191 3 O
creatinine	1195 10 B-Chemical
was	1206 3 O
3	1210 1 O
.	1211 1 O
3	1212 1 O
mg	1214 2 O
/	1216 1 O
dL	1217 2 O
.	1219 1 O

The	1221 3 O
patient	1225 7 O
was	1233 3 O
discharged	1237 10 O
and	1248 3 O
continued	1252 9 O
outpatient	1262 10 O
dialysis	1273 8 O
for	1282 3 O
1	1286 1 O
month	1288 5 O
until	1294 5 O
his	1300 3 O
renal	1304 5 O
function	1310 8 O
recovered	1319 9 O
.	1328 1 O

DISCUSSION	1330 10 O
:	1340 1 O
The	1342 3 O
risk	1346 4 O
of	1351 2 O
rhabdomyolysis	1354 14 B-Disease
is	1369 2 O
increased	1372 9 O
in	1382 2 O
the	1385 3 O
presence	1389 8 O
of	1398 2 O
concomitant	1401 11 O
drugs	1413 5 O
that	1419 4 O
inhibit	1424 7 O
simvastatin	1432 11 B-Chemical
metabolism	1444 10 O
.	1454 1 O

Simvastatin	1456 11 B-Chemical
is	1468 2 O
metabolized	1471 11 O
by	1483 2 O
CYP3A4	1486 6 O
.	1492 1 O

Amiodarone	1494 10 B-Chemical
and	1505 3 O
atazanavir	1509 10 B-Chemical
are	1520 3 O
recognized	1524 10 O
CYP3A4	1535 6 O
inhibitors	1542 10 O
.	1552 1 O

CONCLUSIONS	1554 11 O
:	1565 1 O
Pharmacokinetic	1567 15 O
differences	1583 11 O
in	1595 2 O
statins	1598 7 B-Chemical
are	1606 3 O
an	1610 2 O
important	1613 9 O
consideration	1623 13 O
for	1637 3 O
assessing	1641 9 O
the	1651 3 O
risk	1655 4 O
of	1660 2 O
potential	1663 9 O
drug	1673 4 O
interactions	1678 12 O
.	1690 1 O

In	1692 2 O
patients	1695 8 O
requiring	1704 9 O
the	1714 3 O
concurrent	1718 10 O
use	1729 3 O
of	1733 2 O
statins	1736 7 B-Chemical
and	1744 3 O
CYP3A4	1748 6 O
inhibitors	1755 10 O
,	1765 1 O
pravastatin	1767 11 B-Chemical
,	1778 1 O
fluvastatin	1780 11 B-Chemical
,	1791 1 O
and	1793 3 O
rosuvastatin	1797 12 B-Chemical
carry	1810 5 O
the	1816 3 O
lowest	1820 6 O
risk	1827 4 O
of	1832 2 O
drug	1835 4 O
interactions	1840 12 O
;	1852 1 O
atorvastatin	1854 12 B-Chemical
carries	1867 7 O
moderate	1875 8 O
risk	1884 4 O
,	1888 1 O
whereas	1890 7 O
simvastatin	1898 11 B-Chemical
and	1910 3 O
lovastatin	1914 10 B-Chemical
have	1925 4 O
the	1930 3 O
highest	1934 7 O
risk	1942 4 O
and	1947 3 O
should	1951 6 O
be	1958 2 O
avoided	1961 7 O
in	1969 2 O
patients	1972 8 O
taking	1981 6 O
concomitant	1988 11 O
CYP3A4	2000 6 O
inhibitors	2007 10 O
.	2017 1 O

Phase	0 5 O
II	6 2 O
trial	9 5 O
of	15 2 O
vinorelbine	18 11 B-Chemical
in	30 2 O
metastatic	33 10 O
squamous	44 8 B-Disease
cell	53 4 I-Disease
esophageal	58 10 I-Disease
carcinoma	69 9 I-Disease
.	78 1 O

European	80 8 O
Organization	89 12 O
for	102 3 O
Research	106 8 O
and	115 3 O
Treatment	119 9 O
of	129 2 O
Cancer	132 6 B-Disease
Gastrointestinal	139 16 O
Treat	156 5 O
Cancer	162 6 B-Disease
Cooperative	169 11 O
Group	181 5 O
.	186 1 O

PURPOSE	188 7 O
:	195 1 O
To	197 2 O
evaluate	200 8 O
the	209 3 O
response	213 8 O
rate	222 4 O
and	227 3 O
toxic	231 5 O
effects	237 7 O
of	245 2 O
vinorelbine	248 11 B-Chemical
(	260 1 O
VNB	261 3 B-Chemical
)	264 1 O
administered	266 12 O
as	279 2 O
a	282 1 O
single	284 6 O
agent	291 5 O
in	297 2 O
metastatic	300 10 O
squamous	311 8 B-Disease
cell	320 4 I-Disease
esophageal	325 10 I-Disease
carcinoma	336 9 I-Disease
.	345 1 O

PATIENTS	347 8 O
AND	356 3 O
METHODS	360 7 O
:	367 1 O
Forty	369 5 O
-	374 1 O
six	375 3 O
eligible	379 8 O
patients	388 8 O
with	397 4 O
measurable	402 10 O
lesions	413 7 O
were	421 4 O
included	426 8 O
and	435 3 O
were	439 4 O
stratified	444 10 O
according	455 9 O
to	465 2 O
previous	468 8 O
chemotherapy	477 12 O
.	489 1 O

Thirty	491 6 O
patients	498 8 O
without	507 7 O
prior	515 5 O
chemotherapy	521 12 O
and	534 3 O
16	538 2 O
pretreated	541 10 O
with	552 4 O
cisplatin	557 9 B-Chemical
-	566 1 O
based	567 5 O
chemotherapy	573 12 O
were	586 4 O
assessable	591 10 O
for	602 3 O
toxicity	606 8 B-Disease
and	615 3 O
response	619 8 O
.	627 1 O

VNB	629 3 B-Chemical
was	633 3 O
administered	637 12 O
weekly	650 6 O
as	657 2 O
a	660 1 O
25	662 2 O
-	664 1 O
mg	665 2 O
/	667 1 O
m2	668 2 O
short	671 5 O
intravenous	677 11 O
(	689 1 O
i	690 1 O
.	691 1 O
v	692 1 O
.	693 1 O
)	694 1 O
infusion	696 8 O
.	704 1 O

RESULTS	706 7 O
:	713 1 O
Six	715 3 O
of	719 2 O
30	722 2 O
patients	725 8 O
(	734 1 O
20	735 2 O
%	737 1 O
)	738 1 O
without	740 7 O
prior	748 5 O
chemotherapy	754 12 O
achieved	767 8 O
a	776 1 O
partial	778 7 O
response	786 8 O
(	795 1 O
PR	796 2 O
)	798 1 O
(	800 1 O
95	801 2 O
%	803 1 O
confidence	805 10 O
interval	816 8 O
[	825 1 O
CI	826 2 O
]	828 1 O
,	829 1 O
8	831 1 O
%	832 1 O
to	834 2 O
39	837 2 O
%	839 1 O
)	840 1 O
.	841 1 O

The	843 3 O
median	847 6 O
duration	854 8 O
of	863 2 O
response	866 8 O
was	875 3 O
21	879 2 O
weeks	882 5 O
(	888 1 O
range	889 5 O
,	894 1 O
17	896 2 O
to	899 2 O
28	902 2 O
)	904 1 O
.	905 1 O

One	907 3 O
of	911 2 O
16	914 2 O
patients	917 8 O
(	926 1 O
6	927 1 O
%	928 1 O
)	929 1 O
with	931 4 O
prior	936 5 O
chemotherapy	942 12 O
had	955 3 O
a	959 1 O
complete	961 8 O
response	970 8 O
(	979 1 O
CR	980 2 O
)	982 1 O
of	984 2 O
31	987 2 O
weeks	990 5 O
'	995 1 O
duration	997 8 O
(	1006 1 O
95	1007 2 O
%	1009 1 O
CI	1011 2 O
,	1013 1 O
0	1015 1 O
%	1016 1 O
to	1018 2 O
30	1021 2 O
%	1023 1 O
)	1024 1 O
.	1025 1 O

The	1027 3 O
overall	1031 7 O
response	1039 8 O
rate	1048 4 O
(	1053 1 O
World	1054 5 O
Health	1060 6 O
Organization	1067 12 O
[	1080 1 O
WHO	1081 3 O
]	1084 1 O
criteria	1086 8 O
)	1094 1 O
was	1096 3 O
15	1100 2 O
%	1102 1 O
(	1104 1 O
CR	1105 2 O
,	1107 1 O
2	1109 1 O
%	1110 1 O
;	1111 1 O
PR	1113 2 O
13	1116 2 O
%	1118 1 O
;	1119 1 O
95	1121 2 O
%	1123 1 O
CI	1125 2 O
,	1127 1 O
6	1129 1 O
%	1130 1 O
to	1132 2 O
29	1135 2 O
%	1137 1 O
)	1138 1 O
.	1139 1 O

The	1141 3 O
median	1145 6 O
dose	1152 4 O
-	1156 1 O
intensity	1157 9 O
(	1167 1 O
DI	1168 2 O
)	1170 1 O
was	1172 3 O
20	1176 2 O
mg	1179 2 O
/	1181 1 O
m2	1182 2 O
/	1184 1 O
wk	1185 2 O
.	1187 1 O

VNB	1189 3 B-Chemical
was	1193 3 O
well	1197 4 O
tolerated	1202 9 O
and	1212 3 O
zero	1216 4 O
instances	1221 9 O
of	1231 2 O
WHO	1234 3 O
grade	1238 5 O
4	1244 1 O
nonhematologic	1246 14 O
toxicity	1261 8 B-Disease
occurred	1270 8 O
.	1278 1 O

At	1280 2 O
least	1283 5 O
one	1289 3 O
episode	1293 7 O
of	1301 2 O
grade	1304 5 O
3	1310 1 O
or	1312 2 O
4	1315 1 O
granulocytopenia	1317 16 B-Disease
was	1334 3 O
seen	1338 4 O
in	1343 2 O
59	1346 2 O
%	1348 1 O
of	1350 2 O
patients	1353 8 O
.	1361 1 O

A	1363 1 O
grade	1365 5 O
2	1371 1 O
or	1373 2 O
3	1376 1 O
infection	1378 9 B-Disease
occurred	1388 8 O
in	1397 2 O
16	1400 2 O
%	1402 1 O
of	1404 2 O
patients	1407 8 O
,	1415 1 O
but	1417 3 O
no	1421 2 O
toxic	1424 5 O
deaths	1430 6 B-Disease
occurred	1437 8 O
.	1445 1 O

Other	1447 5 O
side	1453 4 O
effects	1458 7 O
were	1466 4 O
rare	1471 4 O
,	1475 1 O
and	1477 3 O
peripheral	1481 10 B-Disease
neurotoxicity	1492 13 I-Disease
has	1506 3 O
been	1510 4 O
minor	1515 5 O
(	1521 1 O
26	1522 2 O
%	1524 1 O
grade	1526 5 O
1	1532 1 O
)	1533 1 O
.	1534 1 O

CONCLUSION	1536 10 O
:	1546 1 O
These	1548 5 O
data	1554 4 O
indicate	1559 8 O
that	1568 4 O
VNB	1573 3 B-Chemical
is	1577 2 O
an	1580 2 O
active	1583 6 O
agent	1590 5 O
in	1596 2 O
metastatic	1599 10 O
esophageal	1610 10 B-Disease
squamous	1621 8 I-Disease
cell	1630 4 I-Disease
carcinoma	1635 9 I-Disease
.	1644 1 O

Given	1646 5 O
its	1652 3 O
excellent	1656 9 O
tolerance	1666 9 O
profile	1676 7 O
and	1684 3 O
low	1688 3 O
toxicity	1692 8 B-Disease
,	1700 1 O
further	1702 7 O
evaluation	1710 10 O
of	1721 2 O
VNB	1724 3 B-Chemical
in	1728 2 O
combination	1731 11 O
therapy	1743 7 O
is	1751 2 O
warranted	1754 9 O
.	1763 1 O

Paclitaxel	0 10 B-Chemical
,	10 1 O
cisplatin	12 9 B-Chemical
,	21 1 O
and	23 3 O
gemcitabine	27 11 B-Chemical
combination	39 11 O
chemotherapy	51 12 O
within	64 6 O
a	71 1 O
multidisciplinary	73 17 O
therapeutic	91 11 O
approach	103 8 O
in	112 2 O
metastatic	115 10 O
nonsmall	126 8 B-Disease
cell	135 4 I-Disease
lung	140 4 I-Disease
carcinoma	145 9 I-Disease
.	154 1 O

BACKGROUND	156 10 O
:	166 1 O
Cisplatin	168 9 B-Chemical
-	177 1 O
based	178 5 O
chemotherapy	184 12 O
combinations	197 12 O
improve	210 7 O
quality	218 7 O
of	226 2 O
life	229 4 O
and	234 3 O
survival	238 8 O
in	247 2 O
advanced	250 8 O
nonsmall	259 8 B-Disease
cell	268 4 I-Disease
lung	273 4 I-Disease
carcinoma	278 9 I-Disease
(	288 1 O
NSCLC	289 5 B-Disease
)	294 1 O
.	295 1 O

The	297 3 O
emergence	301 9 O
of	311 2 O
new	314 3 O
active	318 6 O
drugs	325 5 O
might	331 5 O
translate	337 9 O
into	347 4 O
more	352 4 O
effective	357 9 O
regimens	367 8 O
for	376 3 O
the	380 3 O
treatment	384 9 O
of	394 2 O
this	397 4 O
disease	402 7 O
.	409 1 O

METHODS	411 7 O
:	418 1 O
The	420 3 O
objective	424 9 O
of	434 2 O
this	437 4 O
study	442 5 O
was	448 3 O
to	452 2 O
determine	455 9 O
the	465 3 O
feasibility	469 11 O
,	480 1 O
response	482 8 O
rate	491 4 O
,	495 1 O
and	497 3 O
toxicity	501 8 B-Disease
of	510 2 O
a	513 1 O
paclitaxel	515 10 B-Chemical
,	525 1 O
cisplatin	527 9 B-Chemical
,	536 1 O
and	538 3 O
gemcitabine	542 11 B-Chemical
combination	554 11 O
to	566 2 O
treat	569 5 O
metastatic	575 10 O
NSCLC	586 5 B-Disease
.	591 1 O

Thirty	593 6 O
-	599 1 O
five	600 4 O
consecutive	605 11 O
chemotherapy	617 12 O
-	629 1 O
naive	630 5 O
patients	636 8 O
with	645 4 O
Stage	650 5 O
IV	656 2 O
NSCLC	659 5 B-Disease
and	665 3 O
an	669 2 O
Eastern	672 7 O
Cooperative	680 11 O
Oncology	692 8 O
Group	701 5 O
performance	707 11 O
status	719 6 O
of	726 2 O
0	729 1 O
-	730 1 O
2	731 1 O
were	733 4 O
treated	738 7 O
with	746 4 O
a	751 1 O
combination	753 11 O
of	765 2 O
paclitaxel	768 10 B-Chemical
(	779 1 O
135	780 3 O
mg	784 2 O
/	786 1 O
m	787 1 O
(	788 1 O
2	789 1 O
)	790 1 O
given	792 5 O
intravenously	798 13 O
in	812 2 O
3	815 1 O
hours	817 5 O
)	822 1 O
on	824 2 O
Day	827 3 O
1	831 1 O
,	832 1 O
cisplatin	834 9 B-Chemical
(	844 1 O
120	845 3 O
mg	849 2 O
/	851 1 O
m	852 1 O
(	853 1 O
2	854 1 O
)	855 1 O
given	857 5 O
intravenously	863 13 O
in	877 2 O
6	880 1 O
hours	882 5 O
)	887 1 O
on	889 2 O
Day	892 3 O
1	896 1 O
,	897 1 O
and	899 3 O
gemcitabine	903 11 B-Chemical
(	915 1 O
800	916 3 O
mg	920 2 O
/	922 1 O
m	923 1 O
(	924 1 O
2	925 1 O
)	926 1 O
given	928 5 O
intravenously	934 13 O
in	948 2 O
30	951 2 O
minutes	954 7 O
)	961 1 O
on	963 2 O
Days	966 4 O
1	971 1 O
and	973 3 O
8	977 1 O
,	978 1 O
every	980 5 O
4	986 1 O
weeks	988 5 O
.	993 1 O

Although	995 8 O
responding	1004 10 O
patients	1015 8 O
were	1024 4 O
scheduled	1029 9 O
to	1039 2 O
receive	1042 7 O
consolidation	1050 13 O
radiotherapy	1064 12 O
and	1077 3 O
24	1081 2 O
patients	1084 8 O
received	1093 8 O
preplanned	1102 10 O
second	1113 6 O
-	1119 1 O
line	1120 4 O
chemotherapy	1125 12 O
after	1138 5 O
disease	1144 7 O
progression	1152 11 O
,	1163 1 O
the	1165 3 O
response	1169 8 O
and	1178 3 O
toxicity	1182 8 B-Disease
rates	1191 5 O
reported	1197 8 O
refer	1206 5 O
only	1212 4 O
to	1217 2 O
the	1220 3 O
chemotherapy	1224 12 O
regimen	1237 7 O
given	1245 5 O
.	1250 1 O

RESULTS	1252 7 O
:	1259 1 O
All	1261 3 O
the	1265 3 O
patients	1269 8 O
were	1278 4 O
examined	1283 8 O
for	1292 3 O
toxicity	1296 8 B-Disease
;	1304 1 O
34	1306 2 O
were	1309 4 O
examinable	1314 10 O
for	1325 3 O
response	1329 8 O
.	1337 1 O

An	1339 2 O
objective	1342 9 O
response	1352 8 O
was	1361 3 O
observed	1365 8 O
in	1374 2 O
73	1377 2 O
.	1379 1 O
5	1380 1 O
%	1381 1 O
of	1383 2 O
the	1386 3 O
patients	1390 8 O
(	1399 1 O
95	1400 2 O
%	1402 1 O
confidence	1404 10 O
interval	1415 8 O
[	1424 1 O
CI	1425 2 O
]	1427 1 O
,	1428 1 O
55	1430 2 O
.	1432 1 O
6	1433 1 O
-	1434 1 O
87	1435 2 O
.	1437 1 O
1	1438 1 O
%	1439 1 O
)	1440 1 O
,	1441 1 O
including	1443 9 O
4	1453 1 O
complete	1455 8 O
responses	1464 9 O
(	1474 1 O
11	1475 2 O
.	1477 1 O
7	1478 1 O
%	1479 1 O
)	1480 1 O
.	1481 1 O

According	1483 9 O
to	1493 2 O
intention	1496 9 O
-	1505 1 O
to	1506 2 O
-	1508 1 O
treat	1509 5 O
,	1514 1 O
the	1516 3 O
overall	1520 7 O
response	1528 8 O
rate	1537 4 O
was	1542 3 O
71	1546 2 O
.	1548 1 O
4	1549 1 O
%	1550 1 O
(	1552 1 O
95	1553 2 O
%	1555 1 O
CI	1557 2 O
,	1559 1 O
53	1561 2 O
.	1563 1 O
7	1565 1 O
-	1566 1 O
85	1567 2 O
.	1569 1 O
4	1570 1 O
%	1571 1 O
)	1572 1 O
.	1573 1 O

After	1575 5 O
154	1581 3 O
courses	1585 7 O
of	1593 2 O
therapy	1596 7 O
,	1603 1 O
the	1605 3 O
median	1609 6 O
dose	1616 4 O
intensity	1621 9 O
was	1631 3 O
131	1635 3 O
mg	1639 2 O
/	1641 1 O
m	1642 1 O
(	1643 1 O
2	1644 1 O
)	1645 1 O
for	1647 3 O
paclitaxel	1651 10 B-Chemical
(	1662 1 O
97	1663 2 O
.	1665 1 O
3	1666 1 O
%	1667 1 O
)	1668 1 O
,	1669 1 O
117	1671 3 O
mg	1675 2 O
/	1677 1 O
m	1678 1 O
(	1679 1 O
2	1680 1 O
)	1681 1 O
for	1683 3 O
cisplatin	1687 9 B-Chemical
(	1697 1 O
97	1698 2 O
.	1700 1 O
3	1701 1 O
%	1702 1 O
)	1703 1 O
,	1704 1 O
and	1706 3 O
1378	1710 4 O
mg	1715 2 O
/	1717 1 O
m	1718 1 O
(	1719 1 O
2	1720 1 O
)	1721 1 O
for	1723 3 O
gemcitabine	1727 11 B-Chemical
(	1739 1 O
86	1740 2 O
.	1742 1 O
2	1743 1 O
%	1744 1 O
)	1745 1 O
.	1746 1 O

World	1748 5 O
Health	1754 6 O
Organization	1761 12 O
Grade	1774 5 O
3	1780 1 O
-	1781 1 O
4	1782 1 O
neutropenia	1784 11 B-Disease
and	1796 3 O
thrombocytopenia	1800 16 B-Disease
occurred	1817 8 O
in	1826 2 O
39	1829 2 O
.	1831 1 O
9	1832 1 O
%	1833 1 O
and	1835 3 O
11	1839 2 O
.	1841 1 O
4	1842 1 O
%	1843 1 O
of	1845 2 O
patients	1848 8 O
,	1856 1 O
respectively	1858 12 O
.	1870 1 O

There	1872 5 O
was	1878 3 O
one	1882 3 O
treatment	1886 9 O
-	1895 1 O
related	1896 7 O
death	1904 5 B-Disease
.	1909 1 O

Nonhematologic	1911 14 O
toxicities	1926 10 B-Disease
were	1937 4 O
mild	1942 4 O
.	1946 1 O

After	1948 5 O
a	1954 1 O
median	1956 6 O
follow	1963 6 O
-	1969 1 O
up	1970 2 O
of	1973 2 O
22	1976 2 O
months	1979 6 O
,	1985 1 O
the	1987 3 O
median	1991 6 O
progression	1998 11 O
free	2010 4 O
survival	2015 8 O
rate	2024 4 O
was	2029 3 O
7	2033 1 O
months	2035 6 O
,	2041 1 O
and	2043 3 O
the	2047 3 O
median	2051 6 O
survival	2058 8 O
time	2067 4 O
was	2072 3 O
16	2076 2 O
months	2079 6 O
.	2085 1 O

CONCLUSIONS	2087 11 O
:	2098 1 O
The	2100 3 O
combination	2104 11 O
of	2116 2 O
paclitaxel	2119 10 B-Chemical
,	2129 1 O
cisplatin	2131 9 B-Chemical
,	2140 1 O
and	2142 3 O
gemcitabine	2146 11 B-Chemical
is	2158 2 O
well	2161 4 O
tolerated	2166 9 O
and	2176 3 O
shows	2180 5 O
high	2186 4 O
activity	2191 8 O
in	2200 2 O
metastatic	2203 10 O
NSCLC	2214 5 B-Disease
.	2219 1 O

This	2221 4 O
treatment	2226 9 O
merits	2236 6 O
further	2243 7 O
comparison	2251 10 O
with	2262 4 O
other	2267 5 O
cisplatin	2273 9 B-Chemical
-	2282 1 O
based	2283 5 O
regimens	2289 8 O
.	2297 1 O

Evaluation	0 10 O
of	11 2 O
adverse	14 7 O
reactions	22 9 O
of	32 2 O
aponidine	35 9 B-Chemical
hydrochloride	45 13 I-Chemical
ophthalmic	59 10 O
solution	70 8 O
.	78 1 O

We	80 2 O
prospectively	83 13 O
evaluated	97 9 O
the	107 3 O
adverse	111 7 O
reactions	119 9 O
of	129 2 O
apraclonidine	132 13 B-Chemical
in	146 2 O
20	149 2 O
normal	152 6 O
volunteers	159 10 O
by	170 2 O
instilling	173 10 O
a	184 1 O
single	186 6 O
drop	193 4 O
of	198 2 O
1	201 1 O
%	202 1 O
apraclonidine	204 13 B-Chemical
in	218 2 O
their	221 5 O
right	227 5 O
eyes	233 4 O
.	237 1 O

Examinations	239 12 O
,	251 1 O
including	253 9 O
blood	263 5 O
pressure	269 8 O
,	277 1 O
pulse	279 5 O
rate	285 4 O
,	289 1 O
conjunctiva	291 11 O
and	303 3 O
cornea	307 6 O
,	313 1 O
intraocular	315 11 O
pressure	327 8 O
(	336 1 O
IOP	337 3 O
)	340 1 O
,	341 1 O
pupil	343 5 O
diameter	349 8 O
,	357 1 O
basal	359 5 O
tear	365 4 O
secretion	370 9 O
and	380 3 O
margin	384 6 O
reflex	391 6 O
distance	398 8 O
of	407 2 O
both	410 4 O
upper	415 5 O
and	421 3 O
lower	425 5 O
eyelids	431 7 O
,	438 1 O
were	440 4 O
performed	445 9 O
prior	455 5 O
to	461 2 O
entry	464 5 O
and	470 3 O
at	474 2 O
1	477 1 O
,	478 1 O
3	480 1 O
,	481 1 O
5	483 1 O
and	485 3 O
7	489 1 O
hours	491 5 O
after	497 5 O
instillation	503 12 O
.	515 1 O

The	517 3 O
ocular	521 6 B-Disease
hypotensive	528 11 I-Disease
effects	540 7 O
were	548 4 O
statistically	553 13 O
significant	567 11 O
for	579 3 O
apraclonidine	583 13 B-Chemical
-	596 1 O
treated	597 7 O
eyes	605 4 O
throughout	610 10 O
the	621 3 O
study	625 5 O
and	631 3 O
also	635 4 O
statistically	640 13 O
significant	654 11 O
for	666 3 O
contralateral	670 13 O
eyes	684 4 O
from	689 4 O
three	694 5 O
hours	700 5 O
after	706 5 O
topical	712 7 O
administration	720 14 O
of	735 2 O
1	738 1 O
%	739 1 O
apraclonidine	741 13 B-Chemical
.	754 1 O

Decreases	756 9 B-Disease
in	766 2 I-Disease
systolic	769 8 I-Disease
blood	778 5 I-Disease
pressure	784 8 I-Disease
were	793 4 O
statistically	798 13 O
,	811 1 O
but	813 3 O
not	817 3 O
clinically	821 10 O
,	831 1 O
significant	833 11 O
.	844 1 O

No	846 2 O
significant	849 11 O
changes	861 7 O
in	869 2 O
diastolic	872 9 O
blood	882 5 O
pressure	888 8 O
,	896 1 O
pulse	898 5 O
rate	904 4 O
and	909 3 O
basal	913 5 O
tear	919 4 O
secretion	924 9 O
were	934 4 O
noted	939 5 O
.	944 1 O

Conjunctival	946 12 B-Disease
blanching	959 9 I-Disease
and	969 3 O
mydriasis	973 9 B-Disease
were	983 4 O
commonly	988 8 O
found	997 5 O
.	1002 1 O

Upper	1004 5 O
lid	1010 3 O
retraction	1014 10 O
was	1025 3 O
frequently	1029 10 O
noted	1040 5 O
.	1045 1 O

While	1047 5 O
the	1053 3 O
elevations	1057 10 O
of	1068 2 O
the	1071 3 O
upper	1075 5 O
lid	1081 3 O
margin	1085 6 O
in	1092 2 O
most	1095 4 O
subjects	1100 8 O
were	1109 4 O
not	1114 3 O
more	1118 4 O
than	1123 4 O
2	1128 1 O
mm	1130 2 O
and	1133 3 O
did	1137 3 O
not	1141 3 O
cause	1145 5 O
noticeable	1151 10 O
change	1162 6 O
in	1169 2 O
appearance	1172 10 O
,	1182 1 O
one	1184 3 O
subject	1188 7 O
suffered	1196 8 O
from	1205 4 O
mechanical	1210 10 O
entropion	1221 9 B-Disease
and	1231 3 O
marked	1235 6 O
corneal	1242 7 B-Disease
abrasion	1250 8 I-Disease
3	1259 1 O
hours	1261 5 O
after	1267 5 O
instillation	1273 12 O
of	1286 2 O
the	1289 3 O
medication	1293 10 O
.	1303 1 O

This	1305 4 O
may	1310 3 O
well	1314 4 O
be	1319 2 O
a	1322 1 O
particularly	1324 12 O
notable	1337 7 O
finding	1345 7 O
in	1353 2 O
Asian	1356 5 O
people	1362 6 O
.	1368 1 O

Carmofur	0 8 B-Chemical
-	8 1 O
induced	9 7 O
organic	17 7 B-Disease
mental	25 6 I-Disease
disorders	32 9 I-Disease
.	41 1 O

Organic	43 7 B-Disease
mental	51 6 I-Disease
disorder	58 8 I-Disease
was	67 3 O
observed	71 8 O
in	80 2 O
a	83 1 O
29	85 2 O
-	87 1 O
year	88 4 O
-	92 1 O
old	93 3 O
female	97 6 O
in	104 2 O
the	107 3 O
prognostic	111 10 O
period	122 6 O
after	129 5 O
the	135 3 O
onset	139 5 O
of	145 2 O
carmofur	148 8 B-Chemical
-	156 1 O
induced	157 7 O
leukoencephalopathy	165 19 B-Disease
.	184 1 O

Symptoms	186 8 O
such	195 4 O
as	200 2 O
euphoria	203 8 O
,	211 1 O
emotional	213 9 O
lability	223 8 O
and	232 3 O
puerile	236 7 O
attitude	244 8 O
noted	253 5 O
in	259 2 O
the	262 3 O
patient	266 7 O
were	274 4 O
diagnosed	279 9 O
as	289 2 O
organic	292 7 B-Disease
personality	300 11 I-Disease
syndrome	312 8 I-Disease
according	321 9 O
to	331 2 O
the	334 3 O
criteria	338 8 O
defined	347 7 O
in	355 2 O
the	358 3 O
DSM	362 3 O
-	365 1 O
III	366 3 O
-	369 1 O
R	370 1 O
.	371 1 O

It	373 2 O
is	376 2 O
referred	379 8 O
to	388 2 O
as	391 2 O
a	394 1 O
frontal	396 7 B-Disease
lobe	404 4 I-Disease
syndrome	409 8 I-Disease
.	417 1 O

Brain	419 5 O
CT	425 2 O
revealed	428 8 O
a	437 1 O
periventricular	439 15 O
low	455 3 O
density	459 7 O
area	467 4 O
in	472 2 O
the	475 3 O
frontal	479 7 O
white	487 5 O
matter	493 6 O
and	500 3 O
moderate	504 8 O
dilatation	513 10 O
of	524 2 O
the	527 3 O
lateral	531 7 O
ventricles	539 10 O
especially	550 10 O
at	561 2 O
the	564 3 O
bilateral	568 9 O
anterior	578 8 O
horns	587 5 O
.	592 1 O

Consequently	594 12 O
,	606 1 O
carmofur	608 8 B-Chemical
-	616 1 O
induced	617 7 O
leukoencephalopathy	625 19 B-Disease
may	645 3 O
uncommonly	649 10 O
result	660 6 O
in	667 2 O
organic	670 7 B-Disease
personality	678 11 I-Disease
syndrome	690 8 I-Disease
in	699 2 O
the	702 3 O
residual	706 8 O
state	715 5 O
.	720 1 O

It	722 2 O
may	725 3 O
be	729 2 O
attributed	732 10 O
to	743 2 O
the	746 3 O
structural	750 10 B-Disease
damage	761 6 I-Disease
to	768 2 I-Disease
the	771 3 I-Disease
frontal	775 7 I-Disease
lobe	783 4 I-Disease
.	787 1 O

International	0 13 O
mexiletine	14 10 B-Chemical
and	25 3 O
placebo	29 7 O
antiarrhythmic	37 14 O
coronary	52 8 O
trial	61 5 O
:	66 1 O
I	68 1 O
.	69 1 O

Report	71 6 O
on	78 2 O
arrhythmia	81 10 B-Disease
and	92 3 O
other	96 5 O
findings	102 8 O
.	110 1 O

Impact	112 6 O
Research	119 8 O
Group	128 5 O
.	133 1 O

The	135 3 O
antiarrhythmic	139 14 O
effects	154 7 O
of	162 2 O
the	165 3 O
sustained	169 9 O
release	179 7 O
form	187 4 O
of	192 2 O
mexiletine	195 10 B-Chemical
(	206 1 O
Mexitil	207 7 B-Chemical
-	214 1 I-Chemical
Perlongets	215 10 I-Chemical
)	225 1 O
were	227 4 O
evaluated	232 9 O
in	242 2 O
a	245 1 O
double	247 6 O
-	253 1 O
blind	254 5 O
placebo	260 7 O
trial	268 5 O
in	274 2 O
630	277 3 O
patients	281 8 O
with	290 4 O
recent	295 6 O
documented	302 10 O
myocardial	313 10 B-Disease
infarction	324 10 I-Disease
.	334 1 O

The	336 3 O
primary	340 7 O
response	348 8 O
variable	357 8 O
was	366 3 O
based	370 5 O
on	376 2 O
central	379 7 O
reading	387 7 O
of	395 2 O
24	398 2 O
hour	401 4 O
ambulatory	406 10 O
electrocardiographic	417 20 O
recordings	438 10 O
and	449 3 O
was	453 3 O
defined	457 7 O
as	465 2 O
the	468 3 O
occurrence	472 10 O
of	483 2 O
30	486 2 O
or	489 2 O
more	492 4 O
single	497 6 O
premature	504 9 O
ventricular	514 11 O
complexes	526 9 O
in	536 2 O
any	539 3 O
two	543 3 O
consecutive	547 11 O
30	559 2 O
minute	562 6 O
blocks	569 6 O
or	576 2 O
one	579 3 O
or	583 2 O
more	586 4 O
runs	591 4 O
of	596 2 O
two	599 3 O
or	603 2 O
more	606 4 O
premature	611 9 O
ventricular	621 11 O
complexes	633 9 O
in	643 2 O
the	646 3 O
entire	650 6 O
24	657 2 O
hour	660 4 O
electrocardiographic	665 20 O
recording	686 9 O
.	695 1 O

Large	697 5 O
differences	703 11 O
,	714 1 O
regarded	716 8 O
as	725 2 O
statistically	728 13 O
significant	742 11 O
,	753 1 O
between	755 7 O
the	763 3 O
mexiletine	767 10 B-Chemical
and	778 3 O
placebo	782 7 O
groups	790 6 O
were	797 4 O
noted	802 5 O
in	808 2 O
that	811 4 O
end	816 3 O
point	820 5 O
at	826 2 O
months	829 6 O
1	836 1 O
and	838 3 O
4	842 1 O
,	843 1 O
but	845 3 O
only	849 4 O
trends	854 6 O
were	861 4 O
observed	866 8 O
at	875 2 O
month	878 5 O
12	884 2 O
.	886 1 O

These	888 5 O
differences	894 11 O
were	906 4 O
observed	911 8 O
even	920 4 O
though	925 6 O
the	932 3 O
serum	936 5 O
mexiletine	942 10 B-Chemical
levels	953 6 O
obtained	960 8 O
in	969 2 O
this	972 4 O
study	977 5 O
were	983 4 O
generally	988 9 O
lower	998 5 O
than	1004 4 O
those	1009 5 O
observed	1015 8 O
in	1024 2 O
studies	1027 7 O
that	1035 4 O
have	1040 4 O
used	1045 4 O
the	1050 3 O
regular	1054 7 O
form	1062 4 O
of	1067 2 O
the	1070 3 O
drug	1074 4 O
.	1078 1 O

There	1080 5 O
were	1086 4 O
more	1091 4 O
deaths	1096 6 B-Disease
in	1103 2 O
the	1106 3 O
mexiletine	1110 10 B-Chemical
group	1121 5 O
(	1127 1 O
7	1128 1 O
.	1129 1 O
6	1130 1 O
%	1131 1 O
)	1132 1 O
than	1134 4 O
in	1139 2 O
the	1142 3 O
placebo	1146 7 O
group	1154 5 O
(	1160 1 O
4	1161 1 O
.	1162 1 O
8	1163 1 O
%	1164 1 O
)	1165 1 O
;	1166 1 O
the	1168 3 O
difference	1172 10 O
was	1183 3 O
not	1187 3 O
statistically	1191 13 O
significant	1205 11 O
.	1216 1 O

The	1218 3 O
incidence	1222 9 O
of	1232 2 O
coronary	1235 8 O
events	1244 6 O
was	1251 3 O
similar	1255 7 O
in	1263 2 O
both	1266 4 O
groups	1271 6 O
.	1277 1 O

Previously	1279 10 O
recognized	1290 10 O
side	1301 4 O
effects	1306 7 O
,	1313 1 O
particularly	1315 12 O
tremor	1328 6 B-Disease
and	1335 3 O
gastrointestinal	1339 16 B-Disease
problems	1356 8 I-Disease
,	1364 1 O
were	1366 4 O
more	1371 4 O
frequent	1376 8 O
in	1385 2 O
the	1388 3 O
mexiletine	1392 10 B-Chemical
group	1403 5 O
than	1409 4 O
in	1414 2 O
the	1417 3 O
placebo	1421 7 O
group	1429 5 O
.	1434 1 O

Regional	0 8 O
localization	9 12 O
of	22 2 O
the	25 3 O
antagonism	29 10 O
of	40 2 O
amphetamine	43 11 B-Chemical
-	54 1 O
induced	55 7 O
hyperactivity	63 13 B-Disease
by	77 2 O
intracerebral	80 13 O
calcitonin	94 10 B-Chemical
injections	105 10 O
.	115 1 O

Calcitonin	117 10 B-Chemical
receptors	128 9 O
are	138 3 O
found	142 5 O
in	148 2 O
the	151 3 O
brain	155 5 O
,	160 1 O
and	162 3 O
intracerebral	166 13 O
infusions	180 9 O
of	190 2 O
calcitonin	193 10 B-Chemical
can	204 3 O
produce	208 7 O
behavioral	216 10 O
effects	227 7 O
.	234 1 O

Among	236 5 O
these	242 5 O
behavioral	248 10 O
effects	259 7 O
are	267 3 O
decreases	271 9 O
in	281 2 O
food	284 4 O
intake	289 6 O
and	296 3 O
decreases	300 9 O
in	310 2 O
amphetamine	313 11 B-Chemical
-	324 1 O
induced	325 7 O
locomotor	333 9 O
activity	343 8 O
.	351 1 O

In	353 2 O
previous	356 8 O
experiments	365 11 O
we	377 2 O
found	380 5 O
that	386 4 O
decreases	391 9 O
in	401 2 O
food	404 4 O
intake	409 6 O
were	416 4 O
induced	421 7 O
by	429 2 O
local	432 5 O
administration	438 14 O
of	453 2 O
calcitonin	456 10 B-Chemical
into	467 4 O
several	472 7 O
hypothalamic	480 12 O
sites	493 5 O
and	499 3 O
into	503 4 O
the	508 3 O
nucleus	512 7 O
accumbens	520 9 O
.	529 1 O

In	531 2 O
the	534 3 O
present	538 7 O
experiment	546 10 O
calcitonin	557 10 B-Chemical
decreased	568 9 O
locomotor	578 9 O
activity	588 8 O
when	597 4 O
locally	602 7 O
injected	610 8 O
into	619 4 O
the	624 3 O
same	628 4 O
sites	633 5 O
where	639 5 O
it	645 2 O
decreases	648 9 O
food	658 4 O
intake	663 6 O
.	669 1 O

The	671 3 O
areas	675 5 O
where	681 5 O
calcitonin	687 10 B-Chemical
is	698 2 O
most	701 4 O
effective	706 9 O
in	716 2 O
decreasing	719 10 O
locomotor	730 9 O
activity	740 8 O
are	749 3 O
located	753 7 O
in	761 2 O
the	764 3 O
hypothalamus	768 12 O
and	781 3 O
nucleus	785 7 O
accumbens	793 9 O
,	802 1 O
suggesting	804 10 O
that	815 4 O
these	820 5 O
areas	826 5 O
are	832 3 O
the	836 3 O
major	840 5 O
sites	846 5 O
of	852 2 O
action	855 6 O
of	862 2 O
calcitonin	865 10 B-Chemical
in	876 2 O
inhibiting	879 10 O
amphetamine	890 11 B-Chemical
-	901 1 O
induced	902 7 O
locomotor	910 9 O
activity	920 8 O
.	928 1 O

Fatal	0 5 O
intracranial	6 12 B-Disease
bleeding	19 8 I-Disease
associated	28 10 O
with	39 4 O
prehospital	44 11 O
use	56 3 O
of	60 2 O
epinephrine	63 11 B-Chemical
.	74 1 O

We	76 2 O
present	79 7 O
a	87 1 O
case	89 4 O
of	94 2 O
paramedic	97 9 O
misjudgment	107 11 O
in	119 2 O
the	122 3 O
execution	126 9 O
of	136 2 O
a	139 1 O
protocol	141 8 O
for	150 3 O
the	154 3 O
treatment	158 9 O
of	168 2 O
allergic	171 8 B-Disease
reaction	180 8 I-Disease
in	189 2 O
a	192 1 O
case	194 4 O
of	199 2 O
pulmonary	202 9 B-Disease
edema	212 5 I-Disease
with	218 4 O
wheezing	223 8 B-Disease
.	231 1 O

The	233 3 O
sudden	237 6 O
onset	244 5 O
of	250 2 O
respiratory	253 11 B-Disease
distress	265 8 I-Disease
,	273 1 O
rash	275 4 B-Disease
,	279 1 O
and	281 3 O
a	285 1 O
history	287 7 O
of	295 2 O
a	298 1 O
new	300 3 O
medicine	304 8 O
led	313 3 O
the	317 3 O
two	321 3 O
paramedics	325 10 O
on	336 2 O
the	339 3 O
scene	343 5 O
to	349 2 O
administer	352 10 O
subcutaneous	363 12 O
epinephrine	376 11 B-Chemical
.	387 1 O

Subsequently	389 12 O
,	401 1 O
acute	403 5 O
cardiac	409 7 B-Disease
arrest	417 6 I-Disease
and	424 3 O
fatal	428 5 O
subarachnoid	434 12 B-Disease
hemorrhage	447 10 I-Disease
occurred	458 8 O
.	466 1 O

Epinephrine	468 11 B-Chemical
has	480 3 O
a	484 1 O
proven	486 6 O
role	493 4 O
in	498 2 O
cardiac	501 7 B-Disease
arrest	509 6 I-Disease
in	516 2 O
prehospital	519 11 O
care	531 4 O
;	535 1 O
however	537 7 O
,	544 1 O
use	546 3 O
by	550 2 O
paramedics	553 10 O
in	564 2 O
patients	567 8 O
with	576 4 O
suspected	581 9 O
allergic	591 8 B-Disease
reaction	600 8 I-Disease
and	609 3 O
severe	613 6 O
hypertension	620 12 B-Disease
should	633 6 O
be	640 2 O
viewed	643 6 O
with	650 4 O
caution	655 7 O
.	662 1 O

A	0 1 O
case	2 4 O
of	7 2 O
massive	10 7 O
rhabdomyolysis	18 14 B-Disease
following	33 9 O
molindone	43 9 B-Chemical
administration	53 14 O
.	67 1 O

Rhabdomyolysis	69 14 B-Disease
is	84 2 O
a	87 1 O
potentially	89 11 O
lethal	101 6 O
syndrome	108 8 O
that	117 4 O
psychiatric	122 11 B-Disease
patients	134 8 O
seem	143 4 O
predisposed	148 11 O
to	160 2 O
develop	163 7 O
.	170 1 O

The	172 3 O
clinical	176 8 O
signs	185 5 O
and	191 3 O
symptoms	195 8 O
,	203 1 O
typical	205 7 O
laboratory	213 10 O
features	224 8 O
,	232 1 O
and	234 3 O
complications	238 13 O
of	252 2 O
rhabdomyolysis	255 14 B-Disease
are	270 3 O
presented	274 9 O
.	283 1 O

The	285 3 O
case	289 4 O
of	294 2 O
a	297 1 O
schizophrenic	299 13 B-Disease
patient	313 7 O
is	321 2 O
reported	324 8 O
to	333 2 O
illustrate	336 10 O
massive	347 7 O
rhabdomyolysis	355 14 B-Disease
and	370 3 O
subsequent	374 10 O
acute	385 5 B-Disease
renal	391 5 I-Disease
failure	397 7 I-Disease
following	405 9 O
molindone	415 9 B-Chemical
administration	425 14 O
.	439 1 O

Physicians	441 10 O
who	452 3 O
prescribe	456 9 O
molindone	466 9 B-Chemical
should	476 6 O
be	483 2 O
aware	486 5 O
of	492 2 O
this	495 4 O
reaction	500 8 O
.	508 1 O

Cardiovascular	0 14 B-Disease
alterations	15 11 I-Disease
in	27 2 O
rat	30 3 O
fetuses	34 7 O
exposed	42 7 O
to	50 2 O
calcium	53 7 B-Chemical
channel	61 7 O
blockers	69 8 O
.	77 1 O

Preclinical	79 11 O
toxicologic	91 11 O
investigation	103 13 O
suggested	117 9 O
that	127 4 O
a	132 1 O
new	134 3 O
calcium	138 7 B-Chemical
channel	146 7 O
blocker	154 7 O
,	161 1 O
Ro	163 2 B-Chemical
40	166 2 I-Chemical
-	168 1 I-Chemical
5967	169 4 I-Chemical
,	173 1 O
induced	175 7 O
cardiovascular	183 14 B-Disease
alterations	198 11 I-Disease
in	210 2 O
rat	213 3 O
fetuses	217 7 O
exposed	225 7 O
to	233 2 O
this	236 4 O
agent	241 5 O
during	247 6 O
organogenesis	254 13 O
.	267 1 O

The	269 3 O
present	273 7 O
study	281 5 O
was	287 3 O
designed	291 8 O
to	300 2 O
investigate	303 11 O
the	315 3 O
hypothesis	319 10 O
that	330 4 O
calcium	335 7 B-Chemical
channel	343 7 O
blockers	351 8 O
in	360 2 O
general	363 7 O
induce	371 6 O
cardiovascular	378 14 B-Disease
malformations	393 13 I-Disease
indicating	407 10 O
a	418 1 O
pharmacologic	420 13 O
class	434 5 O
effect	440 6 O
.	446 1 O

We	448 2 O
studied	451 7 O
three	459 5 O
calcium	465 7 B-Chemical
channel	473 7 O
blockers	481 8 O
of	490 2 O
different	493 9 O
structure	503 9 O
,	512 1 O
nifedipine	514 10 B-Chemical
,	524 1 O
diltiazem	526 9 B-Chemical
,	535 1 O
and	537 3 O
verapamil	541 9 B-Chemical
,	550 1 O
along	552 5 O
with	558 4 O
the	563 3 O
new	567 3 O
agent	571 5 O
.	576 1 O

Pregnant	578 8 O
rats	587 4 O
were	592 4 O
administered	597 12 O
one	610 3 O
of	614 2 O
these	617 5 O
calcium	623 7 B-Chemical
channel	631 7 O
blockers	639 8 O
during	648 6 O
the	655 3 O
period	659 6 O
of	666 2 O
cardiac	669 7 O
morphogenesis	677 13 O
and	691 3 O
the	695 3 O
offspring	699 9 O
examined	709 8 O
on	718 2 O
day	721 3 O
20	725 2 O
of	728 2 O
gestation	731 9 O
for	741 3 O
cardiovascular	745 14 B-Disease
malformations	760 13 I-Disease
.	773 1 O

A	775 1 O
low	777 3 O
incidence	781 9 O
of	791 2 O
cardiovascular	794 14 B-Disease
malformations	809 13 I-Disease
was	823 3 O
observed	827 8 O
after	836 5 O
exposure	842 8 O
to	851 2 O
each	854 4 O
of	859 2 O
the	862 3 O
four	866 4 O
calcium	871 7 B-Chemical
channel	879 7 O
blockers	887 8 O
,	895 1 O
but	897 3 O
this	901 4 O
incidence	906 9 O
was	916 3 O
statistically	920 13 O
significant	934 11 O
only	946 4 O
for	951 3 O
verapamil	955 9 B-Chemical
and	965 3 O
nifedipine	969 10 B-Chemical
.	979 1 O

All	981 3 O
four	985 4 O
agents	990 6 O
were	997 4 O
associated	1002 10 O
with	1013 4 O
aortic	1018 6 O
arch	1025 4 O
branching	1030 9 O
variants	1040 8 O
,	1048 1 O
although	1050 8 O
significantly	1059 13 O
increased	1073 9 O
only	1083 4 O
for	1088 3 O
Ro	1092 2 B-Chemical
40	1095 2 I-Chemical
-	1097 1 I-Chemical
5967	1098 4 I-Chemical
and	1103 3 O
verapamil	1107 9 B-Chemical
.	1116 1 O

Differential	0 12 O
impact	13 6 O
of	20 2 O
immune	23 6 O
escape	30 6 O
mutations	37 9 O
G145R	47 5 O
and	53 3 O
P120T	57 5 O
on	63 2 O
the	66 3 O
replication	70 11 O
of	82 2 O
lamivudine	85 10 B-Chemical
-	95 1 O
resistant	96 9 O
hepatitis	106 9 B-Chemical
B	116 1 I-Chemical
virus	118 5 I-Chemical
e	124 1 I-Chemical
antigen	126 7 I-Chemical
-	133 1 O
positive	134 8 O
and	143 3 O
-	147 1 O
negative	148 8 O
strains	157 7 O
.	164 1 O

Immune	166 6 O
escape	173 6 O
variants	180 8 O
of	189 2 O
the	192 3 O
hepatitis	196 9 B-Disease
B	206 1 I-Disease
virus	208 5 O
(	214 1 O
HBV	215 3 O
)	218 1 O
represent	220 9 O
an	230 2 O
emerging	233 8 O
clinical	242 8 O
challenge	251 9 O
,	260 1 O
because	262 7 O
they	270 4 O
can	275 3 O
be	279 2 O
associated	282 10 O
with	293 4 O
vaccine	298 7 O
escape	306 6 O
,	312 1 O
HBV	314 3 O
reactivation	318 12 O
,	330 1 O
and	332 3 O
failure	336 7 O
of	344 2 O
diagnostic	347 10 O
tests	358 5 O
.	363 1 O

Recent	365 6 O
data	372 4 O
suggest	377 7 O
a	385 1 O
preferential	387 12 O
selection	400 9 O
of	410 2 O
immune	413 6 O
escape	420 6 O
mutants	427 7 O
in	435 2 O
distinct	438 8 O
peripheral	447 10 O
blood	458 5 O
leukocyte	464 9 O
compartments	474 12 O
of	487 2 O
infected	490 8 O
individuals	499 11 O
.	510 1 O

We	512 2 O
therefore	515 9 O
systematically	525 14 O
analyzed	540 8 O
the	549 3 O
functional	553 10 O
impact	564 6 O
of	571 2 O
the	574 3 O
most	578 4 O
prevalent	583 9 O
immune	593 6 O
escape	600 6 O
variants	607 8 O
,	615 1 O
the	617 3 O
sG145R	621 6 O
and	628 3 O
sP120T	632 6 O
mutants	639 7 O
,	646 1 O
on	648 2 O
the	651 3 O
viral	655 5 O
replication	661 11 O
efficacy	673 8 O
and	682 3 O
antiviral	686 9 O
drug	696 4 O
susceptibility	701 14 O
of	716 2 O
common	719 6 O
treatment	726 9 O
-	735 1 O
associated	736 10 O
mutants	747 7 O
with	755 4 O
resistance	760 10 O
to	771 2 O
lamivudine	774 10 B-Chemical
(	785 1 O
LAM	786 3 B-Chemical
)	789 1 O
and	791 3 O
/	794 1 O
or	795 2 O
HBeAg	798 5 B-Chemical
negativity	804 10 O
.	814 1 O

Replication	816 11 O
-	827 1 O
competent	828 9 O
HBV	838 3 O
strains	842 7 O
with	850 4 O
sG145R	855 6 O
or	862 2 O
sP120T	865 6 O
and	872 3 O
LAM	876 3 B-Chemical
resistance	880 10 O
(	891 1 O
rtM204I	892 7 O
or	900 2 O
rtL180M	903 7 O
/	910 1 O
rtM204V	911 7 O
)	918 1 O
were	920 4 O
generated	925 9 O
on	935 2 O
an	938 2 O
HBeAg	941 5 B-Chemical
-	946 1 O
positive	947 8 O
and	956 3 O
an	960 2 O
HBeAg	963 5 B-Chemical
-	968 1 O
negative	969 8 O
background	978 10 O
with	989 4 O
precore	994 7 O
(	1002 1 O
PC	1003 2 O
)	1005 1 O
and	1007 3 O
basal	1011 5 O
core	1017 4 O
promoter	1022 8 O
(	1031 1 O
BCP	1032 3 O
)	1035 1 O
mutants	1037 7 O
.	1044 1 O

The	1046 3 O
sG145R	1050 6 O
mutation	1057 8 O
strongly	1066 8 O
reduced	1075 7 O
HBsAg	1083 5 B-Chemical
levels	1089 6 O
and	1096 3 O
was	1100 3 O
able	1104 4 O
to	1109 2 O
fully	1112 5 O
restore	1118 7 O
the	1126 3 O
impaired	1130 8 O
replication	1139 11 O
of	1151 2 O
LAM	1154 3 B-Chemical
-	1157 1 O
resistant	1158 9 O
HBV	1168 3 O
mutants	1172 7 O
to	1180 2 O
the	1183 3 O
levels	1187 6 O
of	1194 2 O
wild	1197 4 O
-	1201 1 O
type	1202 4 O
HBV	1207 3 O
,	1210 1 O
and	1212 3 O
PC	1216 2 O
or	1219 2 O
BCP	1222 3 O
mutations	1226 9 O
further	1236 7 O
enhanced	1244 8 O
viral	1253 5 O
replication	1259 11 O
.	1270 1 O

Although	1272 8 O
the	1281 3 O
sP120T	1285 6 O
substitution	1292 12 O
also	1305 4 O
impaired	1310 8 O
HBsAg	1319 5 B-Chemical
secretion	1325 9 O
,	1334 1 O
it	1336 2 O
did	1339 3 O
not	1343 3 O
enhance	1347 7 O
the	1355 3 O
replication	1359 11 O
of	1371 2 O
LAM	1374 3 B-Chemical
-	1377 1 O
resistant	1378 9 O
clones	1388 6 O
.	1394 1 O

However	1396 7 O
,	1403 1 O
the	1405 3 O
concomitant	1409 11 O
occurrence	1421 10 O
of	1432 2 O
HBeAg	1435 5 B-Chemical
negativity	1441 10 O
(	1452 1 O
PC	1453 2 O
/	1455 1 O
BCP	1456 3 O
)	1459 1 O
,	1460 1 O
sP120T	1462 6 O
,	1468 1 O
and	1470 3 O
LAM	1474 3 B-Chemical
resistance	1478 10 O
resulted	1489 8 O
in	1498 2 O
the	1501 3 O
restoration	1505 11 O
of	1517 2 O
replication	1520 11 O
to	1532 2 O
levels	1535 6 O
of	1542 2 O
wild	1545 4 O
-	1549 1 O
type	1550 4 O
HBV	1555 3 O
.	1558 1 O

In	1560 2 O
all	1563 3 O
clones	1567 6 O
with	1574 4 O
combined	1579 8 O
immune	1588 6 O
escape	1595 6 O
and	1602 3 O
LAM	1606 3 B-Chemical
resistance	1610 10 O
mutations	1621 9 O
,	1630 1 O
the	1632 3 O
nucleotide	1636 10 B-Chemical
analogues	1647 9 O
adefovir	1657 8 B-Chemical
and	1666 3 O
tenofovir	1670 9 B-Chemical
remained	1680 8 O
effective	1689 9 O
in	1699 2 O
suppressing	1702 11 O
viral	1714 5 O
replication	1720 11 O
in	1732 2 O
vitro	1735 5 O
.	1740 1 O

These	1742 5 O
findings	1748 8 O
reveal	1757 6 O
the	1764 3 O
differential	1768 12 O
impact	1781 6 O
of	1788 2 O
immune	1791 6 O
escape	1798 6 O
variants	1805 8 O
on	1814 2 O
the	1817 3 O
replication	1821 11 O
and	1833 3 O
drug	1837 4 O
susceptibility	1842 14 O
of	1857 2 O
complex	1860 7 O
HBV	1868 3 O
mutants	1872 7 O
,	1879 1 O
supporting	1881 10 O
the	1892 3 O
need	1896 4 O
of	1901 2 O
close	1904 5 O
surveillance	1910 12 O
and	1923 3 O
treatment	1927 9 O
adjustment	1937 10 O
in	1948 2 O
response	1951 8 O
to	1960 2 O
the	1963 3 O
selection	1967 9 O
of	1977 2 O
distinct	1980 8 O
mutational	1989 10 O
patterns	2000 8 O
.	2008 1 O

The	0 3 O
effects	4 7 O
of	12 2 O
sevoflurane	15 11 B-Chemical
on	27 2 O
lidocaine	30 9 B-Chemical
-	39 1 O
induced	40 7 O
convulsions	48 11 B-Disease
.	59 1 O

The	61 3 O
influence	65 9 O
of	75 2 O
sevoflurane	78 11 B-Chemical
on	90 2 O
lidocaine	93 9 B-Chemical
-	102 1 O
induced	103 7 O
convulsions	111 11 B-Disease
was	123 3 O
studied	127 7 O
in	135 2 O
cats	138 4 O
.	142 1 O

The	144 3 O
convulsive	148 10 B-Disease
threshold	159 9 O
(	169 1 O
mean	170 4 O
+	175 1 O
/	176 1 O
-	177 1 O
SD	179 2 O
)	181 1 O
was	183 3 O
41	187 2 O
.	189 1 O
4	190 1 O
+	192 1 O
/	193 1 O
-	194 1 O
6	196 1 O
.	197 1 O
5	198 1 O
mg	200 2 O
.	202 1 O

l	204 1 O
(	205 1 O
-	206 1 O
1	207 1 O
)	208 1 O
with	210 4 O
lidocaine	215 9 B-Chemical
infusion	225 8 O
(	234 1 O
6	235 1 O
mg	237 2 O
.	239 1 O
kg	240 2 O
(	242 1 O
-	243 1 O
1	244 1 O
)	245 1 O
.	246 1 O
min	247 3 O
(	250 1 O
-	251 1 O
1	252 1 O
)	253 1 O
)	254 1 O
,	255 1 O
increasing	257 10 O
significantly	268 13 O
to	282 2 O
66	285 2 O
.	287 1 O
6	288 1 O
+	290 1 O
/	291 1 O
-	292 1 O
10	294 2 O
.	296 1 O
9	297 1 O
mg	299 2 O
.	301 1 O

l	303 1 O
(	304 1 O
-	305 1 O
1	306 1 O
)	307 1 O
when	309 4 O
the	314 3 O
end	318 3 O
-	321 1 O
tidal	322 5 O
concentration	328 13 O
of	342 2 O
sevoflurane	345 11 B-Chemical
was	357 3 O
0	361 1 O
.	362 1 O
8	363 1 O
%	364 1 O
.	365 1 O

However	367 7 O
,	374 1 O
the	376 3 O
threshold	380 9 O
(	390 1 O
61	391 2 O
.	393 1 O
6	394 1 O
+	396 1 O
/	397 1 O
-	398 1 O
8	400 1 O
.	401 1 O
7	402 1 O
mg	404 2 O
.	406 1 O
l	408 1 O
(	409 1 O
-	410 1 O
1	411 1 O
)	412 1 O
)	413 1 O
during	415 6 O
1	422 1 O
.	423 1 O
6	424 1 O
%	425 1 O
sevoflurane	427 11 B-Chemical
was	439 3 O
not	443 3 O
significant	447 11 O
from	459 4 O
that	464 4 O
during	469 6 O
0	476 1 O
.	477 1 O
8	478 1 O
%	479 1 O
sevoflurane	481 11 B-Chemical
,	492 1 O
indicating	494 10 O
a	505 1 O
celling	507 7 O
effect	515 6 O
.	521 1 O

There	523 5 O
was	529 3 O
no	533 2 O
significant	536 11 O
difference	548 10 O
in	559 2 O
the	562 3 O
convulsive	566 10 B-Disease
threshold	577 9 O
between	587 7 O
sevoflurane	595 11 B-Chemical
and	607 3 O
enflurane	611 9 B-Chemical
.	620 1 O

The	622 3 O
rise	626 4 O
in	631 2 O
blood	634 5 O
pressure	640 8 O
became	649 6 O
less	656 4 O
marked	661 6 O
when	668 4 O
higher	673 6 O
concentrations	680 14 O
of	695 2 O
sevoflurane	698 11 B-Chemical
or	710 2 O
enflurane	713 9 B-Chemical
were	723 4 O
administered	728 12 O
and	741 3 O
the	745 3 O
blood	749 5 O
pressure	755 8 O
at	764 2 O
convulsions	767 11 B-Disease
decreased	779 9 O
significantly	789 13 O
in	803 2 O
1	806 1 O
.	807 1 O
6	808 1 O
%	809 1 O
sevoflurane	811 11 B-Chemical
,	822 1 O
and	824 3 O
in	828 2 O
0	831 1 O
.	832 1 O
8	833 1 O
%	834 1 O
and	836 3 O
1	840 1 O
.	841 1 O
6	842 1 O
%	843 1 O
enflurane	845 9 B-Chemical
.	854 1 O

However	856 7 O
,	863 1 O
there	865 5 O
was	871 3 O
no	875 2 O
significant	878 11 O
difference	890 10 O
in	901 2 O
the	904 3 O
lidocaine	908 9 B-Chemical
concentrations	918 14 O
measured	933 8 O
when	942 4 O
the	947 3 O
systolic	951 8 O
blood	960 5 O
pressure	966 8 O
became	975 6 O
70	982 2 O
mmHg	985 4 O
.	989 1 O

Apamin	991 6 B-Chemical
,	997 1 O
a	999 1 O
selective	1001 9 O
blocker	1011 7 O
of	1019 2 O
calcium	1022 7 B-Chemical
-	1029 1 O
dependent	1030 9 O
potassium	1040 9 B-Chemical
channels	1050 8 O
,	1058 1 O
was	1060 3 O
administered	1064 12 O
intracerebroventricularly	1077 25 O
in	1103 2 O
rats	1106 4 O
anesthetized	1111 12 O
with	1124 4 O
0	1129 1 O
.	1130 1 O
8	1131 1 O
%	1132 1 O
sevoflurane	1134 11 B-Chemical
to	1146 2 O
investigate	1149 11 O
the	1161 3 O
mechanism	1165 9 O
of	1175 2 O
the	1178 3 O
anticonvulsive	1182 14 O
effects	1197 7 O
.	1204 1 O

Apamin	1206 6 B-Chemical
(	1213 1 O
10	1214 2 O
ng	1217 2 O
)	1219 1 O
had	1221 3 O
a	1225 1 O
tendency	1227 8 O
to	1236 2 O
decrease	1239 8 O
the	1248 3 O
convulsive	1252 10 B-Disease
threshold	1263 9 O
(	1273 1 O
21	1274 2 O
.	1276 1 O
6	1277 1 O
+	1279 1 O
/	1280 1 O
-	1281 1 O
2	1283 1 O
.	1284 1 O
2	1285 1 O
to	1287 2 O
19	1290 2 O
.	1292 1 O
9	1293 1 O
+	1295 1 O
/	1296 1 O
-	1297 1 O
2	1299 1 O
.	1300 1 O
5	1301 1 O
mg	1303 2 O
.	1305 1 O
l	1307 1 O
(	1308 1 O
-	1309 1 O
1	1310 1 O
)	1311 1 O
)	1312 1 O
but	1314 3 O
this	1318 4 O
was	1323 3 O
not	1327 3 O
statistically	1331 13 O
significant	1345 11 O
.	1356 1 O

It	1358 2 O
is	1361 2 O
suggested	1364 9 O
that	1374 4 O
sevoflurane	1379 11 B-Chemical
reduces	1391 7 O
the	1399 3 O
convulsive	1403 10 B-Disease
effect	1414 6 O
of	1421 2 O
lidocaine	1424 9 B-Chemical
toxicity	1434 8 B-Disease
but	1443 3 O
carries	1447 7 O
some	1455 4 O
risk	1460 4 O
due	1465 3 O
to	1469 2 O
circulatory	1472 11 O
depression	1484 10 B-Disease
.	1494 1 O

Anti	0 4 O
-	4 1 O
oxidant	5 7 O
effects	13 7 O
of	21 2 O
atorvastatin	24 12 B-Chemical
in	37 2 O
dexamethasone	40 13 B-Chemical
-	53 1 O
induced	54 7 O
hypertension	62 12 B-Disease
in	75 2 O
the	78 3 O
rat	82 3 O
.	85 1 O

1	87 1 O
.	88 1 O

Dexamethasone	90 13 B-Chemical
(	104 1 O
Dex	105 3 B-Chemical
)	108 1 O
-	109 1 O
induced	110 7 O
hypertension	118 12 B-Disease
is	131 2 O
characterized	134 13 O
by	148 2 O
endothelial	151 11 O
dysfunction	163 11 O
associated	175 10 O
with	186 4 O
nitric	191 6 B-Chemical
oxide	198 5 I-Chemical
(	204 1 O
NO	205 2 B-Chemical
)	207 1 O
deficiency	209 10 O
and	220 3 O
increased	224 9 O
superoxide	234 10 B-Chemical
(	245 1 O
O2	246 2 B-Chemical
-	248 1 I-Chemical
)	249 1 O
production	251 10 O
.	261 1 O

Atorvastatin	263 12 B-Chemical
(	276 1 O
Ato	277 3 B-Chemical
)	280 1 O
possesses	282 9 O
pleiotropic	292 11 O
properties	304 10 O
that	315 4 O
have	320 4 O
been	325 4 O
reported	330 8 O
to	339 2 O
improve	342 7 O
endothelial	350 11 O
function	362 8 O
through	371 7 O
increased	379 9 O
availability	389 12 O
of	402 2 O
NO	405 2 B-Chemical
and	408 3 O
reduced	412 7 O
O2	420 2 B-Chemical
-	422 1 I-Chemical
production	424 10 O
in	435 2 O
various	438 7 O
forms	446 5 O
of	452 2 O
hypertension	455 12 B-Disease
.	467 1 O

In	469 2 O
the	472 3 O
present	476 7 O
study	484 5 O
,	489 1 O
we	491 2 O
investigated	494 12 O
whether	507 7 O
50	515 2 O
mg	518 2 O
/	520 1 O
kg	521 2 O
per	524 3 O
day	528 3 O
,	531 1 O
p	533 1 O
.	534 1 O
o	535 1 O
.	536 1 O
,	537 1 O
Ato	539 3 B-Chemical
could	543 5 O
prevent	549 7 O
endothelial	557 11 O
NO	569 2 B-Chemical
synthase	572 8 O
(	581 1 O
eNOS	582 4 O
)	586 1 O
downregulation	588 14 O
and	603 3 O
the	607 3 O
increase	611 8 O
in	620 2 O
O2	623 2 B-Chemical
-	625 1 I-Chemical
in	627 2 O
Sprague	630 7 O
-	637 1 O
Dawley	638 6 O
(	645 1 O
SD	646 2 O
)	648 1 O
rats	650 4 O
,	654 1 O
thereby	656 7 O
reducing	664 8 O
blood	673 5 O
pressure	679 8 O
.	687 1 O

2	689 1 O
.	690 1 O

Male	692 4 O
SD	697 2 O
rats	700 4 O
(	705 1 O
n	706 1 O
=	708 1 O
30	710 2 O
)	712 1 O
were	714 4 O
treated	719 7 O
with	727 4 O
Ato	732 3 B-Chemical
(	736 1 O
50	737 2 O
mg	740 2 O
/	742 1 O
kg	743 2 O
per	746 3 O
day	750 3 O
in	754 2 O
drinking	757 8 O
water	766 5 O
)	771 1 O
or	773 2 O
tap	776 3 O
water	780 5 O
for	786 3 O
15	790 2 O
days	793 4 O
.	797 1 O

Dexamethasone	799 13 B-Chemical
(	813 1 O
10	814 2 O
microg	817 6 O
/	823 1 O
kg	824 2 O
per	827 3 O
day	831 3 O
,	834 1 O
s	836 1 O
.	837 1 O
c	838 1 O
.	839 1 O
)	840 1 O
or	842 2 O
saline	845 6 O
was	852 3 O
started	856 7 O
after	864 5 O
4	870 1 O
days	872 4 O
in	877 2 O
Ato	880 3 B-Chemical
-	883 1 O
treated	884 7 O
and	892 3 O
non	896 3 O
-	899 1 O
treated	900 7 O
rats	908 4 O
and	913 3 O
continued	917 9 O
for	927 3 O
11	931 2 O
-	933 1 O
13	934 2 O
days	937 4 O
.	941 1 O

Systolic	943 8 O
blood	952 5 O
pressure	958 8 O
(	967 1 O
SBP	968 3 O
)	971 1 O
was	973 3 O
measured	977 8 O
on	986 2 O
alternate	989 9 O
days	999 4 O
using	1004 5 O
the	1010 3 O
tail	1014 4 O
-	1018 1 O
cuff	1019 4 O
method	1024 6 O
.	1030 1 O

Endothelial	1032 11 O
function	1044 8 O
was	1053 3 O
assessed	1057 8 O
by	1066 2 O
acetylcholine	1069 13 B-Chemical
-	1082 1 O
induced	1083 7 O
vasorelaxation	1091 14 O
and	1106 3 O
phenylephrine	1110 13 B-Chemical
-	1123 1 O
induced	1124 7 O
vasoconstriction	1132 16 O
in	1149 2 O
aortic	1152 6 O
segments	1159 8 O
.	1167 1 O

Vascular	1169 8 O
eNOS	1178 4 O
mRNA	1183 4 O
was	1188 3 O
assessed	1192 8 O
by	1201 2 O
semi	1204 4 O
-	1208 1 O
quantitative	1209 12 O
reverse	1222 7 O
transcription	1230 13 O
-	1243 1 O
polymerase	1244 10 O
chain	1255 5 O
reaction	1261 8 O
.	1269 1 O

3	1271 1 O
.	1272 1 O

In	1274 2 O
rats	1277 4 O
treated	1282 7 O
with	1290 4 O
Dex	1295 3 B-Chemical
alone	1299 5 O
,	1304 1 O
SBP	1306 3 O
was	1310 3 O
increased	1314 9 O
from	1324 4 O
109	1329 3 O
+	1333 1 O
/	1334 1 O
-	1335 1 O
2	1337 1 O
to	1339 2 O
133	1342 3 O
+	1346 1 O
/	1347 1 O
-	1348 1 O
2	1350 1 O
mmHg	1352 4 O
on	1357 2 O
Days	1360 4 O
4	1365 1 O
and	1367 3 O
Day	1371 3 O
14	1375 2 O
,	1377 1 O
respectively	1379 12 O
(	1392 1 O
P	1393 1 O
<	1395 1 O
0	1397 1 O
.	1398 1 O
001	1399 3 O
)	1402 1 O
.	1403 1 O

In	1405 2 O
the	1408 3 O
Ato	1412 3 B-Chemical
+	1416 1 O
Dex	1418 3 B-Chemical
group	1422 5 O
,	1427 1 O
SBP	1429 3 O
was	1433 3 O
increased	1437 9 O
from	1447 4 O
113	1452 3 O
+	1456 1 O
/	1457 1 O
-	1458 1 O
2	1460 1 O
to	1462 2 O
119	1465 3 O
+	1469 1 O
/	1470 1 O
-	1471 1 O
2	1473 1 O
mmHg	1475 4 O
on	1480 2 O
Days	1483 4 O
4	1488 1 O
to	1490 2 O
14	1493 2 O
,	1495 1 O
respectively	1497 12 O
(	1510 1 O
P	1511 1 O
<	1513 1 O
0	1515 1 O
.	1516 1 O
001	1517 3 O
)	1520 1 O
,	1521 1 O
but	1523 3 O
was	1527 3 O
significantly	1531 13 O
lower	1545 5 O
than	1551 4 O
SBP	1556 3 O
in	1560 2 O
the	1563 3 O
group	1567 5 O
treated	1573 7 O
with	1581 4 O
Dex	1586 3 B-Chemical
alone	1590 5 O
(	1596 1 O
P	1597 1 O
<	1599 1 O
0	1601 1 O
.	1602 1 O
05	1603 2 O
)	1605 1 O
.	1606 1 O

Endothelial	1608 11 O
-	1619 1 O
dependent	1620 9 O
relaxation	1630 10 O
and	1641 3 O
eNOS	1645 4 O
mRNA	1650 4 O
expression	1655 10 O
were	1666 4 O
greater	1671 7 O
in	1679 2 O
the	1682 3 O
Dex	1686 3 B-Chemical
+	1690 1 O
Ato	1692 3 B-Chemical
group	1696 5 O
than	1702 4 O
in	1707 2 O
the	1710 3 O
Dex	1714 3 B-Chemical
only	1718 4 O
group	1723 5 O
(	1729 1 O
P	1730 1 O
<	1732 1 O
0	1734 1 O
.	1735 1 O
05	1736 2 O
and	1739 3 O
P	1743 1 O
<	1745 1 O
0	1747 1 O
.	1748 1 O
0001	1749 4 O
,	1753 1 O
respectively	1755 12 O
)	1767 1 O
.	1768 1 O

Aortic	1770 6 O
superoxide	1777 10 B-Chemical
production	1788 10 O
was	1799 3 O
lower	1803 5 O
in	1809 2 O
the	1812 3 O
Dex	1816 3 B-Chemical
+	1820 1 O
Ato	1822 3 B-Chemical
group	1826 5 O
compared	1832 8 O
with	1841 4 O
the	1846 3 O
group	1850 5 O
treated	1856 7 O
with	1864 4 O
Dex	1869 3 B-Chemical
alone	1873 5 O
(	1879 1 O
P	1880 1 O
<	1882 1 O
0	1884 1 O
.	1885 1 O
0001	1886 4 O
)	1890 1 O
.	1891 1 O

4	1893 1 O
.	1894 1 O

Treatment	1896 9 O
with	1906 4 O
Ato	1911 3 B-Chemical
improved	1915 8 O
endothelial	1924 11 O
function	1936 8 O
,	1944 1 O
reduced	1946 7 O
superoxide	1954 10 B-Chemical
production	1965 10 O
and	1976 3 O
reduced	1980 7 O
SBP	1988 3 O
in	1992 2 O
Dex	1995 3 B-Chemical
-	1998 1 O
treated	1999 7 O
SD	2007 2 O
rats	2010 4 O
.	2014 1 O

99mTc	0 5 B-Chemical
-	5 1 I-Chemical
glucarate	6 9 I-Chemical
for	16 3 O
detection	20 9 O
of	30 2 O
isoproterenol	33 13 B-Chemical
-	46 1 O
induced	47 7 O
myocardial	55 10 B-Disease
infarction	66 10 I-Disease
in	77 2 O
rats	80 4 O
.	84 1 O

Infarct	86 7 B-Disease
-	93 1 O
avid	94 4 O
radiopharmaceuticals	99 20 O
are	120 3 O
necessary	124 9 O
for	134 3 O
rapid	138 5 O
and	144 3 O
timely	148 6 O
diagnosis	155 9 O
of	165 2 O
acute	168 5 O
myocardial	174 10 B-Disease
infarction	185 10 I-Disease
.	195 1 O

The	197 3 O
animal	201 6 O
model	208 5 O
used	214 4 O
to	219 2 O
produce	222 7 O
infarction	230 10 B-Disease
implies	241 7 O
artery	249 6 O
ligation	256 8 O
but	265 3 O
chemical	269 8 O
induction	278 9 O
can	288 3 O
be	292 2 O
easily	295 6 O
obtained	302 8 O
with	311 4 O
isoproterenol	316 13 B-Chemical
.	329 1 O

A	331 1 O
new	333 3 O
infarct	337 7 B-Disease
-	344 1 O
avid	345 4 O
radiopharmaceutical	350 19 O
based	370 5 O
on	376 2 O
glucaric	379 8 B-Chemical
acid	388 4 I-Chemical
was	393 3 O
prepared	397 8 O
in	406 2 O
the	409 3 O
hospital	413 8 O
radiopharmacy	422 13 O
of	436 2 O
the	439 3 O
INCMNSZ	443 7 O
.	450 1 O

99mTc	452 5 B-Chemical
-	457 1 I-Chemical
glucarate	458 9 I-Chemical
was	468 3 O
easy	472 4 O
to	477 2 O
prepare	480 7 O
,	487 1 O
stable	489 6 O
for	496 3 O
96	500 2 O
h	503 1 O
and	505 3 O
was	509 3 O
used	513 4 O
to	518 2 O
study	521 5 O
its	527 3 O
biodistribution	531 15 O
in	547 2 O
rats	550 4 O
with	555 4 O
isoproterenol	560 13 B-Chemical
-	573 1 O
induced	574 7 O
acute	582 5 O
myocardial	588 10 B-Disease
infarction	599 10 I-Disease
.	609 1 O

Histological	611 12 O
studies	624 7 O
demonstrated	632 12 O
that	645 4 O
the	650 3 O
rats	654 4 O
developed	659 9 O
an	669 2 O
infarct	672 7 B-Disease
18	680 2 O
h	683 1 O
after	685 5 O
isoproterenol	691 13 B-Chemical
administration	705 14 O
.	719 1 O

The	721 3 O
rat	725 3 O
biodistribution	729 15 O
studies	745 7 O
showed	753 6 O
a	760 1 O
rapid	762 5 O
blood	768 5 O
clearance	774 9 O
via	784 3 O
the	788 3 O
kidneys	792 7 O
.	799 1 O

Thirty	801 6 O
minutes	808 7 O
after	816 5 O
99mTc	822 5 B-Chemical
-	827 1 I-Chemical
glucarate	828 9 I-Chemical
administration	838 14 O
the	853 3 O
standardised	857 12 O
heart	870 5 O
uptake	876 6 O
value	883 5 O
S	889 1 O
(	890 1 O
h	891 1 O
)	892 1 O
UV	893 2 O
was	896 3 O
4	900 1 O
.	901 1 O
7	902 1 O
in	904 2 O
infarcted	907 9 O
rat	917 3 O
heart	921 5 O
which	927 5 O
is	933 2 O
six	936 3 O
times	940 5 O
more	946 4 O
than	951 4 O
in	956 2 O
normal	959 6 O
rats	966 4 O
.	970 1 O

ROIs	972 4 O
drawn	977 5 O
over	983 4 O
the	988 3 O
gamma	992 5 O
camera	998 6 O
images	1005 6 O
showed	1012 6 O
a	1019 1 O
ratio	1021 5 O
of	1027 2 O
4	1030 1 O
.	1031 1 O
4	1032 1 O
.	1033 1 O

The	1035 3 O
high	1039 4 O
image	1044 5 O
quality	1050 7 O
suggests	1058 8 O
that	1067 4 O
high	1072 4 O
contrast	1077 8 O
images	1086 6 O
can	1093 3 O
be	1097 2 O
obtained	1100 8 O
in	1109 2 O
humans	1112 6 O
and	1119 3 O
the	1123 3 O
96	1127 2 O
h	1130 1 O
stability	1132 9 O
makes	1142 5 O
it	1148 2 O
an	1151 2 O
ideal	1154 5 O
agent	1160 5 O
to	1166 2 O
detect	1169 6 O
,	1175 1 O
in	1177 2 O
patients	1180 8 O
,	1188 1 O
early	1190 5 O
cardiac	1196 7 B-Disease
infarction	1204 10 I-Disease
.	1214 1 O

A	0 1 O
randomized	2 10 O
,	12 1 O
placebo	14 7 O
-	21 1 O
controlled	22 10 O
dose	33 4 O
-	37 1 O
comparison	38 10 O
trial	49 5 O
of	55 2 O
haloperidol	58 11 B-Chemical
for	70 3 O
psychosis	74 9 B-Disease
and	84 3 O
disruptive	88 10 B-Disease
behaviors	99 9 I-Disease
in	109 2 O
Alzheimer	112 9 B-Disease
'	121 1 I-Disease
s	122 1 I-Disease
disease	124 7 I-Disease
.	131 1 O

OBJECTIVE	133 9 O
:	142 1 O
The	144 3 O
goal	148 4 O
of	153 2 O
this	156 4 O
study	161 5 O
was	167 3 O
to	171 2 O
compare	174 7 O
the	182 3 O
efficacy	186 8 O
and	195 3 O
side	199 4 O
effects	204 7 O
of	212 2 O
two	215 3 O
doses	219 5 O
of	225 2 O
haloperidol	228 11 B-Chemical
and	240 3 O
placebo	244 7 O
in	252 2 O
the	255 3 O
treatment	259 9 O
of	269 2 O
psychosis	272 9 B-Disease
and	282 3 O
disruptive	286 10 B-Disease
behaviors	297 9 I-Disease
in	307 2 O
patients	310 8 O
with	319 4 O
Alzheimer	324 9 B-Disease
'	333 1 I-Disease
s	334 1 I-Disease
disease	336 7 I-Disease
.	343 1 O

METHOD	345 6 O
:	351 1 O
In	353 2 O
a	356 1 O
6	358 1 O
-	359 1 O
week	360 4 O
random	365 6 O
-	371 1 O
assignment	372 10 O
,	382 1 O
double	384 6 O
-	390 1 O
blind	391 5 O
,	396 1 O
placebo	398 7 O
-	405 1 O
controlled	406 10 O
trial	417 5 O
(	423 1 O
phase	424 5 O
A	430 1 O
)	431 1 O
,	432 1 O
haloperidol	434 11 B-Chemical
,	445 1 O
2	447 1 O
-	448 1 O
3	449 1 O
mg	451 2 O
/	453 1 O
day	454 3 O
(	458 1 O
standard	459 8 O
dose	468 4 O
)	472 1 O
,	473 1 O
and	475 3 O
haloperidol	479 11 B-Chemical
,	490 1 O
0	492 1 O
.	493 1 O
50	494 2 O
-	496 1 O
0	497 1 O
.	498 1 O
75	499 2 O
mg	502 2 O
/	504 1 O
day	505 3 O
(	509 1 O
low	510 3 O
dose	514 4 O
)	518 1 O
,	519 1 O
were	521 4 O
compared	526 8 O
in	535 2 O
71	538 2 O
outpatients	541 11 O
with	553 4 O
Alzheimer	558 9 B-Disease
'	567 1 I-Disease
s	568 1 I-Disease
disease	570 7 I-Disease
.	577 1 O

For	579 3 O
the	583 3 O
subsequent	587 10 O
6	598 1 O
-	599 1 O
week	600 4 O
double	605 6 O
-	611 1 O
blind	612 5 O
crossover	618 9 O
phase	628 5 O
(	634 1 O
phase	635 5 O
B	641 1 O
)	642 1 O
,	643 1 O
patients	645 8 O
taking	654 6 O
standard	661 8 O
-	669 1 O
or	671 2 O
low	674 3 O
-	677 1 O
dose	678 4 O
haloperidol	683 11 B-Chemical
were	695 4 O
switched	700 8 O
to	709 2 O
placebo	712 7 O
,	719 1 O
and	721 3 O
patients	725 8 O
taking	734 6 O
placebo	741 7 O
were	749 4 O
randomly	754 8 O
assigned	763 8 O
to	772 2 O
standard	775 8 O
-	783 1 O
or	785 2 O
low	788 3 O
-	791 1 O
dose	792 4 O
haloperidol	797 11 B-Chemical
.	808 1 O

RESULTS	810 7 O
:	817 1 O
For	819 3 O
the	823 3 O
60	827 2 O
patients	830 8 O
who	839 3 O
completed	843 9 O
phase	853 5 O
A	859 1 O
,	860 1 O
standard	862 8 O
-	870 1 O
dose	871 4 O
haloperidol	876 11 B-Chemical
was	888 3 O
efficacious	892 11 O
and	904 3 O
superior	908 8 O
to	917 2 O
both	920 4 O
low	925 3 O
-	928 1 O
dose	929 4 O
haloperidol	934 11 B-Chemical
and	946 3 O
placebo	950 7 O
for	958 3 O
scores	962 6 O
on	969 2 O
the	972 3 O
Brief	976 5 O
Psychiatric	982 11 O
Rating	994 6 O
Scale	1001 5 O
psychosis	1007 9 B-Disease
factor	1017 6 O
and	1024 3 O
on	1028 2 O
psychomotor	1031 11 B-Disease
agitation	1043 9 I-Disease
.	1052 1 O

Response	1054 8 O
rates	1063 5 O
according	1069 9 O
to	1079 2 O
three	1082 5 O
sets	1088 4 O
of	1093 2 O
criteria	1096 8 O
were	1105 4 O
greater	1110 7 O
with	1118 4 O
the	1123 3 O
standard	1127 8 O
dose	1136 4 O
(	1141 1 O
55	1142 2 O
%	1144 1 O
-	1145 1 O
60	1146 2 O
%	1148 1 O
)	1149 1 O
than	1151 4 O
the	1156 3 O
low	1160 3 O
dose	1164 4 O
(	1169 1 O
25	1170 2 O
%	1172 1 O
-	1173 1 O
35	1174 2 O
%	1176 1 O
)	1177 1 O
and	1179 3 O
placebo	1183 7 O
(	1191 1 O
25	1192 2 O
%	1194 1 O
-	1195 1 O
30	1196 2 O
%	1198 1 O
)	1199 1 O
.	1200 1 O

The	1202 3 O
advantage	1206 9 O
of	1216 2 O
standard	1219 8 O
dose	1228 4 O
over	1233 4 O
low	1238 3 O
dose	1242 4 O
was	1247 3 O
replicated	1251 10 O
in	1262 2 O
phase	1265 5 O
B	1271 1 O
.	1272 1 O

In	1274 2 O
phase	1277 5 O
A	1283 1 O
,	1284 1 O
extrapyramidal	1286 14 B-Disease
signs	1301 5 I-Disease
tended	1307 6 O
to	1314 2 O
be	1317 2 O
greater	1320 7 O
with	1328 4 O
the	1333 3 O
standard	1337 8 O
dose	1346 4 O
than	1351 4 O
in	1356 2 O
the	1359 3 O
other	1363 5 O
two	1369 3 O
conditions	1373 10 O
,	1383 1 O
primarily	1385 9 O
because	1395 7 O
of	1403 2 O
a	1406 1 O
subgroup	1408 8 O
(	1417 1 O
20	1418 2 O
%	1420 1 O
)	1421 1 O
who	1423 3 O
developed	1427 9 O
moderate	1437 8 O
to	1446 2 O
severe	1449 6 O
signs	1456 5 O
.	1461 1 O

Low	1463 3 O
-	1466 1 O
dose	1467 4 O
haloperidol	1472 11 B-Chemical
did	1484 3 O
not	1488 3 O
differ	1492 6 O
from	1499 4 O
placebo	1504 7 O
on	1512 2 O
any	1515 3 O
measure	1519 7 O
of	1527 2 O
efficacy	1530 8 O
or	1539 2 O
side	1542 4 O
effects	1547 7 O
.	1554 1 O

CONCLUSIONS	1556 11 O
:	1567 1 O
The	1569 3 O
results	1573 7 O
indicated	1581 9 O
a	1591 1 O
favorable	1593 9 O
therapeutic	1603 11 O
profile	1615 7 O
for	1623 3 O
haloperidol	1627 11 B-Chemical
in	1639 2 O
doses	1642 5 O
of	1648 2 O
2	1651 1 O
-	1652 1 O
3	1653 1 O
mg	1655 2 O
/	1657 1 O
day	1658 3 O
,	1661 1 O
although	1663 8 O
a	1672 1 O
subgroup	1674 8 O
developed	1683 9 O
moderate	1693 8 O
to	1702 2 O
severe	1705 6 O
extrapyramidal	1712 14 B-Disease
signs	1727 5 I-Disease
.	1732 1 O

A	1734 1 O
starting	1736 8 O
dose	1745 4 O
of	1750 2 O
1	1753 1 O
mg	1755 2 O
/	1757 1 O
day	1758 3 O
with	1762 4 O
gradual	1767 7 O
,	1774 1 O
upward	1776 6 O
dose	1783 4 O
titration	1788 9 O
is	1798 2 O
recommended	1801 11 O
.	1812 1 O

The	1814 3 O
narrow	1818 6 O
therapeutic	1825 11 O
window	1837 6 O
observed	1844 8 O
with	1853 4 O
haloperidol	1858 11 B-Chemical
may	1870 3 O
also	1874 4 O
apply	1879 5 O
to	1885 2 O
other	1888 5 O
neuroleptics	1894 12 O
used	1907 4 O
in	1912 2 O
Alzheimer	1915 9 B-Disease
'	1924 1 I-Disease
s	1925 1 I-Disease
disease	1927 7 I-Disease
patients	1935 8 O
with	1944 4 O
psychosis	1949 9 B-Disease
and	1959 3 O
disruptive	1963 10 B-Disease
behaviors	1974 9 I-Disease
.	1983 1 O

Individual	0 10 O
differences	11 11 O
in	23 2 O
renal	26 5 O
ACE	32 3 O
activity	36 8 O
in	45 2 O
healthy	48 7 O
rats	56 4 O
predict	61 7 O
susceptibility	69 14 O
to	84 2 O
adriamycin	87 10 B-Chemical
-	97 1 O
induced	98 7 O
renal	106 5 B-Disease
damage	112 6 I-Disease
.	118 1 O

BACKGROUND	120 10 O
:	130 1 O
In	132 2 O
man	135 3 O
,	138 1 O
differences	140 11 O
in	152 2 O
angiotensin	155 11 B-Chemical
-	166 1 O
converting	167 10 O
enzyme	178 6 O
(	185 1 O
ACE	186 3 O
)	189 1 O
levels	191 6 O
,	197 1 O
related	199 7 O
to	207 2 O
ACE	210 3 O
(	214 1 O
I	215 1 O
/	216 1 O
D	217 1 O
)	218 1 O
genotype	220 8 O
,	228 1 O
are	230 3 O
associated	234 10 O
with	245 4 O
renal	250 5 O
prognosis	256 9 O
.	265 1 O

This	267 4 O
raises	272 6 O
the	279 3 O
hypothesis	283 10 O
that	294 4 O
individual	299 10 O
differences	310 11 O
in	322 2 O
renal	325 5 O
ACE	331 3 O
activity	335 8 O
are	344 3 O
involved	348 8 O
in	357 2 O
renal	360 5 O
susceptibility	366 14 O
to	381 2 O
inflicted	384 9 O
damage	394 6 O
.	400 1 O

Therefore	402 9 O
,	411 1 O
we	413 2 O
studied	416 7 O
the	424 3 O
predictive	428 10 O
effect	439 6 O
of	446 2 O
renal	449 5 O
ACE	455 3 O
activity	459 8 O
for	468 3 O
the	472 3 O
severity	476 8 O
of	485 2 O
renal	488 5 B-Disease
damage	494 6 I-Disease
induced	501 7 O
by	509 2 O
a	512 1 O
single	514 6 O
injection	521 9 O
of	531 2 O
adriamycin	534 10 B-Chemical
in	545 2 O
rats	548 4 O
.	552 1 O

METHODS	554 7 O
:	561 1 O
Renal	563 5 O
ACE	569 3 O
activity	573 8 O
(	582 1 O
Hip	583 3 B-Chemical
-	586 1 I-Chemical
His	587 3 I-Chemical
-	590 1 I-Chemical
Leu	591 3 I-Chemical
cleavage	595 8 O
by	604 2 O
cortical	607 8 O
homogenates	616 11 O
)	627 1 O
was	629 3 O
determined	633 10 O
by	644 2 O
renal	647 5 O
biopsy	653 6 O
in	660 2 O
27	663 2 O
adult	666 5 O
male	672 4 O
Wistar	677 6 O
rats	684 4 O
.	688 1 O

After	690 5 O
1	696 1 O
week	698 4 O
of	703 2 O
recovery	706 8 O
,	714 1 O
proteinuria	716 11 B-Disease
was	728 3 O
induced	732 7 O
by	740 2 O
adriamycin	743 10 B-Chemical
[	754 1 O
1	755 1 O
.	756 1 O
5	757 1 O
mg	759 2 O
/	761 1 O
kg	762 2 O
intravenously	765 13 O
(	779 1 O
i	780 1 O
.	781 1 O
v	782 1 O
.	783 1 O
)	784 1 O
n	786 1 O
=	788 1 O
18	790 2 O
;	792 1 O
controls	794 8 O
,	802 1 O
saline	804 6 O
i	811 1 O
.	812 1 O
v	813 1 O
.	814 1 O
n	816 1 O
=	818 1 O
9	820 1 O
]	821 1 O
.	822 1 O

Proteinuria	824 11 B-Disease
was	836 3 O
measured	840 8 O
every	849 5 O
2	855 1 O
weeks	857 5 O
.	862 1 O

After	864 5 O
12	870 2 O
weeks	873 5 O
,	878 1 O
rats	880 4 O
were	885 4 O
sacrificed	890 10 O
and	901 3 O
their	905 5 O
kidneys	911 7 O
harvested	919 9 O
.	928 1 O

RESULTS	930 7 O
:	937 1 O
As	939 2 O
anticipated	942 11 O
,	953 1 O
adriamycin	955 10 B-Chemical
elicited	966 8 O
nephrotic	975 9 B-Disease
range	985 5 O
proteinuria	991 11 B-Disease
,	1002 1 O
renal	1004 5 B-Disease
interstitial	1010 12 I-Disease
damage	1023 6 I-Disease
and	1030 3 O
mild	1034 4 O
focal	1039 5 B-Disease
glomerulosclerosis	1045 18 I-Disease
.	1063 1 O

Baseline	1065 8 O
renal	1074 5 O
ACE	1080 3 O
positively	1084 10 O
correlated	1095 10 O
with	1106 4 O
the	1111 3 O
relative	1115 8 O
rise	1124 4 O
in	1129 2 O
proteinuria	1132 11 B-Disease
after	1144 5 O
adriamycin	1150 10 B-Chemical
(	1161 1 O
r	1162 1 O
=	1164 1 O
0	1166 1 O
.	1167 1 O
62	1168 2 O
,	1170 1 O
P	1172 1 O
<	1173 1 O
0	1174 1 O
.	1175 1 O
01	1176 2 O
)	1178 1 O
,	1179 1 O
renal	1181 5 O
interstitial	1187 12 O
alpha	1200 5 O
-	1205 1 O
smooth	1206 6 O
muscle	1213 6 O
actin	1220 5 O
(	1226 1 O
r	1227 1 O
=	1229 1 O
0	1231 1 O
.	1232 1 O
49	1233 2 O
,	1235 1 O
P	1237 1 O
<	1238 1 O
0	1239 1 O
.	1240 1 O
05	1241 2 O
)	1243 1 O
,	1244 1 O
interstitial	1246 12 O
macrophage	1259 10 O
influx	1270 6 O
(	1277 1 O
r	1278 1 O
=	1280 1 O
0	1282 1 O
.	1283 1 O
56	1284 2 O
,	1286 1 O
P	1288 1 O
<	1289 1 O
0	1290 1 O
.	1291 1 O
05	1292 2 O
)	1294 1 O
,	1295 1 O
interstitial	1297 12 O
collagen	1310 8 O
III	1319 3 O
(	1323 1 O
r	1324 1 O
=	1326 1 O
0	1328 1 O
.	1329 1 O
53	1330 2 O
,	1332 1 O
P	1334 1 O
<	1335 1 O
0	1336 1 O
.	1337 1 O
05	1338 2 O
)	1340 1 O
,	1341 1 O
glomerular	1343 10 O
alpha	1354 5 O
-	1359 1 O
smooth	1360 6 O
muscle	1367 6 O
actin	1374 5 O
(	1380 1 O
r	1381 1 O
=	1383 1 O
0	1385 1 O
.	1386 1 O
74	1387 2 O
,	1389 1 O
P	1391 1 O
<	1392 1 O
0	1393 1 O
.	1394 1 O
01	1395 2 O
)	1397 1 O
and	1399 3 O
glomerular	1403 10 O
desmin	1414 6 O
(	1421 1 O
r	1422 1 O
=	1424 1 O
0	1426 1 O
.	1427 1 O
48	1428 2 O
,	1430 1 O
P	1432 1 O
<	1433 1 O
0	1434 1 O
.	1435 1 O
05	1436 2 O
)	1438 1 O
.	1439 1 O

Baseline	1441 8 O
renal	1450 5 O
ACE	1456 3 O
did	1460 3 O
not	1464 3 O
correlate	1468 9 O
with	1478 4 O
focal	1483 5 B-Disease
glomerulosclerosis	1489 18 I-Disease
(	1508 1 O
r	1509 1 O
=	1511 1 O
0	1513 1 O
.	1514 1 O
22	1515 2 O
,	1517 1 O
NS	1519 2 O
)	1521 1 O
.	1522 1 O

In	1524 2 O
controls	1527 8 O
,	1535 1 O
no	1537 2 O
predictive	1540 10 O
values	1551 6 O
for	1558 3 O
renal	1562 5 O
parameters	1568 10 O
were	1579 4 O
observed	1584 8 O
.	1592 1 O

CONCLUSION	1594 10 O
:	1604 1 O
Individual	1606 10 O
differences	1617 11 O
in	1629 2 O
renal	1632 5 O
ACE	1638 3 O
activity	1642 8 O
predict	1651 7 O
the	1659 3 O
severity	1663 8 O
of	1672 2 O
adriamycin	1675 10 B-Chemical
-	1685 1 O
induced	1686 7 O
renal	1694 5 B-Disease
damage	1700 6 I-Disease
in	1707 2 O
this	1710 4 O
outbred	1715 7 O
rat	1723 3 O
strain	1727 6 O
.	1733 1 O

This	1735 4 O
supports	1740 8 O
the	1749 3 O
assumption	1753 10 O
that	1764 4 O
differences	1769 11 O
in	1781 2 O
renal	1784 5 O
ACE	1790 3 O
activity	1794 8 O
predispose	1803 10 O
to	1814 2 O
a	1817 1 O
less	1819 4 O
favourable	1824 10 O
course	1835 6 O
of	1842 2 O
renal	1845 5 B-Disease
damage	1851 6 I-Disease
.	1857 1 O

Clinical	0 8 O
nephrotoxicity	9 14 B-Disease
of	24 2 O
tobramycin	27 10 B-Chemical
and	38 3 O
gentamicin	42 10 B-Chemical
.	52 1 O

A	54 1 O
prospective	56 11 O
study	68 5 O
.	73 1 O

Nearly	75 6 O
3	82 1 O
.	83 1 O
2	84 1 O
million	86 7 O
people	94 6 O
in	101 2 O
this	104 4 O
country	109 7 O
receive	117 7 O
aminoglycoside	125 14 B-Chemical
antibiotics	140 11 O
annually	152 8 O
.	160 1 O

Gentamicin	162 10 B-Chemical
sulfate	173 7 I-Chemical
and	181 3 O
tobramycin	185 10 B-Chemical
sulfate	196 7 I-Chemical
continue	204 8 O
to	213 2 O
demonstrate	216 11 O
ototoxicity	228 11 B-Disease
and	240 3 O
nephrotoxicity	244 14 B-Disease
in	259 2 O
both	262 4 O
animal	267 6 O
and	274 3 O
clinical	278 8 O
studies	287 7 O
.	294 1 O

In	296 2 O
this	299 4 O
study	304 5 O
,	309 1 O
62	311 2 O
patients	314 8 O
with	323 4 O
confirmed	328 9 O
initial	338 7 O
normal	346 6 O
renal	353 5 O
function	359 8 O
and	368 3 O
treated	372 7 O
with	380 4 O
2	385 1 O
to	387 2 O
5	390 1 O
mg	392 2 O
/	394 1 O
kg	395 2 O
/	397 1 O
day	398 3 O
of	402 2 O
gentamicin	405 10 B-Chemical
sulfate	416 7 I-Chemical
or	424 2 O
tobramycin	427 10 B-Chemical
sulfate	438 7 I-Chemical
for	446 3 O
a	450 1 O
minimum	452 7 O
of	460 2 O
seven	463 5 O
days	469 4 O
were	474 4 O
followed	479 8 O
up	488 2 O
prospectively	491 13 O
for	505 3 O
the	509 3 O
development	513 11 O
of	525 2 O
aminoglycoside	528 14 B-Chemical
-	542 1 O
related	543 7 O
renal	551 5 B-Disease
failure	557 7 I-Disease
,	564 1 O
defined	566 7 O
as	574 2 O
at	577 2 O
least	580 5 O
a	586 1 O
one	588 3 O
-	591 1 O
third	592 5 O
reduction	598 9 O
in	608 2 O
renal	611 5 O
function	617 8 O
.	625 1 O

In	627 2 O
these	630 5 O
62	636 2 O
patients	639 8 O
,	647 1 O
no	649 2 O
other	652 5 O
causes	658 6 O
for	665 3 O
renal	669 5 B-Disease
failure	675 7 I-Disease
could	683 5 O
be	689 2 O
identified	692 10 O
.	702 1 O

Five	704 4 O
of	709 2 O
33	712 2 O
(	715 1 O
15	716 2 O
%	718 1 O
)	719 1 O
of	721 2 O
the	724 3 O
tobramycin	728 10 B-Chemical
-	738 1 O
treated	739 7 O
patients	747 8 O
and	756 3 O
16	760 2 O
of	763 2 O
29	766 2 O
(	769 1 O
55	770 2 O
.	772 1 O
2	773 1 O
%	774 1 O
)	775 1 O
of	777 2 O
the	780 3 O
gentamicin	784 10 B-Chemical
-	794 1 O
treated	795 7 O
patients	803 8 O
had	812 3 O
renal	816 5 B-Disease
failure	822 7 I-Disease
.	829 1 O

Thus	831 4 O
,	835 1 O
gentamicin	837 10 B-Chemical
was	848 3 O
associated	852 10 O
with	863 4 O
renal	868 5 B-Disease
failure	874 7 I-Disease
more	882 4 O
than	887 4 O
three	892 5 O
times	898 5 O
as	904 2 O
often	907 5 O
as	913 2 O
was	916 3 O
tobramycin	920 10 B-Chemical
.	930 1 O

Neuroprotective	0 15 O
action	16 6 O
of	23 2 O
MPEP	26 4 B-Chemical
,	30 1 O
a	32 1 O
selective	34 9 O
mGluR5	44 6 O
antagonist	51 10 O
,	61 1 O
in	63 2 O
methamphetamine	66 15 B-Chemical
-	81 1 O
induced	82 7 O
dopaminergic	90 12 O
neurotoxicity	103 13 B-Disease
is	117 2 O
associated	120 10 O
with	131 4 O
a	136 1 O
decrease	138 8 O
in	147 2 O
dopamine	150 8 B-Chemical
outflow	159 7 O
and	167 3 O
inhibition	171 10 O
of	182 2 O
hyperthermia	185 12 B-Disease
in	198 2 O
rats	201 4 O
.	205 1 O

The	207 3 O
aim	211 3 O
of	215 2 O
this	218 4 O
study	223 5 O
was	229 3 O
to	233 2 O
examine	236 7 O
the	244 3 O
role	248 4 O
of	253 2 O
metabotropic	256 12 O
glutamate	269 9 B-Chemical
receptor	279 8 O
5	288 1 O
(	290 1 O
mGluR5	291 6 O
)	297 1 O
in	299 2 O
the	302 3 O
toxic	306 5 O
action	312 6 O
of	319 2 O
methamphetamine	322 15 B-Chemical
on	338 2 O
dopaminergic	341 12 O
neurones	354 8 O
in	363 2 O
rats	366 4 O
.	370 1 O

Methamphetamine	372 15 B-Chemical
(	388 1 O
10	389 2 O
mg	392 2 O
/	394 1 O
kg	395 2 O
sc	398 2 O
)	400 1 O
,	401 1 O
administered	403 12 O
five	416 4 O
times	421 5 O
,	426 1 O
reduced	428 7 O
the	436 3 O
levels	440 6 O
of	447 2 O
dopamine	450 8 B-Chemical
and	459 3 O
its	463 3 O
metabolites	467 11 O
in	479 2 O
striatal	482 8 O
tissue	491 6 O
when	498 4 O
measured	503 8 O
72	512 2 O
h	515 1 O
after	517 5 O
the	523 3 O
last	527 4 O
injection	532 9 O
.	541 1 O

A	543 1 O
selective	545 9 O
antagonist	555 10 O
of	566 2 O
mGluR5	569 6 O
,	575 1 O
2	577 1 B-Chemical
-	578 1 I-Chemical
methyl	579 6 I-Chemical
-	585 1 I-Chemical
6	586 1 I-Chemical
-	587 1 I-Chemical
(	588 1 I-Chemical
phenylethynyl	589 13 I-Chemical
)	602 1 I-Chemical
pyridine	603 8 I-Chemical
(	612 1 O
MPEP	613 4 B-Chemical
;	617 1 O
5	619 1 O
mg	621 2 O
/	623 1 O
kg	624 2 O
ip	627 2 O
)	629 1 O
,	630 1 O
when	632 4 O
administered	637 12 O
five	650 4 O
times	655 5 O
immediately	661 11 O
before	673 6 O
each	680 4 O
methamphetamine	685 15 B-Chemical
injection	701 9 O
reversed	711 8 O
the	720 3 O
above	724 5 O
-	729 1 O
mentioned	730 9 O
methamphetamine	740 15 B-Chemical
effects	756 7 O
.	763 1 O

A	765 1 O
single	767 6 O
MPEP	774 4 B-Chemical
(	779 1 O
5	780 1 O
mg	782 2 O
/	784 1 O
kg	785 2 O
ip	788 2 O
)	790 1 O
injection	792 9 O
reduced	802 7 O
the	810 3 O
basal	814 5 O
extracellular	820 13 O
dopamine	834 8 B-Chemical
level	843 5 O
in	849 2 O
the	852 3 O
striatum	856 8 O
,	864 1 O
as	866 2 O
well	869 4 O
as	874 2 O
dopamine	877 8 B-Chemical
release	886 7 O
stimulated	894 10 O
either	905 6 O
by	912 2 O
methamphetamine	915 15 B-Chemical
(	931 1 O
10	932 2 O
mg	935 2 O
/	937 1 O
kg	938 2 O
sc	941 2 O
)	943 1 O
or	945 2 O
by	948 2 O
intrastriatally	951 15 O
administered	967 12 O
veratridine	980 11 B-Chemical
(	992 1 O
100	993 3 O
microM	997 6 O
)	1003 1 O
.	1004 1 O

Moreover	1006 8 O
,	1014 1 O
it	1016 2 O
transiently	1019 11 O
diminished	1031 10 O
the	1042 3 O
methamphetamine	1046 15 B-Chemical
(	1062 1 O
10	1063 2 O
mg	1066 2 O
/	1068 1 O
kg	1069 2 O
sc	1072 2 O
)	1074 1 O
-	1075 1 O
induced	1076 7 O
hyperthermia	1084 12 B-Disease
and	1097 3 O
reduced	1101 7 O
basal	1109 5 O
body	1115 4 O
temperature	1120 11 O
.	1131 1 O

MPEP	1133 4 B-Chemical
administered	1138 12 O
into	1151 4 O
the	1156 3 O
striatum	1160 8 O
at	1169 2 O
high	1172 4 O
concentrations	1177 14 O
(	1192 1 O
500	1193 3 O
microM	1197 6 O
)	1203 1 O
increased	1205 9 O
extracellular	1215 13 O
dopamine	1229 8 B-Chemical
levels	1238 6 O
,	1244 1 O
while	1246 5 O
lower	1252 5 O
concentrations	1258 14 O
(	1273 1 O
50	1274 2 O
-	1276 1 O
100	1277 3 O
microM	1281 6 O
)	1287 1 O
were	1289 4 O
devoid	1294 6 O
of	1301 2 O
any	1304 3 O
effect	1308 6 O
.	1314 1 O

The	1316 3 O
results	1320 7 O
of	1328 2 O
this	1331 4 O
study	1336 5 O
suggest	1342 7 O
that	1350 4 O
the	1355 3 O
blockade	1359 8 O
of	1368 2 O
mGluR5	1371 6 O
by	1378 2 O
MPEP	1381 4 B-Chemical
may	1386 3 O
protect	1390 7 O
dopaminergic	1398 12 O
neurones	1411 8 O
against	1420 7 O
methamphetamine	1428 15 B-Chemical
-	1443 1 O
induced	1444 7 O
toxicity	1452 8 B-Disease
.	1460 1 O

Neuroprotection	1462 15 O
rendered	1478 8 O
by	1487 2 O
MPEP	1490 4 B-Chemical
may	1495 3 O
be	1499 2 O
associated	1502 10 O
with	1513 4 O
the	1518 3 O
reduction	1522 9 O
of	1532 2 O
the	1535 3 O
methamphetamine	1539 15 B-Chemical
-	1554 1 O
induced	1555 7 O
dopamine	1563 8 B-Chemical
efflux	1572 6 O
in	1579 2 O
the	1582 3 O
striatum	1586 8 O
due	1595 3 O
to	1599 2 O
the	1602 3 O
blockade	1606 8 O
of	1615 2 O
extrastriatal	1618 13 O
mGluR5	1632 6 O
,	1638 1 O
and	1640 3 O
with	1644 4 O
a	1649 1 O
decrease	1651 8 O
in	1660 2 O
hyperthermia	1663 12 B-Disease
.	1675 1 O

Pharmacokinetics	0 16 O
of	17 2 O
desipramine	20 11 B-Chemical
HCl	32 3 I-Chemical
when	36 4 O
administered	41 12 O
with	54 4 O
cinacalcet	59 10 B-Chemical
HCl	70 3 I-Chemical
.	73 1 O

OBJECTIVE	75 9 O
:	84 1 O
In	86 2 O
vitro	89 5 O
work	95 4 O
has	100 3 O
demonstrated	104 12 O
that	117 4 O
cinacalcet	122 10 B-Chemical
is	133 2 O
a	136 1 O
strong	138 6 O
inhibitor	145 9 O
of	155 2 O
cytochrome	158 10 O
P450	169 4 O
isoenzyme	174 9 O
(	184 1 O
CYP	185 3 O
)	188 1 O
2D6	190 3 O
.	193 1 O

The	195 3 O
purpose	199 7 O
of	207 2 O
this	210 4 O
study	215 5 O
was	221 3 O
to	225 2 O
evaluate	228 8 O
the	237 3 O
effect	241 6 O
of	248 2 O
cinacalcet	251 10 B-Chemical
on	262 2 O
CYP2D6	265 6 O
activity	272 8 O
,	280 1 O
using	282 5 O
desipramine	288 11 B-Chemical
as	300 2 O
a	303 1 O
probe	305 5 O
substrate	311 9 O
,	320 1 O
in	322 2 O
healthy	325 7 O
subjects	333 8 O
.	341 1 O

METHODS	343 7 O
:	350 1 O
Seventeen	352 9 O
subjects	362 8 O
who	371 3 O
were	375 4 O
genotyped	380 9 O
as	390 2 O
CYP2D6	393 6 O
extensive	400 9 O
metabolizers	410 12 O
were	423 4 O
enrolled	428 8 O
in	437 2 O
this	440 4 O
randomized	445 10 O
,	455 1 O
open	457 4 O
-	461 1 O
label	462 5 O
,	467 1 O
crossover	469 9 O
study	479 5 O
to	485 2 O
receive	488 7 O
a	496 1 O
single	498 6 O
oral	505 4 O
dose	510 4 O
of	515 2 O
desipramine	518 11 B-Chemical
(	530 1 O
50	531 2 O
mg	534 2 O
)	536 1 O
on	538 2 O
two	541 3 O
separate	545 8 O
occasions	554 9 O
,	563 1 O
once	565 4 O
alone	570 5 O
and	576 3 O
once	580 4 O
after	585 5 O
multiple	591 8 O
doses	600 5 O
of	606 2 O
cinacalcet	609 10 B-Chemical
(	620 1 O
90	621 2 O
mg	624 2 O
for	627 3 O
7	631 1 O
days	633 4 O
)	637 1 O
.	638 1 O

Blood	640 5 O
samples	646 7 O
were	654 4 O
obtained	659 8 O
predose	668 7 O
and	676 3 O
up	680 2 O
to	683 2 O
72	686 2 O
h	689 1 O
postdose	691 8 O
.	699 1 O

RESULTS	701 7 O
:	708 1 O
Fourteen	710 8 O
subjects	719 8 O
completed	728 9 O
both	738 4 O
treatment	743 9 O
arms	753 4 O
.	757 1 O

Relative	759 8 O
to	768 2 O
desipramine	771 11 B-Chemical
alone	783 5 O
,	788 1 O
mean	790 4 O
AUC	795 3 O
and	799 3 O
C	803 1 O
(	804 1 O
max	805 3 O
)	808 1 O
of	810 2 O
desipramine	813 11 B-Chemical
increased	825 9 O
3	835 1 O
.	836 1 O
6	837 1 O
-	838 1 O
and	840 3 O
1	844 1 O
.	845 1 O
8	846 1 O
-	847 1 O
fold	848 4 O
when	853 4 O
coadministered	858 14 O
with	873 4 O
cinacalcet	878 10 B-Chemical
.	888 1 O

The	890 3 O
t	894 1 O
(	896 1 O
1	897 1 O
/	898 1 O
2	899 1 O
,	900 1 O
z	901 1 O
)	902 1 O
of	904 2 O
desipramine	907 11 B-Chemical
was	919 3 O
longer	923 6 O
when	930 4 O
desipramine	935 11 B-Chemical
was	947 3 O
coadministered	951 14 O
with	966 4 O
cinacalcet	971 10 B-Chemical
(	982 1 O
21	983 2 O
.	985 1 O
0	986 1 O
versus	988 6 O
43	995 2 O
.	997 1 O
3	998 1 O
hs	1000 2 O
)	1002 1 O
.	1003 1 O

The	1005 3 O
t	1009 1 O
(	1011 1 O
max	1012 3 O
)	1015 1 O
was	1017 3 O
similar	1021 7 O
between	1029 7 O
the	1037 3 O
regimens	1041 8 O
.	1049 1 O

Fewer	1051 5 O
subjects	1057 8 O
reported	1066 8 O
adverse	1075 7 O
events	1083 6 O
following	1090 9 O
treatment	1100 9 O
with	1110 4 O
desipramine	1115 11 B-Chemical
alone	1127 5 O
than	1133 4 O
when	1138 4 O
receiving	1143 9 O
desipramine	1153 11 B-Chemical
with	1165 4 O
cinacalcet	1170 10 B-Chemical
(	1181 1 O
33	1182 2 O
versus	1185 6 O
86	1192 2 O
%	1194 1 O
)	1195 1 O
,	1196 1 O
the	1198 3 O
most	1202 4 O
frequent	1207 8 O
of	1216 2 O
which	1219 5 O
(	1225 1 O
nausea	1226 6 B-Disease
and	1233 3 O
headache	1237 8 B-Disease
)	1245 1 O
have	1247 4 O
been	1252 4 O
reported	1257 8 O
for	1266 3 O
patients	1270 8 O
treated	1279 7 O
with	1287 4 O
either	1292 6 O
desipramine	1299 11 B-Chemical
or	1311 2 O
cinacalcet	1314 10 B-Chemical
.	1324 1 O

CONCLUSION	1326 10 O
:	1336 1 O
This	1338 4 O
study	1343 5 O
demonstrates	1349 12 O
that	1362 4 O
cinacalcet	1367 10 B-Chemical
is	1378 2 O
a	1381 1 O
strong	1383 6 O
inhibitor	1390 9 O
of	1400 2 O
CYP2D6	1403 6 O
.	1409 1 O

These	1411 5 O
data	1417 4 O
suggest	1422 7 O
that	1430 4 O
during	1435 6 O
concomitant	1442 11 O
treatment	1454 9 O
with	1464 4 O
cinacalcet	1469 10 B-Chemical
,	1479 1 O
dose	1481 4 O
adjustment	1486 10 O
may	1497 3 O
be	1501 2 O
necessary	1504 9 O
for	1514 3 O
drugs	1518 5 O
that	1524 4 O
demonstrate	1529 11 O
a	1541 1 O
narrow	1543 6 O
therapeutic	1550 11 O
index	1562 5 O
and	1568 3 O
are	1572 3 O
metabolized	1576 11 O
by	1588 2 O
CYP2D6	1591 6 O
.	1597 1 O

Proteomic	0 9 O
analysis	10 8 O
of	19 2 O
striatal	22 8 O
proteins	31 8 O
in	40 2 O
the	43 3 O
rat	47 3 O
model	51 5 O
of	57 2 O
L	60 1 B-Chemical
-	61 1 I-Chemical
DOPA	62 4 I-Chemical
-	66 1 O
induced	67 7 O
dyskinesia	75 10 B-Disease
.	85 1 O

L	87 1 B-Chemical
-	88 1 I-Chemical
DOPA	89 4 I-Chemical
-	93 1 O
induced	94 7 O
dyskinesia	102 10 B-Disease
(	113 1 O
LID	114 3 B-Disease
)	117 1 O
is	119 2 O
among	122 5 O
the	128 3 O
motor	132 5 O
complications	138 13 O
that	152 4 O
arise	157 5 O
in	163 2 O
Parkinson	166 9 B-Disease
'	175 1 I-Disease
s	176 1 I-Disease
disease	178 7 I-Disease
(	186 1 O
PD	187 2 B-Disease
)	189 1 O
patients	191 8 O
after	200 5 O
a	206 1 O
prolonged	208 9 O
treatment	218 9 O
with	228 4 O
L	233 1 B-Chemical
-	234 1 I-Chemical
DOPA	235 4 I-Chemical
.	239 1 O

To	241 2 O
this	244 4 O
day	249 3 O
,	252 1 O
transcriptome	254 13 O
analysis	268 8 O
has	277 3 O
been	281 4 O
performed	286 9 O
in	296 2 O
a	299 1 O
rat	301 3 O
model	305 5 O
of	311 2 O
LID	314 3 B-Disease
[	318 1 O
Neurobiol	319 9 O
.	328 1 O
Dis	330 3 O
.	333 1 O
,	334 1 O
17	336 2 O
(	339 1 O
2004	340 4 O
)	344 1 O
,	345 1 O
219	347 3 O
]	350 1 O
but	352 3 O
information	356 11 O
regarding	368 9 O
the	378 3 O
proteome	382 8 O
is	391 2 O
still	394 5 O
lacking	400 7 O
.	407 1 O

In	409 2 O
the	412 3 O
present	416 7 O
study	424 5 O
,	429 1 O
we	431 2 O
investigated	434 12 O
the	447 3 O
changes	451 7 O
occurring	459 9 O
at	469 2 O
the	472 3 O
protein	476 7 O
level	484 5 O
in	490 2 O
striatal	493 8 O
samples	502 7 O
obtained	510 8 O
from	519 4 O
the	524 3 O
unilaterally	528 12 O
6	541 1 B-Chemical
-	542 1 I-Chemical
hydroxydopamine	543 15 I-Chemical
-	558 1 O
lesion	559 6 O
rat	566 3 O
model	570 5 O
of	576 2 O
PD	579 2 B-Disease
treated	582 7 O
with	590 4 O
saline	595 6 O
,	601 1 O
L	603 1 B-Chemical
-	604 1 I-Chemical
DOPA	605 4 I-Chemical
or	610 2 O
bromocriptine	613 13 B-Chemical
using	627 5 O
two	633 3 O
-	636 1 O
dimensional	637 11 O
difference	649 10 O
gel	660 3 O
electrophoresis	664 15 O
and	680 3 O
mass	684 4 O
spectrometry	689 12 O
(	702 1 O
MS	703 2 O
)	705 1 O
.	706 1 O

Rats	708 4 O
treated	713 7 O
with	721 4 O
L	726 1 B-Chemical
-	727 1 I-Chemical
DOPA	728 4 I-Chemical
were	733 4 O
allocated	738 9 O
to	748 2 O
two	751 3 O
groups	755 6 O
based	762 5 O
on	768 2 O
the	771 3 O
presence	775 8 O
or	784 2 O
absence	787 7 O
of	795 2 O
LID	798 3 B-Disease
.	801 1 O

Among	803 5 O
the	809 3 O
2000	813 4 O
spots	818 5 O
compared	824 8 O
for	833 3 O
statistical	837 11 O
difference	849 10 O
,	859 1 O
67	861 2 O
spots	864 5 O
were	870 4 O
significantly	875 13 O
changed	889 7 O
in	897 2 O
abundance	900 9 O
and	910 3 O
identified	914 10 O
using	925 5 O
matrix	931 6 O
-	937 1 O
assisted	938 8 O
laser	947 5 O
desorption	953 10 O
/	963 1 O
ionization	964 10 O
time	975 4 O
-	979 1 O
of	980 2 O
-	982 1 O
flight	983 6 O
MS	990 2 O
,	992 1 O
atmospheric	994 11 O
pressure	1006 8 O
matrix	1015 6 O
-	1021 1 O
assisted	1022 8 O
laser	1031 5 O
desorption	1037 10 O
/	1047 1 O
ionization	1048 10 O
and	1059 3 O
HPLC	1063 4 O
coupled	1068 7 O
tandem	1076 6 O
MS	1083 2 O
(	1086 1 O
LC	1087 2 O
/	1089 1 O
MS	1090 2 O
/	1092 1 O
MS	1093 2 O
)	1095 1 O
.	1096 1 O

Out	1098 3 O
of	1102 2 O
these	1105 5 O
67	1111 2 O
proteins	1114 8 O
,	1122 1 O
LID	1124 3 B-Disease
significantly	1128 13 O
changed	1142 7 O
the	1150 3 O
expression	1154 10 O
level	1165 5 O
of	1171 2 O
five	1174 4 O
proteins	1179 8 O
:	1187 1 O
alphabeta	1189 9 O
-	1198 1 O
crystalin	1199 9 O
,	1208 1 O
gamma	1210 5 O
-	1215 1 O
enolase	1216 7 O
,	1223 1 O
guanidoacetate	1225 14 O
methyltransferase	1240 17 O
,	1257 1 O
vinculin	1259 8 O
,	1267 1 O
and	1269 3 O
proteasome	1273 10 O
alpha	1284 5 O
-	1289 1 O
2	1290 1 O
subunit	1292 7 O
.	1299 1 O

Complementary	1301 13 O
techniques	1315 10 O
such	1326 4 O
as	1331 2 O
western	1334 7 O
immunoblotting	1342 14 O
and	1357 3 O
immunohistochemistry	1361 20 O
were	1382 4 O
performed	1387 9 O
to	1397 2 O
investigate	1400 11 O
the	1412 3 O
validity	1416 8 O
of	1425 2 O
the	1428 3 O
data	1432 4 O
obtained	1437 8 O
using	1446 5 O
the	1452 3 O
proteomic	1456 9 O
approach	1466 8 O
.	1474 1 O

In	1476 2 O
conclusion	1479 10 O
,	1489 1 O
this	1491 4 O
study	1496 5 O
provides	1502 8 O
new	1511 3 O
insights	1515 8 O
into	1524 4 O
the	1529 3 O
protein	1533 7 O
changes	1541 7 O
occurring	1549 9 O
in	1559 2 O
LID	1562 3 B-Disease
.	1565 1 O

Pseudo	0 6 O
-	6 1 O
allergic	7 8 B-Disease
reactions	16 9 I-Disease
to	26 2 O
corticosteroids	29 15 B-Chemical
:	44 1 O
diagnosis	46 9 O
and	56 3 O
alternatives	60 12 O
.	72 1 O

Two	74 3 O
patients	78 8 O
treated	87 7 O
with	95 4 O
parenteral	100 10 O
paramethasone	111 13 B-Chemical
(	125 1 O
Triniol	126 7 O
)	133 1 O
and	135 3 O
dexamethasone	139 13 B-Chemical
(	153 1 O
Sedionbel	154 9 O
)	163 1 O
are	165 3 O
described	169 9 O
.	178 1 O

A	180 1 O
few	182 3 O
minutes	186 7 O
after	194 5 O
administration	200 14 O
of	215 2 O
the	218 3 O
drugs	222 5 O
,	227 1 O
they	229 4 O
presented	234 9 O
urticaria	244 9 B-Disease
(	254 1 O
patients	255 8 O
1	264 1 O
and	266 3 O
2	270 1 O
)	271 1 O
and	273 3 O
conjunctivitis	277 14 B-Disease
(	292 1 O
patient	293 7 O
1	301 1 O
)	302 1 O
.	303 1 O

The	305 3 O
purpose	309 7 O
of	317 2 O
our	320 3 O
study	324 5 O
was	330 3 O
to	334 2 O
determine	337 9 O
the	347 3 O
cause	351 5 O
of	357 2 O
the	360 3 O
patients	364 8 O
'	372 1 O
reactions	374 9 O
,	383 1 O
the	385 3 O
immunological	389 13 O
mechanisms	403 10 O
involved	414 8 O
and	423 3 O
whether	427 7 O
these	435 5 O
patients	441 8 O
would	450 5 O
be	456 2 O
able	459 4 O
to	464 2 O
tolerate	467 8 O
any	476 3 O
kind	480 4 O
of	485 2 O
corticoid	488 9 O
.	497 1 O

Clinical	499 8 O
examinations	508 12 O
and	521 3 O
skin	525 4 O
,	529 1 O
oral	531 4 O
and	536 3 O
parenteral	540 10 O
challenges	551 10 O
with	562 4 O
different	567 9 O
corticosteroids	577 15 B-Chemical
and	593 3 O
ELISA	597 5 O
tests	603 5 O
were	609 4 O
performed	614 9 O
.	623 1 O

In	625 2 O
the	628 3 O
two	632 3 O
patients	636 8 O
,	644 1 O
skin	646 4 O
and	651 3 O
ELISA	655 5 O
tests	661 5 O
with	667 4 O
paramethasone	672 13 B-Chemical
were	686 4 O
negative	691 8 O
,	699 1 O
as	701 2 O
was	704 3 O
the	708 3 O
prick	712 5 O
test	718 4 O
with	723 4 O
each	728 4 O
of	733 2 O
its	736 3 O
excipients	740 10 O
.	750 1 O

A	752 1 O
single	754 6 O
-	760 1 O
blind	761 5 O
parenteral	767 10 O
challenge	778 9 O
with	788 4 O
Triniol	793 7 O
was	801 3 O
positive	805 8 O
in	814 2 O
both	817 4 O
patients	822 8 O
after	831 5 O
the	837 3 O
administration	841 14 O
of	856 2 O
1	859 1 O
ml	861 2 O
of	864 2 O
the	867 3 O
drug	871 4 O
,	875 1 O
and	877 3 O
negative	881 8 O
with	890 4 O
its	895 3 O
excipients	899 10 O
.	909 1 O

We	911 2 O
also	914 4 O
carried	919 7 O
out	927 3 O
oral	931 4 O
and	936 3 O
parenteral	940 10 O
challenges	951 10 O
with	962 4 O
other	967 5 O
corticosteroids	973 15 B-Chemical
and	989 3 O
found	993 5 O
intolerance	999 11 O
to	1011 2 O
some	1014 4 O
of	1019 2 O
them	1022 4 O
.	1026 1 O

These	1028 5 O
results	1034 7 O
suggest	1042 7 O
that	1050 4 O
paramethasone	1055 13 B-Chemical
caused	1069 6 O
pseudoallergic	1076 14 O
reactions	1091 9 O
in	1101 2 O
our	1104 3 O
patients	1108 8 O
.	1116 1 O

Corticosteroids	1118 15 O
different	1134 9 O
from	1144 4 O
paramethasone	1149 13 B-Chemical
also	1163 4 O
produced	1168 8 O
hypersensitivity	1177 16 B-Disease
reactions	1194 9 O
in	1204 2 O
these	1207 5 O
patients	1213 8 O
;	1221 1 O
however	1223 7 O
,	1230 1 O
a	1232 1 O
few	1234 3 O
of	1238 2 O
them	1241 4 O
were	1246 4 O
tolerated	1251 9 O
.	1260 1 O

The	1262 3 O
basic	1266 5 O
mechanisms	1272 10 O
of	1283 2 O
those	1286 5 O
reactions	1292 9 O
are	1302 3 O
not	1306 3 O
yet	1310 3 O
fully	1314 5 O
understood	1320 10 O
.	1330 1 O

To	1332 2 O
our	1335 3 O
knowledge	1339 9 O
,	1348 1 O
this	1350 4 O
is	1355 2 O
the	1358 3 O
first	1362 5 O
report	1368 6 O
of	1375 2 O
a	1378 1 O
pseudo	1380 6 O
-	1386 1 O
allergy	1387 7 B-Disease
caused	1395 6 O
by	1402 2 O
paramethasone	1405 13 B-Chemical
.	1418 1 O

Valproic	0 8 B-Chemical
acid	9 4 I-Chemical
induced	14 7 O
encephalopathy	22 14 B-Disease
-	36 1 O
-	37 1 O
19	38 2 O
new	41 3 O
cases	45 5 O
in	51 2 O
Germany	54 7 O
from	62 4 O
1994	67 4 O
to	72 2 O
2003	75 4 O
-	79 1 O
-	80 1 O
a	81 1 O
side	83 4 O
effect	88 6 O
associated	95 10 O
to	106 2 O
VPA	109 3 B-Chemical
-	112 1 O
therapy	113 7 O
not	121 3 O
only	125 4 O
in	130 2 O
young	133 5 O
children	139 8 O
.	147 1 O

Valproic	149 8 B-Chemical
acid	158 4 I-Chemical
(	163 1 O
VPA	164 3 B-Chemical
)	167 1 O
is	169 2 O
a	172 1 O
broad	174 5 O
-	179 1 O
spectrum	180 8 O
antiepileptic	189 13 O
drug	203 4 O
and	208 3 O
is	212 2 O
usually	215 7 O
well	223 4 O
-	227 1 O
tolerated	228 9 O
.	237 1 O

Rare	239 4 O
serious	244 7 O
complications	252 13 O
may	266 3 O
occur	270 5 O
in	276 2 O
some	279 4 O
patients	284 8 O
,	292 1 O
including	294 9 O
haemorrhagic	304 12 O
pancreatitis	317 12 B-Disease
,	329 1 O
bone	331 4 B-Disease
marrow	336 6 I-Disease
suppression	343 11 I-Disease
,	354 1 O
VPA	356 3 B-Chemical
-	359 1 O
induced	360 7 O
hepatotoxicity	368 14 B-Disease
and	383 3 O
VPA	387 3 B-Chemical
-	390 1 O
induced	391 7 O
encephalopathy	399 14 B-Disease
.	413 1 O

The	415 3 O
typical	419 7 O
signs	427 5 O
of	433 2 O
VPA	436 3 B-Chemical
-	439 1 O
induced	440 7 O
encephalopathy	448 14 B-Disease
are	463 3 O
impaired	467 8 B-Disease
consciousness	476 13 I-Disease
,	489 1 O
sometimes	491 9 O
marked	501 6 O
EEG	508 3 O
background	512 10 O
slowing	523 7 O
,	530 1 O
increased	532 9 O
seizure	542 7 B-Disease
frequency	550 9 O
,	559 1 O
with	561 4 O
or	566 2 O
without	569 7 O
hyperammonemia	577 14 B-Disease
.	591 1 O

There	593 5 O
is	599 2 O
still	602 5 O
no	608 2 O
proof	611 5 O
of	617 2 O
causative	620 9 O
effect	630 6 O
of	637 2 O
VPA	640 3 B-Chemical
in	644 2 O
patients	647 8 O
with	656 4 O
encephalopathy	661 14 B-Disease
,	675 1 O
but	677 3 O
only	681 4 O
of	686 2 O
an	689 2 O
association	692 11 O
with	704 4 O
an	709 2 O
assumed	712 7 O
causal	720 6 O
relation	727 8 O
.	735 1 O

We	737 2 O
report	740 6 O
19	747 2 O
patients	750 8 O
with	759 4 O
VPA	764 3 B-Chemical
-	767 1 O
associated	768 10 O
encephalopathy	779 14 B-Disease
in	794 2 O
Germany	797 7 O
from	805 4 O
the	810 3 O
years	814 5 O
1994	820 4 O
to	825 2 O
2003	828 4 O
,	832 1 O
none	834 4 O
of	839 2 O
whom	842 4 O
had	847 3 O
been	851 4 O
published	856 9 O
previously	866 10 O
.	876 1 O

Haemolytic	0 10 B-Disease
-	10 1 I-Disease
uraemic	11 7 I-Disease
syndrome	19 8 I-Disease
after	28 5 O
treatment	34 9 O
with	44 4 O
metronidazole	49 13 B-Chemical
.	62 1 O

This	64 4 O
paper	69 5 O
describes	75 9 O
the	85 3 O
clinical	89 8 O
features	98 8 O
of	107 2 O
six	110 3 O
children	114 8 O
who	123 3 O
developed	127 9 O
the	137 3 O
haemolytic	141 10 B-Disease
-	151 1 I-Disease
uraemic	152 7 I-Disease
syndrome	160 8 I-Disease
after	169 5 O
treatment	175 9 O
with	185 4 O
metronidazole	190 13 B-Chemical
.	203 1 O

These	205 5 O
children	211 8 O
were	220 4 O
older	225 5 O
and	231 3 O
were	235 4 O
more	240 4 O
likely	245 6 O
to	252 2 O
have	255 4 O
undergone	260 9 O
recent	270 6 O
bowel	277 5 O
surgery	283 7 O
than	291 4 O
are	296 3 O
other	300 5 O
children	306 8 O
with	315 4 O
this	320 4 O
condition	325 9 O
.	334 1 O

While	336 5 O
the	342 3 O
involvement	346 11 O
of	358 2 O
metronidazole	361 13 B-Chemical
in	375 2 O
the	378 3 O
aetiology	382 9 O
of	392 2 O
the	395 3 O
haemolytic	399 10 B-Disease
-	409 1 I-Disease
uraemic	410 7 I-Disease
syndrome	418 8 I-Disease
is	427 2 O
not	430 3 O
established	434 11 O
firmly	446 6 O
,	452 1 O
the	454 3 O
action	458 6 O
of	465 2 O
this	468 4 O
drug	473 4 O
in	478 2 O
sensitizing	481 11 O
tissues	493 7 O
to	501 2 O
oxidation	504 9 O
injury	514 6 O
and	521 3 O
the	525 3 O
reported	529 8 O
evidence	538 8 O
of	547 2 O
oxidation	550 9 O
changes	560 7 O
in	568 2 O
the	571 3 O
haemolytic	575 10 B-Disease
-	585 1 I-Disease
uraemic	586 7 I-Disease
syndrome	594 8 I-Disease
suggest	603 7 O
a	611 1 O
possible	613 8 O
link	622 4 O
between	627 7 O
metronidazole	635 13 B-Chemical
treatment	649 9 O
and	659 3 O
some	663 4 O
cases	668 5 O
of	674 2 O
the	677 3 O
haemolytic	681 10 B-Disease
-	691 1 I-Disease
uraemic	692 7 I-Disease
syndrome	700 8 I-Disease
.	708 1 O

Risk	0 4 O
factors	5 7 O
of	13 2 O
sensorineural	16 13 B-Disease
hearing	30 7 I-Disease
loss	38 4 I-Disease
in	43 2 O
preterm	46 7 O
infants	54 7 O
.	61 1 O

Among	63 5 O
547	69 3 O
preterm	73 7 O
infants	81 7 O
of	89 2 O
<	92 1 O
or	94 2 O
=	97 1 O
34	99 2 O
weeks	102 5 O
gestation	108 9 O
born	118 4 O
between	123 7 O
1987	131 4 O
and	136 3 O
1991	140 4 O
,	144 1 O
8	146 1 O
children	148 8 O
(	157 1 O
1	158 1 O
.	159 1 O
46	160 2 O
%	162 1 O
)	163 1 O
developed	165 9 O
severe	175 6 O
progressive	182 11 O
and	194 3 O
bilateral	198 9 O
sensorineural	208 13 B-Disease
hearing	222 7 I-Disease
loss	230 4 I-Disease
.	234 1 O

Perinatal	236 9 O
risk	246 4 O
factors	251 7 O
of	259 2 O
infants	262 7 O
with	270 4 O
hearing	275 7 B-Disease
loss	283 4 I-Disease
were	288 4 O
compared	293 8 O
with	302 4 O
those	307 5 O
of	313 2 O
two	316 3 O
control	320 7 O
groups	328 6 O
matched	335 7 O
for	343 3 O
gestation	347 9 O
and	357 3 O
birth	361 5 O
weight	367 6 O
and	374 3 O
for	378 3 O
perinatal	382 9 O
complications	392 13 O
.	405 1 O

Our	407 3 O
observations	411 12 O
demonstrated	424 12 O
an	437 2 O
association	440 11 O
of	452 2 O
hearing	455 7 B-Disease
loss	463 4 I-Disease
with	468 4 O
a	473 1 O
higher	475 6 O
incidence	482 9 O
of	492 2 O
perinatal	495 9 O
complications	505 13 O
.	518 1 O

Ototoxicity	520 11 B-Disease
appeared	532 8 O
closely	541 7 O
related	549 7 O
to	557 2 O
a	560 1 O
prolonged	562 9 O
administration	572 14 O
and	587 3 O
higher	591 6 O
total	598 5 O
dose	604 4 O
of	609 2 O
ototoxic	612 8 B-Disease
drugs	621 5 O
,	626 1 O
particularly	628 12 O
aminoglycosides	641 15 B-Chemical
and	657 3 O
furosemide	661 10 B-Chemical
.	671 1 O

Finally	673 7 O
,	680 1 O
we	682 2 O
strongly	685 8 O
recommend	694 9 O
to	704 2 O
prospectively	707 13 O
and	721 3 O
regularly	725 9 O
perform	735 7 O
audiologic	743 10 O
assessment	754 10 O
in	765 2 O
sick	768 4 O
preterm	773 7 O
children	781 8 O
as	790 2 O
hearing	793 7 B-Disease
loss	801 4 I-Disease
is	806 2 O
of	809 2 O
delayed	812 7 O
onset	820 5 O
and	826 3 O
in	830 2 O
most	833 4 O
cases	838 5 O
bilateral	844 9 O
and	854 3 O
severe	858 6 O
.	864 1 O

Pharmacokinetic	0 15 O
and	16 3 O
clinical	20 8 O
studies	29 7 O
in	37 2 O
patients	40 8 O
with	49 4 O
cimetidine	54 10 B-Chemical
-	64 1 O
associated	65 10 O
mental	76 6 O
confusion	83 9 B-Disease
.	92 1 O

15	94 2 O
cases	97 5 O
of	103 2 O
cimetidine	106 10 B-Chemical
-	116 1 O
associated	117 10 O
mental	128 6 O
confusion	135 9 B-Disease
have	145 4 O
been	150 4 O
reported	155 8 O
.	163 1 O

In	165 2 O
order	168 5 O
that	174 4 O
this	179 4 O
syndrome	184 8 O
might	193 5 O
be	199 2 O
investigated	202 12 O
changes	215 7 O
in	223 2 O
mental	226 6 O
status	233 6 O
(	240 1 O
M	241 1 O
.	242 1 O
S	243 1 O
.	244 1 O
)	245 1 O
were	247 4 O
correlated	252 10 O
with	263 4 O
serum	268 5 O
concentrations	274 14 O
and	289 3 O
renal	293 5 O
and	299 3 O
hepatic	303 7 O
function	311 8 O
in	320 2 O
36	323 2 O
patients	326 8 O
,	334 1 O
30	336 2 O
patients	339 8 O
had	348 3 O
no	352 2 O
M	355 1 O
.	356 1 O
S	357 1 O
.	358 1 O
change	360 6 O
on	367 2 O
cimetidine	370 10 B-Chemical
and	381 3 O
6	385 1 O
had	387 3 O
moderate	391 8 O
to	400 2 O
severe	403 6 O
changes	410 7 O
.	417 1 O

These	419 5 O
6	425 1 O
patients	427 8 O
had	436 3 O
both	440 4 O
renal	445 5 B-Disease
and	451 3 I-Disease
liver	455 5 I-Disease
dysfunction	461 11 I-Disease
(	473 1 O
P	474 1 O
less	476 4 O
than	481 4 O
0	486 1 O
.	487 1 O
05	488 2 O
)	490 1 O
,	491 1 O
as	493 2 O
well	496 4 O
as	501 2 O
cimetidine	504 10 B-Chemical
trough	515 6 O
-	521 1 O
concentrations	522 14 O
of	537 2 O
more	540 4 O
than	545 4 O
1	550 1 O
.	551 1 O
25	552 2 O
microgram	555 9 O
/	564 1 O
ml	565 2 O
(	568 1 O
P	569 1 O
less	571 4 O
than	576 4 O
0	581 1 O
.	582 1 O
05	583 2 O
)	585 1 O
.	586 1 O

The	588 3 O
severity	592 8 O
of	601 2 O
M	604 1 O
.	605 1 O
S	606 1 O
.	607 1 O
changes	609 7 O
increased	617 9 O
as	627 2 O
trough	630 6 O
-	636 1 O
concentrations	637 14 O
rose	652 4 O
,	656 1 O
5	658 1 O
patients	660 8 O
had	669 3 O
lumbar	673 6 O
puncture	680 8 O
.	688 1 O

The	690 3 O
cerebrospinal	694 13 O
fluid	708 5 O
:	713 1 O
serum	715 5 O
ratio	721 5 O
of	727 2 O
cimetidine	730 10 B-Chemical
concentrations	741 14 O
was	756 3 O
0	760 1 O
.	761 1 O
24	762 2 O
:	764 1 O
1	765 1 O
and	767 3 O
indicates	771 9 O
that	781 4 O
cimetidine	786 10 B-Chemical
passes	797 6 O
the	804 3 O
blood	808 5 O
-	813 1 O
brain	814 5 O
barrier	820 7 O
;	827 1 O
it	829 2 O
also	832 4 O
raises	837 6 O
the	844 3 O
possibility	848 11 O
that	860 4 O
M	865 1 O
.	866 1 O
S	867 1 O
.	868 1 O
changes	870 7 O
are	878 3 O
due	882 3 O
to	886 2 O
blockade	889 8 O
of	898 2 O
histamine	901 9 B-Chemical
H2	911 2 O
-	913 1 O
receptors	914 9 O
in	924 2 O
the	927 3 O
central	931 7 O
nervous	939 7 O
system	947 6 O
.	953 1 O

Patients	955 8 O
likely	964 6 O
to	971 2 O
have	974 4 O
both	979 4 O
raised	984 6 O
trough	991 6 O
-	997 1 O
concentrations	998 14 O
and	1013 3 O
mental	1017 6 O
confusion	1024 9 B-Disease
are	1034 3 O
those	1038 5 O
with	1044 4 O
both	1049 4 O
severe	1054 6 O
renal	1061 5 B-Disease
and	1067 3 I-Disease
hepatic	1071 7 I-Disease
dysfunction	1079 11 I-Disease
.	1090 1 O

They	1092 4 O
should	1097 6 O
be	1104 2 O
closely	1107 7 O
observed	1115 8 O
and	1124 3 O
should	1128 6 O
be	1135 2 O
given	1138 5 O
reduced	1144 7 O
doses	1152 5 O
of	1158 2 O
cimetidine	1161 10 B-Chemical
.	1171 1 O

Different	0 9 O
lobular	10 7 O
distributions	18 13 O
of	32 2 O
altered	35 7 O
hepatocyte	43 10 O
tight	54 5 O
junctions	60 9 O
in	70 2 O
rat	73 3 O
models	77 6 O
of	84 2 O
intrahepatic	87 12 B-Disease
and	100 3 I-Disease
extrahepatic	104 12 I-Disease
cholestasis	117 11 I-Disease
.	128 1 O

Hepatocyte	130 10 O
tight	141 5 O
junctions	147 9 O
(	157 1 O
TJs	158 3 O
)	161 1 O
,	162 1 O
the	164 3 O
only	168 4 O
intercellular	173 13 O
barrier	187 7 O
between	195 7 O
the	203 3 O
sinusoidal	207 10 O
and	218 3 O
the	222 3 O
canalicular	226 11 O
spaces	238 6 O
,	244 1 O
play	246 4 O
a	251 1 O
key	253 3 O
role	257 4 O
in	262 2 O
bile	265 4 O
formation	270 9 O
.	279 1 O

Although	281 8 O
hepatocyte	290 10 O
TJs	301 3 O
are	305 3 O
impaired	309 8 O
in	318 2 O
cholestasis	321 11 B-Disease
,	332 1 O
attempts	334 8 O
to	343 2 O
localize	346 8 O
the	355 3 O
precise	359 7 O
site	367 4 O
of	372 2 O
hepatocyte	375 10 O
TJ	386 2 O
damage	389 6 O
by	396 2 O
freeze	399 6 O
-	405 1 O
fracture	406 8 O
electron	415 8 O
microscopy	424 10 O
have	435 4 O
produced	440 8 O
limited	449 7 O
information	457 11 O
.	468 1 O

Recently	470 8 O
,	478 1 O
several	480 7 O
TJ	488 2 O
-	490 1 O
associated	491 10 O
proteins	502 8 O
like	511 4 O
ZO	516 2 O
-	518 1 O
1	519 1 O
and	521 3 O
7H6	525 3 O
have	529 4 O
been	534 4 O
identified	539 10 O
and	550 3 O
characterized	554 13 O
.	567 1 O

Immunolocalization	569 18 O
of	588 2 O
7H6	591 3 O
appears	595 7 O
to	603 2 O
closely	606 7 O
correlate	614 9 O
with	624 4 O
paracellular	629 12 O
permeability	642 12 O
.	654 1 O

We	656 2 O
used	659 4 O
rat	664 3 O
models	668 6 O
of	675 2 O
intrahepatic	678 12 B-Disease
cholestasis	691 11 I-Disease
by	703 2 O
ethinyl	706 7 B-Chemical
estradiol	714 9 I-Chemical
(	724 1 O
EE	725 2 B-Chemical
)	727 1 O
treatment	729 9 O
and	739 3 O
extrahepatic	743 12 B-Disease
cholestasis	756 11 I-Disease
by	768 2 O
bile	771 4 O
duct	776 4 O
ligation	781 8 O
(	790 1 O
BDL	791 3 O
)	794 1 O
to	796 2 O
precisely	799 9 O
determine	809 9 O
the	819 3 O
site	823 4 O
of	828 2 O
TJ	831 2 O
damage	834 6 O
.	840 1 O

Alterations	842 11 O
in	854 2 O
hepatocyte	857 10 O
TJs	868 3 O
were	872 4 O
assessed	877 8 O
by	886 2 O
double	889 6 O
-	895 1 O
immunolabeling	896 14 O
for	911 3 O
7H6	915 3 O
and	919 3 O
ZO	923 2 O
-	925 1 O
1	926 1 O
using	928 5 O
a	934 1 O
confocal	936 8 O
laser	945 5 O
scanning	951 8 O
microscope	960 10 O
.	970 1 O

In	972 2 O
control	975 7 O
rats	983 4 O
,	987 1 O
immunostaining	989 14 O
for	1004 3 O
7H6	1008 3 O
and	1012 3 O
ZO	1016 2 O
-	1018 1 O
1	1019 1 O
colocalized	1021 11 O
to	1033 2 O
outline	1036 7 O
bile	1044 4 O
canaliculi	1049 10 O
in	1060 2 O
a	1063 1 O
continuous	1065 10 O
fashion	1076 7 O
.	1083 1 O

In	1085 2 O
contrast	1088 8 O
,	1096 1 O
7H6	1098 3 O
and	1102 3 O
ZO	1106 2 O
-	1108 1 O
1	1109 1 O
immunostaining	1111 14 O
was	1126 3 O
more	1130 4 O
discontinuous	1135 13 O
,	1148 1 O
outlining	1150 9 O
the	1160 3 O
bile	1164 4 O
canaliculi	1169 10 O
after	1180 5 O
BDL	1186 3 O
.	1189 1 O

Immunostaining	1191 14 O
for	1206 3 O
7H6	1210 3 O
,	1213 1 O
not	1215 3 O
ZO	1219 2 O
-	1221 1 O
1	1222 1 O
,	1223 1 O
decreased	1225 9 O
and	1235 3 O
predominantly	1239 13 O
appeared	1253 8 O
as	1262 2 O
discrete	1265 8 O
signals	1274 7 O
in	1282 2 O
the	1285 3 O
submembranous	1289 13 O
cytoplasm	1303 9 O
of	1313 2 O
periportal	1316 10 O
hepatocytes	1327 11 O
after	1339 5 O
BDL	1345 3 O
.	1348 1 O

After	1350 5 O
EE	1356 2 B-Chemical
treatment	1359 9 O
,	1368 1 O
changes	1370 7 O
in	1378 2 O
immunostaining	1381 14 O
for	1396 3 O
7H6	1400 3 O
and	1404 3 O
ZO	1408 2 O
-	1410 1 O
1	1411 1 O
were	1413 4 O
similar	1418 7 O
to	1426 2 O
those	1429 5 O
seen	1435 4 O
in	1440 2 O
periportal	1443 10 O
hepatocytes	1454 11 O
after	1466 5 O
BDL	1472 3 O
,	1475 1 O
but	1477 3 O
distributed	1481 11 O
more	1493 4 O
diffusely	1498 9 O
throughout	1508 10 O
the	1519 3 O
lobule	1523 6 O
.	1529 1 O

This	1531 4 O
study	1536 5 O
is	1542 2 O
the	1545 3 O
first	1549 5 O
to	1555 2 O
demonstrate	1558 11 O
that	1570 4 O
impairment	1575 10 O
of	1586 2 O
hepatocyte	1589 10 O
TJs	1600 3 O
occurs	1604 6 O
heterogenously	1611 14 O
in	1626 2 O
the	1629 3 O
liver	1633 5 O
lobule	1639 6 O
after	1646 5 O
BDL	1652 3 O
and	1656 3 O
suggests	1660 8 O
that	1669 4 O
BDL	1674 3 O
and	1678 3 O
EE	1682 2 B-Chemical
treatments	1685 10 O
produce	1696 7 O
different	1704 9 O
lobular	1714 7 O
distributions	1722 13 O
of	1736 2 O
increased	1739 9 O
paracellular	1749 12 O
permeability	1762 12 O
.	1774 1 O

Long	0 4 O
term	5 4 O
audiological	10 12 O
evaluation	23 10 O
of	34 2 O
beta	37 4 B-Disease
-	41 1 I-Disease
thalassemic	42 11 I-Disease
patients	54 8 O
.	62 1 O

OBJECTIVE	64 9 O
:	73 1 O
The	75 3 O
objective	79 9 O
of	89 2 O
this	92 4 O
study	97 5 O
was	103 3 O
to	107 2 O
identify	110 8 O
the	119 3 O
incidence	123 9 O
and	133 3 O
to	137 2 O
monitor	140 7 O
the	148 3 O
progression	152 11 O
of	164 2 O
hearing	167 7 B-Disease
loss	175 4 I-Disease
in	180 2 O
children	183 8 O
and	192 3 O
young	196 5 O
adults	202 6 O
with	209 4 O
beta	214 4 B-Disease
-	218 1 I-Disease
thalassemia	219 11 I-Disease
major	231 5 O
.	236 1 O

METHODS	238 7 O
:	245 1 O
One	247 3 O
hundred	251 7 O
and	259 3 O
four	263 4 O
(	268 1 O
104	269 3 O
)	272 1 O
patients	274 8 O
aged	283 4 O
6	288 1 O
-	289 1 O
35	290 2 O
years	293 5 O
(	299 1 O
mean	300 4 O
17	305 2 O
,	307 1 O
2	308 1 O
years	310 5 O
)	315 1 O
participated	317 12 O
in	330 2 O
the	333 3 O
study	337 5 O
.	342 1 O

All	344 3 O
patients	348 8 O
were	357 4 O
on	362 2 O
a	365 1 O
regular	367 7 O
transfusion	375 11 O
-	386 1 O
chelation	387 9 O
program	397 7 O
maintaining	405 11 O
a	417 1 O
mean	419 4 O
hemoglobin	424 10 O
level	435 5 O
of	441 2 O
9	444 1 O
.	445 1 O
5	446 1 O
gr	448 2 O
/	450 1 O
dl	451 2 O
.	453 1 O

Subjects	455 8 O
were	464 4 O
receiving	469 9 O
desferrioxamine	479 15 B-Chemical
(	495 1 O
DFO	496 3 B-Chemical
)	499 1 O
chelation	501 9 O
treatment	511 9 O
with	521 4 O
a	526 1 O
mean	528 4 O
daily	533 5 O
dose	539 4 O
of	544 2 O
50	547 2 O
-	549 1 O
60	550 2 O
mg	553 2 O
/	555 1 O
kg	556 2 O
,	558 1 O
5	560 1 O
-	561 1 O
6	562 1 O
days	564 4 O
a	569 1 O
week	571 4 O
during	576 6 O
the	583 3 O
first	587 5 O
six	593 3 O
years	597 5 O
of	603 2 O
the	606 3 O
study	610 5 O
,	615 1 O
which	617 5 O
was	623 3 O
then	627 4 O
reduced	632 7 O
to	640 2 O
40	643 2 O
-	645 1 O
50	646 2 O
mg	649 2 O
/	651 1 O
kg	652 2 O
for	655 3 O
the	659 3 O
following	663 9 O
eight	673 5 O
years	679 5 O
.	684 1 O

Patients	686 8 O
were	695 4 O
followed	700 8 O
for	709 3 O
8	713 1 O
-	714 1 O
14	715 2 O
years	718 5 O
.	723 1 O

RESULTS	725 7 O
:	732 1 O
Overall	734 7 O
,	741 1 O
21	743 2 O
out	746 3 O
of	750 2 O
104	753 3 O
patients	757 8 O
(	766 1 O
20	767 2 O
.	769 1 O
2	770 1 O
%	771 1 O
)	772 1 O
presented	774 9 O
with	784 4 O
high	789 4 O
frequency	794 9 O
sensorineural	804 13 B-Disease
hearing	818 7 I-Disease
loss	826 4 I-Disease
(	831 1 O
SNHL	832 4 B-Disease
)	836 1 O
,	837 1 O
either	839 6 O
unilateral	846 10 O
or	857 2 O
bilateral	860 9 O
.	869 1 O

No	871 2 O
ototoxic	874 8 B-Disease
factor	883 6 O
,	889 1 O
other	891 5 O
than	897 4 O
DFO	902 3 B-Chemical
,	905 1 O
was	907 3 O
present	911 7 O
in	919 2 O
any	922 3 O
of	926 2 O
the	929 3 O
patients	933 8 O
.	941 1 O

Patients	943 8 O
with	952 4 O
SNHL	957 4 B-Disease
presented	962 9 O
with	972 4 O
relatively	977 10 O
lower	988 5 O
serum	994 5 O
ferritin	1000 8 O
levels	1009 6 O
than	1016 4 O
those	1021 5 O
with	1027 4 O
normal	1032 6 O
hearing	1039 7 O
,	1046 1 O
however	1048 7 O
,	1055 1 O
no	1057 2 O
statistically	1060 13 O
significant	1074 11 O
difference	1086 10 O
was	1097 3 O
observed	1101 8 O
.	1109 1 O

Subjects	1111 8 O
with	1120 4 O
SNHL	1125 4 B-Disease
were	1130 4 O
submitted	1135 9 O
to	1145 2 O
DFO	1148 3 B-Chemical
reduction	1152 9 O
or	1162 2 O
temporary	1165 9 O
withdrawal	1175 10 O
.	1185 1 O

Following	1187 9 O
intervention	1197 12 O
,	1209 1 O
7	1211 1 O
out	1213 3 O
of	1217 2 O
21	1220 2 O
affected	1223 8 O
patients	1232 8 O
recovered	1241 9 O
,	1250 1 O
10	1252 2 O
remained	1255 8 O
stable	1264 6 O
and	1271 3 O
4	1275 1 O
demonstrated	1277 12 O
aggravation	1290 11 O
.	1301 1 O

CONCLUSION	1303 10 O
:	1313 1 O
The	1315 3 O
findings	1319 8 O
are	1328 3 O
indicative	1332 10 O
of	1343 2 O
DFO	1346 3 B-Chemical
'	1349 1 O
s	1350 1 O
contributing	1352 12 O
role	1365 4 O
in	1370 2 O
the	1373 3 O
development	1377 11 O
of	1389 2 O
hearing	1392 7 B-Disease
impairment	1400 10 I-Disease
.	1410 1 O

Regular	1412 7 O
audiologic	1420 10 O
evaluation	1431 10 O
is	1442 2 O
imperative	1445 10 O
in	1456 2 O
all	1459 3 O
thalassemic	1463 11 B-Disease
patients	1475 8 O
so	1484 2 O
that	1487 4 O
early	1492 5 O
changes	1498 7 O
may	1506 3 O
be	1510 2 O
recognized	1513 10 O
and	1524 3 O
treatment	1528 9 O
may	1538 3 O
be	1542 2 O
judiciously	1545 11 O
adjusted	1557 8 O
in	1566 2 O
order	1569 5 O
to	1575 2 O
prevent	1578 7 O
or	1586 2 O
reverse	1589 7 O
hearing	1597 7 B-Disease
impairment	1605 10 I-Disease
.	1615 1 O

Design	0 6 O
and	7 3 O
analysis	11 8 O
of	20 2 O
the	23 3 O
HYPREN	27 6 O
-	33 1 O
trial	34 5 O
:	39 1 O
safety	41 6 O
of	48 2 O
enalapril	51 9 B-Chemical
and	61 3 O
prazosin	65 8 B-Chemical
in	74 2 O
the	77 3 O
initial	81 7 O
treatment	89 9 O
phase	99 5 O
of	105 2 O
patients	108 8 O
with	117 4 O
congestive	122 10 B-Disease
heart	133 5 I-Disease
failure	139 7 I-Disease
.	146 1 O

Since	148 5 O
the	154 3 O
introduction	158 12 O
of	171 2 O
angiotensin	174 11 B-Chemical
converting	186 10 I-Chemical
enzyme	197 6 I-Chemical
(	204 1 I-Chemical
ACE	205 3 I-Chemical
)	208 1 I-Chemical
inhibitors	210 10 I-Chemical
into	221 4 O
the	226 3 O
adjunctive	230 10 O
treatment	241 9 O
of	251 2 O
patients	254 8 O
with	263 4 O
congestive	268 10 B-Disease
heart	279 5 I-Disease
failure	285 7 I-Disease
,	292 1 O
cases	294 5 O
of	300 2 O
severe	303 6 O
hypotension	310 11 B-Disease
,	321 1 O
especially	323 10 O
on	334 2 O
the	337 3 O
first	341 5 O
day	347 3 O
of	351 2 O
treatment	354 9 O
,	363 1 O
have	365 4 O
occasionally	370 12 O
been	383 4 O
reported	388 8 O
.	396 1 O

To	398 2 O
assess	401 6 O
the	408 3 O
safety	412 6 O
of	419 2 O
the	422 3 O
ACE	426 3 B-Chemical
inhibitor	430 9 I-Chemical
enalapril	440 9 B-Chemical
a	450 1 O
multicenter	452 11 O
,	463 1 O
randomized	465 10 O
,	475 1 O
prazosin	477 8 B-Chemical
-	485 1 O
controlled	486 10 O
trial	497 5 O
was	503 3 O
designed	507 8 O
that	516 4 O
compared	521 8 O
the	530 3 O
incidence	534 9 O
and	544 3 O
severity	548 8 O
of	557 2 O
symptomatic	560 11 O
hypotension	572 11 B-Disease
on	584 2 O
the	587 3 O
first	591 5 O
day	597 3 O
of	601 2 O
treatment	604 9 O
.	613 1 O

Trial	615 5 O
medication	621 10 O
was	632 3 O
2	636 1 O
.	637 1 O
5	638 1 O
mg	640 2 O
enalapril	643 9 B-Chemical
or	653 2 O
0	656 1 O
.	657 1 O
5	658 1 O
prazosin	660 8 B-Chemical
.	668 1 O

Subjects	670 8 O
were	679 4 O
1210	684 4 O
inpatients	689 10 O
with	700 4 O
New	705 3 O
York	709 4 O
Heart	714 5 O
Association	720 11 O
(	732 1 O
NYHA	733 4 O
)	737 1 O
functional	739 10 O
class	750 5 O
II	756 2 O
and	759 3 O
III	763 3 O
.	766 1 O

Patients	768 8 O
who	777 3 O
received	781 8 O
enalapril	790 9 B-Chemical
experienced	800 11 O
clinically	812 10 O
and	823 3 O
statistically	827 13 O
significantly	841 13 O
less	855 4 O
symptomatic	860 11 O
hypotension	872 11 B-Disease
(	884 1 O
5	885 1 O
.	886 1 O
2	887 1 O
%	888 1 O
)	889 1 O
than	891 4 O
the	896 3 O
patients	900 8 O
who	909 3 O
received	913 8 O
prazosin	922 8 B-Chemical
(	931 1 O
12	932 2 O
.	934 1 O
9	935 1 O
%	936 1 O
)	937 1 O
.	938 1 O

All	940 3 O
patients	944 8 O
recovered	953 9 O
.	962 1 O

It	964 2 O
was	967 3 O
concluded	971 9 O
that	981 4 O
treatment	986 9 O
with	996 4 O
enalapril	1001 9 B-Chemical
was	1011 3 O
well	1015 4 O
tolerated	1020 9 O
and	1030 3 O
it	1034 2 O
is	1037 2 O
,	1039 1 O
therefore	1041 9 O
,	1050 1 O
unreasonable	1052 12 O
to	1065 2 O
restrict	1068 8 O
the	1077 3 O
initiation	1081 10 O
of	1092 2 O
treatment	1095 9 O
with	1105 4 O
enalapril	1110 9 B-Chemical
to	1120 2 O
inpatients	1123 10 O
.	1133 1 O

Antagonism	0 10 O
between	11 7 O
interleukin	19 11 O
3	31 1 O
and	33 3 O
erythropoietin	37 14 O
in	52 2 O
mice	55 4 O
with	60 4 O
azidothymidine	65 14 B-Chemical
-	79 1 O
induced	80 7 O
anemia	88 6 B-Disease
and	95 3 O
in	99 2 O
bone	102 4 O
marrow	107 6 O
endothelial	114 11 O
cells	126 5 O
.	131 1 O

Azidothymidine	133 14 B-Chemical
(	148 1 O
AZT	149 3 B-Chemical
)	152 1 O
-	153 1 O
induced	154 7 O
anemia	162 6 B-Disease
in	169 2 O
mice	172 4 O
can	177 3 O
be	181 2 O
reversed	184 8 O
by	193 2 O
the	196 3 O
administration	200 14 O
of	215 2 O
IGF	218 3 O
-	221 1 O
IL	222 2 O
-	224 1 O
3	225 1 O
(	227 1 O
fusion	228 6 O
protein	235 7 O
of	243 2 O
insulin	246 7 O
-	253 1 O
like	254 4 O
growth	259 6 O
factor	266 6 O
II	273 2 O
(	276 1 O
IGF	277 3 O
II	281 2 O
)	283 1 O
and	285 3 O
interleukin	289 11 O
3	301 1 O
)	302 1 O
.	303 1 O

Although	305 8 O
interleukin	314 11 O
3	326 1 O
(	328 1 O
IL	329 2 O
-	331 1 O
3	332 1 O
)	333 1 O
and	335 3 O
erythropoietin	339 14 O
(	354 1 O
EPO	355 3 O
)	358 1 O
are	360 3 O
known	364 5 O
to	370 2 O
act	373 3 O
synergistically	377 15 O
on	393 2 O
hematopoietic	396 13 O
cell	410 4 O
proliferation	415 13 O
in	429 2 O
vitro	432 5 O
,	437 1 O
injection	439 9 O
of	449 2 O
IGF	452 3 O
-	455 1 O
IL	456 2 O
-	458 1 O
3	459 1 O
and	461 3 O
EPO	465 3 O
in	469 2 O
AZT	472 3 B-Chemical
-	475 1 O
treated	476 7 O
mice	484 4 O
resulted	489 8 O
in	498 2 O
a	501 1 O
reduction	503 9 O
of	513 2 O
red	516 3 O
cells	520 5 O
and	526 3 O
an	530 2 O
increase	533 8 O
of	542 2 O
plasma	545 6 O
EPO	552 3 O
levels	556 6 O
as	563 2 O
compared	566 8 O
to	575 2 O
animals	578 7 O
treated	586 7 O
with	594 4 O
IGF	599 3 O
-	602 1 O
IL	603 2 O
-	605 1 O
3	606 1 O
or	608 2 O
EPO	611 3 O
alone	615 5 O
.	620 1 O

We	622 2 O
tested	625 6 O
the	632 3 O
hypothesis	636 10 O
that	647 4 O
the	652 3 O
antagonistic	656 12 O
effect	669 6 O
of	676 2 O
IL	679 2 O
-	681 1 O
3	682 1 O
and	684 3 O
EPO	688 3 O
on	692 2 O
erythroid	695 9 O
cells	705 5 O
may	711 3 O
be	715 2 O
mediated	718 8 O
by	727 2 O
endothelial	730 11 O
cells	742 5 O
.	747 1 O

Bovine	749 6 O
liver	756 5 O
erythroid	762 9 O
cells	772 5 O
were	778 4 O
cultured	783 8 O
on	792 2 O
monolayers	795 10 O
of	806 2 O
human	809 5 O
bone	815 4 O
marrow	820 6 O
endothelial	827 11 O
cells	839 5 O
previously	845 10 O
treated	856 7 O
with	864 4 O
EPO	869 3 O
and	873 3 O
IGF	877 3 O
-	880 1 O
IL	881 2 O
-	883 1 O
3	884 1 O
.	885 1 O

There	887 5 O
was	893 3 O
a	897 1 O
significant	899 11 O
reduction	911 9 O
of	921 2 O
thymidine	924 9 B-Chemical
incorporation	934 13 O
into	948 4 O
both	953 4 O
erythroid	958 9 O
and	968 3 O
endothelial	972 11 O
cells	984 5 O
in	990 2 O
cultures	993 8 O
pre	1002 3 O
-	1005 1 O
treated	1006 7 O
with	1014 4 O
IGF	1019 3 O
-	1022 1 O
IL	1023 2 O
-	1025 1 O
3	1026 1 O
and	1028 3 O
EPO	1032 3 O
.	1035 1 O

Endothelial	1037 11 O
cell	1049 4 O
culture	1054 7 O
supernatants	1062 12 O
separated	1075 9 O
by	1085 2 O
ultrafiltration	1088 15 O
and	1104 3 O
ultracentrifugation	1108 19 O
from	1128 4 O
cells	1133 5 O
treated	1139 7 O
with	1147 4 O
EPO	1152 3 O
and	1156 3 O
IL	1160 2 O
-	1162 1 O
3	1163 1 O
significantly	1165 13 O
reduced	1179 7 O
thymidine	1187 9 B-Chemical
incorporation	1197 13 O
into	1211 4 O
erythroid	1216 9 O
cells	1226 5 O
as	1232 2 O
compared	1235 8 O
to	1244 2 O
identical	1247 9 O
fractions	1257 9 O
obtained	1267 8 O
from	1276 4 O
the	1281 3 O
media	1285 5 O
of	1291 2 O
cells	1294 5 O
cultured	1300 8 O
with	1309 4 O
EPO	1314 3 O
alone	1318 5 O
.	1323 1 O

These	1325 5 O
results	1331 7 O
suggest	1339 7 O
that	1347 4 O
endothelial	1352 11 O
cells	1364 5 O
treated	1370 7 O
simultaneously	1378 14 O
with	1393 4 O
EPO	1398 3 O
and	1402 3 O
IL	1406 2 O
-	1408 1 O
3	1409 1 O
have	1411 4 O
a	1416 1 O
negative	1418 8 O
effect	1427 6 O
on	1434 2 O
erythroid	1437 9 O
cell	1447 4 O
production	1452 10 O
.	1462 1 O

Interactive	0 11 O
effects	12 7 O
of	20 2 O
variations	23 10 O
in	34 2 O
[	37 1 O
Na	38 2 B-Chemical
]	40 1 O
o	41 1 O
and	43 3 O
[	47 1 O
Ca	48 2 B-Chemical
]	50 1 O
o	51 1 O
on	53 2 O
rat	56 3 O
atrial	60 6 O
spontaneous	67 11 O
frequency	79 9 O
.	88 1 O

The	90 3 O
effects	94 7 O
of	102 2 O
varying	105 7 O
the	113 3 O
extracellular	117 13 O
concentrations	131 14 O
of	146 2 O
Na	149 2 B-Chemical
and	152 3 O
Ca	156 2 B-Chemical
(	159 1 O
[	160 1 O
Na	161 2 B-Chemical
]	163 1 O
o	164 1 O
and	166 3 O
[	170 1 O
Ca	171 2 B-Chemical
]	173 1 O
o	174 1 O
)	175 1 O
on	177 2 O
both	180 4 O
,	184 1 O
the	186 3 O
spontaneous	190 11 O
beating	202 7 O
and	210 3 O
the	214 3 O
negative	218 8 O
chronotropic	227 12 O
action	240 6 O
of	247 2 O
verapamil	250 9 B-Chemical
,	259 1 O
were	261 4 O
studied	266 7 O
in	274 2 O
the	277 3 O
isolated	281 8 O
rat	290 3 O
atria	294 5 O
.	299 1 O

Basal	301 5 O
frequency	307 9 O
(	317 1 O
BF	318 2 O
)	320 1 O
evaluated	322 9 O
by	332 2 O
surface	335 7 O
electrogram	343 11 O
was	355 3 O
223	359 3 O
+	363 1 O
/	364 1 O
-	365 1 O
4	367 1 O
beats	369 5 O
/	374 1 O
min	375 3 O
.	378 1 O
in	380 2 O
control	383 7 O
Krebs	391 5 O
-	396 1 O
Ringer	397 6 O
containing	404 10 O
137	415 3 O
mM	419 2 O
Na	422 2 B-Chemical
and	425 3 O
1	429 1 O
.	430 1 O
35	431 2 O
mM	434 2 O
Ca	437 2 B-Chemical
(	440 1 O
N	441 1 O
)	442 1 O
.	443 1 O

It	445 2 O
decreased	448 9 O
by	458 2 O
16	461 2 O
+	464 1 O
/	465 1 O
-	466 1 O
3	468 1 O
%	469 1 O
by	471 2 O
lowering	474 8 O
[	483 1 O
Na	484 2 B-Chemical
]	486 1 O
o	487 1 O
to	489 2 O
78	492 2 O
mM	495 2 O
(	498 1 O
LNa	499 3 O
)	502 1 O
,	503 1 O
23	505 2 O
+	508 1 O
/	509 1 O
-	510 1 O
2	512 1 O
%	513 1 O
by	515 2 O
lowering	518 8 O
simultaneously	527 14 O
[	542 1 O
Na	543 2 B-Chemical
]	545 1 O
o	546 1 O
to	548 2 O
78	551 2 O
mM	554 2 O
and	557 3 O
[	561 1 O
Ca	562 2 B-Chemical
]	564 1 O
o	565 1 O
to	567 2 O
0	570 1 O
.	571 1 O
675	572 3 O
mM	576 2 O
(	579 1 O
LNa	580 3 O
+	583 1 O
LCa	584 3 O
)	587 1 O
and	589 3 O
31	593 2 O
+	596 1 O
/	597 1 O
-	598 1 O
5	600 1 O
%	601 1 O
by	603 2 O
lowering	606 8 O
[	615 1 O
Na	616 2 B-Chemical
]	618 1 O
o	619 1 O
to	621 2 O
78	624 2 O
mM	627 2 O
plus	630 4 O
increasing	635 10 O
[	646 1 O
Ca	647 2 B-Chemical
]	649 1 O
o	650 1 O
to	652 2 O
3	655 1 O
.	656 1 O
6	657 1 O
mM	659 2 O
(	662 1 O
LNa	663 3 O
+	666 1 O
HCa	667 3 O
)	670 1 O
.	671 1 O

At	673 2 O
normal	676 6 O
[	683 1 O
Na	684 2 B-Chemical
]	686 1 O
o	687 1 O
,	688 1 O
decrease	690 8 O
(	699 1 O
0	700 1 O
.	701 1 O
675	702 3 O
mM	706 2 O
)	708 1 O
or	710 2 O
increase	713 8 O
(	722 1 O
3	723 1 O
.	724 1 O
6	725 1 O
mM	727 2 O
)	729 1 O
of	731 2 O
[	734 1 O
Ca	735 2 B-Chemical
]	737 1 O
o	738 1 O
did	740 3 O
not	744 3 O
modify	748 6 O
BF	755 2 O
;	757 1 O
a	759 1 O
reduction	761 9 O
of	771 2 O
ten	774 3 O
times	778 5 O
(	784 1 O
0	785 1 O
.	786 1 O
135	787 3 O
mM	791 2 O
of	794 2 O
normal	797 6 O
[	804 1 O
Ca	805 2 B-Chemical
]	807 1 O
o	808 1 O
was	810 3 O
effective	814 9 O
to	824 2 O
reduce	827 6 O
BF	834 2 O
by	837 2 O
40	840 2 O
+	843 1 O
/	844 1 O
-	845 1 O
13	847 2 O
%	849 1 O
.	850 1 O

All	852 3 O
negative	856 8 O
chronotropic	865 12 O
effects	878 7 O
were	886 4 O
BF	891 2 O
-	893 1 O
dependent	894 9 O
.	903 1 O

Dose	905 4 O
-	909 1 O
dependent	910 9 O
bradycardia	920 11 B-Disease
induced	932 7 O
by	940 2 O
verapamil	943 9 B-Chemical
was	953 3 O
potentiated	957 11 O
by	969 2 O
LNa	972 3 O
,	975 1 O
LCa	977 3 O
,	980 1 O
and	982 3 O
HCa	986 3 O
.	989 1 O

Independent	991 11 O
but	1003 3 O
not	1007 3 O
additive	1011 8 O
effects	1020 7 O
of	1028 2 O
Na	1031 2 B-Chemical
and	1034 3 O
Ca	1038 2 B-Chemical
are	1041 3 O
shown	1045 5 O
by	1051 2 O
decreases	1054 9 O
in	1064 2 O
the	1067 3 O
values	1071 6 O
of	1078 2 O
[	1081 1 O
verapamil	1082 9 B-Chemical
]	1091 1 O
o	1092 1 O
needed	1094 6 O
to	1101 2 O
reduce	1104 6 O
BF	1111 2 O
by	1114 2 O
30	1117 2 O
%	1119 1 O
(	1121 1 O
IC30	1122 4 O
)	1126 1 O
with	1128 4 O
the	1133 3 O
following	1137 9 O
order	1147 5 O
of	1153 2 O
inhibitory	1156 10 O
potency	1167 7 O
:	1174 1 O
LNa	1176 3 O
>	1180 1 O
LCa	1182 3 O
>	1186 1 O
HCa	1188 3 O
>	1192 1 O
N	1194 1 O
,	1195 1 O
resulting	1197 9 O
LNa	1207 3 O
+	1210 1 O
HCa	1211 3 O
similar	1215 7 O
to	1223 2 O
LNa	1226 3 O
.	1229 1 O

The	1231 3 O
[	1235 1 O
verapamil	1236 9 B-Chemical
]	1245 1 O
o	1246 1 O
that	1248 4 O
arrested	1253 8 O
atrial	1262 6 O
beating	1269 7 O
(	1277 1 O
AC	1278 2 O
)	1280 1 O
was	1282 3 O
also	1286 4 O
potentiated	1291 11 O
with	1303 4 O
the	1308 3 O
order	1312 5 O
LNa	1318 3 O
=	1322 1 O
LNa	1324 3 O
+	1327 1 O
LCa	1328 3 O
=	1332 1 O
LNa	1334 3 O
+	1337 1 O
HCa	1338 3 O
=	1342 1 O
LCa	1344 3 O
>	1348 1 O
HCa	1350 3 O
=	1354 1 O
N	1356 1 O
.	1357 1 O

The	1359 3 O
results	1363 7 O
indicate	1371 8 O
that	1380 4 O
rat	1385 3 O
atrial	1389 6 O
spontaneous	1396 11 O
beating	1408 7 O
is	1416 2 O
more	1419 4 O
dependent	1424 9 O
on	1434 2 O
[	1437 1 O
Na	1438 2 B-Chemical
]	1440 1 O
o	1441 1 O
than	1443 4 O
on	1448 2 O
[	1451 1 O
Ca	1452 2 B-Chemical
]	1454 1 O
o	1455 1 O
in	1457 2 O
a	1460 1 O
range	1462 5 O
of	1468 2 O
+	1471 1 O
/	1472 1 O
-	1473 1 O
50	1475 2 O
%	1477 1 O
of	1479 2 O
their	1482 5 O
normal	1488 6 O
concentration	1495 13 O
.	1508 1 O

Also	1510 4 O
the	1515 3 O
enhancement	1519 11 O
of	1531 2 O
verapamil	1534 9 B-Chemical
effects	1544 7 O
on	1552 2 O
atrial	1555 6 O
beating	1562 7 O
was	1570 3 O
more	1574 4 O
pronounced	1579 10 O
at	1590 2 O
LNa	1593 3 O
than	1597 4 O
at	1602 2 O
LCa	1605 3 O
.	1608 1 O
(	1609 1 O
ABSTRACT	1610 8 O
TRUNCATED	1619 9 O
AT	1629 2 O
250	1632 3 O
WORDS	1636 5 O
)	1641 1 O

Sodium	0 6 B-Chemical
status	7 6 O
influences	14 10 O
chronic	25 7 O
amphotericin	33 12 B-Chemical
B	46 1 I-Chemical
nephrotoxicity	48 14 B-Disease
in	63 2 O
rats	66 4 O
.	70 1 O

The	72 3 O
nephrotoxic	76 11 B-Disease
potential	88 9 O
of	98 2 O
amphotericin	101 12 B-Chemical
B	114 1 I-Chemical
(	116 1 O
5	117 1 O
mg	119 2 O
/	121 1 O
kg	122 2 O
per	125 3 O
day	129 3 O
intraperitoneally	133 17 O
for	151 3 O
3	155 1 O
weeks	157 5 O
)	162 1 O
has	164 3 O
been	168 4 O
investigated	173 12 O
in	186 2 O
salt	189 4 O
-	193 1 O
depleted	194 8 O
,	202 1 O
normal	204 6 O
-	210 1 O
salt	211 4 O
,	215 1 O
and	217 3 O
salt	221 4 O
-	225 1 O
loaded	226 6 O
rats	233 4 O
.	237 1 O

In	239 2 O
salt	242 4 O
-	246 1 O
depleted	247 8 O
rats	256 4 O
,	260 1 O
amphotericin	262 12 B-Chemical
B	275 1 I-Chemical
decreased	277 9 O
creatinine	287 10 B-Chemical
clearance	298 9 O
linearly	308 8 O
with	317 4 O
time	322 4 O
,	326 1 O
with	328 4 O
an	333 2 O
85	336 2 O
%	338 1 O
reduction	340 9 O
by	350 2 O
week	353 4 O
3	358 1 O
.	359 1 O

In	361 2 O
contrast	364 8 O
,	372 1 O
in	374 2 O
normal	377 6 O
-	383 1 O
salt	384 4 O
rats	389 4 O
creatinine	394 10 B-Chemical
clearance	405 9 O
was	415 3 O
decreased	419 9 O
but	429 3 O
to	433 2 O
a	436 1 O
lesser	438 6 O
extent	445 6 O
at	452 2 O
week	455 4 O
2	460 1 O
and	462 3 O
3	466 1 O
,	467 1 O
and	469 3 O
in	473 2 O
salt	476 4 O
-	480 1 O
loaded	481 6 O
rats	488 4 O
creatinine	493 10 B-Chemical
clearance	504 9 O
did	514 3 O
not	518 3 O
change	522 6 O
for	529 3 O
2	533 1 O
weeks	535 5 O
and	541 3 O
was	545 3 O
decreased	549 9 O
by	559 2 O
43	562 2 O
%	564 1 O
at	566 2 O
week	569 4 O
3	574 1 O
.	575 1 O

All	577 3 O
rats	581 4 O
in	586 2 O
the	589 3 O
sodium	593 6 B-Chemical
-	599 1 O
depleted	600 8 O
group	609 5 O
had	615 3 O
histopathological	619 17 O
evidence	637 8 O
of	646 2 O
patchy	649 6 O
tubular	656 7 O
cytoplasmic	664 11 O
degeneration	676 12 O
in	689 2 O
tubules	692 7 O
that	700 4 O
was	705 3 O
not	709 3 O
observed	713 8 O
in	722 2 O
any	725 3 O
normal	729 6 O
-	735 1 O
salt	736 4 O
or	741 2 O
salt	744 4 O
-	748 1 O
loaded	749 6 O
rat	756 3 O
.	759 1 O

Concentrations	761 14 O
of	776 2 O
amphotericin	779 12 B-Chemical
B	792 1 I-Chemical
in	794 2 O
plasma	797 6 O
were	804 4 O
not	809 3 O
significantly	813 13 O
different	827 9 O
among	837 5 O
the	843 3 O
three	847 5 O
groups	853 6 O
at	860 2 O
any	863 3 O
time	867 4 O
during	872 6 O
the	879 3 O
study	883 5 O
.	888 1 O

However	890 7 O
,	897 1 O
at	899 2 O
the	902 3 O
end	906 3 O
of	910 2 O
3	913 1 O
weeks	915 5 O
,	920 1 O
amphotericin	922 12 B-Chemical
B	935 1 I-Chemical
levels	937 6 O
in	944 2 O
the	947 3 O
kidneys	951 7 O
and	959 3 O
liver	963 5 O
were	969 4 O
significantly	974 13 O
higher	988 6 O
in	995 2 O
salt	998 4 O
-	1002 1 O
depleted	1003 8 O
and	1012 3 O
normal	1016 6 O
-	1022 1 O
salt	1023 4 O
rats	1028 4 O
than	1033 4 O
those	1038 5 O
in	1044 2 O
salt	1047 4 O
-	1051 1 O
loaded	1052 6 O
rats	1059 4 O
,	1063 1 O
with	1065 4 O
plasma	1070 6 O
/	1076 1 O
kidney	1077 6 O
ratios	1084 6 O
of	1091 2 O
21	1094 2 O
,	1096 1 O
14	1098 2 O
,	1100 1 O
and	1102 3 O
8	1106 1 O
in	1108 2 O
salt	1111 4 O
-	1115 1 O
depleted	1116 8 O
,	1124 1 O
normal	1126 6 O
-	1132 1 O
salt	1133 4 O
,	1137 1 O
and	1139 3 O
salt	1143 4 O
-	1147 1 O
loaded	1148 6 O
rats	1155 4 O
,	1159 1 O
respectively	1161 12 O
.	1173 1 O

In	1175 2 O
conclusion	1178 10 O
,	1188 1 O
reductions	1190 10 O
in	1201 2 O
creatinine	1204 10 B-Chemical
clearance	1215 9 O
and	1225 3 O
renal	1229 5 O
amphotericin	1235 12 B-Chemical
B	1248 1 I-Chemical
accumulation	1250 12 O
after	1263 5 O
chronic	1269 7 O
amphotericin	1277 12 B-Chemical
B	1290 1 I-Chemical
administration	1292 14 O
were	1307 4 O
enhanced	1312 8 O
by	1321 2 O
salt	1324 4 O
depletion	1329 9 O
and	1339 3 O
attenuated	1343 10 O
by	1354 2 O
sodium	1357 6 B-Chemical
loading	1364 7 O
in	1372 2 O
rats	1375 4 O
.	1379 1 O

Reversible	0 10 O
inferior	11 8 B-Disease
colliculus	20 10 I-Disease
lesion	31 6 I-Disease
in	38 2 O
metronidazole	41 13 B-Chemical
-	54 1 O
induced	55 7 O
encephalopathy	63 14 B-Disease
:	77 1 O
magnetic	79 8 O
resonance	88 9 O
findings	98 8 O
on	107 2 O
diffusion	110 9 O
-	119 1 O
weighted	120 8 O
and	129 3 O
fluid	133 5 O
attenuated	139 10 O
inversion	150 9 O
recovery	160 8 O
imaging	169 7 O
.	176 1 O

OBJECTIVE	178 9 O
:	187 1 O
This	189 4 O
is	194 2 O
to	197 2 O
present	200 7 O
reversible	208 10 O
inferior	219 8 B-Disease
colliculus	228 10 I-Disease
lesions	239 7 I-Disease
in	247 2 O
metronidazole	250 13 B-Chemical
-	263 1 O
induced	264 7 O
encephalopathy	272 14 B-Disease
,	286 1 O
to	288 2 O
focus	291 5 O
on	297 2 O
the	300 3 O
diffusion	304 9 O
-	313 1 O
weighted	314 8 O
imaging	323 7 O
(	331 1 O
DWI	332 3 O
)	335 1 O
and	337 3 O
fluid	341 5 O
attenuated	347 10 O
inversion	358 9 O
recovery	368 8 O
(	377 1 O
FLAIR	378 5 O
)	383 1 O
imaging	385 7 O
.	392 1 O

MATERIALS	394 9 O
AND	404 3 O
METHODS	408 7 O
:	415 1 O
From	417 4 O
November	422 8 O
2005	431 4 O
to	436 2 O
September	439 9 O
2007	449 4 O
,	453 1 O
8	455 1 O
patients	457 8 O
(	466 1 O
5	467 1 O
men	469 3 O
and	473 3 O
3	477 1 O
women	479 5 O
)	484 1 O
were	486 4 O
diagnosed	491 9 O
as	501 2 O
having	504 6 O
metronidazole	511 13 B-Chemical
-	524 1 O
induced	525 7 O
encephalopathy	533 14 B-Disease
(	548 1 O
age	549 3 O
range	553 5 O
;	558 1 O
43	560 2 O
-	562 1 O
78	563 2 O
years	566 5 O
)	571 1 O
.	572 1 O

They	574 4 O
had	579 3 O
been	583 4 O
taking	588 6 O
metronidazole	595 13 B-Chemical
(	609 1 O
total	610 5 O
dosage	616 6 O
,	622 1 O
45	624 2 O
-	626 1 O
120	627 3 O
g	631 1 O
;	632 1 O
duration	634 8 O
,	642 1 O
30	644 2 O
days	647 4 O
to	652 2 O
2	655 1 O
months	657 6 O
)	663 1 O
to	665 2 O
treat	668 5 O
the	674 3 O
infection	678 9 B-Disease
in	688 2 O
various	691 7 O
organs	699 6 O
.	705 1 O

Initial	707 7 O
brain	715 5 O
magnetic	721 8 O
resonance	730 9 O
imaging	740 7 O
(	748 1 O
MRI	749 3 O
)	752 1 O
were	754 4 O
obtained	759 8 O
after	768 5 O
the	774 3 O
hospitalization	778 15 O
,	793 1 O
including	795 9 O
DWI	805 3 O
(	809 1 O
8	810 1 O
/	811 1 O
8	812 1 O
)	813 1 O
,	814 1 O
apparent	816 8 O
diffusion	825 9 O
coefficient	835 11 O
(	847 1 O
ADC	848 3 O
)	851 1 O
map	853 3 O
(	857 1 O
4	858 1 O
/	859 1 O
8	860 1 O
)	861 1 O
,	862 1 O
FLAIR	864 5 O
(	870 1 O
7	871 1 O
/	872 1 O
8	873 1 O
)	874 1 O
,	875 1 O
and	877 3 O
T2	881 2 O
-	883 1 O
weighted	884 8 O
image	893 5 O
(	899 1 O
8	900 1 O
/	901 1 O
8	902 1 O
)	903 1 O
.	904 1 O

Follow	906 6 O
-	912 1 O
up	913 2 O
MRIs	916 4 O
were	921 4 O
performed	926 9 O
on	936 2 O
5	939 1 O
patients	941 8 O
from	950 4 O
third	955 5 O
to	961 2 O
14th	964 4 O
days	969 4 O
after	974 5 O
discontinuation	980 15 O
of	996 2 O
metronidazole	999 13 B-Chemical
administration	1013 14 O
.	1027 1 O

Findings	1029 8 O
of	1038 2 O
initial	1041 7 O
and	1049 3 O
follow	1053 6 O
-	1059 1 O
up	1060 2 O
MRIs	1063 4 O
were	1068 4 O
retrospectively	1073 15 O
evaluated	1089 9 O
by	1099 2 O
2	1102 1 O
neuroradiologists	1104 17 O
by	1122 2 O
consensus	1125 9 O
,	1134 1 O
to	1136 2 O
analyze	1139 7 O
the	1147 3 O
presence	1151 8 O
of	1160 2 O
abnormal	1163 8 O
signal	1172 6 O
intensities	1179 11 O
,	1190 1 O
their	1192 5 O
locations	1198 9 O
,	1207 1 O
and	1209 3 O
signal	1213 6 O
changes	1220 7 O
on	1228 2 O
follow	1231 6 O
-	1237 1 O
up	1238 2 O
images	1241 6 O
.	1247 1 O

RESULTS	1249 7 O
:	1256 1 O
Initial	1258 7 O
MRIs	1266 4 O
showed	1271 6 O
abnormal	1278 8 O
high	1287 4 O
signal	1292 6 O
intensities	1299 11 O
on	1311 2 O
DWI	1314 3 O
and	1318 3 O
FLAIR	1322 5 O
(	1328 1 O
or	1329 2 O
T2	1332 2 O
-	1334 1 O
weighted	1335 8 O
image	1344 5 O
)	1349 1 O
at	1351 2 O
the	1354 3 O
dentate	1358 7 O
nucleus	1366 7 O
(	1374 1 O
8	1375 1 O
/	1376 1 O
8	1377 1 O
)	1378 1 O
,	1379 1 O
inferior	1381 8 O
colliculus	1390 10 O
(	1401 1 O
6	1402 1 O
/	1403 1 O
8	1404 1 O
)	1405 1 O
,	1406 1 O
corpus	1408 6 O
callosum	1415 8 O
(	1424 1 O
2	1425 1 O
/	1426 1 O
8	1427 1 O
)	1428 1 O
,	1429 1 O
pons	1431 4 O
(	1436 1 O
2	1437 1 O
/	1438 1 O
8	1439 1 O
)	1440 1 O
,	1441 1 O
medulla	1443 7 O
(	1451 1 O
1	1452 1 O
/	1453 1 O
8	1454 1 O
)	1455 1 O
,	1456 1 O
and	1458 3 O
bilateral	1462 9 O
cerebral	1472 8 O
white	1481 5 O
matter	1487 6 O
(	1494 1 O
1	1495 1 O
/	1496 1 O
8	1497 1 O
)	1498 1 O
.	1499 1 O

High	1501 4 O
-	1505 1 O
signal	1506 6 O
intensity	1513 9 O
lesions	1523 7 O
on	1531 2 O
DWI	1534 3 O
tended	1538 6 O
to	1545 2 O
show	1548 4 O
low	1553 3 O
signal	1557 6 O
intensity	1564 9 O
on	1574 2 O
ADC	1577 3 O
map	1581 3 O
(	1585 1 O
3	1586 1 O
/	1587 1 O
4	1588 1 O
)	1589 1 O
,	1590 1 O
but	1592 3 O
in	1596 2 O
one	1599 3 O
patient	1603 7 O
,	1610 1 O
high	1612 4 O
signal	1617 6 O
intensity	1624 9 O
was	1634 3 O
shown	1638 5 O
at	1644 2 O
bilateral	1647 9 O
dentate	1657 7 O
nuclei	1665 6 O
on	1672 2 O
not	1675 3 O
only	1679 4 O
DWI	1684 3 O
but	1688 3 O
also	1692 4 O
ADC	1697 3 O
map	1701 3 O
.	1704 1 O

All	1706 3 O
the	1710 3 O
lesions	1714 7 O
in	1722 2 O
dentate	1725 7 O
,	1732 1 O
inferior	1734 8 O
colliculus	1743 10 O
,	1753 1 O
pons	1755 4 O
,	1759 1 O
and	1761 3 O
medullas	1765 8 O
had	1774 3 O
been	1778 4 O
resolved	1783 8 O
completely	1792 10 O
on	1803 2 O
follow	1806 6 O
-	1812 1 O
up	1813 2 O
MRIs	1816 4 O
in	1821 2 O
5	1824 1 O
patients	1826 8 O
,	1834 1 O
but	1836 3 O
in	1840 2 O
1	1843 1 O
patient	1845 7 O
of	1853 2 O
them	1856 4 O
,	1860 1 O
corpus	1862 6 O
callosal	1869 8 B-Disease
lesion	1878 6 I-Disease
persisted	1885 9 O
.	1894 1 O

CONCLUSIONS	1896 11 O
:	1907 1 O
Reversible	1909 10 O
inferior	1920 8 B-Disease
colliculus	1929 10 I-Disease
lesions	1940 7 I-Disease
could	1948 5 O
be	1954 2 O
considered	1957 10 O
as	1968 2 O
the	1971 3 O
characteristic	1975 14 O
for	1990 3 O
metronidazole	1994 13 B-Chemical
-	2007 1 O
induced	2008 7 O
encephalopathy	2016 14 B-Disease
,	2030 1 O
next	2032 4 O
to	2037 2 O
the	2040 3 O
dentate	2044 7 O
nucleus	2052 7 O
involvement	2060 11 O
.	2071 1 O

Comparison	0 10 O
of	11 2 O
the	14 3 O
respiratory	18 11 O
effects	30 7 O
of	38 2 O
i	41 1 O
.	42 1 O
v	43 1 O
.	44 1 O
infusions	46 9 O
of	56 2 O
morphine	59 8 B-Chemical
and	68 3 O
regional	72 8 O
analgesia	81 9 O
by	91 2 O
extradural	94 10 O
block	105 5 O
.	110 1 O

The	112 3 O
incidence	116 9 O
of	126 2 O
postoperative	129 13 O
respiratory	143 11 O
apnoea	155 6 B-Disease
was	162 3 O
compared	166 8 O
between	175 7 O
five	183 4 O
patients	188 8 O
receiving	197 9 O
a	207 1 O
continuous	209 10 O
i	220 1 O
.	221 1 O
v	222 1 O
.	223 1 O
infusion	225 8 O
of	234 2 O
morphine	237 8 B-Chemical
(	246 1 O
mean	247 4 O
73	252 2 O
.	254 1 O
6	255 1 O
mg	257 2 O
)	259 1 O
and	261 3 O
five	265 4 O
patients	270 8 O
receiving	279 9 O
a	289 1 O
continuous	291 10 O
extradural	302 10 O
infusion	313 8 O
of	322 2 O
0	325 1 O
.	326 1 O
25	327 2 O
%	329 1 O
bupivacaine	331 11 B-Chemical
(	343 1 O
mean	344 4 O
192	349 3 O
mg	353 2 O
)	355 1 O
in	357 2 O
the	360 3 O
24	364 2 O
-	366 1 O
h	367 1 O
period	369 6 O
following	376 9 O
upper	386 5 O
abdominal	392 9 O
surgery	402 7 O
.	409 1 O

Monitoring	411 10 O
consisted	422 9 O
of	432 2 O
airflow	435 7 O
detection	443 9 O
by	453 2 O
a	456 1 O
carbon	458 6 B-Chemical
dioxide	465 7 I-Chemical
analyser	473 8 O
,	481 1 O
chest	483 5 O
wall	489 4 O
movement	494 8 O
detected	503 8 O
by	512 2 O
pneumatic	515 9 O
capsules	525 8 O
,	533 1 O
and	535 3 O
continuous	539 10 O
electrocardiograph	550 18 O
recorded	569 8 O
with	578 4 O
a	583 1 O
Holter	585 6 O
ambulatory	592 10 O
monitor	603 7 O
.	610 1 O

Both	612 4 O
obstructive	617 11 B-Disease
(	629 1 I-Disease
P	630 1 I-Disease
less	632 4 I-Disease
than	637 4 I-Disease
0	642 1 I-Disease
.	643 1 I-Disease
05	644 2 I-Disease
)	646 1 I-Disease
and	648 3 I-Disease
central	652 7 I-Disease
apnoea	660 6 I-Disease
(	667 1 O
P	668 1 O
less	670 4 O
than	675 4 O
0	680 1 O
.	681 1 O
05	682 2 O
)	684 1 O
occurred	686 8 O
more	695 4 O
frequently	700 10 O
in	711 2 O
patients	714 8 O
who	723 3 O
had	727 3 O
a	731 1 O
morphine	733 8 B-Chemical
infusion	742 8 O
.	750 1 O

There	752 5 O
was	758 3 O
also	762 4 O
a	767 1 O
higher	769 6 O
incidence	776 9 O
of	786 2 O
tachyarrhythmias	789 16 B-Disease
(	806 1 O
P	807 1 O
less	809 4 O
than	814 4 O
0	819 1 O
.	820 1 O
05	821 2 O
)	823 1 O
and	825 3 O
ventricular	829 11 B-Disease
ectopic	841 7 I-Disease
beats	849 5 I-Disease
(	855 1 O
P	856 1 O
less	858 4 O
than	863 4 O
0	868 1 O
.	869 1 O
05	870 2 O
)	872 1 O
in	874 2 O
the	877 3 O
morphine	881 8 B-Chemical
infusion	890 8 O
group	899 5 O
.	904 1 O

Magnetic	0 8 O
resonance	9 9 O
volumetry	19 9 O
of	29 2 O
the	32 3 O
cerebellum	36 10 O
in	47 2 O
epileptic	50 9 B-Disease
patients	60 8 O
after	69 5 O
phenytoin	75 9 B-Chemical
overdosages	85 11 B-Disease
.	96 1 O

The	98 3 O
aim	102 3 O
of	106 2 O
this	109 4 O
study	114 5 O
was	120 3 O
to	124 2 O
evaluate	127 8 O
the	136 3 O
relationship	140 12 O
between	153 7 O
phenytoin	161 9 B-Chemical
medication	171 10 O
and	182 3 O
cerebellar	186 10 B-Disease
atrophy	197 7 I-Disease
in	205 2 O
patients	208 8 O
who	217 3 O
had	221 3 O
experienced	225 11 O
clinical	237 8 O
intoxication	246 12 O
.	258 1 O

Five	260 4 O
females	265 7 O
and	273 3 O
6	277 1 O
males	279 5 O
,	284 1 O
21	286 2 O
-	288 1 O
59	289 2 O
years	292 5 O
of	298 2 O
age	301 3 O
,	304 1 O
were	306 4 O
examined	311 8 O
with	320 4 O
a	325 1 O
1	327 1 O
.	328 1 O
5	329 1 O
-	330 1 O
T	331 1 O
whole	333 5 O
-	338 1 O
body	339 4 O
system	344 6 O
using	351 5 O
a	357 1 O
circular	359 8 O
polarized	368 9 O
head	378 4 O
coil	383 4 O
.	387 1 O

Conventional	389 12 O
spin	402 4 O
echo	407 4 O
images	412 6 O
were	419 4 O
acquired	424 8 O
in	433 2 O
the	436 3 O
sagittal	440 8 O
and	449 3 O
transverse	453 10 O
orientation	464 11 O
.	475 1 O

In	477 2 O
addition	480 8 O
,	488 1 O
we	490 2 O
performed	493 9 O
a	503 1 O
high	505 4 O
-	509 1 O
resolution	510 10 O
3D	521 2 O
gradient	524 8 O
echo	533 4 O
,	537 1 O
T1	539 2 O
-	541 1 O
weighted	542 8 O
sequences	551 9 O
at	561 2 O
a	564 1 O
1	566 1 O
-	567 1 O
mm	568 2 O
slice	571 5 O
thickness	577 9 O
.	586 1 O

The	588 3 O
images	592 6 O
were	599 4 O
subsequently	604 12 O
processed	617 9 O
to	627 2 O
obtain	630 6 O
volumetric	637 10 O
data	648 4 O
for	653 3 O
the	657 3 O
cerebellum	661 10 O
.	671 1 O

Cerebellar	673 10 O
volume	684 6 O
for	691 3 O
the	695 3 O
patient	699 7 O
group	707 5 O
ranged	713 6 O
between	720 7 O
67	728 2 O
.	730 1 O
66	731 2 O
and	734 3 O
131	738 3 O
.	741 1 O
08	742 2 O
ml	745 2 O
(	748 1 O
mean	749 4 O
108	754 3 O
.	757 1 O
9	758 1 O
ml	760 2 O
)	762 1 O
.	763 1 O

In	765 2 O
addition	768 8 O
3D	777 2 O
gradient	780 8 O
echo	789 4 O
data	794 4 O
sets	799 4 O
from	804 4 O
10	809 2 O
healthy	812 7 O
male	820 4 O
and	825 3 O
10	829 2 O
healthy	832 7 O
female	840 6 O
age	847 3 O
-	850 1 O
matched	851 7 O
volunteers	859 10 O
were	870 4 O
used	875 4 O
to	880 2 O
compare	883 7 O
cerebellar	891 10 O
volumes	902 7 O
.	909 1 O

Using	911 5 O
linear	917 6 O
regression	924 10 O
we	935 2 O
found	938 5 O
that	944 4 O
no	949 2 O
correlation	952 11 O
exists	964 6 O
between	971 7 O
seizure	979 7 B-Disease
duration	987 8 O
,	995 1 O
elevation	997 9 O
of	1007 2 O
phenytoin	1010 9 B-Chemical
serum	1020 5 O
levels	1026 6 O
and	1033 3 O
cerebellar	1037 10 O
volume	1048 6 O
.	1054 1 O

However	1056 7 O
,	1063 1 O
multiple	1065 8 O
regression	1074 10 O
for	1085 3 O
the	1089 3 O
daily	1093 5 O
dosage	1099 6 O
,	1105 1 O
duration	1107 8 O
of	1116 2 O
phenytoin	1119 9 B-Chemical
treatment	1129 9 O
and	1139 3 O
cerebellar	1143 10 O
volume	1154 6 O
revealed	1161 8 O
a	1170 1 O
correlation	1172 11 O
of	1184 2 O
these	1187 5 O
parameters	1193 10 O
.	1203 1 O

We	1205 2 O
conclude	1208 8 O
that	1217 4 O
phenytoin	1222 9 B-Chemical
overdosage	1232 10 B-Disease
does	1243 4 O
not	1248 3 O
necessarily	1252 11 O
result	1264 6 O
in	1271 2 O
cerebellar	1274 10 B-Disease
atrophy	1285 7 I-Disease
and	1293 3 O
it	1297 2 O
is	1300 2 O
unlikely	1303 8 O
that	1312 4 O
phenytoin	1317 9 B-Chemical
medication	1327 10 O
was	1338 3 O
the	1342 3 O
only	1346 4 O
cause	1351 5 O
of	1357 2 O
cerebellar	1360 10 B-Disease
atrophy	1371 7 I-Disease
in	1379 2 O
the	1382 3 O
remaining	1386 9 O
patients	1396 8 O
.	1404 1 O

Quantitative	1406 12 O
morphometric	1419 12 O
studies	1432 7 O
of	1440 2 O
the	1443 3 O
cerebellum	1447 10 O
provide	1458 7 O
valuable	1466 8 O
insights	1475 8 O
into	1484 4 O
the	1489 3 O
pathogenesis	1493 12 O
of	1506 2 O
cerebellar	1509 10 B-Disease
disorders	1520 9 I-Disease
.	1529 1 O

Evaluation	0 10 O
of	11 2 O
cardiac	14 7 O
troponin	22 8 O
I	31 1 O
and	33 3 O
T	37 1 O
levels	39 6 O
as	46 2 O
markers	49 7 O
of	57 2 O
myocardial	60 10 B-Disease
damage	71 6 I-Disease
in	78 2 O
doxorubicin	81 11 B-Chemical
-	92 1 O
induced	93 7 O
cardiomyopathy	101 14 B-Disease
rats	116 4 O
,	120 1 O
and	122 3 O
their	126 5 O
relationship	132 12 O
with	145 4 O
echocardiographic	150 17 O
and	168 3 O
histological	172 12 O
findings	185 8 O
.	193 1 O

BACKGROUND	195 10 O
:	205 1 O
Cardiac	207 7 O
troponins	215 9 O
I	225 1 O
(	227 1 O
cTnI	228 4 O
)	232 1 O
and	234 3 O
T	238 1 O
(	240 1 O
cTnT	241 4 O
)	245 1 O
have	247 4 O
been	252 4 O
shown	257 5 O
to	263 2 O
be	266 2 O
highly	269 6 O
sensitive	276 9 O
and	286 3 O
specific	290 8 O
markers	299 7 O
of	307 2 O
myocardial	310 10 B-Disease
cell	321 4 I-Disease
injury	326 6 I-Disease
.	332 1 O

We	334 2 O
investigated	337 12 O
the	350 3 O
diagnostic	354 10 O
value	365 5 O
of	371 2 O
cTnI	374 4 O
and	379 3 O
cTnT	383 4 O
for	388 3 O
the	392 3 O
diagnosis	396 9 O
of	406 2 O
myocardial	409 10 B-Disease
damage	420 6 I-Disease
in	427 2 O
a	430 1 O
rat	432 3 O
model	436 5 O
of	442 2 O
doxorubicin	445 11 B-Chemical
(	457 1 O
DOX	458 3 B-Chemical
)	461 1 O
-	462 1 O
induced	463 7 O
cardiomyopathy	471 14 B-Disease
,	485 1 O
and	487 3 O
we	491 2 O
examined	494 8 O
the	503 3 O
relationship	507 12 O
between	520 7 O
serial	528 6 O
cTnI	535 4 O
and	540 3 O
cTnT	544 4 O
with	549 4 O
the	554 3 O
development	558 11 O
of	570 2 O
cardiac	573 7 B-Disease
disorders	581 9 I-Disease
monitored	591 9 O
by	601 2 O
echocardiography	604 16 O
and	621 3 O
histological	625 12 O
examinations	638 12 O
in	651 2 O
this	654 4 O
model	659 5 O
.	664 1 O

METHODS	666 7 O
:	673 1 O
Thirty	675 6 O
-	681 1 O
five	682 4 O
Wistar	687 6 O
rats	694 4 O
were	699 4 O
given	704 5 O
1	710 1 O
.	711 1 O
5	712 1 O
mg	714 2 O
/	716 1 O
kg	717 2 O
DOX	720 3 B-Chemical
,	723 1 O
i	725 1 O
.	726 1 O
v	727 1 O
.	728 1 O
,	729 1 O
weekly	731 6 O
for	738 3 O
up	742 2 O
to	745 2 O
8	748 1 O
weeks	750 5 O
for	756 3 O
a	760 1 O
total	762 5 O
cumulative	768 10 O
dose	779 4 O
of	784 2 O
12	787 2 O
mg	790 2 O
/	792 1 O
kg	793 2 O
BW	796 2 O
.	798 1 O

Ten	800 3 O
rats	804 4 O
received	809 8 O
saline	818 6 O
as	825 2 O
a	828 1 O
control	830 7 O
group	838 5 O
.	843 1 O

cTnI	845 4 O
was	850 3 O
measured	854 8 O
with	863 4 O
Access	868 6 O
(	874 1 O
R	875 1 O
)	876 1 O
(	878 1 O
ng	879 2 O
/	881 1 O
ml	882 2 O
)	884 1 O
and	886 3 O
a	890 1 O
research	892 8 O
immunoassay	901 11 O
(	913 1 O
pg	914 2 O
/	916 1 O
ml	917 2 O
)	919 1 O
,	920 1 O
and	922 3 O
compared	926 8 O
with	935 4 O
cTnT	940 4 O
,	944 1 O
CK	946 2 O
-	948 1 O
MB	949 2 O
mass	952 4 O
and	957 3 O
CK	961 2 O
.	963 1 O

By	965 2 O
using	968 5 O
transthoracic	974 13 O
echocardiography	988 16 O
,	1004 1 O
anterior	1006 8 O
and	1015 3 O
posterior	1019 9 O
wall	1029 4 O
thickness	1034 9 O
,	1043 1 O
LV	1045 2 O
diameters	1048 9 O
and	1058 3 O
LV	1062 2 O
fractional	1065 10 O
shortening	1076 10 O
(	1087 1 O
FS	1088 2 O
)	1090 1 O
were	1092 4 O
measured	1097 8 O
in	1106 2 O
all	1109 3 O
rats	1113 4 O
before	1118 6 O
DOX	1125 3 B-Chemical
or	1129 2 O
saline	1132 6 O
,	1138 1 O
and	1140 3 O
at	1144 2 O
weeks	1147 5 O
6	1153 1 O
and	1155 3 O
9	1159 1 O
after	1161 5 O
treatment	1167 9 O
in	1177 2 O
all	1180 3 O
surviving	1184 9 O
rats	1194 4 O
.	1198 1 O

Histology	1200 9 O
was	1210 3 O
performed	1214 9 O
in	1224 2 O
DOX	1227 3 B-Chemical
-	1230 1 O
rats	1231 4 O
at	1236 2 O
6	1239 1 O
and	1241 3 O
9	1245 1 O
weeks	1247 5 O
after	1253 5 O
the	1259 3 O
last	1263 4 O
DOX	1268 3 B-Chemical
dose	1272 4 O
and	1277 3 O
in	1281 2 O
all	1284 3 O
controls	1288 8 O
.	1296 1 O

RESULTS	1298 7 O
:	1305 1 O
Eighteen	1307 8 O
of	1316 2 O
the	1319 3 O
DOX	1323 3 B-Chemical
rats	1327 4 O
died	1332 4 O
prematurely	1337 11 O
of	1349 2 O
general	1352 7 O
toxicity	1360 8 B-Disease
during	1369 6 O
the	1376 3 O
9	1380 1 O
-	1381 1 O
week	1382 4 O
period	1387 6 O
.	1393 1 O

End	1395 3 O
-	1398 1 O
diastolic	1399 9 O
(	1409 1 O
ED	1410 2 O
)	1412 1 O
and	1414 3 O
end	1418 3 O
-	1421 1 O
systolic	1422 8 O
(	1431 1 O
ES	1432 2 O
)	1434 1 O
LV	1436 2 O
diameters	1439 9 O
/	1448 1 O
BW	1449 2 O
significantly	1452 13 O
increased	1466 9 O
,	1475 1 O
whereas	1477 7 O
LV	1485 2 O
FS	1488 2 O
was	1491 3 O
decreased	1495 9 O
after	1505 5 O
9	1511 1 O
weeks	1513 5 O
in	1519 2 O
the	1522 3 O
DOX	1526 3 B-Chemical
group	1530 5 O
(	1536 1 O
p	1537 1 O
<	1538 1 O
0	1539 1 O
.	1540 1 O
001	1541 3 O
)	1544 1 O
.	1545 1 O

These	1547 5 O
parameters	1553 10 O
remained	1564 8 O
unchanged	1573 9 O
in	1583 2 O
controls	1586 8 O
.	1594 1 O

Histological	1596 12 O
evaluation	1609 10 O
of	1620 2 O
hearts	1623 6 O
from	1630 4 O
all	1635 3 O
rats	1639 4 O
given	1644 5 O
DOX	1650 3 B-Chemical
revealed	1654 8 O
significant	1663 11 O
slight	1675 6 O
degrees	1682 7 O
of	1690 2 O
perivascular	1693 12 O
and	1706 3 O
interstitial	1710 12 O
fibrosis	1723 8 B-Disease
.	1731 1 O

In	1733 2 O
7	1736 1 O
of	1738 2 O
the	1741 3 O
18	1745 2 O
rats	1748 4 O
,	1752 1 O
degeneration	1754 12 O
and	1767 3 O
myocyte	1771 7 O
vacuolisation	1779 13 O
were	1793 4 O
found	1798 5 O
.	1803 1 O

Only	1805 4 O
five	1810 4 O
of	1815 2 O
the	1818 3 O
controls	1822 8 O
exhibited	1831 9 O
evidence	1841 8 O
of	1850 2 O
very	1853 4 O
slight	1858 6 O
perivascular	1865 12 O
fibrosis	1878 8 B-Disease
.	1886 1 O

A	1888 1 O
significant	1890 11 O
rise	1902 4 O
in	1907 2 O
cTnT	1910 4 O
was	1915 3 O
found	1919 5 O
in	1925 2 O
DOX	1928 3 B-Chemical
rats	1932 4 O
after	1937 5 O
cumulative	1943 10 O
doses	1954 5 O
of	1960 2 O
7	1963 1 O
.	1964 1 O
5	1965 1 O
and	1967 3 O
12	1971 2 O
mg	1974 2 O
/	1976 1 O
kg	1977 2 O
in	1980 2 O
comparison	1983 10 O
with	1994 4 O
baseline	1999 8 O
(	2008 1 O
p	2009 1 O
<	2010 1 O
0	2011 1 O
.	2012 1 O
05	2013 2 O
)	2015 1 O
.	2016 1 O

cTnT	2018 4 O
found	2023 5 O
in	2029 2 O
rats	2032 4 O
after	2037 5 O
12	2043 2 O
mg	2046 2 O
/	2048 1 O
kg	2049 2 O
were	2052 4 O
significantly	2057 13 O
greater	2071 7 O
than	2079 4 O
that	2084 4 O
found	2089 5 O
after	2095 5 O
7	2101 1 O
.	2102 1 O
5	2103 1 O
mg	2105 2 O
/	2107 1 O
kg	2108 2 O
DOX	2111 3 B-Chemical
.	2114 1 O

Maximal	2116 7 O
cTnI	2124 4 O
(	2129 1 O
pg	2130 2 O
/	2132 1 O
ml	2133 2 O
)	2135 1 O
and	2137 3 O
cTnT	2141 4 O
levels	2146 6 O
were	2153 4 O
significantly	2158 13 O
increased	2172 9 O
in	2182 2 O
DOX	2185 3 B-Chemical
rats	2189 4 O
compared	2194 8 O
with	2203 4 O
controls	2208 8 O
(	2217 1 O
p	2218 1 O
=	2219 1 O
0	2220 1 O
.	2221 1 O
006	2222 3 O
,	2225 1 O
0	2227 1 O
.	2228 1 O
007	2229 3 O
)	2232 1 O
.	2233 1 O

cTnI	2235 4 O
(	2240 1 O
ng	2241 2 O
/	2243 1 O
ml	2244 2 O
)	2246 1 O
,	2247 1 O
CK	2249 2 O
-	2251 1 O
MB	2252 2 O
mass	2255 4 O
and	2260 3 O
CK	2264 2 O
remained	2267 8 O
unchanged	2276 9 O
in	2286 2 O
DOX	2289 3 B-Chemical
rats	2293 4 O
compared	2298 8 O
with	2307 4 O
controls	2312 8 O
.	2320 1 O

All	2322 3 O
markers	2326 7 O
remained	2334 8 O
stable	2343 6 O
in	2350 2 O
controls	2353 8 O
.	2361 1 O

Analysis	2363 8 O
of	2372 2 O
data	2375 4 O
revealed	2380 8 O
a	2389 1 O
significant	2391 11 O
correlation	2403 11 O
between	2415 7 O
maximal	2423 7 O
cTnT	2431 4 O
and	2436 3 O
ED	2440 2 O
and	2443 3 O
ES	2447 2 O
LV	2450 2 O
diameters	2453 9 O
/	2462 1 O
BW	2463 2 O
(	2466 1 O
r	2467 1 O
=	2468 1 O
0	2469 1 O
.	2470 1 O
81	2471 2 O
and	2474 3 O
0	2478 1 O
.	2479 1 O
65	2480 2 O
;	2482 1 O
p	2484 1 O
<	2485 1 O
0	2486 1 O
.	2487 1 O
0001	2488 4 O
)	2492 1 O
.	2493 1 O

A	2495 1 O
significant	2497 11 O
relationship	2509 12 O
was	2522 3 O
observed	2526 8 O
between	2535 7 O
maximal	2543 7 O
cTnT	2551 4 O
and	2556 3 O
the	2560 3 O
extent	2564 6 O
of	2571 2 O
myocardial	2574 10 O
morphological	2585 13 O
changes	2599 7 O
,	2606 1 O
and	2608 3 O
between	2612 7 O
LV	2620 2 O
diameters	2623 9 O
/	2632 1 O
BW	2633 2 O
and	2636 3 O
histological	2640 12 O
findings	2653 8 O
.	2661 1 O

CONCLUSIONS	2663 11 O
:	2674 1 O
Among	2676 5 O
markers	2682 7 O
of	2690 2 O
ischemic	2693 8 B-Disease
injury	2702 6 I-Disease
after	2709 5 O
DOX	2715 3 B-Chemical
in	2719 2 O
rats	2722 4 O
,	2726 1 O
cTnT	2728 4 O
showed	2733 6 O
the	2740 3 O
greatest	2744 8 O
ability	2753 7 O
to	2761 2 O
detect	2764 6 O
myocardial	2771 10 B-Disease
damage	2782 6 I-Disease
assessed	2789 8 O
by	2798 2 O
echocardiographic	2801 17 O
detection	2819 9 O
and	2829 3 O
histological	2833 12 O
changes	2846 7 O
.	2853 1 O

Although	2855 8 O
there	2864 5 O
was	2870 3 O
a	2874 1 O
discrepancy	2876 11 O
between	2888 7 O
the	2896 3 O
amount	2900 6 O
of	2907 2 O
cTnI	2910 4 O
and	2915 3 O
cTnT	2919 4 O
after	2924 5 O
DOX	2930 3 B-Chemical
,	2933 1 O
probably	2935 8 O
due	2944 3 O
to	2948 2 O
heterogeneity	2951 13 O
in	2965 2 O
cross	2968 5 O
-	2973 1 O
reactivities	2974 12 O
of	2987 2 O
mAbs	2990 4 O
to	2995 2 O
various	2998 7 O
cTnI	3006 4 O
and	3011 3 O
cTnT	3015 4 O
forms	3020 5 O
,	3025 1 O
it	3027 2 O
is	3030 2 O
likely	3033 6 O
that	3040 4 O
cTnT	3045 4 O
in	3050 2 O
rats	3053 4 O
after	3058 5 O
DOX	3064 3 B-Chemical
indicates	3068 9 O
cell	3078 4 O
damage	3083 6 O
determined	3090 10 O
by	3101 2 O
the	3104 3 O
magnitude	3108 9 O
of	3118 2 O
injury	3121 6 O
induced	3128 7 O
and	3136 3 O
that	3140 4 O
cTnT	3145 4 O
should	3150 6 O
be	3157 2 O
a	3160 1 O
useful	3162 6 O
marker	3169 6 O
for	3176 3 O
the	3180 3 O
prediction	3184 10 O
of	3195 2 O
experimentally	3198 14 O
induced	3213 7 O
cardiotoxicity	3221 14 B-Disease
and	3236 3 O
possibly	3240 8 O
for	3249 3 O
cardioprotective	3253 16 O
experiments	3270 11 O
.	3281 1 O

Calcineurin	0 11 O
-	11 1 O
inhibitor	12 9 O
induced	22 7 O
pain	30 4 B-Disease
syndrome	35 8 O
(	44 1 O
CIPS	45 4 B-Disease
)	49 1 O
:	50 1 O
a	52 1 O
severe	54 6 O
disabling	61 9 O
complication	71 12 O
after	84 5 O
organ	90 5 O
transplantation	96 15 O
.	111 1 O

Bone	113 4 O
pain	118 4 B-Disease
after	123 5 O
transplantation	129 15 O
is	145 2 O
a	148 1 O
frequent	150 8 O
complication	159 12 O
that	172 4 O
can	177 3 O
be	181 2 O
caused	184 6 O
by	191 2 O
several	194 7 O
diseases	202 8 O
.	210 1 O

Treatment	212 9 O
strategies	222 10 O
depend	233 6 O
on	240 2 O
the	243 3 O
correct	247 7 O
diagnosis	255 9 O
of	265 2 O
the	268 3 O
pain	272 4 B-Disease
.	276 1 O

Nine	278 4 O
patients	283 8 O
with	292 4 O
severe	297 6 O
pain	304 4 B-Disease
in	309 2 O
their	312 5 O
feet	318 4 O
,	322 1 O
which	324 5 O
was	330 3 O
registered	334 10 O
after	345 5 O
transplantation	351 15 O
,	366 1 O
were	368 4 O
investigated	373 12 O
.	385 1 O

Bone	387 4 O
scans	392 5 O
showed	398 6 O
an	405 2 O
increased	408 9 O
tracer	418 6 O
uptake	425 6 O
of	432 2 O
the	435 3 O
foot	439 4 O
bones	444 5 O
.	449 1 O

Magnetic	451 8 O
resonance	460 9 O
imaging	470 7 O
demonstrated	478 12 O
bone	491 4 B-Disease
marrow	496 6 I-Disease
oedema	503 6 I-Disease
in	510 2 O
the	513 3 O
painful	517 7 O
bones	525 5 O
.	530 1 O

Pain	532 4 B-Disease
was	537 3 O
not	541 3 O
explained	545 9 O
by	555 2 O
other	558 5 O
diseases	564 8 O
causing	573 7 O
foot	581 4 O
pain	586 4 B-Disease
,	590 1 O
like	592 4 O
reflex	597 6 B-Disease
sympathetic	604 11 I-Disease
dystrophy	616 9 I-Disease
,	625 1 O
polyneuropathy	627 14 B-Disease
,	641 1 O
Morton	643 6 B-Disease
'	649 1 I-Disease
s	650 1 I-Disease
neuralgia	652 9 I-Disease
,	661 1 O
gout	663 4 B-Disease
,	667 1 O
osteoporosis	669 12 B-Disease
,	681 1 O
avascular	683 9 B-Disease
necrosis	693 8 I-Disease
,	701 1 O
intermittent	703 12 B-Disease
claudication	716 12 I-Disease
,	728 1 O
orthopaedic	730 11 O
foot	742 4 B-Disease
deformities	747 11 I-Disease
,	758 1 O
stress	760 6 B-Disease
fractures	767 9 I-Disease
,	776 1 O
and	778 3 O
hyperparathyroidism	782 19 B-Disease
.	801 1 O

The	803 3 O
reduction	807 9 O
of	817 2 O
cyclosporine	820 12 B-Chemical
-	832 1 O
or	834 2 O
tacrolimus	837 10 B-Chemical
trough	848 6 O
levels	855 6 O
and	862 3 O
the	866 3 O
administration	870 14 O
of	885 2 O
calcium	888 7 B-Chemical
channel	896 7 O
blockers	904 8 O
led	913 3 O
to	917 2 O
relief	920 6 O
of	927 2 O
pain	930 4 B-Disease
.	934 1 O

The	936 3 O
Calcineurin	940 11 O
-	951 1 O
inhibitor	952 9 O
Induced	962 7 O
Pain	970 4 B-Disease
Syndrome	975 8 O
(	984 1 O
CIPS	985 4 B-Disease
)	989 1 O
is	991 2 O
a	994 1 O
rare	996 4 O
but	1001 3 O
severe	1005 6 O
side	1012 4 O
effect	1017 6 O
of	1024 2 O
cyclosporine	1027 12 B-Chemical
or	1040 2 O
tacrolimus	1043 10 B-Chemical
and	1054 3 O
is	1058 2 O
accurately	1061 10 O
diagnosed	1072 9 O
by	1082 2 O
its	1085 3 O
typical	1089 7 O
presentation	1097 12 O
,	1109 1 O
magnetic	1111 8 O
resonance	1120 9 O
imaging	1130 7 O
and	1138 3 O
bone	1142 4 O
scans	1147 5 O
.	1152 1 O

Incorrect	1154 9 O
diagnosis	1164 9 O
of	1174 2 O
the	1177 3 O
syndrome	1181 8 O
will	1190 4 O
lead	1195 4 O
to	1200 2 O
a	1203 1 O
significant	1205 11 O
reduction	1217 9 O
of	1227 2 O
life	1230 4 O
quality	1235 7 O
in	1243 2 O
patients	1246 8 O
suffering	1255 9 O
from	1265 4 O
CIPS	1270 4 B-Disease
.	1274 1 O

The	0 3 O
haemodynamic	4 12 O
effects	17 7 O
of	25 2 O
propofol	28 8 B-Chemical
in	37 2 O
combination	40 11 O
with	52 4 O
ephedrine	57 9 B-Chemical
in	67 2 O
elderly	70 7 O
patients	78 8 O
(	87 1 O
ASA	88 3 O
groups	92 6 O
3	99 1 O
and	101 3 O
4	105 1 O
)	106 1 O
.	107 1 O

The	109 3 O
marked	113 6 O
vasodilator	120 11 O
and	132 3 O
negative	136 8 O
inotropic	145 9 O
effects	155 7 O
of	163 2 O
propofol	166 8 B-Chemical
are	175 3 O
disadvantages	179 13 O
in	193 2 O
frail	196 5 O
elderly	202 7 O
patients	210 8 O
.	218 1 O

We	220 2 O
investigated	223 12 O
the	236 3 O
safety	240 6 O
and	247 3 O
efficacy	251 8 O
of	260 2 O
adding	263 6 O
different	270 9 O
doses	280 5 O
of	286 2 O
ephedrine	289 9 B-Chemical
to	299 2 O
propofol	302 8 B-Chemical
in	311 2 O
order	314 5 O
to	320 2 O
obtund	323 6 O
the	330 3 O
hypotensive	334 11 B-Disease
response	346 8 O
.	354 1 O

The	356 3 O
haemodynamic	360 12 O
effects	373 7 O
of	381 2 O
adding	384 6 O
15	391 2 O
,	393 1 O
20	395 2 O
or	398 2 O
25	401 2 O
mg	404 2 O
of	407 2 O
ephedrine	410 9 B-Chemical
to	420 2 O
200	423 3 O
mg	427 2 O
of	430 2 O
propofol	433 8 B-Chemical
were	442 4 O
compared	447 8 O
to	456 2 O
control	459 7 O
in	467 2 O
40	470 2 O
ASA	473 3 O
3	477 1 O
/	478 1 O
4	479 1 O
patients	481 8 O
over	490 4 O
60	495 2 O
years	498 5 O
presenting	504 10 O
for	515 3 O
genito	519 6 O
-	525 1 O
urinary	526 7 O
surgery	534 7 O
.	541 1 O

The	543 3 O
addition	547 8 O
of	556 2 O
ephedrine	559 9 B-Chemical
to	569 2 O
propofol	572 8 B-Chemical
appears	581 7 O
to	589 2 O
be	592 2 O
an	595 2 O
effective	598 9 O
method	608 6 O
of	615 2 O
obtunding	618 9 O
the	628 3 O
hypotensive	632 11 B-Disease
response	644 8 O
to	653 2 O
propofol	656 8 B-Chemical
at	665 2 O
all	668 3 O
doses	672 5 O
used	678 4 O
in	683 2 O
this	686 4 O
study	691 5 O
.	696 1 O

However	698 7 O
,	705 1 O
marked	707 6 O
tachycardia	714 11 B-Disease
associated	726 10 O
with	737 4 O
the	742 3 O
use	746 3 O
of	750 2 O
ephedrine	753 9 B-Chemical
in	763 2 O
combination	766 11 O
with	778 4 O
propofol	783 8 B-Chemical
occurred	792 8 O
in	801 2 O
the	804 3 O
majority	808 8 O
of	817 2 O
patients	820 8 O
,	828 1 O
occasionally	830 12 O
reaching	843 8 O
high	852 4 O
levels	857 6 O
in	864 2 O
individual	867 10 O
patients	878 8 O
.	886 1 O

Due	888 3 O
to	892 2 O
the	895 3 O
risk	899 4 O
of	904 2 O
this	907 4 O
tachycardia	912 11 B-Disease
inducing	924 8 O
myocardial	933 10 B-Disease
ischemia	944 8 I-Disease
,	952 1 O
we	954 2 O
would	957 5 O
not	963 3 O
recommend	967 9 O
the	977 3 O
use	981 3 O
in	985 2 O
elderly	988 7 O
patients	996 8 O
of	1005 2 O
any	1008 3 O
of	1012 2 O
the	1015 3 O
ephedrine	1019 9 B-Chemical
/	1028 1 O
propofol	1029 8 B-Chemical
/	1037 1 O
mixtures	1038 8 O
studied	1047 7 O
.	1054 1 O

Neurotoxicity	0 13 B-Disease
of	14 2 O
halogenated	17 11 B-Chemical
hydroxyquinolines	29 17 I-Chemical
:	46 1 O
clinical	48 8 O
analysis	57 8 O
of	66 2 O
cases	69 5 O
reported	75 8 O
outside	84 7 O
Japan	92 5 O
.	97 1 O

An	99 2 O
analysis	102 8 O
is	111 2 O
presented	114 9 O
of	124 2 O
220	127 3 O
cases	131 5 O
of	137 2 O
possible	140 8 O
neurotoxic	149 10 B-Disease
reactions	160 9 O
to	170 2 O
halogenated	173 11 B-Chemical
hydroxyquinolines	185 17 I-Chemical
reported	203 8 O
from	212 4 O
outside	217 7 O
Japan	225 5 O
.	230 1 O

In	232 2 O
80	235 2 O
cases	238 5 O
insufficient	244 12 O
information	257 11 O
was	269 3 O
available	273 9 O
for	283 3 O
adequate	287 8 O
comment	296 7 O
and	304 3 O
in	308 2 O
29	311 2 O
a	314 1 O
relationship	316 12 O
to	329 2 O
the	332 3 O
administration	336 14 O
of	351 2 O
clioquinol	354 10 B-Chemical
could	365 5 O
be	371 2 O
excluded	374 8 O
.	382 1 O

Of	384 2 O
the	387 3 O
remainder	391 9 O
,	400 1 O
a	402 1 O
relationship	404 12 O
to	417 2 O
clioquinol	420 10 B-Chemical
was	431 3 O
considered	435 10 O
probable	446 8 O
in	455 2 O
42	458 2 O
and	461 3 O
possible	465 8 O
in	474 2 O
69	477 2 O
cases	480 5 O
.	485 1 O

In	487 2 O
six	490 3 O
of	494 2 O
the	497 3 O
probable	501 8 O
cases	510 5 O
the	516 3 O
neurological	520 12 B-Disease
disturbance	533 11 I-Disease
consisted	545 9 O
of	555 2 O
an	558 2 O
acute	561 5 O
reversible	567 10 O
encephalopathy	578 14 B-Disease
usually	593 7 O
related	601 7 O
to	609 2 O
the	612 3 O
ingestion	616 9 O
of	626 2 O
a	629 1 O
high	631 4 O
dose	636 4 O
of	641 2 O
clioquinol	644 10 B-Chemical
over	655 4 O
a	660 1 O
short	662 5 O
period	668 6 O
.	674 1 O

The	676 3 O
most	680 4 O
common	685 6 O
manifestation	692 13 O
,	705 1 O
observed	707 8 O
in	716 2 O
15	719 2 O
further	722 7 O
cases	730 5 O
,	735 1 O
was	737 3 O
isolated	741 8 O
optic	750 5 B-Disease
atrophy	756 7 I-Disease
.	763 1 O

This	765 4 O
was	770 3 O
most	774 4 O
frequently	779 10 O
found	790 5 O
in	796 2 O
children	799 8 O
,	807 1 O
many	809 4 O
of	814 2 O
whom	817 4 O
had	822 3 O
received	826 8 O
clioquinol	835 10 B-Chemical
as	846 2 O
treatment	849 9 O
for	859 3 O
acrodermatitis	863 14 B-Disease
enteropathica	878 13 I-Disease
.	891 1 O

In	893 2 O
the	896 3 O
remaining	900 9 O
cases	910 5 O
,	915 1 O
a	917 1 O
combination	919 11 O
of	931 2 O
myelopathy	934 10 B-Disease
,	944 1 O
visual	946 6 B-Disease
disturbance	953 11 I-Disease
,	964 1 O
and	966 3 O
peripheral	970 10 B-Disease
neuropathy	981 10 I-Disease
was	992 3 O
the	996 3 O
most	1000 4 O
common	1005 6 O
manifestation	1012 13 O
.	1025 1 O

Isolated	1027 8 O
myelopathy	1036 10 B-Disease
or	1047 2 O
peripheral	1050 10 B-Disease
neuropathy	1061 10 I-Disease
,	1071 1 O
or	1073 2 O
these	1076 5 O
manifestations	1082 14 O
occurring	1097 9 O
together	1107 8 O
,	1115 1 O
were	1117 4 O
infrequent	1122 10 O
.	1132 1 O

The	1134 3 O
onset	1138 5 O
of	1144 2 O
all	1147 3 O
manifestations	1151 14 O
(	1166 1 O
except	1167 6 O
toxic	1174 5 O
encephalopathy	1180 14 B-Disease
)	1194 1 O
was	1196 3 O
usually	1200 7 O
subacute	1208 8 O
,	1216 1 O
with	1218 4 O
subsequent	1223 10 O
partial	1234 7 O
recovery	1242 8 O
.	1250 1 O

Older	1252 5 O
subjects	1258 8 O
tended	1267 6 O
to	1274 2 O
display	1277 7 O
more	1285 4 O
side	1290 4 O
effects	1295 7 O
.	1302 1 O

The	1304 3 O
full	1308 4 O
syndrome	1313 8 O
of	1322 2 O
subacute	1325 8 O
myelo	1334 5 B-Disease
-	1339 1 I-Disease
optic	1340 5 I-Disease
neuropathy	1346 10 I-Disease
was	1357 3 O
more	1361 4 O
frequent	1366 8 O
in	1375 2 O
women	1378 5 O
,	1383 1 O
but	1385 3 O
they	1389 4 O
tended	1394 6 O
to	1401 2 O
have	1404 4 O
taken	1409 5 O
greater	1415 7 O
quantities	1423 10 O
of	1434 2 O
the	1437 3 O
drug	1441 4 O
.	1445 1 O

Epileptic	0 9 B-Disease
seizures	10 8 I-Disease
following	19 9 O
cortical	29 8 O
application	38 11 O
of	50 2 O
fibrin	53 6 O
sealants	60 8 O
containing	69 10 O
tranexamic	80 10 B-Chemical
acid	91 4 I-Chemical
in	96 2 O
rats	99 4 O
.	103 1 O

BACKGROUND	105 10 O
:	115 1 O
Fibrin	117 6 O
sealants	124 8 O
(	133 1 O
FS	134 2 O
)	136 1 O
derived	138 7 O
from	146 4 O
human	151 5 O
plasma	157 6 O
are	164 3 O
frequently	168 10 O
used	179 4 O
in	184 2 O
neurosurgery	187 12 O
.	199 1 O

In	201 2 O
order	204 5 O
to	210 2 O
increase	213 8 O
clot	222 4 O
stability	227 9 O
,	236 1 O
FS	238 2 O
typically	241 9 O
contain	251 7 O
aprotinin	259 9 O
,	268 1 O
a	270 1 O
natural	272 7 O
fibrinolysis	280 12 O
inhibitor	293 9 O
.	302 1 O

Recently	304 8 O
,	312 1 O
synthetic	314 9 O
fibrinolysis	324 12 O
inhibitors	337 10 O
such	348 4 O
as	353 2 O
tranexamic	356 10 B-Chemical
acid	367 4 I-Chemical
(	372 1 O
tAMCA	373 5 B-Chemical
)	378 1 O
have	380 4 O
been	385 4 O
considered	390 10 O
as	401 2 O
substitutes	404 11 O
for	416 3 O
aprotinin	420 9 O
.	429 1 O

However	431 7 O
,	438 1 O
tAMCA	440 5 B-Chemical
has	446 3 O
been	450 4 O
shown	455 5 O
to	461 2 O
cause	464 5 O
epileptic	470 9 B-Disease
seizures	480 8 I-Disease
.	488 1 O

We	490 2 O
wanted	493 6 O
to	500 2 O
study	503 5 O
whether	509 7 O
tAMCA	517 5 B-Chemical
retains	523 7 O
its	531 3 O
convulsive	535 10 B-Disease
action	546 6 O
if	553 2 O
incorporated	556 12 O
into	569 4 O
a	574 1 O
FS	576 2 O
.	578 1 O

METHOD	580 6 O
:	586 1 O
FS	588 2 O
containing	591 10 O
aprotinin	602 9 O
or	612 2 O
different	615 9 O
concentrations	625 14 O
of	640 2 O
tAMCA	643 5 B-Chemical
(	649 1 O
0	650 1 O
.	651 1 O
5	652 1 O
-	653 1 O
47	654 2 O
.	656 1 O
5	657 1 O
mg	659 2 O
/	661 1 O
ml	662 2 O
)	664 1 O
were	666 4 O
applied	671 7 O
to	679 2 O
the	682 3 O
pial	686 4 O
surface	691 7 O
of	699 2 O
the	702 3 O
cortex	706 6 O
of	713 2 O
anaesthetized	716 13 O
rats	730 4 O
.	734 1 O

The	736 3 O
response	740 8 O
of	749 2 O
the	752 3 O
animals	756 7 O
was	764 3 O
evaluated	768 9 O
using	778 5 O
electroencephalography	784 22 O
and	807 3 O
by	811 2 O
monitoring	814 10 O
the	825 3 O
clinical	829 8 O
behaviour	838 9 O
during	848 6 O
and	855 3 O
after	859 5 O
recovery	865 8 O
from	874 4 O
anaesthesia	879 11 O
.	890 1 O

FINDINGS	892 8 O
:	900 1 O
FS	902 2 O
containing	905 10 O
tAMCA	916 5 B-Chemical
caused	922 6 O
paroxysmal	929 10 O
brain	940 5 O
activity	946 8 O
which	955 5 O
was	961 3 O
associated	965 10 O
with	976 4 O
distinct	981 8 O
convulsive	990 10 B-Disease
behaviours	1001 10 O
.	1011 1 O

The	1013 3 O
degree	1017 6 O
of	1024 2 O
these	1027 5 O
seizures	1033 8 B-Disease
increased	1042 9 O
with	1052 4 O
increasing	1057 10 O
concentration	1068 13 O
of	1082 2 O
tAMCA	1085 5 B-Chemical
.	1090 1 O

Thus	1092 4 O
,	1096 1 O
FS	1098 2 O
containing	1101 10 O
47	1112 2 O
.	1114 1 O
5	1115 1 O
mg	1117 2 O
/	1119 1 O
ml	1120 2 O
tAMCA	1123 5 B-Chemical
evoked	1129 6 O
generalized	1136 11 B-Disease
seizures	1148 8 I-Disease
in	1157 2 O
all	1160 3 O
tested	1164 6 O
rats	1171 4 O
(	1176 1 O
n	1177 1 O
=	1178 1 O
6	1179 1 O
)	1180 1 O
while	1182 5 O
the	1188 3 O
lowest	1192 6 O
concentration	1199 13 O
of	1213 2 O
tAMCA	1216 5 B-Chemical
(	1222 1 O
0	1223 1 O
.	1224 1 O
5	1225 1 O
mg	1227 2 O
/	1229 1 O
ml	1230 2 O
)	1232 1 O
only	1234 4 O
evoked	1239 6 O
brief	1246 5 O
episodes	1252 8 O
of	1261 2 O
jerk	1264 4 O
-	1268 1 O
correlated	1269 10 O
convulsive	1280 10 B-Disease
potentials	1291 10 O
in	1302 2 O
1	1305 1 O
of	1307 2 O
6	1310 1 O
rats	1312 4 O
.	1316 1 O

In	1318 2 O
contrast	1321 8 O
,	1329 1 O
FS	1331 2 O
containing	1334 10 O
aprotinin	1345 9 O
did	1355 3 O
not	1359 3 O
evoke	1363 5 O
any	1369 3 O
paroxysmal	1373 10 O
activity	1384 8 O
.	1392 1 O

INTERPRETATION	1394 14 O
:	1408 1 O
Tranexamic	1410 10 B-Chemical
acid	1421 4 I-Chemical
retains	1426 7 O
its	1434 3 O
convulsive	1438 10 B-Disease
action	1449 6 O
within	1456 6 O
FS	1463 2 O
.	1465 1 O

Thus	1467 4 O
,	1471 1 O
use	1473 3 O
of	1477 2 O
FS	1480 2 O
containing	1483 10 O
tAMCA	1494 5 B-Chemical
for	1500 3 O
surgery	1504 7 O
within	1512 6 O
or	1519 2 O
close	1522 5 O
to	1528 2 O
the	1531 3 O
CNS	1535 3 O
may	1539 3 O
pose	1543 4 O
a	1548 1 O
substantial	1550 11 O
risk	1562 4 O
to	1567 2 O
the	1570 3 O
patient	1574 7 O
.	1581 1 O

A	0 1 O
diet	2 4 O
promoting	7 9 O
sugar	17 5 B-Disease
dependency	23 10 I-Disease
causes	34 6 O
behavioral	41 10 B-Disease
cross	52 5 I-Disease
-	57 1 I-Disease
sensitization	58 13 I-Disease
to	72 2 O
a	75 1 O
low	77 3 O
dose	81 4 O
of	86 2 O
amphetamine	89 11 B-Chemical
.	100 1 O

Previous	102 8 O
research	111 8 O
in	120 2 O
this	123 4 O
laboratory	128 10 O
has	139 3 O
shown	143 5 O
that	149 4 O
a	154 1 O
diet	156 4 O
of	161 2 O
intermittent	164 12 O
excessive	177 9 O
sugar	187 5 O
consumption	193 11 O
produces	205 8 O
a	214 1 O
state	216 5 O
with	222 4 O
neurochemical	227 13 O
and	241 3 O
behavioral	245 10 O
similarities	256 12 O
to	269 2 O
drug	272 4 B-Disease
dependency	277 10 I-Disease
.	287 1 O

The	289 3 O
present	293 7 O
study	301 5 O
examined	307 8 O
whether	316 7 O
female	324 6 O
rats	331 4 O
on	336 2 O
various	339 7 O
regimens	347 8 O
of	356 2 O
sugar	359 5 O
access	365 6 O
would	372 5 O
show	378 4 O
behavioral	383 10 B-Disease
cross	394 5 I-Disease
-	399 1 I-Disease
sensitization	400 13 I-Disease
to	414 2 O
a	417 1 O
low	419 3 O
dose	423 4 O
of	428 2 O
amphetamine	431 11 B-Chemical
.	442 1 O

After	444 5 O
a	450 1 O
30	452 2 O
-	454 1 O
min	455 3 O
baseline	459 8 O
measure	468 7 O
of	476 2 O
locomotor	479 9 O
activity	489 8 O
(	498 1 O
day	499 3 O
0	503 1 O
)	504 1 O
,	505 1 O
animals	507 7 O
were	515 4 O
maintained	520 10 O
on	531 2 O
a	534 1 O
cyclic	536 6 O
diet	543 4 O
of	548 2 O
12	551 2 O
-	553 1 O
h	554 1 O
deprivation	556 11 O
followed	568 8 O
by	577 2 O
12	580 2 O
-	582 1 O
h	583 1 O
access	585 6 O
to	592 2 O
10	595 2 O
%	597 1 O
sucrose	599 7 B-Chemical
solution	607 8 O
and	616 3 O
chow	620 4 O
pellets	625 7 O
(	633 1 O
12	634 2 O
h	637 1 O
access	639 6 O
starting	646 8 O
4	655 1 O
h	657 1 O
after	659 5 O
onset	665 5 O
of	671 2 O
the	674 3 O
dark	678 4 O
period	683 6 O
)	689 1 O
for	691 3 O
21	695 2 O
days	698 4 O
.	702 1 O

Locomotor	704 9 O
activity	714 8 O
was	723 3 O
measured	727 8 O
again	736 5 O
for	742 3 O
30	746 2 O
min	749 3 O
at	753 2 O
the	756 3 O
beginning	760 9 O
of	770 2 O
days	773 4 O
1	778 1 O
and	780 3 O
21	784 2 O
of	787 2 O
sugar	790 5 O
access	796 6 O
.	802 1 O

Beginning	804 9 O
on	814 2 O
day	817 3 O
22	821 2 O
,	823 1 O
all	825 3 O
rats	829 4 O
were	834 4 O
maintained	839 10 O
on	850 2 O
ad	853 2 O
libitum	856 7 O
chow	864 4 O
.	868 1 O

Nine	870 4 O
days	875 4 O
later	880 5 O
locomotor	886 9 O
activity	896 8 O
was	905 3 O
measured	909 8 O
in	918 2 O
response	921 8 O
to	930 2 O
a	933 1 O
single	935 6 O
low	942 3 O
dose	946 4 O
of	951 2 O
amphetamine	954 11 B-Chemical
(	966 1 O
0	967 1 O
.	968 1 O
5	969 1 O
mg	971 2 O
/	973 1 O
kg	974 2 O
)	976 1 O
.	977 1 O

The	979 3 O
animals	983 7 O
that	991 4 O
had	996 3 O
experienced	1000 11 O
cyclic	1012 6 O
sucrose	1019 7 B-Chemical
and	1027 3 O
chow	1031 4 O
were	1036 4 O
hyperactive	1041 11 B-Disease
in	1053 2 O
response	1056 8 O
to	1065 2 O
amphetamine	1068 11 B-Chemical
compared	1080 8 O
with	1089 4 O
four	1094 4 O
control	1099 7 O
groups	1107 6 O
(	1114 1 O
ad	1115 2 O
libitum	1118 7 O
10	1126 2 O
%	1128 1 O
sucrose	1130 7 B-Chemical
and	1138 3 O
chow	1142 4 O
followed	1147 8 O
by	1156 2 O
amphetamine	1159 11 B-Chemical
injection	1171 9 O
,	1180 1 O
cyclic	1182 6 O
chow	1189 4 O
followed	1194 8 O
by	1203 2 O
amphetamine	1206 11 B-Chemical
injection	1218 9 O
,	1227 1 O
ad	1229 2 O
libitum	1232 7 O
chow	1240 4 O
with	1245 4 O
amphetamine	1250 11 B-Chemical
,	1261 1 O
or	1263 2 O
cyclic	1266 6 O
10	1273 2 O
%	1275 1 O
sucrose	1277 7 B-Chemical
and	1285 3 O
chow	1289 4 O
with	1294 4 O
a	1299 1 O
saline	1301 6 O
injection	1308 9 O
)	1317 1 O
.	1318 1 O

These	1320 5 O
results	1326 7 O
suggest	1334 7 O
that	1342 4 O
a	1347 1 O
diet	1349 4 O
comprised	1354 9 O
of	1364 2 O
alternating	1367 11 O
deprivation	1379 11 O
and	1391 3 O
access	1395 6 O
to	1402 2 O
a	1405 1 O
sugar	1407 5 O
solution	1413 8 O
and	1422 3 O
chow	1426 4 O
produces	1431 8 O
bingeing	1440 8 O
on	1449 2 O
sugar	1452 5 O
that	1458 4 O
leads	1463 5 O
to	1469 2 O
a	1472 1 O
long	1474 4 O
lasting	1479 7 O
state	1487 5 O
of	1493 2 O
increased	1496 9 O
sensitivity	1506 11 O
to	1518 2 O
amphetamine	1521 11 B-Chemical
,	1532 1 O
possibly	1534 8 O
due	1543 3 O
to	1547 2 O
a	1550 1 O
lasting	1552 7 O
alteration	1560 10 O
in	1571 2 O
the	1574 3 O
dopamine	1578 8 B-Chemical
system	1587 6 O
.	1593 1 O

D	0 1 B-Chemical
-	1 1 I-Chemical
penicillamine	2 13 I-Chemical
-	15 1 O
induced	16 7 O
angiopathy	24 10 B-Disease
in	35 2 O
rats	38 4 O
.	42 1 O

The	44 3 O
effect	48 6 O
of	55 2 O
high	58 4 O
dose	63 4 O
D	68 1 B-Chemical
-	69 1 I-Chemical
penicillamine	70 13 I-Chemical
treatment	84 9 O
on	94 2 O
aortic	97 6 O
permeability	104 12 O
to	117 2 O
albumin	120 7 O
and	128 3 O
on	132 2 O
the	135 3 O
ultrastructure	139 14 O
of	154 2 O
the	157 3 O
vessel	161 6 O
.	167 1 O

Male	169 4 O
Sprague	174 7 O
-	181 1 O
Dawley	182 6 O
rats	189 4 O
were	194 4 O
treated	199 7 O
with	207 4 O
D	212 1 B-Chemical
-	213 1 I-Chemical
penicillamine	214 13 I-Chemical
(	228 1 O
D	229 1 B-Chemical
-	230 1 I-Chemical
pen	231 3 I-Chemical
)	234 1 O
500	236 3 O
mg	240 2 O
/	242 1 O
kg	243 2 O
/	245 1 O
day	246 3 O
for	250 3 O
10	254 2 O
or	257 2 O
42	260 2 O
days	263 4 O
.	267 1 O

Pair	269 4 O
fed	274 3 O
rats	278 4 O
served	283 6 O
as	290 2 O
controls	293 8 O
.	301 1 O

Changes	303 7 O
in	311 2 O
aortic	314 6 O
morphology	321 10 O
were	332 4 O
examined	337 8 O
by	346 2 O
light	349 5 O
-	354 1 O
and	356 3 O
transmission	360 12 O
-	372 1 O
electron	373 8 O
microscopy	382 10 O
(	393 1 O
TEM	394 3 O
)	397 1 O
.	398 1 O

In	400 2 O
addition	403 8 O
,	411 1 O
the	413 3 O
endothelial	417 11 O
permeability	429 12 O
and	442 3 O
the	446 3 O
penetration	450 11 O
through	462 7 O
the	470 3 O
aortic	474 6 O
wall	481 4 O
of	486 2 O
albumin	489 7 O
were	497 4 O
studied	502 7 O
10	510 2 O
minutes	513 7 O
,	520 1 O
24	522 2 O
and	525 3 O
48	529 2 O
hours	532 5 O
after	538 5 O
i	544 1 O
.	545 1 O
v	547 1 O
.	548 1 O
injection	550 9 O
of	560 2 O
human	563 5 O
serum	569 5 O
131I	575 4 O
-	579 1 O
albumin	580 7 O
(	588 1 O
131I	589 4 O
-	593 1 O
HSA	594 3 O
)	597 1 O
.	598 1 O

TEM	600 3 O
revealed	604 8 O
extensive	613 9 O
elastolysis	623 11 O
in	635 2 O
the	638 3 O
arterial	642 8 O
wall	651 4 O
of	656 2 O
D	659 1 B-Chemical
-	660 1 I-Chemical
pen	661 3 I-Chemical
-	664 1 O
treated	665 7 O
rats	673 4 O
,	677 1 O
consistent	679 10 O
with	690 4 O
an	695 2 O
inhibitory	698 10 O
effect	709 6 O
on	716 2 O
crosslink	719 9 O
formation	729 9 O
.	738 1 O

In	740 2 O
experimental	743 12 O
animals	756 7 O
excess	764 6 O
deposition	771 10 O
of	782 2 O
collagen	785 8 O
and	794 3 O
glycoaminoglycans	798 17 O
was	816 3 O
observed	820 8 O
in	829 2 O
the	832 3 O
subendothelial	836 14 O
and	851 3 O
medial	855 6 O
layer	862 5 O
of	868 2 O
the	871 3 O
aortic	875 6 O
wall	882 4 O
,	886 1 O
together	888 8 O
with	897 4 O
prominent	902 9 O
basal	912 5 O
membrane	918 8 O
substance	927 9 O
around	937 6 O
aortic	944 6 O
smooth	951 6 O
muscle	958 6 O
cells	965 5 O
.	970 1 O

The	972 3 O
aorta	976 5 O
/	981 1 O
serum	982 5 O
-	987 1 O
ratio	988 5 O
and	994 3 O
the	998 3 O
radioactive	1002 11 O
build	1014 5 O
-	1019 1 O
up	1020 2 O
24	1023 2 O
and	1026 3 O
48	1030 2 O
hours	1033 5 O
after	1039 5 O
injection	1045 9 O
of	1055 2 O
131I	1058 4 O
-	1062 1 O
HSA	1063 3 O
was	1067 3 O
reduced	1071 7 O
in	1079 2 O
animals	1082 7 O
treated	1090 7 O
with	1098 4 O
D	1103 1 B-Chemical
-	1104 1 I-Chemical
pen	1105 3 I-Chemical
for	1109 3 O
42	1113 2 O
days	1116 4 O
,	1120 1 O
indicating	1122 10 O
an	1133 2 O
impeded	1136 7 O
transmural	1144 10 O
transport	1155 9 O
of	1165 2 O
tracer	1168 6 O
which	1175 5 O
may	1181 3 O
be	1185 2 O
caused	1188 6 O
by	1195 2 O
a	1198 1 O
steric	1200 6 O
exclusion	1207 9 O
effect	1217 6 O
of	1224 2 O
abundant	1227 8 O
hyaluronate	1236 11 B-Chemical
.	1247 1 O

The	1249 3 O
endothelial	1253 11 O
ultrastructure	1265 14 O
was	1280 3 O
unaffected	1284 10 O
by	1295 2 O
D	1298 1 B-Chemical
-	1299 1 I-Chemical
pen	1300 3 I-Chemical
,	1303 1 O
and	1305 3 O
no	1309 2 O
differences	1312 11 O
in	1324 2 O
aortic	1327 6 O
131I	1334 4 O
-	1338 1 O
HSA	1339 3 O
radioactivity	1343 13 O
or	1357 2 O
aorta	1360 5 O
/	1365 1 O
serum	1366 5 O
-	1371 1 O
ratio	1372 5 O
were	1378 4 O
recorded	1383 8 O
between	1392 7 O
experimental	1400 12 O
and	1413 3 O
control	1417 7 O
groups	1425 6 O
10	1432 2 O
minutes	1435 7 O
after	1443 5 O
tracer	1449 6 O
injection	1456 9 O
,	1465 1 O
indicating	1467 10 O
that	1478 4 O
the	1483 3 O
permeability	1487 12 O
of	1500 2 O
the	1503 3 O
endothelial	1507 11 O
barrier	1519 7 O
to	1527 2 O
albumin	1530 7 O
remained	1538 8 O
unaffected	1547 10 O
by	1558 2 O
D	1561 1 B-Chemical
-	1562 1 I-Chemical
pen	1563 3 I-Chemical
treatment	1567 9 O
.	1576 1 O

These	1578 5 O
observations	1584 12 O
support	1597 7 O
the	1605 3 O
hypothesis	1609 10 O
that	1620 4 O
treatment	1625 9 O
with	1635 4 O
high	1640 4 O
doses	1645 5 O
of	1651 2 O
D	1654 1 B-Chemical
-	1655 1 I-Chemical
pen	1656 3 I-Chemical
may	1660 3 O
induce	1664 6 O
a	1671 1 O
fibroproliferative	1673 18 O
response	1692 8 O
in	1701 2 O
rat	1704 3 O
aorta	1708 5 O
,	1713 1 O
possibly	1715 8 O
by	1724 2 O
an	1727 2 O
inhibitory	1730 10 O
effect	1741 6 O
on	1748 2 O
the	1751 3 O
cross	1755 5 O
-	1760 1 O
linking	1761 7 O
of	1769 2 O
collagen	1772 8 O
and	1781 3 O
elastin	1785 7 O
.	1792 1 O

Brain	0 5 O
natriuretic	6 11 O
peptide	18 7 O
is	26 2 O
a	29 1 O
predictor	31 9 O
of	41 2 O
anthracycline	44 13 B-Chemical
-	57 1 O
induced	58 7 O
cardiotoxicity	66 14 B-Disease
.	80 1 O

Anthracyclines	82 14 B-Chemical
are	97 3 O
effective	101 9 O
antineoplastic	111 14 O
drugs	126 5 O
,	131 1 O
but	133 3 O
they	137 4 O
frequently	142 10 O
cause	153 5 O
dose	159 4 O
-	163 1 O
related	164 7 O
cardiotoxicity	172 14 B-Disease
.	186 1 O

The	188 3 O
cardiotoxicity	192 14 B-Disease
of	207 2 O
conventional	210 12 O
anthracycline	223 13 B-Chemical
therapy	237 7 O
highlights	245 10 O
a	256 1 O
need	258 4 O
to	263 2 O
search	266 6 O
for	273 3 O
methods	277 7 O
that	285 4 O
are	290 3 O
highly	294 6 O
sensitive	301 9 O
and	311 3 O
capable	315 7 O
of	323 2 O
predicting	326 10 O
cardiac	337 7 B-Disease
dysfunction	345 11 I-Disease
.	356 1 O

We	358 2 O
measured	361 8 O
the	370 3 O
plasma	374 6 O
level	381 5 O
of	387 2 O
brain	390 5 O
natriuretic	396 11 O
peptide	408 7 O
(	416 1 O
BNP	417 3 O
)	420 1 O
to	422 2 O
determine	425 9 O
whether	435 7 O
BNP	443 3 O
might	447 5 O
serve	453 5 O
as	459 2 O
a	462 1 O
simple	464 6 O
diagnostic	471 10 O
indicator	482 9 O
of	492 2 O
anthracycline	495 13 B-Chemical
-	508 1 O
induced	509 7 O
cardiotoxicity	517 14 B-Disease
in	532 2 O
patients	535 8 O
with	544 4 O
acute	549 5 B-Disease
leukemia	555 8 I-Disease
treated	564 7 O
with	572 4 O
a	577 1 O
daunorubicin	579 12 B-Chemical
(	592 1 O
DNR	593 3 B-Chemical
)	596 1 O
-	597 1 O
containing	598 10 O
regimen	609 7 O
.	616 1 O

Thirteen	618 8 O
patients	627 8 O
with	636 4 O
acute	641 5 B-Disease
leukemia	647 8 I-Disease
were	656 4 O
treated	661 7 O
with	669 4 O
a	674 1 O
DNR	676 3 B-Chemical
-	679 1 O
containing	680 10 O
regimen	691 7 O
.	698 1 O

Cardiac	700 7 O
functions	708 9 O
were	718 4 O
evaluated	723 9 O
with	733 4 O
radionuclide	738 12 O
angiography	751 11 O
before	763 6 O
chemotherapies	770 14 O
.	784 1 O

The	786 3 O
plasma	790 6 O
levels	797 6 O
of	804 2 O
atrial	807 6 O
natriuretic	814 11 O
peptide	826 7 O
(	834 1 O
ANP	835 3 O
)	838 1 O
and	840 3 O
BNP	844 3 O
were	848 4 O
measured	853 8 O
at	862 2 O
the	865 3 O
time	869 4 O
of	874 2 O
radionuclide	877 12 O
angiography	890 11 O
.	901 1 O

Three	903 5 O
patients	909 8 O
developed	918 9 O
congestive	928 10 B-Disease
heart	939 5 I-Disease
failure	945 7 I-Disease
after	953 5 O
the	959 3 O
completion	963 10 O
of	974 2 O
chemotherapy	977 12 O
.	989 1 O

Five	991 4 O
patients	996 8 O
were	1005 4 O
diagnosed	1010 9 O
as	1020 2 O
having	1023 6 O
subclinical	1030 11 O
heart	1042 5 B-Disease
failure	1048 7 I-Disease
after	1056 5 O
the	1062 3 O
completion	1066 10 O
of	1077 2 O
chemotherapy	1080 12 O
.	1092 1 O

The	1094 3 O
plasma	1098 6 O
levels	1105 6 O
of	1112 2 O
BNP	1115 3 O
in	1119 2 O
all	1122 3 O
the	1126 3 O
patients	1130 8 O
with	1139 4 O
clinical	1144 8 O
and	1153 3 O
subclinical	1157 11 O
heart	1169 5 B-Disease
failure	1175 7 I-Disease
increased	1183 9 O
above	1193 5 O
the	1199 3 O
normal	1203 6 O
limit	1210 5 O
(	1216 1 O
40	1217 2 O
pg	1220 2 O
/	1222 1 O
ml	1223 2 O
)	1225 1 O
before	1227 6 O
the	1234 3 O
detection	1238 9 O
of	1248 2 O
clinical	1251 8 O
or	1260 2 O
subclinical	1263 11 O
heart	1275 5 B-Disease
failure	1281 7 I-Disease
by	1289 2 O
radionuclide	1292 12 O
angiography	1305 11 O
.	1316 1 O

On	1318 2 O
the	1321 3 O
other	1325 5 O
hand	1331 4 O
,	1335 1 O
BNP	1337 3 O
did	1341 3 O
not	1345 3 O
increase	1349 8 O
in	1358 2 O
the	1361 3 O
patients	1365 8 O
without	1374 7 O
heart	1382 5 B-Disease
failure	1388 7 I-Disease
given	1396 5 O
DNR	1402 3 B-Chemical
,	1405 1 O
even	1407 4 O
at	1412 2 O
more	1415 4 O
than	1420 4 O
700	1425 3 O
mg	1429 2 O
/	1431 1 O
m	1432 1 O
(	1433 1 O
2	1434 1 O
)	1435 1 O
.	1436 1 O

The	1438 3 O
plasma	1442 6 O
level	1449 5 O
of	1455 2 O
ANP	1458 3 O
did	1462 3 O
not	1466 3 O
always	1470 6 O
increase	1477 8 O
in	1486 2 O
all	1489 3 O
the	1493 3 O
patients	1497 8 O
with	1506 4 O
clinical	1511 8 O
and	1520 3 O
subclinical	1524 11 O
heart	1536 5 B-Disease
failure	1542 7 I-Disease
.	1549 1 O

These	1551 5 O
preliminary	1557 11 O
results	1569 7 O
suggest	1577 7 O
that	1585 4 O
BNP	1590 3 O
may	1594 3 O
be	1598 2 O
useful	1601 6 O
as	1608 2 O
an	1611 2 O
early	1614 5 O
and	1620 3 O
sensitive	1624 9 O
indicator	1634 9 O
of	1644 2 O
anthracycline	1647 13 B-Chemical
-	1660 1 O
induced	1661 7 O
cardiotoxicity	1669 14 B-Disease
.	1683 1 O

Antibacterial	0 13 O
medication	14 10 O
use	25 3 O
during	29 6 O
pregnancy	36 9 O
and	46 3 O
risk	50 4 O
of	55 2 O
birth	58 5 B-Disease
defects	64 7 I-Disease
:	71 1 O
National	73 8 O
Birth	82 5 B-Disease
Defects	88 7 I-Disease
Prevention	96 10 O
Study	107 5 O
.	112 1 O

OBJECTIVE	114 9 O
:	123 1 O
To	125 2 O
estimate	128 8 O
the	137 3 O
association	141 11 O
between	153 7 O
antibacterial	161 13 O
medications	175 11 O
and	187 3 O
selected	191 8 O
birth	200 5 B-Disease
defects	206 7 I-Disease
.	213 1 O

DESIGN	215 6 O
,	221 1 O
SETTING	223 7 O
,	230 1 O
AND	232 3 O
PARTICIPANTS	236 12 O
:	248 1 O
Population	250 10 O
-	260 1 O
based	261 5 O
,	266 1 O
multisite	268 9 O
,	277 1 O
case	279 4 O
-	283 1 O
control	284 7 O
study	292 5 O
of	298 2 O
women	301 5 O
who	307 3 O
had	311 3 O
pregnancies	315 11 O
affected	327 8 O
by	336 2 O
1	339 1 O
of	341 2 O
more	344 4 O
than	349 4 O
30	354 2 O
eligible	357 8 O
major	366 5 O
birth	372 5 B-Disease
defects	378 7 I-Disease
identified	386 10 O
via	397 3 O
birth	401 5 B-Disease
defect	407 6 I-Disease
surveillance	414 12 O
programs	427 8 O
in	436 2 O
10	439 2 O
states	442 6 O
(	449 1 O
n	450 1 O
=	452 1 O
13	454 2 O
155	457 3 O
)	460 1 O
and	462 3 O
control	466 7 O
women	474 5 O
randomly	480 8 O
selected	489 8 O
from	498 4 O
the	503 3 O
same	507 4 O
geographical	512 12 O
regions	525 7 O
(	533 1 O
n	534 1 O
=	536 1 O
4941	538 4 O
)	542 1 O
.	543 1 O

MAIN	545 4 O
EXPOSURE	550 8 O
:	558 1 O
Reported	560 8 O
maternal	569 8 O
use	578 3 O
of	582 2 O
antibacterials	585 14 O
(	600 1 O
1	601 1 O
month	603 5 O
before	609 6 O
pregnancy	616 9 O
through	626 7 O
the	634 3 O
end	638 3 O
of	642 2 O
the	645 3 O
first	649 5 O
trimester	655 9 O
)	664 1 O
.	665 1 O

MAIN	667 4 O
OUTCOME	672 7 O
MEASURE	680 7 O
:	687 1 O
Odds	689 4 O
ratios	694 6 O
(	701 1 O
ORs	702 3 O
)	705 1 O
measuring	707 9 O
the	717 3 O
association	721 11 O
between	733 7 O
antibacterial	741 13 O
use	755 3 O
and	759 3 O
selected	763 8 O
birth	772 5 B-Disease
defects	778 7 I-Disease
adjusted	786 8 O
for	795 3 O
potential	799 9 O
confounders	809 11 O
.	820 1 O

RESULTS	822 7 O
:	829 1 O
The	831 3 O
reported	835 8 O
use	844 3 O
of	848 2 O
antibacterials	851 14 O
increased	866 9 O
during	876 6 O
pregnancy	883 9 O
,	892 1 O
peaking	894 7 O
during	902 6 O
the	909 3 O
third	913 5 O
month	919 5 O
.	924 1 O

Sulfonamides	926 12 B-Chemical
were	939 4 O
associated	944 10 O
with	955 4 O
anencephaly	960 11 B-Disease
(	972 1 O
adjusted	973 8 O
OR	982 2 O
[	985 1 O
AOR	986 3 O
]	989 1 O
=	991 1 O
3	993 1 O
.	994 1 O
4	995 1 O
;	996 1 O
95	998 2 O
%	1000 1 O
confidence	1002 10 O
interval	1013 8 O
[	1022 1 O
CI	1023 2 O
]	1025 1 O
,	1026 1 O
1	1028 1 O
.	1029 1 O
3	1030 1 O
-	1031 1 O
8	1032 1 O
.	1033 1 O
8	1034 1 O
)	1035 1 O
,	1036 1 O
hypoplastic	1038 11 B-Disease
left	1050 4 I-Disease
heart	1055 5 I-Disease
syndrome	1061 8 I-Disease
(	1070 1 O
AOR	1071 3 O
=	1075 1 O
3	1077 1 O
.	1078 1 O
2	1079 1 O
;	1080 1 O
95	1082 2 O
%	1084 1 O
CI	1086 2 O
,	1088 1 O
1	1090 1 O
.	1091 1 O
3	1092 1 O
-	1093 1 O
7	1094 1 O
.	1095 1 O
6	1096 1 O
)	1097 1 O
,	1098 1 O
coarctation	1100 11 B-Disease
of	1112 2 I-Disease
the	1115 3 I-Disease
aorta	1119 5 I-Disease
(	1125 1 O
AOR	1126 3 O
=	1130 1 O
2	1132 1 O
.	1133 1 O
7	1134 1 O
;	1135 1 O
95	1137 2 O
%	1139 1 O
CI	1141 2 O
,	1143 1 O
1	1145 1 O
.	1146 1 O
3	1147 1 O
-	1148 1 O
5	1149 1 O
.	1150 1 O
6	1151 1 O
)	1152 1 O
,	1153 1 O
choanal	1155 7 B-Disease
atresia	1163 7 I-Disease
(	1171 1 O
AOR	1172 3 O
=	1176 1 O
8	1178 1 O
.	1179 1 O
0	1180 1 O
;	1181 1 O
95	1183 2 O
%	1185 1 O
CI	1187 2 O
,	1189 1 O
2	1191 1 O
.	1192 1 O
7	1193 1 O
-	1194 1 O
23	1195 2 O
.	1197 1 O
5	1198 1 O
)	1199 1 O
,	1200 1 O
transverse	1202 10 B-Disease
limb	1213 4 I-Disease
deficiency	1218 10 I-Disease
(	1229 1 O
AOR	1230 3 O
=	1234 1 O
2	1236 1 O
.	1237 1 O
5	1238 1 O
;	1239 1 O
95	1241 2 O
%	1243 1 O
CI	1245 2 O
,	1247 1 O
1	1249 1 O
.	1250 1 O
0	1251 1 O
-	1252 1 O
5	1253 1 O
.	1254 1 O
9	1255 1 O
)	1256 1 O
,	1257 1 O
and	1259 3 O
diaphragmatic	1263 13 B-Disease
hernia	1277 6 I-Disease
(	1284 1 O
AOR	1285 3 O
=	1289 1 O
2	1291 1 O
.	1292 1 O
4	1293 1 O
;	1294 1 O
95	1296 2 O
%	1298 1 O
CI	1300 2 O
,	1302 1 O
1	1304 1 O
.	1305 1 O
1	1306 1 O
-	1307 1 O
5	1308 1 O
.	1309 1 O
4	1310 1 O
)	1311 1 O
.	1312 1 O

Nitrofurantoins	1314 15 B-Chemical
were	1330 4 O
associated	1335 10 O
with	1346 4 O
anophthalmia	1351 12 B-Disease
or	1364 2 O
microphthalmos	1367 14 B-Disease
(	1382 1 O
AOR	1383 3 O
=	1387 1 O
3	1389 1 O
.	1390 1 O
7	1391 1 O
;	1392 1 O
95	1394 2 O
%	1396 1 O
CI	1398 2 O
,	1400 1 O
1	1402 1 O
.	1403 1 O
1	1404 1 O
-	1405 1 O
12	1406 2 O
.	1408 1 O
2	1409 1 O
)	1410 1 O
,	1411 1 O
hypoplastic	1413 11 B-Disease
left	1425 4 I-Disease
heart	1430 5 I-Disease
syndrome	1436 8 I-Disease
(	1445 1 O
AOR	1446 3 O
=	1450 1 O
4	1452 1 O
.	1453 1 O
2	1454 1 O
;	1455 1 O
95	1457 2 O
%	1459 1 O
CI	1461 2 O
,	1463 1 O
1	1465 1 O
.	1466 1 O
9	1467 1 O
-	1468 1 O
9	1469 1 O
.	1470 1 O
1	1471 1 O
)	1472 1 O
,	1473 1 O
atrial	1475 6 B-Disease
septal	1482 6 I-Disease
defects	1489 7 I-Disease
(	1497 1 O
AOR	1498 3 O
=	1502 1 O
1	1504 1 O
.	1505 1 O
9	1506 1 O
;	1507 1 O
95	1509 2 O
%	1511 1 O
CI	1513 2 O
,	1515 1 O
1	1517 1 O
.	1518 1 O
1	1519 1 O
-	1520 1 O
3	1521 1 O
.	1522 1 O
4	1523 1 O
)	1524 1 O
,	1525 1 O
and	1527 3 O
cleft	1531 5 B-Disease
lip	1537 3 I-Disease
with	1541 4 O
cleft	1546 5 B-Disease
palate	1552 6 I-Disease
(	1559 1 O
AOR	1560 3 O
=	1564 1 O
2	1566 1 O
.	1567 1 O
1	1568 1 O
;	1569 1 O
95	1571 2 O
%	1573 1 O
CI	1575 2 O
,	1577 1 O
1	1579 1 O
.	1580 1 O
2	1581 1 O
-	1582 1 O
3	1583 1 O
.	1584 1 O
9	1585 1 O
)	1586 1 O
.	1587 1 O

Other	1589 5 O
antibacterial	1595 13 O
agents	1609 6 O
that	1616 4 O
showed	1621 6 O
associations	1628 12 O
included	1641 8 O
erythromycins	1650 13 B-Chemical
(	1664 1 O
2	1665 1 O
defects	1667 7 O
)	1674 1 O
,	1675 1 O
penicillins	1677 11 B-Chemical
(	1689 1 O
1	1690 1 O
defect	1692 6 O
)	1698 1 O
,	1699 1 O
cephalosporins	1701 14 B-Chemical
(	1716 1 O
1	1717 1 O
defect	1719 6 O
)	1725 1 O
,	1726 1 O
and	1728 3 O
quinolones	1732 10 B-Chemical
(	1743 1 O
1	1744 1 O
defect	1746 6 O
)	1752 1 O
.	1753 1 O

CONCLUSIONS	1755 11 O
:	1766 1 O
Reassuringly	1768 12 O
,	1780 1 O
penicillins	1782 11 B-Chemical
,	1793 1 O
erythromycins	1795 13 B-Chemical
,	1808 1 O
and	1810 3 O
cephalosporins	1814 14 B-Chemical
,	1828 1 O
although	1830 8 O
used	1839 4 O
commonly	1844 8 O
by	1853 2 O
pregnant	1856 8 O
women	1865 5 O
,	1870 1 O
were	1872 4 O
not	1877 3 O
associated	1881 10 O
with	1892 4 O
many	1897 4 O
birth	1902 5 B-Disease
defects	1908 7 I-Disease
.	1915 1 O

Sulfonamides	1917 12 B-Chemical
and	1930 3 O
nitrofurantoins	1934 15 B-Chemical
were	1950 4 O
associated	1955 10 O
with	1966 4 O
several	1971 7 O
birth	1979 5 B-Disease
defects	1985 7 I-Disease
,	1992 1 O
indicating	1994 10 O
a	2005 1 O
need	2007 4 O
for	2012 3 O
additional	2016 10 O
scrutiny	2027 8 O
.	2035 1 O

Incidence	0 9 O
of	10 2 O
neoplasms	13 9 B-Disease
in	23 2 O
patients	26 8 O
with	35 4 O
rheumatoid	40 10 B-Disease
arthritis	51 9 I-Disease
exposed	61 7 O
to	69 2 O
different	72 9 O
treatment	82 9 O
regimens	92 8 O
.	100 1 O

Immunosuppressive	102 17 O
drugs	120 5 O
have	126 4 O
been	131 4 O
used	136 4 O
during	141 6 O
the	148 3 O
last	152 4 O
30	157 2 O
years	160 5 O
in	166 2 O
treatment	169 9 O
of	179 2 O
patients	182 8 O
with	191 4 O
severe	196 6 O
rheumatoid	203 10 B-Disease
arthritis	214 9 I-Disease
.	223 1 O

The	225 3 O
drugs	229 5 O
commonly	235 8 O
used	244 4 O
are	249 3 O
cyclophosphamide	253 16 B-Chemical
and	270 3 O
chlorambucil	274 12 B-Chemical
(	287 1 O
alkylating	288 10 B-Chemical
agents	299 6 I-Chemical
)	305 1 O
,	306 1 O
azathioprine	308 12 B-Chemical
(	321 1 O
purine	322 6 B-Chemical
analogue	329 8 O
)	337 1 O
,	338 1 O
and	340 3 O
methotrexate	344 12 B-Chemical
(	357 1 O
folic	358 5 B-Chemical
acid	364 4 I-Chemical
analogue	369 8 O
)	377 1 O
.	378 1 O

There	380 5 O
is	386 2 O
evidence	389 8 O
that	398 4 O
all	403 3 O
four	407 4 O
immunosuppressive	412 17 O
drugs	430 5 O
can	436 3 O
reduce	440 6 O
synovitis	447 9 B-Disease
,	456 1 O
but	458 3 O
disease	462 7 O
activity	470 8 O
almost	479 6 O
always	486 6 O
recurs	493 6 O
after	500 5 O
therapy	506 7 O
is	514 2 O
stopped	517 7 O
.	524 1 O

Since	526 5 O
adverse	532 7 O
reactions	540 9 O
are	550 3 O
frequent	554 8 O
,	562 1 O
less	564 4 O
than	569 4 O
50	574 2 O
percent	577 7 O
of	585 2 O
patients	588 8 O
are	597 3 O
able	601 4 O
to	606 2 O
continue	609 8 O
a	618 1 O
particular	620 10 O
drug	631 4 O
for	636 3 O
more	640 4 O
than	645 4 O
one	650 3 O
year	654 4 O
.	658 1 O

Since	660 5 O
it	666 2 O
takes	669 5 O
three	675 5 O
to	681 2 O
12	684 2 O
months	687 6 O
to	694 2 O
achieve	697 7 O
maximal	705 7 O
effects	713 7 O
,	720 1 O
those	722 5 O
patients	728 8 O
who	737 3 O
are	741 3 O
unable	745 6 O
to	752 2 O
continue	755 8 O
the	764 3 O
drug	768 4 O
receive	773 7 O
little	781 6 O
benefit	788 7 O
from	796 4 O
it	801 2 O
.	803 1 O

Patients	805 8 O
treated	814 7 O
with	822 4 O
alkylating	827 10 B-Chemical
agents	838 6 I-Chemical
have	845 4 O
an	850 2 O
increased	853 9 O
risk	863 4 O
of	868 2 O
development	871 11 O
of	883 2 O
acute	886 5 B-Disease
nonlymphocytic	892 14 I-Disease
leukemia	907 8 I-Disease
,	915 1 O
and	917 3 O
both	921 4 O
alkylating	926 10 B-Chemical
agents	937 6 I-Chemical
and	944 3 O
azathioprine	948 12 B-Chemical
are	961 3 O
associated	965 10 O
with	976 4 O
the	981 3 O
development	985 11 O
of	997 2 O
non	1000 3 B-Disease
-	1003 1 I-Disease
Hodgkin	1004 7 I-Disease
'	1011 1 I-Disease
s	1012 1 I-Disease
lymphoma	1014 8 I-Disease
.	1022 1 O

Cyclophosphamide	1024 16 B-Chemical
therapy	1041 7 O
increases	1049 9 O
the	1059 3 O
risk	1063 4 O
of	1068 2 O
carcinoma	1071 9 B-Disease
of	1081 2 I-Disease
the	1084 3 I-Disease
bladder	1088 7 I-Disease
.	1095 1 O

There	1097 5 O
have	1103 4 O
been	1108 4 O
several	1113 7 O
long	1121 4 O
-	1125 1 O
term	1126 4 O
studies	1131 7 O
of	1139 2 O
patients	1142 8 O
with	1151 4 O
rheumatoid	1156 10 B-Disease
arthritis	1167 9 I-Disease
treated	1177 7 O
with	1185 4 O
azathioprine	1190 12 B-Chemical
and	1203 3 O
cyclophosphamide	1207 16 B-Chemical
and	1224 3 O
the	1228 3 O
incidence	1232 9 O
of	1242 2 O
most	1245 4 O
of	1250 2 O
the	1253 3 O
common	1257 6 O
cancers	1264 7 B-Disease
is	1272 2 O
not	1275 3 O
increased	1279 9 O
.	1288 1 O

Data	1290 4 O
on	1295 2 O
the	1298 3 O
possible	1302 8 O
increased	1311 9 O
risk	1321 4 O
of	1326 2 O
malignancy	1329 10 B-Disease
in	1340 2 O
rheumatoid	1343 10 B-Disease
arthritis	1354 9 I-Disease
are	1364 3 O
still	1368 5 O
being	1374 5 O
collected	1380 9 O
,	1389 1 O
and	1391 3 O
until	1395 5 O
further	1401 7 O
information	1409 11 O
is	1421 2 O
available	1424 9 O
,	1433 1 O
the	1435 3 O
use	1439 3 O
of	1443 2 O
immunosuppressive	1446 17 O
drugs	1464 5 O
,	1469 1 O
particularly	1471 12 O
alkylating	1484 10 B-Chemical
agents	1495 6 I-Chemical
,	1501 1 O
in	1503 2 O
the	1506 3 O
treatment	1510 9 O
of	1520 2 O
rheumatoid	1523 10 B-Disease
arthritis	1534 9 I-Disease
should	1544 6 O
be	1551 2 O
reserved	1554 8 O
for	1563 3 O
patients	1567 8 O
with	1576 4 O
severe	1581 6 O
progressive	1588 11 O
disease	1600 7 O
or	1608 2 O
life	1611 4 O
-	1615 1 O
threatening	1616 11 O
complications	1628 13 O
.	1641 1 O

Patterns	0 8 O
of	9 2 O
hepatic	12 7 B-Disease
injury	20 6 I-Disease
induced	27 7 O
by	35 2 O
methyldopa	38 10 B-Chemical
.	48 1 O

Twelve	50 6 O
patients	57 8 O
with	66 4 O
liver	71 5 B-Disease
disease	77 7 I-Disease
related	85 7 O
to	93 2 O
methyldopa	96 10 B-Chemical
were	107 4 O
seen	112 4 O
between	117 7 O
1967	125 4 O
and	130 3 O
1977	134 4 O
.	138 1 O

Illness	140 7 O
occurred	148 8 O
within	157 6 O
1	164 1 O
-	165 1 O
-	166 1 O
9	167 1 O
weeks	169 5 O
of	175 2 O
commencement	178 12 O
of	191 2 O
therapy	194 7 O
in	202 2 O
9	205 1 O
patients	207 8 O
,	215 1 O
the	217 3 O
remaining	221 9 O
3	231 1 O
patients	233 8 O
having	242 6 O
received	249 8 O
the	258 3 O
drug	262 4 O
for	267 3 O
13	271 2 O
months	274 6 O
,	280 1 O
15	282 2 O
months	285 6 O
and	292 3 O
7	296 1 O
years	298 5 O
before	304 6 O
experiencing	311 12 O
symptoms	324 8 O
.	332 1 O

Jaundice	334 8 B-Disease
with	343 4 O
tender	348 6 O
hepatomegaly	355 12 B-Disease
,	367 1 O
usually	369 7 O
preceded	377 8 O
by	386 2 O
symptoms	389 8 O
of	398 2 O
malaise	401 7 O
,	408 1 O
anorexia	410 8 B-Disease
,	418 1 O
nausea	420 6 B-Disease
and	427 3 O
vomiting	431 8 B-Disease
,	439 1 O
and	441 3 O
associated	445 10 O
with	456 4 O
upper	461 5 O
abdominal	467 9 B-Disease
pain	477 4 I-Disease
,	481 1 O
was	483 3 O
an	487 2 O
invariable	490 10 O
finding	501 7 O
in	509 2 O
all	512 3 O
patients	516 8 O
.	524 1 O

Biochemical	526 11 O
liver	538 5 O
function	544 8 O
tests	553 5 O
indicated	559 9 O
hepatocellular	569 14 O
necrosis	584 8 B-Disease
and	593 3 O
correlated	597 10 O
with	608 4 O
histopathological	613 17 O
evidence	631 8 O
of	640 2 O
hepatic	643 7 B-Disease
injury	651 6 I-Disease
,	657 1 O
the	659 3 O
spectrum	663 8 O
of	672 2 O
which	675 5 O
ranged	681 6 O
from	688 4 O
fatty	693 5 B-Disease
change	699 6 I-Disease
and	706 3 O
focal	710 5 O
hepatocellular	716 14 O
necrosis	731 8 B-Disease
to	740 2 O
massive	743 7 B-Disease
hepatic	751 7 I-Disease
necrosis	759 8 I-Disease
.	767 1 O

Most	769 4 O
patients	774 8 O
showed	783 6 O
moderate	790 8 O
to	799 2 O
severe	802 6 O
acute	809 5 B-Disease
hepatitis	815 9 I-Disease
or	825 2 O
chronic	828 7 B-Disease
active	836 6 I-Disease
hepatitis	843 9 I-Disease
with	853 4 O
associated	858 10 O
cholestasis	869 11 B-Disease
.	880 1 O

The	882 3 O
drug	886 4 O
was	891 3 O
withdrawn	895 9 O
on	905 2 O
presentation	908 12 O
to	921 2 O
hospital	924 8 O
in	933 2 O
11	936 2 O
patients	939 8 O
,	947 1 O
with	949 4 O
rapid	954 5 O
clinical	960 8 O
improvement	969 11 O
in	981 2 O
9	984 1 O
.	985 1 O

One	987 3 O
patient	991 7 O
died	999 4 O
,	1003 1 O
having	1005 6 O
presented	1012 9 O
in	1022 2 O
hepatic	1025 7 B-Disease
failure	1033 7 I-Disease
,	1040 1 O
and	1042 3 O
another	1046 7 O
,	1053 1 O
who	1055 3 O
had	1059 3 O
been	1063 4 O
taking	1068 6 O
methyldopa	1075 10 B-Chemical
for	1086 3 O
7	1090 1 O
years	1092 5 O
,	1097 1 O
showed	1099 6 O
slower	1106 6 O
clinical	1113 8 O
and	1122 3 O
biochemical	1126 11 O
resolution	1138 10 O
over	1149 4 O
a	1154 1 O
period	1156 6 O
of	1163 2 O
several	1166 7 O
months	1174 6 O
.	1180 1 O

The	1182 3 O
remaining	1186 9 O
patient	1196 7 O
in	1204 2 O
the	1207 3 O
series	1211 6 O
developed	1218 9 O
fulminant	1228 9 B-Disease
hepatitis	1238 9 I-Disease
when	1248 4 O
the	1253 3 O
drug	1257 4 O
was	1262 3 O
accidentally	1266 12 O
recommenced	1279 11 O
1	1291 1 O
year	1293 4 O
after	1298 5 O
a	1304 1 O
prior	1306 5 O
episode	1312 7 O
of	1320 2 O
methyldopa	1323 10 B-Chemical
-	1333 1 O
induced	1334 7 O
hepatitis	1342 9 B-Disease
.	1351 1 O

In	1353 2 O
this	1356 4 O
latter	1361 6 O
patient	1368 7 O
,	1375 1 O
and	1377 3 O
in	1381 2 O
2	1384 1 O
others	1386 6 O
,	1392 1 O
the	1394 3 O
causal	1398 6 O
relationship	1405 12 O
between	1418 7 O
methyldopa	1426 10 B-Chemical
and	1437 3 O
hepatic	1441 7 B-Disease
dysfunction	1449 11 I-Disease
was	1461 3 O
proved	1465 6 O
with	1472 4 O
the	1477 3 O
recurrence	1481 10 O
of	1492 2 O
hepatitis	1495 9 B-Disease
within	1505 6 O
2	1512 1 O
weeks	1514 5 O
of	1520 2 O
re	1523 2 O
-	1525 1 O
exposure	1526 8 O
to	1535 2 O
the	1538 3 O
drug	1542 4 O
.	1546 1 O

A	0 1 O
phase	2 5 O
I	8 1 O
/	9 1 O
II	10 2 O
study	13 5 O
of	19 2 O
paclitaxel	22 10 B-Chemical
plus	33 4 O
cisplatin	38 9 B-Chemical
as	48 2 O
first	51 5 O
-	56 1 O
line	57 4 O
therapy	62 7 O
for	70 3 O
head	74 4 B-Disease
and	79 3 I-Disease
neck	83 4 I-Disease
cancers	88 7 I-Disease
:	95 1 O
preliminary	97 11 O
results	109 7 O
.	116 1 O

Improved	118 8 O
outcomes	127 8 O
among	136 5 O
patients	142 8 O
with	151 4 O
head	156 4 B-Disease
and	161 3 I-Disease
neck	165 4 I-Disease
carcinomas	170 10 I-Disease
require	181 7 O
investigations	189 14 O
of	204 2 O
new	207 3 O
drugs	211 5 O
for	217 3 O
induction	221 9 O
therapy	231 7 O
.	238 1 O

Preliminary	240 11 O
results	252 7 O
of	260 2 O
an	263 2 O
Eastern	266 7 O
Cooperative	274 11 O
Oncology	286 8 O
Group	295 5 O
study	301 5 O
of	307 2 O
single	310 6 O
-	316 1 O
agent	317 5 O
paclitaxel	323 10 B-Chemical
(	334 1 O
Taxol	335 5 B-Chemical
;	340 1 O
Bristol	342 7 O
-	349 1 O
Myers	350 5 O
Squibb	356 6 O
Company	363 7 O
,	370 1 O
Princeton	372 9 O
,	381 1 O
NJ	383 2 O
)	385 1 O
reported	387 8 O
a	396 1 O
37	398 2 O
%	400 1 O
response	402 8 O
rate	411 4 O
in	416 2 O
patients	419 8 O
with	428 4 O
head	433 4 B-Disease
and	438 3 I-Disease
neck	442 4 I-Disease
cancer	447 6 I-Disease
,	453 1 O
and	455 3 O
the	459 3 O
paclitaxel	463 10 B-Chemical
/	473 1 O
cisplatin	474 9 B-Chemical
combination	484 11 O
has	496 3 O
been	500 4 O
used	505 4 O
successfully	510 12 O
and	523 3 O
has	527 3 O
significantly	531 13 O
improved	545 8 O
median	554 6 O
response	561 8 O
duration	570 8 O
in	579 2 O
ovarian	582 7 B-Disease
cancer	590 6 I-Disease
patients	597 8 O
.	605 1 O

We	607 2 O
initiated	610 9 O
a	620 1 O
phase	622 5 O
I	628 1 O
/	629 1 O
II	630 2 O
trial	633 5 O
to	639 2 O
determine	642 9 O
the	652 3 O
response	656 8 O
and	665 3 O
toxicity	669 8 B-Disease
of	678 2 O
escalating	681 10 O
paclitaxel	692 10 B-Chemical
doses	703 5 O
combined	709 8 O
with	718 4 O
fixed	723 5 O
-	728 1 O
dose	729 4 O
cisplatin	734 9 B-Chemical
with	744 4 O
granulocyte	749 11 O
colony	761 6 O
-	767 1 O
stimulating	768 11 O
factor	780 6 O
support	787 7 O
in	795 2 O
patients	798 8 O
with	807 4 O
untreated	812 9 O
locally	822 7 O
advanced	830 8 O
inoperable	839 10 O
head	850 4 B-Disease
and	855 3 I-Disease
neck	859 4 I-Disease
carcinoma	864 9 I-Disease
.	873 1 O

To	875 2 O
date	878 4 O
,	882 1 O
23	884 2 O
men	887 3 O
with	891 4 O
a	896 1 O
median	898 6 O
age	905 3 O
of	909 2 O
50	912 2 O
years	915 5 O
and	921 3 O
good	925 4 O
performance	930 11 O
status	942 6 O
have	949 4 O
entered	954 7 O
the	962 3 O
trial	966 5 O
.	971 1 O

Primary	973 7 O
tumor	981 5 B-Disease
sites	987 5 O
were	993 4 O
oropharynx	998 10 O
,	1008 1 O
10	1010 2 O
patients	1013 8 O
;	1021 1 O
hypopharynx	1023 11 O
,	1034 1 O
four	1036 4 O
;	1040 1 O
larynx	1042 6 O
,	1048 1 O
two	1050 3 O
;	1053 1 O
oral	1055 4 O
cavity	1060 6 O
,	1066 1 O
three	1068 5 O
;	1073 1 O
unknown	1075 7 O
primary	1083 7 O
,	1090 1 O
two	1092 3 O
;	1095 1 O
and	1097 3 O
nasal	1101 5 O
cavity	1107 6 O
and	1114 3 O
parotid	1118 7 O
gland	1126 5 O
,	1131 1 O
one	1133 3 O
each	1137 4 O
.	1141 1 O

Of	1143 2 O
20	1146 2 O
patients	1149 8 O
evaluable	1158 9 O
for	1168 3 O
toxicity	1172 8 B-Disease
,	1180 1 O
four	1182 4 O
had	1187 3 O
stage	1191 5 O
III	1197 3 O
and	1201 3 O
16	1205 2 O
had	1208 3 O
stage	1212 5 O
IV	1218 2 O
disease	1221 7 O
.	1228 1 O

Treatment	1230 9 O
,	1239 1 O
given	1241 5 O
every	1247 5 O
21	1253 2 O
days	1256 4 O
for	1261 3 O
a	1265 1 O
maximum	1267 7 O
of	1275 2 O
three	1278 5 O
cycles	1284 6 O
,	1290 1 O
consisted	1292 9 O
of	1302 2 O
paclitaxel	1305 10 B-Chemical
by	1316 2 O
3	1319 1 O
-	1320 1 O
hour	1321 4 O
infusion	1326 8 O
followed	1335 8 O
the	1344 3 O
next	1348 4 O
day	1353 3 O
by	1357 2 O
a	1360 1 O
fixed	1362 5 O
dose	1368 4 O
of	1373 2 O
cisplatin	1376 9 B-Chemical
(	1386 1 O
75	1387 2 O
mg	1390 2 O
/	1392 1 O
m2	1393 2 O
)	1395 1 O
.	1396 1 O

The	1398 3 O
dose	1402 4 O
levels	1407 6 O
incorporate	1414 11 O
escalating	1426 10 O
paclitaxel	1437 10 B-Chemical
doses	1448 5 O
,	1453 1 O
and	1455 3 O
intrapatient	1459 12 O
escalations	1472 11 O
within	1484 6 O
a	1491 1 O
given	1493 5 O
dose	1499 4 O
level	1504 5 O
are	1510 3 O
permitted	1514 9 O
if	1524 2 O
toxicity	1527 8 B-Disease
permits	1536 7 O
.	1543 1 O

At	1545 2 O
the	1548 3 O
time	1552 4 O
of	1557 2 O
this	1560 4 O
writing	1565 7 O
,	1572 1 O
dose	1574 4 O
level	1579 5 O
4	1585 1 O
(	1587 1 O
260	1588 3 O
,	1591 1 O
270	1593 3 O
,	1596 1 O
and	1598 3 O
280	1602 3 O
mg	1606 2 O
/	1608 1 O
m2	1609 2 O
)	1611 1 O
is	1613 2 O
being	1616 5 O
evaluated	1622 9 O
;	1631 1 O
three	1633 5 O
patients	1639 8 O
from	1648 4 O
this	1653 4 O
level	1658 5 O
are	1664 3 O
evaluable	1668 9 O
.	1677 1 O

With	1679 4 O
paclitaxel	1684 10 B-Chemical
doses	1695 5 O
of	1701 2 O
200	1704 3 O
mg	1708 2 O
/	1710 1 O
m2	1711 2 O
and	1714 3 O
higher	1718 6 O
,	1724 1 O
granulocyte	1726 11 O
colony	1738 6 O
-	1744 1 O
stimulating	1745 11 O
factor	1757 6 O
5	1764 1 O
micrograms	1766 10 O
/	1776 1 O
kg	1777 2 O
/	1779 1 O
d	1780 1 O
is	1782 2 O
given	1785 5 O
(	1791 1 O
days	1792 4 O
4	1797 1 O
through	1799 7 O
12	1807 2 O
)	1809 1 O
.	1810 1 O

Of	1812 2 O
18	1815 2 O
patients	1818 8 O
evaluable	1827 9 O
for	1837 3 O
response	1841 8 O
,	1849 1 O
seven	1851 5 O
(	1857 1 O
39	1858 2 O
%	1860 1 O
)	1861 1 O
achieved	1863 8 O
a	1872 1 O
complete	1874 8 O
response	1883 8 O
and	1892 3 O
six	1896 3 O
(	1900 1 O
33	1901 2 O
%	1903 1 O
)	1904 1 O
achieved	1906 8 O
a	1915 1 O
partial	1917 7 O
response	1925 8 O
.	1933 1 O

Three	1935 5 O
patients	1941 8 O
had	1950 3 O
no	1954 2 O
change	1957 6 O
and	1964 3 O
disease	1968 7 O
progressed	1976 10 O
in	1987 2 O
two	1990 3 O
.	1993 1 O

The	1995 3 O
overall	1999 7 O
response	2007 8 O
rate	2016 4 O
is	2021 2 O
72	2024 2 O
%	2026 1 O
.	2027 1 O

Eleven	2029 6 O
responding	2036 10 O
patients	2047 8 O
had	2056 3 O
subsequent	2060 10 O
surgery	2071 7 O
/	2078 1 O
radiotherapy	2079 12 O
or	2092 2 O
radical	2095 7 O
radiotherapy	2103 12 O
.	2115 1 O

Two	2117 3 O
pathologic	2121 10 O
complete	2132 8 O
responses	2141 9 O
were	2151 4 O
observed	2156 8 O
in	2165 2 O
patients	2168 8 O
who	2177 3 O
had	2181 3 O
achieved	2185 8 O
clinical	2194 8 O
complete	2203 8 O
responses	2212 9 O
.	2221 1 O

Alopecia	2223 8 B-Disease
,	2231 1 O
paresthesias	2233 12 B-Disease
,	2245 1 O
and	2247 3 O
arthralgias	2251 11 B-Disease
/	2262 1 O
myalgias	2263 8 B-Disease
have	2272 4 O
occurred	2277 8 O
frequently	2286 10 O
,	2296 1 O
but	2298 3 O
with	2302 4 O
one	2307 3 O
exception	2311 9 O
(	2321 1 O
a	2322 1 O
grade	2324 5 O
3	2330 1 O
myalgia	2332 7 B-Disease
)	2339 1 O
they	2341 4 O
have	2346 4 O
been	2351 4 O
grade	2356 5 O
1	2362 1 O
or	2364 2 O
2	2367 1 O
.	2368 1 O

No	2370 2 O
dose	2373 4 O
-	2377 1 O
limiting	2378 8 O
hematologic	2387 11 O
toxicity	2399 8 B-Disease
has	2408 3 O
been	2412 4 O
seen	2417 4 O
.	2421 1 O

Paclitaxel	2423 10 B-Chemical
/	2433 1 O
cisplatin	2434 9 B-Chemical
is	2444 2 O
an	2447 2 O
effective	2450 9 O
first	2460 5 O
-	2465 1 O
line	2466 4 O
regimen	2471 7 O
for	2479 3 O
locoregionally	2483 14 O
advanced	2498 8 O
head	2507 4 B-Disease
and	2512 3 I-Disease
neck	2516 4 I-Disease
cancer	2521 6 I-Disease
and	2528 3 O
continued	2532 9 O
study	2542 5 O
is	2548 2 O
warranted	2551 9 O
.	2560 1 O

Results	2562 7 O
thus	2570 4 O
far	2575 3 O
suggest	2579 7 O
no	2587 2 O
dose	2590 4 O
-	2594 1 O
response	2595 8 O
effect	2604 6 O
for	2611 3 O
paclitaxel	2615 10 B-Chemical
doses	2626 5 O
above	2632 5 O
200	2638 3 O
mg	2642 2 O
/	2644 1 O
m2	2645 2 O
.	2647 1 O

A	0 1 O
phase	2 5 O
I	8 1 O
study	10 5 O
of	16 2 O
4	19 1 B-Chemical
'	20 1 I-Chemical
-	21 1 I-Chemical
0	22 1 I-Chemical
-	23 1 I-Chemical
tetrahydropyranyladriamycin	24 27 I-Chemical
.	51 1 O

Clinical	53 8 O
pharmacology	62 12 O
and	75 3 O
pharmacokinetics	79 16 O
.	95 1 O

A	97 1 O
Phase	99 5 O
I	105 1 O
study	107 5 O
of	113 2 O
intravenous	116 11 O
(	128 1 O
IV	129 2 O
)	131 1 O
bolus	133 5 O
4	139 1 B-Chemical
'	140 1 I-Chemical
-	141 1 I-Chemical
0	142 1 I-Chemical
-	143 1 I-Chemical
tetrahydropyranyladriamycin	144 27 I-Chemical
(	172 1 O
Pirarubicin	173 11 B-Chemical
)	184 1 O
was	186 3 O
done	190 4 O
in	195 2 O
55	198 2 O
patients	201 8 O
in	210 2 O
good	213 4 O
performance	218 11 O
status	230 6 O
with	237 4 O
refractory	242 10 O
tumors	253 6 B-Disease
.	259 1 O

Twenty	261 6 O
-	267 1 O
six	268 3 O
had	272 3 O
minimal	276 7 O
prior	284 5 O
therapy	290 7 O
(	298 1 O
good	299 4 O
risk	304 4 O
)	308 1 O
,	309 1 O
23	311 2 O
had	314 3 O
extensive	318 9 O
prior	328 5 O
therapy	334 7 O
(	342 1 O
poor	343 4 O
risk	348 4 O
)	352 1 O
,	353 1 O
and	355 3 O
six	359 3 O
had	363 3 O
renal	367 5 B-Disease
and	373 3 I-Disease
/	376 1 I-Disease
or	377 2 I-Disease
hepatic	380 7 I-Disease
dysfunction	388 11 I-Disease
.	399 1 O

A	401 1 O
total	403 5 O
of	409 2 O
167	412 3 O
courses	416 7 O
at	424 2 O
doses	427 5 O
of	433 2 O
15	436 2 O
to	439 2 O
70	442 2 O
mg	445 2 O
/	447 1 O
m2	448 2 O
were	451 4 O
evaluable	456 9 O
.	465 1 O

Maximum	467 7 O
tolerated	475 9 O
dose	485 4 O
in	490 2 O
good	493 4 O
-	497 1 O
risk	498 4 O
patients	503 8 O
was	512 3 O
70	516 2 O
mg	519 2 O
/	521 1 O
m2	522 2 O
,	524 1 O
and	526 3 O
in	530 2 O
poor	533 4 O
-	537 1 O
risk	538 4 O
patients	543 8 O
,	551 1 O
60	553 2 O
mg	556 2 O
/	558 1 O
m2	559 2 O
.	561 1 O

The	563 3 O
dose	567 4 O
-	571 1 O
limiting	572 8 O
toxic	581 5 O
effect	587 6 O
was	594 3 O
transient	598 9 O
noncumulative	608 13 O
granulocytopenia	622 16 B-Disease
.	638 1 O

Granulocyte	640 11 O
nadir	652 5 O
was	658 3 O
on	662 2 O
day	665 3 O
14	669 2 O
(	672 1 O
range	673 5 O
,	678 1 O
4	680 1 O
-	681 1 O
22	682 2 O
)	684 1 O
.	685 1 O

Less	687 4 O
frequent	692 8 O
toxic	701 5 O
effects	707 7 O
included	715 8 O
thrombocytopenia	724 16 B-Disease
,	740 1 O
anemia	742 6 B-Disease
,	748 1 O
nausea	750 6 B-Disease
,	756 1 O
mild	758 4 O
alopecia	763 8 B-Disease
,	771 1 O
phlebitis	773 9 B-Disease
,	782 1 O
and	784 3 O
mucositis	788 9 B-Disease
.	797 1 O

Myelosuppression	799 16 B-Disease
was	816 3 O
more	820 4 O
in	825 2 O
patients	828 8 O
with	837 4 O
hepatic	842 7 B-Disease
dysfunction	850 11 I-Disease
.	861 1 O

Pharmacokinetic	863 15 O
analyses	879 8 O
in	888 2 O
21	891 2 O
patients	894 8 O
revealed	903 8 O
Pirarubicin	912 11 B-Chemical
plasma	924 6 O
T	931 1 O
1	933 1 O
/	934 1 O
2	935 1 O
alpha	937 5 O
(	943 1 O
+	944 1 O
/	945 1 O
-	946 1 O
SE	948 2 O
)	950 1 O
of	952 2 O
2	955 1 O
.	956 1 O
5	957 1 O
+	959 1 O
/	960 1 O
-	961 1 O
0	963 1 O
.	964 1 O
85	965 2 O
minutes	968 7 O
,	975 1 O
T	977 1 O
beta	979 4 O
1	984 1 O
/	985 1 O
2	986 1 O
of	988 2 O
25	991 2 O
.	993 1 O
6	994 1 O
+	996 1 O
/	997 1 O
-	998 1 O
6	1000 1 O
.	1001 1 O
5	1002 1 O
minutes	1004 7 O
,	1011 1 O
and	1013 3 O
T	1017 1 O
1	1019 1 O
/	1020 1 O
2	1021 1 O
gamma	1023 5 O
of	1029 2 O
23	1032 2 O
.	1034 1 O
6	1035 1 O
+	1037 1 O
/	1038 1 O
-	1039 1 O
7	1041 1 O
.	1042 1 O
6	1043 1 O
hours	1045 5 O
.	1050 1 O

The	1052 3 O
area	1056 4 O
under	1061 5 O
the	1067 3 O
curve	1071 5 O
was	1077 3 O
537	1081 3 O
+	1085 1 O
/	1086 1 O
-	1087 1 O
149	1089 3 O
ng	1093 2 O
/	1095 1 O
ml	1096 2 O
x	1099 1 O
hours	1101 5 O
,	1106 1 O
volume	1108 6 O
of	1115 2 O
distribution	1118 12 O
(	1131 1 O
Vd	1132 2 O
)	1134 1 O
3504	1136 4 O
+	1141 1 O
/	1142 1 O
-	1143 1 O
644	1145 3 O
l	1149 1 O
/	1150 1 O
m2	1151 2 O
,	1153 1 O
and	1155 3 O
total	1159 5 O
clearance	1165 9 O
(	1175 1 O
ClT	1176 3 O
)	1179 1 O
was	1181 3 O
204	1185 3 O
+	1189 1 O
39	1191 2 O
.	1193 1 O
3	1194 1 O
l	1196 1 O
/	1197 1 O
hour	1198 4 O
/	1202 1 O
m2	1203 2 O
.	1205 1 O

Adriamycinol	1207 12 B-Chemical
,	1219 1 O
doxorubicin	1221 11 B-Chemical
,	1232 1 O
adriamycinone	1234 13 B-Chemical
,	1247 1 O
and	1249 3 O
tetrahydropyranyladriamycinol	1253 29 B-Chemical
were	1283 4 O
the	1288 3 O
metabolites	1292 11 O
detected	1304 8 O
in	1313 2 O
plasma	1316 6 O
and	1323 3 O
the	1327 3 O
amount	1331 6 O
of	1338 2 O
doxorubicin	1341 11 B-Chemical
was	1353 3 O
less	1357 4 O
than	1362 4 O
or	1367 2 O
equal	1370 5 O
to	1376 2 O
10	1379 2 O
%	1381 1 O
of	1383 2 O
the	1386 3 O
total	1390 5 O
metabolites	1396 11 O
.	1407 1 O

Urinary	1409 7 O
excretion	1417 9 O
of	1427 2 O
Pirarubicin	1430 11 B-Chemical
in	1442 2 O
the	1445 3 O
first	1449 5 O
24	1455 2 O
hours	1458 5 O
was	1464 3 O
less	1468 4 O
than	1473 4 O
or	1478 2 O
equal	1481 5 O
to	1487 2 O
10	1490 2 O
%	1492 1 O
.	1493 1 O

Activity	1495 8 O
was	1504 3 O
noted	1508 5 O
in	1514 2 O
mesothelioma	1517 12 B-Disease
,	1529 1 O
leiomyosarcoma	1531 14 B-Disease
,	1545 1 O
and	1547 3 O
basal	1551 5 B-Disease
cell	1557 4 I-Disease
carcinoma	1562 9 I-Disease
.	1571 1 O

The	1573 3 O
recommended	1577 11 O
starting	1589 8 O
dose	1598 4 O
for	1603 3 O
Phase	1607 5 O
II	1613 2 O
trials	1616 6 O
is	1623 2 O
60	1626 2 O
mg	1629 2 O
/	1631 1 O
m2	1632 2 O
IV	1635 2 O
bolus	1638 5 O
every	1644 5 O
3	1650 1 O
weeks	1652 5 O
.	1657 1 O

Differential	0 12 O
effects	13 7 O
of	21 2 O
gamma	24 5 B-Chemical
-	29 1 I-Chemical
hexachlorocyclohexane	30 21 I-Chemical
(	52 1 O
lindane	53 7 B-Chemical
)	60 1 O
on	62 2 O
pharmacologically	65 17 O
-	82 1 O
induced	83 7 O
seizures	91 8 B-Disease
.	99 1 O

Gamma	101 5 B-Chemical
-	106 1 I-Chemical
hexachlorocyclohexane	107 21 I-Chemical
(	129 1 O
gamma	130 5 B-Chemical
-	135 1 I-Chemical
HCH	136 3 I-Chemical
)	139 1 O
,	140 1 O
the	142 3 O
active	146 6 O
ingredient	153 10 O
of	164 2 O
the	167 3 O
insecticide	171 11 O
lindane	183 7 B-Chemical
,	190 1 O
has	192 3 O
been	196 4 O
shown	201 5 O
to	207 2 O
decrease	210 8 O
seizure	219 7 B-Disease
threshold	227 9 O
to	237 2 O
pentylenetrazol	240 15 O
(	256 1 O
PTZ	257 3 B-Chemical
)	260 1 O
3	262 1 O
h	264 1 O
after	266 5 O
exposure	272 8 O
to	281 2 O
gamma	284 5 B-Chemical
-	289 1 I-Chemical
HCH	290 3 I-Chemical
and	294 3 O
conversely	298 10 O
increase	309 8 O
threshold	318 9 O
to	328 2 O
PTZ	331 3 B-Chemical
-	334 1 O
induced	335 7 O
seizures	343 8 B-Disease
24	352 2 O
h	355 1 O
after	357 5 O
exposure	363 8 O
to	372 2 O
gamma	375 5 B-Chemical
-	380 1 I-Chemical
HCH	381 3 I-Chemical
(	385 1 O
Vohland	386 7 O
et	394 2 O
al	397 2 O
.	399 1 O
1981	401 4 O
)	405 1 O
.	406 1 O

In	408 2 O
this	411 4 O
study	416 5 O
,	421 1 O
the	423 3 O
severity	427 8 O
of	436 2 O
response	439 8 O
to	448 2 O
other	451 5 O
seizure	457 7 B-Disease
-	464 1 O
inducing	465 8 O
agents	474 6 O
was	481 3 O
tested	485 6 O
in	492 2 O
mice	495 4 O
1	500 1 O
and	502 3 O
24	506 2 O
h	509 1 O
after	511 5 O
intraperitoneal	517 15 O
administration	533 14 O
of	548 2 O
80	551 2 O
mg	554 2 O
/	556 1 O
kg	557 2 O
gamma	560 5 B-Chemical
-	565 1 I-Chemical
HCH	566 3 I-Chemical
.	569 1 O

One	571 3 O
hour	575 4 O
after	580 5 O
the	586 3 O
administration	590 14 O
of	605 2 O
gamma	608 5 B-Chemical
-	613 1 I-Chemical
HCH	614 3 I-Chemical
,	617 1 O
the	619 3 O
activity	623 8 O
of	632 2 O
seizure	635 7 B-Disease
-	642 1 O
inducing	643 8 O
agents	652 6 O
was	659 3 O
increased	663 9 O
,	672 1 O
regardless	674 10 O
of	685 2 O
their	688 5 O
mechanism	694 9 O
,	703 1 O
while	705 5 O
24	711 2 O
h	714 1 O
after	716 5 O
gamma	722 5 B-Chemical
-	727 1 I-Chemical
HCH	728 3 I-Chemical
a	732 1 O
differential	734 12 O
response	747 8 O
was	756 3 O
observed	760 8 O
.	768 1 O

Seizure	770 7 B-Disease
activity	778 8 O
due	787 3 O
to	791 2 O
PTZ	794 3 B-Chemical
and	798 3 O
picrotoxin	802 10 B-Chemical
(	813 1 O
PTX	814 3 B-Chemical
)	817 1 O
was	819 3 O
significantly	823 13 O
decreased	837 9 O
;	846 1 O
however	848 7 O
,	855 1 O
seizure	857 7 B-Disease
activity	865 8 O
due	874 3 O
to	878 2 O
3	881 1 B-Chemical
-	882 1 I-Chemical
mercaptopropionic	883 17 I-Chemical
acid	901 4 I-Chemical
(	906 1 O
MPA	907 3 B-Chemical
)	910 1 O
,	911 1 O
bicuculline	913 11 B-Chemical
(	925 1 O
BCC	926 3 B-Chemical
)	929 1 O
,	930 1 O
methyl	932 6 B-Chemical
6	939 1 I-Chemical
,	940 1 I-Chemical
7	941 1 I-Chemical
-	942 1 I-Chemical
dimethoxy	943 9 I-Chemical
-	952 1 I-Chemical
4	953 1 I-Chemical
-	954 1 I-Chemical
ethyl	955 5 I-Chemical
-	960 1 I-Chemical
B	961 1 I-Chemical
-	962 1 I-Chemical
carboline	963 9 I-Chemical
-	972 1 I-Chemical
3	973 1 I-Chemical
-	974 1 I-Chemical
carboxylate	975 11 I-Chemical
(	987 1 O
DMCM	988 4 B-Chemical
)	992 1 O
,	993 1 O
or	995 2 O
strychnine	998 10 B-Chemical
(	1009 1 O
STR	1010 3 B-Chemical
)	1013 1 O
was	1015 3 O
not	1019 3 O
different	1023 9 O
from	1033 4 O
control	1038 7 O
.	1045 1 O

In	1047 2 O
vitro	1050 5 O
,	1055 1 O
gamma	1057 5 B-Chemical
-	1062 1 I-Chemical
HCH	1063 3 I-Chemical
,	1066 1 O
pentylenetetrazol	1068 17 B-Chemical
and	1086 3 O
picrotoxin	1090 10 B-Chemical
were	1101 4 O
shown	1106 5 O
to	1112 2 O
inhibit	1115 7 O
3H	1123 2 B-Chemical
-	1125 1 I-Chemical
TBOB	1126 4 I-Chemical
binding	1131 7 O
in	1139 2 O
mouse	1142 5 O
whole	1148 5 O
brain	1154 5 O
,	1159 1 O
with	1161 4 O
IC50	1166 4 O
values	1171 6 O
of	1178 2 O
4	1181 1 O
.	1182 1 O
6	1183 1 O
,	1184 1 O
404	1186 3 O
and	1190 3 O
9	1194 1 O
.	1195 1 O
4	1196 1 O
microM	1198 6 O
,	1204 1 O
respectively	1206 12 O
.	1218 1 O

MPA	1220 3 B-Chemical
,	1223 1 O
BCC	1225 3 B-Chemical
,	1228 1 O
DMCM	1230 4 B-Chemical
,	1234 1 O
and	1236 3 O
STR	1240 3 B-Chemical
showed	1244 6 O
no	1251 2 O
inhibition	1254 10 O
of	1265 2 O
3H	1268 2 B-Chemical
-	1270 1 I-Chemical
TBOB	1271 4 I-Chemical
(	1276 1 O
t	1277 1 B-Chemical
-	1278 1 I-Chemical
butyl	1279 5 I-Chemical
bicyclo	1285 7 I-Chemical
-	1292 1 I-Chemical
orthobenzoate	1293 13 I-Chemical
)	1306 1 O
binding	1308 7 O
at	1316 2 O
concentrations	1319 14 O
of	1334 2 O
100	1337 3 O
micron	1341 6 O
.	1347 1 O

The	1349 3 O
pharmacological	1353 15 O
challenge	1369 9 O
data	1379 4 O
suggest	1384 7 O
that	1392 4 O
tolerance	1397 9 O
may	1407 3 O
occur	1411 5 O
to	1417 2 O
seizure	1420 7 B-Disease
activity	1428 8 O
induced	1437 7 O
by	1445 2 O
PTZ	1448 3 B-Chemical
and	1452 3 O
PTX	1456 3 B-Chemical
24	1460 2 O
h	1463 1 O
after	1465 5 O
gamma	1471 5 B-Chemical
-	1476 1 I-Chemical
HCH	1477 3 I-Chemical
,	1480 1 O
since	1482 5 O
the	1488 3 O
response	1492 8 O
to	1501 2 O
only	1504 4 O
these	1509 5 O
two	1515 3 O
seizure	1519 7 B-Disease
-	1526 1 O
inducing	1527 8 O
agents	1536 6 O
is	1543 2 O
decreased	1546 9 O
.	1555 1 O

The	1557 3 O
in	1561 2 O
vitro	1564 5 O
data	1570 4 O
suggest	1575 7 O
that	1583 4 O
the	1588 3 O
site	1592 4 O
responsible	1597 11 O
for	1609 3 O
the	1613 3 O
decrease	1617 8 O
in	1626 2 O
seizure	1629 7 B-Disease
activity	1637 8 O
24	1646 2 O
h	1649 1 O
after	1651 5 O
gamma	1657 5 B-Chemical
-	1662 1 I-Chemical
HCH	1663 3 I-Chemical
may	1667 3 O
be	1671 2 O
the	1674 3 O
GABA	1678 4 B-Chemical
-	1682 1 O
A	1683 1 O
receptor	1685 8 O
-	1693 1 O
linked	1694 6 O
chloride	1701 8 O
channel	1710 7 O
.	1717 1 O

Severe	0 6 O
ocular	7 6 B-Disease
and	14 3 I-Disease
orbital	18 7 I-Disease
toxicity	26 8 I-Disease
after	35 5 O
intracarotid	41 12 O
injection	54 9 O
of	64 2 O
carboplatin	67 11 B-Chemical
for	79 3 O
recurrent	83 9 O
glioblastomas	93 13 B-Disease
.	106 1 O

BACKGROUND	108 10 O
:	118 1 O
Glioblastoma	120 12 B-Disease
is	133 2 O
a	136 1 O
malignant	138 9 B-Disease
tumor	148 5 I-Disease
that	154 4 O
occurs	159 6 O
in	166 2 O
the	169 3 O
cerebrum	173 8 O
during	182 6 O
adulthood	189 9 O
.	198 1 O

With	200 4 O
current	205 7 O
treatment	213 9 O
regimens	223 8 O
including	232 9 O
combined	242 8 O
surgery	251 7 O
,	258 1 O
radiation	260 9 O
and	270 3 O
chemotherapy	274 12 O
,	286 1 O
the	288 3 O
average	292 7 O
life	300 4 O
expectancy	305 10 O
of	316 2 O
the	319 3 O
patients	323 8 O
is	332 2 O
limited	335 7 O
to	343 2 O
approximately	346 13 O
1	360 1 O
year	362 4 O
.	366 1 O

Therefore	368 9 O
,	377 1 O
patients	379 8 O
with	388 4 O
glioblastoma	393 12 B-Disease
sometimes	406 9 O
have	416 4 O
intracarotid	421 12 O
injection	434 9 O
of	444 2 O
carcinostatics	447 14 O
added	462 5 O
to	468 2 O
the	471 3 O
treatment	475 9 O
regimen	485 7 O
.	492 1 O

Generally	494 9 O
,	503 1 O
carboplatin	505 11 B-Chemical
is	517 2 O
said	520 4 O
to	525 2 O
have	528 4 O
milder	533 6 O
side	540 4 O
effects	545 7 O
than	553 4 O
cisplatin	558 9 B-Chemical
,	567 1 O
whose	569 5 O
ocular	575 6 B-Disease
and	582 3 I-Disease
orbital	586 7 I-Disease
toxicity	594 8 I-Disease
are	603 3 O
well	607 4 O
known	612 5 O
.	617 1 O

However	619 7 O
,	626 1 O
we	628 2 O
experienced	631 11 O
a	643 1 O
case	645 4 O
of	650 2 O
severe	653 6 O
ocular	660 6 B-Disease
and	667 3 I-Disease
orbital	671 7 I-Disease
toxicity	679 8 I-Disease
after	688 5 O
intracarotid	694 12 O
injection	707 9 O
of	717 2 O
carboplatin	720 11 B-Chemical
,	731 1 O
which	733 5 O
is	739 2 O
infrequently	742 12 O
reported	755 8 O
.	763 1 O

CASE	765 4 O
:	769 1 O
A	771 1 O
58	773 2 O
-	775 1 O
year	776 4 O
-	780 1 O
old	781 3 O
man	785 3 O
received	789 8 O
an	798 2 O
intracarotid	801 12 O
injection	814 9 O
of	824 2 O
carboplatin	827 11 B-Chemical
for	839 3 O
recurrent	843 9 O
glioblastomas	853 13 B-Disease
in	867 2 O
his	870 3 O
left	874 4 O
temporal	879 8 O
lobe	888 4 O
.	892 1 O

He	894 2 O
complained	897 10 O
of	908 2 O
pain	911 4 B-Disease
and	916 3 I-Disease
visual	920 6 I-Disease
disturbance	927 11 I-Disease
in	939 2 I-Disease
the	942 3 I-Disease
ipsilateral	946 11 I-Disease
eye	958 3 I-Disease
30	962 2 O
h	965 1 O
after	967 5 O
the	973 3 O
injection	977 9 O
.	986 1 O

Various	988 7 O
ocular	996 6 O
symptoms	1003 8 O
and	1012 3 O
findings	1016 8 O
caused	1025 6 O
by	1032 2 O
carboplatin	1035 11 B-Chemical
toxicity	1047 8 B-Disease
were	1056 4 O
seen	1061 4 O
.	1065 1 O

RESULTS	1067 7 O
:	1074 1 O
He	1076 2 O
was	1079 3 O
treated	1083 7 O
with	1091 4 O
intravenous	1096 11 O
administration	1108 14 O
of	1123 2 O
corticosteroids	1126 15 O
and	1142 3 O
glycerin	1146 8 B-Chemical
for	1155 3 O
6	1159 1 O
days	1161 4 O
after	1166 5 O
the	1172 3 O
injection	1176 9 O
.	1185 1 O

Although	1187 8 O
the	1196 3 O
intraocular	1200 11 O
pressure	1212 8 O
elevation	1221 9 O
caused	1231 6 O
by	1238 2 O
secondary	1241 9 O
acute	1251 5 O
angle	1257 5 O
-	1262 1 O
closure	1263 7 O
glaucoma	1271 8 B-Disease
decreased	1280 9 O
and	1290 3 O
ocular	1294 6 B-Disease
pain	1301 4 I-Disease
diminished	1306 10 O
,	1316 1 O
inexorable	1318 10 O
papilledema	1329 11 B-Disease
and	1341 3 O
exudative	1345 9 O
retinal	1355 7 B-Disease
detachment	1363 10 I-Disease
continued	1374 9 O
for	1384 3 O
3	1388 1 O
weeks	1390 5 O
.	1395 1 O

Finally	1397 7 O
,	1404 1 O
6	1406 1 O
weeks	1408 5 O
later	1414 5 O
,	1419 1 O
diffuse	1421 7 O
chorioretinal	1429 13 B-Disease
atrophy	1443 7 I-Disease
with	1451 4 O
optic	1456 5 B-Disease
atrophy	1462 7 I-Disease
occurred	1470 8 O
and	1479 3 O
the	1483 3 O
vision	1487 6 O
in	1494 2 O
his	1497 3 O
left	1501 4 O
eye	1506 3 O
was	1510 3 O
lost	1514 4 O
.	1518 1 O

CONCLUSION	1520 10 O
:	1530 1 O
When	1532 4 O
performing	1537 10 O
intracarotid	1548 12 O
injection	1561 9 O
of	1571 2 O
carboplatin	1574 11 B-Chemical
,	1585 1 O
we	1587 2 O
must	1590 4 O
be	1595 2 O
aware	1598 5 O
of	1604 2 O
its	1607 3 O
potentially	1611 11 O
blinding	1623 8 O
ocular	1632 6 B-Disease
toxicity	1639 8 I-Disease
.	1647 1 O

It	1649 2 O
is	1652 2 O
recommended	1655 11 O
that	1667 4 O
further	1672 7 O
studies	1680 7 O
and	1688 3 O
investigations	1692 14 O
are	1707 3 O
undertaken	1711 10 O
in	1722 2 O
the	1725 3 O
effort	1729 6 O
to	1736 2 O
minimize	1739 8 O
such	1748 4 O
severe	1753 6 O
side	1760 4 O
effects	1765 7 O
.	1772 1 O

Phase	0 5 O
II	6 2 O
study	9 5 O
of	15 2 O
the	18 3 O
amsacrine	22 9 B-Chemical
analogue	32 8 O
CI	41 2 B-Chemical
-	43 1 I-Chemical
921	44 3 I-Chemical
(	48 1 O
NSC	49 3 B-Chemical
343499	53 6 I-Chemical
)	59 1 O
in	61 2 O
non	64 3 B-Disease
-	67 1 I-Disease
small	68 5 I-Disease
cell	74 4 I-Disease
lung	79 4 I-Disease
cancer	84 6 I-Disease
.	90 1 O

CI	92 2 B-Chemical
-	94 1 I-Chemical
921	95 3 I-Chemical
(	99 1 O
NSC	100 3 B-Chemical
343499	104 6 I-Chemical
;	110 1 O
9	112 1 B-Chemical
-	113 1 I-Chemical
[	114 1 I-Chemical
[	115 1 I-Chemical
2	116 1 I-Chemical
-	117 1 I-Chemical
methoxy	118 7 I-Chemical
-	125 1 I-Chemical
4	126 1 I-Chemical
-	127 1 I-Chemical
[	128 1 I-Chemical
(	129 1 I-Chemical
methylsulphonyl	130 15 I-Chemical
)	145 1 I-Chemical
amino	146 5 I-Chemical
]	151 1 I-Chemical
phenyl	152 6 I-Chemical
]	158 1 I-Chemical
amino	159 5 I-Chemical
]	164 1 I-Chemical
-	166 1 I-Chemical
N	167 1 I-Chemical
,	168 1 I-Chemical
5	169 1 I-Chemical
-	170 1 I-Chemical
dimethyl	171 8 I-Chemical
-	179 1 I-Chemical
4	181 1 I-Chemical
-	182 1 I-Chemical
acridinecarboxamide	183 19 I-Chemical
)	202 1 O
is	204 2 O
a	207 1 O
topoisomerase	209 13 O
II	223 2 O
poison	226 6 O
with	233 4 O
high	238 4 O
experimental	243 12 O
antitumour	256 10 O
activity	267 8 O
.	275 1 O

It	277 2 O
was	280 3 O
administered	284 12 O
by	297 2 O
15	300 2 O
min	303 3 O
infusion	307 8 O
to	316 2 O
16	319 2 O
evaluable	322 9 O
patients	332 8 O
with	341 4 O
non	346 3 B-Disease
-	349 1 I-Disease
small	350 5 I-Disease
cell	356 4 I-Disease
lung	361 4 I-Disease
cancer	366 6 I-Disease
(	373 1 O
NSCLC	374 5 B-Disease
)	379 1 O
(	381 1 O
7	382 1 O
with	384 4 O
no	389 2 O
prior	392 5 O
treatment	398 9 O
,	407 1 O
9	409 1 O
patients	411 8 O
in	420 2 O
relapse	423 7 O
following	431 9 O
surgery	441 7 O
/	448 1 O
radiotherapy	449 12 O
)	461 1 O
at	463 2 O
a	466 1 O
dose	468 4 O
(	473 1 O
648	474 3 O
mg	478 2 O
/	480 1 O
m2	481 2 O
divided	484 7 O
over	492 4 O
3	497 1 O
days	499 4 O
,	503 1 O
repeated	505 8 O
every	514 5 O
3	520 1 O
weeks	522 5 O
)	527 1 O
determined	529 10 O
by	540 2 O
phase	543 5 O
I	549 1 O
trial	551 5 O
.	556 1 O

Patients	558 8 O
had	567 3 O
a	571 1 O
median	573 6 O
performance	580 11 O
status	592 6 O
of	599 2 O
1	602 1 O
(	604 1 O
WHO	605 3 O
)	608 1 O
,	609 1 O
and	611 3 O
median	615 6 O
age	622 3 O
of	626 2 O
61	629 2 O
years	632 5 O
.	637 1 O

The	639 3 O
histology	643 9 O
comprised	653 9 O
squamous	663 8 B-Disease
carcinoma	672 9 I-Disease
(	682 1 O
11	683 2 O
)	685 1 O
,	686 1 O
adenocarcinoma	688 14 B-Disease
(	703 1 O
1	704 1 O
)	705 1 O
,	706 1 O
mixed	708 5 O
histology	714 9 O
(	724 1 O
2	725 1 O
)	726 1 O
,	727 1 O
bronchio	729 8 B-Disease
-	737 1 I-Disease
alveolar	738 8 I-Disease
carcinoma	747 9 I-Disease
(	757 1 O
1	758 1 O
)	759 1 O
and	761 3 O
large	765 5 O
cell	771 4 O
undifferentiated	776 16 B-Disease
carcinoma	793 9 I-Disease
(	803 1 O
1	804 1 O
)	805 1 O
.	806 1 O

Neutropenia	808 11 B-Disease
grade	820 5 O
greater	826 7 O
than	834 4 O
or	839 2 O
equal	842 5 O
to	848 2 O
3	851 1 O
was	853 3 O
seen	857 4 O
in	862 2 O
15	865 2 O
patients	868 8 O
,	876 1 O
infections	878 10 B-Disease
with	889 4 O
recovery	894 8 O
in	903 2 O
3	906 1 O
,	907 1 O
and	909 3 O
grand	913 5 O
mal	919 3 O
seizures	923 8 B-Disease
in	932 2 O
1	935 1 O
patient	937 7 O
.	944 1 O

Grade	946 5 O
less	952 4 O
than	957 4 O
or	962 2 O
equal	965 5 O
to	971 2 O
2	974 1 O
nausea	976 6 B-Disease
and	983 3 O
vomiting	987 8 B-Disease
occurred	996 8 O
in	1005 2 O
66	1008 2 O
%	1010 1 O
courses	1012 7 O
and	1020 3 O
phlebitis	1024 9 B-Disease
in	1034 2 O
the	1037 3 O
infusion	1041 8 O
arm	1050 3 O
in	1054 2 O
37	1057 2 O
%	1059 1 O
.	1060 1 O

1	1062 1 O
patient	1064 7 O
with	1072 4 O
squamous	1077 8 B-Disease
cell	1086 4 I-Disease
carcinoma	1091 9 I-Disease
achieved	1101 8 O
a	1110 1 O
partial	1112 7 O
response	1120 8 O
lasting	1129 7 O
5	1137 1 O
months	1139 6 O
.	1145 1 O

Further	1147 7 O
testing	1155 7 O
in	1163 2 O
this	1166 4 O
and	1171 3 O
other	1175 5 O
tumour	1181 6 B-Disease
types	1188 5 O
using	1194 5 O
multiple	1200 8 O
daily	1209 5 O
schedules	1215 9 O
is	1225 2 O
warranted	1228 9 O
.	1237 1 O

Alpha	0 5 B-Chemical
-	5 1 I-Chemical
lipoic	6 6 I-Chemical
acid	13 4 I-Chemical
prevents	18 8 O
mitochondrial	27 13 B-Disease
damage	41 6 I-Disease
and	48 3 O
neurotoxicity	52 13 B-Disease
in	66 2 O
experimental	69 12 O
chemotherapy	82 12 O
neuropathy	95 10 B-Disease
.	105 1 O

The	107 3 O
study	111 5 O
investigates	117 12 O
if	130 2 O
alpha	133 5 B-Chemical
-	138 1 I-Chemical
lipoic	139 6 I-Chemical
acid	146 4 I-Chemical
is	151 2 O
neuroprotective	154 15 O
against	170 7 O
chemotherapy	178 12 O
induced	191 7 O
neurotoxicity	199 13 B-Disease
,	212 1 O
if	214 2 O
mitochondrial	217 13 B-Disease
damage	231 6 I-Disease
plays	238 5 O
a	244 1 O
critical	246 8 O
role	255 4 O
in	260 2 O
toxic	263 5 B-Disease
neurodegenerative	269 17 I-Disease
cascade	287 7 I-Disease
,	294 1 O
and	296 3 O
if	300 2 O
neuroprotective	303 15 O
effects	319 7 O
of	327 2 O
alpha	330 5 B-Chemical
-	335 1 I-Chemical
lipoic	336 6 I-Chemical
acid	343 4 I-Chemical
depend	348 6 O
on	355 2 O
mitochondria	358 12 O
protection	371 10 O
.	381 1 O

We	383 2 O
used	386 4 O
an	391 2 O
in	394 2 O
vitro	397 5 O
model	403 5 O
of	409 2 O
chemotherapy	412 12 O
induced	425 7 O
peripheral	433 10 B-Disease
neuropathy	444 10 I-Disease
that	455 4 O
closely	460 7 O
mimic	468 5 O
the	474 3 O
in	478 2 O
vivo	481 4 O
condition	486 9 O
by	496 2 O
exposing	499 8 O
primary	508 7 O
cultures	516 8 O
of	525 2 O
dorsal	528 6 O
root	535 4 O
ganglion	540 8 O
(	549 1 O
DRG	550 3 O
)	553 1 O
sensory	555 7 O
neurons	563 7 O
to	571 2 O
paclitaxel	574 10 B-Chemical
and	585 3 O
cisplatin	589 9 B-Chemical
,	598 1 O
two	600 3 O
widely	604 6 O
used	611 4 O
and	616 3 O
highly	620 6 O
effective	627 9 O
chemotherapeutic	637 16 O
drugs	654 5 O
.	659 1 O

This	661 4 O
approach	666 8 O
allowed	675 7 O
investigating	683 13 O
the	697 3 O
efficacy	701 8 O
of	710 2 O
alpha	713 5 B-Chemical
-	718 1 I-Chemical
lipoic	719 6 I-Chemical
acid	726 4 I-Chemical
in	731 2 O
preventing	734 10 O
axonal	745 6 B-Disease
damage	752 6 I-Disease
and	759 3 O
apoptosis	763 9 O
and	773 3 O
the	777 3 O
function	781 8 O
and	790 3 O
ultrastructural	794 15 O
morphology	810 10 O
of	821 2 O
mitochondria	824 12 O
after	837 5 O
exposure	843 8 O
to	852 2 O
toxic	855 5 O
agents	861 6 O
and	868 3 O
alpha	872 5 B-Chemical
-	877 1 I-Chemical
lipoic	878 6 I-Chemical
acid	885 4 I-Chemical
.	889 1 O

Our	891 3 O
results	895 7 O
demonstrate	903 11 O
that	915 4 O
both	920 4 O
cisplatin	925 9 B-Chemical
and	935 3 O
paclitaxel	939 10 B-Chemical
cause	950 5 O
early	956 5 O
mitochondrial	962 13 B-Disease
impairment	976 10 I-Disease
with	987 4 O
loss	992 4 O
of	997 2 O
membrane	1000 8 O
potential	1009 9 O
and	1019 3 O
induction	1023 9 O
of	1033 2 O
autophagic	1036 10 O
vacuoles	1047 8 O
in	1056 2 O
neurons	1059 7 O
.	1066 1 O

Alpha	1068 5 B-Chemical
-	1073 1 I-Chemical
lipoic	1074 6 I-Chemical
acid	1081 4 I-Chemical
exerts	1086 6 O
neuroprotective	1093 15 O
effects	1109 7 O
against	1117 7 O
chemotherapy	1125 12 O
induced	1138 7 O
neurotoxicity	1146 13 B-Disease
in	1160 2 O
sensory	1163 7 O
neurons	1171 7 O
:	1178 1 O
it	1180 2 O
rescues	1183 7 O
the	1191 3 O
mitochondrial	1195 13 B-Disease
toxicity	1209 8 I-Disease
and	1218 3 O
induces	1222 7 O
the	1230 3 O
expression	1234 10 O
of	1245 2 O
frataxin	1248 8 O
,	1256 1 O
an	1258 2 O
essential	1261 9 O
mitochondrial	1271 13 O
protein	1285 7 O
with	1293 4 O
anti	1298 4 O
-	1302 1 O
oxidant	1303 7 O
and	1311 3 O
chaperone	1315 9 O
properties	1325 10 O
.	1335 1 O

In	1337 2 O
conclusion	1340 10 O
mitochondrial	1351 13 B-Disease
toxicity	1365 8 I-Disease
is	1374 2 O
an	1377 2 O
early	1380 5 O
common	1386 6 O
event	1393 5 O
both	1399 4 O
in	1404 2 O
paclitaxel	1407 10 B-Chemical
and	1418 3 O
cisplatin	1422 9 B-Chemical
induced	1432 7 O
neurotoxicity	1440 13 B-Disease
.	1453 1 O

Alpha	1455 5 B-Chemical
-	1460 1 I-Chemical
lipoic	1461 6 I-Chemical
acid	1468 4 I-Chemical
protects	1473 8 O
sensory	1482 7 O
neurons	1490 7 O
through	1498 7 O
its	1506 3 O
anti	1510 4 O
-	1514 1 O
oxidant	1515 7 O
and	1523 3 O
mitochondrial	1527 13 O
regulatory	1541 10 O
functions	1552 9 O
,	1561 1 O
possibly	1563 8 O
inducing	1572 8 O
the	1581 3 O
expression	1585 10 O
of	1596 2 O
frataxin	1599 8 O
.	1607 1 O

These	1609 5 O
findings	1615 8 O
suggest	1624 7 O
that	1632 4 O
alpha	1637 5 B-Chemical
-	1642 1 I-Chemical
lipoic	1643 6 I-Chemical
acid	1650 4 I-Chemical
might	1655 5 O
reduce	1661 6 O
the	1668 3 O
risk	1672 4 O
of	1677 2 O
developing	1680 10 O
peripheral	1691 10 B-Disease
nerve	1702 5 I-Disease
toxicity	1708 8 I-Disease
in	1717 2 O
patients	1720 8 O
undergoing	1729 10 O
chemotherapy	1740 12 O
and	1753 3 O
encourage	1757 9 O
further	1767 7 O
confirmatory	1775 12 O
clinical	1788 8 O
trials	1797 6 O
.	1803 1 O

Optimising	0 10 O
stroke	11 6 B-Disease
prevention	18 10 O
in	29 2 O
non	32 3 O
-	35 1 O
valvular	36 8 O
atrial	45 6 B-Disease
fibrillation	52 12 I-Disease
.	64 1 O

Atrial	66 6 B-Disease
fibrillation	73 12 I-Disease
is	86 2 O
associated	89 10 O
with	100 4 O
substantial	105 11 O
morbidity	117 9 O
and	127 3 O
mortality	131 9 O
.	140 1 O

Pooled	142 6 O
data	149 4 O
from	154 4 O
trials	159 6 O
comparing	166 9 O
antithrombotic	176 14 O
treatment	191 9 O
with	201 4 O
placebo	206 7 O
have	214 4 O
shown	219 5 O
that	225 4 O
warfarin	230 8 B-Chemical
reduces	239 7 O
the	247 3 O
risk	251 4 O
of	256 2 O
stroke	259 6 B-Disease
by	266 2 O
62	269 2 O
%	271 1 O
,	272 1 O
and	274 3 O
that	278 4 O
aspirin	283 7 B-Chemical
alone	291 5 O
reduces	297 7 O
the	305 3 O
risk	309 4 O
by	314 2 O
22	317 2 O
%	319 1 O
.	320 1 O

Overall	322 7 O
,	329 1 O
in	331 2 O
high	334 4 O
-	338 1 O
risk	339 4 O
patients	344 8 O
,	352 1 O
warfarin	354 8 B-Chemical
is	363 2 O
superior	366 8 O
to	375 2 O
aspirin	378 7 B-Chemical
in	386 2 O
preventing	389 10 O
strokes	400 7 B-Disease
,	407 1 O
with	409 4 O
a	414 1 O
relative	416 8 O
risk	425 4 O
reduction	430 9 O
of	440 2 O
36	443 2 O
%	445 1 O
.	446 1 O

Ximelagatran	448 12 B-Chemical
,	460 1 O
an	462 2 O
oral	465 4 O
direct	470 6 O
thrombin	477 8 O
inhibitor	486 9 O
,	495 1 O
was	497 3 O
found	501 5 O
to	507 2 O
be	510 2 O
as	513 2 O
efficient	516 9 O
as	526 2 O
vitamin	529 7 B-Chemical
K	537 1 I-Chemical
antagonist	539 10 O
drugs	550 5 O
in	556 2 O
the	559 3 O
prevention	563 10 O
of	574 2 O
embolic	577 7 B-Disease
events	585 6 I-Disease
,	591 1 O
but	593 3 O
has	597 3 O
been	601 4 O
recently	606 8 O
withdrawn	615 9 O
because	625 7 O
of	633 2 O
abnormal	636 8 B-Disease
liver	645 5 I-Disease
function	651 8 I-Disease
tests	660 5 O
.	665 1 O

The	667 3 O
ACTIVE	671 6 O
-	677 1 O
W	678 1 O
(	680 1 O
Atrial	681 6 B-Disease
Fibrillation	688 12 I-Disease
Clopidogrel	701 11 B-Chemical
Trial	713 5 O
with	719 4 O
Irbesartan	724 10 B-Chemical
for	735 3 O
Prevention	739 10 O
of	750 2 O
Vascular	753 8 O
Events	762 6 O
)	768 1 O
study	770 5 O
has	776 3 O
demonstrated	780 12 O
that	793 4 O
warfarin	798 8 B-Chemical
is	807 2 O
superior	810 8 O
to	819 2 O
platelet	822 8 O
therapy	831 7 O
(	839 1 O
clopidogrel	840 11 B-Chemical
plus	852 4 O
aspirin	857 7 B-Chemical
)	864 1 O
in	866 2 O
the	869 3 O
prevention	873 10 O
af	884 2 O
embolic	887 7 B-Disease
events	895 6 I-Disease
.	901 1 O

Idraparinux	903 11 B-Chemical
,	914 1 O
a	916 1 O
Factor	918 6 O
Xa	925 2 O
inhibitor	928 9 O
,	937 1 O
is	939 2 O
being	942 5 O
evaluated	948 9 O
in	958 2 O
patients	961 8 O
with	970 4 O
atrial	975 6 B-Disease
fibrillation	982 12 I-Disease
.	994 1 O

Angiotensin	996 11 B-Chemical
-	1007 1 O
converting	1008 10 O
enzyme	1019 6 O
inhibitors	1026 10 O
and	1037 3 O
angiotensin	1041 11 B-Chemical
II	1053 2 I-Chemical
receptor	1056 8 O
-	1064 1 O
blocking	1065 8 O
drugs	1074 5 O
hold	1080 4 O
promise	1085 7 O
in	1093 2 O
atrial	1096 6 B-Disease
fibrillation	1103 12 I-Disease
through	1116 7 O
cardiac	1124 7 B-Disease
remodelling	1132 11 I-Disease
.	1143 1 O

Preliminary	1145 11 O
studies	1157 7 O
suggest	1165 7 O
that	1173 4 O
statins	1178 7 B-Chemical
could	1186 5 O
interfere	1192 9 O
with	1202 4 O
the	1207 3 O
risk	1211 4 O
of	1216 2 O
recurrence	1219 10 O
after	1230 5 O
electrical	1236 10 O
cardioversion	1247 13 O
.	1260 1 O

Finally	1262 7 O
,	1269 1 O
percutaneous	1271 12 O
methods	1284 7 O
for	1292 3 O
the	1296 3 O
exclusion	1300 9 O
of	1310 2 O
left	1313 4 O
atrial	1318 6 O
appendage	1325 9 O
are	1335 3 O
under	1339 5 O
investigation	1345 13 O
in	1359 2 O
high	1362 4 O
-	1366 1 O
risk	1367 4 O
patients	1372 8 O
.	1380 1 O

Interaction	0 11 O
of	12 2 O
cyclosporin	15 11 B-Chemical
A	27 1 I-Chemical
with	29 4 O
antineoplastic	34 14 O
agents	49 6 O
.	55 1 O

A	57 1 O
synergistic	59 11 O
effect	71 6 O
of	78 2 O
etoposide	81 9 B-Chemical
and	91 3 O
cyclosporin	95 11 B-Chemical
A	107 1 I-Chemical
was	109 3 O
observed	113 8 O
in	122 2 O
a	125 1 O
patient	127 7 O
with	135 4 O
acute	140 5 B-Disease
T	146 1 I-Disease
-	147 1 I-Disease
lymphocytic	148 11 I-Disease
leukemia	160 8 I-Disease
in	169 2 O
relapse	172 7 O
.	179 1 O

The	181 3 O
concomitant	185 11 O
administration	197 14 O
of	212 2 O
etoposide	215 9 B-Chemical
and	225 3 O
cyclosporin	229 11 B-Chemical
A	241 1 I-Chemical
resulted	243 8 O
in	252 2 O
eradication	255 11 O
of	267 2 O
hitherto	270 8 O
refractory	279 10 O
leukemic	290 8 B-Disease
infiltration	299 12 I-Disease
of	312 2 O
bone	315 4 O
marrow	320 6 O
.	326 1 O

Severe	328 6 O
side	335 4 O
effects	340 7 O
in	348 2 O
terms	351 5 O
of	357 2 O
mental	360 6 O
confusion	367 9 B-Disease
and	377 3 O
progressive	381 11 O
hyperbilirubinemia	393 18 B-Disease
,	411 1 O
however	413 7 O
,	420 1 O
point	422 5 O
to	428 2 O
an	431 2 O
enhancement	434 11 O
not	446 3 O
only	450 4 O
of	455 2 O
antineoplastic	458 14 O
effects	473 7 O
but	481 3 O
also	485 4 O
of	490 2 O
toxicity	493 8 B-Disease
in	502 2 O
normal	505 6 O
tissues	512 7 O
.	519 1 O

This	521 4 O
report	526 6 O
demonstrates	533 12 O
for	546 3 O
the	550 3 O
first	554 5 O
time	560 4 O
that	565 4 O
the	570 3 O
pharmacodynamic	574 15 O
properties	590 10 O
of	601 2 O
cyclosporin	604 11 B-Chemical
A	616 1 I-Chemical
may	618 3 O
not	622 3 O
be	626 2 O
confined	629 8 O
strictly	638 8 O
to	647 2 O
suppression	650 11 O
of	662 2 O
normal	665 6 O
T	672 1 O
-	673 1 O
cell	674 4 O
functions	679 9 O
.	688 1 O

The	0 3 O
hematologic	4 11 O
effects	16 7 O
of	24 2 O
cefonicid	27 9 B-Chemical
and	37 3 O
cefazedone	41 10 B-Chemical
in	52 2 O
the	55 3 O
dog	59 3 O
:	62 1 O
a	64 1 O
potential	66 9 O
model	76 5 O
of	82 2 O
cephalosporin	85 13 B-Chemical
hematotoxicity	99 14 B-Disease
in	114 2 O
man	117 3 O
.	120 1 O

Cephalosporin	122 13 B-Chemical
antibiotics	136 11 O
cause	148 5 O
a	154 1 O
variety	156 7 O
of	164 2 O
hematologic	167 11 B-Disease
disturbances	179 12 I-Disease
in	192 2 O
man	195 3 O
,	198 1 O
the	200 3 O
pathogeneses	204 12 O
and	217 3 O
hematopathology	221 15 O
of	237 2 O
which	240 5 O
remain	246 6 O
poorly	253 6 O
characterized	260 13 O
.	273 1 O

There	275 5 O
is	281 2 O
a	284 1 O
need	286 4 O
for	291 3 O
a	295 1 O
well	297 4 O
-	301 1 O
defined	302 7 O
animal	310 6 O
model	317 5 O
in	323 2 O
which	326 5 O
these	332 5 O
blood	338 5 B-Disease
dyscrasias	344 10 I-Disease
can	355 3 O
be	359 2 O
studied	362 7 O
.	369 1 O

In	371 2 O
four	374 4 O
subacute	379 8 O
toxicity	388 8 B-Disease
studies	397 7 O
,	404 1 O
the	406 3 O
intravenous	410 11 O
administration	422 14 O
of	437 2 O
cefonicid	440 9 B-Chemical
or	450 2 O
cefazedone	453 10 B-Chemical
to	464 2 O
beagle	467 6 O
dogs	474 4 O
caused	479 6 O
a	486 1 O
dose	488 4 O
-	492 1 O
dependent	493 9 O
incidence	503 9 O
of	513 2 O
anemia	516 6 B-Disease
,	522 1 O
neutropenia	524 11 B-Disease
,	535 1 O
and	537 3 O
thrombocytopenia	541 16 B-Disease
after	558 5 O
1	564 1 O
-	565 1 O
3	566 1 O
months	568 6 O
of	575 2 O
treatment	578 9 O
.	587 1 O

A	589 1 O
nonregenerative	591 15 O
anemia	607 6 B-Disease
was	614 3 O
the	618 3 O
most	622 4 O
compromising	627 12 O
of	640 2 O
the	643 3 O
cytopenias	647 10 B-Disease
and	658 3 O
occurred	662 8 O
in	671 2 O
approximately	674 13 O
50	688 2 O
%	690 1 O
of	692 2 O
dogs	695 4 O
receiving	700 9 O
400	710 3 O
-	713 1 O
500	714 3 O
mg	718 2 O
/	720 1 O
kg	721 2 O
cefonicid	724 9 B-Chemical
or	734 2 O
540	737 3 O
-	740 1 O
840	741 3 O
mg	745 2 O
/	747 1 O
kg	748 2 O
cefazedone	751 10 B-Chemical
.	761 1 O

All	763 3 O
three	767 5 O
cytopenias	773 10 B-Disease
were	784 4 O
completely	789 10 O
reversible	800 10 O
following	811 9 O
cessation	821 9 O
of	831 2 O
treatment	834 9 O
;	843 1 O
the	845 3 O
time	849 4 O
required	854 8 O
for	863 3 O
recovery	867 8 O
of	876 2 O
the	879 3 O
erythron	883 8 O
(	892 1 O
approximately	893 13 O
1	907 1 O
month	909 5 O
)	914 1 O
was	916 3 O
considerably	920 12 O
longer	933 6 O
than	940 4 O
that	945 4 O
of	950 2 O
the	953 3 O
granulocytes	957 12 O
and	970 3 O
platelets	974 9 O
(	984 1 O
hours	985 5 O
to	991 2 O
a	994 1 O
few	996 3 O
days	1000 4 O
)	1004 1 O
.	1005 1 O

Upon	1007 4 O
rechallenge	1012 11 O
with	1024 4 O
either	1029 6 O
cephalosporin	1036 13 B-Chemical
,	1049 1 O
the	1051 3 O
hematologic	1055 11 B-Disease
syndrome	1067 8 I-Disease
was	1076 3 O
reproduced	1080 10 O
in	1091 2 O
most	1094 4 O
dogs	1099 4 O
tested	1104 6 O
;	1110 1 O
cefonicid	1112 9 B-Chemical
(	1122 1 O
but	1123 3 O
not	1127 3 O
cefazedone	1131 10 B-Chemical
)	1141 1 O
-	1142 1 O
treated	1143 7 O
dogs	1151 4 O
showed	1156 6 O
a	1163 1 O
substantially	1165 13 O
reduced	1179 7 O
induction	1187 9 O
period	1197 6 O
(	1204 1 O
15	1205 2 O
+	1208 1 O
/	1209 1 O
-	1210 1 O
5	1212 1 O
days	1214 4 O
)	1218 1 O
compared	1220 8 O
to	1229 2 O
that	1232 4 O
of	1237 2 O
the	1240 3 O
first	1244 5 O
exposure	1250 8 O
to	1259 2 O
the	1262 3 O
drug	1266 4 O
(	1271 1 O
61	1272 2 O
+	1275 1 O
/	1276 1 O
-	1277 1 O
24	1279 2 O
days	1282 4 O
)	1286 1 O
.	1287 1 O

This	1289 4 O
observation	1294 11 O
,	1305 1 O
along	1307 5 O
with	1313 4 O
the	1318 3 O
rapid	1322 5 O
rate	1328 4 O
of	1333 2 O
decline	1336 7 O
in	1344 2 O
red	1347 3 O
cell	1351 4 O
mass	1356 4 O
parameters	1361 10 O
of	1372 2 O
affected	1375 8 O
dogs	1384 4 O
,	1388 1 O
suggests	1390 8 O
that	1399 4 O
a	1404 1 O
hemolytic	1406 9 B-Disease
component	1416 9 O
complicated	1426 11 O
the	1438 3 O
red	1442 3 O
cell	1446 4 O
production	1451 10 O
problem	1462 7 O
and	1470 3 O
that	1474 4 O
multiple	1479 8 O
toxicologic	1488 11 O
mechanisms	1500 10 O
contributed	1511 11 O
to	1523 2 O
the	1526 3 O
cytopenia	1530 9 B-Disease
.	1539 1 O

We	1541 2 O
conclude	1544 8 O
that	1553 4 O
the	1558 3 O
administration	1562 14 O
of	1577 2 O
high	1580 4 O
doses	1585 5 O
of	1591 2 O
cefonicid	1594 9 B-Chemical
or	1604 2 O
cefazedone	1607 10 B-Chemical
to	1618 2 O
dogs	1621 4 O
can	1626 3 O
induce	1630 6 O
hematotoxicity	1637 14 B-Disease
similar	1652 7 O
to	1660 2 O
the	1663 3 O
cephalosporin	1667 13 B-Chemical
-	1680 1 O
induced	1681 7 O
blood	1689 5 B-Disease
dyscrasias	1695 10 I-Disease
described	1706 9 O
in	1716 2 O
man	1719 3 O
and	1723 3 O
thus	1727 4 O
provides	1732 8 O
a	1741 1 O
useful	1743 6 O
model	1750 5 O
for	1756 3 O
studying	1760 8 O
the	1769 3 O
mechanisms	1773 10 O
of	1784 2 O
these	1787 5 O
disorders	1793 9 O
.	1802 1 O

A	0 1 O
pyridoxine	2 10 B-Chemical
-	12 1 O
dependent	13 9 O
behavioral	23 10 B-Disease
disorder	34 8 I-Disease
unmasked	43 8 O
by	52 2 O
isoniazid	55 9 B-Chemical
.	64 1 O

A	66 1 O
3	68 1 O
-	69 1 O
year	70 4 O
-	74 1 O
old	75 3 O
girl	79 4 O
had	84 3 O
behavioral	88 10 B-Disease
deterioration	99 13 I-Disease
,	112 1 O
with	114 4 O
hyperkinesis	119 12 B-Disease
,	131 1 O
irritability	133 12 B-Disease
,	145 1 O
and	147 3 O
sleeping	151 8 B-Disease
difficulties	160 12 I-Disease
after	173 5 O
the	179 3 O
therapeutic	183 11 O
administration	195 14 O
of	210 2 O
isoniazid	213 9 B-Chemical
.	222 1 O

The	224 3 O
administration	228 14 O
of	243 2 O
pharmacologic	246 13 O
doses	260 5 O
of	266 2 O
pyridoxine	269 10 B-Chemical
hydrochloride	280 13 I-Chemical
led	294 3 O
to	298 2 O
a	301 1 O
disappearance	303 13 O
of	317 2 O
symptoms	320 8 O
.	328 1 O

After	330 5 O
discontinuing	336 13 O
isoniazid	350 9 B-Chemical
therapy	360 7 O
a	368 1 O
similar	370 7 O
pattern	378 7 O
of	386 2 O
behavior	389 8 O
was	398 3 O
noted	402 5 O
that	408 4 O
was	413 3 O
controlled	417 10 O
by	428 2 O
pyridoxine	431 10 B-Chemical
.	441 1 O

A	443 1 O
placebo	445 7 O
had	453 3 O
no	457 2 O
effect	460 6 O
,	466 1 O
but	468 3 O
niacinamide	472 11 B-Chemical
was	484 3 O
as	488 2 O
effective	491 9 O
as	501 2 O
pyridoxine	504 10 B-Chemical
.	514 1 O

Periodic	516 8 O
withdrawal	525 10 O
of	536 2 O
pyridoxine	539 10 B-Chemical
was	550 3 O
associated	554 10 O
with	565 4 O
return	570 6 O
of	577 2 O
the	580 3 O
hyperkinesis	584 12 B-Disease
.	596 1 O

The	598 3 O
level	602 5 O
of	608 2 O
pyridoxal	611 9 B-Chemical
in	621 2 O
the	624 3 O
blood	628 5 O
was	634 3 O
normal	638 6 O
during	645 6 O
the	652 3 O
periods	656 7 O
of	664 2 O
relapse	667 7 O
.	674 1 O

Metabolic	676 9 O
studies	686 7 O
suggested	694 9 O
a	704 1 O
block	706 5 O
in	712 2 O
the	715 3 O
kynurenine	719 10 B-Chemical
pathway	730 7 O
of	738 2 O
tryptophan	741 10 B-Chemical
metabolism	752 10 O
.	762 1 O

The	764 3 O
patient	768 7 O
has	776 3 O
been	780 4 O
followed	785 8 O
for	794 3 O
six	798 3 O
years	802 5 O
and	808 3 O
has	812 3 O
required	816 8 O
pharmacologic	825 13 O
doses	839 5 O
of	845 2 O
pyridoxine	848 10 B-Chemical
to	859 2 O
control	862 7 O
her	870 3 O
behavior	874 8 O
.	882 1 O

A	0 1 O
selective	2 9 O
dopamine	12 8 B-Chemical
D4	21 2 O
receptor	24 8 O
antagonist	33 10 O
,	43 1 O
NRA0160	45 7 B-Chemical
:	52 1 O
a	54 1 O
preclinical	56 11 O
neuropharmacological	68 20 O
profile	89 7 O
.	96 1 O

NRA0160	98 7 B-Chemical
,	105 1 O
5	107 1 B-Chemical
-	109 1 I-Chemical
[	111 1 I-Chemical
2	112 1 I-Chemical
-	113 1 I-Chemical
(	115 1 I-Chemical
4	117 1 I-Chemical
-	118 1 I-Chemical
(	120 1 I-Chemical
3	122 1 I-Chemical
-	124 1 I-Chemical
fluorobenzylidene	126 17 I-Chemical
)	143 1 I-Chemical
piperidin	145 9 I-Chemical
-	154 1 I-Chemical
1	155 1 I-Chemical
-	156 1 I-Chemical
yl	157 2 I-Chemical
)	159 1 I-Chemical
ethyl	161 5 I-Chemical
]	166 1 I-Chemical
-	168 1 I-Chemical
4	170 1 I-Chemical
-	172 1 I-Chemical
(	173 1 I-Chemical
4	174 1 I-Chemical
-	175 1 I-Chemical
fluorophenyl	176 12 I-Chemical
)	188 1 I-Chemical
thiazole	190 8 I-Chemical
-	198 1 I-Chemical
2	199 1 I-Chemical
-	200 1 I-Chemical
carboxamide	201 11 I-Chemical
,	212 1 O
has	214 3 O
a	218 1 O
high	220 4 O
affinity	225 8 O
for	234 3 O
human	238 5 O
cloned	244 6 O
dopamine	251 8 B-Chemical
D4	260 2 O
.	262 1 O
2	263 1 O
,	264 1 O
D4	266 2 O
.	268 1 O
4	269 1 O
and	271 3 O
D4	275 2 O
.	277 1 O
7	278 1 O
receptors	280 9 O
,	289 1 O
with	291 4 O
Ki	296 2 O
values	299 6 O
of	306 2 O
0	309 1 O
.	310 1 O
5	311 1 O
,	312 1 O
0	314 1 O
.	315 1 O
9	316 1 O
and	318 3 O
2	322 1 O
.	323 1 O
7	324 1 O
nM	326 2 O
,	328 1 O
respectively	330 12 O
.	342 1 O

NRA0160	344 7 B-Chemical
is	352 2 O
over	355 4 O
20	360 2 O
,	362 1 O
000fold	363 7 O
more	371 4 O
potent	376 6 O
at	383 2 O
the	386 3 O
dopamine	390 8 B-Chemical
D4	399 2 O
.	401 1 O
2	402 1 O
receptor	404 8 O
compared	413 8 O
with	422 4 O
the	427 3 O
human	431 5 O
cloned	437 6 O
dopamine	444 8 B-Chemical
D2L	453 3 O
receptor	457 8 O
.	465 1 O

NRA0160	467 7 B-Chemical
has	475 3 O
negligible	479 10 O
affinity	490 8 O
for	499 3 O
the	503 3 O
human	507 5 O
cloned	513 6 O
dopamine	520 8 B-Chemical
D3	529 2 O
receptor	532 8 O
(	541 1 O
Ki	542 2 O
=	544 1 O
39	545 2 O
nM	548 2 O
)	550 1 O
,	551 1 O
rat	553 3 O
serotonin	557 9 B-Chemical
(	567 1 O
5	568 1 B-Chemical
-	569 1 I-Chemical
HT	570 2 I-Chemical
)	572 1 O
2A	573 2 O
receptors	576 9 O
(	586 1 O
Ki	587 2 O
=	589 1 O
180	590 3 O
nM	594 2 O
)	596 1 O
and	598 3 O
rat	602 3 O
alpha1	606 6 O
adrenoceptor	613 12 O
(	626 1 O
Ki	627 2 O
=	629 1 O
237	630 3 O
nM	634 2 O
)	636 1 O
.	637 1 O

NRA0160	639 7 B-Chemical
and	647 3 O
clozapine	651 9 B-Chemical
antagonized	661 11 O
locomotor	673 9 O
hyperactivity	683 13 B-Disease
induced	697 7 O
by	705 2 O
methamphetamine	708 15 B-Chemical
(	724 1 O
MAP	725 3 B-Chemical
)	728 1 O
in	730 2 O
mice	733 4 O
.	737 1 O

NRA0160	739 7 B-Chemical
and	747 3 O
clozapine	751 9 B-Chemical
antagonized	761 11 O
MAP	773 3 B-Chemical
-	776 1 O
induced	777 7 O
stereotyped	785 11 O
behavior	797 8 O
in	806 2 O
mice	809 4 O
,	813 1 O
although	815 8 O
their	824 5 O
effects	830 7 O
did	838 3 O
not	842 3 O
exceed	846 6 O
50	853 2 O
%	855 1 O
inhibition	857 10 O
,	867 1 O
even	869 4 O
at	874 2 O
the	877 3 O
highest	881 7 O
dose	889 4 O
given	894 5 O
.	899 1 O

NRA0160	901 7 B-Chemical
and	909 3 O
clozapine	913 9 B-Chemical
significantly	923 13 O
induced	937 7 O
catalepsy	945 9 B-Disease
in	955 2 O
rats	958 4 O
,	962 1 O
although	964 8 O
their	973 5 O
effects	979 7 O
did	987 3 O
not	991 3 O
exceed	995 6 O
50	1002 2 O
%	1004 1 O
induction	1006 9 O
even	1016 4 O
at	1021 2 O
the	1024 3 O
highest	1028 7 O
dose	1036 4 O
given	1041 5 O
.	1046 1 O

NRA0160	1048 7 B-Chemical
and	1056 3 O
clozapine	1060 9 B-Chemical
significantly	1070 13 O
reversed	1084 8 O
the	1093 3 O
disruption	1097 10 O
of	1108 2 O
prepulse	1111 8 O
inhibition	1120 10 O
(	1131 1 O
PPI	1132 3 O
)	1135 1 O
in	1137 2 O
rats	1140 4 O
produced	1145 8 O
by	1154 2 O
apomorphine	1157 11 B-Chemical
.	1168 1 O

NRA0160	1170 7 B-Chemical
and	1178 3 O
clozapine	1182 9 B-Chemical
significantly	1192 13 O
shortened	1206 9 O
the	1216 3 O
phencyclidine	1220 13 B-Chemical
(	1234 1 O
PCP	1235 3 B-Chemical
)	1238 1 O
-	1239 1 O
induced	1240 7 O
prolonged	1248 9 O
swimming	1258 8 O
latency	1267 7 O
in	1275 2 O
rats	1278 4 O
in	1283 2 O
a	1286 1 O
water	1288 5 O
maze	1294 4 O
task	1299 4 O
.	1303 1 O

These	1305 5 O
findings	1311 8 O
suggest	1320 7 O
that	1328 4 O
NRA0160	1333 7 B-Chemical
may	1341 3 O
have	1345 4 O
unique	1350 6 O
antipsychotic	1357 13 O
activities	1371 10 O
without	1382 7 O
the	1390 3 O
liability	1394 9 O
of	1404 2 O
motor	1407 5 O
side	1413 4 O
effects	1418 7 O
typical	1426 7 O
of	1434 2 O
classical	1437 9 O
antipsychotics	1447 14 O
.	1461 1 O

Prolonged	0 9 O
cholestasis	10 11 B-Disease
after	22 5 O
troleandomycin	28 14 B-Chemical
-	42 1 O
induced	43 7 O
acute	51 5 O
hepatitis	57 9 B-Disease
.	66 1 O

We	68 2 O
report	71 6 O
the	78 3 O
case	82 4 O
of	87 2 O
a	90 1 O
patient	92 7 O
in	100 2 O
whom	103 4 O
troleandomycin	108 14 B-Chemical
-	122 1 O
induced	123 7 O
hepatitis	131 9 B-Disease
was	141 3 O
followed	145 8 O
by	154 2 O
prolonged	157 9 O
anicteric	167 9 O
cholestasis	177 11 B-Disease
.	188 1 O

Jaundice	190 8 B-Disease
occurred	199 8 O
after	208 5 O
administration	214 14 O
of	229 2 O
troleandomycin	232 14 B-Chemical
for	247 3 O
7	251 1 O
days	253 4 O
and	258 3 O
was	262 3 O
associated	266 10 O
with	277 4 O
hypereosinophilia	282 17 B-Disease
.	299 1 O

Jaundice	301 8 B-Disease
disappeared	310 11 O
within	322 6 O
3	329 1 O
months	331 6 O
but	338 3 O
was	342 3 O
followed	346 8 O
by	355 2 O
prolonged	358 9 O
anicteric	368 9 O
cholestasis	378 11 B-Disease
marked	390 6 O
by	397 2 O
pruritus	400 8 B-Disease
and	409 3 O
high	413 4 O
levels	418 6 O
of	425 2 O
alkaline	428 8 O
phosphatase	437 11 O
and	449 3 O
gammaglutamyltransferase	453 24 O
activities	478 10 O
.	488 1 O

Finally	490 7 O
,	497 1 O
pruritus	499 8 B-Disease
disappeared	508 11 O
within	520 6 O
19	527 2 O
months	530 6 O
,	536 1 O
and	538 3 O
liver	542 5 O
tests	548 5 O
returned	554 8 O
to	563 2 O
normal	566 6 O
27	573 2 O
months	576 6 O
after	583 5 O
the	589 3 O
onset	593 5 O
of	599 2 O
hepatitis	602 9 B-Disease
.	611 1 O

This	613 4 O
observation	618 11 O
demonstrates	630 12 O
that	643 4 O
prolonged	648 9 O
cholestasis	658 11 B-Disease
can	670 3 O
follow	674 6 O
troleandomycin	681 14 B-Chemical
-	695 1 O
induced	696 7 O
acute	704 5 O
hepatitis	710 9 B-Disease
.	719 1 O

HMG	0 3 O
CoA	4 3 O
reductase	8 9 O
inhibitors	18 10 O
.	28 1 O

Current	30 7 O
clinical	38 8 O
experience	47 10 O
.	57 1 O

Lovastatin	59 10 B-Chemical
and	70 3 O
simvastatin	74 11 B-Chemical
are	86 3 O
the	90 3 O
2	94 1 O
best	96 4 O
-	100 1 O
known	101 5 O
members	107 7 O
of	115 2 O
the	118 3 O
class	122 5 O
of	128 2 O
hypolipidaemic	131 14 O
agents	146 6 O
known	153 5 O
as	159 2 O
HMG	162 3 O
CoA	166 3 O
reductase	170 9 O
inhibitors	180 10 O
.	190 1 O

Clinical	192 8 O
experience	201 10 O
with	212 4 O
lovastatin	217 10 B-Chemical
includes	228 8 O
over	237 4 O
5000	242 4 O
patients	247 8 O
,	255 1 O
700	257 3 O
of	261 2 O
whom	264 4 O
have	269 4 O
been	274 4 O
treated	279 7 O
for	287 3 O
2	291 1 O
years	293 5 O
or	299 2 O
more	302 4 O
,	306 1 O
and	308 3 O
experience	312 10 O
with	323 4 O
simvastatin	328 11 B-Chemical
includes	340 8 O
over	349 4 O
3500	354 4 O
patients	359 8 O
,	367 1 O
of	369 2 O
whom	372 4 O
350	377 3 O
have	381 4 O
been	386 4 O
treated	391 7 O
for	399 3 O
18	403 2 O
months	406 6 O
or	413 2 O
more	416 4 O
.	420 1 O

Lovastatin	422 10 B-Chemical
has	433 3 O
been	437 4 O
marketed	442 8 O
in	451 2 O
the	454 3 O
United	458 6 O
States	465 6 O
for	472 3 O
over	476 4 O
6	481 1 O
months	483 6 O
.	489 1 O

Both	491 4 O
agents	496 6 O
show	503 4 O
substantial	508 11 O
clinical	520 8 O
efficacy	529 8 O
,	537 1 O
with	539 4 O
reductions	544 10 O
in	555 2 O
total	558 5 O
cholesterol	564 11 B-Chemical
of	576 2 O
over	579 4 O
30	584 2 O
%	586 1 O
and	588 3 O
in	592 2 O
LDL	595 3 O
-	598 1 O
cholesterol	599 11 B-Chemical
of	611 2 O
40	614 2 O
%	616 1 O
in	618 2 O
clinical	621 8 O
studies	630 7 O
.	637 1 O

Modest	639 6 O
increases	646 9 O
in	656 2 O
HDL	659 3 O
-	662 1 O
cholesterol	663 11 B-Chemical
levels	675 6 O
of	682 2 O
about	685 5 O
10	691 2 O
%	693 1 O
are	695 3 O
also	699 4 O
reported	704 8 O
.	712 1 O

Clinical	714 8 O
tolerability	723 12 O
of	736 2 O
both	739 4 O
agents	744 6 O
has	751 3 O
been	755 4 O
good	760 4 O
,	764 1 O
with	766 4 O
fewer	771 5 O
than	777 4 O
3	782 1 O
%	783 1 O
of	785 2 O
patients	788 8 O
withdrawn	797 9 O
from	807 4 O
treatment	812 9 O
because	822 7 O
of	830 2 O
clinical	833 8 O
adverse	842 7 O
experiences	850 11 O
.	861 1 O

Ophthalmological	863 16 O
examinations	880 12 O
in	893 2 O
over	896 4 O
1100	901 4 O
patients	906 8 O
treated	915 7 O
with	923 4 O
one	928 3 O
or	932 2 O
the	935 3 O
other	939 5 O
agent	945 5 O
have	951 4 O
revealed	956 8 O
no	965 2 O
evidence	968 8 O
of	977 2 O
significant	980 11 O
short	992 5 O
term	998 4 O
(	1003 1 O
up	1004 2 O
to	1007 2 O
2	1010 1 O
years	1012 5 O
)	1017 1 O
cataractogenic	1019 14 O
potential	1034 9 O
.	1043 1 O

One	1045 3 O
to	1049 2 O
2	1052 1 O
%	1053 1 O
of	1055 2 O
patients	1058 8 O
have	1067 4 O
elevations	1072 10 O
of	1083 2 O
serum	1086 5 O
transaminases	1092 13 O
to	1106 2 O
greater	1109 7 O
than	1117 4 O
3	1122 1 O
times	1124 5 O
the	1130 3 O
upper	1134 5 O
limit	1140 5 O
of	1146 2 O
normal	1149 6 O
.	1155 1 O

These	1157 5 O
episodes	1163 8 O
are	1172 3 O
asymptomatic	1176 12 O
and	1189 3 O
reversible	1193 10 O
when	1204 4 O
therapy	1209 7 O
is	1217 2 O
discontinued	1220 12 O
.	1232 1 O

Minor	1234 5 O
elevations	1240 10 O
of	1251 2 O
creatine	1254 8 B-Chemical
kinase	1263 6 O
levels	1270 6 O
are	1277 3 O
reported	1281 8 O
in	1290 2 O
about	1293 5 O
5	1299 1 O
%	1300 1 O
of	1302 2 O
patients	1305 8 O
.	1313 1 O

Myopathy	1315 8 B-Disease
,	1323 1 O
associated	1325 10 O
in	1336 2 O
some	1339 4 O
cases	1344 5 O
with	1350 4 O
myoglobinuria	1355 13 B-Disease
,	1368 1 O
and	1370 3 O
in	1374 2 O
2	1377 1 O
cases	1379 5 O
with	1385 4 O
transient	1390 9 O
renal	1400 5 B-Disease
failure	1406 7 I-Disease
,	1413 1 O
has	1415 3 O
been	1419 4 O
rarely	1424 6 O
reported	1431 8 O
with	1440 4 O
lovastatin	1445 10 B-Chemical
,	1455 1 O
especially	1457 10 O
in	1468 2 O
patients	1471 8 O
concomitantly	1480 13 O
treated	1494 7 O
with	1502 4 O
cyclosporin	1507 11 B-Chemical
,	1518 1 O
gemfibrozil	1520 11 B-Chemical
or	1532 2 O
niacin	1535 6 B-Chemical
.	1541 1 O

Lovastatin	1543 10 B-Chemical
and	1554 3 O
simvastatin	1558 11 B-Chemical
are	1570 3 O
both	1574 4 O
effective	1579 9 O
and	1589 3 O
well	1593 4 O
-	1597 1 O
tolerated	1598 9 O
agents	1608 6 O
for	1615 3 O
lowering	1619 8 O
elevated	1628 8 O
levels	1637 6 O
of	1644 2 O
serum	1647 5 O
cholesterol	1653 11 B-Chemical
.	1664 1 O

As	1666 2 O
wider	1669 5 O
use	1675 3 O
confirms	1679 8 O
their	1688 5 O
safety	1694 6 O
profile	1701 7 O
,	1708 1 O
they	1710 4 O
will	1715 4 O
gain	1720 4 O
increasing	1725 10 O
importance	1736 10 O
in	1747 2 O
the	1750 3 O
therapeutic	1754 11 O
approach	1766 8 O
to	1775 2 O
hypercholesterolaemia	1778 21 B-Disease
and	1800 3 O
its	1804 3 O
consequences	1808 12 O
.	1820 1 O

Sulfasalazine	0 13 B-Chemical
-	13 1 O
induced	14 7 O
lupus	22 5 B-Disease
erythematosus	28 13 I-Disease
.	41 1 O

Pneumonitis	43 11 B-Disease
,	54 1 O
bilateral	56 9 O
pleural	66 7 B-Disease
effusions	74 9 I-Disease
,	83 1 O
echocardiographic	85 17 O
evidence	103 8 O
of	112 2 O
cardiac	115 7 B-Disease
tamponade	123 9 I-Disease
,	132 1 O
and	134 3 O
positive	138 8 O
autoantibodies	147 14 O
developed	162 9 O
in	172 2 O
a	175 1 O
43	177 2 O
-	179 1 O
year	180 4 O
-	184 1 O
old	185 3 O
man	189 3 O
,	192 1 O
who	194 3 O
was	198 3 O
receiving	202 9 O
long	212 4 O
-	216 1 O
term	217 4 O
sulfasalazine	222 13 B-Chemical
therapy	236 7 O
for	244 3 O
chronic	248 7 O
ulcerative	256 10 B-Disease
colitis	267 7 I-Disease
.	274 1 O

After	276 5 O
cessation	282 9 O
of	292 2 O
the	295 3 O
sulfasalazine	299 13 B-Chemical
and	313 3 O
completion	317 10 O
of	328 2 O
a	331 1 O
six	333 3 O
-	336 1 O
week	337 4 O
course	342 6 O
of	349 2 O
corticosteroids	352 15 O
,	367 1 O
these	369 5 O
problems	375 8 O
resolved	384 8 O
over	393 4 O
a	398 1 O
period	400 6 O
of	407 2 O
four	410 4 O
to	415 2 O
six	418 3 O
months	422 6 O
.	428 1 O

It	430 2 O
is	433 2 O
suggested	436 9 O
that	446 4 O
the	451 3 O
patient	455 7 O
had	463 3 O
sulfasalazine	467 13 B-Chemical
-	480 1 O
induced	481 7 O
lupus	489 5 B-Disease
,	494 1 O
which	496 5 O
manifested	502 10 O
with	513 4 O
serositis	518 9 B-Disease
and	528 3 O
pulmonary	532 9 O
parenchymal	542 11 O
involvement	554 11 O
in	566 2 O
the	569 3 O
absence	573 7 O
of	581 2 O
joint	584 5 O
symptoms	590 8 O
.	598 1 O

Physicians	600 10 O
who	611 3 O
use	615 3 O
sulfasalazine	619 13 B-Chemical
to	633 2 O
treat	636 5 O
patients	642 8 O
with	651 4 O
inflammatory	656 12 B-Disease
bowel	669 5 I-Disease
disease	675 7 I-Disease
should	683 6 O
be	690 2 O
aware	693 5 O
of	699 2 O
the	702 3 O
signs	706 5 O
of	712 2 O
sulfasalazine	715 13 B-Chemical
-	728 1 O
induced	729 7 O
lupus	737 5 B-Disease
syndrome	743 8 I-Disease
.	751 1 O

Optimization	0 12 O
of	13 2 O
levodopa	16 8 B-Chemical
therapy	25 7 O
.	32 1 O

While	34 5 O
there	40 5 O
is	46 2 O
no	49 2 O
single	52 6 O
correct	59 7 O
starting	67 8 O
dose	76 4 O
for	81 3 O
levodopa	85 8 B-Chemical
therapy	94 7 O
,	101 1 O
many	103 4 O
individuals	108 11 O
can	120 3 O
be	124 2 O
started	127 7 O
on	135 2 O
either	138 6 O
the	145 3 O
25	149 2 O
/	151 1 O
100	152 3 O
or	156 2 O
controlled	159 10 O
-	169 1 O
release	170 7 O
formula	178 7 O
,	185 1 O
following	187 9 O
the	197 3 O
general	201 7 O
rule	209 4 O
not	214 3 O
to	218 2 O
attempt	221 7 O
to	229 2 O
titrate	232 7 O
carbidopa	240 9 B-Chemical
-	249 1 O
levodopa	250 8 B-Chemical
to	259 2 O
the	262 3 O
point	266 5 O
of	272 2 O
"	275 1 O
normality	276 9 O
,	285 1 O
"	286 1 O
which	288 5 O
can	294 3 O
lead	298 4 O
to	303 2 O
toxicity	306 8 B-Disease
.	314 1 O

The	316 3 O
physician	320 9 O
should	330 6 O
also	337 4 O
determine	342 9 O
the	352 3 O
proper	356 6 O
use	363 3 O
of	367 2 O
any	370 3 O
adjunctive	374 10 O
medications	385 11 O
;	396 1 O
such	398 4 O
combined	403 8 O
therapy	412 7 O
has	420 3 O
become	424 6 O
the	431 3 O
standard	435 8 O
approach	444 8 O
to	453 2 O
treatment	456 9 O
.	465 1 O

Following	467 9 O
the	477 3 O
initial	481 7 O
period	489 6 O
of	496 2 O
therapy	499 7 O
,	506 1 O
emerging	508 8 O
difficulties	517 12 O
require	530 7 O
a	538 1 O
reassessment	540 12 O
of	553 2 O
therapeutic	556 11 O
approaches	568 10 O
,	578 1 O
such	580 4 O
as	585 2 O
dosage	588 6 O
adjustment	595 10 O
or	606 2 O
introduction	609 12 O
of	622 2 O
a	625 1 O
dopamine	627 8 B-Chemical
agonist	636 7 O
.	643 1 O

Other	645 5 O
possible	651 8 O
adverse	660 7 O
effects	668 7 O
-	675 1 O
-	676 1 O
such	677 4 O
as	682 2 O
gastrointestinal	685 16 B-Disease
disorders	702 9 I-Disease
,	711 1 O
orthostatic	713 11 B-Disease
hypotension	725 11 I-Disease
,	736 1 O
levodopa	738 8 B-Chemical
-	746 1 O
induced	747 7 O
psychosis	755 9 B-Disease
,	764 1 O
sleep	766 5 B-Disease
disturbances	772 12 I-Disease
or	785 2 O
parasomnias	788 11 B-Disease
,	799 1 O
or	801 2 O
drug	804 4 O
interactions	809 12 O
-	821 1 O
-	822 1 O
also	823 4 O
require	828 7 O
carefully	836 9 O
monitored	846 9 O
individual	856 10 O
treatment	867 9 O
.	876 1 O

Nonpharmacologic	878 16 O
concerns	895 8 O
can	904 3 O
help	908 4 O
the	913 3 O
Parkinson	917 9 B-Disease
'	926 1 I-Disease
s	927 1 I-Disease
disease	929 7 I-Disease
patient	937 7 O
achieve	945 7 O
and	953 3 O
maintain	957 8 O
optimal	966 7 O
functioning	974 11 O
,	985 1 O
including	987 9 O
daily	997 5 O
exercise	1003 8 O
,	1011 1 O
physical	1013 8 O
therapy	1022 7 O
,	1029 1 O
and	1031 3 O
involvement	1035 11 O
with	1047 4 O
support	1052 7 O
groups	1060 6 O
.	1066 1 O

Alpha	0 5 O
and	6 3 O
beta	10 4 O
coma	15 4 B-Disease
in	20 2 O
drug	23 4 O
intoxication	28 12 O
uncomplicated	41 13 O
by	55 2 O
cerebral	58 8 B-Disease
hypoxia	67 7 I-Disease
.	74 1 O

Four	76 4 O
patients	81 8 O
who	90 3 O
were	94 4 O
rendered	99 8 O
comatose	108 8 B-Disease
or	117 2 O
stuporous	120 9 B-Disease
by	130 2 O
drug	133 4 O
intoxication	138 12 O
,	150 1 O
but	152 3 O
who	156 3 O
were	160 4 O
not	165 3 O
hypoxic	169 7 O
,	176 1 O
are	178 3 O
described	182 9 O
.	191 1 O

Three	193 5 O
patients	199 8 O
received	208 8 O
high	217 4 O
doses	222 5 O
of	228 2 O
chlormethiazole	231 15 B-Chemical
for	247 3 O
alcohol	251 7 B-Chemical
withdrawal	259 10 B-Disease
symptoms	270 8 I-Disease
,	278 1 O
and	280 3 O
one	284 3 O
took	288 4 O
a	293 1 O
suicidal	295 8 O
overdose	304 8 B-Disease
of	313 2 O
nitrazepam	316 10 B-Chemical
.	326 1 O

The	328 3 O
patient	332 7 O
with	340 4 O
nitrazepam	345 10 B-Chemical
overdose	356 8 B-Disease
and	365 3 O
two	369 3 O
of	373 2 O
those	376 5 O
with	382 4 O
chlormethiazole	387 15 B-Chemical
intoxication	403 12 O
conformed	416 9 O
to	426 2 O
the	429 3 O
criteria	433 8 O
of	442 2 O
'	445 1 O
alpha	446 5 O
coma	452 4 B-Disease
'	456 1 O
,	457 1 O
showing	459 7 O
non	467 3 O
-	470 1 O
reactive	471 8 O
generalized	480 11 O
or	492 2 O
frontally	495 9 O
predominant	505 11 O
alpha	517 5 O
activity	523 8 O
in	532 2 O
the	535 3 O
EEG	539 3 O
.	542 1 O

The	544 3 O
fourth	548 6 O
patient	555 7 O
who	563 3 O
was	567 3 O
unconscious	571 11 O
after	583 5 O
chlormethiazole	589 15 B-Chemical
administration	605 14 O
exhibite	620 8 O
generalized	629 11 O
non	641 3 O
-	644 1 O
reactive	645 8 O
activity	654 8 O
in	663 2 O
the	666 3 O
slow	670 4 O
beta	675 4 O
range	680 5 O
.	685 1 O

All	687 3 O
four	691 4 O
recovered	696 9 O
completely	706 10 O
without	717 7 O
neurological	725 12 B-Disease
sequelae	738 8 I-Disease
following	747 9 O
the	757 3 O
withdrawal	761 10 O
of	772 2 O
the	775 3 O
offending	779 9 O
agents	789 6 O
.	795 1 O

The	797 3 O
similarities	801 12 O
between	814 7 O
the	822 3 O
effects	826 7 O
of	834 2 O
structural	837 10 O
lesions	848 7 O
and	856 3 O
pharmacological	860 15 O
depression	876 10 B-Disease
of	887 2 O
the	890 3 O
brain	894 5 O
stem	900 4 O
reticular	905 9 O
formation	915 9 O
are	925 3 O
discussed	929 9 O
.	938 1 O

It	940 2 O
is	943 2 O
suggested	946 9 O
that	956 4 O
in	961 2 O
both	964 4 O
situations	969 10 O
disturbed	980 9 O
reticulo	990 8 O
-	998 1 O
thalamic	999 8 O
interactions	1008 12 O
are	1021 3 O
important	1025 9 O
in	1035 2 O
the	1038 3 O
pathogenesis	1042 12 O
of	1055 2 O
alpha	1058 5 O
coma	1064 4 B-Disease
.	1068 1 O

It	1070 2 O
is	1073 2 O
concluded	1076 9 O
that	1086 4 O
when	1091 4 O
this	1096 4 O
electroencephalographic	1101 23 O
and	1125 3 O
behavioural	1129 11 O
picture	1141 7 O
is	1149 2 O
seen	1152 4 O
in	1157 2 O
drug	1160 4 O
intoxication	1165 12 O
,	1177 1 O
in	1179 2 O
the	1182 3 O
absence	1186 7 O
of	1194 2 O
significant	1197 11 O
hypoxaemia	1209 10 B-Disease
,	1219 1 O
a	1221 1 O
favourable	1223 10 O
outcome	1234 7 O
may	1242 3 O
be	1246 2 O
anticipated	1249 11 O
.	1260 1 O

Omitting	0 8 O
fentanyl	9 8 B-Chemical
reduces	18 7 O
nausea	26 6 B-Disease
and	33 3 O
vomiting	37 8 B-Disease
,	45 1 O
without	47 7 O
increasing	55 10 O
pain	66 4 B-Disease
,	70 1 O
after	72 5 O
sevoflurane	78 11 B-Chemical
for	90 3 O
day	94 3 O
surgery	98 7 O
.	105 1 O

BACKGROUND	107 10 O
AND	118 3 O
OBJECTIVE	122 9 O
:	131 1 O
Despite	133 7 O
advantages	141 10 O
of	152 2 O
induction	155 9 O
and	165 3 O
maintenance	169 11 O
of	181 2 O
anaesthesia	184 11 O
with	196 4 O
sevoflurane	201 11 B-Chemical
,	212 1 O
postoperative	214 13 B-Disease
nausea	228 6 I-Disease
and	235 3 I-Disease
vomiting	239 8 I-Disease
occurs	248 6 O
frequently	255 10 O
.	265 1 O

Fentanyl	267 8 B-Chemical
is	276 2 O
a	279 1 O
commonly	281 8 O
used	290 4 O
supplement	295 10 O
that	306 4 O
may	311 3 O
contribute	315 10 O
to	326 2 O
this	329 4 O
,	333 1 O
although	335 8 O
it	344 2 O
may	347 3 O
also	351 4 O
improve	356 7 O
analgesia	364 9 O
.	373 1 O

METHODS	375 7 O
:	382 1 O
This	384 4 O
double	389 6 O
-	395 1 O
blind	396 5 O
study	402 5 O
examined	408 8 O
the	417 3 O
incidence	421 9 O
and	431 3 O
severity	435 8 O
of	444 2 O
postoperative	447 13 B-Disease
nausea	461 6 I-Disease
and	468 3 I-Disease
vomiting	472 8 I-Disease
and	481 3 O
pain	485 4 B-Disease
in	490 2 O
the	493 3 O
first	497 5 O
24	503 2 O
h	506 1 O
after	508 5 O
sevoflurane	514 11 B-Chemical
anaesthesia	526 11 O
in	538 2 O
216	541 3 O
adult	545 5 O
day	551 3 O
surgery	555 7 O
patients	563 8 O
.	571 1 O

Patients	573 8 O
were	582 4 O
randomly	587 8 O
allocated	596 9 O
to	606 2 O
either	609 6 O
receive	616 7 O
or	624 2 O
not	627 3 O
receive	631 7 O
1	639 1 O
1	641 1 O
fentanyl	643 8 B-Chemical
,	651 1 O
while	653 5 O
a	659 1 O
third	661 5 O
group	667 5 O
received	673 8 O
dexamethasone	682 13 B-Chemical
in	696 2 O
addition	699 8 O
to	708 2 O
fentanyl	711 8 B-Chemical
.	719 1 O

RESULTS	721 7 O
:	728 1 O
Omission	730 8 O
of	739 2 O
fentanyl	742 8 B-Chemical
did	751 3 O
not	755 3 O
reduce	759 6 O
the	766 3 O
overall	770 7 O
incidence	778 9 O
of	788 2 O
postoperative	791 13 B-Disease
nausea	805 6 I-Disease
and	812 3 I-Disease
vomiting	816 8 I-Disease
,	824 1 O
but	826 3 O
did	830 3 O
reduce	834 6 O
the	841 3 O
incidence	845 9 O
of	855 2 O
vomiting	858 8 B-Disease
and	867 3 O
/	870 1 O
or	871 2 O
moderate	874 8 O
to	883 2 O
severe	886 6 O
nausea	893 6 B-Disease
prior	900 5 O
to	906 2 O
discharge	909 9 O
from	919 4 O
20	924 2 O
%	926 1 O
and	928 3 O
17	932 2 O
%	934 1 O
with	936 4 O
fentanyl	941 8 B-Chemical
and	950 3 O
fentanyl	954 8 B-Chemical
-	962 1 O
dexamethasone	963 13 B-Chemical
,	976 1 O
respectively	978 12 O
,	990 1 O
to	992 2 O
5	995 1 O
%	996 1 O
(	998 1 O
P	999 1 O
=	1001 1 O
0	1003 1 O
.	1004 1 O
013	1005 3 O
)	1008 1 O
.	1009 1 O

Antiemetic	1011 10 O
requirements	1022 12 O
were	1035 4 O
reduced	1040 7 O
from	1048 4 O
24	1053 2 O
%	1055 1 O
and	1057 3 O
31	1061 2 O
%	1063 1 O
to	1065 2 O
7	1068 1 O
%	1069 1 O
(	1071 1 O
P	1072 1 O
=	1074 1 O
0	1076 1 O
.	1077 1 O
0012	1078 4 O
)	1082 1 O
.	1083 1 O

Dexamethasone	1085 13 B-Chemical
had	1099 3 O
no	1103 2 O
significant	1106 11 O
effect	1118 6 O
on	1125 2 O
the	1128 3 O
incidence	1132 9 O
or	1142 2 O
severity	1145 8 O
of	1154 2 O
postoperative	1157 13 B-Disease
nausea	1171 6 I-Disease
and	1178 3 I-Disease
vomiting	1182 8 I-Disease
.	1190 1 O

Combining	1192 9 O
the	1202 3 O
two	1206 3 O
fentanyl	1210 8 B-Chemical
groups	1219 6 O
revealed	1226 8 O
further	1235 7 O
significant	1243 11 O
benefits	1255 8 O
from	1264 4 O
the	1269 3 O
avoidance	1273 9 O
of	1283 2 O
opioids	1286 7 O
,	1293 1 O
reducing	1295 8 O
postoperative	1304 13 B-Disease
nausea	1318 6 I-Disease
and	1325 3 I-Disease
vomiting	1329 8 I-Disease
and	1338 3 O
nausea	1342 6 B-Disease
prior	1349 5 O
to	1355 2 O
discharge	1358 9 O
from	1368 4 O
35	1373 2 O
%	1375 1 O
and	1377 3 O
33	1381 2 O
%	1383 1 O
to	1385 2 O
22	1388 2 O
%	1390 1 O
and	1392 3 O
19	1396 2 O
%	1398 1 O
(	1400 1 O
P	1401 1 O
=	1403 1 O
0	1405 1 O
.	1406 1 O
049	1407 3 O
and	1411 3 O
P	1415 1 O
=	1417 1 O
0	1419 1 O
.	1420 1 O
035	1421 3 O
)	1424 1 O
,	1425 1 O
respectively	1427 12 O
,	1439 1 O
while	1441 5 O
nausea	1447 6 B-Disease
in	1454 2 O
the	1457 3 O
first	1461 5 O
24	1467 2 O
h	1470 1 O
was	1472 3 O
decreased	1476 9 O
from	1486 4 O
42	1491 2 O
%	1493 1 O
to	1495 2 O
27	1498 2 O
%	1500 1 O
(	1502 1 O
P	1503 1 O
=	1505 1 O
0	1507 1 O
.	1508 1 O
034	1509 3 O
)	1512 1 O
.	1513 1 O

Pain	1515 4 B-Disease
severity	1520 8 O
and	1529 3 O
analgesic	1533 9 O
requirements	1543 12 O
were	1556 4 O
unaffected	1561 10 O
by	1572 2 O
the	1575 3 O
omission	1579 8 O
of	1588 2 O
fentanyl	1591 8 B-Chemical
.	1599 1 O

Fentanyl	1601 8 B-Chemical
did	1610 3 O
reduce	1614 6 O
minor	1621 5 O
intraoperative	1627 14 O
movement	1642 8 O
but	1651 3 O
had	1655 3 O
no	1659 2 O
sevoflurane	1662 11 B-Chemical
-	1673 1 O
sparing	1674 7 O
effect	1682 6 O
and	1689 3 O
increased	1693 9 O
respiratory	1703 11 B-Disease
depression	1715 10 I-Disease
,	1725 1 O
hypotension	1727 11 B-Disease
and	1739 3 O
bradycardia	1743 11 B-Disease
.	1754 1 O

CONCLUSION	1756 10 O
:	1766 1 O
As	1768 2 O
fentanyl	1771 8 B-Chemical
exacerbated	1780 11 O
postoperative	1792 13 B-Disease
nausea	1806 6 I-Disease
and	1813 3 I-Disease
vomiting	1817 8 I-Disease
without	1826 7 O
an	1834 2 O
improvement	1837 11 O
in	1849 2 O
postoperative	1852 13 B-Disease
pain	1866 4 I-Disease
and	1871 3 O
also	1875 4 O
had	1880 3 O
adverse	1884 7 O
cardiorespiratory	1892 17 O
effects	1910 7 O
,	1917 1 O
it	1919 2 O
appears	1922 7 O
to	1930 2 O
be	1933 2 O
an	1936 2 O
unnecessary	1939 11 O
and	1951 3 O
possibly	1955 8 O
detrimental	1964 11 O
supplement	1976 10 O
to	1987 2 O
sevoflurane	1990 11 B-Chemical
in	2002 2 O
day	2005 3 O
surgery	2009 7 O
.	2016 1 O

Renal	0 5 B-Disease
Fanconi	6 7 I-Disease
syndrome	14 8 I-Disease
and	23 3 O
myopathy	27 8 B-Disease
after	36 5 O
liver	42 5 O
transplantation	48 15 O
:	63 1 O
drug	65 4 O
-	69 1 O
related	70 7 O
mitochondrial	78 13 B-Disease
cytopathy	92 9 I-Disease
?	101 1 O

Advances	103 8 O
in	112 2 O
the	115 3 O
field	119 5 O
of	125 2 O
transplantation	128 15 O
provide	144 7 O
a	152 1 O
better	154 6 O
quality	161 7 O
of	169 2 O
life	172 4 O
and	177 3 O
allow	181 5 O
more	187 4 O
favorable	192 9 O
conditions	202 10 O
for	213 3 O
growth	217 6 O
and	224 3 O
development	228 11 O
in	240 2 O
children	243 8 O
.	251 1 O

However	253 7 O
,	260 1 O
combinations	262 12 O
of	275 2 O
different	278 9 O
therapeutic	288 11 O
regimens	300 8 O
require	309 7 O
consideration	317 13 O
of	331 2 O
potential	334 9 O
adverse	344 7 O
reactions	352 9 O
.	361 1 O

We	363 2 O
describe	366 8 O
a	375 1 O
15	377 2 O
-	379 1 O
yr	380 2 O
-	382 1 O
old	383 3 O
girl	387 4 O
who	392 3 O
had	396 3 O
orthotopic	400 10 O
liver	411 5 O
transplantation	417 15 O
because	433 7 O
of	441 2 O
Wilson	444 6 B-Disease
'	450 1 I-Disease
s	451 1 I-Disease
disease	453 7 I-Disease
.	460 1 O

Tacrolimus	462 10 B-Chemical
,	472 1 O
MMF	474 3 B-Chemical
,	477 1 O
and	479 3 O
steroids	483 8 B-Chemical
were	492 4 O
given	497 5 O
as	503 2 O
immunosuppressant	506 17 O
.	523 1 O

Lamivudine	525 10 B-Chemical
was	536 3 O
added	540 5 O
because	546 7 O
of	554 2 O
de	557 2 O
nova	560 4 O
hepatitis	565 9 B-Disease
B	575 1 I-Disease
infection	577 9 I-Disease
during	587 6 O
her	594 3 O
follow	598 6 O
-	604 1 O
up	605 2 O
.	607 1 O

Three	609 5 O
yr	615 2 O
after	618 5 O
transplantation	624 15 O
she	640 3 O
developed	644 9 O
renal	654 5 B-Disease
Fanconi	660 7 I-Disease
syndrome	668 8 I-Disease
with	677 4 O
severe	682 6 O
metabolic	689 9 B-Disease
acidosis	699 8 I-Disease
,	707 1 O
hypophosphatemia	709 16 B-Disease
,	725 1 O
glycosuria	727 10 B-Disease
,	737 1 O
and	739 3 O
aminoaciduria	743 13 B-Disease
.	756 1 O

Although	758 8 O
tacrolimus	767 10 B-Chemical
was	778 3 O
suspected	782 9 O
to	792 2 O
be	795 2 O
the	798 3 O
cause	802 5 O
of	808 2 O
late	811 4 O
post	816 4 O
-	820 1 O
transplant	821 10 O
renal	832 5 O
acidosis	838 8 B-Disease
and	847 3 O
was	851 3 O
replaced	855 8 O
by	864 2 O
sirolimus	867 9 B-Chemical
,	876 1 O
acidosis	878 8 B-Disease
,	886 1 O
and	888 3 O
electrolyte	892 11 O
imbalance	904 9 O
got	914 3 O
worse	918 5 O
.	923 1 O

Proximal	925 8 O
muscle	934 6 B-Disease
weakness	941 8 I-Disease
has	950 3 O
developed	954 9 O
during	964 6 O
her	971 3 O
follow	975 6 O
-	981 1 O
up	982 2 O
.	984 1 O

Fanconi	986 7 B-Disease
syndrome	994 8 I-Disease
,	1002 1 O
as	1004 2 O
well	1007 4 O
as	1012 2 O
myopathy	1015 8 B-Disease
,	1023 1 O
is	1025 2 O
well	1028 4 O
recognized	1033 10 O
in	1044 2 O
patients	1047 8 O
with	1056 4 O
mitochondrial	1061 13 B-Disease
disorders	1075 9 I-Disease
and	1085 3 O
caused	1089 6 O
by	1096 2 O
depletion	1099 9 O
of	1109 2 O
mtDNA	1112 5 O
.	1117 1 O

We	1119 2 O
suggest	1122 7 O
that	1130 4 O
our	1135 3 O
patient	1139 7 O
'	1146 1 O
s	1147 1 O
tubular	1149 7 B-Disease
dysfunction	1157 11 I-Disease
and	1169 3 O
myopathy	1173 8 B-Disease
may	1182 3 O
have	1186 4 O
resulted	1191 8 O
from	1200 4 O
mitochondrial	1205 13 B-Disease
dysfunction	1219 11 I-Disease
which	1231 5 O
is	1237 2 O
triggered	1240 9 O
by	1250 2 O
tacrolimus	1253 10 B-Chemical
and	1264 3 O
augmented	1268 9 O
by	1278 2 O
lamivudine	1281 10 B-Chemical
.	1291 1 O

Antipsychotic	0 13 O
-	13 1 O
like	14 4 O
profile	19 7 O
of	27 2 O
thioperamide	30 12 B-Chemical
,	42 1 O
a	44 1 O
selective	46 9 O
H3	56 2 O
-	58 1 O
receptor	59 8 O
antagonist	68 10 O
in	79 2 O
mice	82 4 O
.	86 1 O

Experimental	88 12 O
and	101 3 O
clinical	105 8 O
evidence	114 8 O
points	123 6 O
to	130 2 O
a	133 1 O
role	135 4 O
of	140 2 O
central	143 7 O
histaminergic	151 13 O
system	165 6 O
in	172 2 O
the	175 3 O
pathogenesis	179 12 O
of	192 2 O
schizophrenia	195 13 B-Disease
.	208 1 O

The	210 3 O
present	214 7 O
study	222 5 O
was	228 3 O
designed	232 8 O
to	241 2 O
study	244 5 O
the	250 3 O
effect	254 6 O
of	261 2 O
histamine	264 9 B-Chemical
H	274 1 O
(	275 1 O
3	276 1 O
)	277 1 O
-	278 1 O
receptor	279 8 O
ligands	288 7 O
on	296 2 O
neuroleptic	299 11 O
-	310 1 O
induced	311 7 O
catalepsy	319 9 B-Disease
,	328 1 O
apomorphine	330 11 B-Chemical
-	341 1 O
induced	342 7 O
climbing	350 8 O
behavior	359 8 O
and	368 3 O
amphetamine	372 11 B-Chemical
-	383 1 O
induced	384 7 O
locomotor	392 9 O
activities	402 10 O
in	413 2 O
mice	416 4 O
.	420 1 O

Catalepsy	422 9 B-Disease
was	432 3 O
induced	436 7 O
by	444 2 O
haloperidol	447 11 B-Chemical
(	459 1 O
2	460 1 O
mg	462 2 O
/	464 1 O
kg	465 2 O
p	468 1 O
.	469 1 O
o	470 1 O
.	471 1 O
)	472 1 O
,	473 1 O
while	475 5 O
apomorphine	481 11 B-Chemical
(	493 1 O
1	494 1 O
.	495 1 O
5	496 1 O
mg	498 2 O
/	500 1 O
kg	501 2 O
s	504 1 O
.	505 1 O
c	506 1 O
.	507 1 O
)	508 1 O
and	510 3 O
amphetamine	514 11 B-Chemical
(	526 1 O
2	527 1 O
mg	529 2 O
/	531 1 O
kg	532 2 O
s	535 1 O
.	536 1 O
c	537 1 O
.	538 1 O
)	539 1 O
were	541 4 O
used	546 4 O
for	551 3 O
studying	555 8 O
climbing	564 8 O
behavior	573 8 O
and	582 3 O
locomotor	586 9 O
activities	596 10 O
,	606 1 O
respectively	608 12 O
.	620 1 O

(	622 1 B-Chemical
R	623 1 I-Chemical
)	624 1 I-Chemical
-	625 1 I-Chemical
alpha	626 5 I-Chemical
-	631 1 I-Chemical
methylhistamine	632 15 I-Chemical
(	648 1 O
RAMH	649 4 B-Chemical
)	653 1 O
(	655 1 O
5	656 1 O
microg	658 6 O
i	665 1 O
.	666 1 O
c	667 1 O
.	668 1 O
v	669 1 O
.	670 1 O
)	671 1 O
and	673 3 O
thioperamide	677 12 B-Chemical
(	690 1 O
THP	691 3 B-Chemical
)	694 1 O
(	696 1 O
15	697 2 O
mg	700 2 O
/	702 1 O
kg	703 2 O
i	706 1 O
.	707 1 O
p	708 1 O
.	709 1 O
)	710 1 O
,	711 1 O
per	713 3 O
se	717 2 O
did	720 3 O
not	724 3 O
cause	728 5 O
catalepsy	734 9 B-Disease
.	743 1 O

Administration	745 14 O
of	760 2 O
THP	763 3 B-Chemical
(	767 1 O
3	768 1 O
.	769 1 O
75	770 2 O
,	772 1 O
7	774 1 O
.	775 1 O
5	776 1 O
and	778 3 O
15	782 2 O
mg	785 2 O
/	787 1 O
kg	788 2 O
i	791 1 O
.	792 1 O
p	793 1 O
.	794 1 O
)	795 1 O
1	797 1 O
h	799 1 O
prior	801 5 O
to	807 2 O
haloperidol	810 11 B-Chemical
resulted	822 8 O
in	831 2 O
a	834 1 O
dose	836 4 O
-	840 1 O
dependent	841 9 O
increase	851 8 O
in	860 2 O
the	863 3 O
catalepsy	867 9 B-Disease
times	877 5 O
(	883 1 O
P	884 1 O
<	886 1 O
0	888 1 O
.	889 1 O
05	890 2 O
)	892 1 O
.	893 1 O

However	895 7 O
,	902 1 O
pretreatment	904 12 O
with	917 4 O
RAMH	922 4 B-Chemical
significantly	927 13 O
reversed	941 8 O
such	950 4 O
an	955 2 O
effect	958 6 O
of	965 2 O
THP	968 3 B-Chemical
(	972 1 O
15	973 2 O
mg	976 2 O
/	978 1 O
kg	979 2 O
i	982 1 O
.	983 1 O
p	984 1 O
.	985 1 O
)	986 1 O
.	987 1 O

RAMH	989 4 B-Chemical
per	994 3 O
se	998 2 O
showed	1001 6 O
significant	1008 11 O
reduction	1020 9 O
in	1030 2 O
locomotor	1033 9 O
time	1043 4 O
,	1047 1 O
distance	1049 8 O
traveled	1058 8 O
and	1067 3 O
average	1071 7 O
speed	1079 5 O
but	1085 3 O
THP	1089 3 B-Chemical
(	1093 1 O
15	1094 2 O
mg	1097 2 O
/	1099 1 O
kg	1100 2 O
i	1103 1 O
.	1104 1 O
p	1105 1 O
.	1106 1 O
)	1107 1 O
per	1109 3 O
se	1113 2 O
had	1116 3 O
no	1120 2 O
effect	1123 6 O
on	1130 2 O
these	1133 5 O
parameters	1139 10 O
.	1149 1 O

On	1151 2 O
amphetamine	1154 11 B-Chemical
-	1165 1 O
induced	1166 7 O
hyperactivity	1174 13 B-Disease
,	1187 1 O
THP	1189 3 B-Chemical
(	1193 1 O
3	1194 1 O
.	1195 1 O
75	1196 2 O
and	1199 3 O
7	1203 1 O
.	1204 1 O
5	1205 1 O
mg	1207 2 O
/	1209 1 O
kg	1210 2 O
i	1213 1 O
.	1214 1 O
p	1215 1 O
.	1216 1 O
)	1217 1 O
reduced	1219 7 O
locomotor	1227 9 O
time	1237 4 O
,	1241 1 O
distance	1243 8 O
traveled	1252 8 O
and	1261 3 O
average	1265 7 O
speed	1273 5 O
(	1279 1 O
P	1280 1 O
<	1282 1 O
0	1284 1 O
.	1285 1 O
05	1286 2 O
)	1288 1 O
.	1289 1 O

Pretreatment	1291 12 O
with	1304 4 O
RAMH	1309 4 B-Chemical
(	1314 1 O
5	1315 1 O
microg	1317 6 O
i	1324 1 O
.	1325 1 O
c	1326 1 O
.	1327 1 O
v	1328 1 O
.	1329 1 O
)	1330 1 O
could	1332 5 O
partially	1338 9 O
reverse	1348 7 O
such	1356 4 O
effects	1361 7 O
of	1369 2 O
THP	1372 3 B-Chemical
(	1376 1 O
3	1377 1 O
.	1378 1 O
75	1379 2 O
mg	1382 2 O
/	1384 1 O
kg	1385 2 O
i	1388 1 O
.	1389 1 O
p	1390 1 O
.	1391 1 O
)	1392 1 O
.	1393 1 O

Climbing	1395 8 O
behavior	1404 8 O
induced	1413 7 O
by	1421 2 O
apomorphine	1424 11 B-Chemical
was	1436 3 O
reduced	1440 7 O
in	1448 2 O
animals	1451 7 O
treated	1459 7 O
with	1467 4 O
THP	1472 3 B-Chemical
.	1475 1 O

Such	1477 4 O
an	1482 2 O
effect	1485 6 O
was	1492 3 O
,	1495 1 O
however	1497 7 O
,	1504 1 O
reversed	1506 8 O
in	1515 2 O
presence	1518 8 O
of	1527 2 O
RAMH	1530 4 B-Chemical
.	1534 1 O

THP	1536 3 B-Chemical
exhibited	1540 9 O
an	1550 2 O
antipsychotic	1553 13 O
-	1566 1 O
like	1567 4 O
profile	1572 7 O
by	1580 2 O
potentiating	1583 12 O
haloperidol	1596 11 B-Chemical
-	1607 1 O
induced	1608 7 O
catalepsy	1616 9 B-Disease
,	1625 1 O
reducing	1627 8 O
amphetamine	1636 11 B-Chemical
-	1647 1 O
induced	1648 7 O
hyperactivity	1656 13 B-Disease
and	1670 3 O
reducing	1674 8 O
apomorphine	1683 11 B-Chemical
-	1694 1 O
induced	1695 7 O
climbing	1703 8 O
in	1712 2 O
mice	1715 4 O
.	1719 1 O

Such	1721 4 O
effects	1726 7 O
of	1734 2 O
THP	1737 3 B-Chemical
were	1741 4 O
reversed	1746 8 O
by	1755 2 O
RAMH	1758 4 B-Chemical
indicating	1763 10 O
the	1774 3 O
involvement	1778 11 O
of	1790 2 O
histamine	1793 9 B-Chemical
H	1803 1 O
(	1804 1 O
3	1805 1 O
)	1806 1 O
-	1807 1 O
receptors	1808 9 O
.	1817 1 O

Findings	1819 8 O
suggest	1828 7 O
a	1836 1 O
potential	1838 9 O
for	1848 3 O
H	1852 1 O
(	1853 1 O
3	1854 1 O
)	1855 1 O
-	1856 1 O
receptor	1857 8 O
antagonists	1866 11 O
in	1878 2 O
improving	1881 9 O
the	1891 3 O
refractory	1895 10 O
cases	1906 5 O
of	1912 2 O
schizophrenia	1915 13 B-Disease
.	1928 1 O

Transient	0 9 O
platypnea	10 9 B-Disease
-	19 1 I-Disease
orthodeoxia	20 11 I-Disease
-	31 1 I-Disease
like	32 4 I-Disease
syndrome	37 8 I-Disease
induced	46 7 O
by	54 2 O
propafenone	57 11 B-Chemical
overdose	69 8 B-Disease
in	78 2 O
a	81 1 O
young	83 5 O
woman	89 5 O
with	95 4 O
Ebstein	100 7 B-Disease
'	107 1 I-Disease
s	108 1 I-Disease
anomaly	110 7 I-Disease
.	117 1 O

In	119 2 O
this	122 4 O
report	127 6 O
we	134 2 O
describe	137 8 O
the	146 3 O
case	150 4 O
of	155 2 O
a	158 1 O
37	160 2 O
-	162 1 O
year	163 4 O
-	167 1 O
old	168 3 O
white	172 5 O
woman	178 5 O
with	184 4 O
Ebstein	189 7 B-Disease
'	196 1 I-Disease
s	197 1 I-Disease
anomaly	199 7 I-Disease
,	206 1 O
who	208 3 O
developed	212 9 O
a	222 1 O
rare	224 4 O
syndrome	229 8 O
called	238 6 O
platypnea	245 9 B-Disease
-	254 1 I-Disease
orthodeoxia	255 11 I-Disease
,	266 1 O
characterized	268 13 O
by	282 2 O
massive	285 7 O
right	293 5 O
-	298 1 O
to	299 2 O
-	301 1 O
left	302 4 O
interatrial	307 11 O
shunting	319 8 O
with	328 4 O
transient	333 9 O
profound	343 8 O
hypoxia	352 7 B-Disease
and	360 3 O
cyanosis	364 8 B-Disease
.	372 1 O

This	374 4 O
shunt	379 5 O
of	385 2 O
blood	388 5 O
via	394 3 O
a	398 1 O
patent	400 6 B-Disease
foramen	407 7 I-Disease
ovale	415 5 I-Disease
occurred	421 8 O
in	430 2 O
the	433 3 O
presence	437 8 O
of	446 2 O
a	449 1 O
normal	451 6 O
pulmonary	458 9 O
artery	468 6 O
pressure	475 8 O
,	483 1 O
and	485 3 O
was	489 3 O
probably	493 8 O
precipitated	502 12 O
by	515 2 O
a	518 1 O
propafenone	520 11 B-Chemical
overdose	532 8 B-Disease
.	540 1 O

This	542 4 O
drug	547 4 O
caused	552 6 O
biventricular	559 13 B-Disease
dysfunction	573 11 I-Disease
,	584 1 O
due	586 3 O
to	590 2 O
its	593 3 O
negative	597 8 O
inotropic	606 9 O
effect	616 6 O
,	622 1 O
and	624 3 O
hypotension	628 11 B-Disease
,	639 1 O
due	641 3 O
to	645 2 O
its	648 3 O
peripheral	652 10 O
vasodilatory	663 12 O
effect	676 6 O
.	682 1 O

These	684 5 O
effects	690 7 O
gave	698 4 O
rise	703 4 O
to	708 2 O
an	711 2 O
increase	714 8 O
in	723 2 O
the	726 3 O
right	730 5 O
atrial	736 6 O
pressure	743 8 O
and	752 3 O
a	756 1 O
decrease	758 8 O
in	767 2 O
the	770 3 O
left	774 4 O
one	779 3 O
with	783 4 O
a	788 1 O
consequent	790 10 O
stretching	801 10 O
of	812 2 O
the	815 3 O
foramen	819 7 O
ovale	827 5 O
and	833 3 O
the	837 3 O
creation	841 8 O
of	850 2 O
massive	853 7 O
right	861 5 O
-	866 1 O
to	867 2 O
-	869 1 O
left	870 4 O
shunting	875 8 O
.	883 1 O

In	885 2 O
our	888 3 O
case	892 4 O
this	897 4 O
interatrial	902 11 O
shunt	914 5 O
was	920 3 O
very	924 4 O
accurately	929 10 O
detected	940 8 O
at	949 2 O
bubble	952 6 O
contrast	959 8 O
echocardiography	968 16 O
.	984 1 O

A	0 1 O
Phase	2 5 O
II	8 2 O
trial	11 5 O
of	17 2 O
cisplatin	20 9 B-Chemical
plus	30 4 O
WR	35 2 B-Chemical
-	37 1 I-Chemical
2721	38 4 I-Chemical
(	43 1 O
amifostine	44 10 B-Chemical
)	54 1 O
for	56 3 O
metastatic	60 10 O
breast	71 6 B-Disease
carcinoma	78 9 I-Disease
:	87 1 O
an	89 2 O
Eastern	92 7 O
Cooperative	100 11 O
Oncology	112 8 O
Group	121 5 O
Study	127 5 O
(	133 1 O
E8188	134 5 O
)	139 1 O
.	140 1 O

BACKGROUND	142 10 O
:	152 1 O
Cisplatin	154 9 B-Chemical
has	164 3 O
minimal	168 7 O
antitumor	176 9 O
activity	186 8 O
when	195 4 O
used	200 4 O
as	205 2 O
second	208 6 O
-	214 1 O
or	216 2 O
third	219 5 O
-	224 1 O
line	225 4 O
treatment	230 9 O
of	240 2 O
metastatic	243 10 O
breast	254 6 B-Disease
carcinoma	261 9 I-Disease
.	270 1 O

Older	272 5 O
reports	278 7 O
suggest	286 7 O
an	294 2 O
objective	297 9 O
response	307 8 O
rate	316 4 O
of	321 2 O
8	324 1 O
%	325 1 O
when	327 4 O
60	332 2 O
-	334 1 O
120	335 3 O
mg	339 2 O
/	341 1 O
m2	342 2 O
of	345 2 O
cisplatin	348 9 B-Chemical
is	358 2 O
administered	361 12 O
every	374 5 O
3	380 1 O
-	381 1 O
4	382 1 O
weeks	384 5 O
.	389 1 O

Although	391 8 O
a	400 1 O
dose	402 4 O
-	406 1 O
response	407 8 O
effect	416 6 O
has	423 3 O
been	427 4 O
observed	432 8 O
with	441 4 O
cisplatin	446 9 B-Chemical
,	455 1 O
the	457 3 O
dose	461 4 O
-	465 1 O
limiting	466 8 O
toxicities	475 10 B-Disease
associated	486 10 O
with	497 4 O
cisplatin	502 9 B-Chemical
(	512 1 O
e	513 1 O
.	514 1 O
g	515 1 O
.	516 1 O
,	517 1 O
nephrotoxicity	519 14 B-Disease
,	533 1 O
ototoxicity	535 11 B-Disease
,	546 1 O
and	548 3 O
neurotoxicity	552 13 B-Disease
)	565 1 O
have	567 4 O
limited	572 7 O
its	580 3 O
use	584 3 O
as	588 2 O
a	591 1 O
treatment	593 9 O
for	603 3 O
breast	607 6 B-Disease
carcinoma	614 9 I-Disease
.	623 1 O

WR	625 2 B-Chemical
-	627 1 I-Chemical
2721	628 4 I-Chemical
or	633 2 O
amifostine	636 10 B-Chemical
initially	647 9 O
was	657 3 O
developed	661 9 O
to	671 2 O
protect	674 7 O
military	682 8 O
personnel	691 9 O
in	701 2 O
the	704 3 O
event	708 5 O
of	714 2 O
nuclear	717 7 O
war	725 3 O
.	728 1 O

Amifostine	730 10 B-Chemical
subsequently	741 12 O
was	754 3 O
shown	758 5 O
to	764 2 O
protect	767 7 O
normal	775 6 O
tissues	782 7 O
from	790 4 O
the	795 3 O
toxic	799 5 O
effects	805 7 O
of	813 2 O
alkylating	816 10 B-Chemical
agents	827 6 I-Chemical
and	834 3 O
cisplatin	838 9 B-Chemical
without	848 7 O
decreasing	856 10 O
the	867 3 O
antitumor	871 9 O
effect	881 6 O
of	888 2 O
the	891 3 O
chemotherapy	895 12 O
.	907 1 O

Early	909 5 O
trials	915 6 O
of	922 2 O
cisplatin	925 9 B-Chemical
and	935 3 O
amifostine	939 10 B-Chemical
also	950 4 O
suggested	955 9 O
that	965 4 O
the	970 3 O
incidence	974 9 O
and	984 3 O
severity	988 8 O
of	997 2 O
cisplatin	1000 9 B-Chemical
-	1009 1 O
induced	1010 7 O
nephrotoxicity	1018 14 B-Disease
,	1032 1 O
ototoxicity	1034 11 B-Disease
,	1045 1 O
and	1047 3 O
neuropathy	1051 10 B-Disease
were	1062 4 O
reduced	1067 7 O
.	1074 1 O

METHODS	1076 7 O
:	1083 1 O
A	1085 1 O
Phase	1087 5 O
II	1093 2 O
study	1096 5 O
of	1102 2 O
the	1105 3 O
combination	1109 11 O
of	1121 2 O
cisplatin	1124 9 B-Chemical
plus	1134 4 O
amifostine	1139 10 B-Chemical
was	1150 3 O
conducted	1154 9 O
in	1164 2 O
patients	1167 8 O
with	1176 4 O
progressive	1181 11 O
metastatic	1193 10 O
breast	1204 6 B-Disease
carcinoma	1211 9 I-Disease
who	1221 3 O
had	1225 3 O
received	1229 8 O
one	1238 3 O
,	1241 1 O
but	1243 3 O
not	1247 3 O
more	1251 4 O
than	1256 4 O
one	1261 3 O
,	1264 1 O
chemotherapy	1266 12 O
regimen	1279 7 O
for	1287 3 O
metastatic	1291 10 O
disease	1302 7 O
.	1309 1 O

Patients	1311 8 O
received	1320 8 O
amifostine	1329 10 B-Chemical
,	1339 1 O
910	1341 3 O
mg	1345 2 O
/	1347 1 O
m2	1348 2 O
intravenously	1351 13 O
over	1365 4 O
15	1370 2 O
minutes	1373 7 O
.	1380 1 O

After	1382 5 O
completion	1388 10 O
of	1399 2 O
the	1402 3 O
amifostine	1406 10 B-Chemical
infusion	1417 8 O
,	1425 1 O
cisplatin	1427 9 B-Chemical
120	1437 3 O
mg	1441 2 O
/	1443 1 O
m2	1444 2 O
was	1447 3 O
administered	1451 12 O
over	1464 4 O
30	1469 2 O
minutes	1472 7 O
.	1479 1 O

Intravenous	1481 11 O
hydration	1493 9 O
and	1503 3 O
mannitol	1507 8 B-Chemical
was	1516 3 O
administered	1520 12 O
before	1533 6 O
and	1540 3 O
after	1544 5 O
cisplatin	1550 9 B-Chemical
.	1559 1 O

Treatment	1561 9 O
was	1571 3 O
administered	1575 12 O
every	1588 5 O
3	1594 1 O
weeks	1596 5 O
until	1602 5 O
disease	1608 7 O
progression	1616 11 O
.	1627 1 O

RESULTS	1629 7 O
:	1636 1 O
Forty	1638 5 O
-	1643 1 O
four	1644 4 O
patients	1649 8 O
were	1658 4 O
enrolled	1663 8 O
in	1672 2 O
the	1675 3 O
study	1679 5 O
of	1685 2 O
which	1688 5 O
7	1694 1 O
(	1696 1 O
16	1697 2 O
%	1699 1 O
)	1700 1 O
were	1702 4 O
ineligible	1707 10 O
.	1717 1 O

A	1719 1 O
median	1721 6 O
of	1728 2 O
2	1731 1 O
cycles	1733 6 O
of	1740 2 O
therapy	1743 7 O
was	1751 3 O
administered	1755 12 O
to	1768 2 O
the	1771 3 O
37	1775 2 O
eligible	1778 8 O
patients	1787 8 O
.	1795 1 O

Six	1797 3 O
partial	1801 7 O
responses	1809 9 O
were	1819 4 O
observed	1824 8 O
for	1833 3 O
an	1837 2 O
overall	1840 7 O
response	1848 8 O
rate	1857 4 O
of	1862 2 O
16	1865 2 O
%	1867 1 O
.	1868 1 O

Most	1870 4 O
patients	1875 8 O
(	1884 1 O
57	1885 2 O
%	1887 1 O
)	1888 1 O
stopped	1890 7 O
treatment	1898 9 O
because	1908 7 O
of	1916 2 O
disease	1919 7 O
progression	1927 11 O
.	1938 1 O

Neurologic	1940 10 B-Disease
toxicity	1951 8 I-Disease
was	1960 3 O
reported	1964 8 O
in	1973 2 O
52	1976 2 O
%	1978 1 O
of	1980 2 O
patients	1983 8 O
.	1991 1 O

Seven	1993 5 O
different	1999 9 O
life	2009 4 O
-	2013 1 O
threatening	2014 11 O
toxicities	2026 10 B-Disease
were	2037 4 O
observed	2042 8 O
in	2051 2 O
patients	2054 8 O
while	2063 5 O
receiving	2069 9 O
treatment	2079 9 O
.	2088 1 O

CONCLUSIONS	2090 11 O
:	2101 1 O
The	2103 3 O
combination	2107 11 O
of	2119 2 O
cisplatin	2122 9 B-Chemical
and	2132 3 O
amifostine	2136 10 B-Chemical
in	2147 2 O
this	2150 4 O
study	2155 5 O
resulted	2161 8 O
in	2170 2 O
an	2173 2 O
overall	2176 7 O
response	2184 8 O
rate	2193 4 O
of	2198 2 O
16	2201 2 O
%	2203 1 O
.	2204 1 O

Neither	2206 7 O
a	2214 1 O
tumor	2216 5 B-Disease
-	2221 1 O
protective	2222 10 O
effect	2233 6 O
nor	2240 3 O
reduced	2244 7 O
toxicity	2252 8 B-Disease
to	2261 2 O
normal	2264 6 O
tissues	2271 7 O
was	2279 3 O
observed	2283 8 O
with	2292 4 O
the	2297 3 O
addition	2301 8 O
of	2310 2 O
amifostine	2313 10 B-Chemical
to	2324 2 O
cisplatin	2327 9 B-Chemical
in	2337 2 O
this	2340 4 O
trial	2345 5 O
.	2350 1 O

Warfarin	0 8 B-Chemical
-	8 1 O
induced	9 7 O
iliopsoas	17 9 O
hemorrhage	27 10 B-Disease
with	38 4 O
subsequent	43 10 O
femoral	54 7 B-Disease
nerve	62 5 I-Disease
palsy	68 5 I-Disease
.	73 1 O

We	75 2 O
present	78 7 O
the	86 3 O
case	90 4 O
of	95 2 O
a	98 1 O
28	100 2 O
-	102 1 O
year	103 4 O
-	107 1 O
old	108 3 O
man	112 3 O
on	116 2 O
chronic	119 7 O
warfarin	127 8 B-Chemical
therapy	136 7 O
who	144 3 O
sustained	148 9 O
a	158 1 O
minor	160 5 O
muscle	166 6 B-Disease
tear	173 4 I-Disease
and	178 3 O
developed	182 9 O
increasing	192 10 O
pain	203 4 B-Disease
and	208 3 O
a	212 1 O
flexure	214 7 O
contracture	222 11 B-Disease
of	234 2 O
the	237 3 O
right	241 5 O
hip	247 3 O
.	250 1 O

Surgical	252 8 O
exploration	261 11 O
revealed	273 8 O
an	282 2 O
iliopsoas	285 9 O
hematoma	295 8 B-Disease
and	304 3 O
femoral	308 7 O
nerve	316 5 B-Disease
entrapment	322 10 I-Disease
,	332 1 O
resulting	334 9 O
in	344 2 O
a	347 1 O
femoral	349 7 B-Disease
nerve	357 5 I-Disease
palsy	363 5 I-Disease
and	369 3 O
partial	373 7 B-Disease
loss	381 4 I-Disease
of	386 2 I-Disease
quadriceps	389 10 I-Disease
functions	400 9 I-Disease
.	409 1 O

Anticoagulant	411 13 O
-	424 1 O
induced	425 7 O
femoral	433 7 B-Disease
nerve	441 5 I-Disease
palsy	447 5 I-Disease
represents	453 10 O
the	464 3 O
most	468 4 O
common	473 6 O
form	480 4 O
of	485 2 O
warfarin	488 8 B-Chemical
-	496 1 O
induced	497 7 O
peripheral	505 10 B-Disease
neuropathy	516 10 I-Disease
;	526 1 O
it	528 2 O
is	531 2 O
characterized	534 13 O
by	548 2 O
severe	551 6 O
pain	558 4 B-Disease
in	563 2 O
the	566 3 O
inguinal	570 8 O
region	579 6 O
,	585 1 O
varying	587 7 O
degrees	595 7 O
of	603 2 O
motor	606 5 B-Disease
and	612 3 I-Disease
sensory	616 7 I-Disease
impairment	624 10 I-Disease
,	634 1 O
and	636 3 O
flexure	640 7 O
contracture	648 11 B-Disease
of	660 2 O
the	663 3 O
involved	667 8 O
extremity	676 9 O
.	685 1 O

Myasthenia	0 10 B-Disease
gravis	11 6 I-Disease
caused	18 6 O
by	25 2 O
penicillamine	28 13 B-Chemical
and	42 3 O
chloroquine	46 11 B-Chemical
therapy	58 7 O
for	66 3 O
rheumatoid	70 10 B-Disease
arthritis	81 9 I-Disease
.	90 1 O

We	92 2 O
have	95 4 O
described	100 9 O
a	110 1 O
unique	112 6 O
patient	119 7 O
who	127 3 O
had	131 3 O
reversible	135 10 O
and	146 3 O
dose	150 4 O
-	154 1 O
related	155 7 O
myasthenia	163 10 B-Disease
gravis	174 6 I-Disease
after	181 5 O
penicillamine	187 13 B-Chemical
and	201 3 O
chloroquine	205 11 B-Chemical
therapy	217 7 O
for	225 3 O
rheumatoid	229 10 B-Disease
arthritis	240 9 I-Disease
.	249 1 O

Although	251 8 O
acetylcholine	260 13 B-Chemical
receptor	274 8 O
antibodies	283 10 O
were	294 4 O
not	299 3 O
detectable	303 10 O
,	313 1 O
the	315 3 O
time	319 4 O
course	324 6 O
was	331 3 O
consistent	335 10 O
with	346 4 O
an	351 2 O
autoimmune	354 10 O
process	365 7 O
.	372 1 O

Nephrotoxicity	0 14 B-Disease
of	15 2 O
combined	18 8 O
cephalothin	27 11 B-Chemical
-	38 1 O
gentamicin	39 10 B-Chemical
regimen	50 7 O
.	57 1 O

Two	59 3 O
patients	63 8 O
developed	72 9 O
acute	82 5 B-Disease
tubular	88 7 I-Disease
necrosis	96 8 I-Disease
,	104 1 O
characterized	106 13 O
clinically	120 10 O
by	131 2 O
acute	134 5 O
oliguric	140 8 B-Disease
renal	149 5 I-Disease
failure	155 7 I-Disease
,	162 1 O
while	164 5 O
they	170 4 O
were	175 4 O
receiving	180 9 O
a	190 1 O
combination	192 11 O
of	204 2 O
cephalothin	207 11 B-Chemical
sodium	219 6 I-Chemical
and	226 3 O
gentamicin	230 10 B-Chemical
sulfate	241 7 I-Chemical
therapy	249 7 O
.	256 1 O

Patients	258 8 O
who	267 3 O
are	271 3 O
given	275 5 O
this	281 4 O
drug	286 4 O
regimen	291 7 O
should	299 6 O
be	306 2 O
observed	309 8 O
very	318 4 O
carefully	323 9 O
for	333 3 O
early	337 5 O
signs	343 5 O
of	349 2 O
nephrotoxicity	352 14 B-Disease
.	366 1 O

High	368 4 O
doses	373 5 O
of	379 2 O
this	382 4 O
antibiotic	387 10 O
combination	398 11 O
should	410 6 O
be	417 2 O
avoided	420 7 O
especially	428 10 O
in	439 2 O
elderly	442 7 O
patients	450 8 O
.	458 1 O

Patients	460 8 O
with	469 4 O
renal	474 5 B-Disease
insufficiency	480 13 I-Disease
should	494 6 O
not	501 3 O
be	505 2 O
given	508 5 O
this	514 4 O
regimen	519 7 O
.	526 1 O

Components	0 10 O
of	11 2 O
lemon	14 5 O
essential	20 9 O
oil	30 3 O
attenuate	34 9 O
dementia	44 8 B-Disease
induced	53 7 O
by	61 2 O
scopolamine	64 11 B-Chemical
.	75 1 O

The	77 3 O
anti	81 4 O
-	85 1 O
dementia	86 8 B-Disease
effects	95 7 O
of	103 2 O
s	106 1 B-Chemical
-	107 1 I-Chemical
limonene	108 8 I-Chemical
and	117 3 O
s	121 1 B-Chemical
-	122 1 I-Chemical
perillyl	123 8 I-Chemical
alcohol	132 7 I-Chemical
were	140 4 O
observed	145 8 O
using	154 5 O
the	160 3 O
passive	164 7 O
avoidance	172 9 O
test	182 4 O
(	187 1 O
PA	188 2 O
)	190 1 O
and	192 3 O
the	196 3 O
open	200 4 O
field	205 5 O
habituation	211 11 O
test	223 4 O
(	228 1 O
OFH	229 3 O
)	232 1 O
.	233 1 O

These	235 5 O
lemon	241 5 O
essential	247 9 O
oils	257 4 O
showed	262 6 O
strong	269 6 O
ability	276 7 O
to	284 2 O
improve	287 7 O
memory	295 6 B-Disease
impaired	302 8 I-Disease
by	311 2 O
scopolamine	314 11 B-Chemical
;	325 1 O
however	327 7 O
,	334 1 O
s	336 1 B-Chemical
-	337 1 I-Chemical
perillyl	338 8 I-Chemical
alcohol	347 7 I-Chemical
relieved	355 8 O
the	364 3 O
deficit	368 7 B-Disease
of	376 2 I-Disease
associative	379 11 I-Disease
memory	391 6 I-Disease
in	398 2 O
PA	401 2 O
only	404 4 O
,	408 1 O
and	410 3 O
did	414 3 O
not	418 3 O
improve	422 7 O
non	430 3 O
-	433 1 O
associative	434 11 O
memory	446 6 O
significantly	453 13 O
in	467 2 O
OFH	470 3 O
.	473 1 O

Analysis	475 8 O
of	484 2 O
neurotransmitter	487 16 O
concentration	504 13 O
in	518 2 O
some	521 4 O
brain	526 5 O
regions	532 7 O
on	540 2 O
the	543 3 O
test	547 4 O
day	552 3 O
showed	556 6 O
that	563 4 O
dopamine	568 8 B-Chemical
concentration	577 13 O
of	591 2 O
the	594 3 O
vehicle	598 7 O
/	605 1 O
scopolamine	606 11 B-Chemical
group	618 5 O
was	624 3 O
significantly	628 13 O
lower	642 5 O
than	648 4 O
that	653 4 O
of	658 2 O
the	661 3 O
vehicle	665 7 O
/	672 1 O
vehicle	673 7 O
group	681 5 O
,	686 1 O
but	688 3 O
this	692 4 O
phenomenon	697 10 O
was	708 3 O
reversed	712 8 O
when	721 4 O
s	726 1 B-Chemical
-	727 1 I-Chemical
limonene	728 8 I-Chemical
or	737 2 O
s	740 1 B-Chemical
-	741 1 I-Chemical
perillyl	742 8 I-Chemical
alcohol	751 7 I-Chemical
were	759 4 O
administered	764 12 O
before	777 6 O
the	784 3 O
injection	788 9 O
of	798 2 O
scopolamine	801 11 B-Chemical
.	812 1 O

Simultaneously	814 14 O
,	828 1 O
we	830 2 O
found	833 5 O
that	839 4 O
these	844 5 O
two	850 3 O
lemon	854 5 O
essential	860 9 O
oil	870 3 O
components	874 10 O
could	885 5 O
inhibit	891 7 O
acetylcholinesterase	899 20 O
activity	920 8 O
in	929 2 O
vitro	932 5 O
using	938 5 O
the	944 3 O
Ellman	948 6 O
method	955 6 O
.	961 1 O

The	0 3 O
selective	4 9 O
5	14 1 O
-	15 1 O
HT6	16 3 O
receptor	20 8 O
antagonist	29 10 O
Ro4368554	40 9 B-Chemical
restores	50 8 O
memory	59 6 O
performance	66 11 O
in	78 2 O
cholinergic	81 11 O
and	93 3 O
serotonergic	97 12 O
models	110 6 O
of	117 2 O
memory	120 6 B-Disease
deficiency	127 10 I-Disease
in	138 2 O
the	141 3 O
rat	145 3 O
.	148 1 O

Antagonists	150 11 O
at	162 2 O
serotonin	165 9 B-Chemical
type	175 4 O
6	180 1 O
(	182 1 O
5	183 1 B-Chemical
-	184 1 I-Chemical
HT	185 2 I-Chemical
(	187 1 O
6	188 1 O
)	189 1 O
)	190 1 O
receptors	192 9 O
show	202 4 O
activity	207 8 O
in	216 2 O
models	219 6 O
of	226 2 O
learning	229 8 O
and	238 3 O
memory	242 6 O
.	248 1 O

Although	250 8 O
the	259 3 O
underlying	263 10 O
mechanism	274 9 O
(	283 1 O
s	284 1 O
)	285 1 O
are	287 3 O
not	291 3 O
well	295 4 O
understood	300 10 O
,	310 1 O
these	312 5 O
effects	318 7 O
may	326 3 O
involve	330 7 O
an	338 2 O
increase	341 8 O
in	350 2 O
acetylcholine	353 13 B-Chemical
(	367 1 O
ACh	368 3 B-Chemical
)	371 1 O
levels	373 6 O
.	379 1 O

The	381 3 O
present	385 7 O
study	393 5 O
sought	399 6 O
to	406 2 O
characterize	409 12 O
the	422 3 O
cognitive	426 9 O
-	435 1 O
enhancing	436 9 O
effects	446 7 O
of	454 2 O
the	457 3 O
5	461 1 B-Chemical
-	462 1 I-Chemical
HT	463 2 I-Chemical
(	465 1 O
6	466 1 O
)	467 1 O
antagonist	469 10 O
Ro4368554	480 9 B-Chemical
(	490 1 O
3	491 1 B-Chemical
-	492 1 I-Chemical
benzenesulfonyl	493 15 I-Chemical
-	508 1 I-Chemical
7	509 1 I-Chemical
-	510 1 I-Chemical
(	511 1 I-Chemical
4	512 1 I-Chemical
-	513 1 I-Chemical
methyl	514 6 I-Chemical
-	520 1 I-Chemical
piperazin	521 9 I-Chemical
-	530 1 I-Chemical
1	531 1 I-Chemical
-	532 1 I-Chemical
yl	533 2 I-Chemical
)	535 1 I-Chemical
1H	536 2 I-Chemical
-	538 1 I-Chemical
indole	539 6 I-Chemical
)	545 1 O
in	547 2 O
a	550 1 O
rat	552 3 O
object	556 6 O
recognition	563 11 O
task	575 4 O
employing	580 9 O
a	590 1 O
cholinergic	592 11 O
(	604 1 O
scopolamine	605 11 B-Chemical
pretreatment	617 12 O
)	629 1 O
and	631 3 O
a	635 1 O
serotonergic	637 12 O
-	649 1 O
(	651 1 O
tryptophan	652 10 B-Chemical
(	663 1 O
TRP	664 3 B-Chemical
)	667 1 O
depletion	669 9 O
)	678 1 O
deficient	680 9 O
model	690 5 O
,	695 1 O
and	697 3 O
compared	701 8 O
its	710 3 O
pattern	714 7 O
of	722 2 O
action	725 6 O
with	732 4 O
that	737 4 O
of	742 2 O
the	745 3 O
acetylcholinesterase	749 20 O
inhibitor	770 9 O
metrifonate	780 11 B-Chemical
.	791 1 O

Initial	793 7 O
testing	801 7 O
in	809 2 O
a	812 1 O
time	814 4 O
-	818 1 O
dependent	819 9 O
forgetting	829 10 O
task	840 4 O
employing	845 9 O
a	855 1 O
24	857 2 O
-	859 1 O
h	860 1 O
delay	862 5 O
between	868 7 O
training	876 8 O
and	885 3 O
testing	889 7 O
showed	897 6 O
that	904 4 O
metrifonate	909 11 B-Chemical
improved	921 8 O
object	930 6 O
recognition	937 11 O
(	949 1 O
at	950 2 O
10	953 2 O
and	956 3 O
30	960 2 O
mg	963 2 O
/	965 1 O
kg	966 2 O
,	968 1 O
p	970 1 O
.	971 1 O
o	972 1 O
.	973 1 O
)	974 1 O
,	975 1 O
whereas	977 7 O
Ro4368554	985 9 B-Chemical
was	995 3 O
inactive	999 8 O
.	1007 1 O

Both	1009 4 O
,	1013 1 O
Ro4368554	1015 9 B-Chemical
(	1025 1 O
3	1026 1 O
and	1028 3 O
10	1032 2 O
mg	1035 2 O
/	1037 1 O
kg	1038 2 O
,	1040 1 O
intraperitoneally	1042 17 O
(	1060 1 O
i	1061 1 O
.	1062 1 O
p	1063 1 O
.	1064 1 O
)	1065 1 O
)	1066 1 O
and	1068 3 O
metrifonate	1072 11 B-Chemical
(	1084 1 O
10	1085 2 O
mg	1088 2 O
/	1090 1 O
kg	1091 2 O
,	1093 1 O
p	1095 1 O
.	1096 1 O
o	1097 1 O
.	1098 1 O
,	1099 1 O
respectively	1101 12 O
)	1113 1 O
reversed	1115 8 O
memory	1124 6 B-Disease
deficits	1131 8 I-Disease
induced	1140 7 O
by	1148 2 O
scopolamine	1151 11 B-Chemical
and	1163 3 O
TRP	1167 3 B-Chemical
depletion	1171 9 O
(	1181 1 O
10	1182 2 O
mg	1185 2 O
/	1187 1 O
kg	1188 2 O
,	1190 1 O
i	1192 1 O
.	1193 1 O
p	1194 1 O
.	1195 1 O
,	1196 1 O
and	1198 3 O
3	1202 1 O
mg	1204 2 O
/	1206 1 O
kg	1207 2 O
,	1209 1 O
p	1211 1 O
.	1212 1 O
o	1213 1 O
.	1214 1 O
,	1215 1 O
respectively	1217 12 O
)	1229 1 O
.	1230 1 O

In	1232 2 O
conclusion	1235 10 O
,	1245 1 O
although	1247 8 O
Ro4368554	1256 9 B-Chemical
did	1266 3 O
not	1270 3 O
improve	1274 7 O
a	1282 1 O
time	1284 4 O
-	1288 1 O
related	1289 7 O
retention	1297 9 O
deficit	1307 7 O
,	1314 1 O
it	1316 2 O
reversed	1319 8 O
a	1328 1 O
cholinergic	1330 11 O
and	1342 3 O
a	1346 1 O
serotonergic	1348 12 O
memory	1361 6 B-Disease
deficit	1368 7 I-Disease
,	1375 1 O
suggesting	1377 10 O
that	1388 4 O
both	1393 4 O
mechanisms	1398 10 O
may	1409 3 O
be	1413 2 O
involved	1416 8 O
in	1425 2 O
the	1428 3 O
facilitation	1432 12 O
of	1445 2 O
object	1448 6 O
memory	1455 6 O
by	1462 2 O
Ro4368554	1465 9 B-Chemical
and	1475 3 O
,	1478 1 O
possibly	1480 8 O
,	1488 1 O
other	1490 5 O
5	1496 1 B-Chemical
-	1497 1 I-Chemical
HT	1498 2 I-Chemical
(	1500 1 O
6	1501 1 O
)	1502 1 O
receptor	1504 8 O
antagonists	1513 11 O
.	1524 1 O

Lone	0 4 O
atrial	5 6 B-Disease
fibrillation	12 12 I-Disease
associated	25 10 O
with	36 4 O
creatine	41 8 B-Chemical
monohydrate	50 11 O
supplementation	62 15 O
.	77 1 O

Atrial	79 6 B-Disease
fibrillation	86 12 I-Disease
in	99 2 O
young	102 5 O
patients	108 8 O
without	117 7 O
structural	125 10 O
heart	136 5 B-Disease
disease	142 7 I-Disease
is	150 2 O
rare	153 4 O
.	157 1 O

Therefore	159 9 O
,	168 1 O
when	170 4 O
the	175 3 O
arrhythmia	179 10 B-Disease
is	190 2 O
present	193 7 O
in	201 2 O
this	204 4 O
population	209 10 O
,	219 1 O
reversible	221 10 O
causes	232 6 O
must	239 4 O
be	244 2 O
identified	247 10 O
and	258 3 O
resolved	262 8 O
.	270 1 O

Thyroid	272 7 B-Disease
disorders	280 9 I-Disease
,	289 1 O
illicit	291 7 O
drug	299 4 O
or	304 2 O
stimulant	307 9 O
use	317 3 O
,	320 1 O
and	322 3 O
acute	326 5 B-Disease
alcohol	332 7 I-Disease
intoxication	340 12 I-Disease
are	353 3 O
among	357 5 O
these	363 5 O
causes	369 6 O
.	375 1 O

We	377 2 O
report	380 6 O
the	387 3 O
case	391 4 O
of	396 2 O
a	399 1 O
30	401 2 O
-	403 1 O
year	404 4 O
-	408 1 O
old	409 3 O
Caucasian	413 9 O
man	423 3 O
who	427 3 O
came	431 4 O
to	436 2 O
the	439 3 O
emergency	443 9 O
department	453 10 O
in	464 2 O
atrial	467 6 B-Disease
fibrillation	474 12 I-Disease
with	487 4 O
rapid	492 5 O
ventricular	498 11 O
response	510 8 O
.	518 1 O

His	520 3 O
medical	524 7 O
history	532 7 O
was	540 3 O
unremarkable	544 12 O
,	556 1 O
except	558 6 O
for	565 3 O
minor	569 5 O
fractures	575 9 B-Disease
of	585 2 O
the	588 3 O
fingers	592 7 O
and	600 3 O
foot	604 4 O
.	608 1 O

Thyroid	610 7 O
-	617 1 O
stimulating	618 11 O
hormone	630 7 O
,	637 1 O
magnesium	639 9 B-Chemical
,	648 1 O
and	650 3 O
potassium	654 9 B-Chemical
levels	664 6 O
were	671 4 O
within	676 6 O
normal	683 6 O
limits	690 6 O
,	696 1 O
urine	698 5 O
drug	704 4 O
screen	709 6 O
was	716 3 O
negative	720 8 O
,	728 1 O
and	730 3 O
alcohol	734 7 B-Chemical
use	742 3 O
was	746 3 O
denied	750 6 O
.	756 1 O

However	758 7 O
,	765 1 O
when	767 4 O
the	772 3 O
patient	776 7 O
was	784 3 O
questioned	788 10 O
about	799 5 O
use	805 3 O
of	809 2 O
herbal	812 6 O
products	819 8 O
and	828 3 O
supplements	832 11 O
,	843 1 O
the	845 3 O
use	849 3 O
of	853 2 O
creatine	856 8 B-Chemical
monohydrate	865 11 O
was	877 3 O
revealed	881 8 O
.	889 1 O

The	891 3 O
patient	895 7 O
was	903 3 O
admitted	907 8 O
to	916 2 O
the	919 3 O
hospital	923 8 O
,	931 1 O
anticoagulated	933 14 O
with	948 4 O
unfractionated	953 14 O
heparin	968 7 B-Chemical
,	975 1 O
and	977 3 O
given	981 5 O
intravenous	987 11 O
diltiazem	999 9 B-Chemical
for	1009 3 O
rate	1013 4 O
control	1018 7 O
and	1026 3 O
intravenous	1030 11 O
amiodarone	1042 10 B-Chemical
for	1053 3 O
rate	1057 4 O
and	1062 3 O
rhythm	1066 6 O
control	1073 7 O
.	1080 1 O

When	1082 4 O
discharged	1087 10 O
less	1098 4 O
than	1103 4 O
24	1108 2 O
hours	1111 5 O
later	1117 5 O
,	1122 1 O
he	1124 2 O
was	1127 3 O
receiving	1131 9 O
metoprolol	1141 10 B-Chemical
and	1152 3 O
aspirin	1156 7 B-Chemical
,	1163 1 O
with	1165 4 O
follow	1170 6 O
-	1176 1 O
up	1177 2 O
plans	1180 5 O
for	1186 3 O
echocardiography	1190 16 O
and	1207 3 O
nuclear	1211 7 O
imaging	1219 7 O
to	1227 2 O
assess	1230 6 O
perfusion	1237 9 O
.	1246 1 O

Exogenous	1248 9 O
creatine	1258 8 B-Chemical
is	1267 2 O
used	1270 4 O
by	1275 2 O
athletes	1278 8 O
to	1287 2 O
theoretically	1290 13 O
improve	1304 7 O
exercise	1312 8 O
performance	1321 11 O
.	1332 1 O

Vegetarians	1334 11 O
may	1346 3 O
also	1350 4 O
take	1355 4 O
creatine	1360 8 B-Chemical
to	1369 2 O
replace	1372 7 O
what	1380 4 O
they	1385 4 O
are	1390 3 O
not	1394 3 O
consuming	1398 9 O
from	1408 4 O
meat	1413 4 O
,	1417 1 O
fish	1419 4 O
,	1423 1 O
and	1425 3 O
other	1429 5 O
animal	1435 6 O
products	1442 8 O
.	1450 1 O

Previous	1452 8 O
anecdotal	1461 9 O
reports	1471 7 O
have	1479 4 O
linked	1484 6 O
creatine	1491 8 B-Chemical
to	1500 2 O
the	1503 3 O
development	1507 11 O
of	1519 2 O
arrhythmia	1522 10 B-Disease
.	1532 1 O

Clinicians	1534 10 O
must	1545 4 O
be	1550 2 O
diligent	1553 8 O
when	1562 4 O
interviewing	1567 12 O
patients	1580 8 O
about	1589 5 O
their	1595 5 O
drug	1601 4 O
therapy	1606 7 O
histories	1614 9 O
and	1624 3 O
include	1628 7 O
questions	1636 9 O
about	1646 5 O
their	1652 5 O
use	1658 3 O
of	1662 2 O
herbal	1665 6 O
products	1672 8 O
and	1681 3 O
dietary	1685 7 O
supplements	1693 11 O
.	1704 1 O

In	1706 2 O
addition	1709 8 O
,	1717 1 O
it	1719 2 O
is	1722 2 O
important	1725 9 O
to	1735 2 O
report	1738 6 O
adverse	1745 7 O
effects	1753 7 O
associated	1761 10 O
with	1772 4 O
frequently	1777 10 O
consumed	1788 8 O
supplements	1797 11 O
and	1809 3 O
herbal	1813 6 O
products	1820 8 O
to	1829 2 O
the	1832 3 O
Food	1836 4 O
and	1841 3 O
Drug	1845 4 O
Administration	1850 14 O
and	1865 3 O
in	1869 2 O
the	1872 3 O
literature	1876 10 O
.	1886 1 O

Comparison	0 10 O
of	11 2 O
developmental	14 13 O
toxicity	28 8 B-Disease
of	37 2 O
selective	40 9 O
and	50 3 O
non	54 3 O
-	57 1 O
selective	58 9 O
cyclooxygenase	68 14 O
-	82 1 O
2	83 1 O
inhibitors	85 10 O
in	96 2 O
CRL	99 3 O
:	102 1 O
(	103 1 O
WI	104 2 O
)	106 1 O
WUBR	107 4 O
Wistar	112 6 O
rats	119 4 O
-	123 1 O
-	124 1 O
DFU	125 3 B-Chemical
and	129 3 O
piroxicam	133 9 B-Chemical
study	143 5 O
.	148 1 O

BACKGROUND	150 10 O
:	160 1 O
Cyclooxygenase	162 14 O
(	177 1 O
COX	178 3 O
)	181 1 O
inhibitors	183 10 O
are	194 3 O
one	198 3 O
of	202 2 O
the	205 3 O
most	209 4 O
often	214 5 O
ingested	220 8 O
drugs	229 5 O
during	235 6 O
pregnancy	242 9 O
.	251 1 O

Unlike	253 6 O
general	260 7 O
toxicity	268 8 B-Disease
data	277 4 O
,	281 1 O
their	283 5 O
prenatal	289 8 O
toxic	298 5 O
effects	304 7 O
were	312 4 O
not	317 3 O
extensively	321 11 O
studied	333 7 O
before	341 6 O
.	347 1 O

The	349 3 O
aim	353 3 O
of	357 2 O
the	360 3 O
experiment	364 10 O
was	375 3 O
to	379 2 O
evaluate	382 8 O
the	391 3 O
developmental	395 13 O
toxicity	409 8 B-Disease
of	418 2 O
the	421 3 O
non	425 3 O
-	428 1 O
selective	429 9 O
(	439 1 O
piroxicam	440 9 B-Chemical
)	449 1 O
and	451 3 O
selective	455 9 O
(	465 1 O
DFU	466 3 B-Chemical
;	469 1 O
5	471 1 B-Chemical
,	472 1 I-Chemical
5	473 1 I-Chemical
-	474 1 I-Chemical
dimethyl	475 8 I-Chemical
-	483 1 I-Chemical
3	484 1 I-Chemical
-	485 1 I-Chemical
(	486 1 I-Chemical
3	487 1 I-Chemical
-	488 1 I-Chemical
fluorophenyl	489 12 I-Chemical
)	501 1 I-Chemical
-	502 1 I-Chemical
4	503 1 I-Chemical
-	504 1 I-Chemical
(	505 1 I-Chemical
4	506 1 I-Chemical
-	507 1 I-Chemical
methylsulphonyl	508 15 I-Chemical
)	523 1 I-Chemical
phenyl	525 6 I-Chemical
-	531 1 I-Chemical
2	532 1 I-Chemical
(	533 1 I-Chemical
5H	534 2 I-Chemical
)	536 1 I-Chemical
-	537 1 I-Chemical
furanon	538 7 I-Chemical
)	545 1 O
COX	547 3 O
-	550 1 O
2	551 1 O
inhibitors	553 10 O
.	563 1 O

METHODS	565 7 O
:	572 1 O
Drugs	574 5 O
were	580 4 O
separately	585 10 O
,	595 1 O
orally	597 6 O
once	604 4 O
daily	609 5 O
dosed	615 5 O
to	621 2 O
pregnant	624 8 O
rats	633 4 O
from	638 4 O
day	643 3 O
8	647 1 O
to	649 2 O
21	652 2 O
(	655 1 O
GD1	656 3 O
=	659 1 O
plug	660 4 O
day	665 3 O
)	668 1 O
.	669 1 O

Doses	671 5 O
were	677 4 O
set	682 3 O
at	686 2 O
0	689 1 O
.	690 1 O
3	691 1 O
,	692 1 O
3	694 1 O
.	695 1 O
0	696 1 O
and	698 3 O
30	702 2 O
.	704 1 O
0mg	705 3 O
/	708 1 O
kg	709 2 O
for	712 3 O
piroxicam	716 9 B-Chemical
and	726 3 O
0	730 1 O
.	731 1 O
2	732 1 O
,	733 1 O
2	735 1 O
.	736 1 O
0	737 1 O
and	739 3 O
20	743 2 O
.	745 1 O
0mg	746 3 O
/	749 1 O
kg	750 2 O
for	753 3 O
DFU	757 3 B-Chemical
.	760 1 O

Fetuses	762 7 O
were	770 4 O
delivered	775 9 O
on	785 2 O
GD	788 2 O
21	791 2 O
and	794 3 O
routinely	798 9 O
examined	808 8 O
.	816 1 O

Comprehensive	818 13 O
clinical	832 8 O
and	841 3 O
developmental	845 13 O
measurements	859 12 O
were	872 4 O
done	877 4 O
.	881 1 O

The	883 3 O
pooled	887 6 O
statistical	894 11 O
analysis	906 8 O
for	915 3 O
ventricular	919 11 B-Disease
septal	931 6 I-Disease
(	938 1 I-Disease
VSD	939 3 I-Disease
)	942 1 I-Disease
and	944 3 I-Disease
midline	948 7 I-Disease
(	956 1 I-Disease
MD	957 2 I-Disease
)	959 1 I-Disease
defects	961 7 I-Disease
was	969 3 O
performed	973 9 O
for	983 3 O
rat	987 3 O
fetuses	991 7 O
exposed	999 7 O
to	1007 2 O
piroxicam	1010 9 B-Chemical
,	1019 1 O
selective	1021 9 O
and	1031 3 O
non	1035 3 O
-	1038 1 O
selective	1039 9 O
COX	1049 3 O
-	1052 1 O
2	1053 1 O
inhibitor	1055 9 O
based	1065 5 O
on	1071 2 O
present	1074 7 O
and	1082 3 O
historic	1086 8 O
data	1095 4 O
.	1099 1 O

RESULTS	1101 7 O
:	1108 1 O
Maternal	1110 8 O
toxicity	1119 8 B-Disease
,	1127 1 O
intrauterine	1129 12 B-Disease
growth	1142 6 I-Disease
retardation	1149 11 I-Disease
,	1160 1 O
and	1162 3 O
increase	1166 8 B-Disease
of	1175 2 I-Disease
external	1178 8 I-Disease
and	1187 3 I-Disease
skeletal	1191 8 I-Disease
variations	1200 10 I-Disease
were	1211 4 O
found	1216 5 O
in	1222 2 O
rats	1225 4 O
treated	1230 7 O
with	1238 4 O
the	1243 3 O
highest	1247 7 O
dose	1255 4 O
of	1260 2 O
piroxicam	1263 9 B-Chemical
.	1272 1 O

Decrease	1274 8 O
of	1283 2 O
fetal	1286 5 O
length	1292 6 O
was	1299 3 O
the	1303 3 O
only	1307 4 O
signs	1312 5 O
of	1318 2 O
the	1321 3 O
DFU	1325 3 B-Chemical
developmental	1329 13 O
toxicity	1343 8 B-Disease
observed	1352 8 O
in	1361 2 O
pups	1364 4 O
exposed	1369 7 O
to	1377 2 O
the	1380 3 O
highest	1384 7 O
compound	1392 8 O
dose	1401 4 O
.	1405 1 O

Lack	1407 4 O
of	1412 2 O
teratogenicity	1415 14 O
was	1430 3 O
found	1434 5 O
in	1440 2 O
piroxicam	1443 9 B-Chemical
and	1453 3 O
DFU	1457 3 B-Chemical
-	1460 1 O
exposed	1461 7 O
groups	1469 6 O
.	1475 1 O

Prenatal	1477 8 O
exposure	1486 8 O
to	1495 2 O
non	1498 3 O
-	1501 1 O
selective	1502 9 O
COX	1512 3 O
inhibitors	1516 10 O
increases	1527 9 O
the	1537 3 O
risk	1541 4 O
of	1546 2 O
VSD	1549 3 O
and	1553 3 O
MD	1557 2 O
when	1560 4 O
compared	1565 8 O
to	1574 2 O
historic	1577 8 O
control	1586 7 O
but	1594 3 O
not	1598 3 O
with	1602 4 O
selective	1607 9 O
COX	1617 3 O
-	1620 1 O
2	1621 1 O
inhibitors	1623 10 O
.	1633 1 O

CONCLUSION	1635 10 O
:	1645 1 O
Both	1647 4 O
selective	1652 9 O
and	1662 3 O
non	1666 3 O
-	1669 1 O
selective	1670 9 O
COX	1680 3 O
-	1683 1 O
2	1684 1 O
inhibitors	1686 10 O
were	1697 4 O
toxic	1702 5 O
for	1708 3 O
rats	1712 4 O
fetuses	1717 7 O
when	1725 4 O
administered	1730 12 O
in	1743 2 O
the	1746 3 O
highest	1750 7 O
dose	1758 4 O
.	1762 1 O

Unlike	1764 6 O
DFU	1771 3 B-Chemical
,	1774 1 O
piroxicam	1776 9 B-Chemical
was	1786 3 O
also	1790 4 O
highly	1795 6 O
toxic	1802 5 O
to	1808 2 O
the	1811 3 O
dams	1815 4 O
.	1819 1 O

Prenatal	1821 8 O
exposure	1830 8 O
to	1839 2 O
selective	1842 9 O
COX	1852 3 O
-	1855 1 O
2	1856 1 O
inhibitors	1858 10 O
does	1869 4 O
not	1874 3 O
increase	1878 8 O
the	1887 3 O
risk	1891 4 O
of	1896 2 O
ventricular	1899 11 B-Disease
septal	1911 6 I-Disease
and	1918 3 I-Disease
midline	1922 7 I-Disease
defects	1930 7 I-Disease
in	1938 2 O
rat	1941 3 O
when	1945 4 O
compared	1950 8 O
to	1959 2 O
non	1962 3 O
-	1965 1 O
selective	1966 9 O
drugs	1976 5 O
and	1982 3 O
historic	1986 8 O
control	1995 7 O
.	2002 1 O

Protective	0 10 O
efficacy	11 8 O
of	20 2 O
neuroactive	23 11 O
steroids	35 8 B-Chemical
against	44 7 O
cocaine	52 7 B-Chemical
kindled	60 7 O
-	67 1 O
seizures	68 8 B-Disease
in	77 2 O
mice	80 4 O
.	84 1 O

Neuroactive	86 11 O
steroids	98 8 B-Chemical
demonstrate	107 11 O
pharmacological	119 15 O
actions	135 7 O
that	143 4 O
have	148 4 O
relevance	153 9 O
for	163 3 O
a	167 1 O
host	169 4 O
of	174 2 O
neurological	177 12 B-Disease
and	190 3 I-Disease
psychiatric	194 11 I-Disease
disorders	206 9 I-Disease
.	215 1 O

They	217 4 O
offer	222 5 O
protection	228 10 O
against	239 7 O
seizures	247 8 B-Disease
in	256 2 O
a	259 1 O
range	261 5 O
of	267 2 O
models	270 6 O
and	277 3 O
seem	281 4 O
to	286 2 O
inhibit	289 7 O
certain	297 7 O
stages	305 6 O
of	312 2 O
drug	315 4 B-Disease
dependence	320 10 I-Disease
in	331 2 O
preclinical	334 11 O
assessments	346 11 O
.	357 1 O

The	359 3 O
present	363 7 O
study	371 5 O
was	377 3 O
designed	381 8 O
to	390 2 O
evaluate	393 8 O
two	402 3 O
endogenous	406 10 O
and	417 3 O
one	421 3 O
synthetic	425 9 O
neuroactive	435 11 O
steroid	447 7 B-Chemical
that	455 4 O
positively	460 10 O
modulate	471 8 O
the	480 3 O
gamma	484 5 B-Chemical
-	489 1 I-Chemical
aminobutyric	490 12 I-Chemical
acid	503 4 I-Chemical
(	508 1 O
GABA	509 4 B-Chemical
(	513 1 O
A	514 1 O
)	515 1 O
)	516 1 O
receptor	518 8 O
against	527 7 O
the	535 3 O
increase	539 8 O
in	548 2 O
sensitivity	551 11 O
to	563 2 O
the	566 3 O
convulsant	570 10 O
effects	581 7 O
of	589 2 O
cocaine	592 7 B-Chemical
engendered	600 10 O
by	611 2 O
repeated	614 8 O
cocaine	623 7 B-Chemical
administration	631 14 O
(	646 1 O
seizure	647 7 B-Disease
kindling	655 8 O
)	663 1 O
.	664 1 O

Allopregnanolone	666 16 B-Chemical
(	683 1 O
3alpha	684 6 B-Chemical
-	690 1 I-Chemical
hydroxy	691 7 I-Chemical
-	698 1 I-Chemical
5alpha	699 6 I-Chemical
-	705 1 I-Chemical
pregnan	706 7 I-Chemical
-	713 1 I-Chemical
20	714 2 I-Chemical
-	716 1 I-Chemical
one	717 3 I-Chemical
)	720 1 O
,	721 1 O
pregnanolone	723 12 B-Chemical
(	736 1 O
3alpha	737 6 B-Chemical
-	743 1 I-Chemical
hydroxy	744 7 I-Chemical
-	751 1 I-Chemical
5beta	752 5 I-Chemical
-	757 1 I-Chemical
pregnan	758 7 I-Chemical
-	765 1 I-Chemical
20	766 2 I-Chemical
-	768 1 I-Chemical
one	769 3 I-Chemical
)	772 1 O
and	774 3 O
ganaxolone	778 10 B-Chemical
(	789 1 O
a	790 1 O
synthetic	792 9 O
derivative	802 10 O
of	813 2 O
allopregnanolone	816 16 B-Chemical
3alpha	833 6 B-Chemical
-	839 1 I-Chemical
hydroxy	840 7 I-Chemical
-	847 1 I-Chemical
3beta	848 5 I-Chemical
-	853 1 I-Chemical
methyl	854 6 I-Chemical
-	860 1 I-Chemical
5alpha	861 6 I-Chemical
-	867 1 I-Chemical
pregnan	868 7 I-Chemical
-	875 1 I-Chemical
20	876 2 I-Chemical
-	878 1 I-Chemical
one	879 3 I-Chemical
)	882 1 O
were	884 4 O
tested	889 6 O
for	896 3 O
their	900 5 O
ability	906 7 O
to	914 2 O
suppress	917 8 O
the	926 3 O
expression	930 10 O
(	941 1 O
anticonvulsant	942 14 O
effect	957 6 O
)	963 1 O
and	965 3 O
development	969 11 O
(	981 1 O
antiepileptogenic	982 17 O
effect	1000 6 O
)	1006 1 O
of	1008 2 O
cocaine	1011 7 B-Chemical
-	1018 1 O
kindled	1019 7 O
seizures	1027 8 B-Disease
in	1036 2 O
male	1039 4 O
,	1043 1 O
Swiss	1045 5 O
-	1050 1 O
Webster	1051 7 O
mice	1059 4 O
.	1063 1 O

Kindled	1065 7 O
seizures	1073 8 B-Disease
were	1082 4 O
induced	1087 7 O
by	1095 2 O
daily	1098 5 O
administration	1104 14 O
of	1119 2 O
60	1122 2 O
mg	1125 2 O
/	1127 1 O
kg	1128 2 O
cocaine	1131 7 B-Chemical
for	1139 3 O
5	1143 1 O
days	1145 4 O
.	1149 1 O

All	1151 3 O
of	1155 2 O
these	1158 5 O
positive	1164 8 O
GABA	1173 4 B-Chemical
(	1177 1 O
A	1178 1 O
)	1179 1 O
modulators	1181 10 O
suppressed	1192 10 O
the	1203 3 O
expression	1207 10 O
of	1218 2 O
kindled	1221 7 O
seizures	1229 8 B-Disease
,	1237 1 O
whereas	1239 7 O
only	1247 4 O
allopregnanolone	1252 16 B-Chemical
and	1269 3 O
ganaxolone	1273 10 B-Chemical
inhibited	1284 9 O
the	1294 3 O
development	1298 11 O
of	1310 2 O
kindling	1313 8 O
.	1321 1 O

Allopregnanolone	1323 16 B-Chemical
and	1340 3 O
pregnanolone	1344 12 B-Chemical
,	1356 1 O
but	1358 3 O
not	1362 3 O
ganaxolone	1366 10 B-Chemical
,	1376 1 O
also	1378 4 O
reduced	1383 7 O
cumulative	1391 10 O
lethality	1402 9 O
associated	1412 10 O
with	1423 4 O
kindling	1428 8 O
.	1436 1 O

These	1438 5 O
findings	1444 8 O
demonstrate	1453 11 O
that	1465 4 O
some	1470 4 O
neuroactive	1475 11 O
steroids	1487 8 B-Chemical
attenuate	1496 9 O
convulsant	1506 10 O
and	1517 3 O
sensitizing	1521 11 O
properties	1533 10 O
of	1544 2 O
cocaine	1547 7 B-Chemical
and	1555 3 O
add	1559 3 O
to	1563 2 O
a	1566 1 O
growing	1568 7 O
literature	1576 10 O
on	1587 2 O
their	1590 5 O
potential	1596 9 O
use	1606 3 O
in	1610 2 O
the	1613 3 O
modulation	1617 10 O
of	1628 2 O
effects	1631 7 O
of	1639 2 O
drugs	1642 5 O
of	1648 2 O
abuse	1651 5 O
.	1656 1 O

Kidney	0 6 O
function	7 8 O
and	16 3 O
morphology	20 10 O
after	31 5 O
short	37 5 O
-	42 1 O
term	43 4 O
combination	48 11 O
therapy	60 7 O
with	68 4 O
cyclosporine	73 12 B-Chemical
A	86 1 I-Chemical
,	87 1 O
tacrolimus	89 10 B-Chemical
and	100 3 O
sirolimus	104 9 B-Chemical
in	114 2 O
the	117 3 O
rat	121 3 O
.	124 1 O

BACKGROUND	126 10 O
:	136 1 O
Sirolimus	138 9 B-Chemical
(	148 1 O
SRL	149 3 B-Chemical
)	152 1 O
may	154 3 O
supplement	158 10 O
calcineurin	169 11 O
inhibitors	181 10 O
in	192 2 O
clinical	195 8 O
organ	204 5 O
transplantation	210 15 O
.	225 1 O

These	227 5 O
are	233 3 O
nephrotoxic	237 11 B-Disease
,	248 1 O
but	250 3 O
SRL	254 3 B-Chemical
seems	258 5 O
to	264 2 O
act	267 3 O
differently	271 11 O
displaying	283 10 O
only	294 4 O
minor	299 5 O
nephrotoxic	305 11 B-Disease
effects	317 7 O
,	324 1 O
although	326 8 O
this	335 4 O
question	340 8 O
is	349 2 O
still	352 5 O
open	358 4 O
.	362 1 O

In	364 2 O
a	367 1 O
number	369 6 O
of	376 2 O
treatment	379 9 O
protocols	389 9 O
where	399 5 O
SRL	405 3 B-Chemical
was	409 3 O
combined	413 8 O
with	422 4 O
a	427 1 O
calcineurin	429 11 O
inhibitor	441 9 O
indications	451 11 O
of	463 2 O
a	466 1 O
synergistic	468 11 O
nephrotoxic	480 11 B-Disease
effect	492 6 O
were	499 4 O
described	504 9 O
.	513 1 O

The	515 3 O
aim	519 3 O
of	523 2 O
this	526 4 O
study	531 5 O
was	537 3 O
to	541 2 O
examine	544 7 O
further	552 7 O
the	560 3 O
renal	564 5 O
function	570 8 O
,	578 1 O
including	580 9 O
morphological	590 13 O
analysis	604 8 O
of	613 2 O
the	616 3 O
kidneys	620 7 O
of	628 2 O
male	631 4 O
Sprague	636 7 O
-	643 1 O
Dawley	644 6 O
rats	651 4 O
treated	656 7 O
with	664 4 O
either	669 6 O
cyclosporine	676 12 B-Chemical
A	689 1 I-Chemical
(	691 1 O
CsA	692 3 B-Chemical
)	695 1 O
,	696 1 O
tacrolimus	698 10 B-Chemical
(	709 1 O
FK506	710 5 B-Chemical
)	715 1 O
or	717 2 O
SRL	720 3 B-Chemical
as	724 2 O
monotherapies	727 13 O
or	741 2 O
in	744 2 O
different	747 9 O
combinations	757 12 O
.	769 1 O

METHODS	771 7 O
:	778 1 O
For	780 3 O
a	784 1 O
period	786 6 O
of	793 2 O
2	796 1 O
weeks	798 5 O
,	803 1 O
CsA	805 3 B-Chemical
15	809 2 O
mg	812 2 O
/	814 1 O
kg	815 2 O
/	817 1 O
day	818 3 O
(	822 1 O
given	823 5 O
orally	829 6 O
)	835 1 O
,	836 1 O
FK506	838 5 B-Chemical
3	844 1 O
.	845 1 O
0	846 1 O
mg	848 2 O
/	850 1 O
kg	851 2 O
/	853 1 O
day	854 3 O
(	858 1 O
given	859 5 O
orally	865 6 O
)	871 1 O
or	873 2 O
SRL	876 3 B-Chemical
0	880 1 O
.	881 1 O
4	882 1 O
mg	884 2 O
/	886 1 O
kg	887 2 O
/	889 1 O
day	890 3 O
(	894 1 O
given	895 5 O
intraperitoneally	901 17 O
)	918 1 O
was	920 3 O
administered	924 12 O
once	937 4 O
a	942 1 O
day	944 3 O
as	948 2 O
these	951 5 O
doses	957 5 O
have	963 4 O
earlier	968 7 O
been	976 4 O
found	981 5 O
to	987 2 O
achieve	990 7 O
a	998 1 O
significant	1000 11 O
immunosuppressive	1012 17 O
effect	1030 6 O
in	1037 2 O
Sprague	1040 7 O
-	1047 1 O
Dawley	1048 6 O
rats	1055 4 O
.	1059 1 O

In	1061 2 O
the	1064 3 O
'	1068 1 O
conscious	1069 9 O
catheterized	1079 12 O
rat	1092 3 O
'	1095 1 O
model	1097 5 O
,	1102 1 O
the	1104 3 O
glomerular	1108 10 O
filtration	1119 10 O
rate	1130 4 O
(	1135 1 O
GFR	1136 3 O
)	1139 1 O
was	1141 3 O
measured	1145 8 O
as	1154 2 O
the	1157 3 O
clearance	1161 9 O
of	1171 2 O
Cr	1174 2 O
(	1176 1 O
EDTA	1177 4 O
)	1181 1 O
.	1182 1 O

The	1184 3 O
morphological	1188 13 O
analysis	1202 8 O
of	1211 2 O
the	1214 3 O
kidneys	1218 7 O
included	1226 8 O
a	1235 1 O
semi	1237 4 O
-	1241 1 O
quantitative	1242 12 O
scoring	1255 7 O
system	1263 6 O
analysing	1270 9 O
the	1280 3 O
degree	1284 6 O
of	1291 2 O
striped	1294 7 O
fibrosis	1302 8 B-Disease
,	1310 1 O
subcapsular	1312 11 O
fibrosis	1324 8 B-Disease
and	1333 3 O
the	1337 3 O
number	1341 6 O
of	1348 2 O
basophilic	1351 10 O
tubules	1362 7 O
,	1369 1 O
plus	1371 4 O
an	1376 2 O
additional	1379 10 O
stereological	1390 13 O
analysis	1404 8 O
of	1413 2 O
the	1416 3 O
total	1420 5 O
grade	1426 5 O
of	1432 2 O
fibrosis	1435 8 B-Disease
in	1444 2 O
the	1447 3 O
cortex	1451 6 O
stained	1458 7 O
with	1466 4 O
Sirius	1471 6 O
Red	1478 3 O
.	1481 1 O

RESULTS	1483 7 O
:	1490 1 O
CsA	1492 3 B-Chemical
,	1495 1 O
FK506	1497 5 B-Chemical
and	1503 3 O
SRL	1507 3 B-Chemical
all	1511 3 O
significantly	1515 13 O
decreased	1529 9 O
the	1539 3 O
GFR	1543 3 O
.	1546 1 O

A	1548 1 O
further	1550 7 O
deterioration	1558 13 O
was	1572 3 O
seen	1576 4 O
when	1581 4 O
CsA	1586 3 B-Chemical
was	1590 3 O
combined	1594 8 O
with	1603 4 O
either	1608 6 O
FK506	1615 5 B-Chemical
or	1621 2 O
SRL	1624 3 B-Chemical
,	1627 1 O
whereas	1629 7 O
the	1637 3 O
GFR	1641 3 O
remained	1645 8 O
unchanged	1654 9 O
in	1664 2 O
the	1667 3 O
group	1671 5 O
treated	1677 7 O
with	1685 4 O
FK506	1690 5 B-Chemical
plus	1696 4 O
SRL	1701 3 B-Chemical
when	1705 4 O
compared	1710 8 O
with	1719 4 O
treatment	1724 9 O
with	1734 4 O
any	1739 3 O
of	1743 2 O
the	1746 3 O
single	1750 6 O
substances	1757 10 O
.	1767 1 O

The	1769 3 O
morphological	1773 13 O
changes	1787 7 O
presented	1795 9 O
a	1805 1 O
similar	1807 7 O
pattern	1815 7 O
.	1822 1 O

The	1824 3 O
semi	1828 4 O
-	1832 1 O
quantitative	1833 12 O
scoring	1846 7 O
was	1854 3 O
significantly	1858 13 O
worst	1872 5 O
in	1878 2 O
the	1881 3 O
group	1885 5 O
treated	1891 7 O
with	1899 4 O
CsA	1904 3 B-Chemical
plus	1908 4 O
SRL	1913 3 B-Chemical
(	1917 1 O
P	1918 1 O
<	1919 1 O
0	1920 1 O
.	1921 1 O
001	1922 3 O
compared	1926 8 O
with	1935 4 O
controls	1940 8 O
)	1948 1 O
and	1950 3 O
the	1954 3 O
analysis	1958 8 O
of	1967 2 O
the	1970 3 O
total	1974 5 O
grade	1980 5 O
of	1986 2 O
fibrosis	1989 8 B-Disease
also	1998 4 O
showed	2003 6 O
the	2010 3 O
highest	2014 7 O
proportion	2022 10 O
in	2033 2 O
the	2036 3 O
same	2040 4 O
group	2045 5 O
and	2051 3 O
was	2055 3 O
significantly	2059 13 O
different	2073 9 O
from	2083 4 O
controls	2088 8 O
(	2097 1 O
P	2098 1 O
<	2099 1 O
0	2100 1 O
.	2101 1 O
02	2102 2 O
)	2104 1 O
.	2105 1 O

The	2107 3 O
FK506	2111 5 B-Chemical
plus	2117 4 O
SRL	2122 3 B-Chemical
combination	2126 11 O
showed	2138 6 O
only	2145 4 O
a	2150 1 O
marginally	2152 10 O
higher	2163 6 O
degree	2170 6 O
of	2177 2 O
fibrosis	2180 8 B-Disease
as	2189 2 O
compared	2192 8 O
with	2201 4 O
controls	2206 8 O
(	2215 1 O
P	2216 1 O
=	2217 1 O
0	2218 1 O
.	2219 1 O
05	2220 2 O
)	2222 1 O
.	2223 1 O

CONCLUSION	2225 10 O
:	2235 1 O
This	2237 4 O
rat	2242 3 O
study	2246 5 O
demonstrated	2252 12 O
a	2265 1 O
synergistic	2267 11 O
nephrotoxic	2279 11 B-Disease
effect	2291 6 O
of	2298 2 O
CsA	2301 3 B-Chemical
plus	2305 4 O
SRL	2310 3 B-Chemical
,	2313 1 O
whereas	2315 7 O
FK506	2323 5 B-Chemical
plus	2329 4 O
SRL	2334 3 B-Chemical
was	2338 3 O
better	2342 6 O
tolerated	2349 9 O
.	2358 1 O

Effect	0 6 O
of	7 2 O
fucoidan	10 8 B-Chemical
treatment	19 9 O
on	29 2 O
collagenase	32 11 O
-	43 1 O
induced	44 7 O
intracerebral	52 13 B-Disease
hemorrhage	66 10 I-Disease
in	77 2 O
rats	80 4 O
.	84 1 O

Inflammatory	86 12 O
cells	99 5 O
are	105 3 O
postulated	109 10 O
to	120 2 O
mediate	123 7 O
some	131 4 O
of	136 2 O
the	139 3 O
brain	143 5 B-Disease
damage	149 6 I-Disease
following	156 9 O
ischemic	166 8 B-Disease
stroke	175 6 I-Disease
.	181 1 O

Intracerebral	183 13 B-Disease
hemorrhage	197 10 I-Disease
is	208 2 O
associated	211 10 O
with	222 4 O
more	227 4 O
inflammation	232 12 B-Disease
than	245 4 O
ischemic	250 8 B-Disease
stroke	259 6 I-Disease
.	265 1 O

We	267 2 O
tested	270 6 O
the	277 3 O
sulfated	281 8 O
polysaccharide	290 14 O
fucoidan	305 8 B-Chemical
,	313 1 O
which	315 5 O
has	321 3 O
been	325 4 O
reported	330 8 O
to	339 2 O
reduce	342 6 O
inflammatory	349 12 O
brain	362 5 B-Disease
damage	368 6 I-Disease
,	374 1 O
in	376 2 O
a	379 1 O
rat	381 3 O
model	385 5 O
of	391 2 O
intracerebral	394 13 B-Disease
hemorrhage	408 10 I-Disease
induced	419 7 O
by	427 2 O
injection	430 9 O
of	440 2 O
bacterial	443 9 O
collagenase	453 11 O
into	465 4 O
the	470 3 O
caudate	474 7 O
nucleus	482 7 O
.	489 1 O

Rats	491 4 O
were	496 4 O
treated	501 7 O
with	509 4 O
seven	514 5 O
day	520 3 O
intravenous	524 11 O
infusion	536 8 O
of	545 2 O
fucoidan	548 8 B-Chemical
(	557 1 O
30	558 2 O
micrograms	561 10 O
h	572 1 O
-	573 1 O
1	574 1 O
)	575 1 O
or	577 2 O
vehicle	580 7 O
.	587 1 O

The	589 3 O
hematoma	593 8 B-Disease
was	602 3 O
assessed	606 8 O
in	615 2 O
vivo	618 4 O
by	623 2 O
magnetic	626 8 O
resonance	635 9 O
imaging	645 7 O
.	652 1 O

Motor	654 5 O
behavior	660 8 O
,	668 1 O
passive	670 7 O
avoidance	678 9 O
,	687 1 O
and	689 3 O
skilled	693 7 O
forelimb	701 8 O
function	710 8 O
were	719 4 O
tested	724 6 O
repeatedly	731 10 O
for	742 3 O
six	746 3 O
weeks	750 5 O
.	755 1 O

Fucoidan	757 8 B-Chemical
-	765 1 O
treated	766 7 O
rats	774 4 O
exhibited	779 9 O
evidence	789 8 O
of	798 2 O
impaired	801 8 B-Disease
blood	810 5 I-Disease
clotting	816 8 I-Disease
and	825 3 O
hemodilution	829 12 B-Disease
,	841 1 O
had	843 3 O
larger	847 6 O
hematomas	854 9 B-Disease
,	863 1 O
and	865 3 O
tended	869 6 O
to	876 2 O
have	879 4 O
less	884 4 O
inflammation	889 12 B-Disease
in	902 2 O
the	905 3 O
vicinity	909 8 O
of	918 2 O
the	921 3 O
hematoma	925 8 B-Disease
after	934 5 O
three	940 5 O
days	946 4 O
.	950 1 O

They	952 4 O
showed	957 6 O
significantly	964 13 O
more	978 4 O
rapid	983 5 O
improvement	989 11 O
of	1001 2 O
motor	1004 5 O
function	1010 8 O
in	1019 2 O
the	1022 3 O
first	1026 5 O
week	1032 4 O
following	1037 9 O
hemorrhage	1047 10 B-Disease
and	1058 3 O
better	1062 6 O
memory	1069 6 O
retention	1076 9 O
in	1086 2 O
the	1089 3 O
passive	1093 7 O
avoidance	1101 9 O
test	1111 4 O
.	1115 1 O

Acute	1117 5 O
white	1123 5 B-Disease
matter	1129 6 I-Disease
edema	1136 5 I-Disease
and	1142 3 O
eventual	1146 8 O
neuronal	1155 8 B-Disease
loss	1164 4 I-Disease
in	1169 2 O
the	1172 3 O
striatum	1176 8 O
adjacent	1185 8 O
to	1194 2 O
the	1197 3 O
hematoma	1201 8 B-Disease
did	1210 3 O
not	1214 3 O
differ	1218 6 O
between	1225 7 O
the	1233 3 O
two	1237 3 O
groups	1241 6 O
.	1247 1 O

Investigation	1249 13 O
of	1263 2 O
more	1266 4 O
specific	1271 8 O
anti	1280 4 O
-	1284 1 O
inflammatory	1285 12 O
agents	1298 6 O
and	1305 3 O
hemodiluting	1309 12 O
agents	1322 6 O
are	1329 3 O
warranted	1333 9 O
in	1343 2 O
intracerebral	1346 13 B-Disease
hemorrhage	1360 10 I-Disease
.	1370 1 O

Paracetamol	0 11 B-Chemical
-	11 1 O
associated	12 10 O
coma	23 4 B-Disease
,	27 1 O
metabolic	29 9 B-Disease
acidosis	39 8 I-Disease
,	47 1 O
renal	49 5 B-Disease
and	55 3 I-Disease
hepatic	59 7 I-Disease
failure	67 7 I-Disease
.	74 1 O

A	76 1 O
case	78 4 O
of	83 2 O
metabolic	86 9 B-Disease
acidosis	96 8 I-Disease
,	104 1 O
acute	106 5 B-Disease
renal	112 5 I-Disease
failure	118 7 I-Disease
and	126 3 I-Disease
hepatic	130 7 I-Disease
failure	138 7 I-Disease
following	146 9 O
paracetamol	156 11 B-Chemical
ingestion	168 9 O
is	178 2 O
presented	181 9 O
.	190 1 O

The	192 3 O
diagnostic	196 10 O
difficulty	207 10 O
at	218 2 O
presentation	221 12 O
is	234 2 O
highlighted	237 11 O
.	248 1 O

Continuous	250 10 O
arteriovenous	261 13 O
haemofiltration	275 15 O
proved	291 6 O
a	298 1 O
valuable	300 8 O
means	309 5 O
of	315 2 O
maintaining	318 11 O
fluid	330 5 O
and	336 3 O
electrolyte	340 11 O
balance	352 7 O
.	359 1 O

The	361 3 O
patient	365 7 O
recovered	373 9 O
.	382 1 O

Hepatic	0 7 O
reactions	8 9 O
associated	18 10 O
with	29 4 O
ketoconazole	34 12 B-Chemical
in	47 2 O
the	50 3 O
United	54 6 O
Kingdom	61 7 O
.	68 1 O

Ketoconazole	70 12 B-Chemical
was	83 3 O
introduced	87 10 O
in	98 2 O
the	101 3 O
United	105 6 O
Kingdom	112 7 O
in	120 2 O
1981	123 4 O
.	127 1 O

By	129 2 O
November	132 8 O
1984	141 4 O
the	146 3 O
Committee	150 9 O
on	160 2 O
Safety	163 6 O
of	170 2 O
Medicines	173 9 O
had	183 3 O
received	187 8 O
82	196 2 O
reports	199 7 O
of	207 2 O
possible	210 8 O
hepatotoxicity	219 14 B-Disease
associated	234 10 O
with	245 4 O
the	250 3 O
drug	254 4 O
,	258 1 O
including	260 9 O
five	270 4 O
deaths	275 6 B-Disease
.	281 1 O

An	283 2 O
analysis	286 8 O
of	295 2 O
the	298 3 O
75	302 2 O
cases	305 5 O
that	311 4 O
had	316 3 O
been	320 4 O
adequately	325 10 O
followed	336 8 O
up	345 2 O
suggested	348 9 O
that	358 4 O
16	363 2 O
,	365 1 O
including	367 9 O
three	377 5 O
deaths	383 6 B-Disease
,	389 1 O
were	391 4 O
probably	396 8 O
related	405 7 O
to	413 2 O
treatment	416 9 O
with	426 4 O
the	431 3 O
drug	435 4 O
.	439 1 O

Of	441 2 O
the	444 3 O
remainder	448 9 O
,	457 1 O
48	459 2 O
were	462 4 O
possibly	467 8 O
related	476 7 O
to	484 2 O
treatment	487 9 O
,	496 1 O
five	498 4 O
were	503 4 O
unlikely	508 8 O
to	517 2 O
be	520 2 O
so	523 2 O
,	525 1 O
and	527 3 O
six	531 3 O
were	535 4 O
unclassifiable	540 14 O
.	554 1 O

The	556 3 O
mean	560 4 O
age	565 3 O
of	569 2 O
patients	572 8 O
in	581 2 O
the	584 3 O
16	588 2 O
probable	591 8 O
cases	600 5 O
was	606 3 O
57	610 2 O
.	612 1 O
9	613 1 O
,	614 1 O
with	616 4 O
hepatotoxicity	621 14 B-Disease
being	636 5 O
more	642 4 O
common	647 6 O
in	654 2 O
women	657 5 O
.	662 1 O

The	664 3 O
average	668 7 O
duration	676 8 O
of	685 2 O
treatment	688 9 O
before	698 6 O
the	705 3 O
onset	709 5 O
of	715 2 O
jaundice	718 8 B-Disease
was	727 3 O
61	731 2 O
days	734 4 O
.	738 1 O

None	740 4 O
of	745 2 O
these	748 5 O
well	754 4 O
validated	759 9 O
cases	769 5 O
occurred	775 8 O
within	784 6 O
the	791 3 O
first	795 5 O
10	801 2 O
days	804 4 O
after	809 5 O
treatment	815 9 O
.	824 1 O

The	826 3 O
results	830 7 O
of	838 2 O
serum	841 5 O
liver	847 5 O
function	853 8 O
tests	862 5 O
suggested	868 9 O
hepatocellular	878 14 B-Disease
injury	893 6 I-Disease
in	900 2 O
10	903 2 O
(	906 1 O
63	907 2 O
%	909 1 O
)	910 1 O
;	911 1 O
the	913 3 O
rest	917 4 O
showed	922 6 O
a	929 1 O
mixed	931 5 O
pattern	937 7 O
.	944 1 O

In	946 2 O
contrast	949 8 O
,	957 1 O
the	959 3 O
results	963 7 O
of	971 2 O
histological	974 12 O
examination	987 11 O
of	999 2 O
the	1002 3 O
liver	1006 5 O
often	1012 5 O
showed	1018 6 O
evidence	1025 8 O
of	1034 2 O
cholestasis	1037 11 B-Disease
.	1048 1 O

The	1050 3 O
characteristics	1054 15 O
of	1070 2 O
the	1073 3 O
48	1077 2 O
patients	1080 8 O
in	1089 2 O
the	1092 3 O
possible	1096 8 O
cases	1105 5 O
were	1111 4 O
similar	1116 7 O
.	1123 1 O

Allergic	1125 8 O
manifestations	1134 14 O
such	1149 4 O
as	1154 2 O
rash	1157 4 B-Disease
and	1162 3 O
eosinophilia	1166 12 B-Disease
were	1179 4 O
rare	1184 4 O
.	1188 1 O

Hepatitis	1190 9 B-Disease
was	1200 3 O
usually	1204 7 O
reversible	1212 10 O
when	1223 4 O
treatment	1228 9 O
was	1238 3 O
stopped	1242 7 O
,	1249 1 O
with	1251 4 O
the	1256 3 O
results	1260 7 O
of	1268 2 O
liver	1271 5 O
function	1277 8 O
tests	1286 5 O
returning	1292 9 O
to	1302 2 O
normal	1305 6 O
after	1312 5 O
an	1318 2 O
average	1321 7 O
of	1329 2 O
3	1332 1 O
.	1333 1 O
1	1334 1 O
months	1336 6 O
.	1342 1 O

In	1344 2 O
two	1347 3 O
of	1351 2 O
the	1354 3 O
three	1358 5 O
deaths	1364 6 B-Disease
probably	1371 8 O
associated	1380 10 O
with	1391 4 O
ketoconazole	1396 12 B-Chemical
treatment	1409 9 O
the	1419 3 O
drug	1423 4 O
had	1428 3 O
been	1432 4 O
continued	1437 9 O
after	1447 5 O
the	1453 3 O
onset	1457 5 O
of	1463 2 O
jaundice	1466 8 B-Disease
and	1475 3 O
other	1479 5 O
symptoms	1485 8 O
of	1494 2 O
hepatitis	1497 9 B-Disease
.	1506 1 O

Clinical	1508 8 O
and	1517 3 O
biochemical	1521 11 O
monitoring	1533 10 O
at	1544 2 O
regular	1547 7 O
intervals	1555 9 O
for	1565 3 O
evidence	1569 8 O
of	1578 2 O
hepatitis	1581 9 B-Disease
is	1591 2 O
advised	1594 7 O
during	1602 6 O
long	1609 4 O
term	1614 4 O
treatment	1619 9 O
with	1629 4 O
ketoconazole	1634 12 B-Chemical
to	1647 2 O
prevent	1650 7 O
possible	1658 8 O
serious	1667 7 O
hepatic	1675 7 B-Disease
injury	1683 6 I-Disease
.	1689 1 O

Combined	0 8 O
effects	9 7 O
of	17 2 O
prolonged	20 9 O
prostaglandin	30 13 B-Chemical
E1	44 2 I-Chemical
-	46 1 O
induced	47 7 O
hypotension	55 11 B-Disease
and	67 3 O
haemodilution	71 13 B-Disease
on	85 2 O
human	88 5 O
hepatic	94 7 O
function	102 8 O
.	110 1 O

Combined	112 8 O
effects	121 7 O
of	129 2 O
prolonged	132 9 O
prostaglandin	142 13 B-Chemical
E1	156 2 I-Chemical
(	159 1 O
PGE1	160 4 B-Chemical
)	164 1 O
-	165 1 O
induced	166 7 O
hypotension	174 11 B-Disease
and	186 3 O
haemodilution	190 13 B-Disease
on	204 2 O
hepatic	207 7 O
function	215 8 O
were	224 4 O
studied	229 7 O
in	237 2 O
30	240 2 O
patients	243 8 O
undergoing	252 10 O
hip	263 3 O
surgery	267 7 O
.	274 1 O

The	276 3 O
patients	280 8 O
were	289 4 O
randomly	294 8 O
allocated	303 9 O
to	313 2 O
one	316 3 O
of	320 2 O
three	323 5 O
groups	329 6 O
;	335 1 O
those	337 5 O
in	343 2 O
group	346 5 O
A	352 1 O
(	354 1 O
n	355 1 O
=	357 1 O
10	359 2 O
)	361 1 O
were	363 4 O
subjected	368 9 O
to	378 2 O
controlled	381 10 O
hypotension	392 11 B-Disease
alone	404 5 O
,	409 1 O
those	411 5 O
in	417 2 O
group	420 5 O
B	426 1 O
(	428 1 O
n	429 1 O
=	431 1 O
10	433 2 O
)	435 1 O
to	437 2 O
haemodilution	440 13 B-Disease
alone	454 5 O
and	460 3 O
those	464 5 O
in	470 2 O
group	473 5 O
C	479 1 O
(	481 1 O
n	482 1 O
=	484 1 O
10	486 2 O
)	488 1 O
to	490 2 O
both	493 4 O
controlled	498 10 O
hypotension	509 11 B-Disease
and	521 3 O
haemodilution	525 13 B-Disease
.	538 1 O

Haemodilution	540 13 B-Disease
in	554 2 O
groups	557 6 O
B	564 1 O
and	566 3 O
C	570 1 O
was	572 3 O
produced	576 8 O
by	585 2 O
withdrawing	588 11 O
approximately	600 13 O
1000	614 4 O
mL	619 2 O
of	622 2 O
blood	625 5 O
and	631 3 O
replacing	635 9 O
it	645 2 O
with	648 4 O
the	653 3 O
same	657 4 O
amount	662 6 O
of	669 2 O
dextran	672 7 B-Chemical
solution	680 8 O
,	688 1 O
and	690 3 O
final	694 5 O
haematocrit	700 11 O
values	712 6 O
were	719 4 O
21	724 2 O
or	727 2 O
22	730 2 O
%	732 1 O
.	733 1 O

Controlled	735 10 O
hypotension	746 11 B-Disease
in	758 2 O
groups	761 6 O
A	768 1 O
and	770 3 O
C	774 1 O
was	776 3 O
induced	780 7 O
with	788 4 O
PGE1	793 4 B-Chemical
to	798 2 O
maintain	801 8 O
mean	810 4 O
arterial	815 8 O
blood	824 5 O
pressure	830 8 O
at	839 2 O
55	842 2 O
mmHg	845 4 O
for	850 3 O
180	854 3 O
min	858 3 O
.	861 1 O

Measurements	863 12 O
included	876 8 O
arterial	885 8 O
ketone	894 6 O
body	901 4 O
ratio	906 5 O
(	912 1 O
AKBR	913 4 O
,	917 1 O
aceto	919 5 B-Chemical
-	924 1 I-Chemical
acetate	925 7 I-Chemical
/	932 1 O
3	933 1 B-Chemical
-	934 1 I-Chemical
hydroxybutyrate	935 15 I-Chemical
)	950 1 O
and	952 3 O
clinical	956 8 O
hepatic	965 7 O
function	973 8 O
parameters	982 10 O
.	992 1 O

AKBR	994 4 O
and	999 3 O
biological	1003 10 O
hepatic	1014 7 O
function	1022 8 O
tests	1031 5 O
showed	1037 6 O
no	1044 2 O
change	1047 6 O
throughout	1054 10 O
the	1065 3 O
time	1069 4 O
course	1074 6 O
in	1081 2 O
groups	1084 6 O
A	1091 1 O
and	1093 3 O
B	1097 1 O
.	1098 1 O

In	1100 2 O
group	1103 5 O
C	1109 1 O
,	1110 1 O
AKBR	1112 4 O
showed	1117 6 O
a	1124 1 O
significant	1126 11 O
decrease	1138 8 O
at	1147 2 O
120	1150 3 O
min	1154 3 O
(	1158 1 O
-	1159 1 O
40	1160 2 O
%	1162 1 O
)	1163 1 O
and	1165 3 O
at	1169 2 O
180	1172 3 O
min	1176 3 O
(	1180 1 O
-	1181 1 O
49	1182 2 O
%	1184 1 O
)	1185 1 O
after	1187 5 O
the	1193 3 O
start	1197 5 O
of	1203 2 O
hypotension	1206 11 B-Disease
and	1218 3 O
at	1222 2 O
60	1225 2 O
min	1228 3 O
(	1232 1 O
-	1233 1 O
32	1234 2 O
%	1236 1 O
)	1237 1 O
after	1239 5 O
recovery	1245 8 O
of	1254 2 O
normotension	1257 12 O
,	1269 1 O
and	1271 3 O
SGOT	1275 4 O
,	1279 1 O
SGPT	1281 4 O
,	1285 1 O
LDH	1287 3 O
and	1291 3 O
total	1295 5 O
bilirubin	1301 9 B-Chemical
showed	1311 6 O
significant	1318 11 O
increases	1330 9 O
after	1340 5 O
operation	1346 9 O
.	1355 1 O

The	1357 3 O
results	1361 7 O
suggest	1369 7 O
that	1377 4 O
a	1382 1 O
prolonged	1384 9 O
combination	1394 11 O
of	1406 2 O
more	1409 4 O
than	1414 4 O
120	1419 3 O
min	1423 3 O
of	1427 2 O
PGE1	1430 4 B-Chemical
-	1434 1 O
induced	1435 7 O
hypotension	1443 11 B-Disease
and	1455 3 O
moderate	1459 8 O
haemodilution	1468 13 B-Disease
would	1482 5 O
cause	1488 5 O
impairment	1494 10 B-Disease
of	1505 2 I-Disease
hepatic	1508 7 I-Disease
function	1516 8 I-Disease
.	1524 1 O

Levodopa	0 8 B-Chemical
-	8 1 O
induced	9 7 O
dyskinesias	17 11 B-Disease
in	29 2 O
patients	32 8 O
with	41 4 O
Parkinson	46 9 B-Disease
'	55 1 I-Disease
s	56 1 I-Disease
disease	58 7 I-Disease
:	65 1 O
filling	67 7 O
the	75 3 O
bench	79 5 O
-	84 1 O
to	85 2 O
-	87 1 O
bedside	88 7 O
gap	96 3 O
.	99 1 O

Levodopa	101 8 B-Chemical
is	110 2 O
the	113 3 O
most	117 4 O
effective	122 9 O
drug	132 4 O
for	137 3 O
the	141 3 O
treatment	145 9 O
of	155 2 O
Parkinson	158 9 B-Disease
'	167 1 I-Disease
s	168 1 I-Disease
disease	170 7 I-Disease
.	177 1 O

However	179 7 O
,	186 1 O
the	188 3 O
long	192 4 O
-	196 1 O
term	197 4 O
use	202 3 O
of	206 2 O
this	209 4 O
dopamine	214 8 B-Chemical
precursor	223 9 O
is	233 2 O
complicated	236 11 O
by	248 2 O
highly	251 6 O
disabling	258 9 O
fluctuations	268 12 O
and	281 3 O
dyskinesias	285 11 B-Disease
.	296 1 O

Although	298 8 O
preclinical	307 11 O
and	319 3 O
clinical	323 8 O
findings	332 8 O
suggest	341 7 O
pulsatile	349 9 O
stimulation	359 11 O
of	371 2 O
striatal	374 8 O
postsynaptic	383 12 O
receptors	396 9 O
as	406 2 O
a	409 1 O
key	411 3 O
mechanism	415 9 O
underlying	425 10 O
levodopa	436 8 B-Chemical
-	444 1 O
induced	445 7 O
dyskinesias	453 11 B-Disease
,	464 1 O
their	466 5 O
pathogenesis	472 12 O
is	485 2 O
still	488 5 O
unclear	494 7 O
.	501 1 O

In	503 2 O
recent	506 6 O
years	513 5 O
,	518 1 O
evidence	520 8 O
from	529 4 O
animal	534 6 O
models	541 6 O
of	548 2 O
Parkinson	551 9 B-Disease
'	560 1 I-Disease
s	561 1 I-Disease
disease	563 7 I-Disease
has	571 3 O
provided	575 8 O
important	584 9 O
information	594 11 O
to	606 2 O
understand	609 10 O
the	620 3 O
effect	624 6 O
of	631 2 O
specific	634 8 O
receptor	643 8 O
and	652 3 O
post	656 4 O
-	660 1 O
receptor	661 8 O
molecular	670 9 O
mechanisms	680 10 O
underlying	691 10 O
the	702 3 O
development	706 11 O
of	718 2 O
dyskinetic	721 10 B-Disease
movements	732 9 I-Disease
.	741 1 O

Recent	743 6 O
preclinical	750 11 O
and	762 3 O
clinical	766 8 O
data	775 4 O
from	780 4 O
promising	785 9 O
lines	795 5 O
of	801 2 O
research	804 8 O
focus	813 5 O
on	819 2 O
the	822 3 O
differential	826 12 O
role	839 4 O
of	844 2 O
presynaptic	847 11 O
versus	859 6 O
postsynaptic	866 12 O
mechanisms	879 10 O
,	889 1 O
dopamine	891 8 B-Chemical
receptor	900 8 O
subtypes	909 8 O
,	917 1 O
ionotropic	919 10 O
and	930 3 O
metabotropic	934 12 O
glutamate	947 9 B-Chemical
receptors	957 9 O
,	966 1 O
and	968 3 O
non	972 3 O
-	975 1 O
dopaminergic	976 12 O
neurotransmitter	989 16 O
systems	1006 7 O
in	1014 2 O
the	1017 3 O
pathophysiology	1021 15 O
of	1037 2 O
levodopa	1040 8 B-Chemical
-	1048 1 O
induced	1049 7 O
dyskinesias	1057 11 B-Disease
.	1068 1 O

Prevention	0 10 O
of	11 2 O
seizures	14 8 B-Disease
and	23 3 O
reorganization	27 14 O
of	42 2 O
hippocampal	45 11 O
functions	57 9 O
by	67 2 O
transplantation	70 15 O
of	86 2 O
bone	89 4 O
marrow	94 6 O
cells	101 5 O
in	107 2 O
the	110 3 O
acute	114 5 O
phase	120 5 O
of	126 2 O
experimental	129 12 O
epilepsy	142 8 B-Disease
.	150 1 O

In	152 2 O
this	155 4 O
study	160 5 O
,	165 1 O
we	167 2 O
investigated	170 12 O
the	183 3 O
therapeutic	187 11 O
potential	199 9 O
of	209 2 O
bone	212 4 O
marrow	217 6 O
mononuclear	224 11 O
cells	236 5 O
(	242 1 O
BMCs	243 4 O
)	247 1 O
in	249 2 O
a	252 1 O
model	254 5 O
of	260 2 O
epilepsy	263 8 B-Disease
induced	272 7 O
by	280 2 O
pilocarpine	283 11 B-Chemical
in	295 2 O
rats	298 4 O
.	302 1 O

BMCs	304 4 O
obtained	309 8 O
from	318 4 O
green	323 5 O
fluorescent	329 11 O
protein	341 7 O
(	349 1 O
GFP	350 3 O
)	353 1 O
transgenic	355 10 O
mice	366 4 O
or	371 2 O
rats	374 4 O
were	379 4 O
transplanted	384 12 O
intravenously	397 13 O
after	411 5 O
induction	417 9 O
of	427 2 O
status	430 6 B-Disease
epilepticus	437 11 I-Disease
(	449 1 O
SE	450 2 B-Disease
)	452 1 O
.	453 1 O

Spontaneous	455 11 B-Disease
recurrent	467 9 I-Disease
seizures	477 8 I-Disease
(	486 1 O
SRS	487 3 B-Disease
)	490 1 O
were	492 4 O
monitored	497 9 O
using	507 5 O
Racine	513 6 O
'	519 1 O
s	520 1 O
seizure	522 7 B-Disease
severity	530 8 O
scale	539 5 O
.	544 1 O

All	546 3 O
of	550 2 O
the	553 3 O
rats	557 4 O
in	562 2 O
the	565 3 O
saline	569 6 O
-	575 1 O
treated	576 7 O
epileptic	584 9 B-Disease
control	594 7 O
group	602 5 O
developed	608 9 O
SRS	618 3 B-Disease
,	621 1 O
whereas	623 7 O
none	631 4 O
of	636 2 O
the	639 3 O
BMC	643 3 O
-	646 1 O
treated	647 7 O
epileptic	655 9 B-Disease
animals	665 7 O
had	673 3 O
seizures	677 8 B-Disease
in	686 2 O
the	689 3 O
short	693 5 O
term	699 4 O
(	704 1 O
15	705 2 O
days	708 4 O
after	713 5 O
transplantation	719 15 O
)	734 1 O
,	735 1 O
regardless	737 10 O
of	748 2 O
the	751 3 O
BMC	755 3 O
source	759 6 O
.	765 1 O

Over	767 4 O
the	772 3 O
long	776 4 O
-	780 1 O
term	781 4 O
chronic	786 7 O
phase	794 5 O
(	800 1 O
120	801 3 O
days	805 4 O
after	810 5 O
transplantation	816 15 O
)	831 1 O
,	832 1 O
only	834 4 O
25	839 2 O
%	841 1 O
of	843 2 O
BMC	846 3 O
-	849 1 O
treated	850 7 O
epileptic	858 9 B-Disease
animals	868 7 O
had	876 3 O
seizures	880 8 B-Disease
,	888 1 O
but	890 3 O
with	894 4 O
a	899 1 O
lower	901 5 O
frequency	907 9 O
and	917 3 O
duration	921 8 O
compared	930 8 O
to	939 2 O
the	942 3 O
epileptic	946 9 B-Disease
control	956 7 O
group	964 5 O
.	969 1 O

The	971 3 O
density	975 7 O
of	983 2 O
hippocampal	986 11 O
neurons	998 7 O
in	1006 2 O
the	1009 3 O
brains	1013 6 O
of	1020 2 O
animals	1023 7 O
treated	1031 7 O
with	1039 4 O
BMCs	1044 4 O
was	1049 3 O
markedly	1053 8 O
preserved	1062 9 O
.	1071 1 O

At	1073 2 O
hippocampal	1076 11 O
Schaeffer	1088 9 O
collateral	1098 10 O
-	1108 1 O
CA1	1109 3 O
synapses	1113 8 O
,	1121 1 O
long	1123 4 O
-	1127 1 O
term	1128 4 O
potentiation	1133 12 O
was	1146 3 O
preserved	1150 9 O
in	1160 2 O
BMC	1163 3 O
-	1166 1 O
transplanted	1167 12 O
rats	1180 4 O
compared	1185 8 O
to	1194 2 O
epileptic	1197 9 B-Disease
controls	1207 8 O
.	1215 1 O

The	1217 3 O
donor	1221 5 O
-	1226 1 O
derived	1227 7 O
GFP	1235 3 O
(	1238 1 O
+	1239 1 O
)	1240 1 O
cells	1242 5 O
were	1248 4 O
rarely	1253 6 O
found	1260 5 O
in	1266 2 O
the	1269 3 O
brains	1273 6 O
of	1280 2 O
transplanted	1283 12 O
epileptic	1296 9 B-Disease
rats	1306 4 O
.	1310 1 O

In	1312 2 O
conclusion	1315 10 O
,	1325 1 O
treatment	1327 9 O
with	1337 4 O
BMCs	1342 4 O
can	1347 3 O
prevent	1351 7 O
the	1359 3 O
development	1363 11 O
of	1375 2 O
chronic	1378 7 O
seizures	1386 8 B-Disease
,	1394 1 O
reduce	1396 6 O
neuronal	1403 8 B-Disease
loss	1412 4 I-Disease
,	1416 1 O
and	1418 3 O
influence	1422 9 O
the	1432 3 O
reorganization	1436 14 O
of	1451 2 O
the	1454 3 O
hippocampal	1458 11 O
neuronal	1470 8 O
network	1479 7 O
.	1486 1 O

Cardioprotective	0 16 O
effect	17 6 O
of	24 2 O
salvianolic	27 11 B-Chemical
acid	39 4 I-Chemical
A	44 1 I-Chemical
on	46 2 O
isoproterenol	49 13 B-Chemical
-	62 1 O
induced	63 7 O
myocardial	71 10 B-Disease
infarction	82 10 I-Disease
in	93 2 O
rats	96 4 O
.	100 1 O

The	102 3 O
present	106 7 O
study	114 5 O
was	120 3 O
designed	124 8 O
to	133 2 O
evaluate	136 8 O
the	145 3 O
cardioprotective	149 16 O
potential	166 9 O
of	176 2 O
salvianolic	179 11 B-Chemical
acid	191 4 I-Chemical
A	196 1 I-Chemical
on	198 2 O
isoproterenol	201 13 B-Chemical
-	214 1 O
induced	215 7 O
myocardial	223 10 B-Disease
infarction	234 10 I-Disease
in	245 2 O
rats	248 4 O
.	252 1 O

Hemodynamic	254 11 O
parameters	266 10 O
and	277 3 O
lead	281 4 O
II	286 2 O
electrocardiograph	289 18 O
were	308 4 O
monitored	313 9 O
and	323 3 O
recorded	327 8 O
continuously	336 12 O
.	348 1 O

Cardiac	350 7 O
marker	358 6 O
enzymes	365 7 O
and	373 3 O
antioxidative	377 13 O
parameters	391 10 O
in	402 2 O
serum	405 5 O
and	411 3 O
heart	415 5 O
tissues	421 7 O
were	429 4 O
measured	434 8 O
.	442 1 O

Assay	444 5 O
for	450 3 O
mitochondrial	454 13 O
respiratory	468 11 O
function	480 8 O
and	489 3 O
histopathological	493 17 O
examination	511 11 O
of	523 2 O
heart	526 5 O
tissues	532 7 O
were	540 4 O
performed	545 9 O
.	554 1 O

Isoproterenol	556 13 B-Chemical
-	569 1 O
treated	570 7 O
rats	578 4 O
showed	583 6 O
significant	590 11 O
increases	602 9 O
in	612 2 O
the	615 3 O
levels	619 6 O
of	626 2 O
lactate	629 7 B-Chemical
dehydrogenase	637 13 O
,	650 1 O
aspartate	652 9 B-Chemical
transaminase	662 12 O
,	674 1 O
creatine	676 8 B-Chemical
kinase	685 6 O
and	692 3 O
malondialdehyde	696 15 B-Chemical
and	712 3 O
significant	716 11 O
decreases	728 9 O
in	738 2 O
the	741 3 O
activities	745 10 O
of	756 2 O
superoxide	759 10 B-Chemical
dismutase	770 9 O
,	779 1 O
catalase	781 8 O
and	790 3 O
glutathione	794 11 B-Chemical
peroxidase	806 10 O
in	817 2 O
serum	820 5 O
and	826 3 O
heart	830 5 O
.	835 1 O

These	837 5 O
rats	843 4 O
also	848 4 O
showed	853 6 O
declines	860 8 O
in	869 2 O
left	872 4 O
ventricular	877 11 O
systolic	889 8 O
pressure	898 8 O
,	906 1 O
maximum	908 7 O
and	916 3 O
minimum	920 7 O
rate	928 4 O
of	933 2 O
developed	936 9 O
left	946 4 O
ventricular	951 11 O
pressure	963 8 O
,	971 1 O
and	973 3 O
elevation	977 9 O
of	987 2 O
left	990 4 O
ventricular	995 11 O
end	1007 3 O
-	1010 1 O
diastolic	1011 9 O
pressure	1021 8 O
and	1030 3 O
ST	1034 2 O
-	1036 1 O
segment	1037 7 O
.	1044 1 O

In	1046 2 O
addition	1049 8 O
,	1057 1 O
mitochondrial	1059 13 O
respiratory	1073 11 B-Disease
dysfunction	1085 11 I-Disease
characterized	1097 13 O
by	1111 2 O
decreased	1114 9 O
respiratory	1124 11 O
control	1136 7 O
ratio	1144 5 O
and	1150 3 O
ADP	1154 3 B-Chemical
/	1157 1 O
O	1158 1 O
was	1160 3 O
observed	1164 8 O
in	1173 2 O
isoproterenol	1176 13 B-Chemical
-	1189 1 O
treated	1190 7 O
rats	1198 4 O
.	1202 1 O

Administration	1204 14 O
of	1219 2 O
salvianolic	1222 11 B-Chemical
acid	1234 4 I-Chemical
A	1239 1 I-Chemical
for	1241 3 O
a	1245 1 O
period	1247 6 O
of	1254 2 O
8	1257 1 O
days	1259 4 O
significantly	1264 13 O
attenuated	1278 10 O
isoproterenol	1289 13 B-Chemical
-	1302 1 O
induced	1303 7 O
cardiac	1311 7 B-Disease
dysfunction	1319 11 I-Disease
and	1331 3 O
myocardial	1335 10 B-Disease
injury	1346 6 I-Disease
and	1353 3 O
improved	1357 8 O
mitochondrial	1366 13 O
respiratory	1380 11 O
function	1392 8 O
.	1400 1 O

The	1402 3 O
protective	1406 10 O
role	1417 4 O
of	1422 2 O
salvianolic	1425 11 B-Chemical
acid	1437 4 I-Chemical
A	1442 1 I-Chemical
against	1444 7 O
isoproterenol	1452 13 B-Chemical
-	1465 1 O
induced	1466 7 O
myocardial	1474 10 B-Disease
damage	1485 6 I-Disease
was	1492 3 O
further	1496 7 O
confirmed	1504 9 O
by	1514 2 O
histopathological	1517 17 O
examination	1535 11 O
.	1546 1 O

The	1548 3 O
results	1552 7 O
of	1560 2 O
our	1563 3 O
study	1567 5 O
suggest	1573 7 O
that	1581 4 O
salvianolic	1586 11 B-Chemical
acid	1598 4 I-Chemical
A	1603 1 I-Chemical
possessing	1605 10 O
antioxidant	1616 11 O
activity	1628 8 O
has	1637 3 O
a	1641 1 O
significant	1643 11 O
protective	1655 10 O
effect	1666 6 O
against	1673 7 O
isoproterenol	1681 13 B-Chemical
-	1694 1 O
induced	1695 7 O
myocardial	1703 10 B-Disease
infarction	1714 10 I-Disease
.	1724 1 O

Acute	0 5 O
effects	6 7 O
of	14 2 O
N	17 1 B-Chemical
-	18 1 I-Chemical
(	19 1 I-Chemical
2	20 1 I-Chemical
-	21 1 I-Chemical
propylpentanoyl	22 15 I-Chemical
)	37 1 I-Chemical
urea	38 4 I-Chemical
on	43 2 O
hippocampal	46 11 O
amino	58 5 B-Chemical
acid	64 4 I-Chemical
neurotransmitters	69 17 O
in	87 2 O
pilocarpine	90 11 B-Chemical
-	101 1 O
induced	102 7 O
seizure	110 7 B-Disease
in	118 2 O
rats	121 4 O
.	125 1 O

The	127 3 O
present	131 7 O
study	139 5 O
aimed	145 5 O
to	151 2 O
investigate	154 11 O
the	166 3 O
anticonvulsant	170 14 O
activity	185 8 O
as	194 2 O
well	197 4 O
as	202 2 O
the	205 3 O
effects	209 7 O
on	217 2 O
the	220 3 O
level	224 5 O
of	230 2 O
hippocampal	233 11 O
amino	245 5 B-Chemical
acid	251 4 I-Chemical
neurotransmitters	256 17 O
(	274 1 O
glutamate	275 9 B-Chemical
,	284 1 O
aspartate	286 9 B-Chemical
,	295 1 O
glycine	297 7 B-Chemical
and	305 3 O
GABA	309 4 B-Chemical
)	313 1 O
of	315 2 O
N	318 1 B-Chemical
-	319 1 I-Chemical
(	320 1 I-Chemical
2	321 1 I-Chemical
-	322 1 I-Chemical
propylpentanoyl	323 15 I-Chemical
)	338 1 I-Chemical
urea	339 4 I-Chemical
(	344 1 O
VPU	345 3 B-Chemical
)	348 1 O
in	350 2 O
comparison	353 10 O
to	364 2 O
its	367 3 O
parent	371 6 O
compound	378 8 O
,	386 1 O
valproic	388 8 B-Chemical
acid	397 4 I-Chemical
(	402 1 O
VPA	403 3 B-Chemical
)	406 1 O
.	407 1 O

VPU	409 3 B-Chemical
was	413 3 O
more	417 4 O
potent	422 6 O
than	429 4 O
VPA	434 3 B-Chemical
,	437 1 O
exhibiting	439 10 O
the	450 3 O
median	454 6 O
effective	461 9 O
dose	471 4 O
(	476 1 O
ED	477 2 O
(	479 1 O
50	480 2 O
)	482 1 O
)	483 1 O
of	485 2 O
49	488 2 O
mg	491 2 O
/	493 1 O
kg	494 2 O
in	497 2 O
protecting	500 10 O
rats	511 4 O
against	516 7 O
pilocarpine	524 11 B-Chemical
-	535 1 O
induced	536 7 O
seizure	544 7 B-Disease
whereas	552 7 O
the	560 3 O
corresponding	564 13 O
value	578 5 O
for	584 3 O
VPA	588 3 B-Chemical
was	592 3 O
322	596 3 O
mg	600 2 O
/	602 1 O
kg	603 2 O
.	605 1 O

In	607 2 O
vivo	610 4 O
microdialysis	615 13 O
demonstrated	629 12 O
that	642 4 O
an	647 2 O
intraperitoneal	650 15 O
administration	666 14 O
of	681 2 O
pilocarpine	684 11 B-Chemical
induced	696 7 O
a	704 1 O
pronounced	706 10 O
increment	717 9 O
of	727 2 O
hippocampal	730 11 O
glutamate	742 9 B-Chemical
and	752 3 O
aspartate	756 9 B-Chemical
whereas	766 7 O
no	774 2 O
significant	777 11 O
change	789 6 O
was	796 3 O
observed	800 8 O
on	809 2 O
the	812 3 O
level	816 5 O
of	822 2 O
glycine	825 7 B-Chemical
and	833 3 O
GABA	837 4 B-Chemical
.	841 1 O

Pretreatment	843 12 O
with	856 4 O
either	861 6 O
VPU	868 3 B-Chemical
(	872 1 O
50	873 2 O
and	876 3 O
100	880 3 O
mg	884 2 O
/	886 1 O
kg	887 2 O
)	889 1 O
or	891 2 O
VPA	894 3 B-Chemical
(	898 1 O
300	899 3 O
and	903 3 O
600	907 3 O
mg	911 2 O
/	913 1 O
kg	914 2 O
)	916 1 O
completely	918 10 O
abolished	929 9 O
pilocarpine	939 11 B-Chemical
-	950 1 O
evoked	951 6 O
increases	958 9 O
in	968 2 O
extracellular	971 13 O
glutamate	985 9 B-Chemical
and	995 3 O
aspartate	999 9 B-Chemical
.	1008 1 O

In	1010 2 O
addition	1013 8 O
,	1021 1 O
a	1023 1 O
statistically	1025 13 O
significant	1039 11 O
reduction	1051 9 O
was	1061 3 O
also	1065 4 O
observed	1070 8 O
on	1079 2 O
the	1082 3 O
level	1086 5 O
of	1092 2 O
GABA	1095 4 B-Chemical
and	1100 3 O
glycine	1104 7 B-Chemical
but	1112 3 O
less	1116 4 O
than	1121 4 O
a	1126 1 O
drastic	1128 7 O
reduction	1136 9 O
of	1146 2 O
glutamate	1149 9 B-Chemical
and	1159 3 O
aspartate	1163 9 B-Chemical
level	1173 5 O
.	1178 1 O

Based	1180 5 O
on	1186 2 O
the	1189 3 O
finding	1193 7 O
that	1201 4 O
VPU	1206 3 B-Chemical
and	1210 3 O
VPA	1214 3 B-Chemical
could	1218 5 O
protect	1224 7 O
the	1232 3 O
animals	1236 7 O
against	1244 7 O
pilocarpine	1252 11 B-Chemical
-	1263 1 O
induced	1264 7 O
seizure	1272 7 B-Disease
it	1280 2 O
is	1283 2 O
suggested	1286 9 O
that	1296 4 O
the	1301 3 O
reduction	1305 9 O
of	1315 2 O
inhibitory	1318 10 O
amino	1329 5 B-Chemical
acid	1335 4 I-Chemical
neurotransmitters	1340 17 O
was	1358 3 O
comparatively	1362 13 O
minor	1376 5 O
and	1382 3 O
offset	1386 6 O
by	1393 2 O
a	1396 1 O
pronounced	1398 10 O
reduction	1409 9 O
of	1419 2 O
glutamate	1422 9 B-Chemical
and	1432 3 O
aspartate	1436 9 B-Chemical
.	1445 1 O

Therefore	1447 9 O
,	1456 1 O
like	1458 4 O
VPA	1463 3 B-Chemical
,	1466 1 O
the	1468 3 O
finding	1472 7 O
that	1480 4 O
VPU	1485 3 B-Chemical
could	1489 5 O
drastically	1495 11 O
reduce	1507 6 O
pilocarpine	1514 11 B-Chemical
-	1525 1 O
induced	1526 7 O
increases	1534 9 O
in	1544 2 O
glutamate	1547 9 B-Chemical
and	1557 3 O
aspartate	1561 9 B-Chemical
should	1571 6 O
account	1578 7 O
,	1585 1 O
at	1587 2 O
least	1590 5 O
partly	1596 6 O
,	1602 1 O
for	1604 3 O
its	1608 3 O
anticonvulsant	1612 14 O
activity	1627 8 O
observed	1636 8 O
in	1645 2 O
pilocarpine	1648 11 B-Chemical
-	1659 1 O
induced	1660 7 O
seizure	1668 7 B-Disease
in	1676 2 O
experimental	1679 12 O
animals	1692 7 O
.	1699 1 O

Some	1701 4 O
other	1706 5 O
mechanism	1712 9 O
than	1722 4 O
those	1727 5 O
being	1733 5 O
reported	1739 8 O
herein	1748 6 O
should	1755 6 O
be	1762 2 O
further	1765 7 O
investigated	1773 12 O
.	1785 1 O

Acute	0 5 O
hepatitis	6 9 B-Disease
attack	16 6 O
after	23 5 O
exposure	29 8 O
to	38 2 O
telithromycin	41 13 B-Chemical
.	54 1 O

INTRODUCTION	56 12 O
:	68 1 O
Antibiotic	70 10 O
-	80 1 O
associated	81 10 O
hepatotoxicity	92 14 B-Disease
is	107 2 O
rare	110 4 O
.	114 1 O

With	116 4 O
widespread	121 10 O
use	132 3 O
of	136 2 O
antimicrobial	139 13 O
agents	153 6 O
,	159 1 O
however	161 7 O
,	168 1 O
hepatic	170 7 B-Disease
injury	178 6 I-Disease
occurs	185 6 O
frequently	192 10 O
,	202 1 O
and	204 3 O
among	208 5 O
adverse	214 7 B-Disease
drug	222 4 I-Disease
reactions	227 9 I-Disease
,	236 1 O
idiosyncratic	238 13 O
reactions	252 9 O
are	262 3 O
the	266 3 O
most	270 4 O
serious	275 7 O
.	282 1 O

CASE	284 4 O
SUMMARY	289 7 O
:	296 1 O
A	298 1 O
25	300 2 O
-	302 1 O
year	303 4 O
-	307 1 O
old	308 3 O
male	312 4 O
patient	317 7 O
,	324 1 O
with	326 4 O
a	331 1 O
height	333 6 O
of	340 2 O
175	343 3 O
cm	347 2 O
and	350 3 O
weight	354 6 O
of	361 2 O
72	364 2 O
kg	367 2 O
presented	370 9 O
to	380 2 O
Marmara	383 7 O
University	391 10 O
Hospital	402 8 O
Emergency	411 9 O
Department	421 10 O
,	431 1 O
Istanbul	433 8 O
,	441 1 O
Turkey	443 6 O
,	449 1 O
with	451 4 O
5	456 1 O
days	458 4 O
'	462 1 O
history	464 7 O
of	472 2 O
jaundice	475 8 B-Disease
,	483 1 O
malaise	485 7 O
,	492 1 O
nausea	494 6 B-Disease
,	500 1 O
and	502 3 O
vomiting	506 8 B-Disease
.	514 1 O

He	516 2 O
had	519 3 O
been	523 4 O
prescribed	528 10 O
telithromycin	539 13 B-Chemical
400	553 3 O
mg	557 2 O
/	559 1 O
d	560 1 O
PO	562 2 O
to	565 2 O
treat	568 5 O
an	574 2 O
upper	577 5 B-Disease
respiratory	583 11 I-Disease
tract	595 5 I-Disease
infection	601 9 I-Disease
7	611 1 O
days	613 4 O
prior	618 5 O
.	623 1 O

Admission	625 9 O
laboratory	635 10 O
tests	646 5 O
were	652 4 O
as	657 2 O
follows	660 7 O
:	667 1 O
alanine	669 7 B-Chemical
aminotransferase	677 16 O
,	693 1 O
67	695 2 O
U	698 1 O
/	699 1 O
L	700 1 O
(	702 1 O
reference	703 9 O
range	713 5 O
,	718 1 O
10	720 2 O
-	722 1 O
37	723 2 O
U	726 1 O
/	727 1 O
L	728 1 O
)	729 1 O
;	730 1 O
aspartate	732 9 B-Chemical
aminotransferase	742 16 O
,	758 1 O
98	760 2 O
U	763 1 O
/	764 1 O
L	765 1 O
(	767 1 O
10	768 2 O
-	770 1 O
40	771 2 O
U	774 1 O
/	775 1 O
L	776 1 O
)	777 1 O
;	778 1 O
alkaline	780 8 O
phosphatase	789 11 O
,	800 1 O
513	802 3 O
U	806 1 O
/	807 1 O
L	808 1 O
(	810 1 O
0	811 1 O
-	812 1 O
270	813 3 O
U	817 1 O
/	818 1 O
L	819 1 O
)	820 1 O
;	821 1 O
gamma	823 5 O
-	828 1 O
glutamyltransferase	829 19 O
,	848 1 O
32	850 2 O
U	853 1 O
/	854 1 O
L	855 1 O
(	857 1 O
7	858 1 O
-	859 1 O
49	860 2 O
U	863 1 O
/	864 1 O
L	865 1 O
)	866 1 O
;	867 1 O
amylase	869 7 O
,	876 1 O
46	878 2 O
U	881 1 O
/	882 1 O
L	883 1 O
(	885 1 O
0	886 1 O
-	887 1 O
220	888 3 O
U	892 1 O
/	893 1 O
L	894 1 O
)	895 1 O
;	896 1 O
total	898 5 O
bilirubin	904 9 B-Chemical
,	913 1 O
20	915 2 O
.	917 1 O
1	918 1 O
mg	920 2 O
/	922 1 O
dL	923 2 O
(	926 1 O
0	927 1 O
.	928 1 O
2	929 1 O
-	930 1 O
1	931 1 O
.	932 1 O
0	933 1 O
mg	935 2 O
/	937 1 O
dL	938 2 O
)	940 1 O
;	941 1 O
direct	943 6 O
bilirubin	950 9 B-Chemical
,	959 1 O
14	961 2 O
.	963 1 O
8	964 1 O
mg	966 2 O
/	968 1 O
dL	969 2 O
(	972 1 O
0	973 1 O
-	974 1 O
0	975 1 O
.	976 1 O
3	977 1 O
mg	979 2 O
/	981 1 O
dL	982 2 O
)	984 1 O
;	985 1 O
and	987 3 O
albumin	991 7 O
,	998 1 O
4	1000 1 O
.	1001 1 O
7	1002 1 O
mg	1004 2 O
/	1006 1 O
dL	1007 2 O
(	1010 1 O
3	1011 1 O
.	1012 1 O
5	1013 1 O
-	1014 1 O
5	1015 1 O
.	1016 1 O
4	1017 1 O
mg	1019 2 O
/	1021 1 O
dL	1022 2 O
)	1024 1 O
.	1025 1 O

No	1027 2 O
toxin	1030 5 O
,	1035 1 O
alcohol	1037 7 B-Chemical
,	1044 1 O
or	1046 2 O
other	1049 5 O
drugs	1055 5 O
were	1061 4 O
reported	1066 8 O
.	1074 1 O

The	1076 3 O
patient	1080 7 O
had	1088 3 O
suffered	1092 8 O
a	1101 1 O
previous	1103 8 O
episode	1112 7 O
of	1120 2 O
"	1123 1 O
acute	1124 5 O
hepatitis	1130 9 B-Disease
of	1140 2 O
unknown	1143 7 O
origin	1151 6 O
,	1157 1 O
"	1158 1 O
that	1160 4 O
occurred	1165 8 O
after	1174 5 O
telithromycin	1180 13 B-Chemical
usage	1194 5 O
.	1199 1 O

Both	1201 4 O
incidents	1206 9 O
occurred	1216 8 O
within	1225 6 O
a	1232 1 O
year	1234 4 O
.	1238 1 O

DISCUSSION	1240 10 O
:	1250 1 O
Telithromycin	1252 13 B-Chemical
is	1266 2 O
the	1269 3 O
first	1273 5 O
of	1279 2 O
the	1282 3 O
ketolide	1286 8 O
antibacterials	1295 14 O
to	1310 2 O
receive	1313 7 O
US	1321 2 O
Food	1324 4 O
and	1329 3 O
Drug	1333 4 O
Administration	1338 14 O
approval	1353 8 O
for	1362 3 O
clinical	1366 8 O
use	1375 3 O
.	1378 1 O

It	1380 2 O
has	1383 3 O
been	1387 4 O
associated	1392 10 O
with	1403 4 O
infrequent	1408 10 O
and	1419 3 O
usually	1423 7 O
reversible	1431 10 O
severe	1442 6 O
hepatic	1449 7 B-Disease
dysfunction	1457 11 I-Disease
.	1468 1 O

Based	1470 5 O
on	1476 2 O
a	1479 1 O
score	1481 5 O
of	1487 2 O
8	1490 1 O
on	1492 2 O
the	1495 3 O
Naranjo	1499 7 O
adverse	1507 7 B-Disease
drug	1515 4 I-Disease
reaction	1520 8 I-Disease
probability	1529 11 O
scale	1541 5 O
,	1546 1 O
telithromycin	1548 13 B-Chemical
was	1562 3 O
the	1566 3 O
probable	1570 8 O
cause	1579 5 O
of	1585 2 O
acute	1588 5 O
hepatitis	1594 9 B-Disease
in	1604 2 O
this	1607 4 O
patient	1612 7 O
,	1619 1 O
and	1621 3 O
pathological	1625 12 O
findings	1638 8 O
suggested	1647 9 O
drug	1657 4 O
-	1661 1 O
induced	1662 7 O
toxic	1670 5 B-Disease
hepatitis	1676 9 I-Disease
.	1685 1 O

Recurrence	1687 10 O
of	1698 2 O
hepatitis	1701 9 B-Disease
attack	1711 6 O
might	1718 5 O
have	1724 4 O
been	1729 4 O
avoided	1734 7 O
if	1742 2 O
the	1745 3 O
initial	1749 7 O
incident	1757 8 O
had	1766 3 O
been	1770 4 O
communicated	1775 12 O
to	1788 2 O
the	1791 3 O
attending	1795 9 O
physician	1805 9 O
who	1815 3 O
prescribed	1819 10 O
telithromycin	1830 13 B-Chemical
the	1844 3 O
second	1848 6 O
time	1855 4 O
.	1859 1 O

CONCLUSION	1861 10 O
:	1871 1 O
Here	1873 4 O
we	1878 2 O
report	1881 6 O
a	1888 1 O
case	1890 4 O
of	1895 2 O
acute	1898 5 O
hepatitis	1904 9 B-Disease
probably	1914 8 O
associated	1923 10 O
with	1934 4 O
the	1939 3 O
administration	1943 14 O
of	1958 2 O
telithromycin	1961 13 B-Chemical
.	1974 1 O

Spironolactone	0 14 B-Chemical
-	14 1 O
induced	15 7 O
renal	23 5 B-Disease
insufficiency	29 13 I-Disease
and	43 3 O
hyperkalemia	47 12 B-Disease
in	60 2 O
patients	63 8 O
with	72 4 O
heart	77 5 B-Disease
failure	83 7 I-Disease
.	90 1 O

BACKGROUND	92 10 O
:	102 1 O
A	104 1 O
previous	106 8 O
randomized	115 10 O
controlled	126 10 O
trial	137 5 O
evaluating	143 10 O
the	154 3 O
use	158 3 O
of	162 2 O
spironolactone	165 14 B-Chemical
in	180 2 O
heart	183 5 B-Disease
failure	189 7 I-Disease
patients	197 8 O
reported	206 8 O
a	215 1 O
low	217 3 O
risk	221 4 O
of	226 2 O
hyperkalemia	229 12 B-Disease
(	242 1 O
2	243 1 O
%	244 1 O
)	245 1 O
and	247 3 O
renal	251 5 B-Disease
insufficiency	257 13 I-Disease
(	271 1 O
0	272 1 O
%	273 1 O
)	274 1 O
.	275 1 O

Because	277 7 O
treatments	285 10 O
for	296 3 O
heart	300 5 B-Disease
failure	306 7 I-Disease
have	314 4 O
changed	319 7 O
since	327 5 O
the	333 3 O
benefits	337 8 O
of	346 2 O
spironolactone	349 14 B-Chemical
were	364 4 O
reported	369 8 O
,	377 1 O
the	379 3 O
prevalence	383 10 O
of	394 2 O
these	397 5 O
complications	403 13 O
may	417 3 O
differ	421 6 O
in	428 2 O
current	431 7 O
clinical	439 8 O
practice	448 8 O
.	456 1 O

We	458 2 O
therefore	461 9 O
sought	471 6 O
to	478 2 O
determine	481 9 O
the	491 3 O
prevalence	495 10 O
and	506 3 O
clinical	510 8 O
associations	519 12 O
of	532 2 O
hyperkalemia	535 12 B-Disease
and	548 3 O
renal	552 5 B-Disease
insufficiency	558 13 I-Disease
in	572 2 O
heart	575 5 B-Disease
failure	581 7 I-Disease
patients	589 8 O
treated	598 7 O
with	606 4 O
spironolactone	611 14 B-Chemical
.	625 1 O

METHODS	627 7 O
:	634 1 O
We	636 2 O
performed	639 9 O
a	649 1 O
case	651 4 O
control	656 7 O
study	664 5 O
of	670 2 O
heart	673 5 B-Disease
failure	679 7 I-Disease
patients	687 8 O
treated	696 7 O
with	704 4 O
spironolactone	709 14 B-Chemical
in	724 2 O
our	727 3 O
clinical	731 8 O
practice	740 8 O
.	748 1 O

Cases	750 5 O
were	756 4 O
patients	761 8 O
who	770 3 O
developed	774 9 O
hyperkalemia	784 12 B-Disease
(	797 1 O
K	798 1 B-Chemical
(	799 1 O
+	800 1 O
)	801 1 O
>	803 1 O
5	804 1 O
.	805 1 O
0	806 1 O
mEq	808 3 O
/	811 1 O
L	812 1 O
)	813 1 O
or	815 2 O
renal	818 5 B-Disease
insufficiency	824 13 I-Disease
(	838 1 O
Cr	839 2 B-Chemical
>	842 1 O
or	843 2 O
=	845 1 O
2	846 1 O
.	847 1 O
5	848 1 O
mg	850 2 O
/	852 1 O
dL	853 2 O
)	855 1 O
,	856 1 O
and	858 3 O
they	862 4 O
were	867 4 O
compared	872 8 O
to	881 2 O
2	884 1 O
randomly	886 8 O
selected	895 8 O
controls	904 8 O
per	913 3 O
case	917 4 O
.	921 1 O

Clinical	923 8 O
characteristics	932 15 O
,	947 1 O
medications	949 11 O
,	960 1 O
and	962 3 O
serum	966 5 O
chemistries	972 11 O
at	984 2 O
baseline	987 8 O
and	996 3 O
follow	1000 6 O
-	1006 1 O
up	1007 2 O
time	1010 4 O
periods	1015 7 O
were	1023 4 O
compared	1028 8 O
.	1036 1 O

RESULTS	1038 7 O
:	1045 1 O
Sixty	1047 5 O
-	1052 1 O
seven	1053 5 O
of	1059 2 O
926	1062 3 O
patients	1066 8 O
(	1075 1 O
7	1076 1 O
.	1077 1 O
2	1078 1 O
%	1079 1 O
)	1080 1 O
required	1082 8 O
discontinuation	1091 15 O
of	1107 2 O
spironolactone	1110 14 B-Chemical
due	1125 3 O
to	1129 2 O
hyperkalemia	1132 12 B-Disease
(	1145 1 O
n	1146 1 O
=	1148 1 O
33	1150 2 O
)	1152 1 O
or	1154 2 O
renal	1157 5 B-Disease
failure	1163 7 I-Disease
(	1171 1 O
n	1172 1 O
=	1174 1 O
34	1176 2 O
)	1178 1 O
.	1179 1 O

Patients	1181 8 O
who	1190 3 O
developed	1194 9 O
hyperkalemia	1204 12 B-Disease
were	1217 4 O
older	1222 5 O
and	1228 3 O
more	1232 4 O
likely	1237 6 O
to	1244 2 O
have	1247 4 O
diabetes	1252 8 B-Disease
,	1260 1 O
had	1262 3 O
higher	1266 6 O
baseline	1273 8 O
serum	1282 5 O
potassium	1288 9 B-Chemical
levels	1298 6 O
and	1305 3 O
lower	1309 5 O
baseline	1315 8 O
potassium	1324 9 B-Chemical
supplement	1334 10 O
doses	1345 5 O
,	1350 1 O
and	1352 3 O
were	1356 4 O
more	1361 4 O
likely	1366 6 O
to	1373 2 O
be	1376 2 O
treated	1379 7 O
with	1387 4 O
beta	1392 4 O
-	1396 1 O
blockers	1397 8 O
than	1406 4 O
controls	1411 8 O
(	1420 1 O
n	1421 1 O
=	1423 1 O
134	1425 3 O
)	1428 1 O
.	1429 1 O

Patients	1431 8 O
who	1440 3 O
developed	1444 9 O
renal	1454 5 B-Disease
insufficiency	1460 13 I-Disease
had	1474 3 O
lower	1478 5 O
baseline	1484 8 O
body	1493 4 O
weight	1498 6 O
and	1505 3 O
higher	1509 6 O
baseline	1516 8 O
serum	1525 5 O
creatinine	1531 10 B-Chemical
,	1541 1 O
required	1543 8 O
higher	1552 6 O
doses	1559 5 O
of	1565 2 O
loop	1568 4 O
diuretics	1573 9 O
,	1582 1 O
and	1584 3 O
were	1588 4 O
more	1593 4 O
likely	1598 6 O
to	1605 2 O
be	1608 2 O
treated	1611 7 O
with	1619 4 O
thiazide	1624 8 B-Chemical
diuretics	1633 9 O
than	1643 4 O
controls	1648 8 O
.	1656 1 O

CONCLUSIONS	1658 11 O
:	1669 1 O
Spironolactone	1671 14 B-Chemical
-	1685 1 O
induced	1686 7 O
hyperkalemia	1694 12 B-Disease
and	1707 3 O
renal	1711 5 B-Disease
insufficiency	1717 13 I-Disease
are	1731 3 O
more	1735 4 O
common	1740 6 O
in	1747 2 O
our	1750 3 O
clinical	1754 8 O
experience	1763 10 O
than	1774 4 O
reported	1779 8 O
previously	1788 10 O
.	1798 1 O

This	1800 4 O
difference	1805 10 O
is	1816 2 O
explained	1819 9 O
by	1829 2 O
patient	1832 7 O
comorbidities	1840 13 O
and	1854 3 O
more	1858 4 O
frequent	1863 8 O
use	1872 3 O
of	1876 2 O
beta	1879 4 O
-	1883 1 O
blockers	1884 8 O
.	1892 1 O

End	0 3 B-Disease
-	3 1 I-Disease
stage	4 5 I-Disease
renal	10 5 I-Disease
disease	16 7 I-Disease
(	24 1 O
ESRD	25 4 B-Disease
)	29 1 O
after	31 5 O
orthotopic	37 10 O
liver	48 5 O
transplantation	54 15 O
(	70 1 O
OLTX	71 4 O
)	75 1 O
using	77 5 O
calcineurin	83 11 O
-	94 1 O
based	95 5 O
immunotherapy	101 13 O
:	114 1 O
risk	116 4 O
of	121 2 O
development	124 11 O
and	136 3 O
treatment	140 9 O
.	149 1 O

BACKGROUND	151 10 O
:	161 1 O
The	163 3 O
calcineurin	167 11 O
inhibitors	179 10 O
cyclosporine	190 12 B-Chemical
and	203 3 O
tacrolimus	207 10 B-Chemical
are	218 3 O
both	222 4 O
known	227 5 O
to	233 2 O
be	236 2 O
nephrotoxic	239 11 B-Disease
.	250 1 O

Their	252 5 O
use	258 3 O
in	262 2 O
orthotopic	265 10 O
liver	276 5 O
transplantation	282 15 O
(	298 1 O
OLTX	299 4 O
)	303 1 O
has	305 3 O
dramatically	309 12 O
improved	322 8 O
success	331 7 O
rates	339 5 O
.	344 1 O

Recently	346 8 O
,	354 1 O
however	356 7 O
,	363 1 O
we	365 2 O
have	368 4 O
had	373 3 O
an	377 2 O
increase	380 8 O
of	389 2 O
patients	392 8 O
who	401 3 O
are	405 3 O
presenting	409 10 O
after	420 5 O
OLTX	426 4 O
with	431 4 O
end	436 3 B-Disease
-	439 1 I-Disease
stage	440 5 I-Disease
renal	446 5 I-Disease
disease	452 7 I-Disease
(	460 1 O
ESRD	461 4 B-Disease
)	465 1 O
.	466 1 O

This	468 4 O
retrospective	473 13 O
study	487 5 O
examines	493 8 O
the	502 3 O
incidence	506 9 O
and	516 3 O
treatment	520 9 O
of	530 2 O
ESRD	533 4 B-Disease
and	538 3 O
chronic	542 7 B-Disease
renal	550 5 I-Disease
failure	556 7 I-Disease
(	564 1 O
CRF	565 3 B-Disease
)	568 1 O
in	570 2 O
OLTX	573 4 O
patients	578 8 O
.	586 1 O

METHODS	588 7 O
:	595 1 O
Patients	597 8 O
receiving	606 9 O
an	616 2 O
OLTX	619 4 O
only	624 4 O
from	629 4 O
June	634 4 O
1985	639 4 O
through	644 7 O
December	652 8 O
of	661 2 O
1994	664 4 O
who	669 3 O
survived	673 8 O
6	682 1 O
months	684 6 O
postoperatively	691 15 O
were	707 4 O
studied	712 7 O
(	720 1 O
n	721 1 O
=	722 1 O
834	723 3 O
)	726 1 O
.	727 1 O

Our	729 3 O
prospectively	733 13 O
collected	747 9 O
database	757 8 O
was	766 3 O
the	770 3 O
source	774 6 O
of	781 2 O
information	784 11 O
.	795 1 O

Patients	797 8 O
were	806 4 O
divided	811 7 O
into	819 4 O
three	824 5 O
groups	830 6 O
:	836 1 O
Controls	838 8 O
,	846 1 O
no	848 2 O
CRF	851 3 B-Disease
or	855 2 O
ESRD	858 4 B-Disease
,	862 1 O
n	864 1 O
=	865 1 O
748	866 3 O
;	869 1 O
CRF	871 3 B-Disease
,	874 1 O
sustained	876 9 O
serum	886 5 O
creatinine	892 10 B-Chemical
>	903 1 O
2	904 1 O
.	905 1 O
5	906 1 O
mg	908 2 O
/	910 1 O
dl	911 2 O
,	913 1 O
n	915 1 O
=	916 1 O
41	917 2 O
;	919 1 O
and	921 3 O
ESRD	925 4 B-Disease
,	929 1 O
n	931 1 O
=	932 1 O
45	933 2 O
.	935 1 O

Groups	937 6 O
were	944 4 O
compared	949 8 O
for	958 3 O
preoperative	962 12 O
laboratory	975 10 O
variables	986 9 O
,	995 1 O
diagnosis	997 9 O
,	1006 1 O
postoperative	1008 13 O
variables	1022 9 O
,	1031 1 O
survival	1033 8 O
,	1041 1 O
type	1043 4 O
of	1048 2 O
ESRD	1051 4 B-Disease
therapy	1056 7 O
,	1063 1 O
and	1065 3 O
survival	1069 8 O
from	1078 4 O
onset	1083 5 O
of	1089 2 O
ESRD	1092 4 B-Disease
.	1096 1 O

RESULTS	1098 7 O
:	1105 1 O
At	1107 2 O
13	1110 2 O
years	1113 5 O
after	1119 5 O
OLTX	1125 4 O
,	1129 1 O
the	1131 3 O
incidence	1135 9 O
of	1145 2 O
severe	1148 6 O
renal	1155 5 B-Disease
dysfunction	1161 11 I-Disease
was	1173 3 O
18	1177 2 O
.	1179 1 O
1	1180 1 O
%	1181 1 O
(	1183 1 O
CRF	1184 3 B-Disease
8	1188 1 O
.	1189 1 O
6	1190 1 O
%	1191 1 O
and	1193 3 O
ESRD	1197 4 B-Disease
9	1202 1 O
.	1203 1 O
5	1204 1 O
%	1205 1 O
)	1206 1 O
.	1207 1 O

Compared	1209 8 O
with	1218 4 O
control	1223 7 O
patients	1231 8 O
,	1239 1 O
CRF	1241 3 B-Disease
and	1245 3 O
ESRD	1249 4 B-Disease
patients	1254 8 O
had	1263 3 O
higher	1267 6 O
preoperative	1274 12 O
serum	1287 5 O
creatinine	1293 10 B-Chemical
levels	1304 6 O
,	1310 1 O
a	1312 1 O
greater	1314 7 O
percentage	1322 10 O
of	1333 2 O
patients	1336 8 O
with	1345 4 O
hepatorenal	1350 11 B-Disease
syndrome	1362 8 I-Disease
,	1370 1 O
higher	1372 6 O
percentage	1379 10 O
requirement	1390 11 O
for	1402 3 O
dialysis	1406 8 O
in	1415 2 O
the	1418 3 O
first	1422 5 O
3	1428 1 O
months	1430 6 O
postoperatively	1437 15 O
,	1452 1 O
and	1454 3 O
a	1458 1 O
higher	1460 6 O
1	1467 1 O
-	1468 1 O
year	1469 4 O
serum	1474 5 O
creatinine	1480 10 B-Chemical
.	1490 1 O

Multivariate	1492 12 O
stepwise	1505 8 O
logistic	1514 8 O
regression	1523 10 O
analysis	1534 8 O
using	1543 5 O
preoperative	1549 12 O
and	1562 3 O
postoperative	1566 13 O
variables	1580 9 O
identified	1590 10 O
that	1601 4 O
an	1606 2 O
increase	1609 8 O
of	1618 2 O
serum	1621 5 O
creatinine	1627 10 B-Chemical
compared	1638 8 O
with	1647 4 O
average	1652 7 O
at	1660 2 O
1	1663 1 O
year	1665 4 O
,	1669 1 O
3	1671 1 O
months	1673 6 O
,	1679 1 O
and	1681 3 O
4	1685 1 O
weeks	1687 5 O
postoperatively	1693 15 O
were	1709 4 O
independent	1714 11 O
risk	1726 4 O
factors	1731 7 O
for	1739 3 O
the	1743 3 O
development	1747 11 O
of	1759 2 O
CRF	1762 3 B-Disease
or	1766 2 O
ESRD	1769 4 B-Disease
with	1774 4 O
odds	1779 4 O
ratios	1784 6 O
of	1791 2 O
2	1794 1 O
.	1795 1 O
6	1796 1 O
,	1797 1 O
2	1799 1 O
.	1800 1 O
2	1801 1 O
,	1802 1 O
and	1804 3 O
1	1808 1 O
.	1809 1 O
6	1810 1 O
,	1811 1 O
respectively	1813 12 O
.	1825 1 O

Overall	1827 7 O
survival	1835 8 O
from	1844 4 O
the	1849 3 O
time	1853 4 O
of	1858 2 O
OLTX	1861 4 O
was	1866 3 O
not	1870 3 O
significantly	1874 13 O
different	1888 9 O
among	1898 5 O
groups	1904 6 O
,	1910 1 O
but	1912 3 O
by	1916 2 O
year	1919 4 O
13	1924 2 O
,	1926 1 O
the	1928 3 O
survival	1932 8 O
of	1941 2 O
the	1944 3 O
patients	1948 8 O
who	1957 3 O
had	1961 3 O
ESRD	1965 4 B-Disease
was	1970 3 O
only	1974 4 O
28	1979 2 O
.	1981 1 O
2	1982 1 O
%	1983 1 O
compared	1985 8 O
with	1994 4 O
54	1999 2 O
.	2001 1 O
6	2002 1 O
%	2003 1 O
in	2005 2 O
the	2008 3 O
control	2012 7 O
group	2020 5 O
.	2025 1 O

Patients	2027 8 O
developing	2036 10 O
ESRD	2047 4 B-Disease
had	2052 3 O
a	2056 1 O
6	2058 1 O
-	2059 1 O
year	2060 4 O
survival	2065 8 O
after	2074 5 O
onset	2080 5 O
of	2086 2 O
ESRD	2089 4 B-Disease
of	2094 2 O
27	2097 2 O
%	2099 1 O
for	2101 3 O
the	2105 3 O
patients	2109 8 O
receiving	2118 9 O
hemodialysis	2128 12 O
versus	2141 6 O
71	2148 2 O
.	2150 1 O
4	2151 1 O
%	2152 1 O
for	2154 3 O
the	2158 3 O
patients	2162 8 O
developing	2171 10 O
ESRD	2182 4 B-Disease
who	2187 3 O
subsequently	2191 12 O
received	2204 8 O
kidney	2213 6 O
transplants	2220 11 O
.	2231 1 O

CONCLUSIONS	2233 11 O
:	2244 1 O
Patients	2246 8 O
who	2255 3 O
are	2259 3 O
more	2263 4 O
than	2268 4 O
10	2273 2 O
years	2276 5 O
post	2282 4 O
-	2286 1 O
OLTX	2287 4 O
have	2292 4 O
CRF	2297 3 B-Disease
and	2301 3 O
ESRD	2305 4 B-Disease
at	2310 2 O
a	2313 1 O
high	2315 4 O
rate	2320 4 O
.	2324 1 O

The	2326 3 O
development	2330 11 O
of	2342 2 O
ESRD	2345 4 B-Disease
decreases	2350 9 O
survival	2360 8 O
,	2368 1 O
particularly	2370 12 O
in	2383 2 O
those	2386 5 O
patients	2392 8 O
treated	2401 7 O
with	2409 4 O
dialysis	2414 8 O
only	2423 4 O
.	2427 1 O

Patients	2429 8 O
who	2438 3 O
develop	2442 7 O
ESRD	2450 4 B-Disease
have	2455 4 O
a	2460 1 O
higher	2462 6 O
preoperative	2469 12 O
and	2482 3 O
1	2486 1 O
-	2487 1 O
year	2488 4 O
serum	2493 5 O
creatinine	2499 10 B-Chemical
and	2510 3 O
are	2514 3 O
more	2518 4 O
likely	2523 6 O
to	2530 2 O
have	2533 4 O
hepatorenal	2538 11 B-Disease
syndrome	2550 8 I-Disease
.	2558 1 O

However	2560 7 O
,	2567 1 O
an	2569 2 O
increase	2572 8 O
of	2581 2 O
serum	2584 5 O
creatinine	2590 10 B-Chemical
at	2601 2 O
various	2604 7 O
times	2612 5 O
postoperatively	2618 15 O
is	2634 2 O
more	2637 4 O
predictive	2642 10 O
of	2653 2 O
the	2656 3 O
development	2660 11 O
of	2672 2 O
CRF	2675 3 B-Disease
or	2679 2 O
ESRD	2682 4 B-Disease
.	2686 1 O

New	2688 3 O
strategies	2692 10 O
for	2703 3 O
long	2707 4 O
-	2711 1 O
term	2712 4 O
immunosuppression	2717 17 O
may	2735 3 O
be	2739 2 O
needed	2742 6 O
to	2749 2 O
decrease	2752 8 O
this	2761 4 O
complication	2766 12 O
.	2778 1 O

Effect	0 6 O
of	7 2 O
intravenous	10 11 O
nimodipine	22 10 B-Chemical
on	33 2 O
blood	36 5 O
pressure	42 8 O
and	51 3 O
outcome	55 7 O
after	63 5 O
acute	69 5 B-Disease
stroke	75 6 I-Disease
.	81 1 O

BACKGROUND	83 10 O
AND	94 3 O
PURPOSE	98 7 O
:	105 1 O
The	107 3 O
Intravenous	111 11 O
Nimodipine	123 10 B-Chemical
West	134 4 O
European	139 8 O
Stroke	148 6 B-Disease
Trial	155 5 O
(	161 1 O
INWEST	162 6 O
)	168 1 O
found	170 5 O
a	176 1 O
correlation	178 11 O
between	190 7 O
nimodipine	198 10 B-Chemical
-	208 1 O
induced	209 7 O
reduction	217 9 B-Disease
in	227 2 I-Disease
blood	230 5 I-Disease
pressure	236 8 I-Disease
(	245 1 O
BP	246 2 O
)	248 1 O
and	250 3 O
an	254 2 O
unfavorable	257 11 O
outcome	269 7 O
in	277 2 O
acute	280 5 B-Disease
stroke	286 6 I-Disease
.	292 1 O

We	294 2 O
sought	297 6 O
to	304 2 O
confirm	307 7 O
this	315 4 O
correlation	320 11 O
with	332 4 O
and	337 3 O
without	341 7 O
adjustment	349 10 O
for	360 3 O
prognostic	364 10 O
variables	375 9 O
and	385 3 O
to	389 2 O
investigate	392 11 O
outcome	404 7 O
in	412 2 O
subgroups	415 9 O
with	425 4 O
increasing	430 10 O
levels	441 6 O
of	448 2 O
BP	451 2 B-Disease
reduction	454 9 I-Disease
.	463 1 O

METHODS	465 7 O
:	472 1 O
Patients	474 8 O
with	483 4 O
a	488 1 O
clinical	490 8 O
diagnosis	499 9 O
of	509 2 O
ischemic	512 8 B-Disease
stroke	521 6 I-Disease
(	528 1 O
within	529 6 O
24	536 2 O
hours	539 5 O
)	544 1 O
were	546 4 O
consecutively	551 13 O
allocated	565 9 O
to	575 2 O
receive	578 7 O
placebo	586 7 O
(	594 1 O
n	595 1 O
=	596 1 O
100	597 3 O
)	600 1 O
,	601 1 O
1	603 1 O
mg	605 2 O
/	607 1 O
h	608 1 O
(	610 1 O
low	611 3 O
-	614 1 O
dose	615 4 O
)	619 1 O
nimodipine	621 10 B-Chemical
(	632 1 O
n	633 1 O
=	634 1 O
101	635 3 O
)	638 1 O
,	639 1 O
or	641 2 O
2	644 1 O
mg	646 2 O
/	648 1 O
h	649 1 O
(	651 1 O
high	652 4 O
-	656 1 O
dose	657 4 O
)	661 1 O
nimodipine	663 10 B-Chemical
(	674 1 O
n	675 1 O
=	676 1 O
94	677 2 O
)	679 1 O
.	680 1 O

The	682 3 O
correlation	686 11 O
between	698 7 O
average	706 7 O
BP	714 2 O
change	717 6 O
during	724 6 O
the	731 3 O
first	735 5 O
2	741 1 O
days	743 4 O
and	748 3 O
the	752 3 O
outcome	756 7 O
at	764 2 O
day	767 3 O
21	771 2 O
was	774 3 O
analyzed	778 8 O
.	786 1 O

RESULTS	788 7 O
:	795 1 O
Two	797 3 O
hundred	801 7 O
sixty	809 5 O
-	814 1 O
five	815 4 O
patients	820 8 O
were	829 4 O
included	834 8 O
in	843 2 O
this	846 4 O
analysis	851 8 O
(	860 1 O
n	861 1 O
=	862 1 O
92	863 2 O
,	865 1 O
93	867 2 O
,	869 1 O
and	871 3 O
80	875 2 O
for	878 3 O
placebo	882 7 O
,	889 1 O
low	891 3 O
dose	895 4 O
,	899 1 O
and	901 3 O
high	905 4 O
dose	910 4 O
,	914 1 O
respectively	916 12 O
)	928 1 O
.	929 1 O

Nimodipine	931 10 B-Chemical
treatment	942 9 O
resulted	952 8 O
in	961 2 O
a	964 1 O
statistically	966 13 O
significant	980 11 O
reduction	992 9 B-Disease
in	1002 2 I-Disease
systolic	1005 8 I-Disease
BP	1014 2 I-Disease
(	1017 1 O
SBP	1018 3 O
)	1021 1 O
and	1023 3 O
diastolic	1027 9 O
BP	1037 2 O
(	1040 1 O
DBP	1041 3 O
)	1044 1 O
from	1046 4 O
baseline	1051 8 O
compared	1060 8 O
with	1069 4 O
placebo	1074 7 O
during	1082 6 O
the	1089 3 O
first	1093 5 O
few	1099 3 O
days	1103 4 O
.	1107 1 O

In	1109 2 O
multivariate	1112 12 O
analysis	1125 8 O
,	1133 1 O
a	1135 1 O
significant	1137 11 O
correlation	1149 11 O
between	1161 7 O
DBP	1169 3 B-Disease
reduction	1173 9 I-Disease
and	1183 3 O
worsening	1187 9 O
of	1197 2 O
the	1200 3 O
neurological	1204 12 O
score	1217 5 O
was	1223 3 O
found	1227 5 O
for	1233 3 O
the	1237 3 O
high	1241 4 O
-	1245 1 O
dose	1246 4 O
group	1251 5 O
(	1257 1 O
beta	1258 4 O
=	1262 1 O
0	1263 1 O
.	1264 1 O
49	1265 2 O
,	1267 1 O
P	1269 1 O
=	1270 1 O
0	1271 1 O
.	1272 1 O
048	1274 3 O
)	1277 1 O
.	1278 1 O

Patients	1280 8 O
with	1289 4 O
a	1294 1 O
DBP	1296 3 B-Disease
reduction	1300 9 I-Disease
of	1310 2 O
>	1313 1 O
or	1315 2 O
=	1318 1 O
20	1319 2 O
%	1321 1 O
in	1323 2 O
the	1326 3 O
high	1330 4 O
-	1334 1 O
dose	1335 4 O
group	1340 5 O
had	1346 3 O
a	1350 1 O
significantly	1352 13 O
increased	1366 9 O
adjusted	1376 8 O
OR	1385 2 O
for	1388 3 O
the	1392 3 O
compound	1396 8 O
outcome	1405 7 O
variable	1413 8 O
death	1422 5 B-Disease
or	1428 2 O
dependency	1431 10 O
(	1442 1 O
Barthel	1443 7 O
Index	1451 5 O
<	1457 1 O
60	1458 2 O
)	1460 1 O
(	1462 1 O
n	1463 1 O
/	1464 1 O
N	1465 1 O
=	1466 1 O
25	1467 2 O
/	1469 1 O
26	1470 2 O
,	1472 1 O
OR	1474 2 O
10	1477 2 O
.	1479 1 O
16	1481 2 O
,	1483 1 O
95	1485 2 O
%	1487 1 O
CI	1489 2 O
1	1492 1 O
.	1493 1 O
02	1494 2 O
to	1497 2 O
101	1500 3 O
.	1503 1 O
74	1504 2 O
)	1506 1 O
and	1508 3 O
death	1512 5 B-Disease
alone	1518 5 O
(	1524 1 O
n	1525 1 O
/	1526 1 O
N	1527 1 O
=	1528 1 O
9	1529 1 O
/	1530 1 O
26	1531 2 O
,	1533 1 O
OR	1535 2 O
4	1538 1 O
.	1539 1 O
336	1540 3 O
,	1543 1 O
95	1545 2 O
%	1547 1 O
CI	1549 2 O
1	1552 1 O
.	1553 1 O
131	1554 3 O
16	1558 2 O
.	1560 1 O
619	1561 3 O
)	1564 1 O
compared	1566 8 O
with	1575 4 O
all	1580 3 O
placebo	1584 7 O
patients	1592 8 O
(	1601 1 O
n	1602 1 O
/	1603 1 O
N	1604 1 O
=	1605 1 O
62	1606 2 O
/	1608 1 O
92	1609 2 O
and	1612 3 O
14	1616 2 O
/	1618 1 O
92	1619 2 O
,	1621 1 O
respectively	1623 12 O
)	1635 1 O
.	1636 1 O

There	1638 5 O
was	1644 3 O
no	1648 2 O
correlation	1651 11 O
between	1663 7 O
SBP	1671 3 O
change	1675 6 O
and	1682 3 O
outcome	1686 7 O
.	1693 1 O

CONCLUSIONS	1695 11 O
:	1706 1 O
DBP	1708 3 O
,	1711 1 O
but	1713 3 O
not	1717 3 O
SBP	1721 3 O
,	1724 1 O
reduction	1726 9 O
was	1736 3 O
associated	1740 10 O
with	1751 4 O
neurological	1756 12 O
worsening	1769 9 O
after	1779 5 O
the	1785 3 O
intravenous	1789 11 O
administration	1801 14 O
of	1816 2 O
high	1819 4 O
-	1823 1 O
dose	1824 4 O
nimodipine	1829 10 B-Chemical
after	1840 5 O
acute	1846 5 B-Disease
stroke	1852 6 I-Disease
.	1858 1 O

For	1860 3 O
low	1864 3 O
-	1867 1 O
dose	1868 4 O
nimodipine	1873 10 B-Chemical
,	1883 1 O
the	1885 3 O
results	1889 7 O
were	1897 4 O
not	1902 3 O
conclusive	1906 10 O
.	1916 1 O

These	1918 5 O
results	1924 7 O
do	1932 2 O
not	1935 3 O
confirm	1939 7 O
or	1947 2 O
exclude	1950 7 O
a	1958 1 O
neuroprotective	1960 15 O
property	1976 8 O
of	1985 2 O
nimodipine	1988 10 B-Chemical
.	1998 1 O

Transient	0 9 B-Disease
neurologic	10 10 I-Disease
symptoms	21 8 I-Disease
after	30 5 O
spinal	36 6 O
anesthesia	43 10 O
:	53 1 O
a	55 1 O
lower	57 5 O
incidence	63 9 O
with	73 4 O
prilocaine	78 10 B-Chemical
and	89 3 O
bupivacaine	93 11 B-Chemical
than	105 4 O
with	110 4 O
lidocaine	115 9 B-Chemical
.	124 1 O

BACKGROUND	126 10 O
:	136 1 O
Recent	138 6 O
evidence	145 8 O
suggests	154 8 O
that	163 4 O
transient	168 9 B-Disease
neurologic	178 10 I-Disease
symptoms	189 8 I-Disease
(	198 1 O
TNSs	199 4 B-Disease
)	203 1 O
frequently	205 10 O
follow	216 6 O
lidocaine	223 9 B-Chemical
spinal	233 6 O
anesthesia	240 10 O
but	251 3 O
are	255 3 O
infrequent	259 10 O
with	270 4 O
bupivacaine	275 11 B-Chemical
.	286 1 O

However	288 7 O
,	295 1 O
identification	297 14 O
of	312 2 O
a	315 1 O
short	317 5 O
-	322 1 O
acting	323 6 O
local	330 5 O
anesthetic	336 10 O
to	347 2 O
substitute	350 10 O
for	361 3 O
lidocaine	365 9 B-Chemical
for	375 3 O
brief	379 5 O
surgical	385 8 O
procedures	394 10 O
remains	405 7 O
an	413 2 O
important	416 9 O
goal	426 4 O
.	430 1 O

Prilocaine	432 10 B-Chemical
is	443 2 O
an	446 2 O
amide	449 5 O
local	455 5 O
anesthetic	461 10 O
with	472 4 O
a	477 1 O
duration	479 8 O
of	488 2 O
action	491 6 O
similar	498 7 O
to	506 2 O
that	509 4 O
of	514 2 O
lidocaine	517 9 B-Chemical
.	526 1 O

Accordingly	528 11 O
,	539 1 O
the	541 3 O
present	545 7 O
,	552 1 O
prospective	554 11 O
double	566 6 O
-	572 1 O
blind	573 5 O
study	579 5 O
compares	585 8 O
prilocaine	594 10 B-Chemical
with	605 4 O
lidocaine	610 9 B-Chemical
and	620 3 O
bupivacaine	624 11 B-Chemical
with	636 4 O
respect	641 7 O
to	649 2 O
duration	652 8 O
of	661 2 O
action	664 6 O
and	671 3 O
relative	675 8 O
risk	684 4 O
of	689 2 O
TNSs	692 4 B-Disease
.	696 1 O

METHODS	698 7 O
:	705 1 O
Ninety	707 6 O
patients	714 8 O
classified	723 10 O
as	734 2 O
American	737 8 O
Society	746 7 O
of	754 2 O
Anesthesiologists	757 17 O
physical	775 8 O
status	784 6 O
I	791 1 O
or	793 2 O
II	796 2 O
who	799 3 O
were	803 4 O
scheduled	808 9 O
for	818 3 O
short	822 5 O
gynecologic	828 11 O
procedures	840 10 O
under	851 5 O
spinal	857 6 O
anesthesia	864 10 O
were	875 4 O
randomly	880 8 O
allocated	889 9 O
to	899 2 O
receive	902 7 O
2	910 1 O
.	911 1 O
5	912 1 O
ml	914 2 O
2	917 1 O
%	918 1 O
lidocaine	920 9 B-Chemical
in	930 2 O
7	933 1 O
.	934 1 O
5	935 1 O
%	936 1 O
glucose	938 7 B-Chemical
,	945 1 O
2	947 1 O
%	948 1 O
prilocaine	950 10 B-Chemical
in	961 2 O
7	964 1 O
.	965 1 O
5	966 1 O
%	967 1 O
glucose	969 7 B-Chemical
,	976 1 O
or	978 2 O
0	981 1 O
.	982 1 O
5	983 1 O
%	984 1 O
bupivacaine	986 11 B-Chemical
in	998 2 O
7	1001 1 O
.	1002 1 O
5	1003 1 O
%	1004 1 O
glucose	1006 7 B-Chemical
.	1013 1 O

All	1015 3 O
solutions	1019 9 O
were	1029 4 O
provided	1034 8 O
in	1043 2 O
blinded	1046 7 O
vials	1054 5 O
by	1060 2 O
the	1063 3 O
hospital	1067 8 O
pharmacy	1076 8 O
.	1084 1 O

Details	1086 7 O
of	1094 2 O
spinal	1097 6 O
puncture	1104 8 O
,	1112 1 O
extension	1114 9 O
and	1124 3 O
regression	1128 10 O
of	1139 2 O
spinal	1142 6 O
block	1149 5 O
,	1154 1 O
and	1156 3 O
the	1160 3 O
times	1164 5 O
to	1170 2 O
reach	1173 5 O
discharge	1179 9 O
criteria	1189 8 O
were	1198 4 O
noted	1203 5 O
.	1208 1 O

In	1210 2 O
the	1213 3 O
evening	1217 7 O
of	1225 2 O
postoperative	1228 13 O
day	1242 3 O
1	1246 1 O
,	1247 1 O
patients	1249 8 O
were	1258 4 O
evaluated	1263 9 O
for	1273 3 O
TNSs	1277 4 B-Disease
by	1282 2 O
a	1285 1 O
physician	1287 9 O
unaware	1297 7 O
of	1305 2 O
the	1308 3 O
drug	1312 4 O
administered	1317 12 O
and	1330 3 O
the	1334 3 O
details	1338 7 O
of	1346 2 O
the	1349 3 O
anesthetic	1353 10 O
procedure	1364 9 O
.	1373 1 O

RESULTS	1375 7 O
:	1382 1 O
Nine	1384 4 O
of	1389 2 O
30	1392 2 O
patients	1395 8 O
receiving	1404 9 O
lidocaine	1414 9 B-Chemical
experienced	1424 11 O
TNSs	1436 4 B-Disease
,	1440 1 O
1	1442 1 O
of	1444 2 O
30	1447 2 O
patients	1450 8 O
receiving	1459 9 O
prilocaine	1469 10 B-Chemical
(	1480 1 O
P	1481 1 O
=	1483 1 O
0	1485 1 O
.	1486 1 O
03	1487 2 O
)	1489 1 O
had	1491 3 O
them	1495 4 O
,	1499 1 O
and	1501 3 O
none	1505 4 O
of	1510 2 O
30	1513 2 O
patients	1516 8 O
receiving	1525 9 O
bupivacaine	1535 11 B-Chemical
had	1547 3 O
TNSs	1551 4 B-Disease
.	1555 1 O

Times	1557 5 O
to	1563 2 O
ambulate	1566 8 O
and	1575 3 O
to	1579 2 O
void	1582 4 O
were	1587 4 O
similar	1592 7 O
after	1600 5 O
lidocaine	1606 9 B-Chemical
and	1616 3 O
prilocaine	1620 10 B-Chemical
(	1631 1 O
150	1632 3 O
vs	1636 2 O
.	1638 1 O
165	1640 3 O
min	1644 3 O
and	1648 3 O
238	1652 3 O
vs	1656 2 O
.	1658 1 O
253	1660 3 O
min	1664 3 O
,	1667 1 O
respectively	1669 12 O
)	1681 1 O
but	1683 3 O
prolonged	1687 9 O
after	1697 5 O
bupivacaine	1703 11 B-Chemical
(	1715 1 O
200	1716 3 O
and	1720 3 O
299	1724 3 O
min	1728 3 O
,	1731 1 O
respectively	1733 12 O
;	1745 1 O
P	1747 1 O
<	1749 1 O
0	1751 1 O
.	1752 1 O
05	1753 2 O
)	1755 1 O
.	1756 1 O

CONCLUSIONS	1758 11 O
:	1769 1 O
Prilocaine	1771 10 B-Chemical
may	1782 3 O
be	1786 2 O
preferable	1789 10 O
to	1800 2 O
lidocaine	1803 9 B-Chemical
for	1813 3 O
short	1817 5 O
surgical	1823 8 O
procedures	1832 10 O
because	1843 7 O
it	1851 2 O
has	1854 3 O
a	1858 1 O
similar	1860 7 O
duration	1868 8 O
of	1877 2 O
action	1880 6 O
but	1887 3 O
a	1891 1 O
lower	1893 5 O
incidence	1899 9 O
of	1909 2 O
TNSs	1912 4 B-Disease
.	1916 1 O

The	0 3 O
role	4 4 O
of	9 2 O
nicotine	12 8 B-Chemical
in	21 2 O
smoking	24 7 O
-	31 1 O
related	32 7 O
cardiovascular	40 14 B-Disease
disease	55 7 I-Disease
.	62 1 O

Nicotine	64 8 B-Chemical
activates	73 9 O
the	83 3 O
sympathetic	87 11 O
nervous	99 7 O
system	107 6 O
and	114 3 O
in	118 2 O
this	121 4 O
way	126 3 O
could	130 5 O
contribute	136 10 O
to	147 2 O
cardiovascular	150 14 B-Disease
disease	165 7 I-Disease
.	172 1 O

Animal	174 6 O
studies	181 7 O
and	189 3 O
mechanistic	193 11 O
studies	205 7 O
indicate	213 8 O
that	222 4 O
nicotine	227 8 B-Chemical
could	236 5 O
play	242 4 O
a	247 1 O
role	249 4 O
in	254 2 O
accelerating	257 12 O
atherosclerosis	270 15 B-Disease
,	285 1 O
but	287 3 O
evidence	291 8 O
among	300 5 O
humans	306 6 O
is	313 2 O
too	316 3 O
inadequate	320 10 O
to	331 2 O
be	334 2 O
definitive	337 10 O
about	348 5 O
such	354 4 O
an	359 2 O
effect	362 6 O
.	368 1 O

Almost	370 6 O
certainly	377 9 O
,	386 1 O
nicotine	388 8 B-Chemical
via	397 3 O
its	401 3 O
hemodynamic	405 11 O
effects	417 7 O
contributes	425 11 O
to	437 2 O
acute	440 5 O
cardiovascular	446 14 O
events	461 6 O
,	467 1 O
although	469 8 O
current	478 7 O
evidence	486 8 O
suggests	495 8 O
that	504 4 O
the	509 3 O
effects	513 7 O
of	521 2 O
nicotine	524 8 B-Chemical
are	533 3 O
much	537 4 O
less	542 4 O
important	547 9 O
than	557 4 O
are	562 3 O
the	566 3 O
prothrombotic	570 13 O
effects	584 7 O
of	592 2 O
cigarette	595 9 O
smoking	605 7 O
or	613 2 O
the	616 3 O
effects	620 7 O
of	628 2 O
carbon	631 6 B-Chemical
monoxide	638 8 I-Chemical
.	646 1 O

Nicotine	648 8 B-Chemical
does	657 4 O
not	662 3 O
appear	666 6 O
to	673 2 O
enhance	676 7 O
thrombosis	684 10 B-Disease
among	695 5 O
humans	701 6 O
.	707 1 O

Clinical	709 8 O
studies	718 7 O
of	726 2 O
pipe	729 4 O
smokers	734 7 O
and	742 3 O
people	746 6 O
using	753 5 O
transdermal	759 11 O
nicotine	771 8 B-Chemical
support	780 7 O
the	788 3 O
idea	792 4 O
that	797 4 O
toxins	802 6 O
other	809 5 O
than	815 4 O
nicotine	820 8 B-Chemical
are	829 3 O
the	833 3 O
most	837 4 O
important	842 9 O
causes	852 6 O
of	859 2 O
acute	862 5 O
cardiovascular	868 14 O
events	883 6 O
.	889 1 O

Finally	891 7 O
,	898 1 O
the	900 3 O
dose	904 4 O
response	909 8 O
for	918 3 O
cardiovascular	922 14 O
events	937 6 O
of	944 2 O
nicotine	947 8 B-Chemical
appears	956 7 O
to	964 2 O
be	967 2 O
flat	970 4 O
,	974 1 O
suggesting	976 10 O
that	987 4 O
if	992 2 O
nicotine	995 8 B-Chemical
is	1004 2 O
involved	1007 8 O
,	1015 1 O
adverse	1017 7 O
effects	1025 7 O
might	1033 5 O
be	1039 2 O
seen	1042 4 O
with	1047 4 O
relatively	1052 10 O
low	1063 3 O
-	1066 1 O
level	1067 5 O
cigarette	1073 9 O
exposures	1083 9 O
.	1092 1 O

Seizure	0 7 B-Disease
resulting	8 9 O
from	18 4 O
a	23 1 O
venlafaxine	25 11 B-Chemical
overdose	37 8 B-Disease
.	45 1 O

OBJECTIVE	47 9 O
:	56 1 O
To	58 2 O
report	61 6 O
a	68 1 O
case	70 4 O
of	75 2 O
venlafaxine	78 11 B-Chemical
overdose	90 8 B-Disease
.	98 1 O

CASE	100 4 O
SUMMARY	105 7 O
:	112 1 O
A	114 1 O
40	116 2 O
-	118 1 O
year	119 4 O
-	123 1 O
old	124 3 O
woman	128 5 O
with	134 4 O
major	139 5 B-Disease
depression	145 10 I-Disease
took	156 4 O
an	161 2 O
overdose	164 8 B-Disease
of	173 2 O
venlafaxine	176 11 B-Chemical
in	188 2 O
an	191 2 O
apparent	194 8 O
suicide	203 7 O
attempt	211 7 O
.	218 1 O

After	220 5 O
the	226 3 O
ingestion	230 9 O
of	240 2 O
26	243 2 O
venlafaxine	246 11 B-Chemical
50	258 2 O
-	260 1 O
mg	261 2 O
tablets	264 7 O
,	271 1 O
the	273 3 O
patient	277 7 O
experienced	285 11 O
a	297 1 O
witnessed	299 9 O
generalized	309 11 O
seizure	321 7 B-Disease
.	328 1 O

She	330 3 O
was	334 3 O
admitted	338 8 O
to	347 2 O
the	350 3 O
medical	354 7 O
intensive	362 9 O
care	372 4 O
unit	377 4 O
,	381 1 O
venlafaxine	383 11 B-Chemical
was	395 3 O
discontinued	399 12 O
,	411 1 O
and	413 3 O
no	417 2 O
further	420 7 O
sequelae	428 8 O
were	437 4 O
seen	442 4 O
.	446 1 O

DISCUSSION	448 10 O
:	458 1 O
To	460 2 O
our	463 3 O
knowledge	467 9 O
,	476 1 O
this	478 4 O
is	483 2 O
the	486 3 O
first	490 5 O
reported	496 8 O
case	505 4 O
of	510 2 O
venlafaxine	513 11 B-Chemical
overdose	525 8 B-Disease
that	534 4 O
resulted	539 8 O
in	548 2 O
a	551 1 O
generalized	553 11 O
seizure	565 7 B-Disease
.	572 1 O

Based	574 5 O
on	580 2 O
nonoverdose	583 11 O
pharmacokinetics	595 16 O
and	612 3 O
pharmacodynamics	616 16 O
of	633 2 O
venlafaxine	636 11 B-Chemical
and	648 3 O
the	652 3 O
potential	656 9 O
risks	666 5 O
of	672 2 O
available	675 9 O
interventions	685 13 O
,	698 1 O
no	700 2 O
emergent	703 8 O
therapy	712 7 O
was	720 3 O
instituted	724 10 O
.	734 1 O

CONCLUSIONS	736 11 O
:	747 1 O
The	749 3 O
venlafaxine	753 11 B-Chemical
overdose	765 8 B-Disease
in	774 2 O
our	777 3 O
patient	781 7 O
resulted	789 8 O
in	798 2 O
a	801 1 O
single	803 6 O
episode	810 7 O
of	818 2 O
generalized	821 11 O
seizure	833 7 B-Disease
but	841 3 O
elicited	845 8 O
no	854 2 O
further	857 7 O
sequelae	865 8 O
.	873 1 O

Effect	0 6 O
of	7 2 O
nifedipine	10 10 B-Chemical
on	21 2 O
renal	24 5 O
function	30 8 O
in	39 2 O
liver	42 5 O
transplant	48 10 O
recipients	59 10 O
receiving	70 9 O
tacrolimus	80 10 B-Chemical
.	90 1 O

The	92 3 O
effect	96 6 O
of	103 2 O
nifedipine	106 10 B-Chemical
on	117 2 O
renal	120 5 O
function	126 8 O
in	135 2 O
liver	138 5 O
transplant	144 10 O
recipients	155 10 O
who	166 3 O
were	170 4 O
receiving	175 9 O
tacrolimus	185 10 B-Chemical
was	196 3 O
evaluated	200 9 O
between	210 7 O
January	218 7 O
1992	226 4 O
and	231 3 O
January	235 7 O
1996	243 4 O
.	247 1 O

Two	249 3 O
groups	253 6 O
of	260 2 O
patients	263 8 O
receiving	272 9 O
tacrolimus	282 10 B-Chemical
were	293 4 O
compared	298 8 O
over	307 4 O
a	312 1 O
period	314 6 O
of	321 2 O
1	324 1 O
year	326 4 O
,	330 1 O
one	332 3 O
group	336 5 O
comprising	342 10 O
hypertensive	353 12 B-Disease
patients	366 8 O
who	375 3 O
were	379 4 O
receiving	384 9 O
nifedipine	394 10 B-Chemical
,	404 1 O
and	406 3 O
the	410 3 O
other	414 5 O
comprising	420 10 O
nonhypertensive	431 15 O
patients	447 8 O
not	456 3 O
receiving	460 9 O
nifedipine	470 10 B-Chemical
.	480 1 O

The	482 3 O
time	486 4 O
from	491 4 O
transplant	496 10 O
to	507 2 O
baseline	510 8 O
was	519 3 O
similar	523 7 O
in	531 2 O
all	534 3 O
patients	538 8 O
.	546 1 O

Nifedipine	548 10 B-Chemical
significantly	559 13 O
improved	573 8 O
kidney	582 6 O
function	589 8 O
as	598 2 O
indicated	601 9 O
by	611 2 O
a	614 1 O
significant	616 11 O
lowering	628 8 O
of	637 2 O
serum	640 5 O
creatinine	646 10 B-Chemical
levels	657 6 O
at	664 2 O
6	667 1 O
and	669 3 O
12	673 2 O
months	676 6 O
.	682 1 O

The	684 3 O
observed	688 8 O
positive	697 8 O
impact	706 6 O
of	713 2 O
nifedipine	716 10 B-Chemical
on	727 2 O
reducing	730 8 O
the	739 3 O
nephrotoxicity	743 14 B-Disease
associated	758 10 O
with	769 4 O
tacrolimus	774 10 B-Chemical
in	785 2 O
liver	788 5 O
transplant	794 10 O
recipients	805 10 O
should	816 6 O
be	823 2 O
an	826 2 O
important	829 9 O
factor	839 6 O
in	846 2 O
selecting	849 9 O
an	859 2 O
agent	862 5 O
to	868 2 O
treat	871 5 O
hypertension	877 12 B-Disease
in	890 2 O
this	893 4 O
population	898 10 O
.	908 1 O

Sinus	0 5 B-Disease
arrest	6 6 I-Disease
associated	13 10 O
with	24 4 O
continuous	29 10 O
-	39 1 O
infusion	40 8 O
cimetidine	49 10 B-Chemical
.	59 1 O

The	61 3 O
administration	65 14 O
of	80 2 O
intermittent	83 12 O
intravenous	96 11 O
infusions	108 9 O
of	118 2 O
cimetidine	121 10 B-Chemical
is	132 2 O
infrequently	135 12 O
associated	148 10 O
with	159 4 O
the	164 3 O
development	168 11 O
of	180 2 O
bradyarrhythmias	183 16 B-Disease
.	199 1 O

A	201 1 O
40	203 2 O
-	205 1 O
year	206 4 O
-	210 1 O
old	211 3 O
man	215 3 O
with	219 4 O
leukemia	224 8 B-Disease
and	233 3 O
no	237 2 O
history	240 7 O
of	248 2 O
cardiac	251 7 B-Disease
disease	259 7 I-Disease
developed	267 9 O
recurrent	277 9 O
,	286 1 O
brief	288 5 O
episodes	294 8 O
of	303 2 O
apparent	306 8 O
sinus	315 5 B-Disease
arrest	321 6 I-Disease
while	328 5 O
receiving	334 9 O
continuous	344 10 O
-	354 1 O
infusion	355 8 O
cimetidine	364 10 B-Chemical
50	375 2 O
mg	378 2 O
/	380 1 O
hour	381 4 O
.	385 1 O

The	387 3 O
arrhythmias	391 11 B-Disease
were	403 4 O
temporally	408 10 O
related	419 7 O
to	427 2 O
cimetidine	430 10 B-Chemical
administration	441 14 O
,	455 1 O
disappeared	457 11 O
after	469 5 O
dechallenge	475 11 O
,	486 1 O
and	488 3 O
did	492 3 O
not	496 3 O
recur	500 5 O
during	506 6 O
ranitidine	513 10 B-Chemical
treatment	524 9 O
.	533 1 O

This	535 4 O
is	540 2 O
the	543 3 O
first	547 5 O
reported	553 8 O
case	562 4 O
of	567 2 O
sinus	570 5 B-Disease
arrest	576 6 I-Disease
associated	583 10 O
with	594 4 O
continuous	599 10 O
-	609 1 O
infusion	610 8 O
cimetidine	619 10 B-Chemical
.	629 1 O

Composition	0 11 O
of	12 2 O
gall	15 4 B-Disease
bladder	20 7 I-Disease
stones	28 6 I-Disease
associated	35 10 O
with	46 4 O
octreotide	51 10 B-Chemical
:	61 1 O
response	63 8 O
to	72 2 O
oral	75 4 O
ursodeoxycholic	80 15 B-Chemical
acid	96 4 I-Chemical
.	100 1 O

Octreotide	102 10 B-Chemical
,	112 1 O
an	114 2 O
effective	117 9 O
treatment	127 9 O
for	137 3 O
acromegaly	141 10 B-Disease
,	151 1 O
induces	153 7 O
gall	161 4 B-Disease
bladder	166 7 I-Disease
stones	174 6 I-Disease
in	181 2 O
13	184 2 O
-	186 1 O
60	187 2 O
%	189 1 O
of	191 2 O
patients	194 8 O
.	202 1 O

Because	204 7 O
knowledge	212 9 O
of	222 2 O
stone	225 5 O
composition	231 11 O
is	243 2 O
essential	246 9 O
for	256 3 O
studies	260 7 O
of	268 2 O
their	271 5 O
pathogenesis	277 12 O
,	289 1 O
treatment	291 9 O
,	300 1 O
and	302 3 O
prevention	306 10 O
,	316 1 O
this	318 4 O
was	323 3 O
investigated	327 12 O
by	340 2 O
direct	343 6 O
and	350 3 O
indirect	354 8 O
methods	363 7 O
in	371 2 O
14	374 2 O
octreotide	377 10 B-Chemical
treated	388 7 O
acromegalic	396 11 B-Disease
patients	408 8 O
with	417 4 O
gall	422 4 B-Disease
stones	427 6 I-Disease
.	433 1 O

Chemical	435 8 O
analysis	444 8 O
of	453 2 O
gall	456 4 B-Disease
stones	461 6 I-Disease
retrieved	468 9 O
at	478 2 O
cholecystectomy	481 15 O
from	497 4 O
two	502 3 O
patients	506 8 O
,	514 1 O
showed	516 6 O
that	523 4 O
they	528 4 O
contained	533 9 O
71	543 2 O
%	545 1 O
and	547 3 O
87	551 2 O
%	553 1 O
cholesterol	555 11 B-Chemical
by	567 2 O
weight	570 6 O
.	576 1 O

In	578 2 O
the	581 3 O
remaining	585 9 O
12	595 2 O
patients	598 8 O
,	606 1 O
localised	608 9 O
computed	618 8 O
tomography	627 10 O
of	638 2 O
the	641 3 O
gall	645 4 O
bladder	650 7 O
showed	658 6 O
that	665 4 O
eight	670 5 O
had	676 3 O
stones	680 6 O
with	687 4 O
maximum	692 7 O
attenuation	700 11 O
scores	712 6 O
of	719 2 O
<	722 1 O
100	724 3 O
Hounsfield	728 10 O
units	739 5 O
(	745 1 O
values	746 6 O
of	753 2 O
<	756 1 O
100	758 3 O
HU	762 2 O
predict	765 7 O
cholesterol	773 11 B-Chemical
rich	785 4 O
,	789 1 O
dissolvable	791 11 O
stones	803 6 O
)	809 1 O
.	810 1 O

Gall	812 4 O
bladder	817 7 O
bile	825 4 O
was	830 3 O
obtained	834 8 O
by	843 2 O
ultrasound	846 10 O
guided	857 6 O
,	863 1 O
fine	865 4 O
needle	870 6 O
puncture	877 8 O
from	886 4 O
six	891 3 O
patients	895 8 O
.	903 1 O

All	905 3 O
six	909 3 O
patients	913 8 O
had	922 3 O
supersaturated	926 14 O
bile	941 4 O
(	946 1 O
mean	947 4 O
(	952 1 O
SEM	953 3 O
)	956 1 O
cholesterol	958 11 B-Chemical
saturation	970 10 O
index	981 5 O
of	987 2 O
1	990 1 O
.	991 1 O
19	992 2 O
(	995 1 O
0	996 1 O
.	997 1 O
08	998 2 O
)	1000 1 O
(	1002 1 O
range	1003 5 O
1	1009 1 O
.	1010 1 O
01	1011 2 O
-	1013 1 O
1	1014 1 O
.	1015 1 O
53	1016 2 O
)	1018 1 O
)	1019 1 O
and	1021 3 O
all	1025 3 O
had	1029 3 O
abnormally	1033 10 O
rapid	1044 5 O
cholesterol	1050 11 B-Chemical
microcrystal	1062 12 O
nucleation	1075 10 O
times	1086 5 O
(	1092 1 O
<	1093 1 O
4	1095 1 O
days	1097 4 O
(	1102 1 O
range	1103 5 O
1	1109 1 O
-	1110 1 O
4	1111 1 O
)	1112 1 O
)	1113 1 O
,	1114 1 O
whilst	1116 6 O
in	1123 2 O
four	1126 4 O
,	1130 1 O
the	1132 3 O
bile	1136 4 O
contained	1141 9 O
cholesterol	1151 11 B-Chemical
microcrystals	1163 13 O
immediately	1177 11 O
after	1189 5 O
sampling	1195 8 O
.	1203 1 O

Of	1205 2 O
the	1208 3 O
12	1212 2 O
patients	1215 8 O
considered	1224 10 O
for	1235 3 O
oral	1239 4 O
ursodeoxycholic	1244 15 B-Chemical
acid	1260 4 I-Chemical
(	1265 1 O
UDCA	1266 4 B-Chemical
)	1270 1 O
treatment	1272 9 O
,	1281 1 O
two	1283 3 O
had	1287 3 O
a	1291 1 O
blocked	1293 7 O
cystic	1301 6 O
duct	1308 4 O
and	1313 3 O
were	1317 4 O
not	1322 3 O
started	1326 7 O
on	1334 2 O
UDCA	1337 4 B-Chemical
while	1342 5 O
one	1348 3 O
was	1352 3 O
lost	1356 4 O
to	1361 2 O
follow	1364 6 O
up	1371 2 O
.	1373 1 O

After	1375 5 O
one	1381 3 O
year	1385 4 O
of	1390 2 O
treatment	1393 9 O
,	1402 1 O
five	1404 4 O
of	1409 2 O
the	1412 3 O
remaining	1416 9 O
nine	1426 4 O
patients	1431 8 O
showed	1440 6 O
either	1447 6 O
partial	1454 7 O
(	1462 1 O
n	1463 1 O
=	1465 1 O
3	1467 1 O
)	1468 1 O
or	1470 2 O
complete	1473 8 O
(	1482 1 O
n	1483 1 O
=	1485 1 O
2	1487 1 O
)	1488 1 O
gall	1490 4 B-Disease
stone	1495 5 I-Disease
dissolution	1501 11 O
,	1512 1 O
suggesting	1514 10 O
that	1525 4 O
their	1530 5 O
stones	1536 6 O
were	1543 4 O
cholesterol	1548 11 B-Chemical
rich	1560 4 O
.	1564 1 O

This	1566 4 O
corresponds	1571 11 O
,	1582 1 O
by	1584 2 O
actuarial	1587 9 O
(	1597 1 O
life	1598 4 O
table	1603 5 O
)	1608 1 O
analysis	1610 8 O
,	1618 1 O
to	1620 2 O
a	1623 1 O
combined	1625 8 O
gall	1634 4 B-Disease
stone	1639 5 I-Disease
dissolution	1645 11 O
rate	1657 4 O
of	1662 2 O
58	1665 2 O
.	1667 1 O
3	1668 1 O
(	1670 1 O
15	1671 2 O
.	1673 1 O
9	1674 1 O
%	1675 1 O
)	1676 1 O
.	1677 1 O

In	1679 2 O
conclusion	1682 10 O
,	1692 1 O
octreotide	1694 10 B-Chemical
induced	1705 7 O
gall	1713 4 B-Disease
stones	1718 6 I-Disease
are	1725 3 O
generally	1729 9 O
small	1739 5 O
,	1744 1 O
multiple	1746 8 O
,	1754 1 O
and	1756 3 O
cholesterol	1760 11 B-Chemical
rich	1772 4 O
although	1777 8 O
,	1785 1 O
in	1787 2 O
common	1790 6 O
with	1797 4 O
spontaneous	1802 11 O
gall	1814 4 B-Disease
stone	1819 5 I-Disease
disease	1825 7 I-Disease
,	1832 1 O
at	1834 2 O
presentation	1837 12 O
some	1850 4 O
patients	1855 8 O
will	1864 4 O
have	1869 4 O
a	1874 1 O
blocked	1876 7 O
cystic	1884 6 O
duct	1891 4 O
and	1896 3 O
some	1900 4 O
gall	1905 4 B-Disease
stones	1910 6 I-Disease
containing	1917 10 O
calcium	1928 7 B-Chemical
.	1935 1 O

Cardiovascular	0 14 B-Disease
complications	15 13 I-Disease
associated	29 10 O
with	40 4 O
terbutaline	45 11 B-Chemical
treatment	57 9 O
for	67 3 O
preterm	71 7 B-Disease
labor	79 5 I-Disease
.	84 1 O

Severe	86 6 O
cardiovascular	93 14 B-Disease
complications	108 13 I-Disease
occurred	122 8 O
in	131 2 O
eight	134 5 O
of	140 2 O
160	143 3 O
patients	147 8 O
treated	156 7 O
with	164 4 O
terbutaline	169 11 B-Chemical
for	181 3 O
preterm	185 7 B-Disease
labor	193 5 I-Disease
.	198 1 O

Associated	200 10 O
corticosteroid	211 14 O
therapy	226 7 O
and	234 3 O
twin	238 4 O
gestations	243 10 O
appear	254 6 O
to	261 2 O
be	264 2 O
predisposing	267 12 O
factors	280 7 O
.	287 1 O

Potential	289 9 O
mechanisms	299 10 O
of	310 2 O
the	313 3 O
pathophysiology	317 15 O
are	333 3 O
briefly	337 7 O
discussed	345 9 O
.	354 1 O

Neurologic	0 10 O
effects	11 7 O
of	19 2 O
subarachnoid	22 12 O
administration	35 14 O
of	50 2 O
2	53 1 B-Chemical
-	54 1 I-Chemical
chloroprocaine	55 14 I-Chemical
-	69 1 I-Chemical
CE	70 2 I-Chemical
,	72 1 O
bupivacaine	74 11 B-Chemical
,	85 1 O
and	87 3 O
low	91 3 O
pH	95 2 O
normal	98 6 O
saline	105 6 O
in	112 2 O
dogs	115 4 O
.	119 1 O

The	121 3 O
purpose	125 7 O
of	133 2 O
this	136 4 O
study	141 5 O
was	147 3 O
to	151 2 O
evaluate	154 8 O
the	163 3 O
neurologic	167 10 O
consequences	178 12 O
of	191 2 O
deliberate	194 10 O
subarachnoid	205 12 O
injection	218 9 O
of	228 2 O
large	231 5 O
volumes	237 7 O
of	245 2 O
2	248 1 B-Chemical
-	249 1 I-Chemical
chloroprocaine	250 14 I-Chemical
-	264 1 I-Chemical
CE	265 2 I-Chemical
in	268 2 O
experimental	271 12 O
animals	284 7 O
.	291 1 O

The	293 3 O
possible	297 8 O
role	306 4 O
of	311 2 O
low	314 3 O
pH	318 2 O
as	321 2 O
well	324 4 O
as	329 2 O
total	332 5 O
volume	338 6 O
as	345 2 O
potential	348 9 O
factors	358 7 O
in	366 2 O
causing	369 7 O
neurotoxicity	377 13 B-Disease
was	391 3 O
evaluated	395 9 O
.	404 1 O

The	406 3 O
65	410 2 O
dogs	413 4 O
in	418 2 O
the	421 3 O
study	425 5 O
received	431 8 O
injections	440 10 O
in	451 2 O
the	454 3 O
subarachnoid	458 12 O
space	471 5 O
as	477 2 O
follows	480 7 O
:	487 1 O
6	489 1 O
to	491 2 O
8	494 1 O
ml	496 2 O
of	499 2 O
bupivacaine	502 11 B-Chemical
(	514 1 O
N	515 1 O
=	517 1 O
15	519 2 O
)	521 1 O
,	522 1 O
2	524 1 B-Chemical
-	525 1 I-Chemical
chloroprocaine	526 14 I-Chemical
-	540 1 I-Chemical
CE	541 2 I-Chemical
(	544 1 O
N	545 1 O
=	547 1 O
20	549 2 O
)	551 1 O
,	552 1 O
low	554 3 O
pH	558 2 O
normal	561 6 O
saline	568 6 O
(	575 1 O
pH	576 2 O
3	579 1 O
.	580 1 O
0	581 1 O
)	582 1 O
(	584 1 O
N	585 1 O
=	587 1 O
20	589 2 O
)	591 1 O
,	592 1 O
or	594 2 O
normal	597 6 O
saline	604 6 O
(	611 1 O
N	612 1 O
=	614 1 O
10	616 2 O
)	618 1 O
.	619 1 O

Of	621 2 O
the	624 3 O
20	628 2 O
animals	631 7 O
that	639 4 O
received	644 8 O
subarachnoid	653 12 O
injection	666 9 O
of	676 2 O
2	679 1 B-Chemical
-	680 1 I-Chemical
chloroprocaine	681 14 I-Chemical
-	695 1 I-Chemical
CE	696 2 I-Chemical
seven	699 5 O
(	705 1 O
35	706 2 O
%	708 1 O
)	709 1 O
developed	711 9 O
hind	721 4 O
-	725 1 O
limb	726 4 O
paralysis	731 9 B-Disease
.	740 1 O

None	742 4 O
of	747 2 O
the	750 3 O
animals	754 7 O
that	762 4 O
received	767 8 O
bupivacaine	776 11 B-Chemical
,	787 1 O
normal	789 6 O
saline	796 6 O
,	802 1 O
or	804 2 O
normal	807 6 O
saline	814 6 O
titrated	821 8 O
to	830 2 O
a	833 1 O
pH	835 2 O
3	838 1 O
.	839 1 O
0	840 1 O
developed	842 9 O
hind	852 4 O
-	856 1 O
limb	857 4 O
paralysis	862 9 B-Disease
.	871 1 O

Of	873 2 O
the	876 3 O
15	880 2 O
spinal	883 6 O
cords	890 5 O
of	896 2 O
the	899 3 O
animals	903 7 O
that	911 4 O
received	916 8 O
2	925 1 B-Chemical
-	926 1 I-Chemical
chloroprocaine	927 14 I-Chemical
-	941 1 I-Chemical
CE	942 2 I-Chemical
,	944 1 O
13	946 2 O
showed	949 6 O
subpial	956 7 B-Disease
necrosis	964 8 I-Disease
;	972 1 O
the	974 3 O
nerve	978 5 O
roots	984 5 O
and	990 3 O
subarachnoid	994 12 O
vessels	1007 7 O
were	1015 4 O
normal	1020 6 O
.	1026 1 O

The	1028 3 O
spinal	1032 6 O
cords	1039 5 O
of	1045 2 O
the	1048 3 O
animals	1052 7 O
that	1060 4 O
received	1065 8 O
bupivacaine	1074 11 B-Chemical
,	1085 1 O
low	1087 3 O
pH	1091 2 O
normal	1094 6 O
saline	1101 6 O
(	1108 1 O
pH	1109 2 O
3	1112 1 O
.	1113 1 O
0	1114 1 O
)	1115 1 O
,	1116 1 O
or	1118 2 O
normal	1121 6 O
saline	1128 6 O
did	1135 3 O
not	1139 3 O
show	1143 4 O
abnormal	1148 8 O
findings	1157 8 O
.	1165 1 O

Early	0 5 O
adjuvant	6 8 O
adriamycin	15 10 B-Chemical
in	26 2 O
superficial	29 11 O
bladder	41 7 B-Disease
carcinoma	49 9 I-Disease
.	58 1 O

A	60 1 O
multicenter	62 11 O
study	74 5 O
was	80 3 O
performed	84 9 O
in	94 2 O
110	97 3 O
patients	101 8 O
with	110 4 O
superficial	115 11 O
transitional	127 12 O
cell	140 4 O
carcinoma	145 9 B-Disease
of	155 2 I-Disease
the	158 3 I-Disease
bladder	162 7 I-Disease
.	169 1 O

Adriamycin	171 10 B-Chemical
(	182 1 O
50	183 2 O
mg	186 2 O
/	188 1 O
50	189 2 O
ml	192 2 O
)	194 1 O
was	196 3 O
administered	200 12 O
intravesically	213 14 O
within	228 6 O
24	235 2 O
h	238 1 O
after	240 5 O
transurethral	246 13 O
resection	260 9 O
of	270 2 O
TA	273 2 O
-	275 1 O
T1	276 2 O
(	279 1 O
O	280 1 O
-	281 1 O
A	282 1 O
)	283 1 O
bladder	285 7 B-Disease
tumors	293 6 I-Disease
.	299 1 O

Instillation	301 12 O
was	314 3 O
repeated	318 8 O
twice	327 5 O
during	333 6 O
the	340 3 O
first	344 5 O
week	350 4 O
,	354 1 O
then	356 4 O
weekly	361 6 O
during	368 6 O
the	375 3 O
first	379 5 O
month	385 5 O
and	391 3 O
afterwards	395 10 O
monthly	406 7 O
for	414 3 O
1	418 1 O
year	420 4 O
.	424 1 O

The	426 3 O
tolerance	430 9 O
was	440 3 O
evaluated	444 9 O
in	454 2 O
these	457 5 O
110	463 3 O
patients	467 8 O
,	475 1 O
and	477 3 O
29	481 2 O
patients	484 8 O
presented	493 9 O
with	503 4 O
local	508 5 O
side	514 4 O
-	518 1 O
effects	519 7 O
.	526 1 O

In	528 2 O
24	531 2 O
of	534 2 O
these	537 5 O
patients	543 8 O
chemical	552 8 O
cystitis	561 8 B-Disease
was	570 3 O
severe	574 6 O
enough	581 6 O
for	588 3 O
them	592 4 O
to	597 2 O
drop	600 4 O
out	605 3 O
of	609 2 O
the	612 3 O
study	616 5 O
.	621 1 O

No	623 2 O
systemic	626 8 O
side	635 4 O
-	639 1 O
effects	640 7 O
were	648 4 O
observed	653 8 O
.	661 1 O

Recurrence	663 10 O
was	674 3 O
studied	678 7 O
in	686 2 O
82	689 2 O
evaluable	692 9 O
patients	702 8 O
after	711 5 O
1	717 1 O
year	719 4 O
of	724 2 O
follow	727 6 O
-	733 1 O
up	734 2 O
and	737 3 O
in	741 2 O
72	744 2 O
patients	747 8 O
followed	756 8 O
for	765 3 O
2	769 1 O
-	770 1 O
3	771 1 O
years	773 5 O
(	779 1 O
mean	780 4 O
32	785 2 O
months	788 6 O
)	794 1 O
.	795 1 O

Of	797 2 O
the	800 3 O
82	804 2 O
patients	807 8 O
studied	816 7 O
after	824 5 O
1	830 1 O
year	832 4 O
,	836 1 O
23	838 2 O
had	841 3 O
primary	845 7 O
and	853 3 O
59	857 2 O
recurrent	860 9 O
disease	870 7 O
.	877 1 O

Of	879 2 O
the	882 3 O
82	886 2 O
evaluable	889 9 O
patients	899 8 O
,	907 1 O
50	909 2 O
did	912 3 O
not	916 3 O
show	920 4 O
any	925 3 O
recurrence	929 10 O
after	940 5 O
1	946 1 O
year	948 4 O
(	953 1 O
61	954 2 O
%	956 1 O
)	957 1 O
,	958 1 O
while	960 5 O
32	966 2 O
presented	969 9 O
with	979 4 O
one	984 3 O
or	988 2 O
more	991 4 O
recurrences	996 11 O
(	1008 1 O
39	1009 2 O
%	1011 1 O
)	1012 1 O
.	1013 1 O

Of	1015 2 O
these	1018 5 O
recurrences	1024 11 O
,	1035 1 O
27	1037 2 O
were	1040 4 O
T1	1045 2 O
tumors	1048 6 B-Disease
while	1055 5 O
five	1061 4 O
progressed	1066 10 O
to	1077 2 O
more	1080 4 O
highly	1085 6 O
invasive	1092 8 O
lesions	1101 7 O
.	1108 1 O

In	1110 2 O
patients	1113 8 O
that	1122 4 O
were	1127 4 O
free	1132 4 O
of	1137 2 O
recurrence	1140 10 O
during	1151 6 O
the	1158 3 O
first	1162 5 O
year	1168 4 O
,	1172 1 O
80	1174 2 O
%	1176 1 O
remained	1178 8 O
tumor	1187 5 B-Disease
-	1192 1 O
free	1193 4 O
during	1198 6 O
the	1205 3 O
2	1209 1 O
-	1210 1 O
to	1212 2 O
3	1215 1 O
-	1216 1 O
year	1217 4 O
follow	1222 6 O
-	1228 1 O
up	1229 2 O
period	1232 6 O
.	1238 1 O

Of	1240 2 O
the	1243 3 O
patients	1247 8 O
developing	1256 10 O
one	1267 3 O
or	1271 2 O
more	1274 4 O
recurrences	1279 11 O
during	1291 6 O
the	1298 3 O
first	1302 5 O
year	1308 4 O
,	1312 1 O
only	1314 4 O
50	1319 2 O
%	1321 1 O
presented	1323 9 O
with	1333 4 O
further	1338 7 O
recurrence	1346 10 O
once	1357 4 O
the	1362 3 O
instillations	1366 13 O
were	1380 4 O
stopped	1385 7 O
.	1392 1 O

The	1394 3 O
beneficial	1398 10 O
effect	1409 6 O
of	1416 2 O
Adriamycin	1419 10 B-Chemical
appears	1430 7 O
obvious	1438 7 O
and	1446 3 O
might	1450 5 O
be	1456 2 O
related	1459 7 O
to	1467 2 O
the	1470 3 O
drug	1474 4 O
itself	1479 6 O
,	1485 1 O
the	1487 3 O
early	1491 5 O
and	1497 3 O
repeated	1501 8 O
instillations	1510 13 O
after	1524 5 O
TUR	1530 3 O
,	1533 1 O
or	1535 2 O
both	1538 4 O
.	1542 1 O

Hyperkalemia	0 12 B-Disease
associated	13 10 O
with	24 4 O
sulindac	29 8 B-Chemical
therapy	38 7 O
.	45 1 O

Hyperkalemia	47 12 B-Disease
has	60 3 O
recently	64 8 O
been	73 4 O
recognized	78 10 O
as	89 2 O
a	92 1 O
complication	94 12 O
of	107 2 O
nonsteroidal	110 12 O
antiinflammatory	123 16 O
agents	140 6 O
(	147 1 O
NSAID	148 5 O
)	153 1 O
such	155 4 O
as	160 2 O
indomethacin	163 12 B-Chemical
.	175 1 O

Several	177 7 O
recent	185 6 O
studies	192 7 O
have	200 4 O
stressed	205 8 O
the	214 3 O
renal	218 5 O
sparing	224 7 O
features	232 8 O
of	241 2 O
sulindac	244 8 B-Chemical
,	252 1 O
owing	254 5 O
to	260 2 O
its	263 3 O
lack	267 4 O
of	272 2 O
interference	275 12 O
with	288 4 O
renal	293 5 O
prostacyclin	299 12 B-Chemical
synthesis	312 9 O
.	321 1 O

We	323 2 O
describe	326 8 O
4	335 1 O
patients	337 8 O
in	346 2 O
whom	349 4 O
hyperkalemia	354 12 B-Disease
ranging	367 7 O
from	375 4 O
6	380 1 O
.	381 1 O
1	382 1 O
to	384 2 O
6	387 1 O
.	388 1 O
9	389 1 O
mEq	391 3 O
/	394 1 O
l	395 1 O
developed	397 9 O
within	407 6 O
3	414 1 O
to	416 2 O
8	419 1 O
days	421 4 O
of	426 2 O
sulindac	429 8 B-Chemical
administration	438 14 O
.	452 1 O

In	454 2 O
all	457 3 O
of	461 2 O
them	464 4 O
normal	469 6 O
serum	476 5 O
potassium	482 9 B-Chemical
levels	492 6 O
reached	499 7 O
within	507 6 O
2	514 1 O
to	516 2 O
4	519 1 O
days	521 4 O
of	526 2 O
stopping	529 8 O
sulindac	538 8 B-Chemical
.	546 1 O

As	548 2 O
no	551 2 O
other	554 5 O
medications	560 11 O
known	572 5 O
to	578 2 O
effect	581 6 O
serum	588 5 O
potassium	594 9 B-Chemical
had	604 3 O
been	608 4 O
given	613 5 O
concomitantly	619 13 O
,	632 1 O
this	634 4 O
course	639 6 O
of	646 2 O
events	649 6 O
is	656 2 O
suggestive	659 10 O
of	670 2 O
a	673 1 O
cause	675 5 O
-	680 1 O
and	681 3 O
-	684 1 O
effect	685 6 O
relationship	692 12 O
between	705 7 O
sulindac	713 8 B-Chemical
and	722 3 O
hyperkalemia	726 12 B-Disease
.	738 1 O

These	740 5 O
observations	746 12 O
indicate	759 8 O
that	768 4 O
initial	773 7 O
hopes	781 5 O
that	787 4 O
sulindac	792 8 B-Chemical
may	801 3 O
not	805 3 O
be	809 2 O
associated	812 10 O
with	823 4 O
the	828 3 O
adverse	832 7 O
renal	840 5 O
effects	846 7 O
of	854 2 O
other	857 5 O
NSAID	863 5 O
are	869 3 O
probably	873 8 O
not	882 3 O
justified	886 9 O
.	895 1 O

Ventricular	0 11 B-Disease
tachyarrhythmias	12 16 I-Disease
during	29 6 O
cesarean	36 8 O
section	45 7 O
after	53 5 O
ritodrine	59 9 B-Chemical
therapy	69 7 O
:	76 1 O
interaction	78 11 O
with	90 4 O
anesthetics	95 11 O
.	106 1 O

This	108 4 O
case	113 4 O
illustrates	118 11 O
that	130 4 O
patients	135 8 O
receiving	144 9 O
ritodrine	154 9 B-Chemical
for	164 3 O
preterm	168 7 B-Disease
labor	176 5 I-Disease
may	182 3 O
risk	186 4 O
interactions	191 12 O
between	204 7 O
the	212 3 O
residual	216 8 O
betamimetic	225 11 O
effects	237 7 O
of	245 2 O
ritodrine	248 9 B-Chemical
and	258 3 O
the	262 3 O
effects	266 7 O
of	274 2 O
anesthetics	277 11 O
during	289 6 O
cesarean	296 8 O
section	305 7 O
.	312 1 O

Such	314 4 O
interactions	319 12 O
may	332 3 O
result	336 6 O
in	343 2 O
serious	346 7 O
cardiovascular	354 14 B-Disease
complications	369 13 I-Disease
even	383 4 O
after	388 5 O
cessation	394 9 O
of	404 2 O
an	407 2 O
infusion	410 8 O
of	419 2 O
ritodrine	422 9 B-Chemical
.	431 1 O

Preoperative	433 12 O
assessment	446 10 O
should	457 6 O
focus	464 5 O
on	470 2 O
cardiovascular	473 14 O
status	488 6 O
and	495 3 O
serum	499 5 O
potassium	505 9 B-Chemical
level	515 5 O
.	520 1 O

Delaying	522 8 O
induction	531 9 O
of	541 2 O
anesthesia	544 10 O
should	555 6 O
be	562 2 O
considered	565 10 O
whenever	576 8 O
possible	585 8 O
.	593 1 O

Careful	595 7 O
fluid	603 5 O
administration	609 14 O
and	624 3 O
cautious	628 8 O
use	637 3 O
of	641 2 O
titrated	644 8 O
doses	653 5 O
of	659 2 O
ephedrine	662 9 B-Chemical
are	672 3 O
advised	676 7 O
.	683 1 O

After	685 5 O
delivery	691 8 O
of	700 2 O
the	703 3 O
infant	707 6 O
,	713 1 O
there	715 5 O
should	721 6 O
be	728 2 O
no	731 2 O
contraindication	734 16 O
to	751 2 O
the	754 3 O
use	758 3 O
of	762 2 O
an	765 2 O
alpha	768 5 O
-	773 1 O
adrenergic	774 10 O
vasopressor	785 11 O
such	797 4 O
as	802 2 O
phenylephrine	805 13 B-Chemical
to	819 2 O
treat	822 5 O
hypotensive	828 11 B-Disease
patients	840 8 O
with	849 4 O
tachycardia	854 11 B-Disease
.	865 1 O

Immunohistochemical	0 19 O
,	19 1 O
electron	21 8 O
microscopic	30 11 O
and	42 3 O
morphometric	46 12 O
studies	59 7 O
of	67 2 O
estrogen	70 8 B-Chemical
-	78 1 O
induced	79 7 O
rat	87 3 O
prolactinomas	91 13 B-Disease
after	105 5 O
bromocriptine	111 13 B-Chemical
treatment	125 9 O
.	134 1 O

To	136 2 O
clarify	139 7 O
the	147 3 O
effects	151 7 O
of	159 2 O
bromocriptine	162 13 B-Chemical
on	176 2 O
prolactinoma	179 12 B-Disease
cells	192 5 O
in	198 2 O
vivo	201 4 O
,	205 1 O
immunohistochemical	207 19 O
,	226 1 O
ultrastructural	228 15 O
and	244 3 O
morphometrical	248 14 O
analyses	263 8 O
were	272 4 O
applied	277 7 O
to	285 2 O
estrogen	288 8 B-Chemical
-	296 1 O
induced	297 7 O
rat	305 3 O
prolactinoma	309 12 B-Disease
cells	322 5 O
1	328 1 O
h	330 1 O
and	332 3 O
6	336 1 O
h	338 1 O
after	340 5 O
injection	346 9 O
of	356 2 O
bromocriptine	359 13 B-Chemical
(	373 1 O
3	374 1 O
mg	376 2 O
/	378 1 O
kg	379 2 O
of	382 2 O
body	385 4 O
weight	390 6 O
)	396 1 O
.	397 1 O

One	399 3 O
h	403 1 O
after	405 5 O
treatment	411 9 O
,	420 1 O
serum	422 5 O
prolactin	428 9 O
levels	438 6 O
decreased	445 9 O
markedly	455 8 O
.	463 1 O

Electron	465 8 O
microscopy	474 10 O
disclosed	485 9 O
many	495 4 O
secretory	500 9 O
granules	510 8 O
,	518 1 O
slightly	520 8 O
distorted	529 9 O
rough	539 5 O
endoplasmic	545 11 O
reticulum	557 9 O
,	566 1 O
and	568 3 O
partially	572 9 O
dilated	582 7 O
Golgi	590 5 O
cisternae	596 9 O
in	606 2 O
the	609 3 O
prolactinoma	613 12 B-Disease
cells	626 5 O
.	631 1 O

Morphometric	633 12 O
analysis	646 8 O
revealed	655 8 O
that	664 4 O
the	669 3 O
volume	673 6 O
density	680 7 O
of	688 2 O
secretory	691 9 O
granules	701 8 O
increased	710 9 O
,	719 1 O
while	721 5 O
the	727 3 O
volume	731 6 O
density	738 7 O
of	746 2 O
cytoplasmic	749 11 O
microtubules	761 12 O
decreased	774 9 O
.	783 1 O

These	785 5 O
findings	791 8 O
suggest	800 7 O
that	808 4 O
lowered	813 7 O
serum	821 5 O
prolactin	827 9 O
levels	837 6 O
in	844 2 O
the	847 3 O
early	851 5 O
phase	857 5 O
of	863 2 O
bromocriptine	866 13 B-Chemical
treatment	880 9 O
may	890 3 O
result	894 6 O
from	901 4 O
an	906 2 O
impaired	909 8 O
secretion	918 9 O
of	928 2 O
prolactin	931 9 O
due	941 3 O
to	945 2 O
decreasing	948 10 O
numbers	959 7 O
of	967 2 O
cytoplasmic	970 11 O
microtubules	982 12 O
.	994 1 O

At	996 2 O
6	999 1 O
h	1001 1 O
after	1003 5 O
injection	1009 9 O
,	1018 1 O
serum	1020 5 O
prolactin	1026 9 O
levels	1036 6 O
were	1043 4 O
still	1048 5 O
considerably	1054 12 O
lower	1067 5 O
than	1073 4 O
in	1078 2 O
controls	1081 8 O
.	1089 1 O

The	1091 3 O
prolactinoma	1095 12 B-Disease
cells	1108 5 O
at	1114 2 O
this	1117 4 O
time	1122 4 O
were	1127 4 O
well	1132 4 O
granulated	1137 10 O
,	1147 1 O
with	1149 4 O
vesiculated	1154 11 O
rough	1166 5 O
endoplasmic	1172 11 O
reticulum	1184 9 O
and	1194 3 O
markedly	1198 8 O
dilated	1207 7 O
Golgi	1215 5 O
cisternae	1221 9 O
.	1230 1 O

Electron	1232 8 O
microscopical	1241 13 O
immunohistochemistry	1255 20 O
revealed	1276 8 O
positive	1285 8 O
reaction	1294 8 O
products	1303 8 O
noted	1312 5 O
on	1318 2 O
the	1321 3 O
secretory	1325 9 O
granules	1335 8 O
,	1343 1 O
Golgi	1345 5 O
cisternae	1351 9 O
,	1360 1 O
and	1362 3 O
endoplasmic	1366 11 O
reticulum	1378 9 O
of	1388 2 O
the	1391 3 O
untreated	1395 9 O
rat	1405 3 O
prolactinoma	1409 12 B-Disease
cells	1422 5 O
.	1427 1 O

However	1429 7 O
,	1436 1 O
only	1438 4 O
secretory	1443 9 O
granules	1453 8 O
showed	1462 6 O
the	1469 3 O
positive	1473 8 O
reaction	1482 8 O
products	1491 8 O
for	1500 3 O
prolactin	1504 9 O
6	1514 1 O
h	1516 1 O
after	1518 5 O
bromocriptine	1524 13 B-Chemical
treatment	1538 9 O
of	1548 2 O
the	1551 3 O
adenoma	1555 7 B-Disease
cells	1563 5 O
.	1568 1 O

An	1570 2 O
increase	1573 8 O
in	1582 2 O
the	1585 3 O
volume	1589 6 O
density	1596 7 O
of	1604 2 O
secretory	1607 9 O
granules	1617 8 O
and	1626 3 O
a	1630 1 O
decrease	1632 8 O
in	1641 2 O
the	1644 3 O
volume	1648 6 O
densities	1655 9 O
of	1665 2 O
rough	1668 5 O
endoplasmic	1674 11 O
reticulum	1686 9 O
and	1696 3 O
microtubules	1700 12 O
was	1713 3 O
determined	1717 10 O
by	1728 2 O
morphometric	1731 12 O
analysis	1744 8 O
,	1752 1 O
suggesting	1754 10 O
that	1765 4 O
bromocriptine	1770 13 B-Chemical
inhibits	1784 8 O
protein	1793 7 O
synthesis	1801 9 O
as	1811 2 O
well	1814 4 O
as	1819 2 O
bringing	1822 8 O
about	1831 5 O
a	1837 1 O
disturbance	1839 11 O
of	1851 2 O
the	1854 3 O
prolactin	1858 9 O
secretion	1868 9 O
.	1877 1 O

On	0 2 O
two	3 3 O
paradoxical	7 11 O
side	19 4 O
-	23 1 O
effects	24 7 O
of	32 2 O
prednisolone	35 12 B-Chemical
in	48 2 O
rats	51 4 O
,	55 1 O
ribosomal	57 9 O
RNA	67 3 O
biosyntheses	71 12 O
,	83 1 O
and	85 3 O
a	89 1 O
mechanism	91 9 O
of	101 2 O
action	104 6 O
.	110 1 O

Liver	112 5 B-Disease
enlargement	118 11 I-Disease
and	130 3 O
muscle	134 6 B-Disease
wastage	141 7 I-Disease
occurred	149 8 O
in	158 2 O
Wistar	161 6 O
rats	168 4 O
following	173 9 O
the	183 3 O
subcutaneous	187 12 O
administration	200 14 O
of	215 2 O
prednisolone	218 12 B-Chemical
.	230 1 O

In	232 2 O
the	235 3 O
liver	239 5 O
both	245 4 O
the	250 3 O
content	254 7 O
of	262 2 O
RNA	265 3 O
and	269 3 O
the	273 3 O
biosynthesis	277 12 O
of	290 2 O
ribosomal	293 9 O
RNA	303 3 O
increased	307 9 O
while	317 5 O
both	323 4 O
the	328 3 O
RNA	332 3 O
content	336 7 O
and	344 3 O
ribosomal	348 9 O
RNA	358 3 O
biosynthesis	362 12 O
were	375 4 O
reduced	380 7 O
in	388 2 O
the	391 3 O
gastrocnemius	395 13 O
muscle	409 6 O
.	415 1 O

It	417 2 O
is	420 2 O
suggested	423 9 O
that	433 4 O
the	438 3 O
drug	442 4 O
acted	447 5 O
in	453 2 O
a	456 1 O
selective	458 9 O
and	468 3 O
tissue	472 6 O
-	478 1 O
specific	479 8 O
manner	488 6 O
to	495 2 O
enhance	498 7 O
ribosomal	506 9 O
RNA	516 3 O
synthesis	520 9 O
in	530 2 O
the	533 3 O
liver	537 5 O
and	543 3 O
depress	547 7 O
such	555 4 O
synthesis	560 9 O
in	570 2 O
the	573 3 O
muscle	577 6 O
.	583 1 O

This	585 4 O
view	590 4 O
supports	595 8 O
the	604 3 O
contention	608 10 O
that	619 4 O
the	624 3 O
liver	628 5 O
and	634 3 O
muscle	638 6 O
are	645 3 O
independent	649 11 O
sites	661 5 O
of	667 2 O
prednisolone	670 12 B-Chemical
action	683 6 O
.	689 1 O

Possible	0 8 O
intramuscular	9 13 O
midazolam	23 9 B-Chemical
-	32 1 O
associated	33 10 O
cardiorespiratory	44 17 B-Disease
arrest	62 6 I-Disease
and	69 3 O
death	73 5 B-Disease
.	78 1 O

Midazolam	80 9 B-Chemical
hydrochloride	90 13 I-Chemical
is	104 2 O
commonly	107 8 O
used	116 4 O
for	121 3 O
dental	125 6 O
or	132 2 O
endoscopic	135 10 O
procedures	146 10 O
.	156 1 O

Although	158 8 O
generally	167 9 O
consisted	177 9 O
safe	187 4 O
when	192 4 O
given	197 5 O
intramuscularly	203 15 O
,	218 1 O
intravenous	220 11 O
administration	232 14 O
is	247 2 O
known	250 5 O
to	256 2 O
cause	259 5 O
respiratory	265 11 B-Disease
and	277 3 I-Disease
cardiovascular	281 14 I-Disease
depression	296 10 I-Disease
.	306 1 O

This	308 4 O
report	313 6 O
describes	320 9 O
the	330 3 O
first	334 5 O
published	340 9 O
case	350 4 O
of	355 2 O
cardiorespiratory	358 17 B-Disease
arrest	376 6 I-Disease
and	383 3 O
death	387 5 B-Disease
associated	393 10 O
with	404 4 O
intramuscular	409 13 O
administration	423 14 O
of	438 2 O
midazolam	441 9 B-Chemical
.	450 1 O

Information	452 11 O
regarding	464 9 O
midazolam	474 9 B-Chemical
use	484 3 O
is	488 2 O
reviewed	491 8 O
to	500 2 O
provide	503 7 O
recommendation	511 14 O
for	526 3 O
safe	530 4 O
administration	535 14 O
.	549 1 O

Serial	0 6 O
epilepsy	7 8 B-Disease
caused	16 6 O
by	23 2 O
levodopa	26 8 B-Chemical
/	34 1 I-Chemical
carbidopa	35 9 I-Chemical
administration	45 14 O
in	60 2 O
two	63 3 O
patients	67 8 O
on	76 2 O
hemodialysis	79 12 O
.	91 1 O

Two	93 3 O
patients	97 8 O
with	106 4 O
similar	111 7 O
clinical	119 8 O
features	128 8 O
are	137 3 O
presented	141 9 O
:	150 1 O
both	152 4 O
patients	157 8 O
had	166 3 O
chronic	170 7 B-Disease
renal	178 5 I-Disease
failure	184 7 I-Disease
,	191 1 O
on	193 2 O
hemodialysis	196 12 O
for	209 3 O
many	213 4 O
years	218 5 O
but	224 3 O
recently	228 8 O
begun	237 5 O
on	243 2 O
a	246 1 O
high	248 4 O
-	252 1 O
flux	253 4 O
dialyzer	258 8 O
;	266 1 O
both	268 4 O
had	273 3 O
been	277 4 O
receiving	282 9 O
a	292 1 O
carbidopa	294 9 B-Chemical
/	303 1 I-Chemical
levodopa	304 8 I-Chemical
preparation	313 11 O
;	324 1 O
and	326 3 O
both	330 4 O
had	335 3 O
the	339 3 O
onset	343 5 O
of	349 2 O
hallucinosis	352 12 B-Disease
and	365 3 O
recurrent	369 9 O
seizures	379 8 B-Disease
,	387 1 O
which	389 5 O
were	395 4 O
refractory	400 10 O
to	411 2 O
anticonvulsants	414 15 O
.	429 1 O

The	431 3 O
first	435 5 O
patient	441 7 O
died	449 4 O
without	454 7 O
a	462 1 O
diagnosis	464 9 O
;	473 1 O
the	475 3 O
second	479 6 O
patient	486 7 O
had	494 3 O
a	498 1 O
dramatic	500 8 O
recovery	509 8 O
following	518 9 O
the	528 3 O
administration	532 14 O
of	547 2 O
vitamin	550 7 B-Chemical
B6	558 2 I-Chemical
.	560 1 O

Neither	562 7 O
patient	570 7 O
was	578 3 O
considered	582 10 O
to	593 2 O
have	596 4 O
a	601 1 O
renal	603 5 O
state	609 5 O
sufficiently	615 12 O
severe	628 6 O
enough	635 6 O
to	642 2 O
explain	645 7 O
their	653 5 O
presentation	659 12 O
.	671 1 O

Effect	0 6 O
of	7 2 O
L	10 1 B-Chemical
-	11 1 I-Chemical
alpha	12 5 I-Chemical
-	17 1 I-Chemical
glyceryl	18 8 I-Chemical
-	26 1 I-Chemical
phosphorylcholine	27 17 I-Chemical
on	45 2 O
amnesia	48 7 B-Disease
caused	56 6 O
by	63 2 O
scopolamine	66 11 B-Chemical
.	77 1 O

The	79 3 O
present	83 7 O
study	91 5 O
was	97 3 O
carried	101 7 O
out	109 3 O
to	113 2 O
test	116 4 O
the	121 3 O
effects	125 7 O
of	133 2 O
L	136 1 B-Chemical
-	137 1 I-Chemical
alpha	138 5 I-Chemical
-	143 1 I-Chemical
glycerylphosphorylcholine	144 25 I-Chemical
(	170 1 O
L	171 1 B-Chemical
-	172 1 I-Chemical
alpha	173 5 I-Chemical
-	178 1 I-Chemical
GFC	179 3 I-Chemical
)	182 1 O
on	184 2 O
memory	187 6 B-Disease
impairment	194 10 I-Disease
induced	205 7 O
by	213 2 O
scopolamine	216 11 B-Chemical
in	228 2 O
man	231 3 O
.	234 1 O

Thirty	236 6 O
-	242 1 O
two	243 3 O
healthy	247 7 O
young	255 5 O
volunteers	261 10 O
were	272 4 O
randomly	277 8 O
allocated	286 9 O
to	296 2 O
four	299 4 O
different	304 9 O
groups	314 6 O
.	320 1 O

They	322 4 O
were	327 4 O
given	332 5 O
a	338 1 O
ten	340 3 O
day	344 3 O
pretreatment	348 12 O
with	361 4 O
either	366 6 O
L	373 1 B-Chemical
-	374 1 I-Chemical
alpha	375 5 I-Chemical
-	380 1 I-Chemical
GFC	381 3 I-Chemical
or	385 2 O
placebo	388 7 O
,	395 1 O
p	397 1 O
.	398 1 O
o	399 1 O
.	400 1 O
,	401 1 O
and	403 3 O
on	407 2 O
the	410 3 O
eleventh	414 8 O
day	423 3 O
either	427 6 O
scopolamine	434 11 B-Chemical
or	446 2 O
placebo	449 7 O
,	456 1 O
i	458 1 O
.	459 1 O
m	460 1 O
.	461 1 O

Before	463 6 O
and	470 3 O
0	474 1 O
.	475 1 O
5	476 1 O
,	477 1 O
1	479 1 O
,	480 1 O
2	482 1 O
,	483 1 O
3	485 1 O
,	486 1 O
and	488 3 O
6	492 1 O
h	494 1 O
after	496 5 O
injection	502 9 O
the	512 3 O
subjects	516 8 O
were	525 4 O
given	530 5 O
attention	536 9 O
and	546 3 O
mnemonic	550 8 O
tests	559 5 O
.	564 1 O

The	566 3 O
findings	570 8 O
of	579 2 O
this	582 4 O
study	587 5 O
indicate	593 8 O
that	602 4 O
the	607 3 O
drug	611 4 O
is	616 2 O
able	619 4 O
to	624 2 O
antagonize	627 10 O
impairment	638 10 B-Disease
of	649 2 I-Disease
attention	652 9 I-Disease
and	662 3 I-Disease
memory	666 6 I-Disease
induced	673 7 O
by	681 2 O
scopolamine	684 11 B-Chemical
.	695 1 O

Seizures	0 8 B-Disease
induced	9 7 O
by	17 2 O
the	20 3 O
cocaine	24 7 B-Chemical
metabolite	32 10 O
benzoylecgonine	43 15 B-Chemical
in	59 2 O
rats	62 4 O
.	66 1 O

The	68 3 O
half	72 4 O
-	76 1 O
life	77 4 O
(	82 1 O
t1	83 2 O
/	85 1 O
2	86 1 O
)	87 1 O
of	89 2 O
cocaine	92 7 B-Chemical
is	100 2 O
relatively	103 10 O
short	114 5 O
,	119 1 O
but	121 3 O
some	125 4 O
of	130 2 O
the	133 3 O
consequences	137 12 O
of	150 2 O
its	153 3 O
use	157 3 O
,	160 1 O
such	162 4 O
as	167 2 O
seizures	170 8 B-Disease
and	179 3 O
strokes	183 7 B-Disease
,	190 1 O
can	192 3 O
occur	196 5 O
hours	202 5 O
after	208 5 O
exposure	214 8 O
.	222 1 O

This	224 4 O
led	229 3 O
us	233 2 O
to	236 2 O
hypothesize	239 11 O
that	251 4 O
a	256 1 O
metabolite	258 10 O
of	269 2 O
cocaine	272 7 B-Chemical
may	280 3 O
be	284 2 O
responsible	287 11 O
for	299 3 O
some	303 4 O
of	308 2 O
those	311 5 O
delayed	317 7 O
sequelae	325 8 O
.	333 1 O

We	335 2 O
evaluated	338 9 O
the	348 3 O
potential	352 9 O
of	362 2 O
the	365 3 O
major	369 5 O
metabolite	375 10 O
of	386 2 O
cocaine	389 7 B-Chemical
,	396 1 O
benzoylecgonine	398 15 B-Chemical
(	414 1 O
BE	415 2 B-Chemical
)	417 1 O
,	418 1 O
to	420 2 O
cause	423 5 O
seizures	429 8 B-Disease
.	437 1 O

Two	439 3 O
separate	443 8 O
equimolar	452 9 O
doses	462 5 O
(	468 1 O
0	469 1 O
.	470 1 O
2	471 1 O
and	473 3 O
0	477 1 O
.	478 1 O
4	479 1 O
mumol	481 5 O
)	486 1 O
of	488 2 O
either	491 6 O
cocaine	498 7 B-Chemical
or	506 2 O
BE	509 2 B-Chemical
were	512 4 O
injected	517 8 O
ventricularly	526 13 O
in	540 2 O
unanesthetized	543 14 O
juvenile	558 8 O
rats	567 4 O
.	571 1 O

Treated	573 7 O
rats	581 4 O
were	586 4 O
then	591 4 O
evaluated	596 9 O
for	606 3 O
incidence	610 9 O
,	619 1 O
latency	621 7 O
,	628 1 O
and	630 3 O
seizure	634 7 B-Disease
pattern	642 7 O
or	650 2 O
for	653 3 O
locomotor	657 9 O
activity	667 8 O
in	676 2 O
animals	679 7 O
without	687 7 O
seizures	695 8 B-Disease
.	703 1 O

BE	705 2 B-Chemical
-	707 1 O
Induced	708 7 O
seizures	716 8 B-Disease
occurred	725 8 O
more	734 4 O
frequently	739 10 O
and	750 3 O
had	754 3 O
significantly	758 13 O
longer	772 6 O
latencies	779 9 O
than	789 4 O
those	794 5 O
induced	800 7 O
by	808 2 O
equimolar	811 9 O
amounts	821 7 O
of	829 2 O
cocaine	832 7 B-Chemical
.	839 1 O

Whereas	841 7 O
cocaine	849 7 B-Chemical
-	856 1 O
induced	857 7 O
seizures	865 8 B-Disease
were	874 4 O
best	879 4 O
characterized	884 13 O
as	898 2 O
brief	901 5 O
,	906 1 O
generalized	908 11 O
,	919 1 O
and	921 3 O
tonic	925 5 O
and	931 3 O
resulted	935 8 O
in	944 2 O
death	947 5 B-Disease
,	952 1 O
those	954 5 O
induced	960 7 O
by	968 2 O
BE	971 2 B-Chemical
were	974 4 O
prolonged	979 9 O
,	988 1 O
often	990 5 O
multiple	996 8 O
and	1005 3 O
mixed	1009 5 O
in	1015 2 O
type	1018 4 O
,	1022 1 O
and	1024 3 O
rarely	1028 6 O
resulted	1035 8 O
in	1044 2 O
death	1047 5 B-Disease
.	1052 1 O

Electrical	1054 10 O
recordings	1065 10 O
from	1076 4 O
the	1081 3 O
hippocampus	1085 11 O
showed	1097 6 O
a	1104 1 O
rhythmic	1106 8 O
progression	1115 11 O
in	1127 2 O
EEG	1130 3 O
frequency	1134 9 O
and	1144 3 O
voltage	1148 7 O
with	1156 4 O
clinical	1161 8 O
seizure	1170 7 B-Disease
expression	1178 10 O
.	1188 1 O

BE	1190 2 B-Chemical
-	1192 1 O
Injected	1193 8 O
rats	1202 4 O
that	1207 4 O
did	1212 3 O
not	1216 3 O
have	1220 4 O
seizures	1225 8 B-Disease
had	1234 3 O
significantly	1238 13 O
more	1252 4 O
locomotor	1257 9 O
activity	1267 8 O
than	1276 4 O
cocaine	1281 7 B-Chemical
-	1288 1 O
injected	1289 8 O
animals	1298 7 O
without	1306 7 O
seizures	1314 8 B-Disease
.	1322 1 O

The	1324 3 O
finding	1328 7 O
that	1336 4 O
cocaine	1341 7 B-Chemical
-	1348 1 O
and	1350 3 O
BE	1354 2 B-Chemical
-	1356 1 O
induced	1357 7 O
seizures	1365 8 B-Disease
differ	1374 6 O
in	1381 2 O
several	1384 7 O
respects	1392 8 O
suggests	1401 8 O
more	1410 4 O
than	1415 4 O
one	1420 3 O
mechanism	1424 9 O
for	1434 3 O
cocaine	1438 7 B-Chemical
-	1445 1 O
induced	1446 7 O
seizures	1454 8 B-Disease
and	1463 3 O
emphasizes	1467 10 O
the	1478 3 O
importance	1482 10 O
of	1493 2 O
a	1496 1 O
cocaine	1498 7 B-Chemical
metabolite	1506 10 O
,	1516 1 O
BE	1518 2 B-Chemical
.	1520 1 O

Protection	0 10 O
against	11 7 O
amphetamine	19 11 B-Chemical
-	30 1 O
induced	31 7 O
neurotoxicity	39 13 B-Disease
toward	53 6 O
striatal	60 8 O
dopamine	69 8 B-Chemical
neurons	78 7 O
in	86 2 O
rodents	89 7 O
by	97 2 O
LY274614	100 8 B-Chemical
,	108 1 O
an	110 2 O
excitatory	113 10 O
amino	124 5 B-Chemical
acid	130 4 I-Chemical
antagonist	135 10 O
.	145 1 O

LY274614	147 8 B-Chemical
,	155 1 O
3SR	157 3 B-Chemical
,	160 1 I-Chemical
4aRS	161 4 I-Chemical
,	165 1 I-Chemical
6SR	166 3 I-Chemical
,	169 1 I-Chemical
8aRS	170 4 I-Chemical
-	174 1 I-Chemical
6	175 1 I-Chemical
-	176 1 I-Chemical
[	177 1 I-Chemical
phosphonomethyl	178 15 I-Chemical
]	193 1 I-Chemical
decahydr	194 8 I-Chemical
oisoquinoline	203 13 I-Chemical
-	216 1 I-Chemical
3	217 1 I-Chemical
-	218 1 I-Chemical
carboxylic	220 10 I-Chemical
acid	231 4 I-Chemical
,	235 1 O
has	237 3 O
been	241 4 O
described	246 9 O
as	256 2 O
a	259 1 O
potent	261 6 O
antagonist	268 10 O
of	279 2 O
the	282 3 O
N	286 1 B-Chemical
-	287 1 I-Chemical
methyl	288 6 I-Chemical
-	294 1 I-Chemical
D	295 1 I-Chemical
-	296 1 I-Chemical
aspartate	297 9 I-Chemical
(	307 1 O
NMDA	308 4 B-Chemical
)	312 1 O
subtype	314 7 O
of	322 2 O
glutamate	325 9 B-Chemical
receptor	335 8 O
.	343 1 O

Here	345 4 O
its	350 3 O
ability	354 7 O
to	362 2 O
antagonize	365 10 O
the	376 3 O
prolonged	380 9 O
depletion	390 9 O
of	400 2 O
dopamine	403 8 B-Chemical
in	412 2 O
the	415 3 O
striatum	419 8 O
by	428 2 O
amphetamine	431 11 B-Chemical
in	443 2 O
iprindole	446 9 B-Chemical
-	455 1 O
treated	456 7 O
rats	464 4 O
is	469 2 O
reported	472 8 O
.	480 1 O

A	482 1 O
single	484 6 O
18	491 2 O
.	493 1 O
4	494 1 O
mg	496 2 O
/	498 1 O
kg	499 2 O
(	502 1 O
i	503 1 O
.	504 1 O
p	505 1 O
.	506 1 O
)	507 1 O
dose	509 4 O
of	514 2 O
(	517 1 O
+	518 1 O
/	519 1 O
-	520 1 O
)	521 1 O
-	522 1 O
amphetamine	523 11 B-Chemical
hemisulfate	535 11 O
,	546 1 O
given	548 5 O
to	554 2 O
rats	557 4 O
pretreated	562 10 O
with	573 4 O
iprindole	578 9 B-Chemical
,	587 1 O
resulted	589 8 O
in	598 2 O
persistent	601 10 O
depletion	612 9 O
of	622 2 O
dopamine	625 8 B-Chemical
in	634 2 O
the	637 3 O
striatum	641 8 O
1	650 1 O
week	652 4 O
later	657 5 O
.	662 1 O

This	664 4 O
prolonged	669 9 O
depletion	679 9 O
of	689 2 O
dopamine	692 8 B-Chemical
in	701 2 O
the	704 3 O
striatum	708 8 O
was	717 3 O
antagonized	721 11 O
by	733 2 O
dizocilpine	736 11 B-Chemical
(	748 1 O
MK	749 2 B-Chemical
-	751 1 I-Chemical
801	752 3 I-Chemical
,	755 1 O
a	757 1 O
non	759 3 O
-	762 1 O
competitive	763 11 O
antagonist	775 10 O
of	786 2 O
NMDA	789 4 B-Chemical
receptors	794 9 O
)	803 1 O
or	805 2 O
by	808 2 O
LY274614	811 8 B-Chemical
(	820 1 O
a	821 1 O
competitive	823 11 O
antagonist	835 10 O
of	846 2 O
NMDA	849 4 B-Chemical
receptors	854 9 O
)	863 1 O
.	864 1 O

The	866 3 O
protective	870 10 O
effect	881 6 O
of	888 2 O
LY274614	891 8 B-Chemical
was	900 3 O
dose	904 4 O
-	908 1 O
dependent	909 9 O
,	918 1 O
being	920 5 O
maximum	926 7 O
at	934 2 O
10	937 2 O
-	939 1 O
40	940 2 O
mgkg	943 4 O
(	948 1 O
i	949 1 O
.	950 1 O
p	951 1 O
.	952 1 O
)	953 1 O
.	954 1 O

A	956 1 O
10	958 2 O
mg	961 2 O
/	963 1 O
kg	964 2 O
dose	967 4 O
of	972 2 O
LY274614	975 8 B-Chemical
was	984 3 O
effective	988 9 O
in	998 2 O
antagonizing	1001 12 O
the	1014 3 O
depletion	1018 9 O
of	1028 2 O
dopamine	1031 8 B-Chemical
in	1040 2 O
the	1043 3 O
striatum	1047 8 O
,	1055 1 O
when	1057 4 O
given	1062 5 O
as	1068 2 O
long	1071 4 O
as	1076 2 O
8	1079 1 O
hr	1081 2 O
prior	1084 5 O
to	1090 2 O
amphetamine	1093 11 B-Chemical
but	1105 3 O
not	1109 3 O
when	1113 4 O
given	1118 5 O
24	1124 2 O
hr	1127 2 O
prior	1130 5 O
to	1136 2 O
amphetamine	1139 11 B-Chemical
.	1150 1 O

Depletion	1152 9 O
of	1162 2 O
dopamine	1165 8 B-Chemical
in	1174 2 O
the	1177 3 O
striatum	1181 8 O
was	1190 3 O
also	1194 4 O
antagonized	1199 11 O
when	1211 4 O
LY274614	1216 8 B-Chemical
was	1225 3 O
given	1229 5 O
after	1235 5 O
the	1241 3 O
injection	1245 9 O
of	1255 2 O
amphetamine	1258 11 B-Chemical
;	1269 1 O
LY274614	1271 8 B-Chemical
protected	1280 9 O
when	1290 4 O
given	1295 5 O
up	1301 2 O
to	1304 2 O
4	1307 1 O
hr	1309 2 O
after	1312 5 O
but	1318 3 O
not	1322 3 O
when	1326 4 O
given	1331 5 O
8	1337 1 O
or	1339 2 O
24	1342 2 O
hr	1345 2 O
after	1348 5 O
amphetamine	1354 11 B-Chemical
.	1365 1 O

The	1367 3 O
prolonged	1371 9 O
depletion	1381 9 O
of	1391 2 O
dopamine	1394 8 B-Chemical
in	1403 2 O
the	1406 3 O
striatum	1410 8 O
in	1419 2 O
mice	1422 4 O
,	1426 1 O
given	1428 5 O
multiple	1434 8 O
injections	1443 10 O
of	1454 2 O
methamphetamine	1457 15 B-Chemical
,	1472 1 O
was	1474 3 O
also	1478 4 O
antagonized	1483 11 O
dose	1495 4 O
-	1499 1 O
dependently	1500 11 O
and	1512 3 O
completely	1516 10 O
by	1527 2 O
LY274614	1530 8 B-Chemical
.	1538 1 O

The	1540 3 O
data	1544 4 O
strengthen	1549 10 O
the	1560 3 O
evidence	1564 8 O
that	1573 4 O
the	1578 3 O
neurotoxic	1582 10 B-Disease
effect	1593 6 O
of	1600 2 O
amphetamine	1603 11 B-Chemical
and	1615 3 O
related	1619 7 O
compounds	1627 9 O
toward	1637 6 O
nigrostriatal	1644 13 O
dopamine	1658 8 B-Chemical
neurons	1667 7 O
involves	1675 8 O
NMDA	1684 4 B-Chemical
receptors	1689 9 O
and	1699 3 O
that	1703 4 O
LY274614	1708 8 B-Chemical
is	1717 2 O
an	1720 2 O
NMDA	1723 4 B-Chemical
receptor	1728 8 O
antagonist	1737 10 O
with	1748 4 O
long	1753 4 O
-	1757 1 O
lasting	1758 7 O
in	1766 2 O
vivo	1769 4 O
effects	1774 7 O
in	1782 2 O
rats	1785 4 O
.	1789 1 O

Neonatal	0 8 O
pyridoxine	9 10 B-Chemical
responsive	20 10 O
convulsions	31 11 B-Disease
due	43 3 O
to	47 2 O
isoniazid	50 9 B-Chemical
therapy	60 7 O
.	67 1 O

A	69 1 O
17	71 2 O
-	73 1 O
day	74 3 O
-	77 1 O
old	78 3 O
infant	82 6 O
on	89 2 O
isoniazid	92 9 B-Chemical
therapy	102 7 O
13	110 2 O
mg	113 2 O
/	115 1 O
kg	116 2 O
daily	119 5 O
from	125 4 O
birth	130 5 O
because	136 7 O
of	144 2 O
maternal	147 8 O
tuberculosis	156 12 B-Disease
was	169 3 O
admitted	173 8 O
after	182 5 O
4	188 1 O
days	190 4 O
of	195 2 O
clonic	198 6 B-Disease
fits	205 4 I-Disease
.	209 1 O

No	211 2 O
underlying	214 10 O
infective	225 9 O
or	235 2 O
biochemical	238 11 O
cause	250 5 O
could	256 5 O
be	262 2 O
found	265 5 O
.	270 1 O

The	272 3 O
fits	276 4 B-Disease
ceased	281 6 O
within	288 6 O
4	295 1 O
hours	297 5 O
of	303 2 O
administering	306 13 O
intramuscular	320 13 O
pyridoxine	334 10 B-Chemical
,	344 1 O
suggesting	346 10 O
an	357 2 O
aetiology	360 9 O
of	370 2 O
pyridoxine	373 10 B-Chemical
deficiency	384 10 O
secondary	395 9 O
to	405 2 O
isoniazid	408 9 B-Chemical
medication	418 10 O
.	428 1 O

Reversal	0 8 O
by	9 2 O
phenylephrine	12 13 B-Chemical
of	26 2 O
the	29 3 O
beneficial	33 10 O
effects	44 7 O
of	52 2 O
intravenous	55 11 O
nitroglycerin	67 13 B-Chemical
in	81 2 O
patients	84 8 O
with	93 4 O
acute	98 5 B-Disease
myocardial	104 10 I-Disease
infarction	115 10 I-Disease
.	125 1 O

Nitroglycerin	127 13 B-Chemical
has	141 3 O
been	145 4 O
shown	150 5 O
to	156 2 O
reduce	159 6 O
ST	166 2 O
-	168 1 O
segment	169 7 O
elevation	177 9 O
during	187 6 O
acute	194 5 B-Disease
myocardial	200 10 I-Disease
infarction	211 10 I-Disease
,	221 1 O
an	223 2 O
effect	226 6 O
potentiated	233 11 O
in	245 2 O
the	248 3 O
dog	252 3 O
by	256 2 O
agents	259 6 O
that	266 4 O
reverse	271 7 O
nitroglycerin	279 13 B-Chemical
-	292 1 O
induced	293 7 O
hypotension	301 11 B-Disease
.	312 1 O

Our	314 3 O
study	318 5 O
was	324 3 O
designed	328 8 O
to	337 2 O
determine	340 9 O
the	350 3 O
effects	354 7 O
of	362 2 O
combined	365 8 O
nitroglycerin	374 13 B-Chemical
and	388 3 O
phenylephrine	392 13 B-Chemical
therapy	406 7 O
.	413 1 O

Ten	415 3 O
patients	419 8 O
with	428 4 O
acute	433 5 O
transmural	439 10 O
myocardial	450 10 B-Disease
infarctions	461 11 I-Disease
received	473 8 O
intravenous	482 11 O
nitroglycerin	494 13 B-Chemical
,	507 1 O
sufficient	509 10 O
to	520 2 O
reduce	523 6 O
mean	530 4 O
arterial	535 8 O
pressure	544 8 O
from	553 4 O
107	558 3 O
+	562 1 O
/	563 1 O
-	564 1 O
6	566 1 O
to	568 2 O
85	571 2 O
+	574 1 O
/	575 1 O
-	576 1 O
6	578 1 O
mm	580 2 O
Hg	583 2 O
(	586 1 O
P	587 1 O
less	589 4 O
than	594 4 O
0	599 1 O
.	600 1 O
001	601 3 O
)	604 1 O
,	605 1 O
for	607 3 O
60	611 2 O
minutes	614 7 O
.	621 1 O

Left	623 4 O
ventricular	628 11 O
filling	640 7 O
pressure	648 8 O
decreased	657 9 O
from	667 4 O
19	672 2 O
+	675 1 O
/	676 1 O
-	677 1 O
2	679 1 O
to	681 2 O
11	684 2 O
+	687 1 O
/	688 1 O
-	689 1 O
2	691 1 O
mm	693 2 O
Hg	696 2 O
(	699 1 O
P	700 1 O
less	702 4 O
than	707 4 O
0	712 1 O
.	713 1 O
001	714 3 O
)	717 1 O
.	718 1 O

SigmaST	720 7 O
,	727 1 O
the	729 3 O
sum	733 3 O
of	737 2 O
ST	740 2 O
-	742 1 O
segment	743 7 O
elevations	751 10 O
in	762 2 O
16	765 2 O
precordial	768 10 O
leads	779 5 O
,	784 1 O
decreased	786 9 O
(	796 1 O
P	797 1 O
less	799 4 O
than	804 4 O
0	809 1 O
.	810 1 O
02	811 2 O
)	813 1 O
with	815 4 O
intravenous	820 11 O
nitroglycerin	832 13 B-Chemical
.	845 1 O

Subsequent	847 10 O
addition	858 8 O
of	867 2 O
phenylephrine	870 13 B-Chemical
infusion	884 8 O
,	892 1 O
sufficient	894 10 O
to	905 2 O
re	908 2 O
-	910 1 O
elevate	911 7 O
mean	919 4 O
arterial	924 8 O
pressure	933 8 O
to	942 2 O
106	945 3 O
+	949 1 O
/	950 1 O
-	951 1 O
4	953 1 O
mm	955 2 O
Hg	958 2 O
(	961 1 O
P	962 1 O
less	964 4 O
than	969 4 O
0	974 1 O
.	975 1 O
001	976 3 O
)	979 1 O
for	981 3 O
30	985 2 O
minutes	988 7 O
,	995 1 O
increased	997 9 O
left	1007 4 O
ventricular	1012 11 O
filling	1024 7 O
pressure	1032 8 O
to	1041 2 O
17	1044 2 O
+	1047 1 O
/	1048 1 O
-	1049 1 O
2	1051 1 O
mm	1053 2 O
Hg	1056 2 O
(	1059 1 O
P	1060 1 O
less	1062 4 O
than	1067 4 O
0	1072 1 O
.	1073 1 O
05	1074 2 O
)	1076 1 O
and	1078 3 O
also	1082 4 O
significantly	1087 13 O
increased	1101 9 O
sigmaST	1111 7 O
(	1119 1 O
P	1120 1 O
less	1122 4 O
than	1127 4 O
0	1132 1 O
.	1133 1 O
05	1134 2 O
)	1136 1 O
.	1137 1 O

Our	1139 3 O
results	1143 7 O
suggest	1151 7 O
that	1159 4 O
addition	1164 8 O
of	1173 2 O
phenylephrine	1176 13 B-Chemical
to	1190 2 O
nitroglycerin	1193 13 B-Chemical
is	1207 2 O
not	1210 3 O
beneficial	1214 10 O
in	1225 2 O
the	1228 3 O
treatment	1232 9 O
of	1242 2 O
patients	1245 8 O
with	1254 4 O
acute	1259 5 B-Disease
myocardial	1265 10 I-Disease
infarction	1276 10 I-Disease
.	1286 1 O

Elevation	0 9 O
of	10 2 O
ADAM10	13 6 O
,	19 1 O
ADAM17	21 6 O
,	27 1 O
MMP	29 3 O
-	32 1 O
2	33 1 O
and	35 3 O
MMP	39 3 O
-	42 1 O
9	43 1 O
expression	45 10 O
with	56 4 O
media	61 5 O
degeneration	67 12 O
features	80 8 O
CaCl2	89 5 B-Chemical
-	94 1 O
induced	95 7 O
thoracic	103 8 B-Disease
aortic	112 6 I-Disease
aneurysm	119 8 I-Disease
in	128 2 O
a	131 1 O
rat	133 3 O
model	137 5 O
.	142 1 O

PURPOSE	144 7 O
:	151 1 O
This	153 4 O
study	158 5 O
was	164 3 O
designed	168 8 O
to	177 2 O
establish	180 9 O
a	190 1 O
rat	192 3 O
model	196 5 O
of	202 2 O
thoracic	205 8 B-Disease
aortic	214 6 I-Disease
aneurysm	221 8 I-Disease
(	230 1 O
TAA	231 3 B-Disease
)	234 1 O
by	236 2 O
calcium	239 7 B-Chemical
chloride	247 8 I-Chemical
(	256 1 O
CaCl	257 4 B-Chemical
(	261 1 I-Chemical
2	262 1 I-Chemical
)	263 1 I-Chemical
)	264 1 O
-	265 1 O
induced	266 7 O
arterial	274 8 B-Disease
injury	283 6 I-Disease
and	290 3 O
to	294 2 O
explore	297 7 O
the	305 3 O
potential	309 9 O
role	319 4 O
of	324 2 O
a	327 1 O
disintegrin	329 11 O
and	341 3 O
metalloproteinase	345 17 O
(	363 1 O
ADAM	364 4 O
)	368 1 O
,	369 1 O
matrix	371 6 O
metalloproteinases	378 18 O
(	397 1 O
MMPs	398 4 O
)	402 1 O
and	404 3 O
their	408 5 O
endogenous	414 10 O
inhibitors	425 10 O
(	436 1 O
TIMPs	437 5 O
)	442 1 O
in	444 2 O
TAA	447 3 B-Disease
formation	451 9 O
.	460 1 O

METHODS	462 7 O
:	469 1 O
Thoracic	471 8 O
aorta	480 5 O
of	486 2 O
male	489 4 O
Sprague	494 7 O
-	501 1 O
Dawley	502 6 O
rats	509 4 O
was	514 3 O
exposed	518 7 O
to	526 2 O
0	529 1 O
.	530 1 O
5M	531 2 O
CaCl	534 4 B-Chemical
(	538 1 I-Chemical
2	539 1 I-Chemical
)	540 1 I-Chemical
or	542 2 O
normal	545 6 O
saline	552 6 O
(	559 1 O
NaCl	560 4 B-Chemical
)	564 1 O
.	565 1 O

After	567 5 O
12weeks	573 7 O
,	580 1 O
animals	582 7 O
were	590 4 O
euthanized	595 10 O
,	605 1 O
and	607 3 O
CaCl	611 4 B-Chemical
(	615 1 I-Chemical
2	616 1 I-Chemical
)	617 1 I-Chemical
-	618 1 O
treated	619 7 O
,	626 1 O
CaCl	628 4 B-Chemical
(	632 1 I-Chemical
2	633 1 I-Chemical
)	634 1 I-Chemical
-	635 1 O
untreated	636 9 O
(	646 1 O
n	647 1 O
=	648 1 O
12	649 2 O
)	651 1 O
and	653 3 O
NaCl	657 4 B-Chemical
-	661 1 O
treated	662 7 O
aortic	670 6 O
segments	677 8 O
(	686 1 O
n	687 1 O
=	688 1 O
12	689 2 O
)	691 1 O
were	693 4 O
collected	698 9 O
for	708 3 O
histological	712 12 O
and	725 3 O
molecular	729 9 O
assessments	739 11 O
.	750 1 O

MMP	752 3 O
-	755 1 O
TIMP	756 4 O
and	761 3 O
ADAM	765 4 O
mRNAs	770 5 O
were	776 4 O
semi	781 4 O
-	785 1 O
quantitatively	786 14 O
analyzed	801 8 O
and	810 3 O
protein	814 7 O
expressions	822 11 O
were	834 4 O
determined	839 10 O
by	850 2 O
immunohistochemistry	853 20 O
.	873 1 O

RESULTS	875 7 O
:	882 1 O
Despite	884 7 O
similar	892 7 O
external	900 8 O
diameters	909 9 O
among	919 5 O
CaCl	925 4 B-Chemical
(	929 1 I-Chemical
2	930 1 I-Chemical
)	931 1 I-Chemical
-	932 1 O
treated	933 7 O
,	940 1 O
non	942 3 O
-	945 1 O
CaCl	946 4 B-Chemical
(	950 1 I-Chemical
2	951 1 I-Chemical
)	952 1 I-Chemical
-	953 1 O
treated	954 7 O
and	962 3 O
NaCl	966 4 B-Chemical
-	970 1 O
treated	971 7 O
segments	979 8 O
,	987 1 O
aneurymal	989 9 O
alteration	999 10 O
(	1010 1 O
n	1011 1 O
=	1012 1 O
6	1013 1 O
,	1014 1 O
50	1016 2 O
%	1018 1 O
)	1019 1 O
,	1020 1 O
media	1022 5 O
degeneration	1028 12 O
with	1041 4 O
regional	1046 8 O
disruption	1055 10 O
,	1065 1 O
fragmentation	1067 13 O
of	1081 2 O
elastic	1084 7 O
fiber	1092 5 O
,	1097 1 O
and	1099 3 O
increased	1103 9 O
collagen	1113 8 O
deposition	1122 10 O
(	1133 1 O
n	1134 1 O
=	1135 1 O
12	1136 2 O
,	1138 1 O
100	1140 3 O
%	1143 1 O
)	1144 1 O
were	1146 4 O
demonstrated	1151 12 O
in	1164 2 O
CaCl	1167 4 B-Chemical
(	1171 1 I-Chemical
2	1172 1 I-Chemical
)	1173 1 I-Chemical
-	1174 1 O
treated	1175 7 O
segments	1183 8 O
.	1191 1 O

MMP	1193 3 O
-	1196 1 O
2	1197 1 O
,	1198 1 O
MMP	1200 3 O
-	1203 1 O
9	1204 1 O
,	1205 1 O
ADAM	1207 4 O
-	1211 1 O
10	1212 2 O
and	1215 3 O
ADAM	1219 4 O
-	1223 1 O
17	1224 2 O
mRNA	1227 4 O
levels	1232 6 O
were	1239 4 O
increased	1244 9 O
in	1254 2 O
CaCl	1257 4 B-Chemical
(	1261 1 I-Chemical
2	1262 1 I-Chemical
)	1263 1 I-Chemical
-	1264 1 O
treated	1265 7 O
segments	1273 8 O
(	1282 1 O
all	1283 3 O
p	1287 1 O
<	1288 1 O
0	1289 1 O
.	1290 1 O
01	1291 2 O
)	1293 1 O
,	1294 1 O
with	1296 4 O
trends	1301 6 O
of	1308 2 O
elevation	1311 9 O
in	1321 2 O
CaCl	1324 4 B-Chemical
(	1328 1 I-Chemical
2	1329 1 I-Chemical
)	1330 1 I-Chemical
-	1331 1 O
untreated	1332 9 O
segments	1342 8 O
,	1350 1 O
as	1352 2 O
compared	1355 8 O
with	1364 4 O
NaCl	1369 4 B-Chemical
-	1373 1 O
treated	1374 7 O
segments	1382 8 O
.	1390 1 O

Immunohistochemistry	1392 20 O
displayed	1413 9 O
significantly	1423 13 O
increased	1437 9 O
expressions	1447 11 O
of	1459 2 O
MMP	1462 3 O
-	1465 1 O
2	1466 1 O
,	1467 1 O
MMP	1469 3 O
-	1472 1 O
9	1473 1 O
,	1474 1 O
ADAM	1476 4 O
-	1480 1 O
10	1481 2 O
and	1484 3 O
ADAM	1488 4 O
-	1492 1 O
17	1493 2 O
(	1496 1 O
all	1497 3 O
p	1501 1 O
<	1502 1 O
0	1503 1 O
.	1504 1 O
01	1505 2 O
)	1507 1 O
in	1509 2 O
intima	1512 6 O
and	1519 3 O
media	1523 5 O
for	1529 3 O
CaCl	1533 4 B-Chemical
(	1537 1 I-Chemical
2	1538 1 I-Chemical
)	1539 1 I-Chemical
-	1540 1 O
treated	1541 7 O
segments	1549 8 O
.	1557 1 O

TIMP	1559 4 O
mRNA	1564 4 O
and	1569 3 O
tissue	1573 6 O
levels	1580 6 O
did	1587 3 O
not	1591 3 O
differ	1595 6 O
obviously	1602 9 O
among	1612 5 O
the	1618 3 O
three	1622 5 O
aortic	1628 6 O
segments	1635 8 O
.	1643 1 O

CONCLUSION	1645 10 O
:	1655 1 O
This	1657 4 O
study	1662 5 O
establishes	1668 11 O
a	1680 1 O
TAA	1682 3 B-Disease
model	1686 5 O
by	1692 2 O
periarterial	1695 12 O
CaCl	1708 4 B-Chemical
(	1712 1 I-Chemical
2	1713 1 I-Chemical
)	1714 1 I-Chemical
exposure	1716 8 O
in	1725 2 O
rats	1728 4 O
,	1732 1 O
and	1734 3 O
demonstrates	1738 12 O
a	1751 1 O
significant	1753 11 O
elevation	1765 9 O
of	1775 2 O
expression	1778 10 O
of	1789 2 O
MMP	1792 3 O
-	1795 1 O
2	1796 1 O
,	1797 1 O
MMP	1799 3 O
-	1802 1 O
9	1803 1 O
,	1804 1 O
ADAM10	1806 6 O
and	1813 3 O
ADAM17	1817 6 O
in	1824 2 O
the	1827 3 O
pathogenesis	1831 12 O
of	1844 2 O
vascular	1847 8 O
remodeling	1856 10 O
.	1866 1 O

When	0 4 O
drugs	5 5 O
disappear	11 9 O
from	21 4 O
the	26 3 O
patient	30 7 O
:	37 1 O
elimination	39 11 O
of	51 2 O
intravenous	54 11 O
medication	66 10 O
by	77 2 O
hemodiafiltration	80 17 O
.	97 1 O

Twenty	99 6 O
-	105 1 O
three	106 5 O
hours	112 5 O
after	118 5 O
heart	124 5 O
transplantation	130 15 O
,	145 1 O
life	147 4 O
-	151 1 O
threatening	152 11 O
acute	164 5 O
right	170 5 B-Disease
heart	176 5 I-Disease
failure	182 7 I-Disease
was	190 3 O
diagnosed	194 9 O
in	204 2 O
a	207 1 O
patient	209 7 O
requiring	217 9 O
continuous	227 10 O
venovenous	238 10 O
hemodiafiltration	249 17 O
(	267 1 O
CVVHDF	268 6 O
)	274 1 O
.	275 1 O

Increasing	277 10 O
doses	288 5 O
of	294 2 O
catecholamines	297 14 B-Chemical
,	311 1 O
sedatives	313 9 O
,	322 1 O
and	324 3 O
muscle	328 6 O
relaxants	335 9 O
administered	345 12 O
through	358 7 O
a	366 1 O
central	368 7 O
venous	376 6 O
catheter	383 8 O
were	392 4 O
ineffective	397 11 O
.	408 1 O

However	410 7 O
,	417 1 O
a	419 1 O
bolus	421 5 O
of	427 2 O
epinephrine	430 11 B-Chemical
injected	442 8 O
through	451 7 O
an	459 2 O
alternative	462 11 O
catheter	474 8 O
provoked	483 8 O
a	492 1 O
hypertensive	494 12 B-Disease
crisis	507 6 O
.	513 1 O

Thus	515 4 O
,	519 1 O
interference	521 12 O
with	534 4 O
the	539 3 O
central	543 7 O
venous	551 6 O
infusion	558 8 O
by	567 2 O
the	570 3 O
dialysis	574 8 O
catheter	583 8 O
was	592 3 O
suspected	596 9 O
.	605 1 O

The	607 3 O
catheters	611 9 O
were	621 4 O
changed	626 7 O
,	633 1 O
and	635 3 O
hemodynamics	639 12 O
stabilized	652 10 O
at	663 2 O
lower	666 5 O
catecholamine	672 13 B-Chemical
doses	686 5 O
.	691 1 O

When	693 4 O
the	698 3 O
effects	702 7 O
of	710 2 O
IV	713 2 O
drugs	716 5 O
are	722 3 O
inadequate	726 10 O
in	737 2 O
patients	740 8 O
receiving	749 9 O
CVVHDF	759 6 O
,	765 1 O
interference	767 12 O
with	780 4 O
adjacent	785 8 O
catheters	794 9 O
resulting	804 9 O
in	814 2 O
elimination	817 11 O
of	829 2 O
the	832 3 O
drug	836 4 O
by	841 2 O
CVVHDF	844 6 O
should	851 6 O
be	858 2 O
suspected	861 9 O
.	870 1 O

Long	0 4 O
-	4 1 O
term	5 4 O
glutamate	10 9 B-Chemical
supplementation	20 15 O
failed	36 6 O
to	43 2 O
protect	46 7 O
against	54 7 O
peripheral	62 10 B-Disease
neurotoxicity	73 13 I-Disease
of	87 2 O
paclitaxel	90 10 B-Chemical
.	100 1 O

Toxic	102 5 O
peripheral	108 10 B-Disease
neuropathy	119 10 I-Disease
is	130 2 O
still	133 5 O
a	139 1 O
significant	141 11 O
limiting	153 8 O
factor	162 6 O
for	169 3 O
chemotherapy	173 12 O
with	186 4 O
paclitaxel	191 10 B-Chemical
(	202 1 O
PAC	203 3 B-Chemical
)	206 1 O
,	207 1 O
although	209 8 O
glutamate	218 9 B-Chemical
and	228 3 O
its	232 3 O
closely	236 7 O
related	244 7 O
amino	252 5 B-Chemical
acid	258 4 I-Chemical
glutamine	263 9 B-Chemical
were	273 4 O
claimed	278 7 O
to	286 2 O
ameliorate	289 10 O
PAC	300 3 B-Chemical
neurotoxicity	304 13 B-Disease
.	317 1 O

This	319 4 O
pilot	324 5 O
trial	330 5 O
aimed	336 5 O
to	342 2 O
evaluate	345 8 O
the	354 3 O
role	358 4 O
of	363 2 O
glutamate	366 9 B-Chemical
supplementation	376 15 O
for	392 3 O
preventing	396 10 O
PAC	407 3 B-Chemical
-	410 1 O
induced	411 7 O
peripheral	419 10 B-Disease
neuropathy	430 10 I-Disease
in	441 2 O
a	444 1 O
randomized	446 10 O
,	456 1 O
placebo	458 7 O
-	465 1 O
controlled	466 10 O
,	476 1 O
double	478 6 O
-	484 1 O
blinded	485 7 O
clinical	493 8 O
and	502 3 O
electro	506 7 O
-	513 1 O
diagnostic	514 10 O
study	525 5 O
.	530 1 O

Forty	532 5 O
-	537 1 O
three	538 5 O
ovarian	544 7 B-Disease
cancer	552 6 I-Disease
patients	559 8 O
were	568 4 O
available	573 9 O
for	583 3 O
analysis	587 8 O
following	596 9 O
six	606 3 O
cycles	610 6 O
of	617 2 O
the	620 3 O
same	624 4 O
PAC	629 3 B-Chemical
-	632 1 O
containing	633 10 O
regimen	644 7 O
:	651 1 O
23	653 2 O
had	656 3 O
been	660 4 O
supplemented	665 12 O
by	678 2 O
glutamate	681 9 B-Chemical
all	691 3 O
along	695 5 O
the	701 3 O
treatment	705 9 O
period	715 6 O
,	721 1 O
at	723 2 O
a	726 1 O
daily	728 5 O
dose	734 4 O
of	739 2 O
three	742 5 O
times	748 5 O
500	754 3 O
mg	758 2 O
(	761 1 O
group	762 5 O
G	768 1 O
)	769 1 O
,	770 1 O
and	772 3 O
20	776 2 O
had	779 3 O
received	783 8 O
a	792 1 O
placebo	794 7 O
(	802 1 O
group	803 5 O
P	809 1 O
)	810 1 O
.	811 1 O

Patients	813 8 O
were	822 4 O
evaluated	827 9 O
by	837 2 O
neurological	840 12 O
examinations	853 12 O
,	865 1 O
questionnaires	867 14 O
and	882 3 O
sensory	886 7 O
-	893 1 O
motor	894 5 O
nerve	900 5 O
conduction	906 10 O
studies	917 7 O
.	924 1 O

There	926 5 O
was	932 3 O
no	936 2 O
significant	939 11 O
difference	951 10 O
in	962 2 O
the	965 3 O
frequency	969 9 O
of	979 2 O
signs	982 5 O
or	988 2 O
symptoms	991 8 O
between	1000 7 O
the	1008 3 O
two	1012 3 O
groups	1016 6 O
although	1023 8 O
neurotoxicity	1032 13 B-Disease
symptoms	1046 8 O
presented	1055 9 O
mostly	1065 6 O
with	1072 4 O
lower	1077 5 O
scores	1083 6 O
of	1090 2 O
severity	1093 8 O
in	1102 2 O
group	1105 5 O
G	1111 1 O
.	1112 1 O

However	1114 7 O
,	1121 1 O
this	1123 4 O
difference	1128 10 O
reached	1139 7 O
statistical	1147 11 O
significance	1159 12 O
only	1172 4 O
with	1177 4 O
regard	1182 6 O
to	1189 2 O
reported	1192 8 O
pain	1201 4 B-Disease
sensation	1206 9 O
(	1216 1 O
P	1217 1 O
=	1219 1 O
0	1221 1 O
.	1222 1 O
011	1223 3 O
)	1226 1 O
.	1227 1 O

Also	1229 4 O
the	1234 3 O
frequency	1238 9 O
of	1248 2 O
abnormal	1251 8 O
electro	1260 7 O
-	1267 1 O
diagnostic	1268 10 O
findings	1279 8 O
showed	1288 6 O
similarity	1295 10 O
between	1306 7 O
the	1314 3 O
two	1318 3 O
groups	1322 6 O
(	1329 1 O
G	1330 1 O
:	1331 1 O
7	1333 1 O
/	1334 1 O
23	1335 2 O
=	1338 1 O
30	1340 2 O
.	1342 1 O
4	1343 1 O
%	1344 1 O
;	1345 1 O
P	1347 1 O
:	1348 1 O
6	1350 1 O
/	1351 1 O
20	1352 2 O
=	1355 1 O
30	1357 2 O
%	1359 1 O
)	1360 1 O
.	1361 1 O

This	1363 4 O
pilot	1368 5 O
study	1374 5 O
leads	1380 5 O
to	1386 2 O
the	1389 3 O
conclusion	1393 10 O
that	1404 4 O
glutamate	1409 9 B-Chemical
supplementation	1419 15 O
at	1435 2 O
the	1438 3 O
chosen	1442 6 O
regimen	1449 7 O
fails	1457 5 O
to	1463 2 O
protect	1466 7 O
against	1474 7 O
peripheral	1482 10 B-Disease
neurotoxicity	1493 13 I-Disease
of	1507 2 O
PAC	1510 3 B-Chemical
.	1513 1 O

Attentional	0 11 O
modulation	12 10 O
of	23 2 O
perceived	26 9 O
pain	36 4 B-Disease
intensity	41 9 O
in	51 2 O
capsaicin	54 9 B-Chemical
-	63 1 O
induced	64 7 O
secondary	72 9 O
hyperalgesia	82 12 B-Disease
.	94 1 O

Perceived	96 9 O
pain	106 4 B-Disease
intensity	111 9 O
is	121 2 O
modulated	124 9 O
by	134 2 O
attention	137 9 O
.	146 1 O

However	148 7 O
,	155 1 O
it	157 2 O
is	160 2 O
not	163 3 O
known	167 5 O
that	173 4 O
how	178 3 O
pain	182 4 B-Disease
intensity	187 9 O
ratings	197 7 O
are	205 3 O
affected	209 8 O
by	218 2 O
attention	221 9 O
in	231 2 O
capsaicin	234 9 B-Chemical
-	243 1 O
induced	244 7 O
secondary	252 9 O
hyperalgesia	262 12 B-Disease
.	274 1 O

Here	276 4 O
we	281 2 O
show	284 4 O
that	289 4 O
perceived	294 9 O
pain	304 4 B-Disease
intensity	309 9 O
in	319 2 O
secondary	322 9 O
hyperalgesia	332 12 B-Disease
is	345 2 O
decreased	348 9 O
when	358 4 O
attention	363 9 O
is	373 2 O
distracted	376 10 O
away	387 4 O
from	392 4 O
the	397 3 O
painful	401 7 O
pinprick	409 8 O
stimulus	418 8 O
with	427 4 O
a	432 1 O
visual	434 6 O
task	441 4 O
.	445 1 O

Furthermore	447 11 O
,	458 1 O
it	460 2 O
was	463 3 O
found	467 5 O
that	473 4 O
the	478 3 O
magnitude	482 9 O
of	492 2 O
attentional	495 11 O
modulation	507 10 O
in	518 2 O
secondary	521 9 O
hyperalgesia	531 12 B-Disease
is	544 2 O
very	547 4 O
similar	552 7 O
to	560 2 O
that	563 4 O
of	568 2 O
capsaicin	571 9 B-Chemical
-	580 1 O
untreated	581 9 O
,	590 1 O
control	592 7 O
condition	600 9 O
.	609 1 O

Our	611 3 O
findings	615 8 O
,	623 1 O
showing	625 7 O
no	633 2 O
interaction	636 11 O
between	648 7 O
capsaicin	656 9 B-Chemical
treatment	666 9 O
and	676 3 O
attentional	680 11 O
modulation	692 10 O
suggest	703 7 O
that	711 4 O
capsaicin	716 9 B-Chemical
-	725 1 O
induced	726 7 O
secondary	734 9 O
hyperalgesia	744 12 B-Disease
and	757 3 O
attention	761 9 O
might	771 5 O
affect	777 6 O
mechanical	784 10 O
pain	795 4 B-Disease
through	800 7 O
independent	808 11 O
mechanisms	820 10 O
.	830 1 O

Testosterone	0 12 B-Chemical
-	12 1 O
dependent	13 9 O
hypertension	23 12 B-Disease
and	36 3 O
upregulation	40 12 O
of	53 2 O
intrarenal	56 10 O
angiotensinogen	67 15 O
in	83 2 O
Dahl	86 4 O
salt	91 4 B-Chemical
-	95 1 O
sensitive	96 9 O
rats	106 4 O
.	110 1 O

Blood	112 5 O
pressure	118 8 O
(	127 1 O
BP	128 2 O
)	130 1 O
is	132 2 O
more	135 4 O
salt	140 4 B-Chemical
sensitive	145 9 O
in	155 2 O
men	158 3 O
than	162 4 O
in	167 2 O
premenopausal	170 13 O
women	184 5 O
.	189 1 O

In	191 2 O
Dahl	194 4 O
salt	199 4 B-Chemical
-	203 1 O
sensitive	204 9 O
rats	214 4 O
(	219 1 O
DS	220 2 O
)	222 1 O
,	223 1 O
high	225 4 O
-	229 1 O
salt	230 4 B-Chemical
(	235 1 O
HS	236 2 O
)	238 1 O
diet	240 4 O
increases	245 9 O
BP	255 2 O
more	258 4 O
in	263 2 O
males	266 5 O
than	272 4 O
females	277 7 O
.	284 1 O

In	286 2 O
contrast	289 8 O
to	298 2 O
the	301 3 O
systemic	305 8 O
renin	314 5 O
-	319 1 O
angiotensin	320 11 B-Chemical
system	332 6 O
,	338 1 O
which	340 5 O
is	346 2 O
suppressed	349 10 O
in	360 2 O
response	363 8 O
to	372 2 O
HS	375 2 O
in	378 2 O
male	381 4 O
DS	386 2 O
,	388 1 O
intrarenal	390 10 O
angiotensinogen	401 15 O
expression	417 10 O
is	428 2 O
increased	431 9 O
,	440 1 O
and	442 3 O
intrarenal	446 10 O
levels	457 6 O
of	464 2 O
ANG	467 3 O
II	471 2 O
are	474 3 O
not	478 3 O
suppressed	482 10 O
.	492 1 O

In	494 2 O
this	497 4 O
study	502 5 O
,	507 1 O
the	509 3 O
hypothesis	513 10 O
was	524 3 O
tested	528 6 O
that	535 4 O
there	540 5 O
is	546 2 O
a	549 1 O
sexual	551 6 O
dimorphism	558 10 O
in	569 2 O
HS	572 2 O
-	574 1 O
induced	575 7 O
upregulation	583 12 O
of	596 2 O
intrarenal	599 10 O
angiotensinogen	610 15 O
mediated	626 8 O
by	635 2 O
testosterone	638 12 B-Chemical
that	651 4 O
also	656 4 O
causes	661 6 O
increases	668 9 O
in	678 2 O
BP	681 2 O
and	684 3 O
renal	688 5 B-Disease
injury	694 6 I-Disease
.	700 1 O

On	702 2 O
a	705 1 O
low	707 3 O
-	710 1 O
salt	711 4 B-Chemical
(	716 1 O
LS	717 2 O
)	719 1 O
diet	721 4 O
,	725 1 O
male	727 4 O
DS	732 2 O
had	735 3 O
higher	739 6 O
levels	746 6 O
of	753 2 O
intrarenal	756 10 O
angiotensinogen	767 15 O
mRNA	783 4 O
than	788 4 O
females	793 7 O
.	800 1 O

HS	802 2 O
diet	805 4 O
for	810 3 O
4	814 1 O
wk	816 2 O
increased	819 9 O
renal	829 5 O
cortical	835 8 O
angiotensinogen	844 15 O
mRNA	860 4 O
and	865 3 O
protein	869 7 O
only	877 4 O
in	882 2 O
male	885 4 O
DS	890 2 O
,	892 1 O
which	894 5 O
was	900 3 O
prevented	904 9 O
by	914 2 O
castration	917 10 O
.	927 1 O

Ovariectomy	929 11 O
of	941 2 O
female	944 6 O
DS	951 2 O
had	954 3 O
no	958 2 O
effect	961 6 O
on	968 2 O
intrarenal	971 10 O
angiotensinogen	982 15 O
expression	998 10 O
on	1009 2 O
either	1012 6 O
diet	1019 4 O
.	1023 1 O

Radiotelemetric	1025 15 O
BP	1041 2 O
was	1044 3 O
similar	1048 7 O
between	1056 7 O
males	1064 5 O
and	1070 3 O
castrated	1074 9 O
rats	1084 4 O
on	1089 2 O
LS	1092 2 O
diet	1095 4 O
.	1099 1 O

HS	1101 2 O
diet	1104 4 O
for	1109 3 O
4	1113 1 O
wk	1115 2 O
caused	1118 6 O
a	1125 1 O
progressive	1127 11 O
increase	1139 8 O
in	1148 2 O
BP	1151 2 O
,	1153 1 O
protein	1155 7 O
and	1163 3 O
albumin	1167 7 O
excretion	1175 9 O
,	1184 1 O
and	1186 3 O
glomerular	1190 10 B-Disease
sclerosis	1201 9 I-Disease
in	1211 2 O
male	1214 4 O
DS	1219 2 O
rats	1222 4 O
,	1226 1 O
which	1228 5 O
were	1234 4 O
attenuated	1239 10 O
by	1250 2 O
castration	1253 10 O
.	1263 1 O

Testosterone	1265 12 B-Chemical
replacement	1278 11 O
in	1290 2 O
castrated	1293 9 O
DS	1303 2 O
rats	1306 4 O
increased	1311 9 O
BP	1321 2 O
,	1323 1 O
renal	1325 5 B-Disease
injury	1331 6 I-Disease
,	1337 1 O
and	1339 3 O
upregulation	1343 12 O
of	1356 2 O
renal	1359 5 O
angiotensinogen	1365 15 O
associated	1381 10 O
with	1392 4 O
HS	1397 2 O
diet	1400 4 O
.	1404 1 O

Testosterone	1406 12 B-Chemical
contributes	1419 11 O
to	1431 2 O
the	1434 3 O
development	1438 11 O
of	1450 2 O
hypertension	1453 12 B-Disease
and	1466 3 O
renal	1470 5 B-Disease
injury	1476 6 I-Disease
in	1483 2 O
male	1486 4 O
DS	1491 2 O
rats	1494 4 O
on	1499 2 O
HS	1502 2 O
diet	1505 4 O
possibly	1510 8 O
through	1519 7 O
upregulation	1527 12 O
of	1540 2 O
the	1543 3 O
intrarenal	1547 10 O
renin	1558 5 O
-	1563 1 O
angiotensin	1564 11 B-Chemical
system	1576 6 O
.	1582 1 O

Prenatal	0 8 O
protein	9 7 O
deprivation	17 11 O
alters	29 6 O
dopamine	36 8 B-Chemical
-	44 1 O
mediated	45 8 O
behaviors	54 9 O
and	64 3 O
dopaminergic	68 12 O
and	81 3 O
glutamatergic	85 13 O
receptor	99 8 O
binding	108 7 O
.	115 1 O

Epidemiological	117 15 O
evidence	133 8 O
indicates	142 9 O
that	152 4 O
prenatal	157 8 O
nutritional	166 11 O
deprivation	178 11 O
may	190 3 O
increase	194 8 O
the	203 3 O
risk	207 4 O
of	212 2 O
schizophrenia	215 13 B-Disease
.	228 1 O

The	230 3 O
goal	234 4 O
of	239 2 O
these	242 5 O
studies	248 7 O
was	256 3 O
to	260 2 O
use	263 3 O
an	267 2 O
animal	270 6 O
model	277 5 O
to	283 2 O
examine	286 7 O
the	294 3 O
effects	298 7 O
of	306 2 O
prenatal	309 8 O
protein	318 7 O
deprivation	326 11 O
on	338 2 O
behaviors	341 9 O
and	351 3 O
receptor	355 8 O
binding	364 7 O
with	372 4 O
relevance	377 9 O
to	387 2 O
schizophrenia	390 13 B-Disease
.	403 1 O

We	405 2 O
report	408 6 O
that	415 4 O
prenatally	420 10 O
protein	431 7 O
deprived	439 8 O
(	448 1 O
PD	449 2 O
)	451 1 O
female	453 6 O
rats	460 4 O
showed	465 6 O
an	472 2 O
increased	475 9 O
stereotypic	485 11 O
response	497 8 O
to	506 2 O
apomorphine	509 11 B-Chemical
and	521 3 O
an	525 2 O
increased	528 9 O
locomotor	538 9 O
response	548 8 O
to	557 2 O
amphetamine	560 11 B-Chemical
in	572 2 O
adulthood	575 9 O
.	584 1 O

These	586 5 O
differences	592 11 O
were	604 4 O
not	609 3 O
observed	613 8 O
during	622 6 O
puberty	629 7 O
.	636 1 O

No	638 2 O
changes	641 7 O
in	649 2 O
haloperidol	652 11 B-Chemical
-	663 1 O
induced	664 7 O
catalepsy	672 9 B-Disease
or	682 2 O
MK	685 2 B-Chemical
-	687 1 I-Chemical
801	688 3 I-Chemical
-	691 1 O
induced	692 7 O
locomotion	700 10 O
were	711 4 O
seen	716 4 O
following	721 9 O
PD	731 2 O
.	733 1 O

In	735 2 O
addition	738 8 O
,	746 1 O
PD	748 2 O
female	751 6 O
rats	758 4 O
showed	763 6 O
increased	770 9 O
(	780 1 O
3	781 1 O
)	782 1 O
H	783 1 B-Chemical
-	784 1 O
MK	785 2 B-Chemical
-	787 1 I-Chemical
801	788 3 I-Chemical
binding	792 7 O
in	800 2 O
the	803 3 O
striatum	807 8 O
and	816 3 O
hippocampus	820 11 O
,	831 1 O
but	833 3 O
not	837 3 O
in	841 2 O
the	844 3 O
cortex	848 6 O
.	854 1 O

PD	856 2 O
female	859 6 O
rats	866 4 O
also	871 4 O
showed	876 6 O
increased	883 9 O
(	893 1 O
3	894 1 O
)	895 1 O
H	896 1 B-Chemical
-	897 1 O
haloperidol	898 11 B-Chemical
binding	910 7 O
and	918 3 O
decreased	922 9 O
dopamine	932 8 B-Chemical
transporter	941 11 O
binding	953 7 O
in	961 2 O
striatum	964 8 O
.	972 1 O

No	974 2 O
statistically	977 13 O
significant	991 11 O
changes	1003 7 O
in	1011 2 O
behavior	1014 8 O
or	1023 2 O
receptor	1026 8 O
binding	1035 7 O
were	1043 4 O
found	1048 5 O
in	1054 2 O
PD	1057 2 O
males	1060 5 O
with	1066 4 O
the	1071 3 O
exception	1075 9 O
of	1085 2 O
increased	1088 9 O
(	1098 1 O
3	1099 1 O
)	1100 1 O
H	1101 1 B-Chemical
-	1102 1 O
MK	1103 2 B-Chemical
-	1105 1 I-Chemical
801	1106 3 I-Chemical
binding	1110 7 O
in	1118 2 O
cortex	1121 6 O
.	1127 1 O

This	1129 4 O
animal	1134 6 O
model	1141 5 O
may	1147 3 O
be	1151 2 O
useful	1154 6 O
to	1161 2 O
explore	1164 7 O
the	1172 3 O
mechanisms	1176 10 O
by	1187 2 O
which	1190 5 O
prenatal	1196 8 O
nutritional	1205 11 B-Disease
deficiency	1217 10 I-Disease
enhances	1228 8 O
risk	1237 4 O
for	1242 3 O
schizophrenia	1246 13 B-Disease
in	1260 2 O
humans	1263 6 O
and	1270 3 O
may	1274 3 O
also	1278 4 O
have	1283 4 O
implications	1288 12 O
for	1301 3 O
developmental	1305 13 O
processes	1319 9 O
leading	1329 7 O
to	1337 2 O
differential	1340 12 O
sensitivity	1353 11 O
to	1365 2 O
drugs	1368 5 O
of	1374 2 O
abuse	1377 5 O
.	1382 1 O

mToR	0 4 O
inhibitors	5 10 O
-	15 1 O
induced	16 7 O
proteinuria	24 11 B-Disease
:	35 1 O
mechanisms	37 10 O
,	47 1 O
significance	49 12 O
,	61 1 O
and	63 3 O
management	67 10 O
.	77 1 O

Massive	79 7 O
urinary	87 7 O
protein	95 7 O
excretion	103 9 O
has	113 3 O
been	117 4 O
observed	122 8 O
after	131 5 O
conversion	137 10 O
from	148 4 O
calcineurin	153 11 O
inhibitors	165 10 O
to	176 2 O
mammalian	179 9 O
target	189 6 O
of	196 2 O
rapamycin	199 9 B-Chemical
(	209 1 O
mToR	210 4 O
)	214 1 O
inhibitors	216 10 O
,	226 1 O
especially	228 10 O
sirolimus	239 9 B-Chemical
,	248 1 O
in	250 2 O
renal	253 5 O
transplant	259 10 O
recipients	270 10 O
with	281 4 O
chronic	286 7 B-Disease
allograft	294 9 I-Disease
nephropathy	304 11 I-Disease
.	315 1 O

Because	317 7 O
proteinuria	325 11 B-Disease
is	337 2 O
a	340 1 O
major	342 5 O
predictive	348 10 O
factor	359 6 O
of	366 2 O
poor	369 4 O
transplantation	374 15 O
outcome	390 7 O
,	397 1 O
many	399 4 O
studies	404 7 O
focused	412 7 O
on	420 2 O
this	423 4 O
adverse	428 7 O
event	436 5 O
during	442 6 O
the	449 3 O
past	453 4 O
years	458 5 O
.	463 1 O

Whether	465 7 O
proteinuria	473 11 B-Disease
was	485 3 O
due	489 3 O
to	493 2 O
sirolimus	496 9 B-Chemical
or	506 2 O
only	509 4 O
a	514 1 O
consequence	516 11 O
of	528 2 O
calcineurin	531 11 O
inhibitors	543 10 O
withdrawal	554 10 O
remained	565 8 O
unsolved	574 8 O
until	583 5 O
high	589 4 O
range	594 5 O
proteinuria	600 11 B-Disease
has	612 3 O
been	616 4 O
observed	621 8 O
during	630 6 O
sirolimus	637 9 B-Chemical
therapy	647 7 O
in	655 2 O
islet	658 5 O
transplantation	664 15 O
and	680 3 O
in	684 2 O
patients	687 8 O
who	696 3 O
received	700 8 O
sirolimus	709 9 B-Chemical
de	719 2 O
novo	722 4 O
.	726 1 O

Podocyte	728 8 O
injury	737 6 O
and	744 3 O
focal	748 5 O
segmental	754 9 O
glomerulosclerosis	764 18 B-Disease
have	783 4 O
been	788 4 O
related	793 7 O
to	801 2 O
mToR	804 4 O
inhibition	809 10 O
in	820 2 O
some	823 4 O
patients	828 8 O
,	836 1 O
but	838 3 O
the	842 3 O
pathways	846 8 O
underlying	855 10 O
these	866 5 O
lesions	872 7 O
remain	880 6 O
hypothetic	887 10 O
.	897 1 O

We	899 2 O
discuss	902 7 O
herein	910 6 O
the	917 3 O
possible	921 8 O
mechanisms	930 10 O
and	941 3 O
the	945 3 O
significance	949 12 O
of	962 2 O
mToR	965 4 O
blockade	970 8 O
-	978 1 O
induced	979 7 O
proteinuria	987 11 B-Disease
.	998 1 O

Hypothalamic	0 12 O
prolactin	13 9 O
receptor	23 8 O
messenger	32 9 O
ribonucleic	42 11 B-Chemical
acid	54 4 I-Chemical
levels	59 6 O
,	65 1 O
prolactin	67 9 O
signaling	77 9 O
,	86 1 O
and	88 3 O
hyperprolactinemic	92 18 B-Disease
inhibition	111 10 O
of	122 2 O
pulsatile	125 9 O
luteinizing	135 11 O
hormone	147 7 O
secretion	155 9 O
are	165 3 O
dependent	169 9 O
on	179 2 O
estradiol	182 9 B-Chemical
.	191 1 O

Hyperprolactinemia	193 18 B-Disease
can	212 3 O
reduce	216 6 O
fertility	223 9 O
and	233 3 O
libido	237 6 O
.	243 1 O

Although	245 8 O
central	254 7 O
prolactin	262 9 O
actions	272 7 O
are	280 3 O
thought	284 7 O
to	292 2 O
contribute	295 10 O
to	306 2 O
this	309 4 O
,	313 1 O
the	315 3 O
mechanisms	319 10 O
are	330 3 O
poorly	334 6 O
understood	341 10 O
.	351 1 O

We	353 2 O
first	356 5 O
tested	362 6 O
whether	369 7 O
chronic	377 7 O
hyperprolactinemia	385 18 B-Disease
inhibited	404 9 O
two	414 3 O
neuroendocrine	418 14 O
parameters	433 10 O
necessary	444 9 O
for	454 3 O
female	458 6 O
fertility	465 9 O
:	474 1 O
pulsatile	476 9 O
LH	486 2 O
secretion	489 9 O
and	499 3 O
the	503 3 O
estrogen	507 8 B-Chemical
-	515 1 O
induced	516 7 O
LH	524 2 O
surge	527 5 O
.	532 1 O

Chronic	534 7 O
hyperprolactinemia	542 18 B-Disease
induced	561 7 O
by	569 2 O
the	572 3 O
dopamine	576 8 B-Chemical
antagonist	585 10 O
sulpiride	596 9 B-Chemical
caused	606 6 O
a	613 1 O
40	615 2 O
%	617 1 O
reduction	619 9 O
LH	629 2 O
pulse	632 5 O
frequency	638 9 O
in	648 2 O
ovariectomized	651 14 O
rats	666 4 O
,	670 1 O
but	672 3 O
only	676 4 O
in	681 2 O
the	684 3 O
presence	688 8 O
of	697 2 O
chronic	700 7 O
low	708 3 O
levels	712 6 O
of	719 2 O
estradiol	722 9 B-Chemical
.	731 1 O

Sulpiride	733 9 B-Chemical
did	743 3 O
not	747 3 O
affect	751 6 O
the	758 3 O
magnitude	762 9 O
of	772 2 O
a	775 1 O
steroid	777 7 B-Chemical
-	784 1 O
induced	785 7 O
LH	793 2 O
surge	796 5 O
or	802 2 O
the	805 3 O
percentage	809 10 O
of	820 2 O
GnRH	823 4 O
neurons	828 7 O
activated	836 9 O
during	846 6 O
the	853 3 O
surge	857 5 O
.	862 1 O

Estradiol	864 9 B-Chemical
is	874 2 O
known	877 5 O
to	883 2 O
influence	886 9 O
expression	896 10 O
of	907 2 O
the	910 3 O
long	914 4 O
form	919 4 O
of	924 2 O
prolactin	927 9 O
receptors	937 9 O
(	947 1 O
PRL	948 3 O
-	951 1 O
R	952 1 O
)	953 1 O
and	955 3 O
components	959 10 O
of	970 2 O
prolactin	973 9 O
'	982 1 O
s	983 1 O
signaling	985 9 O
pathway	995 7 O
.	1002 1 O

To	1004 2 O
test	1007 4 O
the	1012 3 O
hypothesis	1016 10 O
that	1027 4 O
estrogen	1032 8 B-Chemical
increases	1041 9 O
PRL	1051 3 O
-	1054 1 O
R	1055 1 O
expression	1057 10 O
and	1068 3 O
sensitivity	1072 11 O
to	1084 2 O
prolactin	1087 9 O
,	1096 1 O
we	1098 2 O
next	1101 4 O
demonstrated	1106 12 O
that	1119 4 O
estradiol	1124 9 B-Chemical
greatly	1134 7 O
augments	1142 8 O
prolactin	1151 9 O
-	1160 1 O
induced	1161 7 O
STAT5	1169 5 O
activation	1175 10 O
.	1185 1 O

Lastly	1187 6 O
,	1193 1 O
we	1195 2 O
measured	1198 8 O
PRL	1207 3 O
-	1210 1 O
R	1211 1 O
and	1213 3 O
suppressor	1217 10 O
of	1228 2 O
cytokine	1231 8 O
signaling	1240 9 O
(	1250 1 O
SOCS	1251 4 O
-	1255 1 O
1	1256 1 O
and	1258 3 O
-	1262 1 O
3	1263 1 O
and	1265 3 O
CIS	1269 3 O
,	1272 1 O
which	1274 5 O
reflect	1280 7 O
the	1288 3 O
level	1292 5 O
of	1298 2 O
prolactin	1301 9 O
signaling	1311 9 O
)	1320 1 O
mRNAs	1322 5 O
in	1328 2 O
response	1331 8 O
to	1340 2 O
sulpiride	1343 9 B-Chemical
and	1353 3 O
estradiol	1357 9 B-Chemical
.	1366 1 O

Sulpiride	1368 9 B-Chemical
induced	1378 7 O
only	1386 4 O
SOCS	1391 4 O
-	1395 1 O
1	1396 1 O
in	1398 2 O
the	1401 3 O
medial	1405 6 O
preoptic	1412 8 O
area	1421 4 O
,	1425 1 O
where	1427 5 O
GnRH	1433 4 O
neurons	1438 7 O
are	1446 3 O
regulated	1450 9 O
,	1459 1 O
but	1461 3 O
in	1465 2 O
the	1468 3 O
arcuate	1472 7 O
nucleus	1480 7 O
and	1488 3 O
choroid	1492 7 O
plexus	1500 6 O
,	1506 1 O
PRL	1508 3 O
-	1511 1 O
R	1512 1 O
,	1513 1 O
SOCS	1515 4 O
-	1519 1 O
3	1520 1 O
,	1521 1 O
and	1523 3 O
CIS	1527 3 O
mRNA	1531 4 O
levels	1536 6 O
were	1543 4 O
also	1548 4 O
induced	1553 7 O
.	1560 1 O

Estradiol	1562 9 B-Chemical
enhanced	1572 8 O
these	1581 5 O
effects	1587 7 O
on	1595 2 O
SOCS	1598 4 O
-	1602 1 O
3	1603 1 O
and	1605 3 O
CIS	1609 3 O
.	1612 1 O

Interestingly	1614 13 O
,	1627 1 O
estradiol	1629 9 B-Chemical
also	1639 4 O
induced	1644 7 O
PRL	1652 3 O
-	1655 1 O
R	1656 1 O
,	1657 1 O
SOCS	1659 4 O
-	1663 1 O
3	1664 1 O
,	1665 1 O
and	1667 3 O
CIS	1671 3 O
mRNA	1675 4 O
levels	1680 6 O
independently	1687 13 O
.	1700 1 O

These	1702 5 O
data	1708 4 O
show	1713 4 O
that	1718 4 O
GnRH	1723 4 O
pulse	1728 5 O
frequency	1734 9 O
is	1744 2 O
inhibited	1747 9 O
by	1757 2 O
chronic	1760 7 O
hyperprolactinemia	1768 18 B-Disease
in	1787 2 O
a	1790 1 O
steroid	1792 7 B-Chemical
-	1799 1 O
dependent	1800 9 O
manner	1810 6 O
.	1816 1 O

They	1818 4 O
also	1823 4 O
provide	1828 7 O
evidence	1836 8 O
for	1845 3 O
estradiol	1849 9 B-Chemical
-	1858 1 O
dependent	1859 9 O
and	1869 3 O
brain	1873 5 O
region	1879 6 O
-	1885 1 O
specific	1886 8 O
regulation	1895 10 O
of	1906 2 O
PRL	1909 3 O
-	1912 1 O
R	1913 1 O
expression	1915 10 O
and	1926 3 O
signaling	1930 9 O
responses	1940 9 O
by	1950 2 O
prolactin	1953 9 O
.	1962 1 O

Estrogen	0 8 O
prevents	9 8 O
cholesteryl	18 11 B-Chemical
ester	30 5 I-Chemical
accumulation	36 12 O
in	49 2 O
macrophages	52 11 O
induced	64 7 O
by	72 2 O
the	75 3 O
HIV	79 3 O
protease	83 8 O
inhibitor	92 9 O
ritonavir	102 9 B-Chemical
.	111 1 O

Individuals	113 11 O
with	125 4 O
HIV	130 3 O
can	134 3 O
now	138 3 O
live	142 4 O
long	147 4 O
lives	152 5 O
with	158 4 O
drug	163 4 O
therapy	168 7 O
that	176 4 O
often	181 5 O
includes	187 8 O
protease	196 8 O
inhibitors	205 10 O
such	216 4 O
as	221 2 O
ritonavir	224 9 B-Chemical
.	233 1 O

Many	235 4 O
patients	240 8 O
,	248 1 O
however	250 7 O
,	257 1 O
develop	259 7 O
negative	267 8 O
long	276 4 O
-	280 1 O
term	281 4 O
side	286 4 O
effects	291 7 O
such	299 4 O
as	304 2 O
premature	307 9 B-Disease
atherosclerosis	317 15 I-Disease
.	332 1 O

We	334 2 O
have	337 4 O
previously	342 10 O
demonstrated	353 12 O
that	366 4 O
ritonavir	371 9 B-Chemical
treatment	381 9 O
increases	391 9 O
atherosclerotic	401 15 B-Disease
lesion	417 6 I-Disease
formation	424 9 O
in	434 2 O
male	437 4 O
mice	442 4 O
to	447 2 O
a	450 1 O
greater	452 7 O
extent	460 6 O
than	467 4 O
in	472 2 O
female	475 6 O
mice	482 4 O
.	486 1 O

Furthermore	488 11 O
,	499 1 O
peripheral	501 10 O
blood	512 5 O
monocytes	518 9 O
isolated	528 8 O
from	537 4 O
ritonavir	542 9 B-Chemical
-	551 1 O
treated	552 7 O
females	560 7 O
had	568 3 O
less	572 4 O
cholesteryl	577 11 B-Chemical
ester	589 5 I-Chemical
accumulation	595 12 O
.	607 1 O

In	609 2 O
the	612 3 O
present	616 7 O
study	624 5 O
,	629 1 O
we	631 2 O
have	634 4 O
investigated	639 12 O
the	652 3 O
molecular	656 9 O
mechanisms	666 10 O
by	677 2 O
which	680 5 O
female	686 6 O
hormones	693 8 O
influence	702 9 O
cholesterol	712 11 B-Chemical
metabolism	724 10 O
in	735 2 O
macrophages	738 11 O
in	750 2 O
response	753 8 O
to	762 2 O
the	765 3 O
HIV	769 3 O
protease	773 8 O
inhibitor	782 9 O
ritonavir	792 9 B-Chemical
.	801 1 O

We	803 2 O
have	806 4 O
utilized	811 8 O
the	820 3 O
human	824 5 O
monocyte	830 8 O
cell	839 4 O
line	844 4 O
,	848 1 O
THP	850 3 O
-	853 1 O
1	854 1 O
as	856 2 O
a	859 1 O
model	861 5 O
to	867 2 O
address	870 7 O
this	878 4 O
question	883 8 O
.	891 1 O

Briefly	893 7 O
,	900 1 O
cells	902 5 O
were	908 4 O
differentiated	913 14 O
for	928 3 O
72	932 2 O
h	935 1 O
with	937 4 O
100	942 3 O
nM	946 2 O
PMA	949 3 O
to	953 2 O
obtain	956 6 O
a	963 1 O
macrophage	965 10 O
-	975 1 O
like	976 4 O
phenotype	981 9 O
in	991 2 O
the	994 3 O
presence	998 8 O
or	1007 2 O
absence	1010 7 O
of	1018 2 O
1	1021 1 O
nM	1023 2 O
17beta	1026 6 B-Chemical
-	1032 1 I-Chemical
estradiol	1033 9 I-Chemical
(	1043 1 O
E2	1044 2 B-Chemical
)	1046 1 O
,	1047 1 O
100	1049 3 O
nM	1053 2 O
progesterone	1056 12 B-Chemical
or	1069 2 O
vehicle	1072 7 O
(	1080 1 O
0	1081 1 O
.	1082 1 O
01	1083 2 O
%	1085 1 O
ethanol	1087 7 B-Chemical
)	1094 1 O
.	1095 1 O

Cells	1097 5 O
were	1103 4 O
then	1108 4 O
treated	1113 7 O
with	1121 4 O
30	1126 2 O
ng	1129 2 O
/	1131 1 O
ml	1132 2 O
ritonavir	1135 9 B-Chemical
or	1145 2 O
vehicle	1148 7 O
in	1156 2 O
the	1159 3 O
presence	1163 8 O
of	1172 2 O
aggregated	1175 10 O
LDL	1186 3 O
for	1190 3 O
24	1194 2 O
h	1197 1 O
.	1198 1 O

Cell	1200 4 O
extracts	1205 8 O
were	1214 4 O
harvested	1219 9 O
,	1228 1 O
and	1230 3 O
lipid	1234 5 O
or	1240 2 O
total	1243 5 O
RNA	1249 3 O
was	1253 3 O
isolated	1257 8 O
.	1265 1 O

E2	1267 2 B-Chemical
decreased	1270 9 O
the	1280 3 O
accumulation	1284 12 O
of	1297 2 O
cholesteryl	1300 11 B-Chemical
esters	1312 6 I-Chemical
in	1319 2 O
macrophages	1322 11 O
following	1334 9 O
ritonavir	1344 9 B-Chemical
treatment	1354 9 O
.	1363 1 O

Ritonavir	1365 9 B-Chemical
increased	1375 9 O
the	1385 3 O
expression	1389 10 O
of	1400 2 O
the	1403 3 O
scavenger	1407 9 O
receptor	1417 8 O
,	1425 1 O
CD36	1427 4 O
mRNA	1432 4 O
,	1436 1 O
responsible	1438 11 O
for	1450 3 O
the	1454 3 O
uptake	1458 6 O
of	1465 2 O
LDL	1468 3 O
.	1471 1 O

Additionally	1473 12 O
,	1485 1 O
ritonavir	1487 9 B-Chemical
treatment	1497 9 O
selectively	1507 11 O
increased	1519 9 O
the	1529 3 O
relative	1533 8 O
levels	1542 6 O
of	1549 2 O
PPARgamma	1552 9 O
mRNA	1562 4 O
,	1566 1 O
a	1568 1 O
transcription	1570 13 O
factor	1584 6 O
responsible	1591 11 O
for	1603 3 O
the	1607 3 O
regulation	1611 10 O
of	1622 2 O
CD36	1625 4 O
mRNA	1630 4 O
expression	1635 10 O
.	1645 1 O

Treatment	1647 9 O
with	1657 4 O
E2	1662 2 B-Chemical
,	1664 1 O
however	1666 7 O
,	1673 1 O
failed	1675 6 O
to	1682 2 O
prevent	1685 7 O
these	1693 5 O
increases	1699 9 O
at	1709 2 O
the	1712 3 O
mRNA	1716 4 O
level	1721 5 O
.	1726 1 O

E2	1728 2 B-Chemical
did	1731 3 O
,	1734 1 O
however	1736 7 O
,	1743 1 O
significantly	1745 13 O
suppress	1759 8 O
CD36	1768 4 O
protein	1773 7 O
levels	1781 6 O
as	1788 2 O
measured	1791 8 O
by	1800 2 O
fluorescent	1803 11 O
immunocytochemistry	1815 19 O
.	1834 1 O

This	1836 4 O
data	1841 4 O
suggests	1846 8 O
that	1855 4 O
E2	1860 2 B-Chemical
modifies	1863 8 O
the	1872 3 O
expression	1876 10 O
of	1887 2 O
CD36	1890 4 O
at	1895 2 O
the	1898 3 O
level	1902 5 O
of	1908 2 O
protein	1911 7 O
expression	1919 10 O
in	1930 2 O
monocyte	1933 8 O
-	1941 1 O
derived	1942 7 O
macrophages	1950 11 O
resulting	1962 9 O
in	1972 2 O
reduced	1975 7 O
cholesteryl	1983 11 B-Chemical
ester	1995 5 I-Chemical
accumulation	2001 12 O
following	2014 9 O
ritonavir	2024 9 B-Chemical
treatment	2034 9 O
.	2043 1 O

Upregulation	0 12 O
of	13 2 O
brain	16 5 O
expression	22 10 O
of	33 2 O
P	36 1 O
-	37 1 O
glycoprotein	38 12 O
in	51 2 O
MRP2	54 4 O
-	58 1 O
deficient	59 9 O
TR	69 2 O
(	71 1 O
-	72 1 O
)	73 1 O
rats	75 4 O
resembles	80 9 O
seizure	90 7 B-Disease
-	97 1 O
induced	98 7 O
up	106 2 O
-	108 1 O
regulation	109 10 O
of	120 2 O
this	123 4 O
drug	128 4 O
efflux	133 6 O
transporter	140 11 O
in	152 2 O
normal	155 6 O
rats	162 4 O
.	166 1 O

PURPOSE	168 7 O
:	175 1 O
The	177 3 O
multidrug	181 9 O
resistance	191 10 O
protein	202 7 O
2	210 1 O
(	212 1 O
MRP2	213 4 O
)	217 1 O
is	219 2 O
a	222 1 O
drug	224 4 O
efflux	229 6 O
transporter	236 11 O
that	248 4 O
is	253 2 O
expressed	256 9 O
predominantly	266 13 O
at	280 2 O
the	283 3 O
apical	287 6 O
domain	294 6 O
of	301 2 O
hepatocytes	304 11 O
but	316 3 O
seems	320 5 O
also	326 4 O
to	331 2 O
be	334 2 O
expressed	337 9 O
at	347 2 O
the	350 3 O
apical	354 6 O
membrane	361 8 O
of	370 2 O
brain	373 5 O
capillary	379 9 O
endothelial	389 11 O
cells	401 5 O
that	407 4 O
form	412 4 O
the	417 3 O
blood	421 5 O
-	426 1 O
brain	427 5 O
barrier	433 7 O
(	441 1 O
BBB	442 3 O
)	445 1 O
.	446 1 O

MRP2	448 4 O
is	453 2 O
absent	456 6 O
in	463 2 O
the	466 3 O
transport	470 9 O
-	479 1 O
deficient	480 9 O
(	490 1 O
TR	491 2 O
(	493 1 O
-	494 1 O
)	495 1 O
)	496 1 O
Wistar	498 6 O
rat	505 3 O
mutant	509 6 O
,	515 1 O
so	517 2 O
that	520 4 O
this	525 4 O
rat	530 3 O
strain	534 6 O
was	541 3 O
very	545 4 O
helpful	550 7 O
in	558 2 O
defining	561 8 O
substrates	570 10 O
of	581 2 O
MRP2	584 4 O
by	589 2 O
comparing	592 9 O
tissue	602 6 O
concentrations	609 14 O
or	624 2 O
functional	627 10 O
activities	638 10 O
of	649 2 O
compounds	652 9 O
in	662 2 O
MRP2	665 4 O
-	669 1 O
deficient	670 9 O
rats	680 4 O
with	685 4 O
those	690 5 O
in	696 2 O
transport	699 9 O
-	708 1 O
competent	709 9 O
Wistar	719 6 O
rats	726 4 O
.	730 1 O

By	732 2 O
using	735 5 O
this	741 4 O
strategy	746 8 O
to	755 2 O
study	758 5 O
the	764 3 O
involvement	768 11 O
of	780 2 O
MRP2	783 4 O
in	788 2 O
brain	791 5 O
access	797 6 O
of	804 2 O
antiepileptic	807 13 O
drugs	821 5 O
(	827 1 O
AEDs	828 4 O
)	832 1 O
,	833 1 O
we	835 2 O
recently	838 8 O
reported	847 8 O
that	856 4 O
phenytoin	861 9 B-Chemical
is	871 2 O
a	874 1 O
substrate	876 9 O
for	886 3 O
MRP2	890 4 O
in	895 2 O
the	898 3 O
BBB	902 3 O
.	905 1 O

However	907 7 O
,	914 1 O
one	916 3 O
drawback	920 8 O
of	929 2 O
such	932 4 O
studies	937 7 O
in	945 2 O
genetically	948 11 O
deficient	960 9 O
rats	970 4 O
is	975 2 O
the	978 3 O
fact	982 4 O
that	987 4 O
compensatory	992 12 O
changes	1005 7 O
with	1013 4 O
upregulation	1018 12 O
of	1031 2 O
other	1034 5 O
transporters	1040 12 O
can	1053 3 O
occur	1057 5 O
.	1062 1 O

This	1064 4 O
prompted	1069 8 O
us	1078 2 O
to	1081 2 O
study	1084 5 O
the	1090 3 O
brain	1094 5 O
expression	1100 10 O
of	1111 2 O
P	1114 1 O
-	1115 1 O
glycoprotein	1116 12 O
(	1129 1 O
Pgp	1130 3 O
)	1133 1 O
,	1134 1 O
a	1136 1 O
major	1138 5 O
drug	1144 4 O
efflux	1149 6 O
transporter	1156 11 O
in	1168 2 O
many	1171 4 O
tissues	1176 7 O
,	1183 1 O
including	1185 9 O
the	1195 3 O
BBB	1199 3 O
,	1202 1 O
in	1204 2 O
TR	1207 2 O
(	1209 1 O
-	1210 1 O
)	1211 1 O
rats	1213 4 O
compared	1218 8 O
with	1227 4 O
nonmutant	1232 9 O
(	1242 1 O
wild	1243 4 O
-	1247 1 O
type	1248 4 O
)	1252 1 O
Wistar	1254 6 O
rats	1261 4 O
.	1265 1 O

METHODS	1267 7 O
:	1274 1 O
The	1276 3 O
expression	1280 10 O
of	1291 2 O
MRP2	1294 4 O
and	1299 3 O
Pgp	1303 3 O
in	1307 2 O
brain	1310 5 O
and	1316 3 O
liver	1320 5 O
sections	1326 8 O
of	1335 2 O
TR	1338 2 O
(	1340 1 O
-	1341 1 O
)	1342 1 O
rats	1344 4 O
and	1349 3 O
normal	1353 6 O
Wistar	1360 6 O
rats	1367 4 O
was	1372 3 O
determined	1376 10 O
with	1387 4 O
immunohistochemistry	1392 20 O
,	1412 1 O
by	1414 2 O
using	1417 5 O
a	1423 1 O
novel	1425 5 O
,	1430 1 O
highly	1432 6 O
selective	1439 9 O
monoclonal	1449 10 O
MRP2	1460 4 O
antibody	1465 8 O
and	1474 3 O
the	1478 3 O
monoclonal	1482 10 O
Pgp	1493 3 O
antibody	1497 8 O
C219	1506 4 O
,	1510 1 O
respectively	1512 12 O
.	1524 1 O

RESULTS	1526 7 O
:	1533 1 O
Immunofluorescence	1535 18 O
staining	1554 8 O
with	1563 4 O
the	1568 3 O
MRP2	1572 4 O
antibody	1577 8 O
was	1586 3 O
found	1590 5 O
to	1596 2 O
label	1599 5 O
a	1605 1 O
high	1607 4 O
number	1612 6 O
of	1619 2 O
microvessels	1622 12 O
throughout	1635 10 O
the	1646 3 O
brain	1650 5 O
in	1656 2 O
normal	1659 6 O
Wistar	1666 6 O
rats	1673 4 O
,	1677 1 O
whereas	1679 7 O
such	1687 4 O
labeling	1692 8 O
was	1701 3 O
absent	1705 6 O
in	1712 2 O
TR	1715 2 O
(	1717 1 O
-	1718 1 O
)	1719 1 O
rats	1721 4 O
.	1725 1 O

TR	1727 2 O
(	1729 1 O
-	1730 1 O
)	1731 1 O
rats	1733 4 O
exhibited	1738 9 O
a	1748 1 O
significant	1750 11 O
up	1762 2 O
-	1764 1 O
regulation	1765 10 O
of	1776 2 O
Pgp	1779 3 O
in	1783 2 O
brain	1786 5 O
capillary	1792 9 O
endothelial	1802 11 O
cells	1814 5 O
compared	1820 8 O
with	1829 4 O
wild	1834 4 O
-	1838 1 O
type	1839 4 O
controls	1844 8 O
.	1852 1 O

No	1854 2 O
such	1857 4 O
obvious	1862 7 O
upregulation	1870 12 O
of	1883 2 O
Pgp	1886 3 O
was	1890 3 O
observed	1894 8 O
in	1903 2 O
liver	1906 5 O
sections	1912 8 O
.	1920 1 O

A	1922 1 O
comparable	1924 10 O
overexpression	1935 14 O
of	1950 2 O
Pgp	1953 3 O
in	1957 2 O
the	1960 3 O
BBB	1964 3 O
was	1968 3 O
obtained	1972 8 O
after	1981 5 O
pilocarpine	1987 11 B-Chemical
-	1998 1 O
induced	1999 7 O
seizures	2007 8 B-Disease
in	2016 2 O
wild	2019 4 O
-	2023 1 O
type	2024 4 O
Wistar	2029 6 O
rats	2036 4 O
.	2040 1 O

Experiments	2042 11 O
with	2054 4 O
systemic	2059 8 O
administration	2068 14 O
of	2083 2 O
the	2086 3 O
Pgp	2090 3 O
substrate	2094 9 O
phenobarbital	2104 13 B-Chemical
and	2118 3 O
the	2122 3 O
selective	2126 9 O
Pgp	2136 3 O
inhibitor	2140 9 O
tariquidar	2150 10 B-Chemical
in	2161 2 O
TR	2164 2 O
(	2166 1 O
-	2167 1 O
)	2168 1 O
rats	2170 4 O
substantiated	2175 13 O
that	2189 4 O
Pgp	2194 3 O
is	2198 2 O
functional	2201 10 O
and	2212 3 O
compensates	2216 11 O
for	2228 3 O
the	2232 3 O
lack	2236 4 O
of	2241 2 O
MRP2	2244 4 O
in	2249 2 O
the	2252 3 O
BBB	2256 3 O
.	2259 1 O

CONCLUSIONS	2261 11 O
:	2272 1 O
The	2274 3 O
data	2278 4 O
on	2283 2 O
TR	2286 2 O
(	2288 1 O
-	2289 1 O
)	2290 1 O
rats	2292 4 O
indicate	2297 8 O
that	2306 4 O
Pgp	2311 3 O
plays	2315 5 O
an	2321 2 O
important	2324 9 O
role	2334 4 O
in	2339 2 O
the	2342 3 O
compensation	2346 12 O
of	2359 2 O
MRP2	2362 4 O
deficiency	2367 10 O
in	2378 2 O
the	2381 3 O
BBB	2385 3 O
.	2388 1 O

Because	2390 7 O
such	2398 4 O
a	2403 1 O
compensatory	2405 12 O
mechanism	2418 9 O
most	2428 4 O
likely	2433 6 O
occurs	2440 6 O
to	2447 2 O
reduce	2450 6 O
injury	2457 6 B-Disease
to	2464 2 I-Disease
the	2467 3 I-Disease
brain	2471 5 I-Disease
from	2477 4 O
cytotoxic	2482 9 O
compounds	2492 9 O
,	2501 1 O
the	2503 3 O
present	2507 7 O
data	2515 4 O
substantiate	2520 12 O
the	2533 3 O
concept	2537 7 O
that	2545 4 O
MRP2	2550 4 O
performs	2555 8 O
a	2564 1 O
protective	2566 10 O
role	2577 4 O
in	2582 2 O
the	2585 3 O
BBB	2589 3 O
.	2592 1 O

Furthermore	2594 11 O
,	2605 1 O
our	2607 3 O
data	2611 4 O
suggest	2616 7 O
that	2624 4 O
TR	2629 2 O
(	2631 1 O
-	2632 1 O
)	2633 1 O
rats	2635 4 O
are	2640 3 O
an	2644 2 O
interesting	2647 11 O
tool	2659 4 O
to	2664 2 O
study	2667 5 O
consequences	2673 12 O
of	2686 2 O
overexpression	2689 14 O
of	2704 2 O
Pgp	2707 3 O
in	2711 2 O
the	2714 3 O
BBB	2718 3 O
on	2722 2 O
access	2725 6 O
of	2732 2 O
drugs	2735 5 O
in	2741 2 O
the	2744 3 O
brain	2748 5 O
,	2753 1 O
without	2755 7 O
the	2763 3 O
need	2767 4 O
of	2772 2 O
inducing	2775 8 O
seizures	2784 8 B-Disease
or	2793 2 O
other	2796 5 O
Pgp	2802 3 O
-	2805 1 O
enhancing	2806 9 O
events	2816 6 O
for	2823 3 O
this	2827 4 O
purpose	2832 7 O
.	2839 1 O

Use	0 3 O
of	4 2 O
chromosome	7 10 O
substitution	18 12 O
strains	31 7 O
to	39 2 O
identify	42 8 O
seizure	51 7 B-Disease
susceptibility	59 14 O
loci	74 4 O
in	79 2 O
mice	82 4 O
.	86 1 O

Seizure	88 7 B-Disease
susceptibility	96 14 O
varies	111 6 O
among	118 5 O
inbred	124 6 O
mouse	131 5 O
strains	137 7 O
.	144 1 O

Chromosome	146 10 O
substitution	157 12 O
strains	170 7 O
(	178 1 O
CSS	179 3 O
)	182 1 O
,	183 1 O
in	185 2 O
which	188 5 O
a	194 1 O
single	196 6 O
chromosome	203 10 O
from	214 4 O
one	219 3 O
inbred	223 6 O
strain	230 6 O
(	237 1 O
donor	238 5 O
)	243 1 O
has	245 3 O
been	249 4 O
transferred	254 11 O
onto	266 4 O
a	271 1 O
second	273 6 O
strain	280 6 O
(	287 1 O
host	288 4 O
)	292 1 O
by	294 2 O
repeated	297 8 O
backcrossing	306 12 O
,	318 1 O
may	320 3 O
be	324 2 O
used	327 4 O
to	332 2 O
identify	335 8 O
quantitative	344 12 O
trait	357 5 O
loci	363 4 O
(	368 1 O
QTLs	369 4 O
)	373 1 O
that	375 4 O
contribute	380 10 O
to	391 2 O
seizure	394 7 B-Disease
susceptibility	402 14 O
.	416 1 O

QTLs	418 4 O
for	423 3 O
susceptibility	427 14 O
to	442 2 O
pilocarpine	445 11 B-Chemical
-	456 1 O
induced	457 7 O
seizures	465 8 B-Disease
,	473 1 O
a	475 1 O
model	477 5 O
of	483 2 O
temporal	486 8 B-Disease
lobe	495 4 I-Disease
epilepsy	500 8 I-Disease
,	508 1 O
have	510 4 O
not	515 3 O
been	519 4 O
reported	524 8 O
,	532 1 O
and	534 3 O
CSS	538 3 O
have	542 4 O
not	547 3 O
previously	551 10 O
been	562 4 O
used	567 4 O
to	572 2 O
localize	575 8 O
seizure	584 7 B-Disease
susceptibility	592 14 O
genes	607 5 O
.	612 1 O

We	614 2 O
report	617 6 O
QTLs	624 4 O
identified	629 10 O
using	640 5 O
a	646 1 O
B6	648 2 O
(	651 1 O
host	652 4 O
)	656 1 O
x	658 1 O
A	660 1 O
/	661 1 O
J	662 1 O
(	664 1 O
donor	665 5 O
)	670 1 O
CSS	672 3 O
panel	676 5 O
to	682 2 O
localize	685 8 O
genes	694 5 O
involved	700 8 O
in	709 2 O
susceptibility	712 14 O
to	727 2 O
pilocarpine	730 11 B-Chemical
-	741 1 O
induced	742 7 O
seizures	750 8 B-Disease
.	758 1 O

Three	760 5 O
hundred	766 7 O
fifty	774 5 O
-	779 1 O
five	780 4 O
adult	785 5 O
male	791 4 O
CSS	796 3 O
mice	800 4 O
,	804 1 O
58	806 2 O
B6	809 2 O
,	811 1 O
and	813 3 O
39	817 2 O
A	820 1 O
/	821 1 O
J	822 1 O
were	824 4 O
tested	829 6 O
for	836 3 O
susceptibility	840 14 O
to	855 2 O
pilocarpine	858 11 B-Chemical
-	869 1 O
induced	870 7 O
seizures	878 8 B-Disease
.	886 1 O

Highest	888 7 O
stage	896 5 O
reached	902 7 O
and	910 3 O
latency	914 7 O
to	922 2 O
each	925 4 O
stage	930 5 O
were	936 4 O
recorded	941 8 O
for	950 3 O
all	954 3 O
mice	958 4 O
.	962 1 O

B6	964 2 O
mice	967 4 O
were	972 4 O
resistant	977 9 O
to	987 2 O
seizures	990 8 B-Disease
and	999 3 O
slower	1003 6 O
to	1010 2 O
reach	1013 5 O
stages	1019 6 O
compared	1026 8 O
to	1035 2 O
A	1038 1 O
/	1039 1 O
J	1040 1 O
mice	1042 4 O
.	1046 1 O

The	1048 3 O
CSS	1052 3 O
for	1056 3 O
Chromosomes	1060 11 O
10	1072 2 O
and	1075 3 O
18	1079 2 O
progressed	1082 10 O
to	1093 2 O
the	1096 3 O
most	1100 4 O
severe	1105 6 O
stages	1112 6 O
,	1118 1 O
diverging	1120 9 O
dramatically	1130 12 O
from	1143 4 O
the	1148 3 O
B6	1152 2 O
phenotype	1155 9 O
.	1164 1 O

Latencies	1166 9 O
to	1176 2 O
stages	1179 6 O
were	1186 4 O
also	1191 4 O
significantly	1196 13 O
shorter	1210 7 O
for	1218 3 O
CSS10	1222 5 O
and	1228 3 O
CSS18	1232 5 O
mice	1238 4 O
.	1242 1 O

CSS	1244 3 O
mapping	1248 7 O
suggests	1256 8 O
seizure	1265 7 B-Disease
susceptibility	1273 14 O
loci	1288 4 O
on	1293 2 O
mouse	1296 5 O
Chromosomes	1302 11 O
10	1314 2 O
and	1317 3 O
18	1321 2 O
.	1323 1 O

This	1325 4 O
approach	1330 8 O
provides	1339 8 O
a	1348 1 O
framework	1350 9 O
for	1360 3 O
identifying	1364 11 O
potentially	1376 11 O
novel	1388 5 O
homologous	1394 10 O
candidate	1405 9 O
genes	1415 5 O
for	1421 3 O
human	1425 5 O
temporal	1431 8 B-Disease
lobe	1440 4 I-Disease
epilepsy	1445 8 I-Disease
.	1453 1 O

Investigation	0 13 O
of	14 2 O
mitochondrial	17 13 O
involvement	31 11 O
in	43 2 O
the	46 3 O
experimental	50 12 O
model	63 5 O
of	69 2 O
epilepsy	72 8 B-Disease
induced	81 7 O
by	89 2 O
pilocarpine	92 11 B-Chemical
.	103 1 O

Mitochondrial	105 13 B-Disease
abnormalities	119 13 I-Disease
have	133 4 O
been	138 4 O
associated	143 10 O
with	154 4 O
several	159 7 O
aspects	167 7 O
of	175 2 O
epileptogenesis	178 15 O
,	193 1 O
such	195 4 O
as	200 2 O
energy	203 6 O
generation	210 10 O
,	220 1 O
control	222 7 O
of	230 2 O
cell	233 4 O
death	238 5 B-Disease
,	243 1 O
neurotransmitter	245 16 O
synthesis	262 9 O
,	271 1 O
and	273 3 O
free	277 4 O
radical	282 7 O
(	290 1 O
FR	291 2 O
)	293 1 O
production	295 10 O
.	305 1 O

Increased	307 9 O
production	317 10 O
of	328 2 O
FRs	331 3 O
may	335 3 O
cause	339 5 O
mtDNA	345 5 O
damage	351 6 O
leading	358 7 O
to	366 2 O
decreased	369 9 O
activities	379 10 O
of	390 2 O
oxidative	393 9 O
phosphorylation	403 15 O
complexes	419 9 O
containing	429 10 O
mtDNA	440 5 O
-	445 1 O
encoded	446 7 O
subunits	454 8 O
.	462 1 O

In	464 2 O
this	467 4 O
study	472 5 O
,	477 1 O
we	479 2 O
investigated	482 12 O
whether	495 7 O
increased	503 9 O
generation	513 10 O
of	524 2 O
FR	527 2 O
during	530 6 O
status	537 6 B-Disease
epilepticus	544 11 I-Disease
would	556 5 O
be	562 2 O
sufficient	565 10 O
to	576 2 O
provoke	579 7 O
abnormalities	587 13 O
in	601 2 O
mtDNA	604 5 O
and	610 3 O
in	614 2 O
the	617 3 O
expression	621 10 O
and	632 3 O
activity	636 8 O
of	645 2 O
cytochrome	648 10 O
c	659 1 O
oxidase	661 7 O
(	669 1 O
CCO	670 3 O
)	673 1 O
,	674 1 O
complex	676 7 O
IV	684 2 O
of	687 2 O
the	690 3 O
respiratory	694 11 O
chain	706 5 O
,	711 1 O
in	713 2 O
the	716 3 O
chronic	720 7 O
phase	728 5 O
of	734 2 O
the	737 3 O
pilocarpine	741 11 B-Chemical
model	753 5 O
of	759 2 O
temporal	762 8 B-Disease
lobe	771 4 I-Disease
epilepsy	776 8 I-Disease
.	784 1 O

DNA	786 3 O
analysis	790 8 O
revealed	799 8 O
low	808 3 O
amounts	812 7 O
of	820 2 O
a	823 1 O
4	825 1 O
.	826 1 O
8	827 1 O
kb	829 2 O
mtDNA	832 5 O
deletion	838 8 O
but	847 3 O
with	851 4 O
no	856 2 O
differences	859 11 O
in	871 2 O
frequency	874 9 O
or	884 2 O
quantity	887 8 O
in	896 2 O
the	899 3 O
control	903 7 O
and	911 3 O
experimental	915 12 O
groups	928 6 O
.	934 1 O

We	936 2 O
did	939 3 O
not	943 3 O
find	947 4 O
abnormalities	952 13 O
in	966 2 O
the	969 3 O
expression	973 10 O
and	984 3 O
distribution	988 12 O
of	1001 2 O
an	1004 2 O
mtDNA	1007 5 O
-	1012 1 O
encoded	1013 7 O
subunit	1021 7 O
of	1029 2 O
CCO	1032 3 O
(	1036 1 O
CCO	1037 3 O
-	1040 1 O
I	1041 1 O
)	1042 1 O
or	1044 2 O
a	1047 1 O
relative	1049 8 O
decrease	1058 8 O
in	1067 2 O
CCO	1070 3 O
-	1073 1 O
I	1074 1 O
when	1076 4 O
compared	1081 8 O
with	1090 4 O
nuclear	1095 7 O
-	1102 1 O
encoded	1103 7 O
subunits	1111 8 O
(	1120 1 O
CCO	1121 3 O
-	1124 1 O
IV	1125 2 O
and	1128 3 O
SDH	1132 3 O
-	1135 1 O
fp	1136 2 O
)	1138 1 O
.	1139 1 O

No	1141 2 O
abnormality	1144 11 O
in	1156 2 O
CCO	1159 3 O
activity	1163 8 O
was	1172 3 O
observed	1176 8 O
through	1185 7 O
histochemistry	1193 14 O
.	1207 1 O

Although	1209 8 O
evidences	1218 9 O
of	1228 2 O
mitochondrial	1231 13 B-Disease
abnormalities	1245 13 I-Disease
were	1259 4 O
found	1264 5 O
in	1270 2 O
previously	1273 10 O
published	1284 9 O
studies	1294 7 O
,	1301 1 O
our	1303 3 O
results	1307 7 O
do	1315 2 O
not	1318 3 O
suggest	1322 7 O
that	1330 4 O
the	1335 3 O
FRs	1339 3 O
,	1342 1 O
generated	1344 9 O
during	1354 6 O
the	1361 3 O
acute	1365 5 O
phase	1371 5 O
,	1376 1 O
determined	1378 10 O
important	1389 9 O
abnormalities	1399 13 O
in	1413 2 O
mtDNA	1416 5 O
,	1421 1 O
in	1423 2 O
expression	1426 10 O
of	1437 2 O
CCO	1440 3 O
-	1443 1 O
I	1444 1 O
,	1445 1 O
and	1447 3 O
in	1451 2 O
CCO	1454 3 O
activity	1458 8 O
.	1466 1 O

Causes	0 6 O
of	7 2 O
acute	10 5 O
thrombotic	16 10 B-Disease
microangiopathy	27 15 I-Disease
in	43 2 O
patients	46 8 O
receiving	55 9 O
kidney	65 6 O
transplantation	72 15 O
.	87 1 O

OBJECTIVES	89 10 O
:	99 1 O
Thrombotic	101 10 B-Disease
microangiopathy	112 15 I-Disease
is	128 2 O
a	131 1 O
well	133 4 O
-	137 1 O
known	138 5 O
problem	144 7 O
in	152 2 O
patients	155 8 O
following	164 9 O
renal	174 5 O
transplantation	180 15 O
.	195 1 O

In	197 2 O
postrenal	200 9 O
transplantation	210 15 O
,	225 1 O
thrombotic	227 10 B-Disease
microangiopathy	238 15 I-Disease
is	254 2 O
often	257 5 O
a	263 1 O
reflection	265 10 O
of	276 2 O
hemolytic	279 9 B-Disease
uremic	289 6 I-Disease
syndrome	296 8 I-Disease
.	304 1 O

We	306 2 O
aimed	309 5 O
to	315 2 O
determine	318 9 O
the	328 3 O
causes	332 6 O
of	339 2 O
thrombotic	342 10 B-Disease
microangiopathy	353 15 I-Disease
in	369 2 O
a	372 1 O
population	374 10 O
of	385 2 O
renal	388 5 O
transplantation	394 15 O
recipients	410 10 O
and	421 3 O
discuss	425 7 O
the	433 3 O
literature	437 10 O
.	447 1 O

MATERIALS	449 9 O
AND	459 3 O
METHODS	463 7 O
:	470 1 O
We	472 2 O
investigated	475 12 O
the	488 3 O
causes	492 6 O
of	499 2 O
thrombotic	502 10 B-Disease
microangiopathy	513 15 I-Disease
during	529 6 O
a	536 1 O
1	538 1 O
-	539 1 O
year	540 4 O
period	545 6 O
,	551 1 O
from	553 4 O
June	558 4 O
2003	563 4 O
to	568 2 O
June	571 4 O
2004	576 4 O
,	580 1 O
at	582 2 O
the	585 3 O
King	589 4 O
Fahad	594 5 O
National	600 8 O
Guard	609 5 O
Hospital	615 8 O
in	624 2 O
Riyadh	627 6 O
,	633 1 O
Saudi	635 5 O
Arabia	641 6 O
,	647 1 O
by	649 2 O
reviewing	652 9 O
the	662 3 O
slides	666 6 O
of	673 2 O
all	676 3 O
transplant	680 10 O
biopsies	691 8 O
(	700 1 O
n	701 1 O
=	702 1 O
25	703 2 O
)	705 1 O
performed	707 9 O
during	717 6 O
this	724 4 O
interval	729 8 O
.	737 1 O

Pre	739 3 O
-	742 1 O
and	744 3 O
posttransplant	748 14 O
crossmatching	763 13 O
was	777 3 O
done	781 4 O
when	786 4 O
possible	791 8 O
.	799 1 O

RESULTS	801 7 O
:	808 1 O
Five	810 4 O
cases	815 5 O
of	821 2 O
thrombotic	824 10 B-Disease
microangiopathy	835 15 I-Disease
were	851 4 O
found	856 5 O
.	861 1 O

Three	863 5 O
of	869 2 O
these	872 5 O
cases	878 5 O
were	884 4 O
from	889 4 O
the	894 3 O
25	898 2 O
transplantations	901 16 O
performed	918 9 O
at	928 2 O
King	931 4 O
Fahad	936 5 O
National	942 8 O
Guard	951 5 O
Hospital	957 8 O
,	965 1 O
while	967 5 O
the	973 3 O
other	977 5 O
2	983 1 O
transplantations	985 16 O
had	1002 3 O
been	1006 4 O
performed	1011 9 O
abroad	1021 6 O
and	1028 3 O
were	1032 4 O
referred	1037 8 O
to	1046 2 O
us	1049 2 O
for	1052 3 O
follow	1056 6 O
-	1062 1 O
up	1063 2 O
.	1065 1 O

Three	1067 5 O
cases	1073 5 O
were	1079 4 O
related	1084 7 O
to	1092 2 O
cyclosporine	1095 12 B-Chemical
,	1107 1 O
and	1109 3 O
1	1113 1 O
case	1115 4 O
was	1120 3 O
secondary	1124 9 O
to	1134 2 O
both	1137 4 O
cyclosporine	1142 12 B-Chemical
and	1155 3 O
tacrolimus	1159 10 B-Chemical
.	1169 1 O

The	1171 3 O
fifth	1175 5 O
case	1181 4 O
had	1186 3 O
features	1190 8 O
of	1199 2 O
thrombotic	1202 10 B-Disease
microangiopathy	1213 15 I-Disease
related	1229 7 O
to	1237 2 O
an	1240 2 O
antiphospholipid	1243 16 B-Disease
syndrome	1260 8 I-Disease
in	1269 2 O
a	1272 1 O
patient	1274 7 O
with	1282 4 O
systemic	1287 8 B-Disease
lupus	1296 5 I-Disease
erythematosus	1302 13 I-Disease
.	1315 1 O

CONCLUSIONS	1317 11 O
:	1328 1 O
In	1330 2 O
the	1333 3 O
literature	1337 10 O
,	1347 1 O
the	1349 3 O
most	1353 4 O
-	1357 1 O
frequent	1358 8 O
cause	1367 5 O
of	1373 2 O
hemolytic	1376 9 B-Disease
uremic	1386 6 I-Disease
syndrome	1393 8 I-Disease
in	1402 2 O
patients	1405 8 O
following	1414 9 O
renal	1424 5 O
transplantation	1430 15 O
is	1446 2 O
recurrence	1449 10 O
of	1460 2 O
the	1463 3 O
hemolytic	1467 9 B-Disease
uremic	1477 6 I-Disease
syndrome	1484 8 I-Disease
.	1492 1 O

Other	1494 5 O
causes	1500 6 O
include	1507 7 O
drug	1515 4 O
-	1519 1 O
related	1520 7 O
(	1528 1 O
cyclosporine	1529 12 B-Chemical
,	1541 1 O
tacrolimus	1543 10 B-Chemical
)	1553 1 O
toxicity	1555 8 B-Disease
,	1563 1 O
procoagulant	1565 12 O
status	1578 6 O
,	1584 1 O
and	1586 3 O
antibody	1590 8 O
-	1598 1 O
mediated	1599 8 O
rejection	1608 9 O
.	1617 1 O

We	1619 2 O
found	1622 5 O
that	1628 4 O
the	1633 3 O
most	1637 4 O
-	1641 1 O
frequent	1642 8 O
cause	1651 5 O
of	1657 2 O
thrombotic	1660 10 B-Disease
microangiopathy	1671 15 I-Disease
was	1687 3 O
drug	1691 4 O
related	1696 7 O
,	1703 1 O
secondary	1705 9 O
mainly	1715 6 O
to	1722 2 O
cyclosporine	1725 12 B-Chemical
.	1737 1 O

In	1739 2 O
the	1742 3 O
current	1746 7 O
study	1754 5 O
,	1759 1 O
the	1761 3 O
frequency	1765 9 O
of	1775 2 O
thrombotic	1778 10 B-Disease
microangiopathy	1789 15 I-Disease
was	1805 3 O
similar	1809 7 O
to	1817 2 O
the	1820 3 O
percentage	1824 10 O
reported	1835 8 O
in	1844 2 O
the	1847 3 O
literature	1851 10 O
(	1862 1 O
20	1863 2 O
%	1865 1 O
)	1866 1 O
.	1867 1 O

Severe	0 6 O
reversible	7 10 O
left	18 4 B-Disease
ventricular	23 11 I-Disease
systolic	35 8 I-Disease
and	44 3 I-Disease
diastolic	48 9 I-Disease
dysfunction	58 11 I-Disease
due	70 3 O
to	74 2 O
accidental	77 10 O
iatrogenic	88 10 O
epinephrine	99 11 B-Chemical
overdose	111 8 B-Disease
.	119 1 O

Catecholamine	121 13 B-Chemical
-	134 1 O
induced	135 7 O
cardiomyopathy	143 14 B-Disease
due	158 3 O
to	162 2 O
chronic	165 7 O
excess	173 6 O
of	180 2 O
endogenous	183 10 O
catecholamines	194 14 B-Chemical
has	209 3 O
been	213 4 O
recognized	218 10 O
for	229 3 O
decades	233 7 O
as	241 2 O
a	244 1 O
clinical	246 8 O
phenomenon	255 10 O
.	265 1 O

In	267 2 O
contrast	270 8 O
,	278 1 O
reports	280 7 O
of	288 2 O
myocardial	291 10 B-Disease
dysfunction	302 11 I-Disease
due	314 3 O
to	318 2 O
acute	321 5 O
iatrogenic	327 10 O
overdose	338 8 B-Disease
are	347 3 O
rare	351 4 O
.	355 1 O

A	357 1 O
35	359 2 O
-	361 1 O
year	362 4 O
-	366 1 O
old	367 3 O
woman	371 5 O
whose	377 5 O
cervix	383 6 O
uteri	390 5 O
was	396 3 O
inadvertently	400 13 O
injected	414 8 O
with	423 4 O
8	428 1 O
mg	430 2 O
of	433 2 O
epinephrine	436 11 B-Chemical
developed	448 9 O
myocardial	458 10 B-Disease
stunning	469 8 I-Disease
that	478 4 O
was	483 3 O
characterized	487 13 O
by	501 2 O
severe	504 6 O
hemodynamic	511 11 O
compromise	523 10 O
,	533 1 O
profound	535 8 O
,	543 1 O
albeit	545 6 O
transient	552 9 O
,	561 1 O
left	563 4 B-Disease
ventricular	568 11 I-Disease
systolic	580 8 I-Disease
and	589 3 I-Disease
diastolic	593 9 I-Disease
dysfunction	603 11 I-Disease
,	614 1 O
and	616 3 O
only	620 4 O
modestly	625 8 O
elevated	634 8 O
biochemical	643 11 O
markers	655 7 O
of	663 2 O
myocardial	666 10 B-Disease
necrosis	677 8 I-Disease
.	685 1 O

Our	687 3 O
case	691 4 O
illustrates	696 11 O
the	708 3 O
serious	712 7 O
consequences	720 12 O
of	733 2 O
medical	736 7 O
errors	744 6 O
that	751 4 O
can	756 3 O
be	760 2 O
avoided	763 7 O
through	771 7 O
improved	779 8 O
medication	788 10 O
labeling	799 8 O
and	808 3 O
staff	812 5 O
supervision	818 11 O
.	829 1 O

Urinary	0 7 B-Disease
bladder	8 7 I-Disease
cancer	16 6 I-Disease
in	23 2 O
Wegener	26 7 B-Disease
'	33 1 I-Disease
s	34 1 I-Disease
granulomatosis	36 14 I-Disease
:	50 1 O
risks	52 5 O
and	58 3 O
relation	62 8 O
to	71 2 O
cyclophosphamide	74 16 B-Chemical
.	90 1 O

OBJECTIVE	92 9 O
:	101 1 O
To	103 2 O
assess	106 6 O
and	113 3 O
characterise	117 12 O
the	130 3 O
risk	134 4 O
of	139 2 O
bladder	142 7 B-Disease
cancer	150 6 I-Disease
,	156 1 O
and	158 3 O
its	162 3 O
relation	166 8 O
to	175 2 O
cyclophosphamide	178 16 B-Chemical
,	194 1 O
in	196 2 O
patients	199 8 O
with	208 4 O
Wegener	213 7 B-Disease
'	220 1 I-Disease
s	221 1 I-Disease
granulomatosis	223 14 I-Disease
.	237 1 O

METHODS	239 7 O
:	246 1 O
In	248 2 O
the	251 3 O
population	255 10 O
based	266 5 O
,	271 1 O
nationwide	273 10 O
Swedish	284 7 O
Inpatient	292 9 O
Register	302 8 O
a	311 1 O
cohort	313 6 O
of	320 2 O
1065	323 4 O
patients	328 8 O
with	337 4 O
Wegener	342 7 B-Disease
'	349 1 I-Disease
s	350 1 I-Disease
granulomatosis	352 14 I-Disease
,	366 1 O
1969	368 4 O
-	372 1 O
95	373 2 O
,	375 1 O
was	377 3 O
identified	381 10 O
.	391 1 O

Through	393 7 O
linkage	401 7 O
with	409 4 O
the	414 3 O
Swedish	418 7 O
Cancer	426 6 B-Disease
Register	433 8 O
,	441 1 O
all	443 3 O
subjects	447 8 O
in	456 2 O
this	459 4 O
cohort	464 6 O
diagnosed	471 9 O
with	481 4 O
bladder	486 7 B-Disease
cancer	494 6 I-Disease
were	501 4 O
identified	506 10 O
.	516 1 O

Nested	518 6 O
within	525 6 O
the	532 3 O
cohort	536 6 O
,	542 1 O
a	544 1 O
matched	546 7 O
case	554 4 O
-	558 1 O
control	559 7 O
study	567 5 O
was	573 3 O
performed	577 9 O
to	587 2 O
estimate	590 8 O
the	599 3 O
association	603 11 O
between	615 7 O
cyclophosphamide	623 16 B-Chemical
and	640 3 O
bladder	644 7 B-Disease
cancer	652 6 I-Disease
using	659 5 O
odds	665 4 O
ratios	670 6 O
(	677 1 O
ORs	678 3 O
)	681 1 O
as	683 2 O
relative	686 8 O
risk	695 4 O
.	699 1 O

In	701 2 O
the	704 3 O
cohort	708 6 O
the	715 3 O
cumulative	719 10 O
risk	730 4 O
of	735 2 O
bladder	738 7 B-Disease
cancer	746 6 I-Disease
after	753 5 O
Wegener	759 7 B-Disease
'	766 1 I-Disease
s	767 1 I-Disease
granulomatosis	769 14 I-Disease
,	783 1 O
and	785 3 O
the	789 3 O
relative	793 8 O
prevalence	802 10 O
of	813 2 O
a	816 1 O
history	818 7 O
of	826 2 O
bladder	829 7 B-Disease
cancer	837 6 I-Disease
at	844 2 O
the	847 3 O
time	851 4 O
of	856 2 O
diagnosis	859 9 O
of	869 2 O
Wegener	872 7 B-Disease
'	879 1 I-Disease
s	880 1 I-Disease
granulomatosis	882 14 I-Disease
,	896 1 O
were	898 4 O
also	903 4 O
estimated	908 9 O
.	917 1 O

RESULTS	919 7 O
:	926 1 O
The	928 3 O
median	932 6 O
cumulative	939 10 O
doses	950 5 O
of	956 2 O
cyclophosphamide	959 16 B-Chemical
among	976 5 O
cases	982 5 O
(	988 1 O
n	989 1 O
=	991 1 O
11	993 2 O
)	995 1 O
and	997 3 O
controls	1001 8 O
(	1010 1 O
n	1011 1 O
=	1013 1 O
25	1015 2 O
)	1017 1 O
were	1019 4 O
113	1024 3 O
g	1028 1 O
and	1030 3 O
25	1034 2 O
g	1037 1 O
,	1038 1 O
respectively	1040 12 O
.	1052 1 O

The	1054 3 O
risk	1058 4 O
of	1063 2 O
bladder	1066 7 B-Disease
cancer	1074 6 I-Disease
doubled	1081 7 O
for	1089 3 O
every	1093 5 O
10	1099 2 O
g	1102 1 O
increment	1104 9 O
in	1114 2 O
cyclophosphamide	1117 16 B-Chemical
(	1134 1 O
OR	1135 2 O
=	1138 1 O
2	1140 1 O
.	1141 1 O
0	1142 1 O
,	1143 1 O
95	1145 2 O
%	1147 1 O
confidence	1149 10 O
interval	1160 8 O
(	1169 1 O
CI	1170 2 O
)	1172 1 O
0	1174 1 O
.	1175 1 O
8	1176 1 O
to	1178 2 O
4	1181 1 O
.	1182 1 O
9	1183 1 O
)	1184 1 O
.	1185 1 O

Treatment	1187 9 O
duration	1197 8 O
longer	1206 6 O
than	1213 4 O
1	1218 1 O
year	1220 4 O
was	1225 3 O
associated	1229 10 O
with	1240 4 O
an	1245 2 O
eightfold	1248 9 O
increased	1258 9 O
risk	1268 4 O
(	1273 1 O
OR	1274 2 O
=	1277 1 O
7	1279 1 O
.	1280 1 O
7	1281 1 O
,	1282 1 O
95	1284 2 O
%	1286 1 O
CI	1288 2 O
0	1291 1 O
.	1292 1 O
9	1293 1 O
to	1295 2 O
69	1298 2 O
)	1300 1 O
.	1301 1 O

The	1303 3 O
absolute	1307 8 O
risk	1316 4 O
for	1321 3 O
bladder	1325 7 B-Disease
cancer	1333 6 I-Disease
in	1340 2 O
the	1343 3 O
cohort	1347 6 O
reached	1354 7 O
10	1362 2 O
%	1364 1 O
16	1366 2 O
years	1369 5 O
after	1375 5 O
diagnosis	1381 9 O
of	1391 2 O
Wegener	1394 7 B-Disease
'	1401 1 I-Disease
s	1402 1 I-Disease
granulomatosis	1404 14 I-Disease
,	1418 1 O
and	1420 3 O
a	1424 1 O
history	1426 7 O
of	1434 2 O
bladder	1437 7 B-Disease
cancer	1445 6 I-Disease
was	1452 3 O
(	1456 1 O
non	1457 3 O
-	1460 1 O
significantly	1461 13 O
)	1474 1 O
twice	1476 5 O
as	1482 2 O
common	1485 6 O
as	1492 2 O
expected	1495 8 O
at	1504 2 O
the	1507 3 O
time	1511 4 O
of	1516 2 O
diagnosis	1519 9 O
of	1529 2 O
Wegener	1532 7 B-Disease
'	1539 1 I-Disease
s	1540 1 I-Disease
granulomatosis	1542 14 I-Disease
.	1556 1 O

CONCLUSION	1558 10 O
:	1568 1 O
The	1570 3 O
results	1574 7 O
indicate	1582 8 O
a	1591 1 O
dose	1593 4 O
-	1597 1 O
response	1598 8 O
relationship	1607 12 O
between	1620 7 O
cyclophosphamide	1628 16 B-Chemical
and	1645 3 O
the	1649 3 O
risk	1653 4 O
of	1658 2 O
bladder	1661 7 B-Disease
cancer	1669 6 I-Disease
,	1675 1 O
high	1677 4 O
cumulative	1682 10 O
risks	1693 5 O
in	1699 2 O
the	1702 3 O
entire	1706 6 O
cohort	1713 6 O
,	1719 1 O
and	1721 3 O
also	1725 4 O
the	1730 3 O
possibility	1734 11 O
of	1746 2 O
risk	1749 4 O
factors	1754 7 O
operating	1762 9 O
even	1772 4 O
before	1777 6 O
Wegener	1784 7 B-Disease
'	1791 1 I-Disease
s	1792 1 I-Disease
granulomatosis	1794 14 I-Disease
.	1808 1 O

L	0 1 B-Chemical
-	1 1 I-Chemical
arginine	2 8 I-Chemical
transport	11 9 O
in	21 2 O
humans	24 6 O
with	31 4 O
cortisol	36 8 B-Chemical
-	44 1 O
induced	45 7 O
hypertension	53 12 B-Disease
.	65 1 O

A	67 1 O
deficient	69 9 O
L	79 1 B-Chemical
-	80 1 I-Chemical
arginine	81 8 I-Chemical
-	89 1 O
nitric	90 6 B-Chemical
oxide	97 5 I-Chemical
system	103 6 O
is	110 2 O
implicated	113 10 O
in	124 2 O
cortisol	127 8 B-Chemical
-	135 1 O
induced	136 7 O
hypertension	144 12 B-Disease
.	156 1 O

We	158 2 O
investigate	161 11 O
whether	173 7 O
abnormalities	181 13 O
in	195 2 O
L	198 1 B-Chemical
-	199 1 I-Chemical
arginine	200 8 I-Chemical
uptake	209 6 O
contribute	216 10 O
to	227 2 O
this	230 4 O
deficiency	235 10 O
.	245 1 O

Eight	247 5 O
healthy	253 7 O
men	261 3 O
were	265 4 O
recruited	270 9 O
.	279 1 O

Hydrocortisone	281 14 B-Chemical
acetate	296 7 I-Chemical
(	304 1 O
50	305 2 O
mg	308 2 O
)	310 1 O
was	312 3 O
given	316 5 O
orally	322 6 O
every	329 5 O
6	335 1 O
hours	337 5 O
for	343 3 O
24	347 2 O
hours	350 5 O
after	356 5 O
a	362 1 O
5	364 1 O
-	365 1 O
day	366 3 O
fixed	370 5 O
-	375 1 O
salt	376 4 O
diet	381 4 O
(	386 1 O
150	387 3 O
mmol	391 4 O
/	395 1 O
d	396 1 O
)	397 1 O
.	398 1 O

Crossover	400 9 O
studies	410 7 O
were	418 4 O
performed	423 9 O
2	433 1 O
weeks	435 5 O
apart	441 5 O
.	446 1 O

Thirty	448 6 O
milliliters	455 11 O
of	467 2 O
blood	470 5 O
was	476 3 O
obtained	480 8 O
for	489 3 O
isolation	493 9 O
of	503 2 O
peripheral	506 10 O
blood	517 5 O
mononuclear	523 11 O
cells	535 5 O
after	541 5 O
each	547 4 O
treatment	552 9 O
period	562 6 O
.	568 1 O

L	570 1 B-Chemical
-	571 1 I-Chemical
arginine	572 8 I-Chemical
uptake	581 6 O
was	588 3 O
assessed	592 8 O
in	601 2 O
mononuclear	604 11 O
cells	616 5 O
incubated	622 9 O
with	632 4 O
L	637 1 B-Chemical
-	638 1 I-Chemical
arginine	639 8 I-Chemical
(	648 1 O
1	649 1 O
to	651 2 O
300	654 3 O
micromol	658 8 O
/	666 1 O
L	667 1 O
)	668 1 O
,	669 1 O
incorporating	671 13 O
100	685 3 O
nmol	689 4 O
/	693 1 O
L	694 1 O
[	696 1 B-Chemical
3H	697 2 I-Chemical
]	699 1 I-Chemical
-	700 1 I-Chemical
l	701 1 I-Chemical
-	702 1 I-Chemical
arginine	703 8 I-Chemical
for	712 3 O
a	716 1 O
period	718 6 O
of	725 2 O
5	728 1 O
minutes	730 7 O
at	738 2 O
37	741 2 O
degrees	744 7 O
C	752 1 O
.	753 1 O

Forearm	755 7 O
[	763 1 B-Chemical
3H	764 2 I-Chemical
]	766 1 I-Chemical
-	767 1 I-Chemical
L	768 1 I-Chemical
-	769 1 I-Chemical
arginine	770 8 I-Chemical
extraction	779 10 O
was	790 3 O
calculated	794 10 O
after	805 5 O
infusion	811 8 O
of	820 2 O
[	823 1 B-Chemical
3H	824 2 I-Chemical
]	826 1 I-Chemical
-	827 1 I-Chemical
L	828 1 I-Chemical
-	829 1 I-Chemical
arginine	830 8 I-Chemical
into	839 4 O
the	844 3 O
brachial	848 8 O
artery	857 6 O
at	864 2 O
a	867 1 O
rate	869 4 O
of	874 2 O
100	877 3 O
nCi	881 3 O
/	884 1 O
min	885 3 O
for	889 3 O
80	893 2 O
minutes	896 7 O
.	903 1 O

Deep	905 4 O
forearm	910 7 O
venous	918 6 O
samples	925 7 O
were	933 4 O
collected	938 9 O
for	948 3 O
determination	952 13 O
of	966 2 O
L	969 1 B-Chemical
-	970 1 I-Chemical
arginine	971 8 I-Chemical
extraction	980 10 O
.	990 1 O

Plasma	992 6 O
cortisol	999 8 B-Chemical
concentrations	1008 14 O
were	1023 4 O
significantly	1028 13 O
raised	1042 6 O
during	1049 6 O
the	1056 3 O
active	1060 6 O
phase	1067 5 O
(	1073 1 O
323	1074 3 O
+	1077 1 O
/	1078 1 O
-	1079 1 O
43	1080 2 O
to	1083 2 O
1082	1086 4 O
+	1090 1 O
/	1091 1 O
-	1092 1 O
245	1093 3 O
mmol	1097 4 O
/	1101 1 O
L	1102 1 O
,	1103 1 O
P	1105 1 O
<	1106 1 O
0	1107 1 O
.	1108 1 O
05	1109 2 O
)	1111 1 O
.	1112 1 O

Systolic	1114 8 O
blood	1123 5 O
pressure	1129 8 O
was	1138 3 O
elevated	1142 8 O
by	1151 2 O
an	1154 2 O
average	1157 7 O
of	1165 2 O
7	1168 1 O
mm	1170 2 O
Hg	1173 2 O
.	1175 1 O

Neither	1177 7 O
L	1185 1 B-Chemical
-	1186 1 I-Chemical
arginine	1187 8 I-Chemical
transport	1196 9 O
into	1206 4 O
mononuclear	1211 11 O
cells	1223 5 O
(	1229 1 O
placebo	1230 7 O
vs	1238 2 O
active	1241 6 O
,	1247 1 O
26	1249 2 O
.	1251 1 O
3	1252 1 O
+	1253 1 O
/	1254 1 O
-	1255 1 O
3	1256 1 O
.	1257 1 O
6	1258 1 O
vs	1260 2 O
29	1263 2 O
.	1265 1 O
0	1266 1 O
+	1267 1 O
/	1268 1 O
-	1269 1 O
2	1270 1 O
.	1271 1 O
1	1272 1 O
pmol	1274 4 O
/	1278 1 O
10	1279 2 O
000	1282 3 O
cells	1286 5 O
per	1292 3 O
5	1296 1 O
minutes	1298 7 O
,	1305 1 O
respectively	1307 12 O
,	1319 1 O
at	1321 2 O
an	1324 2 O
l	1327 1 B-Chemical
-	1328 1 I-Chemical
arginine	1329 8 I-Chemical
concentration	1338 13 O
of	1352 2 O
300	1355 3 O
micromol	1359 8 O
/	1367 1 O
L	1368 1 O
)	1369 1 O
nor	1371 3 O
L	1375 1 B-Chemical
-	1376 1 I-Chemical
arginine	1377 8 I-Chemical
extraction	1386 10 O
in	1397 2 O
the	1400 3 O
forearm	1404 7 O
(	1412 1 O
at	1413 2 O
80	1416 2 O
minutes	1419 7 O
,	1426 1 O
placebo	1428 7 O
vs	1436 2 O
active	1439 6 O
,	1445 1 O
1	1447 1 O
868	1449 3 O
904	1453 3 O
+	1456 1 O
/	1457 1 O
-	1458 1 O
434	1459 3 O
962	1463 3 O
vs	1467 2 O
2	1470 1 O
013	1472 3 O
910	1476 3 O
+	1479 1 O
/	1480 1 O
-	1481 1 O
770	1482 3 O
619	1486 3 O
disintegrations	1490 15 O
per	1506 3 O
minute	1510 6 O
)	1516 1 O
was	1518 3 O
affected	1522 8 O
by	1531 2 O
cortisol	1534 8 B-Chemical
treatment	1543 9 O
;	1552 1 O
ie	1554 2 O
,	1556 1 O
that	1558 4 O
L	1563 1 B-Chemical
-	1564 1 I-Chemical
arginine	1565 8 I-Chemical
uptake	1574 6 O
is	1581 2 O
not	1584 3 O
affected	1588 8 O
by	1597 2 O
short	1600 5 O
-	1605 1 O
term	1606 4 O
cortisol	1611 8 B-Chemical
treatment	1620 9 O
.	1629 1 O

We	1631 2 O
conclude	1634 8 O
that	1643 4 O
cortisol	1648 8 B-Chemical
-	1656 1 O
induced	1657 7 O
increases	1665 9 B-Disease
in	1675 2 I-Disease
blood	1678 5 I-Disease
pressure	1684 8 I-Disease
are	1693 3 O
not	1697 3 O
associated	1701 10 O
with	1712 4 O
abnormalities	1717 13 O
in	1731 2 O
the	1734 3 O
l	1738 1 B-Chemical
-	1739 1 I-Chemical
arginine	1740 8 I-Chemical
transport	1749 9 O
system	1759 6 O
.	1765 1 O

MR	0 2 O
imaging	3 7 O
with	11 4 O
quantitative	16 12 O
diffusion	29 9 O
mapping	39 7 O
of	47 2 O
tacrolimus	50 10 B-Chemical
-	60 1 O
induced	61 7 O
neurotoxicity	69 13 B-Disease
in	83 2 O
organ	86 5 O
transplant	92 10 O
patients	103 8 O
.	111 1 O

Our	113 3 O
objective	117 9 O
was	127 3 O
to	131 2 O
investigate	134 11 O
brain	146 5 O
MR	152 2 O
imaging	155 7 O
findings	163 8 O
and	172 3 O
the	176 3 O
utility	180 7 O
of	188 2 O
diffusion	191 9 O
-	200 1 O
weighted	201 8 O
(	210 1 O
DW	211 2 O
)	213 1 O
imaging	215 7 O
in	223 2 O
organ	226 5 O
transplant	232 10 O
patients	243 8 O
who	252 3 O
developed	256 9 O
neurologic	266 10 O
symptoms	277 8 O
during	286 6 O
tacrolimus	293 10 B-Chemical
therapy	304 7 O
.	311 1 O

Brain	313 5 O
MR	319 2 O
studies	322 7 O
,	329 1 O
including	331 9 O
DW	341 2 O
imaging	344 7 O
,	351 1 O
were	353 4 O
prospectively	358 13 O
performed	372 9 O
in	382 2 O
14	385 2 O
organ	388 5 O
transplant	394 10 O
patients	405 8 O
receiving	414 9 O
tacrolimus	424 10 B-Chemical
who	435 3 O
developed	439 9 O
neurologic	449 10 B-Disease
complications	460 13 I-Disease
.	473 1 O

In	475 2 O
each	478 4 O
patient	483 7 O
who	491 3 O
had	495 3 O
abnormalities	499 13 O
on	513 2 O
the	516 3 O
initial	520 7 O
MR	528 2 O
study	531 5 O
,	536 1 O
a	538 1 O
follow	540 6 O
-	546 1 O
up	547 2 O
MR	550 2 O
study	553 5 O
was	559 3 O
performed	563 9 O
1	573 1 O
month	575 5 O
later	581 5 O
.	586 1 O

Apparent	588 8 O
diffusion	597 9 O
coefficient	607 11 O
(	619 1 O
ADC	620 3 O
)	623 1 O
values	625 6 O
on	632 2 O
the	635 3 O
initial	639 7 O
MR	647 2 O
study	650 5 O
were	656 4 O
correlated	661 10 O
with	672 4 O
reversibility	677 13 O
of	691 2 O
the	694 3 O
lesions	698 7 O
.	705 1 O

Of	707 2 O
the	710 3 O
14	714 2 O
patients	717 8 O
,	725 1 O
5	727 1 O
(	729 1 O
35	730 2 O
.	732 1 O
7	733 1 O
%	734 1 O
)	735 1 O
had	737 3 O
white	741 5 B-Disease
matter	747 6 I-Disease
abnormalities	754 13 I-Disease
,	767 1 O
1	769 1 O
(	771 1 O
7	772 1 O
.	773 1 O
1	774 1 O
%	775 1 O
)	776 1 O
had	778 3 O
putaminal	782 9 B-Disease
hemorrhage	792 10 I-Disease
,	802 1 O
and	804 3 O
8	808 1 O
(	810 1 O
57	811 2 O
.	813 1 O
1	814 1 O
%	815 1 O
)	816 1 O
had	818 3 O
normal	822 6 O
findings	829 8 O
on	838 2 O
initial	841 7 O
MR	849 2 O
images	852 6 O
.	858 1 O

Among	860 5 O
the	866 3 O
5	870 1 O
patients	872 8 O
with	881 4 O
white	886 5 B-Disease
matter	892 6 I-Disease
abnormalities	899 13 I-Disease
,	912 1 O
4	914 1 O
patients	916 8 O
(	925 1 O
80	926 2 O
.	928 1 O
0	929 1 O
%	930 1 O
)	931 1 O
showed	933 6 O
higher	940 6 O
than	947 4 O
normal	952 6 O
ADC	959 3 O
values	963 6 O
on	970 2 O
initial	973 7 O
MR	981 2 O
images	984 6 O
,	990 1 O
and	992 3 O
all	996 3 O
showed	1000 6 O
complete	1007 8 O
resolution	1016 10 O
on	1027 2 O
follow	1030 6 O
-	1036 1 O
up	1037 2 O
images	1040 6 O
.	1046 1 O

The	1048 3 O
remaining	1052 9 O
1	1062 1 O
patient	1064 7 O
(	1072 1 O
20	1073 2 O
.	1075 1 O
0	1076 1 O
%	1077 1 O
)	1078 1 O
showed	1080 6 O
lower	1087 5 O
than	1093 4 O
normal	1098 6 O
ADC	1105 3 O
value	1109 5 O
and	1115 3 O
showed	1119 6 O
incomplete	1126 10 O
resolution	1137 10 O
with	1148 4 O
cortical	1153 8 B-Disease
laminar	1162 7 I-Disease
necrosis	1170 8 I-Disease
.	1178 1 O

Diffusion	1180 9 O
-	1189 1 O
weighted	1190 8 O
imaging	1199 7 O
may	1207 3 O
be	1211 2 O
useful	1214 6 O
in	1221 2 O
predicting	1224 10 O
the	1235 3 O
outcomes	1239 8 O
of	1248 2 O
the	1251 3 O
lesions	1255 7 O
of	1263 2 O
tacrolimus	1266 10 B-Chemical
-	1276 1 O
induced	1277 7 O
neurotoxicity	1285 13 B-Disease
.	1298 1 O

Octreotide	0 10 B-Chemical
-	10 1 O
induced	11 7 O
hypoxemia	19 9 B-Disease
and	29 3 O
pulmonary	33 9 B-Disease
hypertension	43 12 I-Disease
in	56 2 O
premature	59 9 O
neonates	69 8 O
.	77 1 O

The	79 3 O
authors	83 7 O
report	91 6 O
2	98 1 O
cases	100 5 O
of	106 2 O
premature	109 9 O
neonates	119 8 O
who	128 3 O
had	132 3 O
enterocutaneous	136 15 O
fistula	152 7 B-Disease
complicating	160 12 O
necrotizing	173 11 B-Disease
enterocolitis	185 13 I-Disease
.	198 1 O

Pulmonary	200 9 B-Disease
hypertension	210 12 I-Disease
developed	223 9 O
after	233 5 O
administration	239 14 O
of	254 2 O
a	257 1 O
somatostatin	259 12 O
analogue	272 8 O
,	280 1 O
octreotide	282 10 B-Chemical
,	292 1 O
to	294 2 O
enhance	297 7 O
resolution	305 10 O
of	316 2 O
the	319 3 O
fistula	323 7 B-Disease
.	330 1 O

The	332 3 O
authors	336 7 O
discuss	344 7 O
the	352 3 O
mechanism	356 9 O
of	366 2 O
the	369 3 O
occurrence	373 10 O
of	384 2 O
this	387 4 O
complication	392 12 O
and	405 3 O
recommend	409 9 O
caution	419 7 O
of	427 2 O
its	430 3 O
use	434 3 O
in	438 2 O
high	441 4 O
-	445 1 O
risk	446 4 O
premature	451 9 O
neonates	461 8 O
.	469 1 O

Sequential	0 10 O
observations	11 12 O
of	24 2 O
exencephaly	27 11 B-Disease
and	39 3 O
subsequent	43 10 O
morphological	54 13 O
changes	68 7 O
by	76 2 O
mouse	79 5 O
exo	85 3 O
utero	89 5 O
development	95 11 O
system	107 6 O
:	113 1 O
analysis	115 8 O
of	124 2 O
the	127 3 O
mechanism	131 9 O
of	141 2 O
transformation	144 14 O
from	159 4 O
exencephaly	164 11 B-Disease
to	176 2 O
anencephaly	179 11 B-Disease
.	190 1 O

Anencephaly	192 11 B-Disease
has	204 3 O
been	208 4 O
suggested	213 9 O
to	223 2 O
develop	226 7 O
from	234 4 O
exencephaly	239 11 B-Disease
;	250 1 O
however	252 7 O
,	259 1 O
there	261 5 O
is	267 2 O
little	270 6 O
direct	277 6 O
experimental	284 12 O
evidence	297 8 O
to	306 2 O
support	309 7 O
this	317 4 O
,	321 1 O
and	323 3 O
the	327 3 O
mechanism	331 9 O
of	341 2 O
transformation	344 14 O
remains	359 7 O
unclear	367 7 O
.	374 1 O

We	376 2 O
examined	379 8 O
this	388 4 O
theory	393 6 O
using	400 5 O
the	406 3 O
exo	410 3 O
utero	414 5 O
development	420 11 O
system	432 6 O
that	439 4 O
allows	444 6 O
direct	451 6 O
and	458 3 O
sequential	462 10 O
observations	473 12 O
of	486 2 O
mid	489 3 O
-	492 1 O
to	494 2 O
late	497 4 O
-	501 1 O
gestation	502 9 O
mouse	512 5 O
embryos	518 7 O
.	525 1 O

We	527 2 O
observed	530 8 O
the	539 3 O
exencephaly	543 11 B-Disease
induced	555 7 O
by	563 2 O
5	566 1 B-Chemical
-	567 1 I-Chemical
azacytidine	568 11 I-Chemical
at	580 2 O
embryonic	583 9 O
day	593 3 O
13	597 2 O
.	599 1 O
5	600 1 O
(	602 1 O
E13	603 3 O
.	606 1 O
5	607 1 O
)	608 1 O
,	609 1 O
let	611 3 O
the	615 3 O
embryos	619 7 O
develop	627 7 O
exo	635 3 O
utero	639 5 O
until	645 5 O
E18	651 3 O
.	654 1 O
5	655 1 O
,	656 1 O
and	658 3 O
re	662 2 O
-	664 1 O
observed	665 8 O
the	674 3 O
same	678 4 O
embryos	683 7 O
at	691 2 O
E18	694 3 O
.	697 1 O
5	698 1 O
.	699 1 O

We	701 2 O
confirmed	704 9 O
several	714 7 O
cases	722 5 O
of	728 2 O
transformation	731 14 O
from	746 4 O
exencephaly	751 11 B-Disease
to	763 2 O
anencephaly	766 11 B-Disease
.	777 1 O

However	779 7 O
,	786 1 O
in	788 2 O
many	791 4 O
cases	796 5 O
,	801 1 O
the	803 3 O
exencephalic	807 12 B-Disease
brain	820 5 O
tissue	826 6 O
was	833 3 O
preserved	837 9 O
with	847 4 O
more	852 4 O
or	857 2 O
less	860 4 O
reduction	865 9 O
during	875 6 O
this	882 4 O
period	887 6 O
.	893 1 O

To	895 2 O
analyze	898 7 O
the	906 3 O
transformation	910 14 O
patterns	925 8 O
,	933 1 O
we	935 2 O
classified	938 10 O
the	949 3 O
exencephaly	953 11 B-Disease
by	965 2 O
size	968 4 O
and	973 3 O
shape	977 5 O
of	983 2 O
the	986 3 O
exencephalic	990 12 B-Disease
tissue	1003 6 O
into	1010 4 O
several	1015 7 O
types	1023 5 O
at	1029 2 O
E13	1032 3 O
.	1035 1 O
5	1036 1 O
and	1038 3 O
E18	1042 3 O
.	1045 1 O
5	1046 1 O
.	1047 1 O

It	1049 2 O
was	1052 3 O
found	1056 5 O
that	1062 4 O
the	1067 3 O
transformation	1071 14 O
of	1086 2 O
exencephalic	1089 12 B-Disease
tissue	1102 6 O
was	1109 3 O
not	1113 3 O
simply	1117 6 O
size	1124 4 O
-	1128 1 O
dependent	1129 9 O
,	1138 1 O
and	1140 3 O
all	1144 3 O
cases	1148 5 O
of	1154 2 O
anencephaly	1157 11 B-Disease
at	1169 2 O
E18	1172 3 O
.	1175 1 O
5	1176 1 O
resulted	1178 8 O
from	1187 4 O
embryos	1192 7 O
with	1200 4 O
a	1205 1 O
large	1207 5 O
amount	1213 6 O
of	1220 2 O
exencephalic	1223 12 B-Disease
tissue	1236 6 O
at	1243 2 O
E13	1246 3 O
.	1249 1 O
5	1250 1 O
.	1251 1 O

Microscopic	1253 11 O
observation	1265 11 O
showed	1277 6 O
the	1284 3 O
configuration	1288 13 O
of	1302 2 O
exencephaly	1305 11 B-Disease
at	1317 2 O
E13	1320 3 O
.	1323 1 O
5	1324 1 O
,	1325 1 O
frequent	1327 8 O
hemorrhaging	1336 12 B-Disease
and	1349 3 O
detachment	1353 10 O
of	1364 2 O
the	1367 3 O
neural	1371 6 O
plate	1378 5 O
from	1384 4 O
surface	1389 7 O
ectoderm	1397 8 O
in	1406 2 O
the	1409 3 O
exencephalic	1413 12 B-Disease
head	1426 4 O
at	1431 2 O
E15	1434 3 O
.	1437 1 O
5	1438 1 O
,	1439 1 O
and	1441 3 O
multiple	1445 8 O
modes	1454 5 O
of	1460 2 O
reduction	1463 9 O
in	1473 2 O
the	1476 3 O
exencephalic	1480 12 B-Disease
tissue	1493 6 O
at	1500 2 O
E18	1503 3 O
.	1506 1 O
5	1507 1 O
.	1508 1 O

From	1510 4 O
observations	1515 12 O
of	1528 2 O
the	1531 3 O
vasculature	1535 11 O
,	1546 1 O
altered	1548 7 O
distribution	1556 12 O
patterns	1569 8 O
of	1578 2 O
vessels	1581 7 O
were	1589 4 O
identified	1594 10 O
in	1605 2 O
the	1608 3 O
exencephalic	1612 12 B-Disease
head	1625 4 O
.	1629 1 O

These	1631 5 O
findings	1637 8 O
suggest	1646 7 O
that	1654 4 O
overgrowth	1659 10 O
of	1670 2 O
the	1673 3 O
exencephalic	1677 12 B-Disease
neural	1690 6 O
tissue	1697 6 O
causes	1704 6 O
the	1711 3 O
altered	1715 7 O
distribution	1723 12 O
patterns	1736 8 O
of	1745 2 O
vessels	1748 7 O
,	1755 1 O
subsequent	1757 10 O
peripheral	1768 10 O
circulatory	1779 11 B-Disease
failure	1791 7 I-Disease
and	1799 3 O
/	1802 1 O
or	1803 2 O
hemorrhaging	1806 12 B-Disease
in	1819 2 O
various	1822 7 O
parts	1830 5 O
of	1836 2 O
the	1839 3 O
exencephalic	1843 12 B-Disease
head	1856 4 O
,	1860 1 O
leading	1862 7 O
to	1870 2 O
the	1873 3 O
multiple	1877 8 O
modes	1886 5 O
of	1892 2 O
tissue	1895 6 O
reduction	1902 9 O
during	1912 6 O
transformation	1919 14 O
from	1934 4 O
exencephaly	1939 11 B-Disease
to	1951 2 O
anencephaly	1954 11 B-Disease
.	1965 1 O

Acute	0 5 O
cocaine	6 7 B-Chemical
-	13 1 O
induced	14 7 O
seizures	22 8 B-Disease
:	30 1 O
differential	32 12 O
sensitivity	45 11 O
of	57 2 O
six	60 3 O
inbred	64 6 O
mouse	71 5 O
strains	77 7 O
.	84 1 O

Mature	86 6 O
male	93 4 O
and	98 3 O
female	102 6 O
mice	109 4 O
from	114 4 O
six	119 3 O
inbred	123 6 O
stains	130 6 O
were	137 4 O
tested	142 6 O
for	149 3 O
susceptibility	153 14 O
to	168 2 O
behavioral	171 10 O
seizures	182 8 B-Disease
induced	191 7 O
by	199 2 O
a	202 1 O
single	204 6 O
injection	211 9 O
of	221 2 O
cocaine	224 7 B-Chemical
.	231 1 O

Cocaine	233 7 B-Chemical
was	241 3 O
injected	245 8 O
ip	254 2 O
over	257 4 O
a	262 1 O
range	264 5 O
of	270 2 O
doses	273 5 O
(	279 1 O
50	280 2 O
-	282 1 O
100	283 3 O
mg	287 2 O
/	289 1 O
kg	290 2 O
)	292 1 O
and	294 3 O
behavior	298 8 O
was	307 3 O
monitored	311 9 O
for	321 3 O
20	325 2 O
minutes	328 7 O
.	335 1 O

Seizure	337 7 B-Disease
end	345 3 O
points	349 6 O
included	356 8 O
latency	365 7 O
to	373 2 O
forelimb	376 8 O
or	385 2 O
hindlimb	388 8 O
clonus	397 6 O
,	403 1 O
latency	405 7 O
to	413 2 O
clonic	416 6 O
running	423 7 O
seizure	431 7 B-Disease
and	439 3 O
latency	443 7 O
to	451 2 O
jumping	454 7 O
bouncing	462 8 O
seizure	471 7 B-Disease
.	478 1 O

A	480 1 O
range	482 5 O
of	488 2 O
strain	491 6 O
specific	498 8 O
sensitivities	507 13 O
was	521 3 O
documented	525 10 O
with	536 4 O
A	541 1 O
/	542 1 O
J	543 1 O
and	545 3 O
SJL	549 3 O
mice	553 4 O
being	558 5 O
most	564 4 O
sensitive	569 9 O
and	579 3 O
C57BL	583 5 O
/	588 1 O
6J	589 2 O
most	592 4 O
resistant	597 9 O
.	606 1 O

DBA	608 3 O
/	611 1 O
2J	612 2 O
,	614 1 O
BALB	616 4 O
/	620 1 O
cByJ	621 4 O
and	626 3 O
NZW	630 3 O
/	633 1 O
LacJ	634 4 O
strains	639 7 O
exhibited	647 9 O
intermediate	657 12 O
sensitivity	670 11 O
.	681 1 O

EEG	683 3 O
recordings	687 10 O
were	698 4 O
made	703 4 O
in	708 2 O
SJL	711 3 O
,	714 1 O
A	716 1 O
/	717 1 O
J	718 1 O
and	720 3 O
C57BL	724 5 O
/	729 1 O
6J	730 2 O
mice	733 4 O
revealing	738 9 O
a	748 1 O
close	750 5 O
correspondence	756 14 O
between	771 7 O
electrical	779 10 O
activity	790 8 O
and	799 3 O
behavior	803 8 O
.	811 1 O

Additionally	813 12 O
,	825 1 O
levels	827 6 O
of	834 2 O
cocaine	837 7 B-Chemical
determined	845 10 O
in	856 2 O
hippocampus	859 11 O
and	871 3 O
cortex	875 6 O
were	882 4 O
not	887 3 O
different	891 9 O
between	901 7 O
sensitive	909 9 O
and	919 3 O
resistant	923 9 O
strains	933 7 O
.	940 1 O

Additional	942 10 O
studies	953 7 O
of	961 2 O
these	964 5 O
murine	970 6 O
strains	977 7 O
may	985 3 O
be	989 2 O
useful	992 6 O
for	999 3 O
investigating	1003 13 O
genetic	1017 7 O
influences	1025 10 O
on	1036 2 O
cocaine	1039 7 B-Chemical
-	1046 1 O
induced	1047 7 O
seizures	1055 8 B-Disease
.	1063 1 O

Microangiopathic	0 16 B-Disease
hemolytic	17 9 I-Disease
anemia	27 6 I-Disease
complicating	34 12 O
FK506	47 5 B-Chemical
(	53 1 O
tacrolimus	54 10 B-Chemical
)	64 1 O
therapy	66 7 O
.	73 1 O

We	75 2 O
describe	78 8 O
3	87 1 O
episodes	89 8 O
of	98 2 O
microangiopathic	101 16 B-Disease
hemolytic	118 9 I-Disease
anemia	128 6 I-Disease
(	135 1 O
MAHA	136 4 B-Disease
)	140 1 O
in	142 2 O
2	145 1 O
solid	147 5 O
organ	153 5 O
recipients	159 10 O
under	170 5 O
FK506	176 5 B-Chemical
(	182 1 O
tacrolimus	183 10 B-Chemical
)	193 1 O
therapy	195 7 O
.	202 1 O

In	204 2 O
both	207 4 O
cases	212 5 O
,	217 1 O
discontinuation	219 15 O
of	235 2 O
FK506	238 5 B-Chemical
and	244 3 O
treatment	248 9 O
with	258 4 O
plasma	263 6 O
exchange	270 8 O
,	278 1 O
fresh	280 5 O
frozen	286 6 O
plasma	293 6 O
replacement	300 11 O
,	311 1 O
corticosteroids	313 15 B-Chemical
,	328 1 O
aspirin	330 7 B-Chemical
,	337 1 O
and	339 3 O
dipyridamole	343 12 B-Chemical
led	356 3 O
to	360 2 O
resolution	363 10 O
of	374 2 O
MAHA	377 4 B-Disease
.	381 1 O

In	383 2 O
one	386 3 O
patient	390 7 O
,	397 1 O
reintroduction	399 14 O
of	414 2 O
FK506	417 5 B-Chemical
led	423 3 O
to	427 2 O
rapid	430 5 O
recurrence	436 10 O
of	447 2 O
MAHA	450 4 B-Disease
.	454 1 O

FK506	456 5 B-Chemical
-	461 1 O
associated	462 10 O
MAHA	473 4 B-Disease
is	478 2 O
probably	481 8 O
rare	490 4 O
but	495 3 O
physicians	499 10 O
must	510 4 O
be	515 2 O
aware	518 5 O
of	524 2 O
this	527 4 O
severe	532 6 O
complication	539 12 O
.	551 1 O

In	553 2 O
our	556 3 O
experience	560 10 O
and	571 3 O
according	575 9 O
to	585 2 O
the	588 3 O
literature	592 10 O
,	602 1 O
FK506	604 5 B-Chemical
does	610 4 O
not	615 3 O
seem	619 4 O
to	624 2 O
cross	627 5 O
-	632 1 O
react	633 5 O
with	639 4 O
cyclosporin	644 11 B-Chemical
A	656 1 I-Chemical
(	658 1 O
CyA	659 3 B-Chemical
)	662 1 O
,	663 1 O
an	665 2 O
immuno	668 6 O
-	674 1 O
suppressive	675 11 O
drug	687 4 O
already	692 7 O
known	700 5 O
to	706 2 O
induce	709 6 O
MAHA	716 4 B-Disease
.	720 1 O

Variant	0 7 O
ventricular	8 11 B-Disease
tachycardia	20 11 I-Disease
in	32 2 O
desipramine	35 11 B-Chemical
toxicity	47 8 B-Disease
.	55 1 O

We	57 2 O
report	60 6 O
a	67 1 O
case	69 4 O
of	74 2 O
variant	77 7 O
ventricular	85 11 B-Disease
tachycardia	97 11 I-Disease
induced	109 7 O
by	117 2 O
desipramine	120 11 B-Chemical
toxicity	132 8 B-Disease
.	140 1 O

Unusual	142 7 O
features	150 8 O
of	159 2 O
the	162 3 O
arrhythmia	166 10 B-Disease
are	177 3 O
repetitive	181 10 O
group	192 5 O
beating	198 7 O
,	205 1 O
progressive	207 11 O
shortening	219 10 O
of	230 2 O
the	233 3 O
R	237 1 O
-	238 1 O
R	239 1 O
interval	241 8 O
,	249 1 O
progressive	251 11 O
widening	263 8 O
of	272 2 O
the	275 3 O
QRS	279 3 O
complex	283 7 O
with	291 4 O
eventual	296 8 O
failure	305 7 O
of	313 2 O
intraventricular	316 16 O
conduction	333 10 O
,	343 1 O
and	345 3 O
changes	349 7 O
in	357 2 O
direction	360 9 O
of	370 2 O
the	373 3 O
QRS	377 3 O
axis	381 4 O
.	385 1 O

Recognition	387 11 O
of	399 2 O
variant	402 7 O
ventricular	410 11 B-Disease
tachycardia	422 11 I-Disease
is	434 2 O
important	437 9 O
because	447 7 O
therapy	455 7 O
differs	463 7 O
from	471 4 O
that	476 4 O
of	481 2 O
classic	484 7 O
ventricular	492 11 B-Disease
tachycardia	504 11 I-Disease
.	515 1 O

Desipramine	0 11 B-Chemical
-	11 1 O
induced	12 7 O
delirium	20 8 B-Disease
at	29 2 O
"	32 1 O
subtherapeutic	33 14 O
"	47 1 O
concentrations	49 14 O
:	63 1 O
a	65 1 O
case	67 4 O
report	72 6 O
.	78 1 O

An	80 2 O
elderly	83 7 O
patient	91 7 O
treated	99 7 O
with	107 4 O
low	112 3 O
dose	116 4 O
Desipramine	121 11 B-Chemical
developed	133 9 O
a	143 1 O
delirium	145 8 B-Disease
while	154 5 O
her	160 3 O
plasma	164 6 O
level	171 5 O
was	177 3 O
in	181 2 O
the	184 3 O
"	188 1 O
subtherapeutic	189 14 O
"	203 1 O
range	205 5 O
.	210 1 O

Delirium	212 8 B-Disease
,	220 1 O
which	222 5 O
may	228 3 O
be	232 2 O
induced	235 7 O
by	243 2 O
tricyclic	246 9 O
drug	256 4 O
therapy	261 7 O
in	269 2 O
the	272 3 O
elderly	276 7 O
,	283 1 O
can	285 3 O
be	289 2 O
caused	292 6 O
by	299 2 O
tricyclics	302 10 O
with	313 4 O
low	318 3 O
anticholinergic	322 15 O
potency	338 7 O
.	345 1 O

Therapeutic	347 11 O
ranges	359 6 O
for	366 3 O
antidepressants	370 15 B-Chemical
that	386 4 O
have	391 4 O
been	396 4 O
derived	401 7 O
from	409 4 O
general	414 7 O
adult	422 5 O
population	428 10 O
studies	439 7 O
may	447 3 O
not	451 3 O
be	455 2 O
appropriate	458 11 O
for	470 3 O
the	474 3 O
elderly	478 7 O
.	485 1 O

Further	487 7 O
studies	495 7 O
of	503 2 O
specifically	506 12 O
elderly	519 7 O
patients	527 8 O
are	536 3 O
now	540 3 O
required	544 8 O
to	553 2 O
establish	556 9 O
safer	566 5 O
and	572 3 O
more	576 4 O
appropriate	581 11 O
guidelines	593 10 O
for	604 3 O
drug	608 4 O
therapy	613 7 O
.	620 1 O

Mouse	0 5 O
strain	6 6 O
-	12 1 O
dependent	13 9 O
effect	23 6 O
of	30 2 O
amantadine	33 10 B-Chemical
on	44 2 O
motility	47 8 O
and	56 3 O
brain	60 5 O
biogenic	66 8 O
amines	75 6 B-Chemical
.	81 1 O

The	83 3 O
effect	87 6 O
of	94 2 O
amantadine	97 10 B-Chemical
hydrochloride	108 13 I-Chemical
,	121 1 O
injected	123 8 O
i	132 1 O
.	133 1 O
p	134 1 O
.	135 1 O
in	137 2 O
6	140 1 O
increments	142 10 O
of	153 2 O
100	156 3 O
mg	160 2 O
/	162 1 O
kg	163 2 O
each	166 4 O
over	171 4 O
30	176 2 O
hr	179 2 O
,	181 1 O
on	183 2 O
mouse	186 5 O
motility	192 8 O
and	201 3 O
whole	205 5 O
brain	211 5 O
content	217 7 O
of	225 2 O
selected	228 8 O
biogenic	237 8 O
amines	246 6 B-Chemical
and	253 3 O
major	257 5 O
metabolites	263 11 O
was	275 3 O
studied	279 7 O
in	287 2 O
4	290 1 O
strains	292 7 O
of	300 2 O
mice	303 4 O
.	307 1 O

These	309 5 O
were	315 4 O
the	320 3 O
albino	324 6 O
Sprague	331 7 O
-	338 1 O
Dawley	339 6 O
ICR	346 3 O
and	350 3 O
BALB	354 4 O
/	358 1 O
C	359 1 O
,	360 1 O
the	362 3 O
black	366 5 O
C57BL	372 5 O
/	377 1 O
6	378 1 O
and	380 3 O
the	384 3 O
brown	388 5 O
CDF	394 3 O
-	397 1 O
I	398 1 O
mouse	400 5 O
strains	406 7 O
.	413 1 O

Amantadine	415 10 B-Chemical
treatment	426 9 O
produced	436 8 O
a	445 1 O
biphasic	447 8 O
effect	456 6 O
on	463 2 O
mouse	466 5 O
motility	472 8 O
.	480 1 O

The	482 3 O
initial	486 7 O
dose	494 4 O
of	499 2 O
amantadine	502 10 B-Chemical
depressed	513 9 B-Disease
locomotor	523 9 O
activity	533 8 O
in	542 2 O
all	545 3 O
mouse	549 5 O
strains	555 7 O
studied	563 7 O
with	571 4 O
the	576 3 O
BALB	580 4 O
/	584 1 O
C	585 1 O
mice	587 4 O
being	592 5 O
the	598 3 O
most	602 4 O
sensitive	607 9 O
.	616 1 O

Subsequent	618 10 O
amantadine	629 10 B-Chemical
treatments	640 10 O
produced	651 8 O
enhancement	660 11 O
of	672 2 O
motility	675 8 O
from	684 4 O
corresponding	689 13 O
control	703 7 O
in	711 2 O
all	714 3 O
mouse	718 5 O
strains	724 7 O
with	732 4 O
the	737 3 O
BALB	741 4 O
/	745 1 O
C	746 1 O
mice	748 4 O
being	753 5 O
the	759 3 O
least	763 5 O
sensitive	769 9 O
.	778 1 O

The	780 3 O
locomotor	784 9 O
activity	794 8 O
was	803 3 O
decreased	807 9 O
from	817 4 O
corresponding	822 13 O
controls	836 8 O
in	845 2 O
all	848 3 O
strains	852 7 O
studied	860 7 O
,	867 1 O
except	869 6 O
for	876 3 O
the	880 3 O
ICR	884 3 O
mice	888 4 O
,	892 1 O
during	894 6 O
an	901 2 O
overnight	904 9 O
drug	914 4 O
-	918 1 O
free	919 4 O
period	924 6 O
following	931 9 O
the	941 3 O
fourth	945 6 O
amantadine	952 10 B-Chemical
treatment	963 9 O
.	972 1 O

Readministration	974 16 O
of	991 2 O
amantadine	994 10 B-Chemical
,	1004 1 O
after	1006 5 O
a	1012 1 O
drug	1014 4 O
-	1018 1 O
free	1019 4 O
overnight	1024 9 O
period	1034 6 O
,	1040 1 O
increased	1042 9 O
motility	1052 8 O
from	1061 4 O
respective	1066 10 O
saline	1077 6 O
control	1084 7 O
in	1092 2 O
all	1095 3 O
strains	1099 7 O
with	1107 4 O
exception	1112 9 O
of	1122 2 O
the	1125 3 O
BALB	1129 4 O
/	1133 1 O
C	1134 1 O
mice	1136 4 O
where	1141 5 O
suppression	1147 11 B-Disease
of	1159 2 I-Disease
motility	1162 8 I-Disease
occurred	1171 8 O
.	1179 1 O

Treatment	1181 9 O
with	1191 4 O
amantadine	1196 10 B-Chemical
did	1207 3 O
not	1211 3 O
alter	1215 5 O
whole	1221 5 O
brain	1227 5 O
dopamine	1233 8 B-Chemical
levels	1242 6 O
but	1249 3 O
decreased	1253 9 O
the	1263 3 O
amounts	1267 7 O
of	1275 2 O
3	1278 1 B-Chemical
,	1279 1 I-Chemical
4	1280 1 I-Chemical
-	1281 1 I-Chemical
dihydroxyphenylacetic	1282 21 I-Chemical
acid	1304 4 I-Chemical
in	1309 2 O
the	1312 3 O
BALB	1316 4 O
/	1320 1 O
C	1321 1 O
mice	1323 4 O
compared	1328 8 O
to	1337 2 O
saline	1340 6 O
control	1347 7 O
.	1354 1 O

Conversely	1356 10 O
,	1366 1 O
brain	1368 5 O
normetanephrine	1374 15 B-Chemical
concentration	1390 13 O
was	1404 3 O
increased	1408 9 O
from	1418 4 O
saline	1423 6 O
control	1430 7 O
by	1438 2 O
amantadine	1441 10 B-Chemical
in	1452 2 O
the	1455 3 O
BALB	1459 4 O
/	1463 1 O
C	1464 1 O
mice	1466 4 O
.	1470 1 O

The	1472 3 O
results	1476 7 O
suggest	1484 7 O
a	1492 1 O
strain	1494 6 O
-	1500 1 O
dependent	1501 9 O
effect	1511 6 O
of	1518 2 O
amantadine	1521 10 B-Chemical
on	1532 2 O
motility	1535 8 O
and	1544 3 O
indicate	1548 8 O
a	1557 1 O
differential	1559 12 O
response	1572 8 O
to	1581 2 O
the	1584 3 O
acute	1588 5 O
and	1594 3 O
multiple	1598 8 O
dose	1607 4 O
regimens	1612 8 O
used	1621 4 O
.	1625 1 O

The	1627 3 O
BALB	1631 4 O
/	1635 1 O
C	1636 1 O
mouse	1638 5 O
was	1644 3 O
the	1648 3 O
most	1652 4 O
sensitive	1657 9 O
strain	1667 6 O
and	1674 3 O
could	1678 5 O
serve	1684 5 O
as	1690 2 O
the	1693 3 O
strain	1697 6 O
of	1704 2 O
choice	1707 6 O
for	1714 3 O
evaluating	1718 10 O
the	1729 3 O
side	1733 4 O
effects	1738 7 O
of	1746 2 O
amantadine	1749 10 B-Chemical
.	1759 1 O

The	1761 3 O
biochemical	1765 11 O
results	1777 7 O
of	1785 2 O
brain	1788 5 O
biogenic	1794 8 O
amines	1803 6 B-Chemical
of	1810 2 O
BALB	1813 4 O
/	1817 1 O
C	1818 1 O
mouse	1820 5 O
strain	1826 6 O
suggest	1833 7 O
a	1841 1 O
probable	1843 8 O
decrease	1852 8 O
of	1861 2 O
catecholamine	1864 13 B-Chemical
turnover	1878 8 O
rate	1887 4 O
and	1892 3 O
/	1895 1 O
or	1896 2 O
metabolism	1899 10 O
by	1910 2 O
monoamine	1913 9 O
oxidase	1923 7 O
and	1931 3 O
a	1935 1 O
resulting	1937 9 O
increase	1947 8 O
in	1956 2 O
O	1959 1 O
-	1960 1 O
methylation	1961 11 O
of	1973 2 O
norepinephrine	1976 14 B-Chemical
which	1991 5 O
may	1997 3 O
account	2001 7 O
for	2009 3 O
a	2013 1 O
behavioral	2015 10 B-Disease
depression	2026 10 I-Disease
caused	2037 6 O
by	2044 2 O
amantadine	2047 10 B-Chemical
in	2058 2 O
the	2061 3 O
BALB	2065 4 O
/	2069 1 O
C	2070 1 O
mice	2072 4 O
.	2076 1 O

No	0 2 O
enhancement	3 11 O
by	15 2 O
phenobarbital	18 13 B-Chemical
of	32 2 O
the	35 3 O
hepatocarcinogenicity	39 21 O
of	61 2 O
a	64 1 O
choline	66 7 B-Chemical
-	73 1 O
devoid	74 6 O
diet	81 4 O
in	86 2 O
the	89 3 O
rat	93 3 O
.	96 1 O

An	98 2 O
experiment	101 10 O
was	112 3 O
performed	116 9 O
to	126 2 O
test	129 4 O
whether	134 7 O
inclusion	142 9 O
of	152 2 O
phenobarbital	155 13 B-Chemical
in	169 2 O
a	172 1 O
choline	174 7 B-Chemical
-	181 1 O
devoid	182 6 O
diet	189 4 O
would	194 5 O
increase	200 8 O
the	209 3 O
hepatocarcinogenicity	213 21 O
of	235 2 O
the	238 3 O
diet	242 4 O
.	246 1 O

Groups	248 6 O
of	255 2 O
5	258 1 O
-	259 1 O
week	260 4 O
old	265 3 O
male	269 4 O
Fischer	274 7 O
-	281 1 O
344	282 3 O
rats	286 4 O
were	291 4 O
fed	296 3 O
for	300 3 O
7	304 1 O
-	305 1 O
25	306 2 O
months	309 6 O
semipurified	316 12 O
choline	329 7 B-Chemical
-	336 1 O
devoid	337 6 O
or	344 2 O
choline	347 7 B-Chemical
-	354 1 O
supplemented	355 12 O
diets	368 5 O
,	373 1 O
containing	375 10 O
or	386 2 O
not	389 3 O
0	393 1 O
.	394 1 O
06	395 2 O
%	397 1 O
phenobarbital	399 13 B-Chemical
.	412 1 O

No	414 2 O
hepatic	417 7 O
preneoplastic	425 13 O
nodules	439 7 O
or	447 2 O
hepatocellular	450 14 B-Disease
carcinomas	465 10 I-Disease
developed	476 9 O
in	486 2 O
rats	489 4 O
fed	494 3 O
the	498 3 O
plain	502 5 O
choline	508 7 B-Chemical
-	515 1 O
supplemented	516 12 O
diet	529 4 O
,	533 1 O
while	535 5 O
one	541 3 O
preneoplastic	545 13 O
nodule	559 6 O
and	566 3 O
one	570 3 O
hepatocellular	574 14 B-Disease
carcinoma	589 9 I-Disease
developed	599 9 O
in	609 2 O
two	612 3 O
rats	616 4 O
fed	621 3 O
the	625 3 O
same	629 4 O
diet	634 4 O
containing	639 10 O
phenobarbital	650 13 B-Chemical
.	663 1 O

The	665 3 O
incidence	669 9 O
of	679 2 O
preneoplastic	682 13 O
nodules	696 7 O
and	704 3 O
of	708 2 O
hepatocellular	711 14 B-Disease
carcinomas	726 10 I-Disease
was	737 3 O
10	741 2 O
%	743 1 O
and	745 3 O
37	749 2 O
%	751 1 O
,	752 1 O
respectively	754 12 O
,	766 1 O
in	768 2 O
rats	771 4 O
fed	776 3 O
the	780 3 O
plain	784 5 O
choline	790 7 B-Chemical
-	797 1 O
devoid	798 6 O
diet	805 4 O
,	809 1 O
and	811 3 O
17	815 2 O
%	817 1 O
and	819 3 O
30	823 2 O
%	825 1 O
,	826 1 O
in	828 2 O
rats	831 4 O
fed	836 3 O
the	840 3 O
phenobarbital	844 13 B-Chemical
-	857 1 O
containing	858 10 O
choline	869 7 B-Chemical
-	876 1 O
devoid	877 6 O
diet	884 4 O
.	888 1 O

The	890 3 O
results	894 7 O
evinced	902 7 O
no	910 2 O
enhancement	913 11 O
of	925 2 O
the	928 3 O
hepatocarcinogenicity	932 21 O
of	954 2 O
the	957 3 O
choline	961 7 B-Chemical
-	968 1 O
devoid	969 6 O
diet	976 4 O
by	981 2 O
phenobarbital	984 13 B-Chemical
.	997 1 O

Sporadic	999 8 O
neoplastic	1008 10 O
lesions	1019 7 O
were	1027 4 O
observed	1032 8 O
in	1041 2 O
organs	1044 6 O
other	1051 5 O
than	1057 4 O
the	1062 3 O
liver	1066 5 O
of	1072 2 O
some	1075 4 O
of	1080 2 O
the	1083 3 O
animals	1087 7 O
,	1094 1 O
irrespective	1096 12 O
of	1109 2 O
the	1112 3 O
diet	1116 4 O
fed	1121 3 O
.	1124 1 O

Effect	0 6 O
of	7 2 O
direct	10 6 O
intracoronary	17 13 O
administration	31 14 O
of	46 2 O
methylergonovine	49 16 B-Chemical
in	66 2 O
patients	69 8 O
with	78 4 O
and	83 3 O
without	87 7 O
variant	95 7 B-Disease
angina	103 6 I-Disease
.	109 1 O

The	111 3 O
effects	115 7 O
of	123 2 O
intracoronary	126 13 O
administration	140 14 O
of	155 2 O
methylergonovine	158 16 B-Chemical
were	175 4 O
studied	180 7 O
in	188 2 O
21	191 2 O
patients	194 8 O
with	203 4 O
variant	208 7 B-Disease
angina	216 6 I-Disease
and	223 3 O
22	227 2 O
patients	230 8 O
with	239 4 O
atypical	244 8 O
chest	253 5 B-Disease
pain	259 4 I-Disease
and	264 3 O
in	268 2 O
others	271 6 O
without	278 7 O
angina	286 6 B-Disease
pectoris	293 8 I-Disease
(	302 1 O
control	303 7 O
group	311 5 O
)	316 1 O
.	317 1 O

Methylergonovine	319 16 B-Chemical
was	336 3 O
administered	340 12 O
continuously	353 12 O
at	366 2 O
a	369 1 O
rate	371 4 O
of	376 2 O
10	379 2 O
micrograms	382 10 O
/	392 1 O
min	393 3 O
up	397 2 O
to	400 2 O
50	403 2 O
micrograms	406 10 O
.	416 1 O

In	418 2 O
all	421 3 O
patients	425 8 O
with	434 4 O
variant	439 7 B-Disease
angina	447 6 I-Disease
,	453 1 O
coronary	455 8 B-Disease
spasm	464 5 I-Disease
was	470 3 O
provoked	474 8 O
at	483 2 O
a	486 1 O
mean	488 4 O
dose	493 4 O
of	498 2 O
28	501 2 O
+	504 1 O
/	505 1 O
-	506 1 O
13	508 2 O
micrograms	511 10 O
(	522 1 O
mean	523 4 O
+	528 1 O
/	529 1 O
-	530 1 O
SD	532 2 O
)	534 1 O
.	535 1 O

In	537 2 O
the	540 3 O
control	544 7 O
group	552 5 O
neither	558 7 O
ischemic	566 8 O
ST	575 2 O
change	578 6 O
nor	585 3 O
localized	589 9 O
spasm	599 5 B-Disease
occurred	605 8 O
.	613 1 O

The	615 3 O
basal	619 5 O
tone	625 4 O
of	630 2 O
the	633 3 O
right	637 5 O
coronary	643 8 O
artery	652 6 O
was	659 3 O
significantly	663 13 O
lower	677 5 O
than	683 4 O
that	688 4 O
of	693 2 O
the	696 3 O
left	700 4 O
coronary	705 8 O
artery	714 6 O
.	720 1 O

The	722 3 O
percentage	726 10 O
of	737 2 O
vasoconstriction	740 16 O
of	757 2 O
the	760 3 O
right	764 5 O
coronary	770 8 O
artery	779 6 O
was	786 3 O
significantly	790 13 O
higher	804 6 O
than	811 4 O
that	816 4 O
of	821 2 O
the	824 3 O
left	828 4 O
coronary	833 8 O
artery	842 6 O
.	848 1 O

These	850 5 O
results	856 7 O
suggest	864 7 O
that	872 4 O
spasm	877 5 B-Disease
provocation	883 11 O
tests	895 5 O
,	900 1 O
which	902 5 O
use	908 3 O
an	912 2 O
intracoronary	915 13 O
injection	929 9 O
of	939 2 O
a	942 1 O
relatively	944 10 O
low	955 3 O
dose	959 4 O
of	964 2 O
methylergonovine	967 16 B-Chemical
,	983 1 O
have	985 4 O
a	990 1 O
high	992 4 O
sensitivity	997 11 O
in	1009 2 O
variant	1012 7 B-Disease
angina	1020 6 I-Disease
and	1027 3 O
the	1031 3 O
vasoreactivity	1035 14 O
of	1050 2 O
the	1053 3 O
right	1057 5 O
coronary	1063 8 O
artery	1072 6 O
may	1079 3 O
be	1083 2 O
greater	1086 7 O
than	1094 4 O
that	1099 4 O
of	1104 2 O
the	1107 3 O
other	1111 5 O
coronary	1117 8 O
arteries	1126 8 O
.	1134 1 O

Dobutamine	0 10 B-Chemical
stress	11 6 O
echocardiography	18 16 O
:	34 1 O
a	36 1 O
sensitive	38 9 O
indicator	48 9 O
of	58 2 O
diminished	61 10 O
myocardial	72 10 O
function	83 8 O
in	92 2 O
asymptomatic	95 12 O
doxorubicin	108 11 B-Chemical
-	119 1 O
treated	120 7 O
long	128 4 O
-	132 1 O
term	133 4 O
survivors	138 9 O
of	148 2 O
childhood	151 9 O
cancer	161 6 B-Disease
.	167 1 O

Doxorubicin	169 11 B-Chemical
is	181 2 O
an	184 2 O
effective	187 9 O
anticancer	197 10 O
chemotherapeutic	208 16 O
agent	225 5 O
known	231 5 O
to	237 2 O
cause	240 5 O
acute	246 5 O
and	252 3 O
chronic	256 7 O
cardiomyopathy	264 14 B-Disease
.	278 1 O

To	280 2 O
develop	283 7 O
a	291 1 O
more	293 4 O
sensitive	298 9 O
echocardiographic	308 17 O
screening	326 9 O
test	336 4 O
for	341 3 O
cardiac	345 7 B-Disease
damage	353 6 I-Disease
due	360 3 O
to	364 2 O
doxorubicin	367 11 B-Chemical
,	378 1 O
a	380 1 O
cohort	382 6 O
study	389 5 O
was	395 3 O
performed	399 9 O
using	409 5 O
dobutamine	415 10 B-Chemical
infusion	426 8 O
to	435 2 O
differentiate	438 13 O
asymptomatic	452 12 O
long	465 4 O
-	469 1 O
term	470 4 O
survivors	475 9 O
of	485 2 O
childhood	488 9 O
cancer	498 6 B-Disease
treated	505 7 O
with	513 4 O
doxorubicin	518 11 B-Chemical
from	530 4 O
healthy	535 7 O
control	543 7 O
subjects	551 8 O
.	559 1 O

Echocardiographic	561 17 O
data	579 4 O
from	584 4 O
the	589 3 O
experimental	593 12 O
group	606 5 O
of	612 2 O
21	615 2 O
patients	618 8 O
(	627 1 O
mean	628 4 O
age	633 3 O
16	637 2 O
+	640 1 O
/	641 1 O
-	642 1 O
5	644 1 O
years	646 5 O
)	651 1 O
treated	653 7 O
from	661 4 O
1	666 1 O
.	667 1 O
6	668 1 O
to	670 2 O
14	673 2 O
.	675 1 O
3	676 1 O
years	678 5 O
(	684 1 O
median	685 6 O
5	692 1 O
.	693 1 O
3	694 1 O
)	695 1 O
before	697 6 O
this	704 4 O
study	709 5 O
with	715 4 O
27	720 2 O
to	723 2 O
532	726 3 O
mg	730 2 O
/	732 1 O
m2	733 2 O
of	736 2 O
doxorubicin	739 11 B-Chemical
(	751 1 O
mean	752 4 O
196	757 3 O
)	760 1 O
were	762 4 O
compared	767 8 O
with	776 4 O
echocardiographic	781 17 O
data	799 4 O
from	804 4 O
12	809 2 O
normal	812 6 O
age	819 3 O
-	822 1 O
matched	823 7 O
control	831 7 O
subjects	839 8 O
.	847 1 O

Graded	849 6 O
dobutamine	856 10 B-Chemical
infusions	867 9 O
of	877 2 O
0	880 1 O
.	881 1 O
5	882 1 O
,	883 1 O
2	885 1 O
.	886 1 O
5	887 1 O
,	888 1 O
5	890 1 O
and	892 3 O
10	896 2 O
micrograms	899 10 O
/	909 1 O
kg	910 2 O
per	913 3 O
min	917 3 O
were	921 4 O
administered	926 12 O
.	938 1 O

Echocardiographic	940 17 O
Doppler	958 7 O
studies	966 7 O
were	974 4 O
performed	979 9 O
before	989 6 O
infusion	996 8 O
and	1005 3 O
after	1009 5 O
15	1015 2 O
min	1018 3 O
of	1022 2 O
infusion	1025 8 O
at	1034 2 O
each	1037 4 O
rate	1042 4 O
.	1046 1 O

Dobutamine	1048 10 B-Chemical
infusion	1059 8 O
at	1068 2 O
10	1071 2 O
micrograms	1074 10 O
/	1084 1 O
kg	1085 2 O
per	1088 3 O
min	1092 3 O
was	1096 3 O
discontinued	1100 12 O
after	1113 5 O
six	1119 3 O
studies	1123 7 O
secondary	1131 9 O
to	1141 2 O
a	1144 1 O
50	1146 2 O
%	1148 1 O
incidence	1150 9 O
rate	1160 4 O
of	1165 2 O
adverse	1168 7 O
symptoms	1176 8 O
.	1184 1 O

The	1186 3 O
most	1190 4 O
important	1195 9 O
findings	1205 8 O
were	1214 4 O
that	1219 4 O
compared	1224 8 O
with	1233 4 O
values	1238 6 O
in	1245 2 O
control	1248 7 O
subjects	1256 8 O
,	1264 1 O
end	1266 3 O
-	1269 1 O
systolic	1270 8 O
left	1279 4 O
ventricular	1284 11 O
posterior	1296 9 O
wall	1306 4 O
dimension	1311 9 O
and	1321 3 O
percent	1325 7 O
of	1333 2 O
left	1336 4 O
ventricular	1341 11 O
posterior	1353 9 O
wall	1363 4 O
thickening	1368 10 O
in	1379 2 O
doxorubicin	1382 11 B-Chemical
-	1393 1 O
treated	1394 7 O
patients	1402 8 O
were	1411 4 O
decreased	1416 9 O
at	1426 2 O
baseline	1429 8 O
study	1438 5 O
and	1444 3 O
these	1448 5 O
findings	1454 8 O
were	1463 4 O
more	1468 4 O
clearly	1473 7 O
delineated	1481 10 O
with	1492 4 O
dobutamine	1497 10 B-Chemical
stimulation	1508 11 O
.	1519 1 O

End	1521 3 O
-	1524 1 O
systolic	1525 8 O
left	1534 4 O
ventricular	1539 11 O
posterior	1551 9 O
wall	1561 4 O
dimension	1566 9 O
at	1576 2 O
baseline	1579 8 O
for	1588 3 O
the	1592 3 O
doxorubicin	1596 11 B-Chemical
-	1607 1 O
treated	1608 7 O
group	1616 5 O
was	1622 3 O
11	1626 2 O
+	1629 1 O
/	1630 1 O
-	1631 1 O
1	1633 1 O
.	1634 1 O
9	1635 1 O
mm	1637 2 O
versus	1640 6 O
13	1647 2 O
.	1649 1 O
1	1650 1 O
+	1652 1 O
/	1653 1 O
-	1654 1 O
1	1656 1 O
.	1657 1 O
5	1658 1 O
mm	1660 2 O
for	1663 3 O
control	1667 7 O
subjects	1675 8 O
(	1684 1 O
p	1685 1 O
less	1687 4 O
than	1692 4 O
0	1697 1 O
.	1698 1 O
01	1699 2 O
)	1701 1 O
.	1702 1 O

End	1704 3 O
-	1707 1 O
systolic	1708 8 O
left	1717 4 O
ventricular	1722 11 O
posterior	1734 9 O
wall	1744 4 O
dimension	1749 9 O
at	1759 2 O
the	1762 3 O
5	1766 1 O
-	1767 1 O
micrograms	1768 10 O
/	1778 1 O
kg	1779 2 O
per	1782 3 O
min	1786 3 O
dobutamine	1790 10 B-Chemical
infusion	1801 8 O
for	1810 3 O
the	1814 3 O
doxorubicin	1818 11 B-Chemical
-	1829 1 O
treated	1830 7 O
group	1838 5 O
was	1844 3 O
14	1848 2 O
.	1850 1 O
1	1851 1 O
+	1853 1 O
/	1854 1 O
-	1855 1 O
2	1857 1 O
.	1858 1 O
4	1859 1 O
mm	1861 2 O
versus	1864 6 O
19	1871 2 O
.	1873 1 O
3	1874 1 O
+	1876 1 O
/	1877 1 O
-	1878 1 O
2	1880 1 O
.	1881 1 O
6	1882 1 O
mm	1884 2 O
for	1887 3 O
control	1891 7 O
subjects	1899 8 O
(	1908 1 O
p	1909 1 O
less	1911 4 O
than	1916 4 O
0	1921 1 O
.	1922 1 O
01	1923 2 O
)	1925 1 O
.	1926 1 O
(	1927 1 O
ABSTRACT	1928 8 O
TRUNCATED	1937 9 O
AT	1947 2 O
250	1950 3 O
WORDS	1954 5 O
)	1959 1 O

Effects	0 7 O
of	8 2 O
aminophylline	11 13 B-Chemical
on	25 2 O
the	28 3 O
threshold	32 9 O
for	42 3 O
initiating	46 10 O
ventricular	57 11 B-Disease
fibrillation	69 12 I-Disease
during	82 6 O
respiratory	89 11 B-Disease
failure	101 7 I-Disease
.	108 1 O

Cardiac	110 7 B-Disease
arrhythmias	118 11 I-Disease
have	130 4 O
frequently	135 10 O
been	146 4 O
reported	151 8 O
in	160 2 O
association	163 11 O
with	175 4 O
respiratory	180 11 B-Disease
failure	192 7 I-Disease
.	199 1 O

The	201 3 O
possible	205 8 O
additive	214 8 O
role	223 4 O
of	228 2 O
pharmacologic	231 13 O
agents	245 6 O
in	252 2 O
precipitating	255 13 O
cardiac	269 7 B-Disease
disturbances	277 12 I-Disease
in	290 2 O
patients	293 8 O
with	302 4 O
respiratory	307 11 B-Disease
failure	319 7 I-Disease
has	327 3 O
only	331 4 O
recently	336 8 O
been	345 4 O
emphasized	350 10 O
.	360 1 O

The	362 3 O
effects	366 7 O
of	374 2 O
aminophylline	377 13 B-Chemical
on	391 2 O
the	394 3 O
ventricular	398 11 B-Disease
fibrillation	410 12 I-Disease
threshold	423 9 O
during	433 6 O
normal	440 6 O
acid	447 4 O
-	451 1 O
base	452 4 O
conditions	457 10 O
and	468 3 O
during	472 6 O
respiratory	479 11 B-Disease
failure	491 7 I-Disease
were	499 4 O
studied	504 7 O
in	512 2 O
anesthetized	515 12 O
open	528 4 O
chest	533 5 O
dogs	539 4 O
.	543 1 O

The	545 3 O
ventricular	549 11 B-Disease
fibrillation	561 12 I-Disease
threshold	574 9 O
was	584 3 O
measured	588 8 O
by	597 2 O
passing	600 7 O
a	608 1 O
gated	610 5 O
train	616 5 O
of	622 2 O
12	625 2 O
constant	628 8 O
current	637 7 O
pulses	645 6 O
through	652 7 O
the	660 3 O
ventricular	664 11 O
myocardium	676 10 O
during	687 6 O
the	694 3 O
vulnerable	698 10 O
period	709 6 O
of	716 2 O
the	719 3 O
cardiac	723 7 O
cycle	731 5 O
.	736 1 O

During	738 6 O
the	745 3 O
infusion	749 8 O
of	758 2 O
aminophylline	761 13 B-Chemical
,	774 1 O
the	776 3 O
ventricular	780 11 B-Disease
fibrillation	792 12 I-Disease
threshold	805 9 O
was	815 3 O
reduced	819 7 O
by	827 2 O
30	830 2 O
to	833 2 O
40	836 2 O
percent	839 7 O
of	847 2 O
the	850 3 O
control	854 7 O
when	862 4 O
pH	867 2 O
and	870 3 O
partial	874 7 O
pressures	882 9 O
of	892 2 O
oxygen	895 6 B-Chemical
(	902 1 O
PO2	903 3 B-Chemical
)	906 1 O
and	908 3 O
carbon	912 6 B-Chemical
dioxide	919 7 I-Chemical
(	927 1 O
CO2	928 3 B-Chemical
)	931 1 O
were	933 4 O
kept	938 4 O
within	943 6 O
normal	950 6 O
limits	957 6 O
.	963 1 O

When	965 4 O
respiratory	970 11 B-Disease
failure	982 7 I-Disease
was	990 3 O
produced	994 8 O
by	1003 2 O
hypoventilation	1006 15 B-Disease
(	1022 1 O
pH	1023 2 O
7	1026 1 O
.	1027 1 O
05	1028 2 O
to	1031 2 O
7	1034 1 O
.	1035 1 O
25	1036 2 O
;	1038 1 O
PC02	1040 4 O
70	1045 2 O
to	1048 2 O
100	1051 3 O
mm	1055 2 O
Hg	1058 2 O
:	1060 1 O
P02	1062 3 O
20	1066 2 O
to	1069 2 O
40	1072 2 O
mm	1075 2 O
Hg	1078 2 O
)	1080 1 O
,	1081 1 O
infusion	1083 8 O
of	1092 2 O
aminophylline	1095 13 B-Chemical
resulted	1109 8 O
in	1118 2 O
an	1121 2 O
even	1124 4 O
greater	1129 7 O
decrease	1137 8 O
in	1146 2 O
ventricular	1149 11 B-Disease
fibrillation	1161 12 I-Disease
threshold	1174 9 O
to	1184 2 O
60	1187 2 O
percent	1190 7 O
of	1198 2 O
the	1201 3 O
control	1205 7 O
level	1213 5 O
.	1218 1 O

These	1220 5 O
experiments	1226 11 O
suggest	1238 7 O
that	1246 4 O
although	1251 8 O
many	1260 4 O
factors	1265 7 O
may	1273 3 O
contribute	1277 10 O
to	1288 2 O
the	1291 3 O
increased	1295 9 O
incidence	1305 9 O
of	1315 2 O
ventricular	1318 11 B-Disease
arrhythmias	1330 11 I-Disease
in	1342 2 O
respiratory	1345 11 B-Disease
failure	1357 7 I-Disease
,	1364 1 O
pharmacologic	1366 13 O
agents	1380 6 O
,	1386 1 O
particularly	1388 12 O
aminophylline	1401 13 B-Chemical
,	1414 1 O
may	1416 3 O
play	1420 4 O
a	1425 1 O
significant	1427 11 O
role	1439 4 O
.	1443 1 O

Case	0 4 O
report	5 6 O
:	11 1 O
acute	13 5 O
unintentional	19 13 O
carbachol	33 9 B-Chemical
intoxication	43 12 O
.	55 1 O

INTRODUCTION	57 12 O
:	69 1 O
Intoxications	71 13 O
with	85 4 O
carbachol	90 9 B-Chemical
,	99 1 O
a	101 1 O
muscarinic	103 10 O
cholinergic	114 11 O
receptor	126 8 O
agonist	135 7 O
are	143 3 O
rare	147 4 O
.	151 1 O

We	153 2 O
report	156 6 O
an	163 2 O
interesting	166 11 O
case	178 4 O
investigating	183 13 O
a	197 1 O
(	199 1 O
near	200 4 O
)	204 1 O
fatal	206 5 O
poisoning	212 9 B-Disease
.	221 1 O

METHODS	223 7 O
:	230 1 O
The	232 3 O
son	236 3 O
of	240 2 O
an	243 2 O
84	246 2 O
-	248 1 O
year	249 4 O
-	253 1 O
old	254 3 O
male	258 4 O
discovered	263 10 O
a	274 1 O
newspaper	276 9 O
report	286 6 O
stating	293 7 O
clinical	301 8 O
success	310 7 O
with	318 4 O
plant	323 5 O
extracts	329 8 O
in	338 2 O
Alzheimer	341 9 B-Disease
'	350 1 I-Disease
s	351 1 I-Disease
disease	353 7 I-Disease
.	360 1 O

The	362 3 O
mode	366 4 O
of	371 2 O
action	374 6 O
was	381 3 O
said	385 4 O
to	390 2 O
be	393 2 O
comparable	396 10 O
to	407 2 O
that	410 4 O
of	415 2 O
the	418 3 O
synthetic	422 9 O
compound	432 8 O
'	441 1 O
carbamylcholin	442 14 B-Chemical
'	456 1 O
;	457 1 O
that	459 4 O
is	464 2 O
,	466 1 O
carbachol	468 9 B-Chemical
.	477 1 O

He	479 2 O
bought	482 6 O
25	489 2 O
g	492 1 O
of	494 2 O
carbachol	497 9 B-Chemical
as	507 2 O
pure	510 4 O
substance	515 9 O
in	525 2 O
a	528 1 O
pharmacy	530 8 O
,	538 1 O
and	540 3 O
the	544 3 O
father	548 6 O
was	555 3 O
administered	559 12 O
400	572 3 O
to	576 2 O
500	579 3 O
mg	583 2 O
.	585 1 O

Carbachol	587 9 B-Chemical
concentrations	597 14 O
in	612 2 O
serum	615 5 O
and	621 3 O
urine	625 5 O
on	631 2 O
day	634 3 O
1	638 1 O
and	640 3 O
2	644 1 O
of	646 2 O
hospital	649 8 O
admission	658 9 O
were	668 4 O
analysed	673 8 O
by	682 2 O
HPLC	685 4 O
-	689 1 O
mass	690 4 O
spectrometry	695 12 O
.	707 1 O

RESULTS	709 7 O
:	716 1 O
Minutes	718 7 O
after	726 5 O
oral	732 4 O
administration	737 14 O
,	751 1 O
the	753 3 O
patient	757 7 O
developed	765 9 O
nausea	775 6 B-Disease
,	781 1 O
sweating	783 8 O
and	792 3 O
hypotension	796 11 B-Disease
,	807 1 O
and	809 3 O
finally	813 7 O
collapsed	821 9 O
.	830 1 O

Bradycardia	832 11 B-Disease
,	843 1 O
cholinergic	845 11 O
symptoms	857 8 O
and	866 3 O
asystole	870 8 B-Disease
occurred	879 8 O
.	887 1 O

Initial	889 7 O
cardiopulmonary	897 15 O
resuscitation	913 13 O
and	927 3 O
immediate	931 9 O
treatment	941 9 O
with	951 4 O
adrenaline	956 10 B-Chemical
(	967 1 O
epinephrine	968 11 B-Chemical
)	979 1 O
,	980 1 O
atropine	982 8 B-Chemical
and	991 3 O
furosemide	995 10 B-Chemical
was	1006 3 O
successful	1010 10 O
.	1020 1 O

On	1022 2 O
hospital	1025 8 O
admission	1034 9 O
,	1043 1 O
blood	1045 5 O
pressure	1051 8 O
of	1060 2 O
the	1063 3 O
intubated	1067 9 O
,	1076 1 O
bradyarrhythmic	1078 15 O
patient	1094 7 O
was	1102 3 O
100	1106 3 O
/	1109 1 O
65	1110 2 O
mmHg	1113 4 O
.	1117 1 O

Further	1119 7 O
signs	1127 5 O
were	1133 4 O
hyperhidrosis	1138 13 B-Disease
,	1151 1 O
hypersalivation	1153 15 B-Disease
,	1168 1 O
bronchorrhoea	1170 13 B-Disease
,	1183 1 O
and	1185 3 O
severe	1189 6 O
miosis	1196 6 B-Disease
;	1202 1 O
the	1204 3 O
electrocardiographic	1208 20 O
finding	1229 7 O
was	1237 3 O
atrio	1241 5 B-Disease
-	1246 1 I-Disease
ventricular	1247 11 I-Disease
dissociation	1259 12 I-Disease
.	1271 1 O

High	1273 4 O
doses	1278 5 O
of	1284 2 O
atropine	1287 8 B-Chemical
(	1296 1 O
up	1297 2 O
to	1300 2 O
50	1303 2 O
mg	1306 2 O
per	1309 3 O
24	1313 2 O
hours	1316 5 O
)	1321 1 O
,	1322 1 O
adrenaline	1324 10 B-Chemical
and	1335 3 O
dopamine	1339 8 B-Chemical
were	1348 4 O
necessary	1353 9 O
.	1362 1 O

The	1364 3 O
patient	1368 7 O
was	1376 3 O
extubated	1380 9 O
1	1390 1 O
week	1392 4 O
later	1397 5 O
.	1402 1 O

However	1404 7 O
,	1411 1 O
increased	1413 9 O
dyspnoea	1423 8 B-Disease
and	1432 3 O
bronchospasm	1436 12 B-Disease
necessitated	1449 12 O
reintubation	1462 12 O
.	1474 1 O

Respiratory	1476 11 B-Disease
insufficiency	1488 13 I-Disease
was	1502 3 O
further	1506 7 O
worsened	1514 8 O
by	1523 2 O
Proteus	1526 7 B-Disease
mirabilis	1534 9 I-Disease
infection	1544 9 I-Disease
and	1554 3 O
severe	1558 6 O
bronchoconstriction	1565 19 O
.	1584 1 O

One	1586 3 O
week	1590 4 O
later	1595 5 O
,	1600 1 O
the	1602 3 O
patient	1606 7 O
was	1614 3 O
again	1618 5 O
extubated	1624 9 O
and	1634 3 O
3	1638 1 O
days	1640 4 O
later	1645 5 O
was	1651 3 O
transferred	1655 11 O
to	1667 2 O
a	1670 1 O
peripheral	1672 10 O
ward	1683 4 O
.	1687 1 O

On	1689 2 O
the	1692 3 O
next	1696 4 O
day	1701 3 O
he	1705 2 O
died	1708 4 O
,	1712 1 O
probably	1714 8 O
as	1723 2 O
a	1726 1 O
result	1728 6 O
of	1735 2 O
heart	1738 5 B-Disease
failure	1744 7 I-Disease
.	1751 1 O

Serum	1753 5 O
samples	1759 7 O
from	1767 4 O
the	1772 3 O
first	1776 5 O
and	1782 3 O
second	1786 6 O
days	1793 4 O
contained	1798 9 O
3	1808 1 O
.	1809 1 O
6	1810 1 O
and	1812 3 O
1	1816 1 O
.	1817 1 O
9	1818 1 O
mg	1820 2 O
/	1822 1 O
l	1823 1 O
carbachol	1825 9 B-Chemical
,	1834 1 O
respectively	1836 12 O
.	1848 1 O

The	1850 3 O
corresponding	1854 13 O
urine	1868 5 O
concentrations	1874 14 O
amounted	1889 8 O
to	1898 2 O
374	1901 3 O
and	1905 3 O
554	1909 3 O
mg	1913 2 O
/	1915 1 O
l	1916 1 O
.	1917 1 O

CONCLUSION	1919 10 O
:	1929 1 O
This	1931 4 O
case	1936 4 O
started	1941 7 O
with	1949 4 O
a	1954 1 O
media	1956 5 O
report	1962 6 O
in	1969 2 O
a	1972 1 O
popular	1974 7 O
newspaper	1982 9 O
,	1991 1 O
initiated	1993 9 O
by	2003 2 O
published	2006 9 O
,	2015 1 O
peer	2017 4 O
-	2021 1 O
reviewed	2022 8 O
research	2031 8 O
on	2040 2 O
herbals	2043 7 O
,	2050 1 O
and	2052 3 O
involved	2056 8 O
human	2065 5 O
failure	2071 7 O
in	2079 2 O
a	2082 1 O
case	2084 4 O
history	2089 7 O
,	2096 1 O
medical	2098 7 O
examination	2106 11 O
and	2118 3 O
clinical	2122 8 O
treatment	2131 9 O
.	2140 1 O

For	2142 3 O
the	2146 3 O
first	2150 5 O
time	2156 4 O
,	2160 1 O
an	2162 2 O
analytical	2165 10 O
method	2176 6 O
for	2183 3 O
the	2187 3 O
determination	2191 13 O
of	2205 2 O
carbachol	2208 9 B-Chemical
in	2218 2 O
plasma	2221 6 O
and	2228 3 O
urine	2232 5 O
has	2238 3 O
been	2242 4 O
developed	2247 9 O
.	2256 1 O

The	2258 3 O
analysed	2262 8 O
carbachol	2271 9 B-Chemical
concentration	2281 13 O
exceeded	2295 8 O
the	2304 3 O
supposed	2308 8 O
serum	2317 5 O
level	2323 5 O
resulting	2329 9 O
from	2339 4 O
a	2344 1 O
therapeutic	2346 11 O
dose	2358 4 O
by	2363 2 O
a	2366 1 O
factor	2368 6 O
of	2375 2 O
130	2378 3 O
to	2382 2 O
260	2385 3 O
.	2388 1 O

Especially	2390 10 O
in	2401 2 O
old	2404 3 O
patients	2408 8 O
,	2416 1 O
intensivists	2418 12 O
should	2431 6 O
consider	2438 8 O
intoxications	2447 13 O
(	2461 1 O
with	2462 4 O
cholinergics	2467 12 O
)	2479 1 O
as	2481 2 O
a	2484 1 O
cause	2486 5 O
of	2492 2 O
acute	2495 5 B-Disease
cardiovascular	2501 14 I-Disease
failure	2516 7 I-Disease
.	2523 1 O

Crossover	0 9 O
comparison	10 10 O
of	21 2 O
efficacy	24 8 O
and	33 3 O
preference	37 10 O
for	48 3 O
rizatriptan	52 11 B-Chemical
10	64 2 O
mg	67 2 O
versus	70 6 O
ergotamine	77 10 B-Chemical
/	87 1 O
caffeine	88 8 B-Chemical
in	97 2 O
migraine	100 8 B-Disease
.	108 1 O

Rizatriptan	110 11 B-Chemical
is	122 2 O
a	125 1 O
selective	127 9 O
5	137 1 B-Chemical
-	138 1 I-Chemical
HT	139 2 I-Chemical
(	141 1 O
1B	142 2 O
/	144 1 O
1D	145 2 O
)	147 1 O
receptor	149 8 O
agonist	158 7 O
with	166 4 O
rapid	171 5 O
oral	177 4 O
absorption	182 10 O
and	193 3 O
early	197 5 O
onset	203 5 O
of	209 2 O
action	212 6 O
in	219 2 O
the	222 3 O
acute	226 5 O
treatment	232 9 O
of	242 2 O
migraine	245 8 B-Disease
.	253 1 O

This	255 4 O
randomized	260 10 O
double	271 6 O
-	277 1 O
blind	279 5 O
crossover	285 9 O
outpatient	295 10 O
study	306 5 O
assessed	312 8 O
the	321 3 O
preference	325 10 O
for	336 3 O
1	340 1 O
rizatriptan	342 11 B-Chemical
10	354 2 O
mg	357 2 O
tablet	360 6 O
to	367 2 O
2	370 1 O
ergotamine	372 10 B-Chemical
1	383 1 O
mg	385 2 O
/	387 1 O
caffeine	388 8 B-Chemical
100	397 3 O
mg	401 2 O
tablets	404 7 O
in	412 2 O
439	415 3 O
patients	419 8 O
treating	428 8 O
a	437 1 O
single	439 6 O
migraine	446 8 B-Disease
attack	455 6 O
with	462 4 O
each	467 4 O
therapy	472 7 O
.	479 1 O

Of	481 2 O
patients	484 8 O
expressing	493 10 O
a	504 1 O
preference	506 10 O
(	517 1 O
89	518 2 O
.	520 1 O
1	521 1 O
%	522 1 O
)	523 1 O
,	524 1 O
more	526 4 O
than	531 4 O
twice	536 5 O
as	542 2 O
many	545 4 O
preferred	550 9 O
rizatriptan	560 11 B-Chemical
to	572 2 O
ergotamine	575 10 B-Chemical
/	585 1 O
caffeine	586 8 B-Chemical
(	595 1 O
69	596 2 O
.	598 1 O
9	599 1 O
vs	601 2 O
.	603 1 O
30	605 2 O
.	607 1 O
1	608 1 O
%	609 1 O
,	610 1 O
p	612 1 O
<	614 1 O
or	616 2 O
=	619 1 O
0	621 1 O
.	622 1 O
001	623 3 O
)	626 1 O
.	627 1 O

Faster	629 6 O
relief	636 6 O
of	643 2 O
headache	646 8 B-Disease
was	655 3 O
the	659 3 O
most	663 4 O
important	668 9 O
reason	678 6 O
for	685 3 O
preference	689 10 O
,	699 1 O
cited	701 5 O
by	707 2 O
67	710 2 O
.	712 1 O
3	713 1 O
%	714 1 O
of	716 2 O
patients	719 8 O
preferring	728 10 O
rizatriptan	739 11 B-Chemical
and	751 3 O
54	755 2 O
.	757 1 O
2	758 1 O
%	759 1 O
of	761 2 O
patients	764 8 O
who	773 3 O
preferred	777 9 O
ergotamine	787 10 B-Chemical
/	797 1 O
caffeine	798 8 B-Chemical
.	806 1 O

The	808 3 O
co	812 2 O
-	814 1 O
primary	815 7 O
endpoint	823 8 O
of	832 2 O
being	835 5 O
pain	841 4 B-Disease
free	846 4 O
at	851 2 O
2	854 1 O
h	856 1 O
was	858 3 O
also	862 4 O
in	867 2 O
favor	870 5 O
of	876 2 O
rizatriptan	879 11 B-Chemical
.	890 1 O

Forty	892 5 O
-	897 1 O
nine	898 4 O
percent	903 7 O
of	911 2 O
patients	914 8 O
were	923 4 O
pain	928 4 B-Disease
free	933 4 O
2	938 1 O
h	940 1 O
after	942 5 O
rizatriptan	948 11 B-Chemical
,	959 1 O
compared	961 8 O
with	970 4 O
24	975 2 O
.	977 1 O
3	978 1 O
%	979 1 O
treated	981 7 O
with	989 4 O
ergotamine	994 10 B-Chemical
/	1004 1 O
caffeine	1005 8 B-Chemical
(	1014 1 O
p	1015 1 O
<	1017 1 O
or	1019 2 O
=	1022 1 O
0	1024 1 O
.	1025 1 O
001	1026 3 O
)	1029 1 O
,	1030 1 O
rizatriptan	1032 11 B-Chemical
being	1044 5 O
superior	1050 8 O
within	1059 6 O
1	1066 1 O
h	1068 1 O
of	1070 2 O
treatment	1073 9 O
.	1082 1 O

Headache	1084 8 B-Disease
relief	1093 6 O
at	1100 2 O
2	1103 1 O
h	1105 1 O
was	1107 3 O
75	1111 2 O
.	1113 1 O
9	1114 1 O
%	1115 1 O
for	1117 3 O
rizatriptan	1121 11 B-Chemical
and	1133 3 O
47	1137 2 O
.	1139 1 O
3	1140 1 O
%	1141 1 O
for	1143 3 O
ergotamine	1147 10 B-Chemical
/	1157 1 O
caffeine	1158 8 B-Chemical
(	1167 1 O
p	1168 1 O
<	1170 1 O
or	1172 2 O
=	1175 1 O
0	1177 1 O
.	1178 1 O
001	1179 3 O
)	1182 1 O
,	1183 1 O
with	1185 4 O
rizatriptan	1190 11 B-Chemical
being	1202 5 O
superior	1208 8 O
to	1217 2 O
ergotamine	1220 10 B-Chemical
/	1230 1 O
caffeine	1231 8 B-Chemical
within	1240 6 O
30	1247 2 O
min	1250 3 O
of	1254 2 O
dosing	1257 6 O
.	1263 1 O

Almost	1265 6 O
36	1272 2 O
%	1274 1 O
of	1276 2 O
patients	1279 8 O
taking	1288 6 O
rizatriptan	1295 11 B-Chemical
were	1307 4 O
pain	1312 4 B-Disease
free	1317 4 O
at	1322 2 O
2	1325 1 O
h	1327 1 O
and	1329 3 O
had	1333 3 O
no	1337 2 O
recurrence	1340 10 O
or	1351 2 O
need	1354 4 O
for	1359 3 O
additional	1363 10 O
medication	1374 10 O
within	1385 6 O
24	1392 2 O
h	1395 1 O
,	1396 1 O
compared	1398 8 O
to	1407 2 O
20	1410 2 O
%	1412 1 O
of	1414 2 O
patients	1417 8 O
on	1426 2 O
ergotamine	1429 10 B-Chemical
/	1439 1 O
caffeine	1440 8 B-Chemical
(	1449 1 O
p	1450 1 O
<	1452 1 O
or	1454 2 O
=	1457 1 O
0	1459 1 O
.	1460 1 O
001	1461 3 O
)	1464 1 O
.	1465 1 O

Rizatriptan	1467 11 B-Chemical
was	1479 3 O
also	1483 4 O
superior	1488 8 O
to	1497 2 O
ergotamine	1500 10 B-Chemical
/	1510 1 O
caffeine	1511 8 B-Chemical
in	1520 2 O
the	1523 3 O
proportions	1527 11 O
of	1539 2 O
patients	1542 8 O
with	1551 4 O
no	1556 2 O
nausea	1559 6 B-Disease
,	1565 1 O
vomiting	1567 8 B-Disease
,	1575 1 O
phonophobia	1577 11 B-Disease
or	1589 2 O
photophobia	1592 11 B-Disease
and	1604 3 O
for	1608 3 O
patients	1612 8 O
with	1621 4 O
normal	1626 6 O
function	1633 8 O
2	1642 1 O
h	1644 1 O
after	1646 5 O
drug	1652 4 O
intake	1657 6 O
(	1664 1 O
p	1665 1 O
<	1667 1 O
or	1669 2 O
=	1672 1 O
0	1674 1 O
.	1675 1 O
001	1676 3 O
)	1679 1 O
.	1680 1 O

More	1682 4 O
patients	1687 8 O
were	1696 4 O
(	1701 1 O
completely	1702 10 O
,	1712 1 O
very	1714 4 O
or	1719 2 O
somewhat	1722 8 O
)	1730 1 O
satisfied	1732 9 O
2	1742 1 O
h	1744 1 O
after	1746 5 O
treatment	1752 9 O
with	1762 4 O
rizatriptan	1767 11 B-Chemical
(	1779 1 O
69	1780 2 O
.	1782 1 O
8	1783 1 O
%	1784 1 O
)	1785 1 O
than	1787 4 O
at	1792 2 O
2	1795 1 O
h	1797 1 O
after	1799 5 O
treatment	1805 9 O
with	1815 4 O
ergotamine	1820 10 B-Chemical
/	1830 1 O
caffeine	1831 8 B-Chemical
(	1840 1 O
38	1841 2 O
.	1843 1 O
6	1844 1 O
%	1845 1 O
,	1846 1 O
p	1848 1 O
<	1850 1 O
or	1852 2 O
=	1855 1 O
0	1857 1 O
.	1858 1 O
001	1859 3 O
)	1862 1 O
.	1863 1 O

Recurrence	1865 10 O
rates	1876 5 O
were	1882 4 O
31	1887 2 O
.	1889 1 O
4	1890 1 O
%	1891 1 O
with	1893 4 O
rizatriptan	1898 11 B-Chemical
and	1910 3 O
15	1914 2 O
.	1916 1 O
3	1917 1 O
%	1918 1 O
with	1920 4 O
ergotamine	1925 10 B-Chemical
/	1935 1 O
caffeine	1936 8 B-Chemical
.	1944 1 O

Both	1946 4 O
active	1951 6 O
treatments	1958 10 O
were	1969 4 O
well	1974 4 O
tolerated	1979 9 O
.	1988 1 O

The	1990 3 O
most	1994 4 O
common	1999 6 O
adverse	2006 7 O
events	2014 6 O
(	2021 1 O
incidence	2022 9 O
>	2032 1 O
or	2034 2 O
=	2037 1 O
5	2039 1 O
%	2040 1 O
in	2042 2 O
one	2045 3 O
group	2049 5 O
)	2054 1 O
after	2056 5 O
rizatriptan	2062 11 B-Chemical
and	2074 3 O
ergotamine	2078 10 B-Chemical
/	2088 1 O
caffeine	2089 8 B-Chemical
,	2097 1 O
respectively	2099 12 O
,	2111 1 O
were	2113 4 O
dizziness	2118 9 B-Disease
(	2128 1 O
6	2129 1 O
.	2130 1 O
7	2131 1 O
and	2133 3 O
5	2137 1 O
.	2138 1 O
3	2139 1 O
%	2140 1 O
)	2141 1 O
,	2142 1 O
nausea	2144 6 B-Disease
(	2151 1 O
4	2152 1 O
.	2153 1 O
2	2154 1 O
and	2156 3 O
8	2160 1 O
.	2161 1 O
5	2162 1 O
%	2163 1 O
)	2164 1 O
and	2166 3 O
somnolence	2170 10 B-Disease
(	2181 1 O
5	2182 1 O
.	2183 1 O
5	2184 1 O
and	2186 3 O
2	2190 1 O
.	2191 1 O
3	2192 1 O
%	2193 1 O
)	2194 1 O
.	2195 1 O

Thrombotic	0 10 B-Disease
microangiopathy	11 15 I-Disease
and	27 3 O
renal	31 5 B-Disease
failure	37 7 I-Disease
associated	45 10 O
with	56 4 O
antineoplastic	61 14 O
chemotherapy	76 12 O
.	88 1 O

Five	90 4 O
patients	95 8 O
with	104 4 O
carcinoma	109 9 B-Disease
developed	119 9 O
thrombotic	129 10 B-Disease
microangiopathy	140 15 I-Disease
(	156 1 O
characterized	157 13 O
by	171 2 O
renal	174 5 B-Disease
insufficiency	180 13 I-Disease
,	193 1 O
microangiopathic	195 16 B-Disease
hemolytic	212 9 I-Disease
anemia	222 6 I-Disease
,	228 1 O
and	230 3 O
usually	234 7 O
thrombocytopenia	242 16 B-Disease
)	258 1 O
after	260 5 O
treatment	266 9 O
with	276 4 O
cisplatin	281 9 B-Chemical
,	290 1 O
bleomycin	292 9 B-Chemical
,	301 1 O
and	303 3 O
a	307 1 O
vinca	309 5 B-Chemical
alkaloid	315 8 I-Chemical
.	323 1 O

One	325 3 O
patient	329 7 O
had	337 3 O
thrombotic	341 10 B-Disease
thrombocytopenic	352 16 I-Disease
purpura	369 7 I-Disease
,	376 1 O
three	378 5 O
the	384 3 O
hemolytic	388 9 B-Disease
-	397 1 I-Disease
uremic	398 6 I-Disease
syndrome	405 8 I-Disease
,	413 1 O
and	415 3 O
one	419 3 O
an	423 2 O
apparent	426 8 O
forme	435 5 O
fruste	441 6 O
of	448 2 O
one	451 3 O
of	455 2 O
these	458 5 O
disorders	464 9 O
.	473 1 O

Histologic	475 10 O
examination	486 11 O
of	498 2 O
the	501 3 O
renal	505 5 O
tissue	511 6 O
showed	518 6 O
evidence	525 8 O
of	534 2 O
intravascular	537 13 B-Disease
coagulation	551 11 I-Disease
,	562 1 O
primarily	564 9 O
affecting	574 9 O
the	584 3 O
small	588 5 O
arteries	594 8 O
,	602 1 O
arterioles	604 10 O
,	614 1 O
and	616 3 O
glomeruli	620 9 O
.	629 1 O

Because	631 7 O
each	639 4 O
patient	644 7 O
was	652 3 O
tumor	656 5 B-Disease
-	661 1 O
free	662 4 O
or	667 2 O
had	670 3 O
only	674 4 O
a	679 1 O
small	681 5 O
tumor	687 5 B-Disease
at	693 2 O
the	696 3 O
onset	700 5 O
of	706 2 O
this	709 4 O
syndrome	714 8 O
,	722 1 O
the	724 3 O
thrombotic	728 10 B-Disease
microangiopathy	739 15 I-Disease
may	755 3 O
have	759 4 O
been	764 4 O
induced	769 7 O
by	777 2 O
chemotherapy	780 12 O
.	792 1 O

Diagnosis	794 9 O
of	804 2 O
this	807 4 O
potentially	812 11 O
fatal	824 5 O
complication	830 12 O
may	843 3 O
be	847 2 O
delayed	850 7 O
or	858 2 O
missed	861 6 O
if	868 2 O
renal	871 5 O
tissue	877 6 O
or	884 2 O
the	887 3 O
peripheral	891 10 O
blood	902 5 O
smear	908 5 O
is	914 2 O
not	917 3 O
examined	921 8 O
,	929 1 O
because	931 7 O
renal	939 5 B-Disease
failure	945 7 I-Disease
may	953 3 O
be	957 2 O
ascribed	960 8 O
to	969 2 O
cisplatin	972 9 B-Chemical
nephrotoxicity	982 14 B-Disease
and	997 3 O
the	1001 3 O
anemia	1005 6 B-Disease
and	1012 3 O
thrombocytopenia	1016 16 B-Disease
to	1033 2 O
drug	1036 4 O
-	1040 1 O
induced	1041 7 O
bone	1049 4 B-Disease
marrow	1054 6 I-Disease
suppression	1061 11 I-Disease
.	1072 1 O

Salvage	0 7 O
therapy	8 7 O
with	16 4 O
nelarabine	21 10 B-Chemical
,	31 1 O
etoposide	33 9 B-Chemical
,	42 1 O
and	44 3 O
cyclophosphamide	48 16 B-Chemical
in	65 2 O
relapsed	68 8 O
/	76 1 O
refractory	77 10 O
paediatric	88 10 O
T	99 1 B-Disease
-	100 1 I-Disease
cell	101 4 I-Disease
lymphoblastic	106 13 I-Disease
leukaemia	120 9 I-Disease
and	130 3 I-Disease
lymphoma	134 8 I-Disease
.	142 1 O

A	144 1 O
combination	146 11 O
of	158 2 O
5	161 1 O
d	163 1 O
of	165 2 O
nelarabine	168 10 B-Chemical
(	179 1 O
AraG	180 4 B-Chemical
)	184 1 O
with	186 4 O
5	191 1 O
d	193 1 O
of	195 2 O
etoposide	198 9 B-Chemical
(	208 1 O
VP	209 2 B-Chemical
)	211 1 O
and	213 3 O
cyclophosphamide	217 16 B-Chemical
(	234 1 O
CPM	235 3 B-Chemical
)	238 1 O
and	240 3 O
prophylactic	244 12 O
intrathecal	257 11 O
chemotherapy	269 12 O
was	282 3 O
used	286 4 O
as	291 2 O
salvage	294 7 O
therapy	302 7 O
in	310 2 O
seven	313 5 O
children	319 8 O
with	328 4 O
refractory	333 10 O
or	344 2 O
relapsed	347 8 O
T	356 1 B-Disease
-	357 1 I-Disease
cell	358 4 I-Disease
leukaemia	363 9 I-Disease
or	373 2 I-Disease
lymphoma	376 8 I-Disease
.	384 1 O

The	386 3 O
most	390 4 O
common	395 6 O
side	402 4 O
effects	407 7 O
attributable	415 12 O
to	428 2 O
the	431 3 O
AraG	435 4 B-Chemical
included	440 8 O
Grade	449 5 O
2	455 1 O
and	457 3 O
3	461 1 O
sensory	463 7 O
and	471 3 O
motor	475 5 O
neuropathy	481 10 B-Disease
and	492 3 O
musculoskeletal	496 15 B-Disease
pain	512 4 I-Disease
.	516 1 O

Haematological	518 14 B-Disease
toxicity	533 8 I-Disease
was	542 3 O
greater	546 7 O
for	554 3 O
the	558 3 O
combination	562 11 O
than	574 4 O
AraG	579 4 B-Chemical
alone	584 5 O
,	589 1 O
although	591 8 O
median	600 6 O
time	607 4 O
to	612 2 O
neutrophil	615 10 O
and	626 3 O
platelet	630 8 O
recovery	639 8 O
was	648 3 O
consistent	652 10 O
with	663 4 O
other	668 5 O
salvage	674 7 O
therapies	682 9 O
.	691 1 O

All	693 3 O
patients	697 8 O
had	706 3 O
some	710 4 O
response	715 8 O
to	724 2 O
the	727 3 O
combined	731 8 O
therapy	740 7 O
and	748 3 O
five	752 4 O
of	757 2 O
the	760 3 O
seven	764 5 O
went	770 4 O
into	775 4 O
complete	780 8 O
remission	789 9 O
after	799 5 O
one	805 3 O
or	809 2 O
two	812 3 O
courses	816 7 O
of	824 2 O
AraG	827 4 B-Chemical
/	831 1 O
VP	832 2 B-Chemical
/	834 1 O
CPM	835 3 B-Chemical
.	838 1 O

Our	840 3 O
experience	844 10 O
supports	855 8 O
the	864 3 O
safety	868 6 O
of	875 2 O
giving	878 6 O
AraG	885 4 B-Chemical
as	890 2 O
salvage	893 7 O
therapy	901 7 O
in	909 2 O
synchrony	912 9 O
with	922 4 O
etoposide	927 9 B-Chemical
and	937 3 O
cyclophosphamide	941 16 B-Chemical
,	957 1 O
although	959 8 O
neurological	968 12 B-Disease
toxicity	981 8 I-Disease
must	990 4 O
be	995 2 O
closely	998 7 O
monitored	1006 9 O
.	1015 1 O

The	0 3 O
3	4 1 O
-	5 1 O
week	6 4 O
sulphasalazine	11 14 B-Chemical
syndrome	26 8 O
strikes	35 7 O
again	43 5 O
.	48 1 O

A	50 1 O
34	52 2 O
-	54 1 O
year	55 4 O
-	59 1 O
old	60 3 O
lady	64 4 O
developed	69 9 O
a	79 1 O
constellation	81 13 O
of	95 2 O
dermatitis	98 10 B-Disease
,	108 1 O
fever	110 5 B-Disease
,	115 1 O
lymphadenopathy	117 15 B-Disease
and	133 3 O
hepatitis	137 9 B-Disease
,	146 1 O
beginning	148 9 O
on	158 2 O
the	161 3 O
17th	165 4 O
day	170 3 O
of	174 2 O
a	177 1 O
course	179 6 O
of	186 2 O
oral	189 4 O
sulphasalazine	194 14 B-Chemical
for	209 3 O
sero	213 4 O
-	217 1 O
negative	218 8 O
rheumatoid	227 10 B-Disease
arthritis	238 9 I-Disease
.	247 1 O

Cervical	249 8 O
and	258 3 O
inguinal	262 8 O
lymph	271 5 O
node	277 4 O
biopsies	282 8 O
showed	291 6 O
the	298 3 O
features	302 8 O
of	311 2 O
severe	314 6 O
necrotising	321 11 O
lymphadenitis	333 13 B-Disease
,	346 1 O
associated	348 10 O
with	359 4 O
erythrophagocytosis	364 19 O
and	384 3 O
prominent	388 9 O
eosinophilic	398 12 O
infiltrates	411 11 O
,	422 1 O
without	424 7 O
viral	432 5 O
inclusion	438 9 O
bodies	448 6 O
,	454 1 O
suggestive	456 10 O
of	467 2 O
an	470 2 O
adverse	473 7 B-Disease
drug	481 4 I-Disease
reaction	486 8 I-Disease
.	494 1 O
A	495 1 O
week	497 4 O
later	502 5 O
,	507 1 O
fulminant	509 9 O
drug	519 4 B-Disease
-	523 1 I-Disease
induced	524 7 I-Disease
hepatitis	532 9 I-Disease
,	541 1 O
associated	543 10 O
with	554 4 O
the	559 3 O
presence	563 8 O
of	572 2 O
anti	575 4 O
-	579 1 O
nuclear	580 7 O
autoantibodies	588 14 O
(	603 1 O
but	604 3 O
not	608 3 O
with	612 4 O
other	617 5 O
markers	623 7 O
of	631 2 O
autoimmunity	634 12 B-Disease
)	646 1 O
,	647 1 O
and	649 3 O
accompanied	653 11 O
by	665 2 O
multi	668 5 B-Disease
-	673 1 I-Disease
organ	674 5 I-Disease
failure	680 7 I-Disease
and	688 3 O
sepsis	692 6 B-Disease
,	698 1 O
supervened	700 10 O
.	710 1 O

She	712 3 O
subsequently	716 12 O
died	729 4 O
some	734 4 O
5	739 1 O
weeks	741 5 O
after	747 5 O
the	753 3 O
commencement	757 12 O
of	770 2 O
her	773 3 O
drug	777 4 O
therapy	782 7 O
.	789 1 O
Post	790 4 O
-	794 1 O
mortem	795 6 O
examination	802 11 O
showed	814 6 O
evidence	821 8 O
of	830 2 O
massive	833 7 B-Disease
hepatocellular	841 14 I-Disease
necrosis	856 8 I-Disease
,	864 1 O
acute	866 5 O
hypersensitivity	872 16 O
myocarditis	889 11 B-Disease
,	900 1 O
focal	902 5 O
acute	908 5 O
tubulo	914 6 O
-	920 1 O
interstitial	921 12 O
nephritis	934 9 B-Disease
and	944 3 O
extensive	948 9 O
bone	958 4 B-Disease
marrow	963 6 I-Disease
necrosis	970 8 I-Disease
,	978 1 O
with	980 4 O
no	985 2 O
evidence	988 8 O
of	997 2 O
malignancy	1000 10 B-Disease
.	1010 1 O

It	1012 2 O
is	1015 2 O
thought	1018 7 O
that	1026 4 O
the	1031 3 O
clinico	1035 7 O
-	1042 1 O
pathological	1043 12 O
features	1056 8 O
and	1065 3 O
chronology	1069 10 O
of	1080 2 O
this	1083 4 O
case	1088 4 O
bore	1093 4 O
the	1098 3 O
hallmarks	1102 9 O
of	1112 2 O
the	1115 3 O
so	1119 2 O
-	1121 1 O
called	1122 6 O
"	1129 1 O
3	1130 1 O
-	1131 1 O
week	1132 4 O
sulphasalazine	1137 14 B-Chemical
syndrome	1152 8 O
"	1160 1 O
,	1161 1 O
a	1163 1 O
rare	1165 4 O
,	1169 1 O
but	1171 3 O
often	1175 5 O
fatal	1181 5 O
,	1186 1 O
immunoallergic	1188 14 O
reaction	1203 8 O
to	1212 2 O
sulphasalazine	1215 14 B-Chemical
.	1229 1 O

Bupropion	0 9 B-Chemical
(	10 1 O
Zyban	11 5 B-Chemical
)	16 1 O
toxicity	18 8 B-Disease
.	26 1 O

Bupropion	28 9 B-Chemical
is	38 2 O
a	41 1 O
monocyclic	43 10 O
antidepressant	54 14 B-Chemical
structurally	69 12 O
related	82 7 O
to	90 2 O
amphetamine	93 11 B-Chemical
.	104 1 O

Zyban	106 5 B-Chemical
,	111 1 O
a	113 1 O
sustained	115 9 O
-	124 1 O
release	125 7 O
formulation	133 11 O
of	145 2 O
bupropion	148 9 B-Chemical
hydrochloride	158 13 I-Chemical
,	171 1 O
was	173 3 O
recently	177 8 O
released	186 8 O
in	195 2 O
Ireland	198 7 O
,	205 1 O
as	207 2 O
a	210 1 O
smoking	212 7 O
cessation	220 9 O
aid	230 3 O
.	233 1 O

In	235 2 O
the	238 3 O
initial	242 7 O
6	250 1 O
months	252 6 O
since	259 5 O
it	265 2 O
'	267 1 O
s	268 1 O
introduction	270 12 O
,	282 1 O
12	284 2 O
overdose	287 8 B-Disease
cases	296 5 O
have	302 4 O
been	307 4 O
reported	312 8 O
to	321 2 O
The	324 3 O
National	328 8 O
Poisons	337 7 O
Information	345 11 O
Centre	357 6 O
.	363 1 O

8	365 1 O
patients	367 8 O
developed	376 9 O
symptoms	386 8 O
of	395 2 O
toxicity	398 8 B-Disease
.	406 1 O

Common	408 6 O
features	415 8 O
included	424 8 O
tachycardia	433 11 B-Disease
,	444 1 O
drowsiness	446 10 O
,	456 1 O
hallucinations	458 14 B-Disease
and	473 3 O
convulsions	477 11 B-Disease
.	488 1 O

Two	490 3 O
patients	494 8 O
developed	503 9 O
severe	513 6 O
cardiac	520 7 B-Disease
arrhythmias	528 11 I-Disease
,	539 1 O
including	541 9 O
one	551 3 O
patient	555 7 O
who	563 3 O
was	567 3 O
resuscitated	571 12 O
following	584 9 O
a	594 1 O
cardiac	596 7 B-Disease
arrest	604 6 I-Disease
.	610 1 O

All	612 3 O
patients	616 8 O
recovered	625 9 O
without	635 7 O
sequelae	643 8 O
.	651 1 O

We	653 2 O
report	656 6 O
a	663 1 O
case	665 4 O
of	670 2 O
a	673 1 O
31	675 2 O
year	678 4 O
old	683 3 O
female	687 6 O
who	694 3 O
required	698 8 O
admission	707 9 O
to	717 2 O
the	720 3 O
Intensive	724 9 O
Care	734 4 O
Unit	739 4 O
for	744 3 O
ventilation	748 11 O
and	760 3 O
full	764 4 O
supportive	769 10 O
therapy	780 7 O
,	787 1 O
following	789 9 O
ingestion	799 9 O
of	809 2 O
13	812 2 O
.	814 1 O
5g	815 2 O
bupropion	818 9 B-Chemical
.	827 1 O

Recurrent	829 9 O
seizures	839 8 B-Disease
were	848 4 O
treated	853 7 O
with	861 4 O
diazepam	866 8 B-Chemical
and	875 3 O
broad	879 5 O
complex	885 7 O
tachycardia	893 11 B-Disease
was	905 3 O
successfully	909 12 O
treated	922 7 O
with	930 4 O
adenosine	935 9 B-Chemical
.	944 1 O

Zyban	946 5 B-Chemical
caused	952 6 O
significant	959 11 O
neurological	971 12 B-Disease
and	984 3 I-Disease
cardiovascular	988 14 I-Disease
toxicity	1003 8 I-Disease
in	1012 2 O
overdose	1015 8 B-Disease
.	1023 1 O

The	1025 3 O
potential	1029 9 O
toxic	1039 5 O
effects	1045 7 O
should	1053 6 O
be	1060 2 O
considered	1063 10 O
when	1074 4 O
prescribing	1079 11 O
it	1091 2 O
as	1094 2 O
a	1097 1 O
smoking	1099 7 O
cessation	1107 9 O
aid	1117 3 O
.	1120 1 O

Survey	0 6 O
of	7 2 O
complications	10 13 O
of	24 2 O
indocyanine	27 11 B-Chemical
green	39 5 I-Chemical
angiography	45 11 O
in	57 2 O
Japan	60 5 O
.	65 1 O

PURPOSE	67 7 O
:	74 1 O
We	76 2 O
evaluated	79 9 O
the	89 3 O
safety	93 6 O
of	100 2 O
indocyanine	103 11 B-Chemical
green	115 5 I-Chemical
for	121 3 O
use	125 3 O
in	129 2 O
fundus	132 6 O
angiography	139 11 O
.	150 1 O

METHODS	152 7 O
:	159 1 O
We	161 2 O
sent	164 4 O
a	169 1 O
questionnaire	171 13 O
concerning	185 10 O
complications	196 13 O
of	210 2 O
indocyanine	213 11 B-Chemical
green	225 5 I-Chemical
to	231 2 O
32	234 2 O
institutions	237 12 O
in	250 2 O
Japan	253 5 O
,	258 1 O
which	260 5 O
were	266 4 O
selected	271 8 O
on	280 2 O
the	283 3 O
basis	287 5 O
of	293 2 O
the	296 3 O
client	300 6 O
list	307 4 O
from	312 4 O
the	317 3 O
Topcon	321 6 O
Company	328 7 O
,	335 1 O
which	337 5 O
manufactures	343 12 O
the	356 3 O
indocyanine	360 11 B-Chemical
green	372 5 I-Chemical
fundus	378 6 O
camera	385 6 O
.	391 1 O

RESULTS	393 7 O
:	400 1 O
Ophthalmologists	402 16 O
at	419 2 O
15	422 2 O
institutions	425 12 O
responded	438 9 O
,	447 1 O
reporting	449 9 O
a	459 1 O
total	461 5 O
of	467 2 O
3	470 1 O
,	471 1 O
774	472 3 O
indocyanine	476 11 B-Chemical
green	488 5 I-Chemical
angiograms	494 10 O
performed	505 9 O
on	515 2 O
2	518 1 O
,	519 1 O
820	520 3 O
patients	524 8 O
between	533 7 O
June	541 4 O
1984	546 4 O
and	551 3 O
September	555 9 O
1992	565 4 O
.	569 1 O

Before	571 6 O
angiography	578 11 O
,	589 1 O
intradermal	591 11 O
or	603 2 O
intravenous	606 11 O
indocyanine	618 11 B-Chemical
green	630 5 I-Chemical
testing	636 7 O
,	643 1 O
or	645 2 O
both	648 4 O
was	653 3 O
performed	657 9 O
at	667 2 O
13	670 2 O
of	673 2 O
15	676 2 O
institutions	679 12 O
.	691 1 O

For	693 3 O
three	697 5 O
patients	703 8 O
,	711 1 O
the	713 3 O
decision	717 8 O
was	726 3 O
made	730 4 O
not	735 3 O
to	739 2 O
proceed	742 7 O
with	750 4 O
angiography	755 11 O
after	767 5 O
positive	773 8 O
preangiographic	782 15 O
testing	798 7 O
.	805 1 O

The	807 3 O
dosage	811 6 O
of	818 2 O
indocyanine	821 11 B-Chemical
green	833 5 I-Chemical
used	839 4 O
for	844 3 O
angiography	848 11 O
varied	860 6 O
from	867 4 O
25	872 2 O
to	875 2 O
75	878 2 O
mg	881 2 O
,	883 1 O
depending	885 9 O
upon	895 4 O
the	900 3 O
institution	904 11 O
.	915 1 O

There	917 5 O
were	923 4 O
13	928 2 O
cases	931 5 O
of	937 2 O
adverse	940 7 O
reactions	948 9 O
(	958 1 O
0	959 1 O
.	960 1 O
34	961 2 O
%	963 1 O
)	964 1 O
,	965 1 O
ten	967 3 O
of	971 2 O
which	974 5 O
were	980 4 O
mild	985 4 O
reactions	990 9 O
such	1000 4 O
as	1005 2 O
nausea	1008 6 B-Disease
,	1014 1 O
exanthema	1016 9 B-Disease
,	1025 1 O
urtication	1027 10 B-Disease
,	1037 1 O
itchiness	1039 9 B-Disease
,	1048 1 O
and	1050 3 O
urgency	1054 7 O
to	1062 2 O
defecate	1065 8 O
,	1073 1 O
and	1075 3 O
did	1079 3 O
not	1083 3 O
require	1087 7 O
treatment	1095 9 O
.	1104 1 O

Also	1106 4 O
recorded	1111 8 O
were	1120 4 O
one	1125 3 O
case	1129 4 O
of	1134 2 O
pain	1137 4 B-Disease
of	1142 2 O
the	1145 3 O
vein	1149 4 O
,	1153 1 O
which	1155 5 O
required	1161 8 O
treatment	1170 9 O
,	1179 1 O
and	1181 3 O
two	1185 3 O
cases	1189 5 O
of	1195 2 O
hypotension	1198 11 B-Disease
.	1209 1 O

The	1211 3 O
two	1215 3 O
hypotensive	1219 11 B-Disease
patients	1231 8 O
required	1240 8 O
treatment	1249 9 O
for	1259 3 O
shock	1263 5 B-Disease
.	1268 1 O

CONCLUSIONS	1270 11 O
:	1281 1 O
A	1283 1 O
comparison	1285 10 O
of	1296 2 O
frequency	1299 9 O
of	1309 2 O
adverse	1312 7 O
reactions	1320 9 O
to	1330 2 O
indocyanine	1333 11 B-Chemical
green	1345 5 I-Chemical
with	1351 4 O
the	1356 3 O
previously	1360 10 O
reported	1371 8 O
frequency	1380 9 O
of	1390 2 O
such	1393 4 O
reactions	1398 9 O
to	1408 2 O
fluorescein	1411 11 B-Chemical
sodium	1423 6 I-Chemical
indicated	1430 9 O
that	1440 4 O
indocyanine	1445 11 B-Chemical
green	1457 5 I-Chemical
is	1463 2 O
a	1466 1 O
safe	1468 4 O
as	1473 2 O
fluorescein	1476 11 B-Chemical
for	1488 3 O
use	1492 3 O
in	1496 2 O
angiography	1499 11 O
.	1510 1 O

Bradykinin	0 10 B-Chemical
receptors	11 9 O
antagonists	21 11 O
and	33 3 O
nitric	37 6 B-Chemical
oxide	44 5 I-Chemical
synthase	50 8 O
inhibitors	59 10 O
in	70 2 O
vincristine	73 11 B-Chemical
and	85 3 O
streptozotocin	89 14 B-Chemical
induced	104 7 O
hyperalgesia	112 12 B-Disease
in	125 2 O
chemotherapy	128 12 O
and	141 3 O
diabetic	145 8 B-Disease
neuropathy	154 10 I-Disease
rat	165 3 O
model	169 5 O
.	174 1 O

PURPOSE	176 7 O
:	183 1 O
The	185 3 O
influence	189 9 O
of	199 2 O
an	202 2 O
irreversible	205 12 O
inhibitor	218 9 O
of	228 2 O
constitutive	231 12 O
NO	244 2 B-Chemical
synthase	247 8 O
(	256 1 O
L	257 1 O
-	258 1 O
NOArg	259 5 O
;	264 1 O
1	266 1 O
.	267 1 O
0	268 1 O
mg	270 2 O
/	272 1 O
kg	273 2 O
ip	276 2 O
)	278 1 O
,	279 1 O
a	281 1 O
relatively	283 10 O
selective	294 9 O
inhibitor	304 9 O
of	314 2 O
inducible	317 9 O
NO	327 2 B-Chemical
synthase	330 8 O
(	339 1 O
L	340 1 O
-	341 1 O
NIL	342 3 O
;	345 1 O
1	347 1 O
.	348 1 O
0	349 1 O
mg	351 2 O
/	353 1 O
kg	354 2 O
ip	357 2 O
)	359 1 O
and	361 3 O
a	365 1 O
relatively	367 10 O
specific	378 8 O
inhibitor	387 9 O
of	397 2 O
neuronal	400 8 O
NO	409 2 B-Chemical
synthase	412 8 O
(	421 1 O
7	422 1 O
-	423 1 O
NI	424 2 O
;	426 1 O
0	428 1 O
.	429 1 O
1	430 1 O
mg	432 2 O
/	434 1 O
kg	435 2 O
ip	438 2 O
)	440 1 O
,	441 1 O
on	443 2 O
antihyperalgesic	446 16 O
action	463 6 O
of	470 2 O
selective	473 9 O
antagonists	483 11 O
of	495 2 O
B2	498 2 O
and	501 3 O
B1	505 2 O
receptors	508 9 O
:	517 1 O
D	519 1 O
-	520 1 O
Arg	521 3 O
-	524 1 O
[	525 1 O
Hyp3	526 4 O
,	530 1 O
Thi5	531 4 O
,	535 1 O
D	536 1 O
-	537 1 O
Tic7	538 4 O
,	542 1 O
Oic8	543 4 O
]	547 1 O
bradykinin	549 10 B-Chemical
(	560 1 O
HOE	561 3 B-Chemical
140	565 3 I-Chemical
;	568 1 O
70	570 2 O
nmol	573 4 O
/	577 1 O
kg	578 2 O
ip	581 2 O
)	583 1 O
or	585 2 O
des	588 3 B-Chemical
Arg10	592 5 I-Chemical
HOE	598 3 I-Chemical
140	602 3 I-Chemical
(	606 1 O
70	607 2 O
nmol	610 4 O
/	614 1 O
kg	615 2 O
ip	618 2 O
)	620 1 O
respectively	622 12 O
,	634 1 O
in	636 2 O
model	639 5 O
of	645 2 O
diabetic	648 8 B-Disease
(	657 1 I-Disease
streptozotocin	658 14 I-Disease
-	672 1 I-Disease
induced	673 7 I-Disease
)	680 1 I-Disease
and	682 3 I-Disease
toxic	686 5 I-Disease
(	692 1 I-Disease
vincristine	693 11 I-Disease
-	704 1 I-Disease
induced	705 7 I-Disease
)	712 1 I-Disease
neuropathy	714 10 I-Disease
was	725 3 O
investigated	729 12 O
.	741 1 O

METHODS	743 7 O
:	750 1 O
The	752 3 O
changes	756 7 O
in	764 2 O
pain	767 4 B-Disease
thresholds	772 10 O
were	783 4 O
determined	788 10 O
using	799 5 O
mechanical	805 10 O
stimuli	816 7 O
-	823 1 O
-	824 1 O
the	825 3 O
modification	829 12 O
of	842 2 O
the	845 3 O
classic	849 7 O
paw	857 3 O
withdrawal	861 10 O
test	872 4 O
described	877 9 O
by	887 2 O
Randall	890 7 O
-	897 1 O
Selitto	898 7 O
.	905 1 O

RESULTS	907 7 O
:	914 1 O
The	916 3 O
results	920 7 O
of	928 2 O
this	931 4 O
paper	936 5 O
confirm	942 7 O
that	950 4 O
inhibition	955 10 O
of	966 2 O
bradykinin	969 10 B-Chemical
receptors	980 9 O
and	990 3 O
inducible	994 9 O
NO	1004 2 B-Chemical
synthase	1007 8 O
but	1016 3 O
not	1020 3 O
neuronal	1024 8 O
NO	1033 2 B-Chemical
synthase	1036 8 O
activity	1045 8 O
reduces	1054 7 O
diabetic	1062 8 B-Disease
hyperalgesia	1071 12 I-Disease
.	1083 1 O

Pretreatment	1085 12 O
with	1098 4 O
L	1103 1 O
-	1104 1 O
NOArg	1105 5 O
and	1111 3 O
L	1115 1 O
-	1116 1 O
NIL	1117 3 O
but	1121 3 O
not	1125 3 O
7	1129 1 O
-	1130 1 O
NI	1131 2 O
,	1133 1 O
significantly	1135 13 O
increases	1149 9 O
antihyperalgesic	1159 16 O
activity	1176 8 O
both	1185 4 O
HOE	1190 3 B-Chemical
140	1194 3 I-Chemical
and	1198 3 O
des	1202 3 B-Chemical
Arg10	1206 5 I-Chemical
HOE	1212 3 I-Chemical
140	1216 3 I-Chemical
.	1219 1 O

It	1221 2 O
was	1224 3 O
also	1228 4 O
shown	1233 5 O
that	1239 4 O
both	1244 4 O
products	1249 8 O
of	1258 2 O
inducible	1261 9 O
NO	1271 2 B-Chemical
synthase	1274 8 O
and	1283 3 O
neuronal	1287 8 O
NO	1296 2 B-Chemical
synthase	1299 8 O
activation	1308 10 O
as	1319 2 O
well	1322 4 O
as	1327 2 O
bradykinin	1330 10 B-Chemical
are	1341 3 O
involved	1345 8 O
in	1354 2 O
hyperalgesia	1357 12 B-Disease
produced	1370 8 O
by	1379 2 O
vincristine	1382 11 B-Chemical
.	1393 1 O

Moreover	1395 8 O
,	1403 1 O
L	1405 1 O
-	1406 1 O
NOArg	1407 5 O
and	1413 3 O
7	1417 1 O
-	1418 1 O
NI	1419 2 O
but	1422 3 O
not	1426 3 O
L	1430 1 O
-	1431 1 O
NIL	1432 3 O
intensify	1436 9 O
antihyperalgesic	1446 16 O
activity	1463 8 O
of	1472 2 O
HOE	1475 3 B-Chemical
140	1479 3 I-Chemical
or	1483 2 O
des	1486 3 B-Chemical
-	1489 1 I-Chemical
Arg10HOE	1490 8 I-Chemical
140	1499 3 I-Chemical
in	1503 2 O
toxic	1506 5 B-Disease
neuropathy	1512 10 I-Disease
.	1522 1 O

CONCLUSIONS	1524 11 O
:	1535 1 O
Results	1537 7 O
of	1545 2 O
these	1548 5 O
studies	1554 7 O
suggest	1562 7 O
that	1570 4 O
B1	1575 2 O
and	1578 3 O
B2	1582 2 O
receptors	1585 9 O
are	1595 3 O
engaged	1599 7 O
in	1607 2 O
transmission	1610 12 O
of	1623 2 O
nociceptive	1626 11 O
stimuli	1638 7 O
in	1646 2 O
both	1649 4 O
diabetic	1654 8 B-Disease
and	1663 3 I-Disease
toxic	1667 5 I-Disease
neuropathy	1673 10 I-Disease
.	1683 1 O

In	1685 2 O
streptozotocin	1688 14 B-Chemical
-	1702 1 O
induced	1703 7 O
hyperalgesia	1711 12 B-Disease
,	1723 1 O
inducible	1725 9 O
NO	1735 2 B-Chemical
synthase	1738 8 O
participates	1747 12 O
in	1760 2 O
pronociceptive	1763 14 O
activity	1778 8 O
of	1787 2 O
bradykinin	1790 10 B-Chemical
,	1800 1 O
whereas	1802 7 O
in	1810 2 O
vincristine	1813 11 B-Chemical
-	1824 1 O
induced	1825 7 O
hyperalgesia	1833 12 B-Disease
bradykinin	1846 10 B-Chemical
seemed	1857 6 O
to	1864 2 O
activate	1867 8 O
neuronal	1876 8 O
NO	1885 2 B-Chemical
synthase	1888 8 O
pathway	1897 7 O
.	1904 1 O

Therefore	1906 9 O
,	1915 1 O
concomitant	1917 11 O
administration	1929 14 O
of	1944 2 O
small	1947 5 O
doses	1953 5 O
of	1959 2 O
bradykinin	1962 10 B-Chemical
receptor	1973 8 O
antagonists	1982 11 O
and	1994 3 O
NO	1998 2 B-Chemical
synthase	2001 8 O
inhibitors	2010 10 O
can	2021 3 O
be	2025 2 O
effective	2028 9 O
in	2038 2 O
alleviation	2041 11 O
of	2053 2 O
neuropathic	2056 11 B-Disease
pain	2068 4 I-Disease
,	2072 1 O
even	2074 4 O
in	2079 2 O
hospital	2082 8 O
care	2091 4 O
.	2095 1 O

Cardiac	0 7 B-Disease
toxicity	8 8 I-Disease
observed	17 8 O
in	26 2 O
association	29 11 O
with	41 4 O
high	46 4 O
-	50 1 O
dose	51 4 O
cyclophosphamide	56 16 B-Chemical
-	72 1 O
based	73 5 O
chemotherapy	79 12 O
for	92 3 O
metastatic	96 10 O
breast	107 6 B-Disease
cancer	114 6 I-Disease
.	120 1 O

INTRODUCTION	122 12 O
:	134 1 O
Cyclophosphamide	136 16 B-Chemical
is	153 2 O
an	156 2 O
alkylating	159 10 O
agent	170 5 O
given	176 5 O
frequently	182 10 O
as	193 2 O
a	196 1 O
component	198 9 O
of	208 2 O
many	211 4 O
conditioning	216 12 O
regimens	229 8 O
.	237 1 O

In	239 2 O
high	242 4 O
doses	247 5 O
,	252 1 O
its	254 3 O
nonhematological	258 16 O
dose	275 4 O
-	279 1 O
limiting	280 8 O
toxicity	289 8 B-Disease
is	298 2 O
cardiomyopathy	301 14 B-Disease
.	315 1 O

STUDY	317 5 O
DESIGN	323 6 O
:	329 1 O
We	331 2 O
combined	334 8 O
paclitaxel	343 10 B-Chemical
,	353 1 O
melphalan	355 9 B-Chemical
and	365 3 O
high	369 4 O
-	373 1 O
dose	374 4 O
cyclophosphamide	379 16 B-Chemical
,	395 1 O
thiotepa	397 8 B-Chemical
,	405 1 O
and	407 3 O
carboplatin	411 11 B-Chemical
in	423 2 O
a	426 1 O
triple	428 6 O
sequential	435 10 O
high	446 4 O
-	450 1 O
dose	451 4 O
regimen	456 7 O
for	464 3 O
patients	468 8 O
with	477 4 O
metastatic	482 10 O
breast	493 6 B-Disease
cancer	500 6 I-Disease
.	506 1 O

Analysis	508 8 O
was	517 3 O
performed	521 9 O
on	531 2 O
61	534 2 O
women	537 5 O
with	543 4 O
chemotherapy	548 12 O
-	560 1 O
responsive	561 10 O
metastatic	572 10 O
breast	583 6 B-Disease
cancer	590 6 I-Disease
receiving	597 9 O
96	607 2 O
-	609 1 O
h	610 1 O
infusional	612 10 O
cyclophosphamide	623 16 B-Chemical
as	640 2 O
part	643 4 O
of	648 2 O
a	651 1 O
triple	653 6 O
sequential	660 10 O
high	671 4 O
-	675 1 O
dose	676 4 O
regimen	681 7 O
to	689 2 O
assess	692 6 O
association	699 11 O
between	711 7 O
presence	719 8 O
of	728 2 O
peritransplant	731 14 O
congestive	746 10 B-Disease
heart	757 5 I-Disease
failure	763 7 I-Disease
(	771 1 O
CHF	772 3 B-Disease
)	775 1 O
and	777 3 O
the	781 3 O
following	785 9 O
pretreatment	795 12 O
characteristics	808 15 O
:	823 1 O
presence	825 8 O
of	834 2 O
electrocardiogram	837 17 O
(	855 1 O
EKG	856 3 O
)	859 1 O
abnormalities	861 13 O
,	874 1 O
age	876 3 O
,	879 1 O
hypertension	881 12 B-Disease
,	893 1 O
prior	895 5 O
cardiac	901 7 O
history	909 7 O
,	916 1 O
smoking	918 7 O
,	925 1 O
diabetes	927 8 B-Disease
mellitus	936 8 I-Disease
,	944 1 O
prior	946 5 O
use	952 3 O
of	956 2 O
anthracyclines	959 14 B-Chemical
,	973 1 O
and	975 3 O
left	979 4 O
-	983 1 O
sided	984 5 O
chest	990 5 O
irradiation	996 11 O
.	1007 1 O

RESULTS	1009 7 O
:	1016 1 O
Six	1018 3 O
of	1022 2 O
61	1025 2 O
women	1028 5 O
(	1034 1 O
10	1035 2 O
%	1037 1 O
)	1038 1 O
developed	1040 9 O
clinically	1050 10 O
reversible	1061 10 O
grade	1072 5 O
3	1078 1 O
CHF	1080 3 B-Disease
following	1084 9 O
infusional	1094 10 O
cyclophosphamide	1105 16 B-Chemical
with	1122 4 O
a	1127 1 O
median	1129 6 O
percent	1136 7 O
decline	1144 7 O
in	1152 2 O
ejection	1155 8 O
fraction	1164 8 O
of	1173 2 O
31	1176 2 O
%	1178 1 O
.	1179 1 O

Incidence	1181 9 O
of	1191 2 O
transient	1194 9 O
cyclophosphamide	1204 16 B-Chemical
-	1220 1 O
related	1221 7 O
cardiac	1229 7 B-Disease
toxicity	1237 8 I-Disease
(	1246 1 O
10	1247 2 O
%	1249 1 O
)	1250 1 O
is	1252 2 O
comparable	1255 10 O
to	1266 2 O
previous	1269 8 O
recorded	1278 8 O
literature	1287 10 O
.	1297 1 O

Older	1299 5 O
age	1305 3 O
was	1309 3 O
significantly	1313 13 O
correlated	1327 10 O
with	1338 4 O
the	1343 3 O
CHF	1347 3 B-Disease
development	1351 11 O
;	1362 1 O
with	1364 4 O
median	1369 6 O
ages	1376 4 O
for	1381 3 O
the	1385 3 O
entire	1389 6 O
group	1396 5 O
and	1402 3 O
for	1406 3 O
patients	1410 8 O
developing	1419 10 O
CHF	1430 3 B-Disease
of	1434 2 O
45	1437 2 O
and	1440 3 O
59	1444 2 O
,	1446 1 O
respectively	1448 12 O
.	1460 1 O

No	1462 2 O
association	1465 11 O
was	1477 3 O
found	1481 5 O
with	1487 4 O
other	1492 5 O
pretreatment	1498 12 O
characteristics	1511 15 O
.	1526 1 O

CONCLUSIONS	1528 11 O
:	1539 1 O
As	1541 2 O
a	1544 1 O
result	1546 6 O
of	1553 2 O
these	1556 5 O
findings	1562 8 O
,	1570 1 O
oncologists	1572 11 O
should	1584 6 O
carefully	1591 9 O
monitor	1601 7 O
fluid	1609 5 O
balance	1615 7 O
in	1623 2 O
older	1626 5 O
patients	1632 8 O
.	1640 1 O

Routine	1642 7 O
EKG	1650 3 O
monitoring	1654 10 O
during	1665 6 O
infusional	1672 10 O
cyclophosphamide	1683 16 B-Chemical
did	1700 3 O
not	1704 3 O
predict	1708 7 O
CHF	1716 3 B-Disease
development	1720 11 O
.	1731 1 O

Inappropriate	0 13 O
use	14 3 O
of	18 2 O
carbamazepine	21 13 B-Chemical
and	35 3 O
vigabatrin	39 10 B-Chemical
in	50 2 O
typical	53 7 O
absence	61 7 B-Disease
seizures	69 8 I-Disease
.	77 1 O

Carbamazepine	79 13 B-Chemical
and	93 3 O
vigabatrin	97 10 B-Chemical
are	108 3 O
contraindicated	112 15 O
in	128 2 O
typical	131 7 O
absence	139 7 B-Disease
seizures	147 8 I-Disease
.	155 1 O

Of	157 2 O
18	160 2 O
consecutive	163 11 O
referrals	175 9 O
of	185 2 O
children	188 8 O
with	197 4 O
resistant	202 9 O
typical	212 7 O
absences	220 8 O
only	229 4 O
,	233 1 O
eight	235 5 O
were	241 4 O
erroneously	246 11 O
treated	258 7 O
with	266 4 O
carbamazepine	271 13 B-Chemical
either	285 6 O
as	292 2 O
monotherapy	295 11 O
or	307 2 O
as	310 2 O
an	313 2 O
add	316 3 O
-	319 1 O
on	320 2 O
.	322 1 O

Vigabatrin	324 10 B-Chemical
was	335 3 O
also	339 4 O
used	344 4 O
in	349 2 O
the	352 3 O
treatment	356 9 O
of	366 2 O
two	369 3 O
children	373 8 O
.	381 1 O

Frequency	383 9 O
of	393 2 O
absences	396 8 O
increased	405 9 O
in	415 2 O
four	418 4 O
children	423 8 O
treated	432 7 O
with	440 4 O
carbamazepine	445 13 B-Chemical
and	459 3 O
two	463 3 O
of	467 2 O
these	470 5 O
developed	476 9 O
myoclonic	486 9 B-Disease
jerks	496 5 I-Disease
,	501 1 O
which	503 5 O
resolved	509 8 O
on	518 2 O
withdrawal	521 10 O
of	532 2 O
carbamazepine	535 13 B-Chemical
.	548 1 O

Absences	550 8 O
were	559 4 O
aggravated	564 10 O
in	575 2 O
both	578 4 O
cases	583 5 O
where	589 5 O
vigabatrin	595 10 B-Chemical
was	606 3 O
added	610 5 O
on	616 2 O
to	619 2 O
concurrent	622 10 O
treatment	633 9 O
.	642 1 O

Optimal	644 7 O
control	652 7 O
of	660 2 O
the	663 3 O
absences	667 8 O
was	676 3 O
achieved	680 8 O
with	689 4 O
sodium	694 6 B-Chemical
valproate	701 9 I-Chemical
,	710 1 O
lamotrigine	712 11 B-Chemical
,	723 1 O
or	725 2 O
ethosuximide	728 12 B-Chemical
alone	741 5 O
or	747 2 O
in	750 2 O
combination	753 11 O
.	764 1 O

Hemolytic	0 9 B-Disease
anemia	10 6 I-Disease
associated	17 10 O
with	28 4 O
the	33 3 O
use	37 3 O
of	41 2 O
omeprazole	44 10 B-Chemical
.	54 1 O

Omeprazole	56 10 B-Chemical
is	67 2 O
the	70 3 O
first	74 5 O
drug	80 4 O
designed	85 8 O
to	94 2 O
block	97 5 O
the	103 3 O
final	107 5 O
step	113 4 O
in	118 2 O
the	121 3 O
acid	125 4 O
secretory	130 9 O
process	140 7 O
within	148 6 O
the	155 3 O
parietal	159 8 O
cell	168 4 O
.	172 1 O

It	174 2 O
has	177 3 O
been	181 4 O
shown	186 5 O
to	192 2 O
be	195 2 O
extremely	198 9 O
effective	208 9 O
in	218 2 O
the	221 3 O
treatment	225 9 O
of	235 2 O
peptic	238 6 B-Disease
ulcer	245 5 I-Disease
disease	251 7 I-Disease
,	258 1 O
reflux	260 6 B-Disease
esophagitis	267 11 I-Disease
,	278 1 O
and	280 3 O
the	284 3 O
Zollinger	288 9 B-Disease
-	297 1 I-Disease
Ellison	298 7 I-Disease
syndrome	306 8 I-Disease
.	314 1 O

Although	316 8 O
clinical	325 8 O
experience	334 10 O
with	345 4 O
omeprazole	350 10 B-Chemical
is	361 2 O
still	364 5 O
limited	370 7 O
,	377 1 O
many	379 4 O
controlled	384 10 O
studies	395 7 O
have	403 4 O
established	408 11 O
the	420 3 O
short	424 5 O
-	429 1 O
term	430 4 O
safety	435 6 O
of	442 2 O
this	445 4 O
drug	450 4 O
.	454 1 O

We	456 2 O
report	459 6 O
the	466 3 O
first	470 5 O
case	476 4 O
of	481 2 O
a	484 1 O
serious	486 7 O
short	494 5 O
-	499 1 O
term	500 4 O
adverse	505 7 O
reaction	513 8 O
with	522 4 O
the	527 3 O
use	531 3 O
of	535 2 O
omeprazole	538 10 B-Chemical
:	548 1 O
hemolytic	550 9 B-Disease
anemia	560 6 I-Disease
.	566 1 O

The	568 3 O
patient	572 7 O
developed	580 9 O
weakness	590 8 O
,	598 1 O
lethargy	600 8 B-Disease
,	608 1 O
and	610 3 O
shortness	614 9 B-Disease
of	624 2 I-Disease
breath	627 6 I-Disease
2	634 1 O
days	636 4 O
after	641 5 O
starting	647 8 O
therapy	656 7 O
with	664 4 O
omeprazole	669 10 B-Chemical
.	679 1 O

Two	681 3 O
weeks	685 5 O
after	691 5 O
the	697 3 O
initiation	701 10 O
of	712 2 O
therapy	715 7 O
,	722 1 O
her	724 3 O
hematocrit	728 10 O
had	739 3 O
decreased	743 9 O
from	753 4 O
44	758 2 O
.	760 1 O
1	761 1 O
%	762 1 O
to	764 2 O
20	767 2 O
.	769 1 O
4	770 1 O
%	771 1 O
,	772 1 O
and	774 3 O
she	778 3 O
had	782 3 O
a	786 1 O
positive	788 8 O
direct	797 6 O
Coombs	804 6 O
antiglobulin	811 12 O
test	824 4 O
and	829 3 O
an	833 2 O
elevated	836 8 O
indirect	845 8 O
bilirubin	854 9 B-Chemical
.	863 1 O

After	865 5 O
she	871 3 O
discontinued	875 12 O
the	888 3 O
omeprazole	892 10 B-Chemical
,	902 1 O
her	904 3 O
hemoglobin	908 10 O
and	919 3 O
hematocrit	923 10 O
gradually	934 9 O
returned	944 8 O
to	953 2 O
normal	956 6 O
.	962 1 O

The	964 3 O
mechanism	968 9 O
by	978 2 O
which	981 5 O
omeprazole	987 10 B-Chemical
caused	998 6 O
the	1005 3 O
patient	1009 7 O
'	1016 1 O
s	1017 1 O
hemolytic	1019 9 B-Disease
anemia	1029 6 I-Disease
is	1036 2 O
uncertain	1039 9 O
,	1048 1 O
but	1050 3 O
physicians	1054 10 O
should	1065 6 O
be	1072 2 O
alerted	1075 7 O
to	1083 2 O
this	1086 4 O
possible	1091 8 O
adverse	1100 7 O
effect	1108 6 O
.	1114 1 O

The	0 3 O
use	4 3 O
and	8 3 O
toxicity	12 8 B-Disease
of	21 2 O
didanosine	24 10 B-Chemical
(	35 1 O
ddI	36 3 B-Chemical
)	39 1 O
in	41 2 O
HIV	44 3 B-Disease
antibody	48 8 I-Disease
-	56 1 I-Disease
positive	57 8 I-Disease
individuals	66 11 O
intolerant	78 10 O
to	89 2 O
zidovudine	92 10 B-Chemical
(	103 1 O
AZT	104 3 B-Chemical
)	107 1 O

One	109 3 O
hundred	113 7 O
and	121 3 O
fifty	125 5 O
-	130 1 O
one	131 3 O
patients	135 8 O
intolerant	144 10 O
to	155 2 O
zidovudine	158 10 B-Chemical
(	169 1 O
AZT	170 3 B-Chemical
)	173 1 O
received	175 8 O
didanosine	184 10 B-Chemical
(	195 1 O
ddI	196 3 B-Chemical
)	199 1 O
to	201 2 O
a	204 1 O
maximum	206 7 O
dose	214 4 O
of	219 2 O
12	222 2 O
.	224 1 O
5	225 1 O
mg	227 2 O
/	229 1 O
kg	230 2 O
/	232 1 O
day	233 3 O
.	236 1 O

Patient	238 7 O
response	246 8 O
was	255 3 O
assessed	259 8 O
using	268 5 O
changes	274 7 O
in	282 2 O
CD4	285 3 O
+	288 1 O
lymphocyte	290 10 O
subset	301 6 O
count	308 5 O
,	313 1 O
HIV	315 3 O
p24	319 3 O
antigen	323 7 O
,	330 1 O
weight	332 6 O
,	338 1 O
and	340 3 O
quality	344 7 O
of	352 2 O
life	355 4 O
.	359 1 O

Seventy	361 7 O
patients	369 8 O
developed	378 9 O
major	388 5 O
opportunistic	394 13 B-Disease
infections	408 10 I-Disease
whilst	419 6 O
on	426 2 O
therapy	429 7 O
;	436 1 O
this	438 4 O
was	443 3 O
the	447 3 O
first	451 5 O
AIDS	457 4 B-Disease
diagnosis	462 9 O
in	472 2 O
17	475 2 O
.	477 1 O

Only	479 4 O
minor	484 5 O
changes	490 7 O
in	498 2 O
CD4	501 3 O
+	504 1 O
lymphocyte	506 10 O
subset	517 6 O
count	524 5 O
were	530 4 O
observed	535 8 O
in	544 2 O
AIDS	547 4 B-Disease
patients	552 8 O
,	560 1 O
although	562 8 O
a	571 1 O
more	573 4 O
significant	578 11 O
rise	590 4 O
occurred	595 8 O
in	604 2 O
those	607 5 O
with	613 4 O
earlier	618 7 O
stages	626 6 O
of	633 2 O
disease	636 7 O
.	643 1 O

Of	645 2 O
those	648 5 O
positive	654 8 O
for	663 3 O
p24	667 3 O
antigen	671 7 O
at	679 2 O
the	682 3 O
commencement	686 12 O
of	699 2 O
the	702 3 O
study	706 5 O
67	712 2 O
%	714 1 O
showed	716 6 O
a	723 1 O
positive	725 8 O
response	734 8 O
,	742 1 O
and	744 3 O
this	748 4 O
was	753 3 O
most	757 4 O
likely	762 6 O
in	769 2 O
those	772 5 O
with	778 4 O
CD4	783 3 O
+	786 1 O
lymphocyte	788 10 O
subset	799 6 O
counts	806 6 O
above	813 5 O
100	819 3 O
mm3	823 3 O
.	826 1 O

A	828 1 O
positive	830 8 O
weight	839 6 O
response	846 8 O
was	855 3 O
seen	859 4 O
in	864 2 O
16	867 2 O
%	869 1 O
of	871 2 O
patients	874 8 O
.	882 1 O

Most	884 4 O
patients	889 8 O
showed	898 6 O
improvement	905 11 O
in	917 2 O
individual	920 10 O
parameters	931 10 O
and	942 3 O
global	946 6 O
score	953 5 O
of	959 2 O
quality	962 7 O
of	970 2 O
life	973 4 O
.	977 1 O

Adverse	979 7 O
reactions	987 9 O
possibly	997 8 O
attributable	1006 12 O
to	1019 2 O
didanosine	1022 10 B-Chemical
were	1033 4 O
common	1038 6 O
.	1044 1 O

The	1046 3 O
most	1050 4 O
common	1055 6 O
side	1062 4 O
-	1066 1 O
effect	1067 6 O
was	1074 3 O
diarrhoea	1078 9 B-Disease
,	1087 1 O
which	1089 5 O
resulted	1095 8 O
in	1104 2 O
cessation	1107 9 O
of	1117 2 O
therapy	1120 7 O
in	1128 2 O
19	1131 2 O
individuals	1134 11 O
.	1145 1 O

Peripheral	1147 10 B-Disease
neuropathy	1158 10 I-Disease
occurred	1169 8 O
in	1178 2 O
12	1181 2 O
patients	1184 8 O
and	1193 3 O
pancreatitis	1197 12 B-Disease
in	1210 2 O
six	1213 3 O
.	1216 1 O

Thirteen	1218 8 O
patients	1227 8 O
developed	1236 9 O
a	1246 1 O
raised	1248 6 O
serum	1255 5 O
amylase	1261 7 O
without	1269 7 O
abdominal	1277 9 B-Disease
pain	1287 4 I-Disease
.	1291 1 O

Seven	1293 5 O
patients	1299 8 O
developed	1308 9 O
glucose	1318 7 B-Disease
tolerance	1326 9 I-Disease
curves	1336 6 I-Disease
characteristic	1343 14 O
of	1358 2 O
diabetes	1361 8 B-Disease
but	1370 3 O
these	1374 5 O
were	1380 4 O
mild	1385 4 O
,	1389 1 O
did	1391 3 O
not	1395 3 O
require	1399 7 O
treatment	1407 9 O
and	1417 3 O
returned	1421 8 O
to	1430 2 O
normal	1433 6 O
on	1440 2 O
ceasing	1443 7 O
didanosine	1451 10 B-Chemical
.	1461 1 O

Can	0 3 O
angiogenesis	4 12 O
be	17 2 O
a	20 1 O
target	22 6 O
of	29 2 O
treatment	32 9 O
for	42 3 O
ribavirin	46 9 B-Chemical
associated	56 10 O
hemolytic	67 9 B-Disease
anemia	77 6 I-Disease
?	83 1 O

BACKGROUND	85 10 O
/	95 1 O
AIMS	96 4 O
:	100 1 O
Recently	102 8 O
ribavirin	111 9 B-Chemical
has	121 3 O
been	125 4 O
found	130 5 O
to	136 2 O
inhibit	139 7 O
angiogenesis	147 12 O
and	160 3 O
a	164 1 O
number	166 6 O
of	173 2 O
angiogenesis	176 12 O
inhibitors	189 10 O
such	200 4 O
as	205 2 O
sunitinib	208 9 B-Chemical
and	218 3 O
sorafenib	222 9 B-Chemical
have	232 4 O
been	237 4 O
found	242 5 O
to	248 2 O
cause	251 5 O
acute	257 5 O
hemolysis	263 9 B-Disease
.	272 1 O

We	274 2 O
aimed	277 5 O
to	283 2 O
investigate	286 11 O
whether	298 7 O
there	306 5 O
is	312 2 O
a	315 1 O
relation	317 8 O
between	326 7 O
hemoglobin	334 10 O
,	344 1 O
haptoglobin	346 11 O
and	358 3 O
angiogenesis	362 12 O
soluble	375 7 O
markers	383 7 O
which	391 5 O
are	397 3 O
modifiable	401 10 O
and	412 3 O
can	416 3 O
help	420 4 O
in	425 2 O
developing	428 10 O
strategies	439 10 O
against	450 7 O
anemia	458 6 B-Disease
.	464 1 O

METHODS	466 7 O
:	473 1 O
Fourteen	475 8 O
patients	484 8 O
chronically	493 11 B-Disease
infected	505 8 I-Disease
with	514 4 I-Disease
hepatitis	519 9 I-Disease
C	529 1 I-Disease
virus	531 5 I-Disease
were	537 4 O
treated	542 7 O
by	550 2 O
pegylated	553 9 B-Chemical
interferon	563 10 I-Chemical
alpha	574 5 I-Chemical
2a	580 2 I-Chemical
and	583 3 O
ribavirin	587 9 B-Chemical
.	596 1 O

Serum	598 5 O
hemoglobin	604 10 O
,	614 1 O
haptoglobin	616 11 O
and	628 3 O
angiogenesis	632 12 O
markers	645 7 O
of	653 2 O
vascular	656 8 O
endothelial	665 11 O
growth	677 6 O
factor	684 6 O
and	691 3 O
angiopoetin	695 11 O
-	706 1 O
2	707 1 O
were	709 4 O
investigated	714 12 O
before	727 6 O
and	734 3 O
after	738 5 O
therapy	744 7 O
.	751 1 O

RESULTS	753 7 O
:	760 1 O
We	762 2 O
observed	765 8 O
a	774 1 O
significant	776 11 O
decrease	788 8 O
in	797 2 O
haptoglobin	800 11 O
levels	812 6 O
at	819 2 O
the	822 3 O
end	826 3 O
of	830 2 O
the	833 3 O
treatment	837 9 O
period	847 6 O
.	853 1 O

Hemoglobin	855 10 O
levels	866 6 O
also	873 4 O
decreased	878 9 O
but	888 3 O
insignificantly	892 15 O
by	908 2 O
treatment	911 9 O
.	920 1 O

In	922 2 O
contrast	925 8 O
with	934 4 O
the	939 3 O
literature	943 10 O
,	953 1 O
serum	955 5 O
levels	961 6 O
of	968 2 O
angiogenesis	971 12 O
factors	984 7 O
did	992 3 O
not	996 3 O
change	1000 6 O
significantly	1007 13 O
by	1021 2 O
pegylated	1024 9 B-Chemical
interferon	1034 10 I-Chemical
and	1045 3 O
ribavirin	1049 9 B-Chemical
therapy	1059 7 O
.	1066 1 O

We	1068 2 O
found	1071 5 O
no	1077 2 O
correlation	1080 11 O
of	1092 2 O
angiogenesis	1095 12 O
soluble	1108 7 O
markers	1116 7 O
with	1124 4 O
either	1129 6 O
hemoglobin	1136 10 O
or	1147 2 O
haptoglobin	1150 11 O
.	1161 1 O

CONCLUSION	1163 10 O
:	1173 1 O
This	1175 4 O
is	1180 2 O
the	1183 3 O
first	1187 5 O
study	1193 5 O
in	1199 2 O
the	1202 3 O
literature	1206 10 O
investigating	1217 13 O
a	1231 1 O
link	1233 4 O
between	1238 7 O
angiogenesis	1246 12 O
soluble	1259 7 O
markers	1267 7 O
and	1275 3 O
ribavirin	1279 9 B-Chemical
induced	1289 7 O
anemia	1297 6 B-Disease
in	1304 2 O
patients	1307 8 O
with	1316 4 O
hepatitis	1321 9 B-Disease
C	1331 1 I-Disease
and	1333 3 O
we	1337 2 O
could	1340 5 O
not	1346 3 O
find	1350 4 O
any	1355 3 O
relation	1359 8 O
.	1367 1 O

Future	1369 6 O
research	1376 8 O
with	1385 4 O
larger	1390 6 O
number	1397 6 O
of	1404 2 O
patients	1407 8 O
is	1416 2 O
needed	1419 6 O
to	1426 2 O
find	1429 4 O
out	1434 3 O
modifiable	1438 10 O
factors	1449 7 O
that	1457 4 O
will	1462 4 O
improve	1467 7 O
the	1475 3 O
safety	1479 6 O
of	1486 2 O
ribavirin	1489 9 B-Chemical
therapy	1499 7 O
.	1506 1 O

Cocaine	0 7 B-Chemical
causes	8 6 O
memory	15 6 B-Disease
and	22 3 I-Disease
learning	26 8 I-Disease
impairments	35 11 I-Disease
in	47 2 O
rats	50 4 O
:	54 1 O
involvement	56 11 O
of	68 2 O
nuclear	71 7 O
factor	79 6 O
kappa	86 5 O
B	92 1 O
and	94 3 O
oxidative	98 9 O
stress	108 6 O
,	114 1 O
and	116 3 O
prevention	120 10 O
by	131 2 O
topiramate	134 10 B-Chemical
.	144 1 O

Different	146 9 O
mechanisms	156 10 O
have	167 4 O
been	172 4 O
suggested	177 9 O
for	187 3 O
cocaine	191 7 B-Chemical
toxicity	199 8 B-Disease
including	208 9 O
an	218 2 O
increase	221 8 O
in	230 2 O
oxidative	233 9 O
stress	243 6 O
but	250 3 O
the	254 3 O
association	258 11 O
between	270 7 O
oxidative	278 9 O
status	288 6 O
in	295 2 O
the	298 3 O
brain	302 5 O
and	308 3 O
cocaine	312 7 B-Chemical
induced	320 7 O
-	327 1 O
behaviour	328 9 O
is	338 2 O
poorly	341 6 O
understood	348 10 O
.	358 1 O

Nuclear	360 7 O
factor	368 6 O
kappa	375 5 O
B	381 1 O
(	383 1 O
NFkappaB	384 8 O
)	392 1 O
is	394 2 O
a	397 1 O
sensor	399 6 O
of	406 2 O
oxidative	409 9 O
stress	419 6 O
and	426 3 O
participates	430 12 O
in	443 2 O
memory	446 6 O
formation	453 9 O
that	463 4 O
could	468 5 O
be	474 2 O
involved	477 8 O
in	486 2 O
drug	489 4 O
toxicity	494 8 B-Disease
and	503 3 O
addiction	507 9 O
mechanisms	517 10 O
.	527 1 O

Therefore	529 9 O
NFkappaB	539 8 O
activity	548 8 O
,	556 1 O
oxidative	558 9 O
stress	568 6 O
,	574 1 O
neuronal	576 8 O
nitric	585 6 B-Chemical
oxide	592 5 I-Chemical
synthase	598 8 O
(	607 1 O
nNOS	608 4 O
)	612 1 O
activity	614 8 O
,	622 1 O
spatial	624 7 O
learning	632 8 O
and	641 3 O
memory	645 6 O
as	652 2 O
well	655 4 O
as	660 2 O
the	663 3 O
effect	667 6 O
of	674 2 O
topiramate	677 10 B-Chemical
,	687 1 O
a	689 1 O
previously	691 10 O
proposed	702 8 O
therapy	711 7 O
for	719 3 O
cocaine	723 7 B-Disease
addiction	731 9 I-Disease
,	740 1 O
were	742 4 O
evaluated	747 9 O
in	757 2 O
an	760 2 O
experimental	763 12 O
model	776 5 O
of	782 2 O
cocaine	785 7 B-Chemical
administration	793 14 O
in	808 2 O
rats	811 4 O
.	815 1 O

NFkappaB	817 8 O
activity	826 8 O
was	835 3 O
decreased	839 9 O
in	849 2 O
the	852 3 O
frontal	856 7 O
cortex	864 6 O
of	871 2 O
cocaine	874 7 B-Chemical
treated	882 7 O
rats	890 4 O
,	894 1 O
as	896 2 O
well	899 4 O
as	904 2 O
GSH	907 3 B-Chemical
concentration	911 13 O
and	925 3 O
glutathione	929 11 B-Chemical
peroxidase	941 10 O
activity	952 8 O
in	961 2 O
the	964 3 O
hippocampus	968 11 O
,	979 1 O
whereas	981 7 O
nNOS	989 4 O
activity	994 8 O
in	1003 2 O
the	1006 3 O
hippocampus	1010 11 O
was	1022 3 O
increased	1026 9 O
.	1035 1 O

Memory	1037 6 O
retrieval	1044 9 O
of	1054 2 O
experiences	1057 11 O
acquired	1069 8 O
prior	1078 5 O
to	1084 2 O
cocaine	1087 7 B-Chemical
administration	1095 14 O
was	1110 3 O
impaired	1114 8 O
and	1123 3 O
negatively	1127 10 O
correlated	1138 10 O
with	1149 4 O
NFkappaB	1154 8 O
activity	1163 8 O
in	1172 2 O
the	1175 3 O
frontal	1179 7 O
cortex	1187 6 O
.	1193 1 O

In	1195 2 O
contrast	1198 8 O
,	1206 1 O
learning	1208 8 O
of	1217 2 O
new	1220 3 O
tasks	1224 5 O
was	1230 3 O
enhanced	1234 8 O
and	1243 3 O
correlated	1247 10 O
with	1258 4 O
the	1263 3 O
increase	1267 8 O
of	1276 2 O
nNOS	1279 4 O
activity	1284 8 O
and	1293 3 O
the	1297 3 O
decrease	1301 8 O
of	1310 2 O
glutathione	1313 11 B-Chemical
peroxidase	1325 10 O
.	1335 1 O

These	1337 5 O
results	1343 7 O
provide	1351 7 O
evidence	1359 8 O
for	1368 3 O
a	1372 1 O
possible	1374 8 O
mechanistic	1383 11 O
role	1395 4 O
of	1400 2 O
oxidative	1403 9 O
and	1413 3 O
nitrosative	1417 11 O
stress	1429 6 O
and	1436 3 O
NFkappaB	1440 8 O
in	1449 2 O
the	1452 3 O
alterations	1456 11 O
induced	1468 7 O
by	1476 2 O
cocaine	1479 7 B-Chemical
.	1486 1 O

Topiramate	1488 10 B-Chemical
prevented	1499 9 O
all	1509 3 O
the	1513 3 O
alterations	1517 11 O
observed	1529 8 O
,	1537 1 O
showing	1539 7 O
novel	1547 5 O
neuroprotective	1553 15 O
properties	1569 10 O
.	1579 1 O

Antinociceptive	0 15 O
and	16 3 O
antiamnesic	20 11 O
properties	32 10 O
of	43 2 O
the	46 3 O
presynaptic	50 11 O
cholinergic	62 11 O
amplifier	74 9 O
PG	84 2 B-Chemical
-	86 1 I-Chemical
9	87 1 I-Chemical
.	88 1 O

The	90 3 O
antinociceptive	94 15 O
effect	110 6 O
of	117 2 O
3	120 1 B-Chemical
alpha	122 5 I-Chemical
-	127 1 I-Chemical
tropyl	128 6 I-Chemical
2	135 1 I-Chemical
-	136 1 I-Chemical
(	137 1 I-Chemical
p	138 1 I-Chemical
-	139 1 I-Chemical
bromophenyl	140 11 I-Chemical
)	151 1 I-Chemical
propionate	152 10 I-Chemical
[	163 1 O
(	164 1 O
+	165 1 O
/	166 1 O
-	167 1 O
)	168 1 O
-	169 1 O
PG	170 2 B-Chemical
-	172 1 I-Chemical
9	173 1 I-Chemical
]	174 1 O
(	176 1 O
10	177 2 O
-	179 1 O
40	180 2 O
mg	183 2 O
kg	186 2 O
-	188 1 O
1	189 1 O
s	191 1 O
.	192 1 O
c	193 1 O
.	194 1 O
;	195 1 O
30	197 2 O
-	199 1 O
60	200 2 O
mg	203 2 O
kg	206 2 O
-	208 1 O
1	209 1 O
p	211 1 O
.	212 1 O
o	213 1 O
.	214 1 O
;	215 1 O
10	217 2 O
-	219 1 O
30	220 2 O
mg	223 2 O
kg	226 2 O
-	228 1 O
1	229 1 O
i	231 1 O
.	232 1 O
v	233 1 O
.	234 1 O
;	235 1 O
10	237 2 O
-	239 1 O
30	240 2 O
micrograms	243 10 O
/	253 1 O
mouse	254 5 O
i	260 1 O
.	261 1 O
c	262 1 O
.	263 1 O
v	264 1 O
.	265 1 O
)	266 1 O
was	268 3 O
examined	272 8 O
in	281 2 O
mice	284 4 O
,	288 1 O
rats	290 4 O
and	295 3 O
guinea	299 6 O
pigs	306 4 O
by	311 2 O
use	314 3 O
of	318 2 O
the	321 3 O
hot	325 3 O
-	328 1 O
plate	329 5 O
,	334 1 O
abdominal	336 9 O
-	345 1 O
constriction	346 12 O
,	358 1 O
tail	360 4 O
-	364 1 O
flick	365 5 O
and	371 3 O
paw	375 3 O
-	378 1 O
pressure	379 8 O
tests	388 5 O
.	393 1 O

(	395 1 O
+	396 1 O
/	397 1 O
-	398 1 O
)	399 1 O
-	400 1 O
PG	401 2 B-Chemical
-	403 1 I-Chemical
9	404 1 I-Chemical
antinociception	406 15 O
peaked	422 6 O
15	429 2 O
min	432 3 O
after	436 5 O
injection	442 9 O
and	452 3 O
then	456 4 O
slowly	461 6 O
diminished	468 10 O
.	478 1 O

The	480 3 O
antinociception	484 15 O
produced	500 8 O
by	509 2 O
(	512 1 O
+	513 1 O
/	514 1 O
-	515 1 O
)	516 1 O
-	517 1 O
PG	518 2 B-Chemical
-	520 1 I-Chemical
9	521 1 I-Chemical
was	523 3 O
prevented	527 9 O
by	537 2 O
the	540 3 O
unselective	544 11 O
muscarinic	556 10 O
antagonist	567 10 O
atropine	578 8 B-Chemical
,	586 1 O
the	588 3 O
M1	592 2 O
-	594 1 O
selective	595 9 O
antagonists	605 11 O
pirenzepine	617 11 B-Chemical
and	629 3 O
dicyclomine	633 11 B-Chemical
and	645 3 O
the	649 3 O
acetylcholine	653 13 B-Chemical
depletor	667 8 O
hemicholinium	676 13 B-Chemical
-	689 1 I-Chemical
3	690 1 I-Chemical
,	691 1 O
but	693 3 O
not	697 3 O
by	701 2 O
the	704 3 O
opioid	708 6 O
antagonist	715 10 O
naloxone	726 8 B-Chemical
,	734 1 O
the	736 3 O
gamma	740 5 B-Chemical
-	745 1 I-Chemical
aminobutyric	746 12 I-Chemical
acidB	759 5 I-Chemical
antagonist	765 10 O
3	776 1 B-Chemical
-	777 1 I-Chemical
aminopropyl	778 11 I-Chemical
-	789 1 I-Chemical
diethoxy	790 8 I-Chemical
-	798 1 I-Chemical
methyl	799 6 I-Chemical
-	805 1 I-Chemical
phosphinic	806 10 I-Chemical
acid	817 4 I-Chemical
,	821 1 O
the	823 3 O
H3	827 2 O
agonist	830 7 O
R	838 1 B-Chemical
-	839 1 I-Chemical
(	840 1 I-Chemical
alpha	841 5 I-Chemical
)	846 1 I-Chemical
-	847 1 I-Chemical
methylhistamine	848 15 I-Chemical
,	863 1 O
the	865 3 O
D2	869 2 O
antagonist	872 10 O
quinpirole	883 10 B-Chemical
,	893 1 O
the	895 3 O
5	899 1 B-Chemical
-	900 1 I-Chemical
hydroxytryptamine4	901 18 I-Chemical
antagonist	920 10 O
2	931 1 B-Chemical
-	932 1 I-Chemical
methoxy	933 7 I-Chemical
-	940 1 I-Chemical
4	941 1 I-Chemical
-	942 1 I-Chemical
amino	943 5 I-Chemical
-	948 1 I-Chemical
5	949 1 I-Chemical
-	950 1 I-Chemical
chlorobenzoic	951 13 I-Chemical
acid	965 4 I-Chemical
2	970 1 I-Chemical
-	971 1 I-Chemical
(	972 1 I-Chemical
diethylamino	973 12 I-Chemical
)	985 1 I-Chemical
ethyl	986 5 I-Chemical
ester	992 5 I-Chemical
hydrochloride	998 13 O
,	1011 1 O
the	1013 3 O
5	1017 1 B-Chemical
-	1018 1 I-Chemical
hydroxytryptamin1A	1019 18 I-Chemical
antagonist	1038 10 O
1	1049 1 B-Chemical
-	1050 1 I-Chemical
(	1051 1 I-Chemical
2	1052 1 I-Chemical
-	1053 1 I-Chemical
methoxyphenyl	1054 13 I-Chemical
)	1067 1 I-Chemical
-	1068 1 I-Chemical
4	1069 1 I-Chemical
-	1070 1 I-Chemical
[	1071 1 I-Chemical
4	1072 1 I-Chemical
-	1073 1 I-Chemical
(	1074 1 I-Chemical
2	1075 1 I-Chemical
-	1076 1 I-Chemical
phthalimido	1077 11 I-Chemical
)	1088 1 I-Chemical
butyl	1089 5 I-Chemical
]	1094 1 I-Chemical
piperazine	1095 10 I-Chemical
hydrobromide	1106 12 O
and	1119 3 O
the	1123 3 O
polyamines	1127 10 O
depletor	1138 8 O
reserpine	1147 9 B-Chemical
.	1156 1 O

Based	1158 5 O
on	1164 2 O
these	1167 5 O
data	1173 4 O
,	1177 1 O
it	1179 2 O
can	1182 3 O
be	1186 2 O
postulated	1189 10 O
that	1200 4 O
(	1205 1 O
+	1206 1 O
/	1207 1 O
-	1208 1 O
)	1209 1 O
-	1210 1 O
PG	1211 2 B-Chemical
-	1213 1 I-Chemical
9	1214 1 I-Chemical
exerted	1216 7 O
an	1224 2 O
antinociceptive	1227 15 O
effect	1243 6 O
mediated	1250 8 O
by	1259 2 O
a	1262 1 O
central	1264 7 O
potentiation	1272 12 O
of	1285 2 O
cholinergic	1288 11 O
transmission	1300 12 O
.	1312 1 O

(	1314 1 O
+	1315 1 O
/	1316 1 O
-	1317 1 O
)	1318 1 O
-	1319 1 O
PG	1320 2 B-Chemical
-	1322 1 I-Chemical
9	1323 1 I-Chemical
(	1325 1 O
10	1326 2 O
-	1328 1 O
40	1329 2 O
mg	1332 2 O
kg	1335 2 O
-	1337 1 O
1	1338 1 O
i	1340 1 O
.	1341 1 O
p	1342 1 O
.	1343 1 O
)	1344 1 O
was	1346 3 O
able	1350 4 O
to	1355 2 O
prevent	1358 7 O
amnesia	1366 7 B-Disease
induced	1374 7 O
by	1382 2 O
scopolamine	1385 11 B-Chemical
(	1397 1 O
1	1398 1 O
mg	1400 2 O
kg	1403 2 O
-	1405 1 O
1	1406 1 O
i	1408 1 O
.	1409 1 O
p	1410 1 O
.	1411 1 O
)	1412 1 O
and	1414 3 O
dicyclomine	1418 11 B-Chemical
(	1430 1 O
2	1431 1 O
mg	1433 2 O
kg	1436 2 O
-	1438 1 O
1	1439 1 O
i	1441 1 O
.	1442 1 O
p	1443 1 O
.	1444 1 O
)	1445 1 O
in	1447 2 O
the	1450 3 O
mouse	1454 5 O
passive	1460 7 O
-	1467 1 O
avoidance	1468 9 O
test	1478 4 O
.	1482 1 O

Affinity	1484 8 O
profiles	1493 8 O
of	1502 2 O
(	1505 1 O
+	1506 1 O
/	1507 1 O
-	1508 1 O
)	1509 1 O
-	1510 1 O
PG	1511 2 B-Chemical
-	1513 1 I-Chemical
9	1514 1 I-Chemical
for	1516 3 O
muscarinic	1520 10 O
receptor	1531 8 O
subtypes	1540 8 O
,	1548 1 O
determined	1550 10 O
by	1561 2 O
functional	1564 10 O
studies	1575 7 O
(	1583 1 O
rabbit	1584 6 O
vas	1591 3 O
deferens	1595 8 O
for	1604 3 O
M1	1608 2 O
,	1610 1 O
guinea	1612 6 O
pig	1619 3 O
atrium	1623 6 O
for	1630 3 O
M2	1634 2 O
,	1636 1 O
guinea	1638 6 O
pig	1645 3 O
ileum	1649 5 O
for	1655 3 O
M3	1659 2 O
and	1662 3 O
immature	1666 8 O
guinea	1675 6 O
pig	1682 3 O
uterus	1686 6 O
for	1693 3 O
putative	1697 8 O
M4	1706 2 O
)	1708 1 O
,	1709 1 O
have	1711 4 O
shown	1716 5 O
an	1722 2 O
M4	1725 2 O
/	1727 1 O
M1	1728 2 O
selectivity	1731 11 O
ratio	1743 5 O
of	1749 2 O
10	1752 2 O
.	1754 1 O
2	1755 1 O
that	1757 4 O
might	1762 5 O
be	1768 2 O
responsible	1771 11 O
for	1783 3 O
the	1787 3 O
antinociception	1791 15 O
and	1807 3 O
the	1811 3 O
anti	1815 4 O
-	1819 1 O
amnesic	1820 7 B-Disease
effect	1828 6 O
induced	1835 7 O
by	1843 2 O
(	1846 1 O
+	1847 1 O
/	1848 1 O
-	1849 1 O
)	1850 1 O
-	1851 1 O
PG	1852 2 B-Chemical
-	1854 1 I-Chemical
9	1855 1 I-Chemical
through	1857 7 O
an	1865 2 O
increase	1868 8 O
in	1877 2 O
acetylcholine	1880 13 B-Chemical
extracellular	1894 13 O
levels	1908 6 O
.	1914 1 O

In	1916 2 O
the	1919 3 O
antinociceptive	1923 15 O
and	1939 3 O
antiamnesic	1943 11 O
dose	1955 4 O
range	1960 5 O
,	1965 1 O
(	1967 1 O
+	1968 1 O
/	1969 1 O
-	1970 1 O
)	1971 1 O
-	1972 1 O
PG	1973 2 B-Chemical
-	1975 1 I-Chemical
9	1976 1 I-Chemical
did	1978 3 O
not	1982 3 O
impair	1986 6 O
mouse	1993 5 O
performance	1999 11 O
evaluated	2011 9 O
by	2021 2 O
the	2024 3 O
rota	2028 4 O
-	2032 1 O
rod	2033 3 O
test	2037 4 O
and	2042 3 O
Animex	2046 6 O
apparatus	2053 9 O
.	2062 1 O

Hyperbaric	0 10 O
oxygen	11 6 B-Chemical
therapy	18 7 O
for	26 3 O
control	30 7 O
of	38 2 O
intractable	41 11 O
cyclophosphamide	53 16 B-Chemical
-	69 1 O
induced	70 7 O
hemorrhagic	78 11 B-Disease
cystitis	90 8 I-Disease
.	98 1 O

We	100 2 O
report	103 6 O
a	110 1 O
case	112 4 O
of	117 2 O
intractable	120 11 O
hemorrhagic	132 11 B-Disease
cystitis	144 8 I-Disease
due	153 3 O
to	157 2 O
cyclophosphamide	160 16 B-Chemical
therapy	177 7 O
for	185 3 O
Wegener	189 7 B-Disease
'	196 1 I-Disease
s	197 1 I-Disease
granulomatosis	199 14 I-Disease
.	213 1 O

Conservative	215 12 O
treatment	228 9 O
,	237 1 O
including	239 9 O
bladder	249 7 O
irrigation	257 10 O
with	268 4 O
physiological	273 13 O
saline	287 6 O
and	294 3 O
instillation	298 12 O
of	311 2 O
prostaglandin	314 13 B-Chemical
F2	328 2 I-Chemical
alpha	331 5 I-Chemical
,	336 1 O
failed	338 6 O
to	345 2 O
totally	348 7 O
control	356 7 O
hemorrhage	364 10 B-Disease
.	374 1 O

We	376 2 O
then	379 4 O
used	384 4 O
hyperbaric	389 10 O
oxygen	400 6 B-Chemical
at	407 2 O
an	410 2 O
absolute	413 8 O
pressure	422 8 O
of	431 2 O
2	434 1 O
atm	436 3 O
,	439 1 O
5	441 1 O
days	443 4 O
a	448 1 O
week	450 4 O
for	455 3 O
8	459 1 O
consecutive	461 11 O
weeks	473 5 O
.	478 1 O

The	480 3 O
bleeding	484 8 B-Disease
ceased	493 6 O
completely	500 10 O
by	511 2 O
the	514 3 O
end	518 3 O
of	522 2 O
treatment	525 9 O
and	535 3 O
the	539 3 O
patient	543 7 O
remained	551 8 O
free	560 4 O
of	565 2 O
hematuria	568 9 B-Disease
thereafter	578 10 O
.	588 1 O

No	590 2 O
side	593 4 O
effect	598 6 O
was	605 3 O
noted	609 5 O
during	615 6 O
the	622 3 O
course	626 6 O
of	633 2 O
therapy	636 7 O
.	643 1 O

In	645 2 O
future	648 6 O
,	654 1 O
this	656 4 O
form	661 4 O
of	666 2 O
therapy	669 7 O
can	677 3 O
offer	681 5 O
a	687 1 O
safe	689 4 O
alternative	694 11 O
in	706 2 O
the	709 3 O
treatment	713 9 O
of	723 2 O
cyclophosphamide	726 16 B-Chemical
-	742 1 O
induced	743 7 O
hemorrhagic	751 11 B-Disease
cystitis	763 8 I-Disease
.	771 1 O

Further	0 7 O
studies	8 7 O
on	16 2 O
effects	19 7 O
of	27 2 O
irrigation	30 10 O
solutions	41 9 O
on	51 2 O
rat	54 3 O
bladders	58 8 O
.	66 1 O

Further	68 7 O
studies	76 7 O
on	84 2 O
the	87 3 O
effects	91 7 O
of	99 2 O
certain	102 7 O
irrigating	110 10 O
fluids	121 6 O
on	128 2 O
the	131 3 O
rat	135 3 O
bladder	139 7 O
for	147 3 O
18	151 2 O
hours	154 5 O
are	160 3 O
reported	164 8 O
.	172 1 O

The	174 3 O
results	178 7 O
have	186 4 O
shown	191 5 O
that	197 4 O
the	202 3 O
degradation	206 11 O
product	218 7 O
p	226 1 B-Chemical
-	227 1 I-Chemical
choloroaniline	228 14 I-Chemical
is	243 2 O
not	246 3 O
a	250 1 O
significant	252 11 O
factor	264 6 O
in	271 2 O
chlorhexidine	274 13 B-Chemical
-	287 1 I-Chemical
digluconate	288 11 I-Chemical
associated	300 10 O
erosive	311 7 O
cystitis	319 8 B-Disease
.	327 1 O

A	329 1 O
high	331 4 O
percentage	336 10 O
of	347 2 O
kanamycin	350 9 B-Chemical
-	359 1 O
colistin	360 8 B-Chemical
and	369 3 O
povidone	373 8 B-Chemical
-	381 1 I-Chemical
iodine	382 6 I-Chemical
irrigations	389 11 O
were	401 4 O
associated	406 10 O
with	417 4 O
erosive	422 7 O
cystitis	430 8 B-Disease
and	439 3 O
suggested	443 9 O
a	453 1 O
possible	455 8 O
complication	464 12 O
with	477 4 O
human	482 5 O
usage	488 5 O
.	493 1 O

Picloxydine	495 11 B-Chemical
irrigations	507 11 O
appeared	519 8 O
to	528 2 O
have	531 4 O
a	536 1 O
lower	538 5 O
incidence	544 9 O
of	554 2 O
erosive	557 7 O
cystitis	565 8 B-Disease
but	574 3 O
further	578 7 O
studies	586 7 O
would	594 5 O
have	600 4 O
to	605 2 O
be	608 2 O
performed	611 9 O
before	621 6 O
it	628 2 O
could	631 5 O
be	637 2 O
recommended	640 11 O
for	652 3 O
use	656 3 O
in	660 2 O
urological	663 10 O
procedures	674 10 O
.	684 1 O

Clinical	0 8 O
experiences	9 11 O
in	21 2 O
an	24 2 O
open	27 4 O
and	32 3 O
a	36 1 O
double	38 6 O
-	44 1 O
blind	45 5 O
trial	51 5 O
.	56 1 O

A	58 1 O
total	60 5 O
of	66 2 O
sixty	69 5 O
patients	75 8 O
were	84 4 O
trated	89 6 O
with	96 4 O
bromperidol	101 11 B-Chemical
first	113 5 O
in	119 2 O
open	122 4 O
conditions	127 10 O
(	138 1 O
20	139 2 O
patients	142 8 O
)	150 1 O
,	151 1 O
then	153 4 O
on	158 2 O
a	161 1 O
double	163 6 O
blind	170 5 O
basis	176 5 O
(	182 1 O
40	183 2 O
patients	186 8 O
)	194 1 O
with	196 4 O
haloperidol	201 11 B-Chemical
as	213 2 O
the	216 3 O
reference	220 9 O
substance	230 9 O
.	239 1 O

The	241 3 O
open	245 4 O
study	250 5 O
lasted	256 6 O
for	263 3 O
four	267 4 O
weeks	272 5 O
;	277 1 O
the	279 3 O
drug	283 4 O
was	288 3 O
administrated	292 13 O
in	306 2 O
the	309 3 O
form	313 4 O
of	318 2 O
1	321 1 O
mg	323 2 O
tablets	326 7 O
.	333 1 O

The	335 3 O
daily	339 5 O
dose	345 4 O
(	350 1 O
initial	351 7 O
dose	359 4 O
:	363 1 O
1	365 1 O
mg	367 2 O
;	369 1 O
mean	371 4 O
dose	376 4 O
at	381 2 O
the	384 3 O
end	388 3 O
of	392 2 O
the	395 3 O
trial	399 5 O
:	404 1 O
4	406 1 O
.	407 1 O
47	408 2 O
mg	411 2 O
)	413 1 O
was	415 3 O
always	419 6 O
administered	426 12 O
in	439 2 O
one	442 3 O
single	446 6 O
dose	453 4 O
.	457 1 O

Nineteen	459 8 O
patients	468 8 O
finished	477 8 O
the	486 3 O
trial	490 5 O
,	495 1 O
and	497 3 O
in	501 2 O
18	504 2 O
cases	507 5 O
the	513 3 O
therapeutic	517 11 O
result	529 6 O
was	536 3 O
considered	540 10 O
very	551 4 O
good	556 4 O
to	561 2 O
good	564 4 O
.	568 1 O

These	570 5 O
results	576 7 O
were	584 4 O
confirmed	589 9 O
by	599 2 O
statistical	602 11 O
analysis	614 8 O
.	622 1 O

Nine	624 4 O
patients	629 8 O
exhibited	638 9 O
mild	648 4 O
to	653 2 O
moderate	656 8 O
extrapyramidal	665 14 B-Disease
concomitant	680 11 I-Disease
symptoms	692 8 I-Disease
;	700 1 O
no	702 2 O
other	705 5 O
side	711 4 O
effects	716 7 O
were	724 4 O
observed	729 8 O
.	737 1 O

The	739 3 O
results	743 7 O
of	751 2 O
detailed	754 8 O
laboratory	763 10 O
tests	774 5 O
and	780 3 O
evaluations	784 11 O
of	796 2 O
various	799 7 O
quantitative	807 12 O
and	820 3 O
qualitative	824 11 O
tolerability	836 12 O
parameters	849 10 O
were	860 4 O
not	865 3 O
indicative	869 10 O
of	880 2 O
toxic	883 5 O
effects	889 7 O
.	896 1 O

In	898 2 O
the	901 3 O
double	905 6 O
blind	912 5 O
study	918 5 O
with	924 4 O
haloperidol	929 11 B-Chemical
,	940 1 O
both	942 4 O
substances	947 10 O
were	958 4 O
found	963 5 O
to	969 2 O
be	972 2 O
highly	975 6 O
effective	982 9 O
in	992 2 O
the	995 3 O
treatment	999 9 O
of	1009 2 O
psychotic	1012 9 B-Disease
syndromes	1022 9 I-Disease
belonging	1032 9 I-Disease
predominantly	1042 13 I-Disease
to	1056 2 I-Disease
the	1059 3 I-Disease
schizophrenia	1063 13 I-Disease
group	1077 5 I-Disease
.	1082 1 O

Certain	1084 7 O
clues	1092 5 O
,	1097 1 O
including	1099 9 O
the	1109 3 O
onset	1113 5 O
of	1119 2 O
action	1122 6 O
,	1128 1 O
seem	1130 4 O
to	1135 2 O
be	1138 2 O
indicative	1141 10 O
of	1152 2 O
the	1155 3 O
superiority	1159 11 O
of	1171 2 O
bromperidol	1174 11 B-Chemical
.	1185 1 O

No	1187 2 O
differences	1190 11 O
were	1202 4 O
observed	1207 8 O
with	1216 4 O
respect	1221 7 O
to	1229 2 O
side	1232 4 O
effects	1237 7 O
and	1245 3 O
general	1249 7 O
tolerability	1257 12 O
.	1269 1 O

Curcumin	0 8 B-Chemical
ameliorates	9 11 O
cognitive	21 9 B-Disease
dysfunction	31 11 I-Disease
and	43 3 O
oxidative	47 9 O
damage	57 6 O
in	64 2 O
phenobarbitone	67 14 B-Chemical
and	82 3 O
carbamazepine	86 13 B-Chemical
administered	100 12 O
rats	113 4 O
.	117 1 O

The	119 3 O
antiepileptic	123 13 O
drugs	137 5 O
,	142 1 O
phenobarbitone	144 14 B-Chemical
and	159 3 O
carbamazepine	163 13 B-Chemical
are	177 3 O
well	181 4 O
known	186 5 O
to	192 2 O
cause	195 5 O
cognitive	201 9 B-Disease
impairment	211 10 I-Disease
on	222 2 O
chronic	225 7 O
use	233 3 O
.	236 1 O

The	238 3 O
increase	242 8 O
in	251 2 O
free	254 4 O
radical	259 7 O
generation	267 10 O
has	278 3 O
been	282 4 O
implicated	287 10 O
as	298 2 O
one	301 3 O
of	305 2 O
the	308 3 O
important	312 9 O
mechanisms	322 10 O
of	333 2 O
cognitive	336 9 B-Disease
impairment	346 10 I-Disease
by	357 2 O
antiepileptic	360 13 O
drugs	374 5 O
.	379 1 O

Curcumin	381 8 B-Chemical
has	390 3 O
shown	394 5 O
antioxidant	400 11 O
,	411 1 O
anti	413 4 O
-	417 1 O
inflammatory	418 12 O
and	431 3 O
neuro	435 5 O
-	440 1 O
protective	441 10 O
properties	452 10 O
.	462 1 O

Therefore	464 9 O
,	473 1 O
the	475 3 O
present	479 7 O
study	487 5 O
was	493 3 O
carried	497 7 O
out	505 3 O
to	509 2 O
investigate	512 11 O
the	524 3 O
effect	528 6 O
of	535 2 O
chronic	538 7 O
curcumin	546 8 B-Chemical
administration	555 14 O
on	570 2 O
phenobarbitone	573 14 B-Chemical
-	587 1 O
and	589 3 O
carbamazepine	593 13 B-Chemical
-	606 1 O
induced	607 7 O
cognitive	615 9 B-Disease
impairment	625 10 I-Disease
and	636 3 O
oxidative	640 9 O
stress	650 6 O
in	657 2 O
rats	660 4 O
.	664 1 O

Pharmacokinetic	666 15 O
interactions	682 12 O
of	695 2 O
curcumin	698 8 B-Chemical
with	707 4 O
phenobarbitone	712 14 B-Chemical
and	727 3 O
carbamazepine	731 13 B-Chemical
were	745 4 O
also	750 4 O
studied	755 7 O
.	762 1 O

Vehicle	764 7 O
/	771 1 O
drugs	772 5 O
were	778 4 O
administered	783 12 O
daily	796 5 O
for	802 3 O
21days	806 6 O
to	813 2 O
male	816 4 O
Wistar	821 6 O
rats	828 4 O
.	832 1 O

Passive	834 7 O
avoidance	842 9 O
paradigm	852 8 O
and	861 3 O
elevated	865 8 O
plus	874 4 O
maze	879 4 O
test	884 4 O
were	889 4 O
used	894 4 O
to	899 2 O
assess	902 6 O
cognitive	909 9 O
function	919 8 O
.	927 1 O

At	929 2 O
the	932 3 O
end	936 3 O
of	940 2 O
study	943 5 O
period	949 6 O
,	955 1 O
serum	957 5 O
phenobarbitone	963 14 B-Chemical
and	978 3 O
carbamazepine	982 13 B-Chemical
,	995 1 O
whole	997 5 O
brain	1003 5 O
malondialdehyde	1009 15 B-Chemical
and	1025 3 O
reduced	1029 7 O
glutathione	1037 11 B-Chemical
levels	1049 6 O
were	1056 4 O
estimated	1061 9 O
.	1070 1 O

The	1072 3 O
administration	1076 14 O
of	1091 2 O
phenobarbitone	1094 14 B-Chemical
and	1109 3 O
carbamazepine	1113 13 B-Chemical
for	1127 3 O
21days	1131 6 O
caused	1138 6 O
a	1145 1 O
significant	1147 11 O
impairment	1159 10 B-Disease
of	1170 2 I-Disease
learning	1173 8 I-Disease
and	1182 3 I-Disease
memory	1186 6 I-Disease
as	1193 2 O
well	1196 4 O
as	1201 2 O
an	1204 2 O
increased	1207 9 O
oxidative	1217 9 O
stress	1227 6 O
.	1233 1 O

Concomitant	1235 11 O
curcumin	1247 8 B-Chemical
administration	1256 14 O
prevented	1271 9 O
the	1281 3 O
cognitive	1285 9 B-Disease
impairment	1295 10 I-Disease
and	1306 3 O
decreased	1310 9 O
the	1320 3 O
increased	1324 9 O
oxidative	1334 9 O
stress	1344 6 O
induced	1351 7 O
by	1359 2 O
these	1362 5 O
antiepileptic	1368 13 O
drugs	1382 5 O
.	1387 1 O

Curcumin	1389 8 B-Chemical
co	1398 2 O
-	1400 1 O
administration	1401 14 O
did	1416 3 O
not	1420 3 O
cause	1424 5 O
any	1430 3 O
significant	1434 11 O
alteration	1446 10 O
in	1457 2 O
the	1460 3 O
serum	1464 5 O
concentrations	1470 14 O
of	1485 2 O
both	1488 4 O
phenobarbitone	1493 14 B-Chemical
as	1508 2 O
well	1511 4 O
as	1516 2 O
carbamazepine	1519 13 B-Chemical
.	1532 1 O

These	1534 5 O
results	1540 7 O
show	1548 4 O
that	1553 4 O
curcumin	1558 8 B-Chemical
has	1567 3 O
beneficial	1571 10 O
effect	1582 6 O
in	1589 2 O
mitigating	1592 10 O
the	1603 3 O
deterioration	1607 13 B-Disease
of	1621 2 I-Disease
cognitive	1624 9 I-Disease
functions	1634 9 I-Disease
and	1644 3 O
oxidative	1648 9 O
damage	1658 6 O
in	1665 2 O
rats	1668 4 O
treated	1673 7 O
with	1681 4 O
phenobarbitone	1686 14 B-Chemical
and	1701 3 O
carbamazepine	1705 13 B-Chemical
without	1719 7 O
significantly	1727 13 O
altering	1741 8 O
their	1750 5 O
serum	1756 5 O
concentrations	1762 14 O
.	1776 1 O

The	1778 3 O
findings	1782 8 O
suggest	1791 7 O
that	1799 4 O
curcumin	1804 8 B-Chemical
can	1813 3 O
be	1817 2 O
considered	1820 10 O
as	1831 2 O
a	1834 1 O
potential	1836 9 O
safe	1846 4 O
and	1851 3 O
effective	1855 9 O
adjuvant	1865 8 O
to	1874 2 O
phenobarbitone	1877 14 B-Chemical
and	1892 3 O
carbamazepine	1896 13 B-Chemical
therapy	1910 7 O
in	1918 2 O
preventing	1921 10 O
cognitive	1932 9 B-Disease
impairment	1942 10 I-Disease
associated	1953 10 O
with	1964 4 O
these	1969 5 O
drugs	1975 5 O
.	1980 1 O

Pyrrolidine	0 11 B-Chemical
dithiocarbamate	12 15 I-Chemical
protects	28 8 O
the	37 3 O
piriform	41 8 O
cortex	50 6 O
in	57 2 O
the	60 3 O
pilocarpine	64 11 B-Chemical
status	76 6 B-Disease
epilepticus	83 11 I-Disease
model	95 5 O
.	100 1 O

Pyrrolidine	102 11 B-Chemical
dithiocarbamate	114 15 I-Chemical
(	130 1 O
PDTC	131 4 B-Chemical
)	135 1 O
has	137 3 O
a	141 1 O
dual	143 4 O
mechanism	148 9 O
of	158 2 O
action	161 6 O
as	168 2 O
an	171 2 O
antioxidant	174 11 O
and	186 3 O
an	190 2 O
inhibitor	193 9 O
of	203 2 O
the	206 3 O
transcription	210 13 O
factor	224 6 O
kappa	231 5 O
-	236 1 O
beta	237 4 O
.	241 1 O

Both	243 4 O
,	247 1 O
production	249 10 O
of	260 2 O
reactive	263 8 O
oxygen	272 6 B-Chemical
species	279 7 O
as	287 2 O
well	290 4 O
as	295 2 O
activation	298 10 O
of	309 2 O
NF	312 2 O
-	314 1 O
kappaB	315 6 O
have	322 4 O
been	327 4 O
implicated	332 10 O
in	343 2 O
severe	346 6 O
neuronal	353 8 B-Disease
damage	362 6 I-Disease
in	369 2 O
different	372 9 O
sub	382 3 O
-	385 1 O
regions	386 7 O
of	394 2 O
the	397 3 O
hippocampus	401 11 O
as	413 2 O
well	416 4 O
as	421 2 O
in	424 2 O
the	427 3 O
surrounding	431 11 O
cortices	443 8 O
.	451 1 O

The	453 3 O
effect	457 6 O
of	464 2 O
PDTC	467 4 B-Chemical
on	472 2 O
status	475 6 B-Disease
epilepticus	482 11 I-Disease
-	493 1 O
associated	494 10 O
cell	505 4 O
loss	510 4 O
in	515 2 O
the	518 3 O
hippocampus	522 11 O
and	534 3 O
piriform	538 8 O
cortex	547 6 O
was	554 3 O
evaluated	558 9 O
in	568 2 O
the	571 3 O
rat	575 3 O
fractionated	579 12 O
pilocarpine	592 11 B-Chemical
model	604 5 O
.	609 1 O

Treatment	611 9 O
with	621 4 O
150	626 3 O
mg	630 2 O
/	632 1 O
kg	633 2 O
PDTC	636 4 B-Chemical
before	641 6 O
and	648 3 O
following	652 9 O
status	662 6 B-Disease
epilepticus	669 11 I-Disease
significantly	681 13 O
increased	695 9 O
the	705 3 O
mortality	709 9 O
rate	719 4 O
to	724 2 O
100	727 3 O
%	730 1 O
.	731 1 O

Administration	733 14 O
of	748 2 O
50	751 2 O
mg	754 2 O
/	756 1 O
kg	757 2 O
PDTC	760 4 B-Chemical
(	765 1 O
low	766 3 O
-	769 1 O
dose	770 4 O
)	774 1 O
did	776 3 O
not	780 3 O
exert	784 5 O
major	790 5 O
effects	796 7 O
on	804 2 O
the	807 3 O
development	811 11 O
of	823 2 O
a	826 1 O
status	828 6 B-Disease
epilepticus	835 11 I-Disease
or	847 2 O
the	850 3 O
mortality	854 9 O
rate	864 4 O
.	868 1 O

In	870 2 O
vehicle	873 7 O
-	880 1 O
treated	881 7 O
rats	889 4 O
,	893 1 O
status	895 6 B-Disease
epilepticus	902 11 I-Disease
caused	914 6 O
pronounced	921 10 O
neuronal	932 8 B-Disease
damage	941 6 I-Disease
in	948 2 O
the	951 3 O
piriform	955 8 O
cortex	964 6 O
comprising	971 10 O
both	982 4 O
pyramidal	987 9 O
cells	997 5 O
and	1003 3 O
interneurons	1007 12 O
.	1019 1 O

Low	1021 3 O
-	1024 1 O
dose	1025 4 O
PDTC	1030 4 B-Chemical
treatment	1035 9 O
almost	1045 6 O
completely	1052 10 O
protected	1063 9 O
from	1073 4 O
lesions	1078 7 O
in	1086 2 O
the	1089 3 O
piriform	1093 8 O
cortex	1102 6 O
.	1108 1 O

A	1110 1 O
significant	1112 11 O
decrease	1124 8 O
in	1133 2 O
neuronal	1136 8 O
density	1145 7 O
of	1153 2 O
the	1156 3 O
hippocampal	1160 11 O
hilar	1172 5 O
formation	1178 9 O
was	1188 3 O
identified	1192 10 O
in	1203 2 O
vehicle	1206 7 O
-	1213 1 O
and	1215 3 O
PDTC	1219 4 B-Chemical
-	1223 1 O
treated	1224 7 O
rats	1232 4 O
following	1237 9 O
status	1247 6 B-Disease
epilepticus	1254 11 I-Disease
.	1265 1 O

In	1267 2 O
conclusion	1270 10 O
,	1280 1 O
the	1282 3 O
NF	1286 2 O
-	1288 1 O
kappaB	1289 6 O
inhibitor	1296 9 O
and	1306 3 O
antioxidant	1310 11 O
PDTC	1322 4 B-Chemical
protected	1327 9 O
the	1337 3 O
piriform	1341 8 O
cortex	1350 6 O
,	1356 1 O
whereas	1358 7 O
it	1366 2 O
did	1369 3 O
not	1373 3 O
affect	1377 6 O
hilar	1384 5 O
neuronal	1390 8 B-Disease
loss	1399 4 I-Disease
.	1403 1 O

These	1405 5 O
data	1411 4 O
might	1416 5 O
indicate	1422 8 O
that	1431 4 O
the	1436 3 O
generation	1440 10 O
of	1451 2 O
reactive	1454 8 O
oxygen	1463 6 B-Chemical
species	1470 7 O
and	1478 3 O
activation	1482 10 O
of	1493 2 O
NF	1496 2 O
-	1498 1 O
kappaB	1499 6 O
plays	1506 5 O
a	1512 1 O
more	1514 4 O
central	1519 7 O
role	1527 4 O
in	1532 2 O
seizure	1535 7 B-Disease
-	1542 1 O
associated	1543 10 O
neuronal	1554 8 B-Disease
damage	1563 6 I-Disease
in	1570 2 O
the	1573 3 O
temporal	1577 8 O
cortex	1586 6 O
as	1593 2 O
compared	1596 8 O
to	1605 2 O
the	1608 3 O
hippocampal	1612 11 O
hilus	1624 5 O
.	1629 1 O

However	1631 7 O
,	1638 1 O
future	1640 6 O
investigations	1647 14 O
are	1662 3 O
necessary	1666 9 O
to	1676 2 O
exactly	1679 7 O
analyze	1687 7 O
the	1695 3 O
biochemical	1699 11 O
mechanisms	1711 10 O
by	1722 2 O
which	1725 5 O
PDTC	1731 4 B-Chemical
exerted	1736 7 O
its	1744 3 O
beneficial	1748 10 O
effects	1759 7 O
in	1767 2 O
the	1770 3 O
piriform	1774 8 O
cortex	1783 6 O
.	1789 1 O

Safety	0 6 O
profile	7 7 O
of	15 2 O
a	18 1 O
nicotine	20 8 B-Chemical
lozenge	29 7 O
compared	37 8 O
with	46 4 O
that	51 4 O
of	56 2 O
nicotine	59 8 B-Chemical
gum	68 3 O
in	72 2 O
adult	75 5 O
smokers	81 7 O
with	89 4 O
underlying	94 10 O
medical	105 7 O
conditions	113 10 O
:	123 1 O
a	125 1 O
12	127 2 O
-	129 1 O
week	130 4 O
,	134 1 O
randomized	136 10 O
,	146 1 O
open	148 4 O
-	152 1 O
label	153 5 O
study	159 5 O
.	164 1 O

BACKGROUND	166 10 O
:	176 1 O
Nicotine	178 8 B-Chemical
polacrilex	187 10 O
lozenges	198 8 O
deliver	207 7 O
25	215 2 O
%	217 1 O
to	219 2 O
27	222 2 O
%	224 1 O
more	226 4 O
nicotine	231 8 B-Chemical
compared	240 8 O
with	249 4 O
equivalent	254 10 O
doses	265 5 O
of	271 2 O
nicotine	274 8 B-Chemical
polacrilex	283 10 O
gum	294 3 O
.	297 1 O

The	299 3 O
increased	303 9 O
nicotine	313 8 B-Chemical
exposure	322 8 O
from	331 4 O
the	336 3 O
lozenge	340 7 O
has	348 3 O
raised	352 6 O
questions	359 9 O
about	369 5 O
the	375 3 O
relative	379 8 O
safety	388 6 O
of	395 2 O
the	398 3 O
lozenge	402 7 O
and	410 3 O
gum	414 3 O
.	417 1 O

OBJECTIVE	419 9 O
:	428 1 O
The	430 3 O
objective	434 9 O
of	444 2 O
this	447 4 O
study	452 5 O
was	458 3 O
to	462 2 O
compare	465 7 O
the	473 3 O
safety	477 6 O
profiles	484 8 O
of	493 2 O
the	496 3 O
4	500 1 O
-	501 1 O
mg	502 2 O
nicotine	505 8 B-Chemical
lozenge	514 7 O
and	522 3 O
4	526 1 O
-	527 1 O
mg	528 2 O
nicotine	531 8 B-Chemical
gum	540 3 O
in	544 2 O
smokers	547 7 O
with	555 4 O
selected	560 8 O
label	569 5 O
-	574 1 O
restricted	575 10 O
diseases	586 8 O
.	594 1 O

METHODS	596 7 O
:	603 1 O
This	605 4 O
was	610 3 O
a	614 1 O
multicenter	616 11 O
,	627 1 O
randomized	629 10 O
,	639 1 O
open	641 4 O
-	645 1 O
label	646 5 O
study	652 5 O
in	658 2 O
adult	661 5 O
smokers	667 7 O
with	675 4 O
heart	680 5 B-Disease
disease	686 7 I-Disease
,	693 1 O
hypertension	695 12 B-Disease
not	708 3 O
controlled	712 10 O
by	723 2 O
medication	726 10 O
,	736 1 O
and	738 3 O
/	741 1 O
or	742 2 O
diabetes	745 8 B-Disease
mellitus	754 8 I-Disease
.	762 1 O

Patients	764 8 O
were	773 4 O
randomized	778 10 O
in	789 2 O
a	792 1 O
1	794 1 O
:	795 1 O
1	796 1 O
ratio	798 5 O
to	804 2 O
receive	807 7 O
the	815 3 O
4	819 1 O
-	820 1 O
mg	821 2 O
nicotine	824 8 B-Chemical
lozenge	833 7 O
or	841 2 O
4	844 1 O
-	845 1 O
mg	846 2 O
nicotine	849 8 B-Chemical
gum	858 3 O
.	861 1 O

Safety	863 6 O
assessments	870 11 O
were	882 4 O
made	887 4 O
at	892 2 O
baseline	895 8 O
and	904 3 O
at	908 2 O
2	911 1 O
,	912 1 O
4	914 1 O
,	915 1 O
6	917 1 O
,	918 1 O
and	920 3 O
12	924 2 O
weeks	927 5 O
after	933 5 O
the	939 3 O
start	943 5 O
of	949 2 O
product	952 7 O
use	960 3 O
.	963 1 O

RESULTS	965 7 O
:	972 1 O
Nine	974 4 O
hundred	979 7 O
one	987 3 O
patients	991 8 O
were	1000 4 O
randomized	1005 10 O
to	1016 2 O
treatment	1019 9 O
,	1028 1 O
447	1030 3 O
who	1034 3 O
received	1038 8 O
the	1047 3 O
lozenge	1051 7 O
and	1059 3 O
454	1063 3 O
who	1067 3 O
received	1071 8 O
the	1080 3 O
gum	1084 3 O
(	1088 1 O
safety	1089 6 O
population	1096 10 O
)	1106 1 O
.	1107 1 O

The	1109 3 O
majority	1113 8 O
were	1122 4 O
women	1127 5 O
(	1133 1 O
52	1134 2 O
.	1136 1 O
7	1137 1 O
%	1138 1 O
)	1139 1 O
.	1140 1 O

Patients	1142 8 O
'	1150 1 O
mean	1152 4 O
age	1157 3 O
was	1161 3 O
53	1165 2 O
.	1167 1 O
9	1168 1 O
years	1170 5 O
,	1175 1 O
their	1177 5 O
mean	1183 4 O
weight	1188 6 O
was	1195 3 O
193	1199 3 O
.	1202 1 O
9	1203 1 O
pounds	1205 6 O
,	1211 1 O
and	1213 3 O
they	1217 4 O
smoked	1222 6 O
a	1229 1 O
mean	1231 4 O
of	1236 2 O
25	1239 2 O
.	1241 1 O
2	1242 1 O
cigarettes	1244 10 O
per	1255 3 O
day	1259 3 O
at	1263 2 O
baseline	1266 8 O
.	1274 1 O

Five	1276 4 O
hundred	1281 7 O
fifty	1289 5 O
-	1294 1 O
three	1295 5 O
patients	1301 8 O
,	1309 1 O
264	1311 3 O
taking	1315 6 O
the	1322 3 O
lozenge	1326 7 O
and	1334 3 O
289	1338 3 O
taking	1342 6 O
the	1349 3 O
gum	1353 3 O
,	1356 1 O
used	1358 4 O
the	1363 3 O
study	1367 5 O
product	1373 7 O
for	1381 3 O
>	1385 1 O
or	1387 2 O
=	1390 1 O
4	1391 1 O
days	1393 4 O
per	1398 3 O
week	1402 4 O
during	1407 6 O
the	1414 3 O
first	1418 5 O
2	1424 1 O
weeks	1426 5 O
(	1432 1 O
evaluable	1433 9 O
population	1443 10 O
)	1453 1 O
.	1454 1 O

The	1456 3 O
nicotine	1460 8 B-Chemical
lozenge	1469 7 O
and	1477 3 O
nicotine	1481 8 B-Chemical
gum	1490 3 O
were	1494 4 O
equally	1499 7 O
well	1507 4 O
tolerated	1512 9 O
,	1521 1 O
despite	1523 7 O
increased	1531 9 O
nicotine	1541 8 B-Chemical
exposure	1550 8 O
from	1559 4 O
the	1564 3 O
lozenge	1568 7 O
.	1575 1 O

The	1577 3 O
incidence	1581 9 O
of	1591 2 O
adverse	1594 7 O
events	1602 6 O
in	1609 2 O
the	1612 3 O
2	1616 1 O
groups	1618 6 O
was	1625 3 O
similar	1629 7 O
during	1637 6 O
the	1644 3 O
first	1648 5 O
2	1654 1 O
weeks	1656 5 O
of	1662 2 O
product	1665 7 O
use	1673 3 O
(	1677 1 O
evaluation	1678 10 O
population	1689 10 O
:	1699 1 O
55	1701 2 O
.	1703 1 O
3	1704 1 O
%	1705 1 O
lozenge	1707 7 O
,	1714 1 O
54	1716 2 O
.	1718 1 O
7	1719 1 O
%	1720 1 O
gum	1722 3 O
)	1725 1 O
,	1726 1 O
as	1728 2 O
well	1731 4 O
as	1736 2 O
during	1739 6 O
the	1746 3 O
entire	1750 6 O
study	1757 5 O
(	1763 1 O
safety	1764 6 O
population	1771 10 O
:	1781 1 O
63	1783 2 O
.	1785 1 O
8	1786 1 O
%	1787 1 O
and	1789 3 O
58	1793 2 O
.	1795 1 O
6	1796 1 O
%	1797 1 O
,	1798 1 O
respectively	1800 12 O
)	1812 1 O
.	1813 1 O

Stratification	1815 14 O
of	1830 2 O
patients	1833 8 O
by	1842 2 O
sex	1845 3 O
,	1848 1 O
age	1850 3 O
,	1853 1 O
extent	1855 6 O
of	1862 2 O
concurrent	1865 10 O
smoking	1876 7 O
,	1883 1 O
extent	1885 6 O
of	1892 2 O
product	1895 7 O
use	1903 3 O
,	1906 1 O
and	1908 3 O
severity	1912 8 O
of	1921 2 O
adverse	1924 7 O
events	1932 6 O
revealed	1939 8 O
no	1948 2 O
clinically	1951 10 O
significant	1962 11 O
differences	1974 11 O
between	1986 7 O
the	1994 3 O
lozenge	1998 7 O
and	2006 3 O
gum	2010 3 O
.	2013 1 O

The	2015 3 O
most	2019 4 O
common	2024 6 O
adverse	2031 7 O
events	2039 6 O
were	2046 4 O
nausea	2051 6 B-Disease
(	2058 1 O
17	2059 2 O
.	2061 1 O
2	2062 1 O
%	2063 1 O
and	2065 3 O
16	2069 2 O
.	2071 1 O
1	2072 1 O
%	2073 1 O
;	2074 1 O
95	2076 2 O
%	2078 1 O
CI	2080 2 O
,	2082 1 O
-	2084 1 O
3	2085 1 O
.	2086 1 O
7	2087 1 O
to	2089 2 O
6	2092 1 O
.	2093 1 O
0	2094 1 O
)	2095 1 O
,	2096 1 O
hiccups	2098 7 B-Disease
(	2106 1 O
10	2107 2 O
.	2109 1 O
7	2110 1 O
%	2111 1 O
and	2113 3 O
6	2117 1 O
.	2118 1 O
6	2119 1 O
%	2120 1 O
;	2121 1 O
95	2123 2 O
%	2125 1 O
CI	2127 2 O
,	2129 1 O
0	2131 1 O
.	2132 1 O
5	2133 1 O
to	2135 2 O
7	2138 1 O
.	2139 1 O
8	2140 1 O
)	2141 1 O
,	2142 1 O
and	2144 3 O
headache	2148 8 B-Disease
(	2157 1 O
8	2158 1 O
.	2159 1 O
7	2160 1 O
%	2161 1 O
and	2163 3 O
9	2167 1 O
.	2168 1 O
9	2169 1 O
%	2170 1 O
;	2171 1 O
95	2173 2 O
%	2175 1 O
Cl	2177 2 O
,	2179 1 O
-	2181 1 O
5	2182 1 O
.	2183 1 O
0	2184 1 O
to	2186 2 O
2	2189 1 O
.	2190 1 O
6	2191 1 O
)	2192 1 O
.	2193 1 O

Serious	2195 7 O
adverse	2203 7 O
events	2211 6 O
were	2218 4 O
reported	2223 8 O
in	2232 2 O
11	2235 2 O
and	2238 3 O
13	2242 2 O
patients	2245 8 O
in	2254 2 O
the	2257 3 O
respective	2261 10 O
groups	2272 6 O
.	2278 1 O

Fewer	2280 5 O
than	2286 4 O
6	2291 1 O
%	2292 1 O
of	2294 2 O
patients	2297 8 O
in	2306 2 O
either	2309 6 O
group	2316 5 O
were	2322 4 O
considered	2327 10 O
by	2338 2 O
the	2341 3 O
investigator	2345 12 O
to	2358 2 O
have	2361 4 O
a	2366 1 O
worsening	2368 9 O
of	2378 2 O
their	2381 5 O
overall	2387 7 O
disease	2395 7 O
condition	2403 9 O
during	2413 6 O
the	2420 3 O
study	2424 5 O
.	2429 1 O

The	2431 3 O
majority	2435 8 O
of	2444 2 O
patients	2447 8 O
(	2456 1 O
>	2457 1 O
60	2458 2 O
%	2460 1 O
)	2461 1 O
experienced	2463 11 O
no	2475 2 O
change	2478 6 O
in	2485 2 O
their	2488 5 O
disease	2494 7 O
status	2502 6 O
from	2509 4 O
baseline	2514 8 O
.	2522 1 O

CONCLUSION	2524 10 O
:	2534 1 O
The	2536 3 O
4	2540 1 O
-	2541 1 O
mg	2542 2 O
nicotine	2545 8 B-Chemical
lozenge	2554 7 O
and	2562 3 O
4	2566 1 O
-	2567 1 O
mg	2568 2 O
nicotine	2571 8 B-Chemical
gum	2580 3 O
had	2584 3 O
comparable	2588 10 O
safety	2599 6 O
profiles	2606 8 O
in	2615 2 O
these	2618 5 O
patients	2624 8 O
with	2633 4 O
label	2638 5 O
-	2643 1 O
restricted	2644 10 O
medical	2655 7 O
conditions	2663 10 O
.	2673 1 O

Development	0 11 O
of	12 2 O
levodopa	15 8 B-Chemical
-	23 1 O
induced	24 7 O
dyskinesias	32 11 B-Disease
in	44 2 O
parkinsonian	47 12 B-Disease
monkeys	60 7 O
may	68 3 O
depend	72 6 O
upon	79 4 O
rate	84 4 O
of	89 2 O
symptom	92 7 O
onset	100 5 O
and	106 3 O
/	109 1 O
or	110 2 O
duration	113 8 O
of	122 2 O
symptoms	125 8 O
.	133 1 O

Levodopa	135 8 B-Chemical
-	143 1 O
induced	144 7 O
dyskinesias	152 11 B-Disease
(	164 1 O
LIDs	165 4 B-Disease
)	169 1 O
present	171 7 O
a	179 1 O
major	181 5 O
problem	187 7 O
for	195 3 O
the	199 3 O
long	203 4 O
-	207 1 O
term	208 4 O
management	213 10 O
of	224 2 O
Parkinson	227 9 B-Disease
'	236 1 I-Disease
s	237 1 I-Disease
disease	239 7 I-Disease
(	247 1 O
PD	248 2 B-Disease
)	250 1 O
patients	252 8 O
.	260 1 O

Due	262 3 O
to	266 2 O
the	269 3 O
interdependence	273 15 O
of	289 2 O
risk	292 4 O
factors	297 7 O
in	305 2 O
clinical	308 8 O
populations	317 11 O
,	328 1 O
it	330 2 O
is	333 2 O
difficult	336 9 O
to	346 2 O
independently	349 13 O
examine	363 7 O
factors	371 7 O
that	379 4 O
may	384 3 O
influence	388 9 O
the	398 3 O
development	402 11 O
of	414 2 O
LIDs	417 4 B-Disease
.	421 1 O

Using	423 5 O
macaque	429 7 O
monkeys	437 7 O
with	445 4 O
different	450 9 O
types	460 5 O
of	466 2 O
MPTP	469 4 B-Chemical
-	473 1 O
induced	474 7 O
parkinsonism	482 12 B-Disease
,	494 1 O
the	496 3 O
current	500 7 O
study	508 5 O
evaluated	514 9 O
the	524 3 O
degree	528 6 O
to	535 2 O
which	538 5 O
rate	544 4 O
of	549 2 O
symptom	552 7 O
progression	560 11 O
,	571 1 O
symptom	573 7 O
severity	581 8 O
,	589 1 O
and	591 3 O
response	595 8 O
to	604 2 O
and	607 3 O
duration	611 8 O
of	620 2 O
levodopa	623 8 B-Chemical
therapy	632 7 O
may	640 3 O
be	644 2 O
involved	647 8 O
in	656 2 O
the	659 3 O
development	663 11 O
of	675 2 O
LIDs	678 4 B-Disease
.	682 1 O

Monkeys	684 7 O
with	692 4 O
acute	697 5 O
(	703 1 O
short	704 5 O
-	709 1 O
term	710 4 O
)	714 1 O
MPTP	716 4 B-Chemical
exposure	721 8 O
,	729 1 O
rapid	731 5 O
symptom	737 7 O
onset	745 5 O
and	751 3 O
short	755 5 O
symptom	761 7 O
duration	769 8 O
prior	778 5 O
to	784 2 O
initiation	787 10 O
of	798 2 O
levodopa	801 8 B-Chemical
therapy	810 7 O
developed	818 9 O
dyskinesia	828 10 B-Disease
between	839 7 O
11	847 2 O
and	850 3 O
24	854 2 O
days	857 4 O
of	862 2 O
daily	865 5 O
levodopa	871 8 B-Chemical
administration	880 14 O
.	894 1 O

In	896 2 O
contrast	899 8 O
,	907 1 O
monkeys	909 7 O
with	917 4 O
long	922 4 O
-	926 1 O
term	927 4 O
MPTP	932 4 B-Chemical
exposure	937 8 O
,	945 1 O
slow	947 4 O
symptom	952 7 O
progression	960 11 O
and	972 3 O
/	975 1 O
or	976 2 O
long	979 4 O
symptom	984 7 O
duration	992 8 O
prior	1001 5 O
to	1007 2 O
initiation	1010 10 O
of	1021 2 O
levodopa	1024 8 B-Chemical
therapy	1033 7 O
were	1041 4 O
more	1046 4 O
resistant	1051 9 O
to	1061 2 O
developing	1064 10 O
LIDs	1075 4 B-Disease
(	1080 1 O
e	1081 1 O
.	1082 1 O
g	1083 1 O
.	1084 1 O
,	1085 1 O
dyskinesia	1087 10 B-Disease
developed	1098 9 O
no	1108 2 O
sooner	1111 6 O
than	1118 4 O
146	1123 3 O
days	1127 4 O
of	1132 2 O
chronic	1135 7 O
levodopa	1143 8 B-Chemical
administration	1152 14 O
)	1166 1 O
.	1167 1 O

All	1169 3 O
animals	1173 7 O
were	1181 4 O
similarly	1186 9 O
symptomatic	1196 11 O
at	1208 2 O
the	1211 3 O
start	1215 5 O
of	1221 2 O
levodopa	1224 8 B-Chemical
treatment	1233 9 O
and	1243 3 O
had	1247 3 O
similar	1251 7 O
therapeutic	1259 11 O
responses	1271 9 O
to	1281 2 O
the	1284 3 O
drug	1288 4 O
.	1292 1 O

These	1294 5 O
data	1300 4 O
suggest	1305 7 O
distinct	1313 8 O
differences	1322 11 O
in	1334 2 O
the	1337 3 O
propensity	1341 10 O
to	1352 2 O
develop	1355 7 O
LIDs	1363 4 B-Disease
in	1368 2 O
monkeys	1371 7 O
with	1379 4 O
different	1384 9 O
rates	1394 5 O
of	1400 2 O
symptom	1403 7 O
progression	1411 11 O
or	1423 2 O
symptom	1426 7 O
durations	1434 9 O
prior	1444 5 O
to	1450 2 O
levodopa	1453 8 B-Chemical
and	1462 3 O
demonstrate	1466 11 O
the	1478 3 O
value	1482 5 O
of	1488 2 O
these	1491 5 O
models	1497 6 O
for	1504 3 O
further	1508 7 O
studying	1516 8 O
the	1525 3 O
pathophysiology	1529 15 O
of	1545 2 O
LIDs	1548 4 B-Disease
.	1552 1 O

Propylthiouracil	0 16 B-Chemical
-	16 1 O
induced	17 7 O
perinuclear	25 11 O
-	36 1 O
staining	37 8 O
antineutrophil	46 14 O
cytoplasmic	61 11 O
autoantibody	73 12 O
-	85 1 O
positive	86 8 O
vasculitis	95 10 B-Disease
in	106 2 O
conjunction	109 11 O
with	121 4 O
pericarditis	126 12 B-Disease
.	138 1 O

OBJECTIVE	140 9 O
:	149 1 O
To	151 2 O
describe	154 8 O
a	163 1 O
case	165 4 O
of	170 2 O
propylthiouracil	173 16 B-Chemical
-	189 1 O
induced	190 7 O
vasculitis	198 10 B-Disease
manifesting	209 11 O
with	221 4 O
pericarditis	226 12 B-Disease
.	238 1 O

METHODS	240 7 O
:	247 1 O
We	249 2 O
present	252 7 O
the	260 3 O
first	264 5 O
case	270 4 O
report	275 6 O
of	282 2 O
a	285 1 O
woman	287 5 O
with	293 4 O
hyperthyroidism	298 15 B-Disease
treated	314 7 O
with	322 4 O
propylthiouracil	327 16 B-Chemical
in	344 2 O
whom	347 4 O
a	352 1 O
syndrome	354 8 O
of	363 2 O
pericarditis	366 12 B-Disease
,	378 1 O
fever	380 5 B-Disease
,	385 1 O
and	387 3 O
glomerulonephritis	391 18 B-Disease
developed	410 9 O
.	419 1 O

Serologic	421 9 O
testing	431 7 O
and	439 3 O
immunologic	443 11 O
studies	455 7 O
were	463 4 O
done	468 4 O
,	472 1 O
and	474 3 O
a	478 1 O
pericardial	480 11 O
biopsy	492 6 O
was	499 3 O
performed	503 9 O
.	512 1 O

RESULTS	514 7 O
:	521 1 O
A	523 1 O
25	525 2 O
-	527 1 O
year	528 4 O
-	532 1 O
old	533 3 O
woman	537 5 O
with	543 4 O
Graves	548 6 B-Disease
'	554 1 I-Disease
disease	556 7 I-Disease
had	564 3 O
a	568 1 O
febrile	570 7 B-Disease
illness	578 7 I-Disease
and	586 3 O
evidence	590 8 O
of	599 2 O
pericarditis	602 12 B-Disease
,	614 1 O
which	616 5 O
was	622 3 O
confirmed	626 9 O
by	636 2 O
biopsy	639 6 O
.	645 1 O

Serologic	647 9 O
evaluation	657 10 O
revealed	668 8 O
the	677 3 O
presence	681 8 O
of	690 2 O
perinuclear	693 11 O
-	704 1 O
staining	705 8 O
antineutrophil	714 14 O
cytoplasmic	729 11 O
autoantibodies	741 14 O
(	756 1 O
pANCA	757 5 O
)	762 1 O
against	764 7 O
myeloperoxidase	772 15 O
(	788 1 O
MPO	789 3 O
)	792 1 O
.	793 1 O

Propylthiouracil	795 16 B-Chemical
therapy	812 7 O
was	820 3 O
withdrawn	824 9 O
,	833 1 O
and	835 3 O
she	839 3 O
was	843 3 O
treated	847 7 O
with	855 4 O
a	860 1 O
1	862 1 O
-	863 1 O
month	864 5 O
course	870 6 O
of	877 2 O
prednisone	880 10 B-Chemical
,	890 1 O
which	892 5 O
alleviated	898 10 O
her	909 3 O
symptoms	913 8 O
.	921 1 O

A	923 1 O
literature	925 10 O
review	936 6 O
revealed	943 8 O
no	952 2 O
prior	955 5 O
reports	961 7 O
of	969 2 O
pericarditis	972 12 B-Disease
in	985 2 O
anti	988 4 O
-	992 1 O
MPO	993 3 O
pANCA	997 5 O
-	1002 1 O
positive	1003 8 O
vasculitis	1012 10 B-Disease
associated	1023 10 O
with	1034 4 O
propylthio	1039 10 B-Chemical
-	1049 1 I-Chemical
uracil	1051 6 I-Chemical
therapy	1058 7 O
.	1065 1 O

CONCLUSION	1067 10 O
:	1077 1 O
Pericarditis	1079 12 B-Disease
may	1092 3 O
be	1096 2 O
the	1099 3 O
initial	1103 7 O
manifestation	1111 13 O
of	1125 2 O
drug	1128 4 O
-	1132 1 O
induced	1133 7 O
vasculitis	1141 10 B-Disease
attributable	1152 12 O
to	1165 2 O
propylthio	1168 10 B-Chemical
-	1178 1 I-Chemical
uracil	1180 6 I-Chemical
therapy	1187 7 O
.	1194 1 O

Two	0 3 O
mouse	4 5 O
lines	10 5 O
selected	16 8 O
for	25 3 O
differential	29 12 O
sensitivities	42 13 O
to	56 2 O
beta	59 4 B-Chemical
-	63 1 I-Chemical
carboline	64 9 I-Chemical
-	73 1 O
induced	74 7 O
seizures	82 8 B-Disease
are	91 3 O
also	95 4 O
differentially	100 14 O
sensitive	115 9 O
to	125 2 O
various	128 7 O
pharmacological	136 15 O
effects	152 7 O
of	160 2 O
other	163 5 O
GABA	169 4 B-Chemical
(	173 1 O
A	174 1 O
)	175 1 O
receptor	177 8 O
ligands	186 7 O
.	193 1 O

Two	195 3 O
mouse	199 5 O
lines	205 5 O
were	211 4 O
selectively	216 11 O
bred	228 4 O
according	233 9 O
to	243 2 O
their	246 5 O
sensitivity	252 11 O
(	264 1 O
BS	265 2 O
line	268 4 O
)	272 1 O
or	274 2 O
resistance	277 10 O
(	288 1 O
BR	289 2 O
line	292 4 O
)	296 1 O
to	298 2 O
seizures	301 8 B-Disease
induced	310 7 O
by	318 2 O
a	321 1 O
single	323 6 O
i	330 1 O
.	331 1 O
p	332 1 O
.	333 1 O
injection	335 9 O
of	345 2 O
methyl	348 6 B-Chemical
beta	355 4 I-Chemical
-	359 1 I-Chemical
carboline	360 9 I-Chemical
-	369 1 I-Chemical
3	370 1 I-Chemical
-	371 1 I-Chemical
carboxylate	372 11 I-Chemical
(	384 1 O
beta	385 4 B-Chemical
-	389 1 I-Chemical
CCM	390 3 I-Chemical
)	393 1 O
,	394 1 O
an	396 2 O
inverse	399 7 O
agonist	407 7 O
of	415 2 O
the	418 3 O
GABA	422 4 B-Chemical
(	426 1 O
A	427 1 O
)	428 1 O
receptor	430 8 O
benzodiazepine	439 14 B-Chemical
site	454 4 O
.	458 1 O

Our	460 3 O
aim	464 3 O
was	468 3 O
to	472 2 O
characterize	475 12 O
both	488 4 O
lines	493 5 O
'	498 1 O
sensitivities	500 13 O
to	514 2 O
various	517 7 O
physiological	525 13 O
effects	539 7 O
of	547 2 O
other	550 5 O
ligands	556 7 O
of	564 2 O
the	567 3 O
GABA	571 4 B-Chemical
(	575 1 O
A	576 1 O
)	577 1 O
receptor	579 8 O
.	587 1 O

We	589 2 O
measured	592 8 O
diazepam	601 8 B-Chemical
-	609 1 O
induced	610 7 O
anxiolysis	618 10 O
with	629 4 O
the	634 3 O
elevated	638 8 O
plus	647 4 O
-	651 1 O
maze	652 4 O
test	657 4 O
,	661 1 O
diazepam	663 8 B-Chemical
-	671 1 O
induced	672 7 O
sedation	680 8 O
by	689 2 O
recording	692 9 O
the	702 3 O
vigilance	706 9 O
states	716 6 O
,	722 1 O
and	724 3 O
picrotoxin	728 10 B-Chemical
-	738 1 O
and	740 3 O
pentylenetetrazol	744 17 B-Chemical
-	761 1 O
induced	762 7 O
seizures	770 8 B-Disease
after	779 5 O
i	785 1 O
.	786 1 O
p	787 1 O
.	788 1 O
injections	790 10 O
.	800 1 O

Results	802 7 O
presented	810 9 O
here	820 4 O
show	825 4 O
that	830 4 O
the	835 3 O
differential	839 12 O
sensitivities	852 13 O
of	866 2 O
BS	869 2 O
and	872 3 O
BR	876 2 O
lines	879 5 O
to	885 2 O
beta	888 4 B-Chemical
-	892 1 I-Chemical
CCM	893 3 I-Chemical
can	897 3 O
be	901 2 O
extended	904 8 O
to	913 2 O
diazepam	916 8 B-Chemical
,	924 1 O
picrotoxin	926 10 B-Chemical
,	936 1 O
and	938 3 O
pentylenetetrazol	942 17 B-Chemical
,	959 1 O
suggesting	961 10 O
a	972 1 O
genetic	974 7 O
selection	982 9 O
of	992 2 O
a	995 1 O
general	997 7 O
sensitivity	1005 11 O
and	1017 3 O
resistance	1021 10 O
to	1032 2 O
several	1035 7 O
ligands	1043 7 O
of	1051 2 O
the	1054 3 O
GABA	1058 4 B-Chemical
(	1062 1 O
A	1063 1 O
)	1064 1 O
receptor	1066 8 O
.	1074 1 O

Analgesic	0 9 O
effect	10 6 O
of	17 2 O
intravenous	20 11 O
ketamine	32 8 B-Chemical
in	41 2 O
cancer	44 6 B-Disease
patients	51 8 O
on	60 2 O
morphine	63 8 B-Chemical
therapy	72 7 O
:	79 1 O
a	81 1 O
randomized	83 10 O
,	93 1 O
controlled	95 10 O
,	105 1 O
double	107 6 O
-	113 1 O
blind	114 5 O
,	119 1 O
crossover	121 9 O
,	130 1 O
double	132 6 O
-	138 1 O
dose	139 4 O
study	144 5 O
.	149 1 O

Pain	151 4 B-Disease
not	156 3 O
responsive	160 10 O
to	171 2 O
morphine	174 8 B-Chemical
is	183 2 O
often	186 5 O
problematic	192 11 O
.	203 1 O

Animal	205 6 O
and	212 3 O
clinical	216 8 O
studies	225 7 O
have	233 4 O
suggested	238 9 O
that	248 4 O
N	253 1 B-Chemical
-	254 1 I-Chemical
methyl	255 6 I-Chemical
-	261 1 I-Chemical
D	262 1 I-Chemical
-	263 1 I-Chemical
aspartate	264 9 I-Chemical
(	274 1 O
NMDA	275 4 B-Chemical
)	279 1 O
antagonists	281 11 O
,	292 1 O
such	294 4 O
as	299 2 O
ketamine	302 8 B-Chemical
,	310 1 O
may	312 3 O
be	316 2 O
effective	319 9 O
in	329 2 O
improving	332 9 O
opioid	342 6 O
analgesia	349 9 O
in	359 2 O
difficult	362 9 O
pain	372 4 B-Disease
syndromes	377 9 O
,	386 1 O
such	388 4 O
as	393 2 O
neuropathic	396 11 B-Disease
pain	408 4 I-Disease
.	412 1 O

A	414 1 O
slow	416 4 O
bolus	421 5 O
of	427 2 O
subhypnotic	430 11 O
doses	442 5 O
of	448 2 O
ketamine	451 8 B-Chemical
(	460 1 O
0	461 1 O
.	462 1 O
25	463 2 O
mg	466 2 O
/	468 1 O
kg	469 2 O
or	472 2 O
0	475 1 O
.	476 1 O
50	477 2 O
mg	480 2 O
/	482 1 O
kg	483 2 O
)	485 1 O
was	487 3 O
given	491 5 O
to	497 2 O
10	500 2 O
cancer	503 6 B-Disease
patients	510 8 O
whose	519 5 O
pain	525 4 B-Disease
was	530 3 O
unrelieved	534 10 O
by	545 2 O
morphine	548 8 B-Chemical
in	557 2 O
a	560 1 O
randomized	562 10 O
,	572 1 O
double	574 6 O
-	580 1 O
blind	581 5 O
,	586 1 O
crossover	588 9 O
,	597 1 O
double	599 6 O
-	605 1 O
dose	606 4 O
study	611 5 O
.	616 1 O

Pain	618 4 B-Disease
intensity	623 9 O
on	633 2 O
a	636 1 O
0	638 1 O
to	640 2 O
10	643 2 O
numerical	646 9 O
scale	656 5 O
;	661 1 O
nausea	663 6 B-Disease
and	670 3 O
vomiting	674 8 B-Disease
,	682 1 O
drowsiness	684 10 O
,	694 1 O
confusion	696 9 B-Disease
,	705 1 O
and	707 3 O
dry	711 3 B-Disease
mouth	715 5 I-Disease
,	720 1 O
using	722 5 O
a	728 1 O
scale	730 5 O
from	736 4 O
0	741 1 O
to	743 2 O
3	746 1 O
(	748 1 O
not	749 3 O
at	753 2 O
all	756 3 O
,	759 1 O
slight	761 6 O
,	767 1 O
a	769 1 O
lot	771 3 O
,	774 1 O
awful	776 5 O
)	781 1 O
;	782 1 O
Mini	784 4 O
-	788 1 O
Mental	789 6 O
State	796 5 O
Examination	802 11 O
(	814 1 O
MMSE	815 4 O
)	819 1 O
(	821 1 O
0	822 1 O
-	823 1 O
30	824 2 O
)	826 1 O
;	827 1 O
and	829 3 O
arterial	833 8 O
pressure	842 8 O
were	851 4 O
recorded	856 8 O
before	865 6 O
administration	872 14 O
of	887 2 O
drugs	890 5 O
(	896 1 O
T0	897 2 O
)	899 1 O
and	901 3 O
after	905 5 O
30	911 2 O
minutes	914 7 O
(	922 1 O
T30	923 3 O
)	926 1 O
,	927 1 O
60	929 2 O
minutes	932 7 O
(	940 1 O
T60	941 3 O
)	944 1 O
,	945 1 O
120	947 3 O
minutes	951 7 O
(	959 1 O
T120	960 4 O
)	964 1 O
,	965 1 O
and	967 3 O
180	971 3 O
minutes	975 7 O
(	983 1 O
T180	984 4 O
)	988 1 O
.	989 1 O

Ketamine	991 8 B-Chemical
,	999 1 O
but	1001 3 O
not	1005 3 O
saline	1009 6 O
solution	1016 8 O
,	1024 1 O
significantly	1026 13 O
reduced	1040 7 O
the	1048 3 O
pain	1052 4 B-Disease
intensity	1057 9 O
in	1067 2 O
almost	1070 6 O
all	1077 3 O
the	1081 3 O
patients	1085 8 O
at	1094 2 O
both	1097 4 O
doses	1102 5 O
.	1107 1 O

This	1109 4 O
effect	1114 6 O
was	1121 3 O
more	1125 4 O
relevant	1130 8 O
in	1139 2 O
patients	1142 8 O
treated	1151 7 O
with	1159 4 O
higher	1164 6 O
doses	1171 5 O
.	1176 1 O

Hallucinations	1178 14 B-Disease
occurred	1193 8 O
in	1202 2 O
4	1205 1 O
patients	1207 8 O
,	1215 1 O
and	1217 3 O
an	1221 2 O
unpleasant	1224 10 O
sensation	1235 9 O
(	1245 1 O
"	1246 1 O
empty	1247 5 O
head	1253 4 O
"	1257 1 O
)	1258 1 O
was	1260 3 O
also	1264 4 O
reported	1269 8 O
by	1278 2 O
2	1281 1 O
patients	1283 8 O
.	1291 1 O

These	1293 5 O
episodes	1299 8 O
reversed	1308 8 O
after	1317 5 O
the	1323 3 O
administration	1327 14 O
of	1342 2 O
diazepam	1345 8 B-Chemical
1	1354 1 O
mg	1356 2 O
intravenously	1359 13 O
.	1372 1 O

Significant	1374 11 O
increases	1386 9 O
in	1396 2 O
drowsiness	1399 10 O
were	1410 4 O
reported	1415 8 O
in	1424 2 O
patients	1427 8 O
treated	1436 7 O
with	1444 4 O
ketamine	1449 8 B-Chemical
in	1458 2 O
both	1461 4 O
groups	1466 6 O
and	1473 3 O
were	1477 4 O
more	1482 4 O
marked	1487 6 O
with	1494 4 O
ketamine	1499 8 B-Chemical
0	1508 1 O
.	1509 1 O
50	1510 2 O
mg	1513 2 O
/	1515 1 O
kg	1516 2 O
.	1518 1 O

A	1520 1 O
significant	1522 11 O
difference	1534 10 O
in	1545 2 O
MMSE	1548 4 O
was	1553 3 O
observed	1557 8 O
at	1566 2 O
T30	1569 3 O
in	1573 2 O
patients	1576 8 O
who	1585 3 O
received	1589 8 O
0	1598 1 O
.	1599 1 O
50	1600 2 O
mg	1603 2 O
/	1605 1 O
kg	1606 2 O
of	1609 2 O
ketamine	1612 8 B-Chemical
.	1620 1 O

Ketamine	1622 8 B-Chemical
can	1631 3 O
improve	1635 7 O
morphine	1643 8 B-Chemical
analgesia	1652 9 O
in	1662 2 O
difficult	1665 9 O
pain	1675 4 B-Disease
syndromes	1680 9 O
,	1689 1 O
such	1691 4 O
as	1696 2 O
neuropathic	1699 11 B-Disease
pain	1711 4 I-Disease
.	1715 1 O

However	1717 7 O
,	1724 1 O
the	1726 3 O
occurrence	1730 10 O
of	1741 2 O
central	1744 7 O
adverse	1752 7 O
effects	1760 7 O
should	1768 6 O
be	1775 2 O
taken	1778 5 O
into	1784 4 O
account	1789 7 O
,	1796 1 O
especially	1798 10 O
when	1809 4 O
using	1814 5 O
higher	1820 6 O
doses	1827 5 O
.	1832 1 O

This	1834 4 O
observation	1839 11 O
should	1851 6 O
be	1858 2 O
tested	1861 6 O
in	1868 2 O
studies	1871 7 O
of	1879 2 O
prolonged	1882 9 O
ketamine	1892 8 B-Chemical
administration	1901 14 O
.	1915 1 O

Endocrine	0 9 O
screening	10 9 O
in	20 2 O
1	23 1 O
,	24 1 O
022	25 3 O
men	29 3 O
with	33 4 O
erectile	38 8 B-Disease
dysfunction	47 11 I-Disease
:	58 1 O
clinical	60 8 O
significance	69 12 O
and	82 3 O
cost	86 4 O
-	90 1 O
effective	91 9 O
strategy	101 8 O
.	109 1 O

PURPOSE	111 7 O
:	118 1 O
We	120 2 O
reviewed	123 8 O
the	132 3 O
results	136 7 O
of	144 2 O
serum	147 5 O
testosterone	153 12 B-Chemical
and	166 3 O
prolactin	170 9 O
determination	180 13 O
in	194 2 O
1	197 1 O
,	198 1 O
022	199 3 O
patients	203 8 O
referred	212 8 O
because	221 7 O
of	229 2 O
erectile	232 8 B-Disease
dysfunction	241 11 I-Disease
and	253 3 O
compared	257 8 O
the	266 3 O
data	270 4 O
with	275 4 O
history	280 7 O
,	287 1 O
results	289 7 O
of	297 2 O
physical	300 8 O
examination	309 11 O
,	320 1 O
other	322 5 O
etiological	328 11 O
investigations	340 14 O
and	355 3 O
effects	359 7 O
of	367 2 O
endocrine	370 9 O
therapy	380 7 O
to	388 2 O
refine	391 6 O
the	398 3 O
rules	402 5 O
of	408 2 O
cost	411 4 O
-	415 1 O
effective	416 9 O
endocrine	426 9 O
screening	436 9 O
and	446 3 O
to	450 2 O
pinpoint	453 8 O
actual	462 6 O
responsibility	469 14 O
for	484 3 O
hormonal	488 8 O
abnormalities	497 13 O
.	510 1 O

MATERIALS	512 9 O
AND	522 3 O
METHODS	526 7 O
:	533 1 O
Testosterone	535 12 B-Chemical
and	548 3 O
prolactin	552 9 O
were	562 4 O
determined	567 10 O
by	578 2 O
radioimmunoassay	581 16 O
.	597 1 O

Every	599 5 O
patient	605 7 O
was	613 3 O
screened	617 8 O
for	626 3 O
testosterone	630 12 B-Chemical
and	643 3 O
451	647 3 O
were	651 4 O
screened	656 8 O
for	665 3 O
prolactin	669 9 O
on	679 2 O
the	682 3 O
basis	686 5 O
of	692 2 O
low	695 3 B-Disease
sexual	699 6 I-Disease
desire	706 6 I-Disease
,	712 1 O
gynecomastia	714 12 B-Disease
or	727 2 O
testosterone	730 12 B-Chemical
less	743 4 O
than	748 4 O
4	753 1 O
ng	755 2 O
.	757 1 O
/	758 1 O
ml	759 2 O
.	761 1 O

Determination	763 13 O
was	777 3 O
repeated	781 8 O
in	790 2 O
case	793 4 O
of	798 2 O
abnormal	801 8 O
first	810 5 O
results	816 7 O
.	823 1 O

Prolactin	825 9 O
results	835 7 O
were	843 4 O
compared	848 8 O
with	857 4 O
those	862 5 O
of	868 2 O
a	871 1 O
previous	873 8 O
personal	882 8 O
cohort	891 6 O
of	898 2 O
1	901 1 O
,	902 1 O
340	903 3 O
patients	907 8 O
with	916 4 O
erectile	921 8 B-Disease
dysfunction	930 11 I-Disease
and	942 3 O
systematic	946 10 O
prolactin	957 9 O
determination	967 13 O
.	980 1 O

Main	982 4 O
clinical	987 8 O
criteria	996 8 O
tested	1005 6 O
regarding	1012 9 O
efficiency	1022 10 O
in	1033 2 O
hormone	1036 7 O
determination	1044 13 O
were	1058 4 O
low	1063 3 B-Disease
sexual	1067 6 I-Disease
desire	1074 6 I-Disease
,	1080 1 O
small	1082 5 O
testes	1088 6 O
and	1095 3 O
gynecomastia	1099 12 B-Disease
.	1111 1 O

Endocrine	1113 9 O
therapy	1123 7 O
consisted	1131 9 O
of	1141 2 O
testosterone	1144 12 B-Chemical
heptylate	1157 9 I-Chemical
or	1167 2 O
human	1170 5 O
chorionic	1176 9 O
gonadotropin	1186 12 O
for	1199 3 O
hypogonadism	1203 12 B-Disease
and	1216 3 O
bromocriptine	1220 13 B-Chemical
for	1234 3 O
hyperprolactinemia	1238 18 B-Disease
.	1256 1 O

RESULTS	1258 7 O
:	1265 1 O
Testosterone	1267 12 B-Chemical
was	1280 3 O
less	1284 4 O
than	1289 4 O
3	1294 1 O
ng	1296 2 O
.	1298 1 O
/	1299 1 O
ml	1300 2 O
.	1302 1 O
in	1304 2 O
107	1307 3 O
patients	1311 8 O
but	1320 3 O
normal	1324 6 O
in	1331 2 O
40	1334 2 O
%	1336 1 O
at	1338 2 O
repeat	1341 6 O
determination	1348 13 O
.	1361 1 O

The	1363 3 O
prevalence	1367 10 O
of	1378 2 O
repeatedly	1381 10 O
low	1392 3 O
testosterone	1396 12 B-Chemical
increased	1409 9 O
with	1419 4 O
age	1424 3 O
(	1428 1 O
4	1429 1 O
%	1430 1 O
before	1432 6 O
age	1439 3 O
50	1443 2 O
years	1446 5 O
and	1452 3 O
9	1456 1 O
%	1457 1 O
50	1459 2 O
years	1462 5 O
or	1468 2 O
older	1471 5 O
)	1476 1 O
.	1477 1 O

Two	1479 3 O
pituitary	1483 9 B-Disease
tumors	1493 6 I-Disease
were	1500 4 O
discovered	1505 10 O
after	1516 5 O
testosterone	1522 12 B-Chemical
determination	1535 13 O
.	1548 1 O

Most	1550 4 O
of	1555 2 O
the	1558 3 O
other	1562 5 O
low	1568 3 O
testosterone	1572 12 B-Chemical
levels	1585 6 O
seemed	1592 6 O
to	1599 2 O
result	1602 6 O
from	1609 4 O
nonorganic	1614 10 O
hypothalamic	1625 12 B-Disease
dysfunction	1638 11 I-Disease
because	1650 7 O
of	1658 2 O
normal	1661 6 O
serum	1668 5 O
luteinizing	1674 11 O
hormone	1686 7 O
and	1694 3 O
prolactin	1698 9 O
and	1708 3 O
to	1712 2 O
have	1715 4 O
only	1720 4 O
a	1725 1 O
small	1727 5 O
role	1733 4 O
in	1738 2 O
erectile	1741 8 B-Disease
dysfunction	1750 11 I-Disease
(	1762 1 O
definite	1763 8 O
improvement	1772 11 O
in	1784 2 O
only	1787 4 O
16	1792 2 O
of	1795 2 O
44	1798 2 O
[	1801 1 O
36	1802 2 O
%	1804 1 O
]	1805 1 O
after	1807 5 O
androgen	1813 8 O
therapy	1822 7 O
,	1829 1 O
normal	1831 6 O
morning	1838 7 O
or	1846 2 O
nocturnal	1849 9 O
erections	1859 9 O
in	1869 2 O
30	1872 2 O
%	1874 1 O
and	1876 3 O
definite	1880 8 O
vasculogenic	1889 12 O
contributions	1902 13 O
in	1916 2 O
42	1919 2 O
%	1921 1 O
)	1922 1 O
.	1923 1 O

Determining	1925 11 O
testosterone	1937 12 B-Chemical
only	1950 4 O
in	1955 2 O
cases	1958 5 O
of	1964 2 O
low	1967 3 B-Disease
sexual	1971 6 I-Disease
desire	1978 6 I-Disease
or	1985 2 O
abnormal	1988 8 O
physical	1997 8 O
examination	2006 11 O
would	2018 5 O
have	2024 4 O
missed	2029 6 O
40	2036 2 O
%	2038 1 O
of	2040 2 O
the	2043 3 O
cases	2047 5 O
with	2053 4 O
low	2058 3 O
testosterone	2062 12 B-Chemical
,	2074 1 O
including	2076 9 O
37	2086 2 O
%	2088 1 O
of	2090 2 O
those	2093 5 O
subsequently	2099 12 O
improved	2112 8 O
by	2121 2 O
androgen	2124 8 O
therapy	2133 7 O
.	2140 1 O

Prolactin	2142 9 O
exceeded	2152 8 O
20	2161 2 O
ng	2164 2 O
.	2166 1 O
/	2167 1 O
ml	2168 2 O
.	2170 1 O
in	2172 2 O
5	2175 1 O
men	2177 3 O
and	2181 3 O
was	2185 3 O
normal	2189 6 O
in	2196 2 O
2	2199 1 O
at	2201 2 O
repeat	2204 6 O
determination	2211 13 O
.	2224 1 O

Only	2226 4 O
1	2231 1 O
prolactinoma	2233 12 B-Disease
was	2246 3 O
discovered	2250 10 O
.	2260 1 O

These	2262 5 O
data	2268 4 O
are	2273 3 O
lower	2277 5 O
than	2283 4 O
those	2288 5 O
we	2294 2 O
found	2297 5 O
during	2303 6 O
the	2310 3 O
last	2314 4 O
2	2319 1 O
decades	2321 7 O
(	2329 1 O
overall	2330 7 O
prolactin	2338 9 O
greater	2348 7 O
than	2356 4 O
20	2361 2 O
ng	2364 2 O
.	2366 1 O
/	2367 1 O
ml	2368 2 O
.	2370 1 O
in	2372 2 O
1	2375 1 O
.	2376 1 O
86	2377 2 O
%	2379 1 O
of	2381 2 O
1	2384 1 O
,	2385 1 O
821	2386 3 O
patients	2390 8 O
,	2398 1 O
prolactinomas	2400 13 B-Disease
in	2414 2 O
7	2417 1 O
,	2418 1 O
0	2420 1 O
.	2421 1 O
38	2422 2 O
%	2424 1 O
)	2425 1 O
.	2426 1 O

Bromocriptine	2428 13 B-Chemical
was	2442 3 O
definitely	2446 10 O
effective	2457 9 O
in	2467 2 O
cases	2470 5 O
with	2476 4 O
prolactin	2481 9 O
greater	2491 7 O
than	2499 4 O
35	2504 2 O
ng	2507 2 O
.	2509 1 O
/	2510 1 O
ml	2511 2 O
.	2513 1 O

(	2515 1 O
8	2516 1 O
of	2518 2 O
12	2521 2 O
compared	2524 8 O
to	2533 2 O
only	2536 4 O
9	2541 1 O
of	2543 2 O
22	2546 2 O
cases	2549 5 O
with	2555 4 O
prolactin	2560 9 O
between	2570 7 O
20	2578 2 O
and	2581 3 O
35	2585 2 O
ng	2588 2 O
.	2590 1 O
/	2591 1 O
ml	2592 2 O
.	2594 1 O
)	2595 1 O
.	2596 1 O

Testosterone	2598 12 B-Chemical
was	2611 3 O
low	2615 3 O
in	2619 2 O
less	2622 4 O
than	2627 4 O
50	2632 2 O
%	2634 1 O
of	2636 2 O
cases	2639 5 O
with	2645 4 O
prolactin	2650 9 O
greater	2660 7 O
than	2668 4 O
35	2673 2 O
ng	2676 2 O
.	2678 1 O
/	2679 1 O
ml	2680 2 O
.	2682 1 O

CONCLUSIONS	2684 11 O
:	2695 1 O
Low	2697 3 O
prevalences	2701 11 O
and	2713 3 O
effects	2717 7 O
of	2725 2 O
low	2728 3 O
testosterone	2732 12 B-Chemical
and	2745 3 O
high	2749 4 O
prolactin	2754 9 O
in	2764 2 O
erectile	2767 8 B-Disease
dysfunction	2776 11 I-Disease
cannot	2788 6 O
justify	2795 7 O
their	2803 5 O
routine	2809 7 O
determination	2817 13 O
.	2830 1 O

However	2832 7 O
,	2839 1 O
cost	2841 4 O
-	2845 1 O
effective	2846 9 O
screening	2856 9 O
strategies	2866 10 O
recommended	2877 11 O
so	2889 2 O
far	2892 3 O
missed	2896 6 O
40	2903 2 O
to	2906 2 O
50	2909 2 O
%	2911 1 O
of	2913 2 O
cases	2916 5 O
improved	2922 8 O
with	2931 4 O
endocrine	2936 9 O
therapy	2946 7 O
and	2954 3 O
the	2958 3 O
pituitary	2962 9 B-Disease
tumors	2972 6 I-Disease
.	2978 1 O

We	2980 2 O
now	2983 3 O
advocate	2987 8 O
that	2996 4 O
before	3001 6 O
age	3008 3 O
50	3012 2 O
years	3015 5 O
testosterone	3021 12 B-Chemical
be	3034 2 O
determined	3037 10 O
only	3048 4 O
in	3053 2 O
cases	3056 5 O
of	3062 2 O
low	3065 3 B-Disease
sexual	3069 6 I-Disease
desire	3076 6 I-Disease
and	3083 3 O
abnormal	3087 8 O
physical	3096 8 O
examination	3105 11 O
but	3117 3 O
that	3121 4 O
it	3126 2 O
be	3129 2 O
measured	3132 8 O
in	3141 2 O
all	3144 3 O
men	3148 3 O
older	3152 5 O
than	3158 4 O
50	3163 2 O
years	3166 5 O
.	3171 1 O

Prolactin	3173 9 O
should	3183 6 O
be	3190 2 O
determined	3193 10 O
only	3204 4 O
in	3209 2 O
cases	3212 5 O
of	3218 2 O
low	3221 3 B-Disease
sexual	3225 6 I-Disease
desire	3232 6 I-Disease
,	3238 1 O
gynecomastia	3240 12 B-Disease
and	3253 3 O
/	3256 1 O
or	3257 2 O
testosterone	3260 12 B-Chemical
less	3273 4 O
than	3278 4 O
4	3283 1 O
ng	3285 2 O
.	3287 1 O
/	3288 1 O
ml	3289 2 O
.	3291 1 O

Thiopentone	0 11 B-Chemical
pretreatment	12 12 O
for	25 3 O
propofol	29 8 B-Chemical
injection	38 9 O
pain	48 4 B-Disease
in	53 2 O
ambulatory	56 10 O
patients	67 8 O
.	75 1 O

This	77 4 O
study	82 5 O
investigated	88 12 O
propofol	101 8 B-Chemical
injection	110 9 O
pain	120 4 B-Disease
in	125 2 O
patients	128 8 O
undergoing	137 10 O
ambulatory	148 10 O
anaesthesia	159 11 O
.	170 1 O

In	172 2 O
a	175 1 O
randomized	177 10 O
,	187 1 O
double	189 6 O
-	195 1 O
blind	196 5 O
trial	202 5 O
,	207 1 O
90	209 2 O
women	212 5 O
were	218 4 O
allocated	223 9 O
to	233 2 O
receive	236 7 O
one	244 3 O
of	248 2 O
three	251 5 O
treatments	257 10 O
prior	268 5 O
to	274 2 O
induction	277 9 O
of	287 2 O
anaesthesia	290 11 O
with	302 4 O
propofol	307 8 B-Chemical
.	315 1 O

Patients	317 8 O
in	326 2 O
Group	329 5 O
C	335 1 O
received	337 8 O
2	346 1 O
ml	348 2 O
normal	351 6 O
saline	358 6 O
,	364 1 O
Group	366 5 O
L	372 1 O
,	373 1 O
2	375 1 O
ml	377 2 O
,	379 1 O
lidocaine	381 9 B-Chemical
2	391 1 O
%	392 1 O
(	394 1 O
40	395 2 O
mg	398 2 O
)	400 1 O
and	402 3 O
Group	406 5 O
T	412 1 O
,	413 1 O
2	415 1 O
ml	417 2 O
thiopentone	420 11 B-Chemical
2	432 1 O
.	433 1 O
5	434 1 O
%	435 1 O
(	437 1 O
50	438 2 O
mg	441 2 O
)	443 1 O
.	444 1 O

Venous	446 6 O
discomfort	453 10 O
was	464 3 O
assessed	468 8 O
with	477 4 O
a	482 1 O
visual	484 6 O
analogue	491 8 O
scale	500 5 O
(	506 1 O
VAS	507 3 O
)	510 1 O
5	512 1 O
-	513 1 O
15	514 2 O
sec	517 3 O
after	521 5 O
commencing	527 10 O
propofol	538 8 B-Chemical
administration	547 14 O
using	562 5 O
an	568 2 O
infusion	571 8 O
pump	580 4 O
(	585 1 O
rate	586 4 O
1000	591 4 O
micrograms	596 10 O
.	606 1 O
kg	607 2 O
-	609 1 O
1	610 1 O
.	611 1 O
min	612 3 O
-	615 1 O
1	616 1 O
)	617 1 O
.	618 1 O

Loss	620 4 B-Disease
of	625 2 I-Disease
consciousness	628 13 I-Disease
occurred	642 8 O
in	651 2 O
60	654 2 O
-	656 1 O
90	657 2 O
sec	660 3 O
.	663 1 O

Visual	665 6 O
analogue	672 8 O
scores	681 6 O
(	688 1 O
mean	689 4 O
+	694 1 O
/	695 1 O
-	696 1 O
SD	698 2 O
)	700 1 O
during	702 6 O
induction	709 9 O
were	719 4 O
lower	724 5 O
in	730 2 O
Groups	733 6 O
L	740 1 O
(	742 1 O
3	743 1 O
.	744 1 O
3	745 1 O
+	747 1 O
/	748 1 O
-	749 1 O
2	751 1 O
.	752 1 O
5	753 1 O
)	754 1 O
and	756 3 O
T	760 1 O
(	762 1 O
4	763 1 O
.	764 1 O
1	765 1 O
+	767 1 O
/	768 1 O
-	769 1 O
2	771 1 O
.	772 1 O
7	773 1 O
)	774 1 O
than	776 4 O
in	781 2 O
Group	784 5 O
C	790 1 O
(	792 1 O
5	793 1 O
.	794 1 O
6	795 1 O
+	797 1 O
/	798 1 O
-	799 1 O
2	801 1 O
.	802 1 O
3	803 1 O
)	804 1 O
;	805 1 O
P	807 1 O
=	809 1 O
0	811 1 O
.	812 1 O
0031	813 4 O
.	817 1 O

The	819 3 O
incidence	823 9 O
of	833 2 O
venous	836 6 O
discomfort	843 10 O
was	854 3 O
lower	858 5 O
in	864 2 O
Group	867 5 O
L	873 1 O
(	875 1 O
76	876 2 O
.	878 1 O
6	879 1 O
%	880 1 O
;	881 1 O
P	883 1 O
<	885 1 O
0	887 1 O
.	888 1 O
05	889 2 O
)	891 1 O
than	893 4 O
in	898 2 O
Group	901 5 O
C	907 1 O
(	909 1 O
100	910 3 O
%	913 1 O
)	914 1 O
but	916 3 O
not	920 3 O
different	924 9 O
from	934 4 O
Group	939 5 O
T	945 1 O
(	947 1 O
90	948 2 O
%	950 1 O
)	951 1 O
.	952 1 O

The	954 3 O
VAS	958 3 O
scores	962 6 O
for	969 3 O
recall	973 6 O
of	980 2 O
pain	983 4 B-Disease
in	988 2 O
the	991 3 O
recovery	995 8 O
room	1004 4 O
were	1009 4 O
correlated	1014 10 O
with	1025 4 O
the	1030 3 O
VAS	1034 3 O
scores	1038 6 O
during	1045 6 O
induction	1052 9 O
(	1062 1 O
r	1063 1 O
=	1065 1 O
0	1067 1 O
.	1068 1 O
7045	1069 4 O
;	1073 1 O
P	1075 1 O
<	1077 1 O
0	1079 1 O
.	1080 1 O
0001	1081 4 O
)	1085 1 O
.	1086 1 O

Recovery	1088 8 O
room	1097 4 O
discharge	1102 9 O
times	1112 5 O
were	1118 4 O
similar	1123 7 O
:	1130 1 O
C	1132 1 O
(	1134 1 O
75	1135 2 O
.	1137 1 O
9	1138 1 O
+	1140 1 O
/	1141 1 O
-	1142 1 O
19	1144 2 O
.	1146 1 O
4	1147 1 O
min	1149 3 O
)	1152 1 O
;	1153 1 O
L	1155 1 O
73	1157 2 O
.	1159 1 O
6	1160 1 O
+	1162 1 O
/	1163 1 O
-	1164 1 O
21	1166 2 O
.	1168 1 O
6	1169 1 O
min	1171 3 O
)	1174 1 O
;	1175 1 O
T	1177 1 O
(	1179 1 O
77	1180 2 O
.	1182 1 O
1	1183 1 O
+	1185 1 O
/	1186 1 O
-	1187 1 O
18	1189 2 O
.	1191 1 O
9	1192 1 O
min	1194 3 O
)	1197 1 O
.	1198 1 O

Assessing	1200 9 O
their	1210 5 O
overall	1216 7 O
satisfaction	1224 12 O
,	1236 1 O
89	1238 2 O
.	1240 1 O
7	1241 1 O
%	1242 1 O
would	1244 5 O
choose	1250 6 O
propofol	1257 8 B-Chemical
anaesthesia	1266 11 O
again	1278 5 O
.	1283 1 O

We	1285 2 O
conclude	1288 8 O
that	1297 4 O
lidocaine	1302 9 B-Chemical
reduces	1312 7 O
the	1320 3 O
incidence	1324 9 O
and	1334 3 O
severity	1338 8 O
of	1347 2 O
propofol	1350 8 B-Chemical
injection	1359 9 O
pain	1369 4 B-Disease
in	1374 2 O
ambulatory	1377 10 O
patients	1388 8 O
whereas	1397 7 O
thiopentone	1405 11 B-Chemical
only	1417 4 O
reduces	1422 7 O
its	1430 3 O
severity	1434 8 O
.	1442 1 O

Comparison	0 10 O
of	11 2 O
i	14 1 O
.	15 1 O
v	16 1 O
.	17 1 O
glycopyrrolate	19 14 B-Chemical
and	34 3 O
atropine	38 8 B-Chemical
in	47 2 O
the	50 3 O
prevention	54 10 O
of	65 2 O
bradycardia	68 11 B-Disease
and	80 3 O
arrhythmias	84 11 B-Disease
following	96 9 O
repeated	106 8 O
doses	115 5 O
of	121 2 O
suxamethonium	124 13 B-Chemical
in	138 2 O
children	141 8 O
.	149 1 O

The	151 3 O
effectiveness	155 13 O
of	169 2 O
administration	172 14 O
of	187 2 O
glycopyrrolate	190 14 B-Chemical
5	205 1 O
and	207 3 O
10	211 2 O
micrograms	214 10 O
kg	225 2 O
-	227 1 O
1	228 1 O
and	230 3 O
atropine	234 8 B-Chemical
10	243 2 O
and	246 3 O
20	250 2 O
micrograms	253 10 O
kg	264 2 O
-	266 1 O
1	267 1 O
i	269 1 O
.	270 1 O
v	271 1 O
.	272 1 O
immediately	274 11 O
before	286 6 O
the	293 3 O
induction	297 9 O
of	307 2 O
anaesthesia	310 11 O
,	321 1 O
to	323 2 O
prevent	326 7 O
arrhythmia	334 10 B-Disease
and	345 3 O
bradycardia	349 11 B-Disease
following	361 9 O
repeated	371 8 O
doses	380 5 O
of	386 2 O
suxamethonium	389 13 B-Chemical
in	403 2 O
children	406 8 O
,	414 1 O
was	416 3 O
studied	420 7 O
.	427 1 O

A	429 1 O
control	431 7 O
group	439 5 O
was	445 3 O
included	449 8 O
for	458 3 O
comparison	462 10 O
with	473 4 O
the	478 3 O
lower	482 5 O
dose	488 4 O
range	493 5 O
of	499 2 O
glycopyrrolate	502 14 B-Chemical
and	517 3 O
atropine	521 8 B-Chemical
.	529 1 O

A	531 1 O
frequency	533 9 O
of	543 2 O
bradycardia	546 11 B-Disease
of	558 2 O
50	561 2 O
%	563 1 O
was	565 3 O
noted	569 5 O
in	575 2 O
the	578 3 O
control	582 7 O
group	590 5 O
,	595 1 O
but	597 3 O
this	601 4 O
was	606 3 O
not	610 3 O
significantly	614 13 O
different	628 9 O
from	638 4 O
the	643 3 O
frequency	647 9 O
with	657 4 O
the	662 3 O
active	666 6 O
drugs	673 5 O
.	678 1 O

Bradycardia	680 11 B-Disease
(	692 1 O
defined	693 7 O
as	701 2 O
a	704 1 O
decrease	706 8 O
in	715 2 O
heart	718 5 O
rate	724 4 O
to	729 2 O
less	732 4 O
than	737 4 O
50	742 2 O
beat	745 4 O
min	750 3 O
-	753 1 O
1	754 1 O
)	755 1 O
was	757 3 O
prevented	761 9 O
when	771 4 O
the	776 3 O
larger	780 6 O
dose	787 4 O
of	792 2 O
either	795 6 O
active	802 6 O
drug	809 4 O
was	814 3 O
used	818 4 O
.	822 1 O

It	824 2 O
is	827 2 O
recommended	830 11 O
that	842 4 O
either	847 6 O
glycopyrrolate	854 14 B-Chemical
10	869 2 O
micrograms	872 10 O
kg	883 2 O
-	885 1 O
1	886 1 O
or	888 2 O
atropine	891 8 B-Chemical
20	900 2 O
micrograms	903 10 O
kg	914 2 O
-	916 1 O
1	917 1 O
i	919 1 O
.	920 1 O
v	921 1 O
.	922 1 O
should	924 6 O
immediately	931 11 O
precede	943 7 O
induction	951 9 O
of	961 2 O
anaesthesia	964 11 O
,	975 1 O
in	977 2 O
children	980 8 O
,	988 1 O
if	990 2 O
the	993 3 O
repeated	997 8 O
administration	1006 14 O
of	1021 2 O
suxamethonium	1024 13 B-Chemical
is	1038 2 O
anticipated	1041 11 O
.	1052 1 O

Reduction	0 9 O
in	10 2 O
caffeine	13 8 B-Chemical
toxicity	22 8 B-Disease
by	31 2 O
acetaminophen	34 13 B-Chemical
.	47 1 O

A	49 1 O
patient	51 7 O
who	59 3 O
allegedly	63 9 O
consumed	73 8 O
100	82 3 O
tablets	86 7 O
of	94 2 O
an	97 2 O
over	100 4 O
-	104 1 O
the	105 3 O
-	108 1 O
counter	109 7 O
analgesic	117 9 O
containing	127 10 O
sodium	138 6 B-Chemical
acetylsalicylate	145 16 I-Chemical
,	161 1 O
caffeine	163 8 B-Chemical
,	171 1 O
and	173 3 O
acetaminophen	177 13 B-Chemical
displayed	191 9 O
no	201 2 O
significant	204 11 O
CNS	216 3 O
stimulation	220 11 O
despite	232 7 O
the	240 3 O
presence	244 8 O
of	253 2 O
175	256 3 O
micrograms	260 10 O
of	271 2 O
caffeine	274 8 B-Chemical
per	283 3 O
mL	287 2 O
of	290 2 O
serum	293 5 O
.	298 1 O

Because	300 7 O
salicylates	308 11 O
have	320 4 O
been	325 4 O
reported	330 8 O
to	339 2 O
augment	342 7 O
the	350 3 O
stimulatory	354 11 O
effects	366 7 O
of	374 2 O
caffeine	377 8 B-Chemical
on	386 2 O
the	389 3 O
CNS	393 3 O
,	396 1 O
attention	398 9 O
was	408 3 O
focused	412 7 O
on	420 2 O
the	423 3 O
possibility	427 11 O
that	439 4 O
the	444 3 O
presence	448 8 O
of	457 2 O
acetaminophen	460 13 B-Chemical
(	474 1 O
52	475 2 O
micrograms	478 10 O
/	488 1 O
mL	489 2 O
)	491 1 O
reduced	493 7 O
the	501 3 O
CNS	505 3 O
toxicity	509 8 B-Disease
of	518 2 O
caffeine	521 8 B-Chemical
.	529 1 O

Studies	531 7 O
in	539 2 O
DBA	542 3 O
/	545 1 O
2J	546 2 O
mice	549 4 O
showed	554 6 O
that	561 4 O
:	565 1 O
1	567 1 O
)	568 1 O
pretreatment	570 12 O
with	583 4 O
acetaminophen	588 13 B-Chemical
(	602 1 O
100	603 3 O
mg	607 2 O
/	609 1 O
kg	610 2 O
)	612 1 O
increased	614 9 O
the	624 3 O
interval	628 8 O
between	637 7 O
the	645 3 O
administration	649 14 O
of	664 2 O
caffeine	667 8 B-Chemical
(	676 1 O
300	677 3 O
to	681 2 O
450	684 3 O
mg	688 2 O
/	690 1 O
kg	691 2 O
IP	694 2 O
)	696 1 O
and	698 3 O
the	702 3 O
onset	706 5 O
of	712 2 O
fatal	715 5 O
convulsions	721 11 B-Disease
by	733 2 O
a	736 1 O
factor	738 6 O
of	745 2 O
about	748 5 O
two	754 3 O
;	757 1 O
and	759 3 O
2	763 1 O
)	764 1 O
pretreatment	766 12 O
with	779 4 O
acetaminophen	784 13 B-Chemical
(	798 1 O
75	799 2 O
mg	802 2 O
/	804 1 O
kg	805 2 O
)	807 1 O
reduced	809 7 O
the	817 3 O
incidence	821 9 O
of	831 2 O
audiogenic	834 10 O
seizures	845 8 B-Disease
produced	854 8 O
in	863 2 O
the	866 3 O
presence	870 8 O
of	879 2 O
caffeine	882 8 B-Chemical
(	891 1 O
12	892 2 O
.	894 1 O
5	895 1 O
to	897 2 O
75	900 2 O
mg	903 2 O
/	905 1 O
kg	906 2 O
IP	909 2 O
)	911 1 O
.	912 1 O

The	914 3 O
frequency	918 9 O
of	928 2 O
sound	931 5 O
-	936 1 O
induced	937 7 O
seizures	945 8 B-Disease
after	954 5 O
12	960 2 O
.	962 1 O
5	963 1 O
or	965 2 O
25	968 2 O
mg	971 2 O
/	973 1 O
kg	974 2 O
caffeine	977 8 B-Chemical
was	986 3 O
reduced	990 7 O
from	998 4 O
50	1003 2 O
to	1006 2 O
5	1009 1 O
%	1010 1 O
by	1012 2 O
acetaminophen	1015 13 B-Chemical
.	1028 1 O

In	1030 2 O
the	1033 3 O
absence	1037 7 O
of	1045 2 O
caffeine	1048 8 B-Chemical
,	1056 1 O
acetaminophen	1058 13 B-Chemical
(	1072 1 O
up	1073 2 O
to	1076 2 O
300	1079 3 O
mg	1083 2 O
/	1085 1 O
kg	1086 2 O
)	1088 1 O
did	1090 3 O
not	1094 3 O
modify	1098 6 O
the	1105 3 O
seizures	1109 8 B-Disease
induced	1118 7 O
by	1126 2 O
maximal	1129 7 O
electroshock	1137 12 O
and	1150 3 O
did	1154 3 O
not	1158 3 O
alter	1162 5 O
the	1168 3 O
convulsant	1172 10 O
dose	1183 4 O
of	1188 2 O
pentylenetetrezol	1191 17 B-Chemical
in	1209 2 O
mice	1212 4 O
(	1217 1 O
tests	1218 5 O
performed	1224 9 O
by	1234 2 O
the	1237 3 O
Anticonvulsant	1241 14 O
Screening	1256 9 O
Project	1266 7 O
of	1274 2 O
NINCDS	1277 6 O
)	1283 1 O
.	1284 1 O

Acetaminophen	1286 13 B-Chemical
(	1300 1 O
up	1301 2 O
to	1304 2 O
150	1307 3 O
micrograms	1311 10 O
/	1321 1 O
mL	1322 2 O
)	1324 1 O
did	1326 3 O
not	1330 3 O
retard	1334 6 O
the	1341 3 O
incorporation	1345 13 O
of	1359 2 O
radioactive	1362 11 O
adenosine	1374 9 B-Chemical
into	1384 4 O
ATP	1389 3 B-Chemical
in	1393 2 O
slices	1396 6 O
of	1403 2 O
rat	1406 3 O
cerebral	1410 8 O
cortex	1419 6 O
.	1425 1 O

Thus	1427 4 O
the	1432 3 O
mechanism	1436 9 O
by	1446 2 O
which	1449 5 O
acetaminophen	1455 13 B-Chemical
antagonizes	1469 11 O
the	1481 3 O
actions	1485 7 O
of	1493 2 O
caffeine	1496 8 B-Chemical
in	1505 2 O
the	1508 3 O
CNS	1512 3 O
remains	1516 7 O
unknown	1524 7 O
.	1531 1 O

Flestolol	0 9 B-Chemical
:	9 1 O
an	11 2 O
ultra	14 5 O
-	19 1 O
short	20 5 O
-	25 1 O
acting	26 6 O
beta	33 4 O
-	37 1 O
adrenergic	38 10 O
blocking	49 8 O
agent	58 5 O
.	63 1 O

Flestolol	65 9 B-Chemical
(	75 1 O
ACC	76 3 B-Chemical
-	79 1 I-Chemical
9089	80 4 I-Chemical
)	84 1 O
is	86 2 O
a	89 1 O
nonselective	91 12 O
,	103 1 O
competitive	105 11 O
,	116 1 O
ultra	118 5 O
-	123 1 O
short	124 5 O
-	129 1 O
acting	130 6 O
beta	137 4 O
-	141 1 O
adrenergic	142 10 O
blocking	153 8 O
agent	162 5 O
,	167 1 O
without	169 7 O
any	177 3 O
intrinsic	181 9 O
sympathomimetic	191 15 O
activity	207 8 O
.	215 1 O

Flestolol	217 9 B-Chemical
is	227 2 O
metabolized	230 11 O
by	242 2 O
plasma	245 6 O
esterases	252 9 O
and	262 3 O
has	266 3 O
an	270 2 O
elimination	273 11 O
half	285 4 O
-	289 1 O
life	290 4 O
of	295 2 O
approximately	298 13 O
6	312 1 O
.	313 1 O
5	314 1 O
minutes	316 7 O
.	323 1 O

This	325 4 O
agent	330 5 O
was	336 3 O
well	340 4 O
tolerated	345 9 O
in	355 2 O
healthy	358 7 O
volunteers	366 10 O
at	377 2 O
doses	380 5 O
up	386 2 O
to	389 2 O
100	392 3 O
micrograms	396 10 O
/	406 1 O
kg	407 2 O
/	409 1 O
min	410 3 O
.	413 1 O

In	415 2 O
long	418 4 O
-	422 1 O
term	423 4 O
infusion	428 8 O
studies	437 7 O
,	444 1 O
flestolol	446 9 B-Chemical
was	456 3 O
well	460 4 O
tolerated	465 9 O
at	475 2 O
the	478 3 O
effective	482 9 O
beta	492 4 O
-	496 1 O
blocking	497 8 O
dose	506 4 O
(	511 1 O
5	512 1 O
micrograms	514 10 O
/	524 1 O
kg	525 2 O
/	527 1 O
min	528 3 O
)	531 1 O
for	533 3 O
up	537 2 O
to	540 2 O
seven	543 5 O
days	549 4 O
.	553 1 O

Flestolol	555 9 B-Chemical
blood	565 5 O
concentrations	571 14 O
increased	586 9 O
linearly	596 8 O
with	605 4 O
increasing	610 10 O
dose	621 4 O
and	626 3 O
good	630 4 O
correlation	635 11 O
exists	647 6 O
between	654 7 O
blood	662 5 O
concentrations	668 14 O
of	683 2 O
flestolol	686 9 B-Chemical
and	696 3 O
beta	700 4 O
-	704 1 O
adrenergic	705 10 O
blockade	716 8 O
.	724 1 O

Flestolol	726 9 B-Chemical
produced	736 8 O
a	745 1 O
dose	747 4 O
-	751 1 O
dependent	752 9 O
attenuation	762 11 O
of	774 2 O
isoproterenol	777 13 B-Chemical
-	790 1 O
induced	791 7 O
tachycardia	799 11 B-Disease
.	810 1 O

Electrophysiologic	812 18 O
and	831 3 O
hemodynamic	835 11 O
effects	847 7 O
of	855 2 O
flestolol	858 9 B-Chemical
are	868 3 O
similar	872 7 O
to	880 2 O
those	883 5 O
of	889 2 O
other	892 5 O
beta	898 4 O
blockers	903 8 O
.	911 1 O

In	913 2 O
contrast	916 8 O
with	925 4 O
other	930 5 O
beta	936 4 O
blockers	941 8 O
,	949 1 O
flestolol	951 9 B-Chemical
-	960 1 O
induced	961 7 O
effects	969 7 O
reverse	977 7 O
rapidly	985 7 O
(	993 1 O
within	994 6 O
30	1001 2 O
minutes	1004 7 O
)	1011 1 O
following	1013 9 O
discontinuation	1023 15 O
because	1039 7 O
of	1047 2 O
its	1050 3 O
short	1054 5 O
half	1060 4 O
-	1064 1 O
life	1065 4 O
.	1069 1 O

Flestolol	1071 9 B-Chemical
effectively	1081 11 O
reduced	1093 7 O
heart	1101 5 O
rate	1107 4 O
in	1112 2 O
patients	1115 8 O
with	1124 4 O
supraventricular	1129 16 B-Disease
tachyarrhythmia	1146 15 I-Disease
.	1161 1 O

In	1163 2 O
patients	1166 8 O
with	1175 4 O
unstable	1180 8 B-Disease
angina	1189 6 I-Disease
,	1195 1 O
flestolol	1197 9 B-Chemical
infusion	1207 8 O
was	1216 3 O
found	1220 5 O
to	1226 2 O
be	1229 2 O
safe	1232 4 O
and	1237 3 O
effective	1241 9 O
in	1251 2 O
controlling	1254 11 O
chest	1266 5 B-Disease
pain	1272 4 I-Disease
.	1276 1 O

It	1278 2 O
is	1281 2 O
concluded	1284 9 O
that	1294 4 O
flestolol	1299 9 B-Chemical
is	1309 2 O
a	1312 1 O
potent	1314 6 O
,	1320 1 O
well	1322 4 O
-	1326 1 O
tolerated	1327 9 O
,	1336 1 O
ultra	1338 5 O
-	1343 1 O
short	1344 5 O
-	1349 1 O
acting	1350 6 O
beta	1357 4 O
-	1361 1 O
adrenergic	1362 10 O
blocking	1373 8 O
agent	1382 5 O
.	1387 1 O

Use	1389 3 O
of	1393 2 O
flestolol	1396 9 B-Chemical
in	1406 2 O
the	1409 3 O
critical	1413 8 O
care	1422 4 O
setting	1427 7 O
is	1435 2 O
currently	1438 9 O
undergoing	1448 10 O
investigation	1459 13 O
.	1472 1 O

Adverse	0 7 O
effect	8 6 O
of	15 2 O
the	18 3 O
calcium	22 7 B-Chemical
channel	30 7 O
blocker	38 7 O
nitrendipine	46 12 B-Chemical
on	59 2 O
nephrosclerosis	62 15 B-Disease
in	78 2 O
rats	81 4 O
with	86 4 O
renovascular	91 12 B-Disease
hypertension	104 12 I-Disease
.	116 1 O

The	118 3 O
effect	122 6 O
of	129 2 O
a	132 1 O
6	134 1 O
-	135 1 O
week	136 4 O
treatment	141 9 O
with	151 4 O
the	156 3 O
calcium	160 7 B-Chemical
channel	168 7 O
blocker	176 7 O
nitrendipine	184 12 B-Chemical
or	197 2 O
the	200 3 O
angiotensin	204 11 B-Chemical
converting	216 10 O
enzyme	227 6 O
inhibitor	234 9 O
enalapril	244 9 B-Chemical
on	254 2 O
blood	257 5 O
pressure	263 8 O
,	271 1 O
albuminuria	273 11 B-Disease
,	284 1 O
renal	286 5 O
hemodynamics	292 12 O
,	304 1 O
and	306 3 O
morphology	310 10 O
of	321 2 O
the	324 3 O
nonclipped	328 10 O
kidney	339 6 O
was	346 3 O
studied	350 7 O
in	358 2 O
rats	361 4 O
with	366 4 O
two	371 3 O
-	374 1 O
kidney	375 6 O
,	381 1 O
one	383 3 O
clip	387 4 O
renovascular	392 12 B-Disease
hypertension	405 12 I-Disease
.	417 1 O

Six	419 3 O
weeks	423 5 O
after	429 5 O
clipping	435 8 O
of	444 2 O
one	447 3 O
renal	451 5 O
artery	457 6 O
,	463 1 O
hypertensive	465 12 B-Disease
rats	478 4 O
(	483 1 O
178	484 3 O
+	488 1 O
/	489 1 O
-	490 1 O
4	492 1 O
mm	494 2 O
Hg	497 2 O
)	499 1 O
were	501 4 O
randomly	506 8 O
assigned	515 8 O
to	524 2 O
three	527 5 O
groups	533 6 O
:	539 1 O
untreated	541 9 O
hypertensive	551 12 B-Disease
controls	564 8 O
(	573 1 O
n	574 1 O
=	576 1 O
8	578 1 O
)	579 1 O
,	580 1 O
enalapril	582 9 B-Chemical
-	591 1 O
treated	592 7 O
(	600 1 O
n	601 1 O
=	603 1 O
8	605 1 O
)	606 1 O
,	607 1 O
or	609 2 O
nitrendipine	612 12 B-Chemical
-	624 1 O
treated	625 7 O
(	633 1 O
n	634 1 O
=	636 1 O
10	638 2 O
)	640 1 O
.	641 1 O

Sham	643 4 O
-	647 1 O
operated	648 8 O
rats	657 4 O
served	662 6 O
as	669 2 O
normotensive	672 12 O
controls	685 8 O
(	694 1 O
128	695 3 O
+	699 1 O
/	700 1 O
-	701 1 O
3	703 1 O
mm	705 2 O
Hg	708 2 O
,	710 1 O
n	712 1 O
=	714 1 O
8	716 1 O
)	717 1 O
.	718 1 O

After	720 5 O
6	726 1 O
weeks	728 5 O
of	734 2 O
treatment	737 9 O
,	746 1 O
renal	748 5 O
hemodynamics	754 12 O
(	767 1 O
glomerular	768 10 O
filtration	779 10 O
rate	790 4 O
and	795 3 O
renal	799 5 O
plasma	805 6 O
flow	812 4 O
)	816 1 O
were	818 4 O
measured	823 8 O
in	832 2 O
the	835 3 O
anesthetized	839 12 O
rats	852 4 O
.	856 1 O

Renal	858 5 O
tissue	864 6 O
was	871 3 O
obtained	875 8 O
for	884 3 O
determination	888 13 O
of	902 2 O
glomerular	905 10 O
size	916 4 O
and	921 3 O
sclerosis	925 9 O
.	934 1 O

Enalapril	936 9 B-Chemical
but	946 3 O
not	950 3 O
nitrendipine	954 12 B-Chemical
reduced	967 7 O
blood	975 5 O
pressure	981 8 O
significantly	990 13 O
.	1003 1 O

After	1005 5 O
6	1011 1 O
weeks	1013 5 O
of	1019 2 O
therapy	1022 7 O
,	1029 1 O
glomerular	1031 10 O
filtration	1042 10 O
rate	1053 4 O
was	1058 3 O
not	1062 3 O
different	1066 9 O
among	1076 5 O
the	1082 3 O
studied	1086 7 O
groups	1094 6 O
.	1100 1 O

Renal	1102 5 O
plasma	1108 6 O
flow	1115 4 O
increased	1120 9 O
,	1129 1 O
but	1131 3 O
albumin	1135 7 O
excretion	1143 9 O
and	1153 3 O
glomerulosclerosis	1157 18 B-Disease
did	1176 3 O
not	1180 3 O
change	1184 6 O
after	1191 5 O
enalapril	1197 9 B-Chemical
treatment	1207 9 O
.	1216 1 O

In	1218 2 O
contrast	1221 8 O
,	1229 1 O
in	1231 2 O
the	1234 3 O
nitrendipine	1238 12 B-Chemical
-	1250 1 O
treated	1251 7 O
group	1259 5 O
albuminuria	1265 11 B-Disease
increased	1277 9 O
from	1287 4 O
12	1292 2 O
.	1294 1 O
8	1295 1 O
+	1297 1 O
/	1298 1 O
-	1299 1 O
2	1301 1 O
progressively	1303 13 O
to	1317 2 O
163	1320 3 O
+	1324 1 O
/	1325 1 O
-	1326 1 O
55	1328 2 O
compared	1331 8 O
with	1340 4 O
19	1345 2 O
.	1347 1 O
2	1348 1 O
+	1350 1 O
/	1351 1 O
-	1352 1 O
9	1354 1 O
mg	1356 2 O
/	1358 1 O
24	1359 2 O
hr	1362 2 O
in	1365 2 O
the	1368 3 O
hypertensive	1372 12 B-Disease
controls	1385 8 O
.	1393 1 O

Furthermore	1395 11 O
,	1406 1 O
glomerulosclerosis	1408 18 B-Disease
index	1427 5 O
was	1433 3 O
significantly	1437 13 O
increased	1451 9 O
in	1461 2 O
the	1464 3 O
nitrendipine	1468 12 B-Chemical
-	1480 1 O
treated	1481 7 O
group	1489 5 O
compared	1495 8 O
with	1504 4 O
the	1509 3 O
hypertensive	1513 12 B-Disease
controls	1526 8 O
(	1535 1 O
0	1536 1 O
.	1537 1 O
38	1538 2 O
+	1541 1 O
/	1542 1 O
-	1543 1 O
0	1545 1 O
.	1546 1 O
1	1547 1 O
versus	1549 6 O
0	1556 1 O
.	1557 1 O
13	1558 2 O
+	1561 1 O
/	1562 1 O
-	1563 1 O
0	1565 1 O
.	1566 1 O
04	1567 2 O
)	1569 1 O
.	1570 1 O

In	1572 2 O
addition	1575 8 O
,	1583 1 O
glomerular	1585 10 O
size	1596 4 O
was	1601 3 O
higher	1605 6 O
in	1612 2 O
the	1615 3 O
nitrendipine	1619 12 B-Chemical
-	1631 1 O
treated	1632 7 O
group	1640 5 O
(	1646 1 O
14	1647 2 O
.	1649 1 O
9	1650 1 O
+	1652 1 O
/	1653 1 O
-	1654 1 O
0	1656 1 O
.	1657 1 O
17	1658 2 O
10	1661 2 O
(	1663 1 O
-	1664 1 O
3	1665 1 O
)	1666 1 O
mm2	1668 3 O
)	1671 1 O
but	1673 3 O
lower	1677 5 O
in	1683 2 O
the	1686 3 O
enalapril	1690 9 B-Chemical
-	1699 1 O
treated	1700 7 O
group	1708 5 O
(	1714 1 O
11	1715 2 O
.	1717 1 O
5	1718 1 O
+	1720 1 O
/	1721 1 O
-	1722 1 O
0	1724 1 O
.	1725 1 O
15	1726 2 O
10	1729 2 O
(	1731 1 O
-	1732 1 O
3	1733 1 O
)	1734 1 O
mm2	1736 3 O
)	1739 1 O
compared	1741 8 O
with	1750 4 O
the	1755 3 O
hypertensive	1759 12 B-Disease
controls	1772 8 O
(	1781 1 O
12	1782 2 O
.	1784 1 O
1	1785 1 O
+	1787 1 O
/	1788 1 O
-	1789 1 O
0	1791 1 O
.	1792 1 O
17	1793 2 O
10	1796 2 O
(	1798 1 O
-	1799 1 O
3	1800 1 O
)	1801 1 O
mm2	1803 3 O
)	1806 1 O
.	1807 1 O
(	1808 1 O
ABSTRACT	1809 8 O
TRUNCATED	1818 9 O
AT	1828 2 O
250	1831 3 O
WORDS	1835 5 O
)	1840 1 O

Treatment	0 9 O
of	10 2 O
tinnitus	13 8 B-Disease
by	22 2 O
intratympanic	25 13 O
instillation	39 12 O
of	52 2 O
lignocaine	55 10 B-Chemical
(	66 1 O
lidocaine	67 9 B-Chemical
)	76 1 O
2	78 1 O
per	80 3 O
cent	84 4 O
through	89 7 O
ventilation	97 11 O
tubes	109 5 O
.	114 1 O

Idiopathic	116 10 B-Disease
subjective	127 10 I-Disease
tinnitus	138 8 I-Disease
(	147 1 O
IST	148 3 B-Disease
)	151 1 O
is	153 2 O
one	156 3 O
of	160 2 O
the	163 3 O
most	167 4 O
obscure	172 7 O
otological	180 10 O
pathologies	191 11 O
.	202 1 O

This	204 4 O
paper	209 5 O
presents	215 8 O
the	224 3 O
results	228 7 O
of	236 2 O
treating	239 8 O
IST	248 3 B-Disease
by	252 2 O
intratympanic	255 13 O
instillation	269 12 O
of	282 2 O
lignocaine	285 10 B-Chemical
(	296 1 O
lidocaine	297 9 B-Chemical
)	306 1 O
2	308 1 O
per	310 3 O
cent	314 4 O
through	319 7 O
a	327 1 O
grommet	329 7 O
,	336 1 O
for	338 3 O
five	342 4 O
weekly	347 6 O
courses	354 7 O
.	361 1 O

Fifty	363 5 O
-	368 1 O
two	369 3 O
patients	373 8 O
suffering	382 9 O
from	392 4 O
intractable	397 11 O
tinnitus	409 8 B-Disease
entered	418 7 O
this	426 4 O
therapeutic	431 11 O
trial	443 5 O
,	448 1 O
but	450 3 O
only	454 4 O
nine	459 4 O
finished	464 8 O
all	473 3 O
five	477 4 O
courses	482 7 O
.	489 1 O

In	491 2 O
one	494 3 O
patient	498 7 O
,	505 1 O
the	507 3 O
tinnitus	511 8 B-Disease
was	520 3 O
almost	524 6 O
completely	531 10 O
abolished	542 9 O
,	551 1 O
but	553 3 O
in	557 2 O
all	560 3 O
the	564 3 O
nine	568 4 O
patients	573 8 O
the	582 3 O
decompensated	586 13 O
tinnitus	600 8 B-Disease
changed	609 7 O
to	617 2 O
a	620 1 O
compensated	622 11 O
one	634 3 O
.	637 1 O

We	639 2 O
suggest	642 7 O
this	650 4 O
mode	655 4 O
of	660 2 O
treatment	663 9 O
for	673 3 O
patients	677 8 O
that	686 4 O
were	691 4 O
previously	696 10 O
treated	707 7 O
by	715 2 O
drugs	718 5 O
,	723 1 O
acupuncture	725 11 O
and	737 3 O
biofeedback	741 11 O
,	752 1 O
with	754 4 O
disappointing	759 13 O
results	773 7 O
.	780 1 O

Patients	782 8 O
should	791 6 O
be	798 2 O
warned	801 6 O
about	808 5 O
the	814 3 O
side	818 4 O
effects	823 7 O
of	831 2 O
vertigo	834 7 B-Disease
and	842 3 O
vomiting	846 8 B-Disease
,	854 1 O
which	856 5 O
subsides	862 8 O
gradually	871 9 O
with	881 4 O
every	886 5 O
new	892 3 O
instillation	896 12 O
,	908 1 O
and	910 3 O
that	914 4 O
the	919 3 O
tinnitus	923 8 B-Disease
may	932 3 O
not	936 3 O
disappear	940 9 O
but	950 3 O
will	954 4 O
be	959 2 O
alleviated	962 10 O
,	972 1 O
enabling	974 8 O
them	983 4 O
to	988 2 O
cope	991 4 O
more	996 4 O
easily	1001 6 O
with	1008 4 O
the	1013 3 O
disease	1017 7 O
and	1025 3 O
lead	1029 4 O
a	1034 1 O
more	1036 4 O
normal	1041 6 O
life	1048 4 O
.	1052 1 O

Perhexiline	0 11 B-Chemical
maleate	12 7 I-Chemical
and	20 3 O
peripheral	24 10 B-Disease
neuropathy	35 10 I-Disease
.	45 1 O

Peripheral	47 10 B-Disease
neuropathy	58 10 I-Disease
has	69 3 O
been	73 4 O
noted	78 5 O
as	84 2 O
a	87 1 O
complication	89 12 O
of	102 2 O
therapy	105 7 O
with	113 4 O
perhexiline	118 11 B-Chemical
maleate	130 7 I-Chemical
,	137 1 O
a	139 1 O
drug	141 4 O
widely	146 6 O
used	153 4 O
in	158 2 O
France	161 6 O
(	168 1 O
and	169 3 O
in	173 2 O
clinical	176 8 O
trials	185 6 O
in	192 2 O
the	195 3 O
United	199 6 O
States	206 6 O
)	212 1 O
for	214 3 O
the	218 3 O
prophylactic	222 12 O
treatment	235 9 O
of	245 2 O
angina	248 6 B-Disease
pectoris	255 8 I-Disease
.	263 1 O

In	265 2 O
24	268 2 O
patients	271 8 O
with	280 4 O
this	285 4 O
complication	290 12 O
,	302 1 O
the	304 3 O
marked	308 6 O
slowing	315 7 O
of	323 2 O
motor	326 5 O
nerve	332 5 O
conduction	338 10 O
velocity	349 8 O
and	358 3 O
the	362 3 O
electromyographic	366 17 O
changes	384 7 O
imply	392 5 O
mainly	398 6 O
a	405 1 O
demyelinating	407 13 B-Disease
disorder	421 8 I-Disease
.	429 1 O

Improvement	431 11 O
was	443 3 O
noted	447 5 O
with	453 4 O
cessation	458 9 O
of	468 2 O
therapy	471 7 O
.	478 1 O

In	480 2 O
a	483 1 O
few	485 3 O
cases	489 5 O
the	495 3 O
presence	499 8 O
of	508 2 O
active	511 6 O
denervation	518 11 O
signified	530 9 O
a	540 1 O
poor	542 4 O
prognosis	547 9 O
,	556 1 O
with	558 4 O
only	563 4 O
slight	568 6 O
improvement	575 11 O
.	586 1 O

The	588 3 O
underlying	592 10 O
mechanism	603 9 O
causing	613 7 O
the	621 3 O
neuropathy	625 10 B-Disease
is	636 2 O
not	639 3 O
yet	643 3 O
fully	647 5 O
known	653 5 O
,	658 1 O
although	660 8 O
some	669 4 O
evidence	674 8 O
indicates	683 9 O
that	693 4 O
it	698 2 O
may	701 3 O
be	705 2 O
a	708 1 O
lipid	710 5 O
storage	716 7 O
process	724 7 O
.	731 1 O

Effect	0 6 O
of	7 2 O
humoral	10 7 O
modulators	18 10 O
of	29 2 O
morphine	32 8 B-Chemical
-	40 1 O
induced	41 7 O
increase	49 8 B-Disease
in	58 2 I-Disease
locomotor	61 9 I-Disease
activity	71 8 I-Disease
of	80 2 O
mice	83 4 O
.	87 1 O

The	89 3 O
effect	93 6 O
of	100 2 O
humoral	103 7 O
modulators	111 10 O
on	122 2 O
the	125 3 O
morphine	129 8 B-Chemical
-	137 1 O
induced	138 7 O
increase	146 8 B-Disease
in	155 2 I-Disease
locomotor	158 9 I-Disease
activity	168 8 I-Disease
of	177 2 O
mice	180 4 O
was	185 3 O
studied	189 7 O
.	196 1 O

The	198 3 O
subcutaneous	202 12 O
administration	215 14 O
of	230 2 O
10	233 2 O
mg	236 2 O
/	238 1 O
kg	239 2 O
of	242 2 O
morphine	245 8 B-Chemical
-	253 1 O
HC1	254 3 O
produced	258 8 O
a	267 1 O
marked	269 6 O
increase	276 8 B-Disease
in	285 2 I-Disease
locomotor	288 9 I-Disease
activity	298 8 I-Disease
in	307 2 O
mice	310 4 O
.	314 1 O

The	316 3 O
morphine	320 8 B-Chemical
-	328 1 O
induced	329 7 O
hyperactivity	337 13 B-Disease
was	351 3 O
potentiated	355 11 O
by	367 2 O
scopolamine	370 11 B-Chemical
and	382 3 O
attenuated	386 10 O
by	397 2 O
physostigmine	400 13 B-Chemical
.	413 1 O

In	415 2 O
contrast	418 8 O
,	426 1 O
both	428 4 O
methscopolamine	433 15 B-Chemical
and	449 3 O
neostigmine	453 11 B-Chemical
,	464 1 O
which	466 5 O
do	472 2 O
not	475 3 O
penetrate	479 9 O
the	489 3 O
blood	493 5 O
-	498 1 O
brain	499 5 O
barrier	505 7 O
,	512 1 O
had	514 3 O
no	518 2 O
effect	521 6 O
on	528 2 O
the	531 3 O
hyperactivity	535 13 B-Disease
produced	549 8 O
by	558 2 O
morphine	561 8 B-Chemical
.	569 1 O

Pretreatment	571 12 O
of	584 2 O
mice	587 4 O
with	592 4 O
alpha	597 5 B-Chemical
-	602 1 I-Chemical
methyltyrosine	603 14 I-Chemical
(	618 1 O
20	619 2 O
mg	622 2 O
/	624 1 O
kg	625 2 O
i	628 1 O
.	629 1 O
p	630 1 O
.	631 1 O
,	632 1 O
one	634 3 O
hour	638 4 O
)	642 1 O
,	643 1 O
an	645 2 O
inhibitor	648 9 O
of	658 2 O
tyrosine	661 8 B-Chemical
hydroxylase	670 11 O
,	681 1 O
significantly	683 13 O
decreased	697 9 O
the	707 3 O
activity	711 8 O
-	719 1 O
increasing	720 10 O
effects	731 7 O
of	739 2 O
morphine	742 8 B-Chemical
.	750 1 O

On	752 2 O
the	755 3 O
other	759 5 O
hand	765 4 O
,	769 1 O
pretreatment	771 12 O
with	784 4 O
p	789 1 B-Chemical
-	790 1 I-Chemical
chlorophenylalamine	791 19 I-Chemical
(	811 1 O
3	812 1 O
X	814 1 O
320	816 3 O
mg	820 2 O
/	822 1 O
kg	823 2 O
i	826 1 O
.	827 1 O
p	828 1 O
.	829 1 O
,	830 1 O
24	832 2 O
hr	835 2 O
)	837 1 O
,	838 1 O
a	840 1 O
serotonin	842 9 B-Chemical
depletor	852 8 O
,	860 1 O
caused	862 6 O
no	869 2 O
significant	872 11 O
change	884 6 O
in	891 2 O
the	894 3 O
hyperactivity	898 13 B-Disease
.	911 1 O

The	913 3 O
study	917 5 O
suggests	923 8 O
that	932 4 O
the	937 3 O
activity	941 8 O
-	949 1 O
increasing	950 10 O
effects	961 7 O
of	969 2 O
morphine	972 8 B-Chemical
are	981 3 O
mediated	985 8 O
by	994 2 O
the	997 3 O
release	1001 7 O
of	1009 2 O
catecholamines	1012 14 B-Chemical
from	1027 4 O
adrenergic	1032 10 O
neurons	1043 7 O
in	1051 2 O
the	1054 3 O
brain	1058 5 O
.	1063 1 O

And	1065 3 O
the	1069 3 O
results	1073 7 O
are	1081 3 O
consistent	1085 10 O
with	1096 4 O
the	1101 3 O
hypothesis	1105 10 O
that	1116 4 O
morphine	1121 8 B-Chemical
acts	1130 4 O
by	1135 2 O
retarding	1138 9 O
the	1148 3 O
release	1152 7 O
of	1160 2 O
acetylcholine	1163 13 B-Chemical
at	1177 2 O
some	1180 4 O
central	1185 7 O
cholinergic	1193 11 O
synapses	1205 8 O
.	1213 1 O

It	1215 2 O
is	1218 2 O
also	1221 4 O
suggested	1226 9 O
from	1236 4 O
collected	1241 9 O
evidence	1251 8 O
that	1260 4 O
the	1265 3 O
activity	1269 8 O
-	1277 1 O
increasing	1278 10 O
effects	1289 7 O
of	1297 2 O
morphine	1300 8 B-Chemical
in	1309 2 O
mice	1312 4 O
are	1317 3 O
mediated	1321 8 O
by	1330 2 O
mechanisms	1333 10 O
different	1344 9 O
from	1354 4 O
those	1359 5 O
which	1365 5 O
mediate	1371 7 O
the	1379 3 O
activity	1383 8 O
-	1391 1 O
increasing	1392 10 O
effects	1403 7 O
of	1411 2 O
morphine	1414 8 B-Chemical
in	1423 2 O
rats	1426 4 O
.	1430 1 O

Mechanisms	0 10 O
of	11 2 O
FK	14 2 B-Chemical
506	17 3 I-Chemical
-	20 1 O
induced	21 7 O
hypertension	29 12 B-Disease
in	42 2 O
the	45 3 O
rat	49 3 O
.	52 1 O

-	54 1 O
Tacrolimus	55 10 B-Chemical
(	66 1 O
FK	67 2 B-Chemical
506	70 3 I-Chemical
)	73 1 O
is	75 2 O
a	78 1 O
powerful	80 8 O
,	88 1 O
widely	90 6 O
used	97 4 O
immunosuppressant	102 17 O
.	119 1 O

The	121 3 O
clinical	125 8 O
utility	134 7 O
of	142 2 O
FK	145 2 B-Chemical
506	148 3 I-Chemical
is	152 2 O
complicated	155 11 O
by	167 2 O
substantial	170 11 O
hypertension	182 12 B-Disease
and	195 3 O
nephrotoxicity	199 14 B-Disease
.	213 1 O

To	215 2 O
clarify	218 7 O
the	226 3 O
mechanisms	230 10 O
of	241 2 O
FK	244 2 B-Chemical
506	247 3 I-Chemical
-	250 1 O
induced	251 7 O
hypertension	259 12 B-Disease
,	271 1 O
we	273 2 O
studied	276 7 O
the	284 3 O
chronic	288 7 O
effects	296 7 O
of	304 2 O
FK	307 2 B-Chemical
506	310 3 I-Chemical
on	314 2 O
the	317 3 O
synthesis	321 9 O
of	331 2 O
endothelin	334 10 O
-	344 1 O
1	345 1 O
(	347 1 O
ET	348 2 O
-	350 1 O
1	351 1 O
)	352 1 O
,	353 1 O
the	355 3 O
expression	359 10 O
of	370 2 O
mRNA	373 4 O
of	378 2 O
ET	381 2 O
-	383 1 O
1	384 1 O
and	386 3 O
endothelin	390 10 O
-	400 1 O
converting	401 10 O
enzyme	412 6 O
-	418 1 O
1	419 1 O
(	421 1 O
ECE	422 3 O
-	425 1 O
1	426 1 O
)	427 1 O
,	428 1 O
the	430 3 O
endothelial	434 11 O
nitric	446 6 B-Chemical
oxide	453 5 I-Chemical
synthase	459 8 O
(	468 1 O
eNOS	469 4 O
)	473 1 O
activity	475 8 O
,	483 1 O
and	485 3 O
the	489 3 O
expression	493 10 O
of	504 2 O
mRNA	507 4 O
of	512 2 O
eNOS	515 4 O
and	520 3 O
C	524 1 O
-	525 1 O
type	526 4 O
natriuretic	531 11 O
peptide	543 7 O
(	551 1 O
CNP	552 3 O
)	555 1 O
in	557 2 O
rat	560 3 O
blood	564 5 O
vessels	570 7 O
.	577 1 O

In	579 2 O
addition	582 8 O
,	590 1 O
the	592 3 O
effect	596 6 O
of	603 2 O
the	606 3 O
specific	610 8 O
endothelin	619 10 O
type	630 4 O
A	635 1 O
receptor	637 8 O
antagonist	646 10 O
FR	657 2 B-Chemical
139317	660 6 I-Chemical
on	667 2 O
FK	670 2 B-Chemical
506	673 3 I-Chemical
-	676 1 O
induced	677 7 O
hypertension	685 12 B-Disease
in	698 2 O
rats	701 4 O
was	706 3 O
studied	710 7 O
.	717 1 O

FK	719 2 B-Chemical
506	722 3 I-Chemical
,	725 1 O
5	727 1 O
mg	729 2 O
.	731 1 O

kg	733 2 O
-	735 1 O
1	736 1 O
.	737 1 O

d	739 1 O
-	740 1 O
1	741 1 O
given	743 5 O
for	749 3 O
4	753 1 O
weeks	755 5 O
,	760 1 O
elevated	762 8 O
blood	771 5 O
pressure	777 8 O
from	786 4 O
102	791 3 O
+	794 1 O
/	795 1 O
-	796 1 O
13	797 2 O
to	800 2 O
152	803 3 O
+	806 1 O
/	807 1 O
-	808 1 O
15	809 2 O
mm	812 2 O
Hg	815 2 O
and	818 3 O
increased	822 9 O
the	832 3 O
synthesis	836 9 O
of	846 2 O
ET	849 2 O
-	851 1 O
1	852 1 O
and	854 3 O
the	858 3 O
levels	862 6 O
of	869 2 O
ET	872 2 O
-	874 1 O
1	875 1 O
mRNA	877 4 O
in	882 2 O
the	885 3 O
mesenteric	889 10 O
artery	900 6 O
(	907 1 O
240	908 3 O
%	911 1 O
and	913 3 O
230	917 3 O
%	920 1 O
,	921 1 O
respectively	923 12 O
)	935 1 O
.	936 1 O

Little	938 6 O
change	945 6 O
was	952 3 O
observed	956 8 O
in	965 2 O
the	968 3 O
expression	972 10 O
of	983 2 O
ECE	986 3 O
-	989 1 O
1	990 1 O
mRNA	992 4 O
and	997 3 O
CNP	1001 3 O
mRNA	1005 4 O
.	1009 1 O

FK	1011 2 B-Chemical
506	1014 3 I-Chemical
decreased	1018 9 O
eNOS	1028 4 O
activity	1033 8 O
and	1042 3 O
the	1046 3 O
levels	1050 6 O
of	1057 2 O
eNOS	1060 4 O
mRNA	1065 4 O
in	1070 2 O
the	1073 3 O
aorta	1077 5 O
(	1083 1 O
48	1084 2 O
%	1086 1 O
and	1088 3 O
55	1092 2 O
%	1094 1 O
,	1095 1 O
respectively	1097 12 O
)	1109 1 O
.	1110 1 O

The	1112 3 O
administration	1116 14 O
of	1131 2 O
FR	1134 2 B-Chemical
139317	1137 6 I-Chemical
(	1144 1 O
10	1145 2 O
mg	1148 2 O
.	1150 1 O
kg	1152 2 O
-	1154 1 O
1	1155 1 O
.	1156 1 O
d	1158 1 O
-	1159 1 O
1	1160 1 O
)	1161 1 O
prevented	1163 9 O
FK	1173 2 B-Chemical
506	1176 3 I-Chemical
-	1179 1 O
induced	1180 7 O
hypertension	1188 12 B-Disease
in	1201 2 O
rats	1204 4 O
.	1208 1 O

These	1210 5 O
results	1216 7 O
indicate	1224 8 O
that	1233 4 O
FK	1238 2 B-Chemical
506	1241 3 I-Chemical
may	1245 3 O
increase	1249 8 O
blood	1258 5 O
pressure	1264 8 O
not	1273 3 O
only	1277 4 O
by	1282 2 O
increasing	1285 10 O
ET	1296 2 O
-	1298 1 O
1	1299 1 O
production	1301 10 O
but	1312 3 O
also	1316 4 O
by	1321 2 O
decreasing	1324 10 O
NO	1335 2 B-Chemical
synthesis	1338 9 O
in	1348 2 O
the	1351 3 O
vasculature	1355 11 O
.	1366 1 O

Suxamethonium	0 13 B-Chemical
induced	14 7 O
prolonged	22 9 O
apnea	32 5 B-Disease
in	38 2 O
a	41 1 O
patient	43 7 O
receiving	51 9 O
electroconvulsive	61 17 O
therapy	79 7 O
.	86 1 O

Suxamethonium	88 13 B-Chemical
causes	102 6 O
prolonged	109 9 O
apnea	119 5 B-Disease
in	125 2 O
patients	128 8 O
in	137 2 O
whom	140 4 O
pseudocholinesterase	145 20 O
enzyme	166 6 O
gets	173 4 O
deactivated	178 11 O
by	190 2 O
organophosphorus	193 16 B-Chemical
(	210 1 I-Chemical
OP	211 2 I-Chemical
)	213 1 I-Chemical
poisons	215 7 I-Chemical
.	222 1 O

Here	224 4 O
,	228 1 O
we	230 2 O
present	233 7 O
a	241 1 O
similar	243 7 O
incident	251 8 O
in	260 2 O
a	263 1 O
severely	265 8 O
depressed	274 9 B-Disease
patient	284 7 O
who	292 3 O
received	296 8 O
electroconvulsive	305 17 O
therapy	323 7 O
(	331 1 O
ECT	332 3 O
)	335 1 O
.	336 1 O

Prolonged	338 9 O
apnea	348 5 B-Disease
in	354 2 O
our	357 3 O
case	361 4 O
ensued	366 6 O
because	373 7 O
the	381 3 O
information	385 11 O
about	397 5 O
suicidal	403 8 O
attempt	412 7 O
by	420 2 O
OP	423 2 B-Chemical
compound	426 8 I-Chemical
was	435 3 O
concealed	439 9 O
from	449 4 O
the	454 3 O
treating	458 8 O
team	467 4 O
.	471 1 O

The	0 3 O
effects	4 7 O
of	12 2 O
the	15 3 O
adjunctive	19 10 O
bupropion	30 9 B-Chemical
on	40 2 O
male	43 4 O
sexual	48 6 B-Disease
dysfunction	55 11 I-Disease
induced	67 7 O
by	75 2 O
a	78 1 O
selective	80 9 B-Chemical
serotonin	90 9 I-Chemical
reuptake	100 8 I-Chemical
inhibitor	109 9 I-Chemical
:	118 1 O
a	120 1 O
double	122 6 O
-	128 1 O
blind	129 5 O
placebo	135 7 O
-	142 1 O
controlled	143 10 O
and	154 3 O
randomized	158 10 O
study	169 5 O
.	174 1 O

OBJECTIVE	176 9 O
:	185 1 O
To	187 2 O
determine	190 9 O
the	200 3 O
safety	204 6 O
and	211 3 O
efficacy	215 8 O
of	224 2 O
adjunctive	227 10 O
bupropion	238 9 B-Chemical
sustained	248 9 O
-	257 1 O
release	258 7 O
(	266 1 O
SR	267 2 O
)	269 1 O
on	271 2 O
male	274 4 O
sexual	279 6 B-Disease
dysfunction	286 11 I-Disease
(	298 1 O
SD	299 2 B-Disease
)	301 1 O
induced	303 7 O
by	311 2 O
a	314 1 O
selective	316 9 B-Chemical
serotonin	326 9 I-Chemical
reuptake	336 8 I-Chemical
inhibitor	345 9 I-Chemical
(	355 1 O
SSRI	356 4 B-Chemical
)	360 1 O
,	361 1 O
as	363 2 O
SD	366 2 B-Disease
is	369 2 O
a	372 1 O
common	374 6 O
side	381 4 O
-	385 1 O
effect	386 6 O
of	393 2 O
SSRIs	396 5 B-Chemical
and	402 3 O
the	406 3 O
most	410 4 O
effective	415 9 O
treatments	425 10 O
have	436 4 O
yet	441 3 O
to	445 2 O
be	448 2 O
determined	451 10 O
.	461 1 O

PATIENTS	463 8 O
AND	472 3 O
METHODS	476 7 O
:	483 1 O
The	485 3 O
randomized	489 10 O
sample	500 6 O
consisted	507 9 O
of	517 2 O
234	520 3 O
euthymic	524 8 O
men	533 3 O
who	537 3 O
were	541 4 O
receiving	546 9 O
some	556 4 O
type	561 4 O
of	566 2 O
SSRI	569 4 B-Chemical
.	573 1 O

The	575 3 O
men	579 3 O
were	583 4 O
randomly	588 8 O
assigned	597 8 O
to	606 2 O
bupropion	609 9 B-Chemical
SR	619 2 O
(	622 1 O
150	623 3 O
mg	627 2 O
twice	630 5 O
daily	636 5 O
,	641 1 O
117	643 3 O
)	646 1 O
or	648 2 O
placebo	651 7 O
(	659 1 O
twice	660 5 O
daily	666 5 O
,	671 1 O
117	673 3 O
)	676 1 O
for	678 3 O
12	682 2 O
weeks	685 5 O
.	690 1 O

Efficacy	692 8 O
was	701 3 O
evaluated	705 9 O
using	715 5 O
the	721 3 O
Clinical	725 8 O
Global	734 6 O
Impression	741 10 O
-	751 1 O
Sexual	752 6 O
Function	759 8 O
(	768 1 O
CGI	769 3 O
-	772 1 O
SF	773 2 O
;	775 1 O
the	777 3 O
primary	781 7 O
outcome	789 7 O
measure	797 7 O
)	804 1 O
,	805 1 O
the	807 3 O
International	811 13 O
Index	825 5 O
of	831 2 O
Erectile	834 8 O
Function	843 8 O
(	852 1 O
IIEF	853 4 O
)	857 1 O
,	858 1 O
Arizona	860 7 O
Sexual	868 6 O
Experience	875 10 O
Scale	886 5 O
(	892 1 O
ASEX	893 4 O
)	897 1 O
,	898 1 O
and	900 3 O
Erectile	904 8 B-Disease
Dysfunction	913 11 I-Disease
Inventory	925 9 O
of	935 2 O
Treatment	938 9 O
Satisfaction	948 12 O
(	961 1 O
EDITS	962 5 O
)	967 1 O
(	969 1 O
secondary	970 9 O
outcome	980 7 O
measures	988 8 O
)	996 1 O
.	997 1 O

Participants	999 12 O
were	1012 4 O
followed	1017 8 O
biweekly	1026 8 O
during	1035 6 O
study	1042 5 O
period	1048 6 O
.	1054 1 O

RESULTS	1056 7 O
:	1063 1 O
After	1065 5 O
12	1071 2 O
weeks	1074 5 O
of	1080 2 O
treatment	1083 9 O
,	1092 1 O
the	1094 3 O
mean	1098 4 O
(	1103 1 O
sd	1104 2 O
)	1106 1 O
scores	1108 6 O
for	1115 3 O
CGI	1119 3 O
-	1122 1 O
SF	1123 2 O
were	1126 4 O
significantly	1131 13 O
lower	1145 5 O
,	1150 1 O
i	1152 1 O
.	1153 1 O
e	1154 1 O
.	1155 1 O
better	1157 6 O
,	1163 1 O
in	1165 2 O
patients	1168 8 O
on	1177 2 O
bupropion	1180 9 B-Chemical
SR	1190 2 O
,	1192 1 O
at	1194 2 O
2	1197 1 O
.	1198 1 O
4	1199 1 O
(	1201 1 O
1	1202 1 O
.	1203 1 O
2	1204 1 O
)	1205 1 O
,	1206 1 O
than	1208 4 O
in	1213 2 O
the	1216 3 O
placebo	1220 7 O
group	1228 5 O
,	1233 1 O
at	1235 2 O
3	1238 1 O
.	1239 1 O
9	1240 1 O
(	1242 1 O
1	1243 1 O
.	1244 1 O
1	1245 1 O
)	1246 1 O
(	1248 1 O
P	1249 1 O
=	1250 1 O
0	1252 1 O
.	1253 1 O
01	1254 2 O
)	1256 1 O
.	1257 1 O

Men	1259 3 O
who	1263 3 O
received	1267 8 O
bupropion	1276 9 B-Chemical
had	1286 3 O
a	1290 1 O
significant	1292 11 O
increase	1304 8 O
in	1313 2 O
the	1316 3 O
total	1320 5 O
IIEF	1326 4 O
score	1331 5 O
(	1337 1 O
54	1338 2 O
.	1340 1 O
4	1341 1 O
%	1342 1 O
vs	1344 2 O
1	1347 1 O
.	1348 1 O
2	1349 1 O
%	1350 1 O
;	1351 1 O
P	1353 1 O
=	1354 1 O
0	1356 1 O
.	1357 1 O
003	1358 3 O
)	1361 1 O
,	1362 1 O
and	1364 3 O
in	1368 2 O
the	1371 3 O
five	1375 4 O
different	1380 9 O
domains	1390 7 O
of	1398 2 O
the	1401 3 O
IIEF	1405 4 O
.	1409 1 O

Total	1411 5 O
ASEX	1417 4 O
scores	1422 6 O
were	1429 4 O
significantly	1434 13 O
lower	1448 5 O
,	1453 1 O
i	1455 1 O
.	1456 1 O
e	1457 1 O
.	1458 1 O
better	1460 6 O
,	1466 1 O
among	1468 5 O
men	1474 3 O
who	1478 3 O
received	1482 8 O
bupropion	1491 9 B-Chemical
than	1501 4 O
placebo	1506 7 O
,	1513 1 O
at	1515 2 O
15	1518 2 O
.	1520 1 O
5	1521 1 O
(	1523 1 O
4	1524 1 O
.	1525 1 O
3	1526 1 O
)	1527 1 O
vs	1529 2 O
21	1532 2 O
.	1534 1 O
5	1535 1 O
(	1537 1 O
4	1538 1 O
.	1539 1 O
7	1540 1 O
)	1541 1 O
(	1543 1 O
P	1544 1 O
=	1545 1 O
0	1547 1 O
.	1548 1 O
002	1549 3 O
)	1552 1 O
.	1553 1 O

The	1555 3 O
EDITS	1559 5 O
scores	1565 6 O
were	1572 4 O
67	1577 2 O
.	1579 1 O
4	1580 1 O
(	1582 1 O
10	1583 2 O
.	1585 1 O
2	1586 1 O
)	1587 1 O
for	1589 3 O
the	1593 3 O
bupropion	1597 9 B-Chemical
and	1607 3 O
36	1611 2 O
.	1613 1 O
3	1614 1 O
(	1616 1 O
11	1617 2 O
.	1619 1 O
7	1620 1 O
)	1621 1 O
for	1623 3 O
the	1627 3 O
placebo	1631 7 O
group	1639 5 O
(	1645 1 O
P	1646 1 O
=	1647 1 O
0	1649 1 O
.	1650 1 O
001	1651 3 O
)	1654 1 O
.	1655 1 O

The	1657 3 O
ASEX	1661 4 O
score	1666 5 O
and	1672 3 O
CGI	1676 3 O
-	1679 1 O
SF	1680 2 O
score	1683 5 O
were	1689 4 O
correlated	1694 10 O
(	1705 1 O
P	1706 1 O
=	1707 1 O
0	1709 1 O
.	1710 1 O
003	1711 3 O
)	1714 1 O
.	1715 1 O

In	1717 2 O
linear	1720 6 O
regression	1727 10 O
analyses	1738 8 O
the	1747 3 O
CGI	1751 3 O
-	1754 1 O
SF	1755 2 O
score	1758 5 O
was	1764 3 O
not	1768 3 O
affected	1772 8 O
significantly	1781 13 O
by	1795 2 O
the	1798 3 O
duration	1802 8 O
of	1811 2 O
SD	1814 2 B-Disease
,	1816 1 O
type	1818 4 O
of	1823 2 O
SSRI	1826 4 B-Chemical
used	1831 4 O
and	1836 3 O
age	1840 3 O
.	1843 1 O

CONCLUSIONS	1845 11 O
:	1856 1 O
Bupropion	1858 9 B-Chemical
is	1868 2 O
an	1871 2 O
effective	1874 9 O
treatment	1884 9 O
for	1894 3 O
male	1898 4 O
SD	1903 2 B-Disease
induced	1906 7 O
by	1914 2 O
SSRIs	1917 5 B-Chemical
.	1922 1 O

These	1924 5 O
results	1930 7 O
provide	1938 7 O
empirical	1946 9 O
support	1956 7 O
for	1964 3 O
conducting	1968 10 O
a	1979 1 O
further	1981 7 O
study	1989 5 O
of	1995 2 O
bupropion	1998 9 B-Chemical
.	2007 1 O

Lamivudine	0 10 B-Chemical
for	11 3 O
the	15 3 O
prevention	19 10 O
of	30 2 O
hepatitis	33 9 B-Disease
B	43 1 I-Disease
virus	45 5 O
reactivation	51 12 O
in	64 2 O
hepatitis	67 9 B-Chemical
-	76 1 I-Chemical
B	77 1 I-Chemical
surface	79 7 I-Chemical
antigen	87 7 I-Chemical
(	95 1 O
HBSAG	96 5 B-Chemical
)	101 1 O
seropositive	103 12 O
cancer	116 6 B-Disease
patients	123 8 O
undergoing	132 10 O
cytotoxic	143 9 O
chemotherapy	153 12 O
.	165 1 O

Hepatitis	167 9 B-Disease
B	177 1 I-Disease
virus	179 5 O
(	185 1 O
HBV	186 3 O
)	189 1 O
is	191 2 O
one	194 3 O
of	198 2 O
the	201 3 O
major	205 5 O
causes	211 6 O
of	218 2 O
chronic	221 7 O
liver	229 5 B-Disease
disease	235 7 I-Disease
worldwide	243 9 O
.	252 1 O

Cancer	254 6 B-Disease
patients	261 8 O
who	270 3 O
are	274 3 O
chronic	278 7 O
carriers	286 8 O
of	295 2 O
HBV	298 3 O
have	302 4 O
a	307 1 O
higher	309 6 O
hepatic	316 7 B-Disease
complication	324 12 I-Disease
rate	337 4 O
while	342 5 O
receiving	348 9 O
cytotoxic	358 9 O
chemotherapy	368 12 O
(	381 1 O
CT	382 2 O
)	384 1 O
and	386 3 O
this	390 4 O
has	395 3 O
mainly	399 6 O
been	406 4 O
attributed	411 10 O
to	422 2 O
HBV	425 3 O
reactivation	429 12 O
.	441 1 O

In	443 2 O
this	446 4 O
study	451 5 O
,	456 1 O
cancer	458 6 B-Disease
patients	465 8 O
who	474 3 O
have	478 4 O
solid	483 5 O
and	489 3 O
hematological	493 13 B-Disease
malignancies	507 12 I-Disease
with	520 4 O
chronic	525 7 O
HBV	533 3 B-Disease
infection	537 9 I-Disease
received	547 8 O
the	556 3 O
antiviral	560 9 O
agent	570 5 O
lamivudine	576 10 B-Chemical
prior	587 5 O
and	593 3 O
during	597 6 O
CT	604 2 O
compared	607 8 O
with	616 4 O
historical	621 10 O
control	632 7 O
group	640 5 O
who	646 3 O
did	650 3 O
not	654 3 O
receive	658 7 O
lamivudine	666 10 B-Chemical
.	676 1 O

The	678 3 O
objectives	682 10 O
were	693 4 O
to	698 2 O
assess	701 6 O
the	708 3 O
efficacy	712 8 O
of	721 2 O
lamivudine	724 10 B-Chemical
in	735 2 O
reducing	738 8 O
the	747 3 O
incidence	751 9 O
of	761 2 O
HBV	764 3 O
reactivation	768 12 O
,	780 1 O
and	782 3 O
diminishing	786 11 O
morbidity	798 9 O
and	808 3 O
mortality	812 9 O
during	822 6 O
CT	829 2 O
.	831 1 O

Two	833 3 O
groups	837 6 O
were	844 4 O
compared	849 8 O
in	858 2 O
this	861 4 O
study	866 5 O
.	871 1 O

The	873 3 O
prophylactic	877 12 O
lamivudin	890 9 B-Chemical
group	900 5 O
consisted	906 9 O
of	916 2 O
37	919 2 O
patients	922 8 O
who	931 3 O
received	935 8 O
prophylactic	944 12 O
lamivudine	957 10 B-Chemical
treatment	968 9 O
.	977 1 O

The	979 3 O
historical	983 10 O
controls	994 8 O
consisted	1003 9 O
of	1013 2 O
50	1016 2 O
consecutive	1019 11 O
patients	1031 8 O
who	1040 3 O
underwent	1044 9 O
CT	1054 2 O
without	1057 7 O
prophylactic	1065 12 O
lamivudine	1078 10 B-Chemical
.	1088 1 O

They	1090 4 O
were	1095 4 O
followed	1100 8 O
up	1109 2 O
during	1112 6 O
and	1119 3 O
for	1123 3 O
8	1127 1 O
weeks	1129 5 O
after	1135 5 O
CT	1141 2 O
.	1143 1 O

The	1145 3 O
outcomes	1149 8 O
were	1158 4 O
compared	1163 8 O
for	1172 3 O
both	1176 4 O
groups	1181 6 O
.	1187 1 O

Of	1189 2 O
our	1192 3 O
control	1196 7 O
group	1204 5 O
(	1210 1 O
n	1211 1 O
=	1212 1 O
50	1214 2 O
)	1216 1 O
,	1217 1 O
21	1219 2 O
patients	1222 8 O
(	1231 1 O
42	1232 2 O
%	1234 1 O
)	1235 1 O
were	1237 4 O
established	1242 11 O
hepatitis	1254 9 B-Disease
.	1263 1 O

Twelve	1265 6 O
(	1272 1 O
24	1273 2 O
%	1275 1 O
)	1276 1 O
of	1278 2 O
them	1281 4 O
were	1286 4 O
evaluated	1291 9 O
as	1301 2 O
severe	1304 6 O
hepatitis	1311 9 B-Disease
.	1320 1 O

In	1322 2 O
the	1325 3 O
prophylactic	1329 12 O
lamivudine	1342 10 B-Chemical
group	1353 5 O
severe	1359 6 O
hepatitis	1366 9 B-Disease
were	1376 4 O
observed	1381 8 O
only	1390 4 O
in	1395 2 O
1	1398 1 O
patient	1400 7 O
(	1408 1 O
2	1409 1 O
.	1410 1 O
7	1411 1 O
%	1412 1 O
)	1413 1 O
of	1415 2 O
37	1418 2 O
patients	1421 8 O
(	1430 1 O
p	1431 1 O
<	1433 1 O
0	1435 1 O
.	1436 1 O
006	1437 3 O
)	1440 1 O
.	1441 1 O

Comparison	1443 10 O
of	1454 2 O
the	1457 3 O
mean	1461 4 O
ALT	1466 3 O
values	1470 6 O
revealed	1477 8 O
significantly	1486 13 O
higher	1500 6 O
mean	1507 4 O
alanine	1512 7 B-Chemical
aminotransferase	1520 16 O
(	1537 1 O
ALT	1538 3 O
)	1541 1 O
values	1543 6 O
in	1550 2 O
the	1553 3 O
control	1557 7 O
group	1565 5 O
than	1571 4 O
the	1576 3 O
prophylactic	1580 12 O
lamivudine	1593 10 B-Chemical
group	1604 5 O
;	1609 1 O
154	1611 3 O
:	1614 1 O
64	1615 2 O
(	1618 1 O
p	1619 1 O
<	1621 1 O
0	1623 1 O
.	1624 1 O
32	1625 2 O
)	1627 1 O
.	1628 1 O

Our	1630 3 O
study	1634 5 O
suggests	1640 8 O
that	1649 4 O
prophylactic	1654 12 O
lamivudine	1667 10 B-Chemical
significantly	1678 13 O
decreases	1692 9 O
the	1702 3 O
incidence	1706 9 O
of	1716 2 O
HBV	1719 3 O
reactivation	1723 12 O
and	1736 3 O
overall	1740 7 O
morbidity	1748 9 O
in	1758 2 O
cancer	1761 6 B-Disease
patients	1768 8 O
during	1777 6 O
and	1784 3 O
after	1788 5 O
immunosuppressive	1794 17 O
therapy	1812 7 O
.	1819 1 O

Further	1821 7 O
studies	1829 7 O
are	1837 3 O
needed	1841 6 O
to	1848 2 O
determine	1851 9 O
the	1861 3 O
most	1865 4 O
appropriate	1870 11 O
nucleoside	1882 10 B-Chemical
or	1893 2 O
nucleotide	1896 10 B-Chemical
analogue	1907 8 O
for	1916 3 O
antiviral	1920 9 O
prophylaxis	1930 11 O
during	1942 6 O
CT	1949 2 O
and	1952 3 O
the	1956 3 O
optimal	1960 7 O
duration	1968 8 O
of	1977 2 O
administration	1980 14 O
after	1995 5 O
completion	2001 10 O
of	2012 2 O
CT	2015 2 O
.	2017 1 O

Ginsenoside	0 11 B-Chemical
Rg1	12 3 I-Chemical
restores	16 8 O
the	25 3 O
impairment	29 10 B-Disease
of	40 2 I-Disease
learning	43 8 I-Disease
induced	52 7 O
by	60 2 O
chronic	63 7 O
morphine	71 8 B-Chemical
administration	80 14 O
in	95 2 O
rats	98 4 O
.	102 1 O

Rg1	104 3 B-Chemical
,	107 1 O
as	109 2 O
a	112 1 O
ginsenoside	114 11 B-Chemical
extracted	126 9 O
from	136 4 O
Panax	141 5 O
ginseng	147 7 O
,	154 1 O
could	156 5 O
ameliorate	162 10 O
spatial	173 7 O
learning	181 8 B-Disease
impairment	190 10 I-Disease
.	200 1 O

Previous	202 8 O
studies	211 7 O
have	219 4 O
demonstrated	224 12 O
that	237 4 O
Rg1	242 3 B-Chemical
might	246 5 O
be	252 2 O
a	255 1 O
useful	257 6 O
agent	264 5 O
for	270 3 O
the	274 3 O
prevention	278 10 O
and	289 3 O
treatment	293 9 O
of	303 2 O
the	306 3 O
adverse	310 7 O
effects	318 7 O
of	326 2 O
morphine	329 8 B-Chemical
.	337 1 O

The	339 3 O
aim	343 3 O
of	347 2 O
this	350 4 O
study	355 5 O
was	361 3 O
to	365 2 O
investigate	368 11 O
the	380 3 O
effect	384 6 O
of	391 2 O
Rg1	394 3 B-Chemical
on	398 2 O
learning	401 8 B-Disease
impairment	410 10 I-Disease
by	421 2 O
chronic	424 7 O
morphine	432 8 B-Chemical
administration	441 14 O
and	456 3 O
the	460 3 O
mechanism	464 9 O
responsible	474 11 O
for	486 3 O
this	490 4 O
effect	495 6 O
.	501 1 O

Male	503 4 O
rats	508 4 O
were	513 4 O
subcutaneously	518 14 O
injected	533 8 O
with	542 4 O
morphine	547 8 B-Chemical
(	556 1 O
10	557 2 O
mg	560 2 O
/	562 1 O
kg	563 2 O
)	565 1 O
twice	567 5 O
a	573 1 O
day	575 3 O
at	579 2 O
12	582 2 O
hour	585 4 O
intervals	590 9 O
for	600 3 O
10	604 2 O
days	607 4 O
,	611 1 O
and	613 3 O
Rg1	617 3 B-Chemical
(	621 1 O
30	622 2 O
mg	625 2 O
/	627 1 O
kg	628 2 O
)	630 1 O
was	632 3 O
intraperitoneally	636 17 O
injected	654 8 O
2	663 1 O
hours	665 5 O
after	671 5 O
the	677 3 O
second	681 6 O
injection	688 9 O
of	698 2 O
morphine	701 8 B-Chemical
once	710 4 O
a	715 1 O
day	717 3 O
for	721 3 O
10	725 2 O
days	728 4 O
.	732 1 O

Spatial	734 7 O
learning	742 8 O
capacity	751 8 O
was	760 3 O
assessed	764 8 O
in	773 2 O
the	776 3 O
Morris	780 6 O
water	787 5 O
maze	793 4 O
.	797 1 O

The	799 3 O
results	803 7 O
showed	811 6 O
that	818 4 O
rats	823 4 O
treated	828 7 O
with	836 4 O
Morphine	841 8 B-Chemical
/	849 1 O
Rg1	850 3 B-Chemical
decreased	854 9 O
escape	864 6 O
latency	871 7 O
and	879 3 O
increased	883 9 O
the	893 3 O
time	897 4 O
spent	902 5 O
in	908 2 O
platform	911 8 O
quadrant	920 8 O
and	929 3 O
entering	933 8 O
frequency	942 9 O
.	951 1 O

By	953 2 O
implantation	956 12 O
of	969 2 O
electrodes	972 10 O
and	983 3 O
electrophysiological	987 20 O
recording	1008 9 O
in	1018 2 O
vivo	1021 4 O
,	1025 1 O
the	1027 3 O
results	1031 7 O
showed	1039 6 O
that	1046 4 O
Rg1	1051 3 B-Chemical
restored	1055 8 O
the	1064 3 O
long	1068 4 O
-	1072 1 O
term	1073 4 O
potentiation	1078 12 O
(	1091 1 O
LTP	1092 3 O
)	1095 1 O
impaired	1097 8 O
by	1106 2 O
morphine	1109 8 B-Chemical
in	1118 2 O
both	1121 4 O
freely	1126 6 O
moving	1133 6 O
and	1140 3 O
anaesthetised	1144 13 O
rats	1158 4 O
.	1162 1 O

The	1164 3 O
electrophysiological	1168 20 O
recording	1189 9 O
in	1199 2 O
vitro	1202 5 O
showed	1208 6 O
that	1215 4 O
Rg1	1220 3 B-Chemical
restored	1224 8 O
the	1233 3 O
LTP	1237 3 O
in	1241 2 O
slices	1244 6 O
from	1251 4 O
the	1256 3 O
rats	1260 4 O
treated	1265 7 O
with	1273 4 O
morphine	1278 8 B-Chemical
,	1286 1 O
but	1288 3 O
not	1292 3 O
changed	1296 7 O
LTP	1304 3 O
in	1308 2 O
the	1311 3 O
slices	1315 6 O
from	1322 4 O
normal	1327 6 O
saline	1334 6 O
-	1340 1 O
or	1342 2 O
morphine	1345 8 B-Chemical
/	1353 1 O
Rg1	1354 3 B-Chemical
-	1357 1 O
treated	1358 7 O
rats	1366 4 O
;	1370 1 O
this	1372 4 O
restoration	1377 11 O
could	1389 5 O
be	1395 2 O
inhibited	1398 9 O
by	1408 2 O
N	1411 1 B-Chemical
-	1412 1 I-Chemical
methyl	1413 6 I-Chemical
-	1419 1 I-Chemical
D	1420 1 I-Chemical
-	1421 1 I-Chemical
aspartate	1422 9 I-Chemical
(	1432 1 O
NMDA	1433 4 B-Chemical
)	1437 1 O
receptor	1439 8 O
antagonist	1448 10 O
MK801	1459 5 B-Chemical
.	1464 1 O

We	1466 2 O
conclude	1469 8 O
that	1478 4 O
Rg1	1483 3 B-Chemical
may	1487 3 O
significantly	1491 13 O
improve	1505 7 O
the	1513 3 O
spatial	1517 7 O
learning	1525 8 O
capacity	1534 8 O
impaired	1543 8 O
by	1552 2 O
chonic	1555 6 O
morphine	1562 8 B-Chemical
administration	1571 14 O
and	1586 3 O
restore	1590 7 O
the	1598 3 O
morphine	1602 8 B-Chemical
-	1610 1 O
inhibited	1611 9 O
LTP	1621 3 O
.	1624 1 O

This	1626 4 O
effect	1631 6 O
is	1638 2 O
NMDA	1641 4 B-Chemical
receptor	1646 8 O
dependent	1655 9 O
.	1664 1 O

A	0 1 O
study	2 5 O
on	8 2 O
the	11 3 O
effect	15 6 O
of	22 2 O
the	25 3 O
duration	29 8 O
of	38 2 O
subcutaneous	41 12 O
heparin	54 7 B-Chemical
injection	62 9 O
on	72 2 O
bruising	75 8 B-Disease
and	84 3 O
pain	88 4 B-Disease
.	92 1 O

AIM	94 3 O
:	97 1 O
This	99 4 O
study	104 5 O
was	110 3 O
carried	114 7 O
out	122 3 O
to	126 2 O
determine	129 9 O
the	139 3 O
effect	143 6 O
of	150 2 O
injection	153 9 O
duration	163 8 O
on	172 2 O
bruising	175 8 B-Disease
and	184 3 O
pain	188 4 B-Disease
following	193 9 O
the	203 3 O
administration	207 14 O
of	222 2 O
the	225 3 O
subcutaneous	229 12 O
injection	242 9 O
of	252 2 O
heparin	255 7 B-Chemical
.	262 1 O

BACKGROUND	264 10 O
:	274 1 O
Although	276 8 O
different	285 9 O
methods	295 7 O
to	303 2 O
prevent	306 7 O
bruising	314 8 B-Disease
and	323 3 O
pain	327 4 B-Disease
following	332 9 O
the	342 3 O
subcutaneous	346 12 O
injection	359 9 O
of	369 2 O
heparin	372 7 B-Chemical
have	380 4 O
been	385 4 O
widely	390 6 O
studied	397 7 O
and	405 3 O
described	409 9 O
,	418 1 O
the	420 3 O
effect	424 6 O
of	431 2 O
injection	434 9 O
duration	444 8 O
on	453 2 O
the	456 3 O
occurrence	460 10 O
of	471 2 O
bruising	474 8 B-Disease
and	483 3 O
pain	487 4 B-Disease
is	492 2 O
little	495 6 O
documented	502 10 O
.	512 1 O

DESIGN	514 6 O
:	520 1 O
This	522 4 O
study	527 5 O
was	533 3 O
designed	537 8 O
as	546 2 O
within	549 6 O
-	555 1 O
subject	556 7 O
,	563 1 O
quasi	565 5 O
-	570 1 O
experimental	571 12 O
research	584 8 O
.	592 1 O

METHOD	594 6 O
:	600 1 O
The	602 3 O
sample	606 6 O
for	613 3 O
the	617 3 O
study	621 5 O
consisted	627 9 O
of	637 2 O
50	640 2 O
patients	643 8 O
to	652 2 O
whom	655 4 O
subcutaneous	660 12 O
heparin	673 7 B-Chemical
was	681 3 O
administered	685 12 O
.	697 1 O

Heparin	699 7 B-Chemical
was	707 3 O
injected	711 8 O
over	720 4 O
10	725 2 O
seconds	728 7 O
on	736 2 O
the	739 3 O
right	743 5 O
abdominal	749 9 O
site	759 4 O
and	764 3 O
30	768 2 O
seconds	771 7 O
on	779 2 O
the	782 3 O
left	786 4 O
abdominal	791 9 O
site	801 4 O
.	805 1 O

Injections	807 10 O
areas	818 5 O
were	824 4 O
assessed	829 8 O
for	838 3 O
the	842 3 O
presence	846 8 O
of	855 2 O
bruising	858 8 B-Disease
at	867 2 O
48	870 2 O
and	873 3 O
72	877 2 O
hours	880 5 O
after	886 5 O
each	892 4 O
injection	897 9 O
.	906 1 O

Dimensions	908 10 O
of	919 2 O
the	922 3 O
bruising	926 8 B-Disease
on	935 2 O
the	938 3 O
heparin	942 7 B-Chemical
applied	950 7 O
areas	958 5 O
were	964 4 O
measured	969 8 O
using	978 5 O
transparent	984 11 O
millimetric	996 11 O
measuring	1008 9 O
paper	1018 5 O
.	1023 1 O

The	1025 3 O
visual	1029 6 O
analog	1036 6 O
scale	1043 5 O
(	1049 1 O
VAS	1050 3 O
)	1053 1 O
was	1055 3 O
used	1059 4 O
to	1064 2 O
measure	1067 7 O
pain	1075 4 B-Disease
intensity	1080 9 O
and	1090 3 O
a	1094 1 O
stop	1096 4 O
-	1100 1 O
watch	1101 5 O
was	1107 3 O
used	1111 4 O
to	1116 2 O
time	1119 4 O
the	1124 3 O
pain	1128 4 B-Disease
period	1133 6 O
.	1139 1 O

Data	1141 4 O
were	1146 4 O
analysed	1151 8 O
using	1160 5 O
chi	1166 3 O
-	1169 1 O
square	1170 6 O
test	1177 4 O
,	1181 1 O
Mann	1183 4 O
-	1187 1 O
Whitney	1188 7 O
U	1196 1 O
,	1197 1 O
Wilcoxon	1199 8 O
signed	1208 6 O
ranks	1215 5 O
tests	1221 5 O
and	1227 3 O
correlation	1231 11 O
.	1242 1 O

RESULTS	1244 7 O
:	1251 1 O
The	1253 3 O
percentage	1257 10 O
of	1268 2 O
bruising	1271 8 B-Disease
occurrence	1280 10 O
was	1291 3 O
64	1295 2 O
%	1297 1 O
with	1299 4 O
the	1304 3 O
injection	1308 9 O
of	1318 2 O
10	1321 2 O
seconds	1324 7 O
duration	1332 8 O
and	1341 3 O
42	1345 2 O
%	1347 1 O
in	1349 2 O
the	1352 3 O
30	1356 2 O
-	1358 1 O
second	1359 6 O
injection	1366 9 O
.	1375 1 O

It	1377 2 O
was	1380 3 O
determined	1384 10 O
that	1395 4 O
the	1400 3 O
size	1404 4 O
of	1409 2 O
the	1412 3 O
bruising	1416 8 B-Disease
was	1425 3 O
smaller	1429 7 O
in	1437 2 O
the	1440 3 O
30	1444 2 O
-	1446 1 O
second	1447 6 O
injection	1454 9 O
.	1463 1 O

Pain	1465 4 B-Disease
intensity	1470 9 O
and	1480 3 O
pain	1484 4 B-Disease
period	1489 6 O
were	1496 4 O
statistically	1501 13 O
significantly	1515 13 O
lower	1529 5 O
for	1535 3 O
the	1539 3 O
30	1543 2 O
-	1545 1 O
second	1546 6 O
injection	1553 9 O
than	1563 4 O
for	1568 3 O
the	1572 3 O
10	1576 2 O
-	1578 1 O
second	1579 6 O
injection	1586 9 O
.	1595 1 O

CONCLUSIONS	1597 11 O
:	1608 1 O
It	1610 2 O
was	1613 3 O
determined	1617 10 O
that	1628 4 O
injection	1633 9 O
duration	1643 8 O
had	1652 3 O
an	1656 2 O
effect	1659 6 O
on	1666 2 O
bruising	1669 8 B-Disease
and	1678 3 O
pain	1682 4 B-Disease
following	1687 9 O
the	1697 3 O
subcutaneous	1701 12 O
administration	1714 14 O
of	1729 2 O
heparin	1732 7 B-Chemical
.	1739 1 O

This	1741 4 O
study	1746 5 O
should	1752 6 O
be	1759 2 O
repeated	1762 8 O
on	1771 2 O
a	1774 1 O
larger	1776 6 O
sample	1783 6 O
.	1789 1 O

RELEVANCE	1791 9 O
TO	1801 2 O
CLINICAL	1804 8 O
PRACTICE	1813 8 O
:	1821 1 O
When	1823 4 O
administering	1828 13 O
subcutaneous	1842 12 O
heparin	1855 7 B-Chemical
injections	1863 10 O
,	1873 1 O
it	1875 2 O
is	1878 2 O
important	1881 9 O
to	1891 2 O
extend	1894 6 O
the	1901 3 O
duration	1905 8 O
of	1914 2 O
the	1917 3 O
injection	1921 9 O
.	1930 1 O

Acute	0 5 O
reserpine	6 9 B-Chemical
and	16 3 O
subchronic	20 10 O
haloperidol	31 11 B-Chemical
treatments	43 10 O
change	54 6 O
synaptosomal	61 12 O
brain	74 5 O
glutamate	80 9 B-Chemical
uptake	90 6 O
and	97 3 O
elicit	101 6 O
orofacial	108 9 B-Disease
dyskinesia	118 10 I-Disease
in	129 2 O
rats	132 4 O
.	136 1 O

Reserpine	138 9 B-Chemical
-	147 1 O
and	149 3 O
haloperidol	153 11 B-Chemical
-	164 1 O
induced	165 7 O
orofacial	173 9 B-Disease
dyskinesia	183 10 I-Disease
are	194 3 O
putative	198 8 O
animal	207 6 O
models	214 6 O
of	221 2 O
tardive	224 7 B-Disease
dyskinesia	232 10 I-Disease
(	243 1 O
TD	244 2 B-Disease
)	246 1 O
whose	248 5 O
pathophysiology	254 15 O
has	270 3 O
been	274 4 O
related	279 7 O
to	287 2 O
free	290 4 O
radical	295 7 O
generation	303 10 O
and	314 3 O
oxidative	318 9 O
stress	328 6 O
.	334 1 O

In	336 2 O
the	339 3 O
present	343 7 O
study	351 5 O
,	356 1 O
the	358 3 O
authors	362 7 O
induced	370 7 O
orofacial	378 9 B-Disease
dyskinesia	388 10 I-Disease
by	399 2 O
acute	402 5 O
reserpine	408 9 B-Chemical
and	418 3 O
subchronic	422 10 O
haloperidol	433 11 B-Chemical
administration	445 14 O
to	460 2 O
rats	463 4 O
.	467 1 O

Reserpine	469 9 B-Chemical
injection	479 9 O
(	489 1 O
one	490 3 O
dose	494 4 O
of	499 2 O
1	502 1 O
mg	504 2 O
/	506 1 O
kg	507 2 O
s	510 1 O
.	511 1 O
c	512 1 O
.	513 1 O
)	514 1 O
every	516 5 O
other	522 5 O
day	528 3 O
for	532 3 O
3	536 1 O
days	538 4 O
caused	543 6 O
a	550 1 O
significant	552 11 O
increase	564 8 O
in	573 2 O
vacuous	576 7 O
chewing	584 7 O
,	591 1 O
tongue	593 6 O
protrusion	600 10 O
and	611 3 O
duration	615 8 O
of	624 2 O
facial	627 6 O
twitching	634 9 O
,	643 1 O
compared	645 8 O
to	654 2 O
the	657 3 O
control	661 7 O
.	668 1 O

Haloperidol	670 11 B-Chemical
administration	682 14 O
(	697 1 O
one	698 3 O
dose	702 4 O
of	707 2 O
12	710 2 O
mg	713 2 O
/	715 1 O
kg	716 2 O
once	719 4 O
a	724 1 O
week	726 4 O
s	731 1 O
.	732 1 O
c	733 1 O
.	734 1 O
)	735 1 O
for	737 3 O
4	741 1 O
weeks	743 5 O
caused	749 6 O
an	756 2 O
increase	759 8 O
in	768 2 O
vacuous	771 7 O
chewing	779 7 O
,	786 1 O
tongue	788 6 O
protrusion	795 10 O
and	806 3 O
duration	810 8 O
of	819 2 O
facial	822 6 O
twitching	829 9 O
observed	839 8 O
in	848 2 O
four	851 4 O
weekly	856 6 O
evaluations	863 11 O
.	874 1 O

After	876 5 O
the	882 3 O
treatments	886 10 O
and	897 3 O
behavioral	901 10 O
observation	912 11 O
,	923 1 O
glutamate	925 9 B-Chemical
uptake	935 6 O
by	942 2 O
segments	945 8 O
of	954 2 O
the	957 3 O
brain	961 5 O
was	967 3 O
analyzed	971 8 O
.	979 1 O

A	981 1 O
decreased	983 9 O
glutamate	993 9 B-Chemical
uptake	1003 6 O
was	1010 3 O
observed	1014 8 O
in	1023 2 O
the	1026 3 O
subcortical	1030 11 O
parts	1042 5 O
of	1048 2 O
animals	1051 7 O
treated	1059 7 O
with	1067 4 O
reserpine	1072 9 B-Chemical
and	1082 3 O
haloperidol	1086 11 B-Chemical
,	1097 1 O
compared	1099 8 O
to	1108 2 O
the	1111 3 O
control	1115 7 O
.	1122 1 O

Importantly	1124 11 O
,	1135 1 O
a	1137 1 O
decrease	1139 8 O
in	1148 2 O
glutamate	1151 9 B-Chemical
uptake	1161 6 O
correlates	1168 10 O
negatively	1179 10 O
with	1190 4 O
an	1195 2 O
increase	1198 8 O
in	1207 2 O
the	1210 3 O
incidence	1214 9 O
of	1224 2 O
orofacial	1227 9 B-Disease
diskinesia	1237 10 I-Disease
.	1247 1 O

These	1249 5 O
results	1255 7 O
indicate	1263 8 O
that	1272 4 O
early	1277 5 O
changes	1283 7 O
in	1291 2 O
glutamate	1294 9 B-Chemical
transport	1304 9 O
may	1314 3 O
be	1318 2 O
related	1321 7 O
to	1329 2 O
the	1332 3 O
development	1336 11 O
of	1348 2 O
vacuous	1351 7 O
chewing	1359 7 O
movements	1367 9 O
in	1377 2 O
rats	1380 4 O
.	1384 1 O

Acute	0 5 B-Disease
psychosis	6 9 I-Disease
due	16 3 O
to	20 2 O
treatment	23 9 O
with	33 4 O
phenytoin	38 9 B-Chemical
in	48 2 O
a	51 1 O
nonepileptic	53 12 O
patient	66 7 O
.	73 1 O

The	75 3 O
development	79 11 O
of	91 2 O
psychosis	94 9 B-Disease
related	104 7 O
to	112 2 O
antiepileptic	115 13 O
drug	129 4 O
treatment	134 9 O
is	144 2 O
usually	147 7 O
attributed	155 10 O
to	166 2 O
the	169 3 O
interaction	173 11 O
between	185 7 O
the	193 3 O
epileptic	197 9 B-Disease
brain	207 5 O
substratum	213 10 O
and	224 3 O
the	228 3 O
antiepileptic	232 13 O
drugs	246 5 O
.	251 1 O

The	253 3 O
case	257 4 O
of	262 2 O
a	265 1 O
nonepileptic	267 12 O
patient	280 7 O
who	288 3 O
developed	292 9 O
psychosis	302 9 B-Disease
following	312 9 O
phenytoin	322 9 B-Chemical
treatment	332 9 O
for	342 3 O
trigeminal	346 10 B-Disease
neuralgia	357 9 I-Disease
is	367 2 O
described	370 9 O
.	379 1 O

This	381 4 O
case	386 4 O
suggests	391 8 O
that	400 4 O
the	405 3 O
psychotic	409 9 B-Disease
symptoms	419 8 I-Disease
that	428 4 O
occur	433 5 O
following	439 9 O
phenytoin	449 9 B-Chemical
treatment	459 9 O
in	469 2 O
some	472 4 O
epileptic	477 9 B-Disease
patients	487 8 O
may	496 3 O
be	500 2 O
the	503 3 O
direct	507 6 O
result	514 6 O
of	521 2 O
medication	524 10 O
,	534 1 O
unrelated	536 9 O
to	546 2 O
seizures	549 8 B-Disease
.	557 1 O

The	0 3 O
effect	4 6 O
of	11 2 O
treatment	14 9 O
with	24 4 O
gum	29 3 B-Chemical
Arabic	33 6 I-Chemical
on	40 2 O
gentamicin	43 10 B-Chemical
nephrotoxicity	54 14 B-Disease
in	69 2 O
rats	72 4 O
:	76 1 O
a	78 1 O
preliminary	80 11 O
study	92 5 O
.	97 1 O

In	99 2 O
the	102 3 O
present	106 7 O
work	114 4 O
we	119 2 O
assessed	122 8 O
the	131 3 O
effect	135 6 O
of	142 2 O
treatment	145 9 O
of	155 2 O
rats	158 4 O
with	163 4 O
gum	168 3 B-Chemical
Arabic	172 6 I-Chemical
on	179 2 O
acute	182 5 B-Disease
renal	188 5 I-Disease
failure	194 7 I-Disease
induced	202 7 O
by	210 2 O
gentamicin	213 10 B-Chemical
(	224 1 O
GM	225 2 B-Chemical
)	227 1 O
nephrotoxicity	229 14 B-Disease
.	243 1 O

Rats	245 4 O
were	250 4 O
treated	255 7 O
with	263 4 O
the	268 3 O
vehicle	272 7 O
(	280 1 O
2	281 1 O
mL	283 2 O
/	285 1 O
kg	286 2 O
of	289 2 O
distilled	292 9 O
water	302 5 O
and	308 3 O
5	312 1 O
%	313 1 O
w	315 1 O
/	316 1 O
v	317 1 O
cellulose	319 9 O
,	328 1 O
10	330 2 O
days	333 4 O
)	337 1 O
,	338 1 O
gum	340 3 B-Chemical
Arabic	344 6 I-Chemical
(	351 1 O
2	352 1 O
mL	354 2 O
/	356 1 O
kg	357 2 O
of	360 2 O
a	363 1 O
10	365 2 O
%	367 1 O
w	369 1 O
/	370 1 O
v	371 1 O
aqueous	373 7 O
suspension	381 10 O
of	392 2 O
gum	395 3 B-Chemical
Arabic	399 6 I-Chemical
powder	406 6 O
,	412 1 O
orally	414 6 O
for	421 3 O
10	425 2 O
days	428 4 O
)	432 1 O
,	433 1 O
or	435 2 O
gum	438 3 B-Chemical
Arabic	442 6 I-Chemical
concomitantly	449 13 O
with	463 4 O
GM	468 2 B-Chemical
(	471 1 O
80mg	472 4 O
/	476 1 O
kg	477 2 O
/	479 1 O
day	480 3 O
intramuscularly	484 15 O
,	499 1 O
during	501 6 O
the	508 3 O
last	512 4 O
six	517 3 O
days	521 4 O
of	526 2 O
the	529 3 O
treatment	533 9 O
period	543 6 O
)	549 1 O
.	550 1 O

Nephrotoxicity	552 14 B-Disease
was	567 3 O
assessed	571 8 O
by	580 2 O
measuring	583 9 O
the	593 3 O
concentrations	597 14 O
of	612 2 O
creatinine	615 10 B-Chemical
and	626 3 O
urea	630 4 B-Chemical
in	635 2 O
the	638 3 O
plasma	642 6 O
and	649 3 O
reduced	653 7 O
glutathione	661 11 B-Chemical
(	673 1 O
GSH	674 3 B-Chemical
)	677 1 O
in	679 2 O
the	682 3 O
kidney	686 6 O
cortex	693 6 O
,	699 1 O
and	701 3 O
by	705 2 O
light	708 5 O
microscopic	714 11 O
examination	726 11 O
of	738 2 O
kidney	741 6 O
sections	748 8 O
.	756 1 O

The	758 3 O
results	762 7 O
indicated	770 9 O
that	780 4 O
concomitant	785 11 O
treatment	797 9 O
with	807 4 O
gum	812 3 B-Chemical
Arabic	816 6 I-Chemical
and	823 3 O
GM	827 2 B-Chemical
significantly	830 13 O
increased	844 9 O
creatinine	854 10 B-Chemical
and	865 3 O
urea	869 4 B-Chemical
by	874 2 O
about	877 5 O
183	883 3 O
and	887 3 O
239	891 3 O
%	894 1 O
,	895 1 O
respectively	897 12 O
(	910 1 O
compared	911 8 O
to	920 2 O
432	923 3 O
and	927 3 O
346	931 3 O
%	934 1 O
,	935 1 O
respectively	937 12 O
,	949 1 O
in	951 2 O
rats	954 4 O
treated	959 7 O
with	967 4 O
cellulose	972 9 O
and	982 3 O
GM	986 2 B-Chemical
)	988 1 O
,	989 1 O
and	991 3 O
decreased	995 9 O
that	1005 4 O
of	1010 2 O
cortical	1013 8 O
GSH	1022 3 B-Chemical
by	1026 2 O
21	1029 2 O
%	1031 1 O
(	1033 1 O
compared	1034 8 O
to	1043 2 O
27	1046 2 O
%	1048 1 O
in	1050 2 O
the	1053 3 O
cellulose	1057 9 O
plus	1067 4 O
GM	1072 2 B-Chemical
group	1075 5 O
)	1080 1 O
The	1082 3 O
GM	1086 2 B-Chemical
-	1088 1 O
induced	1089 7 O
proximal	1097 8 O
tubular	1106 7 B-Disease
necrosis	1114 8 I-Disease
appeared	1123 8 O
to	1132 2 O
be	1135 2 O
slightly	1138 8 O
less	1147 4 O
severe	1152 6 O
in	1159 2 O
rats	1162 4 O
given	1167 5 O
GM	1173 2 B-Chemical
together	1176 8 O
with	1185 4 O
gum	1190 3 B-Chemical
Arabic	1194 6 I-Chemical
than	1201 4 O
in	1206 2 O
those	1209 5 O
given	1215 5 O
GM	1221 2 B-Chemical
and	1224 3 O
cellulose	1228 9 O
.	1237 1 O

It	1239 2 O
could	1242 5 O
be	1248 2 O
inferred	1251 8 O
that	1260 4 O
gum	1265 3 B-Chemical
Arabic	1269 6 I-Chemical
treatment	1276 9 O
has	1286 3 O
induced	1290 7 O
a	1298 1 O
modest	1300 6 O
amelioration	1307 12 O
of	1320 2 O
some	1323 4 O
of	1328 2 O
the	1331 3 O
histological	1335 12 O
and	1348 3 O
biochemical	1352 11 O
indices	1364 7 O
of	1372 2 O
GM	1375 2 B-Chemical
nephrotoxicity	1378 14 B-Disease
.	1392 1 O

Further	1394 7 O
work	1402 4 O
is	1407 2 O
warranted	1410 9 O
on	1420 2 O
the	1423 3 O
effect	1427 6 O
of	1434 2 O
the	1437 3 O
treatments	1441 10 O
on	1452 2 O
renal	1455 5 O
functional	1461 10 O
aspects	1472 7 O
in	1480 2 O
models	1483 6 O
of	1490 2 O
chronic	1493 7 B-Disease
renal	1501 5 I-Disease
failure	1507 7 I-Disease
,	1514 1 O
and	1516 3 O
on	1520 2 O
the	1523 3 O
mechanism	1527 9 O
(	1536 1 O
s	1537 1 O
)	1538 1 O
involved	1540 8 O
.	1548 1 O

Visual	0 6 B-Disease
hallucinations	7 14 I-Disease
associated	22 10 O
with	33 4 O
zonisamide	38 10 B-Chemical
.	48 1 O

Zonisamide	50 10 B-Chemical
is	61 2 O
a	64 1 O
broad	66 5 O
-	71 1 O
spectrum	72 8 O
antiepileptic	81 13 O
drug	95 4 O
used	100 4 O
to	105 2 O
treat	108 5 O
various	114 7 O
types	122 5 O
of	128 2 O
seizures	131 8 B-Disease
.	139 1 O

Although	141 8 O
visual	150 6 B-Disease
hallucinations	157 14 I-Disease
have	172 4 O
not	177 3 O
been	181 4 O
reported	186 8 O
as	195 2 O
an	198 2 O
adverse	201 7 O
effect	209 6 O
of	216 2 O
this	219 4 O
agent	224 5 O
,	229 1 O
we	231 2 O
describe	234 8 O
three	243 5 O
patients	249 8 O
who	258 3 O
experienced	262 11 O
complex	274 7 O
visual	282 6 B-Disease
hallucinations	289 14 I-Disease
and	304 3 O
altered	308 7 O
mental	316 6 O
status	323 6 O
after	330 5 O
zonisamide	336 10 B-Chemical
treatment	347 9 O
was	357 3 O
begun	361 5 O
or	367 2 O
its	370 3 O
dosage	374 6 O
increased	381 9 O
.	390 1 O

All	392 3 O
three	396 5 O
had	402 3 O
been	406 4 O
diagnosed	411 9 O
earlier	421 7 O
with	429 4 O
epilepsy	434 8 B-Disease
,	442 1 O
and	444 3 O
their	448 5 O
electroencephalogram	454 20 O
(	475 1 O
EEG	476 3 O
)	479 1 O
findings	481 8 O
were	490 4 O
abnormal	495 8 O
.	503 1 O

During	505 6 O
monitoring	512 10 O
,	522 1 O
visual	524 6 B-Disease
hallucinations	531 14 I-Disease
did	546 3 O
not	550 3 O
correlate	554 9 O
with	564 4 O
EEG	569 3 O
readings	573 8 O
,	581 1 O
nor	583 3 O
did	587 3 O
video	591 5 O
recording	597 9 O
capture	607 7 O
any	615 3 O
of	619 2 O
the	622 3 O
described	626 9 O
events	636 6 O
.	642 1 O

None	644 4 O
of	649 2 O
the	652 3 O
patients	656 8 O
had	665 3 O
experienced	669 11 O
visual	681 6 B-Disease
hallucinations	688 14 I-Disease
before	703 6 O
this	710 4 O
event	715 5 O
.	720 1 O

The	722 3 O
only	726 4 O
recent	731 6 O
change	738 6 O
in	745 2 O
their	748 5 O
treatment	754 9 O
was	764 3 O
the	768 3 O
introduction	772 12 O
or	785 2 O
increased	788 9 O
dosage	798 6 O
of	805 2 O
zonisamide	808 10 B-Chemical
.	818 1 O

With	820 4 O
either	825 6 O
discontinuation	832 15 O
or	848 2 O
decreased	851 9 O
dosage	861 6 O
of	868 2 O
the	871 3 O
drug	875 4 O
the	880 3 O
symptoms	884 8 O
disappeared	893 11 O
and	905 3 O
did	909 3 O
not	913 3 O
recur	917 5 O
.	922 1 O

Further	924 7 O
observations	932 12 O
and	945 3 O
reports	949 7 O
will	957 4 O
help	962 4 O
clarify	967 7 O
this	975 4 O
adverse	980 7 O
effect	988 6 O
.	994 1 O

Until	996 5 O
then	1002 4 O
,	1006 1 O
clinicians	1008 10 O
need	1019 4 O
to	1024 2 O
be	1027 2 O
aware	1030 5 O
of	1036 2 O
this	1039 4 O
possible	1044 8 O
complication	1053 12 O
associated	1066 10 O
with	1077 4 O
zonisamide	1082 10 B-Chemical
.	1092 1 O

GLEPP1	0 6 O
receptor	7 8 O
tyrosine	16 8 B-Chemical
phosphatase	25 11 O
(	37 1 O
Ptpro	38 5 O
)	43 1 O
in	45 2 O
rat	48 3 O
PAN	52 3 B-Chemical
nephrosis	56 9 B-Disease
.	65 1 O

A	67 1 O
marker	69 6 O
of	76 2 O
acute	79 5 O
podocyte	85 8 O
injury	94 6 O
.	100 1 O

Glomerular	102 10 O
epithelial	113 10 O
protein	124 7 O
1	132 1 O
(	134 1 O
GLEPP1	135 6 O
)	141 1 O
is	143 2 O
a	146 1 O
podocyte	148 8 O
receptor	157 8 O
membrane	166 8 O
protein	175 7 O
tyrosine	183 8 B-Chemical
phosphatase	192 11 O
located	204 7 O
on	212 2 O
the	215 3 O
apical	219 6 O
cell	226 4 O
membrane	231 8 O
of	240 2 O
visceral	243 8 O
glomerular	252 10 O
epithelial	263 10 O
cell	274 4 O
and	279 3 O
foot	283 4 O
processes	288 9 O
.	297 1 O

This	299 4 O
receptor	304 8 O
plays	313 5 O
a	319 1 O
role	321 4 O
in	326 2 O
regulating	329 10 O
the	340 3 O
structure	344 9 O
and	354 3 O
function	358 8 O
of	367 2 O
podocyte	370 8 O
foot	379 4 O
process	384 7 O
.	391 1 O

To	393 2 O
better	396 6 O
understand	403 10 O
the	414 3 O
utility	418 7 O
of	426 2 O
GLEPP1	429 6 O
as	436 2 O
a	439 1 O
marker	441 6 O
of	448 2 O
glomerular	451 10 B-Disease
injury	462 6 I-Disease
,	468 1 O
the	470 3 O
amount	474 6 O
and	481 3 O
distribution	485 12 O
of	498 2 O
GLEPP1	501 6 O
protein	508 7 O
and	516 3 O
mRNA	520 4 O
were	525 4 O
examined	530 8 O
by	539 2 O
immunohistochemistry	542 20 O
,	562 1 O
Western	564 7 O
blot	572 4 O
and	577 3 O
RNase	581 5 O
protection	587 10 O
assay	598 5 O
in	604 2 O
a	607 1 O
model	609 5 O
of	615 2 O
podocyte	618 8 O
injury	627 6 O
in	634 2 O
the	637 3 O
rat	641 3 O
.	644 1 O

Puromycin	646 9 B-Chemical
aminonucleoside	656 15 I-Chemical
nephrosis	672 9 B-Disease
was	682 3 O
induced	686 7 O
by	694 2 O
single	697 6 O
intraperitoneal	704 15 O
injection	720 9 O
of	730 2 O
puromycin	733 9 B-Chemical
aminonucleoside	743 15 I-Chemical
(	759 1 O
PAN	760 3 B-Chemical
,	763 1 O
20	765 2 O
mg	768 2 O
/	770 1 O
100g	771 4 O
BW	776 2 O
)	778 1 O
.	779 1 O

Tissues	781 7 O
were	789 4 O
analyzed	794 8 O
at	803 2 O
0	806 1 O
,	807 1 O
5	809 1 O
,	810 1 O
7	812 1 O
,	813 1 O
11	815 2 O
,	817 1 O
21	819 2 O
,	821 1 O
45	823 2 O
,	825 1 O
80	827 2 O
and	830 3 O
126	834 3 O
days	838 4 O
after	843 5 O
PAN	849 3 B-Chemical
injection	853 9 O
so	863 2 O
as	866 2 O
to	869 2 O
include	872 7 O
both	880 4 O
the	885 3 O
acute	889 5 O
phase	895 5 O
of	901 2 O
proteinuria	904 11 B-Disease
associated	916 10 O
with	927 4 O
foot	932 4 O
process	937 7 O
effacement	945 10 O
(	956 1 O
days	957 4 O
5	962 1 O
-	963 1 O
11	964 2 O
)	966 1 O
and	968 3 O
the	972 3 O
chronic	976 7 O
phase	984 5 O
of	990 2 O
proteinuria	993 11 B-Disease
associated	1005 10 O
with	1016 4 O
glomerulosclerosis	1021 18 B-Disease
(	1040 1 O
days	1041 4 O
45	1046 2 O
-	1048 1 O
126	1049 3 O
)	1052 1 O
.	1053 1 O

At	1055 2 O
day	1058 3 O
5	1062 1 O
,	1063 1 O
GLEPP1	1065 6 O
protein	1072 7 O
and	1080 3 O
mRNA	1084 4 O
were	1089 4 O
reduced	1094 7 O
from	1102 4 O
the	1107 3 O
normal	1111 6 O
range	1118 5 O
(	1124 1 O
265	1125 3 O
.	1128 1 O
2	1129 1 O
+	1131 1 O
/	1132 1 O
-	1133 1 O
79	1135 2 O
.	1137 1 O
6	1138 1 O
x	1140 1 O
10	1142 2 O
(	1144 1 O
6	1145 1 O
)	1146 1 O
moles	1148 5 O
/	1153 1 O
glomerulus	1154 10 O
and	1165 3 O
100	1169 3 O
%	1172 1 O
)	1173 1 O
to	1175 2 O
15	1178 2 O
%	1180 1 O
of	1182 2 O
normal	1185 6 O
(	1192 1 O
41	1193 2 O
.	1195 1 O
8	1196 1 O
+	1198 1 O
/	1199 1 O
-	1200 1 O
4	1202 1 O
.	1203 1 O
8	1204 1 O
x	1206 1 O
10	1208 2 O
(	1210 1 O
6	1211 1 O
)	1212 1 O
moles	1214 5 O
/	1219 1 O
glomerulus	1220 10 O
,	1230 1 O
p	1232 1 O
<	1234 1 O
0	1236 1 O
.	1237 1 O
005	1238 3 O
)	1241 1 O
.	1242 1 O

This	1244 4 O
occurred	1249 8 O
in	1258 2 O
association	1261 11 O
with	1273 4 O
an	1278 2 O
increase	1281 8 O
in	1290 2 O
urinary	1293 7 O
protein	1301 7 O
content	1309 7 O
from	1317 4 O
1	1322 1 O
.	1323 1 O
8	1324 1 O
+	1326 1 O
/	1327 1 O
-	1328 1 O
1	1330 1 O
to	1332 2 O
99	1335 2 O
.	1337 1 O
0	1338 1 O
+	1340 1 O
/	1341 1 O
-	1342 1 O
61	1344 2 O
mg	1347 2 O
/	1349 1 O
day	1350 3 O
(	1354 1 O
p	1355 1 O
<	1357 1 O
0	1359 1 O
.	1360 1 O
001	1361 3 O
)	1364 1 O
.	1365 1 O

In	1367 2 O
contrast	1370 8 O
,	1378 1 O
podocalyxin	1380 11 O
did	1392 3 O
not	1396 3 O
change	1400 6 O
significantly	1407 13 O
at	1421 2 O
this	1424 4 O
time	1429 4 O
.	1433 1 O

By	1435 2 O
day	1438 3 O
11	1442 2 O
,	1444 1 O
GLEPP1	1446 6 O
protein	1453 7 O
and	1461 3 O
mRNA	1465 4 O
had	1470 3 O
begun	1474 5 O
to	1480 2 O
return	1483 6 O
towards	1490 7 O
baseline	1498 8 O
.	1506 1 O

By	1508 2 O
day	1511 3 O
45	1515 2 O
-	1517 1 O
126	1518 3 O
,	1521 1 O
at	1523 2 O
a	1526 1 O
time	1528 4 O
when	1533 4 O
glomerular	1538 10 O
scarring	1549 8 O
was	1558 3 O
present	1562 7 O
,	1569 1 O
GLEPP1	1571 6 O
was	1578 3 O
absent	1582 6 O
from	1589 4 O
glomerulosclerotic	1594 18 O
areas	1613 5 O
although	1619 8 O
the	1628 3 O
total	1632 5 O
glomerular	1638 10 O
content	1649 7 O
of	1657 2 O
GLEPP1	1660 6 O
was	1667 3 O
not	1671 3 O
different	1675 9 O
from	1685 4 O
normal	1690 6 O
.	1696 1 O

We	1698 2 O
conclude	1701 8 O
that	1710 4 O
GLEPP1	1715 6 O
expression	1722 10 O
,	1732 1 O
unlike	1734 6 O
podocalyxin	1741 11 O
,	1752 1 O
reflects	1754 8 O
podocyte	1763 8 O
injury	1772 6 O
induced	1779 7 O
by	1787 2 O
PAN	1790 3 B-Chemical
.	1793 1 O

GLEPP1	1795 6 O
expression	1802 10 O
may	1813 3 O
be	1817 2 O
a	1820 1 O
useful	1822 6 O
marker	1829 6 O
of	1836 2 O
podocyte	1839 8 O
injury	1848 6 O
.	1854 1 O

Ticlopidine	0 11 B-Chemical
-	11 1 O
induced	12 7 O
aplastic	20 8 B-Disease
anemia	29 6 I-Disease
:	35 1 O
report	37 6 O
of	44 2 O
three	47 5 O
Chinese	53 7 O
patients	61 8 O
and	70 3 O
review	74 6 O
of	81 2 O
the	84 3 O
literature	88 10 O
.	98 1 O

In	100 2 O
this	103 4 O
study	108 5 O
,	113 1 O
three	115 5 O
Chinese	121 7 O
patients	129 8 O
with	138 4 O
ticlopidine	143 11 B-Chemical
-	154 1 O
induced	155 7 O
aplastic	163 8 B-Disease
anemia	172 6 I-Disease
were	179 4 O
reported	184 8 O
and	193 3 O
another	197 7 O
13	205 2 O
patients	208 8 O
in	217 2 O
the	220 3 O
English	224 7 O
literature	232 10 O
were	243 4 O
reviewed	248 8 O
.	256 1 O

We	258 2 O
attempted	261 9 O
to	271 2 O
find	274 4 O
underlying	279 10 O
similarities	290 12 O
,	302 1 O
evaluate	304 8 O
the	313 3 O
risk	317 4 O
factors	322 7 O
,	329 1 O
and	331 3 O
identify	335 8 O
appropriate	344 11 O
treatment	356 9 O
for	366 3 O
this	370 4 O
complication	375 12 O
.	387 1 O

All	389 3 O
but	393 3 O
one	397 3 O
of	401 2 O
the	404 3 O
patients	408 8 O
were	417 4 O
over	422 4 O
60	427 2 O
years	430 5 O
old	436 3 O
,	439 1 O
and	441 3 O
the	445 3 O
6	449 1 O
who	451 3 O
died	455 4 O
were	460 4 O
all	465 3 O
older	469 5 O
than	475 4 O
65	480 2 O
.	482 1 O

Therefore	484 9 O
,	493 1 O
old	495 3 O
age	499 3 O
may	503 3 O
be	507 2 O
a	510 1 O
risk	512 4 O
factor	517 6 O
for	524 3 O
developing	528 10 O
this	539 4 O
complication	544 12 O
.	556 1 O

Agranulocytosis	558 15 B-Disease
occurred	574 8 O
3	583 1 O
-	584 1 O
20	585 2 O
weeks	588 5 O
after	594 5 O
initiation	600 10 O
of	611 2 O
ticlopidine	614 11 B-Chemical
,	625 1 O
so	627 2 O
frequent	630 8 O
examination	639 11 O
of	651 2 O
white	654 5 O
cell	660 4 O
count	665 5 O
during	671 6 O
treatment	678 9 O
is	688 2 O
recommended	691 11 O
.	702 1 O

There	704 5 O
seemed	710 6 O
to	717 2 O
be	720 2 O
no	723 2 O
direct	726 6 O
correlation	733 11 O
between	745 7 O
the	753 3 O
dose	757 4 O
or	762 2 O
duration	765 8 O
used	774 4 O
and	779 3 O
the	783 3 O
severity	787 8 O
of	796 2 O
bone	799 4 B-Disease
marrow	804 6 I-Disease
suppression	811 11 I-Disease
.	822 1 O

Treatment	824 9 O
for	834 3 O
ticlopidine	838 11 B-Chemical
-	849 1 O
induced	850 7 O
aplastic	858 8 B-Disease
anemia	867 6 I-Disease
with	874 4 O
colony	879 6 O
-	885 1 O
stimulating	886 11 O
factors	898 7 O
seemed	906 6 O
to	913 2 O
have	916 4 O
little	921 6 O
effect	928 6 O
.	934 1 O

The	936 3 O
fact	940 4 O
that	945 4 O
5	950 1 O
of	952 2 O
the	955 3 O
6	959 1 O
patients	961 8 O
who	970 3 O
received	974 8 O
concurrent	983 10 O
calcium	994 7 B-Chemical
channel	1002 7 O
blockers	1010 8 O
died	1019 4 O
,	1023 1 O
should	1025 6 O
alert	1032 5 O
clinicians	1038 10 O
to	1049 2 O
be	1052 2 O
more	1055 4 O
cautious	1060 8 O
when	1069 4 O
using	1074 5 O
these	1080 5 O
two	1086 3 O
drugs	1090 5 O
simultaneously	1096 14 O
.	1110 1 O

Facilitation	0 12 O
of	13 2 O
memory	16 6 O
retrieval	23 9 O
by	33 2 O
pre	36 3 O
-	39 1 O
test	40 4 O
morphine	45 8 B-Chemical
and	54 3 O
its	58 3 O
state	62 5 O
dependency	68 10 O
in	79 2 O
the	82 3 O
step	86 4 O
-	90 1 O
through	91 7 O
type	99 4 O
passive	104 7 O
avoidance	112 9 O
learning	122 8 O
test	131 4 O
in	136 2 O
mice	139 4 O
.	143 1 O

Amnesia	145 7 B-Disease
produced	153 8 O
by	162 2 O
scopolamine	165 11 B-Chemical
and	177 3 O
cycloheximide	181 13 B-Chemical
were	195 4 O
reversed	200 8 O
by	209 2 O
morphine	212 8 B-Chemical
given	221 5 O
30	227 2 O
min	230 3 O
before	234 6 O
the	241 3 O
test	245 4 O
trial	250 5 O
(	256 1 O
pre	257 3 O
-	260 1 O
test	261 4 O
)	265 1 O
,	266 1 O
and	268 3 O
pre	272 3 O
-	275 1 O
test	276 4 O
morphine	281 8 B-Chemical
also	290 4 O
facilitated	295 11 O
the	307 3 O
memory	311 6 O
retrieval	318 9 O
in	328 2 O
the	331 3 O
animals	335 7 O
administered	343 12 O
naloxone	356 8 B-Chemical
during	365 6 O
the	372 3 O
training	376 8 O
trial	385 5 O
.	390 1 O

Similarly	392 9 O
,	401 1 O
pre	403 3 O
-	406 1 O
test	407 4 O
scopolamine	412 11 B-Chemical
partially	424 9 O
reversed	434 8 O
the	443 3 O
scopolamine	447 11 B-Chemical
-	458 1 O
induced	459 7 O
amnesia	467 7 B-Disease
,	474 1 O
but	476 3 O
not	480 3 O
significantly	484 13 O
;	497 1 O
and	499 3 O
pre	503 3 O
-	506 1 O
test	507 4 O
cycloheximide	512 13 B-Chemical
failed	526 6 O
to	533 2 O
reverse	536 7 O
the	544 3 O
cycloheximide	548 13 B-Chemical
-	561 1 O
induced	562 7 O
amnesia	570 7 B-Disease
.	577 1 O

These	579 5 O
results	585 7 O
suggest	593 7 O
that	601 4 O
the	606 3 O
facilitation	610 12 O
of	623 2 O
memory	626 6 O
retrieval	633 9 O
by	643 2 O
pre	646 3 O
-	649 1 O
test	650 4 O
morphine	655 8 B-Chemical
might	664 5 O
be	670 2 O
the	673 3 O
direct	677 6 O
action	684 6 O
of	691 2 O
morphine	694 8 B-Chemical
rather	703 6 O
than	710 4 O
a	715 1 O
state	717 5 O
dependent	723 9 O
effect	733 6 O
.	739 1 O

Test	0 4 O
conditions	5 10 O
influence	16 9 O
the	26 3 O
response	30 8 O
to	39 2 O
a	42 1 O
drug	44 4 O
challenge	49 9 O
in	59 2 O
rodents	62 7 O
.	69 1 O

These	71 5 O
studies	77 7 O
were	85 4 O
conducted	90 9 O
to	100 2 O
examine	103 7 O
the	111 3 O
differential	115 12 O
response	128 8 O
to	137 2 O
a	140 1 O
drug	142 4 O
challenge	147 9 O
under	157 5 O
varied	163 6 O
experimental	170 12 O
test	183 4 O
conditions	188 10 O
routinely	199 9 O
employed	209 8 O
to	218 2 O
study	221 5 O
drug	227 4 O
-	231 1 O
induced	232 7 O
behavioral	240 10 O
and	251 3 O
neurophysiological	255 18 O
responses	274 9 O
in	284 2 O
rodents	287 7 O
.	294 1 O

Apomorphine	296 11 B-Chemical
,	307 1 O
a	309 1 O
nonselective	311 12 O
dopamine	324 8 B-Chemical
agonist	333 7 I-Chemical
,	340 1 O
was	342 3 O
selected	346 8 O
due	355 3 O
to	359 2 O
its	362 3 O
biphasic	366 8 O
behavioral	375 10 O
effects	386 7 O
,	393 1 O
its	395 3 O
ability	399 7 O
to	407 2 O
induce	410 6 O
hypothermia	417 11 B-Disease
,	428 1 O
and	430 3 O
to	434 2 O
produce	437 7 O
distinct	445 8 O
changes	454 7 O
to	462 2 O
dopamine	465 8 B-Chemical
turnover	474 8 O
in	483 2 O
the	486 3 O
rodent	490 6 O
brain	497 5 O
.	502 1 O

From	504 4 O
such	509 4 O
experiments	514 11 O
there	526 5 O
is	532 2 O
evidence	535 8 O
that	544 4 O
characterization	549 16 O
and	566 3 O
detection	570 9 O
of	580 2 O
apomorphine	583 11 B-Chemical
-	594 1 O
induced	595 7 O
activity	603 8 O
in	612 2 O
rodents	615 7 O
critically	623 10 O
depends	634 7 O
upon	642 4 O
the	647 3 O
test	651 4 O
conditions	656 10 O
employed	667 8 O
.	675 1 O

In	677 2 O
rats	680 4 O
,	684 1 O
detection	686 9 O
of	696 2 O
apomorphine	699 11 B-Chemical
-	710 1 O
induced	711 7 O
hyperactivity	719 13 B-Disease
was	733 3 O
facilitated	737 11 O
by	749 2 O
a	752 1 O
period	754 6 O
of	761 2 O
acclimatization	764 15 O
to	780 2 O
the	783 3 O
test	787 4 O
conditions	792 10 O
.	802 1 O

Moreover	804 8 O
,	812 1 O
test	814 4 O
conditions	819 10 O
can	830 3 O
impact	834 6 O
upon	841 4 O
other	846 5 O
physiological	852 13 O
responses	866 9 O
to	876 2 O
apomorphine	879 11 B-Chemical
such	891 4 O
as	896 2 O
drug	899 4 O
-	903 1 O
induced	904 7 O
hypothermia	912 11 B-Disease
.	923 1 O

In	925 2 O
mice	928 4 O
,	932 1 O
apomorphine	934 11 B-Chemical
produced	946 8 O
qualitatively	955 13 O
different	969 9 O
responses	979 9 O
under	989 5 O
novel	995 5 O
conditions	1001 10 O
when	1012 4 O
compared	1017 8 O
to	1026 2 O
those	1029 5 O
behaviors	1035 9 O
elicited	1045 8 O
in	1054 2 O
the	1057 3 O
home	1061 4 O
test	1066 4 O
cage	1071 4 O
.	1075 1 O

Drug	1077 4 O
-	1081 1 O
induced	1082 7 O
gross	1090 5 O
activity	1096 8 O
counts	1105 6 O
were	1112 4 O
increased	1117 9 O
in	1127 2 O
the	1130 3 O
novel	1134 5 O
exploratory	1140 11 O
box	1152 3 O
only	1156 4 O
,	1160 1 O
while	1162 5 O
measures	1168 8 O
of	1177 2 O
stereotypic	1180 11 O
behavior	1192 8 O
were	1201 4 O
similar	1206 7 O
in	1214 2 O
both	1217 4 O
.	1221 1 O

By	1223 2 O
contrast	1226 8 O
,	1234 1 O
apomorphine	1236 11 B-Chemical
-	1247 1 O
induced	1248 7 O
locomotion	1256 10 O
was	1267 3 O
more	1271 4 O
prominent	1276 9 O
in	1286 2 O
the	1289 3 O
novel	1293 5 O
exploratory	1299 11 O
box	1311 3 O
.	1314 1 O

Dopamine	1316 8 B-Chemical
turnover	1325 8 O
ratios	1334 6 O
(	1341 1 O
DOPAC	1342 5 B-Chemical
:	1347 1 O
DA	1348 2 B-Chemical
and	1351 3 O
HVA	1355 3 B-Chemical
:	1358 1 O
DA	1359 2 B-Chemical
)	1361 1 O
were	1363 4 O
found	1368 5 O
to	1374 2 O
be	1377 2 O
lower	1380 5 O
in	1386 2 O
those	1389 5 O
animals	1395 7 O
exposed	1403 7 O
to	1411 2 O
the	1414 3 O
exploratory	1418 11 O
box	1430 3 O
when	1434 4 O
compared	1439 8 O
to	1448 2 O
their	1451 5 O
home	1457 4 O
cage	1462 4 O
counterparts	1467 12 O
.	1479 1 O

However	1481 7 O
,	1488 1 O
apomorphine	1490 11 B-Chemical
-	1501 1 O
induced	1502 7 O
reductions	1510 10 O
in	1521 2 O
striatal	1524 8 O
dopamine	1533 8 B-Chemical
turnover	1542 8 O
were	1551 4 O
detected	1556 8 O
in	1565 2 O
both	1568 4 O
novel	1573 5 O
and	1579 3 O
home	1583 4 O
cage	1588 4 O
environments	1593 12 O
.	1605 1 O

The	1607 3 O
implications	1611 12 O
of	1624 2 O
these	1627 5 O
findings	1633 8 O
are	1642 3 O
discussed	1646 9 O
with	1656 4 O
particular	1661 10 O
emphasis	1672 8 O
upon	1681 4 O
conducting	1686 10 O
psychopharmacological	1697 21 O
challenge	1719 9 O
tests	1729 5 O
in	1735 2 O
rodents	1738 7 O
.	1745 1 O

